[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fiMPM_wnUcULiM29_x5ApIptXOelSuMvx7bOeDRwVDss":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":85,"rows":92},"M.D. Anderson Cancer Center",[4],2998,false,1058,134,802527,525,1076,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Leukemia",206,{"name":18,"count":19},"Breast Cancer",141,{"name":21,"count":22},"Lymphoma",136,{"name":24,"count":25},"Lung Cancer",94,{"name":27,"count":28},"Prostate Cancer",82,{"name":30,"count":31},"Myelodysplastic Syndrome",79,{"name":33,"count":34},"Advanced Cancers",69,{"name":36,"count":37},"Acute Myeloid Leukemia",67,[39,44,49,54,58,63,68,72,76,80],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT01375114","The Effects of Ginseng on Cancer-Related Fatigue","2016-05-15","Panax Ginseng",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT01949662","Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer","2016-08-26","Lorazepam",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT02337686","Pembrolizumab in Treating Patients With Recurrent Glioblastoma","2017-05-24","Pembrolizumab",{"nctId":55,"briefTitle":56,"date":57,"intervention":53},"NCT02603887","Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma","2017-12-30",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT02491632","Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer","2019-03-28","Dexamethasone",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT03035409","Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors","2019-12-27","Anamorelin Hydrochloride",{"nctId":69,"briefTitle":70,"date":71,"intervention":62},"NCT00489307","Dexamethasone for Symptom Burden in Advanced Cancer Patients","2021-02-28",{"nctId":73,"briefTitle":74,"date":71,"intervention":75},"NCT00492050","Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia","Bortezomib",{"nctId":77,"briefTitle":78,"date":79,"intervention":62},"NCT03367156","Dexamethasone in Controlling Dyspnea in Patients With Cancer","2021-05-05",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT03021486","Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer","2021-06-05","Chlorpromazine",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,229,295,346,386,411,429,454,479,1259,2176,3005,3471,3791,4388,4497,4895,5091,5182,5289,5373,5424,5749,5816,5855,5878,5900,5931,5962,6012,6045,6090,6116,6153,6180,6202,6220,6249,6267,6291,6314,6332,6373,6413,7497,8207,8977,9456,9845,10352,10657,11232,11522,11707,12049,12234,12534,12796,13008,13121,13374,13722,13973,14176,14287,14345,14511,14621,14807,15007,15133,15228,15299,15457,15591,15638,15733,15791,15973,16082,16144,16187,16273,16377,16496,16589,16672,16758,16816,16883,16932,16992,17046,17107,17145,17183,17227,17266,17303,17350,17509,17695,17777,17956,18127,18260,18344,18394,18449,18513,18564,18604,18650,18684,18714,18748,18782,18916,18997,19066,19140,19206,19268,19339,19384,19442,19480,19526,19565,19614,19644,19683,19722,19752,19778,19813,19841,19870,19907,19933,19972,20257,20320,20480,20634,20699,20754,20800,20869,20935,20999,21050,21104,21174,21212,21255,21301,21351,21381,21411,21441,21474,21503,21536,21565,21591,21619,21650,21702,21730,21756,21788,21816,21852,21880,21902,21927,21949,21971,21993,22019,22044,22072,22097,22122,22144,22166,22194,22216,22238,22260,22282,22307,22344,22371,22398,22427,22449,22473,22573,22605,22652,22684,22714,22740,22762,22788,22851,22930,22979,23030,23068,23112,23152,23197,23234,23269,23309,23339,23365,23403,23429,23457,23486,23515,23544,23566,23588,23610,23632,23654,23679,23707,23729,23760,23782,23809,23831,23849,23874,23892,23910,23928,23946,23971,23989,24007,24032,24050,24068,24089,24107,24125,24143,24161,24183,24201,24225,24243,24261,24279,24297,24315,24333,24351,24369,24387,24405,24423,24441,24459,24494,24512,24530,24548,24566,24584,24602,24620,24641,24659,24682,24700,24718,24736,24757,24775,24793,24811,24829,24854,24872,24894,24912,24930,24948,24970,24993,25011,25033,25056,25081,25102,25124,25142,25160,25182,25200,25218,25236,25254,25281,25303,25321,25339,25363,25381,25405,25423,25446,25464,25482,25500,25522,25540,25565,25591,25609,25627,25645,25669,25692,25716,25740,25758,25776,25794,25812,25837,25855,25873,25896,25914,25935,25953,25971,25989,26011,26029,26047,26065,26083,26105,26123,26141,26159,26181,26199,26217,26235,26261,26279,26297,26315,26333,26351,26369,26387,26405,26423,26441,26465,26483,26501,26519,26537,26555,26583,26601,26619,26637,26656,26680,26703,26727,26745,26763,26781,26804,26822,26845,26863,26940,26980,27017,27055,27093,27179,27209,27235,27265,27304,27326,27350,27377,27399,27449,27483,27575,27662,27712,27742,27772,27798,27828,27858,27880,27902,27930,27964,27990,28012,28042,28074,28099,28127,28153,28174,28197,28215,28233,28260,28278,28296,28319,28348,28366,28384,28402,28424,28442,28467,28485,28503,28521,28539,28557,28581,28604,28622,28640,28658,28680,28704,28722,28746,28764,28782,28800,28823,28841,28864,28888,28911,28929,28951,28969,28991,29009,29027,29045,29063,29088,29109,29127,29145,29166,29184,29207,29225,29243,29261,29279,29297,29315,29333,29351,29373,29391,29416,29469,29487,29505,29526,29550,29597,29629,29687,29709,29731,29753,29777,29795,29813,29831,29849,29867,29885,29906,29929,29957,30003,30038,30067,30089,30107,30125,30143,30167,30185,30207,30229,30251,30269,30295,30316,30363,30396,30435,30473,30495,30521,30542,30560,30578,30602,30620,30638,30656,30674,30692,30710,30728,30753,30776,30794,30812,30960,31042,31113,31159,31206,31263,31305,31343,31377,31420,31473,31511,31546,31583,31615,31641,31677,31708,31738,31767,31793,31819,31841,31870,31892,31914,31936,31969,31991,32020,32044,32069,32096,32120,32149,32171,32193,32211,32234,32252,32270,32288,32306,32330,32353,32371,32389,32411,32429,32447,32465,32488,32506,32524,32545,32563,32581,32599,32620,32642,32665,32683,32701,32719,32741,32759,32784,32805,32826,32847,32865,32887,32905,32923,32941,33011,33070,33137,33183,33260,33304,33351,33389,33432,33470,33504,33543,33588,33618,33655,33698,33728,33764,33801,33831,33867,33897,33929,33968,33994,34027,34057,34083,34115,34141,34167,34197,34223,34265,34297,34327,34353,34389,34426,34452,34482,34508,34541,34567,34599,34624,34646,34668,34690,34712,34737,34759,34783,34805,34827,34858,34880,34902,34926,34948,34973,34995,35023,35045,35067,35089,35111,35133,35155,35177,35199,35221,35246,35268,35290,35317,35339,35364,35386,35411,35436,35458,35480,35502,35534,35556,35582,35604,35626,35648,35675,35697,35719,35737,35755,35773,35791,35815,35838,35856,35874,35892,35910,35933,35951,35969,35987,36009,36030,36048,36066,36089,36107,36129,36147,36165,36183,36201,36222,36240,36258,36276,36294,36318,36344,36368,36386,36404,36422,36440,36458,36481,36499,36517,36538,36559,36577,36595,36613,36631,36649,36667,36688,36706,36724,36746,36767,36785,36806,36830,36848,36866,36888,36906,36924,36942,36964,36985,37003,37025,37043,37061,37083,37101,37122,37146,37168,37186,37204,37222,37245,37263,37281,37299,37322,37340,37372,37395,37415,37437,37455,37473,37497,37515,37533,37561,37579,37597,37615,37633,37651,37677,37695,37713,37737,37755,37773,37794,37812,37830,37848,37866,37884,37902,37920,37938,37956,37974,37997,38015,38033,38055,38073,38091,38109,38131,38149,38167,38185,38203,38221,38239,38257,38279,38297,38315,38333,38354,38372,38395,38413,38431,38449,38467,38491,38509,38527,38545,38568,38586,38604,38622,38640,38658,38676,38694,38712,38730,38751,38769,38792,38810,38828,38846,38864,38882,38900,38918,38936,38958,38979,38997,39022,39040,39058,39080,39101,39119,39137,39155,39173,39191,39214,39235,39256,39278,39299,39320,39342,39367,39385,39403,39421,39439,39457,39479,39497,39518,39536,39554,39576,39594,39612,39633,39654,39676,39698,39721,39739,39763,39781,39799,39817,39839,39863,39881,39902,39920,39943,39961,39979,39997,40018,40036,40058,40076,40094,40112,40130,40148,40166,40184,40202,40220,40241,40264,40282,40300,40318,40344,40362,40380,40398,40416,40434,40452,40470,40488,40511,40529,40547,40565,40586,40604,40622,40640,40658,40676,40694,40712,40730,40748,40772,40790,40808,40830,40848,40866,40890,40908,40926,40944,40962,40983,41001,41019,41037,41061,41082,41100,41121,41139,41160,41182,41203,41224,41242,41267,41288,41310,41328,41351,41369,41387,41405,41423,41445,41463,41487,41505,41523,41541,41559,41580,41598,41616,41637,41661,41679,41697,41715,41733,41757,41775,41803,41830,41861,41883,41908,41933,41957,41975,41996,42017,42035,42053,42075,42093,42111,42132,42150,42168,42186,42204,42222,42243,42261,42279,42300,42322,42340,42358,42376,42394,42412,42433,42451,42469,42487,42505,42523,42544,42562,42580,42602,42620,42642,42660,42678,42696,42714,42732,42750,42768,42786,42808,42829,42847,42865,42883,42905,42923,42944,42965,42988,43012,43030,43048,43071,43092,43113,43131,43152,43170,43188,43209,43235,43253,43271,43289,43307,43328,43346,43364,43385,43403,43424,43447,43465,43483,43510,43528,43546,43564,43585,43606,43627,43645,43663,43685,43703,43721,43739,43757,43775,43798,43821,43843,43865,43886,43904,43925,43943,43965,43983,44004,44022,44043,44065,44083,44101,44122,44140,44158,44176,44200,44218,44239,44261,44282,44300,44318,44339,44357,44375,44393,44414,44432,44454,44477,44495,44513,44536,44557,44575,44596,44614,44632,44653,44679,44707,44725,44743,44761,44779,44797,44815,44833,44851,44872,44894,44917,44935,44953,44974,44992,45010,45035,45053,45071,45089,45112,45138,45160,45184,45202,45220,45243,45265,45283,45306,45419,45493,45578,45644,45708,45750,45792,45839,45883,45923,45957,45993,46023,46062,46097,46130,46156,46185,46214,46243,46269,46300,46324,46346,46368,46393,46422,46444,46462,46480,46501,46524,46545,46563,46585,46603,46621,46639,46657,46679,46700,46723,46741,46764,46782,46800,46818,46839,46861,46882,46907,46928,46946,46968,46990,47008,47026,47044,47062,47080,47098,47116,47134,47152,47174,47196,47219,47237,47255,47277,47295,47317,47335,47356,47377,47400,47423,47441,47459],{"intervention":94,"totalTrials":95,"cells":96},"Nicotine Patch",11,{"EARLY_PHASE1":97,"PHASE1":122,"PHASE2":125,"PHASE3":139,"PHASE4":141,"NA":167},{"trials":98,"activeCount":121,"soonestReadout":104},[99,111],{"nctId":100,"briefTitle":101,"status":102,"phases":103,"primaryCompletion":104,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":109},"NCT03059940","Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer","ACTIVE_NOT_RECRUITING",[86],"2026-06-01","2017-06-16",630,[108],"Smoking Cessation",[94,110],"Anti-Smoking Drug",{"nctId":112,"briefTitle":113,"status":102,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":120},"NCT04200534","Centralized Lung Cancer EARly Detection Among Smokers (CLEAR Study)",[86],"2027-02-28","2020-07-31",358,[119,24],"Smoking",[94],2,{"trials":123,"activeCount":124},[],0,{"trials":126,"activeCount":124},[127],{"nctId":128,"briefTitle":129,"status":130,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":138},"NCT02596711","Project Impact 2: A Culturally Tailored Smoking Cessation Intervention for Latino Smokers","COMPLETED",[87,88],"2017-08-22","2015-11-02",26,[136,137],"Tobacco Use Cessation","Cancer Prevention",[94],{"trials":140,"activeCount":124},[],{"trials":142,"activeCount":166,"soonestReadout":161},[143,157],{"nctId":144,"briefTitle":145,"status":130,"phases":146,"primaryCompletion":147,"completion":148,"start":149,"enrollment":150,"conditions":151,"interventions":154},"NCT02271919","Varenicline and Combined NRT for Smoking Cessation",[90],"2025-06-30","2026-04-01","2015-05-14",631,[152,153],"Cigarette Smoker","Tobacco Use Disorder",[155,94,156],"Nicotine Lozenge","Varenicline",{"nctId":158,"briefTitle":159,"status":102,"phases":160,"primaryCompletion":161,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":165},"NCT02162849","Reward Sensitivity and Pharmacotherapy for Smoking Cessation",[90],"2028-02-28","2015-12-14",204,[136],[156,94],1,{"trials":168,"activeCount":121,"soonestReadout":193},[169,179,189,200,209,220],{"nctId":170,"briefTitle":171,"status":130,"phases":172,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":178},"NCT02224391","Smartphone-Delivered Attentional Bias Modification Training in Helping Patients Quit Smoking",[91],"2021-03-15","2016-01-20",311,[177],"Current Every Day Smoker",[94],{"nctId":180,"briefTitle":181,"status":182,"phases":183,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":188},"NCT02302859","Mobile Media-Rich Interactive Guideline System (MMRIGS) Pilot Study","TERMINATED",[91],"2016-03","2015-01",8,[136],[94],{"nctId":190,"briefTitle":191,"status":102,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":199},"NCT01915810","Physical Activity in Promoting Smoking Cessation in African Americans",[91],"2027-01-31","2014-01-29",45,[197,198],"Current Smoker","Healthy Subject",[94],{"nctId":201,"briefTitle":202,"status":203,"phases":204,"primaryCompletion":205,"start":206,"enrollment":124,"conditions":207,"interventions":208},"NCT02029612","An Evidence Based Smoking Cessation Program for Persons Living With HIV\u002FAIDS (Project Legacy)","WITHDRAWN",[91],"2019-04","2014-04",[136],[94],{"nctId":210,"briefTitle":211,"status":130,"phases":212,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":218},"NCT00310141","Computer-Assisted Counseling in Helping African American Smokers Stop Smoking",[91],"2006-08-17","2016-08-30","2002-04-08",462,[24],[219],"Nicotine patch",{"nctId":221,"briefTitle":222,"status":102,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":228},"NCT02697227","Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation",[91],"2027-12-31","2016-08-05",85,[152,153],[94],{"intervention":156,"totalTrials":230,"cells":231},6,{"EARLY_PHASE1":232,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":270,"NA":293},{"trials":233,"activeCount":166,"soonestReadout":238},[234],{"nctId":235,"briefTitle":236,"status":102,"phases":237,"primaryCompletion":238,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":243},"NCT01098955","Smoking Cessation Treatment for Head & Neck Cancer Patients",[86],"2027-09-30","2010-03-24",51,[242,108],"Head and Neck Cancer",[156],{"trials":245,"activeCount":124},[],{"trials":247,"activeCount":124},[],{"trials":249,"activeCount":124},[250,260],{"nctId":251,"briefTitle":252,"status":130,"phases":253,"primaryCompletion":254,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":258},"NCT00507728","Pharmacogenetics, Emotional Reactivity and Smoking",[88,89],"2019-12-18","2005-12-08",646,[153,108],[259,156],"Bupropion",{"nctId":261,"briefTitle":262,"status":130,"phases":263,"primaryCompletion":264,"completion":265,"start":266,"enrollment":267,"conditions":268,"interventions":269},"NCT00943618","Combining Varenicline and Bupropion for Smoking Cessation",[89],"2020-05-31","2021-09-09","2010-05-17",641,[108],[156,259],{"trials":271,"activeCount":121,"soonestReadout":161},[272,276,289],{"nctId":144,"briefTitle":145,"status":130,"phases":273,"primaryCompletion":147,"completion":148,"start":149,"enrollment":150,"conditions":274,"interventions":275},[90],[152,153],[155,94,156],{"nctId":277,"briefTitle":278,"status":279,"phases":280,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":284,"interventions":286},"NCT04604509","Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial","RECRUITING",[90],"2028-12-31","2020-08-04",2010,[285],"Cigarette Smoking-Related Carcinoma",[287,288,156],"Bupropion Hydrochloride Controlled-release","Nicotine Replacement",{"nctId":158,"briefTitle":159,"status":102,"phases":290,"primaryCompletion":161,"completion":161,"start":162,"enrollment":163,"conditions":291,"interventions":292},[90],[136],[156,94],{"trials":294,"activeCount":124},[],{"intervention":288,"totalTrials":296,"cells":297},4,{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":306,"NA":312},{"trials":299,"activeCount":124},[],{"trials":301,"activeCount":124},[],{"trials":303,"activeCount":124},[],{"trials":305,"activeCount":124},[],{"trials":307,"activeCount":166,"soonestReadout":281},[308],{"nctId":277,"briefTitle":278,"status":279,"phases":309,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":310,"interventions":311},[90],[285],[287,288,156],{"trials":313,"activeCount":166,"soonestReadout":340},[314,326,336],{"nctId":315,"briefTitle":316,"status":130,"phases":317,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":323},"NCT02964182","Very Low Nicotine Content Cigarettes and E-Cigarettes in Promoting Smoking Cessation in Daily and Intermittent Cigarette Smokers",[91],"2025-03-04","2017-10-26",213,[285,322],"Tobacco-Related Carcinoma",[324,288,288,325],"Cigarette","Very Low Nicotine Content Cigarette",{"nctId":327,"briefTitle":328,"status":130,"phases":329,"primaryCompletion":330,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":335},"NCT03856515","Gender Differences in Switching From Smoking Regular Cigarettes to E-Cigarettes",[91],"2024-06-24","2026-01-07","2022-06-02",169,[285],[288],{"nctId":337,"briefTitle":338,"status":102,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":345},"NCT05144542","Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer",[91],"2026-10-17","2022-03-07",140,[344],"Lung Carcinoma",[288,288],{"intervention":347,"totalTrials":121,"cells":348},"Hydromorphone",{"EARLY_PHASE1":349,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":384},{"trials":350,"activeCount":124},[351],{"nctId":352,"briefTitle":353,"status":182,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":362},"NCT03579446","Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer",[86],"2023-06-15","2018-11-29",43,[359,360,361],"Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm",[363,347,364,365,366,367],"Hydrocodone","Levorphanol","Morphine","Oxycodone","Oxymorphone",{"trials":369,"activeCount":124},[],{"trials":371,"activeCount":124},[],{"trials":373,"activeCount":124},[],{"trials":375,"activeCount":166,"soonestReadout":224},[376],{"nctId":377,"briefTitle":378,"status":102,"phases":379,"primaryCompletion":224,"completion":224,"start":380,"enrollment":381,"conditions":382,"interventions":383},"NCT04296305","Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain",[90],"2020-09-10",84,[359,360],[347],{"trials":385,"activeCount":124},[],{"intervention":387,"totalTrials":166,"cells":388},"PCV20",{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":397,"NA":409},{"trials":390,"activeCount":124},[],{"trials":392,"activeCount":124},[],{"trials":394,"activeCount":124},[],{"trials":396,"activeCount":124},[],{"trials":398,"activeCount":166,"soonestReadout":403},[399],{"nctId":400,"briefTitle":401,"status":102,"phases":402,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":408},"NCT06049134","Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy",[90],"2026-12-01","2027-12-01","2023-10-06",30,[21],[387],{"trials":410,"activeCount":124},[],{"intervention":287,"totalTrials":166,"cells":412},{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":419,"PHASE4":421,"NA":427},{"trials":414,"activeCount":124},[],{"trials":416,"activeCount":124},[],{"trials":418,"activeCount":124},[],{"trials":420,"activeCount":124},[],{"trials":422,"activeCount":166,"soonestReadout":281},[423],{"nctId":277,"briefTitle":278,"status":279,"phases":424,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":425,"interventions":426},[90],[285],[287,288,156],{"trials":428,"activeCount":124},[],{"intervention":430,"totalTrials":166,"cells":431},"Methylnaltrexone",{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":438,"PHASE4":440,"NA":452},{"trials":433,"activeCount":124},[],{"trials":435,"activeCount":124},[],{"trials":437,"activeCount":124},[],{"trials":439,"activeCount":124},[],{"trials":441,"activeCount":166,"soonestReadout":446},[442],{"nctId":443,"briefTitle":444,"status":279,"phases":445,"primaryCompletion":446,"completion":446,"start":447,"enrollment":448,"conditions":449,"interventions":451},"NCT06162377","Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A \"Window of Opportunity\" Pilot Study.",[90],"2026-12-31","2024-01-10",25,[450],"Head and Neck Squamous Cell Carcinoma",[430],{"trials":453,"activeCount":124},[],{"intervention":455,"totalTrials":166,"cells":456},"Recombinant Human Papillomavirus Nonavalent Vaccine",{"EARLY_PHASE1":457,"PHASE1":459,"PHASE2":461,"PHASE3":463,"PHASE4":465,"NA":477},{"trials":458,"activeCount":124},[],{"trials":460,"activeCount":124},[],{"trials":462,"activeCount":124},[],{"trials":464,"activeCount":124},[],{"trials":466,"activeCount":166,"soonestReadout":471},[467],{"nctId":468,"briefTitle":469,"status":102,"phases":470,"primaryCompletion":471,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":476},"NCT03023631","Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant",[90],"2026-07-31","2017-04-23",48,[475,359],"Allogeneic Hematopoietic Stem Cell Transplant Recipient",[455],{"trials":478,"activeCount":124},[],{"intervention":480,"totalTrials":34,"cells":481},"Venetoclax",{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":585,"PHASE3":1244,"PHASE4":1255,"NA":1257},{"trials":483,"activeCount":124},[],{"trials":485,"activeCount":186,"soonestReadout":504},[486,500,512,521,532,543,555,567,577],{"nctId":487,"briefTitle":488,"status":279,"phases":489,"primaryCompletion":224,"completion":490,"start":491,"enrollment":492,"conditions":493,"interventions":498},"NCT06466395","A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias",[87],"2031-12-31","2025-02-18",22,[494,495,496,497],"Refractory Acute Leukemia","Relapsed Acute Leukemia","Undifferentiated Leukemia","Bi-Phenotypic Leukemia",[480,499],"Hyper-CVAD",{"nctId":501,"briefTitle":502,"status":279,"phases":503,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":509},"NCT05834244","A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)",[87],"2026-06-30","2028-06-30","2023-10-26",32,[36],[510,480,511],"Azacitidine","NK Cells",{"nctId":513,"briefTitle":514,"status":279,"phases":515,"primaryCompletion":281,"completion":281,"start":516,"enrollment":517,"conditions":518,"interventions":519},"NCT06191978","A Phase Ia\u002FIb Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine\u002FCedazuridine (ASTX727) in Pediatric Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia (AML)",[87],"2024-03-07",40,[36],[520,480],"ASTX727",{"nctId":522,"briefTitle":523,"status":203,"phases":524,"primaryCompletion":525,"completion":525,"start":526,"enrollment":124,"conditions":527,"interventions":530},"NCT03884972","Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor",[87],"2020-03-04","2019-06-18",[528,529],"Refractory Chronic Lymphocytic Leukemia","Refractory Small Lymphocytic Lymphoma",[531,480],"Trabectedin",{"nctId":533,"briefTitle":534,"status":102,"phases":535,"primaryCompletion":536,"completion":537,"start":538,"enrollment":539,"conditions":540,"interventions":541},"NCT06445907","Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia",[87],"2027-07-01","2028-07-01","2025-02-12",17,[36],[510,480,542],"Q702",{"nctId":544,"briefTitle":545,"status":546,"phases":547,"primaryCompletion":548,"completion":490,"start":549,"enrollment":550,"conditions":551,"interventions":553},"NCT07513129","Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma","NOT_YET_RECRUITING",[87],"2029-12-31","2026-09-01",18,[552,21],"T-cell Acute Lymphoblastic Leukemia",[480,62,75,554],"Daratumumab",{"nctId":556,"briefTitle":557,"status":279,"phases":558,"primaryCompletion":446,"completion":446,"start":559,"enrollment":560,"conditions":561,"interventions":562},"NCT05010772","Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission",[87],"2021-10-25",125,[36],[563,564,565,566,480],"Decitabine and Cedazuridine","Enasidenib","Gilteritinib","Ivosidenib",{"nctId":568,"briefTitle":569,"status":279,"phases":570,"primaryCompletion":281,"completion":571,"start":572,"enrollment":492,"conditions":573,"interventions":575},"NCT06397027","A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias",[87],"2030-12-31","2024-12-27",[494,574],"Pediatric Relapsed",[576,480,510],"Ziftomenib",{"nctId":578,"briefTitle":579,"status":279,"phases":580,"primaryCompletion":281,"completion":571,"start":581,"enrollment":492,"conditions":582,"interventions":583},"NCT06448013","A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia",[87],"2025-03-07",[36],[480,584,576],"Gemtuzumab",{"trials":586,"activeCount":1243,"soonestReadout":1238},[587,600,614,622,635,657,670,684,697,706,719,729,750,759,768,776,793,811,820,828,838,856,864,875,884,895,904,918,927,935,943,952,965,975,986,995,1006,1017,1029,1039,1051,1061,1072,1084,1095,1104,1115,1126,1134,1147,1160,1169,1179,1189,1199,1207,1217,1225,1234],{"nctId":588,"briefTitle":589,"status":546,"phases":590,"primaryCompletion":591,"completion":592,"start":104,"enrollment":593,"conditions":594,"interventions":597},"NCT07311746","Phase Ib\u002FII Trial of Cladribine\u002FRuxolitinib\u002FVenetoclax in Patients With Relapsed\u002FRefractory T-cell Prolymphocytic Leukemia",[87,88],"2029-01-31","2031-01-31",36,[595,596],"T-cell Prolymphocytic Leukemia","Refractory T-Cell Prolymphocytic Leukemia",[598,599,480],"Ruxolitinib","Cladribine",{"nctId":601,"briefTitle":602,"status":279,"phases":603,"primaryCompletion":604,"completion":604,"start":605,"enrollment":606,"conditions":607,"interventions":611},"NCT03661307","Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",[87,88],"2028-01-01","2018-10-31",73,[36,30,608,609,610],"Recurrent Acute Myeloid Leukemia","Recurrent Myelodysplastic Syndrome","Refractory Acute Myeloid Leukemia",[612,613,480],"Decitabine","Quizartinib",{"nctId":615,"briefTitle":616,"status":279,"phases":617,"primaryCompletion":618,"completion":618,"start":619,"enrollment":381,"conditions":620,"interventions":621},"NCT04774393","Decitabine\u002FCedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",[87,88],"2027-11-29","2021-05-24",[36,608,610],[563,564,566,480],{"nctId":623,"briefTitle":624,"status":182,"phases":625,"primaryCompletion":626,"completion":626,"start":627,"enrollment":628,"conditions":629,"interventions":633},"NCT04874194","Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1",[87,88],"2024-09-16","2021-12-17",24,[359,630,608,609,631,610,632],"Recurrent Acute Biphenotypic Leukemia","Refractory Acute Biphenotypic Leukemia","Refractory Myelodysplastic Syndrome",[634,480],"Omacetaxine Mepesuccinate",{"nctId":636,"briefTitle":637,"status":279,"phases":638,"primaryCompletion":639,"completion":639,"start":640,"enrollment":641,"conditions":642,"interventions":653},"NCT02115295","Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia",[88],"2030-05-31","2014-05-19",508,[643,36,644,645,646,647,30,648,608,649,610,650,651,652],"Acute Biphenotypic Leukemia","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Blasts 10 Percent or More of Bone Marrow Nucleated Cells","Blasts 10 Percent or More of Peripheral Blood White Cells","de Novo Myelodysplastic Syndrome","Previously Treated Myelodysplastic Syndrome","Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Secondary Acute Myeloid Leukemia","Untreated Adult Acute Myeloid Leukemia",[599,654,565,655,656,480],"Cytarabine","Idarubicin","Midostaurin",{"nctId":658,"briefTitle":659,"status":279,"phases":660,"primaryCompletion":661,"completion":661,"start":662,"enrollment":663,"conditions":664,"interventions":667},"NCT04169737","Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[88],"2026-07-09","2020-07-29",168,[665,666,528,529],"Recurrent Chronic Lymphocytic Leukemia","Recurrent Small Lymphocytic Lymphoma",[668,669,480],"Acalabrutinib","Obinutuzumab",{"nctId":671,"briefTitle":672,"status":102,"phases":673,"primaryCompletion":674,"completion":674,"start":675,"enrollment":676,"conditions":677,"interventions":683},"NCT04062266","AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission",[88],"2030-10-31","2019-09-13",50,[678,679,680,36,681,682],"Acute Myeloid Leukemia in Remission","FLT3 Gene Mutation","Hematologic and Lymphocytic Disorder","Minimal Residual Disease Persistence","Therapy-Related Acute Myeloid Leukemia",[510,480],{"nctId":685,"briefTitle":686,"status":130,"phases":687,"primaryCompletion":688,"completion":688,"start":689,"enrollment":676,"conditions":690,"interventions":691},"NCT03390296","OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia",[87,88],"2022-02-04","2017-12-27",[608,610],[692,693,510,694,695,696,480,510],"Anti-OX40 Agonist Monoclonal Antibody PF-04518600","Avelumab","Gemtuzumab Ozogamicin","Glasdegib","Glasdegib Maleate",{"nctId":698,"briefTitle":699,"status":279,"phases":700,"primaryCompletion":548,"completion":490,"start":701,"enrollment":492,"conditions":702,"interventions":704},"NCT06561074","A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed\u002FRefractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)",[88],"2025-09-25",[552,703],"T-Cell Lymphoblastic Lymphoma",[612,480,705],"Calaspargase pegol-mknl",{"nctId":707,"briefTitle":708,"status":102,"phases":709,"primaryCompletion":115,"completion":115,"start":710,"enrollment":676,"conditions":711,"interventions":717},"NCT02846623","Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome",[88],"2017-01-31",[712,713,714,715,716],"Chronic Lymphocytic Leukemia","Recurrent Transformed Chronic Lymphocytic Leukemia","Refractory Transformed Chronic Lymphocytic Leukemia","Richter Syndrome","Small Lymphocytic Lymphoma",[718,669,480],"Atezolizumab",{"nctId":720,"briefTitle":721,"status":279,"phases":722,"primaryCompletion":238,"completion":238,"start":723,"enrollment":724,"conditions":725,"interventions":728},"NCT03471260","Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies",[87,88],"2018-03-19",96,[36,726,30,727,608,610],"Hematopoietic and Lymphoid System Neoplasm","Myeloproliferative Neoplasm",[510,566,480],{"nctId":730,"briefTitle":731,"status":102,"phases":732,"primaryCompletion":193,"completion":193,"start":733,"enrollment":517,"conditions":734,"interventions":748},"NCT03862157","Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",[87,88],"2019-02-27",[36,735,736,737,738,739,30,740,741,742,727,743,744,745,746,747],"Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative","Chronic Eosinophilic Leukemia, Not Otherwise Specified","Chronic Myelomonocytic Leukemia","Chronic Neutrophilic Leukemia","Essential Thrombocythemia","Myelodysplastic\u002FMyeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis","Myelodysplastic\u002FMyeloproliferative Neoplasm, Unclassifiable","Myeloid Neoplasm","Myeloproliferative Neoplasm, Unclassifiable","Overt Primary Myelofibrosis","Polycythemia Vera","Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase","Prefibrotic\u002FEarly Primary Myelofibrosis",[510,749,480],"Pevonedistat",{"nctId":751,"briefTitle":752,"status":182,"phases":753,"primaryCompletion":754,"completion":754,"start":755,"enrollment":186,"conditions":756,"interventions":758},"NCT03735875","Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia",[87,88],"2023-07-26","2019-01-25",[757,608,494],"Acute Myeloid Leukemia With FLT3\u002FITD Mutation",[613,480],{"nctId":760,"briefTitle":761,"status":102,"phases":762,"primaryCompletion":536,"completion":536,"start":763,"enrollment":764,"conditions":765,"interventions":766},"NCT02756897","Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia",[88],"2016-07-07",234,[712,665,666,528,529,716],[767,480],"Ibrutinib",{"nctId":769,"briefTitle":770,"status":102,"phases":771,"primaryCompletion":772,"completion":772,"start":773,"enrollment":226,"conditions":774,"interventions":775},"NCT04746235","Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia",[88],"2026-10-31","2021-02-22",[36,608,610],[563,480],{"nctId":777,"briefTitle":778,"status":102,"phases":779,"primaryCompletion":780,"completion":780,"start":781,"enrollment":507,"conditions":782,"interventions":792},"NCT03946878","Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",[88],"2028-02-08","2019-08-13",[783,784,785,786,787,788,789,790,791],"Blastoid Variant Mantle Cell Lymphoma","CCND1 Protein Overexpression","CD20 Positive","CD5 Positive","FCER2 Negative","Pleomorphic Variant Mantle Cell Lymphoma","Recurrent Mantle Cell Lymphoma","Refractory Mantle Cell Lymphoma","t(11;14)(q13;q32)",[668,480],{"nctId":794,"briefTitle":795,"status":279,"phases":796,"primaryCompletion":772,"completion":772,"start":797,"enrollment":798,"conditions":799,"interventions":802},"NCT00501826","Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",[88],"2007-07-11",160,[800,801],"T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma",[803,654,62,804,805,806,807,808,809,480,810],"Cyclophosphamide","Doxorubicin Hydrochloride","Mercaptopurine","Methotrexate","Nelarabine","Pegaspargase","Prednisone","Vincristine Sulfate",{"nctId":812,"briefTitle":813,"status":279,"phases":814,"primaryCompletion":815,"completion":815,"start":816,"enrollment":817,"conditions":818,"interventions":819},"NCT03586609","Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia",[88],"2027-04-30","2018-10-25",145,[36],[510,599,654,480],{"nctId":821,"briefTitle":822,"status":279,"phases":823,"primaryCompletion":403,"completion":403,"start":824,"enrollment":357,"conditions":825,"interventions":826},"NCT05360160","A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine\u002FCedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)",[87,88],"2022-10-14",[36],[827,480,520],"SNDX-5613",{"nctId":829,"briefTitle":830,"status":182,"phases":831,"primaryCompletion":832,"completion":832,"start":833,"enrollment":834,"conditions":835,"interventions":836},"NCT03634228","Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia",[87,88],"2022-04-03","2018-12-17",16,[36,608,610],[654,837,480],"Milademetan Tosylate",{"nctId":839,"briefTitle":840,"status":182,"phases":841,"primaryCompletion":842,"completion":842,"start":843,"enrollment":844,"conditions":845,"interventions":855},"NCT03404193","Venetoclax and Decitabine in Treating Participants With Relapsed\u002FRefractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome",[88],"2026-03-05","2018-01-18",235,[36,846,847,737,848,30,630,608,849,850,851,610,852,853,854],"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Blastic Plasmacytoid Dendritic Cell Neoplasm","Mixed Phenotype Acute Leukemia","Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","Recurrent Chronic Myelomonocytic Leukemia","Recurrent Mixed Phenotype Acute Leukemia","Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm","Refractory Chronic Myelomonocytic Leukemia","Refractory Mixed Phenotype Acute Leukemia",[612,480],{"nctId":857,"briefTitle":858,"status":279,"phases":859,"primaryCompletion":860,"completion":860,"start":105,"enrollment":861,"conditions":862,"interventions":863},"NCT03128879","Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL",[88],"2027-05-31",90,[712],[767,480,668],{"nctId":865,"briefTitle":866,"status":130,"phases":867,"primaryCompletion":868,"completion":869,"start":870,"enrollment":871,"conditions":872,"interventions":873},"NCT04487106","Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome",[88],"2023-02-09","2024-01-25","2020-07-21",21,[608,850,609,610,853,632],[510,874,480],"Trametinib",{"nctId":876,"briefTitle":877,"status":182,"phases":878,"primaryCompletion":879,"completion":879,"start":880,"enrollment":240,"conditions":881,"interventions":883},"NCT04160052","Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome",[87,88],"2026-02-03","2019-10-01",[737,30,609,632,882],"Therapy-Related Myelodysplastic Syndrome",[510,480],{"nctId":885,"briefTitle":886,"status":102,"phases":887,"primaryCompletion":115,"completion":888,"start":889,"enrollment":676,"conditions":890,"interventions":892},"NCT06522386","GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma",[88],"2029-02-28","2025-01-30",[891],"Mantle Cell Lymphoma",[893,894,480],"Pirtobrutinib","Rituximab",{"nctId":896,"briefTitle":897,"status":102,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":902,"interventions":903},"NCT04655755","Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",[87,88],"2026-07-20","2021-01-19",52,[737,30],[563,480],{"nctId":905,"briefTitle":906,"status":182,"phases":907,"primaryCompletion":908,"completion":908,"start":909,"enrollment":910,"conditions":911,"interventions":916},"NCT03576547","Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia",[87,88],"2024-06-19","2018-06-26",9,[644,912,913,649,914,650,915],"Philadelphia Chromosome Positive","Recurrent Acute Lymphoblastic Leukemia","Refractory Acute Lymphoblastic Leukemia","t(9;22)",[62,917,894,480],"Ponatinib Hydrochloride",{"nctId":919,"briefTitle":920,"status":279,"phases":921,"primaryCompletion":922,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":926},"NCT05010122","ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[87,88],"2028-01-30","2021-07-08",42,[36,30,608,610],[563,565,480],{"nctId":928,"briefTitle":929,"status":102,"phases":930,"primaryCompletion":931,"completion":931,"start":932,"enrollment":240,"conditions":933,"interventions":934},"NCT03710772","Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",[88],"2027-03-22","2019-05-01",[891],[803,654,62,804,767,806,894,480,810],{"nctId":936,"briefTitle":937,"status":279,"phases":938,"primaryCompletion":446,"completion":446,"start":939,"enrollment":901,"conditions":940,"interventions":941},"NCT03629171","Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia",[88],"2018-10-29",[608,610],[942,480],"Liposome-encapsulated Daunorubicin-Cytarabine",{"nctId":944,"briefTitle":945,"status":203,"phases":946,"primaryCompletion":947,"completion":947,"start":948,"enrollment":124,"conditions":949,"interventions":950},"NCT06085638","Phase I\u002FII Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia",[87,88],"2023-10-20","2023-09-14",[737],[510,951,480],"Tamibarotene",{"nctId":953,"briefTitle":954,"status":279,"phases":955,"primaryCompletion":956,"completion":957,"start":958,"enrollment":959,"conditions":960,"interventions":962},"NCT06445959","Phase 1b\u002F2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib",[87,88],"2027-06-30","2029-06-30","2024-08-29",78,[961],"Mutant IDH1 Inhibitor Olutasidenib",[963,480,612,964],"Olutasidenib","Decitabine\u002Fcedazuridine",{"nctId":966,"briefTitle":967,"status":182,"phases":968,"primaryCompletion":969,"completion":969,"start":970,"enrollment":971,"conditions":972,"interventions":973},"NCT04435691","Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia",[87,88],"2025-03-25","2020-07-28",110,[36,608,610],[510,974,480],"Magrolimab",{"nctId":976,"briefTitle":977,"status":279,"phases":978,"primaryCompletion":404,"completion":979,"start":980,"enrollment":517,"conditions":981,"interventions":984},"NCT06548230","A Phase 1B\u002F2A Trial of NADUNOLIMAB in Combination With Azacitidine (With\u002FWithout Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)",[87,88],"2029-12-01","2025-03-05",[982,983],"Myelodysplastic Syndrome(MDS)","Acute Myelogenous Leukemia (AML)",[985,510,480],"Nadunolimab",{"nctId":987,"briefTitle":988,"status":203,"phases":989,"primaryCompletion":990,"completion":990,"start":991,"enrollment":124,"conditions":992,"interventions":993},"NCT04493099","Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML",[87,88],"2020-10-12","2020-10",[608,610],[994,612,480],"Alvocidib Hydrochloride",{"nctId":996,"briefTitle":997,"status":102,"phases":998,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":1002,"interventions":1003},"NCT02250937","Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome",[88],"2027-10-31","2014-10-27",116,[36,30],[1004,599,1005,480],"Busulfan","Fludarabine Phosphate",{"nctId":1007,"briefTitle":1008,"status":279,"phases":1009,"primaryCompletion":446,"completion":446,"start":1010,"enrollment":517,"conditions":1011,"interventions":1012},"NCT04216524","Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm",[88],"2020-05-29",[847],[803,654,62,1013,805,806,1014,809,894,1015,480,1016],"Doxorubicin","Methylprednisolone","Tagraxofusp-erzs","Vincristine",{"nctId":1018,"briefTitle":1019,"status":102,"phases":1020,"primaryCompletion":1021,"completion":1021,"start":1022,"enrollment":1023,"conditions":1024,"interventions":1027},"NCT02689440","Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia",[88],"2040-12-31","2016-02-19",155,[1025,1026],"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia",[1028,480],"Dasatinib",{"nctId":1030,"briefTitle":1031,"status":279,"phases":1032,"primaryCompletion":224,"completion":224,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1038},"NCT05365035","A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts",[88],"2022-09-23",60,[1036,1037],"Myelodysplastic Syndromes","Myeloproliferative Chronic Myelomonocytic Leukemia",[599,654,480,510],{"nctId":1040,"briefTitle":1041,"status":130,"phases":1042,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":1045,"conditions":1046,"interventions":1048},"NCT02397720","Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory\u002FRelapsed or Newly Diagnosed Acute Myeloid Leukemia",[88],"2023-10-09","2015-04-07",150,[1047,643,846,737,30,608,610,651,682],"Acute Bilineal Leukemia",[510,1049,480,1050],"Ipilimumab","Nivolumab",{"nctId":1052,"briefTitle":1053,"status":279,"phases":1054,"primaryCompletion":1055,"completion":1056,"start":1057,"enrollment":517,"conditions":1058,"interventions":1060},"NCT06967610","Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL).",[88],"2031-06-01","2033-06-01","2025-07-15",[712,1059],"Small Lymphocytic Leukemia (SLL)",[893,480,669],{"nctId":1062,"briefTitle":1063,"status":279,"phases":1064,"primaryCompletion":238,"completion":238,"start":1065,"enrollment":1001,"conditions":1066,"interventions":1068},"NCT03214562","Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia",[87,88],"2017-09-26",[1067,608,610],"High Risk Myelodysplastic Syndrome",[654,1069,1070,655,1071,480],"Filgrastim","Fludarabine","Pegfilgrastim",{"nctId":1073,"briefTitle":1074,"status":546,"phases":1075,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":406,"conditions":1079,"interventions":1081},"NCT07604233","Phase 1\u002F2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML",[87,88],"2031-06-03","2033-06-03","2026-11-30",[1080],"Myeloid Leukemia",[1070,654,655,1069,480,1082,1083],"Asciminib","Blinatumomab",{"nctId":1085,"briefTitle":1086,"status":279,"phases":1087,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":1091,"interventions":1094},"NCT04140487","Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent\u002FRefractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm",[87,88],"2028-09-01","2019-12-17",97,[608,850,1092,610,853,1093],"Recurrent Myelodysplastic\u002FMyeloproliferative Neoplasm","Refractory Myelodysplastic\u002FMyeloproliferative Neoplasm",[510,565,480],{"nctId":1096,"briefTitle":1097,"status":279,"phases":1098,"primaryCompletion":1078,"completion":1078,"start":1099,"enrollment":1100,"conditions":1101,"interventions":1102},"NCT02392572","ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome",[87,88],"2015-11-03",120,[913,608,609,914,610,632],[1103,480],"Akt\u002FERK Inhibitor ONC201",{"nctId":1105,"briefTitle":1106,"status":182,"phases":1107,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":539,"conditions":1110,"interventions":1111},"NCT04752163","DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia",[87,88],"2023-11-08","2021-03-25",[359,913,608,850,609,914,610,853,632],[1112,510,803,654,62,1069,1113,1114,806,809,894,480,1016],"DS-1594b","Leucovorin","Mesna",{"nctId":1116,"briefTitle":1117,"status":182,"phases":1118,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":296,"conditions":1121,"interventions":1123},"NCT05268003","A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia",[88],"2026-04-21","2022-06-07",[1122,15],"Acute Lymphoblastic Leukemia",[1124,480,1125],"Ponatinib","Mini-hyper CVD",{"nctId":1127,"briefTitle":1128,"status":102,"phases":1129,"primaryCompletion":860,"completion":860,"start":1130,"enrollment":1131,"conditions":1132,"interventions":1133},"NCT04975919","Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",[88],"2021-09-29",20,[630,608,631,610],[563,480],{"nctId":1135,"briefTitle":1136,"status":182,"phases":1137,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":1140,"conditions":1141,"interventions":1146},"NCT03808610","Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia",[87,88],"2026-05-05","2019-04-03",53,[1142,1143,1144,1145],"Recurrent B Acute Lymphoblastic Leukemia","Recurrent T Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory T Acute Lymphoblastic Leukemia",[803,654,62,806,807,808,809,894,480,1016],{"nctId":1148,"briefTitle":1149,"status":279,"phases":1150,"primaryCompletion":1151,"completion":1152,"start":1153,"enrollment":1154,"conditions":1155,"interventions":1159},"NCT07032727","Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations",[88],"2027-06-01","2029-06-01","2025-09-12",68,[1156,1157,1158],"Targeted Therapy","IDH1-Mutated Malignancies","Mutations",[963,599,480,565,598,654],{"nctId":1161,"briefTitle":1162,"status":203,"phases":1163,"primaryCompletion":1164,"completion":1164,"start":1165,"enrollment":124,"conditions":1166,"interventions":1167},"NCT04990778","Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma",[88],"2023-03-24","2021-11-30",[789,790],[1168,480],"Eprenetapopt",{"nctId":1170,"briefTitle":1171,"status":279,"phases":1172,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1034,"conditions":1175,"interventions":1176},"NCT05536349","Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)",[88],"2028-04-25","2022-12-20",[15],[893,669,480,1177,1178],"Valacyclovir","Allopurinol",{"nctId":1180,"briefTitle":1181,"status":279,"phases":1182,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":406,"conditions":1185,"interventions":1188},"NCT05529069","Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients",[88],"2027-04-28","2023-01-25",[891,1186,1187],"Non Hodgkin Lymphoma","Hematologic Malignancy",[893,480],{"nctId":1190,"briefTitle":1191,"status":279,"phases":1192,"primaryCompletion":1193,"completion":1194,"start":1195,"enrollment":186,"conditions":1196,"interventions":1197},"NCT06284486","A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib",[87,88],"2026-12-30","2028-12-30","2024-09-23",[36],[480,1198],"Revumenib",{"nctId":1200,"briefTitle":1201,"status":102,"phases":1202,"primaryCompletion":1078,"completion":1078,"start":1203,"enrollment":1131,"conditions":1204,"interventions":1206},"NCT04188405","Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia",[88],"2020-05-17",[1205,36,644,608,649,610,650],"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",[612,1124,480],{"nctId":1208,"briefTitle":1209,"status":182,"phases":1210,"primaryCompletion":1211,"completion":1211,"start":1212,"enrollment":121,"conditions":1213,"interventions":1215},"NCT05464836","Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed\u002FRefractory T-ALL or T-LBL",[88],"2024-08-12","2023-04-06",[1214,15],"Leukemia, Lymphoblastic",[1216,480],"CB-103",{"nctId":1218,"briefTitle":1219,"status":102,"phases":1220,"primaryCompletion":446,"completion":446,"start":1221,"enrollment":1222,"conditions":1223,"interventions":1224},"NCT04128501","Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting",[88],"2020-05-05",100,[1047,643,36,848,800,682],[510,480],{"nctId":1226,"briefTitle":1227,"status":182,"phases":1228,"primaryCompletion":1229,"completion":1229,"start":1230,"enrollment":1231,"conditions":1232,"interventions":1233},"NCT05317936","Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL) Treated With Venetoclax",[87,88],"2025-10-06","2022-11-16",3,[712,716],[893,480],{"nctId":1235,"briefTitle":1236,"status":102,"phases":1237,"primaryCompletion":1238,"completion":1238,"start":1239,"enrollment":1240,"conditions":1241,"interventions":1242},"NCT04550442","Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",[87,88],"2026-03-31","2020-09-04",34,[850,609,853,632,882],[510,480],41,{"trials":1245,"activeCount":166,"soonestReadout":224},[1246],{"nctId":1247,"briefTitle":1248,"status":279,"phases":1249,"primaryCompletion":224,"completion":224,"start":1250,"enrollment":1251,"conditions":1252,"interventions":1253},"NCT04708054","Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS",[88,89],"2021-10-21",324,[36,737,30],[1004,599,1005,1254,480],"Thiotepa",{"trials":1256,"activeCount":124},[],{"trials":1258,"activeCount":124},[],{"intervention":1050,"totalTrials":1260,"cells":1261},66,{"EARLY_PHASE1":1262,"PHASE1":1276,"PHASE2":1474,"PHASE3":2160,"PHASE4":2172,"NA":2174},{"trials":1263,"activeCount":166,"soonestReadout":446},[1264],{"nctId":1265,"briefTitle":1266,"status":102,"phases":1267,"primaryCompletion":446,"completion":446,"start":1268,"enrollment":1269,"conditions":1270,"interventions":1274},"NCT02210117","Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery",[86],"2014-11-25",104,[1271,1272,1273],"Clear Cell Renal Cell Carcinoma","Metastatic Kidney Carcinoma","Stage IV Renal Cell Cancer AJCC v7",[1275,1049,1050],"Bevacizumab",{"trials":1277,"activeCount":230,"soonestReadout":1299},[1278,1286,1295,1303,1321,1336,1380,1393,1403,1413,1422,1432],{"nctId":1279,"briefTitle":1280,"status":203,"phases":1281,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":124,"conditions":1284,"interventions":1285},"NCT04781855","Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation",[87],"2025-02-21","2022-07-14",[359,665,666,528,529,715],[767,1049,1050],{"nctId":1287,"briefTitle":1288,"status":182,"phases":1289,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":166,"conditions":1292,"interventions":1294},"NCT03106610","Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy",[87],"2018-05-16","2017-07-07",[1293],"Bladder Cancer",[1050],{"nctId":1296,"briefTitle":1297,"status":102,"phases":1298,"primaryCompletion":1299,"completion":1299,"start":1300,"enrollment":550,"conditions":1301,"interventions":1302},"NCT05327270","Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions",[87],"2027-02-02","2022-09-13",[242],[1050],{"nctId":1304,"briefTitle":1305,"status":279,"phases":1306,"primaryCompletion":1151,"completion":1151,"start":1307,"enrollment":1308,"conditions":1309,"interventions":1320},"NCT03025256","Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease",[87],"2018-05-02",75,[1310,1311,1312,1313,1314,1315,1316,1317,1318,1319],"Acral Lentiginous Melanoma","Central Nervous System Melanoma","Clinical Stage IV Cutaneous Melanoma AJCC v8","Leptomeningeal Neoplasm","Melanocytoma","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Melanoma","Metastatic Mucosal Melanoma","Metastatic Uveal Melanoma","Stage IV Lung Cancer AJCC v8",[1050],{"nctId":1322,"briefTitle":1323,"status":279,"phases":1324,"primaryCompletion":1325,"completion":1326,"start":1327,"enrollment":1328,"conditions":1329,"interventions":1334},"NCT07401875","A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)",[87],"2027-11-30","2029-11-30","2026-03-24",35,[1330,1331,1332,1333],"Phase 1b","HC-7366","SHARK","Kidney Cancer",[1050,1331,1335],"ipilimumab",{"nctId":1337,"briefTitle":1338,"status":182,"phases":1339,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":1342,"interventions":1367},"NCT02419495","Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies",[87],"2015-06-26",221,[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],"Advanced Malignant Solid Neoplasm","Clinical Stage III Cutaneous Melanoma AJCC v8","Fallopian Tube Carcinoma","Metastatic Renal Cell Carcinoma","Ovarian Carcinoma","Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Primary Peritoneal Carcinoma","Stage III Lung Cancer AJCC v8","Stage III Renal Cell Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8","Triple-Negative Breast Carcinoma","Unresectable Lung Non-Small Cell Carcinoma","Unresectable Melanoma","Unresectable Renal Cell Carcinoma",[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],"Capecitabine","Carboplatin","Eribulin","Fluorouracil","Irinotecan Hydrochloride","Leucovorin Calcium","Olaparib","Oxaliplatin","Paclitaxel","Pemetrexed","Selinexor","Topotecan",{"nctId":1381,"briefTitle":1382,"status":102,"phases":1383,"primaryCompletion":224,"completion":224,"start":675,"enrollment":871,"conditions":1384,"interventions":1392},"NCT04013542","Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer",[87],[1385,1386,1387,1388,1389,1390,1391,1355,1357,1358,1359,1364],"ALK Gene Rearrangement","EGFR Gene Mutation","Locally Advanced Lung Non-Small Cell Carcinoma","Lung Non-Small Cell Carcinoma","Stage II Lung Cancer AJCC v8","Stage IIA Lung Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8",[1049,1050],{"nctId":1394,"briefTitle":1395,"status":203,"phases":1396,"primaryCompletion":991,"completion":991,"start":1397,"enrollment":124,"conditions":1398,"interventions":1401},"NCT03283046","Study of Lenalidomide\u002FDexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma",[87],"2017-10",[1399,1400],"Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic","Multiple Myeloma",[1050,1402,62,1049],"Lenalidomide",{"nctId":1404,"briefTitle":1405,"status":130,"phases":1406,"primaryCompletion":1407,"completion":1407,"start":1408,"enrollment":1409,"conditions":1410,"interventions":1412},"NCT03600155","Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome",[87],"2024-12-02","2018-10-11",29,[1411,30,608,610],"Allogeneic Hematopoietic Stem Cell Transplantation Recipient",[1049,1050],{"nctId":1414,"briefTitle":1415,"status":546,"phases":1416,"primaryCompletion":1417,"completion":1418,"start":1238,"enrollment":834,"conditions":1419,"interventions":1420},"NCT07187869","Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study",[87],"2027-04-07","2029-04-07",[1271],[1421,1050],"Cabozantinib",{"nctId":1423,"briefTitle":1424,"status":546,"phases":1425,"primaryCompletion":490,"completion":1426,"start":1427,"enrollment":550,"conditions":1428,"interventions":1430},"NCT07444619","A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas",[87],"2033-12-31","2026-08-31",[1429],"Soft Tissue Sarcomas",[1431,531,1049,1050],"Pazopanib",{"nctId":1433,"briefTitle":1434,"status":130,"phases":1435,"primaryCompletion":1436,"completion":1436,"start":1437,"enrollment":134,"conditions":1438,"interventions":1473},"NCT03508570","Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis",[87],"2024-11-11","2018-09-21",[1439,1440,1441,1442,1443,1444,1445,1446,1447,1448,1449,1450,1451,1452,1453,1454,1455,1456,1457,1458,1459,1460,1461,1462,1463,1464,1465,1466,1467,1468,1469,1470,1471,1472],"Malignant Peritoneal Neoplasm","Malignant Retroperitoneal Neoplasm","Metastatic Cervical Carcinoma","Metastatic Endometrial Carcinoma","Metastatic Fallopian Tube Carcinoma","Metastatic Malignant Female Reproductive System Neoplasm","Metastatic Ovarian Carcinoma","Metastatic Primary Peritoneal Carcinoma","Peritoneal Carcinomatosis","Platinum-Refractory Fallopian Tube Carcinoma","Platinum-Refractory Malignant Female Reproductive System Neoplasm","Platinum-Refractory Ovarian Carcinoma","Platinum-Refractory Primary Peritoneal Carcinoma","Platinum-Resistant Fallopian Tube Carcinoma","Platinum-Resistant Malignant Female Reproductive System Neoplasm","Platinum-Resistant Ovarian Carcinoma","Platinum-Resistant Primary Peritoneal Carcinoma","Recurrent Cervical Carcinoma","Recurrent Endometrial Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Malignant Female Reproductive System Neoplasm","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Stage IV Fallopian Tube Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Primary Peritoneal Cancer AJCC v8","Stage IVA Fallopian Tube Cancer AJCC v8","Stage IVA Ovarian Cancer AJCC v8","Stage IVA Primary Peritoneal Cancer AJCC v8","Stage IVB Cervical Cancer AJCC v8","Stage IVB Fallopian Tube Cancer AJCC v8","Stage IVB Ovarian Cancer AJCC v8","Stage IVB Primary Peritoneal Cancer AJCC v8","Stage IVB Uterine Corpus Cancer AJCC v8",[1049,1050],{"trials":1475,"activeCount":2159,"soonestReadout":1527},[1476,1490,1501,1514,1523,1533,1553,1563,1579,1602,1623,1658,1685,1694,1711,1721,1731,1741,1751,1761,1788,1821,1830,1840,1850,1859,1870,1882,1892,1917,1927,1935,1946,1953,1966,1970,1979,1989,1998,2012,2030,2039,2057,2066,2079,2092,2100,2110,2117,2126,2137,2148],{"nctId":1477,"briefTitle":1478,"status":1479,"phases":1480,"primaryCompletion":537,"completion":1481,"start":1482,"enrollment":1483,"conditions":1484,"interventions":1487},"NCT07011550","Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine\u002FTipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer","SUSPENDED",[88],"2030-07-01","2025-08-15",7,[1485,1486,1050,1275],"Microsatellite-stable Colorectal Cancer","Standard of Care",[1050,1275,1488,1489],"BMS-986340","Trifluridine + Tipiracil",{"nctId":1491,"briefTitle":1492,"status":182,"phases":1493,"primaryCompletion":1494,"completion":1494,"start":1495,"enrollment":1496,"conditions":1497,"interventions":1500},"NCT03274258","Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma",[88],"2025-11-21","2017-12-13",10,[1498,1499,1356,1360],"Kidney Medullary Carcinoma","Loss of INI 1 Protein Expression",[1049,1050],{"nctId":1502,"briefTitle":1503,"status":102,"phases":1504,"primaryCompletion":999,"completion":999,"start":1505,"enrollment":507,"conditions":1506,"interventions":1513},"NCT03307616","Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery",[88],"2017-10-04",[1507,1508,1509,1510,1511,1512],"Dedifferentiated Liposarcoma","Recurrent Dedifferentiated Liposarcoma","Recurrent Undifferentiated Pleomorphic Sarcoma","Resectable Dedifferentiated Liposarcoma","Resectable Undifferentiated Pleomorphic Sarcoma","Undifferentiated Pleomorphic Sarcoma",[1049,1050],{"nctId":1515,"briefTitle":1516,"status":279,"phases":1517,"primaryCompletion":224,"completion":224,"start":1518,"enrollment":1131,"conditions":1519,"interventions":1522},"NCT05048212","A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases",[88],"2022-09-20",[1520,1521],"Brain Metastases","Renal Cell Carcinoma",[1050,1049,1421],{"nctId":1524,"briefTitle":1525,"status":102,"phases":1526,"primaryCompletion":1527,"completion":1528,"start":1164,"enrollment":1131,"conditions":1529,"interventions":1531},"NCT05715216","EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer",[88],"2025-04-30","2026-02-08",[1530],"Ovarian Cancer",[1050,1532],"Etigilimab",{"nctId":1534,"briefTitle":1535,"status":130,"phases":1536,"primaryCompletion":1537,"completion":1537,"start":1538,"enrollment":1140,"conditions":1539,"interventions":1551},"NCT02519322","Neoadjuvant and Adjuvant Checkpoint Blockade",[88],"2023-01-26","2016-02-02",[1540,1541,1542,1543,1544,1545,1546,1547,1548,1549,1550],"Cutaneous Melanoma","Mucosal Melanoma","Ocular Melanoma","Stage III Acral Lentiginous Melanoma AJCC v7","Stage IIIB Cutaneous Melanoma AJCC v7","Stage IIIB Uveal Melanoma AJCC v7","Stage IIIC Cutaneous Melanoma AJCC v7","Stage IIIC Uveal Melanoma AJCC v7","Stage IV Acral Lentiginous Melanoma AJCC v6 and v7","Stage IV Cutaneous Melanoma AJCC v6 and v7","Stage IV Uveal Melanoma AJCC v7",[1049,1050,1552],"Relatlimab",{"nctId":1554,"briefTitle":1555,"status":130,"phases":1556,"primaryCompletion":1557,"completion":1557,"start":1558,"enrollment":1559,"conditions":1560,"interventions":1561},"NCT02464657","Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)",[87,88],"2020-05-07","2015-07",44,[15,36,30],[1050,655,654,1562,62],"Solu-medrol",{"nctId":1564,"briefTitle":1565,"status":279,"phases":1566,"primaryCompletion":161,"completion":161,"start":1567,"enrollment":1568,"conditions":1569,"interventions":1577},"NCT04380545","Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer",[87,88],"2021-01-13",15,[1570,1571,1572,1573,1574,1575,1576],"Stage III Hepatocellular Carcinoma AJCC v8","Stage IIIA Hepatocellular Carcinoma AJCC v8","Stage IIIB Hepatocellular Carcinoma AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8","Stage IVA Hepatocellular Carcinoma AJCC v8","Stage IVB Hepatocellular Carcinoma AJCC v8","Unresectable Fibrolamellar Carcinoma",[1371,1050,1578],"Recombinant Interferon Alpha 2b-like Protein",{"nctId":1580,"briefTitle":1581,"status":102,"phases":1582,"primaryCompletion":815,"completion":815,"start":1583,"enrollment":406,"conditions":1584,"interventions":1598},"NCT03449108","LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas",[88],"2018-04-27",[1585,1586,1587,1588,360,1589,1454,1590,1591,1460,1592,1593,1594,1595,1596,1597],"Bone Sarcoma","Dedifferentiated Chondrosarcoma","Giant Cell Tumor of Bone","Malignancy in Giant Cell Tumor of Bone","Ovarian Carcinosarcoma","Poorly Differentiated Thyroid Gland Carcinoma","Recurrent Osteosarcoma","Refractory Osteosarcoma","Soft Tissue Sarcoma","Thyroid Gland Anaplastic Carcinoma","Thyroid Gland Squamous Cell Carcinoma","Undifferentiated High Grade Pleomorphic Sarcoma of Bone","Triple Negative Breast Cancer",[1599,1600,1601,803,1070,1049,1050],"Aldesleukin","Autologous Tumor Infiltrating Lymphocytes LN-145","Autologous Tumor Infiltrating Lymphocytes LN-145-S1",{"nctId":1603,"briefTitle":1604,"status":182,"phases":1605,"primaryCompletion":1606,"completion":1607,"start":1608,"enrollment":1609,"conditions":1610,"interventions":1622},"NCT03799445","Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma",[88],"2025-07-25","2026-04-14","2019-07-25",37,[1611,1612,1613,1614,1615,1616,1617,1618,1619,1620,1621],"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma","Oropharyngeal Basaloid Carcinoma","Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Posterior Tongue Squamous Cell Carcinoma","Soft Palate Squamous Cell Carcinoma","Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7","Tonsillar Squamous Cell Carcinoma",[1049,1050],{"nctId":1624,"briefTitle":1625,"status":102,"phases":1626,"primaryCompletion":1193,"completion":1193,"start":1627,"enrollment":507,"conditions":1628,"interventions":1657},"NCT03776487","Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer",[88],"2019-01-07",[1629,1630,1631,1632,1633,1634,1635,1636,1637,1638,1639,1640,1641,1642,1643,1644,1645,1646,1647,1648,1649,1650,1651,1652,1653,1654,1655,1656],"Clinical Stage 0 Gastric Cancer AJCC v8","Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage I Gastric Cancer AJCC v8","Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IIB Gastric Cancer AJCC v8","Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IVA Gastric Cancer AJCC v8","Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Gastric Adenocarcinoma","Localized Gastric Carcinoma","Localized Gastroesophageal Junction Adenocarcinoma","Pathologic Stage 0 Gastric Cancer AJCC v8","Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage I Gastric Cancer AJCC v8","Pathologic Stage IA Gastric Cancer AJCC v8","Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IB Gastric Cancer AJCC v8","Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIA Gastric Cancer AJCC v8","Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIB Gastric Cancer AJCC v8","Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIIA Gastric Cancer AJCC v8","Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",[1371,1049,1050,1375],{"nctId":1659,"briefTitle":1660,"status":102,"phases":1661,"primaryCompletion":1662,"completion":1662,"start":1663,"enrollment":1664,"conditions":1665,"interventions":1682},"NCT04017650","Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer",[87,88],"2027-12-30","2019-06-14",38,[1666,1667,1668,1669,1670,1671,1672,1673,1674,1675,1676,1677,1678,1679,1680,1681],"BRAF NP_004324.2:p.V600E","Metastatic Colon Adenocarcinoma","Metastatic Microsatellite Stable Colorectal Carcinoma","Metastatic Rectal Adenocarcinoma","Progressive Disease","Recurrent Colorectal Carcinoma","Stage III Colorectal Cancer AJCC v8","Stage IIIA Colorectal Cancer AJCC v8","Stage IIIB Colorectal Cancer AJCC v8","Stage IIIC Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Stage IVA Colorectal Cancer AJCC v8","Stage IVB Colorectal Cancer AJCC v8","Stage IVC Colorectal Cancer AJCC v8","Unresectable Colon Adenocarcinoma","Unresectable Rectal Adenocarcinoma",[1683,1684,1050],"Cetuximab","Encorafenib",{"nctId":1686,"briefTitle":1687,"status":130,"phases":1688,"primaryCompletion":1689,"completion":1689,"start":472,"enrollment":924,"conditions":1690,"interventions":1692},"NCT03015740","Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer",[87,88],"2022-09-06",[1271,1272,1691,1273],"Stage III Renal Cell Cancer AJCC v7",[1050,1693],"Sitravatinib",{"nctId":1695,"briefTitle":1696,"status":130,"phases":1697,"primaryCompletion":1698,"completion":1698,"start":105,"enrollment":1699,"conditions":1700,"interventions":1708},"NCT03158129","Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer",[88],"2024-11-13",101,[1701,1702,1703,1704,1705,1706,1707],"Stage I Lung Non-Small Cell Cancer AJCC v7","Stage IA Lung Non-Small Cell Carcinoma AJCC v7","Stage IB Lung Non-Small Cell Carcinoma AJCC v7","Stage II Lung Non-Small Cell Cancer AJCC v7","Stage IIA Lung Non-Small Cell Carcinoma AJCC v7","Stage IIB Lung Non-Small Cell Carcinoma AJCC v7","Stage IIIA Lung Non-Small Cell Cancer AJCC v7",[1369,1709,1710,1049,1050,1377],"Cisplatin","Docetaxel",{"nctId":1712,"briefTitle":1713,"status":279,"phases":1714,"primaryCompletion":1715,"completion":1716,"start":1717,"enrollment":195,"conditions":1718,"interventions":1720},"NCT06561087","Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions",[88],"2027-05-30","2029-05-30","2025-02-27",[1719],"Premalignant Lesion",[1050],{"nctId":1722,"briefTitle":1723,"status":546,"phases":1724,"primaryCompletion":1725,"completion":1726,"start":1727,"enrollment":406,"conditions":1728,"interventions":1730},"NCT06683755","Phase I\u002FIIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)",[87,88],"2030-08-16","2032-08-16","2025-05-01",[1729],"Melanoma",[1050,1552,1049],{"nctId":1732,"briefTitle":1733,"status":279,"phases":1734,"primaryCompletion":1735,"completion":1735,"start":1736,"enrollment":406,"conditions":1737,"interventions":1739},"NCT05704647","Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases",[88],"2028-07-31","2023-02-23",[1738],"Melanoma (Skin)",[1740,1050,1552],"BMS-986213",{"nctId":1742,"briefTitle":1743,"status":102,"phases":1744,"primaryCompletion":1745,"completion":1745,"start":1746,"enrollment":406,"conditions":1747,"interventions":1750},"NCT05347212","Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla",[88],"2027-07-16","2022-09-22",[1748,1749],"Carcinomas","Renal Medullary Carcinoma",[1050,1552],{"nctId":1752,"briefTitle":1753,"status":203,"phases":1754,"primaryCompletion":1755,"completion":1755,"start":1756,"enrollment":124,"conditions":1757,"interventions":1759},"NCT04965714","Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer",[88],"2023-02-10","2022-04-13",[1758],"Resectable Hepatocellular Carcinoma",[1050,1760],"Pegargiminase",{"nctId":1762,"briefTitle":1763,"status":182,"phases":1764,"primaryCompletion":1717,"completion":1717,"start":1765,"enrollment":1766,"conditions":1767,"interventions":1785},"NCT04902040","Plinabulin in Combination With Radiation\u002FImmunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies",[87,88],"2021-04-14",19,[1768,1769,1343,1770,1771,1772,1344,1773,1312,1774,1348,1775,1349,1776,1350,1777,1351,1352,1353,1778,1779,1355,1356,1780,1357,1781,1358,1359,1782,1319,1360,1783,1361,1784,1362],"Advanced Bladder Carcinoma","Advanced Lung Non-Small Cell Carcinoma","Advanced Melanoma","Advanced Merkel Cell Carcinoma","Advanced Renal Cell Carcinoma","Clinical Stage III Merkel Cell Carcinoma AJCC v8","Clinical Stage IV Merkel Cell Carcinoma AJCC v8","Pathologic Stage III Merkel Cell Carcinoma AJCC v8","Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8","Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8","Pathologic Stage IV Merkel Cell Carcinoma AJCC v8","Stage III Bladder Cancer AJCC v8","Stage IIIA Bladder Cancer AJCC v8","Stage IIIB Bladder Cancer AJCC v8","Stage IV Bladder Cancer AJCC v8","Stage IVA Bladder Cancer AJCC v8","Stage IVB Bladder Cancer AJCC v8",[718,693,1786,1050,53,1787],"Durvalumab","Plinabulin",{"nctId":1789,"briefTitle":1790,"status":102,"phases":1791,"primaryCompletion":446,"completion":446,"start":1792,"enrollment":230,"conditions":1793,"interventions":1820},"NCT04953104","ARID1A and\u002For KDM6A Mutation and CXCL13 Expression",[88],"2021-09-21",[1794,1795,1796,1797,1798,1799,1800,1801,1802,1803,1804,1805,1806,1807,1808,1779,1809,1810,1811,1780,1781,1782,1812,1813,1814,1783,1784,1815,1816,1817,1818,1819],"Locally Advanced Bladder Urothelial Carcinoma","Locally Advanced Renal Pelvis Urothelial Carcinoma","Locally Advanced Ureter Urothelial Carcinoma","Locally Advanced Urethral Urothelial Carcinoma","Locally Advanced Urothelial Carcinoma","Metastatic Bladder Urothelial Carcinoma","Metastatic Renal Pelvis Urothelial Carcinoma","Metastatic Ureter Urothelial Carcinoma","Metastatic Urethral Urothelial Carcinoma","Metastatic Urothelial Carcinoma","Recurrent Bladder Urothelial Carcinoma","Recurrent Renal Pelvis Urothelial Carcinoma","Recurrent Ureter Urothelial Carcinoma","Recurrent Urethral Urothelial Carcinoma","Recurrent Urothelial Carcinoma","Stage III Renal Pelvis Cancer AJCC v8","Stage III Ureter Cancer AJCC v8","Stage III Urethral Cancer AJCC v8","Stage IV Renal Pelvis Cancer AJCC v8","Stage IV Ureter Cancer AJCC v8","Stage IV Urethral Cancer AJCC v8","Unresectable Bladder Urothelial Carcinoma","Unresectable Renal Pelvis Urothelial Carcinoma","Unresectable Ureter Urothelial Carcinoma","Unresectable Urethral Urothelial Carcinoma","Unresectable Urothelial Carcinoma",[1050,1552],{"nctId":1822,"briefTitle":1823,"status":130,"phases":1824,"primaryCompletion":1825,"completion":1825,"start":1826,"enrollment":406,"conditions":1827,"interventions":1829},"NCT03222076","Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer",[88],"2022-09-14","2017-09-28",[1828,1758],"Hepatocellular Carcinoma",[1049,1050],{"nctId":1831,"briefTitle":1832,"status":203,"phases":1833,"primaryCompletion":1834,"completion":1834,"start":1834,"enrollment":124,"conditions":1835,"interventions":1838},"NCT05022394","Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1\u002FPD-L1 Inhibitor Therapy, I-OVERCOME Study",[87,88],"2021-02-18",[1388,1836,1837,1389,1390,1391,1355,1357,1358,1359,1319,1361,1362],"Recurrent Lung Non-Small Cell Carcinoma","Stage I Lung Cancer AJCC v8",[1050,1839],"Sapanisertib",{"nctId":1841,"briefTitle":1842,"status":182,"phases":1843,"primaryCompletion":1844,"completion":1844,"start":1845,"enrollment":1568,"conditions":1846,"interventions":1849},"NCT04904302","Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer",[88],"2026-03-11","2022-05-03",[1847,1848,1360],"Advanced Clear Cell Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma",[1050,1693],{"nctId":1851,"briefTitle":1852,"status":130,"phases":1853,"primaryCompletion":1854,"completion":1855,"start":1856,"enrollment":37,"conditions":1857,"interventions":1858},"NCT01585194","Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma",[88],"2019-12-02","2024-05-14","2012-11-29",[1318,1550],[1049,1050],{"nctId":1860,"briefTitle":1861,"status":546,"phases":1862,"primaryCompletion":571,"completion":1863,"start":1864,"enrollment":1568,"conditions":1865,"interventions":1867},"NCT07551583","Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL",[88],"2032-12-31","2026-10-01",[1866],"Hodgkin Lymphoma",[1050,804,1868,1869],"Vinblastine","Dacarbazine",{"nctId":1871,"briefTitle":1872,"status":130,"phases":1873,"primaryCompletion":1874,"completion":1874,"start":1875,"enrollment":240,"conditions":1876,"interventions":1880},"NCT04021043","BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung\u002FChest or Liver Cancers",[87,88],"2025-04-14","2019-08-19",[1343,1877,1878,1879,361],"Metastatic Carcinoma in the Liver","Metastatic Carcinoma in the Lung","Metastatic Malignant Neoplasm in the Thoracic Cavity",[1881,1049,1050],"Anti-GITR Agonistic Monoclonal Antibody BMS-986156",{"nctId":1883,"briefTitle":1884,"status":102,"phases":1885,"primaryCompletion":1886,"completion":1887,"start":1888,"enrollment":296,"conditions":1889,"interventions":1891},"NCT06250335","Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab\u002FNivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients",[88],"2027-01-23","2029-01-23","2024-03-01",[1890],"ICB-refractory Melanoma",[1049,1050],{"nctId":1893,"briefTitle":1894,"status":102,"phases":1895,"primaryCompletion":471,"completion":471,"start":1896,"enrollment":240,"conditions":1897,"interventions":1915},"NCT04599140","SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial",[87,88],"2020-10-14",[1667,1898,1669,1899,1900,1901,1902,1903,1904,1905,1906,1907,1908,1909,1910,1911,1912,1913,1914,1680,1681],"Metastatic Colorectal Carcinoma","Stage III Colon Cancer AJCC v8","Stage III Rectal Cancer AJCC v8","Stage IIIA Colon Cancer AJCC v8","Stage IIIA Rectal Cancer AJCC v8","Stage IIIB Colon Cancer AJCC v8","Stage IIIB Rectal Cancer AJCC v8","Stage IIIC Colon Cancer AJCC v8","Stage IIIC Rectal Cancer AJCC v8","Stage IV Colon Cancer AJCC v8","Stage IV Rectal Cancer AJCC v8","Stage IVA Colon Cancer AJCC v8","Stage IVA Rectal Cancer AJCC v8","Stage IVB Colon Cancer AJCC v8","Stage IVB Rectal Cancer AJCC v8","Stage IVC Colon Cancer AJCC v8","Stage IVC Rectal Cancer AJCC v8",[1916,1050],"CXCR1\u002F2 Inhibitor SX-682",{"nctId":1918,"briefTitle":1919,"status":130,"phases":1920,"primaryCompletion":1165,"completion":1165,"start":1921,"enrollment":1922,"conditions":1923,"interventions":1925},"NCT02426892","Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors",[88],"2015-12-23",33,[1924],"Solid Tumors",[1926,1050],"ISA 101",{"nctId":1928,"briefTitle":1929,"status":102,"phases":1930,"primaryCompletion":238,"completion":238,"start":1931,"enrollment":1932,"conditions":1933,"interventions":1934},"NCT02530463","Nivolumab and\u002For Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome",[88],"2015-09-08",99,[15,30,609],[510,1049,1050],{"nctId":1936,"briefTitle":1937,"status":279,"phases":1938,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1222,"conditions":1941,"interventions":1943},"NCT05663710","Phase 1b\u002F2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC",[87,88],"2027-10-30","2023-06-30",[1942,1271],"Advanced Cancer",[1944,1050,1421,1945],"177Lu girentuximab","ArabinoFuranosylGuanine [18F]F-AraG",{"nctId":1947,"briefTitle":1948,"status":102,"phases":1949,"primaryCompletion":860,"completion":860,"start":1792,"enrollment":834,"conditions":1950,"interventions":1952},"NCT04957615","Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression",[88],[361,1951],"Unresectable Solid Neoplasm",[1050],{"nctId":1954,"briefTitle":1955,"status":102,"phases":1956,"primaryCompletion":1957,"completion":1957,"start":1958,"enrollment":901,"conditions":1959,"interventions":1963},"NCT02910700","Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma",[88],"2027-12-08","2016-12-09",[1960,1316,1961,1962,1544,1546,1549,1365],"Metastatic Malignant Neoplasm in the Brain","Stage III Cutaneous Melanoma AJCC v7","Stage IIIA Cutaneous Melanoma AJCC v7",[1964,1965,1684,1050,874],"Binimetinib","Dabrafenib",{"nctId":1040,"briefTitle":1041,"status":130,"phases":1967,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":1045,"conditions":1968,"interventions":1969},[88],[1047,643,846,737,30,608,610,651,682],[510,1049,480,1050],{"nctId":1971,"briefTitle":1972,"status":102,"phases":1973,"primaryCompletion":224,"completion":224,"start":1974,"enrollment":1975,"conditions":1976,"interventions":1978},"NCT02696993","Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer",[87,88],"2016-12-16",80,[1960,1977],"Stage IV Non-Small Cell Lung Cancer AJCC v7",[1049,1050],{"nctId":1980,"briefTitle":1981,"status":182,"phases":1982,"primaryCompletion":1983,"completion":1983,"start":1984,"enrollment":910,"conditions":1985,"interventions":1988},"NCT03121534","Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation",[88],"2022-02-11","2017-06-22",[1986,1987],"Hematopoietic\u002FLymphoid Cancer","Richter's Transformation",[1083,62,767,1050],{"nctId":1990,"briefTitle":1991,"status":203,"phases":1992,"primaryCompletion":1993,"completion":1993,"start":1994,"enrollment":124,"conditions":1995,"interventions":1997},"NCT05039736","A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET\u002FVEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy",[88],"2023-05-03","2023-02-24",[1828,1996],"Liver Cancer",[1421,1050],{"nctId":1999,"briefTitle":2000,"status":279,"phases":2001,"primaryCompletion":2002,"completion":2002,"start":2003,"enrollment":2004,"conditions":2005,"interventions":2010},"NCT04745949","PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy",[88],"2027-08-03","2021-05-10",31,[2006,2007,2008,2009],"Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma",[2011,803,1013,1050,809,894],"Brentuximab Vedotin",{"nctId":2013,"briefTitle":2014,"status":182,"phases":2015,"primaryCompletion":2016,"completion":2016,"start":2017,"enrollment":2018,"conditions":2019,"interventions":2028},"NCT04785287","Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies",[87,88],"2026-02-26","2021-03-29",13,[2020,1343,2021,2022,2023,361,2024,1355,1357,1358,1359,2025,1319,2026,1361,2027,1362],"Advanced Lung Carcinoma","Malignant Adrenal Gland Neoplasm","Metastatic Liver Carcinoma","Metastatic Lung Carcinoma","Stage III Liver Cancer","Stage IV Liver Cancer","Stage IVA Liver Cancer","Stage IVB Liver Cancer",[2029,1050],"Anti-CTLA4 Monoclonal Antibody BMS-986218",{"nctId":2031,"briefTitle":2032,"status":182,"phases":2033,"primaryCompletion":2034,"completion":2034,"start":2035,"enrollment":1496,"conditions":2036,"interventions":2037},"NCT02599649","Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)",[88],"2019-01-30","2016-03-21",[15],[2038,1050,510],"Lirilumab",{"nctId":2040,"briefTitle":2041,"status":102,"phases":2042,"primaryCompletion":504,"completion":504,"start":2043,"enrollment":342,"conditions":2044,"interventions":2056},"NCT03110978","Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer",[88],"2017-06-26",[2045,2046,2047,2048,2049,2050,2051,1836,1837,2052,2053,2054,2055,1390],"Lung Atypical Carcinoid Tumor","Lung Neuroendocrine Neoplasm","Lung Non-Small Cell Squamous Carcinoma","Minimally Invasive Lung Adenocarcinoma","Neuroendocrine Carcinoma","Recurrent Lung Adenocarcinoma","Recurrent Lung Large Cell Carcinoma","Stage IA1 Lung Cancer AJCC v8","Stage IA2 Lung Cancer AJCC v8","Stage IA3 Lung Cancer AJCC v8","Stage IB Lung Cancer AJCC v8",[1050],{"nctId":2058,"briefTitle":2059,"status":130,"phases":2060,"primaryCompletion":2061,"completion":2061,"start":2062,"enrollment":1609,"conditions":2063,"interventions":2065},"NCT02420912","Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation",[88],"2022-02-14","2015-06-19",[2064,665,666,528,529,715],"Loss of Chromosome 17p",[767,1050],{"nctId":2067,"briefTitle":2068,"status":102,"phases":2069,"primaryCompletion":224,"completion":224,"start":2070,"enrollment":1328,"conditions":2071,"interventions":2077},"NCT04940299","Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma",[88],"2021-09-23",[1344,1312,2072,1794,1387,2073,1795,1796,1797,360,2074,1799,1315,1316,1800,1801,2075,1802,1348,1349,1350,1351,1352,1353,1779,1355,1809,1810,1811,1780,1357,1781,1358,1359,1782,2076,1812,1813,1814,1361,1362,1365],"Locally Advanced Bladder Carcinoma","Locally Advanced Renal Pelvis Carcinoma","Metastatic Bladder Carcinoma","Metastatic Urethral Carcinoma","Stage IV Lung Cancer AJCC v6",[1049,1050,2078],"Tocilizumab",{"nctId":2080,"briefTitle":2081,"status":102,"phases":2082,"primaryCompletion":224,"completion":224,"start":773,"enrollment":1568,"conditions":2083,"interventions":2087},"NCT04729322","Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders",[88],[2084,2085,1676,2086,1677,1678,1679],"Metastatic Colorectal Adenocarcinoma","Metastatic Small Intestinal Adenocarcinoma","Stage IV Small Intestinal Adenocarcinoma AJCC v8",[2088,2089,2090,1050,53,2091],"Fecal Microbiota Transplantation","Metronidazole","Neomycin","Vancomycin",{"nctId":2093,"briefTitle":2094,"status":102,"phases":2095,"primaryCompletion":1864,"completion":1864,"start":2096,"enrollment":1496,"conditions":2097,"interventions":2098},"NCT06284564","A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)",[88],"2024-08-07",[1346],[2099,1050],"Evolocumab",{"nctId":2101,"briefTitle":2102,"status":279,"phases":2103,"primaryCompletion":2104,"completion":2105,"start":2106,"enrollment":473,"conditions":2107,"interventions":2108},"NCT06053658","Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma",[88],"2026-11-01","2028-11-01","2024-01-05",[1521],[2109,1050],"Tivozanib",{"nctId":2111,"briefTitle":2112,"status":102,"phases":2113,"primaryCompletion":2104,"completion":2104,"start":868,"enrollment":676,"conditions":2114,"interventions":2115},"NCT05501054","Phase 1b\u002F2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.",[87,88],[1521],[1049,1050,2116],"Ciforadenant",{"nctId":2118,"briefTitle":2119,"status":203,"phases":2120,"primaryCompletion":2121,"start":2122,"enrollment":124,"conditions":2123,"interventions":2125},"NCT02950038","Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)",[88],"2019-12","2016-12",[2124],"Lung Cancer, Nonsmall Cell, Stage I",[767,1050],{"nctId":2127,"briefTitle":2128,"status":182,"phases":2129,"primaryCompletion":2130,"completion":2130,"start":149,"enrollment":186,"conditions":2131,"interventions":2136},"NCT02421354","Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis",[88],"2018-04-13",[2132,2133,746,2134,2135],"Hepatomegaly","Myelofibrosis Transformation in Essential Thrombocythemia","Primary Myelofibrosis","Splenomegaly",[1050],{"nctId":2138,"briefTitle":2139,"status":130,"phases":2140,"primaryCompletion":2141,"completion":2141,"start":2142,"enrollment":1568,"conditions":2143,"interventions":2147},"NCT02532231","Nivolumab in AML in Remission at High Risk for Relapse",[88],"2023-08-08","2015-10-19",[846,2144,2145,2146],"Adult Acute Myeloid Leukemia in Remission","Blasts Under 10 Percent of Bone Marrow Nucleated Cells","Therapy-Related Myeloid Neoplasm",[1050],{"nctId":2149,"briefTitle":2150,"status":130,"phases":2151,"primaryCompletion":2152,"completion":2152,"start":2153,"enrollment":550,"conditions":2154,"interventions":2158},"NCT03770416","Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma",[88],"2025-02-10","2019-02-15",[2155,2156,2157],"Central Nervous System B-Cell Non-Hodgkin Lymphoma","Recurrent Central Nervous System Lymphoma","Refractory Central Nervous System Lymphoma",[767,1050],27,{"trials":2161,"activeCount":166,"soonestReadout":2166},[2162],{"nctId":2163,"briefTitle":2164,"status":102,"phases":2165,"primaryCompletion":2166,"completion":2166,"start":2167,"enrollment":2168,"conditions":2169,"interventions":2171},"NCT03391869","Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer",[89],"2027-03-31","2017-12-29",339,[2170,1388,1319],"Lung Adenocarcinoma",[1049,1050],{"trials":2173,"activeCount":124},[],{"trials":2175,"activeCount":124},[],{"intervention":62,"totalTrials":381,"cells":2177},{"EARLY_PHASE1":2178,"PHASE1":2197,"PHASE2":2341,"PHASE3":2916,"PHASE4":2960,"NA":2962},{"trials":2179,"activeCount":124},[2180],{"nctId":2181,"briefTitle":2182,"status":203,"phases":2183,"primaryCompletion":2184,"completion":2184,"start":2185,"enrollment":124,"conditions":2186,"interventions":2193},"NCT04776850","Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies",[86],"2022-12-05","2020-12-29",[2187,2188,2189,2190,2191,2192],"Beta Thalassemia Major","Sickle Beta 0 Thalassemia","Sickle Beta Plus Thalassemia","Sickle Beta Thalassemia","Sickle Cell Disease","Sickle Cell-SS Disease",[75,1004,803,62,1005,2194,2195,894,2196],"Lapine T-Lymphocyte Immune Globulin","Mycophenolate Mofetil","Tacrolimus",{"trials":2198,"activeCount":296,"soonestReadout":2276},[2199,2208,2216,2228,2238,2248,2256,2260,2272,2284,2294,2298,2312,2322,2331],{"nctId":2200,"briefTitle":2201,"status":102,"phases":2202,"primaryCompletion":224,"completion":224,"start":2203,"enrollment":507,"conditions":2204,"interventions":2205},"NCT03132454","Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia",[87],"2017-07-25",[913,608,914,610],[612,62,2206,2207],"Palbociclib","Sorafenib",{"nctId":2209,"briefTitle":2210,"status":130,"phases":2211,"primaryCompletion":2212,"completion":2212,"start":2213,"enrollment":593,"conditions":2214,"interventions":2215},"NCT00507858","Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer",[87],"2011-09","2005-09",[242],[1377,62],{"nctId":2217,"briefTitle":2218,"status":130,"phases":2219,"primaryCompletion":2220,"completion":2220,"start":2221,"enrollment":550,"conditions":2222,"interventions":2225},"NCT02095834","Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",[87],"2021-01-07","2014-04-24",[2223,2224],"Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma",[2226,2227,62],"Bendamustine Hydrochloride","Carfilzomib",{"nctId":2229,"briefTitle":2230,"status":203,"phases":2231,"primaryCompletion":2121,"start":2232,"enrollment":124,"conditions":2233,"interventions":2234},"NCT02532192","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",[87],"2015-12",[21],[2235,894,1709,654,62,2236,2237],"Belinostat","Ciprofloxacin","Fluconazole",{"nctId":2239,"briefTitle":2240,"status":182,"phases":2241,"primaryCompletion":2242,"completion":2242,"start":2243,"enrollment":121,"conditions":2244,"interventions":2246},"NCT01985477","Revlimid \u002F All-Trans Retinoic Acid (ATRA) \u002F Dexamethasone in Relapsed\u002FRefractory Multiple Myeloma",[87],"2015-09","2013-12",[2245],"Myeloma",[1402,62,2247],"All-Trans Retinoic Acid",{"nctId":2249,"briefTitle":2250,"status":130,"phases":2251,"primaryCompletion":2252,"completion":2252,"start":2253,"enrollment":121,"conditions":2254,"interventions":2255},"NCT01926665","Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)",[87],"2017-09-17","2014-06-17",[21],[2227,62],{"nctId":544,"briefTitle":545,"status":546,"phases":2257,"primaryCompletion":548,"completion":490,"start":549,"enrollment":550,"conditions":2258,"interventions":2259},[87],[552,21],[480,62,75,554],{"nctId":2261,"briefTitle":2262,"status":130,"phases":2263,"primaryCompletion":2264,"completion":2264,"start":2265,"enrollment":1409,"conditions":2266,"interventions":2268},"NCT03330028","Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology",[87],"2023-04-18","2017-10-27",[2267],"Diseases of Oesophagus Stomach and Duodenum",[62,2269,2270,2271,1709,1376],"Diphenhydramine","Famotidine","Mitomycin C",{"nctId":2273,"briefTitle":2274,"status":102,"phases":2275,"primaryCompletion":2276,"completion":2276,"start":2277,"enrollment":871,"conditions":2278,"interventions":2282},"NCT03283917","Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis",[87],"2027-05-18","2018-02-07",[2279,2280,2281],"Newly Diagnosed Primary Amyloidosis","Recurrent Primary Amyloidosis","Refractory Primary Amyloidosis",[554,62,2283],"Ixazomib",{"nctId":2285,"briefTitle":2286,"status":182,"phases":2287,"primaryCompletion":2288,"completion":2288,"start":2289,"enrollment":1231,"conditions":2290,"interventions":2291},"NCT01807286","Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis",[87],"2016-02","2014-01",[2245],[2292,2293,62],"Pomalidomide","Melphalan",{"nctId":1394,"briefTitle":1395,"status":203,"phases":2295,"primaryCompletion":991,"completion":991,"start":1397,"enrollment":124,"conditions":2296,"interventions":2297},[87],[1399,1400],[1050,1402,62,1049],{"nctId":2299,"briefTitle":2300,"status":279,"phases":2301,"primaryCompletion":2302,"completion":2303,"start":701,"enrollment":406,"conditions":2304,"interventions":2308},"NCT07072234","Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma",[87],"2028-02-01","2030-02-01",[2305,2306,2307],"Clear Cell Carcinoma","Phase 1","Growth Factor",[2309,62,1070,2310,2311],"Lymphodepleting chemotherapy","Cyclophosphamate","TGFBR-2 KO CD70 CAR NK",{"nctId":2313,"briefTitle":2314,"status":130,"phases":2315,"primaryCompletion":2316,"completion":2316,"start":2317,"enrollment":1766,"conditions":2318,"interventions":2320},"NCT00402766","Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma",[87],"2014-02","2006-08",[2319],"Mesothelioma",[1709,2321,1377,62],"Imatinib Mesylate",{"nctId":2323,"briefTitle":2324,"status":182,"phases":2325,"primaryCompletion":2326,"completion":2326,"start":2327,"enrollment":1568,"conditions":2328,"interventions":2329},"NCT00253318","RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer",[87],"2012-04","2005-11-01",[18],[1710,2330,62],"RAD001",{"nctId":2332,"briefTitle":2333,"status":130,"phases":2334,"primaryCompletion":2335,"completion":2335,"start":2336,"enrollment":2337,"conditions":2338,"interventions":2339},"NCT01440582","Combination Therapy of Lenalidomide\u002FBortezomib\u002FDexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients",[87],"2019-02-28","2013-02-18",77,[2245],[2340,75,1402,62],"Panobinostat",{"trials":2342,"activeCount":550,"soonestReadout":71},[2343,2354,2360,2375,2384,2396,2406,2427,2431,2440,2451,2463,2478,2486,2496,2505,2514,2523,2533,2545,2553,2563,2572,2576,2586,2597,2606,2615,2624,2633,2641,2655,2659,2663,2673,2684,2694,2703,2713,2721,2725,2734,2744,2748,2759,2763,2773,2783,2795,2802,2812,2820,2824,2832,2842,2851,2859,2870,2885,2896,2905],{"nctId":2344,"briefTitle":2345,"status":130,"phases":2346,"primaryCompletion":2347,"completion":2347,"start":2348,"enrollment":628,"conditions":2349,"interventions":2350},"NCT01332630","TPI 287 in Breast Cancer Metastatic to the Brain",[88],"2017-04-14","2011-08-16",[18],[2351,62,2352,2353],"TPI 287","Benadryl","Ranitidine",{"nctId":69,"briefTitle":70,"status":102,"phases":2355,"primaryCompletion":71,"completion":161,"start":2356,"enrollment":2357,"conditions":2358,"interventions":2359},[88],"2006-02-02",132,[1924],[62],{"nctId":2361,"briefTitle":2362,"status":203,"phases":2363,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":124,"conditions":2366,"interventions":2367},"NCT02961816","Panobinostat Combined With High-Dose Gemcitabine\u002FBusulfan\u002FMelphalan With Autologous Stem Cell Transplant for Patients With Refractory\u002FRelapsed Lymphoma",[88],"2021-06","2017-06",[21],[2368,2340,2369,1004,2293,894,62,2370,2371,2372,2373,2374],"Palifermin","Gemcitabine","Caphosol","Glutamine","Pyridoxine","Stem Cell","G-CSF",{"nctId":2376,"briefTitle":2377,"status":130,"phases":2378,"primaryCompletion":2379,"completion":2379,"start":2380,"enrollment":2337,"conditions":2381,"interventions":2382},"NCT00966693","Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma",[87,88],"2018-07-20","2009-08-25",[2223,2224],[62,1402,2383],"Thalidomide",{"nctId":2385,"briefTitle":2386,"status":182,"phases":2387,"primaryCompletion":2388,"completion":2388,"start":2389,"enrollment":240,"conditions":2390,"interventions":2393},"NCT05285813","A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure",[88],"2026-05-15","2022-05-06",[2391,2392],"AML","MDS",[2394,62,2395,2269],"Vibecotamab","Acetaminophen",{"nctId":2397,"briefTitle":2398,"status":130,"phases":2399,"primaryCompletion":2400,"completion":2400,"start":2401,"enrollment":2402,"conditions":2403,"interventions":2404},"NCT01983969","Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma",[87,88],"2017-11-22","2013-11-07",61,[33,21],[510,2405,2369,1004,2293,62,2371,2372,894],"Vorinostat",{"nctId":2407,"briefTitle":2408,"status":279,"phases":2409,"primaryCompletion":2410,"completion":2410,"start":2411,"enrollment":924,"conditions":2412,"interventions":2422},"NCT03136146","Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma\u002FLeukemia, or Double-Hit Lymphoma\u002FLeukemia",[88],"2027-08-01","2017-08-09",[913,2413,2414,2415,2416,2417,914,2418,2419,2420,2421],"Recurrent Adult Lymphoblastic Lymphoma","Recurrent Burkitt Leukemia","Recurrent Burkitt Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Burkitt Leukemia","Refractory Burkitt Lymphoma","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Lymphoblastic Lymphoma",[75,2423,803,62,2424,2425,1071,894,2426],"Clofarabine","Etoposide","Ofatumumab","Vincristine Sulfate Liposome",{"nctId":1554,"briefTitle":1555,"status":130,"phases":2428,"primaryCompletion":1557,"completion":1557,"start":1558,"enrollment":1559,"conditions":2429,"interventions":2430},[87,88],[15,36,30],[1050,655,654,1562,62],{"nctId":2432,"briefTitle":2433,"status":130,"phases":2434,"primaryCompletion":2435,"completion":2435,"start":2436,"enrollment":550,"conditions":2437,"interventions":2438},"NCT02385110","Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis",[88],"2023-01-24","2015-09-23",[15],[2439,2424,62,806,2078],"Alemtuzumab",{"nctId":2441,"briefTitle":2442,"status":130,"phases":2443,"primaryCompletion":2444,"completion":2444,"start":2445,"enrollment":2446,"conditions":2447,"interventions":2448},"NCT00290511","Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma",[88],"2021-02-12","2004-06-29",49,[21],[1070,2449,894,2450,62],"Mitoxantrone","Zevalin",{"nctId":2452,"briefTitle":2453,"status":279,"phases":2454,"primaryCompletion":2455,"completion":2456,"start":2457,"enrollment":1559,"conditions":2458,"interventions":2461},"NCT06383572","Phase I\u002FII Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse\u002FRefractory Myeloid Malignancies",[87,88],"2027-04-01","2029-04-01","2024-06-26",[2459,2460],"Lymphodepleting Chemotherapy","Myeloid Malignancies",[803,2462,612,62],"Fludarabine phosphate",{"nctId":2464,"briefTitle":2465,"status":279,"phases":2466,"primaryCompletion":2467,"completion":2467,"start":2468,"enrollment":2469,"conditions":2470,"interventions":2476},"NCT01371630","Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia",[87,88],"2027-12-25","2011-08-26",276,[2471,2472,2473,2474,2475,1142,2415,1144,2419],"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","Burkitt-Like Lymphoma With 11q Aberration","High Grade B-Cell Lymphoma With MYC and BCL2 and\u002For BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified",[1083,803,654,62,2477,805,806,809,894,1016],"Inotuzumab Ozogamicin",{"nctId":2479,"briefTitle":2480,"status":130,"phases":2481,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":1308,"conditions":2484,"interventions":2485},"NCT01237951","High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma",[88],"2017-09-20","2010-11-08",[2245],[2368,62,2369,1004,2293,2374],{"nctId":2487,"briefTitle":2488,"status":102,"phases":2489,"primaryCompletion":2490,"completion":2490,"start":2491,"enrollment":134,"conditions":2492,"interventions":2493},"NCT02106988","Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma",[88],"2034-01-31","2015-01-16",[21],[62,2494,2495,1114,1369],"Etoposide phosphate","Ifosfamide",{"nctId":2497,"briefTitle":2498,"status":279,"phases":2499,"primaryCompletion":2104,"completion":2104,"start":2500,"enrollment":1975,"conditions":2501,"interventions":2504},"NCT02877303","Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia",[88],"2016-11-01",[2502,2503],"B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma",[1083,803,654,62,804,2477,805,806,2425,809,894,810],{"nctId":2506,"briefTitle":2507,"status":182,"phases":2508,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":296,"conditions":2511,"interventions":2513},"NCT03488225","Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia",[88],"2020-04-02","2018-03-28",[2512,2502,2472],"Acute Lymphoblastic Leukemia in Remission",[803,654,62,804,2477,1373,805,806,2425,809,894,810],{"nctId":2515,"briefTitle":2516,"status":182,"phases":2517,"primaryCompletion":2518,"completion":2518,"start":2519,"enrollment":230,"conditions":2520,"interventions":2522},"NCT03518112","Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia",[88],"2021-05-27","2018-04-18",[2521,1142,1144],"Philadelphia Chromosome Negative",[1083,803,654,62,1069,1373,805,806,1071,894,810],{"nctId":2524,"briefTitle":2525,"status":130,"phases":2526,"primaryCompletion":2527,"completion":2527,"start":2528,"enrollment":1609,"conditions":2529,"interventions":2531},"NCT00905034","Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage",[88],"2015-02","2009-03",[2530],"Leukemia, Lymphocytic, Acute",[806,1016,2532,62,894],"PEG-l-asparaginase",{"nctId":2534,"briefTitle":2535,"status":130,"phases":2536,"primaryCompletion":2537,"completion":2537,"start":1000,"enrollment":834,"conditions":2538,"interventions":2543},"NCT02135874","Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia",[88],"2023-02-21",[1047,643,2539,2540,848,2541,2542,851],"Acute Leukemia of Ambiguous Lineage","Acute Undifferentiated Leukemia","Mixed Phenotype Acute Leukemia, B\u002FMyeloid, Not Otherwise Specified","Mixed Phenotype Acute Leukemia, T\u002FMyeloid, Not Otherwise Specified",[2423,654,62,655,894,2207,2544,1016,810],"Sorafenib Tosylate",{"nctId":2546,"briefTitle":2547,"status":130,"phases":2548,"primaryCompletion":2549,"completion":2549,"start":2550,"enrollment":37,"conditions":2551,"interventions":2552},"NCT00290498","Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger",[88],"2017-08-11","2005-08-01",[21],[894,803,1013,1016,62,806,654,809],{"nctId":2554,"briefTitle":2555,"status":130,"phases":2556,"primaryCompletion":2557,"completion":2557,"start":2558,"enrollment":2559,"conditions":2560,"interventions":2562},"NCT00390793","Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.",[88],"2024-02-02","2006-09-28",107,[1122,2561,644,912,913,915],"BCR-ABL1 Fusion Protein Expression",[803,654,1028,62,1013,806,809,1016],{"nctId":2564,"briefTitle":2565,"status":102,"phases":2566,"primaryCompletion":224,"completion":224,"start":2567,"enrollment":1932,"conditions":2568,"interventions":2571},"NCT03583255","Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer",[88],"2018-06-29",[1343,726,2569,361,2570],"Locally Advanced Malignant Solid Neoplasm","Recurrent Malignant Solid Neoplasm",[62],{"nctId":794,"briefTitle":795,"status":279,"phases":2573,"primaryCompletion":772,"completion":772,"start":797,"enrollment":798,"conditions":2574,"interventions":2575},[88],[800,801],[803,654,62,804,805,806,807,808,809,480,810],{"nctId":2577,"briefTitle":2578,"status":130,"phases":2579,"primaryCompletion":1558,"completion":1558,"start":2580,"enrollment":2581,"conditions":2582,"interventions":2583},"NCT00290433","Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma",[88],"2003-09",55,[21],[803,1114,1016,806,2584,62,2374,2585],"Ara-C","Doxil",{"nctId":2587,"briefTitle":2588,"status":182,"phases":2589,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":95,"conditions":2592,"interventions":2595},"NCT02420717","Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia",[88],"2021-01-20","2015-07-15",[1142,2593,1144,2594],"Recurrent Ph-Like Acute Lymphoblastic Leukemia","Refractory Ph-Like Acute Lymphoblastic Leukemia",[803,654,1028,62,1013,1113,805,806,809,894,2596,1016],"Ruxolitinib Phosphate",{"nctId":2598,"briefTitle":2599,"status":203,"phases":2600,"primaryCompletion":2601,"start":2602,"enrollment":124,"conditions":2603,"interventions":2604},"NCT02114502","Carfilzomib\u002FSAHA Combined With High-Dose Gemcitabine\u002FBusulfan\u002FMelphalan With Autologous Stem Cell Transplant in Myeloma",[88],"2018-09","2014-09",[2245],[2227,2605,2369,1004,2293,2368,62,2370,2371,2372],"SAHA",{"nctId":77,"briefTitle":78,"status":102,"phases":2607,"primaryCompletion":79,"completion":2608,"start":2609,"enrollment":2610,"conditions":2611,"interventions":2614},[88],"2025-12-31","2017-12-04",135,[2612,2613],"Dyspnea","Malignant Neoplasm",[62],{"nctId":2616,"briefTitle":2617,"status":130,"phases":2618,"primaryCompletion":2619,"completion":2619,"start":2620,"enrollment":357,"conditions":2621,"interventions":2622},"NCT01692197","E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes",[88],"2017-06-07","2013-02-01",[15],[2623,655,654,62],"E7070",{"nctId":2625,"briefTitle":2626,"status":279,"phases":2627,"primaryCompletion":2628,"completion":674,"start":2629,"enrollment":406,"conditions":2630,"interventions":2632},"NCT05977998","A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology",[88],"2028-10-31","2023-09-08",[1638,2631],"Carcinomatosis",[1376,62,2269,2270],{"nctId":2634,"briefTitle":2635,"status":102,"phases":2636,"primaryCompletion":956,"completion":956,"start":2637,"enrollment":2638,"conditions":2639,"interventions":2640},"NCT02427620","Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma",[88],"2015-06-03",131,[783,891,788],[803,654,62,1013,804,767,806,894,1016,810],{"nctId":2642,"briefTitle":2643,"status":130,"phases":2644,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":2647,"conditions":2648,"interventions":2654},"NCT01363128","Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",[88],"2020-04-08","2011-07-12",72,[1122,2649,2650,2651,785,2652,2653],"Adult Acute Lymphoblastic Leukemia in Complete Remission","Burkitt Leukemia","Burkitt Lymphoma","Childhood Acute Lymphoblastic Leukemia in Complete Remission","Lymphoblastic Lymphoma",[803,654,62,804,806,2425,810],{"nctId":905,"briefTitle":906,"status":182,"phases":2656,"primaryCompletion":908,"completion":908,"start":909,"enrollment":910,"conditions":2657,"interventions":2658},[87,88],[644,912,913,649,914,650,915],[62,917,894,480],{"nctId":928,"briefTitle":929,"status":102,"phases":2660,"primaryCompletion":931,"completion":931,"start":932,"enrollment":240,"conditions":2661,"interventions":2662},[88],[891],[803,654,62,804,767,806,894,480,810],{"nctId":2664,"briefTitle":2665,"status":279,"phases":2666,"primaryCompletion":2667,"completion":2668,"start":2669,"enrollment":924,"conditions":2670,"interventions":2671},"NCT06930651","A Phase I\u002FII Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed\u002FRefractory Myeloid Malignancies",[87,88],"2028-05-01","2030-05-01","2025-09-03",[2460],[62,803,1070,612,2672],"TGFBR2 KO CAR27\u002FIL-15 NK cells",{"nctId":2674,"briefTitle":2675,"status":130,"phases":2676,"primaryCompletion":2677,"completion":2677,"start":2678,"enrollment":2004,"conditions":2679,"interventions":2680},"NCT01319981","Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia",[88],"2020-11-11","2013-03-05",[15],[894,2681,803,1013,1114,2682,2683,806,2584,2374,1071,62],"Imatinib","VSLI","Solu-Medrol",{"nctId":2685,"briefTitle":2686,"status":203,"phases":2687,"primaryCompletion":2688,"completion":2688,"start":2689,"enrollment":124,"conditions":2690,"interventions":2693},"NCT03232307","Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma",[88],"2021-07-01","2019-07-01",[2691,2692,891],"CCND1 Positive","CD20-Positive Neoplastic Cells Present",[62,767,1402,894],{"nctId":2695,"briefTitle":2696,"status":130,"phases":2697,"primaryCompletion":2698,"completion":2698,"start":2699,"enrollment":2700,"conditions":2701,"interventions":2702},"NCT00038610","Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia",[88],"2014-07","2001-03",54,[15],[2321,803,1013,1016,62,806,654,1114,2374],{"nctId":2704,"briefTitle":2705,"status":182,"phases":2706,"primaryCompletion":2707,"completion":2707,"start":2708,"enrollment":871,"conditions":2709,"interventions":2711},"NCT01946152","Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma",[87,88],"2020-03-18","2014-03-05",[2710,2223,2224],"Multiple Myeloma-Light Chain Only",[62,2712,2292],"Filgrastim-sndz",{"nctId":2714,"briefTitle":2715,"status":130,"phases":2716,"primaryCompletion":2717,"completion":2717,"start":2718,"enrollment":2559,"conditions":2719,"interventions":2720},"NCT00477412","Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma",[87,88],"2020-10-28","2007-04-03",[891],[75,803,654,62,1013,806,894,1016],{"nctId":1007,"briefTitle":1008,"status":279,"phases":2722,"primaryCompletion":446,"completion":446,"start":1010,"enrollment":517,"conditions":2723,"interventions":2724},[88],[847],[803,654,62,1013,805,806,1014,809,894,1015,480,1016],{"nctId":2726,"briefTitle":2727,"status":102,"phases":2728,"primaryCompletion":999,"completion":999,"start":2729,"enrollment":2730,"conditions":2731,"interventions":2733},"NCT01424982","Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia",[88],"2011-10-05",88,[1205,1122,2649,2471,644,912,2732],"Untreated Adult Acute Lymphoblastic Leukemia",[803,654,62,1013,804,806,1124,917,809,894,1016,810],{"nctId":2735,"briefTitle":2736,"status":130,"phases":2737,"primaryCompletion":2738,"completion":2739,"start":2740,"enrollment":901,"conditions":2741,"interventions":2743},"NCT01670097","Dexamethasone Dyspnea Study",[88],"2020-08","2021-01-26","2013-01",[33,2742,1924],"Hematologic Disorder",[62],{"nctId":1980,"briefTitle":1981,"status":182,"phases":2745,"primaryCompletion":1983,"completion":1983,"start":1984,"enrollment":910,"conditions":2746,"interventions":2747},[88],[1986,1987],[1083,62,767,1050],{"nctId":2749,"briefTitle":2750,"status":203,"phases":2751,"primaryCompletion":2752,"completion":2752,"start":2753,"enrollment":124,"conditions":2754,"interventions":2756},"NCT05293509","Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders",[88],"2023-09-18","2022-03-02",[2755],"Stem Cell Transplantation",[1070,62,803,75,894,1004,803,2196,2757,2758],"Mycophenolate mofetil","Rabbit ATG",{"nctId":1105,"briefTitle":1106,"status":182,"phases":2760,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":539,"conditions":2761,"interventions":2762},[87,88],[359,913,608,850,609,914,610,853,632],[1112,510,803,654,62,1069,1113,1114,806,809,894,480,1016],{"nctId":2764,"briefTitle":2765,"status":130,"phases":2766,"primaryCompletion":2767,"completion":2767,"start":2768,"enrollment":296,"conditions":2769,"interventions":2771},"NCT01217060","Trimodality Management of T1b Esophageal Cancers",[87,88],"2020-06-14","2010-10",[2770],"Esophageal Cancer",[1710,2772,62],"5-FU",{"nctId":2774,"briefTitle":2775,"status":130,"phases":2776,"primaryCompletion":2777,"completion":2777,"start":2778,"enrollment":2779,"conditions":2780,"interventions":2781},"NCT01531998","Lenalidomide\u002FBortezomib\u002FDexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)",[87,88],"2014-05","2012-05",14,[2245],[1402,75,2782,62],"Siltuximab",{"nctId":2784,"briefTitle":2785,"status":182,"phases":2786,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":1609,"conditions":2789,"interventions":2791},"NCT02732015","Rolapitant Hydrochloride in Preventing Nausea\u002FVomiting in Patients With Sarcoma Receiving Chemotherapy",[88],"2020-07-10","2016-10-12",[2790],"Locally Advanced Sarcoma",[62,1013,2792,2495,1114,2793,2794,810],"Fosaprepitant Dimeglumine","Ondansetron","Rolapitant Hydrochloride",{"nctId":2796,"briefTitle":2797,"status":102,"phases":2798,"primaryCompletion":1939,"completion":1939,"start":2799,"enrollment":517,"conditions":2800,"interventions":2801},"NCT03763162","Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",[88],"2019-01-17",[2223,2224],[75,554,62,2283],{"nctId":2803,"briefTitle":2804,"status":130,"phases":2805,"primaryCompletion":2806,"completion":2806,"start":2807,"enrollment":406,"conditions":2808,"interventions":2810},"NCT00515073","Papillary Serous Carcinoma of the Endometrium",[88],"2013-05","2001-04",[2809],"Endometrial Cancer",[1376,62,2811,2269],"Cimetidine",{"nctId":2813,"briefTitle":2814,"status":279,"phases":2815,"primaryCompletion":224,"completion":548,"start":2816,"enrollment":2159,"conditions":2817,"interventions":2818},"NCT05645718","Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia",[88],"2023-07-14",[15],[803,1016,1083,806,654,805,809,1071,2819,894,62],"Inotuzumab ozogamicin",{"nctId":1135,"briefTitle":1136,"status":182,"phases":2821,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":1140,"conditions":2822,"interventions":2823},[87,88],[1142,1143,1144,1145],[803,654,62,806,807,808,809,894,480,1016],{"nctId":2825,"briefTitle":2826,"status":130,"phases":2827,"primaryCompletion":2326,"completion":2326,"start":2828,"enrollment":676,"conditions":2829,"interventions":2830},"NCT00299182","Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma",[87,88],"2006-03",[21],[2831,894,803,1016,1013,62,806,654],"AMG 531",{"nctId":2833,"briefTitle":2834,"status":130,"phases":2835,"primaryCompletion":2232,"completion":2232,"start":2836,"enrollment":628,"conditions":2837,"interventions":2839},"NCT00968253","RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia",[87,88],"2009-11",[15,2838],"Acute Lymphocytic Leukemia",[2840,803,1016,1013,62,1114,806,2584,2841,2374],"Everolimus","Methylprednisone",{"nctId":2843,"briefTitle":2844,"status":182,"phases":2845,"primaryCompletion":2846,"completion":2846,"start":2847,"enrollment":676,"conditions":2848,"interventions":2849},"NCT00479089","Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer",[88],"2014-08","2004-02",[1293],[1710,2850,62],"ZD1839",{"nctId":2852,"briefTitle":2853,"status":182,"phases":2854,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":296,"conditions":2857,"interventions":2858},"NCT05032183","Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",[87,88],"2024-07-31","2022-02-17",[2413,1142,1143,1144,2421,1145],[803,654,62,2712,1113,805,1114,806,1071,809,894,1015,1016],{"nctId":2860,"briefTitle":2861,"status":279,"phases":2862,"primaryCompletion":2863,"completion":2863,"start":2864,"enrollment":2865,"conditions":2866,"interventions":2869},"NCT06207305","A Phase I\u002FII Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma",[87,88],"2028-01-02","2024-01-30",39,[2867,2868],"Metastatic Appendiceal Adenocarcinoma","Intraperitoneal Paclitaxel",[62,2269,2270,1376],{"nctId":2871,"briefTitle":2872,"status":130,"phases":2873,"primaryCompletion":2874,"completion":2874,"start":2875,"enrollment":1766,"conditions":2876,"interventions":2877},"NCT00003311","Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",[88],"2007-04-18","1998-05-20",[21],[2878,2879,2880,2881,2882,2883,2884],"filgrastim","cyclophosphamide","cytarabine","dexamethasone","doxorubicin hydrochloride","methotrexate","vincristine sulfate",{"nctId":2886,"briefTitle":2887,"status":130,"phases":2888,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":2892,"interventions":2893},"NCT00671658","Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia",[88],"2013-07","2002-11",220,[15,1122],[894,803,1013,1016,62,806,654,2374,1114,2894,1071,2895],"Pegylated asparaginase","Solumedrol",{"nctId":2897,"briefTitle":2898,"status":182,"phases":2899,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":186,"conditions":2902,"interventions":2903},"NCT02589145","Lenalidomide Combined With Vorinostat\u002FGemcitabine\u002FBusulfan\u002FMelphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype",[87,88],"2019-04-08","2016-06-22",[21],[1402,2405,2369,1004,2293,894,62,2370,2371,2372,2904,2368],"Enoxaparin",{"nctId":2906,"briefTitle":2907,"status":130,"phases":2908,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":2912,"interventions":2915},"NCT00669877","Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia\u002FLymphoma",[88],"2015-10","2002-08",56,[2913,2914],"Burkitt's Lymphoma","Burkitt'S-like Lymphoma",[894,803,1013,1016,62,2374,654,806],{"trials":2917,"activeCount":166,"soonestReadout":61},[2918,2928,2940,2949],{"nctId":59,"briefTitle":60,"status":102,"phases":2919,"primaryCompletion":61,"completion":446,"start":2920,"enrollment":861,"conditions":2921,"interventions":2927},[88,89],"2015-08-13",[2922,2923,2924,2925,2926],"Advanced Malignant Neoplasm","Fatigue","Metastatic Malignant Neoplasm","Recurrent Malignant Neoplasm","Refractory Malignant Neoplasm",[62],{"nctId":2929,"briefTitle":2930,"status":130,"phases":2931,"primaryCompletion":2846,"completion":2846,"start":2932,"enrollment":2933,"conditions":2934,"interventions":2937},"NCT00553059","Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer",[89],"2008-05",62,[2935,2936],"Chemotherapy-induced Nausea and Vomiting","Unspecified Adult Solid Tumor, Protocol Specific",[2881,2938,2939],"dronabinol","palonosetron hydrochloride",{"nctId":2941,"briefTitle":2942,"status":130,"phases":2943,"primaryCompletion":2944,"completion":2944,"start":2945,"enrollment":2946,"conditions":2947,"interventions":2948},"NCT00038090","Thalidomide-Dexamethasone for Multiple Myeloma",[88,89],"2005-05","2000-06",83,[1400],[2383,62],{"nctId":2950,"briefTitle":2951,"status":182,"phases":2952,"primaryCompletion":2602,"start":2953,"enrollment":2954,"conditions":2955,"interventions":2956},"NCT00024167","Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer",[89],"2002-04",265,[27],[1710,2957,2958,2959,809,1868,62],"Doxorubicin hydrochloride","Estramustine phosphate sodium","Ketoconazole",{"trials":2961,"activeCount":124},[],{"trials":2963,"activeCount":124},[2964,2980,2993],{"nctId":2965,"briefTitle":2966,"status":130,"phases":2967,"primaryCompletion":2968,"completion":2968,"start":2969,"enrollment":240,"conditions":2970,"interventions":2974},"NCT00410488","Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)",[91],"2011-06","2006-12",[2971,2972,2973],"Sarcoma","Nausea","Vomiting",[2975,2976,2977,2978,2979,1114,1016,62],"Palonosetron - Single Dose","Palonosetron - Triple Dose","Adriamycin","Ifosfamide chemotherapy","Zinecard",{"nctId":2981,"briefTitle":2982,"status":130,"phases":2983,"primaryCompletion":2984,"completion":2984,"start":2985,"enrollment":2986,"conditions":2987,"interventions":2989},"NCT02473042","Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)",[91],"2024-11-26","2016-03-01",188,[2988,18],"Post-Operative Nausea and Vomiting",[2990,62,2991,2992],"Zofran","Phenergan","Pepcid",{"nctId":2994,"briefTitle":2995,"status":130,"phases":2996,"primaryCompletion":184,"completion":184,"start":2778,"enrollment":2997,"conditions":2998,"interventions":3001},"NCT01490060","Fosaprepitant in Patients Receiving Ifosfamide-based Regimen",[91],47,[2971,2935,2999,3000],"Effects of Chemotherapy","Adverse Effects of Medical Drugs",[3002,62,3003,3004,1013,1114,2495,1016],"Fosaprepitant","5HT3 receptor antagonist","Ifosfamide-based chemotherapy",{"intervention":1005,"totalTrials":924,"cells":3006},{"EARLY_PHASE1":3007,"PHASE1":3029,"PHASE2":3198,"PHASE3":3461,"PHASE4":3467,"NA":3469},{"trials":3008,"activeCount":166,"soonestReadout":2166},[3009,3013,3022],{"nctId":2181,"briefTitle":2182,"status":203,"phases":3010,"primaryCompletion":2184,"completion":2184,"start":2185,"enrollment":124,"conditions":3011,"interventions":3012},[86],[2187,2188,2189,2190,2191,2192],[75,1004,803,62,1005,2194,2195,894,2196],{"nctId":3014,"briefTitle":3015,"status":130,"phases":3016,"primaryCompletion":3017,"completion":3017,"start":3018,"enrollment":1231,"conditions":3019,"interventions":3021},"NCT03426969","Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis",[86],"2020-09-21","2018-01-31",[2134,3020],"Secondary Myelofibrosis",[803,1069,1005,2293,2195,2196],{"nctId":3023,"briefTitle":3024,"status":102,"phases":3025,"primaryCompletion":2166,"completion":2166,"start":3026,"enrollment":492,"conditions":3027,"interventions":3028},"NCT05495464","A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma",[86],"2022-11-18",[21,891],[668,894,803,1005],{"trials":3030,"activeCount":3197,"soonestReadout":1078},[3031,3046,3065,3076,3086,3094,3105,3116,3127,3138,3147,3158,3180,3189],{"nctId":3032,"briefTitle":3033,"status":130,"phases":3034,"primaryCompletion":3035,"completion":3035,"start":3036,"enrollment":134,"conditions":3037,"interventions":3044},"NCT02529813","CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies",[87],"2021-11-08","2015-12-16",[643,1122,3038,3039,3040,3041,716,3042,3043],"Blasts 5 Percent or More of Bone Marrow Nucleated Cells","CD19 Positive","Minimal Residual Disease","Non-Hodgkin Lymphoma","Stage III Chronic Lymphocytic Leukemia","Stage IV Chronic Lymphocytic Leukemia",[803,1005,3045],"Tisagenlecleucel",{"nctId":3047,"briefTitle":3048,"status":3049,"phases":3050,"primaryCompletion":3051,"completion":3051,"start":3052,"enrollment":2018,"conditions":3053,"interventions":3063},"NCT01619761","NK Cells in Cord Blood Transplantation","UNKNOWN",[87],"2021-11","2013-05-03",[1205,643,2512,678,1025,3054,3055,3056,3057,3058,30,913,608,665,3059,3060,666,914,528,3061,3062,529,651,682,882],"DS Stage II Plasma Cell Myeloma","DS Stage III Plasma Cell Myeloma","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","ISS Stage II Plasma Cell Myeloma","ISS Stage III Plasma Cell Myeloma","Recurrent Hodgkin Lymphoma","Recurrent Non-Hodgkin Lymphoma","Refractory Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma",[803,1005,1402,2293,2195,3064,894,2196],"Natural Killer Cell Therapy",{"nctId":3066,"briefTitle":3067,"status":102,"phases":3068,"primaryCompletion":2455,"completion":2455,"start":3069,"enrollment":871,"conditions":3070,"interventions":3072},"NCT05470283","Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma",[87],"2022-09-07",[3071,1316,1729],"Tumor",[3073,3074,803,3075,1114,1005],"OBX-115","Acetazolamide","Furosemide",{"nctId":3077,"briefTitle":3078,"status":130,"phases":3079,"primaryCompletion":3080,"completion":3080,"start":3081,"enrollment":3082,"conditions":3083,"interventions":3084},"NCT02083250","Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant",[87],"2021-11-12","2014-03-06",70,[2512,678,1411,30,648,913,608],[3085,1004,2423,1005,2405],"Anti-Thymocyte Globulin",{"nctId":3087,"briefTitle":3088,"status":130,"phases":3089,"primaryCompletion":3090,"completion":3090,"start":3091,"enrollment":834,"conditions":3092,"interventions":3093},"NCT00004246","Radiation Therapy Plus Fludarabine in Treating Patients With Locally Advanced Cancer of the Mouth, Pharynx, or Larynx",[87],"2002-12-02","1995-06-07",[242],[1005],{"nctId":3095,"briefTitle":3096,"status":279,"phases":3097,"primaryCompletion":3098,"completion":3099,"start":3100,"enrollment":2700,"conditions":3101,"interventions":3102},"NCT06066424","Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)",[87],"2038-04-30","2040-04-30","2023-10-24",[1924],[3103,3104,2462,803],"Rimiducid","TROP2-CAR-NK Cells",{"nctId":3106,"briefTitle":3107,"status":130,"phases":3108,"primaryCompletion":3109,"completion":3109,"start":3110,"enrollment":1568,"conditions":3111,"interventions":3114},"NCT02649764","Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[87],"2022-07-12","2016-05-04",[737,608,3112,610,3113],"Recurrent High Risk Myelodysplastic Syndrome","Refractory High Risk Myelodysplastic Syndrome",[654,1005,3115],"Prexasertib",{"nctId":3117,"briefTitle":3118,"status":279,"phases":3119,"primaryCompletion":1078,"completion":3120,"start":3121,"enrollment":1559,"conditions":3122,"interventions":3125},"NCT06083883","Phase I\u002FIb Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1",[87],"2028-11-30","2024-03-27",[3123,3124],"Synovial Sarcoma","Myxoid\u002FRound Cell Liposarcoma",[2462,3126,803],"NY-ESO-1 TCR\u002FIL-15 NK",{"nctId":3128,"briefTitle":3129,"status":130,"phases":3130,"primaryCompletion":3131,"completion":3131,"start":3132,"enrollment":95,"conditions":3133,"interventions":3137},"NCT02960646","Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies",[87],"2023-02-13","2017-01-18",[1122,36,846,3134,644,737,1025,2653,30,727,3135,3136,3059,3060,2223,882],"Aplastic Anemia","Plasma Cell Myeloma","Recurrent Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[803,1069,1005,2293,894,2196],{"nctId":3139,"briefTitle":3140,"status":102,"phases":3141,"primaryCompletion":1939,"completion":1939,"start":3142,"enrollment":1240,"conditions":3143,"interventions":3144},"NCT01955460","Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma",[87],"2014-10-15",[1316,1961,1962,1544,1546,1549],[1599,803,1005,3145,3146],"NGFR-transduced Autologous T Lymphocytes","TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes",{"nctId":3148,"briefTitle":3149,"status":130,"phases":3150,"primaryCompletion":3151,"completion":3151,"start":3152,"enrollment":1568,"conditions":3153,"interventions":3156},"NCT05040568","A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)",[87],"2026-01-15","2022-02-28",[3154,3155],"Colon Cancer","Resected Stage",[1683,3157,2462,803],"Expanded CB-NK cells",{"nctId":3159,"briefTitle":3160,"status":203,"phases":3161,"primaryCompletion":1174,"completion":1174,"start":3162,"enrollment":124,"conditions":3163,"interventions":3179},"NCT04521946","Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer",[87],"2021-01-14",[3164,3165,3166,3167,3168,3169,3170,3171,3172,3173,3174,3175,3176,3177,3178],"Anaplastic Ependymoma","Atypical Teratoid\u002FRhabdoid Tumor","Central Nervous System Germ Cell Tumor","Choroid Plexus Carcinoma","Intracranial Myeloid Sarcoma","Malignant Brain Neoplasm","Malignant Glioma","Medulloblastoma","Primitive Neuroectodermal Tumor","Recurrent Anaplastic Ependymoma","Recurrent Atypical Teratoid\u002FRhabdoid Tumor","Recurrent Malignant Brain Neoplasm","Recurrent Malignant Glioma","Recurrent Medulloblastoma","Recurrent Primitive Neuroectodermal Tumor",[2424,1005,2194,2293,2195,2196,1254],{"nctId":3181,"briefTitle":3182,"status":130,"phases":3183,"primaryCompletion":3184,"completion":3184,"start":640,"enrollment":406,"conditions":3185,"interventions":3187},"NCT01787474","Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[87],"2021-06-17",[3186,610],"Recurrent Adult Acute Myeloid Leukemia",[654,1069,2712,1005,3188],"Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells",{"nctId":3190,"briefTitle":3191,"status":279,"phases":3192,"primaryCompletion":3193,"completion":3193,"start":1407,"enrollment":924,"conditions":3194,"interventions":3196},"NCT06358430","Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)",[87],"2029-01-18",[3195,3040],"Colorectal Cancer",[1005,803,1683,3104,3103],5,{"trials":3199,"activeCount":2779,"soonestReadout":3301},[3200,3209,3217,3221,3237,3246,3254,3264,3284,3297,3308,3318,3327,3340,3349,3359,3363,3373,3387,3403,3412,3421,3434,3442],{"nctId":3201,"briefTitle":3202,"status":130,"phases":3203,"primaryCompletion":3204,"completion":3204,"start":3205,"enrollment":1496,"conditions":3206,"interventions":3207},"NCT01740557","Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma",[87,88],"2023-04-21","2015-01-28",[1316,1961,1549],[1599,3208,803,1005,3145],"CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes",{"nctId":3210,"briefTitle":3211,"status":130,"phases":3212,"primaryCompletion":3213,"completion":3213,"start":3214,"enrollment":1260,"conditions":3215,"interventions":3216},"NCT00794820","Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline",[88],"2014-12","2003-12",[712],[1005,803,894],{"nctId":2452,"briefTitle":2453,"status":279,"phases":3218,"primaryCompletion":2455,"completion":2456,"start":2457,"enrollment":1559,"conditions":3219,"interventions":3220},[87,88],[2459,2460],[803,2462,612,62],{"nctId":3222,"briefTitle":3223,"status":279,"phases":3224,"primaryCompletion":3225,"completion":3225,"start":3226,"enrollment":3227,"conditions":3228,"interventions":3236},"NCT00801489","Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[88],"2028-10-11","2007-04-04",270,[3229,3230,3231,647,1067,3232,3233,3234,3235,652],"Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11","Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11","Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1","Inv(16)","Myelodysplastic Syndrome With Excess Blasts","t(16;16)","t(8;21)",[654,612,2712,1005,694,655],{"nctId":3238,"briefTitle":3239,"status":102,"phases":3240,"primaryCompletion":1427,"completion":1427,"start":225,"enrollment":163,"conditions":3241,"interventions":3245},"NCT02861417","Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant",[88],[359,3242,1067,3243,30,3244,913,608,649,3112,3059,609,3060,2223],"High Risk Acute Myeloid Leukemia","Lymphoproliferative Disorder","Myelodysplastic\u002FMyeloproliferative Neoplasm",[1004,803,1070,1005,2195,2196,1254],{"nctId":3247,"briefTitle":3248,"status":130,"phases":3249,"primaryCompletion":3250,"completion":3250,"start":3251,"enrollment":2159,"conditions":3252,"interventions":3253},"NCT01664910","CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies",[87,88],"2023-06-28","2012-10-29",[359],[3085,2226,1005,2477,806,894,2196],{"nctId":3255,"briefTitle":3256,"status":279,"phases":3257,"primaryCompletion":1427,"completion":3258,"start":3259,"enrollment":1559,"conditions":3260,"interventions":3262},"NCT06066359","Ph I\u002FII Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR\u002FIL-15 for R\u002FR Myeloma",[87,88],"2028-08-31","2023-11-30",[3261],"Relapsed\u002FRefractory Myeloma",[2462,803,3263],"Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells",{"nctId":3265,"briefTitle":3266,"status":130,"phases":3267,"primaryCompletion":3268,"completion":3268,"start":3269,"enrollment":195,"conditions":3270,"interventions":3281},"NCT04074746","Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas",[87,88],"2025-09-22","2020-07-18",[3271,3272,3273,3274,3275,3276,3277,3278,3279,3280],"Recurrent Anaplastic Large Cell Lymphoma","Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Classic Hodgkin Lymphoma","Recurrent Mycosis Fungoides","Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified","Refractory Anaplastic Large Cell Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma","Refractory Classic Hodgkin Lymphoma","Refractory Mycosis Fungoides","Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified",[3282,803,1070,1005,3283],"Anti-CD30\u002FCD16A Monoclonal Antibody AFM13","Genetically Engineered Lymphocyte Therapy",{"nctId":3285,"briefTitle":3286,"status":279,"phases":3287,"primaryCompletion":860,"completion":860,"start":3288,"enrollment":1222,"conditions":3289,"interventions":3295},"NCT02727803","Personalized NK Cell Therapy in CBT",[88],"2016-05-19",[1205,643,1122,2512,3290,3291,2471,3292,737,1025,3056,3057,3058,30,3233,3293,3244,648,608,3186,3059,3060,914,3294,651,882],"Acute Myeloid Leukemia With Myelodysplasia-Related Changes","Acute Myeloid Leukemia With Variant MLL Translocations","Chemotherapy-Related Leukemia","Myelodysplastic Syndrome With Gene Mutation","Refractory Adult Acute Lymphoblastic Leukemia",[3296,3085,1004,2423,803,1005,2293,894],"Allogeneic Natural Killer Cell Line NK-92",{"nctId":3298,"briefTitle":3299,"status":102,"phases":3300,"primaryCompletion":3301,"completion":3302,"start":3303,"enrollment":2004,"conditions":3304,"interventions":3306},"NCT05672459","A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors",[87,88],"2026-06-29","2029-12-29","2023-06-21",[3305],"Solid Tumor",[3307,2462,803],"Single Injection of IVS-3001- Anti - HLA-G CAR-T cells",{"nctId":3309,"briefTitle":3310,"status":130,"phases":3311,"primaryCompletion":3312,"completion":3312,"start":3313,"enrollment":628,"conditions":3314,"interventions":3316},"NCT05115630","Off-the-shelf NK Cells + SCT for Myeloid Malignancies",[88],"2025-05-15","2022-04-08",[2460,36,30,3315],"Chronic Myeloid Leukemia",[803,1114,1069,2293,2462,2196,2757,3317],"Total Body Irradiation One Dose",{"nctId":3319,"briefTitle":3320,"status":130,"phases":3321,"primaryCompletion":3322,"completion":3322,"start":3323,"enrollment":550,"conditions":3324,"interventions":3325},"NCT02500576","Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma",[88],"2022-10-12","2015-08-07",[1316,1544,1546,1549],[1599,803,1005,53,3326],"Therapeutic Tumor Infiltrating Lymphocytes",{"nctId":3328,"briefTitle":3329,"status":279,"phases":3330,"primaryCompletion":281,"completion":571,"start":2855,"enrollment":2997,"conditions":3331,"interventions":3337},"NCT06434363","Phase I\u002FII Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders",[87,88],[3332,3333,3334,3335,3336],"Autoimmune Disorders","Systemic Sclerosis","Systemic Lupus Erythematosus","Lupus","Lupus Nephritis",[3338,2462,803,3339],"Tafasitamab","Tafasitamab and NK cells",{"nctId":3341,"briefTitle":3342,"status":279,"phases":3343,"primaryCompletion":549,"completion":1088,"start":3344,"enrollment":1131,"conditions":3345,"interventions":3347},"NCT06043323","A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed\u002FRefractory Follicular Lymphoma",[88],"2024-01-08",[3346],"Follicular Lymphoma",[3348,803,2462,809,2269,2395],"Axicabtagene Ciloleucel",{"nctId":3350,"briefTitle":3351,"status":279,"phases":3352,"primaryCompletion":1662,"completion":1662,"start":3353,"enrollment":3354,"conditions":3355,"interventions":3357},"NCT05110742","Phase I\u002FII Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed\u002FRefractory Hematological Malignances",[87,88],"2024-04-22",64,[3356],"Hematological Malignancy",[1005,803,3358],"CAR.5\u002FIL15-transduced CB-NK cells",{"nctId":996,"briefTitle":997,"status":102,"phases":3360,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":3361,"interventions":3362},[88],[36,30],[1004,599,1005,480],{"nctId":3364,"briefTitle":3365,"status":279,"phases":3366,"primaryCompletion":238,"completion":238,"start":3367,"enrollment":676,"conditions":3368,"interventions":3371},"NCT05703854","Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma",[87,88],"2023-03-29",[1772,3369,3370],"Advanced Mesothelioma","Advanced Osteosarcoma",[3372,2462,803],"CAR.70\u002FIL15-transduced CB-derived NK cells",{"nctId":3374,"briefTitle":3375,"status":130,"phases":3376,"primaryCompletion":3377,"completion":3377,"start":3378,"enrollment":3379,"conditions":3380,"interventions":3385},"NCT01823198","Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies",[87,88],"2022-05-10","2013-06-11",63,[1205,3381,3382,36,846,678,644,3383,3384,737,1067,30,649,682,882],"Acute Erythroid Leukemia","Acute Megakaryoblastic Leukemia","Blasts Under 20 Percent of Bone Marrow Nucleated Cells","Blasts Under 20 Percent of Peripheral Blood White Cells",[1599,3386,1004,1005],"Allogeneic CD56-positive CD3-negative Natural Killer Cells",{"nctId":3388,"briefTitle":3389,"status":279,"phases":3390,"primaryCompletion":1427,"completion":1427,"start":3391,"enrollment":1975,"conditions":3392,"interventions":3401},"NCT05092451","Phase I\u002FII Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse\u002FRefractory Hematological Malignances",[87,88],"2022-11-01",[3393,3394,3395,1400,3396,1866,3397,3398,3399,3400],"B-Cell Lymphoma","Myelodysplastic Syndromes (MDS)","Acute Myeloid Leukemia (AML)","Plasma Cell Leukemia","T-cell Non-Hodgkin's Lymphoma\u002F T-cell Acute Lymphoblastic Leukmeia","Myelodysplastic Syndrome \u002F Chronic Myelomonocytic Leukemia","Blastic Transformation of Chronic Myeloid Leukemia","Germ Cell Tumors",[803,3402,2462],"CAR.70\u002FIL15-transduced CB-NK cells",{"nctId":3404,"briefTitle":3405,"status":102,"phases":3406,"primaryCompletion":3407,"completion":3407,"start":3408,"enrollment":3409,"conditions":3410,"interventions":3411},"NCT02629809","Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia",[88],"2028-03-31","2016-03-18",81,[712,716],[803,1005,767,669],{"nctId":3413,"briefTitle":3414,"status":130,"phases":3415,"primaryCompletion":2953,"completion":2953,"start":3416,"enrollment":1140,"conditions":3417,"interventions":3419},"NCT00002833","Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia",[88],"1994-10",[3418,15,1036],"Graft Versus Host Disease",[1069,599,3420,654,1005,655,1014],"Cyclosporine",{"nctId":3422,"briefTitle":3423,"status":279,"phases":3424,"primaryCompletion":3425,"completion":3426,"start":3427,"enrollment":406,"conditions":3428,"interventions":3430},"NCT06345495","High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly",[88],"2027-01-01","2029-01-01","2024-10-01",[2135,3429],"Myelofibrosis",[598,3431,3432,1004,3433,2462,803,1114,2196],"Levetiracetam","Eltrombopag","Romiplostim",{"nctId":3435,"briefTitle":3436,"status":130,"phases":3437,"primaryCompletion":3438,"completion":3438,"start":3439,"enrollment":2018,"conditions":3440,"interventions":3441},"NCT00002838","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia",[87,88],"2002-07","1995-12",[15],[1069,803,1005],{"nctId":3443,"briefTitle":3444,"status":182,"phases":3445,"primaryCompletion":3446,"completion":3446,"start":3447,"enrollment":166,"conditions":3448,"interventions":3460},"NCT04530487","Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults",[88],"2024-08-26","2020-08-19",[3449,3450,3451,3452,2570,3453,3454,3455,3456,3457,3458,3459],"Desmoplastic Small Round Cell Tumor","Ewing Sarcoma\u002FPeripheral Primitive Neuroectodermal Tumor","Recurrent Desmoplastic Small Round Cell Tumor","Recurrent Malignant Peripheral Nerve Sheath Tumor","Recurrent Neuroblastoma","Recurrent Rhabdomyosarcoma","Refractory Desmoplastic Small Round Cell Tumor","Refractory Malignant Peripheral Nerve Sheath Tumor","Refractory Malignant Solid Neoplasm","Refractory Neuroblastoma","Refractory Rhabdomyosarcoma",[3420,2424,1005,2194,2293,2195,2196,1254],{"trials":3462,"activeCount":166,"soonestReadout":224},[3463],{"nctId":1247,"briefTitle":1248,"status":279,"phases":3464,"primaryCompletion":224,"completion":224,"start":1250,"enrollment":1251,"conditions":3465,"interventions":3466},[88,89],[36,737,30],[1004,599,1005,1254,480],{"trials":3468,"activeCount":124},[],{"trials":3470,"activeCount":124},[],{"intervention":1049,"totalTrials":473,"cells":3472},{"EARLY_PHASE1":3473,"PHASE1":3487,"PHASE2":3603,"PHASE3":3781,"PHASE4":3787,"NA":3789},{"trials":3474,"activeCount":166,"soonestReadout":446},[3475,3479],{"nctId":1265,"briefTitle":1266,"status":102,"phases":3476,"primaryCompletion":446,"completion":446,"start":1268,"enrollment":1269,"conditions":3477,"interventions":3478},[86],[1271,1272,1273],[1275,1049,1050],{"nctId":3480,"briefTitle":3481,"status":130,"phases":3482,"primaryCompletion":3483,"completion":3483,"start":3484,"enrollment":406,"conditions":3485,"interventions":3486},"NCT02113657","T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer",[86],"2019-11-04","2014-08-20",[27],[1049],{"trials":3488,"activeCount":296,"soonestReadout":446},[3489,3500,3504,3515,3525,3536,3551,3558,3562,3566,3574,3578,3587,3591,3595,3599],{"nctId":3490,"briefTitle":3491,"status":182,"phases":3492,"primaryCompletion":3493,"completion":3493,"start":3494,"enrollment":1766,"conditions":3495,"interventions":3496},"NCT01409174","IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma",[87],"2016-05","2013-02",[1729],[1049,3497,1709,3498,3499],"Temozolomide","Interferon Alfa-2b","Interleukin-2",{"nctId":1279,"briefTitle":1280,"status":203,"phases":3501,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":124,"conditions":3502,"interventions":3503},[87],[359,665,666,528,529,715],[767,1049,1050],{"nctId":3505,"briefTitle":3506,"status":3049,"phases":3507,"primaryCompletion":3508,"completion":3509,"start":3510,"enrollment":1240,"conditions":3511,"interventions":3513},"NCT03068624","Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma",[87],"2022-12-31","2025-07-31","2017-09-08",[3512,1318],"Metastatic Malignant Neoplasm in the Liver",[1599,3514,803,1049],"Autologous CD8+ SLC45A2-specific T Lymphocytes",{"nctId":3516,"briefTitle":3517,"status":182,"phases":3518,"primaryCompletion":3519,"completion":3519,"start":3520,"enrollment":3521,"conditions":3522,"interventions":3523},"NCT02668770","Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies",[87],"2025-11-05","2016-05-11",28,[33,1729],[3524,1049],"MGN1703",{"nctId":3526,"briefTitle":3527,"status":130,"phases":3528,"primaryCompletion":3529,"completion":3530,"start":3531,"enrollment":1154,"conditions":3532,"interventions":3535},"NCT01738139","Ipilimumab and Imatinib Mesylate in Advanced Cancer",[87],"2022-12-13","2023-12-13","2013-02-19",[1343,3533,1312,3534,361,1316,1353,1365,1951],"C-KIT Tyrosine Kinase Protein Overexpression","Metastatic Gastrointestinal Stromal Tumor",[2321,1049],{"nctId":3537,"briefTitle":3538,"status":102,"phases":3539,"primaryCompletion":446,"completion":446,"start":3540,"enrollment":3541,"conditions":3542,"interventions":3549},"NCT04388852","DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers",[87],"2020-08-20",65,[3543,3544,1848,361,3545,1803,3546,1360,3547,3548],"Aggressive Variant Prostate Carcinoma","Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8",[1049,3550],"Valemetostat",{"nctId":3552,"briefTitle":3553,"status":203,"phases":3554,"primaryCompletion":2121,"start":2122,"enrollment":124,"conditions":3555,"interventions":3556},"NCT02210104","Adoptive Therapy Using Antigen-Specific CD4 T-Cells",[87],[1729,2971],[1049,803,3557],"CD4+ T cells",{"nctId":1322,"briefTitle":1323,"status":279,"phases":3559,"primaryCompletion":1325,"completion":1326,"start":1327,"enrollment":1328,"conditions":3560,"interventions":3561},[87],[1330,1331,1332,1333],[1050,1331,1335],{"nctId":1337,"briefTitle":1338,"status":182,"phases":3563,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":3564,"interventions":3565},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"nctId":3567,"briefTitle":3568,"status":130,"phases":3569,"primaryCompletion":3570,"completion":3570,"start":3571,"enrollment":1699,"conditions":3572,"interventions":3573},"NCT01750983","Ipilimumab and Lenalidomide in Advanced Cancer",[87],"2019-02-21","2013-03",[33],[1049,1402],{"nctId":1381,"briefTitle":1382,"status":102,"phases":3575,"primaryCompletion":224,"completion":224,"start":675,"enrollment":871,"conditions":3576,"interventions":3577},[87],[1385,1386,1387,1388,1389,1390,1391,1355,1357,1358,1359,1364],[1049,1050],{"nctId":3579,"briefTitle":3580,"status":130,"phases":3581,"primaryCompletion":3582,"completion":3582,"start":3583,"enrollment":3584,"conditions":3585,"interventions":3586},"NCT02239900","Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors",[87],"2019-10-25","2014-08-26",143,[1996,24],[1049],{"nctId":1394,"briefTitle":1395,"status":203,"phases":3588,"primaryCompletion":991,"completion":991,"start":1397,"enrollment":124,"conditions":3589,"interventions":3590},[87],[1399,1400],[1050,1402,62,1049],{"nctId":1404,"briefTitle":1405,"status":130,"phases":3592,"primaryCompletion":1407,"completion":1407,"start":1408,"enrollment":1409,"conditions":3593,"interventions":3594},[87],[1411,30,608,610],[1049,1050],{"nctId":1423,"briefTitle":1424,"status":546,"phases":3596,"primaryCompletion":490,"completion":1426,"start":1427,"enrollment":550,"conditions":3597,"interventions":3598},[87],[1429],[1431,531,1049,1050],{"nctId":1433,"briefTitle":1434,"status":130,"phases":3600,"primaryCompletion":1436,"completion":1436,"start":1437,"enrollment":134,"conditions":3601,"interventions":3602},[87],[1439,1440,1441,1442,1443,1444,1445,1446,1447,1448,1449,1450,1451,1452,1453,1454,1455,1456,1457,1458,1459,1460,1461,1462,1463,1464,1465,1466,1467,1468,1469,1470,1471,1472],[1049,1050],{"trials":3604,"activeCount":3726,"soonestReadout":2104},[3605,3609,3613,3617,3626,3630,3634,3644,3648,3652,3659,3663,3672,3676,3680,3684,3688,3702,3706,3710,3721,3730,3734,3745,3749,3753,3757,3765,3773],{"nctId":1491,"briefTitle":1492,"status":182,"phases":3606,"primaryCompletion":1494,"completion":1494,"start":1495,"enrollment":1496,"conditions":3607,"interventions":3608},[88],[1498,1499,1356,1360],[1049,1050],{"nctId":1502,"briefTitle":1503,"status":102,"phases":3610,"primaryCompletion":999,"completion":999,"start":1505,"enrollment":507,"conditions":3611,"interventions":3612},[88],[1507,1508,1509,1510,1511,1512],[1049,1050],{"nctId":1515,"briefTitle":1516,"status":279,"phases":3614,"primaryCompletion":224,"completion":224,"start":1518,"enrollment":1131,"conditions":3615,"interventions":3616},[88],[1520,1521],[1050,1049,1421],{"nctId":3618,"briefTitle":3619,"status":130,"phases":3620,"primaryCompletion":3621,"completion":3621,"start":3622,"enrollment":834,"conditions":3623,"interventions":3624},"NCT02027935","CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma",[88],"2024-04-12","2015-01-22",[1316,1549],[1599,3625,803,1049],"Autologous CD8+ Melanoma Specific T Cells",{"nctId":1534,"briefTitle":1535,"status":130,"phases":3627,"primaryCompletion":1537,"completion":1537,"start":1538,"enrollment":1140,"conditions":3628,"interventions":3629},[88],[1540,1541,1542,1543,1544,1545,1546,1547,1548,1549,1550],[1049,1050,1552],{"nctId":1580,"briefTitle":1581,"status":102,"phases":3631,"primaryCompletion":815,"completion":815,"start":1583,"enrollment":406,"conditions":3632,"interventions":3633},[88],[1585,1586,1587,1588,360,1589,1454,1590,1591,1460,1592,1593,1594,1595,1596,1597],[1599,1600,1601,803,1070,1049,1050],{"nctId":3635,"briefTitle":3636,"status":130,"phases":3637,"primaryCompletion":3638,"completion":3638,"start":3639,"enrollment":1243,"conditions":3640,"interventions":3643},"NCT01919619","Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies",[88],"2024-05-03","2013-11-04",[3641,359,15,21,3135,3642],"B-Cell Non-Hodgkin Lymphoma","T-Cell Non-Hodgkin Lymphoma",[1049,1402],{"nctId":1603,"briefTitle":1604,"status":182,"phases":3645,"primaryCompletion":1606,"completion":1607,"start":1608,"enrollment":1609,"conditions":3646,"interventions":3647},[88],[1611,1612,1613,1614,1615,1616,1617,1618,1619,1620,1621],[1049,1050],{"nctId":1624,"briefTitle":1625,"status":102,"phases":3649,"primaryCompletion":1193,"completion":1193,"start":1627,"enrollment":507,"conditions":3650,"interventions":3651},[88],[1629,1630,1631,1632,1633,1634,1635,1636,1637,1638,1639,1640,1641,1642,1643,1644,1645,1646,1647,1648,1649,1650,1651,1652,1653,1654,1655,1656],[1371,1049,1050,1375],{"nctId":3653,"briefTitle":3654,"status":130,"phases":3655,"primaryCompletion":3656,"completion":3656,"start":3570,"enrollment":628,"conditions":3657,"interventions":3658},"NCT03873818","Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain",[88],"2025-08-21",[1312,1960,1316,1353],[1049,53],{"nctId":1695,"briefTitle":1696,"status":130,"phases":3660,"primaryCompletion":1698,"completion":1698,"start":105,"enrollment":1699,"conditions":3661,"interventions":3662},[88],[1701,1702,1703,1704,1705,1706,1707],[1369,1709,1710,1049,1050,1377],{"nctId":3664,"briefTitle":3665,"status":203,"phases":3666,"primaryCompletion":3667,"start":3668,"enrollment":124,"conditions":3669,"interventions":3670},"NCT01409187","IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma",[87,88],"2016-10","2011-10",[1729],[1049,3671,3499],"Interferon",{"nctId":1722,"briefTitle":1723,"status":546,"phases":3673,"primaryCompletion":1725,"completion":1726,"start":1727,"enrollment":406,"conditions":3674,"interventions":3675},[87,88],[1729],[1050,1552,1049],{"nctId":1822,"briefTitle":1823,"status":130,"phases":3677,"primaryCompletion":1825,"completion":1825,"start":1826,"enrollment":406,"conditions":3678,"interventions":3679},[88],[1828,1758],[1049,1050],{"nctId":1851,"briefTitle":1852,"status":130,"phases":3681,"primaryCompletion":1854,"completion":1855,"start":1856,"enrollment":37,"conditions":3682,"interventions":3683},[88],[1318,1550],[1049,1050],{"nctId":1871,"briefTitle":1872,"status":130,"phases":3685,"primaryCompletion":1874,"completion":1874,"start":1875,"enrollment":240,"conditions":3686,"interventions":3687},[87,88],[1343,1877,1878,1879,361],[1881,1049,1050],{"nctId":3689,"briefTitle":3690,"status":102,"phases":3691,"primaryCompletion":3407,"completion":3407,"start":3692,"enrollment":3693,"conditions":3694,"interventions":3698},"NCT02703623","Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer",[88],"2016-05-18",196,[3695,3544,3545,3696,3697],"Castration Levels of Testosterone","PSA Progression","Stage IV Prostate Adenocarcinoma AJCC v7",[3699,3700,3701,1369,1049,809],"Abiraterone Acetate","Apalutamide","Cabazitaxel",{"nctId":1883,"briefTitle":1884,"status":102,"phases":3703,"primaryCompletion":1886,"completion":1887,"start":1888,"enrollment":296,"conditions":3704,"interventions":3705},[88],[1890],[1049,1050],{"nctId":1928,"briefTitle":1929,"status":102,"phases":3707,"primaryCompletion":238,"completion":238,"start":1931,"enrollment":1932,"conditions":3708,"interventions":3709},[88],[15,30,609],[510,1049,1050],{"nctId":3711,"briefTitle":3712,"status":182,"phases":3713,"primaryCompletion":3714,"completion":3714,"start":3715,"enrollment":406,"conditions":3716,"interventions":3717},"NCT01377389","Ipilimumab + Androgen Depravation Therapy in Prostate Cancer",[88],"2017-04-07","2011-06-17",[27],[1049,3718,3719,3720],"Leuprolide","Goserelin","Degarelix",{"nctId":3722,"briefTitle":3723,"status":182,"phases":3724,"primaryCompletion":1558,"completion":1558,"start":3725,"enrollment":3726,"conditions":3727,"interventions":3728},"NCT01590082","Doxycycline, Temozolomide and Ipilimumab in Melanoma",[87,88],"2012-11",12,[1729],[3729,1049,3497],"Doxycycline",{"nctId":1040,"briefTitle":1041,"status":130,"phases":3731,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":1045,"conditions":3732,"interventions":3733},[88],[1047,643,846,737,30,608,610,651,682],[510,1049,480,1050],{"nctId":3735,"briefTitle":3736,"status":279,"phases":3737,"primaryCompletion":3738,"completion":3739,"start":3740,"enrollment":1568,"conditions":3741,"interventions":3743},"NCT06708949","A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)",[88],"2026-12-15","2028-12-15","2025-03-20",[3742],"Renal Cell Carcinoma, Clear Cell",[3744,1049,1740],"Drugs Nivolumab",{"nctId":1971,"briefTitle":1972,"status":102,"phases":3746,"primaryCompletion":224,"completion":224,"start":1974,"enrollment":1975,"conditions":3747,"interventions":3748},[87,88],[1960,1977],[1049,1050],{"nctId":2067,"briefTitle":2068,"status":102,"phases":3750,"primaryCompletion":224,"completion":224,"start":2070,"enrollment":1328,"conditions":3751,"interventions":3752},[88],[1344,1312,2072,1794,1387,2073,1795,1796,1797,360,2074,1799,1315,1316,1800,1801,2075,1802,1348,1349,1350,1351,1352,1353,1779,1355,1809,1810,1811,1780,1357,1781,1358,1359,1782,2076,1812,1813,1814,1361,1362,1365],[1049,1050,2078],{"nctId":2111,"briefTitle":2112,"status":102,"phases":3754,"primaryCompletion":2104,"completion":2104,"start":868,"enrollment":676,"conditions":3755,"interventions":3756},[87,88],[1521],[1049,1050,2116],{"nctId":3758,"briefTitle":3759,"status":130,"phases":3760,"primaryCompletion":3761,"completion":3761,"start":3762,"enrollment":3354,"conditions":3763,"interventions":3764},"NCT01119508","Ipilimumab + Temozolomide in Metastatic Melanoma",[88],"2016-08","2010-05",[1316],[1049,3497],{"nctId":3766,"briefTitle":3767,"status":130,"phases":3768,"primaryCompletion":3017,"completion":3017,"start":3769,"enrollment":871,"conditions":3770,"interventions":3771},"NCT01827111","Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma",[88],"2013-04-25",[1729],[3772,1049],"ABI-007",{"nctId":3774,"briefTitle":3775,"status":130,"phases":3776,"primaryCompletion":2909,"completion":2909,"start":3777,"enrollment":1766,"conditions":3778,"interventions":3779},"NCT01194271","Neoadjuvant Ipilimumab in Prostate Cancer",[88],"2010-09",[27],[3780,1049],"Leuprolide Acetate",{"trials":3782,"activeCount":166,"soonestReadout":2166},[3783],{"nctId":2163,"briefTitle":2164,"status":102,"phases":3784,"primaryCompletion":2166,"completion":2166,"start":2167,"enrollment":2168,"conditions":3785,"interventions":3786},[89],[2170,1388,1319],[1049,1050],{"trials":3788,"activeCount":124},[],{"trials":3790,"activeCount":124},[],{"intervention":1709,"totalTrials":2581,"cells":3792},{"EARLY_PHASE1":3793,"PHASE1":3795,"PHASE2":3920,"PHASE3":4302,"PHASE4":4374,"NA":4376},{"trials":3794,"activeCount":124},[],{"trials":3796,"activeCount":121,"soonestReadout":446},[3797,3801,3810,3814,3824,3828,3838,3849,3863,3875,3885,3893,3897,3906],{"nctId":3490,"briefTitle":3491,"status":182,"phases":3798,"primaryCompletion":3493,"completion":3493,"start":3494,"enrollment":1766,"conditions":3799,"interventions":3800},[87],[1729],[1049,3497,1709,3498,3499],{"nctId":3802,"briefTitle":3803,"status":130,"phases":3804,"primaryCompletion":3805,"start":2580,"enrollment":1131,"conditions":3806,"interventions":3807},"NCT00346801","CPT-11\u002FCisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)",[87],"2012-10",[24],[3808,1709,3809],"Celecoxib","CPT-11",{"nctId":2229,"briefTitle":2230,"status":203,"phases":3811,"primaryCompletion":2121,"start":2232,"enrollment":124,"conditions":3812,"interventions":3813},[87],[21],[2235,894,1709,654,62,2236,2237],{"nctId":3815,"briefTitle":3816,"status":130,"phases":3817,"primaryCompletion":3818,"completion":3818,"start":3819,"enrollment":3820,"conditions":3821,"interventions":3822},"NCT00527761","Taxotere\u002FTemodar\u002FCisplatin Study in Melanoma Patients",[87],"2007-11","2004-08",23,[1316],[1709,1710,3823],"Temodar",{"nctId":2261,"briefTitle":2262,"status":130,"phases":3825,"primaryCompletion":2264,"completion":2264,"start":2265,"enrollment":1409,"conditions":3826,"interventions":3827},[87],[2267],[62,2269,2270,2271,1709,1376],{"nctId":3829,"briefTitle":3830,"status":130,"phases":3831,"primaryCompletion":3832,"completion":3832,"start":3833,"enrollment":1496,"conditions":3834,"interventions":3835},"NCT00970996","Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma",[87],"2012-12","2009-09",[1729],[3497,3836,1709,3499,3837],"Abraxane","Interferon alpha 2b",{"nctId":3839,"briefTitle":3840,"status":130,"phases":3841,"primaryCompletion":3842,"completion":3842,"start":3843,"enrollment":676,"conditions":3844,"interventions":3846},"NCT00254384","Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery",[87],"2024-05-21","2005-10-05",[1836,1702,1703,1705,1706,1707,3845],"Stage IIIB Lung Non-Small Cell Cancer AJCC v7",[1709,1710,3847,3848],"Erlotinib","Erlotinib Hydrochloride",{"nctId":3850,"briefTitle":3851,"status":279,"phases":3852,"primaryCompletion":446,"completion":446,"start":3853,"enrollment":448,"conditions":3854,"interventions":3861},"NCT04169763","Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery",[87],"2020-08-07",[3855,3856,3857,3858,3859,3860],"Stage II Vulvar Cancer AJCC v8","Stage III Vulvar Cancer AJCC v8","Stage IIIA Vulvar Cancer AJCC v8","Stage IIIB Vulvar Cancer AJCC v8","Stage IIIC Vulvar Cancer AJCC v8","Stage IVA Vulvar Cancer AJCC v8",[1709,3862],"Nelfinavir",{"nctId":3864,"briefTitle":3865,"status":130,"phases":3866,"primaryCompletion":3867,"completion":3868,"start":3869,"enrollment":2946,"conditions":3870,"interventions":3874},"NCT02402920","Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer",[87],"2025-12-23","2026-02-09","2015-07-22",[3871,3872,3873],"Extensive Stage Small Cell Lung Carcinoma","Limited Stage Small Cell Lung Carcinoma","Neuroendocrine Neoplasm",[1369,1709,2424,53],{"nctId":3876,"briefTitle":3877,"status":279,"phases":3878,"primaryCompletion":3879,"completion":3880,"start":3881,"enrollment":871,"conditions":3882,"interventions":3883},"NCT05819892","Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer",[87],"2027-03-01","2028-03-01","2023-07-17",[2809],[1376,1369,3884,1709],"Dostarlimab",{"nctId":3886,"briefTitle":3887,"status":130,"phases":3888,"primaryCompletion":3889,"completion":3889,"start":3484,"enrollment":1483,"conditions":3890,"interventions":3891},"NCT01998529","Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy",[87],"2020-08-25",[24],[1709,3892],"Amifostine",{"nctId":2313,"briefTitle":2314,"status":130,"phases":3894,"primaryCompletion":2316,"completion":2316,"start":2317,"enrollment":1766,"conditions":3895,"interventions":3896},[87],[2319],[1709,2321,1377,62],{"nctId":3898,"briefTitle":3899,"status":130,"phases":3900,"primaryCompletion":3901,"completion":3901,"start":3902,"enrollment":240,"conditions":3903,"interventions":3904},"NCT00507962","Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement",[87],"2011-05","2005-03",[1942],[1709,3905],"Liposomal Doxorubicin",{"nctId":3907,"briefTitle":3908,"status":130,"phases":3909,"primaryCompletion":3910,"completion":3910,"start":3911,"enrollment":134,"conditions":3912,"interventions":3918},"NCT02225405","Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer",[87],"2024-05-06","2015-04-03",[3913,3914,3915,3916,3917],"Stage IB Non-Small Cell Lung Carcinoma AJCC v7","Stage II Non-Small Cell Lung Cancer AJCC v7","Stage IIA Non-Small Cell Lung Carcinoma AJCC v7","Stage IIB Non-Small Cell Lung Carcinoma AJCC v7","Stage IIIA Non-Small Cell Lung Cancer AJCC v7",[1709,1710,3919],"Nintedanib",{"trials":3921,"activeCount":3726,"soonestReadout":1727},[3922,3939,3949,3957,3961,3969,3983,3992,4001,4012,4024,4035,4048,4080,4090,4101,4110,4118,4136,4148,4158,4165,4179,4188,4198,4210,4219,4228,4236,4246,4268,4277,4286,4294],{"nctId":3923,"briefTitle":3924,"status":130,"phases":3925,"primaryCompletion":3926,"completion":3926,"start":3927,"enrollment":186,"conditions":3928,"interventions":3938},"NCT03690921","Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial",[88],"2022-06-03","2018-11-08",[3929,3930,3931,3932,3933,3934,3935,3936,3937],"Anal Canal Squamous Cell Carcinoma","Stage I Anal Cancer AJCC v8","Stage II Anal Cancer AJCC v8","Stage IIA Anal Cancer AJCC v8","Stage IIB Anal Cancer AJCC v8","Stage III Anal Cancer AJCC v8","Stage IIIA Anal Cancer AJCC v8","Stage IIIB Anal Cancer AJCC v8","Stage IIIC Anal Cancer AJCC v8",[1709,1371],{"nctId":3940,"briefTitle":3941,"status":279,"phases":3942,"primaryCompletion":3943,"completion":3944,"start":3945,"enrollment":628,"conditions":3946,"interventions":3948},"NCT05967182","A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma",[88],"2027-07-31","2029-07-31","2024-01-16",[3947],"Cholangiocarcinoma",[53,2369,1709],{"nctId":3950,"briefTitle":3951,"status":102,"phases":3952,"primaryCompletion":1727,"completion":504,"start":3953,"enrollment":676,"conditions":3954,"interventions":3955},"NCT00076310","OSI-774\u002FCisplatin\u002FTaxotere in Head & Neck Squamous Cell Cancer",[88],"2004-01-28",[242],[1710,3956,1709],"OSI-774",{"nctId":1695,"briefTitle":1696,"status":130,"phases":3958,"primaryCompletion":1698,"completion":1698,"start":105,"enrollment":1699,"conditions":3959,"interventions":3960},[88],[1701,1702,1703,1704,1705,1706,1707],[1369,1709,1710,1049,1050,1377],{"nctId":3962,"briefTitle":3963,"status":102,"phases":3964,"primaryCompletion":1427,"completion":1427,"start":3965,"enrollment":3726,"conditions":3966,"interventions":3968},"NCT05137262","A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder",[88],"2021-10-13",[3967,1293],"Urothelial Carcinoma",[1786,806,1868,804,1709],{"nctId":3970,"briefTitle":3971,"status":102,"phases":3972,"primaryCompletion":238,"completion":238,"start":3973,"enrollment":2004,"conditions":3974,"interventions":3982},"NCT00707473","Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer",[88],"2008-06-16",[3975,3976,3977,3978,3979,3980,3981],"Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma","Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma","Sinonasal Undifferentiated Carcinoma","Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8","Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC v8","Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC v8","Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC v8",[1369,1709,1710,1371],{"nctId":3984,"briefTitle":3985,"status":130,"phases":3986,"primaryCompletion":3987,"completion":3987,"start":3988,"enrollment":2446,"conditions":3989,"interventions":3991},"NCT00267046","Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma",[88],"2009-07","2005-12",[2971,3990],"Oral Mucositis",[2368,2977,2495,1016,1709],{"nctId":3993,"briefTitle":3994,"status":130,"phases":3995,"primaryCompletion":3996,"completion":3996,"start":3997,"enrollment":406,"conditions":3998,"interventions":4000},"NCT00512096","Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis",[88],"2010-08","1999-08",[3999],"Penile Cancer",[2495,1376,1709],{"nctId":4002,"briefTitle":4003,"status":279,"phases":4004,"primaryCompletion":4005,"completion":4006,"start":4007,"enrollment":676,"conditions":4008,"interventions":4010},"NCT06548412","CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers",[87,88],"2027-05-01","2029-05-01","2025-01-22",[4009],"Metastatic Biliary Tract Cancer",[2369,1709,1786,4011],"CTX-009",{"nctId":4013,"briefTitle":4014,"status":203,"phases":4015,"primaryCompletion":4016,"completion":4016,"start":2264,"enrollment":124,"conditions":4017,"interventions":4021},"NCT04481204","New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study",[88],"2026-04-27",[4018,4019,4020],"Borderline Resectable Pancreatic Adenocarcinoma","Locally Advanced Pancreatic Ductal Adenocarcinoma","Resectable Pancreatic Ductal Adenocarcinoma",[1709,1371,2369,4022,1113,4023,1375],"Irinotecan","Nab-paclitaxel",{"nctId":4025,"briefTitle":4026,"status":279,"phases":4027,"primaryCompletion":4028,"completion":4028,"start":4029,"enrollment":1328,"conditions":4030,"interventions":4034},"NCT05027633","Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity \u002F Paranasal Sinuses (I-NAPA)",[88],"2028-03-30","2021-11-02",[4031,4032,4033],"Squamous Cell Carcinoma","the Nasal Cavity","Paranasal Sinuses",[53,1710,1709,1369],{"nctId":4036,"briefTitle":4037,"status":130,"phases":4038,"primaryCompletion":4039,"completion":4039,"start":4040,"enrollment":3541,"conditions":4041,"interventions":4044},"NCT00080795","Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium",[88],"2006-05","2001-07",[1293,4042,4043],"Transitional Cell Cancer of the Renal Pelvis and Ureter","Urethral Cancer",[2878,4045,2882,4046,4047],"cisplatin","gemcitabine hydrochloride","ifosfamide",{"nctId":4049,"briefTitle":4050,"status":130,"phases":4051,"primaryCompletion":4052,"completion":4052,"start":4053,"enrollment":4054,"conditions":4055,"interventions":4079},"NCT01064479","Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck",[88],"2020-11-03","2010-02-05",123,[4056,4057,4058,4059,4060,4061,4062,4063,4064,4065,4066,4067,4068,4069,4070,1620,4071,4072,4073,4074,4075,4076,4077,4078],"Metastatic Squamous Cell Carcinoma of the Hypopharynx","Metastatic Squamous Cell Carcinoma of the Larynx","Metastatic Squamous Cell Carcinoma of the Oral Cavity","Metastatic Squamous Cell Carcinoma of the Oropharynx","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Oral Cavity Squamous Cell Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7",[1369,1709,1710,3848],{"nctId":4081,"briefTitle":4082,"status":182,"phases":4083,"primaryCompletion":4084,"completion":4085,"start":4086,"enrollment":296,"conditions":4087,"interventions":4089},"NCT00505492","Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT\u002FChemotherapy",[88],"2006-02","2010-12","2002-02",[4088],"Uterine Neoplasms",[1369,1709,1376],{"nctId":4091,"briefTitle":4092,"status":130,"phases":4093,"primaryCompletion":4094,"completion":4094,"start":4095,"enrollment":628,"conditions":4096,"interventions":4098},"NCT02891447","Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer",[88],"2023-04-11","2016-09-01",[1638,4097,1447],"Gastroesophageal Junction Adenocarcinoma",[1709,4099,4100],"Hyperthermic Intraperitoneal Chemotherapy","Mitomycin",{"nctId":4102,"briefTitle":4103,"status":130,"phases":4104,"primaryCompletion":4085,"completion":4085,"start":4105,"enrollment":1409,"conditions":4106,"interventions":4108},"NCT00068575","Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer",[88],"2002-05",[4107],"Pancreatic Cancer",[4109,1709,1371],"Recombinant Interferon Alfa",{"nctId":4111,"briefTitle":4112,"status":130,"phases":4113,"primaryCompletion":4114,"completion":4114,"start":4115,"enrollment":492,"conditions":4116,"interventions":4117},"NCT01277744","Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor",[88],"2018-02-16","2011-05-09",[33,2971],[1709],{"nctId":4119,"briefTitle":4120,"status":130,"phases":4121,"primaryCompletion":4122,"completion":4122,"start":4123,"enrollment":2933,"conditions":4124,"interventions":4134},"NCT02392637","Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers",[88],"2020-08-13","2015-04-02",[4125,4126,4127,4128,4129,4130,4131,4132,4133],"Stage III Intrahepatic Cholangiocarcinoma AJCC v7","Stage IIIA Gallbladder Cancer AJCC v7","Stage IIIB Gallbladder Cancer AJCC v7","Stage IVA Gallbladder Cancer AJCC v7","Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7","Stage IVB Gallbladder Cancer AJCC v7","Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7","Unresectable Extrahepatic Bile Duct Carcinoma","Unresectable Gallbladder Carcinoma",[1709,4135,4023],"Gemcitabine Hydrochloride",{"nctId":4137,"briefTitle":4138,"status":102,"phases":4139,"primaryCompletion":4140,"completion":4141,"start":4142,"enrollment":3521,"conditions":4143,"interventions":4147},"NCT04030455","Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer",[88],"2025-09-04","2026-09-17","2019-08-07",[4144,4145,4146],"Laryngeal Squamous Cell Carcinoma","Stage II Laryngeal Cancer AJCC v8","Stage III Laryngeal Cancer AJCC v8",[1369,1709,1710,53],{"nctId":4149,"briefTitle":4150,"status":182,"phases":4151,"primaryCompletion":4152,"completion":4152,"start":4153,"enrollment":3197,"conditions":4154,"interventions":4155},"NCT00505635","Biochemotherapy With Temozolomide for Metastatic Melanoma",[88],"2010-04","2007-03",[1729],[3497,4156,1709,3499,4157,2383],"Velban","Intron-A",{"nctId":4159,"briefTitle":4160,"status":130,"phases":4161,"primaryCompletion":4162,"completion":4162,"start":3819,"enrollment":871,"conditions":4163,"interventions":4164},"NCT00388154","Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer",[88],"2013-11",[2809],[2369,1709],{"nctId":4166,"briefTitle":4167,"status":130,"phases":4168,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":4172,"interventions":4173},"NCT00002524","Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma",[88],"2005-10","1993-06",46,[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],"Bleomycin Sulfate","Leucovorin calcium","Pentamidine","Trimethoprim-Sulfamethoxazole","Zidovudine",{"nctId":4180,"briefTitle":4181,"status":130,"phases":4182,"primaryCompletion":4183,"completion":4184,"start":4185,"enrollment":1664,"conditions":4186,"interventions":4187},"NCT00984997","Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors",[88],"2007-06","2015-06","1993-10",[24],[1709,2424],{"nctId":4189,"briefTitle":4190,"status":130,"phases":4191,"primaryCompletion":4192,"completion":3987,"start":4193,"enrollment":871,"conditions":4194,"interventions":4197},"NCT00353015","Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract",[88],"2007-12","2003-03",[4195,4196],"Gastrointestinal Cancer","Carcinoma, Neuroendocrine",[1709,4022],{"nctId":4199,"briefTitle":4200,"status":182,"phases":4201,"primaryCompletion":4202,"completion":4202,"start":4203,"enrollment":1231,"conditions":4204,"interventions":4208},"NCT04971187","Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer",[88],"2022-02-21","2021-06-30",[4205,4206,1355,1357,1358,1359,1319,1361,1362,4207],"Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma","Metastatic Lung Non-Squamous Non-Small Cell Carcinoma","Unresectable Lung Non-Squamous Non-Small Cell Carcinoma",[4209,1377,1369,1709],"Bintrafusp Alfa",{"nctId":4211,"briefTitle":4212,"status":102,"phases":4213,"primaryCompletion":2608,"completion":2608,"start":4214,"enrollment":4171,"conditions":4215,"interventions":4217},"NCT00082706","Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant",[88],"2003-04-23",[1293,4043,4216],"Urachal Cancer",[4218,1113,1709,2369],"5-Fluorouracil",{"nctId":4220,"briefTitle":4221,"status":130,"phases":4222,"primaryCompletion":4223,"completion":4223,"start":4224,"enrollment":492,"conditions":4225,"interventions":4226},"NCT00016367","Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[88],"2004-12-14","1999-05-13",[24],[4227,1709,4135],"Trastuzumab",{"nctId":4229,"briefTitle":4230,"status":130,"phases":4231,"primaryCompletion":2846,"completion":2846,"start":4183,"enrollment":1034,"conditions":4232,"interventions":4233},"NCT00506155","Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer",[88],[1293],[4234,1709,1013,806,4235],"Avastin","Vinblastine Sulfate",{"nctId":4237,"briefTitle":4238,"status":279,"phases":4239,"primaryCompletion":4240,"completion":4241,"start":4242,"enrollment":1034,"conditions":4243,"interventions":4245},"NCT06858735","HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma",[88],"2028-11-19","2030-11-19","2025-06-10",[4244],"Advanced Intrahepatic Cholangiocarcinoma",[1786,2369,1709],{"nctId":4247,"briefTitle":4248,"status":102,"phases":4249,"primaryCompletion":4250,"completion":4250,"start":1896,"enrollment":492,"conditions":4251,"interventions":4266},"NCT04580771","A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial",[88],"2027-03-08",[4252,4253,4254,4255,4256,4257,4258,4259,4260,4261,4262,4263,4264,4265],"Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified","Stage IB3 Cervical Cancer FIGO 2018","Stage II Cervical Cancer FIGO 2018","Stage IIA Cervical Cancer FIGO 2018","Stage IIA1 Cervical Cancer FIGO 2018","Stage IIA2 Cervical Cancer FIGO 2018","Stage IIB Cervical Cancer FIGO 2018","Stage III Cervical Cancer FIGO 2018","Stage IIIA Cervical Cancer FIGO 2018","Stage IIIB Cervical Cancer FIGO 2018","Stage IIIC Cervical Cancer FIGO 2018","Stage IIIC1 Cervical Cancer FIGO 2018","Stage IIIC2 Cervical Cancer FIGO 2018","Stage IVA Cervical Cancer FIGO 2018",[1709,4267],"Liposomal HPV-16 E6\u002FE7 Multipeptide Vaccine PDS0101",{"nctId":4269,"briefTitle":4270,"status":130,"phases":4271,"primaryCompletion":4272,"completion":4272,"start":4273,"enrollment":871,"conditions":4274,"interventions":4275},"NCT02092298","Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer",[88],"2020-05-12","2014-05-08",[4195],[2271,1709,4276],"Sodium Thiosulfate",{"nctId":4278,"briefTitle":4279,"status":279,"phases":4280,"primaryCompletion":4281,"completion":4281,"start":4282,"enrollment":2159,"conditions":4283,"interventions":4284},"NCT05118854","A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation",[88],"2027-10-20","2022-03-30",[24],[4285,1709,1369,1377],"AMG 510",{"nctId":4287,"briefTitle":4288,"status":130,"phases":4289,"primaryCompletion":4290,"completion":4290,"start":4039,"enrollment":4291,"conditions":4292,"interventions":4293},"NCT00514540","Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer",[88],"2013-04",121,[27],[1710,1369,2424,1709],{"nctId":4295,"briefTitle":4296,"status":102,"phases":4297,"primaryCompletion":224,"completion":224,"start":4298,"enrollment":4299,"conditions":4300,"interventions":4301},"NCT01154920","Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma",[88],"2010-07-09",128,[450],[1376,1369,1683,1710,1709,1371],{"trials":4303,"activeCount":166,"soonestReadout":3426},[4304,4320,4334,4346,4356,4366],{"nctId":4305,"briefTitle":4306,"status":130,"phases":4307,"primaryCompletion":4308,"completion":4308,"start":4309,"enrollment":2402,"conditions":4310,"interventions":4311},"NCT00002565","Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma",[89],"2007-02-05","1994-05-25",[21],[4312,4313,4045,2879,2880,2882,4314,4315,4047,4316,4317,4318,4319,2884],"bleomycin sulfate","CHOP regimen","etoposide","idarubicin","mesna","methylprednisolone","mitoxantrone hydrochloride","prednisone",{"nctId":4321,"briefTitle":4322,"status":130,"phases":4323,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":4327,"interventions":4328},"NCT00577993","Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients",[89],"2017-08-24","1998-03-16",210,[21],[1070,4329,4330,894,3671,1013,1016,4331,803,2424,1709,2584,4332,4333,809],"Novantrone","Decadron","Bleomycin","Methyl-Prednisolone","Procarbazine",{"nctId":4335,"briefTitle":4336,"status":279,"phases":4337,"primaryCompletion":3426,"completion":3426,"start":4338,"enrollment":4339,"conditions":4340,"interventions":4344},"NCT03583710","Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence",[89],"2018-08-20",240,[4341,4342,4343],"ENSAT Stage I Adrenal Cortex Carcinoma","ENSAT Stage II Adrenal Cortex Carcinoma","ENSAT Stage III Adrenal Cortex Carcinoma",[1709,2424,4345],"Mitotane",{"nctId":4347,"briefTitle":4348,"status":130,"phases":4349,"primaryCompletion":4350,"completion":4351,"start":4352,"enrollment":342,"conditions":4353,"interventions":4355},"NCT00002882","Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma",[89],"2003-08","2006-04","1995-11",[1729,4354],"Skin Cancer",[1599,4109,1709,1869,1868],{"nctId":4357,"briefTitle":4358,"status":130,"phases":4359,"primaryCompletion":4360,"completion":4360,"start":4361,"enrollment":4362,"conditions":4363,"interventions":4364},"NCT00002836","Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer",[89],"2006-03-09","1995-09-26",184,[18],[1069,4365,1709,803,2424,1254],"Carmustine",{"nctId":4367,"briefTitle":4368,"status":130,"phases":4369,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":4372,"interventions":4373},"NCT00002835","Combination Chemotherapy in Treating Patients With Lymphoma",[89],"2004-02-04","1995-10-30",[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":4375,"activeCount":124},[],{"trials":4377,"activeCount":124},[4378],{"nctId":4379,"briefTitle":4380,"status":182,"phases":4381,"primaryCompletion":4382,"completion":4382,"start":2932,"enrollment":1483,"conditions":4383,"interventions":4385},"NCT00673179","Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy",[91],"2010-11",[4384],"Osteosarcoma",[1013,1709,806,1113,4386,2495,2369,4387,1114],"Dexrazoxane","Sargramostim",{"intervention":599,"totalTrials":834,"cells":4389},{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4406,"PHASE3":4487,"PHASE4":4493,"NA":4495},{"trials":4391,"activeCount":124},[],{"trials":4393,"activeCount":124},[4394,4400],{"nctId":4395,"briefTitle":4396,"status":182,"phases":4397,"primaryCompletion":1327,"completion":1327,"start":1043,"enrollment":1231,"conditions":4398,"interventions":4399},"NCT06021600","A Phase 1, Open-Label, Sequential Cross-over, Bioavailability\u002FBioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine",[87],[15,1036,36],[599],{"nctId":4401,"briefTitle":4402,"status":203,"phases":4403,"primaryCompletion":3509,"completion":3509,"start":3509,"enrollment":124,"conditions":4404,"interventions":4405},"NCT06474663","A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias",[87],[494,495],[599,654,2207,612],{"trials":4407,"activeCount":1496,"soonestReadout":815},[4408,4412,4419,4423,4431,4440,4444,4453,4457,4466,4470,4474,4478],{"nctId":588,"briefTitle":589,"status":546,"phases":4409,"primaryCompletion":591,"completion":592,"start":104,"enrollment":593,"conditions":4410,"interventions":4411},[87,88],[595,596],[598,599,480],{"nctId":4413,"briefTitle":4414,"status":279,"phases":4415,"primaryCompletion":2302,"completion":2302,"start":4416,"enrollment":798,"conditions":4417,"interventions":4418},"NCT01515527","Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)",[88],"2012-02-07",[15],[599,654,612],{"nctId":636,"briefTitle":637,"status":279,"phases":4420,"primaryCompletion":639,"completion":639,"start":640,"enrollment":641,"conditions":4421,"interventions":4422},[88],[643,36,644,645,646,647,30,648,608,649,610,650,651,652],[599,654,565,655,656,480],{"nctId":4424,"briefTitle":4425,"status":279,"phases":4426,"primaryCompletion":224,"completion":224,"start":4427,"enrollment":1975,"conditions":4428,"interventions":4430},"NCT04047641","Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[87,88],"2019-10-22",[36,4429,1067,630,608,3112,610,3113],"Blasts 20 Percent or More of Bone Marrow Nucleated Cells",[599,654,655,613],{"nctId":4432,"briefTitle":4433,"status":130,"phases":4434,"primaryCompletion":4435,"completion":4435,"start":4436,"enrollment":1609,"conditions":4437,"interventions":4438},"NCT04848974","Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia",[87,88],"2024-10-30","2021-06-11",[651],[599,654,4439],"Uproleselan",{"nctId":812,"briefTitle":813,"status":279,"phases":4441,"primaryCompletion":815,"completion":815,"start":816,"enrollment":817,"conditions":4442,"interventions":4443},[88],[36],[510,599,654,480],{"nctId":4445,"briefTitle":4446,"status":130,"phases":4447,"primaryCompletion":4448,"completion":4448,"start":4449,"enrollment":1559,"conditions":4450,"interventions":4451},"NCT02096055","Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia",[88],"2020-11-24","2014-04-04",[652],[599,4452,655],"Guadecitabine",{"nctId":996,"briefTitle":997,"status":102,"phases":4454,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":4455,"interventions":4456},[88],[36,30],[1004,599,1005,480],{"nctId":4458,"briefTitle":4459,"status":279,"phases":4460,"primaryCompletion":956,"completion":956,"start":4461,"enrollment":1045,"conditions":4462,"interventions":4465},"NCT00412594","Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia",[88],"2004-06-10",[4463,4464],"Hairy Cell Leukemia","Recurrent Hairy Cell Leukemia",[599,894],{"nctId":1030,"briefTitle":1031,"status":279,"phases":4467,"primaryCompletion":224,"completion":224,"start":1033,"enrollment":1034,"conditions":4468,"interventions":4469},[88],[1036,1037],[599,654,480,510],{"nctId":1148,"briefTitle":1149,"status":279,"phases":4471,"primaryCompletion":1151,"completion":1152,"start":1153,"enrollment":1154,"conditions":4472,"interventions":4473},[88],[1156,1157,1158],[963,599,480,565,598,654],{"nctId":3413,"briefTitle":3414,"status":130,"phases":4475,"primaryCompletion":2953,"completion":2953,"start":3416,"enrollment":1140,"conditions":4476,"interventions":4477},[88],[3418,15,1036],[1069,599,3420,654,1005,655,1014],{"nctId":4479,"briefTitle":4480,"status":279,"phases":4481,"primaryCompletion":224,"completion":224,"start":4482,"enrollment":1222,"conditions":4483,"interventions":4485},"NCT03589729","Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers",[88],"2018-09-19",[36,644,645,1067,4484,727,912],"Myeloid Sarcoma",[599,654,4486,694,655],"Dexrazoxane Hydrochloride",{"trials":4488,"activeCount":166,"soonestReadout":224},[4489],{"nctId":1247,"briefTitle":1248,"status":279,"phases":4490,"primaryCompletion":224,"completion":224,"start":1250,"enrollment":1251,"conditions":4491,"interventions":4492},[88,89],[36,737,30],[1004,599,1005,1254,480],{"trials":4494,"activeCount":124},[],{"trials":4496,"activeCount":124},[],{"intervention":1004,"totalTrials":1140,"cells":4498},{"EARLY_PHASE1":4499,"PHASE1":4505,"PHASE2":4564,"PHASE3":4857,"PHASE4":4891,"NA":4893},{"trials":4500,"activeCount":124},[4501],{"nctId":2181,"briefTitle":2182,"status":203,"phases":4502,"primaryCompletion":2184,"completion":2184,"start":2185,"enrollment":124,"conditions":4503,"interventions":4504},[86],[2187,2188,2189,2190,2191,2192],[75,1004,803,62,1005,2194,2195,894,2196],{"trials":4506,"activeCount":124},[4507,4515,4527,4531,4538,4546,4554],{"nctId":4508,"briefTitle":4509,"status":130,"phases":4510,"primaryCompletion":2242,"completion":2242,"start":4511,"enrollment":959,"conditions":4512,"interventions":4513},"NCT01421173","Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies",[87],"2011-08",[21],[2405,2369,1004,2293,894,2374,2368,4514],"Dexamethasone acetate",{"nctId":4516,"briefTitle":4517,"status":130,"phases":4518,"primaryCompletion":4519,"completion":4519,"start":4520,"enrollment":1922,"conditions":4521,"interventions":4525},"NCT01471067","Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies",[87],"2017-04-25","2012-07-13",[4522,15,21,4523,4524],"Blood And Marrow Transplantation","Transplantation Infection","Transplantation, Bone Marrow",[2293,1070,2757,2196,894,4526,1004,2423],"ATG",{"nctId":3077,"briefTitle":3078,"status":130,"phases":4528,"primaryCompletion":3080,"completion":3080,"start":3081,"enrollment":3082,"conditions":4529,"interventions":4530},[87],[2512,678,1411,30,648,913,608],[3085,1004,2423,1005,2405],{"nctId":4532,"briefTitle":4533,"status":130,"phases":4534,"primaryCompletion":206,"completion":206,"start":4039,"enrollment":1568,"conditions":4535,"interventions":4536},"NCT00402558","Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)",[87],[30,15],[4537,1004,1070,2374,2196,806,3499],"Thymoglobulin",{"nctId":4539,"briefTitle":4540,"status":130,"phases":4541,"primaryCompletion":4542,"completion":4542,"start":2969,"enrollment":817,"conditions":4543,"interventions":4544},"NCT00410982","Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies",[87],"2012-09",[15,21,2245],[1004,2369,2293,4545,2368],"Rituximab for Patients with B-Cell Malignancies",{"nctId":4547,"briefTitle":4548,"status":130,"phases":4549,"primaryCompletion":3667,"completion":3667,"start":4550,"enrollment":4551,"conditions":4552,"interventions":4553},"NCT00498316","Cord Blood Expansion on Mesenchymal Stem Cells",[87],"2007-07-03",98,[30,15],[1004,1070,894,803,2423,2293,2196,2195,2374],{"nctId":4555,"briefTitle":4556,"status":130,"phases":4557,"primaryCompletion":3519,"completion":3519,"start":675,"enrollment":676,"conditions":4558,"interventions":4563},"NCT03259503","Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant",[87],[4559,4560,4561,3061,4562],"Recurrent Diffuse Large B-Cell Lymphoma","Recurrent T-Cell Non-Hodgkin Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory T-Cell Non-Hodgkin Lymphoma",[1004,2369,2293,1374,894,2405],{"trials":4565,"activeCount":1483,"soonestReadout":1427},[4566,4573,4583,4587,4591,4601,4608,4615,4623,4630,4639,4643,4650,4654,4661,4669,4673,4677,4685,4693,4701,4711,4719,4727,4736,4745,4754,4762,4766,4770,4778,4782,4789,4799,4806,4814,4826,4830,4838,4846,4853],{"nctId":4567,"briefTitle":4568,"status":130,"phases":4569,"primaryCompletion":1505,"completion":1505,"start":4570,"enrollment":3379,"conditions":4571,"interventions":4572},"NCT00475020","Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome",[88],"2006-01-04",[3429],[1004,1070,4537],{"nctId":4574,"briefTitle":4575,"status":182,"phases":4576,"primaryCompletion":4577,"completion":4577,"start":4578,"enrollment":296,"conditions":4579,"interventions":4581},"NCT02410551","Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)",[88],"2017-01-20","2015-06-15",[4580],"Myeloproliferative Diseases",[4582,1004,1070],"Pacritinib",{"nctId":2361,"briefTitle":2362,"status":203,"phases":4584,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":124,"conditions":4585,"interventions":4586},[88],[21],[2368,2340,2369,1004,2293,894,62,2370,2371,2372,2373,2374],{"nctId":2397,"briefTitle":2398,"status":130,"phases":4588,"primaryCompletion":2400,"completion":2400,"start":2401,"enrollment":2402,"conditions":4589,"interventions":4590},[87,88],[33,21],[510,2405,2369,1004,2293,62,2371,2372,894],{"nctId":4592,"briefTitle":4593,"status":130,"phases":4594,"primaryCompletion":1518,"completion":1518,"start":4595,"enrollment":230,"conditions":4596,"interventions":4600},"NCT03096782","Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma",[88],"2017-10-13",[1205,643,4597,1122,2512,36,846,3292,712,4598,737,1866,4599,3040,30,3233,3041,3059,914,632,716,882],"Acute Leukemia","Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Langerhans Cell Histiocytosis",[3085,1004,2423,803,2712,1070,2293,2195,894,2196],{"nctId":4602,"briefTitle":4603,"status":130,"phases":4604,"primaryCompletion":4605,"completion":4605,"start":2968,"enrollment":3409,"conditions":4606,"interventions":4607},"NCT01200329","High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease",[88],"2018-12-06",[21],[2369,1004,2293,2368],{"nctId":4609,"briefTitle":4610,"status":130,"phases":4611,"primaryCompletion":3571,"completion":3571,"start":4612,"enrollment":2647,"conditions":4613,"interventions":4614},"NCT00469014","Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia",[88],"2006-09",[36,30,3315],[2423,1004,1070,4537,1069],{"nctId":4616,"briefTitle":4617,"status":130,"phases":4618,"primaryCompletion":3805,"completion":3805,"start":4619,"enrollment":2997,"conditions":4620,"interventions":4621},"NCT00822770","Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin",[87,88],"2009-01",[2755,15],[4622,1069,1070,1004,4526],"Plerixafor",{"nctId":4624,"briefTitle":4625,"status":203,"phases":4626,"primaryCompletion":4619,"completion":4619,"start":4153,"enrollment":124,"conditions":4627,"interventions":4628},"NCT00446173","Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia",[88],[15],[1004,803,2374,4629],"GM-CSF",{"nctId":4631,"briefTitle":4632,"status":130,"phases":4633,"primaryCompletion":4634,"completion":4634,"start":4635,"enrollment":2946,"conditions":4636,"interventions":4638},"NCT02506959","Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma",[88],"2024-06-03","2015-09-14",[3396,4637,2223,2224],"Plasmacytoma",[1004,4135,2293,2340],{"nctId":2479,"briefTitle":2480,"status":130,"phases":4640,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":1308,"conditions":4641,"interventions":4642},[88],[2245],[2368,62,2369,1004,2293,2374],{"nctId":4644,"briefTitle":4645,"status":130,"phases":4646,"primaryCompletion":4382,"completion":4382,"start":4647,"enrollment":663,"conditions":4648,"interventions":4649},"NCT00427765","Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma",[88],"2004-12",[1400,21],[1004,2293],{"nctId":3238,"briefTitle":3239,"status":102,"phases":4651,"primaryCompletion":1427,"completion":1427,"start":225,"enrollment":163,"conditions":4652,"interventions":4653},[88],[359,3242,1067,3243,30,3244,913,608,649,3112,3059,609,3060,2223],[1004,803,1070,1005,2195,2196,1254],{"nctId":4655,"briefTitle":4656,"status":182,"phases":4657,"primaryCompletion":3902,"completion":3902,"start":3438,"enrollment":1231,"conditions":4658,"interventions":4660},"NCT00043810","Study of Gelonin Purging of Autologous Stem Cells for Transplantation",[87,88],[4659,30],"Acute Myelogenous Leukemia",[1004,1070],{"nctId":4662,"briefTitle":4663,"status":182,"phases":4664,"primaryCompletion":2836,"completion":2836,"start":4665,"enrollment":924,"conditions":4666,"interventions":4667},"NCT00499889","Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients",[88],"2003-02",[15],[2321,1070,1004,4668,2196,806],"Antithymocyte Globulin",{"nctId":2598,"briefTitle":2599,"status":203,"phases":4670,"primaryCompletion":2601,"start":2602,"enrollment":124,"conditions":4671,"interventions":4672},[88],[2245],[2227,2605,2369,1004,2293,2368,62,2370,2371,2372],{"nctId":3285,"briefTitle":3286,"status":279,"phases":4674,"primaryCompletion":860,"completion":860,"start":3288,"enrollment":1222,"conditions":4675,"interventions":4676},[88],[1205,643,1122,2512,3290,3291,2471,3292,737,1025,3056,3057,3058,30,3233,3293,3244,648,608,3186,3059,3060,914,3294,651,882],[3296,3085,1004,2423,803,1005,2293,894],{"nctId":4678,"briefTitle":4679,"status":130,"phases":4680,"primaryCompletion":4681,"completion":4681,"start":4682,"enrollment":1034,"conditions":4683,"interventions":4684},"NCT00857389","Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies",[88],"2019-03-09","2009-03-02",[2755,15,21],[1254,2423,1004,4537,2374,2196,806,803,1114],{"nctId":4686,"briefTitle":4687,"status":102,"phases":4688,"primaryCompletion":224,"completion":224,"start":4689,"enrollment":4690,"conditions":4691,"interventions":4692},"NCT03247088","Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant",[87,88],"2017-07-30",74,[608,610],[1004,803,1069,1070,2195,2207,2196],{"nctId":4694,"briefTitle":4695,"status":130,"phases":4696,"primaryCompletion":1558,"start":4697,"enrollment":2911,"conditions":4698,"interventions":4700},"NCT00800839","Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide",[88],"2008-09",[4699,15,21,2245],"Hematologic Diseases",[1004,1070,803],{"nctId":4702,"briefTitle":4703,"status":203,"phases":4704,"primaryCompletion":4705,"completion":4705,"start":4705,"enrollment":124,"conditions":4706,"interventions":4710},"NCT04220008","Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma",[88],"2021-10-29",[4707,3272,2415,4559,4708,4560,4709],"Recurrent Aggressive Non-Hodgkin Lymphoma","Recurrent High Grade B-Cell Lymphoma","Recurrent Transformed B-Cell Non-Hodgkin Lymphoma",[1004,2423,803,2369,2195,894,2196,2405],{"nctId":4712,"briefTitle":4713,"status":130,"phases":4714,"primaryCompletion":4715,"completion":4716,"start":4635,"enrollment":95,"conditions":4717,"interventions":4718},"NCT02441803","Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)",[88],"2020-09-22","2021-09-22",[15],[1004,1070,2423,4537,2373,803,2196,2757,612,654,655],{"nctId":4720,"briefTitle":4721,"status":130,"phases":4722,"primaryCompletion":4192,"completion":4723,"start":3902,"enrollment":628,"conditions":4724,"interventions":4726},"NCT01003054","Autologous Transplantation for Chronic Myelogenous Leukemia",[88],"2009-10",[4725],"Chronic Myelogenous Leukemia",[1004,803,2321],{"nctId":4728,"briefTitle":4729,"status":130,"phases":4730,"primaryCompletion":4731,"completion":4731,"start":4732,"enrollment":4733,"conditions":4734,"interventions":4735},"NCT00502905","Busulfan and Fludarabine in Patients With AML and MDS",[88],"2008-11","2003-10",200,[15],[1004,1070],{"nctId":4737,"briefTitle":4738,"status":130,"phases":4739,"primaryCompletion":4740,"completion":4740,"start":4741,"enrollment":3354,"conditions":4742,"interventions":4744},"NCT01701986","Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma",[87,88],"2024-06-05","2012-10-25",[4743,3277,3061,4562],"Hematopoietic Cell Transplantation Recipient",[3085,1004,2423,4135,2195,894,2196],{"nctId":4746,"briefTitle":4747,"status":182,"phases":4748,"primaryCompletion":4749,"completion":4749,"start":4750,"enrollment":1568,"conditions":4751,"interventions":4753},"NCT01629511","Allogeneic Stem Cell Transplant for CLL",[87,88],"2018-04-25","2012-11-21",[1411,712,4752,715],"Prolymphocytic Leukemia",[3085,1004,2423,1069,2369,806,2196],{"nctId":4755,"briefTitle":4756,"status":130,"phases":4757,"primaryCompletion":4511,"completion":4511,"start":4758,"enrollment":28,"conditions":4759,"interventions":4761},"NCT00506857","Phase I\u002FII Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support",[87,88],"2003-11",[4760],"Hematologic Malignancies",[1004,1070],{"nctId":996,"briefTitle":997,"status":102,"phases":4763,"primaryCompletion":999,"completion":999,"start":1000,"enrollment":1001,"conditions":4764,"interventions":4765},[88],[36,30],[1004,599,1005,480],{"nctId":3374,"briefTitle":3375,"status":130,"phases":4767,"primaryCompletion":3377,"completion":3377,"start":3378,"enrollment":3379,"conditions":4768,"interventions":4769},[87,88],[1205,3381,3382,36,846,678,644,3383,3384,737,1067,30,649,682,882],[1599,3386,1004,1005],{"nctId":4771,"briefTitle":4772,"status":102,"phases":4773,"primaryCompletion":2455,"completion":2455,"start":4774,"enrollment":2004,"conditions":4775,"interventions":4776},"NCT04859946","Itacitinib for the Prevention of Graft Versus Host Disease",[88],"2022-01-11",[680],[1004,803,1070,4777,2196,1254],"Itacitinib",{"nctId":2749,"briefTitle":2750,"status":203,"phases":4779,"primaryCompletion":2752,"completion":2752,"start":2753,"enrollment":124,"conditions":4780,"interventions":4781},[88],[2755],[1070,62,803,75,894,1004,803,2196,2757,2758],{"nctId":4783,"briefTitle":4784,"status":130,"phases":4785,"primaryCompletion":2602,"completion":2602,"start":4786,"enrollment":628,"conditions":4787,"interventions":4788},"NCT00813124","Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)",[88],"2008-12",[2755,15],[1070,1004,4537,510],{"nctId":4790,"briefTitle":4791,"status":279,"phases":4792,"primaryCompletion":548,"completion":490,"start":4793,"enrollment":517,"conditions":4794,"interventions":4797},"NCT06207799","Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma",[88],"2024-07-17",[1400,4795,4796],"Post-transplant MRD-guided Maintenance Therapy","Pre-transplant Purging",[4798,1402,4622,2293,1004,2374],"Elranatamab",{"nctId":4800,"briefTitle":4801,"status":130,"phases":4802,"primaryCompletion":3493,"completion":3493,"start":4723,"enrollment":1100,"conditions":4803,"interventions":4805},"NCT00990249","Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation",[88],[15,21,4804,1122],"Allogeneic Haematopoietic Stem Cell Transplantation",[1004,2423,4537],{"nctId":4807,"briefTitle":4808,"status":130,"phases":4809,"primaryCompletion":4810,"completion":4810,"start":4811,"enrollment":628,"conditions":4812,"interventions":4813},"NCT00002831","Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia",[87,88],"2002-12-31","1995-08-01",[15],[1069,1004,803,3420,612,806,1014,2196],{"nctId":4815,"briefTitle":4816,"status":130,"phases":4817,"primaryCompletion":4818,"completion":4818,"start":4819,"enrollment":4820,"conditions":4821,"interventions":4824},"NCT01572662","Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning",[88],"2022-08-11","2012-04-11",201,[15,36,2838,3315,712,4580,4822,4823,1400,30],"Non-Hodgkins Lymphoma","Hodgkins Lymphoma",[4825,1004,2196,806,2374],"Fludarabine monophosphate",{"nctId":3422,"briefTitle":3423,"status":279,"phases":4827,"primaryCompletion":3425,"completion":3426,"start":3427,"enrollment":406,"conditions":4828,"interventions":4829},[88],[2135,3429],[598,3431,3432,1004,3433,2462,803,1114,2196],{"nctId":4831,"briefTitle":4832,"status":203,"phases":4833,"primaryCompletion":4834,"start":4835,"enrollment":124,"conditions":4836,"interventions":4837},"NCT02701673","Belinostat Combined With Azacitidine\u002FGemcitabine\u002FBusulfan\u002FMelphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma",[87,88],"2019-06","2016-06",[21],[1004,2370,2371,2372,2235,510,2369,2293],{"nctId":4839,"briefTitle":4840,"status":130,"phases":4841,"primaryCompletion":4842,"completion":4842,"start":4843,"enrollment":230,"conditions":4844,"interventions":4845},"NCT01390402","Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine\u002FATG",[88],"2014-11","2012-01",[15,4725],[1070,1004,3499,3085,2196,806,2374],{"nctId":4847,"briefTitle":4848,"status":203,"phases":4849,"primaryCompletion":4715,"completion":4715,"start":4715,"enrollment":124,"conditions":4850,"interventions":4852},"NCT04127721","Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation",[88],[4851,680,359],"Allogeneic Stem Cell Transplant Recipient",[1004,1070,4777,806,2196],{"nctId":2897,"briefTitle":2898,"status":182,"phases":4854,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":186,"conditions":4855,"interventions":4856},[87,88],[21],[1402,2405,2369,1004,2293,894,62,2370,2371,2372,2904,2368],{"trials":4858,"activeCount":166,"soonestReadout":224},[4859,4863,4873,4883],{"nctId":1247,"briefTitle":1248,"status":279,"phases":4860,"primaryCompletion":224,"completion":224,"start":1250,"enrollment":1251,"conditions":4861,"interventions":4862},[88,89],[36,737,30],[1004,599,1005,1254,480],{"nctId":4864,"briefTitle":4865,"status":130,"phases":4866,"primaryCompletion":4867,"completion":4867,"start":4868,"enrollment":4869,"conditions":4870,"interventions":4872},"NCT01471444","Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)",[89],"2020-12-14","2011-11-02",256,[4871,15,4523],"Disorder Related to Bone Marrow Transplantation",[1070,2423,1004,4537,2196,806],{"nctId":4874,"briefTitle":4875,"status":130,"phases":4876,"primaryCompletion":4877,"completion":4877,"start":4878,"enrollment":4879,"conditions":4880,"interventions":4881},"NCT01413178","A Randomized Trial to Compare Busulfan + Melphalan 140 mg\u002Fm2 With Melphalan 200 mg\u002Fm2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma",[89],"2019-03-10","2011-09-30",205,[2245],[1004,2293,2374,4882],"High Dose Melphalan",{"nctId":4884,"briefTitle":4885,"status":130,"phases":4886,"primaryCompletion":4842,"completion":4842,"start":4887,"enrollment":4888,"conditions":4889,"interventions":4890},"NCT00469144","IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome",[89],"2005-06",233,[30,15,36],[1004,1070],{"trials":4892,"activeCount":124},[],{"trials":4894,"activeCount":124},[],{"intervention":4896,"totalTrials":95,"cells":4897},"Chemotherapy",{"EARLY_PHASE1":4898,"PHASE1":4995,"PHASE2":4997,"PHASE3":5050,"PHASE4":5068,"NA":5070},{"trials":4899,"activeCount":121,"soonestReadout":772},[4900,4930,4974,4983],{"nctId":4901,"briefTitle":4902,"status":102,"phases":4903,"primaryCompletion":4904,"completion":4904,"start":4905,"enrollment":1568,"conditions":4906,"interventions":4929},"NCT03943173","Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery",[86],"2027-06-27","2019-06-07",[4907,4908,4909,4910,4911,4912,4913,4914,4915,4916,4917,4918,4919,4920,4921,4922,4923,4924,4925,4926,4927,4928,1462,1463,1464,1465,1466,1467,1469,1470,1471],"BRCA-Mutated Ovarian Carcinoma","BRCA1 Gene Mutation","BRCA2 Gene Mutation","High Grade Fallopian Tube Serous Adenocarcinoma","High Grade Ovarian Serous Adenocarcinoma","Primary Peritoneal High Grade Serous Adenocarcinoma","Stage III Fallopian Tube Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Primary Peritoneal Cancer AJCC v8","Stage IIIA Fallopian Tube Cancer AJCC v8","Stage IIIA Ovarian Cancer AJCC v8","Stage IIIA Primary Peritoneal Cancer AJCC v8","Stage IIIA1 Fallopian Tube Cancer AJCC v8","Stage IIIA1 Ovarian Cancer AJCC v8","Stage IIIA2 Fallopian Tube Cancer AJCC v8","Stage IIIA2 Ovarian Cancer AJCC v8","Stage IIIB Fallopian Tube Cancer AJCC v8","Stage IIIB Ovarian Cancer AJCC v8","Stage IIIB Primary Peritoneal Cancer AJCC v8","Stage IIIC Fallopian Tube Cancer AJCC v8","Stage IIIC Ovarian Cancer AJCC v8","Stage IIIC Primary Peritoneal Cancer AJCC v8",[4896,1374],{"nctId":4931,"briefTitle":4932,"status":130,"phases":4933,"primaryCompletion":4934,"completion":4934,"start":4935,"enrollment":507,"conditions":4936,"interventions":4972},"NCT01504126","Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[86],"2019-08-15","2012-03-09",[4937,4938,4939,4940,4941,4942,4943,4944,4945,4946,4947,4948,4949,4950,4951,4952,4953,4954,4955,4956,4957,4958,4959,4960,4961,4962,4963,4964,4965,4966,4967,4968,4969,4970,4971],"Fallopian Tube Clear Cell Adenocarcinoma","Fallopian Tube Endometrioid Adenocarcinoma","Fallopian Tube Mucinous Adenocarcinoma","Fallopian Tube Serous Adenocarcinoma","Fallopian Tube Undifferentiated Carcinoma","Ovarian Clear Cell Adenocarcinoma","Ovarian Endometrioid Adenocarcinoma","Ovarian Mucinous Adenocarcinoma","Ovarian Seromucinous Carcinoma","Ovarian Serous Adenocarcinoma","Ovarian Undifferentiated Carcinoma","Primary Peritoneal Serous Adenocarcinoma","Stage II Fallopian Tube Cancer AJCC v6 and v7","Stage II Ovarian Cancer AJCC v6 and v7","Stage IIA Fallopian Tube Cancer AJCC v6 and v7","Stage IIA Ovarian Cancer AJCC V6 and v7","Stage IIB Fallopian Tube Cancer AJCC v6 and v7","Stage IIB Ovarian Cancer AJCC v6 and v7","Stage IIC Fallopian Tube Cancer AJCC v6 and v7","Stage IIC Ovarian Cancer AJCC v6 and v7","Stage III Fallopian Tube Cancer AJCC v7","Stage III Ovarian Cancer AJCC v6 and v7","Stage III Primary Peritoneal Cancer AJCC v7","Stage IIIA Fallopian Tube Cancer AJCC v7","Stage IIIA Ovarian Cancer AJCC v6 and v7","Stage IIIA Primary Peritoneal Cancer AJCC v7","Stage IIIB Fallopian Tube Cancer AJCC v7","Stage IIIB Ovarian Cancer AJCC v6 and v7","Stage IIIB Primary Peritoneal Cancer AJCC v7","Stage IIIC Fallopian Tube Cancer AJCC v7","Stage IIIC Ovarian Cancer AJCC v6 and v7","Stage IIIC Primary Peritoneal Cancer AJCC v7","Stage IV Fallopian Tube Cancer AJCC v6 and v7","Stage IV Ovarian Cancer AJCC v6 and v7","Stage IV Primary Peritoneal Cancer AJCC v7",[4896,4973],"Propranolol Hydrochloride",{"nctId":4975,"briefTitle":4976,"status":130,"phases":4977,"primaryCompletion":4978,"completion":4978,"start":4979,"enrollment":1328,"conditions":4980,"interventions":4981},"NCT02405078","Tumor-Specific Clonotype, Metabolic Profile, and PET\u002FCT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",[86],"2022-10-03","2015-10-13",[4559,4561],[4896,4982],"Fludeoxyglucose F-18",{"nctId":4984,"briefTitle":4985,"status":279,"phases":4986,"primaryCompletion":772,"completion":772,"start":4987,"enrollment":1100,"conditions":4988,"interventions":4994},"NCT03594630","Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer",[86],"2024-03-13",[4989,4990,4991,4992,4993,1900,1902,1904,1906],"Rectal Adenocarcinoma","Stage II Rectal Cancer AJCC v8","Stage IIA Rectal Cancer AJCC v8","Stage IIB Rectal Cancer AJCC v8","Stage IIC Rectal Cancer AJCC v8",[4896],{"trials":4996,"activeCount":124},[],{"trials":4998,"activeCount":121,"soonestReadout":446},[4999,5012,5021,5031,5042],{"nctId":5000,"briefTitle":5001,"status":182,"phases":5002,"primaryCompletion":5003,"completion":5003,"start":5004,"enrollment":1409,"conditions":5005,"interventions":5011},"NCT02738606","Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery",[88],"2025-12-05","2016-09-23",[1898,3512,5006,1671,5007,5008,5009,5010],"Metastatic Malignant Neoplasm in the Lung","Resectable Colorectal Carcinoma","Stage IV Colorectal Cancer AJCC v7","Stage IVA Colorectal Cancer AJCC v7","Stage IVB Colorectal Cancer AJCC v7",[4896],{"nctId":5013,"briefTitle":5014,"status":203,"phases":5015,"primaryCompletion":5016,"start":5017,"enrollment":124,"conditions":5018,"interventions":5019},"NCT00005969","Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease",[88],"2001-01","1999-09",[21],[4896,5020],"Tretinoin Liposome",{"nctId":5022,"briefTitle":5023,"status":102,"phases":5024,"primaryCompletion":5025,"completion":5025,"start":5026,"enrollment":517,"conditions":5027,"interventions":5030},"NCT03599752","Chemotherapy and\u002For Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases",[88],"2030-01-31","2018-07-02",[5028,5029,1676,1677,1678,1679],"Colorectal Adenocarcinoma","Colorectal Carcinoma Metastatic in the Lung",[4896],{"nctId":5032,"briefTitle":5033,"status":279,"phases":5034,"primaryCompletion":446,"completion":446,"start":5035,"enrollment":1222,"conditions":5036,"interventions":5041},"NCT03161522","Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer",[88],"2018-02-19",[1638,5037,5038,5039,5040],"Oligometastasis","Stage IV Esophageal Adenocarcinoma AJCC v7","Stage IV Esophageal Cancer AJCC v7","Stage IV Gastric Cancer AJCC v7",[1368,4896,1371],{"nctId":5043,"briefTitle":5044,"status":130,"phases":5045,"primaryCompletion":5046,"completion":5046,"start":5047,"enrollment":2581,"conditions":5048,"interventions":5049},"NCT01927744","Study of Chemotherapy With Cisplatin\u002FCarboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection",[88],"2025-01-06","2013-12-16",[242],[1710,3847,4896],{"trials":5051,"activeCount":166,"soonestReadout":281},[5052],{"nctId":5053,"briefTitle":5054,"status":279,"phases":5055,"primaryCompletion":281,"completion":281,"start":5056,"enrollment":5057,"conditions":5058,"interventions":5067},"NCT04575935","Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial",[89],"2020-08-05",580,[5059,4937,5060,5061,5062,4942,4943,4946,5063,5064,5065,4948,5066,4926,4927,4928,1462,1463,1464,1465,1466,1467,1469,1470,1471],"Advanced Ovarian Carcinoma","Fallopian Tube Endometrioid Tumor","Fallopian Tube Serous Neoplasm","Fallopian Tube Transitional Cell Carcinoma","Ovarian Transitional Cell Carcinoma","Primary Peritoneal Clear Cell Adenocarcinoma","Primary Peritoneal Endometrioid Adenocarcinoma","Primary Peritoneal Transitional Cell Carcinoma",[4896],{"trials":5069,"activeCount":124},[],{"trials":5071,"activeCount":166,"soonestReadout":1078},[5072],{"nctId":5073,"briefTitle":5074,"status":102,"phases":5075,"primaryCompletion":1078,"completion":1078,"start":5076,"enrollment":5077,"conditions":5078,"interventions":5090},"NCT02276443","Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative",[91],"2015-11-09",798,[5079,5080,5081,5082,5083,5084,5085,5086,5087,5088,5089,1363],"Invasive Breast Carcinoma","Stage I Breast Cancer AJCC v7","Stage IA Breast Cancer AJCC v7","Stage IB Breast Cancer AJCC v7","Stage II Breast Cancer AJCC v6 and v7","Stage IIA Breast Cancer AJCC v6 and v7","Stage IIB Breast Cancer AJCC v6 and v7","Stage III Breast Cancer AJCC v7","Stage IIIA Breast Cancer AJCC v7","Stage IIIB Breast Cancer AJCC v7","Stage IIIC Breast Cancer AJCC v7",[4896],{"intervention":3700,"totalTrials":186,"cells":5092},{"EARLY_PHASE1":5093,"PHASE1":5095,"PHASE2":5097,"PHASE3":5166,"PHASE4":5178,"NA":5180},{"trials":5094,"activeCount":124},[],{"trials":5096,"activeCount":124},[],{"trials":5098,"activeCount":296,"soonestReadout":5142},[5099,5115,5125,5134,5138,5148,5157],{"nctId":5100,"briefTitle":5101,"status":279,"phases":5102,"primaryCompletion":5103,"completion":5103,"start":5104,"enrollment":4733,"conditions":5105,"interventions":5112},"NCT04947254","Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer",[88],"2026-06-07","2021-08-05",[5106,5107,5108,5109,5110,5111,3547],"Prostate Carcinoma","Stage IIC Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IIIA Prostate Cancer AJCC v8","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8",[3699,5113,3700,5114,809],"Antiandrogen Therapy","Niraparib",{"nctId":5116,"briefTitle":5117,"status":102,"phases":5118,"primaryCompletion":5119,"completion":5119,"start":5120,"enrollment":1034,"conditions":5121,"interventions":5124},"NCT03821792","Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer",[88],"2026-10-11","2019-07-22",[3545,5122,5123,3546,3547,3548],"Prostate Adenocarcinoma","Prostate Carcinoma Metastatic in the Bone",[3699,3700,809],{"nctId":5126,"briefTitle":5127,"status":203,"phases":5128,"primaryCompletion":5129,"completion":5129,"start":4448,"enrollment":124,"conditions":5130,"interventions":5133},"NCT04585932","Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study",[88],"2021-01-08",[5131,3545,5132,3546,3547,3548],"Biochemically Recurrent Prostate Carcinoma","Oligometastatic Prostate Carcinoma",[3700,3720,3780],{"nctId":3689,"briefTitle":3690,"status":102,"phases":5135,"primaryCompletion":3407,"completion":3407,"start":3692,"enrollment":3693,"conditions":5136,"interventions":5137},[88],[3695,3544,3545,3696,3697],[3699,3700,3701,1369,1049,809],{"nctId":5139,"briefTitle":5140,"status":102,"phases":5141,"primaryCompletion":5142,"completion":5143,"start":5144,"enrollment":195,"conditions":5145,"interventions":5147},"NCT03412396","Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy",[88],"2024-10-03","2026-03-30","2018-03-22",[5122,5146],"Stage IIB Prostate Cancer AJCC v8",[3700],{"nctId":5149,"briefTitle":5150,"status":182,"phases":5151,"primaryCompletion":5152,"completion":5152,"start":5153,"enrollment":1483,"conditions":5154,"interventions":5156},"NCT03360721","Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer",[88],"2026-03-12","2018-03-06",[3544,5155,3546,3547,3548],"Prostate Adenocarcinoma Without Neuroendocrine Differentiation",[3699,3700,809],{"nctId":5158,"briefTitle":5159,"status":130,"phases":5160,"primaryCompletion":5161,"completion":5161,"start":4595,"enrollment":5162,"conditions":5163,"interventions":5164},"NCT03279250","Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer",[88],"2021-05-11",86,[5122,5146,5107,5109,5111],[3699,3700,5165,809],"Gonadotropin-releasing Hormone Analog",{"trials":5167,"activeCount":166,"soonestReadout":956},[5168],{"nctId":5169,"briefTitle":5170,"status":279,"phases":5171,"primaryCompletion":956,"completion":957,"start":5172,"enrollment":1100,"conditions":5173,"interventions":5176},"NCT06274047","PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.",[89],"2024-09-10",[5174,5175,27],"Androgen Axis Suppression","Prostatectomy",[3700,5177],"Androgen Deprivation Therapy",{"trials":5179,"activeCount":124},[],{"trials":5181,"activeCount":124},[],{"intervention":1254,"totalTrials":2779,"cells":5183},{"EARLY_PHASE1":5184,"PHASE1":5186,"PHASE2":5210,"PHASE3":5275,"PHASE4":5285,"NA":5287},{"trials":5185,"activeCount":124},[],{"trials":5187,"activeCount":124},[5188,5196,5206],{"nctId":5189,"briefTitle":5190,"status":203,"phases":5191,"primaryCompletion":2212,"completion":2212,"start":3833,"enrollment":124,"conditions":5192,"interventions":5194},"NCT00972101","Infusion of Expanded Cord Blood T Cells",[87],[2755,15,21,5193],"Pediatric Disorders",[2293,1254,1070,894,2424,5195,2195,2196,2374],"Anti-thymocyte globulin",{"nctId":5197,"briefTitle":5198,"status":130,"phases":5199,"primaryCompletion":5200,"completion":5200,"start":5201,"enrollment":1483,"conditions":5202,"interventions":5204},"NCT00005092","Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",[87],"2002-08-28","1999-05-28",[15,21,5203,1036],"Multiple Myeloma and Plasma Cell Neoplasm",[803,5205,1254],"Psoralen",{"nctId":3159,"briefTitle":3160,"status":203,"phases":5207,"primaryCompletion":1174,"completion":1174,"start":3162,"enrollment":124,"conditions":5208,"interventions":5209},[87],[3164,3165,3166,3167,3168,3169,3170,3171,3172,3173,3174,3175,3176,3177,3178],[2424,1005,2194,2293,2195,2196,1254],{"trials":5211,"activeCount":1231,"soonestReadout":1427},[5212,5220,5224,5228,5236,5248,5252,5263,5271],{"nctId":5213,"briefTitle":5214,"status":279,"phases":5215,"primaryCompletion":1325,"completion":1326,"start":5216,"enrollment":1328,"conditions":5217,"interventions":5218},"NCT06807606","Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation",[88],"2025-03-03",[4760],[5219,1070,1254,2196,2757],"Drugs Cyclophosphamide",{"nctId":3238,"briefTitle":3239,"status":102,"phases":5221,"primaryCompletion":1427,"completion":1427,"start":225,"enrollment":163,"conditions":5222,"interventions":5223},[88],[359,3242,1067,3243,30,3244,913,608,649,3112,3059,609,3060,2223],[1004,803,1070,1005,2195,2196,1254],{"nctId":4678,"briefTitle":4679,"status":130,"phases":5225,"primaryCompletion":4681,"completion":4681,"start":4682,"enrollment":1034,"conditions":5226,"interventions":5227},[88],[2755,15,21],[1254,2423,1004,4537,2374,2196,806,803,1114],{"nctId":5229,"briefTitle":5230,"status":130,"phases":5231,"primaryCompletion":5232,"completion":5232,"start":4183,"enrollment":507,"conditions":5233,"interventions":5235},"NCT00429182","Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer",[88],"2012-02",[18,5234,5079],"Metastatic Breast Carcinoma",[1369,803,1254],{"nctId":5237,"briefTitle":5238,"status":130,"phases":5239,"primaryCompletion":5240,"completion":5240,"start":5241,"enrollment":971,"conditions":5242,"interventions":5246},"NCT00067002","Randomized Double Cord Blood Transplant Study",[88],"2016-07","2003-04",[2530,5243,5244,5245],"Leukemia, Myelocytic, Acute","Leukemia, Myeloid, Chronic","Lymphoma, Non-Hodgkin",[5247,2293,1254,1070,803,1114],"Rituxan",{"nctId":4771,"briefTitle":4772,"status":102,"phases":5249,"primaryCompletion":2455,"completion":2455,"start":4774,"enrollment":2004,"conditions":5250,"interventions":5251},[88],[680],[1004,803,1070,4777,2196,1254],{"nctId":5253,"briefTitle":5254,"status":130,"phases":5255,"primaryCompletion":5256,"completion":5256,"start":5257,"enrollment":5258,"conditions":5259,"interventions":5261},"NCT01010217","Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide",[88],"2017-10-05","2009-11-05",176,[5260,15,4760],"Blood Stem Cell Transplant Failure",[803,1070,2293,1114,894,1254,2196,5262,2374],"Mycofenolate mofetil",{"nctId":5264,"briefTitle":5265,"status":130,"phases":5266,"primaryCompletion":5267,"completion":5267,"start":5268,"enrollment":1409,"conditions":5269,"interventions":5270},"NCT00038857","Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases",[88],"2009-06","2001-09",[15,21],[2293,1254,1070,2758],{"nctId":3443,"briefTitle":3444,"status":182,"phases":5272,"primaryCompletion":3446,"completion":3446,"start":3447,"enrollment":166,"conditions":5273,"interventions":5274},[88],[3449,3450,3451,3452,2570,3453,3454,3455,3456,3457,3458,3459],[3420,2424,1005,2194,2293,2195,2196,1254],{"trials":5276,"activeCount":166,"soonestReadout":224},[5277,5281],{"nctId":1247,"briefTitle":1248,"status":279,"phases":5278,"primaryCompletion":224,"completion":224,"start":1250,"enrollment":1251,"conditions":5279,"interventions":5280},[88,89],[36,737,30],[1004,599,1005,1254,480],{"nctId":4357,"briefTitle":4358,"status":130,"phases":5282,"primaryCompletion":4360,"completion":4360,"start":4361,"enrollment":4362,"conditions":5283,"interventions":5284},[89],[18],[1069,4365,1709,803,2424,1254],{"trials":5286,"activeCount":124},[],{"trials":5288,"activeCount":124},[],{"intervention":5290,"totalTrials":186,"cells":5291},"Methylphenidate",{"EARLY_PHASE1":5292,"PHASE1":5294,"PHASE2":5304,"PHASE3":5315,"PHASE4":5369,"NA":5371},{"trials":5293,"activeCount":124},[],{"trials":5295,"activeCount":124},[5296],{"nctId":5297,"briefTitle":5298,"status":130,"phases":5299,"primaryCompletion":5300,"completion":5300,"start":5301,"enrollment":2004,"conditions":5302,"interventions":5303},"NCT02361125","Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate",[87],"2021-12-28","2002-08-01",[2923],[5290],{"trials":5305,"activeCount":166,"soonestReadout":5310},[5306],{"nctId":5307,"briefTitle":5308,"status":102,"phases":5309,"primaryCompletion":5310,"completion":5310,"start":5311,"enrollment":5312,"conditions":5313,"interventions":5314},"NCT01410942","Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy",[88],"2026-09-30","2012-02-08",175,[27],[5290],{"trials":5316,"activeCount":1231,"soonestReadout":1078},[5317,5326,5334,5340,5351,5358],{"nctId":5318,"briefTitle":5319,"status":130,"phases":5320,"primaryCompletion":5321,"completion":5321,"start":5322,"enrollment":5323,"conditions":5324,"interventions":5325},"NCT00424099","Methylphenidate and a Nursing Telephone Intervention for Fatigue",[88,89],"2021-11-22","2007-01-09",197,[1942,2923],[5290],{"nctId":5327,"briefTitle":5328,"status":102,"phases":5329,"primaryCompletion":446,"completion":446,"start":5330,"enrollment":5331,"conditions":5332,"interventions":5333},"NCT03525873","A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy",[89],"2018-08-02",212,[2922,2924,2925],[5290],{"nctId":5335,"briefTitle":5336,"status":182,"phases":5337,"primaryCompletion":2243,"completion":2243,"start":3819,"enrollment":924,"conditions":5338,"interventions":5339},"NCT00516269","Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients",[89],[18,2923,4195],[5290],{"nctId":5341,"briefTitle":5342,"status":130,"phases":5343,"primaryCompletion":5344,"completion":5345,"start":5346,"enrollment":5347,"conditions":5348,"interventions":5350},"NCT05041946","Patient Controlled Methylphenidate for Cancer Related Fatigue: A Double Blind, Randomized, Placebo Controlled Trial",[89],"2004-12-15","2021-11-19","2003-07-16",112,[2923,5349],"Cancer",[5290],{"nctId":5352,"briefTitle":5353,"status":102,"phases":5354,"primaryCompletion":1078,"completion":1078,"start":5355,"enrollment":4733,"conditions":5356,"interventions":5357},"NCT03772834","Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer",[88,89],"2019-03-25",[5106],[5290],{"nctId":5359,"briefTitle":5360,"status":279,"phases":5361,"primaryCompletion":115,"completion":115,"start":5362,"enrollment":2986,"conditions":5363,"interventions":5367},"NCT05474846","Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer",[88,89],"2022-11-21",[5364,2923,5365,5349,5366],"Sleep","Anxiety","Depression",[5368,5368,5290],"Melatonin",{"trials":5370,"activeCount":124},[],{"trials":5372,"activeCount":124},[],{"intervention":5374,"totalTrials":296,"cells":5375},"Radiation Therapy",{"EARLY_PHASE1":5376,"PHASE1":5387,"PHASE2":5389,"PHASE3":5410,"PHASE4":5420,"NA":5422},{"trials":5377,"activeCount":166,"soonestReadout":5382},[5378],{"nctId":5379,"briefTitle":5380,"status":102,"phases":5381,"primaryCompletion":5382,"completion":5382,"start":5383,"enrollment":448,"conditions":5384,"interventions":5386},"NCT03680586","Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma",[86],"2028-04-30","2019-02-04",[5385],"Gastric Mucosa-Associated Lymphoid Tissue Lymphoma",[5374],{"trials":5388,"activeCount":124},[],{"trials":5390,"activeCount":121,"soonestReadout":5395},[5391,5401],{"nctId":5392,"briefTitle":5393,"status":279,"phases":5394,"primaryCompletion":5395,"completion":5395,"start":5396,"enrollment":406,"conditions":5397,"interventions":5400},"NCT05336383","Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma",[88],"2026-12-07","2022-05-31",[1400,5398,5399],"Plasma Cell Neoplasm","Malignant Plasma Cell Neoplasm",[5374],{"nctId":5402,"briefTitle":5403,"status":279,"phases":5404,"primaryCompletion":1088,"completion":1088,"start":5405,"enrollment":901,"conditions":5406,"interventions":5408},"NCT05100095","Hypofractionated Radiation Therapy for Merkel Cell Carcinoma",[88],"2021-12-14",[5407],"Merkel Cell Carcinoma",[5409],"Radiation therapy",{"trials":5411,"activeCount":166,"soonestReadout":4904},[5412],{"nctId":5413,"briefTitle":5414,"status":279,"phases":5415,"primaryCompletion":4904,"completion":4904,"start":5416,"enrollment":2891,"conditions":5417,"interventions":5419},"NCT06065449","A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases",[89],"2024-01-24",[5418],"Bone Metastases",[5374],{"trials":5421,"activeCount":124},[],{"trials":5423,"activeCount":124},[],{"intervention":2424,"totalTrials":517,"cells":5425},{"EARLY_PHASE1":5426,"PHASE1":5428,"PHASE2":5516,"PHASE3":5705,"PHASE4":5745,"NA":5747},{"trials":5427,"activeCount":124},[],{"trials":5429,"activeCount":124},[5430,5438,5448,5452,5466,5475,5479,5483],{"nctId":5431,"briefTitle":5432,"status":130,"phases":5433,"primaryCompletion":5434,"completion":5434,"start":5435,"enrollment":2779,"conditions":5436,"interventions":5437},"NCT00439361","Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma",[87],"2012-06","2007-02",[1866,21],[75,1369,2424,2495,1114],{"nctId":5439,"briefTitle":5440,"status":130,"phases":5441,"primaryCompletion":5442,"completion":5442,"start":5443,"enrollment":1240,"conditions":5444,"interventions":5446},"NCT00968760","CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies",[87],"2020-04-23","2011-06-20",[21,5445],"B-cell Lymphoma",[5447,4365,2424,654,2293],"IL-2",{"nctId":5189,"briefTitle":5190,"status":203,"phases":5449,"primaryCompletion":2212,"completion":2212,"start":3833,"enrollment":124,"conditions":5450,"interventions":5451},[87],[2755,15,21,5193],[2293,1254,1070,894,2424,5195,2195,2196,2374],{"nctId":5453,"briefTitle":5454,"status":130,"phases":5455,"primaryCompletion":1307,"completion":1307,"start":3251,"enrollment":492,"conditions":5456,"interventions":5464},"NCT01590732","Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma",[87],[5457,3271,5458,5459,5460,3275,3276,5461,5462,5463,3280],"Mycosis Fungoides","Recurrent Angioimmunoblastic T-Cell Lymphoma","Recurrent Enteropathy-Associated T-Cell Lymphoma","Recurrent Hepatosplenic T-Cell Lymphoma","Refractory Angioimmunoblastic T-Cell Lymphoma","Refractory Enteropathy-Associated T-Cell Lymphoma","Refractory Hepatosplenic T-Cell Lymphoma",[1369,2424,2495,5465],"Romidepsin",{"nctId":5467,"briefTitle":5468,"status":130,"phases":5469,"primaryCompletion":4542,"start":5470,"enrollment":186,"conditions":5471,"interventions":5473},"NCT00513162","Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases",[87],"2007-07",[5472,1520,1942],"Neuroectodermal Tumor",[5474,2424],"Valproate",{"nctId":3864,"briefTitle":3865,"status":130,"phases":5476,"primaryCompletion":3867,"completion":3868,"start":3869,"enrollment":2946,"conditions":5477,"interventions":5478},[87],[3871,3872,3873],[1369,1709,2424,53],{"nctId":3159,"briefTitle":3160,"status":203,"phases":5480,"primaryCompletion":1174,"completion":1174,"start":3162,"enrollment":124,"conditions":5481,"interventions":5482},[87],[3164,3165,3166,3167,3168,3169,3170,3171,3172,3173,3174,3175,3176,3177,3178],[2424,1005,2194,2293,2195,2196,1254],{"nctId":5484,"briefTitle":5485,"status":182,"phases":5486,"primaryCompletion":2016,"completion":2016,"start":5487,"enrollment":3726,"conditions":5488,"interventions":5514},"NCT03420963","Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors",[87],"2018-08-31",[5489,5490,5491,1459,5492,5493,5494,5495,5496,5497,5498,2570,5499,5500,5501,5502,5503,5504,5505,5506,5507,5508,5509,5510,5511,3457,5512,5513],"Recurrent Cutaneous Melanoma","Recurrent Lip and Oral Cavity Carcinoma","Recurrent Malignant Endocrine Neoplasm","Recurrent Malignant Male Reproductive System Neoplasm","Recurrent Malignant Mesothelioma","Recurrent Malignant Neoplasm of Multiple Primary Sites","Recurrent Malignant Oral Neoplasm","Recurrent Malignant Pharyngeal Neoplasm","Recurrent Malignant Skin Neoplasm","Recurrent Malignant Soft Tissue Neoplasm","Recurrent Malignant Thyroid Gland Neoplasm","Recurrent Malignant Urinary System Neoplasm","Refractory Cutaneous Melanoma","Refractory Malignant Bone Neoplasm","Refractory Malignant Endocrine Neoplasm","Refractory Malignant Female Reproductive System Neoplasm","Refractory Malignant Male Reproductive System Neoplasm","Refractory Malignant Mesothelioma","Refractory Malignant Neoplasm of Multiple Primary Sites","Refractory Malignant Oral Neoplasm","Refractory Malignant Pharyngeal Neoplasm","Refractory Malignant Skin Neoplasm","Refractory Malignant Soft Tissue Neoplasm","Refractory Malignant Thyroid Gland Neoplasm","Refractory Malignant Urinary System Neoplasm",[5515,803,2424],"Cord Blood-derived Expanded Allogeneic Natural Killer Cells",{"trials":5517,"activeCount":121,"soonestReadout":2410},[5518,5528,5537,5541,5545,5552,5561,5570,5579,5590,5599,5608,5616,5625,5637,5644,5651,5655,5659,5666,5674,5682,5686,5693,5701],{"nctId":5519,"briefTitle":5520,"status":130,"phases":5521,"primaryCompletion":4382,"completion":4382,"start":5522,"enrollment":492,"conditions":5523,"interventions":5524},"NCT00536978","Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies",[88],"2007-09",[21,15],[5525,5526,5527,803,2424,1070,2293,894,806,2196],"ARA-C","BCNU","Campath-1H",{"nctId":5529,"briefTitle":5530,"status":182,"phases":5531,"primaryCompletion":2836,"completion":2836,"start":4193,"enrollment":2159,"conditions":5532,"interventions":5533},"NCT00505921","Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma",[88],[21],[5527,2374,4629,5526,5534,5535,654,2424,2293,5536,1070,803],"Stem Cell Transplant","Preparative Regimen for Allogenic Stem Cell Transplantation","Campath",{"nctId":2407,"briefTitle":2408,"status":279,"phases":5538,"primaryCompletion":2410,"completion":2410,"start":2411,"enrollment":924,"conditions":5539,"interventions":5540},[88],[913,2413,2414,2415,2416,2417,914,2418,2419,2420,2421],[75,2423,803,62,2424,2425,1071,894,2426],{"nctId":2432,"briefTitle":2433,"status":130,"phases":5542,"primaryCompletion":2435,"completion":2435,"start":2436,"enrollment":550,"conditions":5543,"interventions":5544},[88],[15],[2439,2424,62,806,2078],{"nctId":5546,"briefTitle":5547,"status":130,"phases":5548,"primaryCompletion":5434,"completion":5434,"start":3902,"enrollment":5549,"conditions":5550,"interventions":5551},"NCT00472056","Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies",[88],93,[21],[4365,2424,654,2293,894],{"nctId":5553,"briefTitle":5554,"status":130,"phases":5555,"primaryCompletion":5556,"completion":5556,"start":5557,"enrollment":381,"conditions":5558,"interventions":5559},"NCT00499343","G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients",[88],"2008-10","2004-01",[21],[2424,2374,4629,5560,894],"Isophosphamide",{"nctId":5562,"briefTitle":5563,"status":130,"phases":5564,"primaryCompletion":5565,"completion":5565,"start":5566,"enrollment":406,"conditions":5567,"interventions":5569},"NCT00591630","Zevalin\u002FBEAM\u002FRituximab vs BEAM\u002FRituximab With or Without Rituximab in Autologous Stem Cell Transplantation",[88],"2020-03-05","2007-11-14",[5568,21],"Diffuse Large Cell Lymphoma",[2450,4365,2424,654,2293,894],{"nctId":5571,"briefTitle":5572,"status":130,"phases":5573,"primaryCompletion":5574,"completion":5574,"start":5575,"enrollment":1034,"conditions":5576,"interventions":5578},"NCT02636322","Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib",[88],"2022-10-24","2016-03-29",[5577],"Diffuse Large B-Cell Lymphoma Unclassifiable",[803,804,2424,767,1402,809,894,810],{"nctId":5580,"briefTitle":5581,"status":130,"phases":5582,"primaryCompletion":5583,"completion":5583,"start":5584,"enrollment":2779,"conditions":5585,"interventions":5589},"NCT02199184","Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia",[88],"2023-02-17","2015-01-14",[5586,5587,3056,5588,913,2415,914,2419],"AIDS-Related Burkitt Lymphoma","Atypical Burkitt\u002FBurkitt-Like Lymphoma","High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",[803,804,2424,2425,809,894,810],{"nctId":5591,"briefTitle":5592,"status":130,"phases":5593,"primaryCompletion":5594,"completion":5594,"start":5595,"enrollment":517,"conditions":5596,"interventions":5598},"NCT00439556","Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant",[88],"2018-06-07","2007-02-13",[785,359,5597,21],"Lymphocytic Neoplasm",[3085,75,4365,654,2424,1069,2293,806,894,2196],{"nctId":5600,"briefTitle":5601,"status":130,"phases":5602,"primaryCompletion":5603,"completion":5603,"start":5604,"enrollment":3354,"conditions":5605,"interventions":5607},"NCT00936936","High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors",[88],"2024-01-11","2009-06-02",[5606],"Testicular Cancer",[2369,1710,2293,1369,1114,2495,2424],{"nctId":5609,"briefTitle":5610,"status":102,"phases":5611,"primaryCompletion":224,"completion":224,"start":5612,"enrollment":3379,"conditions":5613,"interventions":5615},"NCT04728230","Olaparib and Durvalumab With Carboplatin, Etoposide, and\u002For Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial",[87,88],"2021-01-05",[5614,1319,1361,1362],"Extensive Stage Lung Small Cell Carcinoma",[1369,1786,2424,1374],{"nctId":5617,"briefTitle":5618,"status":130,"phases":5619,"primaryCompletion":5620,"completion":5620,"start":5621,"enrollment":2933,"conditions":5622,"interventions":5624},"NCT01169636","Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma",[87,88],"2017-05-17","2011-01-31",[5623],"Hodgkin's Lymphoma",[2340,2495,1114,1369,2424,1071],{"nctId":5626,"briefTitle":5627,"status":130,"phases":5628,"primaryCompletion":5629,"completion":5629,"start":5630,"enrollment":492,"conditions":5631,"interventions":5636},"NCT03019640","Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma",[88],"2021-08-16","2017-10-10",[891,4559,5632,5633,4561,5634,5635],"Recurrent Follicular Lymphoma","Recurrent Indolent Adult Non-Hodgkin Lymphoma","Refractory Follicular Lymphoma","Refractory Indolent Adult Non-Hodgkin Lymphoma",[4365,5515,654,2424,1069,1402,2293,894],{"nctId":5638,"briefTitle":5639,"status":130,"phases":5640,"primaryCompletion":1307,"completion":1307,"start":5641,"enrollment":1131,"conditions":5642,"interventions":5643},"NCT00967369","Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.",[88],"2009-08-24",[3273,3278],[75,1369,2424,2495],{"nctId":5645,"briefTitle":5646,"status":130,"phases":5647,"primaryCompletion":2953,"completion":2953,"start":5648,"enrollment":195,"conditions":5649,"interventions":5650},"NCT00002829","Bone Marrow Transplantation in Treating Patients With Lymphoma",[88],"1994-02",[21],[4109,803,2424,1114],{"nctId":4166,"briefTitle":4167,"status":130,"phases":5652,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":5653,"interventions":5654},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"nctId":4180,"briefTitle":4181,"status":130,"phases":5656,"primaryCompletion":4183,"completion":4184,"start":4185,"enrollment":1664,"conditions":5657,"interventions":5658},[88],[24],[1709,2424],{"nctId":5660,"briefTitle":5661,"status":130,"phases":5662,"primaryCompletion":4723,"completion":4723,"start":5663,"enrollment":3820,"conditions":5664,"interventions":5665},"NCT00427791","Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia",[88],"2005-07",[15],[2424,894],{"nctId":5667,"briefTitle":5668,"status":130,"phases":5669,"primaryCompletion":5670,"completion":5670,"start":5671,"enrollment":676,"conditions":5672,"interventions":5673},"NCT01329900","Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas",[88],"2019-07-21","2011-08-22",[21],[2425,2495,2424,1114,2374],{"nctId":5675,"briefTitle":5676,"status":130,"phases":5677,"primaryCompletion":3818,"completion":2528,"start":5678,"enrollment":406,"conditions":5679,"interventions":5680},"NCT00504140","Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma",[88],"1996-11",[4384],[2424,5681],"Interferon Alpha",{"nctId":4287,"briefTitle":4288,"status":130,"phases":5683,"primaryCompletion":4290,"completion":4290,"start":4039,"enrollment":4291,"conditions":5684,"interventions":5685},[88],[27],[1710,1369,2424,1709],{"nctId":5687,"briefTitle":5688,"status":130,"phases":5689,"primaryCompletion":2890,"completion":2890,"start":5690,"enrollment":1308,"conditions":5691,"interventions":5692},"NCT00003084","Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer",[88],"1997-12",[27],[804,2958,2424,2959,1376,1868],{"nctId":5694,"briefTitle":5695,"status":203,"phases":5696,"primaryCompletion":5697,"completion":5697,"start":5697,"enrollment":124,"conditions":5698,"interventions":5699},"NCT03579927","CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma",[87,88],"2019-10-03",[3039,891,4559,5632,3277,4561,5634],[4365,654,2424,1069,2293,894,5700],"Umbilical Cord Blood-derived Natural Killer Cells",{"nctId":3443,"briefTitle":3444,"status":182,"phases":5702,"primaryCompletion":3446,"completion":3446,"start":3447,"enrollment":166,"conditions":5703,"interventions":5704},[88],[3449,3450,3451,3452,2570,3453,3454,3455,3456,3457,3458,3459],[3420,2424,1005,2194,2293,2195,2196,1254],{"trials":5706,"activeCount":166,"soonestReadout":3426},[5707,5711,5720,5724,5728,5737,5741],{"nctId":4305,"briefTitle":4306,"status":130,"phases":5708,"primaryCompletion":4308,"completion":4308,"start":4309,"enrollment":2402,"conditions":5709,"interventions":5710},[89],[21],[4312,4313,4045,2879,2880,2882,4314,4315,4047,4316,4317,4318,4319,2884],{"nctId":5712,"briefTitle":5713,"status":182,"phases":5714,"primaryCompletion":5715,"completion":5715,"start":5716,"enrollment":121,"conditions":5717,"interventions":5719},"NCT00500890","Treatment of Tumors of the Choroid Plexus Epithelium",[89],"2017-12-14","2005-09-02",[5718],"Choroid Plexus Tumors",[1369,803,2424,1016],{"nctId":4321,"briefTitle":4322,"status":130,"phases":5721,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":5722,"interventions":5723},[89],[21],[1070,4329,4330,894,3671,1013,1016,4331,803,2424,1709,2584,4332,4333,809],{"nctId":4335,"briefTitle":4336,"status":279,"phases":5725,"primaryCompletion":3426,"completion":3426,"start":4338,"enrollment":4339,"conditions":5726,"interventions":5727},[89],[4341,4342,4343],[1709,2424,4345],{"nctId":5729,"briefTitle":5730,"status":182,"phases":5731,"primaryCompletion":5732,"completion":5732,"start":5733,"enrollment":1231,"conditions":5734,"interventions":5736},"NCT00539500","Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma",[88,89],"2012-09-05","2007-10",[5735],"Neuroblastoma",[1369,2424,2293],{"nctId":4357,"briefTitle":4358,"status":130,"phases":5738,"primaryCompletion":4360,"completion":4360,"start":4361,"enrollment":4362,"conditions":5739,"interventions":5740},[89],[18],[1069,4365,1709,803,2424,1254],{"nctId":4367,"briefTitle":4368,"status":130,"phases":5742,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":5743,"interventions":5744},[89],[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":5746,"activeCount":124},[],{"trials":5748,"activeCount":124},[],{"intervention":5750,"totalTrials":3197,"cells":5751},"Liposomal Bupivacaine",{"EARLY_PHASE1":5752,"PHASE1":5754,"PHASE2":5756,"PHASE3":5779,"PHASE4":5812,"NA":5814},{"trials":5753,"activeCount":124},[],{"trials":5755,"activeCount":124},[],{"trials":5757,"activeCount":121,"soonestReadout":5772},[5758,5768],{"nctId":5759,"briefTitle":5760,"status":102,"phases":5761,"primaryCompletion":5762,"completion":5762,"start":5763,"enrollment":1975,"conditions":5764,"interventions":5766},"NCT05044468","EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement",[88],"2026-05-31","2021-03-23",[5765],"Malignant Pleural Neoplasm",[5767,5750],"Lidocaine",{"nctId":5769,"briefTitle":5770,"status":102,"phases":5771,"primaryCompletion":5772,"completion":446,"start":5773,"enrollment":5774,"conditions":5775,"interventions":5777},"NCT04189783","Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients (\"RESQU-SARC\" Trial)",[88],"2024-10-26","2020-06-08",113,[5776],"Retroperitoneal Sarcoma",[5750,5778],"Quadratus Lumborum Block",{"trials":5780,"activeCount":166,"soonestReadout":471},[5781,5791,5803],{"nctId":5782,"briefTitle":5783,"status":130,"phases":5784,"primaryCompletion":4448,"completion":4448,"start":5785,"enrollment":1308,"conditions":5786,"interventions":5788},"NCT03359811","Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway",[89],"2017-11-27",[5787],"Peritoneal Cancer",[5789,5790,5750],"Local Anesthetic Solution","Bupivacaine HCl",{"nctId":5792,"briefTitle":5793,"status":182,"phases":5794,"primaryCompletion":5795,"completion":5795,"start":5796,"enrollment":5797,"conditions":5798,"interventions":5801},"NCT02740114","Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway",[89],"2020-07-23","2016-08-31",105,[5799,5800],"Malignant Neoplasms of Female Genital Organs","Gynecologic Cancer",[5802,5750,366],"Bupivacaine",{"nctId":5804,"briefTitle":5805,"status":102,"phases":5806,"primaryCompletion":471,"completion":471,"start":1505,"enrollment":1699,"conditions":5807,"interventions":5809},"NCT03214510","Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery",[89],[5808],"Liver and Intrahepatic Bile Duct Disorder",[5802,5810,5811,5750],"Fentanyl","Hydromorphone Hydrochloride",{"trials":5813,"activeCount":124},[],{"trials":5815,"activeCount":124},[],{"intervention":5817,"totalTrials":1231,"cells":5818},"Haloperidol",{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5823,"PHASE3":5825,"PHASE4":5851,"NA":5853},{"trials":5820,"activeCount":124},[],{"trials":5822,"activeCount":124},[],{"trials":5824,"activeCount":124},[],{"trials":5826,"activeCount":1231,"soonestReadout":83},[5827,5834,5843],{"nctId":81,"briefTitle":82,"status":102,"phases":5828,"primaryCompletion":83,"completion":956,"start":5829,"enrollment":3082,"conditions":5830,"interventions":5833},[88,89],"2017-06-05",[2922,5831,5832,2924,2925],"Delirium","Locally Advanced Malignant Neoplasm",[84,5817],{"nctId":5835,"briefTitle":5836,"status":279,"phases":5837,"primaryCompletion":1299,"completion":1299,"start":5838,"enrollment":924,"conditions":5839,"interventions":5842},"NCT05431595","Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy",[88,89],"2022-07-19",[5831,5840,5841],"Epileptics","Neuroleptics",[5817,84,5474],{"nctId":5844,"briefTitle":5845,"status":102,"phases":5846,"primaryCompletion":5847,"completion":446,"start":5848,"enrollment":971,"conditions":5849,"interventions":5850},"NCT03743649","Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care",[88,89],"2026-02-28","2019-07-17",[5831,5832,2924,2925],[5817,48],{"trials":5852,"activeCount":124},[],{"trials":5854,"activeCount":124},[],{"intervention":48,"totalTrials":121,"cells":5856},{"EARLY_PHASE1":5857,"PHASE1":5859,"PHASE2":5861,"PHASE3":5868,"PHASE4":5874,"NA":5876},{"trials":5858,"activeCount":124},[],{"trials":5860,"activeCount":124},[],{"trials":5862,"activeCount":166,"soonestReadout":47},[5863],{"nctId":45,"briefTitle":46,"status":102,"phases":5864,"primaryCompletion":47,"completion":604,"start":2289,"enrollment":5549,"conditions":5865,"interventions":5866},[88],[33],[48,5867],"Haloperidol decanoate",{"trials":5869,"activeCount":166,"soonestReadout":5847},[5870],{"nctId":5844,"briefTitle":5845,"status":102,"phases":5871,"primaryCompletion":5847,"completion":446,"start":5848,"enrollment":971,"conditions":5872,"interventions":5873},[88,89],[5831,5832,2924,2925],[5817,48],{"trials":5875,"activeCount":124},[],{"trials":5877,"activeCount":124},[],{"intervention":84,"totalTrials":121,"cells":5879},{"EARLY_PHASE1":5880,"PHASE1":5882,"PHASE2":5884,"PHASE3":5886,"PHASE4":5896,"NA":5898},{"trials":5881,"activeCount":124},[],{"trials":5883,"activeCount":124},[],{"trials":5885,"activeCount":124},[],{"trials":5887,"activeCount":121,"soonestReadout":83},[5888,5892],{"nctId":81,"briefTitle":82,"status":102,"phases":5889,"primaryCompletion":83,"completion":956,"start":5829,"enrollment":3082,"conditions":5890,"interventions":5891},[88,89],[2922,5831,5832,2924,2925],[84,5817],{"nctId":5835,"briefTitle":5836,"status":279,"phases":5893,"primaryCompletion":1299,"completion":1299,"start":5838,"enrollment":924,"conditions":5894,"interventions":5895},[88,89],[5831,5840,5841],[5817,84,5474],{"trials":5897,"activeCount":124},[],{"trials":5899,"activeCount":124},[],{"intervention":5901,"totalTrials":121,"cells":5902},"tranexamic acid",{"EARLY_PHASE1":5903,"PHASE1":5914,"PHASE2":5916,"PHASE3":5918,"PHASE4":5927,"NA":5929},{"trials":5904,"activeCount":166,"soonestReadout":5762},[5905],{"nctId":5906,"briefTitle":5907,"status":102,"phases":5908,"primaryCompletion":5762,"completion":5762,"start":5909,"enrollment":1975,"conditions":5910,"interventions":5912},"NCT03128866","Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery",[86],"2017-05-19",[5911],"Pelvic Mass",[5913],"Tranexamic Acid",{"trials":5915,"activeCount":124},[],{"trials":5917,"activeCount":124},[],{"trials":5919,"activeCount":166,"soonestReadout":3943},[5920],{"nctId":5921,"briefTitle":5922,"status":279,"phases":5923,"primaryCompletion":3943,"completion":3943,"start":824,"enrollment":1034,"conditions":5924,"interventions":5926},"NCT05053867","A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients",[89],[5925,5349],"Pulmonary Hemorrhage",[5901],{"trials":5928,"activeCount":124},[],{"trials":5930,"activeCount":124},[],{"intervention":67,"totalTrials":121,"cells":5932},{"EARLY_PHASE1":5933,"PHASE1":5935,"PHASE2":5937,"PHASE3":5948,"PHASE4":5958,"NA":5960},{"trials":5934,"activeCount":124},[],{"trials":5936,"activeCount":124},[],{"trials":5938,"activeCount":166,"soonestReadout":66},[5939],{"nctId":64,"briefTitle":65,"status":102,"phases":5940,"primaryCompletion":66,"completion":5847,"start":5941,"enrollment":5942,"conditions":5943,"interventions":5947},[88],"2017-02-08",129,[1343,5944,5945,361,2570,5946],"C-Reactive Protein Measurement","Cancer Fatigue","Weight Loss",[67],{"trials":5949,"activeCount":166,"soonestReadout":446},[5950],{"nctId":5951,"briefTitle":5952,"status":102,"phases":5953,"primaryCompletion":446,"completion":446,"start":5954,"enrollment":448,"conditions":5955,"interventions":5957},"NCT03637816","Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer",[88,89],"2018-11-27",[5956,1388,1355,1357,1358,1359,1319,1361,1362],"Anorexia",[67],{"trials":5959,"activeCount":124},[],{"trials":5961,"activeCount":124},[],{"intervention":365,"totalTrials":3197,"cells":5963},{"EARLY_PHASE1":5964,"PHASE1":5970,"PHASE2":5972,"PHASE3":5982,"PHASE4":6000,"NA":6002},{"trials":5965,"activeCount":124},[5966],{"nctId":352,"briefTitle":353,"status":182,"phases":5967,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":5968,"interventions":5969},[86],[359,360,361],[363,347,364,365,366,367],{"trials":5971,"activeCount":124},[],{"trials":5973,"activeCount":124},[5974],{"nctId":5975,"briefTitle":5976,"status":182,"phases":5977,"primaryCompletion":185,"completion":185,"start":3818,"enrollment":3197,"conditions":5978,"interventions":5980},"NCT00558870","Role of Methadone As Co-Opioid Analgesic",[88],[5979],"Pain",[365,5981],"Methadone",{"trials":5983,"activeCount":166,"soonestReadout":5995},[5984,5991],{"nctId":5985,"briefTitle":5986,"status":182,"phases":5987,"primaryCompletion":185,"completion":185,"start":5988,"enrollment":593,"conditions":5989,"interventions":5990},"NCT00634010","Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain",[89],"2008-02",[1942,1924],[365,5981],{"nctId":5992,"briefTitle":5993,"status":102,"phases":5994,"primaryCompletion":5995,"completion":5995,"start":5996,"enrollment":1045,"conditions":5997,"interventions":5998},"NCT04188418","Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients",[89],"2027-08-31","2020-10-23",[359,360],[5999,365],"Fentanyl Citrate Buccal",{"trials":6001,"activeCount":124},[],{"trials":6003,"activeCount":166,"soonestReadout":6008},[6004],{"nctId":6005,"briefTitle":6006,"status":102,"phases":6007,"primaryCompletion":6008,"completion":6008,"start":6009,"enrollment":2159,"conditions":6010,"interventions":6011},"NCT04119037","Cordotomy in Reducing Pain in Patients With Advanced Cancer",[91],"2028-12-01","2019-09-16",[2922],[365],{"intervention":5802,"totalTrials":1231,"cells":6013},{"EARLY_PHASE1":6014,"PHASE1":6016,"PHASE2":6018,"PHASE3":6020,"PHASE4":6030,"NA":6032},{"trials":6015,"activeCount":124},[],{"trials":6017,"activeCount":124},[],{"trials":6019,"activeCount":124},[],{"trials":6021,"activeCount":166,"soonestReadout":471},[6022,6026],{"nctId":5792,"briefTitle":5793,"status":182,"phases":6023,"primaryCompletion":5795,"completion":5795,"start":5796,"enrollment":5797,"conditions":6024,"interventions":6025},[89],[5799,5800],[5802,5750,366],{"nctId":5804,"briefTitle":5805,"status":102,"phases":6027,"primaryCompletion":471,"completion":471,"start":1505,"enrollment":1699,"conditions":6028,"interventions":6029},[89],[5808],[5802,5810,5811,5750],{"trials":6031,"activeCount":124},[],{"trials":6033,"activeCount":166,"soonestReadout":193},[6034],{"nctId":6035,"briefTitle":6036,"status":279,"phases":6037,"primaryCompletion":193,"completion":193,"start":6038,"enrollment":195,"conditions":6039,"interventions":6043},"NCT06004882","Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study",[91],"2023-08-10",[6040,6041,6042],"Peripheral Nerve Stimulation","Genicular Nerves","Chronic Knee Pain",[6044,5802],"Triamcinolone",{"intervention":5810,"totalTrials":296,"cells":6046},{"EARLY_PHASE1":6047,"PHASE1":6049,"PHASE2":6051,"PHASE3":6059,"PHASE4":6076,"NA":6088},{"trials":6048,"activeCount":124},[],{"trials":6050,"activeCount":124},[],{"trials":6052,"activeCount":124},[6053],{"nctId":6054,"briefTitle":6055,"status":130,"phases":6056,"primaryCompletion":4290,"completion":4290,"start":2326,"enrollment":134,"conditions":6057,"interventions":6058},"NCT01515566","Breakthrough Dyspnea Fentanyl Study in Cancer Patients",[87,88],[33,2612],[5810],{"trials":6060,"activeCount":166,"soonestReadout":471},[6061,6072],{"nctId":6062,"briefTitle":6063,"status":130,"phases":6064,"primaryCompletion":6065,"completion":6065,"start":5522,"enrollment":6066,"conditions":6067,"interventions":6068},"NCT00542542","Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery",[89],"2014-03",89,[18],[6069,5810,6070,6071],"Propofol","Ropivacaine","Midazolam",{"nctId":5804,"briefTitle":5805,"status":102,"phases":6073,"primaryCompletion":471,"completion":471,"start":1505,"enrollment":1699,"conditions":6074,"interventions":6075},[89],[5808],[5802,5810,5811,5750],{"trials":6077,"activeCount":124},[6078],{"nctId":6079,"briefTitle":6080,"status":182,"phases":6081,"primaryCompletion":6082,"completion":6082,"start":6083,"enrollment":1231,"conditions":6084,"interventions":6086},"NCT02623959","Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis",[90],"2017-05-23","2016-04-27",[33,6085],"Malignant Pleural Effusions",[6087,5810,3729],"Fentanyl Patch",{"trials":6089,"activeCount":124},[],{"intervention":5811,"totalTrials":121,"cells":6091},{"EARLY_PHASE1":6092,"PHASE1":6094,"PHASE2":6096,"PHASE3":6098,"PHASE4":6104,"NA":6114},{"trials":6093,"activeCount":124},[],{"trials":6095,"activeCount":124},[],{"trials":6097,"activeCount":124},[],{"trials":6099,"activeCount":166,"soonestReadout":471},[6100],{"nctId":5804,"briefTitle":5805,"status":102,"phases":6101,"primaryCompletion":471,"completion":471,"start":1505,"enrollment":1699,"conditions":6102,"interventions":6103},[89],[5808],[5802,5810,5811,5750],{"trials":6105,"activeCount":124},[6106],{"nctId":6107,"briefTitle":6108,"status":130,"phases":6109,"primaryCompletion":6110,"completion":6110,"start":4635,"enrollment":381,"conditions":6111,"interventions":6112},"NCT02459964","Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain",[90],"2020-06-21",[33,5979],[6113,5811],"Fentanyl Nasal Spray",{"trials":6115,"activeCount":124},[],{"intervention":6117,"totalTrials":121,"cells":6118},"Telotristat Ethyl",{"EARLY_PHASE1":6119,"PHASE1":6121,"PHASE2":6123,"PHASE3":6136,"PHASE4":6149,"NA":6151},{"trials":6120,"activeCount":124},[],{"trials":6122,"activeCount":124},[],{"trials":6124,"activeCount":124},[6125],{"nctId":6126,"briefTitle":6127,"status":203,"phases":6128,"primaryCompletion":6129,"completion":6129,"start":6130,"enrollment":124,"conditions":6131,"interventions":6134},"NCT04776876","Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome",[88],"2021-09-02","2021-03-01",[6132,6133],"Advanced Neuroendocrine Neoplasm","Carcinoid Syndrome",[6135,6117],"Retifanlimab",{"trials":6137,"activeCount":166,"soonestReadout":6142},[6138],{"nctId":6139,"briefTitle":6140,"status":102,"phases":6141,"primaryCompletion":6142,"completion":6143,"start":6144,"enrollment":31,"conditions":6145,"interventions":6148},"NCT04810091","Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor",[89],"2025-08-31","2026-08-03","2021-05-18",[6146,6147],"Locally Advanced Neuroendocrine Neoplasm","Metastatic Neuroendocrine Neoplasm",[6117],{"trials":6150,"activeCount":124},[],{"trials":6152,"activeCount":124},[],{"intervention":4345,"totalTrials":121,"cells":6154},{"EARLY_PHASE1":6155,"PHASE1":6157,"PHASE2":6159,"PHASE3":6170,"PHASE4":6176,"NA":6178},{"trials":6156,"activeCount":124},[],{"trials":6158,"activeCount":124},[],{"trials":6160,"activeCount":124},[6161],{"nctId":6162,"briefTitle":6163,"status":182,"phases":6164,"primaryCompletion":6165,"completion":6165,"start":6166,"enrollment":1231,"conditions":6167,"interventions":6169},"NCT05634577","A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma",[88],"2024-07-10","2023-03-23",[6168],"Adrenocortical Carcinoma",[4345,53],{"trials":6171,"activeCount":166,"soonestReadout":3426},[6172],{"nctId":4335,"briefTitle":4336,"status":279,"phases":6173,"primaryCompletion":3426,"completion":3426,"start":4338,"enrollment":4339,"conditions":6174,"interventions":6175},[89],[4341,4342,4343],[1709,2424,4345],{"trials":6177,"activeCount":124},[],{"trials":6179,"activeCount":124},[],{"intervention":5474,"totalTrials":121,"cells":6181},{"EARLY_PHASE1":6182,"PHASE1":6184,"PHASE2":6190,"PHASE3":6192,"PHASE4":6198,"NA":6200},{"trials":6183,"activeCount":124},[],{"trials":6185,"activeCount":124},[6186],{"nctId":5467,"briefTitle":5468,"status":130,"phases":6187,"primaryCompletion":4542,"start":5470,"enrollment":186,"conditions":6188,"interventions":6189},[87],[5472,1520,1942],[5474,2424],{"trials":6191,"activeCount":124},[],{"trials":6193,"activeCount":166,"soonestReadout":1299},[6194],{"nctId":5835,"briefTitle":5836,"status":279,"phases":6195,"primaryCompletion":1299,"completion":1299,"start":5838,"enrollment":924,"conditions":6196,"interventions":6197},[88,89],[5831,5840,5841],[5817,84,5474],{"trials":6199,"activeCount":124},[],{"trials":6201,"activeCount":124},[],{"intervention":5177,"totalTrials":166,"cells":6203},{"EARLY_PHASE1":6204,"PHASE1":6206,"PHASE2":6208,"PHASE3":6210,"PHASE4":6216,"NA":6218},{"trials":6205,"activeCount":124},[],{"trials":6207,"activeCount":124},[],{"trials":6209,"activeCount":124},[],{"trials":6211,"activeCount":166,"soonestReadout":956},[6212],{"nctId":5169,"briefTitle":5170,"status":279,"phases":6213,"primaryCompletion":956,"completion":957,"start":5172,"enrollment":1100,"conditions":6214,"interventions":6215},[89],[5174,5175,27],[3700,5177],{"trials":6217,"activeCount":124},[],{"trials":6219,"activeCount":124},[],{"intervention":6221,"totalTrials":166,"cells":6222},"Domperidone",{"EARLY_PHASE1":6223,"PHASE1":6225,"PHASE2":6227,"PHASE3":6229,"PHASE4":6245,"NA":6247},{"trials":6224,"activeCount":124},[],{"trials":6226,"activeCount":124},[],{"trials":6228,"activeCount":124},[],{"trials":6230,"activeCount":166,"soonestReadout":999},[6231],{"nctId":6232,"briefTitle":6233,"status":279,"phases":6234,"primaryCompletion":999,"completion":999,"start":6235,"enrollment":4733,"conditions":6236,"interventions":6244},"NCT01696734","Domperidone in Treating Patients With Gastrointestinal Disorders",[89],"2012-10-23",[6237,6238,6239,6240,6241,6242,6243],"Digestive System Disorder","Dyspepsia","Esophagitis","Gastroesophageal Reflux Disease","Gastroparesis","Heartburn","Nausea and Vomiting",[6221],{"trials":6246,"activeCount":124},[],{"trials":6248,"activeCount":124},[],{"intervention":5999,"totalTrials":166,"cells":6250},{"EARLY_PHASE1":6251,"PHASE1":6253,"PHASE2":6255,"PHASE3":6257,"PHASE4":6263,"NA":6265},{"trials":6252,"activeCount":124},[],{"trials":6254,"activeCount":124},[],{"trials":6256,"activeCount":124},[],{"trials":6258,"activeCount":166,"soonestReadout":5995},[6259],{"nctId":5992,"briefTitle":5993,"status":102,"phases":6260,"primaryCompletion":5995,"completion":5995,"start":5996,"enrollment":1045,"conditions":6261,"interventions":6262},[89],[359,360],[5999,365],{"trials":6264,"activeCount":124},[],{"trials":6266,"activeCount":124},[],{"intervention":6268,"totalTrials":166,"cells":6269},"Open Label Placebo",{"EARLY_PHASE1":6270,"PHASE1":6272,"PHASE2":6274,"PHASE3":6276,"PHASE4":6287,"NA":6289},{"trials":6271,"activeCount":124},[],{"trials":6273,"activeCount":124},[],{"trials":6275,"activeCount":124},[],{"trials":6277,"activeCount":166,"soonestReadout":5995},[6278],{"nctId":6279,"briefTitle":6280,"status":279,"phases":6281,"primaryCompletion":5995,"completion":6282,"start":6283,"enrollment":4339,"conditions":6284,"interventions":6286},"NCT06085716","Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers",[88,89],"2029-08-31","2024-02-16",[6285,2923],"Metastatic Cancers",[6268],{"trials":6288,"activeCount":124},[],{"trials":6290,"activeCount":124},[],{"intervention":6292,"totalTrials":166,"cells":6293},"Fluorouracil 5-FU",{"EARLY_PHASE1":6294,"PHASE1":6296,"PHASE2":6298,"PHASE3":6300,"PHASE4":6310,"NA":6312},{"trials":6295,"activeCount":124},[],{"trials":6297,"activeCount":124},[],{"trials":6299,"activeCount":124},[],{"trials":6301,"activeCount":166,"soonestReadout":5995},[6302],{"nctId":6303,"briefTitle":6304,"status":279,"phases":6305,"primaryCompletion":5995,"completion":5995,"start":1229,"enrollment":406,"conditions":6306,"interventions":6308},"NCT06851507","A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses",[89],[6307],"Multiple Actinic Keratoses",[6292,6309],"Fluorouracil\u002FCalcipotriene",{"trials":6311,"activeCount":124},[],{"trials":6313,"activeCount":124},[],{"intervention":6309,"totalTrials":166,"cells":6315},{"EARLY_PHASE1":6316,"PHASE1":6318,"PHASE2":6320,"PHASE3":6322,"PHASE4":6328,"NA":6330},{"trials":6317,"activeCount":124},[],{"trials":6319,"activeCount":124},[],{"trials":6321,"activeCount":124},[],{"trials":6323,"activeCount":166,"soonestReadout":5995},[6324],{"nctId":6303,"briefTitle":6304,"status":279,"phases":6325,"primaryCompletion":5995,"completion":5995,"start":1229,"enrollment":406,"conditions":6326,"interventions":6327},[89],[6307],[6292,6309],{"trials":6329,"activeCount":124},[],{"trials":6331,"activeCount":124},[],{"intervention":5368,"totalTrials":296,"cells":6333},{"EARLY_PHASE1":6334,"PHASE1":6336,"PHASE2":6344,"PHASE3":6346,"PHASE4":6359,"NA":6361},{"trials":6335,"activeCount":124},[],{"trials":6337,"activeCount":124},[6338],{"nctId":6339,"briefTitle":6340,"status":182,"phases":6341,"primaryCompletion":4697,"completion":4697,"start":2847,"enrollment":296,"conditions":6342,"interventions":6343},"NCT00506064","Melatonin Postoperative Sleep Study in Breast Cancer Patients",[87],[18],[5368],{"trials":6345,"activeCount":124},[],{"trials":6347,"activeCount":166,"soonestReadout":115},[6348,6355],{"nctId":6349,"briefTitle":6350,"status":130,"phases":6351,"primaryCompletion":3832,"completion":3832,"start":6352,"enrollment":28,"conditions":6353,"interventions":6354},"NCT00513357","Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients",[89],"2006-06",[4195,24],[5368],{"nctId":5359,"briefTitle":5360,"status":279,"phases":6356,"primaryCompletion":115,"completion":115,"start":5362,"enrollment":2986,"conditions":6357,"interventions":6358},[88,89],[5364,2923,5365,5349,5366],[5368,5368,5290],{"trials":6360,"activeCount":124},[],{"trials":6362,"activeCount":124},[6363],{"nctId":6364,"briefTitle":6365,"status":182,"phases":6366,"primaryCompletion":6367,"completion":6367,"start":5988,"enrollment":1568,"conditions":6368,"interventions":6370},"NCT00625742","Multimodal Treatment Strategy for Cancer Cachexia",[91],"2014-06",[1942,6369],"Cachexia",[5368,6371,6372],"Atenolol","Ibuprofen",{"intervention":6374,"totalTrials":1231,"cells":6375},"Olanzapine",{"EARLY_PHASE1":6376,"PHASE1":6378,"PHASE2":6388,"PHASE3":6390,"PHASE4":6401,"NA":6403},{"trials":6377,"activeCount":124},[],{"trials":6379,"activeCount":124},[6380],{"nctId":6381,"briefTitle":6382,"status":130,"phases":6383,"primaryCompletion":2243,"completion":2243,"start":6384,"enrollment":6385,"conditions":6386,"interventions":6387},"NCT00489593","Olanzapine in Patients With Advanced Cancer and Weight Loss",[87],"2006-10",57,[1942,5946],[6374],{"trials":6389,"activeCount":124},[],{"trials":6391,"activeCount":166,"soonestReadout":2104},[6392],{"nctId":6393,"briefTitle":6394,"status":279,"phases":6395,"primaryCompletion":2104,"completion":2104,"start":6396,"enrollment":6397,"conditions":6398,"interventions":6400},"NCT06200181","Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial",[89],"2024-04-02",87,[6399],"Misuse, Opioid",[6374,6374],{"trials":6402,"activeCount":124},[],{"trials":6404,"activeCount":124},[6405],{"nctId":6406,"briefTitle":6407,"status":130,"phases":6408,"primaryCompletion":6409,"completion":6410,"start":4887,"enrollment":448,"conditions":6411,"interventions":6412},"NCT00512291","Subcutaneous Olanzapine for Hyperactive or Mixed Delirium",[91],"2007-08","2009-08",[1942],[6374],{"intervention":803,"totalTrials":6414,"cells":6415},171,{"EARLY_PHASE1":6416,"PHASE1":6439,"PHASE2":6674,"PHASE3":7429,"PHASE4":7458,"NA":7460},{"trials":6417,"activeCount":166,"soonestReadout":2166},[6418,6427,6431,6435],{"nctId":6419,"briefTitle":6420,"status":130,"phases":6421,"primaryCompletion":6422,"completion":6422,"start":6423,"enrollment":2402,"conditions":6424,"interventions":6426},"NCT00510367","Primary Breast Cancer Occurring Concomitant With Pregnancy",[86],"2020-07-08","2001-08-07",[18,6425],"Pregnancy",[4218,803,1013],{"nctId":2181,"briefTitle":2182,"status":203,"phases":6428,"primaryCompletion":2184,"completion":2184,"start":2185,"enrollment":124,"conditions":6429,"interventions":6430},[86],[2187,2188,2189,2190,2191,2192],[75,1004,803,62,1005,2194,2195,894,2196],{"nctId":3014,"briefTitle":3015,"status":130,"phases":6432,"primaryCompletion":3017,"completion":3017,"start":3018,"enrollment":1231,"conditions":6433,"interventions":6434},[86],[2134,3020],[803,1069,1005,2293,2195,2196],{"nctId":3023,"briefTitle":3024,"status":102,"phases":6436,"primaryCompletion":2166,"completion":2166,"start":3026,"enrollment":492,"conditions":6437,"interventions":6438},[86],[21,891],[668,894,803,1005],{"trials":6440,"activeCount":2018,"soonestReadout":1078},[6441,6455,6459,6463,6467,6471,6480,6488,6495,6499,6508,6517,6526,6535,6539,6546,6553,6568,6572,6576,6580,6589,6593,6597,6601,6605,6613,6620,6624,6631,6640,6647,6657,6661],{"nctId":6442,"briefTitle":6443,"status":130,"phases":6444,"primaryCompletion":6445,"completion":6445,"start":6446,"enrollment":1568,"conditions":6447,"interventions":6452},"NCT03450122","Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma",[87],"2022-12-06","2018-09-13",[6448,6449,6450,6451],"HLA-A*0201 Positive Cells Present","NY-ESO-1 Positive Tumor Cells Present","Recurrent Myxoid Liposarcoma","Recurrent Synovial Sarcoma",[1599,6453,803,6454],"Autologous NY-ESO-1-specific CD8-positive T Lymphocytes","Dendritic Cell-targeting Lentiviral Vector ID-LV305",{"nctId":3032,"briefTitle":3033,"status":130,"phases":6456,"primaryCompletion":3035,"completion":3035,"start":3036,"enrollment":134,"conditions":6457,"interventions":6458},[87],[643,1122,3038,3039,3040,3041,716,3042,3043],[803,1005,3045],{"nctId":3505,"briefTitle":3506,"status":3049,"phases":6460,"primaryCompletion":3508,"completion":3509,"start":3510,"enrollment":1240,"conditions":6461,"interventions":6462},[87],[3512,1318],[1599,3514,803,1049],{"nctId":3047,"briefTitle":3048,"status":3049,"phases":6464,"primaryCompletion":3051,"completion":3051,"start":3052,"enrollment":2018,"conditions":6465,"interventions":6466},[87],[1205,643,2512,678,1025,3054,3055,3056,3057,3058,30,913,608,665,3059,3060,666,914,528,3061,3062,529,651,682,882],[803,1005,1402,2293,2195,3064,894,2196],{"nctId":3066,"briefTitle":3067,"status":102,"phases":6468,"primaryCompletion":2455,"completion":2455,"start":3069,"enrollment":871,"conditions":6469,"interventions":6470},[87],[3071,1316,1729],[3073,3074,803,3075,1114,1005],{"nctId":6472,"briefTitle":6473,"status":546,"phases":6474,"primaryCompletion":6475,"completion":6476,"start":1427,"enrollment":1034,"conditions":6477,"interventions":6479},"NCT07444632","Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed\u002FRefractory Lymphoid Malignancies",[87],"2030-09-30","2032-09-30",[6478,1866],"Lymphoid",[1070,2672,803],{"nctId":6481,"briefTitle":6482,"status":130,"phases":6483,"primaryCompletion":6484,"completion":6484,"start":6485,"enrollment":186,"conditions":6486,"interventions":6487},"NCT02280525","Cord Blood Natural Killer (NK) Cells in Leukemia\u002FLymphoma",[87],"2019-07-09","2015-03-05",[15],[1402,894,1070,803,654],{"nctId":6489,"briefTitle":6490,"status":279,"phases":6491,"primaryCompletion":224,"completion":548,"start":6492,"enrollment":1922,"conditions":6493,"interventions":6494},"NCT07101432","Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)",[87],"2025-11-04",[242],[1070,803],{"nctId":3095,"briefTitle":3096,"status":279,"phases":6496,"primaryCompletion":3098,"completion":3099,"start":3100,"enrollment":2700,"conditions":6497,"interventions":6498},[87],[1924],[3103,3104,2462,803],{"nctId":6500,"briefTitle":6501,"status":279,"phases":6502,"primaryCompletion":571,"completion":1863,"start":6503,"enrollment":517,"conditions":6504,"interventions":6506},"NCT06474676","T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced\u002FMetastatic Soft Tissue and Bone Sarcoma Patients.",[87],"2025-09-29",[6505],"Metastatic Soft-tissue Sarcoma",[803,6507],"T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy",{"nctId":6509,"briefTitle":6510,"status":130,"phases":6511,"primaryCompletion":6512,"completion":6512,"start":6513,"enrollment":3197,"conditions":6514,"interventions":6515},"NCT02423915","Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention",[87],"2020-10-06","2015-07-30",[15,21],[894,1070,803,2757,6516,2374],"Sirolimus",{"nctId":6518,"briefTitle":6519,"status":130,"phases":6520,"primaryCompletion":6521,"completion":6521,"start":6522,"enrollment":2779,"conditions":6523,"interventions":6524},"NCT00667329","Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab",[87],"2022-02-10","1999-07-09",[21],[6525,803,894],"2CdA",{"nctId":6527,"briefTitle":6528,"status":182,"phases":6529,"primaryCompletion":6530,"completion":6530,"start":6531,"enrollment":95,"conditions":6532,"interventions":6533},"NCT03126864","Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia",[87],"2019-10-10","2017-08-04",[1986,36],[1070,803,6534],"CD33-CAR-T Cell",{"nctId":5197,"briefTitle":5198,"status":130,"phases":6536,"primaryCompletion":5200,"completion":5200,"start":5201,"enrollment":1483,"conditions":6537,"interventions":6538},[87],[15,21,5203,1036],[803,5205,1254],{"nctId":6540,"briefTitle":6541,"status":203,"phases":6542,"primaryCompletion":2365,"completion":2365,"start":185,"enrollment":124,"conditions":6543,"interventions":6544},"NCT02194374","Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)",[87],[15],[1070,803,894,6545],"Bendamustine",{"nctId":6547,"briefTitle":6548,"status":203,"phases":6549,"primaryCompletion":6550,"completion":6550,"start":6550,"enrollment":124,"conditions":6551,"interventions":6552},"NCT02274506","Infusion of Allogeneic, 3rd Party CD19-specific T Cells",[87],"2014-10-20",[4522,15,21],[803,1070],{"nctId":6554,"briefTitle":6555,"status":182,"phases":6556,"primaryCompletion":6557,"completion":6557,"start":6558,"enrollment":166,"conditions":6559,"interventions":6566},"NCT02757391","CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors",[87],"2020-10-02","2019-08-09",[5028,6560,1898,6561,6562,6563,6564,5008,5039,5040,6565,5009,5010],"Metastatic Cholangiocarcinoma","Metastatic Digestive System Carcinoma","Metastatic Esophageal Carcinoma","Metastatic Gastric Carcinoma","Metastatic Pancreatic Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v6 and v7",[6567,1599,803,53],"Adoptive Immunotherapy",{"nctId":3552,"briefTitle":3553,"status":203,"phases":6569,"primaryCompletion":2121,"start":2122,"enrollment":124,"conditions":6570,"interventions":6571},[87],[1729,2971],[1049,803,3557],{"nctId":3117,"briefTitle":3118,"status":279,"phases":6573,"primaryCompletion":1078,"completion":3120,"start":3121,"enrollment":1559,"conditions":6574,"interventions":6575},[87],[3123,3124],[2462,3126,803],{"nctId":1337,"briefTitle":1338,"status":182,"phases":6577,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":6578,"interventions":6579},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"nctId":6581,"briefTitle":6582,"status":546,"phases":6583,"primaryCompletion":6584,"completion":6585,"start":1864,"enrollment":517,"conditions":6586,"interventions":6587},"NCT07564232","Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma",[87],"2031-06-06","2033-06-06",[1271],[803,1070,6588],"LNK001",{"nctId":3128,"briefTitle":3129,"status":130,"phases":6590,"primaryCompletion":3131,"completion":3131,"start":3132,"enrollment":95,"conditions":6591,"interventions":6592},[87],[1122,36,846,3134,644,737,1025,2653,30,727,3135,3136,3059,3060,2223,882],[803,1069,1005,2293,894,2196],{"nctId":4547,"briefTitle":4548,"status":130,"phases":6594,"primaryCompletion":3667,"completion":3667,"start":4550,"enrollment":4551,"conditions":6595,"interventions":6596},[87],[30,15],[1004,1070,894,803,2423,2293,2196,2195,2374],{"nctId":3139,"briefTitle":3140,"status":102,"phases":6598,"primaryCompletion":1939,"completion":1939,"start":3142,"enrollment":1240,"conditions":6599,"interventions":6600},[87],[1316,1961,1962,1544,1546,1549],[1599,803,1005,3145,3146],{"nctId":3148,"briefTitle":3149,"status":130,"phases":6602,"primaryCompletion":3151,"completion":3151,"start":3152,"enrollment":1568,"conditions":6603,"interventions":6604},[87],[3154,3155],[1683,3157,2462,803],{"nctId":6606,"briefTitle":6607,"status":279,"phases":6608,"primaryCompletion":193,"completion":591,"start":6609,"enrollment":628,"conditions":6610,"interventions":6611},"NCT06959537","A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)",[87],"2025-08-13",[18],[803,6612,6135],"Axatilimab",{"nctId":6614,"briefTitle":6615,"status":130,"phases":6616,"primaryCompletion":6617,"completion":6617,"start":3378,"enrollment":406,"conditions":6618,"interventions":6619},"NCT01653717","CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)",[87],"2017-08-07",[33,15],[1070,803],{"nctId":5484,"briefTitle":5485,"status":182,"phases":6621,"primaryCompletion":2016,"completion":2016,"start":5487,"enrollment":3726,"conditions":6622,"interventions":6623},[87],[5489,5490,5491,1459,5492,5493,5494,5495,5496,5497,5498,2570,5499,5500,5501,5502,5503,5504,5505,5506,5507,5508,5509,5510,5511,3457,5512,5513],[5515,803,2424],{"nctId":6625,"briefTitle":6626,"status":182,"phases":6627,"primaryCompletion":2836,"completion":2836,"start":6628,"enrollment":296,"conditions":6629,"interventions":6630},"NCT00473551","Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies",[87],"2007-05",[15,21,2245],[894,803,1070,1114,6516],{"nctId":6632,"briefTitle":6633,"status":279,"phases":6634,"primaryCompletion":548,"completion":490,"start":6635,"enrollment":2865,"conditions":6636,"interventions":6639},"NCT06660420","Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and\u002For Refractory Melanoma (PRAMETIME-Mel)",[87],"2025-02-25",[2306,6637,6638],"Recurrent Melanoma","Refractory Melanoma",[803,1070],{"nctId":6641,"briefTitle":6642,"status":279,"phases":6643,"primaryCompletion":238,"completion":238,"start":2629,"enrollment":517,"conditions":6644,"interventions":6645},"NCT05621668","A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced\u002FMetastatic Soft Tissue and Bone Sarcoma",[87],[1593,1585],[803,6646],"attIL2-T cells",{"nctId":6648,"briefTitle":6649,"status":102,"phases":6650,"primaryCompletion":999,"completion":999,"start":6651,"enrollment":2779,"conditions":6652,"interventions":6655},"NCT02389309","Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors",[87],"2015-10-05",[1343,6653,2570,6654],"Recurrent Brain Neoplasm","Refractory Brain Neoplasm",[803,1028,6656],"Temsirolimus",{"nctId":3190,"briefTitle":3191,"status":279,"phases":6658,"primaryCompletion":3193,"completion":3193,"start":1407,"enrollment":924,"conditions":6659,"interventions":6660},[87],[3195,3040],[1005,803,1683,3104,3103],{"nctId":6662,"briefTitle":6663,"status":182,"phases":6664,"primaryCompletion":2518,"completion":2518,"start":6665,"enrollment":296,"conditions":6666,"interventions":6672},"NCT03579888","CD19-Specific T Cells Post AlloSCT",[87],"2020-06-26",[6667,1142,665,6668,789,3060,2593,6669,666,1144,528,6670,790,3062,2594,6671,529],"B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged","Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma",[6673,803,1070],"Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells",{"trials":6675,"activeCount":924,"soonestReadout":3301},[6676,6687,6691,6695,6699,6703,6711,6715,6719,6723,6736,6745,6749,6753,6761,6765,6779,6786,6794,6803,6810,6814,6824,6832,6836,6840,6844,6848,6855,6859,6863,6867,6871,6875,6879,6883,6891,6895,6908,6915,6924,6932,6936,6940,6944,6948,6959,6963,6970,6977,6981,6985,6993,6997,7001,7005,7009,7013,7024,7028,7032,7036,7045,7049,7053,7061,7069,7073,7079,7083,7089,7093,7097,7101,7105,7109,7117,7121,7125,7129,7139,7143,7147,7151,7158,7162,7173,7181,7185,7191,7200,7204,7208,7212,7221,7232,7240,7249,7253,7261,7265,7272,7276,7284,7290,7302,7319,7323,7327,7331,7342,7351,7355,7359,7371,7380,7384,7391,7395,7404,7416,7425],{"nctId":6677,"briefTitle":6678,"status":279,"phases":6679,"primaryCompletion":6680,"completion":6681,"start":6682,"enrollment":240,"conditions":6683,"interventions":6685},"NCT05922930","Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer",[87,88],"2027-10-15","2028-01-15","2023-10-11",[4107,1530,6684],"Adenocarcinoma",[6686,803,1070],"TROP2-CAR-NK",{"nctId":5519,"briefTitle":5520,"status":130,"phases":6688,"primaryCompletion":4382,"completion":4382,"start":5522,"enrollment":492,"conditions":6689,"interventions":6690},[88],[21,15],[5525,5526,5527,803,2424,1070,2293,894,806,2196],{"nctId":3201,"briefTitle":3202,"status":130,"phases":6692,"primaryCompletion":3204,"completion":3204,"start":3205,"enrollment":1496,"conditions":6693,"interventions":6694},[87,88],[1316,1961,1549],[1599,3208,803,1005,3145],{"nctId":5529,"briefTitle":5530,"status":182,"phases":6696,"primaryCompletion":2836,"completion":2836,"start":4193,"enrollment":2159,"conditions":6697,"interventions":6698},[88],[21],[5527,2374,4629,5526,5534,5535,654,2424,2293,5536,1070,803],{"nctId":2407,"briefTitle":2408,"status":279,"phases":6700,"primaryCompletion":2410,"completion":2410,"start":2411,"enrollment":924,"conditions":6701,"interventions":6702},[88],[913,2413,2414,2415,2416,2417,914,2418,2419,2420,2421],[75,2423,803,62,2424,2425,1071,894,2426],{"nctId":6704,"briefTitle":6705,"status":182,"phases":6706,"primaryCompletion":2510,"completion":6707,"start":5671,"enrollment":550,"conditions":6708,"interventions":6709},"NCT01253460","Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL\u002FSLL) With Deletion (11q22-23)",[88],"2019-02-13",[15],[803,894,6710],"Sapacitabine",{"nctId":3210,"briefTitle":3211,"status":130,"phases":6712,"primaryCompletion":3213,"completion":3213,"start":3214,"enrollment":1260,"conditions":6713,"interventions":6714},[88],[712],[1005,803,894],{"nctId":4592,"briefTitle":4593,"status":130,"phases":6716,"primaryCompletion":1518,"completion":1518,"start":4595,"enrollment":230,"conditions":6717,"interventions":6718},[88],[1205,643,4597,1122,2512,36,846,3292,712,4598,737,1866,4599,3040,30,3233,3041,3059,914,632,716,882],[3085,1004,2423,803,2712,1070,2293,2195,894,2196],{"nctId":3618,"briefTitle":3619,"status":130,"phases":6720,"primaryCompletion":3621,"completion":3621,"start":3622,"enrollment":834,"conditions":6721,"interventions":6722},[88],[1316,1549],[1599,3625,803,1049],{"nctId":6724,"briefTitle":6725,"status":102,"phases":6726,"primaryCompletion":6727,"completion":6727,"start":6728,"enrollment":6729,"conditions":6730,"interventions":6731},"NCT00338377","Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma",[88],"2030-02-28","2006-02-01",1230,[1729],[6732,803,1070,6733,3499,1114,6734,6735],"Dendritic Cell Immunization","T-Cells","Intrathecal T-Cells","Intrathecal Interleukin-2",{"nctId":6737,"briefTitle":6738,"status":130,"phases":6739,"primaryCompletion":6740,"completion":6740,"start":6741,"enrollment":2700,"conditions":6742,"interventions":6743},"NCT01593020","Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2",[88],"2020-11-04","2012-08-03",[18],[1376,1370,4218,6744,803,1013],"Epirubicin",{"nctId":1580,"briefTitle":1581,"status":102,"phases":6746,"primaryCompletion":815,"completion":815,"start":1583,"enrollment":406,"conditions":6747,"interventions":6748},[88],[1585,1586,1587,1588,360,1589,1454,1590,1591,1460,1592,1593,1594,1595,1596,1597],[1599,1600,1601,803,1070,1049,1050],{"nctId":2452,"briefTitle":2453,"status":279,"phases":6750,"primaryCompletion":2455,"completion":2456,"start":2457,"enrollment":1559,"conditions":6751,"interventions":6752},[87,88],[2459,2460],[803,2462,612,62],{"nctId":6754,"briefTitle":6755,"status":130,"phases":6756,"primaryCompletion":6757,"completion":6757,"start":6758,"enrollment":861,"conditions":6759,"interventions":6760},"NCT00890656","Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage",[88],"2011-01","2003-06",[1122],[803,1016,1013,4330,2374,806,2584,808],{"nctId":2464,"briefTitle":2465,"status":279,"phases":6762,"primaryCompletion":2467,"completion":2467,"start":2468,"enrollment":2469,"conditions":6763,"interventions":6764},[87,88],[2471,2472,2473,2474,2475,1142,2415,1144,2419],[1083,803,654,62,2477,805,806,809,894,1016],{"nctId":6766,"briefTitle":6767,"status":130,"phases":6768,"primaryCompletion":6769,"completion":6769,"start":6770,"enrollment":492,"conditions":6771,"interventions":6777},"NCT04432506","Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma",[88],"2024-05-28","2020-07-27",[359,4559,4708,6772,6773,4561,6774,6775,6776],"Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Refractory High Grade B-Cell Lymphoma","Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",[6778,3348,803,1070],"Anakinra",{"nctId":6780,"briefTitle":6781,"status":279,"phases":6782,"primaryCompletion":238,"completion":238,"start":6783,"enrollment":1131,"conditions":6784,"interventions":6785},"NCT06083844","Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy",[88],"2023-12-12",[1530],[53,1275,803],{"nctId":6787,"briefTitle":6788,"status":130,"phases":6789,"primaryCompletion":6790,"completion":6790,"start":6791,"enrollment":871,"conditions":6792,"interventions":6793},"NCT00002837","High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer",[87,88],"2002-01","1995-09",[18],[1069,803,804,1376],{"nctId":6795,"briefTitle":6796,"status":130,"phases":6797,"primaryCompletion":6798,"completion":6799,"start":4382,"enrollment":2997,"conditions":6800,"interventions":6801},"NCT01036087","Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer",[88],"2016-02-11","2022-08-09",[18],[6802,4023,1369,4218,6744,803],"Panitumumab",{"nctId":6804,"briefTitle":6805,"status":3049,"phases":6806,"primaryCompletion":2326,"completion":6807,"start":5470,"enrollment":2933,"conditions":6808,"interventions":6809},"NCT00499603","Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer",[88],"2017-04",[18],[1376,4218,6744,803,2330],{"nctId":4624,"briefTitle":4625,"status":203,"phases":6811,"primaryCompletion":4619,"completion":4619,"start":4153,"enrollment":124,"conditions":6812,"interventions":6813},[88],[15],[1004,803,2374,4629],{"nctId":6815,"briefTitle":6816,"status":279,"phases":6817,"primaryCompletion":6818,"completion":6819,"start":6820,"enrollment":3521,"conditions":6821,"interventions":6823},"NCT07411599","Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1\u002F2 Trial (\"Chip-CRC Trial\")",[87,88],"2028-11-15","2030-11-15","2026-04-20",[3195,6822,2631],"Peritoneal Metastases",[803,1070,1683,511],{"nctId":6825,"briefTitle":6826,"status":182,"phases":6827,"primaryCompletion":6828,"completion":6828,"start":5557,"enrollment":517,"conditions":6829,"interventions":6831},"NCT00429026","Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation",[88],"2008-03",[6830],"Renal Cell Cancer",[1070,2293,803],{"nctId":2497,"briefTitle":2498,"status":279,"phases":6833,"primaryCompletion":2104,"completion":2104,"start":2500,"enrollment":1975,"conditions":6834,"interventions":6835},[88],[2502,2503],[1083,803,654,62,804,2477,805,806,2425,809,894,810],{"nctId":3238,"briefTitle":3239,"status":102,"phases":6837,"primaryCompletion":1427,"completion":1427,"start":225,"enrollment":163,"conditions":6838,"interventions":6839},[88],[359,3242,1067,3243,30,3244,913,608,649,3112,3059,609,3060,2223],[1004,803,1070,1005,2195,2196,1254],{"nctId":2506,"briefTitle":2507,"status":182,"phases":6841,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":296,"conditions":6842,"interventions":6843},[88],[2512,2502,2472],[803,654,62,804,2477,1373,805,806,2425,809,894,810],{"nctId":2515,"briefTitle":2516,"status":182,"phases":6845,"primaryCompletion":2518,"completion":2518,"start":2519,"enrollment":230,"conditions":6846,"interventions":6847},[88],[2521,1142,1144],[1083,803,654,62,1069,1373,805,806,1071,894,810],{"nctId":6849,"briefTitle":6850,"status":130,"phases":6851,"primaryCompletion":6757,"completion":6757,"start":6852,"enrollment":1975,"conditions":6853,"interventions":6854},"NCT01082939","Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",[88],"2002-12",[712],[1070,803,2439,894],{"nctId":5571,"briefTitle":5572,"status":130,"phases":6856,"primaryCompletion":5574,"completion":5574,"start":5575,"enrollment":1034,"conditions":6857,"interventions":6858},[88],[5577],[803,804,2424,767,1402,809,894,810],{"nctId":3255,"briefTitle":3256,"status":279,"phases":6860,"primaryCompletion":1427,"completion":3258,"start":3259,"enrollment":1559,"conditions":6861,"interventions":6862},[87,88],[3261],[2462,803,3263],{"nctId":5580,"briefTitle":5581,"status":130,"phases":6864,"primaryCompletion":5583,"completion":5583,"start":5584,"enrollment":2779,"conditions":6865,"interventions":6866},[88],[5586,5587,3056,5588,913,2415,914,2419],[803,804,2424,2425,809,894,810],{"nctId":2546,"briefTitle":2547,"status":130,"phases":6868,"primaryCompletion":2549,"completion":2549,"start":2550,"enrollment":37,"conditions":6869,"interventions":6870},[88],[21],[894,803,1013,1016,62,806,654,809],{"nctId":2554,"briefTitle":2555,"status":130,"phases":6872,"primaryCompletion":2557,"completion":2557,"start":2558,"enrollment":2559,"conditions":6873,"interventions":6874},[88],[1122,2561,644,912,913,915],[803,654,1028,62,1013,806,809,1016],{"nctId":794,"briefTitle":795,"status":279,"phases":6876,"primaryCompletion":772,"completion":772,"start":797,"enrollment":798,"conditions":6877,"interventions":6878},[88],[800,801],[803,654,62,804,805,806,807,808,809,480,810],{"nctId":2577,"briefTitle":2578,"status":130,"phases":6880,"primaryCompletion":1558,"completion":1558,"start":2580,"enrollment":2581,"conditions":6881,"interventions":6882},[88],[21],[803,1114,1016,806,2584,62,2374,2585],{"nctId":6884,"briefTitle":6885,"status":130,"phases":6886,"primaryCompletion":6887,"completion":6887,"start":6888,"enrollment":2446,"conditions":6889,"interventions":6890},"NCT00002844","Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia",[88],"2002-06-05","1991-03-05",[15],[803],{"nctId":2587,"briefTitle":2588,"status":182,"phases":6892,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":95,"conditions":6893,"interventions":6894},[88],[1142,2593,1144,2594],[803,654,1028,62,1013,1113,805,806,809,894,2596,1016],{"nctId":6896,"briefTitle":6897,"status":182,"phases":6898,"primaryCompletion":6899,"completion":6899,"start":6900,"enrollment":834,"conditions":6901,"interventions":6906},"NCT03610490","Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma",[88],"2024-08-21","2018-10-16",[360,2084,1445,6902,1454,6903,6904,6905,1676,1677,1678,1679],"Metastatic Pancreatic Ductal Adenocarcinoma","Recurrent High Grade Ovarian Serous Adenocarcinoma","Recurrent Ovarian Carcinosarcoma","Refractory Colorectal Carcinoma",[6907,803,1070,3499],"Autologous Tumor Infiltrating Lymphocytes MDA-TIL",{"nctId":6909,"briefTitle":6910,"status":546,"phases":6911,"primaryCompletion":537,"completion":1481,"start":549,"enrollment":1496,"conditions":6912,"interventions":6914},"NCT07509008","Phase 1\u002F2 Window Of Opportunity Study Of TROP2 CAR\u002FIL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum",[87,88],[6913],"Gastric Cancer, Metastatic",[2672,3103,1070,803],{"nctId":6916,"briefTitle":6917,"status":182,"phases":6918,"primaryCompletion":184,"completion":184,"start":6919,"enrollment":4171,"conditions":6920,"interventions":6922},"NCT00038142","Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients",[88],"1997-11",[6921],"Ewing's Sarcoma",[1016,1013,803,4386,6923],"ImmTher",{"nctId":6925,"briefTitle":6926,"status":130,"phases":6927,"primaryCompletion":6928,"completion":6928,"start":6929,"enrollment":406,"conditions":6930,"interventions":6931},"NCT00254410","FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) \u003C 70 Years",[88],"2017-09-14","2005-03-14",[712],[1070,803,2449,894,1069],{"nctId":3265,"briefTitle":3266,"status":130,"phases":6933,"primaryCompletion":3268,"completion":3268,"start":3269,"enrollment":195,"conditions":6934,"interventions":6935},[87,88],[3271,3272,3273,3274,3275,3276,3277,3278,3279,3280],[3282,803,1070,1005,3283],{"nctId":3285,"briefTitle":3286,"status":279,"phases":6937,"primaryCompletion":860,"completion":860,"start":3288,"enrollment":1222,"conditions":6938,"interventions":6939},[88],[1205,643,1122,2512,3290,3291,2471,3292,737,1025,3056,3057,3058,30,3233,3293,3244,648,608,3186,3059,3060,914,3294,651,882],[3296,3085,1004,2423,803,1005,2293,894],{"nctId":4678,"briefTitle":4679,"status":130,"phases":6941,"primaryCompletion":4681,"completion":4681,"start":4682,"enrollment":1034,"conditions":6942,"interventions":6943},[88],[2755,15,21],[1254,2423,1004,4537,2374,2196,806,803,1114],{"nctId":3298,"briefTitle":3299,"status":102,"phases":6945,"primaryCompletion":3301,"completion":3302,"start":3303,"enrollment":2004,"conditions":6946,"interventions":6947},[87,88],[3305],[3307,2462,803],{"nctId":6949,"briefTitle":6950,"status":546,"phases":6951,"primaryCompletion":6952,"completion":6953,"start":6954,"enrollment":1222,"conditions":6955,"interventions":6957},"NCT07164469","Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma",[88],"2031-09-30","2033-09-30","2026-06-28",[6956,1866],"Large B-cell Lymphoma",[1070,803,6958,3103],"CD70.CAR NK Cells",{"nctId":4686,"briefTitle":4687,"status":102,"phases":6960,"primaryCompletion":224,"completion":224,"start":4689,"enrollment":4690,"conditions":6961,"interventions":6962},[87,88],[608,610],[1004,803,1069,1070,2195,2207,2196],{"nctId":6964,"briefTitle":6965,"status":130,"phases":6966,"primaryCompletion":3832,"completion":3832,"start":4731,"enrollment":2779,"conditions":6967,"interventions":6968},"NCT00787527","SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma",[87,88],[21],[6969,803,1013,1016,809],"Zolinza",{"nctId":6971,"briefTitle":6972,"status":130,"phases":6973,"primaryCompletion":6974,"completion":6974,"start":5435,"enrollment":3354,"conditions":6975,"interventions":6976},"NCT00448019","FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)",[88],"2014-10",[712],[1070,803,894,1275],{"nctId":4694,"briefTitle":4695,"status":130,"phases":6978,"primaryCompletion":1558,"start":4697,"enrollment":2911,"conditions":6979,"interventions":6980},[88],[4699,15,21,2245],[1004,1070,803],{"nctId":4702,"briefTitle":4703,"status":203,"phases":6982,"primaryCompletion":4705,"completion":4705,"start":4705,"enrollment":124,"conditions":6983,"interventions":6984},[88],[4707,3272,2415,4559,4708,4560,4709],[1004,2423,803,2369,2195,894,2196,2405],{"nctId":6986,"briefTitle":6987,"status":279,"phases":6988,"primaryCompletion":238,"completion":238,"start":6989,"enrollment":3521,"conditions":6990,"interventions":6992},"NCT06318897","Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer",[88],"2024-05-29",[6991,1597],"Stage 1 cT1b-T1cN0M0",[1369,1376,53,1013,803],{"nctId":2634,"briefTitle":2635,"status":102,"phases":6994,"primaryCompletion":956,"completion":956,"start":2637,"enrollment":2638,"conditions":6995,"interventions":6996},[88],[783,891,788],[803,654,62,1013,804,767,806,894,1016,810],{"nctId":2642,"briefTitle":2643,"status":130,"phases":6998,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":2647,"conditions":6999,"interventions":7000},[88],[1122,2649,2650,2651,785,2652,2653],[803,654,62,804,806,2425,810],{"nctId":928,"briefTitle":929,"status":102,"phases":7002,"primaryCompletion":931,"completion":931,"start":932,"enrollment":240,"conditions":7003,"interventions":7004},[88],[891],[803,654,62,804,767,806,894,480,810],{"nctId":2664,"briefTitle":2665,"status":279,"phases":7006,"primaryCompletion":2667,"completion":2668,"start":2669,"enrollment":924,"conditions":7007,"interventions":7008},[87,88],[2460],[62,803,1070,612,2672],{"nctId":4712,"briefTitle":4713,"status":130,"phases":7010,"primaryCompletion":4715,"completion":4716,"start":4635,"enrollment":95,"conditions":7011,"interventions":7012},[88],[15],[1004,1070,2423,4537,2373,803,2196,2757,612,654,655],{"nctId":7014,"briefTitle":7015,"status":182,"phases":7016,"primaryCompletion":1984,"completion":1984,"start":7017,"enrollment":166,"conditions":7018,"interventions":7020},"NCT02419469","Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",[88],"2015-11-13",[15,7019,2653,21],"Precursor-B Acute Lymphoblastic Leukemia",[654,7021,1016,809,7022,2425,894,806,803,805,1013,4514,7023],"Daunorubicin","PEG asparaginase","Thioguanine",{"nctId":5229,"briefTitle":5230,"status":130,"phases":7025,"primaryCompletion":5232,"completion":5232,"start":4183,"enrollment":507,"conditions":7026,"interventions":7027},[88],[18,5234,5079],[1369,803,1254],{"nctId":2674,"briefTitle":2675,"status":130,"phases":7029,"primaryCompletion":2677,"completion":2677,"start":2678,"enrollment":2004,"conditions":7030,"interventions":7031},[88],[15],[894,2681,803,1013,1114,2682,2683,806,2584,2374,1071,62],{"nctId":3309,"briefTitle":3310,"status":130,"phases":7033,"primaryCompletion":3312,"completion":3312,"start":3313,"enrollment":628,"conditions":7034,"interventions":7035},[88],[2460,36,30,3315],[803,1114,1069,2293,2462,2196,2757,3317],{"nctId":7037,"briefTitle":7038,"status":203,"phases":7039,"primaryCompletion":7040,"completion":7040,"start":7041,"enrollment":124,"conditions":7042,"interventions":7043},"NCT02948101","PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[88],"2019-02-06","2018-12-31",[1458,1460,1461],[7044,803],"Anti-CSF1 Monoclonal Antibody PD-0360324",{"nctId":3319,"briefTitle":3320,"status":130,"phases":7046,"primaryCompletion":3322,"completion":3322,"start":3323,"enrollment":550,"conditions":7047,"interventions":7048},[88],[1316,1544,1546,1549],[1599,803,1005,53,3326],{"nctId":3328,"briefTitle":3329,"status":279,"phases":7050,"primaryCompletion":281,"completion":571,"start":2855,"enrollment":2997,"conditions":7051,"interventions":7052},[87,88],[3332,3333,3334,3335,3336],[3338,2462,803,3339],{"nctId":7054,"briefTitle":7055,"status":130,"phases":7056,"primaryCompletion":7057,"completion":7057,"start":7058,"enrollment":1034,"conditions":7059,"interventions":7060},"NCT01039025","TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma",[88],"2006-05-19","2002-02-18",[2245],[1379,803,2293],{"nctId":7062,"briefTitle":7063,"status":279,"phases":7064,"primaryCompletion":1735,"completion":7065,"start":2106,"enrollment":517,"conditions":7066,"interventions":7067},"NCT06045247","Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit\u002FFrail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma",[88],"2030-07-31",[6956],[809,894,803,1016,7068],"Epcoritamab",{"nctId":2695,"briefTitle":2696,"status":130,"phases":7070,"primaryCompletion":2698,"completion":2698,"start":2699,"enrollment":2700,"conditions":7071,"interventions":7072},[88],[15],[2321,803,1013,1016,62,806,654,1114,2374],{"nctId":7074,"briefTitle":7075,"status":130,"phases":7076,"primaryCompletion":3213,"completion":3213,"start":4612,"enrollment":1034,"conditions":7077,"interventions":7078},"NCT00381004","FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia",[88],[712],[803,1070,4387,894],{"nctId":3341,"briefTitle":3342,"status":279,"phases":7080,"primaryCompletion":549,"completion":1088,"start":3344,"enrollment":1131,"conditions":7081,"interventions":7082},[88],[3346],[3348,803,2462,809,2269,2395],{"nctId":7084,"briefTitle":7085,"status":182,"phases":7086,"primaryCompletion":2806,"completion":2806,"start":3901,"enrollment":166,"conditions":7087,"interventions":7088},"NCT01321008","Stage I\u002FII Nasal NK Cell Lymphoma",[87,88],[21],[803,1013,1016,809],{"nctId":4720,"briefTitle":4721,"status":130,"phases":7090,"primaryCompletion":4192,"completion":4723,"start":3902,"enrollment":628,"conditions":7091,"interventions":7092},[88],[4725],[1004,803,2321],{"nctId":5237,"briefTitle":5238,"status":130,"phases":7094,"primaryCompletion":5240,"completion":5240,"start":5241,"enrollment":971,"conditions":7095,"interventions":7096},[88],[2530,5243,5244,5245],[5247,2293,1254,1070,803,1114],{"nctId":5645,"briefTitle":5646,"status":130,"phases":7098,"primaryCompletion":2953,"completion":2953,"start":5648,"enrollment":195,"conditions":7099,"interventions":7100},[88],[21],[4109,803,2424,1114],{"nctId":3350,"briefTitle":3351,"status":279,"phases":7102,"primaryCompletion":1662,"completion":1662,"start":3353,"enrollment":3354,"conditions":7103,"interventions":7104},[87,88],[3356],[1005,803,3358],{"nctId":2714,"briefTitle":2715,"status":130,"phases":7106,"primaryCompletion":2717,"completion":2717,"start":2718,"enrollment":2559,"conditions":7107,"interventions":7108},[87,88],[891],[75,803,654,62,1013,806,894,1016],{"nctId":7110,"briefTitle":7111,"status":130,"phases":7112,"primaryCompletion":3152,"completion":3152,"start":7113,"enrollment":2700,"conditions":7114,"interventions":7116},"NCT01904136","Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia",[87,88],"2014-04-22",[1205,846,7115,644,647,30,608,649,682],"Acute Myeloid Leukemia With Gene Mutations",[803,1070,2293,2195,3064,2196],{"nctId":3364,"briefTitle":3365,"status":279,"phases":7118,"primaryCompletion":238,"completion":238,"start":3367,"enrollment":676,"conditions":7119,"interventions":7120},[87,88],[1772,3369,3370],[3372,2462,803],{"nctId":4166,"briefTitle":4167,"status":130,"phases":7122,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":7123,"interventions":7124},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"nctId":1007,"briefTitle":1008,"status":279,"phases":7126,"primaryCompletion":446,"completion":446,"start":1010,"enrollment":517,"conditions":7127,"interventions":7128},[88],[847],[803,654,62,1013,805,806,1014,809,894,1015,480,1016],{"nctId":7130,"briefTitle":7131,"status":279,"phases":7132,"primaryCompletion":7133,"completion":7134,"start":1282,"enrollment":406,"conditions":7135,"interventions":7137},"NCT06630091","A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study",[88],"2027-07-05","2029-07-05",[7136],"Peripheral T Cell Lymphoma",[7138,803,1013,1016,809],"Golidocitinib",{"nctId":3388,"briefTitle":3389,"status":279,"phases":7140,"primaryCompletion":1427,"completion":1427,"start":3391,"enrollment":1975,"conditions":7141,"interventions":7142},[87,88],[3393,3394,3395,1400,3396,1866,3397,3398,3399,3400],[803,3402,2462],{"nctId":3404,"briefTitle":3405,"status":102,"phases":7144,"primaryCompletion":3407,"completion":3407,"start":3408,"enrollment":3409,"conditions":7145,"interventions":7146},[88],[712,716],[803,1005,767,669],{"nctId":4771,"briefTitle":4772,"status":102,"phases":7148,"primaryCompletion":2455,"completion":2455,"start":4774,"enrollment":2004,"conditions":7149,"interventions":7150},[88],[680],[1004,803,1070,4777,2196,1254],{"nctId":7152,"briefTitle":7153,"status":130,"phases":7154,"primaryCompletion":7155,"completion":7155,"start":4887,"enrollment":1034,"conditions":7156,"interventions":7157},"NCT00525603","CFAR Study in Patients With Chronic Lymphocytic Leukemia",[88],"2011-07",[15,712],[803,1070,2439,894],{"nctId":2726,"briefTitle":2727,"status":102,"phases":7159,"primaryCompletion":999,"completion":999,"start":2729,"enrollment":2730,"conditions":7160,"interventions":7161},[88],[1205,1122,2649,2471,644,912,2732],[803,654,62,1013,804,806,1124,917,809,894,1016,810],{"nctId":7163,"briefTitle":7164,"status":279,"phases":7165,"primaryCompletion":7166,"completion":7167,"start":7168,"enrollment":19,"conditions":7169,"interventions":7171},"NCT06598371","A Phase 1\u002F2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors",[87,88],"2039-08-01","2041-08-01","2024-11-21",[7170],"Select Advanced Solid Tumors",[803,1070,7172,3499],"KSQ-004EX",{"nctId":7174,"briefTitle":7175,"status":182,"phases":7176,"primaryCompletion":7177,"completion":7177,"start":5556,"enrollment":1568,"conditions":7178,"interventions":7179},"NCT00756470","Phase II Neoadjuvant in Inflammatory Breast Cancer",[88],"2013-10",[18],[7180,1376,4218,6744,803],"Lapatinib",{"nctId":5253,"briefTitle":5254,"status":130,"phases":7182,"primaryCompletion":5256,"completion":5256,"start":5257,"enrollment":5258,"conditions":7183,"interventions":7184},[88],[5260,15,4760],[803,1070,2293,1114,894,1254,2196,5262,2374],{"nctId":7186,"briefTitle":7187,"status":130,"phases":7188,"primaryCompletion":2326,"completion":2326,"start":2828,"enrollment":240,"conditions":7189,"interventions":7190},"NCT00412243","Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients",[87,88],[2913,2653,1122],[2423,803],{"nctId":7192,"briefTitle":7193,"status":130,"phases":7194,"primaryCompletion":7195,"completion":7195,"start":7196,"enrollment":7197,"conditions":7198,"interventions":7199},"NCT00759798","Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)",[88],"2020-07-22","2008-08-13",289,[712,15],[1070,803,894],{"nctId":1999,"briefTitle":2000,"status":279,"phases":7201,"primaryCompletion":2002,"completion":2002,"start":2003,"enrollment":2004,"conditions":7202,"interventions":7203},[88],[2006,2007,2008,2009],[2011,803,1013,1050,809,894],{"nctId":2749,"briefTitle":2750,"status":203,"phases":7205,"primaryCompletion":2752,"completion":2752,"start":2753,"enrollment":124,"conditions":7206,"interventions":7207},[88],[2755],[1070,62,803,75,894,1004,803,2196,2757,2758],{"nctId":1105,"briefTitle":1106,"status":182,"phases":7209,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":539,"conditions":7210,"interventions":7211},[87,88],[359,913,608,850,609,914,610,853,632],[1112,510,803,654,62,1069,1113,1114,806,809,894,480,1016],{"nctId":7213,"briefTitle":7214,"status":102,"phases":7215,"primaryCompletion":7216,"completion":7216,"start":7217,"enrollment":2933,"conditions":7218,"interventions":7220},"NCT04978584","Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study",[88],"2027-01-16","2022-03-03",[7219],"Diffuse Large B-Cell Lymphoma",[668,803,804,1402,809,894,3338,1016],{"nctId":7222,"briefTitle":7223,"status":130,"phases":7224,"primaryCompletion":7225,"completion":7225,"start":7226,"enrollment":1100,"conditions":7227,"interventions":7229},"NCT00866749","Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent\u002FYoung Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma",[88],"2018-07-26","2006-09-12",[7228,2653],"Lymphoblastic Leukemia",[7021,1016,7230,7231,803,654,805,806,1013,7023],"PEG-asparaginase","Intrathecal Methotrexate",{"nctId":7233,"briefTitle":7234,"status":182,"phases":7235,"primaryCompletion":5434,"completion":5434,"start":7236,"enrollment":166,"conditions":7237,"interventions":7238},"NCT00698009","Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma",[88],"2008-06",[5735],[1070,803,7239,1114,3499],"Natural Killer Cell",{"nctId":7241,"briefTitle":7242,"status":546,"phases":7243,"primaryCompletion":7065,"completion":7244,"start":115,"enrollment":3082,"conditions":7245,"interventions":7247},"NCT07137481","Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies",[88],"2032-07-31",[7246],"Hematological Malignancies",[7248,894,1070,803],"C9\u002FCD5CAR\u002FIL-15 NK cells",{"nctId":4807,"briefTitle":4808,"status":130,"phases":7250,"primaryCompletion":4810,"completion":4810,"start":4811,"enrollment":628,"conditions":7251,"interventions":7252},[87,88],[15],[1069,1004,803,3420,612,806,1014,2196],{"nctId":7254,"briefTitle":7255,"status":182,"phases":7256,"primaryCompletion":2778,"completion":2778,"start":3987,"enrollment":121,"conditions":7257,"interventions":7259},"NCT00941928","Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)",[88],[15,7258],"Pediatric Cancer",[7260,1070,803,1114,3499],"Epratuzumab",{"nctId":2813,"briefTitle":2814,"status":279,"phases":7262,"primaryCompletion":224,"completion":548,"start":2816,"enrollment":2159,"conditions":7263,"interventions":7264},[88],[15],[803,1016,1083,806,654,805,809,1071,2819,894,62],{"nctId":7266,"briefTitle":7267,"status":130,"phases":7268,"primaryCompletion":2602,"completion":2602,"start":2213,"enrollment":1975,"conditions":7269,"interventions":7270},"NCT00101010","Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma",[88],[21],[1069,1071,894,803,7271,809,810],"Pegylated liposomal doxorubicin hydrochloride",{"nctId":1135,"briefTitle":1136,"status":182,"phases":7273,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":1140,"conditions":7274,"interventions":7275},[87,88],[1142,1143,1144,1145],[803,654,62,806,807,808,809,894,480,1016],{"nctId":7277,"briefTitle":7278,"status":102,"phases":7279,"primaryCompletion":115,"completion":115,"start":7280,"enrollment":492,"conditions":7281,"interventions":7283},"NCT03147612","Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and\u002For BCR-ABL Positive Acute Lymphoblastic Leukemia",[88],"2018-02-08",[1205,1122,7282,644,913,914],"Acute Myeloid Leukemia With BCR-ABL1",[1083,803,654,1069,806,1071,1124,894,1016],{"nctId":7285,"briefTitle":7286,"status":130,"phases":7287,"primaryCompletion":6065,"completion":6065,"start":6410,"enrollment":492,"conditions":7288,"interventions":7289},"NCT00958256","Study of Bortezomib in Combination With Cyclophosphamide and Rituximab",[88],[891,21],[75,894,803,1114,2374],{"nctId":7291,"briefTitle":7292,"status":182,"phases":7293,"primaryCompletion":7294,"completion":7294,"start":5035,"enrollment":1240,"conditions":7295,"interventions":7299},"NCT03101748","Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer",[87,88],"2025-05-13",[7296,7297,5234,5086,5087,5088,5089,7298],"Breast Inflammatory Carcinoma","Locally Advanced Breast Carcinoma","Stage IV Breast Cancer AJCC v6 and v7",[803,1013,7300,1376,7301,4227],"Neratinib","Pertuzumab",{"nctId":7303,"briefTitle":7304,"status":203,"phases":7305,"primaryCompletion":754,"completion":754,"start":7306,"enrollment":124,"conditions":7307,"interventions":7318},"NCT05177796","Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer",[88],"2022-03-11",[7308,7309,7310,7311,7312,7296,5079,7313,7314,7315,7316,7317,1363],"Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8",[1369,803,1013,1376,6802,53],{"nctId":2825,"briefTitle":2826,"status":130,"phases":7320,"primaryCompletion":2326,"completion":2326,"start":2828,"enrollment":676,"conditions":7321,"interventions":7322},[87,88],[21],[2831,894,803,1016,1013,62,806,654],{"nctId":2833,"briefTitle":2834,"status":130,"phases":7324,"primaryCompletion":2232,"completion":2232,"start":2836,"enrollment":628,"conditions":7325,"interventions":7326},[87,88],[15,2838],[2840,803,1016,1013,62,1114,806,2584,2841,2374],{"nctId":3422,"briefTitle":3423,"status":279,"phases":7328,"primaryCompletion":3425,"completion":3426,"start":3427,"enrollment":406,"conditions":7329,"interventions":7330},[88],[2135,3429],[598,3431,3432,1004,3433,2462,803,1114,2196],{"nctId":7332,"briefTitle":7333,"status":102,"phases":7334,"primaryCompletion":3425,"completion":3426,"start":7335,"enrollment":1568,"conditions":7336,"interventions":7340},"NCT06237881","A Phase 1\u002F2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors",[87,88],"2024-01-31",[7337,1729,7338,7339],"Advanced Solid Tumor","Lung Neoplasms","Head and Neck Neoplasms",[7341,3499,803,1070],"KSQ-001EX",{"nctId":7343,"briefTitle":7344,"status":203,"phases":7345,"primaryCompletion":1230,"completion":1230,"start":7346,"enrollment":124,"conditions":7347,"interventions":7349},"NCT04029038","Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma",[87,88],"2019-05-15",[3039,7348,3040,1670,1142,665,3060,1144,528,3062],"CD22 Positive",[7350,803,1070],"Autologous CD19\u002FCD22 Chimeric Antigen Receptor T-cells",{"nctId":3435,"briefTitle":3436,"status":130,"phases":7352,"primaryCompletion":3438,"completion":3438,"start":3439,"enrollment":2018,"conditions":7353,"interventions":7354},[87,88],[15],[1069,803,1005],{"nctId":2852,"briefTitle":2853,"status":182,"phases":7356,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":296,"conditions":7357,"interventions":7358},[87,88],[2413,1142,1143,1144,2421,1145],[803,654,62,2712,1113,805,1114,806,1071,809,894,1015,1016],{"nctId":7360,"briefTitle":7361,"status":130,"phases":7362,"primaryCompletion":7363,"completion":7363,"start":7364,"enrollment":3197,"conditions":7365,"interventions":7368},"NCT03318900","T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer",[87,88],"2023-12-20","2018-09-04",[7366,6448,7367,1460],"COL6A3 Positive","PRAME Positive",[1599,7369,803,7370],"CD8-Positive T-Lymphocyte","Utomilumab",{"nctId":7372,"briefTitle":7373,"status":130,"phases":7374,"primaryCompletion":7375,"completion":7375,"start":7376,"enrollment":7377,"conditions":7378,"interventions":7379},"NCT02529852","A Phase I\u002FII Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma",[87,88],"2022-10-31","2015-11-04",59,[21],[1402,669,803,1013,1016,809],{"nctId":2871,"briefTitle":2872,"status":130,"phases":7381,"primaryCompletion":2874,"completion":2874,"start":2875,"enrollment":1766,"conditions":7382,"interventions":7383},[88],[21],[2878,2879,2880,2881,2882,2883,2884],{"nctId":7385,"briefTitle":7386,"status":279,"phases":7387,"primaryCompletion":3943,"completion":3943,"start":7388,"enrollment":448,"conditions":7389,"interventions":7390},"NCT04022239","Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant",[87,88],"2020-03-13",[726],[6545,803,2712,1070,2293,2195,894,2196],{"nctId":2886,"briefTitle":2887,"status":130,"phases":7392,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":7393,"interventions":7394},[88],[15,1122],[894,803,1013,1016,62,806,654,2374,1114,2894,1071,2895],{"nctId":7396,"briefTitle":7397,"status":130,"phases":7398,"primaryCompletion":7399,"completion":7399,"start":7400,"enrollment":3082,"conditions":7401,"interventions":7402},"NCT00048737","Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies",[87,88],"2011-12","2002-10",[21,15],[7403,894,1070,803],"Zevalin Radioimmunotherapy",{"nctId":7405,"briefTitle":7406,"status":130,"phases":7407,"primaryCompletion":7408,"completion":7408,"start":7409,"enrollment":2446,"conditions":7410,"interventions":7413},"NCT03056339","Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies",[87,88],"2023-03-06","2017-06-21",[7411,2838,712,7412],"B-Lymphoid Malignancies","Non-hodgkin Lymphoma",[1070,803,1114,7414,7415],"iC9\u002FCAR.19\u002FIL15-Transduced CB-NK Cells","AP1903",{"nctId":7417,"briefTitle":7418,"status":102,"phases":7419,"primaryCompletion":404,"completion":404,"start":7420,"enrollment":834,"conditions":7421,"interventions":7423},"NCT03622788","Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant",[87,88],"2019-08-08",[1122,36,3134,7422,712,4598,3346,1866,891,30,727,3041,3135],"Bone Marrow Failure",[3085,803,7424,1070],"Cytokine-treated Veto Cells",{"nctId":2906,"briefTitle":2907,"status":130,"phases":7426,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":7427,"interventions":7428},[88],[2913,2914],[894,803,1013,1016,62,2374,654,806],{"trials":7430,"activeCount":124},[7431,7435,7442,7446,7450,7454],{"nctId":4305,"briefTitle":4306,"status":130,"phases":7432,"primaryCompletion":4308,"completion":4308,"start":4309,"enrollment":2402,"conditions":7433,"interventions":7434},[89],[21],[4312,4313,4045,2879,2880,2882,4314,4315,4047,4316,4317,4318,4319,2884],{"nctId":7436,"briefTitle":7437,"status":130,"phases":7438,"primaryCompletion":6409,"completion":3777,"start":2580,"enrollment":7439,"conditions":7440,"interventions":7441},"NCT00336791","Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer",[89],273,[18],[4218,803,1013,1376,6744],{"nctId":5712,"briefTitle":5713,"status":182,"phases":7443,"primaryCompletion":5715,"completion":5715,"start":5716,"enrollment":121,"conditions":7444,"interventions":7445},[89],[5718],[1369,803,2424,1016],{"nctId":4321,"briefTitle":4322,"status":130,"phases":7447,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":7448,"interventions":7449},[89],[21],[1070,4329,4330,894,3671,1013,1016,4331,803,2424,1709,2584,4332,4333,809],{"nctId":4357,"briefTitle":4358,"status":130,"phases":7451,"primaryCompletion":4360,"completion":4360,"start":4361,"enrollment":4362,"conditions":7452,"interventions":7453},[89],[18],[1069,4365,1709,803,2424,1254],{"nctId":4367,"briefTitle":4368,"status":130,"phases":7455,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":7456,"interventions":7457},[89],[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":7459,"activeCount":124},[],{"trials":7461,"activeCount":124},[7462,7469,7476,7483,7491],{"nctId":7463,"briefTitle":7464,"status":130,"phases":7465,"primaryCompletion":6410,"completion":6410,"start":7466,"enrollment":910,"conditions":7467,"interventions":7468},"NCT00427336","Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia",[91],"2000-12",[3134],[1070,803,4668],{"nctId":7470,"briefTitle":7471,"status":130,"phases":7472,"primaryCompletion":3777,"completion":3777,"start":7473,"enrollment":2446,"conditions":7474,"interventions":7475},"NCT00525876","Non-Myeloablative Allogeneic Stem Cell Transplantation",[91],"2005-01",[21],[803,1070,894,2439],{"nctId":7477,"briefTitle":7478,"status":130,"phases":7479,"primaryCompletion":2212,"completion":2212,"start":6828,"enrollment":3820,"conditions":7480,"interventions":7481},"NCT00651755","Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP\u002FR-CHOP) Chemotherapy Regimen in Lymphoma Patients",[91],[21],[7482,803,1013,1016,809,894,2793],"Aprepitant",{"nctId":7484,"briefTitle":7485,"status":130,"phases":7486,"primaryCompletion":4192,"completion":3777,"start":7487,"enrollment":3541,"conditions":7488,"interventions":7489},"NCT00038844","Safety and Efficacy of Campath in Nonmyeloablative Transplantation",[91],"2001-06",[21,15],[7490,1070,803,894],"Campath-1 H",{"nctId":7492,"briefTitle":7493,"status":203,"phases":7494,"start":3777,"enrollment":124,"conditions":7495,"interventions":7496},"NCT01159236","Molecular Triaging of Newly Diagnosed Breast Cancer",[91],[18],[1376,1371,1013,6744,803,1275],{"intervention":53,"totalTrials":606,"cells":7498},{"EARLY_PHASE1":7499,"PHASE1":7559,"PHASE2":7677,"PHASE3":8201,"PHASE4":8203,"NA":8205},{"trials":7500,"activeCount":121,"soonestReadout":57},[7501,7507,7537],{"nctId":55,"briefTitle":56,"status":102,"phases":7502,"primaryCompletion":57,"completion":224,"start":7503,"enrollment":1131,"conditions":7504,"interventions":7506},[86],"2016-07-20",[7505],"Smoldering Plasma Cell Myeloma",[53],{"nctId":7508,"briefTitle":7509,"status":130,"phases":7510,"primaryCompletion":7511,"completion":7511,"start":7512,"enrollment":910,"conditions":7513,"interventions":7536},"NCT03395847","Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma",[86],"2023-01-27","2018-02-09",[7514,7515,7516,7517,7518,7519,1636,7520,7521,4097,7522,7523,7524,7525,1654,7526,7527,7528,7529,7530,7531,7532,7533,7534,7535],"Advanced Gastroesophageal Junction Adenocarcinoma","Clinical Stage III Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Gastric Cancer AJCC v8","Clinical Stage IV Esophageal Adenocarcinoma AJCC v8","Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVB Gastric Cancer AJCC v8","Metastatic Gastroesophageal Junction Adenocarcinoma","Pathologic Stage III Esophageal Adenocarcinoma AJCC v8","Pathologic Stage III Gastric Cancer AJCC v8","Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IIIB Gastric Cancer AJCC v8","Pathologic Stage IIIC Gastric Cancer AJCC v8","Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IV Gastric Cancer AJCC v8","Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8","Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8","Unresectable Gastroesophageal Junction Adenocarcinoma",[53],{"nctId":7538,"briefTitle":7539,"status":279,"phases":7540,"primaryCompletion":1193,"completion":1193,"start":2061,"enrollment":1568,"conditions":7541,"interventions":7557},"NCT05041153","Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma",[86],[7542,7514,7516,1635,7518,7543,1636,1637,7521,7544,7545,7522,7524,7546,1654,7547,7527,1655,7528,7530,7548,1656,7549,7533,7550,7551,7552,7534,7553,7554,7555,7556,7535],"Advanced Gastric Adenocarcinoma","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","Metastatic Gastric Adenocarcinoma","Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8","Unresectable Gastric Adenocarcinoma",[7558,53],"Lenvatinib",{"trials":7560,"activeCount":230,"soonestReadout":1864},[7561,7570,7580,7590,7606,7620,7624,7628,7632,7640,7659,7668],{"nctId":7562,"briefTitle":7563,"status":203,"phases":7564,"primaryCompletion":7565,"completion":7565,"start":7565,"enrollment":124,"conditions":7566,"interventions":7568},"NCT05431582","Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors",[87],"2022-12-14",[7567,1530,18,24,4107],"Tumors",[7569,1275,53],"ZN-c3",{"nctId":7571,"briefTitle":7572,"status":279,"phases":7573,"primaryCompletion":860,"completion":860,"start":3520,"enrollment":7574,"conditions":7575,"interventions":7576},"NCT02600949","Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer",[87],300,[2084,6902,5008,6565,5009,5010],[7577,53,7578,7579],"Imiquimod","Sotigalimab","Synthetic Tumor-Associated Peptide Vaccine Therapy",{"nctId":7581,"briefTitle":7582,"status":279,"phases":7583,"primaryCompletion":1151,"completion":1152,"start":7584,"enrollment":4299,"conditions":7585,"interventions":7586},"NCT06576037","Phase Ib Study of CBP-1019 in Combination With FOLFOX +\u002F- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin",[87],"2024-10-31",[3305],[7587,1375,1113,7588,1275,53,7589],"CBP-1019","5-FLUOROURACIL","Enzalutamide",{"nctId":7591,"briefTitle":7592,"status":130,"phases":7593,"primaryCompletion":7594,"completion":7594,"start":7595,"enrollment":910,"conditions":7596,"interventions":7604},"NCT02930902","Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery",[87],"2023-01-03","2017-02-20",[7597,7598,7599,7600,7601,7602,7603],"Resectable Pancreatic Carcinoma","Stage I Pancreatic Cancer AJCC v6 and v7","Stage IA Pancreatic Cancer AJCC v6 and v7","Stage IB Pancreatic Cancer AJCC v6 and v7","Stage II Pancreatic Cancer AJCC v6 and v7","Stage IIA Pancreatic Cancer AJCC v6 and v7","Stage IIB Pancreatic Cancer AJCC v6 and v7",[4135,4023,7605,53],"Paricalcitol",{"nctId":7607,"briefTitle":7608,"status":279,"phases":7609,"primaryCompletion":224,"completion":224,"start":7610,"enrollment":1609,"conditions":7611,"interventions":7619},"NCT03295227","Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer",[87],"2017-12-06",[7612,7613,7614,7615,7616,7617,7618],"Stage III Thymoma AJCC v8","Stage IIIA Thymoma AJCC v8","Stage IIIB Thymoma AJCC v8","Stage IV Thymoma AJCC v8","Stage IVA Thymoma AJCC v8","Stage IVB Thymoma AJCC v8","Unresectable Thymic Carcinoma",[53],{"nctId":6554,"briefTitle":6555,"status":182,"phases":7621,"primaryCompletion":6557,"completion":6557,"start":6558,"enrollment":166,"conditions":7622,"interventions":7623},[87],[5028,6560,1898,6561,6562,6563,6564,5008,5039,5040,6565,5009,5010],[6567,1599,803,53],{"nctId":3864,"briefTitle":3865,"status":130,"phases":7625,"primaryCompletion":3867,"completion":3868,"start":3869,"enrollment":2946,"conditions":7626,"interventions":7627},[87],[3871,3872,3873],[1369,1709,2424,53],{"nctId":1337,"briefTitle":1338,"status":182,"phases":7629,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":7630,"interventions":7631},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"nctId":7633,"briefTitle":7634,"status":102,"phases":7635,"primaryCompletion":224,"completion":224,"start":7636,"enrollment":1568,"conditions":7637,"interventions":7638},"NCT05273554","A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma",[87],"2022-08-31",[3071,6684],[53,7639],"lenvatinib",{"nctId":7641,"briefTitle":7642,"status":102,"phases":7643,"primaryCompletion":1864,"completion":1864,"start":7644,"enrollment":550,"conditions":7645,"interventions":7657},"NCT03435952","Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT",[87],"2018-07-10",[7646,7647,7648,5799,7649,7650,7651,7652,7653,7654,7655,7656],"Malignant Neoplasm of Breast","Malignant Neoplasms of Digestive Organs","Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System","Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites","Malignant Neoplasms of Independent (Primary) Multiple Sites","Malignant Neoplasms of Lip Oral Cavity and Pharynx","Malignant Neoplasms of Male Genital Organs","Malignant Neoplasms of Mesothelial and Soft Tissue","Malignant Neoplasms of Respiratory and Intrathoracic Organs","Malignant Neoplasms of Thyroid and Other Endocrine Glands","Malignant Neoplasms of Urinary Tract",[53,7658,3729],"Clostridium Novyi-NT",{"nctId":7660,"briefTitle":7661,"status":102,"phases":7662,"primaryCompletion":7663,"completion":7663,"start":7664,"enrollment":834,"conditions":7665,"interventions":7667},"NCT04522336","Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer",[87],"2027-07-18","2020-09-16",[1635,7543,1637,7544,1640,7666,7546,7547,1655,7548,1656,7549,7550,7551,7552,7553,7554,7555,7535],"Locally Advanced Gastroesophageal Junction Adenocarcinoma",[1710,1371,1375,53],{"nctId":7669,"briefTitle":7670,"status":130,"phases":7671,"primaryCompletion":7672,"completion":4016,"start":7673,"enrollment":448,"conditions":7674,"interventions":7676},"NCT02959463","Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma",[87],"2024-11-15","2017-05-01",[7675],"Pleural Malignant Mesothelioma",[53],{"trials":7678,"activeCount":2159,"soonestReadout":52},[7679,7688,7705,7716,7720,7733,7742,7752,7761,7765,7775,7779,7786,7806,7810,7823,7831,7840,7848,7852,7856,7868,7876,7885,7893,7901,7909,7917,7929,7933,7956,7966,7974,7982,7990,7994,8000,8008,8012,8020,8032,8042,8049,8059,8071,8082,8090,8100,8109,8118,8126,8135,8139,8148,8157,8161,8180,8191],{"nctId":7680,"briefTitle":7681,"status":130,"phases":7682,"primaryCompletion":7683,"completion":7683,"start":7684,"enrollment":628,"conditions":7685,"interventions":7687},"NCT02816021","Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma",[88],"2026-03-19","2017-02-14",[7686,1316],"Melanoma and Other Malignant Neoplasms of Skin",[510,53],{"nctId":7689,"briefTitle":7690,"status":102,"phases":7691,"primaryCompletion":7692,"completion":281,"start":7693,"enrollment":7694,"conditions":7695,"interventions":7704},"NCT02411656","Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy",[88],"2024-06-15","2015-06-11",71,[7696,7697,7698,7699,7700,7701,7702,7703,1363],"Edema","Erythema","Estrogen Receptor Negative","HER2\u002FNeu Negative","Peau d'Orange","Progesterone Receptor Negative","Recurrent Inflammatory Breast Carcinoma","Stage IV Inflammatory Breast Carcinoma",[53],{"nctId":7706,"briefTitle":7707,"status":102,"phases":7708,"primaryCompletion":7709,"completion":7709,"start":7710,"enrollment":406,"conditions":7711,"interventions":7715},"NCT05114421","Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients",[88],"2026-01-31","2021-11-09",[4910,4911,7712,7713,6903,7714],"Peritoneal High Grade Serous Adenocarcinoma","Recurrent High Grade Fallopian Tube Serous Adenocarcinoma","Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma",[7558,53],{"nctId":6780,"briefTitle":6781,"status":279,"phases":7717,"primaryCompletion":238,"completion":238,"start":6783,"enrollment":1131,"conditions":7718,"interventions":7719},[88],[1530],[53,1275,803],{"nctId":7721,"briefTitle":7722,"status":130,"phases":7723,"primaryCompletion":7724,"completion":7725,"start":7726,"enrollment":539,"conditions":7727,"interventions":7732},"NCT03210662","Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",[88],"2025-10-28","2025-10-31","2018-02-01",[7728,4707,7729,3060,4560,6773,7730,3062,4562,6776,7731],"Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma","Refractory Aggressive Non-Hodgkin Lymphoma","Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma",[53],{"nctId":7734,"briefTitle":7735,"status":203,"phases":7736,"primaryCompletion":7737,"completion":7737,"start":7738,"enrollment":124,"conditions":7739,"interventions":7741},"NCT05879120","Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma",[88],"2024-10-02","2024-07-30",[7740],"Recurrent Glioblastoma",[53],{"nctId":7743,"briefTitle":7744,"status":182,"phases":7745,"primaryCompletion":7746,"completion":7746,"start":7747,"enrollment":2779,"conditions":7748,"interventions":7751},"NCT04862455","NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer",[88],"2026-01-21","2021-04-07",[7749,7750],"Metastatic Head and Neck Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma",[53],{"nctId":7753,"briefTitle":7754,"status":203,"phases":7755,"primaryCompletion":7756,"completion":7756,"start":7757,"enrollment":124,"conditions":7758,"interventions":7759},"NCT02719015","Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma",[87,88],"2022-03","2018-03",[1729],[7760,53],"rAd.CD40L",{"nctId":3940,"briefTitle":3941,"status":279,"phases":7762,"primaryCompletion":3943,"completion":3944,"start":3945,"enrollment":628,"conditions":7763,"interventions":7764},[88],[3947],[53,2369,1709],{"nctId":7766,"briefTitle":7767,"status":130,"phases":7768,"primaryCompletion":7769,"completion":7769,"start":7770,"enrollment":3820,"conditions":7771,"interventions":7774},"NCT03319745","Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy",[88],"2023-05-01","2018-01-11",[7772,7773,1779,1780,1781],"Stage I Bladder Cancer AJCC v8","Stage II Bladder Cancer AJCC v8",[53],{"nctId":3653,"briefTitle":3654,"status":130,"phases":7776,"primaryCompletion":3656,"completion":3656,"start":3570,"enrollment":628,"conditions":7777,"interventions":7778},[88],[1312,1960,1316,1353],[1049,53],{"nctId":7780,"briefTitle":7781,"status":279,"phases":7782,"primaryCompletion":161,"completion":161,"start":7783,"enrollment":1269,"conditions":7784,"interventions":7785},"NCT05064280","Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases",[88],"2022-01-20",[1520,3071],[53,7558],{"nctId":7787,"briefTitle":7788,"status":130,"phases":7789,"primaryCompletion":7790,"completion":7790,"start":1958,"enrollment":1568,"conditions":7791,"interventions":7803},"NCT02940496","Pembrolizumab (MK-3475) in Hepatocellular Carcinoma",[88],"2023-08-09",[7792,7793,7794,7795,7796,7797,7798,7799,7800,7801,7802],"BCLC Stage B Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma","Hepatitis C Infection","Refractory Liver Carcinoma","Stage III Hepatocellular Carcinoma AJCC v7","Stage IIIA Hepatocellular Carcinoma AJCC v7","Stage IIIB Hepatocellular Carcinoma AJCC v7","Stage IIIC Hepatocellular Carcinoma AJCC v7","Stage IV Hepatocellular Carcinoma AJCC v7","Stage IVA Hepatocellular Carcinoma AJCC v7","Stage IVB Hepatocellular Carcinoma AJCC v7",[7804,53,7805],"Elbasvir\u002FGrazoprevir","Ribavirin",{"nctId":6162,"briefTitle":6163,"status":182,"phases":7807,"primaryCompletion":6165,"completion":6165,"start":6166,"enrollment":1231,"conditions":7808,"interventions":7809},[88],[6168],[4345,53],{"nctId":7811,"briefTitle":7812,"status":182,"phases":7813,"primaryCompletion":7814,"completion":7815,"start":7816,"enrollment":910,"conditions":7817,"interventions":7821},"NCT05036681","A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma",[88],"2024-09-30","2025-05-06","2021-09-30",[7818,7819,7820],"Metastatic Cancer","Endometrium Cancer","Endometrial Carcinoma",[7822,53],"Futibatinib",{"nctId":7824,"briefTitle":7825,"status":102,"phases":7826,"primaryCompletion":224,"completion":224,"start":7827,"enrollment":2159,"conditions":7828,"interventions":7829},"NCT03131908","Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss",[87,88],"2017-07-17",[7686,1316],[7830,53],"GSK2636771",{"nctId":7832,"briefTitle":7833,"status":130,"phases":7834,"primaryCompletion":405,"completion":405,"start":7835,"enrollment":1131,"conditions":7836,"interventions":7838},"NCT02907099","Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer",[88],"2016-12-01",[6564,7837,6565],"Recurrent Pancreatic Adenocarcinoma",[7839,53],"CXCR4 Antagonist BL-8040",{"nctId":7841,"briefTitle":7842,"status":102,"phases":7843,"primaryCompletion":1939,"completion":1939,"start":7844,"enrollment":448,"conditions":7845,"interventions":7846},"NCT05922904","PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma",[88],"2023-12-14",[1866],[7847,804,53,1869],"Brentuximab vedotin",{"nctId":1762,"briefTitle":1763,"status":182,"phases":7849,"primaryCompletion":1717,"completion":1717,"start":1765,"enrollment":1766,"conditions":7850,"interventions":7851},[87,88],[1768,1769,1343,1770,1771,1772,1344,1773,1312,1774,1348,1775,1349,1776,1350,1777,1351,1352,1353,1778,1779,1355,1356,1780,1357,1781,1358,1359,1782,1319,1360,1783,1361,1784,1362],[718,693,1786,1050,53,1787],{"nctId":4025,"briefTitle":4026,"status":279,"phases":7853,"primaryCompletion":4028,"completion":4028,"start":4029,"enrollment":1328,"conditions":7854,"interventions":7855},[88],[4031,4032,4033],[53,1710,1709,1369],{"nctId":7857,"briefTitle":7858,"status":279,"phases":7859,"primaryCompletion":2105,"completion":7860,"start":7861,"enrollment":1131,"conditions":7862,"interventions":7867},"NCT07283731","Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced\u002FMetastatic Soft-tissue Sarcoma",[88],"2030-11-01","2026-06-02",[7863,7864,53,7865,7866],"Phase 2","Zanzalintinib","Advanced\u002FMetastatic","Soft-Tissue Sarcoma",[7864,53],{"nctId":7869,"briefTitle":7870,"status":130,"phases":7871,"primaryCompletion":7872,"completion":7872,"start":7873,"enrollment":2004,"conditions":7874,"interventions":7875},"NCT02520154","Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[88],"2025-05-22","2016-07-05",[4957,4958,4959,4960,4961,4962,4963,4964,4965,4966,4967,4968,4969,4970,4971],[1369,1376,53],{"nctId":7877,"briefTitle":7878,"status":203,"phases":7879,"primaryCompletion":7880,"completion":7880,"start":7881,"enrollment":124,"conditions":7882,"interventions":7884},"NCT07011849","Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases",[88],"2025-08-07","2025-06-04",[1521,7883],"Brain Metastasis",[53,7558],{"nctId":7886,"briefTitle":7887,"status":182,"phases":7888,"primaryCompletion":7889,"completion":7889,"start":2017,"enrollment":121,"conditions":7890,"interventions":7892},"NCT04800627","Pevonedistat and Pembrolizumab for the Treatment of dMMR\u002FMSI-H Metastatic or Locally Advanced Unresectable Solid Tumor",[87,88],"2022-11-03",[2569,361,7891],"Unresectable Malignant Solid Neoplasm",[53,749],{"nctId":7894,"briefTitle":7895,"status":130,"phases":7896,"primaryCompletion":7897,"completion":7897,"start":7898,"enrollment":1328,"conditions":7899,"interventions":7900},"NCT04082572","Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers",[88],"2024-11-08","2019-10-31",[2569],[53],{"nctId":7902,"briefTitle":7903,"status":102,"phases":7904,"primaryCompletion":7905,"completion":224,"start":7906,"enrollment":593,"conditions":7907,"interventions":7908},"NCT02971748","Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy",[88],"2025-12-10","2017-01-26",[7310,7311,7296,7315,7316],[53],{"nctId":7910,"briefTitle":7911,"status":203,"phases":7912,"primaryCompletion":7913,"completion":7913,"start":7913,"enrollment":124,"conditions":7914,"interventions":7915},"NCT05668949","Phase I\u002FII Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)",[87,88],"2025-09-23",[450],[7916,53],"TTI-101",{"nctId":7918,"briefTitle":7919,"status":546,"phases":7920,"primaryCompletion":7921,"completion":7922,"start":7923,"enrollment":4733,"conditions":7924,"interventions":7927},"NCT07610525","Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial",[88],"2029-01-15","2031-01-15","2026-11-05",[1597,7925,7926,7863],"Blood and Image Guided","Optimization of Neoadjuvant Therapy",[7928,53],"Paclitaxel + Carboplatin",{"nctId":6986,"briefTitle":6987,"status":279,"phases":7930,"primaryCompletion":238,"completion":238,"start":6989,"enrollment":3521,"conditions":7931,"interventions":7932},[88],[6991,1597],[1369,1376,53,1013,803],{"nctId":7934,"briefTitle":7935,"status":102,"phases":7936,"primaryCompletion":281,"completion":281,"start":7937,"enrollment":7938,"conditions":7939,"interventions":7955},"NCT02721732","Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic",[88],"2016-08-15",157,[1343,7940,7941,7942,7943,361,7944,7945,7946,7947,7948,7949,7950,1273,7951,7952,7953,1951,7954],"Carcinoma of Unknown Primary","Metastatic Adrenal Gland Pheochromocytoma","Metastatic Kidney Medullary Carcinoma","Metastatic Malignant Germ Cell Tumor","Metastatic Paraganglioma","Metastatic Penile Carcinoma","Metastatic Skin Squamous Cell Carcinoma","Small Cell Carcinoma","Stage III Adrenal Cortex Carcinoma AJCC v7","Stage IV Adrenal Cortex Carcinoma AJCC v7","Stage IV Penile Cancer AJCC v7","Unresectable Adrenal Gland Pheochromocytoma","Unresectable Paraganglioma","Unresectable Skin Squamous Cell Carcinoma","Vascular Neoplasm",[53],{"nctId":7957,"briefTitle":7958,"status":182,"phases":7959,"primaryCompletion":3446,"completion":3446,"start":7960,"enrollment":296,"conditions":7961,"interventions":7964},"NCT06046482","Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent\u002FMetastatic Head Neck Squamous Cell Carcinoma",[88],"2023-11-28",[7962,7963],"Head Neck","Squamous Cell Carcinoma of Head and Neck",[53,974,7965,1710],"cetuximab",{"nctId":7967,"briefTitle":7968,"status":102,"phases":7969,"primaryCompletion":7970,"completion":7970,"start":7971,"enrollment":406,"conditions":7972,"interventions":7973},"NCT04675710","Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer",[88],"2026-10-30","2021-06-24",[1594,1595],[1965,53,874],{"nctId":7975,"briefTitle":7976,"status":182,"phases":7977,"primaryCompletion":7978,"completion":7978,"start":1983,"enrollment":230,"conditions":7979,"interventions":7981},"NCT05059470","IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC",[88],"2025-07-01",[7980],"Thyroid",[53],{"nctId":7983,"briefTitle":7984,"status":102,"phases":7985,"primaryCompletion":193,"completion":591,"start":7986,"enrollment":186,"conditions":7987,"interventions":7988},"NCT05761951","Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer",[88],"2023-08-29",[2809],[7989,53],"DKN-01",{"nctId":3319,"briefTitle":3320,"status":130,"phases":7991,"primaryCompletion":3322,"completion":3322,"start":3323,"enrollment":550,"conditions":7992,"interventions":7993},[88],[1316,1544,1546,1549],[1599,803,1005,53,3326],{"nctId":50,"briefTitle":51,"status":102,"phases":7995,"primaryCompletion":52,"completion":446,"start":7996,"enrollment":550,"conditions":7997,"interventions":7999},[88],"2015-04-28",[7740,7998],"Recurrent Gliosarcoma",[53],{"nctId":8001,"briefTitle":8002,"status":102,"phases":8003,"primaryCompletion":446,"completion":446,"start":8004,"enrollment":2159,"conditions":8005,"interventions":8006},"NCT05675579","A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)",[88],"2023-05-23",[18],[8007,53],"Sacituzumab Govitecan",{"nctId":4137,"briefTitle":4138,"status":102,"phases":8009,"primaryCompletion":4140,"completion":4141,"start":4142,"enrollment":3521,"conditions":8010,"interventions":8011},[88],[4144,4145,4146],[1369,1709,1710,53],{"nctId":8013,"briefTitle":8014,"status":279,"phases":8015,"primaryCompletion":446,"completion":446,"start":8016,"enrollment":628,"conditions":8017,"interventions":8018},"NCT05355051","A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed\u002FRefractory Hodgkin's Lymphoma",[88],"2022-10-05",[5623],[8019,53],"Azacytidine",{"nctId":8021,"briefTitle":8022,"status":102,"phases":8023,"primaryCompletion":5310,"completion":238,"start":8024,"enrollment":1100,"conditions":8025,"interventions":8030},"NCT07407920","Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial",[88],"2025-10-09",[8026,8027,8028,8029],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Early Stage HER2-Positive Breast Carcinoma","Early Stage Triple-Negative Breast Carcinoma",[8031,53,7301,4227],"Hormone Therapy",{"nctId":8033,"briefTitle":8034,"status":130,"phases":8035,"primaryCompletion":8036,"completion":8036,"start":8037,"enrollment":8038,"conditions":8039,"interventions":8041},"NCT02444741","Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer",[87,88],"2026-02-17","2015-09-17",124,[360,1315,8040],"Stage IV Lung Non-Small Cell Cancer AJCC v7",[53],{"nctId":8043,"briefTitle":8044,"status":102,"phases":8045,"primaryCompletion":224,"completion":224,"start":8046,"enrollment":1609,"conditions":8047,"interventions":8048},"NCT03225664","Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced",[87,88],"2018-02-03",[1315,1836,1355,1357,1358,1359,1319,1361,1362,1364],[53,874],{"nctId":8050,"briefTitle":8051,"status":279,"phases":8052,"primaryCompletion":8053,"completion":8054,"start":8055,"enrollment":1496,"conditions":8056,"interventions":8057},"NCT07187778","Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)",[88],"2027-07-19","2029-07-19","2025-12-19",[1271],[53,8058],"Belzutifan",{"nctId":8060,"briefTitle":8061,"status":102,"phases":8062,"primaryCompletion":8063,"completion":8064,"start":8065,"enrollment":1140,"conditions":8066,"interventions":8070},"NCT02446457","Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma",[88],"2025-03-31","2026-04-30","2015-07-31",[4559,8067,8068,8069],"Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3a Follicular Lymphoma",[1402,53,894],{"nctId":8072,"briefTitle":8073,"status":102,"phases":8074,"primaryCompletion":3943,"completion":3943,"start":8075,"enrollment":2865,"conditions":8076,"interventions":8081},"NCT03278782","Study of Pembrolizumab (MK-3475) in Combination With Romidepsin",[87,88],"2017-11-14",[3271,5458,8077,3274,8078,3276,5461,8079,3279,3280,8080],"Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma","Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",[53,5465],{"nctId":8083,"briefTitle":8084,"status":203,"phases":8085,"primaryCompletion":5362,"completion":5362,"start":8086,"enrollment":124,"conditions":8087,"interventions":8089},"NCT04834349","Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer",[88],"2021-03-09",[7750,8088],"Unresectable Head and Neck Squamous Cell Carcinoma",[53],{"nctId":8091,"briefTitle":8092,"status":130,"phases":8093,"primaryCompletion":8094,"completion":8094,"start":8095,"enrollment":1568,"conditions":8096,"interventions":8099},"NCT02882282","Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia",[88],"2025-07-14","2017-06-14",[8097,8098],"Oral Cavity Carcinoma","Oral Intraepithelial Neoplasia",[53],{"nctId":8101,"briefTitle":8102,"status":279,"phases":8103,"primaryCompletion":3426,"completion":3426,"start":8104,"enrollment":8105,"conditions":8106,"interventions":8108},"NCT06004336","A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)",[88],"2023-10-31",144,[8107],"Oligometastatic Renal Cell Carcinoma",[53],{"nctId":8110,"briefTitle":8111,"status":203,"phases":8112,"primaryCompletion":7375,"completion":7375,"start":8113,"enrollment":124,"conditions":8114,"interventions":8116},"NCT04058964","Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer",[88],"2020-02-01",[6564,8115],"Stage IV Pancreatic Cancer AJCC v8",[8117,53],"Pegylated Recombinant Human Hyaluronidase PH20",{"nctId":8119,"briefTitle":8120,"status":130,"phases":8121,"primaryCompletion":8122,"completion":1844,"start":8123,"enrollment":195,"conditions":8124,"interventions":8125},"NCT03634241","Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study",[88],"2026-01-27","2018-11-13",[1388,1837,2052,2053,2054,2055,1389,1390,1391],[53],{"nctId":8127,"briefTitle":8128,"status":182,"phases":8129,"primaryCompletion":8130,"completion":8130,"start":8131,"enrollment":2004,"conditions":8132,"interventions":8133},"NCT04171219","Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers",[88],"2025-03-11","2020-03-19",[1343,2570],[53,8134],"Talabostat Mesylate",{"nctId":2080,"briefTitle":2081,"status":102,"phases":8136,"primaryCompletion":224,"completion":224,"start":773,"enrollment":1568,"conditions":8137,"interventions":8138},[88],[2084,2085,1676,2086,1677,1678,1679],[2088,2089,2090,1050,53,2091],{"nctId":8140,"briefTitle":8141,"status":182,"phases":8142,"primaryCompletion":8143,"completion":8143,"start":8144,"enrollment":1240,"conditions":8145,"interventions":8146},"NCT02706353","APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma",[87,88],"2025-03-10","2017-06-02",[1729],[8147,53],"APX005M",{"nctId":8149,"briefTitle":8150,"status":130,"phases":8151,"primaryCompletion":8152,"completion":8152,"start":8153,"enrollment":628,"conditions":8154,"interventions":8155},"NCT04555837","Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer",[87,88],"2025-04-08","2020-09-15",[450,360],[8156,53],"Alisertib",{"nctId":7303,"briefTitle":7304,"status":203,"phases":8158,"primaryCompletion":754,"completion":754,"start":7306,"enrollment":124,"conditions":8159,"interventions":8160},[88],[7308,7309,7310,7311,7312,7296,5079,7313,7314,7315,7316,7317,1363],[1369,803,1013,1376,6802,53],{"nctId":8162,"briefTitle":8163,"status":203,"phases":8164,"primaryCompletion":8165,"completion":8166,"start":8167,"enrollment":124,"conditions":8168,"interventions":8178},"NCT03432676","Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer",[88],"2020-04-30","2021-04-30","2019-07-31",[8169,8170,8171,8172,8173,8174,8175,8176,8177,8115],"ATM Gene Mutation","Deleterious BRCA1 Gene Mutation","Deleterious BRCA2 Gene Mutation","Homologous Recombination Deficiency","Pancreatic Ductal Adenocarcinoma","Stage II Pancreatic Cancer AJCC v8","Stage IIA Pancreatic Cancer AJCC v8","Stage IIB Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8",[8179,53],"Epacadostat",{"nctId":8181,"briefTitle":8182,"status":102,"phases":8183,"primaryCompletion":5995,"completion":5995,"start":8184,"enrollment":448,"conditions":8185,"interventions":8190},"NCT04171622","Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer",[88],"2021-11-04",[8186,1590,8187,8188,1595,8189],"Metastatic Thyroid Gland Carcinoma","Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8","Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8","Unresectable Thyroid Gland Carcinoma",[7558,53],{"nctId":8192,"briefTitle":8193,"status":3049,"phases":8194,"primaryCompletion":8195,"completion":8196,"start":8197,"enrollment":517,"conditions":8198,"interventions":8200},"NCT03094637","Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome",[88],"2021-11-06","2023-11-06","2017-11-06",[1067,8199,30],"IPSS Risk Category Intermediate-1",[510,53],{"trials":8202,"activeCount":124},[],{"trials":8204,"activeCount":124},[],{"trials":8206,"activeCount":124},[],{"intervention":894,"totalTrials":9,"cells":8208},{"EARLY_PHASE1":8209,"PHASE1":8219,"PHASE2":8299,"PHASE3":8935,"PHASE4":8948,"NA":8950},{"trials":8210,"activeCount":166,"soonestReadout":2166},[8211,8215],{"nctId":2181,"briefTitle":2182,"status":203,"phases":8212,"primaryCompletion":2184,"completion":2184,"start":2185,"enrollment":124,"conditions":8213,"interventions":8214},[86],[2187,2188,2189,2190,2191,2192],[75,1004,803,62,1005,2194,2195,894,2196],{"nctId":3023,"briefTitle":3024,"status":102,"phases":8216,"primaryCompletion":2166,"completion":2166,"start":3026,"enrollment":492,"conditions":8217,"interventions":8218},[86],[21,891],[668,894,803,1005],{"trials":8220,"activeCount":124},[8221,8225,8229,8233,8237,8241,8245,8249,8253,8257,8267,8271,8275,8279,8283,8292],{"nctId":4508,"briefTitle":4509,"status":130,"phases":8222,"primaryCompletion":2242,"completion":2242,"start":4511,"enrollment":959,"conditions":8223,"interventions":8224},[87],[21],[2405,2369,1004,2293,894,2374,2368,4514],{"nctId":4516,"briefTitle":4517,"status":130,"phases":8226,"primaryCompletion":4519,"completion":4519,"start":4520,"enrollment":1922,"conditions":8227,"interventions":8228},[87],[4522,15,21,4523,4524],[2293,1070,2757,2196,894,4526,1004,2423],{"nctId":3047,"briefTitle":3048,"status":3049,"phases":8230,"primaryCompletion":3051,"completion":3051,"start":3052,"enrollment":2018,"conditions":8231,"interventions":8232},[87],[1205,643,2512,678,1025,3054,3055,3056,3057,3058,30,913,608,665,3059,3060,666,914,528,3061,3062,529,651,682,882],[803,1005,1402,2293,2195,3064,894,2196],{"nctId":6481,"briefTitle":6482,"status":130,"phases":8234,"primaryCompletion":6484,"completion":6484,"start":6485,"enrollment":186,"conditions":8235,"interventions":8236},[87],[15],[1402,894,1070,803,654],{"nctId":2229,"briefTitle":2230,"status":203,"phases":8238,"primaryCompletion":2121,"start":2232,"enrollment":124,"conditions":8239,"interventions":8240},[87],[21],[2235,894,1709,654,62,2236,2237],{"nctId":5189,"briefTitle":5190,"status":203,"phases":8242,"primaryCompletion":2212,"completion":2212,"start":3833,"enrollment":124,"conditions":8243,"interventions":8244},[87],[2755,15,21,5193],[2293,1254,1070,894,2424,5195,2195,2196,2374],{"nctId":6509,"briefTitle":6510,"status":130,"phases":8246,"primaryCompletion":6512,"completion":6512,"start":6513,"enrollment":3197,"conditions":8247,"interventions":8248},[87],[15,21],[894,1070,803,2757,6516,2374],{"nctId":6518,"briefTitle":6519,"status":130,"phases":8250,"primaryCompletion":6521,"completion":6521,"start":6522,"enrollment":2779,"conditions":8251,"interventions":8252},[87],[21],[6525,803,894],{"nctId":6540,"briefTitle":6541,"status":203,"phases":8254,"primaryCompletion":2365,"completion":2365,"start":185,"enrollment":124,"conditions":8255,"interventions":8256},[87],[15],[1070,803,894,6545],{"nctId":8258,"briefTitle":8259,"status":130,"phases":8260,"primaryCompletion":5120,"completion":5120,"start":4612,"enrollment":230,"conditions":8261,"interventions":8265},"NCT00383994","Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation",[87],[21,15,8262,8263,8264],"Transplantation, Stem Cell","Lymphoid Malignancies","Disorder Related to Transplantation",[4629,894,8266],"NK Cell",{"nctId":3128,"briefTitle":3129,"status":130,"phases":8268,"primaryCompletion":3131,"completion":3131,"start":3132,"enrollment":95,"conditions":8269,"interventions":8270},[87],[1122,36,846,3134,644,737,1025,2653,30,727,3135,3136,3059,3060,2223,882],[803,1069,1005,2293,894,2196],{"nctId":4547,"briefTitle":4548,"status":130,"phases":8272,"primaryCompletion":3667,"completion":3667,"start":4550,"enrollment":4551,"conditions":8273,"interventions":8274},[87],[30,15],[1004,1070,894,803,2423,2293,2196,2195,2374],{"nctId":4555,"briefTitle":4556,"status":130,"phases":8276,"primaryCompletion":3519,"completion":3519,"start":675,"enrollment":676,"conditions":8277,"interventions":8278},[87],[4559,4560,4561,3061,4562],[1004,2369,2293,1374,894,2405],{"nctId":6625,"briefTitle":6626,"status":182,"phases":8280,"primaryCompletion":2836,"completion":2836,"start":6628,"enrollment":296,"conditions":8281,"interventions":8282},[87],[15,21,2245],[894,803,1070,1114,6516],{"nctId":8284,"briefTitle":8285,"status":130,"phases":8286,"primaryCompletion":8287,"completion":8287,"start":8288,"enrollment":1034,"conditions":8289,"interventions":8291},"NCT00880815","Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant",[87],"2019-05-28","2009-02-17",[785,712,3346,891,8290,4559,3642],"Marginal Zone Lymphoma",[3085,6545,1069,1070,806,894,2196],{"nctId":8293,"briefTitle":8294,"status":182,"phases":8295,"primaryCompletion":8296,"completion":8296,"start":3769,"enrollment":550,"conditions":8297,"interventions":8298},"NCT01729104","Phase I\u002FII Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed\u002FRefractory Mantle Cell Lymphoma",[87],"2018-10-03",[21],[2227,1402,894],{"trials":8300,"activeCount":406,"soonestReadout":71},[8301,8309,8315,8319,8331,8335,8344,8348,8352,8356,8360,8364,8370,8382,8390,8397,8411,8418,8428,8432,8436,8440,8448,8455,8459,8467,8471,8475,8479,8483,8487,8491,8495,8499,8506,8510,8514,8518,8522,8531,8535,8541,8547,8556,8560,8570,8582,8592,8596,8604,8611,8615,8625,8629,8633,8637,8644,8648,8657,8661,8665,8669,8673,8679,8683,8687,8691,8695,8699,8703,8710,8714,8722,8726,8733,8737,8741,8745,8749,8756,8765,8769,8773,8777,8794,8802,8806,8810,8818,8825,8829,8833,8837,8841,8845,8849,8853,8859,8863,8867,8881,8887,8895,8908,8912,8916,8920,8924,8931],{"nctId":8302,"briefTitle":8303,"status":182,"phases":8304,"primaryCompletion":8305,"completion":8305,"start":8306,"enrollment":2779,"conditions":8307,"interventions":8308},"NCT00901927","Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma",[88],"2016-01","2009-05",[3346],[6545,2449,894],{"nctId":8310,"briefTitle":8311,"status":130,"phases":8312,"primaryCompletion":2698,"completion":2698,"start":4697,"enrollment":1034,"conditions":8313,"interventions":8314},"NCT00759603","Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia",[88],[712,716],[1402,894],{"nctId":5519,"briefTitle":5520,"status":130,"phases":8316,"primaryCompletion":4382,"completion":4382,"start":5522,"enrollment":492,"conditions":8317,"interventions":8318},[88],[21,15],[5525,5526,5527,803,2424,1070,2293,894,806,2196],{"nctId":8320,"briefTitle":8321,"status":130,"phases":8322,"primaryCompletion":8323,"completion":8323,"start":8324,"enrollment":8325,"conditions":8326,"interventions":8330},"NCT00654732","Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma",[88],"2018-09-05","2008-03-19",58,[8327,8328,8329],"Classic Hodgkin Lymphoma","Lugano Classification Stage III Hodgkin Lymphoma AJCC v8","Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8",[4331,1869,804,894,1868],{"nctId":2361,"briefTitle":2362,"status":203,"phases":8332,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":124,"conditions":8333,"interventions":8334},[88],[21],[2368,2340,2369,1004,2293,894,62,2370,2371,2372,2373,2374],{"nctId":8336,"briefTitle":8337,"status":130,"phases":8338,"primaryCompletion":8339,"completion":8339,"start":8340,"enrollment":507,"conditions":8341,"interventions":8342},"NCT00904722","Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma",[88],"2015-04","2010-01",[21],[8343,894],"CT-011",{"nctId":2397,"briefTitle":2398,"status":130,"phases":8345,"primaryCompletion":2400,"completion":2400,"start":2401,"enrollment":2402,"conditions":8346,"interventions":8347},[87,88],[33,21],[510,2405,2369,1004,2293,62,2371,2372,894],{"nctId":2407,"briefTitle":2408,"status":279,"phases":8349,"primaryCompletion":2410,"completion":2410,"start":2411,"enrollment":924,"conditions":8350,"interventions":8351},[88],[913,2413,2414,2415,2416,2417,914,2418,2419,2420,2421],[75,2423,803,62,2424,2425,1071,894,2426],{"nctId":6704,"briefTitle":6705,"status":182,"phases":8353,"primaryCompletion":2510,"completion":6707,"start":5671,"enrollment":550,"conditions":8354,"interventions":8355},[88],[15],[803,894,6710],{"nctId":3210,"briefTitle":3211,"status":130,"phases":8357,"primaryCompletion":3213,"completion":3213,"start":3214,"enrollment":1260,"conditions":8358,"interventions":8359},[88],[712],[1005,803,894],{"nctId":4592,"briefTitle":4593,"status":130,"phases":8361,"primaryCompletion":1518,"completion":1518,"start":4595,"enrollment":230,"conditions":8362,"interventions":8363},[88],[1205,643,4597,1122,2512,36,846,3292,712,4598,737,1866,4599,3040,30,3233,3041,3059,914,632,716,882],[3085,1004,2423,803,2712,1070,2293,2195,894,2196],{"nctId":73,"briefTitle":74,"status":102,"phases":8365,"primaryCompletion":71,"completion":6954,"start":8366,"enrollment":4171,"conditions":8367,"interventions":8369},[88],"2006-08-02",[8368],"Waldenstrom's Macroglobulinemia",[75,894,1177],{"nctId":8371,"briefTitle":8372,"status":102,"phases":8373,"primaryCompletion":8374,"completion":8374,"start":8375,"enrollment":3409,"conditions":8376,"interventions":8381},"NCT01473628","Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma",[87,88],"2027-05-20","2013-05-20",[8377,8378,8379,8380],"Ann Arbor Stage I Grade 1 Follicular Lymphoma","Ann Arbor Stage I Grade 2 Follicular Lymphoma","Ann Arbor Stage II Grade 1 Follicular Lymphoma","Ann Arbor Stage II Grade 2 Follicular Lymphoma",[894],{"nctId":8383,"briefTitle":8384,"status":182,"phases":8385,"primaryCompletion":8386,"completion":8386,"start":4351,"enrollment":230,"conditions":8387,"interventions":8388},"NCT00493454","Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas",[88],"2011-03",[21],[2450,894,8389],"^111 In Ibritumomab Tiuxetan",{"nctId":8391,"briefTitle":8392,"status":102,"phases":8393,"primaryCompletion":504,"completion":504,"start":8394,"enrollment":1100,"conditions":8395,"interventions":8396},"NCT01446133","Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL-SLL)",[88],"2011-12-12",[15,21],[894,1402],{"nctId":8398,"briefTitle":8399,"status":102,"phases":8400,"primaryCompletion":3880,"completion":3880,"start":8401,"enrollment":1034,"conditions":8402,"interventions":8410},"NCT04404088","Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma",[88],"2020-07-16",[8403,8404,8405,8406,8407,8408,8409],"Ann Arbor Stage III Grade 1 Follicular Lymphoma","Ann Arbor Stage III Grade 2 Follicular Lymphoma","Ann Arbor Stage III Grade 3 Follicular Lymphoma","Ann Arbor Stage IV Grade 1 Follicular Lymphoma","Ann Arbor Stage IV Grade 2 Follicular Lymphoma","Ann Arbor Stage IV Grade 3 Follicular Lymphoma","Grade 3a Follicular Lymphoma",[668,1402,894],{"nctId":8412,"briefTitle":8413,"status":130,"phases":8414,"primaryCompletion":5522,"completion":5522,"start":8415,"enrollment":2018,"conditions":8416,"interventions":8417},"NCT00081861","Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma",[88],"2004-03",[21],[4234,894],{"nctId":8419,"briefTitle":8420,"status":203,"phases":8421,"primaryCompletion":8422,"completion":3880,"start":8423,"enrollment":124,"conditions":8424,"interventions":8425},"NCT05929716","An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma",[88],"2026-03-01","2023-09-30",[6956,5445],[974,894,8426,8427],"CAR T leukapheresis","Radiation",{"nctId":2441,"briefTitle":2442,"status":130,"phases":8429,"primaryCompletion":2444,"completion":2444,"start":2445,"enrollment":2446,"conditions":8430,"interventions":8431},[88],[21],[1070,2449,894,2450,62],{"nctId":2464,"briefTitle":2465,"status":279,"phases":8433,"primaryCompletion":2467,"completion":2467,"start":2468,"enrollment":2469,"conditions":8434,"interventions":8435},[87,88],[2471,2472,2473,2474,2475,1142,2415,1144,2419],[1083,803,654,62,2477,805,806,809,894,1016],{"nctId":5546,"briefTitle":5547,"status":130,"phases":8437,"primaryCompletion":5434,"completion":5434,"start":3902,"enrollment":5549,"conditions":8438,"interventions":8439},[88],[21],[4365,2424,654,2293,894],{"nctId":8441,"briefTitle":8442,"status":130,"phases":8443,"primaryCompletion":2519,"completion":2519,"start":8444,"enrollment":861,"conditions":8445,"interventions":8446},"NCT01134575","CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)",[88],"2010-06-04",[1122],[8447,894],"CMC-544",{"nctId":8449,"briefTitle":8450,"status":102,"phases":8451,"primaryCompletion":504,"completion":504,"start":8452,"enrollment":1260,"conditions":8453,"interventions":8454},"NCT02007044","Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia",[88],"2013-12-06",[4752,665,666],[767,894],{"nctId":5553,"briefTitle":5554,"status":130,"phases":8456,"primaryCompletion":5556,"completion":5556,"start":5557,"enrollment":381,"conditions":8457,"interventions":8458},[88],[21],[2424,2374,4629,5560,894],{"nctId":8460,"briefTitle":8461,"status":182,"phases":8462,"primaryCompletion":8463,"completion":8463,"start":8464,"enrollment":1568,"conditions":8465,"interventions":8466},"NCT03856216","Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation",[88],"2025-10-13","2019-10-28",[1122,2502,5597,21],[6545,2712,1070,2477,2293,894,2196],{"nctId":2497,"briefTitle":2498,"status":279,"phases":8468,"primaryCompletion":2104,"completion":2104,"start":2500,"enrollment":1975,"conditions":8469,"interventions":8470},[88],[2502,2503],[1083,803,654,62,804,2477,805,806,2425,809,894,810],{"nctId":3247,"briefTitle":3248,"status":130,"phases":8472,"primaryCompletion":3250,"completion":3250,"start":3251,"enrollment":2159,"conditions":8473,"interventions":8474},[87,88],[359],[3085,2226,1005,2477,806,894,2196],{"nctId":2506,"briefTitle":2507,"status":182,"phases":8476,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":296,"conditions":8477,"interventions":8478},[88],[2512,2502,2472],[803,654,62,804,2477,1373,805,806,2425,809,894,810],{"nctId":2515,"briefTitle":2516,"status":182,"phases":8480,"primaryCompletion":2518,"completion":2518,"start":2519,"enrollment":230,"conditions":8481,"interventions":8482},[88],[2521,1142,1144],[1083,803,654,62,1069,1373,805,806,1071,894,810],{"nctId":6849,"briefTitle":6850,"status":130,"phases":8484,"primaryCompletion":6757,"completion":6757,"start":6852,"enrollment":1975,"conditions":8485,"interventions":8486},[88],[712],[1070,803,2439,894],{"nctId":5562,"briefTitle":5563,"status":130,"phases":8488,"primaryCompletion":5565,"completion":5565,"start":5566,"enrollment":406,"conditions":8489,"interventions":8490},[88],[5568,21],[2450,4365,2424,654,2293,894],{"nctId":5571,"briefTitle":5572,"status":130,"phases":8492,"primaryCompletion":5574,"completion":5574,"start":5575,"enrollment":1034,"conditions":8493,"interventions":8494},[88],[5577],[803,804,2424,767,1402,809,894,810],{"nctId":2524,"briefTitle":2525,"status":130,"phases":8496,"primaryCompletion":2527,"completion":2527,"start":2528,"enrollment":1609,"conditions":8497,"interventions":8498},[88],[2530],[806,1016,2532,62,894],{"nctId":8500,"briefTitle":8501,"status":130,"phases":8502,"primaryCompletion":6757,"completion":6757,"start":8503,"enrollment":473,"conditions":8504,"interventions":8505},"NCT00452374","Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL",[87,88],"2004-11",[15],[654,1070,1375,894],{"nctId":5580,"briefTitle":5581,"status":130,"phases":8507,"primaryCompletion":5583,"completion":5583,"start":5584,"enrollment":2779,"conditions":8508,"interventions":8509},[88],[5586,5587,3056,5588,913,2415,914,2419],[803,804,2424,2425,809,894,810],{"nctId":2534,"briefTitle":2535,"status":130,"phases":8511,"primaryCompletion":2537,"completion":2537,"start":1000,"enrollment":834,"conditions":8512,"interventions":8513},[88],[1047,643,2539,2540,848,2541,2542,851],[2423,654,62,655,894,2207,2544,1016,810],{"nctId":5591,"briefTitle":5592,"status":130,"phases":8515,"primaryCompletion":5594,"completion":5594,"start":5595,"enrollment":517,"conditions":8516,"interventions":8517},[88],[785,359,5597,21],[3085,75,4365,654,2424,1069,2293,806,894,2196],{"nctId":2546,"briefTitle":2547,"status":130,"phases":8519,"primaryCompletion":2549,"completion":2549,"start":2550,"enrollment":37,"conditions":8520,"interventions":8521},[88],[21],[894,803,1013,1016,62,806,654,809],{"nctId":8523,"briefTitle":8524,"status":130,"phases":8525,"primaryCompletion":8526,"completion":8526,"start":8527,"enrollment":8528,"conditions":8529,"interventions":8530},"NCT00940342","Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia",[88],"2017-01-05","2004-10-12",130,[15],[4629,894],{"nctId":2587,"briefTitle":2588,"status":182,"phases":8532,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":95,"conditions":8533,"interventions":8534},[88],[1142,2593,1144,2594],[803,654,1028,62,1013,1113,805,806,809,894,2596,1016],{"nctId":8536,"briefTitle":8537,"status":130,"phases":8538,"primaryCompletion":4612,"completion":6409,"start":7400,"enrollment":473,"conditions":8539,"interventions":8540},"NCT00071396","Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders",[88],[712],[5527,894],{"nctId":8542,"briefTitle":8543,"status":130,"phases":8544,"primaryCompletion":2806,"completion":2806,"start":6790,"enrollment":901,"conditions":8545,"interventions":8546},"NCT00505895","FM 140 vs FM100 Study in Patients With Multiple Myeloma",[88],[1400],[2293,1070,894],{"nctId":8548,"briefTitle":8549,"status":130,"phases":8550,"primaryCompletion":4192,"completion":8551,"start":2953,"enrollment":1328,"conditions":8552,"interventions":8554},"NCT00038623","Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma",[88],"2010-02",[8553],"Lymphoma, Mantle-Cell",[8555,894],"Yttrium-ibritumomab",{"nctId":6925,"briefTitle":6926,"status":130,"phases":8557,"primaryCompletion":6928,"completion":6928,"start":6929,"enrollment":406,"conditions":8558,"interventions":8559},[88],[712],[1070,803,2449,894,1069],{"nctId":8561,"briefTitle":8562,"status":182,"phases":8563,"primaryCompletion":8564,"completion":8565,"start":8566,"enrollment":1231,"conditions":8567,"interventions":8568},"NCT04047797","Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",[88],"2024-06-01","2025-04-11","2019-08-28",[789,790],[2283,8569,894],"Ixazomib Citrate",{"nctId":8571,"briefTitle":8572,"status":279,"phases":8573,"primaryCompletion":8574,"completion":8575,"start":148,"enrollment":406,"conditions":8576,"interventions":8581},"NCT07257055","Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study",[88],"2028-11-24","2030-11-24",[8577,8578,8579,894,8580],"Phase 2 Study","MCL","BTKi","Glofitamab",[668,894,8580],{"nctId":8583,"briefTitle":8584,"status":102,"phases":8585,"primaryCompletion":8586,"completion":8586,"start":8587,"enrollment":1034,"conditions":8588,"interventions":8590},"NCT04458610","Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[88],"2027-05-26","2020-05-26",[8589],"Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[894,8591],"Zanubrutinib",{"nctId":3285,"briefTitle":3286,"status":279,"phases":8593,"primaryCompletion":860,"completion":860,"start":3288,"enrollment":1222,"conditions":8594,"interventions":8595},[88],[1205,643,1122,2512,3290,3291,2471,3292,737,1025,3056,3057,3058,30,3233,3293,3244,648,608,3186,3059,3060,914,3294,651,882],[3296,3085,1004,2423,803,1005,2293,894],{"nctId":8597,"briefTitle":8598,"status":130,"phases":8599,"primaryCompletion":4934,"completion":4934,"start":8600,"enrollment":1483,"conditions":8601,"interventions":8603},"NCT02481297","Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients",[88],"2015-06-23",[15,712,8602],"Lymphocytic Leukemia",[2038,894],{"nctId":8605,"briefTitle":8606,"status":279,"phases":8607,"primaryCompletion":238,"completion":238,"start":8608,"enrollment":1034,"conditions":8609,"interventions":8610},"NCT05683171","A Phase 1\u002F2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma",[87,88],"2023-05-19",[21],[894,1402,3550],{"nctId":885,"briefTitle":886,"status":102,"phases":8612,"primaryCompletion":115,"completion":888,"start":889,"enrollment":676,"conditions":8613,"interventions":8614},[88],[891],[893,894,480],{"nctId":8616,"briefTitle":8617,"status":130,"phases":8618,"primaryCompletion":8619,"completion":8619,"start":2740,"enrollment":1131,"conditions":8620,"interventions":8621},"NCT01490723","Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)",[88],"2019-04-24",[15,21],[894,8622,8623,1070,6545,4537,2196,806,8624,2374],"111In Ibritumomab","90Y IbritumomabTiuxetan","Mycophenolate",{"nctId":6971,"briefTitle":6972,"status":130,"phases":8626,"primaryCompletion":6974,"completion":6974,"start":5435,"enrollment":3354,"conditions":8627,"interventions":8628},[88],[712],[1070,803,894,1275],{"nctId":4702,"briefTitle":4703,"status":203,"phases":8630,"primaryCompletion":4705,"completion":4705,"start":4705,"enrollment":124,"conditions":8631,"interventions":8632},[88],[4707,3272,2415,4559,4708,4560,4709],[1004,2423,803,2369,2195,894,2196,2405],{"nctId":2634,"briefTitle":2635,"status":102,"phases":8634,"primaryCompletion":956,"completion":956,"start":2637,"enrollment":2638,"conditions":8635,"interventions":8636},[88],[783,891,788],[803,654,62,1013,804,767,806,894,1016,810],{"nctId":8638,"briefTitle":8639,"status":102,"phases":8640,"primaryCompletion":8641,"completion":8641,"start":4203,"enrollment":1140,"conditions":8642,"interventions":8643},"NCT04765111","Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma",[88],"2026-08-30",[891],[668,894],{"nctId":905,"briefTitle":906,"status":182,"phases":8645,"primaryCompletion":908,"completion":908,"start":909,"enrollment":910,"conditions":8646,"interventions":8647},[87,88],[644,912,913,649,914,650,915],[62,917,894,480],{"nctId":8649,"briefTitle":8650,"status":102,"phases":8651,"primaryCompletion":471,"completion":471,"start":8652,"enrollment":5774,"conditions":8653,"interventions":8656},"NCT01880567","Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma",[88],"2013-07-15",[2691,8654,8655,785,891,789,790],"CCND2 Positive","CCND3 Positive",[767,894],{"nctId":928,"briefTitle":929,"status":102,"phases":8658,"primaryCompletion":931,"completion":931,"start":932,"enrollment":240,"conditions":8659,"interventions":8660},[88],[891],[803,654,62,804,767,806,894,480,810],{"nctId":7014,"briefTitle":7015,"status":182,"phases":8662,"primaryCompletion":1984,"completion":1984,"start":7017,"enrollment":166,"conditions":8663,"interventions":8664},[88],[15,7019,2653,21],[654,7021,1016,809,7022,2425,894,806,803,805,1013,4514,7023],{"nctId":2674,"briefTitle":2675,"status":130,"phases":8666,"primaryCompletion":2677,"completion":2677,"start":2678,"enrollment":2004,"conditions":8667,"interventions":8668},[88],[15],[894,2681,803,1013,1114,2682,2683,806,2584,2374,1071,62],{"nctId":2685,"briefTitle":2686,"status":203,"phases":8670,"primaryCompletion":2688,"completion":2688,"start":2689,"enrollment":124,"conditions":8671,"interventions":8672},[88],[2691,2692,891],[62,767,1402,894],{"nctId":8674,"briefTitle":8675,"status":279,"phases":8676,"primaryCompletion":2104,"completion":3879,"start":6989,"enrollment":676,"conditions":8677,"interventions":8678},"NCT06263491","Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients",[88],[891],[894,893],{"nctId":7062,"briefTitle":7063,"status":279,"phases":8680,"primaryCompletion":1735,"completion":7065,"start":2106,"enrollment":517,"conditions":8681,"interventions":8682},[88],[6956],[809,894,803,1016,7068],{"nctId":5626,"briefTitle":5627,"status":130,"phases":8684,"primaryCompletion":5629,"completion":5629,"start":5630,"enrollment":492,"conditions":8685,"interventions":8686},[88],[891,4559,5632,5633,4561,5634,5635],[4365,5515,654,2424,1069,1402,2293,894],{"nctId":7074,"briefTitle":7075,"status":130,"phases":8688,"primaryCompletion":3213,"completion":3213,"start":4612,"enrollment":1034,"conditions":8689,"interventions":8690},[88],[712],[803,1070,4387,894],{"nctId":4737,"briefTitle":4738,"status":130,"phases":8692,"primaryCompletion":4740,"completion":4740,"start":4741,"enrollment":3354,"conditions":8693,"interventions":8694},[87,88],[4743,3277,3061,4562],[3085,1004,2423,4135,2195,894,2196],{"nctId":8060,"briefTitle":8061,"status":102,"phases":8696,"primaryCompletion":8063,"completion":8064,"start":8065,"enrollment":1140,"conditions":8697,"interventions":8698},[88],[4559,8067,8068,8069],[1402,53,894],{"nctId":2714,"briefTitle":2715,"status":130,"phases":8700,"primaryCompletion":2717,"completion":2717,"start":2718,"enrollment":2559,"conditions":8701,"interventions":8702},[87,88],[891],[75,803,654,62,1013,806,894,1016],{"nctId":8704,"briefTitle":8705,"status":182,"phases":8706,"primaryCompletion":4085,"completion":4085,"start":8707,"enrollment":166,"conditions":8708,"interventions":8709},"NCT00771602","Alemtuzumab + Rituximab Consolidation in CLL",[88],"2008-08",[712,15],[894,2439],{"nctId":4458,"briefTitle":4459,"status":279,"phases":8711,"primaryCompletion":956,"completion":956,"start":4461,"enrollment":1045,"conditions":8712,"interventions":8713},[88],[4463,4464],[599,894],{"nctId":8715,"briefTitle":8716,"status":130,"phases":8717,"primaryCompletion":8718,"completion":8718,"start":8719,"enrollment":1034,"conditions":8720,"interventions":8721},"NCT00411086","Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma",[88],"2016-11","2006-11",[21],[894,4387],{"nctId":1007,"briefTitle":1008,"status":279,"phases":8723,"primaryCompletion":446,"completion":446,"start":1010,"enrollment":517,"conditions":8724,"interventions":8725},[88],[847],[803,654,62,1013,805,806,1014,809,894,1015,480,1016],{"nctId":8727,"briefTitle":8728,"status":130,"phases":8729,"primaryCompletion":2969,"completion":8730,"start":3997,"enrollment":924,"conditions":8731,"interventions":8732},"NCT01939730","Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma",[88],"2013-09",[21],[894,4629],{"nctId":7152,"briefTitle":7153,"status":130,"phases":8734,"primaryCompletion":7155,"completion":7155,"start":4887,"enrollment":1034,"conditions":8735,"interventions":8736},[88],[15,712],[803,1070,2439,894],{"nctId":2726,"briefTitle":2727,"status":102,"phases":8738,"primaryCompletion":999,"completion":999,"start":2729,"enrollment":2730,"conditions":8739,"interventions":8740},[88],[1205,1122,2649,2471,644,912,2732],[803,654,62,1013,804,806,1124,917,809,894,1016,810],{"nctId":5660,"briefTitle":5661,"status":130,"phases":8742,"primaryCompletion":4723,"completion":4723,"start":5663,"enrollment":3820,"conditions":8743,"interventions":8744},[88],[15],[2424,894],{"nctId":5253,"briefTitle":5254,"status":130,"phases":8746,"primaryCompletion":5256,"completion":5256,"start":5257,"enrollment":5258,"conditions":8747,"interventions":8748},[88],[5260,15,4760],[803,1070,2293,1114,894,1254,2196,5262,2374],{"nctId":8750,"briefTitle":8751,"status":130,"phases":8752,"primaryCompletion":8753,"completion":8753,"start":2699,"enrollment":226,"conditions":8754,"interventions":8755},"NCT00504504","Rituximab and ABVD for Hodgkin's Patients",[88],"2012-03",[21],[894,2977,4331,1868,1869],{"nctId":8757,"briefTitle":8758,"status":130,"phases":8759,"primaryCompletion":8760,"completion":8760,"start":8761,"enrollment":517,"conditions":8762,"interventions":8763},"NCT01520519","Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients",[88],"2018-08-09","2012-02-27",[15],[894,8764],"PCI-32765",{"nctId":7192,"briefTitle":7193,"status":130,"phases":8766,"primaryCompletion":7195,"completion":7195,"start":7196,"enrollment":7197,"conditions":8767,"interventions":8768},[88],[712,15],[1070,803,894],{"nctId":1999,"briefTitle":2000,"status":279,"phases":8770,"primaryCompletion":2002,"completion":2002,"start":2003,"enrollment":2004,"conditions":8771,"interventions":8772},[88],[2006,2007,2008,2009],[2011,803,1013,1050,809,894],{"nctId":2749,"briefTitle":2750,"status":203,"phases":8774,"primaryCompletion":2752,"completion":2752,"start":2753,"enrollment":124,"conditions":8775,"interventions":8776},[88],[2755],[1070,62,803,75,894,1004,803,2196,2757,2758],{"nctId":8778,"briefTitle":8779,"status":102,"phases":8780,"primaryCompletion":8781,"completion":8781,"start":3965,"enrollment":2997,"conditions":8782,"interventions":8792},"NCT05025800","ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma",[87,88],"2028-03-21",[8783,8404,8405,8784,8406,8407,8408,8785,8786,8787,8788,5634,8789,6774,790,8790,6775,6776,8791,715],"Aggressive B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage III Marginal Zone Lymphoma","Ann Arbor Stage IV Marginal Zone Lymphoma","Composite Lymphoma","Indolent B-Cell Non-Hodgkin Lymphoma","Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","Refractory Grade 3b Follicular Lymphoma","Refractory Marginal Zone Lymphoma","Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma",[8793,1402,894],"CD47 Antagonist ALX148",{"nctId":8795,"briefTitle":8796,"status":182,"phases":8797,"primaryCompletion":8798,"completion":8798,"start":8799,"enrollment":2865,"conditions":8800,"interventions":8801},"NCT00899431","Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)",[88],"2018-10-07","2009-05-06",[712],[1402,1070,894,4537,6545,1178],{"nctId":1105,"briefTitle":1106,"status":182,"phases":8803,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":539,"conditions":8804,"interventions":8805},[87,88],[359,913,608,850,609,914,610,853,632],[1112,510,803,654,62,1069,1113,1114,806,809,894,480,1016],{"nctId":7213,"briefTitle":7214,"status":102,"phases":8807,"primaryCompletion":7216,"completion":7216,"start":7217,"enrollment":2933,"conditions":8808,"interventions":8809},[88],[7219],[668,803,804,1402,809,894,3338,1016],{"nctId":8811,"briefTitle":8812,"status":203,"phases":8813,"primaryCompletion":8814,"start":1558,"enrollment":124,"conditions":8815,"interventions":8816},"NCT02420938","Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients",[88],"2020-07",[15],[894,8817],"Urelumab",{"nctId":8819,"briefTitle":8820,"status":130,"phases":8821,"primaryCompletion":5232,"completion":5232,"start":6628,"enrollment":8822,"conditions":8823,"interventions":8824},"NCT00472849","Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias",[87,88],92,[1987,15],[1375,1070,654,894,1071],{"nctId":7241,"briefTitle":7242,"status":546,"phases":8826,"primaryCompletion":7065,"completion":7244,"start":115,"enrollment":3082,"conditions":8827,"interventions":8828},[88],[7246],[7248,894,1070,803],{"nctId":2813,"briefTitle":2814,"status":279,"phases":8830,"primaryCompletion":224,"completion":548,"start":2816,"enrollment":2159,"conditions":8831,"interventions":8832},[88],[15],[803,1016,1083,806,654,805,809,1071,2819,894,62],{"nctId":7266,"briefTitle":7267,"status":130,"phases":8834,"primaryCompletion":2602,"completion":2602,"start":2213,"enrollment":1975,"conditions":8835,"interventions":8836},[88],[21],[1069,1071,894,803,7271,809,810],{"nctId":1135,"briefTitle":1136,"status":182,"phases":8838,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":1140,"conditions":8839,"interventions":8840},[87,88],[1142,1143,1144,1145],[803,654,62,806,807,808,809,894,480,1016],{"nctId":7277,"briefTitle":7278,"status":102,"phases":8842,"primaryCompletion":115,"completion":115,"start":7280,"enrollment":492,"conditions":8843,"interventions":8844},[88],[1205,1122,7282,644,913,914],[1083,803,654,1069,806,1071,1124,894,1016],{"nctId":7285,"briefTitle":7286,"status":130,"phases":8846,"primaryCompletion":6065,"completion":6065,"start":6410,"enrollment":492,"conditions":8847,"interventions":8848},[88],[891,21],[75,894,803,1114,2374],{"nctId":2825,"briefTitle":2826,"status":130,"phases":8850,"primaryCompletion":2326,"completion":2326,"start":2828,"enrollment":676,"conditions":8851,"interventions":8852},[87,88],[21],[2831,894,803,1016,1013,62,806,654],{"nctId":8854,"briefTitle":8855,"status":130,"phases":8856,"primaryCompletion":2288,"completion":2288,"start":4084,"enrollment":2700,"conditions":8857,"interventions":8858},"NCT00294632","Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma",[87,88],[21],[1402,894],{"nctId":5694,"briefTitle":5695,"status":203,"phases":8860,"primaryCompletion":5697,"completion":5697,"start":5697,"enrollment":124,"conditions":8861,"interventions":8862},[87,88],[3039,891,4559,5632,3277,4561,5634],[4365,654,2424,1069,2293,894,5700],{"nctId":2852,"briefTitle":2853,"status":182,"phases":8864,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":296,"conditions":8865,"interventions":8866},[87,88],[2413,1142,1143,1144,2421,1145],[803,654,62,2712,1113,805,1114,806,1071,809,894,1015,1016],{"nctId":8868,"briefTitle":8869,"status":130,"phases":8870,"primaryCompletion":8871,"completion":8871,"start":8872,"enrollment":473,"conditions":8873,"interventions":8880},"NCT02532257","Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma",[88],"2023-08-15","2016-04-11",[8874,8875,8876,8784,8877,8785,785,8878,8879,8409],"Ann Arbor Stage II Follicular Lymphoma","Ann Arbor Stage II Marginal Zone Lymphoma","Ann Arbor Stage III Follicular Lymphoma","Ann Arbor Stage IV Follicular Lymphoma","Grade 1 Follicular Lymphoma","Grade 2 Follicular Lymphoma",[767,1402,894],{"nctId":8882,"briefTitle":8883,"status":130,"phases":8884,"primaryCompletion":4382,"completion":4382,"start":6384,"enrollment":2004,"conditions":8885,"interventions":8886},"NCT00427557","Cellular Therapy With Cord Blood Cells",[88],[1400,15,21],[1070,2293,894],{"nctId":8888,"briefTitle":8889,"status":130,"phases":8890,"primaryCompletion":8891,"completion":8891,"start":8892,"enrollment":240,"conditions":8893,"interventions":8894},"NCT01096992","Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)",[87,88],"2017-03-31","2010-04-19",[15],[6545,1070,894],{"nctId":8896,"briefTitle":8897,"status":130,"phases":8898,"primaryCompletion":8899,"completion":8899,"start":8900,"enrollment":8901,"conditions":8902,"interventions":8907},"NCT00695786","Lenalidomide in Combination With Rituximab in Treating Participants With Stage III\u002FIV Indolent Non-Hodgkin Lymphoma",[88],"2020-07-11","2008-06-10",156,[8403,8404,8903,8784,8904,8406,8407,8905,8785,8906],"Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma","Ann Arbor Stage III Small Lymphocytic Lymphoma","Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma","Ann Arbor Stage IV Small Lymphocytic Lymphoma",[1402,894],{"nctId":7385,"briefTitle":7386,"status":279,"phases":8909,"primaryCompletion":3943,"completion":3943,"start":7388,"enrollment":448,"conditions":8910,"interventions":8911},[87,88],[726],[6545,803,2712,1070,2293,2195,894,2196],{"nctId":2886,"briefTitle":2887,"status":130,"phases":8913,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":8914,"interventions":8915},[88],[15,1122],[894,803,1013,1016,62,806,654,2374,1114,2894,1071,2895],{"nctId":2897,"briefTitle":2898,"status":182,"phases":8917,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":186,"conditions":8918,"interventions":8919},[87,88],[21],[1402,2405,2369,1004,2293,894,62,2370,2371,2372,2904,2368],{"nctId":7396,"briefTitle":7397,"status":130,"phases":8921,"primaryCompletion":7399,"completion":7399,"start":7400,"enrollment":3082,"conditions":8922,"interventions":8923},[87,88],[21,15],[7403,894,1070,803],{"nctId":8925,"briefTitle":8926,"status":130,"phases":8927,"primaryCompletion":8339,"completion":4818,"start":6352,"enrollment":2004,"conditions":8928,"interventions":8929},"NCT00493467","Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas",[88],[21],[8930,894],"Ibritumomab Tiuxetan",{"nctId":2906,"briefTitle":2907,"status":130,"phases":8932,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":8933,"interventions":8934},[88],[2913,2914],[894,803,1013,1016,62,2374,654,806],{"trials":8936,"activeCount":124},[8937,8944],{"nctId":8938,"briefTitle":8939,"status":182,"phases":8940,"primaryCompletion":4351,"completion":4152,"start":4350,"enrollment":296,"conditions":8941,"interventions":8943},"NCT01103388","Rituximab Maintenance After Autologous Transplantation",[89],[8942],"Non-Hodgkin's Lymphoma",[894],{"nctId":4321,"briefTitle":4322,"status":130,"phases":8945,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":8946,"interventions":8947},[89],[21],[1070,4329,4330,894,3671,1013,1016,4331,803,2424,1709,2584,4332,4333,809],{"trials":8949,"activeCount":124},[],{"trials":8951,"activeCount":124},[8952,8959,8965,8969,8973],{"nctId":8953,"briefTitle":8954,"status":130,"phases":8955,"primaryCompletion":8956,"completion":8956,"start":2847,"enrollment":3726,"conditions":8957,"interventions":8958},"NCT00387023","Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma",[91],"2012-07",[8942,21],[894,2450],{"nctId":8960,"briefTitle":8961,"status":130,"phases":8962,"primaryCompletion":8306,"completion":8306,"start":6352,"enrollment":1131,"conditions":8963,"interventions":8964},"NCT00476229","Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies",[91],[21,15],[4537,894],{"nctId":7470,"briefTitle":7471,"status":130,"phases":8966,"primaryCompletion":3777,"completion":3777,"start":7473,"enrollment":2446,"conditions":8967,"interventions":8968},[91],[21],[803,1070,894,2439],{"nctId":7477,"briefTitle":7478,"status":130,"phases":8970,"primaryCompletion":2212,"completion":2212,"start":6828,"enrollment":3820,"conditions":8971,"interventions":8972},[91],[21],[7482,803,1013,1016,809,894,2793],{"nctId":7484,"briefTitle":7485,"status":130,"phases":8974,"primaryCompletion":4192,"completion":3777,"start":7487,"enrollment":3541,"conditions":8975,"interventions":8976},[91],[21,15],[7490,1070,803,894],{"intervention":1070,"totalTrials":8978,"cells":8979},102,{"EARLY_PHASE1":8980,"PHASE1":8982,"PHASE2":9084,"PHASE3":9420,"PHASE4":9434,"NA":9436},{"trials":8981,"activeCount":124},[],{"trials":8983,"activeCount":3197,"soonestReadout":224},[8984,8988,8992,8996,9000,9004,9008,9012,9016,9020,9024,9036,9040,9044,9048,9057,9061,9065,9069,9073,9080],{"nctId":4516,"briefTitle":4517,"status":130,"phases":8985,"primaryCompletion":4519,"completion":4519,"start":4520,"enrollment":1922,"conditions":8986,"interventions":8987},[87],[4522,15,21,4523,4524],[2293,1070,2757,2196,894,4526,1004,2423],{"nctId":6472,"briefTitle":6473,"status":546,"phases":8989,"primaryCompletion":6475,"completion":6476,"start":1427,"enrollment":1034,"conditions":8990,"interventions":8991},[87],[6478,1866],[1070,2672,803],{"nctId":6481,"briefTitle":6482,"status":130,"phases":8993,"primaryCompletion":6484,"completion":6484,"start":6485,"enrollment":186,"conditions":8994,"interventions":8995},[87],[15],[1402,894,1070,803,654],{"nctId":4532,"briefTitle":4533,"status":130,"phases":8997,"primaryCompletion":206,"completion":206,"start":4039,"enrollment":1568,"conditions":8998,"interventions":8999},[87],[30,15],[4537,1004,1070,2374,2196,806,3499],{"nctId":5189,"briefTitle":5190,"status":203,"phases":9001,"primaryCompletion":2212,"completion":2212,"start":3833,"enrollment":124,"conditions":9002,"interventions":9003},[87],[2755,15,21,5193],[2293,1254,1070,894,2424,5195,2195,2196,2374],{"nctId":6489,"briefTitle":6490,"status":279,"phases":9005,"primaryCompletion":224,"completion":548,"start":6492,"enrollment":1922,"conditions":9006,"interventions":9007},[87],[242],[1070,803],{"nctId":6509,"briefTitle":6510,"status":130,"phases":9009,"primaryCompletion":6512,"completion":6512,"start":6513,"enrollment":3197,"conditions":9010,"interventions":9011},[87],[15,21],[894,1070,803,2757,6516,2374],{"nctId":6527,"briefTitle":6528,"status":182,"phases":9013,"primaryCompletion":6530,"completion":6530,"start":6531,"enrollment":95,"conditions":9014,"interventions":9015},[87],[1986,36],[1070,803,6534],{"nctId":6540,"briefTitle":6541,"status":203,"phases":9017,"primaryCompletion":2365,"completion":2365,"start":185,"enrollment":124,"conditions":9018,"interventions":9019},[87],[15],[1070,803,894,6545],{"nctId":6547,"briefTitle":6548,"status":203,"phases":9021,"primaryCompletion":6550,"completion":6550,"start":6550,"enrollment":124,"conditions":9022,"interventions":9023},[87],[4522,15,21],[803,1070],{"nctId":9025,"briefTitle":9026,"status":203,"phases":9027,"primaryCompletion":4016,"completion":4016,"start":4016,"enrollment":124,"conditions":9028,"interventions":9035},"NCT07428486","A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed\u002FRefractory T-Cell Acute Lymphoblastic Leukemia",[87],[9029,9030,9031,9032,9033,9034],"Phase I","FLAG Chemotherapy","Lisaftoclax","Pelcitoclax","Relapsed\u002FRefractory","Lymphoblastic Leukemia Acute",[1070,654,2374,9031,9032],{"nctId":6581,"briefTitle":6582,"status":546,"phases":9037,"primaryCompletion":6584,"completion":6585,"start":1864,"enrollment":517,"conditions":9038,"interventions":9039},[87],[1271],[803,1070,6588],{"nctId":4547,"briefTitle":4548,"status":130,"phases":9041,"primaryCompletion":3667,"completion":3667,"start":4550,"enrollment":4551,"conditions":9042,"interventions":9043},[87],[30,15],[1004,1070,894,803,2423,2293,2196,2195,2374],{"nctId":6614,"briefTitle":6615,"status":130,"phases":9045,"primaryCompletion":6617,"completion":6617,"start":3378,"enrollment":406,"conditions":9046,"interventions":9047},[87],[33,15],[1070,803],{"nctId":9049,"briefTitle":9050,"status":182,"phases":9051,"primaryCompletion":7672,"completion":7672,"start":9052,"enrollment":1766,"conditions":9053,"interventions":9055},"NCT04526795","Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia",[87],"2021-04-09",[644,630,913,608,649,9054,631,914,610,650,596],"Recurrent T-Cell Prolymphocytic Leukemia",[654,1070,9056],"Pegcrisantaspase",{"nctId":2299,"briefTitle":2300,"status":279,"phases":9058,"primaryCompletion":2302,"completion":2303,"start":701,"enrollment":406,"conditions":9059,"interventions":9060},[87],[2305,2306,2307],[2309,62,1070,2310,2311],{"nctId":6625,"briefTitle":6626,"status":182,"phases":9062,"primaryCompletion":2836,"completion":2836,"start":6628,"enrollment":296,"conditions":9063,"interventions":9064},[87],[15,21,2245],[894,803,1070,1114,6516],{"nctId":8284,"briefTitle":8285,"status":130,"phases":9066,"primaryCompletion":8287,"completion":8287,"start":8288,"enrollment":1034,"conditions":9067,"interventions":9068},[87],[785,712,3346,891,8290,4559,3642],[3085,6545,1069,1070,806,894,2196],{"nctId":6632,"briefTitle":6633,"status":279,"phases":9070,"primaryCompletion":548,"completion":490,"start":6635,"enrollment":2865,"conditions":9071,"interventions":9072},[87],[2306,6637,6638],[803,1070],{"nctId":9074,"briefTitle":9075,"status":130,"phases":9076,"primaryCompletion":4085,"completion":4085,"start":6409,"enrollment":3197,"conditions":9077,"interventions":9078},"NCT00521859","Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies",[87],[4760],[9079,1070],"Cloretazine",{"nctId":6662,"briefTitle":6663,"status":182,"phases":9081,"primaryCompletion":2518,"completion":2518,"start":6665,"enrollment":296,"conditions":9082,"interventions":9083},[87],[6667,1142,665,6668,789,3060,2593,6669,666,1144,528,6670,790,3062,2594,6671,529],[6673,803,1070],{"trials":9085,"activeCount":550,"soonestReadout":1427},[9086,9090,9094,9098,9102,9106,9110,9114,9120,9124,9128,9132,9136,9140,9144,9148,9152,9156,9160,9164,9168,9172,9179,9183,9189,9193,9197,9201,9205,9209,9217,9221,9225,9229,9233,9237,9241,9245,9254,9258,9262,9266,9270,9274,9283,9287,9291,9295,9299,9303,9307,9311,9315,9319,9323,9327,9331,9335,9339,9343,9347,9351,9361,9365,9373,9380,9386,9390,9394,9398,9402,9408,9412,9416],{"nctId":6677,"briefTitle":6678,"status":279,"phases":9087,"primaryCompletion":6680,"completion":6681,"start":6682,"enrollment":240,"conditions":9088,"interventions":9089},[87,88],[4107,1530,6684],[6686,803,1070],{"nctId":4567,"briefTitle":4568,"status":130,"phases":9091,"primaryCompletion":1505,"completion":1505,"start":4570,"enrollment":3379,"conditions":9092,"interventions":9093},[88],[3429],[1004,1070,4537],{"nctId":5213,"briefTitle":5214,"status":279,"phases":9095,"primaryCompletion":1325,"completion":1326,"start":5216,"enrollment":1328,"conditions":9096,"interventions":9097},[88],[4760],[5219,1070,1254,2196,2757],{"nctId":5519,"briefTitle":5520,"status":130,"phases":9099,"primaryCompletion":4382,"completion":4382,"start":5522,"enrollment":492,"conditions":9100,"interventions":9101},[88],[21,15],[5525,5526,5527,803,2424,1070,2293,894,806,2196],{"nctId":4574,"briefTitle":4575,"status":182,"phases":9103,"primaryCompletion":4577,"completion":4577,"start":4578,"enrollment":296,"conditions":9104,"interventions":9105},[88],[4580],[4582,1004,1070],{"nctId":5529,"briefTitle":5530,"status":182,"phases":9107,"primaryCompletion":2836,"completion":2836,"start":4193,"enrollment":2159,"conditions":9108,"interventions":9109},[88],[21],[5527,2374,4629,5526,5534,5535,654,2424,2293,5536,1070,803],{"nctId":4592,"briefTitle":4593,"status":130,"phases":9111,"primaryCompletion":1518,"completion":1518,"start":4595,"enrollment":230,"conditions":9112,"interventions":9113},[88],[1205,643,4597,1122,2512,36,846,3292,712,4598,737,1866,4599,3040,30,3233,3041,3059,914,632,716,882],[3085,1004,2423,803,2712,1070,2293,2195,894,2196],{"nctId":9115,"briefTitle":9116,"status":182,"phases":9117,"primaryCompletion":2846,"completion":2846,"start":5232,"enrollment":834,"conditions":9118,"interventions":9119},"NCT01518153","Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)",[88],[15,21,2245,4580],[1070,2293,2439,2196,806,2374],{"nctId":6724,"briefTitle":6725,"status":102,"phases":9121,"primaryCompletion":6727,"completion":6727,"start":6728,"enrollment":6729,"conditions":9122,"interventions":9123},[88],[1729],[6732,803,1070,6733,3499,1114,6734,6735],{"nctId":4609,"briefTitle":4610,"status":130,"phases":9125,"primaryCompletion":3571,"completion":3571,"start":4612,"enrollment":2647,"conditions":9126,"interventions":9127},[88],[36,30,3315],[2423,1004,1070,4537,1069],{"nctId":4616,"briefTitle":4617,"status":130,"phases":9129,"primaryCompletion":3805,"completion":3805,"start":4619,"enrollment":2997,"conditions":9130,"interventions":9131},[87,88],[2755,15],[4622,1069,1070,1004,4526],{"nctId":1580,"briefTitle":1581,"status":102,"phases":9133,"primaryCompletion":815,"completion":815,"start":1583,"enrollment":406,"conditions":9134,"interventions":9135},[88],[1585,1586,1587,1588,360,1589,1454,1590,1591,1460,1592,1593,1594,1595,1596,1597],[1599,1600,1601,803,1070,1049,1050],{"nctId":2441,"briefTitle":2442,"status":130,"phases":9137,"primaryCompletion":2444,"completion":2444,"start":2445,"enrollment":2446,"conditions":9138,"interventions":9139},[88],[21],[1070,2449,894,2450,62],{"nctId":6766,"briefTitle":6767,"status":130,"phases":9141,"primaryCompletion":6769,"completion":6769,"start":6770,"enrollment":492,"conditions":9142,"interventions":9143},[88],[359,4559,4708,6772,6773,4561,6774,6775,6776],[6778,3348,803,1070],{"nctId":6815,"briefTitle":6816,"status":279,"phases":9145,"primaryCompletion":6818,"completion":6819,"start":6820,"enrollment":3521,"conditions":9146,"interventions":9147},[87,88],[3195,6822,2631],[803,1070,1683,511],{"nctId":6825,"briefTitle":6826,"status":182,"phases":9149,"primaryCompletion":6828,"completion":6828,"start":5557,"enrollment":517,"conditions":9150,"interventions":9151},[88],[6830],[1070,2293,803],{"nctId":8460,"briefTitle":8461,"status":182,"phases":9153,"primaryCompletion":8463,"completion":8463,"start":8464,"enrollment":1568,"conditions":9154,"interventions":9155},[88],[1122,2502,5597,21],[6545,2712,1070,2477,2293,894,2196],{"nctId":3238,"briefTitle":3239,"status":102,"phases":9157,"primaryCompletion":1427,"completion":1427,"start":225,"enrollment":163,"conditions":9158,"interventions":9159},[88],[359,3242,1067,3243,30,3244,913,608,649,3112,3059,609,3060,2223],[1004,803,1070,1005,2195,2196,1254],{"nctId":4655,"briefTitle":4656,"status":182,"phases":9161,"primaryCompletion":3902,"completion":3902,"start":3438,"enrollment":1231,"conditions":9162,"interventions":9163},[87,88],[4659,30],[1004,1070],{"nctId":6849,"briefTitle":6850,"status":130,"phases":9165,"primaryCompletion":6757,"completion":6757,"start":6852,"enrollment":1975,"conditions":9166,"interventions":9167},[88],[712],[1070,803,2439,894],{"nctId":4662,"briefTitle":4663,"status":182,"phases":9169,"primaryCompletion":2836,"completion":2836,"start":4665,"enrollment":924,"conditions":9170,"interventions":9171},[88],[15],[2321,1070,1004,4668,2196,806],{"nctId":9173,"briefTitle":9174,"status":130,"phases":9175,"primaryCompletion":2932,"completion":2932,"start":9176,"enrollment":1766,"conditions":9177,"interventions":9178},"NCT00429572","Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer",[88],"1998-01",[18],[1070,2293],{"nctId":8500,"briefTitle":8501,"status":130,"phases":9180,"primaryCompletion":6757,"completion":6757,"start":8503,"enrollment":473,"conditions":9181,"interventions":9182},[87,88],[15],[654,1070,1375,894],{"nctId":9184,"briefTitle":9185,"status":182,"phases":9186,"primaryCompletion":3668,"completion":3668,"start":6409,"enrollment":3197,"conditions":9187,"interventions":9188},"NCT00523809","Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor",[88],[18,1530],[1275,1070,2293,4537],{"nctId":6896,"briefTitle":6897,"status":182,"phases":9190,"primaryCompletion":6899,"completion":6899,"start":6900,"enrollment":834,"conditions":9191,"interventions":9192},[88],[360,2084,1445,6902,1454,6903,6904,6905,1676,1677,1678,1679],[6907,803,1070,3499],{"nctId":6909,"briefTitle":6910,"status":546,"phases":9194,"primaryCompletion":537,"completion":1481,"start":549,"enrollment":1496,"conditions":9195,"interventions":9196},[87,88],[6913],[2672,3103,1070,803],{"nctId":8542,"briefTitle":8543,"status":130,"phases":9198,"primaryCompletion":2806,"completion":2806,"start":6790,"enrollment":901,"conditions":9199,"interventions":9200},[88],[1400],[2293,1070,894],{"nctId":6925,"briefTitle":6926,"status":130,"phases":9202,"primaryCompletion":6928,"completion":6928,"start":6929,"enrollment":406,"conditions":9203,"interventions":9204},[88],[712],[1070,803,2449,894,1069],{"nctId":3265,"briefTitle":3266,"status":130,"phases":9206,"primaryCompletion":3268,"completion":3268,"start":3269,"enrollment":195,"conditions":9207,"interventions":9208},[87,88],[3271,3272,3273,3274,3275,3276,3277,3278,3279,3280],[3282,803,1070,1005,3283],{"nctId":9210,"briefTitle":9211,"status":130,"phases":9212,"primaryCompletion":4542,"completion":4542,"start":2836,"enrollment":9213,"conditions":9214,"interventions":9216},"NCT01019317","Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)",[88],151,[15,2391,2392,9215],"CML",[654,1070],{"nctId":6949,"briefTitle":6950,"status":546,"phases":9218,"primaryCompletion":6952,"completion":6953,"start":6954,"enrollment":1222,"conditions":9219,"interventions":9220},[88],[6956,1866],[1070,803,6958,3103],{"nctId":8616,"briefTitle":8617,"status":130,"phases":9222,"primaryCompletion":8619,"completion":8619,"start":2740,"enrollment":1131,"conditions":9223,"interventions":9224},[88],[15,21],[894,8622,8623,1070,6545,4537,2196,806,8624,2374],{"nctId":4686,"briefTitle":4687,"status":102,"phases":9226,"primaryCompletion":224,"completion":224,"start":4689,"enrollment":4690,"conditions":9227,"interventions":9228},[87,88],[608,610],[1004,803,1069,1070,2195,2207,2196],{"nctId":6971,"briefTitle":6972,"status":130,"phases":9230,"primaryCompletion":6974,"completion":6974,"start":5435,"enrollment":3354,"conditions":9231,"interventions":9232},[88],[712],[1070,803,894,1275],{"nctId":4694,"briefTitle":4695,"status":130,"phases":9234,"primaryCompletion":1558,"start":4697,"enrollment":2911,"conditions":9235,"interventions":9236},[88],[4699,15,21,2245],[1004,1070,803],{"nctId":2664,"briefTitle":2665,"status":279,"phases":9238,"primaryCompletion":2667,"completion":2668,"start":2669,"enrollment":924,"conditions":9239,"interventions":9240},[87,88],[2460],[62,803,1070,612,2672],{"nctId":4712,"briefTitle":4713,"status":130,"phases":9242,"primaryCompletion":4715,"completion":4716,"start":4635,"enrollment":95,"conditions":9243,"interventions":9244},[88],[15],[1004,1070,2423,4537,2373,803,2196,2757,612,654,655],{"nctId":9246,"briefTitle":9247,"status":130,"phases":9248,"primaryCompletion":9249,"completion":9249,"start":9250,"enrollment":9251,"conditions":9252,"interventions":9253},"NCT01289457","Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome",[87,88],"2017-06-28","2011-02-02",282,[15],[2423,655,654,1070],{"nctId":7074,"briefTitle":7075,"status":130,"phases":9255,"primaryCompletion":3213,"completion":3213,"start":4612,"enrollment":1034,"conditions":9256,"interventions":9257},[88],[712],[803,1070,4387,894],{"nctId":4728,"briefTitle":4729,"status":130,"phases":9259,"primaryCompletion":4731,"completion":4731,"start":4732,"enrollment":4733,"conditions":9260,"interventions":9261},[88],[15],[1004,1070],{"nctId":5237,"briefTitle":5238,"status":130,"phases":9263,"primaryCompletion":5240,"completion":5240,"start":5241,"enrollment":971,"conditions":9264,"interventions":9265},[88],[2530,5243,5244,5245],[5247,2293,1254,1070,803,1114],{"nctId":4755,"briefTitle":4756,"status":130,"phases":9267,"primaryCompletion":4511,"completion":4511,"start":4758,"enrollment":28,"conditions":9268,"interventions":9269},[87,88],[4760],[1004,1070],{"nctId":7110,"briefTitle":7111,"status":130,"phases":9271,"primaryCompletion":3152,"completion":3152,"start":7113,"enrollment":2700,"conditions":9272,"interventions":9273},[87,88],[1205,846,7115,644,647,30,608,649,682],[803,1070,2293,2195,3064,2196],{"nctId":9275,"briefTitle":9276,"status":182,"phases":9277,"primaryCompletion":9278,"completion":9278,"start":9279,"enrollment":1231,"conditions":9280,"interventions":9281},"NCT01875237","Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene",[87,88],"2017-03-07","2013-12-27",[15,2245,4580],[1070,2293,2439,2196,9282,2374,7415,1014],"Mini Methotrexate",{"nctId":4771,"briefTitle":4772,"status":102,"phases":9284,"primaryCompletion":2455,"completion":2455,"start":4774,"enrollment":2004,"conditions":9285,"interventions":9286},[88],[680],[1004,803,1070,4777,2196,1254],{"nctId":7152,"briefTitle":7153,"status":130,"phases":9288,"primaryCompletion":7155,"completion":7155,"start":4887,"enrollment":1034,"conditions":9289,"interventions":9290},[88],[15,712],[803,1070,2439,894],{"nctId":7163,"briefTitle":7164,"status":279,"phases":9292,"primaryCompletion":7166,"completion":7167,"start":7168,"enrollment":19,"conditions":9293,"interventions":9294},[87,88],[7170],[803,1070,7172,3499],{"nctId":5253,"briefTitle":5254,"status":130,"phases":9296,"primaryCompletion":5256,"completion":5256,"start":5257,"enrollment":5258,"conditions":9297,"interventions":9298},[88],[5260,15,4760],[803,1070,2293,1114,894,1254,2196,5262,2374],{"nctId":1062,"briefTitle":1063,"status":279,"phases":9300,"primaryCompletion":238,"completion":238,"start":1065,"enrollment":1001,"conditions":9301,"interventions":9302},[87,88],[1067,608,610],[654,1069,1070,655,1071,480],{"nctId":7192,"briefTitle":7193,"status":130,"phases":9304,"primaryCompletion":7195,"completion":7195,"start":7196,"enrollment":7197,"conditions":9305,"interventions":9306},[88],[712,15],[1070,803,894],{"nctId":1073,"briefTitle":1074,"status":546,"phases":9308,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":406,"conditions":9309,"interventions":9310},[87,88],[1080],[1070,654,655,1069,480,1082,1083],{"nctId":2749,"briefTitle":2750,"status":203,"phases":9312,"primaryCompletion":2752,"completion":2752,"start":2753,"enrollment":124,"conditions":9313,"interventions":9314},[88],[2755],[1070,62,803,75,894,1004,803,2196,2757,2758],{"nctId":4783,"briefTitle":4784,"status":130,"phases":9316,"primaryCompletion":2602,"completion":2602,"start":4786,"enrollment":628,"conditions":9317,"interventions":9318},[88],[2755,15],[1070,1004,4537,510],{"nctId":8795,"briefTitle":8796,"status":182,"phases":9320,"primaryCompletion":8798,"completion":8798,"start":8799,"enrollment":2865,"conditions":9321,"interventions":9322},[88],[712],[1402,1070,894,4537,6545,1178],{"nctId":8819,"briefTitle":8820,"status":130,"phases":9324,"primaryCompletion":5232,"completion":5232,"start":6628,"enrollment":8822,"conditions":9325,"interventions":9326},[87,88],[1987,15],[1375,1070,654,894,1071],{"nctId":7233,"briefTitle":7234,"status":182,"phases":9328,"primaryCompletion":5434,"completion":5434,"start":7236,"enrollment":166,"conditions":9329,"interventions":9330},[88],[5735],[1070,803,7239,1114,3499],{"nctId":7241,"briefTitle":7242,"status":546,"phases":9332,"primaryCompletion":7065,"completion":7244,"start":115,"enrollment":3082,"conditions":9333,"interventions":9334},[88],[7246],[7248,894,1070,803],{"nctId":7254,"briefTitle":7255,"status":182,"phases":9336,"primaryCompletion":2778,"completion":2778,"start":3987,"enrollment":121,"conditions":9337,"interventions":9338},[88],[15,7258],[7260,1070,803,1114,3499],{"nctId":5264,"briefTitle":5265,"status":130,"phases":9340,"primaryCompletion":5267,"completion":5267,"start":5268,"enrollment":1409,"conditions":9341,"interventions":9342},[88],[15,21],[2293,1254,1070,2758],{"nctId":7332,"briefTitle":7333,"status":102,"phases":9344,"primaryCompletion":3425,"completion":3426,"start":7335,"enrollment":1568,"conditions":9345,"interventions":9346},[87,88],[7337,1729,7338,7339],[7341,3499,803,1070],{"nctId":7343,"briefTitle":7344,"status":203,"phases":9348,"primaryCompletion":1230,"completion":1230,"start":7346,"enrollment":124,"conditions":9349,"interventions":9350},[87,88],[3039,7348,3040,1670,1142,665,3060,1144,528,3062],[7350,803,1070],{"nctId":9352,"briefTitle":9353,"status":203,"phases":9354,"primaryCompletion":9355,"completion":9356,"start":9357,"enrollment":124,"conditions":9358,"interventions":9359},"NCT02718755","Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies",[88],"2021-05","2022-05","2018-05",[1187],[1070,654,9360],"Erwinase",{"nctId":4839,"briefTitle":4840,"status":130,"phases":9362,"primaryCompletion":4842,"completion":4842,"start":4843,"enrollment":230,"conditions":9363,"interventions":9364},[88],[15,4725],[1070,1004,3499,3085,2196,806,2374],{"nctId":9366,"briefTitle":9367,"status":130,"phases":9368,"primaryCompletion":3902,"completion":6384,"start":9369,"enrollment":2997,"conditions":9370,"interventions":9371},"NCT00038831","Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS",[87,88],"2001-05",[4659,30,712],[9372,1070,2293,5195],"Mylotarg",{"nctId":9374,"briefTitle":9375,"status":130,"phases":9376,"primaryCompletion":3761,"completion":3761,"start":5663,"enrollment":901,"conditions":9377,"interventions":9379},"NCT00385788","Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease",[88],[9378],"Hodgkin's Disease",[2369,1070,2293,4668,2196,1069,806],{"nctId":9381,"briefTitle":9382,"status":182,"phases":9383,"primaryCompletion":3996,"completion":3996,"start":5470,"enrollment":2159,"conditions":9384,"interventions":9385},"NCT00480987","Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)",[87,88],[1036,36,15],[1375,1070,654],{"nctId":8882,"briefTitle":8883,"status":130,"phases":9387,"primaryCompletion":4382,"completion":4382,"start":6384,"enrollment":2004,"conditions":9388,"interventions":9389},[88],[1400,15,21],[1070,2293,894],{"nctId":8888,"briefTitle":8889,"status":130,"phases":9391,"primaryCompletion":8891,"completion":8891,"start":8892,"enrollment":240,"conditions":9392,"interventions":9393},[87,88],[15],[6545,1070,894],{"nctId":4847,"briefTitle":4848,"status":203,"phases":9395,"primaryCompletion":4715,"completion":4715,"start":4715,"enrollment":124,"conditions":9396,"interventions":9397},[88],[4851,680,359],[1004,1070,4777,806,2196],{"nctId":7385,"briefTitle":7386,"status":279,"phases":9399,"primaryCompletion":3943,"completion":3943,"start":7388,"enrollment":448,"conditions":9400,"interventions":9401},[87,88],[726],[6545,803,2712,1070,2293,2195,894,2196],{"nctId":9403,"briefTitle":9404,"status":130,"phases":9405,"primaryCompletion":4184,"completion":4184,"start":2580,"enrollment":1922,"conditions":9406,"interventions":9407},"NCT00506129","Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma",[88],[21,4871],[1070,2293,4537],{"nctId":7396,"briefTitle":7397,"status":130,"phases":9409,"primaryCompletion":7399,"completion":7399,"start":7400,"enrollment":3082,"conditions":9410,"interventions":9411},[87,88],[21,15],[7403,894,1070,803],{"nctId":7405,"briefTitle":7406,"status":130,"phases":9413,"primaryCompletion":7408,"completion":7408,"start":7409,"enrollment":2446,"conditions":9414,"interventions":9415},[87,88],[7411,2838,712,7412],[1070,803,1114,7414,7415],{"nctId":7417,"briefTitle":7418,"status":102,"phases":9417,"primaryCompletion":404,"completion":404,"start":7420,"enrollment":834,"conditions":9418,"interventions":9419},[87,88],[1122,36,3134,7422,712,4598,3346,1866,891,30,727,3041,3135],[3085,803,7424,1070],{"trials":9421,"activeCount":124},[9422,9426,9430],{"nctId":4864,"briefTitle":4865,"status":130,"phases":9423,"primaryCompletion":4867,"completion":4867,"start":4868,"enrollment":4869,"conditions":9424,"interventions":9425},[89],[4871,15,4523],[1070,2423,1004,4537,2196,806],{"nctId":4321,"briefTitle":4322,"status":130,"phases":9427,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":9428,"interventions":9429},[89],[21],[1070,4329,4330,894,3671,1013,1016,4331,803,2424,1709,2584,4332,4333,809],{"nctId":4884,"briefTitle":4885,"status":130,"phases":9431,"primaryCompletion":4842,"completion":4842,"start":4887,"enrollment":4888,"conditions":9432,"interventions":9433},[89],[30,15,36],[1004,1070],{"trials":9435,"activeCount":124},[],{"trials":9437,"activeCount":124},[9438,9442,9446,9452],{"nctId":7463,"briefTitle":7464,"status":130,"phases":9439,"primaryCompletion":6410,"completion":6410,"start":7466,"enrollment":910,"conditions":9440,"interventions":9441},[91],[3134],[1070,803,4668],{"nctId":7470,"briefTitle":7471,"status":130,"phases":9443,"primaryCompletion":3777,"completion":3777,"start":7473,"enrollment":2446,"conditions":9444,"interventions":9445},[91],[21],[803,1070,894,2439],{"nctId":9447,"briefTitle":9448,"status":130,"phases":9449,"primaryCompletion":6409,"completion":6409,"start":9176,"enrollment":4171,"conditions":9450,"interventions":9451},"NCT00423709","Allogeneic Blood Stem Cell Transplantation",[91],[9378],[1070,2293],{"nctId":7484,"briefTitle":7485,"status":130,"phases":9453,"primaryCompletion":4192,"completion":3777,"start":7487,"enrollment":3541,"conditions":9454,"interventions":9455},[91],[21,15],[7490,1070,803,894],{"intervention":654,"totalTrials":1975,"cells":9457},{"EARLY_PHASE1":9458,"PHASE1":9460,"PHASE2":9521,"PHASE3":9831,"PHASE4":9841,"NA":9843},{"trials":9459,"activeCount":124},[],{"trials":9461,"activeCount":124},[9462,9466,9475,9479,9483,9492,9496,9500,9504,9508,9517],{"nctId":5439,"briefTitle":5440,"status":130,"phases":9463,"primaryCompletion":5442,"completion":5442,"start":5443,"enrollment":1240,"conditions":9464,"interventions":9465},[87],[21,5445],[5447,4365,2424,654,2293],{"nctId":9467,"briefTitle":9468,"status":182,"phases":9469,"primaryCompletion":9470,"completion":9470,"start":9471,"enrollment":550,"conditions":9472,"interventions":9473},"NCT01636609","Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",[87],"2019-07-04","2012-11-20",[36,1067],[510,654,9474],"Tosedostat",{"nctId":6481,"briefTitle":6482,"status":130,"phases":9476,"primaryCompletion":6484,"completion":6484,"start":6485,"enrollment":186,"conditions":9477,"interventions":9478},[87],[15],[1402,894,1070,803,654],{"nctId":2229,"briefTitle":2230,"status":203,"phases":9480,"primaryCompletion":2121,"start":2232,"enrollment":124,"conditions":9481,"interventions":9482},[87],[21],[2235,894,1709,654,62,2236,2237],{"nctId":9484,"briefTitle":9485,"status":130,"phases":9486,"primaryCompletion":9487,"completion":9487,"start":9488,"enrollment":593,"conditions":9489,"interventions":9490},"NCT02652871","LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia",[87],"2019-07-16","2016-05-09",[15],[9491,655,654],"LY2510924",{"nctId":3106,"briefTitle":3107,"status":130,"phases":9493,"primaryCompletion":3109,"completion":3109,"start":3110,"enrollment":1568,"conditions":9494,"interventions":9495},[87],[737,608,3112,610,3113],[654,1005,3115],{"nctId":9025,"briefTitle":9026,"status":203,"phases":9497,"primaryCompletion":4016,"completion":4016,"start":4016,"enrollment":124,"conditions":9498,"interventions":9499},[87],[9029,9030,9031,9032,9033,9034],[1070,654,2374,9031,9032],{"nctId":9049,"briefTitle":9050,"status":182,"phases":9501,"primaryCompletion":7672,"completion":7672,"start":9052,"enrollment":1766,"conditions":9502,"interventions":9503},[87],[644,630,913,608,649,9054,631,914,610,650,596],[654,1070,9056],{"nctId":4401,"briefTitle":4402,"status":203,"phases":9505,"primaryCompletion":3509,"completion":3509,"start":3509,"enrollment":124,"conditions":9506,"interventions":9507},[87],[494,495],[599,654,2207,612],{"nctId":9509,"briefTitle":9510,"status":130,"phases":9511,"primaryCompletion":9512,"completion":9512,"start":9513,"enrollment":834,"conditions":9514,"interventions":9515},"NCT00004263","Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome",[87],"2007-01","1999-12",[15,1036],[9516,654],"7-hydroxystaurosporine",{"nctId":3181,"briefTitle":3182,"status":130,"phases":9518,"primaryCompletion":3184,"completion":3184,"start":640,"enrollment":406,"conditions":9519,"interventions":9520},[87],[3186,610],[654,1069,2712,1005,3188],{"trials":9522,"activeCount":871,"soonestReadout":772},[9523,9527,9531,9535,9539,9549,9556,9565,9569,9573,9577,9585,9589,9593,9597,9601,9605,9609,9613,9617,9621,9625,9629,9633,9640,9644,9648,9656,9660,9664,9668,9672,9676,9680,9684,9688,9692,9696,9700,9704,9708,9712,9716,9720,9726,9730,9734,9741,9745,9749,9753,9757,9761,9765,9769,9773,9777,9781,9785,9789,9795,9803,9807,9811,9815,9819,9823],{"nctId":5529,"briefTitle":5530,"status":182,"phases":9524,"primaryCompletion":2836,"completion":2836,"start":4193,"enrollment":2159,"conditions":9525,"interventions":9526},[88],[21],[5527,2374,4629,5526,5534,5535,654,2424,2293,5536,1070,803],{"nctId":4413,"briefTitle":4414,"status":279,"phases":9528,"primaryCompletion":2302,"completion":2302,"start":4416,"enrollment":798,"conditions":9529,"interventions":9530},[88],[15],[599,654,612],{"nctId":636,"briefTitle":637,"status":279,"phases":9532,"primaryCompletion":639,"completion":639,"start":640,"enrollment":641,"conditions":9533,"interventions":9534},[88],[643,36,644,645,646,647,30,648,608,649,610,650,651,652],[599,654,565,655,656,480],{"nctId":1554,"briefTitle":1555,"status":130,"phases":9536,"primaryCompletion":1557,"completion":1557,"start":1558,"enrollment":1559,"conditions":9537,"interventions":9538},[87,88],[15,36,30],[1050,655,654,1562,62],{"nctId":9540,"briefTitle":9541,"status":130,"phases":9542,"primaryCompletion":9543,"completion":9543,"start":9544,"enrollment":606,"conditions":9545,"interventions":9548},"NCT01892371","Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",[87,88],"2023-02-07","2013-11-12",[9546,9547,608,850,609,610,853,632],"FLT3 Gene Mutation Negative","FLT3 Internal Tandem Duplication Positive",[510,654,613],{"nctId":9550,"briefTitle":9551,"status":130,"phases":9552,"primaryCompletion":7770,"completion":7770,"start":9553,"enrollment":3541,"conditions":9554,"interventions":9555},"NCT01794702","Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia",[87,88],"2013-02-20",[15],[612,655,654,2423],{"nctId":9557,"briefTitle":9558,"status":130,"phases":9559,"primaryCompletion":2316,"completion":2316,"start":9560,"enrollment":9561,"conditions":9562,"interventions":9564},"NCT00656617","Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)",[88],"2008-04",106,[3395,9563],"Myelodysplastic Syndrome (MDS)",[655,654,2405],{"nctId":2464,"briefTitle":2465,"status":279,"phases":9566,"primaryCompletion":2467,"completion":2467,"start":2468,"enrollment":2469,"conditions":9567,"interventions":9568},[87,88],[2471,2472,2473,2474,2475,1142,2415,1144,2419],[1083,803,654,62,2477,805,806,809,894,1016],{"nctId":5546,"briefTitle":5547,"status":130,"phases":9570,"primaryCompletion":5434,"completion":5434,"start":3902,"enrollment":5549,"conditions":9571,"interventions":9572},[88],[21],[4365,2424,654,2293,894],{"nctId":4424,"briefTitle":4425,"status":279,"phases":9574,"primaryCompletion":224,"completion":224,"start":4427,"enrollment":1975,"conditions":9575,"interventions":9576},[87,88],[36,4429,1067,630,608,3112,610,3113],[599,654,655,613],{"nctId":9578,"briefTitle":9579,"status":546,"phases":9580,"primaryCompletion":505,"completion":9581,"start":404,"enrollment":8325,"conditions":9582,"interventions":9583},"NCT07053020","A Phase 1b\u002F2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)",[87,88],"2030-06-30",[3395],[654,9584],"Oral Cladribine",{"nctId":3222,"briefTitle":3223,"status":279,"phases":9586,"primaryCompletion":3225,"completion":3225,"start":3226,"enrollment":3227,"conditions":9587,"interventions":9588},[88],[3229,3230,3231,647,1067,3232,3233,3234,3235,652],[654,612,2712,1005,694,655],{"nctId":2497,"briefTitle":2498,"status":279,"phases":9590,"primaryCompletion":2104,"completion":2104,"start":2500,"enrollment":1975,"conditions":9591,"interventions":9592},[88],[2502,2503],[1083,803,654,62,804,2477,805,806,2425,809,894,810],{"nctId":4432,"briefTitle":4433,"status":130,"phases":9594,"primaryCompletion":4435,"completion":4435,"start":4436,"enrollment":1609,"conditions":9595,"interventions":9596},[87,88],[651],[599,654,4439],{"nctId":2506,"briefTitle":2507,"status":182,"phases":9598,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":296,"conditions":9599,"interventions":9600},[88],[2512,2502,2472],[803,654,62,804,2477,1373,805,806,2425,809,894,810],{"nctId":2515,"briefTitle":2516,"status":182,"phases":9602,"primaryCompletion":2518,"completion":2518,"start":2519,"enrollment":230,"conditions":9603,"interventions":9604},[88],[2521,1142,1144],[1083,803,654,62,1069,1373,805,806,1071,894,810],{"nctId":5562,"briefTitle":5563,"status":130,"phases":9606,"primaryCompletion":5565,"completion":5565,"start":5566,"enrollment":406,"conditions":9607,"interventions":9608},[88],[5568,21],[2450,4365,2424,654,2293,894],{"nctId":8500,"briefTitle":8501,"status":130,"phases":9610,"primaryCompletion":6757,"completion":6757,"start":8503,"enrollment":473,"conditions":9611,"interventions":9612},[87,88],[15],[654,1070,1375,894],{"nctId":2534,"briefTitle":2535,"status":130,"phases":9614,"primaryCompletion":2537,"completion":2537,"start":1000,"enrollment":834,"conditions":9615,"interventions":9616},[88],[1047,643,2539,2540,848,2541,2542,851],[2423,654,62,655,894,2207,2544,1016,810],{"nctId":5591,"briefTitle":5592,"status":130,"phases":9618,"primaryCompletion":5594,"completion":5594,"start":5595,"enrollment":517,"conditions":9619,"interventions":9620},[88],[785,359,5597,21],[3085,75,4365,654,2424,1069,2293,806,894,2196],{"nctId":2546,"briefTitle":2547,"status":130,"phases":9622,"primaryCompletion":2549,"completion":2549,"start":2550,"enrollment":37,"conditions":9623,"interventions":9624},[88],[21],[894,803,1013,1016,62,806,654,809],{"nctId":2554,"briefTitle":2555,"status":130,"phases":9626,"primaryCompletion":2557,"completion":2557,"start":2558,"enrollment":2559,"conditions":9627,"interventions":9628},[88],[1122,2561,644,912,913,915],[803,654,1028,62,1013,806,809,1016],{"nctId":794,"briefTitle":795,"status":279,"phases":9630,"primaryCompletion":772,"completion":772,"start":797,"enrollment":798,"conditions":9631,"interventions":9632},[88],[800,801],[803,654,62,804,805,806,807,808,809,480,810],{"nctId":9634,"briefTitle":9635,"status":279,"phases":9636,"primaryCompletion":1325,"completion":1325,"start":9637,"enrollment":861,"conditions":9638,"interventions":9639},"NCT03263572","Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed\u002FRefractory, Acute Lymphoblastic Leukemia",[88],"2017-11-29",[1205,1122,2561,644,912,913,914,915],[1083,654,806,1124],{"nctId":812,"briefTitle":813,"status":279,"phases":9641,"primaryCompletion":815,"completion":815,"start":816,"enrollment":817,"conditions":9642,"interventions":9643},[88],[36],[510,599,654,480],{"nctId":2587,"briefTitle":2588,"status":182,"phases":9645,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":95,"conditions":9646,"interventions":9647},[88],[1142,2593,1144,2594],[803,654,1028,62,1013,1113,805,806,809,894,2596,1016],{"nctId":9649,"briefTitle":9650,"status":130,"phases":9651,"primaryCompletion":9652,"completion":9652,"start":7155,"enrollment":593,"conditions":9653,"interventions":9654},"NCT01272245","Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)",[88],"2017-01",[15],[9655,654],"Omacetaxine",{"nctId":829,"briefTitle":830,"status":182,"phases":9657,"primaryCompletion":832,"completion":832,"start":833,"enrollment":834,"conditions":9658,"interventions":9659},[87,88],[36,608,610],[654,837,480],{"nctId":9210,"briefTitle":9211,"status":130,"phases":9661,"primaryCompletion":4542,"completion":4542,"start":2836,"enrollment":9213,"conditions":9662,"interventions":9663},[88],[15,2391,2392,9215],[654,1070],{"nctId":2616,"briefTitle":2617,"status":130,"phases":9665,"primaryCompletion":2619,"completion":2619,"start":2620,"enrollment":357,"conditions":9666,"interventions":9667},[88],[15],[2623,655,654,62],{"nctId":2634,"briefTitle":2635,"status":102,"phases":9669,"primaryCompletion":956,"completion":956,"start":2637,"enrollment":2638,"conditions":9670,"interventions":9671},[88],[783,891,788],[803,654,62,1013,804,767,806,894,1016,810],{"nctId":2642,"briefTitle":2643,"status":130,"phases":9673,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":2647,"conditions":9674,"interventions":9675},[88],[1122,2649,2650,2651,785,2652,2653],[803,654,62,804,806,2425,810],{"nctId":928,"briefTitle":929,"status":102,"phases":9677,"primaryCompletion":931,"completion":931,"start":932,"enrollment":240,"conditions":9678,"interventions":9679},[88],[891],[803,654,62,804,767,806,894,480,810],{"nctId":4712,"briefTitle":4713,"status":130,"phases":9681,"primaryCompletion":4715,"completion":4716,"start":4635,"enrollment":95,"conditions":9682,"interventions":9683},[88],[15],[1004,1070,2423,4537,2373,803,2196,2757,612,654,655],{"nctId":7014,"briefTitle":7015,"status":182,"phases":9685,"primaryCompletion":1984,"completion":1984,"start":7017,"enrollment":166,"conditions":9686,"interventions":9687},[88],[15,7019,2653,21],[654,7021,1016,809,7022,2425,894,806,803,805,1013,4514,7023],{"nctId":2695,"briefTitle":2696,"status":130,"phases":9689,"primaryCompletion":2698,"completion":2698,"start":2699,"enrollment":2700,"conditions":9690,"interventions":9691},[88],[15],[2321,803,1013,1016,62,806,654,1114,2374],{"nctId":5626,"briefTitle":5627,"status":130,"phases":9693,"primaryCompletion":5629,"completion":5629,"start":5630,"enrollment":492,"conditions":9694,"interventions":9695},[88],[891,4559,5632,5633,4561,5634,5635],[4365,5515,654,2424,1069,1402,2293,894],{"nctId":9246,"briefTitle":9247,"status":130,"phases":9697,"primaryCompletion":9249,"completion":9249,"start":9250,"enrollment":9251,"conditions":9698,"interventions":9699},[87,88],[15],[2423,655,654,1070],{"nctId":2714,"briefTitle":2715,"status":130,"phases":9701,"primaryCompletion":2717,"completion":2717,"start":2718,"enrollment":2559,"conditions":9702,"interventions":9703},[87,88],[891],[75,803,654,62,1013,806,894,1016],{"nctId":4166,"briefTitle":4167,"status":130,"phases":9705,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":9706,"interventions":9707},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"nctId":1007,"briefTitle":1008,"status":279,"phases":9709,"primaryCompletion":446,"completion":446,"start":1010,"enrollment":517,"conditions":9710,"interventions":9711},[88],[847],[803,654,62,1013,805,806,1014,809,894,1015,480,1016],{"nctId":1030,"briefTitle":1031,"status":279,"phases":9713,"primaryCompletion":224,"completion":224,"start":1033,"enrollment":1034,"conditions":9714,"interventions":9715},[88],[1036,1037],[599,654,480,510],{"nctId":2726,"briefTitle":2727,"status":102,"phases":9717,"primaryCompletion":999,"completion":999,"start":2729,"enrollment":2730,"conditions":9718,"interventions":9719},[88],[1205,1122,2649,2471,644,912,2732],[803,654,62,1013,804,806,1124,917,809,894,1016,810],{"nctId":9721,"briefTitle":9722,"status":130,"phases":9723,"primaryCompletion":9652,"completion":9652,"start":2969,"enrollment":5312,"conditions":9724,"interventions":9725},"NCT00422591","Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)",[88],[15,36,2391],[654,655],{"nctId":1062,"briefTitle":1063,"status":279,"phases":9727,"primaryCompletion":238,"completion":238,"start":1065,"enrollment":1001,"conditions":9728,"interventions":9729},[87,88],[1067,608,610],[654,1069,1070,655,1071,480],{"nctId":1073,"briefTitle":1074,"status":546,"phases":9731,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":406,"conditions":9732,"interventions":9733},[87,88],[1080],[1070,654,655,1069,480,1082,1083],{"nctId":9735,"briefTitle":9736,"status":130,"phases":9737,"primaryCompletion":185,"completion":185,"start":5556,"enrollment":9738,"conditions":9739,"interventions":9740},"NCT00778375","Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)",[88],122,[36,30],[2423,654,612],{"nctId":1105,"briefTitle":1106,"status":182,"phases":9742,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":539,"conditions":9743,"interventions":9744},[87,88],[359,913,608,850,609,914,610,853,632],[1112,510,803,654,62,1069,1113,1114,806,809,894,480,1016],{"nctId":7222,"briefTitle":7223,"status":130,"phases":9746,"primaryCompletion":7225,"completion":7225,"start":7226,"enrollment":1100,"conditions":9747,"interventions":9748},[88],[7228,2653],[7021,1016,7230,7231,803,654,805,806,1013,7023],{"nctId":8819,"briefTitle":8820,"status":130,"phases":9750,"primaryCompletion":5232,"completion":5232,"start":6628,"enrollment":8822,"conditions":9751,"interventions":9752},[87,88],[1987,15],[1375,1070,654,894,1071],{"nctId":2813,"briefTitle":2814,"status":279,"phases":9754,"primaryCompletion":224,"completion":548,"start":2816,"enrollment":2159,"conditions":9755,"interventions":9756},[88],[15],[803,1016,1083,806,654,805,809,1071,2819,894,62],{"nctId":1135,"briefTitle":1136,"status":182,"phases":9758,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":1140,"conditions":9759,"interventions":9760},[87,88],[1142,1143,1144,1145],[803,654,62,806,807,808,809,894,480,1016],{"nctId":7277,"briefTitle":7278,"status":102,"phases":9762,"primaryCompletion":115,"completion":115,"start":7280,"enrollment":492,"conditions":9763,"interventions":9764},[88],[1205,1122,7282,644,913,914],[1083,803,654,1069,806,1071,1124,894,1016],{"nctId":1148,"briefTitle":1149,"status":279,"phases":9766,"primaryCompletion":1151,"completion":1152,"start":1153,"enrollment":1154,"conditions":9767,"interventions":9768},[88],[1156,1157,1158],[963,599,480,565,598,654],{"nctId":2825,"briefTitle":2826,"status":130,"phases":9770,"primaryCompletion":2326,"completion":2326,"start":2828,"enrollment":676,"conditions":9771,"interventions":9772},[87,88],[21],[2831,894,803,1016,1013,62,806,654],{"nctId":3413,"briefTitle":3414,"status":130,"phases":9774,"primaryCompletion":2953,"completion":2953,"start":3416,"enrollment":1140,"conditions":9775,"interventions":9776},[88],[3418,15,1036],[1069,599,3420,654,1005,655,1014],{"nctId":4479,"briefTitle":4480,"status":279,"phases":9778,"primaryCompletion":224,"completion":224,"start":4482,"enrollment":1222,"conditions":9779,"interventions":9780},[88],[36,644,645,1067,4484,727,912],[599,654,4486,694,655],{"nctId":9352,"briefTitle":9353,"status":203,"phases":9782,"primaryCompletion":9355,"completion":9356,"start":9357,"enrollment":124,"conditions":9783,"interventions":9784},[88],[1187],[1070,654,9360],{"nctId":5694,"briefTitle":5695,"status":203,"phases":9786,"primaryCompletion":5697,"completion":5697,"start":5697,"enrollment":124,"conditions":9787,"interventions":9788},[87,88],[3039,891,4559,5632,3277,4561,5634],[4365,654,2424,1069,2293,894,5700],{"nctId":9790,"briefTitle":9791,"status":130,"phases":9792,"primaryCompletion":3494,"completion":3494,"start":8340,"enrollment":3379,"conditions":9793,"interventions":9794},"NCT01025154","Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction",[88],[36],[2423,655,654],{"nctId":9796,"briefTitle":9797,"status":130,"phases":9798,"primaryCompletion":9799,"completion":9799,"start":9800,"enrollment":3409,"conditions":9801,"interventions":9802},"NCT01444742","Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)",[88],"2017-01-29","2011-11-16",[15,4580],[2423,654],{"nctId":2852,"briefTitle":2853,"status":182,"phases":9804,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":296,"conditions":9805,"interventions":9806},[87,88],[2413,1142,1143,1144,2421,1145],[803,654,62,2712,1113,805,1114,806,1071,809,894,1015,1016],{"nctId":9381,"briefTitle":9382,"status":182,"phases":9808,"primaryCompletion":3996,"completion":3996,"start":5470,"enrollment":2159,"conditions":9809,"interventions":9810},[87,88],[1036,36,15],[1375,1070,654],{"nctId":2871,"briefTitle":2872,"status":130,"phases":9812,"primaryCompletion":2874,"completion":2874,"start":2875,"enrollment":1766,"conditions":9813,"interventions":9814},[88],[21],[2878,2879,2880,2881,2882,2883,2884],{"nctId":2886,"briefTitle":2887,"status":130,"phases":9816,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":9817,"interventions":9818},[88],[15,1122],[894,803,1013,1016,62,806,654,2374,1114,2894,1071,2895],{"nctId":2906,"briefTitle":2907,"status":130,"phases":9820,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":9821,"interventions":9822},[88],[2913,2914],[894,803,1013,1016,62,2374,654,806],{"nctId":9824,"briefTitle":9825,"status":130,"phases":9826,"primaryCompletion":9827,"completion":9827,"start":9828,"enrollment":861,"conditions":9829,"interventions":9830},"NCT00003239","Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia",[88],"2001-10","1998-03",[15],[4109,654,634],{"trials":9832,"activeCount":124},[9833,9837],{"nctId":4305,"briefTitle":4306,"status":130,"phases":9834,"primaryCompletion":4308,"completion":4308,"start":4309,"enrollment":2402,"conditions":9835,"interventions":9836},[89],[21],[4312,4313,4045,2879,2880,2882,4314,4315,4047,4316,4317,4318,4319,2884],{"nctId":4367,"briefTitle":4368,"status":130,"phases":9838,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":9839,"interventions":9840},[89],[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":9842,"activeCount":124},[],{"trials":9844,"activeCount":124},[],{"intervention":1369,"totalTrials":3082,"cells":9846},{"EARLY_PHASE1":9847,"PHASE1":9849,"PHASE2":9990,"PHASE3":10328,"PHASE4":10338,"NA":10340},{"trials":9848,"activeCount":124},[],{"trials":9850,"activeCount":296,"soonestReadout":8064},[9851,9855,9865,9872,9880,9888,9895,9910,9919,9929,9933,9940,9946,9950,9954,9962,9971,9975],{"nctId":5431,"briefTitle":5432,"status":130,"phases":9852,"primaryCompletion":5434,"completion":5434,"start":5435,"enrollment":2779,"conditions":9853,"interventions":9854},[87],[1866,21],[75,1369,2424,2495,1114],{"nctId":9856,"briefTitle":9857,"status":130,"phases":9858,"primaryCompletion":2846,"completion":2846,"start":9859,"enrollment":2911,"conditions":9860,"interventions":9861},"NCT01178112","Trientine and Carboplatin in Advanced Malignancies",[87],"2010-07",[33],[9862,1369,9863,9864],"Trientine","Trientine MTD","Carboplatin MTD",{"nctId":9866,"briefTitle":9867,"status":130,"phases":9868,"primaryCompletion":8305,"completion":8305,"start":4039,"enrollment":3820,"conditions":9869,"interventions":9870},"NCT00533585","BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)",[87],[24],[9871,1376,1369,1275],"BAY 43-9006",{"nctId":9873,"briefTitle":9874,"status":130,"phases":9875,"primaryCompletion":9876,"completion":9876,"start":9877,"enrollment":1328,"conditions":9878,"interventions":9879},"NCT03430882","Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors",[87],"2022-06-08","2018-03-12",[2570,3457],[1369,1376,1839],{"nctId":9881,"briefTitle":9882,"status":203,"phases":9883,"primaryCompletion":4835,"start":6367,"enrollment":124,"conditions":9884,"interventions":9886},"NCT01562301","Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)",[87],[9885,24],"Chemotherapeutic Agent Toxicity",[1369,1710,9887],"Anvirzel",{"nctId":9889,"briefTitle":9890,"status":130,"phases":9891,"primaryCompletion":3805,"completion":3805,"start":6409,"enrollment":593,"conditions":9892,"interventions":9893},"NCT00529022","Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer",[87],[1924],[510,9894,1369],"Valproic Acid",{"nctId":9896,"briefTitle":9897,"status":279,"phases":9898,"primaryCompletion":999,"completion":999,"start":9899,"enrollment":628,"conditions":9900,"interventions":9909},"NCT04615013","NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer",[87],"2020-11-23",[9901,9902,9903,9904,7515,4097,9905,9906,9907,7523,7525,7526,9908],"Cervical Esophagus Adenocarcinoma","Clinical Stage II Esophageal Adenocarcinoma AJCC v8","Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8","Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8","Pathologic Stage II Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8","Thoracic Esophagus Adenocarcinoma",[1368,1369,1710,1371,1113,1375,1376],{"nctId":9911,"briefTitle":9912,"status":102,"phases":9913,"primaryCompletion":9914,"completion":9914,"start":9915,"enrollment":3726,"conditions":9916,"interventions":9917},"NCT04837716","Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer",[87],"2027-09-23","2021-03-18",[1315,1836,1359,1319,1361,1362],[1275,1369,9918,1377],"Ensartinib",{"nctId":9920,"briefTitle":9921,"status":130,"phases":9922,"primaryCompletion":9923,"completion":9923,"start":5241,"enrollment":871,"conditions":9924,"interventions":9927},"NCT00059618","PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer",[87],"2007-04",[1530,9925,9926],"Primary Peritoneal Cancer","Fallopian Tube Cancer",[9928,1369],"PS-341",{"nctId":5453,"briefTitle":5454,"status":130,"phases":9930,"primaryCompletion":1307,"completion":1307,"start":3251,"enrollment":492,"conditions":9931,"interventions":9932},[87],[5457,3271,5458,5459,5460,3275,3276,5461,5462,5463,3280],[1369,2424,2495,5465],{"nctId":9934,"briefTitle":9935,"status":130,"phases":9936,"primaryCompletion":3805,"start":7236,"enrollment":195,"conditions":9937,"interventions":9938},"NCT00752011","Phase I Study of TAS-106 in Combo With Carboplatin",[87],[5349,1924],[9939,1369],"TAS-106",{"nctId":9941,"briefTitle":9942,"status":130,"phases":9943,"primaryCompletion":8340,"completion":8340,"start":3819,"enrollment":121,"conditions":9944,"interventions":9945},"NCT00502892","Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors",[87],[1924],[1379,2495,1369],{"nctId":3864,"briefTitle":3865,"status":130,"phases":9947,"primaryCompletion":3867,"completion":3868,"start":3869,"enrollment":2946,"conditions":9948,"interventions":9949},[87],[3871,3872,3873],[1369,1709,2424,53],{"nctId":1337,"briefTitle":1338,"status":182,"phases":9951,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":9952,"interventions":9953},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"nctId":9955,"briefTitle":9956,"status":102,"phases":9957,"primaryCompletion":8064,"completion":8064,"start":9958,"enrollment":9959,"conditions":9960,"interventions":9961},"NCT01187199","Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer",[87],"2010-08-19",278,[1942],[6656,1275,1376,2207,1369],{"nctId":9963,"briefTitle":9964,"status":130,"phases":9965,"primaryCompletion":9966,"completion":9966,"start":9967,"enrollment":871,"conditions":9968,"interventions":9969},"NCT01636622","Study of Vemurafenib, Carboplatin, and Paclitaxel",[87],"2020-04-21","2012-07-09",[33],[9970,1369,1376],"Vemurafenib",{"nctId":3876,"briefTitle":3877,"status":279,"phases":9972,"primaryCompletion":3879,"completion":3880,"start":3881,"enrollment":871,"conditions":9973,"interventions":9974},[87],[2809],[1376,1369,3884,1709],{"nctId":9976,"briefTitle":9977,"status":130,"phases":9978,"primaryCompletion":9487,"completion":9487,"start":9979,"enrollment":1231,"conditions":9980,"interventions":9988},"NCT02389751","Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer",[87],"2015-04-10",[4097,9981,9982,9983,9984,9985,9986,9987],"Malignant Neoplasm of the Cervical Esophagus","Malignant Neoplasm of the Thoracic Esophagus","Stage IIA Esophageal Cancer AJCC v7","Stage IIB Esophageal Cancer AJCC v7","Stage IIIA Esophageal Cancer AJCC v7","Stage IIIB Esophageal Cancer AJCC v7","Stage IIIC Esophageal Cancer AJCC v7",[1369,9989,1376],"Ganetespib",{"trials":9991,"activeCount":539,"soonestReadout":4140},[9992,9999,10009,10018,10027,10031,10038,10042,10049,10053,10061,10065,10071,10078,10082,10099,10107,10111,10120,10128,10138,10148,10152,10156,10160,10164,10168,10179,10183,10187,10194,10198,10217,10221,10230,10239,10243,10249,10256,10264,10268,10276,10283,10290,10294,10298,10312,10316,10320],{"nctId":9993,"briefTitle":9994,"status":182,"phases":9995,"primaryCompletion":9560,"completion":9560,"start":6758,"enrollment":3197,"conditions":9996,"interventions":9997},"NCT00063258","Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer",[88],[24],[9998,1376,1369],"Tarceva",{"nctId":10000,"briefTitle":10001,"status":102,"phases":10002,"primaryCompletion":999,"completion":999,"start":10003,"enrollment":924,"conditions":10004,"interventions":10008},"NCT02876107","Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer",[88],"2016-10-06",[10005,10006,7696,7697,7698,7699,10007,5079,7700,7701,1363],"Breast Carcinoma","Breast Lump","Inflammatory Breast Carcinoma",[1369,1376,6802],{"nctId":10010,"briefTitle":10011,"status":130,"phases":10012,"primaryCompletion":10013,"completion":10013,"start":10014,"enrollment":3354,"conditions":10015,"interventions":10016},"NCT01263782","BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer",[88],"2017-08-15","2011-05-17",[24],[1369,1377,1275,10017],"Cixutumumab",{"nctId":10019,"briefTitle":10020,"status":279,"phases":10021,"primaryCompletion":10022,"completion":224,"start":10023,"enrollment":406,"conditions":10024,"interventions":10025},"NCT06085729","Phase I\u002FII Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)",[87,88],"2027-09-02","2024-02-29",[27],[10026,3701,1369],"ADI-PEG 20",{"nctId":6795,"briefTitle":6796,"status":130,"phases":10028,"primaryCompletion":6798,"completion":6799,"start":4382,"enrollment":2997,"conditions":10029,"interventions":10030},[88],[18],[6802,4023,1369,4218,6744,803],{"nctId":10032,"briefTitle":10033,"status":102,"phases":10034,"primaryCompletion":446,"completion":446,"start":10035,"enrollment":473,"conditions":10036,"interventions":10037},"NCT00494182","Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",[88],"2007-04-25",[7749,4056,4057,4058,4059,7750,4060,4061,4062,4063],[1369,1376,2207],{"nctId":2487,"briefTitle":2488,"status":102,"phases":10039,"primaryCompletion":2490,"completion":2490,"start":2491,"enrollment":134,"conditions":10040,"interventions":10041},[88],[21],[62,2494,2495,1114,1369],{"nctId":10043,"briefTitle":10044,"status":102,"phases":10045,"primaryCompletion":224,"completion":224,"start":10046,"enrollment":550,"conditions":10047,"interventions":10048},"NCT02726997","Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)",[87,88],"2016-07-06",[4957,4958,4959,4960,4961,4962,4963,4964,4965,4966,4967,4968,4969,4970,4971],[1369,1786,1376],{"nctId":1695,"briefTitle":1696,"status":130,"phases":10050,"primaryCompletion":1698,"completion":1698,"start":105,"enrollment":1699,"conditions":10051,"interventions":10052},[88],[1701,1702,1703,1704,1705,1706,1707],[1369,1709,1710,1049,1050,1377],{"nctId":10054,"briefTitle":10055,"status":130,"phases":10056,"primaryCompletion":10057,"completion":10057,"start":10058,"enrollment":357,"conditions":10059,"interventions":10060},"NCT02593175","Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC",[88],"2025-04-03","2016-11-03",[5080,5081,5082,5083,5084,5085,5086,5087,5088,5089,1363],[1369,1376,6802],{"nctId":3970,"briefTitle":3971,"status":102,"phases":10062,"primaryCompletion":238,"completion":238,"start":3973,"enrollment":2004,"conditions":10063,"interventions":10064},[88],[3975,3976,3977,3978,3979,3980,3981],[1369,1709,1710,1371],{"nctId":10066,"briefTitle":10067,"status":130,"phases":10068,"primaryCompletion":2212,"completion":2212,"start":4351,"enrollment":473,"conditions":10069,"interventions":10070},"NCT00301028","Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer",[88],[242],[1683,1369,1376],{"nctId":10072,"briefTitle":10073,"status":130,"phases":10074,"primaryCompletion":3571,"completion":3571,"start":10075,"enrollment":2581,"conditions":10076,"interventions":10077},"NCT00147225","AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin",[87,88],"2005-08",[1924,1942],[2831,1369,2977,2495],{"nctId":4025,"briefTitle":4026,"status":279,"phases":10079,"primaryCompletion":4028,"completion":4028,"start":4029,"enrollment":1328,"conditions":10080,"interventions":10081},[88],[4031,4032,4033],[53,1710,1709,1369],{"nctId":10083,"briefTitle":10084,"status":130,"phases":10085,"primaryCompletion":10086,"completion":10086,"start":10087,"enrollment":676,"conditions":10088,"interventions":10098},"NCT02684227","Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer",[88],"2023-09-27","2016-08-24",[10089,10090,10091,10092,10093,10094,10095,10096,10097],"Recurrent Endometrial Endometrioid Adenocarcinoma","Recurrent Uterine Corpus Carcinoma","Stage III Uterine Corpus Cancer AJCC v7","Stage IIIA Uterine Corpus Cancer AJCC v7","Stage IIIB Uterine Corpus Cancer AJCC v7","Stage IIIC Uterine Corpus Cancer AJCC v7","Stage IV Uterine Corpus Cancer AJCC v7","Stage IVA Uterine Corpus Cancer AJCC v7","Stage IVB Uterine Corpus Cancer AJCC v7",[1369,7589,1376],{"nctId":10100,"briefTitle":10101,"status":279,"phases":10102,"primaryCompletion":5310,"completion":5310,"start":10103,"enrollment":240,"conditions":10104,"interventions":10106},"NCT04892953","Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy",[88],"2021-07-07",[1355,10105,1357,1707,1358,3845,1359],"Stage III Lung Non-Small Cell Cancer AJCC v7",[1369,1786,2369,4023,1376,1377],{"nctId":7869,"briefTitle":7870,"status":130,"phases":10108,"primaryCompletion":7872,"completion":7872,"start":7873,"enrollment":2004,"conditions":10109,"interventions":10110},[88],[4957,4958,4959,4960,4961,4962,4963,4964,4965,4966,4967,4968,4969,4970,4971],[1369,1376,53],{"nctId":10112,"briefTitle":10113,"status":130,"phases":10114,"primaryCompletion":10115,"completion":10115,"start":5267,"enrollment":10116,"conditions":10117,"interventions":10119},"NCT00915005","Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence",[88],"2020-02-24",275,[10118],"Non-Small-Cell Lung Carcinoma",[1376,1369],{"nctId":10121,"briefTitle":10122,"status":130,"phases":10123,"primaryCompletion":4382,"completion":4382,"start":10124,"enrollment":3820,"conditions":10125,"interventions":10127},"NCT00502203","Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus",[88],"2001-08",[10126],"Mixed Tumor, Mullerian",[1369,1376],{"nctId":10129,"briefTitle":10130,"status":102,"phases":10131,"primaryCompletion":10132,"completion":10132,"start":10133,"enrollment":901,"conditions":10134,"interventions":10136},"NCT02525757","MPDL3280A With Chemoradiation for Lung Cancer",[88],"2028-01-31","2016-01-26",[24,10135],"Non-Small Cell Lung Cancer",[10137,1369,1376],"MPDL3280A",{"nctId":10139,"briefTitle":10140,"status":203,"phases":10141,"primaryCompletion":10142,"completion":10142,"start":10143,"enrollment":124,"conditions":10144,"interventions":10146},"NCT06522360","Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)",[88],"2025-04-17","2024-12-11",[10145],"Non-small Cell Lung Cancer",[10147,1369,1377],"Brigatinib",{"nctId":5600,"briefTitle":5601,"status":130,"phases":10149,"primaryCompletion":5603,"completion":5603,"start":5604,"enrollment":3354,"conditions":10150,"interventions":10151},[88],[5606],[2369,1710,2293,1369,1114,2495,2424],{"nctId":4049,"briefTitle":4050,"status":130,"phases":10153,"primaryCompletion":4052,"completion":4052,"start":4053,"enrollment":4054,"conditions":10154,"interventions":10155},[88],[4056,4057,4058,4059,4060,4061,4062,4063,4064,4065,4066,4067,4068,4069,4070,1620,4071,4072,4073,4074,4075,4076,4077,4078],[1369,1709,1710,3848],{"nctId":4081,"briefTitle":4082,"status":182,"phases":10157,"primaryCompletion":4084,"completion":4085,"start":4086,"enrollment":296,"conditions":10158,"interventions":10159},[88],[4088],[1369,1709,1376],{"nctId":3689,"briefTitle":3690,"status":102,"phases":10161,"primaryCompletion":3407,"completion":3407,"start":3692,"enrollment":3693,"conditions":10162,"interventions":10163},[88],[3695,3544,3545,3696,3697],[3699,3700,3701,1369,1049,809],{"nctId":6986,"briefTitle":6987,"status":279,"phases":10165,"primaryCompletion":238,"completion":238,"start":6989,"enrollment":3521,"conditions":10166,"interventions":10167},[88],[6991,1597],[1369,1376,53,1013,803],{"nctId":10169,"briefTitle":10170,"status":130,"phases":10171,"primaryCompletion":10172,"completion":10172,"start":10173,"enrollment":10174,"conditions":10175,"interventions":10178},"NCT01505868","Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer",[87,88],"2019-12-09","2012-07-11",170,[3695,3544,10176,3545,5122,5123,10177],"Lymphadenopathy","Prostate Small Cell Carcinoma",[3701,1369],{"nctId":5609,"briefTitle":5610,"status":102,"phases":10180,"primaryCompletion":224,"completion":224,"start":5612,"enrollment":3379,"conditions":10181,"interventions":10182},[87,88],[5614,1319,1361,1362],[1369,1786,2424,1374],{"nctId":5617,"briefTitle":5618,"status":130,"phases":10184,"primaryCompletion":5620,"completion":5620,"start":5621,"enrollment":2933,"conditions":10185,"interventions":10186},[87,88],[5623],[2340,2495,1114,1369,2424,1071],{"nctId":10188,"briefTitle":10189,"status":203,"phases":10190,"primaryCompletion":4834,"start":6367,"enrollment":124,"conditions":10191,"interventions":10192},"NCT02044601","Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)",[87,88],[24],[10193,3847,1376,1369],"Onartuzumab",{"nctId":5229,"briefTitle":5230,"status":130,"phases":10195,"primaryCompletion":5232,"completion":5232,"start":4183,"enrollment":507,"conditions":10196,"interventions":10197},[88],[18,5234,5079],[1369,803,1254],{"nctId":10199,"briefTitle":10200,"status":130,"phases":10201,"primaryCompletion":10202,"completion":1300,"start":10203,"enrollment":1922,"conditions":10204,"interventions":10216},"NCT01097746","First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",[88],"2021-12-07","2010-04-14",[1345,4937,4938,4939,4940,5062,4941,10205,10206,10207,10208,10209,10210,10211,10212,10213,10214,10215,4942,4943,4944,4945,4946,5063,4947,1354,4948],"FIGO Stage III Ovarian Cancer","FIGO Stage IIIA Ovarian Cancer","FIGO Stage IIIA1 Ovarian Cancer","FIGO Stage IIIA1(i) Ovarian Cancer","FIGO Stage IIIA1(ii) Ovarian Cancer","FIGO Stage IIIA2 Ovarian Cancer","FIGO Stage IIIB Ovarian Cancer","FIGO Stage IIIC Ovarian Cancer","FIGO Stage IVA Ovarian Cancer","FIGO Stage IVB Ovarian Cancer","Malignant Ovarian Brenner Tumor",[1275,1369,1376],{"nctId":4137,"briefTitle":4138,"status":102,"phases":10218,"primaryCompletion":4140,"completion":4141,"start":4142,"enrollment":3521,"conditions":10219,"interventions":10220},[88],[4144,4145,4146],[1369,1709,1710,53],{"nctId":10222,"briefTitle":10223,"status":102,"phases":10224,"primaryCompletion":224,"completion":224,"start":2185,"enrollment":1100,"conditions":10225,"interventions":10228},"NCT04592237","Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer",[88],[3543,3544,3545,10226,10227,3546],"Metastatic Prostate Neuroendocrine Carcinoma","Metastatic Prostate Small Cell Carcinoma",[3701,1369,10229,5114],"Cetrelimab",{"nctId":10231,"briefTitle":10232,"status":102,"phases":10233,"primaryCompletion":504,"completion":504,"start":10234,"enrollment":724,"conditions":10235,"interventions":10237},"NCT03263650","Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC",[88],"2017-10-03",[10236,5106],"Prostate Cancer Aggressiveness",[3701,1369,10238,1374],"Prednisone 5Mg",{"nctId":5638,"briefTitle":5639,"status":130,"phases":10240,"primaryCompletion":1307,"completion":1307,"start":5641,"enrollment":1131,"conditions":10241,"interventions":10242},[88],[3273,3278],[75,1369,2424,2495],{"nctId":10244,"briefTitle":10245,"status":182,"phases":10246,"primaryCompletion":4843,"completion":4843,"start":4192,"enrollment":2018,"conditions":10247,"interventions":10248},"NCT00583622","Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients",[88],[1530],[1275,1369,1710,2369,2293],{"nctId":10250,"briefTitle":10251,"status":182,"phases":10252,"primaryCompletion":8730,"completion":8730,"start":4085,"enrollment":1483,"conditions":10253,"interventions":10254},"NCT01200342","Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma",[88],[1729],[10255,1376,1369],"Genasense",{"nctId":10257,"briefTitle":10258,"status":182,"phases":10259,"primaryCompletion":9560,"completion":9560,"start":10260,"enrollment":296,"conditions":10261,"interventions":10262},"NCT00290537","Phase II Study of ZD6474 in Advanced NSCLC",[88],"2006-01",[24],[10263,1369,1376],"ZD6474",{"nctId":4199,"briefTitle":4200,"status":182,"phases":10265,"primaryCompletion":4202,"completion":4202,"start":4203,"enrollment":1231,"conditions":10266,"interventions":10267},[88],[4205,4206,1355,1357,1358,1359,1319,1361,1362,4207],[4209,1377,1369,1709],{"nctId":10269,"briefTitle":10270,"status":130,"phases":10271,"primaryCompletion":4619,"completion":4619,"start":10272,"enrollment":7377,"conditions":10273,"interventions":10274},"NCT00501644","Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer",[88],"2003-01",[1530,9926,5787],[1369,4629,10275],"Interferon Gamma",{"nctId":10277,"briefTitle":10278,"status":130,"phases":10279,"primaryCompletion":8095,"completion":8095,"start":10280,"enrollment":381,"conditions":10281,"interventions":10282},"NCT00495170","Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA\u002FB Non-Small Cell Lung Cancer (NSCLC)",[88],"2006-04-14",[24],[1369,1376],{"nctId":10284,"briefTitle":10285,"status":130,"phases":10286,"primaryCompletion":10287,"completion":10287,"start":3818,"enrollment":1154,"conditions":10288,"interventions":10289},"NCT00563784","TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA\u002FB Non-Small Cell Lung Cancer (NSCLC)",[88],"2018-05-30",[10135,24],[3847,1369,1376],{"nctId":7303,"briefTitle":7304,"status":203,"phases":10291,"primaryCompletion":754,"completion":754,"start":7306,"enrollment":124,"conditions":10292,"interventions":10293},[88],[7308,7309,7310,7311,7312,7296,5079,7313,7314,7315,7316,7317,1363],[1369,803,1013,1376,6802,53],{"nctId":4278,"briefTitle":4279,"status":279,"phases":10295,"primaryCompletion":4281,"completion":4281,"start":4282,"enrollment":2159,"conditions":10296,"interventions":10297},[88],[24],[4285,1709,1369,1377],{"nctId":10299,"briefTitle":10300,"status":182,"phases":10301,"primaryCompletion":10302,"completion":10302,"start":9278,"enrollment":1483,"conditions":10303,"interventions":10310},"NCT02530437","Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer",[87,88],"2022-01-07",[4097,10304,10305,10306,10307,10308,10309],"Stage IB Esophageal Adenocarcinoma AJCC v7","Stage II Esophageal Adenocarcinoma AJCC v7","Stage IIA Esophageal Adenocarcinoma AJCC v7","Stage IIB Esophageal Adenocarcinoma AJCC v7","Stage IIIA Esophageal Adenocarcinoma AJCC v7","Stage IIIB Esophageal Adenocarcinoma AJCC v7",[1369,1376,10311],"Taladegib",{"nctId":4287,"briefTitle":4288,"status":130,"phases":10313,"primaryCompletion":4290,"completion":4290,"start":4039,"enrollment":4291,"conditions":10314,"interventions":10315},[88],[27],[1710,1369,2424,1709],{"nctId":4295,"briefTitle":4296,"status":102,"phases":10317,"primaryCompletion":224,"completion":224,"start":4298,"enrollment":4299,"conditions":10318,"interventions":10319},[88],[450],[1376,1369,1683,1710,1709,1371],{"nctId":10321,"briefTitle":10322,"status":130,"phases":10323,"primaryCompletion":10324,"completion":10324,"start":10325,"enrollment":357,"conditions":10326,"interventions":10327},"NCT00271505","Avastin\u002FDocetaxel\u002FCarboplatin in Non-Small Cell Lung Cancer",[88],"2017-07-27","2005-12-05",[10135],[1275,1369,1710],{"trials":10329,"activeCount":124},[10330,10334],{"nctId":5712,"briefTitle":5713,"status":182,"phases":10331,"primaryCompletion":5715,"completion":5715,"start":5716,"enrollment":121,"conditions":10332,"interventions":10333},[89],[5718],[1369,803,2424,1016],{"nctId":5729,"briefTitle":5730,"status":182,"phases":10335,"primaryCompletion":5732,"completion":5732,"start":5733,"enrollment":1231,"conditions":10336,"interventions":10337},[88,89],[5735],[1369,2424,2293],{"trials":10339,"activeCount":124},[],{"trials":10341,"activeCount":124},[10342],{"nctId":10343,"briefTitle":10344,"status":130,"phases":10345,"primaryCompletion":10346,"completion":10346,"start":10347,"enrollment":1922,"conditions":10348,"interventions":10350},"NCT00038012","rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin",[91],"2004-06","1999-07-23",[10349],"Neoplasms, Gynecologic",[10351,1369],"Thrombopoietin",{"intervention":510,"totalTrials":240,"cells":10353},{"EARLY_PHASE1":10354,"PHASE1":10356,"PHASE2":10422,"PHASE3":10643,"PHASE4":10653,"NA":10655},{"trials":10355,"activeCount":124},[],{"trials":10357,"activeCount":296,"soonestReadout":504},[10358,10364,10370,10374,10378,10387,10391,10395,10402,10406,10414],{"nctId":10359,"briefTitle":10360,"status":130,"phases":10361,"primaryCompletion":4723,"completion":4723,"start":2944,"enrollment":34,"conditions":10362,"interventions":10363},"NCT00496444","Azacytidine and Valproic Acid in Patients With Advanced Cancers",[87],[33],[510,9894],{"nctId":10365,"briefTitle":10366,"status":130,"phases":10367,"primaryCompletion":3996,"completion":3996,"start":4169,"enrollment":861,"conditions":10368,"interventions":10369},"NCT00350818","Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)",[87],[30,15],[510],{"nctId":9467,"briefTitle":9468,"status":182,"phases":10371,"primaryCompletion":9470,"completion":9470,"start":9471,"enrollment":550,"conditions":10372,"interventions":10373},[87],[36,1067],[510,654,9474],{"nctId":501,"briefTitle":502,"status":279,"phases":10375,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":10376,"interventions":10377},[87],[36],[510,480,511],{"nctId":10379,"briefTitle":10380,"status":279,"phases":10381,"primaryCompletion":10382,"completion":10383,"start":889,"enrollment":628,"conditions":10384,"interventions":10385},"NCT06616636","A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)",[87],"2027-08-27","2029-08-27",[30,36],[510,10386],"Rezatapopt",{"nctId":533,"briefTitle":534,"status":102,"phases":10388,"primaryCompletion":536,"completion":537,"start":538,"enrollment":539,"conditions":10389,"interventions":10390},[87],[36],[510,480,542],{"nctId":9889,"briefTitle":9890,"status":130,"phases":10392,"primaryCompletion":3805,"completion":3805,"start":6409,"enrollment":593,"conditions":10393,"interventions":10394},[87],[1924],[510,9894,1369],{"nctId":10396,"briefTitle":10397,"status":182,"phases":10398,"primaryCompletion":2889,"completion":2889,"start":2326,"enrollment":166,"conditions":10399,"interventions":10400},"NCT01200004","Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide",[87],[33],[510,1402,10401],"Grifola Frondosa",{"nctId":568,"briefTitle":569,"status":279,"phases":10403,"primaryCompletion":281,"completion":571,"start":572,"enrollment":492,"conditions":10404,"interventions":10405},[87],[494,574],[576,480,510],{"nctId":10407,"briefTitle":10408,"status":130,"phases":10409,"primaryCompletion":5574,"completion":5574,"start":10410,"enrollment":357,"conditions":10411,"interventions":10412},"NCT04022785","PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome",[87],"2019-09-09",[36,30,3244,727],[510,10413],"BRD4 Inhibitor PLX51107",{"nctId":10415,"briefTitle":10416,"status":130,"phases":10417,"primaryCompletion":4142,"completion":4142,"start":10418,"enrollment":1231,"conditions":10419,"interventions":10420},"NCT01460498","Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)",[87],"2012-08-08",[15],[510,10421,510],"Tyrosine kinase inhibitor",{"trials":10423,"activeCount":1568,"soonestReadout":1238},[10424,10428,10432,10436,10445,10452,10456,10460,10468,10480,10484,10488,10497,10501,10509,10515,10519,10523,10529,10540,10547,10551,10555,10562,10570,10574,10578,10585,10589,10593,10597,10601,10605,10609,10613,10623,10627,10631,10639],{"nctId":7680,"briefTitle":7681,"status":130,"phases":10425,"primaryCompletion":7683,"completion":7683,"start":7684,"enrollment":628,"conditions":10426,"interventions":10427},[88],[7686,1316],[510,53],{"nctId":2397,"briefTitle":2398,"status":130,"phases":10429,"primaryCompletion":2400,"completion":2400,"start":2401,"enrollment":2402,"conditions":10430,"interventions":10431},[87,88],[33,21],[510,2405,2369,1004,2293,62,2371,2372,894],{"nctId":9540,"briefTitle":9541,"status":130,"phases":10433,"primaryCompletion":9543,"completion":9543,"start":9544,"enrollment":606,"conditions":10434,"interventions":10435},[87,88],[9546,9547,608,850,609,610,853,632],[510,654,613],{"nctId":10437,"briefTitle":10438,"status":279,"phases":10439,"primaryCompletion":115,"completion":115,"start":10440,"enrollment":3379,"conditions":10441,"interventions":10444},"NCT03383575","Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome",[88],"2018-01-17",[36,10442,737,10443,3233,3112,3113],"Blasts 20-30 Percent of Bone Marrow Nucleated Cells","IDH2 Gene Mutation",[510,564],{"nctId":10446,"briefTitle":10447,"status":130,"phases":10448,"primaryCompletion":10449,"completion":10449,"start":6757,"enrollment":1034,"conditions":10450,"interventions":10451},"NCT01254890","Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome",[87,88],"2015-03",[15],[510,2207],{"nctId":671,"briefTitle":672,"status":102,"phases":10453,"primaryCompletion":674,"completion":674,"start":675,"enrollment":676,"conditions":10454,"interventions":10455},[88],[678,679,680,36,681,682],[510,480],{"nctId":685,"briefTitle":686,"status":130,"phases":10457,"primaryCompletion":688,"completion":688,"start":689,"enrollment":676,"conditions":10458,"interventions":10459},[87,88],[608,610],[692,693,510,694,695,696,480,510],{"nctId":10461,"briefTitle":10462,"status":130,"phases":10463,"primaryCompletion":8339,"completion":10464,"start":10465,"enrollment":971,"conditions":10466,"interventions":10467},"NCT00948064","Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)",[88],"2017-08-03","2009-09-08",[15],[2405,510],{"nctId":10469,"briefTitle":10470,"status":130,"phases":10471,"primaryCompletion":10472,"completion":10472,"start":10473,"enrollment":3521,"conditions":10474,"interventions":10478},"NCT03047993","Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome",[87,88],"2023-03-16","2017-11-15",[10475,10442,10476,737,1067,10477,30],"Acute Myeloid Leukemia With Multilineage Dysplasia","Blasts 20-30 Percent of Peripheral Blood White Cells","IPSS Risk Category Intermediate-2",[510,10479],"Glutaminase Inhibitor CB-839",{"nctId":720,"briefTitle":721,"status":279,"phases":10481,"primaryCompletion":238,"completion":238,"start":723,"enrollment":724,"conditions":10482,"interventions":10483},[87,88],[36,726,30,727,608,610],[510,566,480],{"nctId":730,"briefTitle":731,"status":102,"phases":10485,"primaryCompletion":193,"completion":193,"start":733,"enrollment":517,"conditions":10486,"interventions":10487},[87,88],[36,735,736,737,738,739,30,740,741,742,727,743,744,745,746,747],[510,749,480],{"nctId":10489,"briefTitle":10490,"status":279,"phases":10491,"primaryCompletion":10492,"completion":10492,"start":10493,"enrollment":676,"conditions":10494,"interventions":10495},"NCT03683433","Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation",[88],"2027-09-20","2018-09-18",[1047,643,737,10443,30,608,610],[510,10496],"Enasidenib Mesylate",{"nctId":812,"briefTitle":813,"status":279,"phases":10498,"primaryCompletion":815,"completion":815,"start":816,"enrollment":817,"conditions":10499,"interventions":10500},[88],[36],[510,599,654,480],{"nctId":10502,"briefTitle":10503,"status":130,"phases":10504,"primaryCompletion":10505,"completion":10505,"start":10506,"enrollment":4291,"conditions":10507,"interventions":10508},"NCT01787487","Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm",[88],"2026-01-20","2013-03-13",[741,2133,746,2134],[510,2596],{"nctId":10510,"briefTitle":10511,"status":130,"phases":10512,"primaryCompletion":4723,"completion":4723,"start":3988,"enrollment":593,"conditions":10513,"interventions":10514},"NCT00569010","Phase I\u002FII Study of 5-Azacytidine With Ara-C in Patients With Relapsed\u002FRefractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)",[87,88],[4659,30,15],[510,2584],{"nctId":865,"briefTitle":866,"status":130,"phases":10516,"primaryCompletion":868,"completion":869,"start":870,"enrollment":871,"conditions":10517,"interventions":10518},[88],[608,850,609,610,853,632],[510,874,480],{"nctId":876,"briefTitle":877,"status":182,"phases":10520,"primaryCompletion":879,"completion":879,"start":880,"enrollment":240,"conditions":10521,"interventions":10522},[87,88],[737,30,609,632,882],[510,480],{"nctId":10524,"briefTitle":10525,"status":130,"phases":10526,"primaryCompletion":9560,"completion":9560,"start":4887,"enrollment":1240,"conditions":10527,"interventions":10528},"NCT00569660","Ph II Study of Azacitidine in Myelofibrosis",[88],[3429],[510],{"nctId":10530,"briefTitle":10531,"status":102,"phases":10532,"primaryCompletion":10533,"completion":10533,"start":10103,"enrollment":628,"conditions":10534,"interventions":10538},"NCT04734990","Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",[87,88],"2027-09-11",[10535,10536,10537,30,850,609],"Chronic Myelomonocytic Leukemia-0","Chronic Myelomonocytic Leukemia-1","Chronic Myelomonocytic Leukemia-2",[510,10539],"Seclidemstat",{"nctId":10541,"briefTitle":10542,"status":130,"phases":10543,"primaryCompletion":8718,"completion":8718,"start":3996,"enrollment":134,"conditions":10544,"interventions":10545},"NCT01193517","Azacitidine and CAPOX in Metastatic Colorectal Cancer",[87,88],[3195],[510,1368,1375,10546],"Azacitidine MTD",{"nctId":944,"briefTitle":945,"status":203,"phases":10548,"primaryCompletion":947,"completion":947,"start":948,"enrollment":124,"conditions":10549,"interventions":10550},[87,88],[737],[510,951,480],{"nctId":1928,"briefTitle":1929,"status":102,"phases":10552,"primaryCompletion":238,"completion":238,"start":1931,"enrollment":1932,"conditions":10553,"interventions":10554},[88],[15,30,609],[510,1049,1050],{"nctId":10556,"briefTitle":10557,"status":102,"phases":10558,"primaryCompletion":224,"completion":224,"start":870,"enrollment":406,"conditions":10559,"interventions":10561},"NCT04493138","Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic\u002FMyeloproliferative Neoplasm With FLT3 or CBL Mutations",[87,88],[737,30,727,850,609,10560],"Recurrent Myeloproliferative Neoplasm",[510,613],{"nctId":10563,"briefTitle":10564,"status":130,"phases":10565,"primaryCompletion":10566,"completion":10566,"start":10567,"enrollment":5774,"conditions":10568,"interventions":10569},"NCT01720225","Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk",[88],"2020-01-08","2012-11-06",[15],[612,510],{"nctId":966,"briefTitle":967,"status":182,"phases":10571,"primaryCompletion":969,"completion":969,"start":970,"enrollment":971,"conditions":10572,"interventions":10573},[87,88],[36,608,610],[510,974,480],{"nctId":976,"briefTitle":977,"status":279,"phases":10575,"primaryCompletion":404,"completion":979,"start":980,"enrollment":517,"conditions":10576,"interventions":10577},[87,88],[982,983],[985,510,480],{"nctId":10579,"briefTitle":10580,"status":182,"phases":10581,"primaryCompletion":10582,"completion":10582,"start":7595,"enrollment":1766,"conditions":10583,"interventions":10584},"NCT02953561","Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia",[87,88],"2019-09-30",[846,608,610],[693,510],{"nctId":1030,"briefTitle":1031,"status":279,"phases":10586,"primaryCompletion":224,"completion":224,"start":1033,"enrollment":1034,"conditions":10587,"interventions":10588},[88],[1036,1037],[599,654,480,510],{"nctId":1040,"briefTitle":1041,"status":130,"phases":10590,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":1045,"conditions":10591,"interventions":10592},[88],[1047,643,846,737,30,608,610,651,682],[510,1049,480,1050],{"nctId":4783,"briefTitle":4784,"status":130,"phases":10594,"primaryCompletion":2602,"completion":2602,"start":4786,"enrollment":628,"conditions":10595,"interventions":10596},[88],[2755,15],[1070,1004,4537,510],{"nctId":1085,"briefTitle":1086,"status":279,"phases":10598,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":10599,"interventions":10600},[87,88],[608,850,1092,610,853,1093],[510,565,480],{"nctId":1105,"briefTitle":1106,"status":182,"phases":10602,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":539,"conditions":10603,"interventions":10604},[87,88],[359,913,608,850,609,914,610,853,632],[1112,510,803,654,62,1069,1113,1114,806,809,894,480,1016],{"nctId":2031,"briefTitle":2032,"status":182,"phases":10606,"primaryCompletion":2034,"completion":2034,"start":2035,"enrollment":1496,"conditions":10607,"interventions":10608},[88],[15],[2038,1050,510],{"nctId":4831,"briefTitle":4832,"status":203,"phases":10610,"primaryCompletion":4834,"start":4835,"enrollment":124,"conditions":10611,"interventions":10612},[87,88],[21],[1004,2370,2371,2372,2235,510,2369,2293],{"nctId":10614,"briefTitle":10615,"status":279,"phases":10616,"primaryCompletion":10617,"completion":10618,"start":10619,"enrollment":901,"conditions":10620,"interventions":10621},"NCT07508982","Phase1b\u002F2 Trial Of AZA + APG1252 In Patients With High-Risk AML",[87,88],"2029-12-12","2031-12-12","2026-05-22",[2391],[510,10622],"APG1252",{"nctId":1218,"briefTitle":1219,"status":102,"phases":10624,"primaryCompletion":446,"completion":446,"start":1221,"enrollment":1222,"conditions":10625,"interventions":10626},[88],[1047,643,36,848,800,682],[510,480],{"nctId":8192,"briefTitle":8193,"status":3049,"phases":10628,"primaryCompletion":8195,"completion":8196,"start":8197,"enrollment":517,"conditions":10629,"interventions":10630},[88],[1067,8199,30],[510,53],{"nctId":10632,"briefTitle":10633,"status":182,"phases":10634,"primaryCompletion":10635,"completion":10635,"start":10636,"enrollment":593,"conditions":10637,"interventions":10638},"NCT02399917","Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia",[88],"2018-07-12","2015-04-20",[643,846,608,610],[510,2038],{"nctId":1235,"briefTitle":1236,"status":102,"phases":10640,"primaryCompletion":1238,"completion":1238,"start":1239,"enrollment":1240,"conditions":10641,"interventions":10642},[87,88],[850,609,853,632,882],[510,480],{"trials":10644,"activeCount":124},[10645],{"nctId":10646,"briefTitle":10647,"status":130,"phases":10648,"primaryCompletion":4338,"completion":4338,"start":10649,"enrollment":10650,"conditions":10651,"interventions":10652},"NCT00887068","Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)",[89],"2009-04-21",187,[15,2391,2392],[510],{"trials":10654,"activeCount":124},[],{"trials":10656,"activeCount":124},[],{"intervention":1275,"totalTrials":37,"cells":10658},{"EARLY_PHASE1":10659,"PHASE1":10683,"PHASE2":10949,"PHASE3":11206,"PHASE4":11208,"NA":11220},{"trials":10660,"activeCount":121,"soonestReadout":446},[10661,10665],{"nctId":1265,"briefTitle":1266,"status":102,"phases":10662,"primaryCompletion":446,"completion":446,"start":1268,"enrollment":1269,"conditions":10663,"interventions":10664},[86],[1271,1272,1273],[1275,1049,1050],{"nctId":10666,"briefTitle":10667,"status":546,"phases":10668,"primaryCompletion":10669,"completion":10670,"start":10671,"enrollment":1222,"conditions":10672,"interventions":10675},"NCT07318389","ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer",[86],"2027-11-14","2029-11-14","2026-06-10",[10673,10674],"Dynamic Tumor Resistance","Metastatic Colorectal Cancer",[1275,1683,6802,10676,10677,1684,10678,10679,10680,10681,10682],"FOLFIRI","FOLFOX","Adagrasib","Trifluridine\u002Ftipiracil","Trastuzumab deruxtecan","Tucatinib","Sotorasib",{"trials":10684,"activeCount":1483,"soonestReadout":8064},[10685,10693,10718,10722,10728,10735,10739,10748,10756,10763,10772,10780,10788,10795,10799,10803,10840,10847,10853,10860,10866,10882,10890,10896,10905,10909,10919,10926,10934,10942],{"nctId":10686,"briefTitle":10687,"status":279,"phases":10688,"primaryCompletion":446,"completion":446,"start":10689,"enrollment":1240,"conditions":10690,"interventions":10691},"NCT05636111","Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer",[87],"2023-07-12",[1530],[1376,1275,10692],"Lurbinectedin",{"nctId":10694,"briefTitle":10695,"status":279,"phases":10696,"primaryCompletion":4028,"completion":505,"start":7816,"enrollment":2700,"conditions":10697,"interventions":10715},"NCT05039801","IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors",[87],[10698,10699,1343,1770,10700,10701,1344,1312,1348,1349,1350,1351,1352,1353,10702,10703,10704,6638,10705,10706,4914,10707,4917,10708,4920,4922,4924,10709,4927,10710,10711,10712,1463,10713,1466,10714,1470,1472],"Advanced Endometrial Carcinoma","Advanced Head and Neck Squamous Cell Carcinoma","Advanced Ovarian Clear Cell Adenocarcinoma","Chondrosarcoma","Recurrent Ovarian High Grade Serous Adenocarcinoma","Refractory Endometrial Carcinoma","Refractory Head and Neck Squamous Cell Carcinoma","Refractory Ovarian Clear Cell Adenocarcinoma","Refractory Ovarian High Grade Serous Adenocarcinoma","Stage III Uterine Corpus Cancer AJCC v8","Stage IIIA Uterine Corpus Cancer AJCC v8","Stage IIIB Uterine Corpus Cancer AJCC v8","Stage IIIC Uterine Corpus Cancer AJCC v8","Stage IIIC1 Uterine Corpus Cancer AJCC v8","Stage IIIC2 Uterine Corpus Cancer AJCC v8","Stage IV Uterine Corpus Cancer AJCC v8","Stage IVA Uterine Corpus Cancer AJCC v8",[1275,10716,1376,10717],"Glutaminase-1 Inhibitor IACS-6274","Capivasertib",{"nctId":7562,"briefTitle":7563,"status":203,"phases":10719,"primaryCompletion":7565,"completion":7565,"start":7565,"enrollment":124,"conditions":10720,"interventions":10721},[87],[7567,1530,18,24,4107],[7569,1275,53],{"nctId":10723,"briefTitle":10724,"status":182,"phases":10725,"primaryCompletion":2836,"completion":2836,"start":6628,"enrollment":1231,"conditions":10726,"interventions":10727},"NCT00426829","Proton Therapy and Bevacizumab for Primary Liver Tumors",[87],[1996,1828,3947],[1275],{"nctId":10729,"briefTitle":10730,"status":130,"phases":10731,"primaryCompletion":2777,"completion":2777,"start":3987,"enrollment":342,"conditions":10732,"interventions":10733},"NCT00941499","Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +\u002F- Cetuximab",[87],[33],[10734,2772,1275,1683,1113,2772,1275],"HAI Oxaliplatin",{"nctId":9866,"briefTitle":9867,"status":130,"phases":10736,"primaryCompletion":8305,"completion":8305,"start":4039,"enrollment":3820,"conditions":10737,"interventions":10738},[87],[24],[9871,1376,1369,1275],{"nctId":10740,"briefTitle":10741,"status":102,"phases":10742,"primaryCompletion":446,"completion":446,"start":10743,"enrollment":1664,"conditions":10744,"interventions":10746},"NCT03203525","Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer",[87],"2020-06-23",[2922,10745,3512,2926],"Colorectal Carcinoma Metastatic in the Liver",[1275,1371,1113,1375,10747,6656],"Pegylated Liposomal Doxorubicin Hydrochloride",{"nctId":10749,"briefTitle":10750,"status":130,"phases":10751,"primaryCompletion":3493,"completion":3493,"start":3996,"enrollment":10752,"conditions":10753,"interventions":10754},"NCT01183663","Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)",[87],180,[33],[1402,1275,2207,6656,1402,1375,1113,10755],"5-fluorouracil",{"nctId":10757,"briefTitle":10758,"status":130,"phases":10759,"primaryCompletion":5240,"completion":5240,"start":10760,"enrollment":539,"conditions":10761,"interventions":10762},"NCT00614653","Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer",[87],"2008-01",[4107],[1275,3847,1368],{"nctId":10764,"briefTitle":10765,"status":130,"phases":10766,"primaryCompletion":10767,"completion":10767,"start":10768,"enrollment":10769,"conditions":10770,"interventions":10771},"NCT00610493","Bevacizumab and Temsirolimus in Patients With Advanced Malignancy",[87],"2017-11-28","2008-01-25",193,[1942],[1275,6656],{"nctId":10773,"briefTitle":10774,"status":130,"phases":10775,"primaryCompletion":10776,"completion":10776,"start":10777,"enrollment":1001,"conditions":10778,"interventions":10779},"NCT01213238","Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab",[87],"2018-09-26","2010-09-30",[33],[1375,1368,1275],{"nctId":10781,"briefTitle":10782,"status":130,"phases":10783,"primaryCompletion":10784,"completion":10784,"start":10785,"enrollment":473,"conditions":10786,"interventions":10787},"NCT00047710","Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer",[87],"2006-07","2002-09",[4107],[1275,1368],{"nctId":10789,"briefTitle":10790,"status":130,"phases":10791,"primaryCompletion":3725,"completion":3725,"start":9512,"enrollment":1269,"conditions":10792,"interventions":10794},"NCT00428545","Bevacizumab and Bortezomib in Patients With Advanced Malignancy",[87],[10793,21,2245,1924],"Advanced Malignancy",[1275,75],{"nctId":7581,"briefTitle":7582,"status":279,"phases":10796,"primaryCompletion":1151,"completion":1152,"start":7584,"enrollment":4299,"conditions":10797,"interventions":10798},[87],[3305],[7587,1375,1113,7588,1275,53,7589],{"nctId":9911,"briefTitle":9912,"status":102,"phases":10800,"primaryCompletion":9914,"completion":9914,"start":9915,"enrollment":3726,"conditions":10801,"interventions":10802},[87],[1315,1836,1359,1319,1361,1362],[1275,1369,9918,1377],{"nctId":10804,"briefTitle":10805,"status":182,"phases":10806,"primaryCompletion":10807,"completion":10807,"start":10808,"enrollment":10809,"conditions":10810,"interventions":10839},"NCT01552434","Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease",[87],"2026-05-08","2012-10-16",154,[2922,10811,10812,10813,10814,10815,10816,10817,10818,2613,10819,10820,10821,10822,2924,1803,10823,10824,10825,10826,10827,10828,10829,2925,10830,10831,2926,10832,5086,10833,5087,5088,5089,7298,10834,10835,10836,10837,10838],"Castleman Disease","Digestive System Carcinoma","Erdheim-Chester Disease","Lip and Oral Cavity Carcinoma","Lymphangioleiomyomatosis","Malignant Endocrine Neoplasm","Malignant Female Reproductive System Neoplasm","Malignant Male Reproductive System Neoplasm","Malignant Respiratory Tract Neoplasm","Malignant Thoracic Neoplasm","Malignant Urinary System Neoplasm","Mesothelial Neoplasm","Neurofibromatosis Type 2","Recurrent Adult Soft Tissue Sarcoma","Recurrent Breast Carcinoma","Recurrent Childhood Soft Tissue Sarcoma","Recurrent Digestive System Carcinoma","Recurrent Female Reproductive System Carcinoma","Recurrent Male Reproductive System Carcinoma","Recurrent Pharyngeal Carcinoma","Recurrent Thyroid Gland Carcinoma","Soft Tissue Neoplasm","Stage III Pharyngeal Cancer","Stage IV Pharyngeal Cancer","Stage IVA Pharyngeal Cancer","Stage IVB Pharyngeal Cancer","Stage IVC Pharyngeal Cancer","Thyroid Gland Neoplasm",[1275,1683,6656,9894],{"nctId":10841,"briefTitle":10842,"status":130,"phases":10843,"primaryCompletion":2777,"completion":2777,"start":10844,"enrollment":7377,"conditions":10845,"interventions":10846},"NCT01152203","Bendamustine and Bevacizumab for Advanced Cancers",[87],"2010-06",[1942],[6545,1275],{"nctId":10848,"briefTitle":10849,"status":130,"phases":10850,"primaryCompletion":2518,"completion":2518,"start":2836,"enrollment":9738,"conditions":10851,"interventions":10852},"NCT01015222","Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies",[87],[1942],[1028,1275,1376],{"nctId":10854,"briefTitle":10855,"status":130,"phases":10856,"primaryCompletion":2777,"completion":2777,"start":8340,"enrollment":959,"conditions":10857,"interventions":10858},"NCT01057264","HAI Abraxane With Gemcitabine and Bevacizumab",[87],[33],[10859,2369,1275,1069],"HAI Abraxane",{"nctId":10861,"briefTitle":10862,"status":130,"phases":10863,"primaryCompletion":4162,"completion":4162,"start":4183,"enrollment":7694,"conditions":10864,"interventions":10865},"NCT00530907","Valproic Acid and Bevacizumab in Patients With Advanced Cancer",[87],[1942],[9894,1275],{"nctId":10867,"briefTitle":10868,"status":279,"phases":10869,"primaryCompletion":10870,"completion":10871,"start":10872,"enrollment":1243,"conditions":10873,"interventions":10880},"NCT07500298","Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer",[87],"2030-12-27","2032-12-27","2026-05-20",[2306,10874,10875,10876,10877,10878,10879],"SAR445877","FOlfox6","Bevacizimab","First Line Treatment","Metastatic Colorectal Cancer (CRC)","Microsatellite Stable",[10874,10881,1275],"FOLFOX6",{"nctId":10883,"briefTitle":10884,"status":203,"phases":10885,"primaryCompletion":10886,"completion":10886,"start":10886,"enrollment":124,"conditions":10887,"interventions":10888},"NCT05510427","Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion\u002FAmplification",[87],"2023-08-07",[3947,1996],[10889,718,1275],"Infigratinib",{"nctId":10891,"briefTitle":10892,"status":130,"phases":10893,"primaryCompletion":3832,"completion":3832,"start":4183,"enrollment":1231,"conditions":10894,"interventions":10895},"NCT00491855","Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis",[87],[5787],[1275,1375,1376],{"nctId":10897,"briefTitle":10898,"status":130,"phases":10899,"primaryCompletion":1567,"completion":1567,"start":10900,"enrollment":10901,"conditions":10902,"interventions":10903},"NCT01197170","Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance",[87],"2010-09-07",277,[1924,1942],[10904,1275,2840,2207,3847],"Anastrozole",{"nctId":9955,"briefTitle":9956,"status":102,"phases":10906,"primaryCompletion":8064,"completion":8064,"start":9958,"enrollment":9959,"conditions":10907,"interventions":10908},[87],[1942],[6656,1275,1376,2207,1369],{"nctId":10910,"briefTitle":10911,"status":130,"phases":10912,"primaryCompletion":10913,"completion":10913,"start":10914,"enrollment":10915,"conditions":10916,"interventions":10917},"NCT00543504","Bevacizumab in Multiple Phase I Combinations",[87],"2020-04-29","2007-10-10",343,[1942],[1275,2207,3847,4227,7180,10918,1683],"Sunitinib",{"nctId":10920,"briefTitle":10921,"status":130,"phases":10922,"primaryCompletion":61,"completion":61,"start":10923,"enrollment":4733,"conditions":10924,"interventions":10925},"NCT00761644","Doxil, Bevacizumab and Temsirolimus Trial",[87],"2008-08-21",[1942],[2585,1275,6656],{"nctId":10927,"briefTitle":10928,"status":130,"phases":10929,"primaryCompletion":10930,"completion":10930,"start":10931,"enrollment":5258,"conditions":10932,"interventions":10933},"NCT01113476","Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies",[87],"2022-08-12","2010-04-27",[1942],[4023,1275,2369],{"nctId":10935,"briefTitle":10936,"status":130,"phases":10937,"primaryCompletion":10938,"completion":10938,"start":3833,"enrollment":10939,"conditions":10940,"interventions":10941},"NCT00980239","HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver",[87],"2015-08",115,[1996,1942],[4022,1275,1375,1683],{"nctId":10943,"briefTitle":10944,"status":130,"phases":10945,"primaryCompletion":2243,"completion":2243,"start":4192,"enrollment":1766,"conditions":10946,"interventions":10948},"NCT00543842","Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer",[87],[10947],"Rectal Cancer",[1275,1368,3847],{"trials":10950,"activeCount":910,"soonestReadout":504},[10951,10955,10959,10965,10973,10981,10992,10996,11003,11010,11022,11026,11036,11045,11052,11060,11068,11072,11080,11084,11112,11118,11122,11130,11138,11149,11156,11165,11171,11179,11183,11189],{"nctId":1477,"briefTitle":1478,"status":1479,"phases":10952,"primaryCompletion":537,"completion":1481,"start":1482,"enrollment":1483,"conditions":10953,"interventions":10954},[88],[1485,1486,1050,1275],[1050,1275,1488,1489],{"nctId":10010,"briefTitle":10011,"status":130,"phases":10956,"primaryCompletion":10013,"completion":10013,"start":10014,"enrollment":3354,"conditions":10957,"interventions":10958},[88],[24],[1369,1377,1275,10017],{"nctId":10960,"briefTitle":10961,"status":130,"phases":10962,"primaryCompletion":3493,"completion":3493,"start":5470,"enrollment":1240,"conditions":10963,"interventions":10964},"NCT00496587","Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma",[88],[1521,1333],[1368,2369,1275],{"nctId":10966,"briefTitle":10967,"status":130,"phases":10968,"primaryCompletion":10969,"completion":10969,"start":10970,"enrollment":539,"conditions":10971,"interventions":10972},"NCT02456857","Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative",[88],"2023-05-24","2016-01-12",[5079,1363],[1275,2840,10747],{"nctId":10974,"briefTitle":10975,"status":182,"phases":10976,"primaryCompletion":5267,"completion":5267,"start":10977,"enrollment":121,"conditions":10978,"interventions":10980},"NCT00508872","Folfox-B Study for Patients With Colorectal Liver Metastases",[88],"2005-11",[10979],"Colorectal Liver Metastases",[4218,1275,1113,1375],{"nctId":10982,"briefTitle":10983,"status":102,"phases":10984,"primaryCompletion":860,"completion":224,"start":10985,"enrollment":834,"conditions":10986,"interventions":10991},"NCT04721132","Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer",[88],"2021-02-10",[1758,10987,10988,10989,10990],"Stage I Hepatocellular Carcinoma AJCC v8","Stage IA Hepatocellular Carcinoma AJCC v8","Stage IB Hepatocellular Carcinoma AJCC v8","Stage II Hepatocellular Carcinoma AJCC v8",[718,1275],{"nctId":6780,"briefTitle":6781,"status":279,"phases":10993,"primaryCompletion":238,"completion":238,"start":6783,"enrollment":1131,"conditions":10994,"interventions":10995},[88],[1530],[53,1275,803],{"nctId":10997,"briefTitle":10998,"status":102,"phases":10999,"primaryCompletion":1299,"completion":1299,"start":11000,"enrollment":1328,"conditions":11001,"interventions":11002},"NCT02884648","Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery",[88],"2016-11-15",[5799,1530,9926,9925],[1275],{"nctId":11004,"briefTitle":11005,"status":130,"phases":11006,"primaryCompletion":2242,"completion":2242,"start":5267,"enrollment":1131,"conditions":11007,"interventions":11009},"NCT00924820","A Pilot Study of Bevacizumab for Neoplastic Meningitis",[87,88],[11008],"Neoplastic Meningitis",[1275],{"nctId":11011,"briefTitle":11012,"status":279,"phases":11013,"primaryCompletion":11014,"completion":11015,"start":11016,"enrollment":448,"conditions":11017,"interventions":11020},"NCT06439485","Phase I\u002FII Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion",[87,88],"2028-02-22","2030-02-22","2024-11-19",[11018,11019],"Advanced Cholangiocarcinoma","FGFR2 Fusion",[11021,718,1275],"Pemigatinib",{"nctId":9184,"briefTitle":9185,"status":182,"phases":11023,"primaryCompletion":3668,"completion":3668,"start":6409,"enrollment":3197,"conditions":11024,"interventions":11025},[88],[18,1530],[1275,1070,2293,4537],{"nctId":11027,"briefTitle":11028,"status":102,"phases":11029,"primaryCompletion":504,"completion":504,"start":11030,"enrollment":1409,"conditions":11031,"interventions":11034},"NCT03175432","Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases",[88],"2017-06-15",[11032,1312,11033,1960,1316,1353,6638],"BRAF V600 Wild Type","Intracranial Melanoma",[718,1275,11035],"Cobimetinib",{"nctId":11037,"briefTitle":11038,"status":203,"phases":11039,"primaryCompletion":2365,"start":11040,"enrollment":124,"conditions":11041,"interventions":11043},"NCT01782976","Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)",[88],"2013-06",[11042],"Glioblastoma",[11044,1275],"Cilengitide",{"nctId":11046,"briefTitle":11047,"status":102,"phases":11048,"primaryCompletion":3943,"completion":3943,"start":10324,"enrollment":676,"conditions":11049,"interventions":11051},"NCT03181100","Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer",[88],[8186,1590,11050,8187,8188,1594,8189],"Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8",[718,1275,11035,4023,1376,9970],{"nctId":11053,"briefTitle":11054,"status":279,"phases":11055,"primaryCompletion":115,"completion":115,"start":11056,"enrollment":1100,"conditions":11057,"interventions":11059},"NCT05062317","ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases",[88],"2022-04-26",[11058],"Liver Metastases",[1113,7588,1375,4022,1368,1275],{"nctId":11061,"briefTitle":11062,"status":130,"phases":11063,"primaryCompletion":11064,"completion":11064,"start":11065,"enrollment":195,"conditions":11066,"interventions":11067},"NCT01180959","Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy",[88],"2021-05-19","2011-04-14",[1996],[1275,3847],{"nctId":6971,"briefTitle":6972,"status":130,"phases":11069,"primaryCompletion":6974,"completion":6974,"start":5435,"enrollment":3354,"conditions":11070,"interventions":11071},[88],[712],[1070,803,894,1275],{"nctId":11073,"briefTitle":11074,"status":182,"phases":11075,"primaryCompletion":7155,"completion":7155,"start":5988,"enrollment":296,"conditions":11076,"interventions":11079},"NCT00626561","Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix",[88],[11077,11078],"Cervical Cancer","Uterine Cancer",[1275,1376],{"nctId":10199,"briefTitle":10200,"status":130,"phases":11081,"primaryCompletion":10202,"completion":1300,"start":10203,"enrollment":1922,"conditions":11082,"interventions":11083},[88],[1345,4937,4938,4939,4940,5062,4941,10205,10206,10207,10208,10209,10210,10211,10212,10213,10214,10215,4942,4943,4944,4945,4946,5063,4947,1354,4948],[1275,1369,1376],{"nctId":11085,"briefTitle":11086,"status":102,"phases":11087,"primaryCompletion":238,"completion":238,"start":11088,"enrollment":11089,"conditions":11090,"interventions":11111},"NCT03074513","Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors",[88],"2017-03-03",133,[11091,11092,11093,11094,11095,2049,11096,11097,11098,11099,11100,11101,11102,11103,11104,11105,11106,11107,11108,11109,11110],"Appendix Adenocarcinoma","Human Papillomavirus-Related Anal Squamous Cell Carcinoma","Human Papillomavirus-Related Cervical Squamous Cell Carcinoma","Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis","Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma","Pancreatic Neuroendocrine Tumor","Recurrent Merkel Cell Carcinoma","Recurrent Nasopharynx Carcinoma","Recurrent Peritoneal Malignant Mesothelioma","Recurrent Pleural Malignant Mesothelioma","Stage III Merkel Cell Carcinoma AJCC v7","Stage III Nasopharyngeal Carcinoma AJCC v7","Stage III Pleural Malignant Mesothelioma AJCC v7","Stage IV Merkel Cell Carcinoma AJCC v7","Stage IV Nasopharyngeal Carcinoma AJCC v7","Stage IV Pleural Malignant Mesothelioma AJCC v7","Stage IVA Nasopharyngeal Carcinoma AJCC v7","Stage IVB Nasopharyngeal Carcinoma AJCC v7","Stage IVC Nasopharyngeal Carcinoma AJCC v7","Vaginal Squamous Cell Carcinoma, Not Otherwise Specified",[718,1275],{"nctId":11113,"briefTitle":11114,"status":203,"phases":11115,"primaryCompletion":6628,"completion":6628,"start":8719,"enrollment":124,"conditions":11116,"interventions":11117},"NCT00411593","Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)",[87,88],[24],[1275,75],{"nctId":10244,"briefTitle":10245,"status":182,"phases":11119,"primaryCompletion":4843,"completion":4843,"start":4192,"enrollment":2018,"conditions":11120,"interventions":11121},[88],[1530],[1275,1369,1710,2369,2293],{"nctId":11123,"briefTitle":11124,"status":203,"phases":11125,"primaryCompletion":11126,"completion":11126,"start":2141,"enrollment":124,"conditions":11127,"interventions":11129},"NCT06006286","A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced \u002F Metastatic Hepatocellular Carcinoma",[87,88],"2023-11-10",[11128],"Metastatic Hepatocellular Carcinoma",[718,1275,10026],{"nctId":11131,"briefTitle":11132,"status":130,"phases":11133,"primaryCompletion":11134,"completion":11134,"start":11135,"enrollment":901,"conditions":11136,"interventions":11137},"NCT00113217","Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma",[88],"2012-08","2005-02",[1521,1333],[1275],{"nctId":11139,"briefTitle":11140,"status":182,"phases":11141,"primaryCompletion":11142,"completion":11142,"start":11143,"enrollment":910,"conditions":11144,"interventions":11147},"NCT02923739","Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[88],"2022-09-27","2017-05-05",[11145,4937,4938,4939,4940,5062,4941,10215,11146,4942,4943,4944,4945,4946,5063,4947,4948,1458,1460,1461],"Fallopian Tube Adenocarcinoma","Ovarian Adenocarcinoma",[1275,11148,1376],"Emactuzumab",{"nctId":11150,"briefTitle":11151,"status":102,"phases":11152,"primaryCompletion":10132,"completion":10132,"start":11153,"enrollment":10752,"conditions":11154,"interventions":11155},"NCT01217931","Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial",[88],"2011-01-19",[1333],[1431,1275,2840],{"nctId":11157,"briefTitle":11158,"status":182,"phases":11159,"primaryCompletion":184,"completion":184,"start":8956,"enrollment":3726,"conditions":11160,"interventions":11163},"NCT01582152","Phase I\u002FII Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma",[87,88],[11161,11162],"Brain Neoplasms","Central Nervous System Neoplasms",[11164,1275],"TPI287",{"nctId":11166,"briefTitle":11167,"status":130,"phases":11168,"primaryCompletion":8386,"completion":8386,"start":7473,"enrollment":2446,"conditions":11169,"interventions":11170},"NCT00354978","Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients",[88],[3195],[4218,1275,1113,4022],{"nctId":11172,"briefTitle":11173,"status":130,"phases":11174,"primaryCompletion":8339,"completion":8339,"start":3987,"enrollment":628,"conditions":11175,"interventions":11178},"NCT00883688","Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma",[88],[11176,11177],"Brain Cancer","Pediatric Cancers",[1275,7180],{"nctId":10321,"briefTitle":10322,"status":130,"phases":11180,"primaryCompletion":10324,"completion":10324,"start":10325,"enrollment":357,"conditions":11181,"interventions":11182},[88],[10135],[1275,1369,1710],{"nctId":11184,"briefTitle":11185,"status":130,"phases":11186,"primaryCompletion":3668,"completion":3668,"start":4169,"enrollment":2933,"conditions":11187,"interventions":11188},"NCT00242502","Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery",[88],[1828,1996],[1275,3847],{"nctId":11190,"briefTitle":11191,"status":130,"phases":11192,"primaryCompletion":11193,"completion":11193,"start":11194,"enrollment":406,"conditions":11195,"interventions":11205},"NCT01208103","Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma",[88],"2018-03-07","2011-05-06",[11196,11197,11198,11199,11200,11201,11202,11203,11204,2086],"Ampulla of Vater Adenocarcinoma","Small Intestinal Adenocarcinoma","Stage III Ampulla of Vater Cancer AJCC v8","Stage III Small Intestinal Adenocarcinoma AJCC v8","Stage IIIA Ampulla of Vater Cancer AJCC v8","Stage IIIA Small Intestinal Adenocarcinoma AJCC v8","Stage IIIB Ampulla of Vater Cancer AJCC v8","Stage IIIB Small Intestinal Adenocarcinoma AJCC v8","Stage IV Ampulla of Vater Cancer AJCC v8",[1275,1368,1375],{"trials":11207,"activeCount":124},[],{"trials":11209,"activeCount":124},[11210],{"nctId":11211,"briefTitle":11212,"status":182,"phases":11213,"primaryCompletion":958,"completion":958,"start":11214,"enrollment":121,"conditions":11215,"interventions":11216},"NCT05717400","Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy",[90],"2023-03-17",[1996],[1275,718,11217,11218,11219,7805],"Sofosbuvir","Velpatasvir","Voxilaprevir",{"trials":11221,"activeCount":166,"soonestReadout":3943},[11222,11228],{"nctId":11223,"briefTitle":11224,"status":102,"phases":11225,"primaryCompletion":3943,"completion":3943,"start":7503,"enrollment":517,"conditions":11226,"interventions":11227},"NCT02698254","Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy",[91],[6653],[1275],{"nctId":7492,"briefTitle":7493,"status":203,"phases":11229,"start":3777,"enrollment":124,"conditions":11230,"interventions":11231},[91],[18],[1376,1371,1013,6744,803,1275],{"intervention":809,"totalTrials":473,"cells":11233},{"EARLY_PHASE1":11234,"PHASE1":11236,"PHASE2":11274,"PHASE3":11500,"PHASE4":11514,"NA":11516},{"trials":11235,"activeCount":124},[],{"trials":11237,"activeCount":166,"soonestReadout":772},[11238,11267],{"nctId":11239,"briefTitle":11240,"status":279,"phases":11241,"primaryCompletion":772,"completion":772,"start":11242,"enrollment":11243,"conditions":11244,"interventions":11264},"NCT03819296","Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer",[87],"2021-02-21",800,[11245,11246,11247,11248,11249,11250,11251,11252,1344,1312,11253,1388,11254,360,11255,11256,11257,11258,11259,11260,11261,11262,1348,1349,1350,1351,1352,1353,11263,1837,2052,2053,2054,2055,1389,1390,1391,1355,1357,1358,1359,1319,1361,1362],"Clinical Stage 0 Cutaneous Melanoma AJCC v8","Clinical Stage I Cutaneous Melanoma AJCC v8","Clinical Stage IA Cutaneous Melanoma AJCC v8","Clinical Stage IB Cutaneous Melanoma AJCC v8","Clinical Stage II Cutaneous Melanoma AJCC v8","Clinical Stage IIA Cutaneous Melanoma AJCC v8","Clinical Stage IIB Cutaneous Melanoma AJCC v8","Clinical Stage IIC Cutaneous Melanoma AJCC v8","Colitis","Malignant Genitourinary System Neoplasm","Pathologic Stage 0 Cutaneous Melanoma AJCC v8","Pathologic Stage I Cutaneous Melanoma AJCC v8","Pathologic Stage IA Cutaneous Melanoma AJCC v8","Pathologic Stage IB Cutaneous Melanoma AJCC v8","Pathologic Stage II Cutaneous Melanoma AJCC v8","Pathologic Stage IIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIC Cutaneous Melanoma AJCC v8","Stage 0 Lung Cancer AJCC v8",[11265,809,11266],"Infliximab","Vedolizumab",{"nctId":11268,"briefTitle":11269,"status":130,"phases":11270,"primaryCompletion":6974,"completion":6974,"start":8340,"enrollment":11271,"conditions":11272,"interventions":11273},"NCT01054313","Docetaxel and Sirolimus in Patients With Advanced Malignancies",[87],103,[1942],[1710,6516,809],{"trials":11275,"activeCount":834,"soonestReadout":5103},[11276,11280,11284,11288,11292,11296,11307,11311,11315,11319,11323,11327,11331,11345,11349,11353,11361,11365,11369,11377,11386,11390,11394,11398,11402,11411,11415,11422,11432,11436,11440,11444,11448,11458,11465,11469,11473,11477,11481,11485,11489,11493],{"nctId":5100,"briefTitle":5101,"status":279,"phases":11277,"primaryCompletion":5103,"completion":5103,"start":5104,"enrollment":4733,"conditions":11278,"interventions":11279},[88],[5106,5107,5108,5109,5110,5111,3547],[3699,5113,3700,5114,809],{"nctId":2464,"briefTitle":2465,"status":279,"phases":11281,"primaryCompletion":2467,"completion":2467,"start":2468,"enrollment":2469,"conditions":11282,"interventions":11283},[87,88],[2471,2472,2473,2474,2475,1142,2415,1144,2419],[1083,803,654,62,2477,805,806,809,894,1016],{"nctId":2497,"briefTitle":2498,"status":279,"phases":11285,"primaryCompletion":2104,"completion":2104,"start":2500,"enrollment":1975,"conditions":11286,"interventions":11287},[88],[2502,2503],[1083,803,654,62,804,2477,805,806,2425,809,894,810],{"nctId":2506,"briefTitle":2507,"status":182,"phases":11289,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":296,"conditions":11290,"interventions":11291},[88],[2512,2502,2472],[803,654,62,804,2477,1373,805,806,2425,809,894,810],{"nctId":5571,"briefTitle":5572,"status":130,"phases":11293,"primaryCompletion":5574,"completion":5574,"start":5575,"enrollment":1034,"conditions":11294,"interventions":11295},[88],[5577],[803,804,2424,767,1402,809,894,810],{"nctId":11297,"briefTitle":11298,"status":130,"phases":11299,"primaryCompletion":9512,"completion":10760,"start":11300,"enrollment":296,"conditions":11301,"interventions":11303},"NCT00002463","Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors",[88],"1989-02",[11302],"Brain and Central Nervous System Tumors",[11304,1373,11305,806,809,11306,810],"MOPP Regimen","Mechlorethamine Hydrochloride","Procarbazine Hydrochloride",{"nctId":5580,"briefTitle":5581,"status":130,"phases":11308,"primaryCompletion":5583,"completion":5583,"start":5584,"enrollment":2779,"conditions":11309,"interventions":11310},[88],[5586,5587,3056,5588,913,2415,914,2419],[803,804,2424,2425,809,894,810],{"nctId":2546,"briefTitle":2547,"status":130,"phases":11312,"primaryCompletion":2549,"completion":2549,"start":2550,"enrollment":37,"conditions":11313,"interventions":11314},[88],[21],[894,803,1013,1016,62,806,654,809],{"nctId":2554,"briefTitle":2555,"status":130,"phases":11316,"primaryCompletion":2557,"completion":2557,"start":2558,"enrollment":2559,"conditions":11317,"interventions":11318},[88],[1122,2561,644,912,913,915],[803,654,1028,62,1013,806,809,1016],{"nctId":794,"briefTitle":795,"status":279,"phases":11320,"primaryCompletion":772,"completion":772,"start":797,"enrollment":798,"conditions":11321,"interventions":11322},[88],[800,801],[803,654,62,804,805,806,807,808,809,480,810],{"nctId":5116,"briefTitle":5117,"status":102,"phases":11324,"primaryCompletion":5119,"completion":5119,"start":5120,"enrollment":1034,"conditions":11325,"interventions":11326},[88],[3545,5122,5123,3546,3547,3548],[3699,3700,809],{"nctId":2587,"briefTitle":2588,"status":182,"phases":11328,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":95,"conditions":11329,"interventions":11330},[88],[1142,2593,1144,2594],[803,654,1028,62,1013,1113,805,806,809,894,2596,1016],{"nctId":11332,"briefTitle":11333,"status":102,"phases":11334,"primaryCompletion":11335,"completion":11335,"start":11336,"enrollment":11337,"conditions":11338,"interventions":11340},"NCT01786265","Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer",[88],"2027-02-01","2013-02-05",310,[5122,11339],"Recurrent Prostate Carcinoma",[3699,11341,3720,11342,11343,3780,11344,809],"Bicalutamide","Flutamide","Goserelin Acetate","Nilutamide",{"nctId":6964,"briefTitle":6965,"status":130,"phases":11346,"primaryCompletion":3832,"completion":3832,"start":4731,"enrollment":2779,"conditions":11347,"interventions":11348},[87,88],[21],[6969,803,1013,1016,809],{"nctId":3689,"briefTitle":3690,"status":102,"phases":11350,"primaryCompletion":3407,"completion":3407,"start":3692,"enrollment":3693,"conditions":11351,"interventions":11352},[88],[3695,3544,3545,3696,3697],[3699,3700,3701,1369,1049,809],{"nctId":11354,"briefTitle":11355,"status":130,"phases":11356,"primaryCompletion":11357,"completion":11357,"start":11358,"enrollment":517,"conditions":11359,"interventions":11360},"NCT00352794","Lenalidomide for Patients With Myelofibrosis (MF)",[88],"2018-03-08","2006-07-07",[3429],[1402,809],{"nctId":7014,"briefTitle":7015,"status":182,"phases":11362,"primaryCompletion":1984,"completion":1984,"start":7017,"enrollment":166,"conditions":11363,"interventions":11364},[88],[15,7019,2653,21],[654,7021,1016,809,7022,2425,894,806,803,805,1013,4514,7023],{"nctId":7062,"briefTitle":7063,"status":279,"phases":11366,"primaryCompletion":1735,"completion":7065,"start":2106,"enrollment":517,"conditions":11367,"interventions":11368},[88],[6956],[809,894,803,1016,7068],{"nctId":11370,"briefTitle":11371,"status":130,"phases":11372,"primaryCompletion":5267,"completion":5267,"start":10346,"enrollment":1568,"conditions":11373,"interventions":11374},"NCT00520468","Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS",[88],[30],[11375,11376,2374,809],"Erythropoietin","Cyclosporin A",{"nctId":11378,"briefTitle":11379,"status":130,"phases":11380,"primaryCompletion":11381,"completion":11381,"start":11382,"enrollment":34,"conditions":11383,"interventions":11384},"NCT01946165","Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide",[88],"2017-07-28","2013-10-31",[27],[3699,809,7589,11385],"LHRHa",{"nctId":3341,"briefTitle":3342,"status":279,"phases":11387,"primaryCompletion":549,"completion":1088,"start":3344,"enrollment":1131,"conditions":11388,"interventions":11389},[88],[3346],[3348,803,2462,809,2269,2395],{"nctId":7084,"briefTitle":7085,"status":182,"phases":11391,"primaryCompletion":2806,"completion":2806,"start":3901,"enrollment":166,"conditions":11392,"interventions":11393},[87,88],[21],[803,1013,1016,809],{"nctId":4166,"briefTitle":4167,"status":130,"phases":11395,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":11396,"interventions":11397},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"nctId":1007,"briefTitle":1008,"status":279,"phases":11399,"primaryCompletion":446,"completion":446,"start":1010,"enrollment":517,"conditions":11400,"interventions":11401},[88],[847],[803,654,62,1013,805,806,1014,809,894,1015,480,1016],{"nctId":11403,"briefTitle":11404,"status":130,"phases":11405,"primaryCompletion":11406,"completion":11406,"start":11407,"enrollment":11408,"conditions":11409,"interventions":11410},"NCT01254864","Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies",[88],"2023-12-07","2011-03-16",190,[27],[3699,809,10918,1028],{"nctId":7130,"briefTitle":7131,"status":279,"phases":11412,"primaryCompletion":7133,"completion":7134,"start":1282,"enrollment":406,"conditions":11413,"interventions":11414},[88],[7136],[7138,803,1013,1016,809],{"nctId":11416,"briefTitle":11417,"status":130,"phases":11418,"primaryCompletion":8323,"completion":8323,"start":11419,"enrollment":2004,"conditions":11420,"interventions":11421},"NCT01375140","Ruxolitinib and Lenalidomide for Patients With Myelofibrosis",[88],"2011-09-22",[4580],[598,1402,809],{"nctId":11423,"briefTitle":11424,"status":130,"phases":11425,"primaryCompletion":11426,"completion":11426,"start":11427,"enrollment":3082,"conditions":11428,"interventions":11430},"NCT00946270","Pomalidomide for Myelofibrosis Patients",[88],"2018-05-22","2009-07-22",[745,11429],"Thrombocythemia",[11431,809,11431],"CC-4047",{"nctId":2726,"briefTitle":2727,"status":102,"phases":11433,"primaryCompletion":999,"completion":999,"start":2729,"enrollment":2730,"conditions":11434,"interventions":11435},[88],[1205,1122,2649,2471,644,912,2732],[803,654,62,1013,804,806,1124,917,809,894,1016,810],{"nctId":1999,"briefTitle":2000,"status":279,"phases":11437,"primaryCompletion":2002,"completion":2002,"start":2003,"enrollment":2004,"conditions":11438,"interventions":11439},[88],[2006,2007,2008,2009],[2011,803,1013,1050,809,894],{"nctId":1105,"briefTitle":1106,"status":182,"phases":11441,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":539,"conditions":11442,"interventions":11443},[87,88],[359,913,608,850,609,914,610,853,632],[1112,510,803,654,62,1069,1113,1114,806,809,894,480,1016],{"nctId":7213,"briefTitle":7214,"status":102,"phases":11445,"primaryCompletion":7216,"completion":7216,"start":7217,"enrollment":2933,"conditions":11446,"interventions":11447},[88],[7219],[668,803,804,1402,809,894,3338,1016],{"nctId":11449,"briefTitle":11450,"status":102,"phases":11451,"primaryCompletion":3943,"completion":3943,"start":11452,"enrollment":1328,"conditions":11453,"interventions":11457},"NCT04151082","High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors",[87,88],"2019-10-16",[11454,11455,11456],"Cranial Nerve Disorder","Head and Neck Carcinoma","Oropharyngeal Carcinoma",[1014,809],{"nctId":11459,"briefTitle":11460,"status":182,"phases":11461,"primaryCompletion":5829,"completion":5829,"start":640,"enrollment":296,"conditions":11462,"interventions":11463},"NCT01994590","Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)",[88],[27],[11464,3699,809],"Dovitinib",{"nctId":2813,"briefTitle":2814,"status":279,"phases":11466,"primaryCompletion":224,"completion":548,"start":2816,"enrollment":2159,"conditions":11467,"interventions":11468},[88],[15],[803,1016,1083,806,654,805,809,1071,2819,894,62],{"nctId":7266,"briefTitle":7267,"status":130,"phases":11470,"primaryCompletion":2602,"completion":2602,"start":2213,"enrollment":1975,"conditions":11471,"interventions":11472},[88],[21],[1069,1071,894,803,7271,809,810],{"nctId":1135,"briefTitle":1136,"status":182,"phases":11474,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":1140,"conditions":11475,"interventions":11476},[87,88],[1142,1143,1144,1145],[803,654,62,806,807,808,809,894,480,1016],{"nctId":5149,"briefTitle":5150,"status":182,"phases":11478,"primaryCompletion":5152,"completion":5152,"start":5153,"enrollment":1483,"conditions":11479,"interventions":11480},[88],[3544,5155,3546,3547,3548],[3699,3700,809],{"nctId":2852,"briefTitle":2853,"status":182,"phases":11482,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":296,"conditions":11483,"interventions":11484},[87,88],[2413,1142,1143,1144,2421,1145],[803,654,62,2712,1113,805,1114,806,1071,809,894,1015,1016],{"nctId":5158,"briefTitle":5159,"status":130,"phases":11486,"primaryCompletion":5161,"completion":5161,"start":4595,"enrollment":5162,"conditions":11487,"interventions":11488},[88],[5122,5146,5107,5109,5111],[3699,3700,5165,809],{"nctId":7372,"briefTitle":7373,"status":130,"phases":11490,"primaryCompletion":7375,"completion":7375,"start":7376,"enrollment":7377,"conditions":11491,"interventions":11492},[87,88],[21],[1402,669,803,1013,1016,809],{"nctId":11494,"briefTitle":11495,"status":203,"phases":11496,"enrollment":124,"conditions":11497,"interventions":11498},"NCT00811031","Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)",[88],[27],[11499,809],"Taxotere",{"trials":11501,"activeCount":124},[11502,11506,11510],{"nctId":4305,"briefTitle":4306,"status":130,"phases":11503,"primaryCompletion":4308,"completion":4308,"start":4309,"enrollment":2402,"conditions":11504,"interventions":11505},[89],[21],[4312,4313,4045,2879,2880,2882,4314,4315,4047,4316,4317,4318,4319,2884],{"nctId":4321,"briefTitle":4322,"status":130,"phases":11507,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":11508,"interventions":11509},[89],[21],[1070,4329,4330,894,3671,1013,1016,4331,803,2424,1709,2584,4332,4333,809],{"nctId":2950,"briefTitle":2951,"status":182,"phases":11511,"primaryCompletion":2602,"start":2953,"enrollment":2954,"conditions":11512,"interventions":11513},[89],[27],[1710,2957,2958,2959,809,1868,62],{"trials":11515,"activeCount":124},[],{"trials":11517,"activeCount":124},[11518],{"nctId":7477,"briefTitle":7478,"status":130,"phases":11519,"primaryCompletion":2212,"completion":2212,"start":6828,"enrollment":3820,"conditions":11520,"interventions":11521},[91],[21],[7482,803,1013,1016,809,894,2793],{"intervention":718,"totalTrials":628,"cells":11523},{"EARLY_PHASE1":11524,"PHASE1":11526,"PHASE2":11561,"PHASE3":11697,"PHASE4":11699,"NA":11705},{"trials":11525,"activeCount":124},[],{"trials":11527,"activeCount":121,"soonestReadout":549},[11528,11546,11557],{"nctId":11529,"briefTitle":11530,"status":279,"phases":11531,"primaryCompletion":549,"completion":549,"start":11532,"enrollment":357,"conditions":11533,"interventions":11544},"NCT05092373","Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax",[87],"2022-04-29",[11534,10698,11535,11536,11537,11538,11539,5059,11540,1772,7308,7309,7310,7311,7312,11541,360,5234,1442,1443,11128,11542,1444,11543,1445,1446,1346,7313,7314,7315,7316,7317,4913,1570,4914,4915,1356,10707,4916,1571,4917,4918,10708,4919,4920,4921,4922,4923,1572,4924,4925,10709,4926,4927,4928,10710,10711,10712,1462,1573,1463,1464,1360,10713,1465,1574,1466,1467,10714,1469,1575,1470,1471,1472],"Advanced Breast Carcinoma","Advanced Fallopian Tube Carcinoma","Advanced Hepatocellular Carcinoma","Advanced Malignant Abdominal Neoplasm","Advanced Malignant Female Reproductive System Neoplasm","Advanced Malignant Thoracic Neoplasm","Advanced Primary Peritoneal Carcinoma","Malignant Abdominal Neoplasm","Metastatic Malignant Abdominal Neoplasm","Metastatic Malignant Thoracic Neoplasm",[718,11545,4023],"Cabozantinib S-malate",{"nctId":11547,"briefTitle":11548,"status":102,"phases":11549,"primaryCompletion":11550,"completion":11551,"start":11552,"enrollment":1483,"conditions":11553,"interventions":11555},"NCT06760481","Phase I\u002FIb Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)",[87],"2028-09-15","2030-09-15","2025-04-13",[11554],"Advanced Solid Malignancies",[11556,718],"Tiragolumab",{"nctId":10883,"briefTitle":10884,"status":203,"phases":11558,"primaryCompletion":10886,"completion":10886,"start":10886,"enrollment":124,"conditions":11559,"interventions":11560},[87],[3947,1996],[10889,718,1275],{"trials":11562,"activeCount":2779,"soonestReadout":504},[11563,11571,11582,11586,11596,11600,11606,11610,11614,11618,11626,11630,11634,11643,11647,11655,11666,11673,11681,11690],{"nctId":11564,"briefTitle":11565,"status":102,"phases":11566,"primaryCompletion":224,"completion":224,"start":2549,"enrollment":1609,"conditions":11567,"interventions":11570},"NCT03202316","Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer",[88],[11568,11569],"Recurrent Breast Inflammatory Carcinoma","Stage IV Breast Inflammatory Carcinoma",[718,11035,1370],{"nctId":11572,"briefTitle":11573,"status":130,"phases":11574,"primaryCompletion":6396,"completion":6396,"start":3714,"enrollment":2446,"conditions":11575,"interventions":11581},"NCT03108131","Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors",[88],[11576,11091,11577,5832,11578,2924,7946,2085,11579,2926,2086,11580],"Skin Squamous Cell Carcinoma","Rare Lesion","Locally Advanced Skin Squamous Cell Carcinoma","Rare Neoplastic Syndrome","Unresectable Malignant Neoplasm",[718,11035],{"nctId":10982,"briefTitle":10983,"status":102,"phases":11583,"primaryCompletion":860,"completion":224,"start":10985,"enrollment":834,"conditions":11584,"interventions":11585},[88],[1758,10987,10988,10989,10990],[718,1275],{"nctId":11587,"briefTitle":11588,"status":279,"phases":11589,"primaryCompletion":224,"completion":224,"start":11590,"enrollment":517,"conditions":11591,"interventions":11595},"NCT05019703","Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study",[88],"2023-04-25",[11592,11593,1591,1592,11594],"Locally Advanced Osteosarcoma","Metastatic Osteosarcoma","Unresectable Osteosarcoma",[718,1421],{"nctId":707,"briefTitle":708,"status":102,"phases":11597,"primaryCompletion":115,"completion":115,"start":710,"enrollment":676,"conditions":11598,"interventions":11599},[88],[712,713,714,715,716],[718,669,480],{"nctId":11601,"briefTitle":11602,"status":279,"phases":11603,"primaryCompletion":224,"completion":224,"start":1033,"enrollment":230,"conditions":11604,"interventions":11605},"NCT05039281","Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma",[87,88],[7740,7998],[718,1421],{"nctId":11011,"briefTitle":11012,"status":279,"phases":11607,"primaryCompletion":11014,"completion":11015,"start":11016,"enrollment":448,"conditions":11608,"interventions":11609},[87,88],[11018,11019],[11021,718,1275],{"nctId":1762,"briefTitle":1763,"status":182,"phases":11611,"primaryCompletion":1717,"completion":1717,"start":1765,"enrollment":1766,"conditions":11612,"interventions":11613},[87,88],[1768,1769,1343,1770,1771,1772,1344,1773,1312,1774,1348,1775,1349,1776,1350,1777,1351,1352,1353,1778,1779,1355,1356,1780,1357,1781,1358,1359,1782,1319,1360,1783,1361,1784,1362],[718,693,1786,1050,53,1787],{"nctId":11027,"briefTitle":11028,"status":102,"phases":11615,"primaryCompletion":504,"completion":504,"start":11030,"enrollment":1409,"conditions":11616,"interventions":11617},[88],[11032,1312,11033,1960,1316,1353,6638],[718,1275,11035],{"nctId":11619,"briefTitle":11620,"status":102,"phases":11621,"primaryCompletion":2104,"completion":2104,"start":11622,"enrollment":1409,"conditions":11623,"interventions":11625},"NCT05681039","Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).",[88],"2023-06-02",[4031,11624],"Oral Cavity Squamous Cell Carcinoma",[11556,718],{"nctId":11046,"briefTitle":11047,"status":102,"phases":11627,"primaryCompletion":3943,"completion":3943,"start":10324,"enrollment":676,"conditions":11628,"interventions":11629},[88],[8186,1590,11050,8187,8188,1594,8189],[718,1275,11035,4023,1376,9970],{"nctId":11085,"briefTitle":11086,"status":102,"phases":11631,"primaryCompletion":238,"completion":238,"start":11088,"enrollment":11089,"conditions":11632,"interventions":11633},[88],[11091,11092,11093,11094,11095,2049,11096,11097,11098,11099,11100,11101,11102,11103,11104,11105,11106,11107,11108,11109,11110],[718,1275],{"nctId":11635,"briefTitle":11636,"status":130,"phases":11637,"primaryCompletion":11638,"completion":11638,"start":11639,"enrollment":1609,"conditions":11640,"interventions":11642},"NCT02530489","Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer",[88],"2025-05-23","2016-02-04",[11641,5079,1363],"Breast Adenocarcinoma",[718,4023],{"nctId":11123,"briefTitle":11124,"status":203,"phases":11644,"primaryCompletion":11126,"completion":11126,"start":2141,"enrollment":124,"conditions":11645,"interventions":11646},[87,88],[11128],[718,1275,10026],{"nctId":11648,"briefTitle":11649,"status":279,"phases":11650,"primaryCompletion":604,"completion":11651,"start":11652,"enrollment":676,"conditions":11653,"interventions":11654},"NCT07049848","SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma",[88],"2030-01-01","2025-09-11",[1593],[718,804],{"nctId":11656,"briefTitle":11657,"status":102,"phases":11658,"primaryCompletion":446,"completion":446,"start":11659,"enrollment":357,"conditions":11660,"interventions":11665},"NCT03784326","Phase I\u002FII Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma",[88],"2019-02-19",[9902,11661,9903,11662,9904,1634,7515,1635,11663,1647,11664,1648,9905,1649,9906,1651,9907,1653,7523,7546,7525,7547,7526,1655],"Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8",[718,1371,1375,11556],{"nctId":11667,"briefTitle":11668,"status":102,"phases":11669,"primaryCompletion":536,"completion":11670,"start":8565,"enrollment":296,"conditions":11671,"interventions":11672},"NCT06754501","A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary",[88],"2029-07-01",[5349],[718,11556],{"nctId":11674,"briefTitle":11675,"status":203,"phases":11676,"primaryCompletion":11677,"completion":11677,"start":1727,"enrollment":124,"conditions":11678,"interventions":11679},"NCT06762808","Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC",[88],"2025-08-08",[4031],[718,11680],"Talazoparib",{"nctId":11682,"briefTitle":11683,"status":130,"phases":11684,"primaryCompletion":11685,"completion":11685,"start":11686,"enrollment":1034,"conditions":11687,"interventions":11689},"NCT03174197","Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma",[87,88],"2025-09-17","2017-06-30",[11042,11688],"Gliosarcoma",[718,3497],{"nctId":11691,"briefTitle":11692,"status":279,"phases":11693,"primaryCompletion":281,"completion":281,"start":1736,"enrollment":1496,"conditions":11694,"interventions":11696},"NCT05394337","Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma",[87,88],[11695],"Metastatic Malignancy",[718,11556],{"trials":11698,"activeCount":124},[],{"trials":11700,"activeCount":124},[11701],{"nctId":11211,"briefTitle":11212,"status":182,"phases":11702,"primaryCompletion":958,"completion":958,"start":11214,"enrollment":121,"conditions":11703,"interventions":11704},[90],[1996],[1275,718,11217,11218,11219,7805],{"trials":11706,"activeCount":124},[],{"intervention":1376,"totalTrials":3541,"cells":11708},{"EARLY_PHASE1":11709,"PHASE1":11711,"PHASE2":11831,"PHASE3":12035,"PHASE4":12041,"NA":12043},{"trials":11710,"activeCount":124},[],{"trials":11712,"activeCount":230,"soonestReadout":8064},[11713,11717,11721,11727,11735,11744,11748,11752,11756,11760,11764,11770,11774,11778,11782,11786,11794,11804,11808,11812,11823],{"nctId":10686,"briefTitle":10687,"status":279,"phases":11714,"primaryCompletion":446,"completion":446,"start":10689,"enrollment":1240,"conditions":11715,"interventions":11716},[87],[1530],[1376,1275,10692],{"nctId":10694,"briefTitle":10695,"status":279,"phases":11718,"primaryCompletion":4028,"completion":505,"start":7816,"enrollment":2700,"conditions":11719,"interventions":11720},[87],[10698,10699,1343,1770,10700,10701,1344,1312,1348,1349,1350,1351,1352,1353,10702,10703,10704,6638,10705,10706,4914,10707,4917,10708,4920,4922,4924,10709,4927,10710,10711,10712,1463,10713,1466,10714,1470,1472],[1275,10716,1376,10717],{"nctId":11722,"briefTitle":11723,"status":130,"phases":11724,"primaryCompletion":2768,"completion":2768,"start":4169,"enrollment":2159,"conditions":11725,"interventions":11726},"NCT00508326","Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement",[87],[1942],[1376],{"nctId":11728,"briefTitle":11729,"status":130,"phases":11730,"primaryCompletion":11731,"completion":4511,"start":2890,"enrollment":11732,"conditions":11733,"interventions":11734},"NCT00050167","Evaluation of Differing Taxanes\u002FTaxane Combinations on the Outcome of Patients With Operable Breast Cancer",[87],"2008-07",603,[18],[1376,1710,1368],{"nctId":11736,"briefTitle":11737,"status":130,"phases":11738,"primaryCompletion":1736,"completion":1736,"start":11739,"enrollment":901,"conditions":11740,"interventions":11742},"NCT03756818","TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors",[87],"2019-03-05",[1343,1347,3457,11741],"Refractory Ovarian Carcinoma",[11743,1376],"Mivavotinib",{"nctId":9866,"briefTitle":9867,"status":130,"phases":11745,"primaryCompletion":8305,"completion":8305,"start":4039,"enrollment":3820,"conditions":11746,"interventions":11747},[87],[24],[9871,1376,1369,1275],{"nctId":9873,"briefTitle":9874,"status":130,"phases":11749,"primaryCompletion":9876,"completion":9876,"start":9877,"enrollment":1328,"conditions":11750,"interventions":11751},[87],[2570,3457],[1369,1376,1839],{"nctId":9896,"briefTitle":9897,"status":279,"phases":11753,"primaryCompletion":999,"completion":999,"start":9899,"enrollment":628,"conditions":11754,"interventions":11755},[87],[9901,9902,9903,9904,7515,4097,9905,9906,9907,7523,7525,7526,9908],[1368,1369,1710,1371,1113,1375,1376],{"nctId":2261,"briefTitle":2262,"status":130,"phases":11757,"primaryCompletion":2264,"completion":2264,"start":2265,"enrollment":1409,"conditions":11758,"interventions":11759},[87],[2267],[62,2269,2270,2271,1709,1376],{"nctId":10848,"briefTitle":10849,"status":130,"phases":11761,"primaryCompletion":2518,"completion":2518,"start":2836,"enrollment":9738,"conditions":11762,"interventions":11763},[87],[1942],[1028,1275,1376],{"nctId":11765,"briefTitle":11766,"status":182,"phases":11767,"primaryCompletion":2232,"completion":2232,"start":6410,"enrollment":539,"conditions":11768,"interventions":11769},"NCT00933426","Lenalidomide and Paclitaxel in Prostate Cancer",[87],[27],[1402,1376],{"nctId":10891,"briefTitle":10892,"status":130,"phases":11771,"primaryCompletion":3832,"completion":3832,"start":4183,"enrollment":1231,"conditions":11772,"interventions":11773},[87],[5787],[1275,1375,1376],{"nctId":1337,"briefTitle":1338,"status":182,"phases":11775,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":11776,"interventions":11777},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"nctId":9955,"briefTitle":9956,"status":102,"phases":11779,"primaryCompletion":8064,"completion":8064,"start":9958,"enrollment":9959,"conditions":11780,"interventions":11781},[87],[1942],[6656,1275,1376,2207,1369],{"nctId":9963,"briefTitle":9964,"status":130,"phases":11783,"primaryCompletion":9966,"completion":9966,"start":9967,"enrollment":871,"conditions":11784,"interventions":11785},[87],[33],[9970,1369,1376],{"nctId":11787,"briefTitle":11788,"status":102,"phases":11789,"primaryCompletion":11790,"completion":11790,"start":11791,"enrollment":2159,"conditions":11792,"interventions":11793},"NCT04220827","Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer",[87],"2028-10-30","2019-12-06",[7518,7543,1636,1637,7521,7544,7545,7522,7530,7548,1656,7549,1447,7534,7553,7554,7555],[1376],{"nctId":11795,"briefTitle":11796,"status":130,"phases":11797,"primaryCompletion":1844,"completion":1844,"start":11798,"enrollment":3521,"conditions":11799,"interventions":11802},"NCT03725436","ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors",[87],"2019-01-24",[1343,7308,7309,7310,7311,11800,7699,361,7313,7314,7315,7316,10825,11801,7891],"Estrogen Receptor Positive","TP53 wt Allele",[11803,1376],"MDM2\u002FMDMX Inhibitor ALRN-6924",{"nctId":3876,"briefTitle":3877,"status":279,"phases":11805,"primaryCompletion":3879,"completion":3880,"start":3881,"enrollment":871,"conditions":11806,"interventions":11807},[87],[2809],[1376,1369,3884,1709],{"nctId":9976,"briefTitle":9977,"status":130,"phases":11809,"primaryCompletion":9487,"completion":9487,"start":9979,"enrollment":1231,"conditions":11810,"interventions":11811},[87],[4097,9981,9982,9983,9984,9985,9986,9987],[1369,9989,1376],{"nctId":11813,"briefTitle":11814,"status":203,"phases":11815,"primaryCompletion":11816,"completion":11816,"start":11817,"enrollment":124,"conditions":11818,"interventions":11820},"NCT05799612","Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma",[87],"2024-11-05","2024-03-22",[11819],"Angiosarcoma",[1376,11821,11822,1069],"mRNA plus Lysate-loaded Dendritic Cell Vaccine","PEGYLATED-INTERFERON ALPHA-2A",{"nctId":11824,"briefTitle":11825,"status":182,"phases":11826,"primaryCompletion":8956,"completion":8956,"start":11827,"enrollment":550,"conditions":11828,"interventions":11829},"NCT00102622","Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer",[87],"2004-12-01",[1530],[11830,1376],"Intraperitoneal tgDCC-E1A",{"trials":11832,"activeCount":1496,"soonestReadout":5310},[11833,11837,11841,11845,11853,11857,11861,11865,11869,11878,11882,11886,11890,11894,11898,11902,11906,11910,11914,11918,11922,11926,11930,11934,11938,11942,11949,11953,11957,11965,11969,11973,11977,11981,11985,11989,11993,11997,12001,12009,12013,12031],{"nctId":9993,"briefTitle":9994,"status":182,"phases":11834,"primaryCompletion":9560,"completion":9560,"start":6758,"enrollment":3197,"conditions":11835,"interventions":11836},[88],[24],[9998,1376,1369],{"nctId":10000,"briefTitle":10001,"status":102,"phases":11838,"primaryCompletion":999,"completion":999,"start":10003,"enrollment":924,"conditions":11839,"interventions":11840},[88],[10005,10006,7696,7697,7698,7699,10007,5079,7700,7701,1363],[1369,1376,6802],{"nctId":6737,"briefTitle":6738,"status":130,"phases":11842,"primaryCompletion":6740,"completion":6740,"start":6741,"enrollment":2700,"conditions":11843,"interventions":11844},[88],[18],[1376,1370,4218,6744,803,1013],{"nctId":11846,"briefTitle":11847,"status":130,"phases":11848,"primaryCompletion":11849,"completion":11849,"start":11850,"enrollment":628,"conditions":11851,"interventions":11852},"NCT02689427","Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer",[88],"2023-11-15","2016-09-22",[5079,5080,5081,5082,5083,5084,5085,5086,5087,5088,5089,1363],[7589,1376],{"nctId":6787,"briefTitle":6788,"status":130,"phases":11854,"primaryCompletion":6790,"completion":6790,"start":6791,"enrollment":871,"conditions":11855,"interventions":11856},[87,88],[18],[1069,803,804,1376],{"nctId":6804,"briefTitle":6805,"status":3049,"phases":11858,"primaryCompletion":2326,"completion":6807,"start":5470,"enrollment":2933,"conditions":11859,"interventions":11860},[88],[18],[1376,4218,6744,803,2330],{"nctId":10032,"briefTitle":10033,"status":102,"phases":11862,"primaryCompletion":446,"completion":446,"start":10035,"enrollment":473,"conditions":11863,"interventions":11864},[88],[7749,4056,4057,4058,4059,7750,4060,4061,4062,4063],[1369,1376,2207],{"nctId":10043,"briefTitle":10044,"status":102,"phases":11866,"primaryCompletion":224,"completion":224,"start":10046,"enrollment":550,"conditions":11867,"interventions":11868},[87,88],[4957,4958,4959,4960,4961,4962,4963,4964,4965,4966,4967,4968,4969,4970,4971],[1369,1786,1376],{"nctId":11870,"briefTitle":11871,"status":130,"phases":11872,"primaryCompletion":11873,"completion":11873,"start":11874,"enrollment":448,"conditions":11875,"interventions":11876},"NCT00038545","A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD\u002F01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma",[88],"2004-04-27","2001-05-18",[8942],[11877,1376,1379],"Filgrastim SD\u002F01",{"nctId":10054,"briefTitle":10055,"status":130,"phases":11879,"primaryCompletion":10057,"completion":10057,"start":10058,"enrollment":357,"conditions":11880,"interventions":11881},[88],[5080,5081,5082,5083,5084,5085,5086,5087,5088,5089,1363],[1369,1376,6802],{"nctId":3993,"briefTitle":3994,"status":130,"phases":11883,"primaryCompletion":3996,"completion":3996,"start":3997,"enrollment":406,"conditions":11884,"interventions":11885},[88],[3999],[2495,1376,1709],{"nctId":10066,"briefTitle":10067,"status":130,"phases":11887,"primaryCompletion":2212,"completion":2212,"start":4351,"enrollment":473,"conditions":11888,"interventions":11889},[88],[242],[1683,1369,1376],{"nctId":10083,"briefTitle":10084,"status":130,"phases":11891,"primaryCompletion":10086,"completion":10086,"start":10087,"enrollment":676,"conditions":11892,"interventions":11893},[88],[10089,10090,10091,10092,10093,10094,10095,10096,10097],[1369,7589,1376],{"nctId":10100,"briefTitle":10101,"status":279,"phases":11895,"primaryCompletion":5310,"completion":5310,"start":10103,"enrollment":240,"conditions":11896,"interventions":11897},[88],[1355,10105,1357,1707,1358,3845,1359],[1369,1786,2369,4023,1376,1377],{"nctId":7869,"briefTitle":7870,"status":130,"phases":11899,"primaryCompletion":7872,"completion":7872,"start":7873,"enrollment":2004,"conditions":11900,"interventions":11901},[88],[4957,4958,4959,4960,4961,4962,4963,4964,4965,4966,4967,4968,4969,4970,4971],[1369,1376,53],{"nctId":10112,"briefTitle":10113,"status":130,"phases":11903,"primaryCompletion":10115,"completion":10115,"start":5267,"enrollment":10116,"conditions":11904,"interventions":11905},[88],[10118],[1376,1369],{"nctId":10121,"briefTitle":10122,"status":130,"phases":11907,"primaryCompletion":4382,"completion":4382,"start":10124,"enrollment":3820,"conditions":11908,"interventions":11909},[88],[10126],[1369,1376],{"nctId":10129,"briefTitle":10130,"status":102,"phases":11911,"primaryCompletion":10132,"completion":10132,"start":10133,"enrollment":901,"conditions":11912,"interventions":11913},[88],[24,10135],[10137,1369,1376],{"nctId":11046,"briefTitle":11047,"status":102,"phases":11915,"primaryCompletion":3943,"completion":3943,"start":10324,"enrollment":676,"conditions":11916,"interventions":11917},[88],[8186,1590,11050,8187,8188,1594,8189],[718,1275,11035,4023,1376,9970],{"nctId":2625,"briefTitle":2626,"status":279,"phases":11919,"primaryCompletion":2628,"completion":674,"start":2629,"enrollment":406,"conditions":11920,"interventions":11921},[88],[1638,2631],[1376,62,2269,2270],{"nctId":4081,"briefTitle":4082,"status":182,"phases":11923,"primaryCompletion":4084,"completion":4085,"start":4086,"enrollment":296,"conditions":11924,"interventions":11925},[88],[4088],[1369,1709,1376],{"nctId":6986,"briefTitle":6987,"status":279,"phases":11927,"primaryCompletion":238,"completion":238,"start":6989,"enrollment":3521,"conditions":11928,"interventions":11929},[88],[6991,1597],[1369,1376,53,1013,803],{"nctId":11073,"briefTitle":11074,"status":182,"phases":11931,"primaryCompletion":7155,"completion":7155,"start":5988,"enrollment":296,"conditions":11932,"interventions":11933},[88],[11077,11078],[1275,1376],{"nctId":10188,"briefTitle":10189,"status":203,"phases":11935,"primaryCompletion":4834,"start":6367,"enrollment":124,"conditions":11936,"interventions":11937},[87,88],[24],[10193,3847,1376,1369],{"nctId":10199,"briefTitle":10200,"status":130,"phases":11939,"primaryCompletion":10202,"completion":1300,"start":10203,"enrollment":1922,"conditions":11940,"interventions":11941},[88],[1345,4937,4938,4939,4940,5062,4941,10205,10206,10207,10208,10209,10210,10211,10212,10213,10214,10215,4942,4943,4944,4945,4946,5063,4947,1354,4948],[1275,1369,1376],{"nctId":11943,"briefTitle":11944,"status":182,"phases":11945,"primaryCompletion":8339,"completion":8339,"start":11946,"enrollment":539,"conditions":11947,"interventions":11948},"NCT00506779","Gleevec\u002FTaxol for Patients With Uterine Papillary Serous Carcinoma",[87,88],"2003-12-29",[11078],[2321,1376],{"nctId":10250,"briefTitle":10251,"status":182,"phases":11950,"primaryCompletion":8730,"completion":8730,"start":4085,"enrollment":1483,"conditions":11951,"interventions":11952},[88],[1729],[10255,1376,1369],{"nctId":10257,"briefTitle":10258,"status":182,"phases":11954,"primaryCompletion":9560,"completion":9560,"start":10260,"enrollment":296,"conditions":11955,"interventions":11956},[88],[24],[10263,1369,1376],{"nctId":11958,"briefTitle":11959,"status":130,"phases":11960,"primaryCompletion":2847,"completion":4647,"start":11961,"enrollment":517,"conditions":11962,"interventions":11963},"NCT00038246","Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma",[87,88],"2000-10",[27],[11964,2383,1376],"Estramustine",{"nctId":7174,"briefTitle":7175,"status":182,"phases":11966,"primaryCompletion":7177,"completion":7177,"start":5556,"enrollment":1568,"conditions":11967,"interventions":11968},[88],[18],[7180,1376,4218,6744,803],{"nctId":11139,"briefTitle":11140,"status":182,"phases":11970,"primaryCompletion":11142,"completion":11142,"start":11143,"enrollment":910,"conditions":11971,"interventions":11972},[88],[11145,4937,4938,4939,4940,5062,4941,10215,11146,4942,4943,4944,4945,4946,5063,4947,4948,1458,1460,1461],[1275,11148,1376],{"nctId":2803,"briefTitle":2804,"status":130,"phases":11974,"primaryCompletion":2806,"completion":2806,"start":2807,"enrollment":406,"conditions":11975,"interventions":11976},[88],[2809],[1376,62,2811,2269],{"nctId":10277,"briefTitle":10278,"status":130,"phases":11978,"primaryCompletion":8095,"completion":8095,"start":10280,"enrollment":381,"conditions":11979,"interventions":11980},[88],[24],[1369,1376],{"nctId":10284,"briefTitle":10285,"status":130,"phases":11982,"primaryCompletion":10287,"completion":10287,"start":3818,"enrollment":1154,"conditions":11983,"interventions":11984},[88],[10135,24],[3847,1369,1376],{"nctId":7291,"briefTitle":7292,"status":182,"phases":11986,"primaryCompletion":7294,"completion":7294,"start":5035,"enrollment":1240,"conditions":11987,"interventions":11988},[87,88],[7296,7297,5234,5086,5087,5088,5089,7298],[803,1013,7300,1376,7301,4227],{"nctId":7303,"briefTitle":7304,"status":203,"phases":11990,"primaryCompletion":754,"completion":754,"start":7306,"enrollment":124,"conditions":11991,"interventions":11992},[88],[7308,7309,7310,7311,7312,7296,5079,7313,7314,7315,7316,7317,1363],[1369,803,1013,1376,6802,53],{"nctId":10299,"briefTitle":10300,"status":182,"phases":11994,"primaryCompletion":10302,"completion":10302,"start":9278,"enrollment":1483,"conditions":11995,"interventions":11996},[87,88],[4097,10304,10305,10306,10307,10308,10309],[1369,1376,10311],{"nctId":4295,"briefTitle":4296,"status":102,"phases":11998,"primaryCompletion":224,"completion":224,"start":4298,"enrollment":4299,"conditions":11999,"interventions":12000},[88],[450],[1376,1369,1683,1710,1709,1371],{"nctId":12002,"briefTitle":12003,"status":130,"phases":12004,"primaryCompletion":2213,"completion":2213,"start":2945,"enrollment":1609,"conditions":12005,"interventions":12007},"NCT00006081","Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer",[88],[2770,12006],"Gastric Cancer",[12008,1376],"Bryostatin-1",{"nctId":5687,"briefTitle":5688,"status":130,"phases":12010,"primaryCompletion":2890,"completion":2890,"start":5690,"enrollment":1308,"conditions":12011,"interventions":12012},[88],[27],[804,2958,2424,2959,1376,1868],{"nctId":12014,"briefTitle":12015,"status":130,"phases":12016,"primaryCompletion":4184,"completion":4184,"start":9923,"enrollment":517,"conditions":12017,"interventions":12029},"NCT00478361","Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function",[88],[12018,12019,12020,12021,12022,12023,12024,12025,12026,12027,12028],"Distal Urethral Cancer","Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter","Proximal Urethral Cancer","Recurrent Bladder Cancer","Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter","Recurrent Urethral Cancer","Regional Transitional Cell Cancer of the Renal Pelvis and Ureter","Stage III Bladder Cancer","Stage IV Bladder Cancer","Transitional Cell Carcinoma of the Bladder","Urethral Cancer Associated With Invasive Bladder Cancer",[12030,1376,2957,1071],"Gemcitabine hydrochloride",{"nctId":2860,"briefTitle":2861,"status":279,"phases":12032,"primaryCompletion":2863,"completion":2863,"start":2864,"enrollment":2865,"conditions":12033,"interventions":12034},[87,88],[2867,2868],[62,2269,2270,1376],{"trials":12036,"activeCount":124},[12037],{"nctId":7436,"briefTitle":7437,"status":130,"phases":12038,"primaryCompletion":6409,"completion":3777,"start":2580,"enrollment":7439,"conditions":12039,"interventions":12040},[89],[18],[4218,803,1013,1376,6744],{"trials":12042,"activeCount":124},[],{"trials":12044,"activeCount":124},[12045],{"nctId":7492,"briefTitle":7493,"status":203,"phases":12046,"start":3777,"enrollment":124,"conditions":12047,"interventions":12048},[91],[18],[1376,1371,1013,6744,803,1275],{"intervention":804,"totalTrials":507,"cells":12050},{"EARLY_PHASE1":12051,"PHASE1":12053,"PHASE2":12069,"PHASE3":12199,"PHASE4":12219,"NA":12221},{"trials":12052,"activeCount":124},[],{"trials":12054,"activeCount":124},[12055,12062],{"nctId":12056,"briefTitle":12057,"status":130,"phases":12058,"primaryCompletion":4040,"completion":4723,"start":12059,"enrollment":593,"conditions":12060,"interventions":12061},"NCT00004123","Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma",[87],"1997-07",[2971],[2957],{"nctId":12063,"briefTitle":12064,"status":130,"phases":12065,"primaryCompletion":5268,"completion":12066,"start":9828,"enrollment":406,"conditions":12067,"interventions":12068},"NCT00004109","Doxorubicin Plus External-Beam Radiation Therapy in Treating Patients With Soft Tissue Sarcoma",[87],"2011-04",[2971],[804],{"trials":12070,"activeCount":2018,"soonestReadout":2608},[12071,12075,12079,12089,12093,12097,12107,12115,12119,12123,12127,12131,12135,12139,12143,12147,12151,12155,12164,12171,12175,12179,12183,12187,12191,12195],{"nctId":8320,"briefTitle":8321,"status":130,"phases":12072,"primaryCompletion":8323,"completion":8323,"start":8324,"enrollment":8325,"conditions":12073,"interventions":12074},[88],[8327,8328,8329],[4331,1869,804,894,1868],{"nctId":6787,"briefTitle":6788,"status":130,"phases":12076,"primaryCompletion":6790,"completion":6790,"start":6791,"enrollment":871,"conditions":12077,"interventions":12078},[87,88],[18],[1069,803,804,1376],{"nctId":12080,"briefTitle":12081,"status":279,"phases":12082,"primaryCompletion":12083,"completion":12084,"start":12085,"enrollment":473,"conditions":12086,"interventions":12088},"NCT07076186","Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS",[88],"2027-12-02","2029-12-02","2025-10-02",[12087],"Uterine Leiomyosarcoma",[531,804],{"nctId":2497,"briefTitle":2498,"status":279,"phases":12090,"primaryCompletion":2104,"completion":2104,"start":2500,"enrollment":1975,"conditions":12091,"interventions":12092},[88],[2502,2503],[1083,803,654,62,804,2477,805,806,2425,809,894,810],{"nctId":2506,"briefTitle":2507,"status":182,"phases":12094,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":296,"conditions":12095,"interventions":12096},[88],[2512,2502,2472],[803,654,62,804,2477,1373,805,806,2425,809,894,810],{"nctId":12098,"briefTitle":12099,"status":130,"phases":12100,"primaryCompletion":2602,"completion":2602,"start":12101,"enrollment":1975,"conditions":12102,"interventions":12103},"NCT00081159","Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases",[88],"2004-07",[7818,27],[2957,12104,12105,12106],"Goserelin acetate","Leuprolide acetate","Zoledronic acid",{"nctId":12108,"briefTitle":12109,"status":102,"phases":12110,"primaryCompletion":193,"completion":193,"start":12111,"enrollment":406,"conditions":12112,"interventions":12114},"NCT03587662","Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",[88],"2018-08-17",[7942,1346,12113,1356,1360],"SMARCB1 Negative",[1013,804,2369,4135,2283,8569],{"nctId":3962,"briefTitle":3963,"status":102,"phases":12116,"primaryCompletion":1427,"completion":1427,"start":3965,"enrollment":3726,"conditions":12117,"interventions":12118},[88],[3967,1293],[1786,806,1868,804,1709],{"nctId":5571,"briefTitle":5572,"status":130,"phases":12120,"primaryCompletion":5574,"completion":5574,"start":5575,"enrollment":1034,"conditions":12121,"interventions":12122},[88],[5577],[803,804,2424,767,1402,809,894,810],{"nctId":7841,"briefTitle":7842,"status":102,"phases":12124,"primaryCompletion":1939,"completion":1939,"start":7844,"enrollment":448,"conditions":12125,"interventions":12126},[88],[1866],[7847,804,53,1869],{"nctId":5580,"briefTitle":5581,"status":130,"phases":12128,"primaryCompletion":5583,"completion":5583,"start":5584,"enrollment":2779,"conditions":12129,"interventions":12130},[88],[5586,5587,3056,5588,913,2415,914,2419],[803,804,2424,2425,809,894,810],{"nctId":794,"briefTitle":795,"status":279,"phases":12132,"primaryCompletion":772,"completion":772,"start":797,"enrollment":798,"conditions":12133,"interventions":12134},[88],[800,801],[803,654,62,804,805,806,807,808,809,480,810],{"nctId":4036,"briefTitle":4037,"status":130,"phases":12136,"primaryCompletion":4039,"completion":4039,"start":4040,"enrollment":3541,"conditions":12137,"interventions":12138},[88],[1293,4042,4043],[2878,4045,2882,4046,4047],{"nctId":1860,"briefTitle":1861,"status":546,"phases":12140,"primaryCompletion":571,"completion":1863,"start":1864,"enrollment":1568,"conditions":12141,"interventions":12142},[88],[1866],[1050,804,1868,1869],{"nctId":2634,"briefTitle":2635,"status":102,"phases":12144,"primaryCompletion":956,"completion":956,"start":2637,"enrollment":2638,"conditions":12145,"interventions":12146},[88],[783,891,788],[803,654,62,1013,804,767,806,894,1016,810],{"nctId":2642,"briefTitle":2643,"status":130,"phases":12148,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":2647,"conditions":12149,"interventions":12150},[88],[1122,2649,2650,2651,785,2652,2653],[803,654,62,804,806,2425,810],{"nctId":928,"briefTitle":929,"status":102,"phases":12152,"primaryCompletion":931,"completion":931,"start":932,"enrollment":240,"conditions":12153,"interventions":12154},[88],[891],[803,654,62,804,767,806,894,480,810],{"nctId":12156,"briefTitle":12157,"status":102,"phases":12158,"primaryCompletion":2608,"completion":2608,"start":12159,"enrollment":6385,"conditions":12160,"interventions":12163},"NCT02420847","Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery",[87,88],"2015-07-03",[1803,12161,12162],"Transitional Cell Carcinoma","Unresectable Transitional Cell Carcinoma",[804,4135,8569],{"nctId":12165,"briefTitle":12166,"status":182,"phases":12167,"primaryCompletion":12168,"completion":7473,"start":4086,"enrollment":2779,"conditions":12169,"interventions":12170},"NCT00080782","Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases",[88],"2004-04",[7818,27],[3808,804],{"nctId":4166,"briefTitle":4167,"status":130,"phases":12172,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":12173,"interventions":12174},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"nctId":11648,"briefTitle":11649,"status":279,"phases":12176,"primaryCompletion":604,"completion":11651,"start":11652,"enrollment":676,"conditions":12177,"interventions":12178},[88],[1593],[718,804],{"nctId":2726,"briefTitle":2727,"status":102,"phases":12180,"primaryCompletion":999,"completion":999,"start":2729,"enrollment":2730,"conditions":12181,"interventions":12182},[88],[1205,1122,2649,2471,644,912,2732],[803,654,62,1013,804,806,1124,917,809,894,1016,810],{"nctId":7213,"briefTitle":7214,"status":102,"phases":12184,"primaryCompletion":7216,"completion":7216,"start":7217,"enrollment":2933,"conditions":12185,"interventions":12186},[88],[7219],[668,803,804,1402,809,894,3338,1016],{"nctId":5687,"briefTitle":5688,"status":130,"phases":12188,"primaryCompletion":2890,"completion":2890,"start":5690,"enrollment":1308,"conditions":12189,"interventions":12190},[88],[27],[804,2958,2424,2959,1376,1868],{"nctId":12014,"briefTitle":12015,"status":130,"phases":12192,"primaryCompletion":4184,"completion":4184,"start":9923,"enrollment":517,"conditions":12193,"interventions":12194},[88],[12018,12019,12020,12021,12022,12023,12024,12025,12026,12027,12028],[12030,1376,2957,1071],{"nctId":2871,"briefTitle":2872,"status":130,"phases":12196,"primaryCompletion":2874,"completion":2874,"start":2875,"enrollment":1766,"conditions":12197,"interventions":12198},[88],[21],[2878,2879,2880,2881,2882,2883,2884],{"trials":12200,"activeCount":124},[12201,12205,12215],{"nctId":4305,"briefTitle":4306,"status":130,"phases":12202,"primaryCompletion":4308,"completion":4308,"start":4309,"enrollment":2402,"conditions":12203,"interventions":12204},[89],[21],[4312,4313,4045,2879,2880,2882,4314,4315,4047,4316,4317,4318,4319,2884],{"nctId":12206,"briefTitle":12207,"status":130,"phases":12208,"primaryCompletion":4887,"completion":4887,"start":12209,"enrollment":12210,"conditions":12211,"interventions":12212},"NCT00002855","Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer",[89],"1996-08",306,[27],[11341,2957,12213,11342,2959,11344,12214,1868],"Estramustine Phosphate Sodium","Therapeutic Hydrocortisone",{"nctId":2950,"briefTitle":2951,"status":182,"phases":12216,"primaryCompletion":2602,"start":2953,"enrollment":2954,"conditions":12217,"interventions":12218},[89],[27],[1710,2957,2958,2959,809,1868,62],{"trials":12220,"activeCount":124},[],{"trials":12222,"activeCount":166,"soonestReadout":281},[12223],{"nctId":12224,"briefTitle":12225,"status":279,"phases":12226,"primaryCompletion":281,"completion":281,"start":6635,"enrollment":1131,"conditions":12227,"interventions":12231},"NCT04199026","Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma",[91],[12228,12229,12230],"Metastatic Sarcoma","Recurrent Sarcoma","Resectable Sarcoma",[1013,804,2840,12232,2495,4022,1431,12233,3497,6656,1016],"Ganitumab","Polyethylene Glycol",{"intervention":2369,"totalTrials":2446,"cells":12235},{"EARLY_PHASE1":12236,"PHASE1":12246,"PHASE2":12343,"PHASE3":12517,"PHASE4":12519,"NA":12521},{"trials":12237,"activeCount":124},[12238],{"nctId":12239,"briefTitle":12240,"status":182,"phases":12241,"primaryCompletion":12242,"completion":12242,"start":6757,"enrollment":550,"conditions":12243,"interventions":12244},"NCT01276613","Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas",[86],"2019-04-19",[4107],[2369,12245],"Losartan",{"trials":12247,"activeCount":296,"soonestReadout":5310},[12248,12258,12267,12271,12278,12282,12286,12293,12299,12307,12317,12321,12325,12337],{"nctId":12249,"briefTitle":12250,"status":182,"phases":12251,"primaryCompletion":12252,"completion":12252,"start":12253,"enrollment":296,"conditions":12254,"interventions":12256},"NCT06199466","A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer",[87],"2025-09-15","2024-01-22",[12255],"Metastatic Pancreatic Cancer",[2369,4023,12257],"YL-13027",{"nctId":12259,"briefTitle":12260,"status":279,"phases":12261,"primaryCompletion":1325,"completion":1325,"start":2400,"enrollment":1559,"conditions":12262,"interventions":12266},"NCT03093909","Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases",[87],[12263,5799,7650,7651,12264,7653,12265,7655,7656,7686],"Malignant Neoplasm of Bone and Articular Cartilage","Malignant Neoplasm of Male Genital Organs","Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma",[2369],{"nctId":4508,"briefTitle":4509,"status":130,"phases":12268,"primaryCompletion":2242,"completion":2242,"start":4511,"enrollment":959,"conditions":12269,"interventions":12270},[87],[21],[2405,2369,1004,2293,894,2374,2368,4514],{"nctId":12272,"briefTitle":12273,"status":130,"phases":12274,"primaryCompletion":3725,"completion":3725,"start":7473,"enrollment":9,"conditions":12275,"interventions":12276},"NCT00500422","Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients",[87],[1924],[2585,2369,12277],"Velcade",{"nctId":4539,"briefTitle":4540,"status":130,"phases":12279,"primaryCompletion":4542,"completion":4542,"start":2969,"enrollment":817,"conditions":12280,"interventions":12281},[87],[15,21,2245],[1004,2369,2293,4545,2368],{"nctId":10854,"briefTitle":10855,"status":130,"phases":12283,"primaryCompletion":2777,"completion":2777,"start":8340,"enrollment":959,"conditions":12284,"interventions":12285},[87],[33],[10859,2369,1275,1069],{"nctId":12287,"briefTitle":12288,"status":130,"phases":12289,"primaryCompletion":10449,"completion":10449,"start":12290,"enrollment":1243,"conditions":12291,"interventions":12292},"NCT02046304","PP-Gemcitabine & External Beam Radiation-Sarcomas",[87],"2001-12",[2971],[2369],{"nctId":12294,"briefTitle":12295,"status":130,"phases":12296,"primaryCompletion":3494,"completion":3494,"start":9512,"enrollment":2700,"conditions":12297,"interventions":12298},"NCT00429234","Gemcitabine and Dasatinib in Advanced Solid Tumors",[87],[1942,1924],[1028,2369],{"nctId":12300,"briefTitle":12301,"status":130,"phases":12302,"primaryCompletion":3805,"completion":3805,"start":3988,"enrollment":2018,"conditions":12303,"interventions":12305},"NCT00270907","CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer",[87],[12304,18],"Metastatic Breast Cancer",[12306,2369],"CT-2103",{"nctId":12308,"briefTitle":12309,"status":102,"phases":12310,"primaryCompletion":1299,"completion":1299,"start":12311,"enrollment":1766,"conditions":12312,"interventions":12314},"NCT05497778","A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.",[87],"2022-10-21",[12313],"Pancreas Cancer",[2369,12315,12316],"Nab paclitaxel","IM156",{"nctId":4555,"briefTitle":4556,"status":130,"phases":12318,"primaryCompletion":3519,"completion":3519,"start":675,"enrollment":676,"conditions":12319,"interventions":12320},[87],[4559,4560,4561,3061,4562],[1004,2369,2293,1374,894,2405],{"nctId":10927,"briefTitle":10928,"status":130,"phases":12322,"primaryCompletion":10930,"completion":10930,"start":10931,"enrollment":5258,"conditions":12323,"interventions":12324},[87],[1942],[4023,1275,2369],{"nctId":12326,"briefTitle":12327,"status":279,"phases":12328,"primaryCompletion":12329,"completion":12330,"start":12331,"enrollment":550,"conditions":12332,"interventions":12335},"NCT06308419","A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions",[87],"2029-02-01","2031-02-01","2024-08-14",[12333,12334],"Leiomyosarcoma","Soft-tissue Sarcomas",[2369,12336],"Nab-Sirolimus",{"nctId":12338,"briefTitle":12339,"status":102,"phases":12340,"primaryCompletion":5310,"completion":5310,"start":2558,"enrollment":1975,"conditions":12341,"interventions":12342},"NCT00479128","Bortezomib With Gemcitabine\u002FDoxorubicin in Patients With Urothelial Cancer and Other Solid Tumors",[87],[3305,4043],[75,2369,1013],{"trials":12344,"activeCount":910,"soonestReadout":2608},[12345,12349,12353,12357,12361,12367,12375,12386,12390,12397,12401,12405,12409,12413,12421,12425,12429,12439,12443,12447,12454,12460,12464,12468,12472,12476,12480,12487,12491,12495,12501,12513],{"nctId":2361,"briefTitle":2362,"status":203,"phases":12346,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":124,"conditions":12347,"interventions":12348},[88],[21],[2368,2340,2369,1004,2293,894,62,2370,2371,2372,2373,2374],{"nctId":2397,"briefTitle":2398,"status":130,"phases":12350,"primaryCompletion":2400,"completion":2400,"start":2401,"enrollment":2402,"conditions":12351,"interventions":12352},[87,88],[33,21],[510,2405,2369,1004,2293,62,2371,2372,894],{"nctId":10960,"briefTitle":10961,"status":130,"phases":12354,"primaryCompletion":3493,"completion":3493,"start":5470,"enrollment":1240,"conditions":12355,"interventions":12356},[88],[1521,1333],[1368,2369,1275],{"nctId":4602,"briefTitle":4603,"status":130,"phases":12358,"primaryCompletion":4605,"completion":4605,"start":2968,"enrollment":3409,"conditions":12359,"interventions":12360},[88],[21],[2369,1004,2293,2368],{"nctId":12362,"briefTitle":12363,"status":182,"phases":12364,"primaryCompletion":3725,"start":4697,"enrollment":3197,"conditions":12365,"interventions":12366},"NCT00766636","Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy",[88],[4107],[2369,3847],{"nctId":12368,"briefTitle":12369,"status":130,"phases":12370,"primaryCompletion":12371,"completion":12371,"start":12372,"enrollment":1240,"conditions":12373,"interventions":12374},"NCT01560949","Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas",[88],"2019-02-20","2012-06-14",[4107],[1375,4022,2772,2369],{"nctId":12376,"briefTitle":12377,"status":102,"phases":12378,"primaryCompletion":1939,"completion":1939,"start":12379,"enrollment":2018,"conditions":12380,"interventions":12384},"NCT04940286","Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable\u002FBorderline Resectable Primary Pancreatic Cancer",[88],"2021-09-28",[4018,12381,12382,12383,8175,8176],"Resectable Pancreatic Adenocarcinoma","Stage IA Pancreatic Cancer AJCC v8","Stage IB Pancreatic Cancer AJCC v8",[1786,2369,4023,12385],"Oleclumab",{"nctId":2479,"briefTitle":2480,"status":130,"phases":12387,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":1308,"conditions":12388,"interventions":12389},[88],[2245],[2368,62,2369,1004,2293,2374],{"nctId":12391,"briefTitle":12392,"status":130,"phases":12393,"primaryCompletion":8956,"completion":8956,"start":4183,"enrollment":1975,"conditions":12394,"interventions":12395},"NCT00837239","Huachansu & Gemcitabine in Pancreatic Cancer",[88],[4107],[2369,12396],"HuaChanSu",{"nctId":3940,"briefTitle":3941,"status":279,"phases":12398,"primaryCompletion":3943,"completion":3944,"start":3945,"enrollment":628,"conditions":12399,"interventions":12400},[88],[3947],[53,2369,1709],{"nctId":12108,"briefTitle":12109,"status":102,"phases":12402,"primaryCompletion":193,"completion":193,"start":12111,"enrollment":406,"conditions":12403,"interventions":12404},[88],[7942,1346,12113,1356,1360],[1013,804,2369,4135,2283,8569],{"nctId":4002,"briefTitle":4003,"status":279,"phases":12406,"primaryCompletion":4005,"completion":4006,"start":4007,"enrollment":676,"conditions":12407,"interventions":12408},[87,88],[4009],[2369,1709,1786,4011],{"nctId":4013,"briefTitle":4014,"status":203,"phases":12410,"primaryCompletion":4016,"completion":4016,"start":2264,"enrollment":124,"conditions":12411,"interventions":12412},[88],[4018,4019,4020],[1709,1371,2369,4022,1113,4023,1375],{"nctId":12414,"briefTitle":12415,"status":102,"phases":12416,"primaryCompletion":860,"completion":860,"start":12417,"enrollment":2004,"conditions":12418,"interventions":12419},"NCT03598595","Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma",[87,88],"2019-01-28",[1591,1592],[1710,2369,12420],"Hydroxychloroquine",{"nctId":10100,"briefTitle":10101,"status":279,"phases":12422,"primaryCompletion":5310,"completion":5310,"start":10103,"enrollment":240,"conditions":12423,"interventions":12424},[88],[1355,10105,1357,1707,1358,3845,1359],[1369,1786,2369,4023,1376,1377],{"nctId":2598,"briefTitle":2599,"status":203,"phases":12426,"primaryCompletion":2601,"start":2602,"enrollment":124,"conditions":12427,"interventions":12428},[88],[2245],[2227,2605,2369,1004,2293,2368,62,2370,2371,2372],{"nctId":12430,"briefTitle":12431,"status":130,"phases":12432,"primaryCompletion":12433,"completion":12433,"start":12434,"enrollment":3409,"conditions":12435,"interventions":12437},"NCT00769483","MK-0646 and Gemcitabine +\u002F- Erlotinib for Patients With Advanced Pancreatic Cancer",[87,88],"2020-09-01","2008-11-13",[4107,12436],"Pancreatic Adenocarcinoma",[12438,2369,3847],"MK-0646",{"nctId":5600,"briefTitle":5601,"status":130,"phases":12440,"primaryCompletion":5603,"completion":5603,"start":5604,"enrollment":3354,"conditions":12441,"interventions":12442},[88],[5606],[2369,1710,2293,1369,1114,2495,2424],{"nctId":4702,"briefTitle":4703,"status":203,"phases":12444,"primaryCompletion":4705,"completion":4705,"start":4705,"enrollment":124,"conditions":12445,"interventions":12446},[88],[4707,3272,2415,4559,4708,4560,4709],[1004,2423,803,2369,2195,894,2196,2405],{"nctId":12448,"briefTitle":12449,"status":130,"phases":12450,"primaryCompletion":5522,"completion":11731,"start":6352,"enrollment":95,"conditions":12451,"interventions":12453},"NCT00336648","Preop Chemoradiation Resectable Pancreas",[88],[12452],"Pancreatic Neoplasms",[4234,2369],{"nctId":12455,"briefTitle":12456,"status":130,"phases":12457,"primaryCompletion":2968,"completion":2968,"start":2213,"enrollment":34,"conditions":12458,"interventions":12459},"NCT00338039","Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients",[88],[4107],[1683,2369,1375,1368],{"nctId":4159,"briefTitle":4160,"status":130,"phases":12461,"primaryCompletion":4162,"completion":4162,"start":3819,"enrollment":871,"conditions":12462,"interventions":12463},[88],[2809],[2369,1709],{"nctId":10244,"briefTitle":10245,"status":182,"phases":12465,"primaryCompletion":4843,"completion":4843,"start":4192,"enrollment":2018,"conditions":12466,"interventions":12467},[88],[1530],[1275,1369,1710,2369,2293],{"nctId":4746,"briefTitle":4747,"status":182,"phases":12469,"primaryCompletion":4749,"completion":4749,"start":4750,"enrollment":1568,"conditions":12470,"interventions":12471},[87,88],[1411,712,4752,715],[3085,1004,2423,1069,2369,806,2196],{"nctId":4211,"briefTitle":4212,"status":102,"phases":12473,"primaryCompletion":2608,"completion":2608,"start":4214,"enrollment":4171,"conditions":12474,"interventions":12475},[88],[1293,4043,4216],[4218,1113,1709,2369],{"nctId":4237,"briefTitle":4238,"status":279,"phases":12477,"primaryCompletion":4240,"completion":4241,"start":4242,"enrollment":1034,"conditions":12478,"interventions":12479},[88],[4244],[1786,2369,1709],{"nctId":12481,"briefTitle":12482,"status":130,"phases":12483,"primaryCompletion":4153,"completion":8340,"start":2847,"enrollment":1409,"conditions":12484,"interventions":12486},"NCT00353145","Gemox as First and Second Line Therapy in Unknown Primary Cancer",[88],[12485],"Unknown Primary Neoplasms",[2369,1375],{"nctId":4831,"briefTitle":4832,"status":203,"phases":12488,"primaryCompletion":4834,"start":4835,"enrollment":124,"conditions":12489,"interventions":12490},[87,88],[21],[1004,2370,2371,2372,2235,510,2369,2293],{"nctId":9374,"briefTitle":9375,"status":130,"phases":12492,"primaryCompletion":3761,"completion":3761,"start":5663,"enrollment":901,"conditions":12493,"interventions":12494},[88],[9378],[2369,1070,2293,4668,2196,1069,806],{"nctId":12496,"briefTitle":12497,"status":182,"phases":12498,"primaryCompletion":2212,"completion":2212,"start":3988,"enrollment":834,"conditions":12499,"interventions":12500},"NCT00491075","Pemetrexed Plus Gemcitabine in Renal Cell Cancer",[88],[1521],[1377,2369],{"nctId":12502,"briefTitle":12503,"status":279,"phases":12504,"primaryCompletion":12505,"completion":12506,"start":12507,"enrollment":1034,"conditions":12508,"interventions":12511},"NCT07283705","A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer",[88],"2029-10-01","2031-10-01","2026-05-18",[8577,12509,12510],"BMS-986504","MTAP-deleted Pancreatic Cancer",[12509,2369,4023,12512],"mFOLFIRINOX",{"nctId":2897,"briefTitle":2898,"status":182,"phases":12514,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":186,"conditions":12515,"interventions":12516},[87,88],[21],[1402,2405,2369,1004,2293,894,62,2370,2371,2372,2904,2368],{"trials":12518,"activeCount":124},[],{"trials":12520,"activeCount":124},[],{"trials":12522,"activeCount":124},[12523,12527],{"nctId":4379,"briefTitle":4380,"status":182,"phases":12524,"primaryCompletion":4382,"completion":4382,"start":2932,"enrollment":1483,"conditions":12525,"interventions":12526},[91],[4384],[1013,1709,806,1113,4386,2495,2369,4387,1114],{"nctId":12528,"briefTitle":12529,"status":182,"phases":12530,"primaryCompletion":12531,"completion":12531,"start":8753,"enrollment":3726,"conditions":12532,"interventions":12533},"NCT01938716","Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy",[91],"2019-06-03",[4107],[2369],{"intervention":612,"totalTrials":517,"cells":12535},{"EARLY_PHASE1":12536,"PHASE1":12538,"PHASE2":12591,"PHASE3":12784,"PHASE4":12792,"NA":12794},{"trials":12537,"activeCount":124},[],{"trials":12539,"activeCount":1231,"soonestReadout":3425},[12540,12544,12551,12557,12568,12572,12582],{"nctId":2200,"briefTitle":2201,"status":102,"phases":12541,"primaryCompletion":224,"completion":224,"start":2203,"enrollment":507,"conditions":12542,"interventions":12543},[87],[913,608,914,610],[612,62,2206,2207],{"nctId":12545,"briefTitle":12546,"status":182,"phases":12547,"primaryCompletion":1984,"completion":1984,"start":12548,"enrollment":121,"conditions":12549,"interventions":12550},"NCT02141477","Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)",[87],"2015-05-06",[15],[9655,612],{"nctId":12552,"briefTitle":12553,"status":130,"phases":12554,"primaryCompletion":6974,"completion":6974,"start":10784,"enrollment":517,"conditions":12555,"interventions":12556},"NCT00349596","A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)",[87],[2838],[612],{"nctId":12558,"briefTitle":12559,"status":279,"phases":12560,"primaryCompletion":3425,"completion":3426,"start":12561,"enrollment":406,"conditions":12562,"interventions":12565},"NCT06401603","A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia",[87],"2024-08-06",[12563,12564],"Advanced Chronic Myeloid Leukemia","Philadelphia Chromosome-Positive Acute Myeloid Leukemia",[612,12566,12567],"Listaftoclax","Olverembatinib",{"nctId":4401,"briefTitle":4402,"status":203,"phases":12569,"primaryCompletion":3509,"completion":3509,"start":3509,"enrollment":124,"conditions":12570,"interventions":12571},[87],[494,495],[599,654,2207,612],{"nctId":12573,"briefTitle":12574,"status":102,"phases":12575,"primaryCompletion":1299,"completion":1299,"start":12576,"enrollment":910,"conditions":12577,"interventions":12580},"NCT04874480","Tegavivint for the Treatment of Relapsed or Refractory Leukemia",[87],"2021-09-27",[12578,12579],"Recurrent Leukemia","Refractory Leukemia",[612,12581],"Tegavivint",{"nctId":12583,"briefTitle":12584,"status":182,"phases":12585,"primaryCompletion":12586,"completion":12586,"start":12587,"enrollment":539,"conditions":12588,"interventions":12589},"NCT00791271","Parallel Phase I\u002FII Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion",[87],"2015-05","2008-09-02",[1729],[612,12590],"Pegylated Interferon Alpha-2b",{"trials":12592,"activeCount":910,"soonestReadout":1078},[12593,12597,12601,12608,12612,12616,12620,12624,12630,12636,12645,12653,12661,12667,12671,12678,12682,12686,12690,12694,12698,12708,12717,12721,12729,12738,12745,12751,12757,12768,12772,12776],{"nctId":601,"briefTitle":602,"status":279,"phases":12594,"primaryCompletion":604,"completion":604,"start":605,"enrollment":606,"conditions":12595,"interventions":12596},[87,88],[36,30,608,609,610],[612,613,480],{"nctId":4413,"briefTitle":4414,"status":279,"phases":12598,"primaryCompletion":2302,"completion":2302,"start":4416,"enrollment":798,"conditions":12599,"interventions":12600},[88],[15],[599,654,612],{"nctId":12602,"briefTitle":12603,"status":182,"phases":12604,"primaryCompletion":12605,"completion":12605,"start":6065,"enrollment":230,"conditions":12606,"interventions":12607},"NCT02010645","Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)",[88],"2019-01-02",[15],[3432,612],{"nctId":9550,"briefTitle":9551,"status":130,"phases":12609,"primaryCompletion":7770,"completion":7770,"start":9553,"enrollment":3541,"conditions":12610,"interventions":12611},[87,88],[15],[612,655,654,2423],{"nctId":2452,"briefTitle":2453,"status":279,"phases":12613,"primaryCompletion":2455,"completion":2456,"start":2457,"enrollment":1559,"conditions":12614,"interventions":12615},[87,88],[2459,2460],[803,2462,612,62],{"nctId":698,"briefTitle":699,"status":279,"phases":12617,"primaryCompletion":548,"completion":490,"start":701,"enrollment":492,"conditions":12618,"interventions":12619},[88],[552,703],[612,480,705],{"nctId":3222,"briefTitle":3223,"status":279,"phases":12621,"primaryCompletion":3225,"completion":3225,"start":3226,"enrollment":3227,"conditions":12622,"interventions":12623},[88],[3229,3230,3231,647,1067,3232,3233,3234,3235,652],[654,612,2712,1005,694,655],{"nctId":12625,"briefTitle":12626,"status":130,"phases":12627,"primaryCompletion":11134,"completion":11134,"start":5988,"enrollment":7694,"conditions":12628,"interventions":12629},"NCT00968071","Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome",[88],[4659,30],[612,694],{"nctId":12631,"briefTitle":12632,"status":130,"phases":12633,"primaryCompletion":8306,"completion":8306,"start":4732,"enrollment":4299,"conditions":12634,"interventions":12635},"NCT00067808","Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)",[88],[30,737],[612,612,612],{"nctId":12637,"briefTitle":12638,"status":130,"phases":12639,"primaryCompletion":12640,"completion":12640,"start":12641,"enrollment":2700,"conditions":12642,"interventions":12643},"NCT00075010","Phase I\u002FII Study of Decitabine and Valproic Acid in Relapsed\u002FRefractory Leukemia or Myelodysplastic Syndromes",[87,88],"2006-11-08","2004-01-23",[15,1036],[612,12644],"Valproic acid",{"nctId":12646,"briefTitle":12647,"status":130,"phases":12648,"primaryCompletion":11134,"completion":11134,"start":12649,"enrollment":357,"conditions":12650,"interventions":12651},"NCT00882102","Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)",[88],"2009-04",[4659,30],[612,12652],"Gemtuzumab ozogamicin",{"nctId":12654,"briefTitle":12655,"status":102,"phases":12656,"primaryCompletion":12657,"completion":12657,"start":12658,"enrollment":3354,"conditions":12659,"interventions":12660},"NCT05038592","Phase I\u002FII Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic\u002FMyeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes",[87,88],"2027-01-29","2022-03-04",[737,10536,10537,3244],[612,1015],{"nctId":12662,"briefTitle":12663,"status":182,"phases":12664,"primaryCompletion":4731,"completion":4731,"start":3902,"enrollment":834,"conditions":12665,"interventions":12666},"NCT00113321","Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure",[88],[30,737],[612],{"nctId":839,"briefTitle":840,"status":182,"phases":12668,"primaryCompletion":842,"completion":842,"start":843,"enrollment":844,"conditions":12669,"interventions":12670},[88],[36,846,847,737,848,30,630,608,849,850,851,610,852,853,854],[612,480],{"nctId":12672,"briefTitle":12673,"status":130,"phases":12674,"primaryCompletion":12586,"completion":12586,"start":2969,"enrollment":12675,"conditions":12676,"interventions":12677},"NCT00414310","Decitabine (DAC) w\u002F or w\u002Fo Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)",[88],153,[30,4659],[612,9894],{"nctId":2664,"briefTitle":2665,"status":279,"phases":12679,"primaryCompletion":2667,"completion":2668,"start":2669,"enrollment":924,"conditions":12680,"interventions":12681},[87,88],[2460],[62,803,1070,612,2672],{"nctId":4712,"briefTitle":4713,"status":130,"phases":12683,"primaryCompletion":4715,"completion":4716,"start":4635,"enrollment":95,"conditions":12684,"interventions":12685},[88],[15],[1004,1070,2423,4537,2373,803,2196,2757,612,654,655],{"nctId":953,"briefTitle":954,"status":279,"phases":12687,"primaryCompletion":956,"completion":957,"start":958,"enrollment":959,"conditions":12688,"interventions":12689},[87,88],[961],[963,480,612,964],{"nctId":10563,"briefTitle":10564,"status":130,"phases":12691,"primaryCompletion":10566,"completion":10566,"start":10567,"enrollment":5774,"conditions":12692,"interventions":12693},[88],[15],[612,510],{"nctId":987,"briefTitle":988,"status":203,"phases":12695,"primaryCompletion":990,"completion":990,"start":991,"enrollment":124,"conditions":12696,"interventions":12697},[87,88],[608,610],[994,612,480],{"nctId":12699,"briefTitle":12700,"status":130,"phases":12701,"primaryCompletion":12702,"completion":12702,"start":12703,"enrollment":406,"conditions":12704,"interventions":12707},"NCT02257138","Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia",[87,88],"2021-03-19","2015-02-12",[12705,12706,3244,608,610],"Blasts More Than 20 Percent of Bone Marrow Nucleated Cells","Blasts More Than 20 Percent of Peripheral Blood White Cells",[612,2596],{"nctId":12709,"briefTitle":12710,"status":182,"phases":12711,"primaryCompletion":12712,"completion":12712,"start":12713,"enrollment":1231,"conditions":12714,"interventions":12715},"NCT02469415","Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)",[88],"2017-06-03","2015-09-30",[15],[4582,12716,612],"5-azacitidine",{"nctId":9735,"briefTitle":9736,"status":130,"phases":12718,"primaryCompletion":185,"completion":185,"start":5556,"enrollment":9738,"conditions":12719,"interventions":12720},[88],[36,30],[2423,654,612],{"nctId":12722,"briefTitle":12723,"status":130,"phases":12724,"primaryCompletion":12725,"completion":12725,"start":12726,"enrollment":2779,"conditions":12727,"interventions":12728},"NCT00002832","Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia",[87,88],"2002-03","1995-08",[15,1036],[1069,3420,612],{"nctId":12730,"briefTitle":12731,"status":130,"phases":12732,"primaryCompletion":12733,"completion":12733,"start":12734,"enrollment":1260,"conditions":12735,"interventions":12736},"NCT01893320","Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome",[87,88],"2021-01-11","2013-07-18",[15],[12737,612],"Vosaroxin",{"nctId":12739,"briefTitle":12740,"status":130,"phases":12741,"primaryCompletion":12742,"completion":12742,"start":11336,"enrollment":4690,"conditions":12743,"interventions":12744},"NCT01786343","Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)",[88],"2019-05-06",[15],[612],{"nctId":12746,"briefTitle":12747,"status":130,"phases":12748,"primaryCompletion":4184,"completion":4184,"start":8340,"enrollment":924,"conditions":12749,"interventions":12750},"NCT00903760","Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)",[88],[30],[612,2423],{"nctId":12752,"briefTitle":12753,"status":182,"phases":12754,"primaryCompletion":2836,"completion":2836,"start":5733,"enrollment":121,"conditions":12755,"interventions":12756},"NCT00561912","Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma",[88],[1521],[612,3498],{"nctId":12758,"briefTitle":12759,"status":130,"phases":12760,"primaryCompletion":12761,"completion":12761,"start":12762,"enrollment":12763,"conditions":12764,"interventions":12765},"NCT02269280","Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)",[88],"2024-07-25","2014-10-13",185,[15],[12766,612,12767],"Azacitidine (AZA) Days 1 - 3","Azacitidine (AZA) Days 1 - 5",{"nctId":4807,"briefTitle":4808,"status":130,"phases":12769,"primaryCompletion":4810,"completion":4810,"start":4811,"enrollment":628,"conditions":12770,"interventions":12771},[87,88],[15],[1069,1004,803,3420,612,806,1014,2196],{"nctId":1200,"briefTitle":1201,"status":102,"phases":12773,"primaryCompletion":1078,"completion":1078,"start":1203,"enrollment":1131,"conditions":12774,"interventions":12775},[88],[1205,36,644,608,649,610,650],[612,1124,480],{"nctId":12777,"briefTitle":12778,"status":182,"phases":12779,"primaryCompletion":12780,"completion":12780,"start":12781,"enrollment":507,"conditions":12782,"interventions":12783},"NCT01498445","An Open-Label, Phase I\u002FII Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)",[87,88],"2019-09-24","2012-06-12",[15],[1028,612,612],{"trials":12785,"activeCount":124},[12786],{"nctId":12787,"briefTitle":12788,"status":130,"phases":12789,"primaryCompletion":2778,"completion":2778,"start":2317,"enrollment":676,"conditions":12790,"interventions":12791},"NCT00398983","Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)",[88,89],[4659],[612],{"trials":12793,"activeCount":124},[],{"trials":12795,"activeCount":124},[],{"intervention":1683,"totalTrials":2004,"cells":12797},{"EARLY_PHASE1":12798,"PHASE1":12804,"PHASE2":12899,"PHASE3":13002,"PHASE4":13004,"NA":13006},{"trials":12799,"activeCount":166,"soonestReadout":10669},[12800],{"nctId":10666,"briefTitle":10667,"status":546,"phases":12801,"primaryCompletion":10669,"completion":10670,"start":10671,"enrollment":1222,"conditions":12802,"interventions":12803},[86],[10673,10674],[1275,1683,6802,10676,10677,1684,10678,10679,10680,10681,10682],{"trials":12805,"activeCount":1231,"soonestReadout":238},[12806,12816,12820,12829,12837,12844,12850,12854,12863,12870,12874,12881,12885,12891,12895],{"nctId":12807,"briefTitle":12808,"status":130,"phases":12809,"primaryCompletion":12810,"completion":12810,"start":12811,"enrollment":2997,"conditions":12812,"interventions":12815},"NCT01787500","Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery",[87],"2022-01-19","2013-02-15",[12813,12814,361,5008,5009,5010,1951],"BRAF NP_004324.2:p.V600X","KRAS wt Allele",[1683,1372,9970],{"nctId":10729,"briefTitle":10730,"status":130,"phases":12817,"primaryCompletion":2777,"completion":2777,"start":3987,"enrollment":342,"conditions":12818,"interventions":12819},[87],[33],[10734,2772,1275,1683,1113,2772,1275],{"nctId":12821,"briefTitle":12822,"status":279,"phases":12823,"primaryCompletion":12824,"completion":12824,"start":12825,"enrollment":2159,"conditions":12826,"interventions":12827},"NCT05985954","Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy",[87],"2028-03-28","2024-01-18",[10674],[1683,12828,1684],"Ulixertinib",{"nctId":12830,"briefTitle":12831,"status":102,"phases":12832,"primaryCompletion":238,"completion":238,"start":12833,"enrollment":628,"conditions":12834,"interventions":12835},"NCT05722327","Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer",[87],"2023-12-06",[3154,3195],[12836,4022,1683],"MRTX849",{"nctId":12838,"briefTitle":12839,"status":130,"phases":12840,"primaryCompletion":12841,"completion":12841,"start":689,"enrollment":1240,"conditions":12842,"interventions":12843},"NCT03290937","Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer",[87],"2025-12-30",[1898,1676,1677,1678,1679],[1683,1372,7370],{"nctId":12845,"briefTitle":12846,"status":130,"phases":12847,"primaryCompletion":1558,"start":12649,"enrollment":3541,"conditions":12848,"interventions":12849},"NCT00895362","Erlotinib in Combination With Cetuximab",[87],[33],[3847,1683],{"nctId":10804,"briefTitle":10805,"status":182,"phases":12851,"primaryCompletion":10807,"completion":10807,"start":10808,"enrollment":10809,"conditions":12852,"interventions":12853},[87],[2922,10811,10812,10813,10814,10815,10816,10817,10818,2613,10819,10820,10821,10822,2924,1803,10823,10824,10825,10826,10827,10828,10829,2925,10830,10831,2926,10832,5086,10833,5087,5088,5089,7298,10834,10835,10836,10837,10838],[1275,1683,6656,9894],{"nctId":12855,"briefTitle":12856,"status":130,"phases":12857,"primaryCompletion":12858,"completion":12858,"start":12859,"enrollment":2865,"conditions":12860,"interventions":12861},"NCT02095054","Regorafenib and Cetuximab in Patients With Advanced Malignancy",[87],"2020-03-27","2014-03-19",[33],[12862,1683],"Regorafenib",{"nctId":12864,"briefTitle":12865,"status":130,"phases":12866,"primaryCompletion":2777,"completion":2777,"start":3987,"enrollment":12867,"conditions":12868,"interventions":12869},"NCT00940381","Sirolimus and Cetuximab in Advanced Malignancies",[87],165,[1942],[6516,1683],{"nctId":3148,"briefTitle":3149,"status":130,"phases":12871,"primaryCompletion":3151,"completion":3151,"start":3152,"enrollment":1568,"conditions":12872,"interventions":12873},[87],[3154,3155],[1683,3157,2462,803],{"nctId":12875,"briefTitle":12876,"status":130,"phases":12877,"primaryCompletion":11088,"completion":11088,"start":12878,"enrollment":5162,"conditions":12879,"interventions":12880},"NCT00501410","FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer",[87],"2007-04-23",[3195],[2772,1683,1028,1113,1375],{"nctId":10910,"briefTitle":10911,"status":130,"phases":12882,"primaryCompletion":10913,"completion":10913,"start":10914,"enrollment":10915,"conditions":12883,"interventions":12884},[87],[1942],[1275,2207,3847,4227,7180,10918,1683],{"nctId":12886,"briefTitle":12887,"status":203,"phases":12888,"primaryCompletion":2121,"start":3832,"enrollment":124,"conditions":12889,"interventions":12890},"NCT01432119","Phase 1 Trial With SIR-Spheres and Cetuximab +\u002F- Erlotinib",[87],[33],[1683,3847],{"nctId":10935,"briefTitle":10936,"status":130,"phases":12892,"primaryCompletion":10938,"completion":10938,"start":3833,"enrollment":10939,"conditions":12893,"interventions":12894},[87],[1996,1942],[4022,1275,1375,1683],{"nctId":3190,"briefTitle":3191,"status":279,"phases":12896,"primaryCompletion":3193,"completion":3193,"start":1407,"enrollment":924,"conditions":12897,"interventions":12898},[87],[3195,3040],[1005,803,1683,3104,3103],{"trials":12900,"activeCount":186,"soonestReadout":549},[12901,12911,12915,12919,12929,12933,12943,12947,12955,12962,12966,12976,12983,12992,12996],{"nctId":12902,"briefTitle":12903,"status":279,"phases":12904,"primaryCompletion":12905,"completion":12905,"start":12906,"enrollment":2004,"conditions":12907,"interventions":12909},"NCT06412198","A Multicenter Phase 1b\u002F2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations",[87,88],"2029-03-01","2024-08-28",[10674,12908],"KRAS G12C Mutations",[1683,12910,10678],"Cemiplimab",{"nctId":1659,"briefTitle":1660,"status":102,"phases":12912,"primaryCompletion":1662,"completion":1662,"start":1663,"enrollment":1664,"conditions":12913,"interventions":12914},[87,88],[1666,1667,1668,1669,1670,1671,1672,1673,1674,1675,1676,1677,1678,1679,1680,1681],[1683,1684,1050],{"nctId":6815,"briefTitle":6816,"status":279,"phases":12916,"primaryCompletion":6818,"completion":6819,"start":6820,"enrollment":3521,"conditions":12917,"interventions":12918},[87,88],[3195,6822,2631],[803,1070,1683,511],{"nctId":12920,"briefTitle":12921,"status":102,"phases":12922,"primaryCompletion":281,"completion":281,"start":12923,"enrollment":4171,"conditions":12924,"interventions":12926},"NCT04616183","LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer",[87,88],"2020-12-02",[1667,1898,1669,1671,1899,1672,1900,1901,1673,1902,1903,1674,1904,1905,1675,1906,1907,1676,1908,1909,1677,1910,1911,1678,1912,1913,1679,1914,1680,12925,1681],"Unresectable Colorectal Carcinoma",[12927,1683,12928],"Abemaciclib","ERK1\u002F2 Inhibitor LY3214996",{"nctId":10066,"briefTitle":10067,"status":130,"phases":12930,"primaryCompletion":2212,"completion":2212,"start":4351,"enrollment":473,"conditions":12931,"interventions":12932},[88],[242],[1683,1369,1376],{"nctId":12934,"briefTitle":12935,"status":279,"phases":12936,"primaryCompletion":12329,"completion":12329,"start":12937,"enrollment":1922,"conditions":12938,"interventions":12940},"NCT06369259","Open-label Phase 2 Study of Avutometinib (RAF\u002FMEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer",[88],"2025-02-24",[12939],"Advanced Colorectal Cancer",[12941,1683,12942],"Defactinib","Avutometinib",{"nctId":7957,"briefTitle":7958,"status":182,"phases":12944,"primaryCompletion":3446,"completion":3446,"start":7960,"enrollment":296,"conditions":12945,"interventions":12946},[88],[7962,7963],[53,974,7965,1710],{"nctId":12948,"briefTitle":12949,"status":279,"phases":12950,"primaryCompletion":12951,"completion":12951,"start":7168,"enrollment":539,"conditions":12952,"interventions":12954},"NCT06448026","Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).",[88],"2027-05-15",[12953],"Locally Recurrent Oral Cavity Squamous Cell Carcinoma",[12910,1683],{"nctId":12956,"briefTitle":12957,"status":203,"phases":12958,"primaryCompletion":4843,"completion":4843,"start":4723,"enrollment":124,"conditions":12959,"interventions":12960},"NCT00766220","Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver",[88],[3154,3195],[12961,1683,4022],"SIR-spheres Agent Administration",{"nctId":12455,"briefTitle":12456,"status":130,"phases":12963,"primaryCompletion":2968,"completion":2968,"start":2213,"enrollment":34,"conditions":12964,"interventions":12965},[88],[4107],[1683,2369,1375,1368],{"nctId":12967,"briefTitle":12968,"status":102,"phases":12969,"primaryCompletion":549,"completion":549,"start":12970,"enrollment":1409,"conditions":12971,"interventions":12975},"NCT05041127","Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma",[88],"2022-05-27",[12972,12973,12974],"Chordoma","Metastatic Chordoma","Unresectable Chordoma",[1683],{"nctId":12977,"briefTitle":12978,"status":203,"phases":12979,"primaryCompletion":4835,"start":11040,"enrollment":124,"conditions":12980,"interventions":12981},"NCT01427205","Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)",[88],[242],[1683,12982],"OSI-906",{"nctId":12984,"briefTitle":12985,"status":130,"phases":12986,"primaryCompletion":12987,"completion":12987,"start":12988,"enrollment":834,"conditions":12989,"interventions":12990},"NCT00957853","Preoperative Treatment With Cetuximab and\u002For IMC-A12",[88],"2018-08-15","2011-10-17",[450],[1683,12991],"IMC-A12",{"nctId":4295,"briefTitle":4296,"status":102,"phases":12993,"primaryCompletion":224,"completion":224,"start":4298,"enrollment":4299,"conditions":12994,"interventions":12995},[88],[450],[1376,1369,1683,1710,1709,1371],{"nctId":12997,"briefTitle":12998,"status":130,"phases":12999,"primaryCompletion":4085,"completion":4085,"start":6384,"enrollment":1922,"conditions":13000,"interventions":13001},"NCT00392769","Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer",[88],[2809],[1683],{"trials":13003,"activeCount":124},[],{"trials":13005,"activeCount":124},[],{"trials":13007,"activeCount":124},[],{"intervention":1083,"totalTrials":834,"cells":13009},{"EARLY_PHASE1":13010,"PHASE1":13012,"PHASE2":13022,"PHASE3":13115,"PHASE4":13117,"NA":13119},{"trials":13011,"activeCount":124},[],{"trials":13013,"activeCount":166,"soonestReadout":6282},[13014],{"nctId":13015,"briefTitle":13016,"status":546,"phases":13017,"primaryCompletion":6282,"completion":13018,"start":12507,"enrollment":1131,"conditions":13019,"interventions":13021},"NCT07283640","A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia",[87],"2031-08-31",[1083,1198,7228,13020],"KMT2A-rearranged",[1198,1083],{"trials":13023,"activeCount":95,"soonestReadout":2104},[13024,13031,13035,13039,13043,13047,13055,13064,13074,13078,13082,13091,13100,13104,13108],{"nctId":13025,"briefTitle":13026,"status":130,"phases":13027,"primaryCompletion":13028,"completion":13028,"start":3761,"enrollment":3820,"conditions":13029,"interventions":13030},"NCT02807883","Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia",[88],"2022-02-01",[1122],[1083],{"nctId":2464,"briefTitle":2465,"status":279,"phases":13032,"primaryCompletion":2467,"completion":2467,"start":2468,"enrollment":2469,"conditions":13033,"interventions":13034},[87,88],[2471,2472,2473,2474,2475,1142,2415,1144,2419],[1083,803,654,62,2477,805,806,809,894,1016],{"nctId":2497,"briefTitle":2498,"status":279,"phases":13036,"primaryCompletion":2104,"completion":2104,"start":2500,"enrollment":1975,"conditions":13037,"interventions":13038},[88],[2502,2503],[1083,803,654,62,804,2477,805,806,2425,809,894,810],{"nctId":2515,"briefTitle":2516,"status":182,"phases":13040,"primaryCompletion":2518,"completion":2518,"start":2519,"enrollment":230,"conditions":13041,"interventions":13042},[88],[2521,1142,1144],[1083,803,654,62,1069,1373,805,806,1071,894,810],{"nctId":9634,"briefTitle":9635,"status":279,"phases":13044,"primaryCompletion":1325,"completion":1325,"start":9637,"enrollment":861,"conditions":13045,"interventions":13046},[88],[1205,1122,2561,644,912,913,914,915],[1083,654,806,1124],{"nctId":13048,"briefTitle":13049,"status":279,"phases":13050,"primaryCompletion":4005,"completion":4006,"start":13051,"enrollment":517,"conditions":13052,"interventions":13054},"NCT06308588","Phase I\u002FII Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",[87,88],"2024-08-05",[13053,1122],"Philadelphia Chromosome-Positive",[1083,1082],{"nctId":13056,"briefTitle":13057,"status":546,"phases":13058,"primaryCompletion":13059,"completion":13060,"start":13061,"enrollment":517,"conditions":13062,"interventions":13063},"NCT07192237","Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia",[88],"2030-10-12","2032-10-12","2026-09-27",[8577,1083,1122],[1083],{"nctId":13065,"briefTitle":13066,"status":102,"phases":13067,"primaryCompletion":6952,"completion":6953,"start":13068,"enrollment":1231,"conditions":13069,"interventions":13071},"NCT07153796","A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia",[88],"2026-01-30",[13070],"B-cell Acute Lymphoblastic Leukemia",[1083,13072,13073],"Mini-CVD","MTX\u002FARA-C",{"nctId":1980,"briefTitle":1981,"status":182,"phases":13075,"primaryCompletion":1983,"completion":1983,"start":1984,"enrollment":910,"conditions":13076,"interventions":13077},[88],[1986,1987],[1083,62,767,1050],{"nctId":1073,"briefTitle":1074,"status":546,"phases":13079,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":406,"conditions":13080,"interventions":13081},[87,88],[1080],[1070,654,655,1069,480,1082,1083],{"nctId":13083,"briefTitle":13084,"status":279,"phases":13085,"primaryCompletion":281,"completion":571,"start":13086,"enrollment":517,"conditions":13087,"interventions":13089},"NCT06287229","Phase Ib\u002FII Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed\u002FRefractory (R\u002FR) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab\u002FHCVAD-inotuzumab-blinatumomab",[87,88],"2024-07-11",[9033,13088],"B-cell Acute Lymphocytic Leukemia",[1083,2477,499,13090],"Mini-hyper-CVD",{"nctId":13092,"briefTitle":13093,"status":546,"phases":13094,"primaryCompletion":6952,"completion":6953,"start":13095,"enrollment":1034,"conditions":13096,"interventions":13098},"NCT07178912","Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and\u002For BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)",[88],"2026-08-27",[13097,1083,12567,7228,912],"Phase II Clinical Trial",[1083,13099],"olverembatinib",{"nctId":2813,"briefTitle":2814,"status":279,"phases":13101,"primaryCompletion":224,"completion":548,"start":2816,"enrollment":2159,"conditions":13102,"interventions":13103},[88],[15],[803,1016,1083,806,654,805,809,1071,2819,894,62],{"nctId":7277,"briefTitle":7278,"status":102,"phases":13105,"primaryCompletion":115,"completion":115,"start":7280,"enrollment":492,"conditions":13106,"interventions":13107},[88],[1205,1122,7282,644,913,914],[1083,803,654,1069,806,1071,1124,894,1016],{"nctId":13109,"briefTitle":13110,"status":130,"phases":13111,"primaryCompletion":13112,"completion":13112,"start":4635,"enrollment":593,"conditions":13113,"interventions":13114},"NCT02458014","Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease",[88],"2025-09-16",[2649,2502,3040,912],[1083],{"trials":13116,"activeCount":124},[],{"trials":13118,"activeCount":124},[],{"trials":13120,"activeCount":124},[],{"intervention":1786,"totalTrials":448,"cells":13122},{"EARLY_PHASE1":13123,"PHASE1":13166,"PHASE2":13225,"PHASE3":13368,"PHASE4":13370,"NA":13372},{"trials":13124,"activeCount":166,"soonestReadout":224},[13125,13141],{"nctId":13126,"briefTitle":13127,"status":130,"phases":13128,"primaryCompletion":13129,"completion":13130,"start":13131,"enrollment":834,"conditions":13132,"interventions":13139},"NCT03132467","Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer",[86],"2019-01-31","2024-05-20","2017-06-13",[8027,13133,13134,7308,7309,7310,7311,11800,7699,13135,13136,13137,13138,7313,7314,7315,7316],"Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Progesterone Receptor Positive","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8",[1786,13140],"Tremelimumab",{"nctId":13142,"briefTitle":13143,"status":102,"phases":13144,"primaryCompletion":224,"completion":224,"start":9278,"enrollment":2700,"conditions":13145,"interventions":13165},"NCT02812420","Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery",[86],[13146,13147,13148,13149,13150,13151,13152,13153,13154,13155,13156,13157,13158,13159,13160,13161,13162,13163,13164],"Hydronephrosis","Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant","Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant","Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant","Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant","Renal Pelvis Urothelial Carcinoma","Stage II Bladder Urothelial Carcinoma AJCC v6 and v7","Stage II Renal Pelvis Cancer AJCC v7","Stage II Ureter Cancer AJCC v7","Stage II Urethral Cancer AJCC v7","Stage III Bladder Urothelial Carcinoma AJCC v6 and v7","Stage III Renal Pelvis Cancer AJCC v7","Stage III Ureter Cancer AJCC v7","Stage III Urethral Cancer AJCC v7","Stage IV Renal Pelvis Cancer AJCC v7","Stage IV Ureter Cancer AJCC v7","Stage IV Urethral Cancer AJCC v7","Ureter Urothelial Carcinoma","Urethral Urothelial Carcinoma",[1786,13140],{"trials":13167,"activeCount":124},[13168,13201,13209,13218],{"nctId":13169,"briefTitle":13170,"status":130,"phases":13171,"primaryCompletion":13172,"completion":13172,"start":13173,"enrollment":1131,"conditions":13174,"interventions":13200},"NCT03452332","Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers",[87],"2023-08-11","2018-07-18",[13175,13176,13177,11093,11095,13178,1441,13179,13180,13181,13182,13183,1456,13184,13185,13186,13187,13188,3856,13189,3857,13190,3858,3859,13191,13192,13193,13194,13195,3860,1468,13196,13197,11110,13198,13199],"Advanced Cervical Adenocarcinoma","Advanced Vaginal Carcinoma","Advanced Vulvar Carcinoma","Metastatic Cervical Adenocarcinoma","Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified","Metastatic Vaginal Adenocarcinoma","Metastatic Vaginal Carcinoma","Metastatic Vulvar Carcinoma","Recurrent Cervical Adenocarcinoma","Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified","Recurrent Vaginal Carcinoma","Recurrent Vulvar Carcinoma","Stage III Cervical Cancer AJCC v8","Stage III Vaginal Cancer AJCC v8","Stage IIIA Cervical Cancer AJCC v8","Stage IIIB Cervical Cancer AJCC v8","Stage IV Cervical Cancer AJCC v8","Stage IV Vaginal Cancer AJCC v8","Stage IV Vulvar Cancer AJCC v8","Stage IVA Cervical Cancer AJCC v8","Stage IVA Vaginal Cancer AJCC v8","Stage IVB Vaginal Cancer AJCC v8","Stage IVB Vulvar Cancer AJCC v8","Vulvar Adenocarcinoma","Vulvar Squamous Cell Carcinoma",[1786,13140],{"nctId":13202,"briefTitle":13203,"status":130,"phases":13204,"primaryCompletion":173,"completion":173,"start":13205,"enrollment":2865,"conditions":13206,"interventions":13208},"NCT03144778","Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer",[87],"2017-07-12",[13207,1619,1620],"Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7",[1786,13140],{"nctId":13210,"briefTitle":13211,"status":130,"phases":13212,"primaryCompletion":13213,"completion":13213,"start":13214,"enrollment":628,"conditions":13215,"interventions":13217},"NCT02754856","Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery",[87],"2023-01-30","2016-08-29",[1877,13216,5008,5009,5010],"Resectable Mass",[1786,13140],{"nctId":13219,"briefTitle":13220,"status":203,"phases":13221,"primaryCompletion":3945,"completion":3945,"start":11590,"enrollment":124,"conditions":13222,"interventions":13224},"NCT05848843","A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations",[87],[24,13223],"Gastro-intestinal Cancer",[1786,10678],{"trials":13226,"activeCount":1496,"soonestReadout":13348},[13227,13236,13240,13248,13256,13270,13274,13278,13282,13291,13295,13299,13303,13313,13324,13331,13335,13344,13357],{"nctId":13228,"briefTitle":13229,"status":130,"phases":13230,"primaryCompletion":13231,"completion":13231,"start":13232,"enrollment":517,"conditions":13233,"interventions":13234},"NCT03581487","Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer",[87,88],"2025-10-30","2019-04-01",[1836,1319,1361,1362],[1786,13235,13140],"Selumetinib",{"nctId":12376,"briefTitle":12377,"status":102,"phases":13237,"primaryCompletion":1939,"completion":1939,"start":12379,"enrollment":2018,"conditions":13238,"interventions":13239},[88],[4018,12381,12382,12383,8175,8176],[1786,2369,4023,12385],{"nctId":13241,"briefTitle":13242,"status":279,"phases":13243,"primaryCompletion":224,"completion":224,"start":13244,"enrollment":2865,"conditions":13245,"interventions":13246},"NCT05632809","REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)",[88],"2023-01-10",[24],[13247,1786],"NKTR-255",{"nctId":13249,"briefTitle":13250,"status":130,"phases":13251,"primaryCompletion":13252,"completion":13252,"start":13253,"enrollment":1409,"conditions":13254,"interventions":13255},"NCT03428126","Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer",[88],"2022-05-05","2018-03-21",[7647,3195,3154],[1786,874],{"nctId":13257,"briefTitle":13258,"status":182,"phases":13259,"primaryCompletion":1518,"completion":1518,"start":13260,"enrollment":1243,"conditions":13261,"interventions":13268},"NCT03439085","DNA Plasmid-encoding Interleukin-12\u002FHPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers",[88],"2018-11-14",[13262,13263,2924,13264,1456,2925,13265,13185,13186,2926,13266,13191,13267,13192,13193,13194,13195,3860,1468,13196,13197],"Human Papillomavirus-16 Positive","Human Papillomavirus-18 Positive","Recurrent Anal Canal Carcinoma","Recurrent Penile Carcinoma","Stage IV Anal Cancer AJCC v8","Stage IV Penile Cancer AJCC v8",[13269,1786],"DNA Plasmid-encoding Interleukin-12\u002FHPV DNA Plasmids Therapeutic Vaccine MEDI0457",{"nctId":10043,"briefTitle":10044,"status":102,"phases":13271,"primaryCompletion":224,"completion":224,"start":10046,"enrollment":550,"conditions":13272,"interventions":13273},[87,88],[4957,4958,4959,4960,4961,4962,4963,4964,4965,4966,4967,4968,4969,4970,4971],[1369,1786,1376],{"nctId":3962,"briefTitle":3963,"status":102,"phases":13275,"primaryCompletion":1427,"completion":1427,"start":3965,"enrollment":3726,"conditions":13276,"interventions":13277},[88],[3967,1293],[1786,806,1868,804,1709],{"nctId":4002,"briefTitle":4003,"status":279,"phases":13279,"primaryCompletion":4005,"completion":4006,"start":4007,"enrollment":676,"conditions":13280,"interventions":13281},[87,88],[4009],[2369,1709,1786,4011],{"nctId":13283,"briefTitle":13284,"status":130,"phases":13285,"primaryCompletion":13286,"completion":13286,"start":13287,"enrollment":2004,"conditions":13288,"interventions":13290},"NCT03204812","Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer",[88],"2021-04-13","2017-07-14",[3544,13289,5122,3546,3547,3548],"Metastatic Malignant Neoplasm in the Bone",[1786,13140],{"nctId":1762,"briefTitle":1763,"status":182,"phases":13292,"primaryCompletion":1717,"completion":1717,"start":1765,"enrollment":1766,"conditions":13293,"interventions":13294},[87,88],[1768,1769,1343,1770,1771,1772,1344,1773,1312,1774,1348,1775,1349,1776,1350,1777,1351,1352,1353,1778,1779,1355,1356,1780,1357,1781,1358,1359,1782,1319,1360,1783,1361,1784,1362],[718,693,1786,1050,53,1787],{"nctId":10100,"briefTitle":10101,"status":279,"phases":13296,"primaryCompletion":5310,"completion":5310,"start":10103,"enrollment":240,"conditions":13297,"interventions":13298},[88],[1355,10105,1357,1707,1358,3845,1359],[1369,1786,2369,4023,1376,1377],{"nctId":5609,"briefTitle":5610,"status":102,"phases":13300,"primaryCompletion":224,"completion":224,"start":5612,"enrollment":3379,"conditions":13301,"interventions":13302},[87,88],[5614,1319,1361,1362],[1369,1786,2424,1374],{"nctId":13304,"briefTitle":13305,"status":203,"phases":13306,"primaryCompletion":13307,"completion":13308,"start":9357,"enrollment":124,"conditions":13309,"interventions":13312},"NCT03004105","MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)",[88],"2023-05","2024-05",[12265,13310,13311],"Advanced Lung Cancer","Recurrent Nonsmall Cell Lung Cancer",[13235,1786],{"nctId":13314,"briefTitle":13315,"status":182,"phases":13316,"primaryCompletion":13317,"completion":13317,"start":13318,"enrollment":3726,"conditions":13319,"interventions":13322},"NCT04019288","AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[87,88],"2024-10-24","2019-12-03",[1452,1454,1455,1458,1460,1461,13320,11741,13321],"Refractory Fallopian Tube Carcinoma","Refractory Primary Peritoneal Carcinoma",[13323,1786],"Batiraxcept",{"nctId":13325,"briefTitle":13326,"status":130,"phases":13327,"primaryCompletion":11652,"completion":11652,"start":13328,"enrollment":1222,"conditions":13329,"interventions":13330},"NCT03026062","Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[88],"2017-05-18",[1452,1454,1455,1458,1460,1461,13320,11741,13321],[1786,13140],{"nctId":4237,"briefTitle":4238,"status":279,"phases":13332,"primaryCompletion":4240,"completion":4241,"start":4242,"enrollment":1034,"conditions":13333,"interventions":13334},[88],[4244],[1786,2369,1709],{"nctId":13336,"briefTitle":13337,"status":130,"phases":13338,"primaryCompletion":13339,"completion":13339,"start":13340,"enrollment":6385,"conditions":13341,"interventions":13343},"NCT02815995","Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes",[88],"2024-06-17","2016-08-16",[13342],"Advanced and\u002For Metastatic Sarcoma",[1786,13140],{"nctId":13345,"briefTitle":13346,"status":102,"phases":13347,"primaryCompletion":13348,"completion":13348,"start":13349,"enrollment":2865,"conditions":13350,"interventions":13355},"NCT02983578","Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer",[88],"2025-08-30","2017-03-02",[13351,1769,1388,13352,6905,13353,13354,8174,1672,1355,8177,1673,1357,1674,1358,1675,1359,1676,1319,8115,1677,1361,1678,1362,1679],"Advanced Colorectal Carcinoma","Mismatch Repair Deficiency","Refractory Lung Carcinoma","Refractory Pancreatic Carcinoma",[13356,1786],"Danvatirsen",{"nctId":13358,"briefTitle":13359,"status":102,"phases":13360,"primaryCompletion":504,"completion":504,"start":13361,"enrollment":1308,"conditions":13362,"interventions":13367},"NCT04668300","Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma",[88],"2020-11-26",[13363,13364,11593,13365,1508,1591,13366,1592],"Metastatic Angiosarcoma","Metastatic Dedifferentiated Liposarcoma","Recurrent Angiosarcoma","Refractory Dedifferentiated Liposarcoma",[1786,12385],{"trials":13369,"activeCount":124},[],{"trials":13371,"activeCount":124},[],{"trials":13373,"activeCount":124},[],{"intervention":1402,"totalTrials":8325,"cells":13375},{"EARLY_PHASE1":13376,"PHASE1":13386,"PHASE2":13448,"PHASE3":13710,"PHASE4":13712,"NA":13714},{"trials":13377,"activeCount":124},[13378],{"nctId":13379,"briefTitle":13380,"status":130,"phases":13381,"primaryCompletion":7905,"completion":7905,"start":13382,"enrollment":406,"conditions":13383,"interventions":13384},"NCT03631043","Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma",[86],"2018-12-21",[7505],[1402,13385],"Vaccine Therapy",{"trials":13387,"activeCount":124},[13388,13392,13396,13404,13408,13412,13416,13420,13426,13430,13434,13440,13444],{"nctId":3047,"briefTitle":3048,"status":3049,"phases":13389,"primaryCompletion":3051,"completion":3051,"start":3052,"enrollment":2018,"conditions":13390,"interventions":13391},[87],[1205,643,2512,678,1025,3054,3055,3056,3057,3058,30,913,608,665,3059,3060,666,914,528,3061,3062,529,651,682,882],[803,1005,1402,2293,2195,3064,894,2196],{"nctId":10749,"briefTitle":10750,"status":130,"phases":13393,"primaryCompletion":3493,"completion":3493,"start":3996,"enrollment":10752,"conditions":13394,"interventions":13395},[87],[33],[1402,1275,2207,6656,1402,1375,1113,10755],{"nctId":13397,"briefTitle":13398,"status":182,"phases":13399,"primaryCompletion":2316,"completion":2316,"start":13400,"enrollment":628,"conditions":13401,"interventions":13403},"NCT00671801","Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I",[87],"2008-04-29",[13402],"Malignant Gliomas",[4022,1402],{"nctId":6481,"briefTitle":6482,"status":130,"phases":13405,"primaryCompletion":6484,"completion":6484,"start":6485,"enrollment":186,"conditions":13406,"interventions":13407},[87],[15],[1402,894,1070,803,654],{"nctId":2239,"briefTitle":2240,"status":182,"phases":13409,"primaryCompletion":2242,"completion":2242,"start":2243,"enrollment":121,"conditions":13410,"interventions":13411},[87],[2245],[1402,62,2247],{"nctId":11765,"briefTitle":11766,"status":182,"phases":13413,"primaryCompletion":2232,"completion":2232,"start":6410,"enrollment":539,"conditions":13414,"interventions":13415},[87],[27],[1402,1376],{"nctId":10396,"briefTitle":10397,"status":182,"phases":13417,"primaryCompletion":2889,"completion":2889,"start":2326,"enrollment":166,"conditions":13418,"interventions":13419},[87],[33],[510,1402,10401],{"nctId":13421,"briefTitle":13422,"status":130,"phases":13423,"primaryCompletion":3805,"start":4183,"enrollment":163,"conditions":13424,"interventions":13425},"NCT00495872","Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor",[87],[1924],[1028,3847,7180,1402,2207,10918,9894],{"nctId":3567,"briefTitle":3568,"status":130,"phases":13427,"primaryCompletion":3570,"completion":3570,"start":3571,"enrollment":1699,"conditions":13428,"interventions":13429},[87],[33],[1049,1402],{"nctId":1394,"briefTitle":1395,"status":203,"phases":13431,"primaryCompletion":991,"completion":991,"start":1397,"enrollment":124,"conditions":13432,"interventions":13433},[87],[1399,1400],[1050,1402,62,1049],{"nctId":13435,"briefTitle":13436,"status":130,"phases":13437,"primaryCompletion":6828,"completion":6828,"start":2213,"enrollment":3521,"conditions":13438,"interventions":13439},"NCT00412581","Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma",[87],[1729],[1402,1869],{"nctId":8293,"briefTitle":8294,"status":182,"phases":13441,"primaryCompletion":8296,"completion":8296,"start":3769,"enrollment":550,"conditions":13442,"interventions":13443},[87],[21],[2227,1402,894],{"nctId":2332,"briefTitle":2333,"status":130,"phases":13445,"primaryCompletion":2335,"completion":2335,"start":2336,"enrollment":2337,"conditions":13446,"interventions":13447},[87],[2245],[2340,75,1402,62],{"trials":13449,"activeCount":95,"soonestReadout":8063},[13450,13454,13458,13465,13472,13476,13480,13489,13496,13500,13510,13516,13520,13528,13534,13544,13552,13556,13567,13571,13577,13581,13590,13594,13598,13606,13610,13619,13623,13627,13631,13635,13639,13650,13660,13669,13676,13680,13686,13690,13694,13698,13702],{"nctId":8310,"briefTitle":8311,"status":130,"phases":13451,"primaryCompletion":2698,"completion":2698,"start":4697,"enrollment":1034,"conditions":13452,"interventions":13453},[88],[712,716],[1402,894],{"nctId":2376,"briefTitle":2377,"status":130,"phases":13455,"primaryCompletion":2379,"completion":2379,"start":2380,"enrollment":2337,"conditions":13456,"interventions":13457},[87,88],[2223,2224],[62,1402,2383],{"nctId":13459,"briefTitle":13460,"status":182,"phases":13461,"primaryCompletion":4511,"completion":4511,"start":9560,"enrollment":3197,"conditions":13462,"interventions":13464},"NCT00675441","Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)",[88],[13463],"Graft-versus-Host Disease",[1402],{"nctId":13466,"briefTitle":13467,"status":182,"phases":13468,"primaryCompletion":9859,"completion":9859,"start":5988,"enrollment":166,"conditions":13469,"interventions":13470},"NCT01222195","Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)",[88],[15],[1402,13471],"Darbepoetin alfa",{"nctId":8391,"briefTitle":8392,"status":102,"phases":13473,"primaryCompletion":504,"completion":504,"start":8394,"enrollment":1100,"conditions":13474,"interventions":13475},[88],[15,21],[894,1402],{"nctId":8398,"briefTitle":8399,"status":102,"phases":13477,"primaryCompletion":3880,"completion":3880,"start":8401,"enrollment":1034,"conditions":13478,"interventions":13479},[88],[8403,8404,8405,8406,8407,8408,8409],[668,1402,894],{"nctId":13481,"briefTitle":13482,"status":279,"phases":13483,"primaryCompletion":224,"completion":224,"start":13484,"enrollment":2402,"conditions":13485,"interventions":13486},"NCT05776979","Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients",[88],"2023-08-17",[1400],[13487,13488],"Isatuximab","lenalidomide",{"nctId":13490,"briefTitle":13491,"status":182,"phases":13492,"primaryCompletion":11064,"completion":11064,"start":13493,"enrollment":910,"conditions":13494,"interventions":13495},"NCT02225275","Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[88],"2016-03-31",[665,666,528,529],[1402,669],{"nctId":3635,"briefTitle":3636,"status":130,"phases":13497,"primaryCompletion":3638,"completion":3638,"start":3639,"enrollment":1243,"conditions":13498,"interventions":13499},[88],[3641,359,15,21,3135,3642],[1049,1402],{"nctId":13501,"briefTitle":13502,"status":130,"phases":13503,"primaryCompletion":2457,"completion":2457,"start":13504,"enrollment":724,"conditions":13505,"interventions":13509},"NCT02871219","Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma",[88],"2016-12-06",[8379,8380,8403,8404,8406,8407,13506,2923,13507,8409,13508,2135,5946],"Bulky Disease","Fever","Night Sweats",[1402,669],{"nctId":13511,"briefTitle":13512,"status":182,"phases":13513,"primaryCompletion":3668,"completion":3668,"start":2932,"enrollment":296,"conditions":13514,"interventions":13515},"NCT00684242","Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain",[88],[1942,5979],[1402],{"nctId":5571,"briefTitle":5572,"status":130,"phases":13517,"primaryCompletion":5574,"completion":5574,"start":5575,"enrollment":1034,"conditions":13518,"interventions":13519},[88],[5577],[803,804,2424,767,1402,809,894,810],{"nctId":13521,"briefTitle":13522,"status":130,"phases":13523,"primaryCompletion":13524,"completion":13524,"start":4731,"enrollment":230,"conditions":13525,"interventions":13527},"NCT00792077","A Pilot Study to Investigate the Effect of Cytotoxic Therapy and\u002For Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue",[88],"2020-08-03",[15,13526],"CLL",[1402],{"nctId":13529,"briefTitle":13530,"status":130,"phases":13531,"primaryCompletion":6410,"completion":6410,"start":3988,"enrollment":195,"conditions":13532,"interventions":13533},"NCT00267059","Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)",[88],[712,15],[1402],{"nctId":13535,"briefTitle":13536,"status":182,"phases":13537,"primaryCompletion":13538,"completion":13538,"start":13539,"enrollment":1231,"conditions":13540,"interventions":13541},"NCT01924169","Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)",[88],"2017-02-21","2014-11-24",[2742],[1402,13542,13543],"Influenza Vaccine","Pneumovax Vaccine",{"nctId":13545,"briefTitle":13546,"status":102,"phases":13547,"primaryCompletion":815,"completion":815,"start":13548,"enrollment":5774,"conditions":13549,"interventions":13550},"NCT02420860","Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma",[88],"2015-04-14",[4743,3135],[13551,1402],"Elotuzumab",{"nctId":8605,"briefTitle":8606,"status":279,"phases":13553,"primaryCompletion":238,"completion":238,"start":8608,"enrollment":1034,"conditions":13554,"interventions":13555},[87,88],[21],[894,1402,3550],{"nctId":13557,"briefTitle":13558,"status":130,"phases":13559,"primaryCompletion":3018,"completion":3018,"start":13560,"enrollment":593,"conditions":13561,"interventions":13566},"NCT01002755","Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[88],"2010-01-19",[712,2923,13507,13562,10176,13563,13508,13564,716,13565],"Hypogammaglobulinemia","Lymphocytosis","Paraproteinemia","Thrombocytopenia",[1402,2425],{"nctId":11354,"briefTitle":11355,"status":130,"phases":13568,"primaryCompletion":11357,"completion":11357,"start":11358,"enrollment":517,"conditions":13569,"interventions":13570},[88],[3429],[1402,809],{"nctId":13572,"briefTitle":13573,"status":130,"phases":13574,"primaryCompletion":3494,"completion":3494,"start":5733,"enrollment":2402,"conditions":13575,"interventions":13576},"NCT00535873","Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older",[88],[15,13526,712,716],[1402],{"nctId":2685,"briefTitle":2686,"status":203,"phases":13578,"primaryCompletion":2688,"completion":2688,"start":2689,"enrollment":124,"conditions":13579,"interventions":13580},[88],[2691,2692,891],[62,767,1402,894],{"nctId":13582,"briefTitle":13583,"status":130,"phases":13584,"primaryCompletion":13585,"completion":13585,"start":13586,"enrollment":25,"conditions":13587,"interventions":13588},"NCT01038635","5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)",[87,88],"2015-11","2009-12",[15],[13589,1402],"5-Azacytidine",{"nctId":5626,"briefTitle":5627,"status":130,"phases":13591,"primaryCompletion":5629,"completion":5629,"start":5630,"enrollment":492,"conditions":13592,"interventions":13593},[88],[891,4559,5632,5633,4561,5634,5635],[4365,5515,654,2424,1069,1402,2293,894],{"nctId":8060,"briefTitle":8061,"status":102,"phases":13595,"primaryCompletion":8063,"completion":8064,"start":8065,"enrollment":1140,"conditions":13596,"interventions":13597},[88],[4559,8067,8068,8069],[1402,53,894],{"nctId":13599,"briefTitle":13600,"status":130,"phases":13601,"primaryCompletion":13602,"completion":13602,"start":13603,"enrollment":3354,"conditions":13604,"interventions":13605},"NCT01718743","Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma",[88],"2023-04-12","2012-12-03",[4743,3135],[8569,1402],{"nctId":11416,"briefTitle":11417,"status":130,"phases":13607,"primaryCompletion":8323,"completion":8323,"start":11419,"enrollment":2004,"conditions":13608,"interventions":13609},[88],[4580],[598,1402,809],{"nctId":13611,"briefTitle":13612,"status":279,"phases":13613,"primaryCompletion":224,"completion":224,"start":13614,"enrollment":25,"conditions":13615,"interventions":13617},"NCT05091372","Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma",[88],"2022-12-01",[13616],"Myeloma Multiple",[13618,1402],"Belantamab mafodotin",{"nctId":8778,"briefTitle":8779,"status":102,"phases":13620,"primaryCompletion":8781,"completion":8781,"start":3965,"enrollment":2997,"conditions":13621,"interventions":13622},[87,88],[8783,8404,8405,8784,8406,8407,8408,8785,8786,8787,8788,5634,8789,6774,790,8790,6775,6776,8791,715],[8793,1402,894],{"nctId":4790,"briefTitle":4791,"status":279,"phases":13624,"primaryCompletion":548,"completion":490,"start":4793,"enrollment":517,"conditions":13625,"interventions":13626},[88],[1400,4795,4796],[4798,1402,4622,2293,1004,2374],{"nctId":8795,"briefTitle":8796,"status":182,"phases":13628,"primaryCompletion":8798,"completion":8798,"start":8799,"enrollment":2865,"conditions":13629,"interventions":13630},[88],[712],[1402,1070,894,4537,6545,1178],{"nctId":7213,"briefTitle":7214,"status":102,"phases":13632,"primaryCompletion":7216,"completion":7216,"start":7217,"enrollment":2933,"conditions":13633,"interventions":13634},[88],[7219],[668,803,804,1402,809,894,3338,1016],{"nctId":2774,"briefTitle":2775,"status":130,"phases":13636,"primaryCompletion":2777,"completion":2777,"start":2778,"enrollment":2779,"conditions":13637,"interventions":13638},[87,88],[2245],[1402,75,2782,62],{"nctId":13640,"briefTitle":13641,"status":279,"phases":13642,"primaryCompletion":13643,"completion":13643,"start":13644,"enrollment":593,"conditions":13645,"interventions":13647},"NCT05615636","A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL",[88],"2027-08-19","2023-04-28",[1866,3393,13646],"Relapsed B-cell NHL",[13648,13649,3338,1402],"Mosunetuzumab","Polatuzumab vedotin",{"nctId":13651,"briefTitle":13652,"status":130,"phases":13653,"primaryCompletion":13654,"completion":13654,"start":13655,"enrollment":1260,"conditions":13656,"interventions":13659},"NCT01995669","Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma",[87,88],"2023-01-23","2014-05-27",[8409,5632,8067,8068,13657,13658,666,5634,8790,529],"Recurrent Grade 3 Follicular Lymphoma","Recurrent Marginal Zone Lymphoma",[1402,669],{"nctId":13661,"briefTitle":13662,"status":130,"phases":13663,"primaryCompletion":13664,"completion":13664,"start":13665,"enrollment":2647,"conditions":13666,"interventions":13667},"NCT01729091","Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma",[88],"2024-06-25","2013-06-10",[3396,3135],[13551,1402,2293,3064,13668],"Umbilical Cord Blood-Derived Lymphocyte Therapy",{"nctId":13670,"briefTitle":13671,"status":130,"phases":13672,"primaryCompletion":10449,"completion":10449,"start":13673,"enrollment":2402,"conditions":13674,"interventions":13675},"NCT01079936","Lenalidomide and High-Dose Melphalan",[87,88],"2010-03",[2245,2755],[1402,2293],{"nctId":8854,"briefTitle":8855,"status":130,"phases":13677,"primaryCompletion":2288,"completion":2288,"start":4084,"enrollment":2700,"conditions":13678,"interventions":13679},[87,88],[21],[1402,894],{"nctId":13681,"briefTitle":13682,"status":130,"phases":13683,"primaryCompletion":2909,"completion":2909,"start":5988,"enrollment":1922,"conditions":13684,"interventions":13685},"NCT00632359","Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease",[88],[712],[1402],{"nctId":8868,"briefTitle":8869,"status":130,"phases":13687,"primaryCompletion":8871,"completion":8871,"start":8872,"enrollment":473,"conditions":13688,"interventions":13689},[88],[8874,8875,8876,8784,8877,8785,785,8878,8879,8409],[767,1402,894],{"nctId":7372,"briefTitle":7373,"status":130,"phases":13691,"primaryCompletion":7375,"completion":7375,"start":7376,"enrollment":7377,"conditions":13692,"interventions":13693},[87,88],[21],[1402,669,803,1013,1016,809],{"nctId":8896,"briefTitle":8897,"status":130,"phases":13695,"primaryCompletion":8899,"completion":8899,"start":8900,"enrollment":8901,"conditions":13696,"interventions":13697},[88],[8403,8404,8903,8784,8904,8406,8407,8905,8785,8906],[1402,894],{"nctId":2897,"briefTitle":2898,"status":182,"phases":13699,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":186,"conditions":13700,"interventions":13701},[87,88],[21],[1402,2405,2369,1004,2293,894,62,2370,2371,2372,2904,2368],{"nctId":13703,"briefTitle":13704,"status":130,"phases":13705,"primaryCompletion":1165,"completion":1165,"start":13706,"enrollment":1409,"conditions":13707,"interventions":13709},"NCT02126553","Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission",[88],"2014-11-13",[13708,651],"Alkylating Agent-Related Acute Myeloid Leukemia",[1402],{"trials":13711,"activeCount":124},[],{"trials":13713,"activeCount":124},[],{"trials":13715,"activeCount":124},[13716],{"nctId":13717,"briefTitle":13718,"status":182,"phases":13719,"primaryCompletion":8718,"completion":8718,"start":2289,"enrollment":1496,"conditions":13720,"interventions":13721},"NCT01927718","Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)",[91],[2245],[2383,1402],{"intervention":806,"totalTrials":6385,"cells":13723},{"EARLY_PHASE1":13724,"PHASE1":13735,"PHASE2":13745,"PHASE3":13955,"PHASE4":13965,"NA":13967},{"trials":13725,"activeCount":124},[13726],{"nctId":13727,"briefTitle":13728,"status":130,"phases":13729,"primaryCompletion":7770,"completion":7770,"start":13730,"enrollment":1483,"conditions":13731,"interventions":13734},"NCT01737671","Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study",[86],"2012-12-27",[13732,13733],"Brain Tumor","Malignant Neoplasm of Fourth Ventricle of Brain",[806,1113],{"trials":13736,"activeCount":124},[13737,13741],{"nctId":4532,"briefTitle":4533,"status":130,"phases":13738,"primaryCompletion":206,"completion":206,"start":4039,"enrollment":1568,"conditions":13739,"interventions":13740},[87],[30,15],[4537,1004,1070,2374,2196,806,3499],{"nctId":8284,"briefTitle":8285,"status":130,"phases":13742,"primaryCompletion":8287,"completion":8287,"start":8288,"enrollment":1034,"conditions":13743,"interventions":13744},[87],[785,712,3346,891,8290,4559,3642],[3085,6545,1069,1070,806,894,2196],{"trials":13746,"activeCount":95,"soonestReadout":1427},[13747,13751,13755,13759,13763,13767,13771,13775,13779,13783,13787,13791,13795,13799,13803,13807,13811,13815,13819,13823,13827,13831,13835,13839,13843,13847,13851,13855,13859,13867,13871,13875,13879,13883,13887,13891,13895,13899,13903,13907,13911,13915,13919,13923,13927,13931,13935,13939,13943,13947,13951],{"nctId":5519,"briefTitle":5520,"status":130,"phases":13748,"primaryCompletion":4382,"completion":4382,"start":5522,"enrollment":492,"conditions":13749,"interventions":13750},[88],[21,15],[5525,5526,5527,803,2424,1070,2293,894,806,2196],{"nctId":9115,"briefTitle":9116,"status":182,"phases":13752,"primaryCompletion":2846,"completion":2846,"start":5232,"enrollment":834,"conditions":13753,"interventions":13754},[88],[15,21,2245,4580],[1070,2293,2439,2196,806,2374],{"nctId":2432,"briefTitle":2433,"status":130,"phases":13756,"primaryCompletion":2435,"completion":2435,"start":2436,"enrollment":550,"conditions":13757,"interventions":13758},[88],[15],[2439,2424,62,806,2078],{"nctId":6754,"briefTitle":6755,"status":130,"phases":13760,"primaryCompletion":6757,"completion":6757,"start":6758,"enrollment":861,"conditions":13761,"interventions":13762},[88],[1122],[803,1016,1013,4330,2374,806,2584,808],{"nctId":2464,"briefTitle":2465,"status":279,"phases":13764,"primaryCompletion":2467,"completion":2467,"start":2468,"enrollment":2469,"conditions":13765,"interventions":13766},[87,88],[2471,2472,2473,2474,2475,1142,2415,1144,2419],[1083,803,654,62,2477,805,806,809,894,1016],{"nctId":2497,"briefTitle":2498,"status":279,"phases":13768,"primaryCompletion":2104,"completion":2104,"start":2500,"enrollment":1975,"conditions":13769,"interventions":13770},[88],[2502,2503],[1083,803,654,62,804,2477,805,806,2425,809,894,810],{"nctId":3247,"briefTitle":3248,"status":130,"phases":13772,"primaryCompletion":3250,"completion":3250,"start":3251,"enrollment":2159,"conditions":13773,"interventions":13774},[87,88],[359],[3085,2226,1005,2477,806,894,2196],{"nctId":2506,"briefTitle":2507,"status":182,"phases":13776,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":296,"conditions":13777,"interventions":13778},[88],[2512,2502,2472],[803,654,62,804,2477,1373,805,806,2425,809,894,810],{"nctId":2515,"briefTitle":2516,"status":182,"phases":13780,"primaryCompletion":2518,"completion":2518,"start":2519,"enrollment":230,"conditions":13781,"interventions":13782},[88],[2521,1142,1144],[1083,803,654,62,1069,1373,805,806,1071,894,810],{"nctId":4662,"briefTitle":4663,"status":182,"phases":13784,"primaryCompletion":2836,"completion":2836,"start":4665,"enrollment":924,"conditions":13785,"interventions":13786},[88],[15],[2321,1070,1004,4668,2196,806],{"nctId":3962,"briefTitle":3963,"status":102,"phases":13788,"primaryCompletion":1427,"completion":1427,"start":3965,"enrollment":3726,"conditions":13789,"interventions":13790},[88],[3967,1293],[1786,806,1868,804,1709],{"nctId":2524,"briefTitle":2525,"status":130,"phases":13792,"primaryCompletion":2527,"completion":2527,"start":2528,"enrollment":1609,"conditions":13793,"interventions":13794},[88],[2530],[806,1016,2532,62,894],{"nctId":11297,"briefTitle":11298,"status":130,"phases":13796,"primaryCompletion":9512,"completion":10760,"start":11300,"enrollment":296,"conditions":13797,"interventions":13798},[88],[11302],[11304,1373,11305,806,809,11306,810],{"nctId":5591,"briefTitle":5592,"status":130,"phases":13800,"primaryCompletion":5594,"completion":5594,"start":5595,"enrollment":517,"conditions":13801,"interventions":13802},[88],[785,359,5597,21],[3085,75,4365,654,2424,1069,2293,806,894,2196],{"nctId":2546,"briefTitle":2547,"status":130,"phases":13804,"primaryCompletion":2549,"completion":2549,"start":2550,"enrollment":37,"conditions":13805,"interventions":13806},[88],[21],[894,803,1013,1016,62,806,654,809],{"nctId":2554,"briefTitle":2555,"status":130,"phases":13808,"primaryCompletion":2557,"completion":2557,"start":2558,"enrollment":2559,"conditions":13809,"interventions":13810},[88],[1122,2561,644,912,913,915],[803,654,1028,62,1013,806,809,1016],{"nctId":794,"briefTitle":795,"status":279,"phases":13812,"primaryCompletion":772,"completion":772,"start":797,"enrollment":798,"conditions":13813,"interventions":13814},[88],[800,801],[803,654,62,804,805,806,807,808,809,480,810],{"nctId":2577,"briefTitle":2578,"status":130,"phases":13816,"primaryCompletion":1558,"completion":1558,"start":2580,"enrollment":2581,"conditions":13817,"interventions":13818},[88],[21],[803,1114,1016,806,2584,62,2374,2585],{"nctId":9634,"briefTitle":9635,"status":279,"phases":13820,"primaryCompletion":1325,"completion":1325,"start":9637,"enrollment":861,"conditions":13821,"interventions":13822},[88],[1205,1122,2561,644,912,913,914,915],[1083,654,806,1124],{"nctId":2587,"briefTitle":2588,"status":182,"phases":13824,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":95,"conditions":13825,"interventions":13826},[88],[1142,2593,1144,2594],[803,654,1028,62,1013,1113,805,806,809,894,2596,1016],{"nctId":4678,"briefTitle":4679,"status":130,"phases":13828,"primaryCompletion":4681,"completion":4681,"start":4682,"enrollment":1034,"conditions":13829,"interventions":13830},[88],[2755,15,21],[1254,2423,1004,4537,2374,2196,806,803,1114],{"nctId":8616,"briefTitle":8617,"status":130,"phases":13832,"primaryCompletion":8619,"completion":8619,"start":2740,"enrollment":1131,"conditions":13833,"interventions":13834},[88],[15,21],[894,8622,8623,1070,6545,4537,2196,806,8624,2374],{"nctId":2634,"briefTitle":2635,"status":102,"phases":13836,"primaryCompletion":956,"completion":956,"start":2637,"enrollment":2638,"conditions":13837,"interventions":13838},[88],[783,891,788],[803,654,62,1013,804,767,806,894,1016,810],{"nctId":2642,"briefTitle":2643,"status":130,"phases":13840,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":2647,"conditions":13841,"interventions":13842},[88],[1122,2649,2650,2651,785,2652,2653],[803,654,62,804,806,2425,810],{"nctId":928,"briefTitle":929,"status":102,"phases":13844,"primaryCompletion":931,"completion":931,"start":932,"enrollment":240,"conditions":13845,"interventions":13846},[88],[891],[803,654,62,804,767,806,894,480,810],{"nctId":7014,"briefTitle":7015,"status":182,"phases":13848,"primaryCompletion":1984,"completion":1984,"start":7017,"enrollment":166,"conditions":13849,"interventions":13850},[88],[15,7019,2653,21],[654,7021,1016,809,7022,2425,894,806,803,805,1013,4514,7023],{"nctId":2674,"briefTitle":2675,"status":130,"phases":13852,"primaryCompletion":2677,"completion":2677,"start":2678,"enrollment":2004,"conditions":13853,"interventions":13854},[88],[15],[894,2681,803,1013,1114,2682,2683,806,2584,2374,1071,62],{"nctId":2695,"briefTitle":2696,"status":130,"phases":13856,"primaryCompletion":2698,"completion":2698,"start":2699,"enrollment":2700,"conditions":13857,"interventions":13858},[88],[15],[2321,803,1013,1016,62,806,654,1114,2374],{"nctId":13860,"briefTitle":13861,"status":130,"phases":13862,"primaryCompletion":2836,"completion":2836,"start":13863,"enrollment":1045,"conditions":13864,"interventions":13865},"NCT00506922","Phase I\u002FII Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT",[87,88],"2000-09",[15,21],[13866,2196,806],"Pentostatin",{"nctId":2714,"briefTitle":2715,"status":130,"phases":13868,"primaryCompletion":2717,"completion":2717,"start":2718,"enrollment":2559,"conditions":13869,"interventions":13870},[87,88],[891],[75,803,654,62,1013,806,894,1016],{"nctId":4746,"briefTitle":4747,"status":182,"phases":13872,"primaryCompletion":4749,"completion":4749,"start":4750,"enrollment":1568,"conditions":13873,"interventions":13874},[87,88],[1411,712,4752,715],[3085,1004,2423,1069,2369,806,2196],{"nctId":4166,"briefTitle":4167,"status":130,"phases":13876,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":13877,"interventions":13878},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"nctId":1007,"briefTitle":1008,"status":279,"phases":13880,"primaryCompletion":446,"completion":446,"start":1010,"enrollment":517,"conditions":13881,"interventions":13882},[88],[847],[803,654,62,1013,805,806,1014,809,894,1015,480,1016],{"nctId":2726,"briefTitle":2727,"status":102,"phases":13884,"primaryCompletion":999,"completion":999,"start":2729,"enrollment":2730,"conditions":13885,"interventions":13886},[88],[1205,1122,2649,2471,644,912,2732],[803,654,62,1013,804,806,1124,917,809,894,1016,810],{"nctId":1105,"briefTitle":1106,"status":182,"phases":13888,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":539,"conditions":13889,"interventions":13890},[87,88],[359,913,608,850,609,914,610,853,632],[1112,510,803,654,62,1069,1113,1114,806,809,894,480,1016],{"nctId":7222,"briefTitle":7223,"status":130,"phases":13892,"primaryCompletion":7225,"completion":7225,"start":7226,"enrollment":1100,"conditions":13893,"interventions":13894},[88],[7228,2653],[7021,1016,7230,7231,803,654,805,806,1013,7023],{"nctId":4229,"briefTitle":4230,"status":130,"phases":13896,"primaryCompletion":2846,"completion":2846,"start":4183,"enrollment":1034,"conditions":13897,"interventions":13898},[88],[1293],[4234,1709,1013,806,4235],{"nctId":4807,"briefTitle":4808,"status":130,"phases":13900,"primaryCompletion":4810,"completion":4810,"start":4811,"enrollment":628,"conditions":13901,"interventions":13902},[87,88],[15],[1069,1004,803,3420,612,806,1014,2196],{"nctId":2813,"briefTitle":2814,"status":279,"phases":13904,"primaryCompletion":224,"completion":548,"start":2816,"enrollment":2159,"conditions":13905,"interventions":13906},[88],[15],[803,1016,1083,806,654,805,809,1071,2819,894,62],{"nctId":1135,"briefTitle":1136,"status":182,"phases":13908,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":1140,"conditions":13909,"interventions":13910},[87,88],[1142,1143,1144,1145],[803,654,62,806,807,808,809,894,480,1016],{"nctId":4815,"briefTitle":4816,"status":130,"phases":13912,"primaryCompletion":4818,"completion":4818,"start":4819,"enrollment":4820,"conditions":13913,"interventions":13914},[88],[15,36,2838,3315,712,4580,4822,4823,1400,30],[4825,1004,2196,806,2374],{"nctId":7277,"briefTitle":7278,"status":102,"phases":13916,"primaryCompletion":115,"completion":115,"start":7280,"enrollment":492,"conditions":13917,"interventions":13918},[88],[1205,1122,7282,644,913,914],[1083,803,654,1069,806,1071,1124,894,1016],{"nctId":2825,"briefTitle":2826,"status":130,"phases":13920,"primaryCompletion":2326,"completion":2326,"start":2828,"enrollment":676,"conditions":13921,"interventions":13922},[87,88],[21],[2831,894,803,1016,1013,62,806,654],{"nctId":2833,"briefTitle":2834,"status":130,"phases":13924,"primaryCompletion":2232,"completion":2232,"start":2836,"enrollment":628,"conditions":13925,"interventions":13926},[87,88],[15,2838],[2840,803,1016,1013,62,1114,806,2584,2841,2374],{"nctId":4839,"briefTitle":4840,"status":130,"phases":13928,"primaryCompletion":4842,"completion":4842,"start":4843,"enrollment":230,"conditions":13929,"interventions":13930},[88],[15,4725],[1070,1004,3499,3085,2196,806,2374],{"nctId":9374,"briefTitle":9375,"status":130,"phases":13932,"primaryCompletion":3761,"completion":3761,"start":5663,"enrollment":901,"conditions":13933,"interventions":13934},[88],[9378],[2369,1070,2293,4668,2196,1069,806],{"nctId":2852,"briefTitle":2853,"status":182,"phases":13936,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":296,"conditions":13937,"interventions":13938},[87,88],[2413,1142,1143,1144,2421,1145],[803,654,62,2712,1113,805,1114,806,1071,809,894,1015,1016],{"nctId":4847,"briefTitle":4848,"status":203,"phases":13940,"primaryCompletion":4715,"completion":4715,"start":4715,"enrollment":124,"conditions":13941,"interventions":13942},[88],[4851,680,359],[1004,1070,4777,806,2196],{"nctId":2871,"briefTitle":2872,"status":130,"phases":13944,"primaryCompletion":2874,"completion":2874,"start":2875,"enrollment":1766,"conditions":13945,"interventions":13946},[88],[21],[2878,2879,2880,2881,2882,2883,2884],{"nctId":2886,"briefTitle":2887,"status":130,"phases":13948,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":13949,"interventions":13950},[88],[15,1122],[894,803,1013,1016,62,806,654,2374,1114,2894,1071,2895],{"nctId":2906,"briefTitle":2907,"status":130,"phases":13952,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":13953,"interventions":13954},[88],[2913,2914],[894,803,1013,1016,62,2374,654,806],{"trials":13956,"activeCount":124},[13957,13961],{"nctId":4864,"briefTitle":4865,"status":130,"phases":13958,"primaryCompletion":4867,"completion":4867,"start":4868,"enrollment":4869,"conditions":13959,"interventions":13960},[89],[4871,15,4523],[1070,2423,1004,4537,2196,806],{"nctId":4367,"briefTitle":4368,"status":130,"phases":13962,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":13963,"interventions":13964},[89],[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":13966,"activeCount":124},[],{"trials":13968,"activeCount":124},[13969],{"nctId":4379,"briefTitle":4380,"status":182,"phases":13970,"primaryCompletion":4382,"completion":4382,"start":2932,"enrollment":1483,"conditions":13971,"interventions":13972},[91],[4384],[1013,1709,806,1113,4386,2495,2369,4387,1114],{"intervention":2840,"totalTrials":628,"cells":13974},{"EARLY_PHASE1":13975,"PHASE1":13977,"PHASE2":14087,"PHASE3":14166,"PHASE4":14168,"NA":14170},{"trials":13976,"activeCount":124},[],{"trials":13978,"activeCount":296,"soonestReadout":14037},[13979,13988,13996,14010,14016,14025,14033,14041,14048,14061,14065,14074],{"nctId":13980,"briefTitle":13981,"status":130,"phases":13982,"primaryCompletion":13983,"completion":13983,"start":13984,"enrollment":9213,"conditions":13985,"interventions":13986},"NCT01582191","Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer",[87],"2025-10-22","2012-05-14",[2922,2924,2925,2926],[2840,13987],"Vandetanib",{"nctId":13989,"briefTitle":13990,"status":130,"phases":13991,"primaryCompletion":5773,"completion":5773,"start":13992,"enrollment":448,"conditions":13993,"interventions":13994},"NCT02138929","LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma",[87],"2014-11-10",[2770],[2840,13995],"LDE 225",{"nctId":13997,"briefTitle":13998,"status":102,"phases":13999,"primaryCompletion":14000,"completion":14000,"start":14001,"enrollment":5549,"conditions":14002,"interventions":14009},"NCT03065387","Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation\u002FAmplification, HER2 Mutation\u002FAmplification, or HER3\u002F4 Mutation or KRAS Mutation",[87],"2028-10-01","2017-10-31",[1343,14003,1386,14004,14005,14006,14007,14008,361,3457],"EGFR Gene Amplification","ERBB2 Gene Amplification","ERBB2 Gene Mutation","ERBB3 Gene Mutation","ERBB4 Gene Mutation","KRAS Gene Mutation",[2840,7300,2206,874],{"nctId":14011,"briefTitle":14012,"status":203,"phases":14013,"primaryCompletion":9357,"start":2777,"enrollment":124,"conditions":14014,"interventions":14015},"NCT01864070","Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease",[87],[1996],[2840],{"nctId":14017,"briefTitle":14018,"status":130,"phases":14019,"primaryCompletion":14020,"completion":14020,"start":14021,"enrollment":6385,"conditions":14022,"interventions":14023},"NCT01624766","Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers",[87],"2021-02-24","2012-06-19",[2922,2924,2925,2926],[6778,14024,2840],"Denosumab",{"nctId":14026,"briefTitle":14027,"status":130,"phases":14028,"primaryCompletion":14029,"completion":14029,"start":14030,"enrollment":2159,"conditions":14031,"interventions":14032},"NCT01596140","Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer",[87],"2020-06-01","2012-12-18",[1942,3305],[9970,2840,6656],{"nctId":14034,"briefTitle":14035,"status":102,"phases":14036,"primaryCompletion":14037,"completion":14037,"start":13673,"enrollment":14038,"conditions":14039,"interventions":14040},"NCT01087554","Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer",[87],"2026-08-18",249,[1942],[6516,2405,2840,6656],{"nctId":14042,"briefTitle":14043,"status":130,"phases":14044,"primaryCompletion":4272,"completion":4272,"start":14045,"enrollment":2933,"conditions":14046,"interventions":14047},"NCT01430572","Pazopanib and Everolimus in PI3KCA Mutation Positive\u002FPTEN Loss Patients",[87],"2011-10-07",[33,1924],[1431,2840],{"nctId":14049,"briefTitle":14050,"status":546,"phases":14051,"primaryCompletion":14052,"completion":14053,"start":14054,"enrollment":2004,"conditions":14055,"interventions":14059},"NCT07318324","Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer",[87],"2028-08-01","2030-08-01","2026-06-03",[14056,12942,14057,14058],"Phase IB","RAS Pathway","Endometrial",[12942,14060,2840],"defactinib",{"nctId":10897,"briefTitle":10898,"status":130,"phases":14062,"primaryCompletion":1567,"completion":1567,"start":10900,"enrollment":10901,"conditions":14063,"interventions":14064},[87],[1924,1942],[10904,1275,2840,2207,3847],{"nctId":14066,"briefTitle":14067,"status":102,"phases":14068,"primaryCompletion":446,"completion":446,"start":2901,"enrollment":1609,"conditions":14069,"interventions":14072},"NCT02321501","Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer",[87],[14070,2569,361,14071,3845,8040],"ALK Positive","ROS1 Gene Rearrangement",[14073,2840],"Ceritinib",{"nctId":14075,"briefTitle":14076,"status":130,"phases":14077,"primaryCompletion":4867,"completion":4867,"start":14078,"enrollment":1609,"conditions":14079,"interventions":14085},"NCT02152943","Everolimus, Letrozole and Trastuzumab in HR- and HER2\u002FNeu-positive Patients",[87],"2014-07-17",[1343,11800,14080,14081,14082,13135,10825,14083,14084,5087,5088,5089,7298],"HER2\u002FNeu Positive","Postmenopausal","Premenopausal","Refractory Breast Carcinoma","Refractory Hormone Receptor Positive Breast Carcinoma",[2840,14086,4227],"Letrozole",{"trials":14088,"activeCount":230,"soonestReadout":5310},[14089,14098,14102,14113,14122,14131,14137,14144,14152,14156,14160],{"nctId":14090,"briefTitle":14091,"status":102,"phases":14092,"primaryCompletion":5310,"completion":5310,"start":2436,"enrollment":8978,"conditions":14093,"interventions":14097},"NCT02397083","Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer",[88],[14094,14095,14096],"Atypical Endometrial Hyperplasia","FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma","FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma",[2840],{"nctId":10966,"briefTitle":10967,"status":130,"phases":14099,"primaryCompletion":10969,"completion":10969,"start":10970,"enrollment":539,"conditions":14100,"interventions":14101},[88],[5079,1363],[1275,2840,10747],{"nctId":14103,"briefTitle":14104,"status":102,"phases":14105,"primaryCompletion":4028,"completion":4028,"start":14106,"enrollment":593,"conditions":14107,"interventions":14112},"NCT03950609","Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors",[88],"2019-07-30",[14108,14109,14110,3873,14111],"Advanced Carcinoid Tumor","Digestive System Neuroendocrine Neoplasm","Multiple Endocrine Neoplasia Type 1","Unresectable Carcinoid Tumor",[2840,7558],{"nctId":14114,"briefTitle":14115,"status":182,"phases":14116,"primaryCompletion":14117,"completion":14117,"start":4542,"enrollment":3820,"conditions":14118,"interventions":14119},"NCT01627067","Exemestane-RAD001-Metformin",[88],"2019-02-01",[18],[2840,14120,14121],"Exemestane","Metformin",{"nctId":14123,"briefTitle":14124,"status":102,"phases":14125,"primaryCompletion":3258,"completion":3258,"start":14126,"enrollment":861,"conditions":14127,"interventions":14129},"NCT03008408","A Phase II, Two-Arm Study of Everolimus and Letrozole, +\u002F- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma",[88],"2017-08-18",[1457,10089,10703,14128,10707,10708,10709,10710,10711,10712,10713,10714,1472],"Refractory Endometrial Endometrioid Adenocarcinoma",[2840,14086,14130],"Ribociclib",{"nctId":14132,"briefTitle":14133,"status":130,"phases":14134,"primaryCompletion":6065,"completion":6065,"start":2836,"enrollment":2004,"conditions":14135,"interventions":14136},"NCT00967044","Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma",[87,88],[21],[2340,2840],{"nctId":14138,"briefTitle":14139,"status":102,"phases":14140,"primaryCompletion":999,"completion":999,"start":14141,"enrollment":2933,"conditions":14142,"interventions":14143},"NCT01797523","A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma",[88],"2013-10-07",[2809],[14121,14086,2840],{"nctId":14145,"briefTitle":14146,"status":102,"phases":14147,"primaryCompletion":14148,"completion":14148,"start":14149,"enrollment":861,"conditions":14150,"interventions":14151},"NCT05012371","Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer",[88],"2027-10-25","2022-02-16",[1847,1848,1356,1360],[1421,2840,7558],{"nctId":11150,"briefTitle":11151,"status":102,"phases":14153,"primaryCompletion":10132,"completion":10132,"start":11153,"enrollment":10752,"conditions":14154,"interventions":14155},[88],[1333],[1431,1275,2840],{"nctId":2833,"briefTitle":2834,"status":130,"phases":14157,"primaryCompletion":2232,"completion":2232,"start":2836,"enrollment":628,"conditions":14158,"interventions":14159},[87,88],[15,2838],[2840,803,1016,1013,62,1114,806,2584,2841,2374],{"nctId":14161,"briefTitle":14162,"status":182,"phases":14163,"primaryCompletion":10410,"completion":10410,"start":3996,"enrollment":606,"conditions":14164,"interventions":14165},"NCT01185366","Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma",[88],[1333],[2840,10918],{"trials":14167,"activeCount":124},[],{"trials":14169,"activeCount":124},[],{"trials":14171,"activeCount":166,"soonestReadout":281},[14172],{"nctId":12224,"briefTitle":12225,"status":279,"phases":14173,"primaryCompletion":281,"completion":281,"start":6635,"enrollment":1131,"conditions":14174,"interventions":14175},[91],[12228,12229,12230],[1013,804,2840,12232,2495,4022,1431,12233,3497,6656,1016],{"intervention":12910,"totalTrials":3726,"cells":14177},{"EARLY_PHASE1":14178,"PHASE1":14180,"PHASE2":14207,"PHASE3":14281,"PHASE4":14283,"NA":14285},{"trials":14179,"activeCount":124},[],{"trials":14181,"activeCount":121,"soonestReadout":4005},[14182,14191,14199],{"nctId":14183,"briefTitle":14184,"status":182,"phases":14185,"primaryCompletion":14186,"completion":14186,"start":14187,"enrollment":1231,"conditions":14188,"interventions":14189},"NCT04729725","SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL",[87],"2022-12-02","2021-02-09",[1343,361,7891],[14190,12910],"Anti-TGF-beta Monoclonal Antibody SAR-439459",{"nctId":14192,"briefTitle":14193,"status":279,"phases":14194,"primaryCompletion":4005,"completion":4006,"start":14195,"enrollment":1034,"conditions":14196,"interventions":14197},"NCT06826768","A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC",[87],"2025-07-09",[27],[14198,12910],"REGN5678",{"nctId":14200,"briefTitle":14201,"status":102,"phases":14202,"primaryCompletion":604,"completion":604,"start":14203,"enrollment":2911,"conditions":14204,"interventions":14205},"NCT05704634","A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.",[87],"2023-08-18",[24],[12910,14206],"Kevzara",{"trials":14208,"activeCount":186,"soonestReadout":815},[14209,14213,14223,14232,14238,14248,14257,14261,14269],{"nctId":12902,"briefTitle":12903,"status":279,"phases":14210,"primaryCompletion":12905,"completion":12905,"start":12906,"enrollment":2004,"conditions":14211,"interventions":14212},[87,88],[10674,12908],[1683,12910,10678],{"nctId":14214,"briefTitle":14215,"status":546,"phases":14216,"primaryCompletion":14217,"completion":14218,"start":549,"enrollment":1131,"conditions":14219,"interventions":14220},"NCT07511036","PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma",[88],"2028-05-24","2030-05-24",[1729],[12910,14221,14222],"Lpilimumab","Fianlimab",{"nctId":14224,"briefTitle":14225,"status":279,"phases":14226,"primaryCompletion":1735,"completion":1735,"start":14227,"enrollment":517,"conditions":14228,"interventions":14230},"NCT06444880","Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies",[88],"2024-10-09",[14229],"SMARCB1-Deficient Malignancies",[14231,12910],"Ubamatamab",{"nctId":14233,"briefTitle":14234,"status":102,"phases":14235,"primaryCompletion":815,"completion":5382,"start":13130,"enrollment":676,"conditions":14236,"interventions":14237},"NCT05961709","The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer",[88],[3154],[12910],{"nctId":14239,"briefTitle":14240,"status":203,"phases":14241,"primaryCompletion":14242,"completion":14242,"start":14243,"enrollment":124,"conditions":14244,"interventions":14246},"NCT05535023","Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma",[88],"2023-07-25","2022-08-24",[4031,14245,242],"Oropharynx Cancer",[14247,12910],"SAR444245",{"nctId":14249,"briefTitle":14250,"status":546,"phases":14251,"primaryCompletion":14252,"completion":14253,"start":5310,"enrollment":3726,"conditions":14254,"interventions":14256},"NCT07470489","Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer",[88],"2030-09-01","2032-09-01",[14255],"Anaplastic Thyroid Cancer",[12910,7864],{"nctId":12948,"briefTitle":12949,"status":279,"phases":14258,"primaryCompletion":12951,"completion":12951,"start":7168,"enrollment":539,"conditions":14259,"interventions":14260},[88],[12953],[12910,1683],{"nctId":14262,"briefTitle":14263,"status":279,"phases":14264,"primaryCompletion":1088,"completion":14252,"start":14265,"enrollment":517,"conditions":14266,"interventions":14267},"NCT06651593","Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors",[88],"2025-07-02",[1924],[14268,12910],"SAR444881",{"nctId":14270,"briefTitle":14271,"status":102,"phases":14272,"primaryCompletion":224,"completion":224,"start":14273,"enrollment":1559,"conditions":14274,"interventions":14280},"NCT03565783","Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery",[88],"2018-07-03",[14275,14276,14277,14278,14279],"Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck","Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck","Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",[12910],{"trials":14282,"activeCount":124},[],{"trials":14284,"activeCount":124},[],{"trials":14286,"activeCount":124},[],{"intervention":668,"totalTrials":1496,"cells":14288},{"EARLY_PHASE1":14289,"PHASE1":14295,"PHASE2":14297,"PHASE3":14339,"PHASE4":14341,"NA":14343},{"trials":14290,"activeCount":166,"soonestReadout":2166},[14291],{"nctId":3023,"briefTitle":3024,"status":102,"phases":14292,"primaryCompletion":2166,"completion":2166,"start":3026,"enrollment":492,"conditions":14293,"interventions":14294},[86],[21,891],[668,894,803,1005],{"trials":14296,"activeCount":124},[],{"trials":14298,"activeCount":910,"soonestReadout":661},[14299,14303,14307,14311,14315,14319,14323,14329,14333],{"nctId":658,"briefTitle":659,"status":279,"phases":14300,"primaryCompletion":661,"completion":661,"start":662,"enrollment":663,"conditions":14301,"interventions":14302},[88],[665,666,528,529],[668,669,480],{"nctId":8398,"briefTitle":8399,"status":102,"phases":14304,"primaryCompletion":3880,"completion":3880,"start":8401,"enrollment":1034,"conditions":14305,"interventions":14306},[88],[8403,8404,8405,8406,8407,8408,8409],[668,1402,894],{"nctId":777,"briefTitle":778,"status":102,"phases":14308,"primaryCompletion":780,"completion":780,"start":781,"enrollment":507,"conditions":14309,"interventions":14310},[88],[783,784,785,786,787,788,789,790,791],[668,480],{"nctId":857,"briefTitle":858,"status":279,"phases":14312,"primaryCompletion":860,"completion":860,"start":105,"enrollment":861,"conditions":14313,"interventions":14314},[88],[712],[767,480,668],{"nctId":8571,"briefTitle":8572,"status":279,"phases":14316,"primaryCompletion":8574,"completion":8575,"start":148,"enrollment":406,"conditions":14317,"interventions":14318},[88],[8577,8578,8579,894,8580],[668,894,8580],{"nctId":8638,"briefTitle":8639,"status":102,"phases":14320,"primaryCompletion":8641,"completion":8641,"start":4203,"enrollment":1140,"conditions":14321,"interventions":14322},[88],[891],[668,894],{"nctId":14324,"briefTitle":14325,"status":102,"phases":14326,"primaryCompletion":956,"completion":956,"start":3853,"enrollment":910,"conditions":14327,"interventions":14328},"NCT04189757","Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma",[88],[891],[668],{"nctId":7213,"briefTitle":7214,"status":102,"phases":14330,"primaryCompletion":7216,"completion":7216,"start":7217,"enrollment":2933,"conditions":14331,"interventions":14332},[88],[7219],[668,803,804,1402,809,894,3338,1016],{"nctId":14334,"briefTitle":14335,"status":279,"phases":14336,"primaryCompletion":956,"completion":956,"start":3889,"enrollment":1034,"conditions":14337,"interventions":14338},"NCT04505254","Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia",[88],[712,716],[668,669],{"trials":14340,"activeCount":124},[],{"trials":14342,"activeCount":124},[],{"trials":14344,"activeCount":124},[],{"intervention":1016,"totalTrials":1664,"cells":14346},{"EARLY_PHASE1":14347,"PHASE1":14349,"PHASE2":14351,"PHASE3":14481,"PHASE4":14491,"NA":14493},{"trials":14348,"activeCount":124},[],{"trials":14350,"activeCount":124},[],{"trials":14352,"activeCount":910,"soonestReadout":446},[14353,14357,14361,14365,14369,14373,14377,14381,14385,14389,14393,14397,14401,14405,14409,14413,14417,14421,14425,14429,14433,14437,14441,14445,14449,14453,14457,14461,14465,14469,14473,14477],{"nctId":6754,"briefTitle":6755,"status":130,"phases":14354,"primaryCompletion":6757,"completion":6757,"start":6758,"enrollment":861,"conditions":14355,"interventions":14356},[88],[1122],[803,1016,1013,4330,2374,806,2584,808],{"nctId":2464,"briefTitle":2465,"status":279,"phases":14358,"primaryCompletion":2467,"completion":2467,"start":2468,"enrollment":2469,"conditions":14359,"interventions":14360},[87,88],[2471,2472,2473,2474,2475,1142,2415,1144,2419],[1083,803,654,62,2477,805,806,809,894,1016],{"nctId":3984,"briefTitle":3985,"status":130,"phases":14362,"primaryCompletion":3987,"completion":3987,"start":3988,"enrollment":2446,"conditions":14363,"interventions":14364},[88],[2971,3990],[2368,2977,2495,1016,1709],{"nctId":2524,"briefTitle":2525,"status":130,"phases":14366,"primaryCompletion":2527,"completion":2527,"start":2528,"enrollment":1609,"conditions":14367,"interventions":14368},[88],[2530],[806,1016,2532,62,894],{"nctId":2534,"briefTitle":2535,"status":130,"phases":14370,"primaryCompletion":2537,"completion":2537,"start":1000,"enrollment":834,"conditions":14371,"interventions":14372},[88],[1047,643,2539,2540,848,2541,2542,851],[2423,654,62,655,894,2207,2544,1016,810],{"nctId":2546,"briefTitle":2547,"status":130,"phases":14374,"primaryCompletion":2549,"completion":2549,"start":2550,"enrollment":37,"conditions":14375,"interventions":14376},[88],[21],[894,803,1013,1016,62,806,654,809],{"nctId":2554,"briefTitle":2555,"status":130,"phases":14378,"primaryCompletion":2557,"completion":2557,"start":2558,"enrollment":2559,"conditions":14379,"interventions":14380},[88],[1122,2561,644,912,913,915],[803,654,1028,62,1013,806,809,1016],{"nctId":2577,"briefTitle":2578,"status":130,"phases":14382,"primaryCompletion":1558,"completion":1558,"start":2580,"enrollment":2581,"conditions":14383,"interventions":14384},[88],[21],[803,1114,1016,806,2584,62,2374,2585],{"nctId":2587,"briefTitle":2588,"status":182,"phases":14386,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":95,"conditions":14387,"interventions":14388},[88],[1142,2593,1144,2594],[803,654,1028,62,1013,1113,805,806,809,894,2596,1016],{"nctId":6916,"briefTitle":6917,"status":182,"phases":14390,"primaryCompletion":184,"completion":184,"start":6919,"enrollment":4171,"conditions":14391,"interventions":14392},[88],[6921],[1016,1013,803,4386,6923],{"nctId":6964,"briefTitle":6965,"status":130,"phases":14394,"primaryCompletion":3832,"completion":3832,"start":4731,"enrollment":2779,"conditions":14395,"interventions":14396},[87,88],[21],[6969,803,1013,1016,809],{"nctId":2634,"briefTitle":2635,"status":102,"phases":14398,"primaryCompletion":956,"completion":956,"start":2637,"enrollment":2638,"conditions":14399,"interventions":14400},[88],[783,891,788],[803,654,62,1013,804,767,806,894,1016,810],{"nctId":7014,"briefTitle":7015,"status":182,"phases":14402,"primaryCompletion":1984,"completion":1984,"start":7017,"enrollment":166,"conditions":14403,"interventions":14404},[88],[15,7019,2653,21],[654,7021,1016,809,7022,2425,894,806,803,805,1013,4514,7023],{"nctId":7062,"briefTitle":7063,"status":279,"phases":14406,"primaryCompletion":1735,"completion":7065,"start":2106,"enrollment":517,"conditions":14407,"interventions":14408},[88],[6956],[809,894,803,1016,7068],{"nctId":2695,"briefTitle":2696,"status":130,"phases":14410,"primaryCompletion":2698,"completion":2698,"start":2699,"enrollment":2700,"conditions":14411,"interventions":14412},[88],[15],[2321,803,1013,1016,62,806,654,1114,2374],{"nctId":7084,"briefTitle":7085,"status":182,"phases":14414,"primaryCompletion":2806,"completion":2806,"start":3901,"enrollment":166,"conditions":14415,"interventions":14416},[87,88],[21],[803,1013,1016,809],{"nctId":2714,"briefTitle":2715,"status":130,"phases":14418,"primaryCompletion":2717,"completion":2717,"start":2718,"enrollment":2559,"conditions":14419,"interventions":14420},[87,88],[891],[75,803,654,62,1013,806,894,1016],{"nctId":1007,"briefTitle":1008,"status":279,"phases":14422,"primaryCompletion":446,"completion":446,"start":1010,"enrollment":517,"conditions":14423,"interventions":14424},[88],[847],[803,654,62,1013,805,806,1014,809,894,1015,480,1016],{"nctId":7130,"briefTitle":7131,"status":279,"phases":14426,"primaryCompletion":7133,"completion":7134,"start":1282,"enrollment":406,"conditions":14427,"interventions":14428},[88],[7136],[7138,803,1013,1016,809],{"nctId":2726,"briefTitle":2727,"status":102,"phases":14430,"primaryCompletion":999,"completion":999,"start":2729,"enrollment":2730,"conditions":14431,"interventions":14432},[88],[1205,1122,2649,2471,644,912,2732],[803,654,62,1013,804,806,1124,917,809,894,1016,810],{"nctId":1105,"briefTitle":1106,"status":182,"phases":14434,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":539,"conditions":14435,"interventions":14436},[87,88],[359,913,608,850,609,914,610,853,632],[1112,510,803,654,62,1069,1113,1114,806,809,894,480,1016],{"nctId":7213,"briefTitle":7214,"status":102,"phases":14438,"primaryCompletion":7216,"completion":7216,"start":7217,"enrollment":2933,"conditions":14439,"interventions":14440},[88],[7219],[668,803,804,1402,809,894,3338,1016],{"nctId":7222,"briefTitle":7223,"status":130,"phases":14442,"primaryCompletion":7225,"completion":7225,"start":7226,"enrollment":1100,"conditions":14443,"interventions":14444},[88],[7228,2653],[7021,1016,7230,7231,803,654,805,806,1013,7023],{"nctId":2813,"briefTitle":2814,"status":279,"phases":14446,"primaryCompletion":224,"completion":548,"start":2816,"enrollment":2159,"conditions":14447,"interventions":14448},[88],[15],[803,1016,1083,806,654,805,809,1071,2819,894,62],{"nctId":1135,"briefTitle":1136,"status":182,"phases":14450,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":1140,"conditions":14451,"interventions":14452},[87,88],[1142,1143,1144,1145],[803,654,62,806,807,808,809,894,480,1016],{"nctId":7277,"briefTitle":7278,"status":102,"phases":14454,"primaryCompletion":115,"completion":115,"start":7280,"enrollment":492,"conditions":14455,"interventions":14456},[88],[1205,1122,7282,644,913,914],[1083,803,654,1069,806,1071,1124,894,1016],{"nctId":2825,"briefTitle":2826,"status":130,"phases":14458,"primaryCompletion":2326,"completion":2326,"start":2828,"enrollment":676,"conditions":14459,"interventions":14460},[87,88],[21],[2831,894,803,1016,1013,62,806,654],{"nctId":2833,"briefTitle":2834,"status":130,"phases":14462,"primaryCompletion":2232,"completion":2232,"start":2836,"enrollment":628,"conditions":14463,"interventions":14464},[87,88],[15,2838],[2840,803,1016,1013,62,1114,806,2584,2841,2374],{"nctId":2852,"briefTitle":2853,"status":182,"phases":14466,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":296,"conditions":14467,"interventions":14468},[87,88],[2413,1142,1143,1144,2421,1145],[803,654,62,2712,1113,805,1114,806,1071,809,894,1015,1016],{"nctId":7372,"briefTitle":7373,"status":130,"phases":14470,"primaryCompletion":7375,"completion":7375,"start":7376,"enrollment":7377,"conditions":14471,"interventions":14472},[87,88],[21],[1402,669,803,1013,1016,809],{"nctId":2886,"briefTitle":2887,"status":130,"phases":14474,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":14475,"interventions":14476},[88],[15,1122],[894,803,1013,1016,62,806,654,2374,1114,2894,1071,2895],{"nctId":2906,"briefTitle":2907,"status":130,"phases":14478,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":14479,"interventions":14480},[88],[2913,2914],[894,803,1013,1016,62,2374,654,806],{"trials":14482,"activeCount":124},[14483,14487],{"nctId":5712,"briefTitle":5713,"status":182,"phases":14484,"primaryCompletion":5715,"completion":5715,"start":5716,"enrollment":121,"conditions":14485,"interventions":14486},[89],[5718],[1369,803,2424,1016],{"nctId":4321,"briefTitle":4322,"status":130,"phases":14488,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":14489,"interventions":14490},[89],[21],[1070,4329,4330,894,3671,1013,1016,4331,803,2424,1709,2584,4332,4333,809],{"trials":14492,"activeCount":124},[],{"trials":14494,"activeCount":166,"soonestReadout":281},[14495,14499,14503,14507],{"nctId":2965,"briefTitle":2966,"status":130,"phases":14496,"primaryCompletion":2968,"completion":2968,"start":2969,"enrollment":240,"conditions":14497,"interventions":14498},[91],[2971,2972,2973],[2975,2976,2977,2978,2979,1114,1016,62],{"nctId":12224,"briefTitle":12225,"status":279,"phases":14500,"primaryCompletion":281,"completion":281,"start":6635,"enrollment":1131,"conditions":14501,"interventions":14502},[91],[12228,12229,12230],[1013,804,2840,12232,2495,4022,1431,12233,3497,6656,1016],{"nctId":7477,"briefTitle":7478,"status":130,"phases":14504,"primaryCompletion":2212,"completion":2212,"start":6828,"enrollment":3820,"conditions":14505,"interventions":14506},[91],[21],[7482,803,1013,1016,809,894,2793],{"nctId":2994,"briefTitle":2995,"status":130,"phases":14508,"primaryCompletion":184,"completion":184,"start":2778,"enrollment":2997,"conditions":14509,"interventions":14510},[91],[2971,2935,2999,3000],[3002,62,3003,3004,1013,1114,2495,1016],{"intervention":1371,"totalTrials":1766,"cells":14512},{"EARLY_PHASE1":14513,"PHASE1":14515,"PHASE2":14551,"PHASE3":14602,"PHASE4":14613,"NA":14615},{"trials":14514,"activeCount":124},[],{"trials":14516,"activeCount":296,"soonestReadout":446},[14517,14521,14532,14536,14543,14547],{"nctId":10740,"briefTitle":10741,"status":102,"phases":14518,"primaryCompletion":446,"completion":446,"start":10743,"enrollment":1664,"conditions":14519,"interventions":14520},[87],[2922,10745,3512,2926],[1275,1371,1113,1375,10747,6656],{"nctId":14522,"briefTitle":14523,"status":102,"phases":14524,"primaryCompletion":281,"completion":281,"start":14525,"enrollment":448,"conditions":14526,"interventions":14531},"NCT04523818","Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma",[87],"2020-08-11",[1631,14527,7516,1636,1638,1646,14528,1650,1652,7524,1654,7527,7528,14529,14530,7533],"Clinical Stage IIA Gastric Cancer AJCC v8","Pathologic Stage II Gastric Cancer AJCC v8","Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8","Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8",[1368,1371],{"nctId":9896,"briefTitle":9897,"status":279,"phases":14533,"primaryCompletion":999,"completion":999,"start":9899,"enrollment":628,"conditions":14534,"interventions":14535},[87],[9901,9902,9903,9904,7515,4097,9905,9906,9907,7523,7525,7526,9908],[1368,1369,1710,1371,1113,1375,1376],{"nctId":14537,"briefTitle":14538,"status":130,"phases":14539,"primaryCompletion":8340,"completion":8340,"start":6352,"enrollment":3379,"conditions":14540,"interventions":14542},"NCT00507585","Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin",[87],[1996,14541],"Advanced Solid Tumors",[1371,4234,1113,1375],{"nctId":1337,"briefTitle":1338,"status":182,"phases":14544,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":14545,"interventions":14546},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"nctId":7660,"briefTitle":7661,"status":102,"phases":14548,"primaryCompletion":7663,"completion":7663,"start":7664,"enrollment":834,"conditions":14549,"interventions":14550},[87],[1635,7543,1637,7544,1640,7666,7546,7547,1655,7548,1656,7549,7550,7551,7552,7553,7554,7555,7535],[1710,1371,1375,53],{"trials":14552,"activeCount":230,"soonestReadout":1193},[14553,14557,14561,14565,14569,14573,14577,14581,14585,14589,14598],{"nctId":1564,"briefTitle":1565,"status":279,"phases":14554,"primaryCompletion":161,"completion":161,"start":1567,"enrollment":1568,"conditions":14555,"interventions":14556},[87,88],[1570,1571,1572,1573,1574,1575,1576],[1371,1050,1578],{"nctId":3923,"briefTitle":3924,"status":130,"phases":14558,"primaryCompletion":3926,"completion":3926,"start":3927,"enrollment":186,"conditions":14559,"interventions":14560},[88],[3929,3930,3931,3932,3933,3934,3935,3936,3937],[1709,1371],{"nctId":1624,"briefTitle":1625,"status":102,"phases":14562,"primaryCompletion":1193,"completion":1193,"start":1627,"enrollment":507,"conditions":14563,"interventions":14564},[88],[1629,1630,1631,1632,1633,1634,1635,1636,1637,1638,1639,1640,1641,1642,1643,1644,1645,1646,1647,1648,1649,1650,1651,1652,1653,1654,1655,1656],[1371,1049,1050,1375],{"nctId":3970,"briefTitle":3971,"status":102,"phases":14566,"primaryCompletion":238,"completion":238,"start":3973,"enrollment":2004,"conditions":14567,"interventions":14568},[88],[3975,3976,3977,3978,3979,3980,3981],[1369,1709,1710,1371],{"nctId":4013,"briefTitle":4014,"status":203,"phases":14570,"primaryCompletion":4016,"completion":4016,"start":2264,"enrollment":124,"conditions":14571,"interventions":14572},[88],[4018,4019,4020],[1709,1371,2369,4022,1113,4023,1375],{"nctId":5032,"briefTitle":5033,"status":279,"phases":14574,"primaryCompletion":446,"completion":446,"start":5035,"enrollment":1222,"conditions":14575,"interventions":14576},[88],[1638,5037,5038,5039,5040],[1368,4896,1371],{"nctId":4102,"briefTitle":4103,"status":130,"phases":14578,"primaryCompletion":4085,"completion":4085,"start":4105,"enrollment":1409,"conditions":14579,"interventions":14580},[88],[4107],[4109,1709,1371],{"nctId":4166,"briefTitle":4167,"status":130,"phases":14582,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":14583,"interventions":14584},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"nctId":11656,"briefTitle":11657,"status":102,"phases":14586,"primaryCompletion":446,"completion":446,"start":11659,"enrollment":357,"conditions":14587,"interventions":14588},[88],[9902,11661,9903,11662,9904,1634,7515,1635,11663,1647,11664,1648,9905,1649,9906,1651,9907,1653,7523,7546,7525,7547,7526,1655],[718,1371,1375,11556],{"nctId":14590,"briefTitle":14591,"status":130,"phases":14592,"primaryCompletion":14593,"completion":14593,"start":14594,"enrollment":517,"conditions":14595,"interventions":14596},"NCT00004142","Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver",[88],"2003-12-09","1998-08-05",[3195,7818],[14597,1371],"Floxuridine",{"nctId":4295,"briefTitle":4296,"status":102,"phases":14599,"primaryCompletion":224,"completion":224,"start":4298,"enrollment":4299,"conditions":14600,"interventions":14601},[88],[450],[1376,1369,1683,1710,1709,1371],{"trials":14603,"activeCount":124},[14604],{"nctId":14605,"briefTitle":14606,"status":130,"phases":14607,"primaryCompletion":8503,"completion":7155,"start":2807,"enrollment":4690,"conditions":14608,"interventions":14609},"NCT00038402","Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer",[89],[18],[14610,14611,1371,14612,6744],"Herceptin","Taxol","Cytoxan",{"trials":14614,"activeCount":124},[],{"trials":14616,"activeCount":124},[14617],{"nctId":7492,"briefTitle":7493,"status":203,"phases":14618,"start":3777,"enrollment":124,"conditions":14619,"interventions":14620},[91],[18],[1376,1371,1013,6744,803,1275],{"intervention":1013,"totalTrials":1243,"cells":14622},{"EARLY_PHASE1":14623,"PHASE1":14629,"PHASE2":14655,"PHASE3":14773,"PHASE4":14783,"NA":14785},{"trials":14624,"activeCount":124},[14625],{"nctId":6419,"briefTitle":6420,"status":130,"phases":14626,"primaryCompletion":6422,"completion":6422,"start":6423,"enrollment":2402,"conditions":14627,"interventions":14628},[86],[18,6425],[4218,803,1013],{"trials":14630,"activeCount":166,"soonestReadout":5310},[14631,14635,14641,14651],{"nctId":1337,"briefTitle":1338,"status":182,"phases":14632,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":14633,"interventions":14634},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"nctId":14636,"briefTitle":14637,"status":130,"phases":14638,"primaryCompletion":8339,"completion":8339,"start":10272,"enrollment":296,"conditions":14639,"interventions":14640},"NCT00502411","Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma",[87],[1593],[1013],{"nctId":14642,"briefTitle":14643,"status":203,"phases":14644,"primaryCompletion":14645,"completion":14645,"start":14646,"enrollment":124,"conditions":14647,"interventions":14650},"NCT03111069","Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children",[87],"2021-08","2018-08",[7653,14648,14649],"Rhabdomyosarcoma, Pelvic","Rhabdomyosarcoma, Abdominal",[1013],{"nctId":12338,"briefTitle":12339,"status":102,"phases":14652,"primaryCompletion":5310,"completion":5310,"start":2558,"enrollment":1975,"conditions":14653,"interventions":14654},[87],[3305,4043],[75,2369,1013],{"trials":14656,"activeCount":1483,"soonestReadout":446},[14657,14661,14665,14669,14673,14677,14681,14685,14689,14693,14697,14701,14705,14709,14713,14717,14721,14725,14729,14733,14737,14741,14745,14749,14753,14757,14761,14765,14769],{"nctId":6737,"briefTitle":6738,"status":130,"phases":14658,"primaryCompletion":6740,"completion":6740,"start":6741,"enrollment":2700,"conditions":14659,"interventions":14660},[88],[18],[1376,1370,4218,6744,803,1013],{"nctId":6754,"briefTitle":6755,"status":130,"phases":14662,"primaryCompletion":6757,"completion":6757,"start":6758,"enrollment":861,"conditions":14663,"interventions":14664},[88],[1122],[803,1016,1013,4330,2374,806,2584,808],{"nctId":12108,"briefTitle":12109,"status":102,"phases":14666,"primaryCompletion":193,"completion":193,"start":12111,"enrollment":406,"conditions":14667,"interventions":14668},[88],[7942,1346,12113,1356,1360],[1013,804,2369,4135,2283,8569],{"nctId":2546,"briefTitle":2547,"status":130,"phases":14670,"primaryCompletion":2549,"completion":2549,"start":2550,"enrollment":37,"conditions":14671,"interventions":14672},[88],[21],[894,803,1013,1016,62,806,654,809],{"nctId":2554,"briefTitle":2555,"status":130,"phases":14674,"primaryCompletion":2557,"completion":2557,"start":2558,"enrollment":2559,"conditions":14675,"interventions":14676},[88],[1122,2561,644,912,913,915],[803,654,1028,62,1013,806,809,1016],{"nctId":2587,"briefTitle":2588,"status":182,"phases":14678,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":95,"conditions":14679,"interventions":14680},[88],[1142,2593,1144,2594],[803,654,1028,62,1013,1113,805,806,809,894,2596,1016],{"nctId":6916,"briefTitle":6917,"status":182,"phases":14682,"primaryCompletion":184,"completion":184,"start":6919,"enrollment":4171,"conditions":14683,"interventions":14684},[88],[6921],[1016,1013,803,4386,6923],{"nctId":6964,"briefTitle":6965,"status":130,"phases":14686,"primaryCompletion":3832,"completion":3832,"start":4731,"enrollment":2779,"conditions":14687,"interventions":14688},[87,88],[21],[6969,803,1013,1016,809],{"nctId":6986,"briefTitle":6987,"status":279,"phases":14690,"primaryCompletion":238,"completion":238,"start":6989,"enrollment":3521,"conditions":14691,"interventions":14692},[88],[6991,1597],[1369,1376,53,1013,803],{"nctId":2634,"briefTitle":2635,"status":102,"phases":14694,"primaryCompletion":956,"completion":956,"start":2637,"enrollment":2638,"conditions":14695,"interventions":14696},[88],[783,891,788],[803,654,62,1013,804,767,806,894,1016,810],{"nctId":7014,"briefTitle":7015,"status":182,"phases":14698,"primaryCompletion":1984,"completion":1984,"start":7017,"enrollment":166,"conditions":14699,"interventions":14700},[88],[15,7019,2653,21],[654,7021,1016,809,7022,2425,894,806,803,805,1013,4514,7023],{"nctId":2674,"briefTitle":2675,"status":130,"phases":14702,"primaryCompletion":2677,"completion":2677,"start":2678,"enrollment":2004,"conditions":14703,"interventions":14704},[88],[15],[894,2681,803,1013,1114,2682,2683,806,2584,2374,1071,62],{"nctId":2695,"briefTitle":2696,"status":130,"phases":14706,"primaryCompletion":2698,"completion":2698,"start":2699,"enrollment":2700,"conditions":14707,"interventions":14708},[88],[15],[2321,803,1013,1016,62,806,654,1114,2374],{"nctId":7084,"briefTitle":7085,"status":182,"phases":14710,"primaryCompletion":2806,"completion":2806,"start":3901,"enrollment":166,"conditions":14711,"interventions":14712},[87,88],[21],[803,1013,1016,809],{"nctId":2714,"briefTitle":2715,"status":130,"phases":14714,"primaryCompletion":2717,"completion":2717,"start":2718,"enrollment":2559,"conditions":14715,"interventions":14716},[87,88],[891],[75,803,654,62,1013,806,894,1016],{"nctId":1007,"briefTitle":1008,"status":279,"phases":14718,"primaryCompletion":446,"completion":446,"start":1010,"enrollment":517,"conditions":14719,"interventions":14720},[88],[847],[803,654,62,1013,805,806,1014,809,894,1015,480,1016],{"nctId":7130,"briefTitle":7131,"status":279,"phases":14722,"primaryCompletion":7133,"completion":7134,"start":1282,"enrollment":406,"conditions":14723,"interventions":14724},[88],[7136],[7138,803,1013,1016,809],{"nctId":2726,"briefTitle":2727,"status":102,"phases":14726,"primaryCompletion":999,"completion":999,"start":2729,"enrollment":2730,"conditions":14727,"interventions":14728},[88],[1205,1122,2649,2471,644,912,2732],[803,654,62,1013,804,806,1124,917,809,894,1016,810],{"nctId":1999,"briefTitle":2000,"status":279,"phases":14730,"primaryCompletion":2002,"completion":2002,"start":2003,"enrollment":2004,"conditions":14731,"interventions":14732},[88],[2006,2007,2008,2009],[2011,803,1013,1050,809,894],{"nctId":7222,"briefTitle":7223,"status":130,"phases":14734,"primaryCompletion":7225,"completion":7225,"start":7226,"enrollment":1100,"conditions":14735,"interventions":14736},[88],[7228,2653],[7021,1016,7230,7231,803,654,805,806,1013,7023],{"nctId":4229,"briefTitle":4230,"status":130,"phases":14738,"primaryCompletion":2846,"completion":2846,"start":4183,"enrollment":1034,"conditions":14739,"interventions":14740},[88],[1293],[4234,1709,1013,806,4235],{"nctId":2784,"briefTitle":2785,"status":182,"phases":14742,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":1609,"conditions":14743,"interventions":14744},[88],[2790],[62,1013,2792,2495,1114,2793,2794,810],{"nctId":7291,"briefTitle":7292,"status":182,"phases":14746,"primaryCompletion":7294,"completion":7294,"start":5035,"enrollment":1240,"conditions":14747,"interventions":14748},[87,88],[7296,7297,5234,5086,5087,5088,5089,7298],[803,1013,7300,1376,7301,4227],{"nctId":7303,"briefTitle":7304,"status":203,"phases":14750,"primaryCompletion":754,"completion":754,"start":7306,"enrollment":124,"conditions":14751,"interventions":14752},[88],[7308,7309,7310,7311,7312,7296,5079,7313,7314,7315,7316,7317,1363],[1369,803,1013,1376,6802,53],{"nctId":2825,"briefTitle":2826,"status":130,"phases":14754,"primaryCompletion":2326,"completion":2326,"start":2828,"enrollment":676,"conditions":14755,"interventions":14756},[87,88],[21],[2831,894,803,1016,1013,62,806,654],{"nctId":2833,"briefTitle":2834,"status":130,"phases":14758,"primaryCompletion":2232,"completion":2232,"start":2836,"enrollment":628,"conditions":14759,"interventions":14760},[87,88],[15,2838],[2840,803,1016,1013,62,1114,806,2584,2841,2374],{"nctId":7372,"briefTitle":7373,"status":130,"phases":14762,"primaryCompletion":7375,"completion":7375,"start":7376,"enrollment":7377,"conditions":14763,"interventions":14764},[87,88],[21],[1402,669,803,1013,1016,809],{"nctId":2886,"briefTitle":2887,"status":130,"phases":14766,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":14767,"interventions":14768},[88],[15,1122],[894,803,1013,1016,62,806,654,2374,1114,2894,1071,2895],{"nctId":2906,"briefTitle":2907,"status":130,"phases":14770,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":14771,"interventions":14772},[88],[2913,2914],[894,803,1013,1016,62,2374,654,806],{"trials":14774,"activeCount":124},[14775,14779],{"nctId":7436,"briefTitle":7437,"status":130,"phases":14776,"primaryCompletion":6409,"completion":3777,"start":2580,"enrollment":7439,"conditions":14777,"interventions":14778},[89],[18],[4218,803,1013,1376,6744],{"nctId":4321,"briefTitle":4322,"status":130,"phases":14780,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":14781,"interventions":14782},[89],[21],[1070,4329,4330,894,3671,1013,1016,4331,803,2424,1709,2584,4332,4333,809],{"trials":14784,"activeCount":124},[],{"trials":14786,"activeCount":166,"soonestReadout":281},[14787,14791,14795,14799,14803],{"nctId":12224,"briefTitle":12225,"status":279,"phases":14788,"primaryCompletion":281,"completion":281,"start":6635,"enrollment":1131,"conditions":14789,"interventions":14790},[91],[12228,12229,12230],[1013,804,2840,12232,2495,4022,1431,12233,3497,6656,1016],{"nctId":4379,"briefTitle":4380,"status":182,"phases":14792,"primaryCompletion":4382,"completion":4382,"start":2932,"enrollment":1483,"conditions":14793,"interventions":14794},[91],[4384],[1013,1709,806,1113,4386,2495,2369,4387,1114],{"nctId":7477,"briefTitle":7478,"status":130,"phases":14796,"primaryCompletion":2212,"completion":2212,"start":6828,"enrollment":3820,"conditions":14797,"interventions":14798},[91],[21],[7482,803,1013,1016,809,894,2793],{"nctId":2994,"briefTitle":2995,"status":130,"phases":14800,"primaryCompletion":184,"completion":184,"start":2778,"enrollment":2997,"conditions":14801,"interventions":14802},[91],[2971,2935,2999,3000],[3002,62,3003,3004,1013,1114,2495,1016],{"nctId":7492,"briefTitle":7493,"status":203,"phases":14804,"start":3777,"enrollment":124,"conditions":14805,"interventions":14806},[91],[18],[1376,1371,1013,6744,803,1275],{"intervention":1710,"totalTrials":1664,"cells":14808},{"EARLY_PHASE1":14809,"PHASE1":14811,"PHASE2":14871,"PHASE3":14991,"PHASE4":15003,"NA":15005},{"trials":14810,"activeCount":124},[],{"trials":14812,"activeCount":121,"soonestReadout":7663},[14813,14817,14824,14828,14832,14836,14840,14847,14851,14859,14863,14867],{"nctId":11728,"briefTitle":11729,"status":130,"phases":14814,"primaryCompletion":11731,"completion":4511,"start":2890,"enrollment":11732,"conditions":14815,"interventions":14816},[87],[18],[1376,1710,1368],{"nctId":14818,"briefTitle":14819,"status":130,"phases":14820,"primaryCompletion":2778,"completion":2778,"start":5435,"enrollment":492,"conditions":14821,"interventions":14822},"NCT00431054","Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer",[87],[1530],[14823,1710],"Perifosine",{"nctId":9881,"briefTitle":9882,"status":203,"phases":14825,"primaryCompletion":4835,"start":6367,"enrollment":124,"conditions":14826,"interventions":14827},[87],[9885,24],[1369,1710,9887],{"nctId":11268,"briefTitle":11269,"status":130,"phases":14829,"primaryCompletion":6974,"completion":6974,"start":8340,"enrollment":11271,"conditions":14830,"interventions":14831},[87],[1942],[1710,6516,809],{"nctId":3815,"briefTitle":3816,"status":130,"phases":14833,"primaryCompletion":3818,"completion":3818,"start":3819,"enrollment":3820,"conditions":14834,"interventions":14835},[87],[1316],[1709,1710,3823],{"nctId":9896,"briefTitle":9897,"status":279,"phases":14837,"primaryCompletion":999,"completion":999,"start":9899,"enrollment":628,"conditions":14838,"interventions":14839},[87],[9901,9902,9903,9904,7515,4097,9905,9906,9907,7523,7525,7526,9908],[1368,1369,1710,1371,1113,1375,1376],{"nctId":14841,"briefTitle":14842,"status":130,"phases":14843,"primaryCompletion":12066,"completion":12066,"start":14844,"enrollment":1496,"conditions":14845,"interventions":14846},"NCT00113347","Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)",[87],"2005-04",[242],[3847,1710],{"nctId":3839,"briefTitle":3840,"status":130,"phases":14848,"primaryCompletion":3842,"completion":3842,"start":3843,"enrollment":676,"conditions":14849,"interventions":14850},[87],[1836,1702,1703,1705,1706,1707,3845],[1709,1710,3847,3848],{"nctId":14852,"briefTitle":14853,"status":130,"phases":14854,"primaryCompletion":2213,"completion":2213,"start":9827,"enrollment":3521,"conditions":14855,"interventions":14856},"NCT00038194","Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer",[87],[27],[14857,14858],"imatinib mesylate","docetaxel",{"nctId":7660,"briefTitle":7661,"status":102,"phases":14860,"primaryCompletion":7663,"completion":7663,"start":7664,"enrollment":834,"conditions":14861,"interventions":14862},[87],[1635,7543,1637,7544,1640,7666,7546,7547,1655,7548,1656,7549,7550,7551,7552,7553,7554,7555,7535],[1710,1371,1375,53],{"nctId":2323,"briefTitle":2324,"status":182,"phases":14864,"primaryCompletion":2326,"completion":2326,"start":2327,"enrollment":1568,"conditions":14865,"interventions":14866},[87],[18],[1710,2330,62],{"nctId":3907,"briefTitle":3908,"status":130,"phases":14868,"primaryCompletion":3910,"completion":3910,"start":3911,"enrollment":134,"conditions":14869,"interventions":14870},[87],[3913,3914,3915,3916,3917],[1709,1710,3919],{"trials":14872,"activeCount":230,"soonestReadout":1727},[14873,14880,14888,14895,14899,14903,14907,14911,14915,14921,14925,14929,14933,14940,14944,14950,14956,14960,14964,14968,14972,14976,14983,14987],{"nctId":14874,"briefTitle":14875,"status":130,"phases":14876,"primaryCompletion":13673,"completion":13673,"start":9512,"enrollment":1483,"conditions":14877,"interventions":14879},"NCT00485485","Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer",[88],[242,14878],"Squamous Cell Cancer",[2321,1710],{"nctId":14881,"briefTitle":14882,"status":130,"phases":14883,"primaryCompletion":10784,"completion":7236,"start":14884,"enrollment":3820,"conditions":14885,"interventions":14886},"NCT00084825","Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008",[88],"2003-05",[7818,27],[1710,14887],"Imatinib mesylate",{"nctId":14889,"briefTitle":14890,"status":130,"phases":14891,"primaryCompletion":4184,"completion":4184,"start":2944,"enrollment":517,"conditions":14892,"interventions":14893},"NCT01076335","Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer",[88],[27],[14894,1710],"Neoadjuvant Hormonal Therapy",{"nctId":3950,"briefTitle":3951,"status":102,"phases":14896,"primaryCompletion":1727,"completion":504,"start":3953,"enrollment":676,"conditions":14897,"interventions":14898},[88],[242],[1710,3956,1709],{"nctId":1695,"briefTitle":1696,"status":130,"phases":14900,"primaryCompletion":1698,"completion":1698,"start":105,"enrollment":1699,"conditions":14901,"interventions":14902},[88],[1701,1702,1703,1704,1705,1706,1707],[1369,1709,1710,1049,1050,1377],{"nctId":3970,"briefTitle":3971,"status":102,"phases":14904,"primaryCompletion":238,"completion":238,"start":3973,"enrollment":2004,"conditions":14905,"interventions":14906},[88],[3975,3976,3977,3978,3979,3980,3981],[1369,1709,1710,1371],{"nctId":4025,"briefTitle":4026,"status":279,"phases":14908,"primaryCompletion":4028,"completion":4028,"start":4029,"enrollment":1328,"conditions":14909,"interventions":14910},[88],[4031,4032,4033],[53,1710,1709,1369],{"nctId":12414,"briefTitle":12415,"status":102,"phases":14912,"primaryCompletion":860,"completion":860,"start":12417,"enrollment":2004,"conditions":14913,"interventions":14914},[87,88],[1591,1592],[1710,2369,12420],{"nctId":14916,"briefTitle":14917,"status":130,"phases":14918,"primaryCompletion":8551,"completion":8551,"start":6758,"enrollment":2865,"conditions":14919,"interventions":14920},"NCT00500110","Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer",[88],[27],[1710,2321,3718,11343],{"nctId":5600,"briefTitle":5601,"status":130,"phases":14922,"primaryCompletion":5603,"completion":5603,"start":5604,"enrollment":3354,"conditions":14923,"interventions":14924},[88],[5606],[2369,1710,2293,1369,1114,2495,2424],{"nctId":4049,"briefTitle":4050,"status":130,"phases":14926,"primaryCompletion":4052,"completion":4052,"start":4053,"enrollment":4054,"conditions":14927,"interventions":14928},[88],[4056,4057,4058,4059,4060,4061,4062,4063,4064,4065,4066,4067,4068,4069,4070,1620,4071,4072,4073,4074,4075,4076,4077,4078],[1369,1709,1710,3848],{"nctId":7957,"briefTitle":7958,"status":182,"phases":14930,"primaryCompletion":3446,"completion":3446,"start":7960,"enrollment":296,"conditions":14931,"interventions":14932},[88],[7962,7963],[53,974,7965,1710],{"nctId":14934,"briefTitle":14935,"status":130,"phases":14936,"primaryCompletion":4184,"completion":4184,"start":3819,"enrollment":4551,"conditions":14937,"interventions":14939},"NCT00526110","Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients",[87,88],[14938],"Gastrointestinal Diseases",[4218,1710,1375],{"nctId":4137,"briefTitle":4138,"status":102,"phases":14941,"primaryCompletion":4140,"completion":4141,"start":4142,"enrollment":3521,"conditions":14942,"interventions":14943},[88],[4144,4145,4146],[1369,1709,1710,53],{"nctId":14945,"briefTitle":14946,"status":130,"phases":14947,"primaryCompletion":10075,"completion":6828,"start":14884,"enrollment":1001,"conditions":14948,"interventions":14949},"NCT00080678","Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases",[88],[7818,27],[1710,2321],{"nctId":14951,"briefTitle":14952,"status":130,"phases":14953,"primaryCompletion":5733,"completion":7155,"start":7473,"enrollment":492,"conditions":14954,"interventions":14955},"NCT01083589","Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)",[88],[10145],[2321,1710],{"nctId":10244,"briefTitle":10245,"status":182,"phases":14957,"primaryCompletion":4843,"completion":4843,"start":4192,"enrollment":2018,"conditions":14958,"interventions":14959},[88],[1530],[1275,1369,1710,2369,2293],{"nctId":5043,"briefTitle":5044,"status":130,"phases":14961,"primaryCompletion":5046,"completion":5046,"start":5047,"enrollment":2581,"conditions":14962,"interventions":14963},[88],[242],[1710,3847,4896],{"nctId":2764,"briefTitle":2765,"status":130,"phases":14965,"primaryCompletion":2767,"completion":2767,"start":2768,"enrollment":296,"conditions":14966,"interventions":14967},[87,88],[2770],[1710,2772,62],{"nctId":4287,"briefTitle":4288,"status":130,"phases":14969,"primaryCompletion":4290,"completion":4290,"start":4039,"enrollment":4291,"conditions":14970,"interventions":14971},[88],[27],[1710,1369,2424,1709],{"nctId":4295,"briefTitle":4296,"status":102,"phases":14973,"primaryCompletion":224,"completion":224,"start":4298,"enrollment":4299,"conditions":14974,"interventions":14975},[88],[450],[1376,1369,1683,1710,1709,1371],{"nctId":14977,"briefTitle":14978,"status":203,"phases":14979,"primaryCompletion":14980,"completion":14980,"start":2910,"enrollment":124,"conditions":14981,"interventions":14982},"NCT00048087","Iressa\u002FDocetaxel in Non-Small-Cell Lung Cancer",[88],"2003-07",[10145],[2850,1710],{"nctId":2843,"briefTitle":2844,"status":182,"phases":14984,"primaryCompletion":2846,"completion":2846,"start":2847,"enrollment":676,"conditions":14985,"interventions":14986},[88],[1293],[1710,2850,62],{"nctId":10321,"briefTitle":10322,"status":130,"phases":14988,"primaryCompletion":10324,"completion":10324,"start":10325,"enrollment":357,"conditions":14989,"interventions":14990},[88],[10135],[1275,1369,1710],{"trials":14992,"activeCount":124},[14993,14999],{"nctId":14994,"briefTitle":14995,"status":130,"phases":14996,"primaryCompletion":2828,"completion":9512,"start":9513,"enrollment":861,"conditions":14997,"interventions":14998},"NCT00008411","Docetaxel in Treating Patients With Metastatic Breast Cancer",[89],[18],[1710,1710],{"nctId":2950,"briefTitle":2951,"status":182,"phases":15000,"primaryCompletion":2602,"start":2953,"enrollment":2954,"conditions":15001,"interventions":15002},[89],[27],[1710,2957,2958,2959,809,1868,62],{"trials":15004,"activeCount":124},[],{"trials":15006,"activeCount":124},[],{"intervention":767,"totalTrials":492,"cells":15008},{"EARLY_PHASE1":15009,"PHASE1":15019,"PHASE2":15032,"PHASE3":15121,"PHASE4":15129,"NA":15131},{"trials":15010,"activeCount":124},[15011],{"nctId":15012,"briefTitle":15013,"status":130,"phases":15014,"primaryCompletion":15015,"completion":15015,"start":15016,"enrollment":166,"conditions":15017,"interventions":15018},"NCT03219047","Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed\u002FRefractory Mantle Cell Lymphoma",[86],"2023-07-03","2018-12-20",[789,790],[767],{"trials":15020,"activeCount":124},[15021,15025],{"nctId":1279,"briefTitle":1280,"status":203,"phases":15022,"primaryCompletion":1282,"completion":1282,"start":1283,"enrollment":124,"conditions":15023,"interventions":15024},[87],[359,665,666,528,529,715],[767,1049,1050],{"nctId":15026,"briefTitle":15027,"status":182,"phases":15028,"primaryCompletion":15029,"completion":15029,"start":10636,"enrollment":186,"conditions":15030,"interventions":15031},"NCT02269085","Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse\u002FRefractory Mantle Cell Lymphoma",[87],"2018-05-29",[21],[767,2227],{"trials":15033,"activeCount":186,"soonestReadout":504},[15034,15038,15046,15050,15054,15058,15062,15066,15070,15074,15080,15089,15093,15097,15101,15105,15109,15117],{"nctId":8449,"briefTitle":8450,"status":102,"phases":15035,"primaryCompletion":504,"completion":504,"start":8452,"enrollment":1260,"conditions":15036,"interventions":15037},[88],[4752,665,666],[767,894],{"nctId":15039,"briefTitle":15040,"status":130,"phases":15041,"primaryCompletion":15042,"completion":15042,"start":15043,"enrollment":2018,"conditions":15044,"interventions":15045},"NCT02321540","A Phase I\u002FII Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer",[87,88],"2021-09-16","2015-03-31",[24],[767],{"nctId":760,"briefTitle":761,"status":102,"phases":15047,"primaryCompletion":536,"completion":536,"start":763,"enrollment":764,"conditions":15048,"interventions":15049},[88],[712,665,666,528,529,716],[767,480],{"nctId":5571,"briefTitle":5572,"status":130,"phases":15051,"primaryCompletion":5574,"completion":5574,"start":5575,"enrollment":1034,"conditions":15052,"interventions":15053},[88],[5577],[803,804,2424,767,1402,809,894,810],{"nctId":857,"briefTitle":858,"status":279,"phases":15055,"primaryCompletion":860,"completion":860,"start":105,"enrollment":861,"conditions":15056,"interventions":15057},[88],[712],[767,480,668],{"nctId":2634,"briefTitle":2635,"status":102,"phases":15059,"primaryCompletion":956,"completion":956,"start":2637,"enrollment":2638,"conditions":15060,"interventions":15061},[88],[783,891,788],[803,654,62,1013,804,767,806,894,1016,810],{"nctId":8649,"briefTitle":8650,"status":102,"phases":15063,"primaryCompletion":471,"completion":471,"start":8652,"enrollment":5774,"conditions":15064,"interventions":15065},[88],[2691,8654,8655,785,891,789,790],[767,894],{"nctId":928,"briefTitle":929,"status":102,"phases":15067,"primaryCompletion":931,"completion":931,"start":932,"enrollment":240,"conditions":15068,"interventions":15069},[88],[891],[803,654,62,804,767,806,894,480,810],{"nctId":2685,"briefTitle":2686,"status":203,"phases":15071,"primaryCompletion":2688,"completion":2688,"start":2689,"enrollment":124,"conditions":15072,"interventions":15073},[88],[2691,2692,891],[62,767,1402,894],{"nctId":15075,"briefTitle":15076,"status":102,"phases":15077,"primaryCompletion":161,"completion":161,"start":5773,"enrollment":1131,"conditions":15078,"interventions":15079},"NCT03282396","Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma",[88],[891],[767],{"nctId":15081,"briefTitle":15082,"status":130,"phases":15083,"primaryCompletion":15084,"completion":15084,"start":15085,"enrollment":3820,"conditions":15086,"interventions":15088},"NCT03207555","Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)",[88],"2024-08-02","2018-05-23",[1399,712,15087],"Small Lymphocytic Leukemia",[767],{"nctId":3404,"briefTitle":3405,"status":102,"phases":15090,"primaryCompletion":3407,"completion":3407,"start":3408,"enrollment":3409,"conditions":15091,"interventions":15092},[88],[712,716],[803,1005,767,669],{"nctId":1980,"briefTitle":1981,"status":182,"phases":15094,"primaryCompletion":1983,"completion":1983,"start":1984,"enrollment":910,"conditions":15095,"interventions":15096},[88],[1986,1987],[1083,62,767,1050],{"nctId":2058,"briefTitle":2059,"status":130,"phases":15098,"primaryCompletion":2061,"completion":2061,"start":2062,"enrollment":1609,"conditions":15099,"interventions":15100},[88],[2064,665,666,528,529,715],[767,1050],{"nctId":2118,"briefTitle":2119,"status":203,"phases":15102,"primaryCompletion":2121,"start":2122,"enrollment":124,"conditions":15103,"interventions":15104},[88],[2124],[767,1050],{"nctId":8868,"briefTitle":8869,"status":130,"phases":15106,"primaryCompletion":8871,"completion":8871,"start":8872,"enrollment":473,"conditions":15107,"interventions":15108},[88],[8874,8875,8876,8784,8877,8785,785,8878,8879,8409],[767,1402,894],{"nctId":15110,"briefTitle":15111,"status":182,"phases":15112,"primaryCompletion":15113,"completion":15113,"start":15114,"enrollment":166,"conditions":15115,"interventions":15116},"NCT02272686","Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma",[88],"2017-12-22","2016-06-03",[21],[767],{"nctId":2149,"briefTitle":2150,"status":130,"phases":15118,"primaryCompletion":2152,"completion":2152,"start":2153,"enrollment":550,"conditions":15119,"interventions":15120},[88],[2155,2156,2157],[767,1050],{"trials":15122,"activeCount":124},[15123],{"nctId":15124,"briefTitle":15125,"status":130,"phases":15126,"primaryCompletion":12417,"completion":12417,"start":10046,"enrollment":95,"conditions":15127,"interventions":15128},"NCT02801578","A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)",[88,89],[712],[767],{"trials":15130,"activeCount":124},[],{"trials":15132,"activeCount":124},[],{"intervention":1374,"totalTrials":3726,"cells":15134},{"EARLY_PHASE1":15135,"PHASE1":15141,"PHASE2":15186,"PHASE3":15222,"PHASE4":15224,"NA":15226},{"trials":15136,"activeCount":166,"soonestReadout":4904},[15137],{"nctId":4901,"briefTitle":4902,"status":102,"phases":15138,"primaryCompletion":4904,"completion":4904,"start":4905,"enrollment":1568,"conditions":15139,"interventions":15140},[86],[4907,4908,4909,4910,4911,4912,4913,4914,4915,4916,4917,4918,4919,4920,4921,4922,4923,4924,4925,4926,4927,4928,1462,1463,1464,1465,1466,1467,1469,1470,1471],[4896,1374],{"trials":15142,"activeCount":1231,"soonestReadout":504},[15143,15152,15158,15166,15170,15174],{"nctId":15144,"briefTitle":15145,"status":279,"phases":15146,"primaryCompletion":5025,"completion":15147,"start":15148,"enrollment":593,"conditions":15149,"interventions":15150},"NCT07382544","Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss",[87],"2032-01-31","2026-02-12",[1942,3305],[15151,1374],"MRTX1719",{"nctId":15153,"briefTitle":15154,"status":102,"phases":15155,"primaryCompletion":8641,"completion":8641,"start":6531,"enrollment":861,"conditions":15156,"interventions":15157},"NCT03162627","Selumetinib and Olaparib in Solid Tumors",[87],[7646,7647,5799,7652,7655],[13235,1374],{"nctId":15159,"briefTitle":15160,"status":182,"phases":15161,"primaryCompletion":15162,"completion":5143,"start":2864,"enrollment":166,"conditions":15163,"interventions":15165},"NCT06130254","Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers",[87],"2024-06-14",[7337,15164],"Non-small Cell Lung Cancers",[10678,1374],{"nctId":1337,"briefTitle":1338,"status":182,"phases":15167,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":15168,"interventions":15169},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"nctId":4555,"briefTitle":4556,"status":130,"phases":15171,"primaryCompletion":3519,"completion":3519,"start":675,"enrollment":676,"conditions":15172,"interventions":15173},[87],[4559,4560,4561,3061,4562],[1004,2369,2293,1374,894,2405],{"nctId":15175,"briefTitle":15176,"status":102,"phases":15177,"primaryCompletion":504,"completion":504,"start":15178,"enrollment":15179,"conditions":15180,"interventions":15184},"NCT02208375","mTORC1\u002F2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian",[87],"2014-11-11",159,[15181,15182,15183,7698,7699,4911,7701,10825,1458,1460,1461,10090,10091,7298,10095,1363],"BRCA1 Mutation Carrier","BRCA2 Mutation Carrier","Endometrial Adenocarcinoma",[10717,1374,15185],"Vistusertib",{"trials":15187,"activeCount":296,"soonestReadout":504},[15188,15198,15202,15210,15214],{"nctId":15189,"briefTitle":15190,"status":279,"phases":15191,"primaryCompletion":224,"completion":224,"start":970,"enrollment":1034,"conditions":15192,"interventions":15195},"NCT04090567","Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer",[88],[11534,7308,7309,7310,7311,7312,15193,15194,7699,5234,7313,7314,7315,7316,7317],"Germline BRCA1 Gene Mutation","Germline BRCA2 Gene Mutation",[15196,15197,1374],"Cediranib","Ceralasertib",{"nctId":5609,"briefTitle":5610,"status":102,"phases":15199,"primaryCompletion":224,"completion":224,"start":5612,"enrollment":3379,"conditions":15200,"interventions":15201},[87,88],[5614,1319,1361,1362],[1369,1786,2424,1374],{"nctId":15203,"briefTitle":15204,"status":102,"phases":15205,"primaryCompletion":446,"completion":446,"start":15206,"enrollment":724,"conditions":15207,"interventions":15208},"NCT03579316","Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[88],"2018-12-07",[1458,1460,1461],[15209,1374,15197],"Adavosertib",{"nctId":10231,"briefTitle":10232,"status":102,"phases":15211,"primaryCompletion":504,"completion":504,"start":10234,"enrollment":724,"conditions":15212,"interventions":15213},[88],[10236,5106],[3701,1369,10238,1374],{"nctId":15215,"briefTitle":15216,"status":130,"phases":15217,"primaryCompletion":15218,"completion":15218,"start":15219,"enrollment":628,"conditions":15220,"interventions":15221},"NCT02677038","Olaparib in Treating Patients With Stage IV Pancreatic Cancer",[88],"2022-07-18","2016-11-11",[6564,8173,6565],[1374],{"trials":15223,"activeCount":124},[],{"trials":15225,"activeCount":124},[],{"trials":15227,"activeCount":124},[],{"intervention":669,"totalTrials":3726,"cells":15229},{"EARLY_PHASE1":15230,"PHASE1":15232,"PHASE2":15234,"PHASE3":15293,"PHASE4":15295,"NA":15297},{"trials":15231,"activeCount":124},[],{"trials":15233,"activeCount":124},[],{"trials":15235,"activeCount":186,"soonestReadout":661},[15236,15240,15244,15248,15252,15261,15269,15273,15277,15281,15285,15289],{"nctId":658,"briefTitle":659,"status":279,"phases":15237,"primaryCompletion":661,"completion":661,"start":662,"enrollment":663,"conditions":15238,"interventions":15239},[88],[665,666,528,529],[668,669,480],{"nctId":13490,"briefTitle":13491,"status":182,"phases":15241,"primaryCompletion":11064,"completion":11064,"start":13493,"enrollment":910,"conditions":15242,"interventions":15243},[88],[665,666,528,529],[1402,669],{"nctId":13501,"briefTitle":13502,"status":130,"phases":15245,"primaryCompletion":2457,"completion":2457,"start":13504,"enrollment":724,"conditions":15246,"interventions":15247},[88],[8379,8380,8403,8404,8406,8407,13506,2923,13507,8409,13508,2135,5946],[1402,669],{"nctId":707,"briefTitle":708,"status":102,"phases":15249,"primaryCompletion":115,"completion":115,"start":710,"enrollment":676,"conditions":15250,"interventions":15251},[88],[712,713,714,715,716],[718,669,480],{"nctId":15253,"briefTitle":15254,"status":279,"phases":15255,"primaryCompletion":193,"completion":193,"start":15256,"enrollment":517,"conditions":15257,"interventions":15259},"NCT06213311","A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma",[88],"2024-05-07",[15258],"B Cell Lymphoma",[8580,669,15260],"Axi-cel",{"nctId":15262,"briefTitle":15263,"status":102,"phases":15264,"primaryCompletion":224,"completion":224,"start":15265,"enrollment":1922,"conditions":15266,"interventions":15267},"NCT06108232","Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma",[88],"2024-03-15",[3346,3071],[669,15268],"CC-99282",{"nctId":3404,"briefTitle":3405,"status":102,"phases":15270,"primaryCompletion":3407,"completion":3407,"start":3408,"enrollment":3409,"conditions":15271,"interventions":15272},[88],[712,716],[803,1005,767,669],{"nctId":1052,"briefTitle":1053,"status":279,"phases":15274,"primaryCompletion":1055,"completion":1056,"start":1057,"enrollment":517,"conditions":15275,"interventions":15276},[88],[712,1059],[893,480,669],{"nctId":13651,"briefTitle":13652,"status":130,"phases":15278,"primaryCompletion":13654,"completion":13654,"start":13655,"enrollment":1260,"conditions":15279,"interventions":15280},[87,88],[8409,5632,8067,8068,13657,13658,666,5634,8790,529],[1402,669],{"nctId":1170,"briefTitle":1171,"status":279,"phases":15282,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1034,"conditions":15283,"interventions":15284},[88],[15],[893,669,480,1177,1178],{"nctId":14334,"briefTitle":14335,"status":279,"phases":15286,"primaryCompletion":956,"completion":956,"start":3889,"enrollment":1034,"conditions":15287,"interventions":15288},[88],[712,716],[668,669],{"nctId":7372,"briefTitle":7373,"status":130,"phases":15290,"primaryCompletion":7375,"completion":7375,"start":7376,"enrollment":7377,"conditions":15291,"interventions":15292},[87,88],[21],[1402,669,803,1013,1016,809],{"trials":15294,"activeCount":124},[],{"trials":15296,"activeCount":124},[],{"trials":15298,"activeCount":124},[],{"intervention":1375,"totalTrials":2004,"cells":15300},{"EARLY_PHASE1":15301,"PHASE1":15303,"PHASE2":15356,"PHASE3":15451,"PHASE4":15453,"NA":15455},{"trials":15302,"activeCount":124},[],{"trials":15304,"activeCount":296,"soonestReadout":446},[15305,15309,15313,15317,15321,15325,15329,15333,15337,15341,15345,15352],{"nctId":10740,"briefTitle":10741,"status":102,"phases":15306,"primaryCompletion":446,"completion":446,"start":10743,"enrollment":1664,"conditions":15307,"interventions":15308},[87],[2922,10745,3512,2926],[1275,1371,1113,1375,10747,6656],{"nctId":10749,"briefTitle":10750,"status":130,"phases":15310,"primaryCompletion":3493,"completion":3493,"start":3996,"enrollment":10752,"conditions":15311,"interventions":15312},[87],[33],[1402,1275,2207,6656,1402,1375,1113,10755],{"nctId":10773,"briefTitle":10774,"status":130,"phases":15314,"primaryCompletion":10776,"completion":10776,"start":10777,"enrollment":1001,"conditions":15315,"interventions":15316},[87],[33],[1375,1368,1275],{"nctId":9896,"briefTitle":9897,"status":279,"phases":15318,"primaryCompletion":999,"completion":999,"start":9899,"enrollment":628,"conditions":15319,"interventions":15320},[87],[9901,9902,9903,9904,7515,4097,9905,9906,9907,7523,7525,7526,9908],[1368,1369,1710,1371,1113,1375,1376],{"nctId":7581,"briefTitle":7582,"status":279,"phases":15322,"primaryCompletion":1151,"completion":1152,"start":7584,"enrollment":4299,"conditions":15323,"interventions":15324},[87],[3305],[7587,1375,1113,7588,1275,53,7589],{"nctId":14537,"briefTitle":14538,"status":130,"phases":15326,"primaryCompletion":8340,"completion":8340,"start":6352,"enrollment":3379,"conditions":15327,"interventions":15328},[87],[1996,14541],[1371,4234,1113,1375],{"nctId":10891,"briefTitle":10892,"status":130,"phases":15330,"primaryCompletion":3832,"completion":3832,"start":4183,"enrollment":1231,"conditions":15331,"interventions":15332},[87],[5787],[1275,1375,1376],{"nctId":1337,"briefTitle":1338,"status":182,"phases":15334,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":15335,"interventions":15336},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"nctId":12875,"briefTitle":12876,"status":130,"phases":15338,"primaryCompletion":11088,"completion":11088,"start":12878,"enrollment":5162,"conditions":15339,"interventions":15340},[87],[3195],[2772,1683,1028,1113,1375],{"nctId":7660,"briefTitle":7661,"status":102,"phases":15342,"primaryCompletion":7663,"completion":7663,"start":7664,"enrollment":834,"conditions":15343,"interventions":15344},[87],[1635,7543,1637,7544,1640,7666,7546,7547,1655,7548,1656,7549,7550,7551,7552,7553,7554,7555,7535],[1710,1371,1375,53],{"nctId":15346,"briefTitle":15347,"status":130,"phases":15348,"primaryCompletion":15349,"completion":15349,"start":640,"enrollment":166,"conditions":15350,"interventions":15351},"NCT02062749","Escalating Doses of Oxaliplatin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Children and Adolescents With Extensive Colon Carcinoma",[87],"2018-06-27",[3195],[1375],{"nctId":10935,"briefTitle":10936,"status":130,"phases":15353,"primaryCompletion":10938,"completion":10938,"start":3833,"enrollment":10939,"conditions":15354,"interventions":15355},[87],[1996,1942],[4022,1275,1375,1683],{"trials":15357,"activeCount":1231,"soonestReadout":1193},[15358,15362,15366,15373,15377,15381,15385,15393,15397,15401,15409,15413,15417,15423,15427,15435,15439,15443,15447],{"nctId":10974,"briefTitle":10975,"status":182,"phases":15359,"primaryCompletion":5267,"completion":5267,"start":10977,"enrollment":121,"conditions":15360,"interventions":15361},[88],[10979],[4218,1275,1113,1375],{"nctId":12368,"briefTitle":12369,"status":130,"phases":15363,"primaryCompletion":12371,"completion":12371,"start":12372,"enrollment":1240,"conditions":15364,"interventions":15365},[88],[4107],[1375,4022,2772,2369],{"nctId":15367,"briefTitle":15368,"status":130,"phases":15369,"primaryCompletion":8956,"completion":8956,"start":12168,"enrollment":1131,"conditions":15370,"interventions":15372},"NCT00093379","Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer",[88],[15371],"Anal Cancer",[1368,1375],{"nctId":1624,"briefTitle":1625,"status":102,"phases":15374,"primaryCompletion":1193,"completion":1193,"start":1627,"enrollment":507,"conditions":15375,"interventions":15376},[88],[1629,1630,1631,1632,1633,1634,1635,1636,1637,1638,1639,1640,1641,1642,1643,1644,1645,1646,1647,1648,1649,1650,1651,1652,1653,1654,1655,1656],[1371,1049,1050,1375],{"nctId":8500,"briefTitle":8501,"status":130,"phases":15378,"primaryCompletion":6757,"completion":6757,"start":8503,"enrollment":473,"conditions":15379,"interventions":15380},[87,88],[15],[654,1070,1375,894],{"nctId":4013,"briefTitle":4014,"status":203,"phases":15382,"primaryCompletion":4016,"completion":4016,"start":2264,"enrollment":124,"conditions":15383,"interventions":15384},[88],[4018,4019,4020],[1709,1371,2369,4022,1113,4023,1375],{"nctId":15386,"briefTitle":15387,"status":130,"phases":15388,"primaryCompletion":8306,"completion":8306,"start":4350,"enrollment":1559,"conditions":15389,"interventions":15392},"NCT00338988","Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma",[88],[15390,15391],"Cancer of the Gallbladder","Cancer of the Biliary Tract",[1368,1375],{"nctId":11053,"briefTitle":11054,"status":279,"phases":15394,"primaryCompletion":115,"completion":115,"start":11056,"enrollment":1100,"conditions":15395,"interventions":15396},[88],[11058],[1113,7588,1375,4022,1368,1275],{"nctId":10541,"briefTitle":10542,"status":130,"phases":15398,"primaryCompletion":8718,"completion":8718,"start":3996,"enrollment":134,"conditions":15399,"interventions":15400},[87,88],[3195],[510,1368,1375,10546],{"nctId":15402,"briefTitle":15403,"status":130,"phases":15404,"primaryCompletion":3571,"completion":3571,"start":14844,"enrollment":15405,"conditions":15406,"interventions":15408},"NCT00525915","Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma",[88],126,[2770,15407],"Gastroesophageal Cancer",[4218,1375],{"nctId":14934,"briefTitle":14935,"status":130,"phases":15410,"primaryCompletion":4184,"completion":4184,"start":3819,"enrollment":4551,"conditions":15411,"interventions":15412},[87,88],[14938],[4218,1710,1375],{"nctId":12455,"briefTitle":12456,"status":130,"phases":15414,"primaryCompletion":2968,"completion":2968,"start":2213,"enrollment":34,"conditions":15415,"interventions":15416},[88],[4107],[1683,2369,1375,1368],{"nctId":15418,"briefTitle":15419,"status":130,"phases":15420,"primaryCompletion":2836,"completion":2836,"start":8503,"enrollment":2004,"conditions":15421,"interventions":15422},"NCT00354887","Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater",[88],[4195],[1368,1375],{"nctId":11656,"briefTitle":11657,"status":102,"phases":15424,"primaryCompletion":446,"completion":446,"start":11659,"enrollment":357,"conditions":15425,"interventions":15426},[88],[9902,11661,9903,11662,9904,1634,7515,1635,11663,1647,11664,1648,9905,1649,9906,1651,9907,1653,7523,7546,7525,7547,7526,1655],[718,1371,1375,11556],{"nctId":15428,"briefTitle":15429,"status":130,"phases":15430,"primaryCompletion":8305,"completion":8305,"start":5557,"enrollment":8325,"conditions":15431,"interventions":15433},"NCT00525785","Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)",[88],[15432,12006],"Stomach Cancer",[4218,15434,1375],"Folinic Acid",{"nctId":8819,"briefTitle":8820,"status":130,"phases":15436,"primaryCompletion":5232,"completion":5232,"start":6628,"enrollment":8822,"conditions":15437,"interventions":15438},[87,88],[1987,15],[1375,1070,654,894,1071],{"nctId":12481,"briefTitle":12482,"status":130,"phases":15440,"primaryCompletion":4153,"completion":8340,"start":2847,"enrollment":1409,"conditions":15441,"interventions":15442},[88],[12485],[2369,1375],{"nctId":9381,"briefTitle":9382,"status":182,"phases":15444,"primaryCompletion":3996,"completion":3996,"start":5470,"enrollment":2159,"conditions":15445,"interventions":15446},[87,88],[1036,36,15],[1375,1070,654],{"nctId":11190,"briefTitle":11191,"status":130,"phases":15448,"primaryCompletion":11193,"completion":11193,"start":11194,"enrollment":406,"conditions":15449,"interventions":15450},[88],[11196,11197,11198,11199,11200,11201,11202,11203,11204,2086],[1275,1368,1375],{"trials":15452,"activeCount":124},[],{"trials":15454,"activeCount":124},[],{"trials":15456,"activeCount":124},[],{"intervention":598,"totalTrials":834,"cells":15458},{"EARLY_PHASE1":15459,"PHASE1":15470,"PHASE2":15488,"PHASE3":15585,"PHASE4":15587,"NA":15589},{"trials":15460,"activeCount":166,"soonestReadout":15465},[15461],{"nctId":15462,"briefTitle":15463,"status":279,"phases":15464,"primaryCompletion":15465,"completion":15465,"start":15466,"enrollment":628,"conditions":15467,"interventions":15469},"NCT04744116","Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease",[86],"2032-03-31","2021-02-17",[359,15468],"Steroid Refractory Graft Versus Host Disease",[598],{"trials":15471,"activeCount":124},[15472,15481],{"nctId":15473,"briefTitle":15474,"status":182,"phases":15475,"primaryCompletion":12780,"completion":12780,"start":15476,"enrollment":186,"conditions":15477,"interventions":15479},"NCT01751425","Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors",[87],"2013-07-24",[4598,15478,3040,1026],"Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission",[1028,2321,15480,598],"Nilotinib",{"nctId":15482,"briefTitle":15483,"status":130,"phases":15484,"primaryCompletion":15485,"completion":15485,"start":2316,"enrollment":2004,"conditions":15486,"interventions":15487},"NCT01895842","Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)",[87],"2019-04-02",[15],[598],{"trials":15489,"activeCount":230,"soonestReadout":3425},[15490,15500,15504,15512,15521,15532,15541,15548,15552,15560,15564,15570,15574],{"nctId":15491,"briefTitle":15492,"status":130,"phases":15493,"primaryCompletion":15494,"completion":15494,"start":15495,"enrollment":2911,"conditions":15496,"interventions":15498},"NCT01712308","Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia",[88],"2022-05-24","2013-02-21",[15497,3244,3429],"Anemia",[15499,598],"Sotatercept",{"nctId":588,"briefTitle":589,"status":546,"phases":15501,"primaryCompletion":591,"completion":592,"start":104,"enrollment":593,"conditions":15502,"interventions":15503},[87,88],[595,596],[598,599,480],{"nctId":15505,"briefTitle":15506,"status":130,"phases":15507,"primaryCompletion":15508,"completion":15508,"start":15509,"enrollment":186,"conditions":15510,"interventions":15511},"NCT02784496","Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis",[88],"2024-01-23","2016-09-29",[3429],[598],{"nctId":15513,"briefTitle":15514,"status":203,"phases":15515,"primaryCompletion":15516,"completion":15516,"start":15517,"enrollment":124,"conditions":15518,"interventions":15519},"NCT06619522","A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis",[88],"2025-05-09","2024-09-11",[3429],[598,15520],"INCB57643",{"nctId":15522,"briefTitle":15523,"status":279,"phases":15524,"primaryCompletion":4006,"completion":15525,"start":15526,"enrollment":1922,"conditions":15527,"interventions":15530},"NCT06327100","Open Label Phase 1\u002F2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)",[87,88],"2031-05-01","2024-08-01",[2134,15528,15529],"Post-polycythemia Vera Myelofibrosis","Post-Essential Thrombocytosis Myelofibrosis",[598,15531],"Tasquinimod",{"nctId":15533,"briefTitle":15534,"status":130,"phases":15535,"primaryCompletion":15536,"completion":15536,"start":15537,"enrollment":448,"conditions":15538,"interventions":15539},"NCT02267278","Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)",[88],"2018-06-01","2015-01-12",[4580],[598,15540],"Pracinostat",{"nctId":15542,"briefTitle":15543,"status":279,"phases":15544,"primaryCompletion":10132,"completion":5025,"start":15545,"enrollment":1975,"conditions":15546,"interventions":15547},"NCT06973668","A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease",[88],"2025-07-22",[2391],[2195,598],{"nctId":11416,"briefTitle":11417,"status":130,"phases":15549,"primaryCompletion":8323,"completion":8323,"start":11419,"enrollment":2004,"conditions":15550,"interventions":15551},[88],[4580],[598,1402,809],{"nctId":15553,"briefTitle":15554,"status":130,"phases":15555,"primaryCompletion":10913,"completion":10913,"start":15556,"enrollment":166,"conditions":15557,"interventions":15559},"NCT03041636","Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",[88],"2017-03-08",[8589,15558],"Untreated Chronic Lymphocytic Leukemia",[598,2596],{"nctId":1148,"briefTitle":1149,"status":279,"phases":15561,"primaryCompletion":1151,"completion":1152,"start":1153,"enrollment":1154,"conditions":15562,"interventions":15563},[88],[1156,1157,1158],[963,599,480,565,598,654],{"nctId":15565,"briefTitle":15566,"status":182,"phases":15567,"primaryCompletion":8956,"completion":8956,"start":4085,"enrollment":2159,"conditions":15568,"interventions":15569},"NCT01251965","Phase l\u002FII Study of Ruxolitinib for Acute Leukemia",[87,88],[15],[598],{"nctId":3422,"briefTitle":3423,"status":279,"phases":15571,"primaryCompletion":3425,"completion":3426,"start":3427,"enrollment":406,"conditions":15572,"interventions":15573},[88],[2135,3429],[598,3431,3432,1004,3433,2462,803,1114,2196],{"nctId":15575,"briefTitle":15576,"status":279,"phases":15577,"primaryCompletion":15578,"completion":15579,"start":15580,"enrollment":1260,"conditions":15581,"interventions":15584},"NCT07128381","Phase I\u002FII Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)",[87,88],"2031-07-31","2033-07-31","2026-01-02",[15582,15583],"Myelofibrosis (MF)","Chronic Myelomonocytic Leukemia (CMML)",[6612,598],{"trials":15586,"activeCount":124},[],{"trials":15588,"activeCount":124},[],{"trials":15590,"activeCount":124},[],{"intervention":563,"totalTrials":1483,"cells":15592},{"EARLY_PHASE1":15593,"PHASE1":15595,"PHASE2":15601,"PHASE3":15632,"PHASE4":15634,"NA":15636},{"trials":15594,"activeCount":124},[],{"trials":15596,"activeCount":166,"soonestReadout":446},[15597],{"nctId":556,"briefTitle":557,"status":279,"phases":15598,"primaryCompletion":446,"completion":446,"start":559,"enrollment":560,"conditions":15599,"interventions":15600},[87],[36],[563,564,565,566,480],{"trials":15602,"activeCount":230,"soonestReadout":899},[15603,15607,15611,15615,15619,15623],{"nctId":615,"briefTitle":616,"status":279,"phases":15604,"primaryCompletion":618,"completion":618,"start":619,"enrollment":381,"conditions":15605,"interventions":15606},[87,88],[36,608,610],[563,564,566,480],{"nctId":769,"briefTitle":770,"status":102,"phases":15608,"primaryCompletion":772,"completion":772,"start":773,"enrollment":226,"conditions":15609,"interventions":15610},[88],[36,608,610],[563,480],{"nctId":896,"briefTitle":897,"status":102,"phases":15612,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":15613,"interventions":15614},[87,88],[737,30],[563,480],{"nctId":919,"briefTitle":920,"status":279,"phases":15616,"primaryCompletion":922,"completion":922,"start":923,"enrollment":924,"conditions":15617,"interventions":15618},[87,88],[36,30,608,610],[563,565,480],{"nctId":1127,"briefTitle":1128,"status":102,"phases":15620,"primaryCompletion":860,"completion":860,"start":1130,"enrollment":1131,"conditions":15621,"interventions":15622},[88],[630,608,631,610],[563,480],{"nctId":15624,"briefTitle":15625,"status":279,"phases":15626,"primaryCompletion":7970,"completion":7970,"start":1250,"enrollment":3082,"conditions":15627,"interventions":15631},"NCT05007873","ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase",[88],[15628,912,15629,15630],"Chronic Phase Chronic Myelogenous Leukemia","BCR-ABL1 Positive Chronic Myelogenous Leukemia","BCR-ABL1 Positive",[1028,563],{"trials":15633,"activeCount":124},[],{"trials":15635,"activeCount":124},[],{"trials":15637,"activeCount":124},[],{"intervention":1421,"totalTrials":3726,"cells":15639},{"EARLY_PHASE1":15640,"PHASE1":15642,"PHASE2":15656,"PHASE3":15716,"PHASE4":15718,"NA":15720},{"trials":15641,"activeCount":124},[],{"trials":15643,"activeCount":166,"soonestReadout":1417},[15644,15652],{"nctId":15645,"briefTitle":15646,"status":130,"phases":15647,"primaryCompletion":1138,"completion":1138,"start":15648,"enrollment":1559,"conditions":15649,"interventions":15650},"NCT05038839","Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors",[87],"2022-02-09",[1343,3457],[1421,15651],"Pamiparib",{"nctId":1414,"briefTitle":1415,"status":546,"phases":15653,"primaryCompletion":1417,"completion":1418,"start":1238,"enrollment":834,"conditions":15654,"interventions":15655},[87],[1271],[1421,1050],{"trials":15657,"activeCount":230,"soonestReadout":3943},[15658,15662,15666,15678,15691,15695,15704,15708,15712],{"nctId":1515,"briefTitle":1516,"status":279,"phases":15659,"primaryCompletion":224,"completion":224,"start":1518,"enrollment":1131,"conditions":15660,"interventions":15661},[88],[1520,1521],[1050,1049,1421],{"nctId":11587,"briefTitle":11588,"status":279,"phases":15663,"primaryCompletion":224,"completion":224,"start":11590,"enrollment":517,"conditions":15664,"interventions":15665},[88],[11592,11593,1591,1592,11594],[718,1421],{"nctId":15667,"briefTitle":15668,"status":130,"phases":15669,"primaryCompletion":15670,"completion":15670,"start":15671,"enrollment":550,"conditions":15672,"interventions":15677},"NCT03370718","Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma",[88],"2024-01-12","2018-02-26",[15673,15674,15675,15676],"Metastatic Carcinoma in the Adrenal Cortex","Stage III Adrenal Cortex Carcinoma AJCC v8","Stage IV Adrenal Cortex Carcinoma AJCC v8","Unresectable Adrenal Cortex Carcinoma",[1421],{"nctId":15679,"briefTitle":15680,"status":102,"phases":15681,"primaryCompletion":3943,"completion":3943,"start":15682,"enrollment":507,"conditions":15683,"interventions":15689},"NCT03541902","Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma",[88],"2018-05-15",[7656,1521,15684,1346,15685,15686,15687,1360,15688],"Chromophobe Renal Cell Carcinoma","Papillary Renal Cell Carcinoma","Renal Cell Carcinoma Associated With Xp11.2 Translocations\u002FTFE3 Gene Fusions","Sarcomatoid Renal Cell Carcinoma","Unclassified Renal Cell Carcinoma",[1421,15690],"Sunitinib Malate",{"nctId":11601,"briefTitle":11602,"status":279,"phases":15692,"primaryCompletion":224,"completion":224,"start":1033,"enrollment":230,"conditions":15693,"interventions":15694},[87,88],[7740,7998],[718,1421],{"nctId":15696,"briefTitle":15697,"status":130,"phases":15698,"primaryCompletion":15699,"completion":15699,"start":15700,"enrollment":2933,"conditions":15701,"interventions":15702},"NCT01630590","Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer",[88],"2021-04-06","2014-01-08",[27],[1421,15703],"Androgen Ablation Therapy",{"nctId":1936,"briefTitle":1937,"status":279,"phases":15705,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1222,"conditions":15706,"interventions":15707},[87,88],[1942,1271],[1944,1050,1421,1945],{"nctId":14145,"briefTitle":14146,"status":102,"phases":15709,"primaryCompletion":14148,"completion":14148,"start":14149,"enrollment":861,"conditions":15710,"interventions":15711},[88],[1847,1848,1356,1360],[1421,2840,7558],{"nctId":1990,"briefTitle":1991,"status":203,"phases":15713,"primaryCompletion":1993,"completion":1993,"start":1994,"enrollment":124,"conditions":15714,"interventions":15715},[88],[1828,1996],[1421,1050],{"trials":15717,"activeCount":124},[],{"trials":15719,"activeCount":124},[],{"trials":15721,"activeCount":124},[15722],{"nctId":15723,"briefTitle":15724,"status":130,"phases":15725,"primaryCompletion":1888,"completion":1888,"start":15726,"enrollment":3820,"conditions":15727,"interventions":15732},"NCT02592356","Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer",[91],"2015-11-16",[15728,15729,15730,15731],"Differentiated Thyroid Gland Carcinoma","Malignant Adrenal Gland Pheochromocytoma","Malignant Paraganglioma","Thyroid Gland Medullary Carcinoma",[1421,7558],{"intervention":7558,"totalTrials":1496,"cells":15734},{"EARLY_PHASE1":15735,"PHASE1":15741,"PHASE2":15755,"PHASE3":15781,"PHASE4":15783,"NA":15785},{"trials":15736,"activeCount":166,"soonestReadout":1193},[15737],{"nctId":7538,"briefTitle":7539,"status":279,"phases":15738,"primaryCompletion":1193,"completion":1193,"start":2061,"enrollment":1568,"conditions":15739,"interventions":15740},[86],[7542,7514,7516,1635,7518,7543,1636,1637,7521,7544,7545,7522,7524,7546,1654,7547,7527,1655,7528,7530,7548,1656,7549,7533,7550,7551,7552,7534,7553,7554,7555,7556,7535],[7558,53],{"trials":15742,"activeCount":166,"soonestReadout":224},[15743,15747],{"nctId":7633,"briefTitle":7634,"status":102,"phases":15744,"primaryCompletion":224,"completion":224,"start":7636,"enrollment":1568,"conditions":15745,"interventions":15746},[87],[3071,6684],[53,7639],{"nctId":15748,"briefTitle":15749,"status":203,"phases":15750,"primaryCompletion":15751,"start":2122,"enrollment":124,"conditions":15752,"interventions":15754},"NCT02915172","Lenvatinib and Capecitabine in Patients With Advanced Malignancies",[87],"2022-12",[1942,7646,15753,7647,7648,5799,7649,7650,7651,7652,7653,7654,7655,7656],"Malignant Neoplasms of Bone and Articular Cartilage",[7558,1368],{"trials":15756,"activeCount":3197,"soonestReadout":7709},[15757,15761,15765,15769,15773,15777],{"nctId":7706,"briefTitle":7707,"status":102,"phases":15758,"primaryCompletion":7709,"completion":7709,"start":7710,"enrollment":406,"conditions":15759,"interventions":15760},[88],[4910,4911,7712,7713,6903,7714],[7558,53],{"nctId":7780,"briefTitle":7781,"status":279,"phases":15762,"primaryCompletion":161,"completion":161,"start":7783,"enrollment":1269,"conditions":15763,"interventions":15764},[88],[1520,3071],[53,7558],{"nctId":14103,"briefTitle":14104,"status":102,"phases":15766,"primaryCompletion":4028,"completion":4028,"start":14106,"enrollment":593,"conditions":15767,"interventions":15768},[88],[14108,14109,14110,3873,14111],[2840,7558],{"nctId":7877,"briefTitle":7878,"status":203,"phases":15770,"primaryCompletion":7880,"completion":7880,"start":7881,"enrollment":124,"conditions":15771,"interventions":15772},[88],[1521,7883],[53,7558],{"nctId":14145,"briefTitle":14146,"status":102,"phases":15774,"primaryCompletion":14148,"completion":14148,"start":14149,"enrollment":861,"conditions":15775,"interventions":15776},[88],[1847,1848,1356,1360],[1421,2840,7558],{"nctId":8181,"briefTitle":8182,"status":102,"phases":15778,"primaryCompletion":5995,"completion":5995,"start":8184,"enrollment":448,"conditions":15779,"interventions":15780},[88],[8186,1590,8187,8188,1595,8189],[7558,53],{"trials":15782,"activeCount":124},[],{"trials":15784,"activeCount":124},[],{"trials":15786,"activeCount":124},[15787],{"nctId":15723,"briefTitle":15724,"status":130,"phases":15788,"primaryCompletion":1888,"completion":1888,"start":15726,"enrollment":3820,"conditions":15789,"interventions":15790},[91],[15728,15729,15730,15731],[1421,7558],{"intervention":2196,"totalTrials":924,"cells":15792},{"EARLY_PHASE1":15793,"PHASE1":15803,"PHASE2":15837,"PHASE3":15963,"PHASE4":15969,"NA":15971},{"trials":15794,"activeCount":124},[15795,15799],{"nctId":2181,"briefTitle":2182,"status":203,"phases":15796,"primaryCompletion":2184,"completion":2184,"start":2185,"enrollment":124,"conditions":15797,"interventions":15798},[86],[2187,2188,2189,2190,2191,2192],[75,1004,803,62,1005,2194,2195,894,2196],{"nctId":3014,"briefTitle":3015,"status":130,"phases":15800,"primaryCompletion":3017,"completion":3017,"start":3018,"enrollment":1231,"conditions":15801,"interventions":15802},[86],[2134,3020],[803,1069,1005,2293,2195,2196],{"trials":15804,"activeCount":124},[15805,15809,15813,15817,15821,15825,15829,15833],{"nctId":4516,"briefTitle":4517,"status":130,"phases":15806,"primaryCompletion":4519,"completion":4519,"start":4520,"enrollment":1922,"conditions":15807,"interventions":15808},[87],[4522,15,21,4523,4524],[2293,1070,2757,2196,894,4526,1004,2423],{"nctId":3047,"briefTitle":3048,"status":3049,"phases":15810,"primaryCompletion":3051,"completion":3051,"start":3052,"enrollment":2018,"conditions":15811,"interventions":15812},[87],[1205,643,2512,678,1025,3054,3055,3056,3057,3058,30,913,608,665,3059,3060,666,914,528,3061,3062,529,651,682,882],[803,1005,1402,2293,2195,3064,894,2196],{"nctId":4532,"briefTitle":4533,"status":130,"phases":15814,"primaryCompletion":206,"completion":206,"start":4039,"enrollment":1568,"conditions":15815,"interventions":15816},[87],[30,15],[4537,1004,1070,2374,2196,806,3499],{"nctId":5189,"briefTitle":5190,"status":203,"phases":15818,"primaryCompletion":2212,"completion":2212,"start":3833,"enrollment":124,"conditions":15819,"interventions":15820},[87],[2755,15,21,5193],[2293,1254,1070,894,2424,5195,2195,2196,2374],{"nctId":3128,"briefTitle":3129,"status":130,"phases":15822,"primaryCompletion":3131,"completion":3131,"start":3132,"enrollment":95,"conditions":15823,"interventions":15824},[87],[1122,36,846,3134,644,737,1025,2653,30,727,3135,3136,3059,3060,2223,882],[803,1069,1005,2293,894,2196],{"nctId":4547,"briefTitle":4548,"status":130,"phases":15826,"primaryCompletion":3667,"completion":3667,"start":4550,"enrollment":4551,"conditions":15827,"interventions":15828},[87],[30,15],[1004,1070,894,803,2423,2293,2196,2195,2374],{"nctId":3159,"briefTitle":3160,"status":203,"phases":15830,"primaryCompletion":1174,"completion":1174,"start":3162,"enrollment":124,"conditions":15831,"interventions":15832},[87],[3164,3165,3166,3167,3168,3169,3170,3171,3172,3173,3174,3175,3176,3177,3178],[2424,1005,2194,2293,2195,2196,1254],{"nctId":8284,"briefTitle":8285,"status":130,"phases":15834,"primaryCompletion":8287,"completion":8287,"start":8288,"enrollment":1034,"conditions":15835,"interventions":15836},[87],[785,712,3346,891,8290,4559,3642],[3085,6545,1069,1070,806,894,2196],{"trials":15838,"activeCount":230,"soonestReadout":1427},[15839,15843,15847,15851,15855,15859,15863,15867,15871,15875,15879,15883,15887,15891,15895,15899,15903,15907,15911,15915,15919,15923,15927,15931,15935,15939,15943,15947,15951,15955,15959],{"nctId":5213,"briefTitle":5214,"status":279,"phases":15840,"primaryCompletion":1325,"completion":1326,"start":5216,"enrollment":1328,"conditions":15841,"interventions":15842},[88],[4760],[5219,1070,1254,2196,2757],{"nctId":5519,"briefTitle":5520,"status":130,"phases":15844,"primaryCompletion":4382,"completion":4382,"start":5522,"enrollment":492,"conditions":15845,"interventions":15846},[88],[21,15],[5525,5526,5527,803,2424,1070,2293,894,806,2196],{"nctId":4592,"briefTitle":4593,"status":130,"phases":15848,"primaryCompletion":1518,"completion":1518,"start":4595,"enrollment":230,"conditions":15849,"interventions":15850},[88],[1205,643,4597,1122,2512,36,846,3292,712,4598,737,1866,4599,3040,30,3233,3041,3059,914,632,716,882],[3085,1004,2423,803,2712,1070,2293,2195,894,2196],{"nctId":9115,"briefTitle":9116,"status":182,"phases":15852,"primaryCompletion":2846,"completion":2846,"start":5232,"enrollment":834,"conditions":15853,"interventions":15854},[88],[15,21,2245,4580],[1070,2293,2439,2196,806,2374],{"nctId":8460,"briefTitle":8461,"status":182,"phases":15856,"primaryCompletion":8463,"completion":8463,"start":8464,"enrollment":1568,"conditions":15857,"interventions":15858},[88],[1122,2502,5597,21],[6545,2712,1070,2477,2293,894,2196],{"nctId":3238,"briefTitle":3239,"status":102,"phases":15860,"primaryCompletion":1427,"completion":1427,"start":225,"enrollment":163,"conditions":15861,"interventions":15862},[88],[359,3242,1067,3243,30,3244,913,608,649,3112,3059,609,3060,2223],[1004,803,1070,1005,2195,2196,1254],{"nctId":3247,"briefTitle":3248,"status":130,"phases":15864,"primaryCompletion":3250,"completion":3250,"start":3251,"enrollment":2159,"conditions":15865,"interventions":15866},[87,88],[359],[3085,2226,1005,2477,806,894,2196],{"nctId":4662,"briefTitle":4663,"status":182,"phases":15868,"primaryCompletion":2836,"completion":2836,"start":4665,"enrollment":924,"conditions":15869,"interventions":15870},[88],[15],[2321,1070,1004,4668,2196,806],{"nctId":5591,"briefTitle":5592,"status":130,"phases":15872,"primaryCompletion":5594,"completion":5594,"start":5595,"enrollment":517,"conditions":15873,"interventions":15874},[88],[785,359,5597,21],[3085,75,4365,654,2424,1069,2293,806,894,2196],{"nctId":4678,"briefTitle":4679,"status":130,"phases":15876,"primaryCompletion":4681,"completion":4681,"start":4682,"enrollment":1034,"conditions":15877,"interventions":15878},[88],[2755,15,21],[1254,2423,1004,4537,2374,2196,806,803,1114],{"nctId":8616,"briefTitle":8617,"status":130,"phases":15880,"primaryCompletion":8619,"completion":8619,"start":2740,"enrollment":1131,"conditions":15881,"interventions":15882},[88],[15,21],[894,8622,8623,1070,6545,4537,2196,806,8624,2374],{"nctId":4686,"briefTitle":4687,"status":102,"phases":15884,"primaryCompletion":224,"completion":224,"start":4689,"enrollment":4690,"conditions":15885,"interventions":15886},[87,88],[608,610],[1004,803,1069,1070,2195,2207,2196],{"nctId":4702,"briefTitle":4703,"status":203,"phases":15888,"primaryCompletion":4705,"completion":4705,"start":4705,"enrollment":124,"conditions":15889,"interventions":15890},[88],[4707,3272,2415,4559,4708,4560,4709],[1004,2423,803,2369,2195,894,2196,2405],{"nctId":4712,"briefTitle":4713,"status":130,"phases":15892,"primaryCompletion":4715,"completion":4716,"start":4635,"enrollment":95,"conditions":15893,"interventions":15894},[88],[15],[1004,1070,2423,4537,2373,803,2196,2757,612,654,655],{"nctId":3309,"briefTitle":3310,"status":130,"phases":15896,"primaryCompletion":3312,"completion":3312,"start":3313,"enrollment":628,"conditions":15897,"interventions":15898},[88],[2460,36,30,3315],[803,1114,1069,2293,2462,2196,2757,3317],{"nctId":13860,"briefTitle":13861,"status":130,"phases":15900,"primaryCompletion":2836,"completion":2836,"start":13863,"enrollment":1045,"conditions":15901,"interventions":15902},[87,88],[15,21],[13866,2196,806],{"nctId":4737,"briefTitle":4738,"status":130,"phases":15904,"primaryCompletion":4740,"completion":4740,"start":4741,"enrollment":3354,"conditions":15905,"interventions":15906},[87,88],[4743,3277,3061,4562],[3085,1004,2423,4135,2195,894,2196],{"nctId":4746,"briefTitle":4747,"status":182,"phases":15908,"primaryCompletion":4749,"completion":4749,"start":4750,"enrollment":1568,"conditions":15909,"interventions":15910},[87,88],[1411,712,4752,715],[3085,1004,2423,1069,2369,806,2196],{"nctId":7110,"briefTitle":7111,"status":130,"phases":15912,"primaryCompletion":3152,"completion":3152,"start":7113,"enrollment":2700,"conditions":15913,"interventions":15914},[87,88],[1205,846,7115,644,647,30,608,649,682],[803,1070,2293,2195,3064,2196],{"nctId":9275,"briefTitle":9276,"status":182,"phases":15916,"primaryCompletion":9278,"completion":9278,"start":9279,"enrollment":1231,"conditions":15917,"interventions":15918},[87,88],[15,2245,4580],[1070,2293,2439,2196,9282,2374,7415,1014],{"nctId":4771,"briefTitle":4772,"status":102,"phases":15920,"primaryCompletion":2455,"completion":2455,"start":4774,"enrollment":2004,"conditions":15921,"interventions":15922},[88],[680],[1004,803,1070,4777,2196,1254],{"nctId":5253,"briefTitle":5254,"status":130,"phases":15924,"primaryCompletion":5256,"completion":5256,"start":5257,"enrollment":5258,"conditions":15925,"interventions":15926},[88],[5260,15,4760],[803,1070,2293,1114,894,1254,2196,5262,2374],{"nctId":2749,"briefTitle":2750,"status":203,"phases":15928,"primaryCompletion":2752,"completion":2752,"start":2753,"enrollment":124,"conditions":15929,"interventions":15930},[88],[2755],[1070,62,803,75,894,1004,803,2196,2757,2758],{"nctId":4807,"briefTitle":4808,"status":130,"phases":15932,"primaryCompletion":4810,"completion":4810,"start":4811,"enrollment":628,"conditions":15933,"interventions":15934},[87,88],[15],[1069,1004,803,3420,612,806,1014,2196],{"nctId":4815,"briefTitle":4816,"status":130,"phases":15936,"primaryCompletion":4818,"completion":4818,"start":4819,"enrollment":4820,"conditions":15937,"interventions":15938},[88],[15,36,2838,3315,712,4580,4822,4823,1400,30],[4825,1004,2196,806,2374],{"nctId":3422,"briefTitle":3423,"status":279,"phases":15940,"primaryCompletion":3425,"completion":3426,"start":3427,"enrollment":406,"conditions":15941,"interventions":15942},[88],[2135,3429],[598,3431,3432,1004,3433,2462,803,1114,2196],{"nctId":4839,"briefTitle":4840,"status":130,"phases":15944,"primaryCompletion":4842,"completion":4842,"start":4843,"enrollment":230,"conditions":15945,"interventions":15946},[88],[15,4725],[1070,1004,3499,3085,2196,806,2374],{"nctId":9374,"briefTitle":9375,"status":130,"phases":15948,"primaryCompletion":3761,"completion":3761,"start":5663,"enrollment":901,"conditions":15949,"interventions":15950},[88],[9378],[2369,1070,2293,4668,2196,1069,806],{"nctId":3443,"briefTitle":3444,"status":182,"phases":15952,"primaryCompletion":3446,"completion":3446,"start":3447,"enrollment":166,"conditions":15953,"interventions":15954},[88],[3449,3450,3451,3452,2570,3453,3454,3455,3456,3457,3458,3459],[3420,2424,1005,2194,2293,2195,2196,1254],{"nctId":4847,"briefTitle":4848,"status":203,"phases":15956,"primaryCompletion":4715,"completion":4715,"start":4715,"enrollment":124,"conditions":15957,"interventions":15958},[88],[4851,680,359],[1004,1070,4777,806,2196],{"nctId":7385,"briefTitle":7386,"status":279,"phases":15960,"primaryCompletion":3943,"completion":3943,"start":7388,"enrollment":448,"conditions":15961,"interventions":15962},[87,88],[726],[6545,803,2712,1070,2293,2195,894,2196],{"trials":15964,"activeCount":124},[15965],{"nctId":4864,"briefTitle":4865,"status":130,"phases":15966,"primaryCompletion":4867,"completion":4867,"start":4868,"enrollment":4869,"conditions":15967,"interventions":15968},[89],[4871,15,4523],[1070,2423,1004,4537,2196,806],{"trials":15970,"activeCount":124},[],{"trials":15972,"activeCount":124},[],{"intervention":655,"totalTrials":492,"cells":15974},{"EARLY_PHASE1":15975,"PHASE1":15977,"PHASE2":15983,"PHASE3":16068,"PHASE4":16078,"NA":16080},{"trials":15976,"activeCount":124},[],{"trials":15978,"activeCount":124},[15979],{"nctId":9484,"briefTitle":9485,"status":130,"phases":15980,"primaryCompletion":9487,"completion":9487,"start":9488,"enrollment":593,"conditions":15981,"interventions":15982},[87],[15],[9491,655,654],{"trials":15984,"activeCount":230,"soonestReadout":238},[15985,15989,15993,15997,16001,16005,16013,16017,16024,16028,16032,16036,16040,16044,16048,16052,16056,16060,16064],{"nctId":636,"briefTitle":637,"status":279,"phases":15986,"primaryCompletion":639,"completion":639,"start":640,"enrollment":641,"conditions":15987,"interventions":15988},[88],[643,36,644,645,646,647,30,648,608,649,610,650,651,652],[599,654,565,655,656,480],{"nctId":1554,"briefTitle":1555,"status":130,"phases":15990,"primaryCompletion":1557,"completion":1557,"start":1558,"enrollment":1559,"conditions":15991,"interventions":15992},[87,88],[15,36,30],[1050,655,654,1562,62],{"nctId":9550,"briefTitle":9551,"status":130,"phases":15994,"primaryCompletion":7770,"completion":7770,"start":9553,"enrollment":3541,"conditions":15995,"interventions":15996},[87,88],[15],[612,655,654,2423],{"nctId":9557,"briefTitle":9558,"status":130,"phases":15998,"primaryCompletion":2316,"completion":2316,"start":9560,"enrollment":9561,"conditions":15999,"interventions":16000},[88],[3395,9563],[655,654,2405],{"nctId":4424,"briefTitle":4425,"status":279,"phases":16002,"primaryCompletion":224,"completion":224,"start":4427,"enrollment":1975,"conditions":16003,"interventions":16004},[87,88],[36,4429,1067,630,608,3112,610,3113],[599,654,655,613],{"nctId":16006,"briefTitle":16007,"status":130,"phases":16008,"primaryCompletion":2288,"completion":2288,"start":2969,"enrollment":959,"conditions":16009,"interventions":16011},"NCT00413166","All-trans Retinoic Acid, and Arsenic +\u002F- Idarubicin",[88],[16010],"Acute Promyelocytic Leukemia",[2247,16012,655,694],"Arsenic Trioxide",{"nctId":3222,"briefTitle":3223,"status":279,"phases":16014,"primaryCompletion":3225,"completion":3225,"start":3226,"enrollment":3227,"conditions":16015,"interventions":16016},[88],[3229,3230,3231,647,1067,3232,3233,3234,3235,652],[654,612,2712,1005,694,655],{"nctId":16018,"briefTitle":16019,"status":130,"phases":16020,"primaryCompletion":3901,"completion":3901,"start":5733,"enrollment":959,"conditions":16021,"interventions":16023},"NCT00542971","Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)",[87,88],[2391,36,16022],"Myelodysplastic Disorders",[655,2207,2584],{"nctId":2534,"briefTitle":2535,"status":130,"phases":16025,"primaryCompletion":2537,"completion":2537,"start":1000,"enrollment":834,"conditions":16026,"interventions":16027},[88],[1047,643,2539,2540,848,2541,2542,851],[2423,654,62,655,894,2207,2544,1016,810],{"nctId":2616,"briefTitle":2617,"status":130,"phases":16029,"primaryCompletion":2619,"completion":2619,"start":2620,"enrollment":357,"conditions":16030,"interventions":16031},[88],[15],[2623,655,654,62],{"nctId":4712,"briefTitle":4713,"status":130,"phases":16033,"primaryCompletion":4715,"completion":4716,"start":4635,"enrollment":95,"conditions":16034,"interventions":16035},[88],[15],[1004,1070,2423,4537,2373,803,2196,2757,612,654,655],{"nctId":4445,"briefTitle":4446,"status":130,"phases":16037,"primaryCompletion":4448,"completion":4448,"start":4449,"enrollment":1559,"conditions":16038,"interventions":16039},[88],[652],[599,4452,655],{"nctId":9246,"briefTitle":9247,"status":130,"phases":16041,"primaryCompletion":9249,"completion":9249,"start":9250,"enrollment":9251,"conditions":16042,"interventions":16043},[87,88],[15],[2423,655,654,1070],{"nctId":9721,"briefTitle":9722,"status":130,"phases":16045,"primaryCompletion":9652,"completion":9652,"start":2969,"enrollment":5312,"conditions":16046,"interventions":16047},[88],[15,36,2391],[654,655],{"nctId":1062,"briefTitle":1063,"status":279,"phases":16049,"primaryCompletion":238,"completion":238,"start":1065,"enrollment":1001,"conditions":16050,"interventions":16051},[87,88],[1067,608,610],[654,1069,1070,655,1071,480],{"nctId":1073,"briefTitle":1074,"status":546,"phases":16053,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":406,"conditions":16054,"interventions":16055},[87,88],[1080],[1070,654,655,1069,480,1082,1083],{"nctId":3413,"briefTitle":3414,"status":130,"phases":16057,"primaryCompletion":2953,"completion":2953,"start":3416,"enrollment":1140,"conditions":16058,"interventions":16059},[88],[3418,15,1036],[1069,599,3420,654,1005,655,1014],{"nctId":4479,"briefTitle":4480,"status":279,"phases":16061,"primaryCompletion":224,"completion":224,"start":4482,"enrollment":1222,"conditions":16062,"interventions":16063},[88],[36,644,645,1067,4484,727,912],[599,654,4486,694,655],{"nctId":9790,"briefTitle":9791,"status":130,"phases":16065,"primaryCompletion":3494,"completion":3494,"start":8340,"enrollment":3379,"conditions":16066,"interventions":16067},[88],[36],[2423,655,654],{"trials":16069,"activeCount":124},[16070,16074],{"nctId":4305,"briefTitle":4306,"status":130,"phases":16071,"primaryCompletion":4308,"completion":4308,"start":4309,"enrollment":2402,"conditions":16072,"interventions":16073},[89],[21],[4312,4313,4045,2879,2880,2882,4314,4315,4047,4316,4317,4318,4319,2884],{"nctId":4367,"briefTitle":4368,"status":130,"phases":16075,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":16076,"interventions":16077},[89],[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":16079,"activeCount":124},[],{"trials":16081,"activeCount":124},[],{"intervention":874,"totalTrials":910,"cells":16083},{"EARLY_PHASE1":16084,"PHASE1":16086,"PHASE2":16092,"PHASE3":16138,"PHASE4":16140,"NA":16142},{"trials":16085,"activeCount":124},[],{"trials":16087,"activeCount":166,"soonestReadout":14000},[16088],{"nctId":13997,"briefTitle":13998,"status":102,"phases":16089,"primaryCompletion":14000,"completion":14000,"start":14001,"enrollment":5549,"conditions":16090,"interventions":16091},[87],[1343,14003,1386,14004,14005,14006,14007,14008,361,3457],[2840,7300,2206,874],{"trials":16093,"activeCount":3197,"soonestReadout":7970},[16094,16098,16107,16115,16119,16123,16127,16131],{"nctId":13249,"briefTitle":13250,"status":130,"phases":16095,"primaryCompletion":13252,"completion":13252,"start":13253,"enrollment":1409,"conditions":16096,"interventions":16097},[88],[7647,3195,3154],[1786,874],{"nctId":16099,"briefTitle":16100,"status":102,"phases":16101,"primaryCompletion":193,"completion":193,"start":2167,"enrollment":7377,"conditions":16102,"interventions":16106},"NCT03087071","Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer",[88],[16103,14008,16104,2084,16105,5008,5009,5010],"EGFR NP_005219.2:p.S492R","MAP2K1 Gene Mutation","Refractory Colorectal Adenocarcinoma",[6802,874],{"nctId":16108,"briefTitle":16109,"status":182,"phases":16110,"primaryCompletion":1043,"completion":1043,"start":16111,"enrollment":296,"conditions":16112,"interventions":16113},"NCT04310397","Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB\u002FC\u002FD Melanoma",[88],"2020-01-29",[1350,1351,1352],[1965,16114,874],"Spartalizumab",{"nctId":865,"briefTitle":866,"status":130,"phases":16116,"primaryCompletion":868,"completion":869,"start":870,"enrollment":871,"conditions":16117,"interventions":16118},[88],[608,850,609,610,853,632],[510,874,480],{"nctId":7967,"briefTitle":7968,"status":102,"phases":16120,"primaryCompletion":7970,"completion":7970,"start":7971,"enrollment":406,"conditions":16121,"interventions":16122},[88],[1594,1595],[1965,53,874],{"nctId":8043,"briefTitle":8044,"status":102,"phases":16124,"primaryCompletion":224,"completion":224,"start":8046,"enrollment":1609,"conditions":16125,"interventions":16126},[87,88],[1315,1836,1355,1357,1358,1359,1319,1361,1362,1364],[53,874],{"nctId":1954,"briefTitle":1955,"status":102,"phases":16128,"primaryCompletion":1957,"completion":1957,"start":1958,"enrollment":901,"conditions":16129,"interventions":16130},[88],[1960,1316,1961,1962,1544,1546,1549,1365],[1964,1965,1684,1050,874],{"nctId":16132,"briefTitle":16133,"status":102,"phases":16134,"primaryCompletion":2455,"completion":2455,"start":16135,"enrollment":8325,"conditions":16136,"interventions":16137},"NCT02231775","Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation",[88],"2014-10-22",[1544,1546],[1965,874],{"trials":16139,"activeCount":124},[],{"trials":16141,"activeCount":124},[],{"trials":16143,"activeCount":124},[],{"intervention":565,"totalTrials":230,"cells":16145},{"EARLY_PHASE1":16146,"PHASE1":16148,"PHASE2":16154,"PHASE3":16181,"PHASE4":16183,"NA":16185},{"trials":16147,"activeCount":124},[],{"trials":16149,"activeCount":166,"soonestReadout":446},[16150],{"nctId":556,"briefTitle":557,"status":279,"phases":16151,"primaryCompletion":446,"completion":446,"start":559,"enrollment":560,"conditions":16152,"interventions":16153},[87],[36],[563,564,565,566,480],{"trials":16155,"activeCount":3197,"soonestReadout":1151},[16156,16165,16169,16173,16177],{"nctId":16157,"briefTitle":16158,"status":279,"phases":16159,"primaryCompletion":16160,"completion":12505,"start":16161,"enrollment":1131,"conditions":16162,"interventions":16163},"NCT06235801","A Phase I\u002FII Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia",[87,88],"2027-10-01","2024-05-22",[1080],[565,16164],"Momelotinib",{"nctId":636,"briefTitle":637,"status":279,"phases":16166,"primaryCompletion":639,"completion":639,"start":640,"enrollment":641,"conditions":16167,"interventions":16168},[88],[643,36,644,645,646,647,30,648,608,649,610,650,651,652],[599,654,565,655,656,480],{"nctId":919,"briefTitle":920,"status":279,"phases":16170,"primaryCompletion":922,"completion":922,"start":923,"enrollment":924,"conditions":16171,"interventions":16172},[87,88],[36,30,608,610],[563,565,480],{"nctId":1085,"briefTitle":1086,"status":279,"phases":16174,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":16175,"interventions":16176},[87,88],[608,850,1092,610,853,1093],[510,565,480],{"nctId":1148,"briefTitle":1149,"status":279,"phases":16178,"primaryCompletion":1151,"completion":1152,"start":1153,"enrollment":1154,"conditions":16179,"interventions":16180},[88],[1156,1157,1158],[963,599,480,565,598,654],{"trials":16182,"activeCount":124},[],{"trials":16184,"activeCount":124},[],{"trials":16186,"activeCount":124},[],{"intervention":810,"totalTrials":550,"cells":16188},{"EARLY_PHASE1":16189,"PHASE1":16191,"PHASE2":16193,"PHASE3":16259,"PHASE4":16269,"NA":16271},{"trials":16190,"activeCount":124},[],{"trials":16192,"activeCount":124},[],{"trials":16194,"activeCount":3197,"soonestReadout":772},[16195,16199,16203,16207,16211,16215,16219,16223,16227,16231,16235,16239,16243,16247,16251,16255],{"nctId":2497,"briefTitle":2498,"status":279,"phases":16196,"primaryCompletion":2104,"completion":2104,"start":2500,"enrollment":1975,"conditions":16197,"interventions":16198},[88],[2502,2503],[1083,803,654,62,804,2477,805,806,2425,809,894,810],{"nctId":2506,"briefTitle":2507,"status":182,"phases":16200,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":296,"conditions":16201,"interventions":16202},[88],[2512,2502,2472],[803,654,62,804,2477,1373,805,806,2425,809,894,810],{"nctId":2515,"briefTitle":2516,"status":182,"phases":16204,"primaryCompletion":2518,"completion":2518,"start":2519,"enrollment":230,"conditions":16205,"interventions":16206},[88],[2521,1142,1144],[1083,803,654,62,1069,1373,805,806,1071,894,810],{"nctId":5571,"briefTitle":5572,"status":130,"phases":16208,"primaryCompletion":5574,"completion":5574,"start":5575,"enrollment":1034,"conditions":16209,"interventions":16210},[88],[5577],[803,804,2424,767,1402,809,894,810],{"nctId":11297,"briefTitle":11298,"status":130,"phases":16212,"primaryCompletion":9512,"completion":10760,"start":11300,"enrollment":296,"conditions":16213,"interventions":16214},[88],[11302],[11304,1373,11305,806,809,11306,810],{"nctId":5580,"briefTitle":5581,"status":130,"phases":16216,"primaryCompletion":5583,"completion":5583,"start":5584,"enrollment":2779,"conditions":16217,"interventions":16218},[88],[5586,5587,3056,5588,913,2415,914,2419],[803,804,2424,2425,809,894,810],{"nctId":2534,"briefTitle":2535,"status":130,"phases":16220,"primaryCompletion":2537,"completion":2537,"start":1000,"enrollment":834,"conditions":16221,"interventions":16222},[88],[1047,643,2539,2540,848,2541,2542,851],[2423,654,62,655,894,2207,2544,1016,810],{"nctId":794,"briefTitle":795,"status":279,"phases":16224,"primaryCompletion":772,"completion":772,"start":797,"enrollment":798,"conditions":16225,"interventions":16226},[88],[800,801],[803,654,62,804,805,806,807,808,809,480,810],{"nctId":2634,"briefTitle":2635,"status":102,"phases":16228,"primaryCompletion":956,"completion":956,"start":2637,"enrollment":2638,"conditions":16229,"interventions":16230},[88],[783,891,788],[803,654,62,1013,804,767,806,894,1016,810],{"nctId":2642,"briefTitle":2643,"status":130,"phases":16232,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":2647,"conditions":16233,"interventions":16234},[88],[1122,2649,2650,2651,785,2652,2653],[803,654,62,804,806,2425,810],{"nctId":928,"briefTitle":929,"status":102,"phases":16236,"primaryCompletion":931,"completion":931,"start":932,"enrollment":240,"conditions":16237,"interventions":16238},[88],[891],[803,654,62,804,767,806,894,480,810],{"nctId":4166,"briefTitle":4167,"status":130,"phases":16240,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":16241,"interventions":16242},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"nctId":2726,"briefTitle":2727,"status":102,"phases":16244,"primaryCompletion":999,"completion":999,"start":2729,"enrollment":2730,"conditions":16245,"interventions":16246},[88],[1205,1122,2649,2471,644,912,2732],[803,654,62,1013,804,806,1124,917,809,894,1016,810],{"nctId":2784,"briefTitle":2785,"status":182,"phases":16248,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":1609,"conditions":16249,"interventions":16250},[88],[2790],[62,1013,2792,2495,1114,2793,2794,810],{"nctId":7266,"briefTitle":7267,"status":130,"phases":16252,"primaryCompletion":2602,"completion":2602,"start":2213,"enrollment":1975,"conditions":16253,"interventions":16254},[88],[21],[1069,1071,894,803,7271,809,810],{"nctId":2871,"briefTitle":2872,"status":130,"phases":16256,"primaryCompletion":2874,"completion":2874,"start":2875,"enrollment":1766,"conditions":16257,"interventions":16258},[88],[21],[2878,2879,2880,2881,2882,2883,2884],{"trials":16260,"activeCount":124},[16261,16265],{"nctId":4305,"briefTitle":4306,"status":130,"phases":16262,"primaryCompletion":4308,"completion":4308,"start":4309,"enrollment":2402,"conditions":16263,"interventions":16264},[89],[21],[4312,4313,4045,2879,2880,2882,4314,4315,4047,4316,4317,4318,4319,2884],{"nctId":4367,"briefTitle":4368,"status":130,"phases":16266,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":16267,"interventions":16268},[89],[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":16270,"activeCount":124},[],{"trials":16272,"activeCount":124},[],{"intervention":2195,"totalTrials":492,"cells":16274},{"EARLY_PHASE1":16275,"PHASE1":16285,"PHASE2":16311,"PHASE3":16371,"PHASE4":16373,"NA":16375},{"trials":16276,"activeCount":124},[16277,16281],{"nctId":2181,"briefTitle":2182,"status":203,"phases":16278,"primaryCompletion":2184,"completion":2184,"start":2185,"enrollment":124,"conditions":16279,"interventions":16280},[86],[2187,2188,2189,2190,2191,2192],[75,1004,803,62,1005,2194,2195,894,2196],{"nctId":3014,"briefTitle":3015,"status":130,"phases":16282,"primaryCompletion":3017,"completion":3017,"start":3018,"enrollment":1231,"conditions":16283,"interventions":16284},[86],[2134,3020],[803,1069,1005,2293,2195,2196],{"trials":16286,"activeCount":124},[16287,16291,16295,16299,16303,16307],{"nctId":4516,"briefTitle":4517,"status":130,"phases":16288,"primaryCompletion":4519,"completion":4519,"start":4520,"enrollment":1922,"conditions":16289,"interventions":16290},[87],[4522,15,21,4523,4524],[2293,1070,2757,2196,894,4526,1004,2423],{"nctId":3047,"briefTitle":3048,"status":3049,"phases":16292,"primaryCompletion":3051,"completion":3051,"start":3052,"enrollment":2018,"conditions":16293,"interventions":16294},[87],[1205,643,2512,678,1025,3054,3055,3056,3057,3058,30,913,608,665,3059,3060,666,914,528,3061,3062,529,651,682,882],[803,1005,1402,2293,2195,3064,894,2196],{"nctId":5189,"briefTitle":5190,"status":203,"phases":16296,"primaryCompletion":2212,"completion":2212,"start":3833,"enrollment":124,"conditions":16297,"interventions":16298},[87],[2755,15,21,5193],[2293,1254,1070,894,2424,5195,2195,2196,2374],{"nctId":6509,"briefTitle":6510,"status":130,"phases":16300,"primaryCompletion":6512,"completion":6512,"start":6513,"enrollment":3197,"conditions":16301,"interventions":16302},[87],[15,21],[894,1070,803,2757,6516,2374],{"nctId":4547,"briefTitle":4548,"status":130,"phases":16304,"primaryCompletion":3667,"completion":3667,"start":4550,"enrollment":4551,"conditions":16305,"interventions":16306},[87],[30,15],[1004,1070,894,803,2423,2293,2196,2195,2374],{"nctId":3159,"briefTitle":3160,"status":203,"phases":16308,"primaryCompletion":1174,"completion":1174,"start":3162,"enrollment":124,"conditions":16309,"interventions":16310},[87],[3164,3165,3166,3167,3168,3169,3170,3171,3172,3173,3174,3175,3176,3177,3178],[2424,1005,2194,2293,2195,2196,1254],{"trials":16312,"activeCount":3197,"soonestReadout":1427},[16313,16317,16321,16325,16329,16333,16337,16341,16345,16351,16355,16359,16363,16367],{"nctId":5213,"briefTitle":5214,"status":279,"phases":16314,"primaryCompletion":1325,"completion":1326,"start":5216,"enrollment":1328,"conditions":16315,"interventions":16316},[88],[4760],[5219,1070,1254,2196,2757],{"nctId":4592,"briefTitle":4593,"status":130,"phases":16318,"primaryCompletion":1518,"completion":1518,"start":4595,"enrollment":230,"conditions":16319,"interventions":16320},[88],[1205,643,4597,1122,2512,36,846,3292,712,4598,737,1866,4599,3040,30,3233,3041,3059,914,632,716,882],[3085,1004,2423,803,2712,1070,2293,2195,894,2196],{"nctId":3238,"briefTitle":3239,"status":102,"phases":16322,"primaryCompletion":1427,"completion":1427,"start":225,"enrollment":163,"conditions":16323,"interventions":16324},[88],[359,3242,1067,3243,30,3244,913,608,649,3112,3059,609,3060,2223],[1004,803,1070,1005,2195,2196,1254],{"nctId":4686,"briefTitle":4687,"status":102,"phases":16326,"primaryCompletion":224,"completion":224,"start":4689,"enrollment":4690,"conditions":16327,"interventions":16328},[87,88],[608,610],[1004,803,1069,1070,2195,2207,2196],{"nctId":4702,"briefTitle":4703,"status":203,"phases":16330,"primaryCompletion":4705,"completion":4705,"start":4705,"enrollment":124,"conditions":16331,"interventions":16332},[88],[4707,3272,2415,4559,4708,4560,4709],[1004,2423,803,2369,2195,894,2196,2405],{"nctId":15542,"briefTitle":15543,"status":279,"phases":16334,"primaryCompletion":10132,"completion":5025,"start":15545,"enrollment":1975,"conditions":16335,"interventions":16336},[88],[2391],[2195,598],{"nctId":4712,"briefTitle":4713,"status":130,"phases":16338,"primaryCompletion":4715,"completion":4716,"start":4635,"enrollment":95,"conditions":16339,"interventions":16340},[88],[15],[1004,1070,2423,4537,2373,803,2196,2757,612,654,655],{"nctId":3309,"briefTitle":3310,"status":130,"phases":16342,"primaryCompletion":3312,"completion":3312,"start":3313,"enrollment":628,"conditions":16343,"interventions":16344},[88],[2460,36,30,3315],[803,1114,1069,2293,2462,2196,2757,3317],{"nctId":16346,"briefTitle":16347,"status":182,"phases":16348,"primaryCompletion":2768,"completion":2768,"start":4612,"enrollment":2018,"conditions":16349,"interventions":16350},"NCT00506948","Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)",[88],[7246,30,15,21],[2195,4537,6516],{"nctId":4737,"briefTitle":4738,"status":130,"phases":16352,"primaryCompletion":4740,"completion":4740,"start":4741,"enrollment":3354,"conditions":16353,"interventions":16354},[87,88],[4743,3277,3061,4562],[3085,1004,2423,4135,2195,894,2196],{"nctId":7110,"briefTitle":7111,"status":130,"phases":16356,"primaryCompletion":3152,"completion":3152,"start":7113,"enrollment":2700,"conditions":16357,"interventions":16358},[87,88],[1205,846,7115,644,647,30,608,649,682],[803,1070,2293,2195,3064,2196],{"nctId":2749,"briefTitle":2750,"status":203,"phases":16360,"primaryCompletion":2752,"completion":2752,"start":2753,"enrollment":124,"conditions":16361,"interventions":16362},[88],[2755],[1070,62,803,75,894,1004,803,2196,2757,2758],{"nctId":3443,"briefTitle":3444,"status":182,"phases":16364,"primaryCompletion":3446,"completion":3446,"start":3447,"enrollment":166,"conditions":16365,"interventions":16366},[88],[3449,3450,3451,3452,2570,3453,3454,3455,3456,3457,3458,3459],[3420,2424,1005,2194,2293,2195,2196,1254],{"nctId":7385,"briefTitle":7386,"status":279,"phases":16368,"primaryCompletion":3943,"completion":3943,"start":7388,"enrollment":448,"conditions":16369,"interventions":16370},[87,88],[726],[6545,803,2712,1070,2293,2195,894,2196],{"trials":16372,"activeCount":124},[],{"trials":16374,"activeCount":124},[],{"trials":16376,"activeCount":124},[],{"intervention":75,"totalTrials":492,"cells":16378},{"EARLY_PHASE1":16379,"PHASE1":16385,"PHASE2":16421,"PHASE3":16490,"PHASE4":16492,"NA":16494},{"trials":16380,"activeCount":124},[16381],{"nctId":2181,"briefTitle":2182,"status":203,"phases":16382,"primaryCompletion":2184,"completion":2184,"start":2185,"enrollment":124,"conditions":16383,"interventions":16384},[86],[2187,2188,2189,2190,2191,2192],[75,1004,803,62,1005,2194,2195,894,2196],{"trials":16386,"activeCount":121,"soonestReadout":5310},[16387,16391,16395,16399,16407,16413,16417],{"nctId":5431,"briefTitle":5432,"status":130,"phases":16388,"primaryCompletion":5434,"completion":5434,"start":5435,"enrollment":2779,"conditions":16389,"interventions":16390},[87],[1866,21],[75,1369,2424,2495,1114],{"nctId":544,"briefTitle":545,"status":546,"phases":16392,"primaryCompletion":548,"completion":490,"start":549,"enrollment":550,"conditions":16393,"interventions":16394},[87],[552,21],[480,62,75,554],{"nctId":10789,"briefTitle":10790,"status":130,"phases":16396,"primaryCompletion":3725,"completion":3725,"start":9512,"enrollment":1269,"conditions":16397,"interventions":16398},[87],[10793,21,2245,1924],[1275,75],{"nctId":16400,"briefTitle":16401,"status":130,"phases":16402,"primaryCompletion":16403,"completion":16403,"start":16404,"enrollment":924,"conditions":16405,"interventions":16406},"NCT00059631","Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone",[87],"2015-06-17","2003-03-20",[27],[2449,75],{"nctId":16408,"briefTitle":16409,"status":130,"phases":16410,"primaryCompletion":1558,"start":12649,"enrollment":628,"conditions":16411,"interventions":16412},"NCT00895687","Study of Erlotinib in Combination With Bortezomib",[87],[1942],[3848,75],{"nctId":2332,"briefTitle":2333,"status":130,"phases":16414,"primaryCompletion":2335,"completion":2335,"start":2336,"enrollment":2337,"conditions":16415,"interventions":16416},[87],[2245],[2340,75,1402,62],{"nctId":12338,"briefTitle":12339,"status":102,"phases":16418,"primaryCompletion":5310,"completion":5310,"start":2558,"enrollment":1975,"conditions":16419,"interventions":16420},[87],[3305,4043],[75,2369,1013],{"trials":16422,"activeCount":1231,"soonestReadout":71},[16423,16427,16431,16438,16446,16452,16456,16462,16466,16470,16474,16478,16482,16486],{"nctId":2407,"briefTitle":2408,"status":279,"phases":16424,"primaryCompletion":2410,"completion":2410,"start":2411,"enrollment":924,"conditions":16425,"interventions":16426},[88],[913,2413,2414,2415,2416,2417,914,2418,2419,2420,2421],[75,2423,803,62,2424,2425,1071,894,2426],{"nctId":73,"briefTitle":74,"status":102,"phases":16428,"primaryCompletion":71,"completion":6954,"start":8366,"enrollment":4171,"conditions":16429,"interventions":16430},[88],[8368],[75,894,1177],{"nctId":16432,"briefTitle":16433,"status":130,"phases":16434,"primaryCompletion":3132,"completion":3132,"start":16435,"enrollment":1568,"conditions":16436,"interventions":16437},"NCT01891968","Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation",[88],"2013-08-07",[15],[75],{"nctId":16439,"briefTitle":16440,"status":182,"phases":16441,"primaryCompletion":3902,"completion":3902,"start":16442,"enrollment":1483,"conditions":16443,"interventions":16444},"NCT00023881","Bortezomib in Treating Patients With Chronic Myelogenous Leukemia",[88],"2001-07-02",[15],[16445],"bortezomib",{"nctId":16447,"briefTitle":16448,"status":182,"phases":16449,"primaryCompletion":4152,"completion":4152,"start":4619,"enrollment":166,"conditions":16450,"interventions":16451},"NCT00810576","Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma",[88],[21],[2405,75],{"nctId":5591,"briefTitle":5592,"status":130,"phases":16453,"primaryCompletion":5594,"completion":5594,"start":5595,"enrollment":517,"conditions":16454,"interventions":16455},[88],[785,359,5597,21],[3085,75,4365,654,2424,1069,2293,806,894,2196],{"nctId":16457,"briefTitle":16458,"status":130,"phases":16459,"primaryCompletion":6409,"completion":3762,"start":5557,"enrollment":186,"conditions":16460,"interventions":16461},"NCT00504634","Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma",[88],[1400],[75],{"nctId":11113,"briefTitle":11114,"status":203,"phases":16463,"primaryCompletion":6628,"completion":6628,"start":8719,"enrollment":124,"conditions":16464,"interventions":16465},[87,88],[24],[1275,75],{"nctId":5638,"briefTitle":5639,"status":130,"phases":16467,"primaryCompletion":1307,"completion":1307,"start":5641,"enrollment":1131,"conditions":16468,"interventions":16469},[88],[3273,3278],[75,1369,2424,2495],{"nctId":2714,"briefTitle":2715,"status":130,"phases":16471,"primaryCompletion":2717,"completion":2717,"start":2718,"enrollment":2559,"conditions":16472,"interventions":16473},[87,88],[891],[75,803,654,62,1013,806,894,1016],{"nctId":2749,"briefTitle":2750,"status":203,"phases":16475,"primaryCompletion":2752,"completion":2752,"start":2753,"enrollment":124,"conditions":16476,"interventions":16477},[88],[2755],[1070,62,803,75,894,1004,803,2196,2757,2758],{"nctId":2774,"briefTitle":2775,"status":130,"phases":16479,"primaryCompletion":2777,"completion":2777,"start":2778,"enrollment":2779,"conditions":16480,"interventions":16481},[87,88],[2245],[1402,75,2782,62],{"nctId":2796,"briefTitle":2797,"status":102,"phases":16483,"primaryCompletion":1939,"completion":1939,"start":2799,"enrollment":517,"conditions":16484,"interventions":16485},[88],[2223,2224],[75,554,62,2283],{"nctId":7285,"briefTitle":7286,"status":130,"phases":16487,"primaryCompletion":6065,"completion":6065,"start":6410,"enrollment":492,"conditions":16488,"interventions":16489},[88],[891,21],[75,894,803,1114,2374],{"trials":16491,"activeCount":124},[],{"trials":16493,"activeCount":124},[],{"trials":16495,"activeCount":124},[],{"intervention":4023,"totalTrials":1568,"cells":16497},{"EARLY_PHASE1":16498,"PHASE1":16500,"PHASE2":16536,"PHASE3":16583,"PHASE4":16585,"NA":16587},{"trials":16499,"activeCount":124},[],{"trials":16501,"activeCount":166,"soonestReadout":549},[16502,16506,16510,16519,16528,16532],{"nctId":12249,"briefTitle":12250,"status":182,"phases":16503,"primaryCompletion":12252,"completion":12252,"start":12253,"enrollment":296,"conditions":16504,"interventions":16505},[87],[12255],[2369,4023,12257],{"nctId":11529,"briefTitle":11530,"status":279,"phases":16507,"primaryCompletion":549,"completion":549,"start":11532,"enrollment":357,"conditions":16508,"interventions":16509},[87],[11534,10698,11535,11536,11537,11538,11539,5059,11540,1772,7308,7309,7310,7311,7312,11541,360,5234,1442,1443,11128,11542,1444,11543,1445,1446,1346,7313,7314,7315,7316,7317,4913,1570,4914,4915,1356,10707,4916,1571,4917,4918,10708,4919,4920,4921,4922,4923,1572,4924,4925,10709,4926,4927,4928,10710,10711,10712,1462,1573,1463,1464,1360,10713,1465,1574,1466,1467,10714,1469,1575,1470,1471,1472],[718,11545,4023],{"nctId":16511,"briefTitle":16512,"status":130,"phases":16513,"primaryCompletion":4842,"completion":4842,"start":16514,"enrollment":406,"conditions":16515,"interventions":16517},"NCT00833807","Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver",[87],"2009-02",[1729,16516],"Liver Metastasis",[16518],"Nab-Paclitaxel",{"nctId":16520,"briefTitle":16521,"status":130,"phases":16522,"primaryCompletion":7636,"completion":7636,"start":16523,"enrollment":448,"conditions":16524,"interventions":16527},"NCT02394535","Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer",[87],"2015-11-12",[4018,16525,12436,7601,7602,7603,16526],"Locally Advanced Pancreatic Adenocarcinoma","Stage III Pancreatic Cancer AJCC v6 and v7",[1368,4023],{"nctId":7591,"briefTitle":7592,"status":130,"phases":16529,"primaryCompletion":7594,"completion":7594,"start":7595,"enrollment":910,"conditions":16530,"interventions":16531},[87],[7597,7598,7599,7600,7601,7602,7603],[4135,4023,7605,53],{"nctId":10927,"briefTitle":10928,"status":130,"phases":16533,"primaryCompletion":10930,"completion":10930,"start":10931,"enrollment":5258,"conditions":16534,"interventions":16535},[87],[1942],[4023,1275,2369],{"trials":16537,"activeCount":296,"soonestReadout":5310},[16538,16542,16546,16550,16563,16567,16571,16575,16579],{"nctId":6795,"briefTitle":6796,"status":130,"phases":16539,"primaryCompletion":6798,"completion":6799,"start":4382,"enrollment":2997,"conditions":16540,"interventions":16541},[88],[18],[6802,4023,1369,4218,6744,803],{"nctId":12376,"briefTitle":12377,"status":102,"phases":16543,"primaryCompletion":1939,"completion":1939,"start":12379,"enrollment":2018,"conditions":16544,"interventions":16545},[88],[4018,12381,12382,12383,8175,8176],[1786,2369,4023,12385],{"nctId":4013,"briefTitle":4014,"status":203,"phases":16547,"primaryCompletion":4016,"completion":4016,"start":2264,"enrollment":124,"conditions":16548,"interventions":16549},[88],[4018,4019,4020],[1709,1371,2369,4022,1113,4023,1375],{"nctId":16551,"briefTitle":16552,"status":182,"phases":16553,"primaryCompletion":3268,"completion":3268,"start":16554,"enrollment":230,"conditions":16555,"interventions":16561},"NCT04216472","Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations",[88],"2020-02-05",[8026,16556,16557,8027,13133,13134,7308,7309,7310,7311,16558,16559,16560,13136,13137,13138,7313,7314,7315,7316,14083,1363],"Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8",[16562,4023],"Alpelisib",{"nctId":10100,"briefTitle":10101,"status":279,"phases":16564,"primaryCompletion":5310,"completion":5310,"start":10103,"enrollment":240,"conditions":16565,"interventions":16566},[88],[1355,10105,1357,1707,1358,3845,1359],[1369,1786,2369,4023,1376,1377],{"nctId":11046,"briefTitle":11047,"status":102,"phases":16568,"primaryCompletion":3943,"completion":3943,"start":10324,"enrollment":676,"conditions":16569,"interventions":16570},[88],[8186,1590,11050,8187,8188,1594,8189],[718,1275,11035,4023,1376,9970],{"nctId":4119,"briefTitle":4120,"status":130,"phases":16572,"primaryCompletion":4122,"completion":4122,"start":4123,"enrollment":2933,"conditions":16573,"interventions":16574},[88],[4125,4126,4127,4128,4129,4130,4131,4132,4133],[1709,4135,4023],{"nctId":11635,"briefTitle":11636,"status":130,"phases":16576,"primaryCompletion":11638,"completion":11638,"start":11639,"enrollment":1609,"conditions":16577,"interventions":16578},[88],[11641,5079,1363],[718,4023],{"nctId":12502,"briefTitle":12503,"status":279,"phases":16580,"primaryCompletion":12505,"completion":12506,"start":12507,"enrollment":1034,"conditions":16581,"interventions":16582},[88],[8577,12509,12510],[12509,2369,4023,12512],{"trials":16584,"activeCount":124},[],{"trials":16586,"activeCount":124},[],{"trials":16588,"activeCount":124},[],{"intervention":1071,"totalTrials":1568,"cells":16590},{"EARLY_PHASE1":16591,"PHASE1":16601,"PHASE2":16603,"PHASE3":16666,"PHASE4":16668,"NA":16670},{"trials":16592,"activeCount":124},[16593],{"nctId":16594,"briefTitle":16595,"status":182,"phases":16596,"primaryCompletion":16597,"completion":16597,"start":162,"enrollment":166,"conditions":16598,"interventions":16599},"NCT02392039","Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma",[86],"2018-04-04",[21],[1071,16600],"Loratadine",{"trials":16602,"activeCount":124},[],{"trials":16604,"activeCount":3197,"soonestReadout":504},[16605,16609,16616,16622,16626,16630,16634,16638,16642,16646,16650,16654,16658,16662],{"nctId":2407,"briefTitle":2408,"status":279,"phases":16606,"primaryCompletion":2410,"completion":2410,"start":2411,"enrollment":924,"conditions":16607,"interventions":16608},[88],[913,2413,2414,2415,2416,2417,914,2418,2419,2420,2421],[75,2423,803,62,2424,2425,1071,894,2426],{"nctId":16610,"briefTitle":16611,"status":279,"phases":16612,"primaryCompletion":504,"completion":504,"start":16613,"enrollment":342,"conditions":16614,"interventions":16615},"NCT01624805","Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and\u002For Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome",[88],"2012-06-25",[3134,647,30,648],[3085,3420,1069,1014,1071],{"nctId":16617,"briefTitle":16618,"status":130,"phases":16619,"primaryCompletion":9923,"completion":9923,"start":3214,"enrollment":676,"conditions":16620,"interventions":16621},"NCT00067639","Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma",[88],[1400],[1071],{"nctId":2515,"briefTitle":2516,"status":182,"phases":16623,"primaryCompletion":2518,"completion":2518,"start":2519,"enrollment":230,"conditions":16624,"interventions":16625},[88],[2521,1142,1144],[1083,803,654,62,1069,1373,805,806,1071,894,810],{"nctId":5617,"briefTitle":5618,"status":130,"phases":16627,"primaryCompletion":5620,"completion":5620,"start":5621,"enrollment":2933,"conditions":16628,"interventions":16629},[87,88],[5623],[2340,2495,1114,1369,2424,1071],{"nctId":2674,"briefTitle":2675,"status":130,"phases":16631,"primaryCompletion":2677,"completion":2677,"start":2678,"enrollment":2004,"conditions":16632,"interventions":16633},[88],[15],[894,2681,803,1013,1114,2682,2683,806,2584,2374,1071,62],{"nctId":1062,"briefTitle":1063,"status":279,"phases":16635,"primaryCompletion":238,"completion":238,"start":1065,"enrollment":1001,"conditions":16636,"interventions":16637},[87,88],[1067,608,610],[654,1069,1070,655,1071,480],{"nctId":8819,"briefTitle":8820,"status":130,"phases":16639,"primaryCompletion":5232,"completion":5232,"start":6628,"enrollment":8822,"conditions":16640,"interventions":16641},[87,88],[1987,15],[1375,1070,654,894,1071],{"nctId":2813,"briefTitle":2814,"status":279,"phases":16643,"primaryCompletion":224,"completion":548,"start":2816,"enrollment":2159,"conditions":16644,"interventions":16645},[88],[15],[803,1016,1083,806,654,805,809,1071,2819,894,62],{"nctId":7266,"briefTitle":7267,"status":130,"phases":16647,"primaryCompletion":2602,"completion":2602,"start":2213,"enrollment":1975,"conditions":16648,"interventions":16649},[88],[21],[1069,1071,894,803,7271,809,810],{"nctId":7277,"briefTitle":7278,"status":102,"phases":16651,"primaryCompletion":115,"completion":115,"start":7280,"enrollment":492,"conditions":16652,"interventions":16653},[88],[1205,1122,7282,644,913,914],[1083,803,654,1069,806,1071,1124,894,1016],{"nctId":12014,"briefTitle":12015,"status":130,"phases":16655,"primaryCompletion":4184,"completion":4184,"start":9923,"enrollment":517,"conditions":16656,"interventions":16657},[88],[12018,12019,12020,12021,12022,12023,12024,12025,12026,12027,12028],[12030,1376,2957,1071],{"nctId":2852,"briefTitle":2853,"status":182,"phases":16659,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":296,"conditions":16660,"interventions":16661},[87,88],[2413,1142,1143,1144,2421,1145],[803,654,62,2712,1113,805,1114,806,1071,809,894,1015,1016],{"nctId":2886,"briefTitle":2887,"status":130,"phases":16663,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":16664,"interventions":16665},[88],[15,1122],[894,803,1013,1016,62,806,654,2374,1114,2894,1071,2895],{"trials":16667,"activeCount":124},[],{"trials":16669,"activeCount":124},[],{"trials":16671,"activeCount":124},[],{"intervention":1377,"totalTrials":2779,"cells":16673},{"EARLY_PHASE1":16674,"PHASE1":16676,"PHASE2":16703,"PHASE3":16752,"PHASE4":16754,"NA":16756},{"trials":16675,"activeCount":124},[],{"trials":16677,"activeCount":166,"soonestReadout":9914},[16678,16682,16686,16690,16694],{"nctId":2209,"briefTitle":2210,"status":130,"phases":16679,"primaryCompletion":2212,"completion":2212,"start":2213,"enrollment":593,"conditions":16680,"interventions":16681},[87],[242],[1377,62],{"nctId":9911,"briefTitle":9912,"status":102,"phases":16683,"primaryCompletion":9914,"completion":9914,"start":9915,"enrollment":3726,"conditions":16684,"interventions":16685},[87],[1315,1836,1359,1319,1361,1362],[1275,1369,9918,1377],{"nctId":1337,"briefTitle":1338,"status":182,"phases":16687,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":16688,"interventions":16689},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"nctId":2313,"briefTitle":2314,"status":130,"phases":16691,"primaryCompletion":2316,"completion":2316,"start":2317,"enrollment":1766,"conditions":16692,"interventions":16693},[87],[2319],[1709,2321,1377,62],{"nctId":16695,"briefTitle":16696,"status":182,"phases":16697,"primaryCompletion":16698,"completion":16698,"start":2326,"enrollment":16699,"conditions":16700,"interventions":16701},"NCT01548144","Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer",[87],"2021-08-26",178,[33],[16702,1431,1377],"Crizotinib",{"trials":16704,"activeCount":296,"soonestReadout":5310},[16705,16709,16718,16728,16732,16736,16740,16744,16748],{"nctId":10010,"briefTitle":10011,"status":130,"phases":16706,"primaryCompletion":10013,"completion":10013,"start":10014,"enrollment":3354,"conditions":16707,"interventions":16708},[88],[24],[1369,1377,1275,10017],{"nctId":16710,"briefTitle":16711,"status":102,"phases":16712,"primaryCompletion":238,"completion":238,"start":16713,"enrollment":1496,"conditions":16714,"interventions":16715},"NCT05335941","A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma",[88],"2023-06-13",[3967,7818],[1377,16716,16717],"Zimberelimab","Etrumadenant",{"nctId":16719,"briefTitle":16720,"status":102,"phases":16721,"primaryCompletion":193,"completion":193,"start":16722,"enrollment":550,"conditions":16723,"interventions":16727},"NCT03744793","Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer",[88],"2019-04-11",[13147,16724,16725,13148,13149,1803,16726],"Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation","Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation","MTAP Negative",[693,1377],{"nctId":1695,"briefTitle":1696,"status":130,"phases":16729,"primaryCompletion":1698,"completion":1698,"start":105,"enrollment":1699,"conditions":16730,"interventions":16731},[88],[1701,1702,1703,1704,1705,1706,1707],[1369,1709,1710,1049,1050,1377],{"nctId":10100,"briefTitle":10101,"status":279,"phases":16733,"primaryCompletion":5310,"completion":5310,"start":10103,"enrollment":240,"conditions":16734,"interventions":16735},[88],[1355,10105,1357,1707,1358,3845,1359],[1369,1786,2369,4023,1376,1377],{"nctId":10139,"briefTitle":10140,"status":203,"phases":16737,"primaryCompletion":10142,"completion":10142,"start":10143,"enrollment":124,"conditions":16738,"interventions":16739},[88],[10145],[10147,1369,1377],{"nctId":4199,"briefTitle":4200,"status":182,"phases":16741,"primaryCompletion":4202,"completion":4202,"start":4203,"enrollment":1231,"conditions":16742,"interventions":16743},[88],[4205,4206,1355,1357,1358,1359,1319,1361,1362,4207],[4209,1377,1369,1709],{"nctId":4278,"briefTitle":4279,"status":279,"phases":16745,"primaryCompletion":4281,"completion":4281,"start":4282,"enrollment":2159,"conditions":16746,"interventions":16747},[88],[24],[4285,1709,1369,1377],{"nctId":12496,"briefTitle":12497,"status":182,"phases":16749,"primaryCompletion":2212,"completion":2212,"start":3988,"enrollment":834,"conditions":16750,"interventions":16751},[88],[1521],[1377,2369],{"trials":16753,"activeCount":124},[],{"trials":16755,"activeCount":124},[],{"trials":16757,"activeCount":124},[],{"intervention":805,"totalTrials":95,"cells":16759},{"EARLY_PHASE1":16760,"PHASE1":16762,"PHASE2":16764,"PHASE3":16810,"PHASE4":16812,"NA":16814},{"trials":16761,"activeCount":124},[],{"trials":16763,"activeCount":124},[],{"trials":16765,"activeCount":3197,"soonestReadout":772},[16766,16770,16774,16778,16782,16786,16790,16794,16798,16802,16806],{"nctId":2464,"briefTitle":2465,"status":279,"phases":16767,"primaryCompletion":2467,"completion":2467,"start":2468,"enrollment":2469,"conditions":16768,"interventions":16769},[87,88],[2471,2472,2473,2474,2475,1142,2415,1144,2419],[1083,803,654,62,2477,805,806,809,894,1016],{"nctId":2497,"briefTitle":2498,"status":279,"phases":16771,"primaryCompletion":2104,"completion":2104,"start":2500,"enrollment":1975,"conditions":16772,"interventions":16773},[88],[2502,2503],[1083,803,654,62,804,2477,805,806,2425,809,894,810],{"nctId":2506,"briefTitle":2507,"status":182,"phases":16775,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":296,"conditions":16776,"interventions":16777},[88],[2512,2502,2472],[803,654,62,804,2477,1373,805,806,2425,809,894,810],{"nctId":2515,"briefTitle":2516,"status":182,"phases":16779,"primaryCompletion":2518,"completion":2518,"start":2519,"enrollment":230,"conditions":16780,"interventions":16781},[88],[2521,1142,1144],[1083,803,654,62,1069,1373,805,806,1071,894,810],{"nctId":794,"briefTitle":795,"status":279,"phases":16783,"primaryCompletion":772,"completion":772,"start":797,"enrollment":798,"conditions":16784,"interventions":16785},[88],[800,801],[803,654,62,804,805,806,807,808,809,480,810],{"nctId":2587,"briefTitle":2588,"status":182,"phases":16787,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":95,"conditions":16788,"interventions":16789},[88],[1142,2593,1144,2594],[803,654,1028,62,1013,1113,805,806,809,894,2596,1016],{"nctId":7014,"briefTitle":7015,"status":182,"phases":16791,"primaryCompletion":1984,"completion":1984,"start":7017,"enrollment":166,"conditions":16792,"interventions":16793},[88],[15,7019,2653,21],[654,7021,1016,809,7022,2425,894,806,803,805,1013,4514,7023],{"nctId":1007,"briefTitle":1008,"status":279,"phases":16795,"primaryCompletion":446,"completion":446,"start":1010,"enrollment":517,"conditions":16796,"interventions":16797},[88],[847],[803,654,62,1013,805,806,1014,809,894,1015,480,1016],{"nctId":7222,"briefTitle":7223,"status":130,"phases":16799,"primaryCompletion":7225,"completion":7225,"start":7226,"enrollment":1100,"conditions":16800,"interventions":16801},[88],[7228,2653],[7021,1016,7230,7231,803,654,805,806,1013,7023],{"nctId":2813,"briefTitle":2814,"status":279,"phases":16803,"primaryCompletion":224,"completion":548,"start":2816,"enrollment":2159,"conditions":16804,"interventions":16805},[88],[15],[803,1016,1083,806,654,805,809,1071,2819,894,62],{"nctId":2852,"briefTitle":2853,"status":182,"phases":16807,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":296,"conditions":16808,"interventions":16809},[87,88],[2413,1142,1143,1144,2421,1145],[803,654,62,2712,1113,805,1114,806,1071,809,894,1015,1016],{"trials":16811,"activeCount":124},[],{"trials":16813,"activeCount":124},[],{"trials":16815,"activeCount":124},[],{"intervention":2477,"totalTrials":1496,"cells":16817},{"EARLY_PHASE1":16818,"PHASE1":16820,"PHASE2":16822,"PHASE3":16877,"PHASE4":16879,"NA":16881},{"trials":16819,"activeCount":124},[],{"trials":16821,"activeCount":124},[],{"trials":16823,"activeCount":3197,"soonestReadout":2104},[16824,16832,16836,16840,16844,16848,16852,16862,16866,16870],{"nctId":16825,"briefTitle":16826,"status":182,"phases":16827,"primaryCompletion":16828,"completion":16828,"start":16829,"enrollment":296,"conditions":16830,"interventions":16831},"NCT03094611","Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia",[88],"2020-03-11","2017-11-30",[7348,913,914],[2477],{"nctId":2464,"briefTitle":2465,"status":279,"phases":16833,"primaryCompletion":2467,"completion":2467,"start":2468,"enrollment":2469,"conditions":16834,"interventions":16835},[87,88],[2471,2472,2473,2474,2475,1142,2415,1144,2419],[1083,803,654,62,2477,805,806,809,894,1016],{"nctId":8460,"briefTitle":8461,"status":182,"phases":16837,"primaryCompletion":8463,"completion":8463,"start":8464,"enrollment":1568,"conditions":16838,"interventions":16839},[88],[1122,2502,5597,21],[6545,2712,1070,2477,2293,894,2196],{"nctId":2497,"briefTitle":2498,"status":279,"phases":16841,"primaryCompletion":2104,"completion":2104,"start":2500,"enrollment":1975,"conditions":16842,"interventions":16843},[88],[2502,2503],[1083,803,654,62,804,2477,805,806,2425,809,894,810],{"nctId":3247,"briefTitle":3248,"status":130,"phases":16845,"primaryCompletion":3250,"completion":3250,"start":3251,"enrollment":2159,"conditions":16846,"interventions":16847},[87,88],[359],[3085,2226,1005,2477,806,894,2196],{"nctId":2506,"briefTitle":2507,"status":182,"phases":16849,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":296,"conditions":16850,"interventions":16851},[88],[2512,2502,2472],[803,654,62,804,2477,1373,805,806,2425,809,894,810],{"nctId":16853,"briefTitle":16854,"status":130,"phases":16855,"primaryCompletion":16856,"completion":16856,"start":16857,"enrollment":492,"conditions":16858,"interventions":16860},"NCT02311998","Phase I\u002FII Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML",[87,88],"2022-03-23","2015-04-16",[2471,644,16859,7348,1026,649,650],"Blasts More Than 5 Percent of Bone Marrow Nucleated Cells",[16861,2477],"Bosutinib",{"nctId":13083,"briefTitle":13084,"status":279,"phases":16863,"primaryCompletion":281,"completion":571,"start":13086,"enrollment":517,"conditions":16864,"interventions":16865},[87,88],[9033,13088],[1083,2477,499,13090],{"nctId":2813,"briefTitle":2814,"status":279,"phases":16867,"primaryCompletion":224,"completion":548,"start":2816,"enrollment":2159,"conditions":16868,"interventions":16869},[88],[15],[803,1016,1083,806,654,805,809,1071,2819,894,62],{"nctId":16871,"briefTitle":16872,"status":102,"phases":16873,"primaryCompletion":115,"completion":115,"start":16874,"enrollment":517,"conditions":16875,"interventions":16876},"NCT03441061","Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease",[88],"2018-02-15",[1122,2502,1142],[2477],{"trials":16878,"activeCount":124},[],{"trials":16880,"activeCount":124},[],{"trials":16882,"activeCount":124},[],{"intervention":613,"totalTrials":1483,"cells":16884},{"EARLY_PHASE1":16885,"PHASE1":16887,"PHASE2":16896,"PHASE3":16926,"PHASE4":16928,"NA":16930},{"trials":16886,"activeCount":124},[],{"trials":16888,"activeCount":166,"soonestReadout":11550},[16889],{"nctId":16890,"briefTitle":16891,"status":279,"phases":16892,"primaryCompletion":11550,"completion":11551,"start":16893,"enrollment":1559,"conditions":16894,"interventions":16895},"NCT06769490","Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia",[87],"2025-07-10",[36],[576,613],{"trials":16897,"activeCount":296,"soonestReadout":224},[16898,16902,16906,16910,16914,16922],{"nctId":601,"briefTitle":602,"status":279,"phases":16899,"primaryCompletion":604,"completion":604,"start":605,"enrollment":606,"conditions":16900,"interventions":16901},[87,88],[36,30,608,609,610],[612,613,480],{"nctId":9540,"briefTitle":9541,"status":130,"phases":16903,"primaryCompletion":9543,"completion":9543,"start":9544,"enrollment":606,"conditions":16904,"interventions":16905},[87,88],[9546,9547,608,850,609,610,853,632],[510,654,613],{"nctId":4424,"briefTitle":4425,"status":279,"phases":16907,"primaryCompletion":224,"completion":224,"start":4427,"enrollment":1975,"conditions":16908,"interventions":16909},[87,88],[36,4429,1067,630,608,3112,610,3113],[599,654,655,613],{"nctId":751,"briefTitle":752,"status":182,"phases":16911,"primaryCompletion":754,"completion":754,"start":755,"enrollment":186,"conditions":16912,"interventions":16913},[87,88],[757,608,494],[613,480],{"nctId":16915,"briefTitle":16916,"status":102,"phases":16917,"primaryCompletion":224,"completion":224,"start":16918,"enrollment":901,"conditions":16919,"interventions":16921},"NCT04128748","Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome",[87,88],"2020-05-27",[36,16920,1067,608,609,610,632],"Blasts More Than 10 Percent of Bone Marrow Nucleated Cells",[942,613],{"nctId":10556,"briefTitle":10557,"status":102,"phases":16923,"primaryCompletion":224,"completion":224,"start":870,"enrollment":406,"conditions":16924,"interventions":16925},[87,88],[737,30,727,850,609,10560],[510,613],{"trials":16927,"activeCount":124},[],{"trials":16929,"activeCount":124},[],{"trials":16931,"activeCount":124},[],{"intervention":942,"totalTrials":1483,"cells":16933},{"EARLY_PHASE1":16934,"PHASE1":16936,"PHASE2":16954,"PHASE3":16986,"PHASE4":16988,"NA":16990},{"trials":16935,"activeCount":124},[],{"trials":16937,"activeCount":166,"soonestReadout":224},[16938,16947],{"nctId":16939,"briefTitle":16940,"status":279,"phases":16941,"primaryCompletion":224,"completion":224,"start":16942,"enrollment":1664,"conditions":16943,"interventions":16946},"NCT03896269","CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",[87],"2019-05-14",[16944,16859,16945,850,3112,853,3113],"Blasts 10-19 Percent of Bone Marrow Nucleated Cells","High Risk Chronic Myelomonocytic Leukemia",[942],{"nctId":16948,"briefTitle":16949,"status":130,"phases":16950,"primaryCompletion":889,"completion":889,"start":16951,"enrollment":166,"conditions":16952,"interventions":16953},"NCT04915612","Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia",[87],"2021-05-21",[846,608,610,651],[694,942],{"trials":16955,"activeCount":296,"soonestReadout":104},[16956,16964,16968,16972,16979],{"nctId":16957,"briefTitle":16958,"status":130,"phases":16959,"primaryCompletion":16960,"completion":16960,"start":16961,"enrollment":2911,"conditions":16962,"interventions":16963},"NCT02286726","CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia",[88],"2020-01-22","2015-05-04",[36,846,651],[942],{"nctId":16915,"briefTitle":16916,"status":102,"phases":16965,"primaryCompletion":224,"completion":224,"start":16918,"enrollment":901,"conditions":16966,"interventions":16967},[87,88],[36,16920,1067,608,609,610,632],[942,613],{"nctId":936,"briefTitle":937,"status":279,"phases":16969,"primaryCompletion":446,"completion":446,"start":939,"enrollment":901,"conditions":16970,"interventions":16971},[88],[608,610],[942,480],{"nctId":16973,"briefTitle":16974,"status":279,"phases":16975,"primaryCompletion":104,"completion":104,"start":16976,"enrollment":406,"conditions":16977,"interventions":16978},"NCT04493164","CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[88],"2020-12-30",[7115,30,727,608,610],[566,942],{"nctId":16980,"briefTitle":16981,"status":102,"phases":16982,"primaryCompletion":1325,"completion":1325,"start":16983,"enrollment":676,"conditions":16984,"interventions":16985},"NCT03672539","Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome",[88],"2018-11-07",[846,737,1067,30,608,610],[694,942],{"trials":16987,"activeCount":124},[],{"trials":16989,"activeCount":124},[],{"trials":16991,"activeCount":124},[],{"intervention":963,"totalTrials":230,"cells":16993},{"EARLY_PHASE1":16994,"PHASE1":16996,"PHASE2":17006,"PHASE3":17040,"PHASE4":17042,"NA":17044},{"trials":16995,"activeCount":124},[],{"trials":16997,"activeCount":166,"soonestReadout":17002},[16998],{"nctId":16999,"briefTitle":17000,"status":546,"phases":17001,"primaryCompletion":17002,"completion":17003,"start":1427,"enrollment":1131,"conditions":17004,"interventions":17005},"NCT07411586","Phase 1\u002F1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia",[87],"2027-01-14","2029-01-14",[36],[576,963],{"trials":17007,"activeCount":296,"soonestReadout":1151},[17008,17016,17020,17027,17031],{"nctId":17009,"briefTitle":17010,"status":279,"phases":17011,"primaryCompletion":5995,"completion":6282,"start":17012,"enrollment":1568,"conditions":17013,"interventions":17015},"NCT06566742","A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic\u002FSyndromes\u002FChronic Myelomonocytic Leukemia.",[88],"2024-12-10",[1036,737,17014],"Clonal Cytopenia of Undetermined Significance",[963],{"nctId":953,"briefTitle":954,"status":279,"phases":17017,"primaryCompletion":956,"completion":957,"start":958,"enrollment":959,"conditions":17018,"interventions":17019},[87,88],[961],[963,480,612,964],{"nctId":17021,"briefTitle":17022,"status":279,"phases":17023,"primaryCompletion":224,"completion":548,"start":17024,"enrollment":2004,"conditions":17025,"interventions":17026},"NCT06668584","A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies",[88],"2024-12-31",[2460],[963],{"nctId":1148,"briefTitle":1149,"status":279,"phases":17028,"primaryCompletion":1151,"completion":1152,"start":1153,"enrollment":1154,"conditions":17029,"interventions":17030},[88],[1156,1157,1158],[963,599,480,565,598,654],{"nctId":17032,"briefTitle":17033,"status":203,"phases":17034,"primaryCompletion":5995,"completion":6282,"start":17035,"enrollment":124,"conditions":17036,"interventions":17039},"NCT06597734","A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm",[88],"2025-01-28",[737,17037,17038],"Advanced Myeloproliferative Neoplasms","IDH1-mutated Higher-Risk Myelodysplastic Syndromes",[963],{"trials":17041,"activeCount":124},[],{"trials":17043,"activeCount":124},[],{"trials":17045,"activeCount":124},[],{"intervention":17047,"totalTrials":230,"cells":17048},"Ivonescimab",{"EARLY_PHASE1":17049,"PHASE1":17051,"PHASE2":17053,"PHASE3":17101,"PHASE4":17103,"NA":17105},{"trials":17050,"activeCount":124},[],{"trials":17052,"activeCount":124},[],{"trials":17054,"activeCount":3197,"soonestReadout":238},[17055,17064,17070,17079,17086,17095],{"nctId":17056,"briefTitle":17057,"status":279,"phases":17058,"primaryCompletion":238,"completion":17059,"start":13983,"enrollment":1409,"conditions":17060,"interventions":17063},"NCT07229417","IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma",[88],"2029-09-30",[17061,17062],"Metastatic Endocrine Refractory","Triple Negative Invasive Lobular Carcinoma",[17047],{"nctId":17065,"briefTitle":17066,"status":279,"phases":17067,"primaryCompletion":10132,"completion":5025,"start":889,"enrollment":195,"conditions":17068,"interventions":17069},"NCT06672575","A Phase I\u002FII Study of IVONESCIMAB in Recurrent Glioblastoma",[87,88],[11042],[17047],{"nctId":17071,"briefTitle":17072,"status":279,"phases":17073,"primaryCompletion":17074,"completion":17075,"start":14265,"enrollment":517,"conditions":17076,"interventions":17078},"NCT06940518","Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma",[88],"2028-01-19","2030-01-19",[17047,17077],"Clear Cell Renal Carcinoma",[17047],{"nctId":17080,"briefTitle":17081,"status":279,"phases":17082,"primaryCompletion":1088,"completion":14252,"start":1407,"enrollment":628,"conditions":17083,"interventions":17085},"NCT06567314","Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma",[88],[17084],"Cutaneous Squamous Cell Carcinoma",[17047],{"nctId":17087,"briefTitle":17088,"status":203,"phases":17089,"primaryCompletion":17090,"completion":17090,"start":17090,"enrollment":124,"conditions":17091,"interventions":17094},"NCT07038915","STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1\u002FPD-L1",[88],"2025-07-28",[17092,17093],"Lung Squamous Cell Carcinoma","Anti-PD1\u002FPDL1 Antibody",[11556,17047],{"nctId":17096,"briefTitle":17097,"status":279,"phases":17098,"primaryCompletion":537,"completion":1481,"start":17090,"enrollment":861,"conditions":17099,"interventions":17100},"NCT06959550","Phase II Study of Anti-PD-1\u002FVEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer",[88],[10674],[17047],{"trials":17102,"activeCount":124},[],{"trials":17104,"activeCount":124},[],{"trials":17106,"activeCount":124},[],{"intervention":11556,"totalTrials":230,"cells":17108},{"EARLY_PHASE1":17109,"PHASE1":17111,"PHASE2":17117,"PHASE3":17139,"PHASE4":17141,"NA":17143},{"trials":17110,"activeCount":124},[],{"trials":17112,"activeCount":166,"soonestReadout":11550},[17113],{"nctId":11547,"briefTitle":11548,"status":102,"phases":17114,"primaryCompletion":11550,"completion":11551,"start":11552,"enrollment":1483,"conditions":17115,"interventions":17116},[87],[11554],[11556,718],{"trials":17118,"activeCount":296,"soonestReadout":2104},[17119,17123,17127,17131,17135],{"nctId":11619,"briefTitle":11620,"status":102,"phases":17120,"primaryCompletion":2104,"completion":2104,"start":11622,"enrollment":1409,"conditions":17121,"interventions":17122},[88],[4031,11624],[11556,718],{"nctId":17087,"briefTitle":17088,"status":203,"phases":17124,"primaryCompletion":17090,"completion":17090,"start":17090,"enrollment":124,"conditions":17125,"interventions":17126},[88],[17092,17093],[11556,17047],{"nctId":11656,"briefTitle":11657,"status":102,"phases":17128,"primaryCompletion":446,"completion":446,"start":11659,"enrollment":357,"conditions":17129,"interventions":17130},[88],[9902,11661,9903,11662,9904,1634,7515,1635,11663,1647,11664,1648,9905,1649,9906,1651,9907,1653,7523,7546,7525,7547,7526,1655],[718,1371,1375,11556],{"nctId":11667,"briefTitle":11668,"status":102,"phases":17132,"primaryCompletion":536,"completion":11670,"start":8565,"enrollment":296,"conditions":17133,"interventions":17134},[88],[5349],[718,11556],{"nctId":11691,"briefTitle":11692,"status":279,"phases":17136,"primaryCompletion":281,"completion":281,"start":1736,"enrollment":1496,"conditions":17137,"interventions":17138},[87,88],[11695],[718,11556],{"trials":17140,"activeCount":124},[],{"trials":17142,"activeCount":124},[],{"trials":17144,"activeCount":124},[],{"intervention":893,"totalTrials":230,"cells":17146},{"EARLY_PHASE1":17147,"PHASE1":17149,"PHASE2":17151,"PHASE3":17177,"PHASE4":17179,"NA":17181},{"trials":17148,"activeCount":124},[],{"trials":17150,"activeCount":124},[],{"trials":17152,"activeCount":3197,"soonestReadout":2104},[17153,17157,17161,17165,17169,17173],{"nctId":885,"briefTitle":886,"status":102,"phases":17154,"primaryCompletion":115,"completion":888,"start":889,"enrollment":676,"conditions":17155,"interventions":17156},[88],[891],[893,894,480],{"nctId":8674,"briefTitle":8675,"status":279,"phases":17158,"primaryCompletion":2104,"completion":3879,"start":6989,"enrollment":676,"conditions":17159,"interventions":17160},[88],[891],[894,893],{"nctId":1052,"briefTitle":1053,"status":279,"phases":17162,"primaryCompletion":1055,"completion":1056,"start":1057,"enrollment":517,"conditions":17163,"interventions":17164},[88],[712,1059],[893,480,669],{"nctId":1170,"briefTitle":1171,"status":279,"phases":17166,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1034,"conditions":17167,"interventions":17168},[88],[15],[893,669,480,1177,1178],{"nctId":1180,"briefTitle":1181,"status":279,"phases":17170,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":406,"conditions":17171,"interventions":17172},[88],[891,1186,1187],[893,480],{"nctId":1226,"briefTitle":1227,"status":182,"phases":17174,"primaryCompletion":1229,"completion":1229,"start":1230,"enrollment":1231,"conditions":17175,"interventions":17176},[87,88],[712,716],[893,480],{"trials":17178,"activeCount":124},[],{"trials":17180,"activeCount":124},[],{"trials":17182,"activeCount":124},[],{"intervention":5114,"totalTrials":3197,"cells":17184},{"EARLY_PHASE1":17185,"PHASE1":17187,"PHASE2":17197,"PHASE3":17221,"PHASE4":17223,"NA":17225},{"trials":17186,"activeCount":124},[],{"trials":17188,"activeCount":166,"soonestReadout":446},[17189],{"nctId":17190,"briefTitle":17191,"status":102,"phases":17192,"primaryCompletion":446,"completion":446,"start":17193,"enrollment":2004,"conditions":17194,"interventions":17195},"NCT03586661","Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[87],"2019-04-29",[8170,8171,15183,4911,1454,4912,1670,1457,1458,1460,1461],[17196,5114],"Copanlisib",{"trials":17198,"activeCount":296,"soonestReadout":5103},[17199,17203,17209,17213],{"nctId":5100,"briefTitle":5101,"status":279,"phases":17200,"primaryCompletion":5103,"completion":5103,"start":5104,"enrollment":4733,"conditions":17201,"interventions":17202},[88],[5106,5107,5108,5109,5110,5111,3547],[3699,5113,3700,5114,809],{"nctId":17204,"briefTitle":17205,"status":279,"phases":17206,"primaryCompletion":548,"completion":548,"start":11622,"enrollment":1100,"conditions":17207,"interventions":17208},"NCT05700721","Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)",[88],[1520],[5114,3884],{"nctId":10222,"briefTitle":10223,"status":102,"phases":17210,"primaryCompletion":224,"completion":224,"start":2185,"enrollment":1100,"conditions":17211,"interventions":17212},[88],[3543,3544,3545,10226,10227,3546],[3701,1369,10229,5114],{"nctId":17214,"briefTitle":17215,"status":102,"phases":17216,"primaryCompletion":815,"completion":815,"start":17217,"enrollment":473,"conditions":17218,"interventions":17220},"NCT04701307","Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas",[88],"2021-02-01",[17219,2049,1355,1357,1358,1359],"Lung Small Cell Carcinoma",[3884,5114],{"trials":17222,"activeCount":124},[],{"trials":17224,"activeCount":124},[],{"trials":17226,"activeCount":124},[],{"intervention":3103,"totalTrials":3197,"cells":17228},{"EARLY_PHASE1":17229,"PHASE1":17231,"PHASE2":17250,"PHASE3":17260,"PHASE4":17262,"NA":17264},{"trials":17230,"activeCount":124},[],{"trials":17232,"activeCount":1231,"soonestReadout":3193},[17233,17242,17246],{"nctId":17234,"briefTitle":17235,"status":546,"phases":17236,"primaryCompletion":17237,"completion":17238,"start":1864,"enrollment":1034,"conditions":17239,"interventions":17240},"NCT07553390","Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers",[87],"2036-03-30","2038-03-30",[18],[17241,10680,3103],"TGFBR2 KO iC9\u002FTROP2.CAR\u002FIL-15 NK cells",{"nctId":3095,"briefTitle":3096,"status":279,"phases":17243,"primaryCompletion":3098,"completion":3099,"start":3100,"enrollment":2700,"conditions":17244,"interventions":17245},[87],[1924],[3103,3104,2462,803],{"nctId":3190,"briefTitle":3191,"status":279,"phases":17247,"primaryCompletion":3193,"completion":3193,"start":1407,"enrollment":924,"conditions":17248,"interventions":17249},[87],[3195,3040],[1005,803,1683,3104,3103],{"trials":17251,"activeCount":121,"soonestReadout":537},[17252,17256],{"nctId":6909,"briefTitle":6910,"status":546,"phases":17253,"primaryCompletion":537,"completion":1481,"start":549,"enrollment":1496,"conditions":17254,"interventions":17255},[87,88],[6913],[2672,3103,1070,803],{"nctId":6949,"briefTitle":6950,"status":546,"phases":17257,"primaryCompletion":6952,"completion":6953,"start":6954,"enrollment":1222,"conditions":17258,"interventions":17259},[88],[6956,1866],[1070,803,6958,3103],{"trials":17261,"activeCount":124},[],{"trials":17263,"activeCount":124},[],{"trials":17265,"activeCount":124},[],{"intervention":1684,"totalTrials":3197,"cells":17267},{"EARLY_PHASE1":17268,"PHASE1":17274,"PHASE2":17280,"PHASE3":17297,"PHASE4":17299,"NA":17301},{"trials":17269,"activeCount":166,"soonestReadout":10669},[17270],{"nctId":10666,"briefTitle":10667,"status":546,"phases":17271,"primaryCompletion":10669,"completion":10670,"start":10671,"enrollment":1222,"conditions":17272,"interventions":17273},[86],[10673,10674],[1275,1683,6802,10676,10677,1684,10678,10679,10680,10681,10682],{"trials":17275,"activeCount":166,"soonestReadout":12824},[17276],{"nctId":12821,"briefTitle":12822,"status":279,"phases":17277,"primaryCompletion":12824,"completion":12824,"start":12825,"enrollment":2159,"conditions":17278,"interventions":17279},[87],[10674],[1683,12828,1684],{"trials":17281,"activeCount":1231,"soonestReadout":1299},[17282,17286,17293],{"nctId":1659,"briefTitle":1660,"status":102,"phases":17283,"primaryCompletion":1662,"completion":1662,"start":1663,"enrollment":1664,"conditions":17284,"interventions":17285},[87,88],[1666,1667,1668,1669,1670,1671,1672,1673,1674,1675,1676,1677,1678,1679,1680,1681],[1683,1684,1050],{"nctId":17287,"briefTitle":17288,"status":279,"phases":17289,"primaryCompletion":1299,"completion":1299,"start":17290,"enrollment":1328,"conditions":17291,"interventions":17292},"NCT05026983","Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases",[88],"2021-12-27",[1312,1316,1353],[1964,1684],{"nctId":1954,"briefTitle":1955,"status":102,"phases":17294,"primaryCompletion":1957,"completion":1957,"start":1958,"enrollment":901,"conditions":17295,"interventions":17296},[88],[1960,1316,1961,1962,1544,1546,1549,1365],[1964,1965,1684,1050,874],{"trials":17298,"activeCount":124},[],{"trials":17300,"activeCount":124},[],{"trials":17302,"activeCount":124},[],{"intervention":7864,"totalTrials":3197,"cells":17304},{"EARLY_PHASE1":17305,"PHASE1":17307,"PHASE2":17309,"PHASE3":17344,"PHASE4":17346,"NA":17348},{"trials":17306,"activeCount":124},[],{"trials":17308,"activeCount":124},[],{"trials":17310,"activeCount":3197,"soonestReadout":3880},[17311,17320,17324,17328,17337],{"nctId":17312,"briefTitle":17313,"status":279,"phases":17314,"primaryCompletion":3880,"completion":17315,"start":15545,"enrollment":195,"conditions":17316,"interventions":17319},"NCT06959511","Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery",[88],"2030-10-01",[17317,17318],"Neoadjuvant Treatment","Thyroid Cancer",[7864],{"nctId":7857,"briefTitle":7858,"status":279,"phases":17321,"primaryCompletion":2105,"completion":7860,"start":7861,"enrollment":1131,"conditions":17322,"interventions":17323},[88],[7863,7864,53,7865,7866],[7864,53],{"nctId":14249,"briefTitle":14250,"status":546,"phases":17325,"primaryCompletion":14252,"completion":14253,"start":5310,"enrollment":3726,"conditions":17326,"interventions":17327},[88],[14255],[12910,7864],{"nctId":17329,"briefTitle":17330,"status":279,"phases":17331,"primaryCompletion":17332,"completion":17333,"start":5003,"enrollment":3082,"conditions":17334,"interventions":17336},"NCT07193550","A Phase 2 Trial of Zanzalintinib in Advanced\u002FMetastatic Bone Sarcomas (ZAMBONE)",[88],"2029-10-31","2031-10-31",[17335],"Bone Sarcomas",[7864],{"nctId":17338,"briefTitle":17339,"status":546,"phases":17340,"primaryCompletion":537,"completion":1481,"start":1864,"enrollment":834,"conditions":17341,"interventions":17343},"NCT07527169","A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma",[88],[17342],"Metastatic Olfactory Neuroblastoma",[7864],{"trials":17345,"activeCount":124},[],{"trials":17347,"activeCount":124},[],{"trials":17349,"activeCount":124},[],{"intervention":1069,"totalTrials":1328,"cells":17351},{"EARLY_PHASE1":17352,"PHASE1":17358,"PHASE2":17380,"PHASE3":17488,"PHASE4":17498,"NA":17500},{"trials":17353,"activeCount":124},[17354],{"nctId":3014,"briefTitle":3015,"status":130,"phases":17355,"primaryCompletion":3017,"completion":3017,"start":3018,"enrollment":1231,"conditions":17356,"interventions":17357},[86],[2134,3020],[803,1069,1005,2293,2195,2196],{"trials":17359,"activeCount":124},[17360,17364,17368,17372,17376],{"nctId":10854,"briefTitle":10855,"status":130,"phases":17361,"primaryCompletion":2777,"completion":2777,"start":8340,"enrollment":959,"conditions":17362,"interventions":17363},[87],[33],[10859,2369,1275,1069],{"nctId":3128,"briefTitle":3129,"status":130,"phases":17365,"primaryCompletion":3131,"completion":3131,"start":3132,"enrollment":95,"conditions":17366,"interventions":17367},[87],[1122,36,846,3134,644,737,1025,2653,30,727,3135,3136,3059,3060,2223,882],[803,1069,1005,2293,894,2196],{"nctId":11813,"briefTitle":11814,"status":203,"phases":17369,"primaryCompletion":11816,"completion":11816,"start":11817,"enrollment":124,"conditions":17370,"interventions":17371},[87],[11819],[1376,11821,11822,1069],{"nctId":8284,"briefTitle":8285,"status":130,"phases":17373,"primaryCompletion":8287,"completion":8287,"start":8288,"enrollment":1034,"conditions":17374,"interventions":17375},[87],[785,712,3346,891,8290,4559,3642],[3085,6545,1069,1070,806,894,2196],{"nctId":3181,"briefTitle":3182,"status":130,"phases":17377,"primaryCompletion":3184,"completion":3184,"start":640,"enrollment":406,"conditions":17378,"interventions":17379},[87],[3186,610],[654,1069,2712,1005,3188],{"trials":17381,"activeCount":3197,"soonestReadout":504},[17382,17386,17390,17394,17398,17402,17406,17410,17414,17418,17422,17426,17432,17436,17440,17444,17448,17452,17456,17460,17464,17468,17472,17476,17480,17484],{"nctId":4609,"briefTitle":4610,"status":130,"phases":17383,"primaryCompletion":3571,"completion":3571,"start":4612,"enrollment":2647,"conditions":17384,"interventions":17385},[88],[36,30,3315],[2423,1004,1070,4537,1069],{"nctId":4616,"briefTitle":4617,"status":130,"phases":17387,"primaryCompletion":3805,"completion":3805,"start":4619,"enrollment":2997,"conditions":17388,"interventions":17389},[87,88],[2755,15],[4622,1069,1070,1004,4526],{"nctId":6787,"briefTitle":6788,"status":130,"phases":17391,"primaryCompletion":6790,"completion":6790,"start":6791,"enrollment":871,"conditions":17392,"interventions":17393},[87,88],[18],[1069,803,804,1376],{"nctId":16610,"briefTitle":16611,"status":279,"phases":17395,"primaryCompletion":504,"completion":504,"start":16613,"enrollment":342,"conditions":17396,"interventions":17397},[88],[3134,647,30,648],[3085,3420,1069,1014,1071],{"nctId":2515,"briefTitle":2516,"status":182,"phases":17399,"primaryCompletion":2518,"completion":2518,"start":2519,"enrollment":230,"conditions":17400,"interventions":17401},[88],[2521,1142,1144],[1083,803,654,62,1069,1373,805,806,1071,894,810],{"nctId":5591,"briefTitle":5592,"status":130,"phases":17403,"primaryCompletion":5594,"completion":5594,"start":5595,"enrollment":517,"conditions":17404,"interventions":17405},[88],[785,359,5597,21],[3085,75,4365,654,2424,1069,2293,806,894,2196],{"nctId":4036,"briefTitle":4037,"status":130,"phases":17407,"primaryCompletion":4039,"completion":4039,"start":4040,"enrollment":3541,"conditions":17408,"interventions":17409},[88],[1293,4042,4043],[2878,4045,2882,4046,4047],{"nctId":6925,"briefTitle":6926,"status":130,"phases":17411,"primaryCompletion":6928,"completion":6928,"start":6929,"enrollment":406,"conditions":17412,"interventions":17413},[88],[712],[1070,803,2449,894,1069],{"nctId":4686,"briefTitle":4687,"status":102,"phases":17415,"primaryCompletion":224,"completion":224,"start":4689,"enrollment":4690,"conditions":17416,"interventions":17417},[87,88],[608,610],[1004,803,1069,1070,2195,2207,2196],{"nctId":3309,"briefTitle":3310,"status":130,"phases":17419,"primaryCompletion":3312,"completion":3312,"start":3313,"enrollment":628,"conditions":17420,"interventions":17421},[88],[2460,36,30,3315],[803,1114,1069,2293,2462,2196,2757,3317],{"nctId":5626,"briefTitle":5627,"status":130,"phases":17423,"primaryCompletion":5629,"completion":5629,"start":5630,"enrollment":492,"conditions":17424,"interventions":17425},[88],[891,4559,5632,5633,4561,5634,5635],[4365,5515,654,2424,1069,1402,2293,894],{"nctId":17427,"briefTitle":17428,"status":130,"phases":17429,"primaryCompletion":4835,"completion":4835,"start":7177,"enrollment":492,"conditions":17430,"interventions":17431},"NCT01818284","Plerixafor for Stem Cell Mobilization in Normal Donors",[88],[4522],[1069,4622],{"nctId":4746,"briefTitle":4747,"status":182,"phases":17433,"primaryCompletion":4749,"completion":4749,"start":4750,"enrollment":1568,"conditions":17434,"interventions":17435},[87,88],[1411,712,4752,715],[3085,1004,2423,1069,2369,806,2196],{"nctId":4166,"briefTitle":4167,"status":130,"phases":17437,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":17438,"interventions":17439},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"nctId":1062,"briefTitle":1063,"status":279,"phases":17441,"primaryCompletion":238,"completion":238,"start":1065,"enrollment":1001,"conditions":17442,"interventions":17443},[87,88],[1067,608,610],[654,1069,1070,655,1071,480],{"nctId":1073,"briefTitle":1074,"status":546,"phases":17445,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":406,"conditions":17446,"interventions":17447},[87,88],[1080],[1070,654,655,1069,480,1082,1083],{"nctId":1105,"briefTitle":1106,"status":182,"phases":17449,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":539,"conditions":17450,"interventions":17451},[87,88],[359,913,608,850,609,914,610,853,632],[1112,510,803,654,62,1069,1113,1114,806,809,894,480,1016],{"nctId":12722,"briefTitle":12723,"status":130,"phases":17453,"primaryCompletion":12725,"completion":12725,"start":12726,"enrollment":2779,"conditions":17454,"interventions":17455},[87,88],[15,1036],[1069,3420,612],{"nctId":4807,"briefTitle":4808,"status":130,"phases":17457,"primaryCompletion":4810,"completion":4810,"start":4811,"enrollment":628,"conditions":17458,"interventions":17459},[87,88],[15],[1069,1004,803,3420,612,806,1014,2196],{"nctId":7266,"briefTitle":7267,"status":130,"phases":17461,"primaryCompletion":2602,"completion":2602,"start":2213,"enrollment":1975,"conditions":17462,"interventions":17463},[88],[21],[1069,1071,894,803,7271,809,810],{"nctId":7277,"briefTitle":7278,"status":102,"phases":17465,"primaryCompletion":115,"completion":115,"start":7280,"enrollment":492,"conditions":17466,"interventions":17467},[88],[1205,1122,7282,644,913,914],[1083,803,654,1069,806,1071,1124,894,1016],{"nctId":3413,"briefTitle":3414,"status":130,"phases":17469,"primaryCompletion":2953,"completion":2953,"start":3416,"enrollment":1140,"conditions":17470,"interventions":17471},[88],[3418,15,1036],[1069,599,3420,654,1005,655,1014],{"nctId":3435,"briefTitle":3436,"status":130,"phases":17473,"primaryCompletion":3438,"completion":3438,"start":3439,"enrollment":2018,"conditions":17474,"interventions":17475},[87,88],[15],[1069,803,1005],{"nctId":5694,"briefTitle":5695,"status":203,"phases":17477,"primaryCompletion":5697,"completion":5697,"start":5697,"enrollment":124,"conditions":17478,"interventions":17479},[87,88],[3039,891,4559,5632,3277,4561,5634],[4365,654,2424,1069,2293,894,5700],{"nctId":9374,"briefTitle":9375,"status":130,"phases":17481,"primaryCompletion":3761,"completion":3761,"start":5663,"enrollment":901,"conditions":17482,"interventions":17483},[88],[9378],[2369,1070,2293,4668,2196,1069,806],{"nctId":2871,"briefTitle":2872,"status":130,"phases":17485,"primaryCompletion":2874,"completion":2874,"start":2875,"enrollment":1766,"conditions":17486,"interventions":17487},[88],[21],[2878,2879,2880,2881,2882,2883,2884],{"trials":17489,"activeCount":124},[17490,17494],{"nctId":4357,"briefTitle":4358,"status":130,"phases":17491,"primaryCompletion":4360,"completion":4360,"start":4361,"enrollment":4362,"conditions":17492,"interventions":17493},[89],[18],[1069,4365,1709,803,2424,1254],{"nctId":4367,"briefTitle":4368,"status":130,"phases":17495,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":17496,"interventions":17497},[89],[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":17499,"activeCount":124},[],{"trials":17501,"activeCount":124},[17502],{"nctId":17503,"briefTitle":17504,"status":182,"phases":17505,"primaryCompletion":4697,"completion":4697,"start":4665,"enrollment":121,"conditions":17506,"interventions":17508},"NCT00501228","Tissue Repair in Stem Cell Transplant Recipients",[91],[17507],"Graft-Versus-Host Disease",[1069],{"intervention":3497,"totalTrials":628,"cells":17510},{"EARLY_PHASE1":17511,"PHASE1":17513,"PHASE2":17585,"PHASE3":17685,"PHASE4":17687,"NA":17689},{"trials":17512,"activeCount":124},[],{"trials":17514,"activeCount":1231,"soonestReadout":17563},[17515,17519,17526,17538,17546,17555,17559,17570,17578],{"nctId":3490,"briefTitle":3491,"status":182,"phases":17516,"primaryCompletion":3493,"completion":3493,"start":3494,"enrollment":1766,"conditions":17517,"interventions":17518},[87],[1729],[1049,3497,1709,3498,3499],{"nctId":17520,"briefTitle":17521,"status":182,"phases":17522,"primaryCompletion":5267,"completion":5267,"start":4084,"enrollment":95,"conditions":17523,"interventions":17524},"NCT00515788","DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis",[87],[11008],[17525,3497],"DepoCyt",{"nctId":17527,"briefTitle":17528,"status":182,"phases":17529,"primaryCompletion":17530,"completion":17530,"start":17531,"enrollment":8105,"conditions":17532,"interventions":17534},"NCT01430351","Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy",[87],"2025-02-02","2011-09-14",[11042,11688,17533],"Supratentorial Glioblastoma",[17535,17536,17537,3497],"Mefloquine","Memantine Hydrochloride","Metformin Hydrochloride",{"nctId":17539,"briefTitle":17540,"status":279,"phases":17541,"primaryCompletion":224,"completion":224,"start":17542,"enrollment":1409,"conditions":17543,"interventions":17544},"NCT04555577","Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma",[87],"2020-09-20",[11042,11688],[17545,3497],"Peposertib",{"nctId":17547,"briefTitle":17548,"status":130,"phases":17549,"primaryCompletion":17550,"completion":17550,"start":17551,"enrollment":539,"conditions":17552,"interventions":17553},"NCT00527657","Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients",[87],"2012-02-02","2006-02-09",[11161,1729],[17554,3497,2383],"Lomustine",{"nctId":3829,"briefTitle":3830,"status":130,"phases":17556,"primaryCompletion":3832,"completion":3832,"start":3833,"enrollment":1496,"conditions":17557,"interventions":17558},[87],[1729],[3497,3836,1709,3499,3837],{"nctId":17560,"briefTitle":17561,"status":102,"phases":17562,"primaryCompletion":17563,"completion":17564,"start":17565,"enrollment":1240,"conditions":17566,"interventions":17568},"NCT00102648","Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide",[87],"2025-03-01","2025-12-01","2004-12-21",[17567,7740,7998],"Malignant Supratentorial Neoplasm",[17569,3497],"Lonafarnib",{"nctId":17571,"briefTitle":17572,"status":279,"phases":17573,"primaryCompletion":446,"completion":281,"start":17574,"enrollment":473,"conditions":17575,"interventions":17577},"NCT06006273","A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors",[87],"2023-08-16",[17576],"Refractory Solid Tumors",[1370,4022,3497],{"nctId":17579,"briefTitle":17580,"status":182,"phases":17581,"primaryCompletion":3832,"completion":3832,"start":17582,"enrollment":550,"conditions":17583,"interventions":17584},"NCT00734526","Phase I Portion of Phase I\u002FII Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma",[87],"2008-12-18",[11042,11688],[3497,2207],{"trials":17586,"activeCount":166,"soonestReadout":446},[17587,17593,17599,17607,17617,17625,17635,17639,17654,17658,17664,17671,17677,17681],{"nctId":17588,"briefTitle":17589,"status":203,"phases":17590,"primaryCompletion":3832,"completion":3832,"start":4786,"enrollment":124,"conditions":17591,"interventions":17592},"NCT02599090","Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma",[88],[11042,11688],[3497,2207],{"nctId":17594,"briefTitle":17595,"status":130,"phases":17596,"primaryCompletion":4835,"completion":4835,"start":2317,"enrollment":2581,"conditions":17597,"interventions":17598},"NCT00525031","Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients",[88],[1729],[3497,12590],{"nctId":17600,"briefTitle":17601,"status":130,"phases":17602,"primaryCompletion":5556,"completion":5556,"start":6852,"enrollment":2581,"conditions":17603,"interventions":17605},"NCT00050986","Phase I\u002FII Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme",[87,88],[17604],"Glioblastoma Multiforme",[3497,17606],"R115777",{"nctId":17608,"briefTitle":17609,"status":182,"phases":17610,"primaryCompletion":17611,"completion":17611,"start":17612,"enrollment":2581,"conditions":17613,"interventions":17615},"NCT00555399","Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)",[87,88],"2020-01-24","2007-11-28",[17604,17614],"Anaplastic Glioma",[2405,17616,3497],"Isotretinoin",{"nctId":17618,"briefTitle":17619,"status":130,"phases":17620,"primaryCompletion":3996,"completion":3996,"start":2580,"enrollment":1308,"conditions":17621,"interventions":17623},"NCT00504660","6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients",[88],[17622,17604,11176],"Anaplastic Glioma of Brain",[1368,3808,3497,17554,17624],"6-Thioguanine",{"nctId":17626,"briefTitle":17627,"status":130,"phases":17628,"primaryCompletion":17629,"completion":17629,"start":17630,"enrollment":3541,"conditions":17631,"interventions":17633},"NCT02661282","Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma",[87,88],"2022-02-23","2016-06-01",[17632,11042,11688,3170,6653,7740],"Cytomegalovirus Positive",[17634,3497],"Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes",{"nctId":4149,"briefTitle":4150,"status":182,"phases":17636,"primaryCompletion":4152,"completion":4152,"start":4153,"enrollment":3197,"conditions":17637,"interventions":17638},[88],[1729],[3497,4156,1709,3499,4157,2383],{"nctId":17640,"briefTitle":17641,"status":279,"phases":17642,"primaryCompletion":446,"completion":446,"start":17643,"enrollment":517,"conditions":17644,"interventions":17653},"NCT04623931","Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas",[88],"2020-01-30",[17645,17646,17647,17648,11042,17649,17650,17651,17652],"Anaplastic Astrocytoma, IDH-Wildtype","Anaplastic Oligoastrocytoma","Anaplastic Oligodendroglioma","Diffuse Astrocytoma, IDH-Wildtype","Oligoastrocytoma","Oligodendroglioma","WHO Grade II Glioma","WHO Grade III Glioma",[3497],{"nctId":3722,"briefTitle":3723,"status":182,"phases":17655,"primaryCompletion":1558,"completion":1558,"start":3725,"enrollment":3726,"conditions":17656,"interventions":17657},[87,88],[1729],[3729,1049,3497],{"nctId":17659,"briefTitle":17660,"status":130,"phases":17661,"primaryCompletion":2602,"completion":2602,"start":2213,"enrollment":16699,"conditions":17662,"interventions":17663},"NCT00112502","Temozolomide Alone or in Combination With Thalidomide and\u002For Isotretinoin and\u002For Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme",[88],[11302,17604],[3808,17616,3497,2383],{"nctId":17665,"briefTitle":17666,"status":130,"phases":17667,"primaryCompletion":6628,"completion":3833,"start":6352,"enrollment":1496,"conditions":17668,"interventions":17669},"NCT00492141","Aerosol L9-NC and Temozolomide in Ewing's Sarcoma",[87,88],[6921],[3497,17670],"L9-NC",{"nctId":17672,"briefTitle":17673,"status":182,"phases":17674,"primaryCompletion":2698,"completion":2698,"start":2968,"enrollment":871,"conditions":17675,"interventions":17676},"NCT01110876","Phase I \u002F II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)",[87,88],[11176,17604],[2405,3847,3497],{"nctId":3758,"briefTitle":3759,"status":130,"phases":17678,"primaryCompletion":3761,"completion":3761,"start":3762,"enrollment":3354,"conditions":17679,"interventions":17680},[88],[1316],[1049,3497],{"nctId":11682,"briefTitle":11683,"status":130,"phases":17682,"primaryCompletion":11685,"completion":11685,"start":11686,"enrollment":1034,"conditions":17683,"interventions":17684},[87,88],[11042,11688],[718,3497],{"trials":17686,"activeCount":124},[],{"trials":17688,"activeCount":124},[],{"trials":17690,"activeCount":166,"soonestReadout":281},[17691],{"nctId":12224,"briefTitle":12225,"status":279,"phases":17692,"primaryCompletion":281,"completion":281,"start":6635,"enrollment":1131,"conditions":17693,"interventions":17694},[91],[12228,12229,12230],[1013,804,2840,12232,2495,4022,1431,12233,3497,6656,1016],{"intervention":1113,"totalTrials":539,"cells":17696},{"EARLY_PHASE1":17697,"PHASE1":17703,"PHASE2":17733,"PHASE3":17767,"PHASE4":17769,"NA":17771},{"trials":17698,"activeCount":124},[17699],{"nctId":13727,"briefTitle":13728,"status":130,"phases":17700,"primaryCompletion":7770,"completion":7770,"start":13730,"enrollment":1483,"conditions":17701,"interventions":17702},[86],[13732,13733],[806,1113],{"trials":17704,"activeCount":1231,"soonestReadout":446},[17705,17709,17713,17717,17721,17725,17729],{"nctId":10729,"briefTitle":10730,"status":130,"phases":17706,"primaryCompletion":2777,"completion":2777,"start":3987,"enrollment":342,"conditions":17707,"interventions":17708},[87],[33],[10734,2772,1275,1683,1113,2772,1275],{"nctId":10740,"briefTitle":10741,"status":102,"phases":17710,"primaryCompletion":446,"completion":446,"start":10743,"enrollment":1664,"conditions":17711,"interventions":17712},[87],[2922,10745,3512,2926],[1275,1371,1113,1375,10747,6656],{"nctId":10749,"briefTitle":10750,"status":130,"phases":17714,"primaryCompletion":3493,"completion":3493,"start":3996,"enrollment":10752,"conditions":17715,"interventions":17716},[87],[33],[1402,1275,2207,6656,1402,1375,1113,10755],{"nctId":9896,"briefTitle":9897,"status":279,"phases":17718,"primaryCompletion":999,"completion":999,"start":9899,"enrollment":628,"conditions":17719,"interventions":17720},[87],[9901,9902,9903,9904,7515,4097,9905,9906,9907,7523,7525,7526,9908],[1368,1369,1710,1371,1113,1375,1376],{"nctId":7581,"briefTitle":7582,"status":279,"phases":17722,"primaryCompletion":1151,"completion":1152,"start":7584,"enrollment":4299,"conditions":17723,"interventions":17724},[87],[3305],[7587,1375,1113,7588,1275,53,7589],{"nctId":14537,"briefTitle":14538,"status":130,"phases":17726,"primaryCompletion":8340,"completion":8340,"start":6352,"enrollment":3379,"conditions":17727,"interventions":17728},[87],[1996,14541],[1371,4234,1113,1375],{"nctId":12875,"briefTitle":12876,"status":130,"phases":17730,"primaryCompletion":11088,"completion":11088,"start":12878,"enrollment":5162,"conditions":17731,"interventions":17732},[87],[3195],[2772,1683,1028,1113,1375],{"trials":17734,"activeCount":121,"soonestReadout":2608},[17735,17739,17743,17747,17751,17755,17759,17763],{"nctId":10974,"briefTitle":10975,"status":182,"phases":17736,"primaryCompletion":5267,"completion":5267,"start":10977,"enrollment":121,"conditions":17737,"interventions":17738},[88],[10979],[4218,1275,1113,1375],{"nctId":4013,"briefTitle":4014,"status":203,"phases":17740,"primaryCompletion":4016,"completion":4016,"start":2264,"enrollment":124,"conditions":17741,"interventions":17742},[88],[4018,4019,4020],[1709,1371,2369,4022,1113,4023,1375],{"nctId":2587,"briefTitle":2588,"status":182,"phases":17744,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":95,"conditions":17745,"interventions":17746},[88],[1142,2593,1144,2594],[803,654,1028,62,1013,1113,805,806,809,894,2596,1016],{"nctId":11053,"briefTitle":11054,"status":279,"phases":17748,"primaryCompletion":115,"completion":115,"start":11056,"enrollment":1100,"conditions":17749,"interventions":17750},[88],[11058],[1113,7588,1375,4022,1368,1275],{"nctId":4211,"briefTitle":4212,"status":102,"phases":17752,"primaryCompletion":2608,"completion":2608,"start":4214,"enrollment":4171,"conditions":17753,"interventions":17754},[88],[1293,4043,4216],[4218,1113,1709,2369],{"nctId":1105,"briefTitle":1106,"status":182,"phases":17756,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":539,"conditions":17757,"interventions":17758},[87,88],[359,913,608,850,609,914,610,853,632],[1112,510,803,654,62,1069,1113,1114,806,809,894,480,1016],{"nctId":11166,"briefTitle":11167,"status":130,"phases":17760,"primaryCompletion":8386,"completion":8386,"start":7473,"enrollment":2446,"conditions":17761,"interventions":17762},[88],[3195],[4218,1275,1113,4022],{"nctId":2852,"briefTitle":2853,"status":182,"phases":17764,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":296,"conditions":17765,"interventions":17766},[87,88],[2413,1142,1143,1144,2421,1145],[803,654,62,2712,1113,805,1114,806,1071,809,894,1015,1016],{"trials":17768,"activeCount":124},[],{"trials":17770,"activeCount":124},[],{"trials":17772,"activeCount":124},[17773],{"nctId":4379,"briefTitle":4380,"status":182,"phases":17774,"primaryCompletion":4382,"completion":4382,"start":2932,"enrollment":1483,"conditions":17775,"interventions":17776},[91],[4384],[1013,1709,806,1113,4386,2495,2369,4387,1114],{"intervention":1368,"totalTrials":406,"cells":17778},{"EARLY_PHASE1":17779,"PHASE1":17781,"PHASE2":17823,"PHASE3":17944,"PHASE4":17952,"NA":17954},{"trials":17780,"activeCount":124},[],{"trials":17782,"activeCount":121,"soonestReadout":999},[17783,17787,17791,17795,17799,17803,17807,17811,17815,17819],{"nctId":11728,"briefTitle":11729,"status":130,"phases":17784,"primaryCompletion":11731,"completion":4511,"start":2890,"enrollment":11732,"conditions":17785,"interventions":17786},[87],[18],[1376,1710,1368],{"nctId":16520,"briefTitle":16521,"status":130,"phases":17788,"primaryCompletion":7636,"completion":7636,"start":16523,"enrollment":448,"conditions":17789,"interventions":17790},[87],[4018,16525,12436,7601,7602,7603,16526],[1368,4023],{"nctId":10757,"briefTitle":10758,"status":130,"phases":17792,"primaryCompletion":5240,"completion":5240,"start":10760,"enrollment":539,"conditions":17793,"interventions":17794},[87],[4107],[1275,3847,1368],{"nctId":10773,"briefTitle":10774,"status":130,"phases":17796,"primaryCompletion":10776,"completion":10776,"start":10777,"enrollment":1001,"conditions":17797,"interventions":17798},[87],[33],[1375,1368,1275],{"nctId":10781,"briefTitle":10782,"status":130,"phases":17800,"primaryCompletion":10784,"completion":10784,"start":10785,"enrollment":473,"conditions":17801,"interventions":17802},[87],[4107],[1275,1368],{"nctId":14522,"briefTitle":14523,"status":102,"phases":17804,"primaryCompletion":281,"completion":281,"start":14525,"enrollment":448,"conditions":17805,"interventions":17806},[87],[1631,14527,7516,1636,1638,1646,14528,1650,1652,7524,1654,7527,7528,14529,14530,7533],[1368,1371],{"nctId":9896,"briefTitle":9897,"status":279,"phases":17808,"primaryCompletion":999,"completion":999,"start":9899,"enrollment":628,"conditions":17809,"interventions":17810},[87],[9901,9902,9903,9904,7515,4097,9905,9906,9907,7523,7525,7526,9908],[1368,1369,1710,1371,1113,1375,1376],{"nctId":1337,"briefTitle":1338,"status":182,"phases":17812,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":17813,"interventions":17814},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"nctId":15748,"briefTitle":15749,"status":203,"phases":17816,"primaryCompletion":15751,"start":2122,"enrollment":124,"conditions":17817,"interventions":17818},[87],[1942,7646,15753,7647,7648,5799,7649,7650,7651,7652,7653,7654,7655,7656],[7558,1368],{"nctId":10943,"briefTitle":10944,"status":130,"phases":17820,"primaryCompletion":2243,"completion":2243,"start":4192,"enrollment":1766,"conditions":17821,"interventions":17822},[87],[10947],[1275,1368,3847],{"trials":17824,"activeCount":121,"soonestReadout":446},[17825,17829,17836,17845,17849,17855,17861,17869,17873,17877,17881,17885,17889,17893,17902,17906,17914,17931,17940],{"nctId":10960,"briefTitle":10961,"status":130,"phases":17826,"primaryCompletion":3493,"completion":3493,"start":5470,"enrollment":1240,"conditions":17827,"interventions":17828},[88],[1521,1333],[1368,2369,1275],{"nctId":17830,"briefTitle":17831,"status":182,"phases":17832,"primaryCompletion":8719,"completion":8719,"start":2213,"enrollment":121,"conditions":17833,"interventions":17834},"NCT00227656","Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer",[88],[18,7818],[17835,1368],"PEG-interferon alfa-2a",{"nctId":17837,"briefTitle":17838,"status":182,"phases":17839,"primaryCompletion":17840,"completion":17840,"start":17841,"enrollment":230,"conditions":17842,"interventions":17843},"NCT03872388","Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy",[88],"2023-10-19","2019-09-23",[13134,7308,7309,7310,7311,7698,7699,10007,7701,13138,7313,7314,7315,7316,5085,5086,5087,5088,5089,1363],[17844,1368],"Atorvastatin",{"nctId":15367,"briefTitle":15368,"status":130,"phases":17846,"primaryCompletion":8956,"completion":8956,"start":12168,"enrollment":1131,"conditions":17847,"interventions":17848},[88],[15371],[1368,1375],{"nctId":17850,"briefTitle":17851,"status":130,"phases":17852,"primaryCompletion":4619,"completion":4619,"start":11135,"enrollment":448,"conditions":17853,"interventions":17854},"NCT00113230","Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer",[88],[10947],[4234,1368],{"nctId":17856,"briefTitle":17857,"status":203,"phases":17858,"primaryCompletion":9560,"completion":9560,"start":5470,"enrollment":124,"conditions":17859,"interventions":17860},"NCT00503932","Proton Therapy With Capecitabine for Rectal Cancer",[87,88],[10947],[1368],{"nctId":17862,"briefTitle":17863,"status":130,"phases":17864,"primaryCompletion":17865,"completion":17865,"start":17866,"enrollment":1922,"conditions":17867,"interventions":17868},"NCT00916578","Xeloda (Capecitabine) and External Beam Radiation",[88],"2017-06-06","2009-06-05",[18],[1368],{"nctId":15386,"briefTitle":15387,"status":130,"phases":17870,"primaryCompletion":8306,"completion":8306,"start":4350,"enrollment":1559,"conditions":17871,"interventions":17872},[88],[15390,15391],[1368,1375],{"nctId":11053,"briefTitle":11054,"status":279,"phases":17874,"primaryCompletion":115,"completion":115,"start":11056,"enrollment":1100,"conditions":17875,"interventions":17876},[88],[11058],[1113,7588,1375,4022,1368,1275],{"nctId":5032,"briefTitle":5033,"status":279,"phases":17878,"primaryCompletion":446,"completion":446,"start":5035,"enrollment":1222,"conditions":17879,"interventions":17880},[88],[1638,5037,5038,5039,5040],[1368,4896,1371],{"nctId":17618,"briefTitle":17619,"status":130,"phases":17882,"primaryCompletion":3996,"completion":3996,"start":2580,"enrollment":1308,"conditions":17883,"interventions":17884},[88],[17622,17604,11176],[1368,3808,3497,17554,17624],{"nctId":10541,"briefTitle":10542,"status":130,"phases":17886,"primaryCompletion":8718,"completion":8718,"start":3996,"enrollment":134,"conditions":17887,"interventions":17888},[87,88],[3195],[510,1368,1375,10546],{"nctId":12455,"briefTitle":12456,"status":130,"phases":17890,"primaryCompletion":2968,"completion":2968,"start":2213,"enrollment":34,"conditions":17891,"interventions":17892},[88],[4107],[1683,2369,1375,1368],{"nctId":17894,"briefTitle":17895,"status":182,"phases":17896,"primaryCompletion":8719,"completion":17897,"start":4647,"enrollment":871,"conditions":17898,"interventions":17899},"NCT00354523","Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma",[87,88],"2013-08",[3305,17318],[1368,17900,17901],"DTIC-Dome","Gleevec",{"nctId":15418,"briefTitle":15419,"status":130,"phases":17903,"primaryCompletion":2836,"completion":2836,"start":8503,"enrollment":2004,"conditions":17904,"interventions":17905},[88],[4195],[1368,1375],{"nctId":17907,"briefTitle":17908,"status":203,"phases":17909,"primaryCompletion":17910,"completion":17910,"start":17911,"enrollment":124,"conditions":17912,"interventions":17913},"NCT00960544","Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism",[88],"2021-01","2019-01",[18],[1368],{"nctId":17915,"briefTitle":17916,"status":182,"phases":17917,"primaryCompletion":17918,"completion":17918,"start":17919,"enrollment":492,"conditions":17920,"interventions":17930},"NCT00745134","Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer",[88],"2022-11-11","2008-08-11",[17921,17922,17923,17924,17925,17926,17927,17928,17929],"Rectal Mucinous Adenocarcinoma","Rectal Signet Ring Cell Adenocarcinoma","Recurrent Rectal Carcinoma","Stage IIA Rectal Cancer AJCC v7","Stage IIB Rectal Cancer AJCC v7","Stage IIC Rectal Cancer AJCC v7","Stage IIIA Rectal Cancer AJCC v7","Stage IIIB Rectal Cancer AJCC v7","Stage IIIC Rectal Cancer AJCC v7",[1368],{"nctId":17932,"briefTitle":17933,"status":130,"phases":17934,"primaryCompletion":4665,"completion":4665,"start":5016,"enrollment":1328,"conditions":17935,"interventions":17938},"NCT00037609","Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients",[87,88],[17936,17937],"Breast Neoplasms","Metastases, Neoplasm",[1368,17939],"Exisulind",{"nctId":11190,"briefTitle":11191,"status":130,"phases":17941,"primaryCompletion":11193,"completion":11193,"start":11194,"enrollment":406,"conditions":17942,"interventions":17943},[88],[11196,11197,11198,11199,11200,11201,11202,11203,11204,2086],[1275,1368,1375],{"trials":17945,"activeCount":124},[17946],{"nctId":17947,"briefTitle":17948,"status":182,"phases":17949,"primaryCompletion":5556,"completion":5556,"start":4084,"enrollment":95,"conditions":17950,"interventions":17951},"NCT00305643","Celecoxib in Preventing Hand\u002FFoot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer",[89],[18,3195,5979],[1368,3808],{"trials":17953,"activeCount":124},[],{"trials":17955,"activeCount":124},[],{"intervention":1028,"totalTrials":134,"cells":17957},{"EARLY_PHASE1":17958,"PHASE1":17960,"PHASE2":18018,"PHASE3":18121,"PHASE4":18123,"NA":18125},{"trials":17959,"activeCount":124},[],{"trials":17961,"activeCount":166,"soonestReadout":999},[17962,17968,17977,17984,17988,17998,18002,18006,18010,18014],{"nctId":17963,"briefTitle":17964,"status":130,"phases":17965,"primaryCompletion":1558,"start":12649,"enrollment":3541,"conditions":17966,"interventions":17967},"NCT00895128","Study of Erlotinib in Combination With Dasatinib",[87],[1942],[3848,1028],{"nctId":17969,"briefTitle":17970,"status":130,"phases":17971,"primaryCompletion":17972,"completion":17972,"start":17973,"enrollment":2911,"conditions":17974,"interventions":17976},"NCT00652574","Dasatinib in Resectable Malignant Pleural Mesothelioma",[87],"2022-10-07","2008-03-12",[17975],"Malignant Pleural Mesothelioma",[1028],{"nctId":17978,"briefTitle":17979,"status":130,"phases":17980,"primaryCompletion":17981,"completion":17981,"start":3571,"enrollment":2933,"conditions":17982,"interventions":17983},"NCT01744652","Dasatinib and Crizotinib in Advanced Cancer",[87],"2019-03",[33],[16702,1028],{"nctId":15473,"briefTitle":15474,"status":182,"phases":17985,"primaryCompletion":12780,"completion":12780,"start":15476,"enrollment":186,"conditions":17986,"interventions":17987},[87],[4598,15478,3040,1026],[1028,2321,15480,598],{"nctId":17989,"briefTitle":17990,"status":182,"phases":17991,"primaryCompletion":17897,"completion":17897,"start":17992,"enrollment":834,"conditions":17993,"interventions":17996},"NCT00895960","Dasatinib Plus Radiation Therapy\u002FTemozolomide in Newly-Diagnosed Glioblastoma",[87],"2009-05-07",[11042,17994,17995],"CNS Disease","Brain Diseases",[1028,17997],"TMZ",{"nctId":10848,"briefTitle":10849,"status":130,"phases":17999,"primaryCompletion":2518,"completion":2518,"start":2836,"enrollment":9738,"conditions":18000,"interventions":18001},[87],[1942],[1028,1275,1376],{"nctId":12294,"briefTitle":12295,"status":130,"phases":18003,"primaryCompletion":3494,"completion":3494,"start":9512,"enrollment":2700,"conditions":18004,"interventions":18005},[87],[1942,1924],[1028,2369],{"nctId":13421,"briefTitle":13422,"status":130,"phases":18007,"primaryCompletion":3805,"start":4183,"enrollment":163,"conditions":18008,"interventions":18009},[87],[1924],[1028,3847,7180,1402,2207,10918,9894],{"nctId":12875,"briefTitle":12876,"status":130,"phases":18011,"primaryCompletion":11088,"completion":11088,"start":12878,"enrollment":5162,"conditions":18012,"interventions":18013},[87],[3195],[2772,1683,1028,1113,1375],{"nctId":6648,"briefTitle":6649,"status":102,"phases":18015,"primaryCompletion":999,"completion":999,"start":6651,"enrollment":2779,"conditions":18016,"interventions":18017},[87],[1343,6653,2570,6654],[803,1028,6656],{"trials":18019,"activeCount":1231,"soonestReadout":7970},[18020,18026,18032,18041,18048,18059,18063,18067,18074,18082,18088,18092,18096,18105,18109,18117],{"nctId":18021,"briefTitle":18022,"status":130,"phases":18023,"primaryCompletion":6367,"completion":6367,"start":16514,"enrollment":1140,"conditions":18024,"interventions":18025},"NCT00826449","Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)",[87,88],[24,10135],[1028,3847],{"nctId":18027,"briefTitle":18028,"status":182,"phases":18029,"primaryCompletion":2846,"completion":2846,"start":8386,"enrollment":1766,"conditions":18030,"interventions":18031},"NCT01092728","Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma",[88],[1729],[1028],{"nctId":18033,"briefTitle":18034,"status":546,"phases":18035,"primaryCompletion":18036,"completion":18036,"start":18037,"enrollment":517,"conditions":18038,"interventions":18039},"NCT07269470","Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",[88],"2029-11-01","2026-05-01",[3315],[1028,18040],"Ropeginterferon alfa-2b",{"nctId":18042,"briefTitle":18043,"status":182,"phases":18044,"primaryCompletion":2777,"completion":2777,"start":5267,"enrollment":1090,"conditions":18045,"interventions":18046},"NCT00780676","Personalized Treatment Selection for Metastatic Breast Cancer",[88],[18],[1028,18047],"AZD6244",{"nctId":18049,"briefTitle":18050,"status":130,"phases":18051,"primaryCompletion":11088,"completion":11088,"start":18052,"enrollment":1154,"conditions":18053,"interventions":18058},"NCT00255346","Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)",[88],"2005-11-15",[36,1036,18054,3429,18055,745,18056,18057],"Agnogenic Myeloid Metaplasia","Hypereosinophilic Syndrome","Mastocytosis","Leukemia, Myelomonocytic, Chronic",[1028],{"nctId":2554,"briefTitle":2555,"status":130,"phases":18060,"primaryCompletion":2557,"completion":2557,"start":2558,"enrollment":2559,"conditions":18061,"interventions":18062},[88],[1122,2561,644,912,913,915],[803,654,1028,62,1013,806,809,1016],{"nctId":2587,"briefTitle":2588,"status":182,"phases":18064,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":95,"conditions":18065,"interventions":18066},[88],[1142,2593,1144,2594],[803,654,1028,62,1013,1113,805,806,809,894,2596,1016],{"nctId":18068,"briefTitle":18069,"status":182,"phases":18070,"primaryCompletion":2806,"completion":2806,"start":2836,"enrollment":95,"conditions":18071,"interventions":18072},"NCT00903006","Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer",[87,88],[18],[18073,12438,1028],"Fulvestrant",{"nctId":18075,"briefTitle":18076,"status":130,"phases":18077,"primaryCompletion":18078,"completion":18078,"start":18079,"enrollment":1045,"conditions":18080,"interventions":18081},"NCT00254423","Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia",[88],"2025-03-14","2005-11-08",[1025,1026],[1028],{"nctId":18083,"briefTitle":18084,"status":130,"phases":18085,"primaryCompletion":3725,"completion":3725,"start":2317,"enrollment":539,"conditions":18086,"interventions":18087},"NCT00364286","Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)",[88],[15,21],[1028],{"nctId":1018,"briefTitle":1019,"status":102,"phases":18089,"primaryCompletion":1021,"completion":1021,"start":1022,"enrollment":1023,"conditions":18090,"interventions":18091},[88],[1025,1026],[1028,480],{"nctId":11403,"briefTitle":11404,"status":130,"phases":18093,"primaryCompletion":11406,"completion":11406,"start":11407,"enrollment":11408,"conditions":18094,"interventions":18095},[88],[27],[3699,809,10918,1028],{"nctId":18097,"briefTitle":18098,"status":130,"phases":18099,"primaryCompletion":18100,"completion":18100,"start":18101,"enrollment":2004,"conditions":18102,"interventions":18103},"NCT00566618","Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis",[87,88],"2020-11-17","2007-11-01",[18,5418],[1028,18104],"Zoledronic Acid",{"nctId":15624,"briefTitle":15625,"status":279,"phases":18106,"primaryCompletion":7970,"completion":7970,"start":1250,"enrollment":3082,"conditions":18107,"interventions":18108},[88],[15628,912,15629,15630],[1028,563],{"nctId":18110,"briefTitle":18111,"status":130,"phases":18112,"primaryCompletion":7335,"completion":18113,"start":18114,"enrollment":134,"conditions":18115,"interventions":18116},"NCT01471106","Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer",[88],"2024-05-30","2014-01-21",[18],[1028],{"nctId":12777,"briefTitle":12778,"status":182,"phases":18118,"primaryCompletion":12780,"completion":12780,"start":12781,"enrollment":507,"conditions":18119,"interventions":18120},[87,88],[15],[1028,612,612],{"trials":18122,"activeCount":124},[],{"trials":18124,"activeCount":124},[],{"trials":18126,"activeCount":124},[],{"intervention":2207,"totalTrials":492,"cells":18128},{"EARLY_PHASE1":18129,"PHASE1":18131,"PHASE2":18187,"PHASE3":18254,"PHASE4":18256,"NA":18258},{"trials":18130,"activeCount":124},[],{"trials":18132,"activeCount":121,"soonestReadout":8064},[18133,18141,18145,18149,18155,18159,18163,18167,18171,18179,18183],{"nctId":18134,"briefTitle":18135,"status":203,"phases":18136,"primaryCompletion":18137,"start":3725,"enrollment":124,"conditions":18138,"interventions":18139},"NCT01608139","Study of Curcumin, Vorinostat, and Sorafenib",[87],"2022-11",[33],[18140,2207,2405],"Curcumin",{"nctId":2200,"briefTitle":2201,"status":102,"phases":18142,"primaryCompletion":224,"completion":224,"start":2203,"enrollment":507,"conditions":18143,"interventions":18144},[87],[913,608,914,610],[612,62,2206,2207],{"nctId":10749,"briefTitle":10750,"status":130,"phases":18146,"primaryCompletion":3493,"completion":3493,"start":3996,"enrollment":10752,"conditions":18147,"interventions":18148},[87],[33],[1402,1275,2207,6656,1402,1375,1113,10755],{"nctId":18150,"briefTitle":18151,"status":182,"phases":18152,"primaryCompletion":6757,"completion":6757,"start":10768,"enrollment":1496,"conditions":18153,"interventions":18154},"NCT00543335","Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer",[87],[24],[2207],{"nctId":10897,"briefTitle":10898,"status":130,"phases":18156,"primaryCompletion":1567,"completion":1567,"start":10900,"enrollment":10901,"conditions":18157,"interventions":18158},[87],[1924,1942],[10904,1275,2840,2207,3847],{"nctId":13421,"briefTitle":13422,"status":130,"phases":18160,"primaryCompletion":3805,"start":4183,"enrollment":163,"conditions":18161,"interventions":18162},[87],[1924],[1028,3847,7180,1402,2207,10918,9894],{"nctId":9955,"briefTitle":9956,"status":102,"phases":18164,"primaryCompletion":8064,"completion":8064,"start":9958,"enrollment":9959,"conditions":18165,"interventions":18166},[87],[1942],[6656,1275,1376,2207,1369],{"nctId":10910,"briefTitle":10911,"status":130,"phases":18168,"primaryCompletion":10913,"completion":10913,"start":10914,"enrollment":10915,"conditions":18169,"interventions":18170},[87],[1942],[1275,2207,3847,4227,7180,10918,1683],{"nctId":18172,"briefTitle":18173,"status":130,"phases":18174,"primaryCompletion":18175,"completion":18175,"start":18176,"enrollment":1922,"conditions":18177,"interventions":18178},"NCT00943943","Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations",[87],"2017-03-23","2010-10-29",[4659,15],[2374,4622,2207],{"nctId":4401,"briefTitle":4402,"status":203,"phases":18180,"primaryCompletion":3509,"completion":3509,"start":3509,"enrollment":124,"conditions":18181,"interventions":18182},[87],[494,495],[599,654,2207,612],{"nctId":17579,"briefTitle":17580,"status":182,"phases":18184,"primaryCompletion":3832,"completion":3832,"start":17582,"enrollment":550,"conditions":18185,"interventions":18186},[87],[11042,11688],[3497,2207],{"trials":18188,"activeCount":121,"soonestReadout":446},[18189,18193,18204,18208,18212,18216,18220,18227,18231,18238,18244],{"nctId":17588,"briefTitle":17589,"status":203,"phases":18190,"primaryCompletion":3832,"completion":3832,"start":4786,"enrollment":124,"conditions":18191,"interventions":18192},[88],[11042,11688],[3497,2207],{"nctId":18194,"briefTitle":18195,"status":130,"phases":18196,"primaryCompletion":18197,"completion":18197,"start":18198,"enrollment":517,"conditions":18199,"interventions":18203},"NCT01900002","Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",[88],"2020-12-10","2013-09-13",[18200,7793,18201,7796,7797,7798,7799,7800,7801,7802,18202],"Advanced Adult Hepatocellular Carcinoma","Recurrent Adult Hepatocellular Carcinoma","Unresectable Hepatocellular Carcinoma",[2207,2544],{"nctId":10446,"briefTitle":10447,"status":130,"phases":18205,"primaryCompletion":10449,"completion":10449,"start":6757,"enrollment":1034,"conditions":18206,"interventions":18207},[87,88],[15],[510,2207],{"nctId":10032,"briefTitle":10033,"status":102,"phases":18209,"primaryCompletion":446,"completion":446,"start":10035,"enrollment":473,"conditions":18210,"interventions":18211},[88],[7749,4056,4057,4058,4059,7750,4060,4061,4062,4063],[1369,1376,2207],{"nctId":16018,"briefTitle":16019,"status":130,"phases":18213,"primaryCompletion":3901,"completion":3901,"start":5733,"enrollment":959,"conditions":18214,"interventions":18215},[87,88],[2391,36,16022],[655,2207,2584],{"nctId":2534,"briefTitle":2535,"status":130,"phases":18217,"primaryCompletion":2537,"completion":2537,"start":1000,"enrollment":834,"conditions":18218,"interventions":18219},[88],[1047,643,2539,2540,848,2541,2542,851],[2423,654,62,655,894,2207,2544,1016,810],{"nctId":18221,"briefTitle":18222,"status":130,"phases":18223,"primaryCompletion":5954,"completion":5954,"start":18224,"enrollment":834,"conditions":18225,"interventions":18226},"NCT02196857","Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation",[88],"2015-02-06",[15],[8019,2207],{"nctId":4686,"briefTitle":4687,"status":102,"phases":18228,"primaryCompletion":224,"completion":224,"start":4689,"enrollment":4690,"conditions":18229,"interventions":18230},[87,88],[608,610],[1004,803,1069,1070,2195,2207,2196],{"nctId":18232,"briefTitle":18233,"status":130,"phases":18234,"primaryCompletion":2900,"completion":2900,"start":18235,"enrollment":539,"conditions":18236,"interventions":18237},"NCT02530476","Phase I\u002FII, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia",[87,88],"2015-12-08",[15,36],[1378,2207],{"nctId":18239,"briefTitle":18240,"status":130,"phases":18241,"primaryCompletion":3725,"completion":3725,"start":8719,"enrollment":5797,"conditions":18242,"interventions":18243},"NCT00411671","BATTLE Program: Sorafenib in Patients With NSCLC",[88],[24],[2207],{"nctId":18245,"briefTitle":18246,"status":130,"phases":18247,"primaryCompletion":18248,"completion":18248,"start":18249,"enrollment":18250,"conditions":18251,"interventions":18252},"NCT01248247","BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer",[88],"2020-11-30","2011-06-02",334,[24],[3847,18047,18253,2207,3847,18253],"MK-2206",{"trials":18255,"activeCount":124},[],{"trials":18257,"activeCount":124},[],{"trials":18259,"activeCount":124},[],{"intervention":14086,"totalTrials":1496,"cells":18261},{"EARLY_PHASE1":18262,"PHASE1":18264,"PHASE2":18270,"PHASE3":18338,"PHASE4":18340,"NA":18342},{"trials":18263,"activeCount":124},[],{"trials":18265,"activeCount":124},[18266],{"nctId":14075,"briefTitle":14076,"status":130,"phases":18267,"primaryCompletion":4867,"completion":4867,"start":14078,"enrollment":1609,"conditions":18268,"interventions":18269},[87],[1343,11800,14080,14081,14082,13135,10825,14083,14084,5087,5088,5089,7298],[2840,14086,4227],{"trials":18271,"activeCount":296,"soonestReadout":18310},[18272,18280,18289,18293,18300,18306,18314,18318,18329],{"nctId":18273,"briefTitle":18274,"status":182,"phases":18275,"primaryCompletion":18276,"completion":18276,"start":18277,"enrollment":296,"conditions":18278,"interventions":18279},"NCT04256941","Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study",[88],"2023-09-22","2019-05-31",[7312,5234,7317],[12927,10904,18073,14086,2206,14130],{"nctId":18281,"briefTitle":18282,"status":182,"phases":18283,"primaryCompletion":18284,"completion":18284,"start":18285,"enrollment":910,"conditions":18286,"interventions":18288},"NCT00414076","Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma",[88],"2017-07-13","2006-12-19",[12333,18287],"Uterine Neoplasm",[14086],{"nctId":14123,"briefTitle":14124,"status":102,"phases":18290,"primaryCompletion":3258,"completion":3258,"start":14126,"enrollment":861,"conditions":18291,"interventions":18292},[88],[1457,10089,10703,14128,10707,10708,10709,10710,10711,10712,10713,10714,1472],[2840,14086,14130],{"nctId":18294,"briefTitle":18295,"status":130,"phases":18296,"primaryCompletion":18297,"completion":18297,"start":4338,"enrollment":1568,"conditions":18298,"interventions":18299},"NCT03774472","Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer",[87,88],"2024-04-17",[8026,16556,16557,8027,13133,13134,7308,7309,7310,7311,7312,16558,16559,16560,13137,13138,7313,7314,7315,7316,7317],[12420,14086,2206],{"nctId":18301,"briefTitle":18302,"status":182,"phases":18303,"primaryCompletion":3762,"completion":3762,"start":2580,"enrollment":834,"conditions":18304,"interventions":18305},"NCT00505661","Letrozole in Patients With Ovarian Tumors",[88],[1530,9926,5787],[14086],{"nctId":18307,"briefTitle":18308,"status":102,"phases":18309,"primaryCompletion":18310,"completion":5382,"start":18311,"enrollment":924,"conditions":18312,"interventions":18313},"NCT01068249","Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer",[88],"2022-04","2010-04-30",[2809],[14086,2330],{"nctId":14138,"briefTitle":14139,"status":102,"phases":18315,"primaryCompletion":999,"completion":999,"start":14141,"enrollment":2933,"conditions":18316,"interventions":18317},[88],[2809],[14121,14086,2840],{"nctId":18319,"briefTitle":18320,"status":279,"phases":18321,"primaryCompletion":18322,"completion":18322,"start":18323,"enrollment":1131,"conditions":18324,"interventions":18326},"NCT05035836","A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2\u002FNeu Positive (HER2+) Breast Cancer (BC)",[88],"2028-12-29","2021-11-16",[18,18325],"HER2-positive",[18327,14086,18328],"Zanidatamab","Tamoxifen",{"nctId":18330,"briefTitle":18331,"status":130,"phases":18332,"primaryCompletion":5954,"completion":5954,"start":18333,"enrollment":7377,"conditions":18334,"interventions":18337},"NCT00338728","Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer",[88],"2003-10-03",[7312,11800,18335,18336,14081,13135,7317],"KIT Positive","PDGFR Positive",[2321,14086],{"trials":18339,"activeCount":124},[],{"trials":18341,"activeCount":124},[],{"trials":18343,"activeCount":124},[],{"intervention":3699,"totalTrials":910,"cells":18345},{"EARLY_PHASE1":18346,"PHASE1":18348,"PHASE2":18350,"PHASE3":18388,"PHASE4":18390,"NA":18392},{"trials":18347,"activeCount":124},[],{"trials":18349,"activeCount":124},[],{"trials":18351,"activeCount":296,"soonestReadout":5103},[18352,18356,18360,18364,18368,18372,18376,18380,18384],{"nctId":5100,"briefTitle":5101,"status":279,"phases":18353,"primaryCompletion":5103,"completion":5103,"start":5104,"enrollment":4733,"conditions":18354,"interventions":18355},[88],[5106,5107,5108,5109,5110,5111,3547],[3699,5113,3700,5114,809],{"nctId":5116,"briefTitle":5117,"status":102,"phases":18357,"primaryCompletion":5119,"completion":5119,"start":5120,"enrollment":1034,"conditions":18358,"interventions":18359},[88],[3545,5122,5123,3546,3547,3548],[3699,3700,809],{"nctId":11332,"briefTitle":11333,"status":102,"phases":18361,"primaryCompletion":11335,"completion":11335,"start":11336,"enrollment":11337,"conditions":18362,"interventions":18363},[88],[5122,11339],[3699,11341,3720,11342,11343,3780,11344,809],{"nctId":3689,"briefTitle":3690,"status":102,"phases":18365,"primaryCompletion":3407,"completion":3407,"start":3692,"enrollment":3693,"conditions":18366,"interventions":18367},[88],[3695,3544,3545,3696,3697],[3699,3700,3701,1369,1049,809],{"nctId":11378,"briefTitle":11379,"status":130,"phases":18369,"primaryCompletion":11381,"completion":11381,"start":11382,"enrollment":34,"conditions":18370,"interventions":18371},[88],[27],[3699,809,7589,11385],{"nctId":11403,"briefTitle":11404,"status":130,"phases":18373,"primaryCompletion":11406,"completion":11406,"start":11407,"enrollment":11408,"conditions":18374,"interventions":18375},[88],[27],[3699,809,10918,1028],{"nctId":11459,"briefTitle":11460,"status":182,"phases":18377,"primaryCompletion":5829,"completion":5829,"start":640,"enrollment":296,"conditions":18378,"interventions":18379},[88],[27],[11464,3699,809],{"nctId":5149,"briefTitle":5150,"status":182,"phases":18381,"primaryCompletion":5152,"completion":5152,"start":5153,"enrollment":1483,"conditions":18382,"interventions":18383},[88],[3544,5155,3546,3547,3548],[3699,3700,809],{"nctId":5158,"briefTitle":5159,"status":130,"phases":18385,"primaryCompletion":5161,"completion":5161,"start":4595,"enrollment":5162,"conditions":18386,"interventions":18387},[88],[5122,5146,5107,5109,5111],[3699,3700,5165,809],{"trials":18389,"activeCount":124},[],{"trials":18391,"activeCount":124},[],{"trials":18393,"activeCount":124},[],{"intervention":694,"totalTrials":910,"cells":18395},{"EARLY_PHASE1":18396,"PHASE1":18398,"PHASE2":18404,"PHASE3":18443,"PHASE4":18445,"NA":18447},{"trials":18397,"activeCount":124},[],{"trials":18399,"activeCount":124},[18400],{"nctId":16948,"briefTitle":16949,"status":130,"phases":18401,"primaryCompletion":889,"completion":889,"start":16951,"enrollment":166,"conditions":18402,"interventions":18403},[87],[846,608,610,651],[694,942],{"trials":18405,"activeCount":296,"soonestReadout":1325},[18406,18410,18414,18418,18422,18426,18435,18439],{"nctId":16006,"briefTitle":16007,"status":130,"phases":18407,"primaryCompletion":2288,"completion":2288,"start":2969,"enrollment":959,"conditions":18408,"interventions":18409},[88],[16010],[2247,16012,655,694],{"nctId":685,"briefTitle":686,"status":130,"phases":18411,"primaryCompletion":688,"completion":688,"start":689,"enrollment":676,"conditions":18412,"interventions":18413},[87,88],[608,610],[692,693,510,694,695,696,480,510],{"nctId":3222,"briefTitle":3223,"status":279,"phases":18415,"primaryCompletion":3225,"completion":3225,"start":3226,"enrollment":3227,"conditions":18416,"interventions":18417},[88],[3229,3230,3231,647,1067,3232,3233,3234,3235,652],[654,612,2712,1005,694,655],{"nctId":12625,"briefTitle":12626,"status":130,"phases":18419,"primaryCompletion":11134,"completion":11134,"start":5988,"enrollment":7694,"conditions":18420,"interventions":18421},[88],[4659,30],[612,694],{"nctId":12646,"briefTitle":12647,"status":130,"phases":18423,"primaryCompletion":11134,"completion":11134,"start":12649,"enrollment":357,"conditions":18424,"interventions":18425},[88],[4659,30],[612,12652],{"nctId":18427,"briefTitle":18428,"status":279,"phases":18429,"primaryCompletion":18430,"completion":18430,"start":2729,"enrollment":9213,"conditions":18431,"interventions":18433},"NCT01409161","Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia",[88],"2027-12-18",[18432],"Acute Promyelocytic Leukemia With PML-RARA",[16012,694,18434],"Tretinoin",{"nctId":4479,"briefTitle":4480,"status":279,"phases":18436,"primaryCompletion":224,"completion":224,"start":4482,"enrollment":1222,"conditions":18437,"interventions":18438},[88],[36,644,645,1067,4484,727,912],[599,654,4486,694,655],{"nctId":16980,"briefTitle":16981,"status":102,"phases":18440,"primaryCompletion":1325,"completion":1325,"start":16983,"enrollment":676,"conditions":18441,"interventions":18442},[88],[846,737,1067,30,608,610],[694,942],{"trials":18444,"activeCount":124},[],{"trials":18446,"activeCount":124},[],{"trials":18448,"activeCount":124},[],{"intervention":2011,"totalTrials":1483,"cells":18450},{"EARLY_PHASE1":18451,"PHASE1":18453,"PHASE2":18466,"PHASE3":18507,"PHASE4":18509,"NA":18511},{"trials":18452,"activeCount":124},[],{"trials":18454,"activeCount":124},[18455],{"nctId":18456,"briefTitle":18457,"status":203,"phases":18458,"primaryCompletion":18459,"completion":18459,"start":7757,"enrollment":124,"conditions":18460,"interventions":18464},"NCT03205891","Study of Brentuximab Vedotin Plus TAK228 for Relapsed\u002FRefractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas",[87],"2021-03",[1399,18461,18462,18463],"Classical Hodgkin Lymphoma","Anaplastic Large Cell Lymphoma","CD30+ Peripheral T-cell Lymphoma",[2011,18465],"TAK228",{"trials":18467,"activeCount":296,"soonestReadout":18503},[18468,18474,18483,18487,18491,18499],{"nctId":18469,"briefTitle":18470,"status":182,"phases":18471,"primaryCompletion":3761,"completion":3761,"start":206,"enrollment":166,"conditions":18472,"interventions":18473},"NCT02096042","Phase I\u002FII - Brentuximab\u002F5-Azacytidine in Acute Myeloid Leukemia (AML)",[87,88],[15],[2011,13589],{"nctId":18475,"briefTitle":18476,"status":279,"phases":18477,"primaryCompletion":4005,"completion":4005,"start":18478,"enrollment":2581,"conditions":18479,"interventions":18482},"NCT03007030","Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery",[88],"2017-04-05",[18480,18481],"CD30-Positive Neoplastic Cells Present","Malignant Mesothelioma",[2011],{"nctId":7841,"briefTitle":7842,"status":102,"phases":18484,"primaryCompletion":1939,"completion":1939,"start":7844,"enrollment":448,"conditions":18485,"interventions":18486},[88],[1866],[7847,804,53,1869],{"nctId":1999,"briefTitle":2000,"status":279,"phases":18488,"primaryCompletion":2002,"completion":2002,"start":2003,"enrollment":2004,"conditions":18489,"interventions":18490},[88],[2006,2007,2008,2009],[2011,803,1013,1050,809,894],{"nctId":18492,"briefTitle":18493,"status":182,"phases":18494,"primaryCompletion":18495,"completion":18495,"start":18496,"enrollment":121,"conditions":18497,"interventions":18498},"NCT02169505","Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)",[88],"2017-08-14","2015-05-22",[21],[2011],{"nctId":18500,"briefTitle":18501,"status":279,"phases":18502,"primaryCompletion":18503,"completion":18503,"start":18504,"enrollment":406,"conditions":18505,"interventions":18506},"NCT05357794","Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides",[88],"2027-01-30","2022-10-13",[5457],[7847],{"trials":18508,"activeCount":124},[],{"trials":18510,"activeCount":124},[],{"trials":18512,"activeCount":124},[],{"intervention":1124,"totalTrials":1483,"cells":18514},{"EARLY_PHASE1":18515,"PHASE1":18517,"PHASE2":18519,"PHASE3":18558,"PHASE4":18560,"NA":18562},{"trials":18516,"activeCount":124},[],{"trials":18518,"activeCount":124},[],{"trials":18520,"activeCount":296,"soonestReadout":1078},[18521,18525,18536,18542,18546,18550,18554],{"nctId":9634,"briefTitle":9635,"status":279,"phases":18522,"primaryCompletion":1325,"completion":1325,"start":9637,"enrollment":861,"conditions":18523,"interventions":18524},[88],[1205,1122,2561,644,912,913,914,915],[1083,654,806,1124],{"nctId":18526,"briefTitle":18527,"status":203,"phases":18528,"primaryCompletion":18529,"start":18530,"enrollment":124,"conditions":18531,"interventions":18534},"NCT02829840","Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)",[87,88],"2021-09","2016-09",[15,18532,18533],"FLT3-Mutated Acute Myeloid Leukemia","FLT3-Mutated High-Risk Myelodysplastic Syndrome",[1124,18535],"5-azacytidine",{"nctId":18537,"briefTitle":18538,"status":182,"phases":18539,"primaryCompletion":3493,"completion":3493,"start":2326,"enrollment":240,"conditions":18540,"interventions":18541},"NCT01570868","Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)",[88],[15],[1124],{"nctId":2726,"briefTitle":2727,"status":102,"phases":18543,"primaryCompletion":999,"completion":999,"start":2729,"enrollment":2730,"conditions":18544,"interventions":18545},[88],[1205,1122,2649,2471,644,912,2732],[803,654,62,1013,804,806,1124,917,809,894,1016,810],{"nctId":1116,"briefTitle":1117,"status":182,"phases":18547,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":296,"conditions":18548,"interventions":18549},[88],[1122,15],[1124,480,1125],{"nctId":7277,"briefTitle":7278,"status":102,"phases":18551,"primaryCompletion":115,"completion":115,"start":7280,"enrollment":492,"conditions":18552,"interventions":18553},[88],[1205,1122,7282,644,913,914],[1083,803,654,1069,806,1071,1124,894,1016],{"nctId":1200,"briefTitle":1201,"status":102,"phases":18555,"primaryCompletion":1078,"completion":1078,"start":1203,"enrollment":1131,"conditions":18556,"interventions":18557},[88],[1205,36,644,608,649,610,650],[612,1124,480],{"trials":18559,"activeCount":124},[],{"trials":18561,"activeCount":124},[],{"trials":18563,"activeCount":124},[],{"intervention":3701,"totalTrials":230,"cells":18565},{"EARLY_PHASE1":18566,"PHASE1":18568,"PHASE2":18570,"PHASE3":18598,"PHASE4":18600,"NA":18602},{"trials":18567,"activeCount":124},[],{"trials":18569,"activeCount":124},[],{"trials":18571,"activeCount":296,"soonestReadout":504},[18572,18576,18582,18586,18590,18594],{"nctId":10019,"briefTitle":10020,"status":279,"phases":18573,"primaryCompletion":10022,"completion":224,"start":10023,"enrollment":406,"conditions":18574,"interventions":18575},[87,88],[27],[10026,3701,1369],{"nctId":18577,"briefTitle":18578,"status":203,"phases":18579,"primaryCompletion":6807,"start":4290,"enrollment":124,"conditions":18580,"interventions":18581},"NCT01740570","Phase I\u002FII Cabazitaxel for Recurrent Malignant Glioma",[87,88],[11176],[3701],{"nctId":3689,"briefTitle":3690,"status":102,"phases":18583,"primaryCompletion":3407,"completion":3407,"start":3692,"enrollment":3693,"conditions":18584,"interventions":18585},[88],[3695,3544,3545,3696,3697],[3699,3700,3701,1369,1049,809],{"nctId":10169,"briefTitle":10170,"status":130,"phases":18587,"primaryCompletion":10172,"completion":10172,"start":10173,"enrollment":10174,"conditions":18588,"interventions":18589},[87,88],[3695,3544,10176,3545,5122,5123,10177],[3701,1369],{"nctId":10222,"briefTitle":10223,"status":102,"phases":18591,"primaryCompletion":224,"completion":224,"start":2185,"enrollment":1100,"conditions":18592,"interventions":18593},[88],[3543,3544,3545,10226,10227,3546],[3701,1369,10229,5114],{"nctId":10231,"briefTitle":10232,"status":102,"phases":18595,"primaryCompletion":504,"completion":504,"start":10234,"enrollment":724,"conditions":18596,"interventions":18597},[88],[10236,5106],[3701,1369,10238,1374],{"trials":18599,"activeCount":124},[],{"trials":18601,"activeCount":124},[],{"trials":18603,"activeCount":124},[],{"intervention":1082,"totalTrials":3197,"cells":18605},{"EARLY_PHASE1":18606,"PHASE1":18608,"PHASE2":18610,"PHASE3":18644,"PHASE4":18646,"NA":18648},{"trials":18607,"activeCount":124},[],{"trials":18609,"activeCount":124},[],{"trials":18611,"activeCount":296,"soonestReadout":446},[18612,18620,18628,18632,18636],{"nctId":18613,"briefTitle":18614,"status":279,"phases":18615,"primaryCompletion":18616,"completion":18617,"start":7335,"enrollment":676,"conditions":18618,"interventions":18619},"NCT06236724","Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.",[88],"2033-07-01","2035-07-01",[3315],[1082],{"nctId":18621,"briefTitle":18622,"status":182,"phases":18623,"primaryCompletion":18624,"completion":18624,"start":662,"enrollment":1483,"conditions":18625,"interventions":18627},"NCT04216563","ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor",[88],"2025-03-17",[18626],"Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia",[1082],{"nctId":13048,"briefTitle":13049,"status":279,"phases":18629,"primaryCompletion":4005,"completion":4006,"start":13051,"enrollment":517,"conditions":18630,"interventions":18631},[87,88],[13053,1122],[1083,1082],{"nctId":1073,"briefTitle":1074,"status":546,"phases":18633,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":406,"conditions":18634,"interventions":18635},[87,88],[1080],[1070,654,655,1069,480,1082,1083],{"nctId":18637,"briefTitle":18638,"status":279,"phases":18639,"primaryCompletion":446,"completion":281,"start":18640,"enrollment":517,"conditions":18641,"interventions":18643},"NCT06629584","Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia",[88],"2025-02-14",[18642],"Malignant Solid Tumors",[1082],{"trials":18645,"activeCount":124},[],{"trials":18647,"activeCount":124},[],{"trials":18649,"activeCount":124},[],{"intervention":1552,"totalTrials":3197,"cells":18651},{"EARLY_PHASE1":18652,"PHASE1":18654,"PHASE2":18656,"PHASE3":18678,"PHASE4":18680,"NA":18682},{"trials":18653,"activeCount":124},[],{"trials":18655,"activeCount":124},[],{"trials":18657,"activeCount":296,"soonestReadout":446},[18658,18662,18666,18670,18674],{"nctId":1534,"briefTitle":1535,"status":130,"phases":18659,"primaryCompletion":1537,"completion":1537,"start":1538,"enrollment":1140,"conditions":18660,"interventions":18661},[88],[1540,1541,1542,1543,1544,1545,1546,1547,1548,1549,1550],[1049,1050,1552],{"nctId":1722,"briefTitle":1723,"status":546,"phases":18663,"primaryCompletion":1725,"completion":1726,"start":1727,"enrollment":406,"conditions":18664,"interventions":18665},[87,88],[1729],[1050,1552,1049],{"nctId":1732,"briefTitle":1733,"status":279,"phases":18667,"primaryCompletion":1735,"completion":1735,"start":1736,"enrollment":406,"conditions":18668,"interventions":18669},[88],[1738],[1740,1050,1552],{"nctId":1742,"briefTitle":1743,"status":102,"phases":18671,"primaryCompletion":1745,"completion":1745,"start":1746,"enrollment":406,"conditions":18672,"interventions":18673},[88],[1748,1749],[1050,1552],{"nctId":1789,"briefTitle":1790,"status":102,"phases":18675,"primaryCompletion":446,"completion":446,"start":1792,"enrollment":230,"conditions":18676,"interventions":18677},[88],[1794,1795,1796,1797,1798,1799,1800,1801,1802,1803,1804,1805,1806,1807,1808,1779,1809,1810,1811,1780,1781,1782,1812,1813,1814,1783,1784,1815,1816,1817,1818,1819],[1050,1552],{"trials":18679,"activeCount":124},[],{"trials":18681,"activeCount":124},[],{"trials":18683,"activeCount":124},[],{"intervention":566,"totalTrials":296,"cells":18685},{"EARLY_PHASE1":18686,"PHASE1":18688,"PHASE2":18694,"PHASE3":18708,"PHASE4":18710,"NA":18712},{"trials":18687,"activeCount":124},[],{"trials":18689,"activeCount":166,"soonestReadout":446},[18690],{"nctId":556,"briefTitle":557,"status":279,"phases":18691,"primaryCompletion":446,"completion":446,"start":559,"enrollment":560,"conditions":18692,"interventions":18693},[87],[36],[563,564,565,566,480],{"trials":18695,"activeCount":1231,"soonestReadout":104},[18696,18700,18704],{"nctId":615,"briefTitle":616,"status":279,"phases":18697,"primaryCompletion":618,"completion":618,"start":619,"enrollment":381,"conditions":18698,"interventions":18699},[87,88],[36,608,610],[563,564,566,480],{"nctId":720,"briefTitle":721,"status":279,"phases":18701,"primaryCompletion":238,"completion":238,"start":723,"enrollment":724,"conditions":18702,"interventions":18703},[87,88],[36,726,30,727,608,610],[510,566,480],{"nctId":16973,"briefTitle":16974,"status":279,"phases":18705,"primaryCompletion":104,"completion":104,"start":16976,"enrollment":406,"conditions":18706,"interventions":18707},[88],[7115,30,727,608,610],[566,942],{"trials":18709,"activeCount":124},[],{"trials":18711,"activeCount":124},[],{"trials":18713,"activeCount":124},[],{"intervention":3884,"totalTrials":296,"cells":18715},{"EARLY_PHASE1":18716,"PHASE1":18718,"PHASE2":18724,"PHASE3":18742,"PHASE4":18744,"NA":18746},{"trials":18717,"activeCount":124},[],{"trials":18719,"activeCount":166,"soonestReadout":3879},[18720],{"nctId":3876,"briefTitle":3877,"status":279,"phases":18721,"primaryCompletion":3879,"completion":3880,"start":3881,"enrollment":871,"conditions":18722,"interventions":18723},[87],[2809],[1376,1369,3884,1709],{"trials":18725,"activeCount":1231,"soonestReadout":815},[18726,18730,18738],{"nctId":17204,"briefTitle":17205,"status":279,"phases":18727,"primaryCompletion":548,"completion":548,"start":11622,"enrollment":1100,"conditions":18728,"interventions":18729},[88],[1520],[5114,3884],{"nctId":18731,"briefTitle":18732,"status":279,"phases":18733,"primaryCompletion":16160,"completion":16160,"start":11126,"enrollment":871,"conditions":18734,"interventions":18736},"NCT06065462","Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100",[87,88],[18735],"Ovarian Clear Cell Carcinoma",[3884,18737],"LB-100",{"nctId":17214,"briefTitle":17215,"status":102,"phases":18739,"primaryCompletion":815,"completion":815,"start":17217,"enrollment":473,"conditions":18740,"interventions":18741},[88],[17219,2049,1355,1357,1358,1359],[3884,5114],{"trials":18743,"activeCount":124},[],{"trials":18745,"activeCount":124},[],{"trials":18747,"activeCount":124},[],{"intervention":2672,"totalTrials":296,"cells":18749},{"EARLY_PHASE1":18750,"PHASE1":18752,"PHASE2":18758,"PHASE3":18776,"PHASE4":18778,"NA":18780},{"trials":18751,"activeCount":124},[],{"trials":18753,"activeCount":166,"soonestReadout":6475},[18754],{"nctId":6472,"briefTitle":6473,"status":546,"phases":18755,"primaryCompletion":6475,"completion":6476,"start":1427,"enrollment":1034,"conditions":18756,"interventions":18757},[87],[6478,1866],[1070,2672,803],{"trials":18759,"activeCount":1231,"soonestReadout":3880},[18760,18764,18768],{"nctId":6909,"briefTitle":6910,"status":546,"phases":18761,"primaryCompletion":537,"completion":1481,"start":549,"enrollment":1496,"conditions":18762,"interventions":18763},[87,88],[6913],[2672,3103,1070,803],{"nctId":2664,"briefTitle":2665,"status":279,"phases":18765,"primaryCompletion":2667,"completion":2668,"start":2669,"enrollment":924,"conditions":18766,"interventions":18767},[87,88],[2460],[62,803,1070,612,2672],{"nctId":18769,"briefTitle":18770,"status":546,"phases":18771,"primaryCompletion":3880,"completion":18772,"start":18773,"enrollment":1609,"conditions":18774,"interventions":18775},"NCT07377526","Phase 1\u002F2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer",[87,88],"2030-03-01","2026-07-01",[4107],[2672],{"trials":18777,"activeCount":124},[],{"trials":18779,"activeCount":124},[],{"trials":18781,"activeCount":124},[],{"intervention":1114,"totalTrials":406,"cells":18783},{"EARLY_PHASE1":18784,"PHASE1":18786,"PHASE2":18800,"PHASE3":18894,"PHASE4":18900,"NA":18902},{"trials":18785,"activeCount":124},[],{"trials":18787,"activeCount":166,"soonestReadout":2455},[18788,18792,18796],{"nctId":5431,"briefTitle":5432,"status":130,"phases":18789,"primaryCompletion":5434,"completion":5434,"start":5435,"enrollment":2779,"conditions":18790,"interventions":18791},[87],[1866,21],[75,1369,2424,2495,1114],{"nctId":3066,"briefTitle":3067,"status":102,"phases":18793,"primaryCompletion":2455,"completion":2455,"start":3069,"enrollment":871,"conditions":18794,"interventions":18795},[87],[3071,1316,1729],[3073,3074,803,3075,1114,1005],{"nctId":6625,"briefTitle":6626,"status":182,"phases":18797,"primaryCompletion":2836,"completion":2836,"start":6628,"enrollment":296,"conditions":18798,"interventions":18799},[87],[15,21,2245],[894,803,1070,1114,6516],{"trials":18801,"activeCount":1231,"soonestReadout":3425},[18802,18806,18810,18814,18818,18822,18826,18830,18834,18838,18842,18846,18850,18854,18858,18862,18866,18870,18874,18878,18882,18886,18890],{"nctId":6724,"briefTitle":6725,"status":102,"phases":18803,"primaryCompletion":6727,"completion":6727,"start":6728,"enrollment":6729,"conditions":18804,"interventions":18805},[88],[1729],[6732,803,1070,6733,3499,1114,6734,6735],{"nctId":2487,"briefTitle":2488,"status":102,"phases":18807,"primaryCompletion":2490,"completion":2490,"start":2491,"enrollment":134,"conditions":18808,"interventions":18809},[88],[21],[62,2494,2495,1114,1369],{"nctId":2577,"briefTitle":2578,"status":130,"phases":18811,"primaryCompletion":1558,"completion":1558,"start":2580,"enrollment":2581,"conditions":18812,"interventions":18813},[88],[21],[803,1114,1016,806,2584,62,2374,2585],{"nctId":4678,"briefTitle":4679,"status":130,"phases":18815,"primaryCompletion":4681,"completion":4681,"start":4682,"enrollment":1034,"conditions":18816,"interventions":18817},[88],[2755,15,21],[1254,2423,1004,4537,2374,2196,806,803,1114],{"nctId":5600,"briefTitle":5601,"status":130,"phases":18819,"primaryCompletion":5603,"completion":5603,"start":5604,"enrollment":3354,"conditions":18820,"interventions":18821},[88],[5606],[2369,1710,2293,1369,1114,2495,2424],{"nctId":5617,"briefTitle":5618,"status":130,"phases":18823,"primaryCompletion":5620,"completion":5620,"start":5621,"enrollment":2933,"conditions":18824,"interventions":18825},[87,88],[5623],[2340,2495,1114,1369,2424,1071],{"nctId":2674,"briefTitle":2675,"status":130,"phases":18827,"primaryCompletion":2677,"completion":2677,"start":2678,"enrollment":2004,"conditions":18828,"interventions":18829},[88],[15],[894,2681,803,1013,1114,2682,2683,806,2584,2374,1071,62],{"nctId":3309,"briefTitle":3310,"status":130,"phases":18831,"primaryCompletion":3312,"completion":3312,"start":3313,"enrollment":628,"conditions":18832,"interventions":18833},[88],[2460,36,30,3315],[803,1114,1069,2293,2462,2196,2757,3317],{"nctId":2695,"briefTitle":2696,"status":130,"phases":18835,"primaryCompletion":2698,"completion":2698,"start":2699,"enrollment":2700,"conditions":18836,"interventions":18837},[88],[15],[2321,803,1013,1016,62,806,654,1114,2374],{"nctId":5237,"briefTitle":5238,"status":130,"phases":18839,"primaryCompletion":5240,"completion":5240,"start":5241,"enrollment":971,"conditions":18840,"interventions":18841},[88],[2530,5243,5244,5245],[5247,2293,1254,1070,803,1114],{"nctId":5645,"briefTitle":5646,"status":130,"phases":18843,"primaryCompletion":2953,"completion":2953,"start":5648,"enrollment":195,"conditions":18844,"interventions":18845},[88],[21],[4109,803,2424,1114],{"nctId":5253,"briefTitle":5254,"status":130,"phases":18847,"primaryCompletion":5256,"completion":5256,"start":5257,"enrollment":5258,"conditions":18848,"interventions":18849},[88],[5260,15,4760],[803,1070,2293,1114,894,1254,2196,5262,2374],{"nctId":1105,"briefTitle":1106,"status":182,"phases":18851,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":539,"conditions":18852,"interventions":18853},[87,88],[359,913,608,850,609,914,610,853,632],[1112,510,803,654,62,1069,1113,1114,806,809,894,480,1016],{"nctId":5667,"briefTitle":5668,"status":130,"phases":18855,"primaryCompletion":5670,"completion":5670,"start":5671,"enrollment":676,"conditions":18856,"interventions":18857},[88],[21],[2425,2495,2424,1114,2374],{"nctId":2784,"briefTitle":2785,"status":182,"phases":18859,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":1609,"conditions":18860,"interventions":18861},[88],[2790],[62,1013,2792,2495,1114,2793,2794,810],{"nctId":7233,"briefTitle":7234,"status":182,"phases":18863,"primaryCompletion":5434,"completion":5434,"start":7236,"enrollment":166,"conditions":18864,"interventions":18865},[88],[5735],[1070,803,7239,1114,3499],{"nctId":7254,"briefTitle":7255,"status":182,"phases":18867,"primaryCompletion":2778,"completion":2778,"start":3987,"enrollment":121,"conditions":18868,"interventions":18869},[88],[15,7258],[7260,1070,803,1114,3499],{"nctId":7285,"briefTitle":7286,"status":130,"phases":18871,"primaryCompletion":6065,"completion":6065,"start":6410,"enrollment":492,"conditions":18872,"interventions":18873},[88],[891,21],[75,894,803,1114,2374],{"nctId":2833,"briefTitle":2834,"status":130,"phases":18875,"primaryCompletion":2232,"completion":2232,"start":2836,"enrollment":628,"conditions":18876,"interventions":18877},[87,88],[15,2838],[2840,803,1016,1013,62,1114,806,2584,2841,2374],{"nctId":3422,"briefTitle":3423,"status":279,"phases":18879,"primaryCompletion":3425,"completion":3426,"start":3427,"enrollment":406,"conditions":18880,"interventions":18881},[88],[2135,3429],[598,3431,3432,1004,3433,2462,803,1114,2196],{"nctId":2852,"briefTitle":2853,"status":182,"phases":18883,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":296,"conditions":18884,"interventions":18885},[87,88],[2413,1142,1143,1144,2421,1145],[803,654,62,2712,1113,805,1114,806,1071,809,894,1015,1016],{"nctId":2886,"briefTitle":2887,"status":130,"phases":18887,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":18888,"interventions":18889},[88],[15,1122],[894,803,1013,1016,62,806,654,2374,1114,2894,1071,2895],{"nctId":7405,"briefTitle":7406,"status":130,"phases":18891,"primaryCompletion":7408,"completion":7408,"start":7409,"enrollment":2446,"conditions":18892,"interventions":18893},[87,88],[7411,2838,712,7412],[1070,803,1114,7414,7415],{"trials":18895,"activeCount":124},[18896],{"nctId":4305,"briefTitle":4306,"status":130,"phases":18897,"primaryCompletion":4308,"completion":4308,"start":4309,"enrollment":2402,"conditions":18898,"interventions":18899},[89],[21],[4312,4313,4045,2879,2880,2882,4314,4315,4047,4316,4317,4318,4319,2884],{"trials":18901,"activeCount":124},[],{"trials":18903,"activeCount":124},[18904,18908,18912],{"nctId":2965,"briefTitle":2966,"status":130,"phases":18905,"primaryCompletion":2968,"completion":2968,"start":2969,"enrollment":240,"conditions":18906,"interventions":18907},[91],[2971,2972,2973],[2975,2976,2977,2978,2979,1114,1016,62],{"nctId":4379,"briefTitle":4380,"status":182,"phases":18909,"primaryCompletion":4382,"completion":4382,"start":2932,"enrollment":1483,"conditions":18910,"interventions":18911},[91],[4384],[1013,1709,806,1113,4386,2495,2369,4387,1114],{"nctId":2994,"briefTitle":2995,"status":130,"phases":18913,"primaryCompletion":184,"completion":184,"start":2778,"enrollment":2997,"conditions":18914,"interventions":18915},[91],[2971,2935,2999,3000],[3002,62,3003,3004,1013,1114,2495,1016],{"intervention":4022,"totalTrials":2779,"cells":18917},{"EARLY_PHASE1":18918,"PHASE1":18920,"PHASE2":18938,"PHASE3":18987,"PHASE4":18989,"NA":18991},{"trials":18919,"activeCount":124},[],{"trials":18921,"activeCount":121,"soonestReadout":446},[18922,18926,18930,18934],{"nctId":12830,"briefTitle":12831,"status":102,"phases":18923,"primaryCompletion":238,"completion":238,"start":12833,"enrollment":628,"conditions":18924,"interventions":18925},[87],[3154,3195],[12836,4022,1683],{"nctId":13397,"briefTitle":13398,"status":182,"phases":18927,"primaryCompletion":2316,"completion":2316,"start":13400,"enrollment":628,"conditions":18928,"interventions":18929},[87],[13402],[4022,1402],{"nctId":17571,"briefTitle":17572,"status":279,"phases":18931,"primaryCompletion":446,"completion":281,"start":17574,"enrollment":473,"conditions":18932,"interventions":18933},[87],[17576],[1370,4022,3497],{"nctId":10935,"briefTitle":10936,"status":130,"phases":18935,"primaryCompletion":10938,"completion":10938,"start":3833,"enrollment":10939,"conditions":18936,"interventions":18937},[87],[1996,1942],[4022,1275,1375,1683],{"trials":18939,"activeCount":166,"soonestReadout":115},[18940,18950,18954,18958,18962,18966,18970,18976,18983],{"nctId":18941,"briefTitle":18942,"status":203,"phases":18943,"primaryCompletion":18944,"completion":18944,"start":18945,"enrollment":124,"conditions":18946,"interventions":18949},"NCT05042934","Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma",[87,88],"2022-08-30","2021-09-15",[18947,18948],"Metastatic Ewing Sarcoma","Recurrent Ewing Sarcoma",[4022,1372,10692],{"nctId":12368,"briefTitle":12369,"status":130,"phases":18951,"primaryCompletion":12371,"completion":12371,"start":12372,"enrollment":1240,"conditions":18952,"interventions":18953},[88],[4107],[1375,4022,2772,2369],{"nctId":4013,"briefTitle":4014,"status":203,"phases":18955,"primaryCompletion":4016,"completion":4016,"start":2264,"enrollment":124,"conditions":18956,"interventions":18957},[88],[4018,4019,4020],[1709,1371,2369,4022,1113,4023,1375],{"nctId":11053,"briefTitle":11054,"status":279,"phases":18959,"primaryCompletion":115,"completion":115,"start":11056,"enrollment":1100,"conditions":18960,"interventions":18961},[88],[11058],[1113,7588,1375,4022,1368,1275],{"nctId":12956,"briefTitle":12957,"status":203,"phases":18963,"primaryCompletion":4843,"completion":4843,"start":4723,"enrollment":124,"conditions":18964,"interventions":18965},[88],[3154,3195],[12961,1683,4022],{"nctId":4189,"briefTitle":4190,"status":130,"phases":18967,"primaryCompletion":4192,"completion":3987,"start":4193,"enrollment":871,"conditions":18968,"interventions":18969},[88],[4195,4196],[1709,4022],{"nctId":18971,"briefTitle":18972,"status":130,"phases":18973,"primaryCompletion":6409,"completion":4843,"start":4193,"enrollment":1664,"conditions":18974,"interventions":18975},"NCT00509860","Irinotecan (Camptosar) in Patients With Advanced Sarcomas",[88],[2971],[4022],{"nctId":18977,"briefTitle":18978,"status":182,"phases":18979,"primaryCompletion":4162,"completion":4162,"start":4511,"enrollment":186,"conditions":18980,"interventions":18981},"NCT01367275","Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF",[88],[3195,5028],[18982,4022],"Brivanib",{"nctId":11166,"briefTitle":11167,"status":130,"phases":18984,"primaryCompletion":8386,"completion":8386,"start":7473,"enrollment":2446,"conditions":18985,"interventions":18986},[88],[3195],[4218,1275,1113,4022],{"trials":18988,"activeCount":124},[],{"trials":18990,"activeCount":124},[],{"trials":18992,"activeCount":166,"soonestReadout":281},[18993],{"nctId":12224,"briefTitle":12225,"status":279,"phases":18994,"primaryCompletion":281,"completion":281,"start":6635,"enrollment":1131,"conditions":18995,"interventions":18996},[91],[12228,12229,12230],[1013,804,2840,12232,2495,4022,1431,12233,3497,6656,1016],{"intervention":1014,"totalTrials":3726,"cells":18998},{"EARLY_PHASE1":18999,"PHASE1":19001,"PHASE2":19003,"PHASE3":19045,"PHASE4":19055,"NA":19057},{"trials":19000,"activeCount":124},[],{"trials":19002,"activeCount":124},[],{"trials":19004,"activeCount":1231,"soonestReadout":504},[19005,19009,19015,19021,19025,19029,19033,19037,19041],{"nctId":16610,"briefTitle":16611,"status":279,"phases":19006,"primaryCompletion":504,"completion":504,"start":16613,"enrollment":342,"conditions":19007,"interventions":19008},[88],[3134,647,30,648],[3085,3420,1069,1014,1071],{"nctId":19010,"briefTitle":19011,"status":130,"phases":19012,"primaryCompletion":5434,"completion":5434,"start":2944,"enrollment":1140,"conditions":19013,"interventions":19014},"NCT00806598","Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome",[88],[30,3134],[4537,3420,1014,2374],{"nctId":19016,"briefTitle":19017,"status":130,"phases":19018,"primaryCompletion":8305,"completion":8305,"start":10760,"enrollment":3409,"conditions":19019,"interventions":19020},"NCT00609609","Photopheresis for the Treatment of Acute Graft Versus Host Disease",[88],[3418],[1014],{"nctId":4166,"briefTitle":4167,"status":130,"phases":19022,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":19023,"interventions":19024},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"nctId":1007,"briefTitle":1008,"status":279,"phases":19026,"primaryCompletion":446,"completion":446,"start":1010,"enrollment":517,"conditions":19027,"interventions":19028},[88],[847],[803,654,62,1013,805,806,1014,809,894,1015,480,1016],{"nctId":9275,"briefTitle":9276,"status":182,"phases":19030,"primaryCompletion":9278,"completion":9278,"start":9279,"enrollment":1231,"conditions":19031,"interventions":19032},[87,88],[15,2245,4580],[1070,2293,2439,2196,9282,2374,7415,1014],{"nctId":11449,"briefTitle":11450,"status":102,"phases":19034,"primaryCompletion":3943,"completion":3943,"start":11452,"enrollment":1328,"conditions":19035,"interventions":19036},[87,88],[11454,11455,11456],[1014,809],{"nctId":4807,"briefTitle":4808,"status":130,"phases":19038,"primaryCompletion":4810,"completion":4810,"start":4811,"enrollment":628,"conditions":19039,"interventions":19040},[87,88],[15],[1069,1004,803,3420,612,806,1014,2196],{"nctId":3413,"briefTitle":3414,"status":130,"phases":19042,"primaryCompletion":2953,"completion":2953,"start":3416,"enrollment":1140,"conditions":19043,"interventions":19044},[88],[3418,15,1036],[1069,599,3420,654,1005,655,1014],{"trials":19046,"activeCount":124},[19047,19051],{"nctId":4305,"briefTitle":4306,"status":130,"phases":19048,"primaryCompletion":4308,"completion":4308,"start":4309,"enrollment":2402,"conditions":19049,"interventions":19050},[89],[21],[4312,4313,4045,2879,2880,2882,4314,4315,4047,4316,4317,4318,4319,2884],{"nctId":4367,"briefTitle":4368,"status":130,"phases":19052,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":19053,"interventions":19054},[89],[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":19056,"activeCount":124},[],{"trials":19058,"activeCount":166,"soonestReadout":1864},[19059],{"nctId":19060,"briefTitle":19061,"status":279,"phases":19062,"primaryCompletion":1864,"completion":1864,"start":19063,"enrollment":4869,"conditions":19064,"interventions":19065},"NCT02464696","Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure",[91],"2015-10-06",[359,360],[1014],{"intervention":4218,"totalTrials":1568,"cells":19067},{"EARLY_PHASE1":19068,"PHASE1":19074,"PHASE2":19084,"PHASE3":19130,"PHASE4":19136,"NA":19138},{"trials":19069,"activeCount":124},[19070],{"nctId":6419,"briefTitle":6420,"status":130,"phases":19071,"primaryCompletion":6422,"completion":6422,"start":6423,"enrollment":2402,"conditions":19072,"interventions":19073},[86],[18,6425],[4218,803,1013],{"trials":19075,"activeCount":166,"soonestReadout":1151},[19076,19080],{"nctId":10749,"briefTitle":10750,"status":130,"phases":19077,"primaryCompletion":3493,"completion":3493,"start":3996,"enrollment":10752,"conditions":19078,"interventions":19079},[87],[33],[1402,1275,2207,6656,1402,1375,1113,10755],{"nctId":7581,"briefTitle":7582,"status":279,"phases":19081,"primaryCompletion":1151,"completion":1152,"start":7584,"enrollment":4299,"conditions":19082,"interventions":19083},[87],[3305],[7587,1375,1113,7588,1275,53,7589],{"trials":19085,"activeCount":121,"soonestReadout":2608},[19086,19090,19094,19098,19102,19106,19110,19114,19118,19122,19126],{"nctId":6737,"briefTitle":6738,"status":130,"phases":19087,"primaryCompletion":6740,"completion":6740,"start":6741,"enrollment":2700,"conditions":19088,"interventions":19089},[88],[18],[1376,1370,4218,6744,803,1013],{"nctId":10974,"briefTitle":10975,"status":182,"phases":19091,"primaryCompletion":5267,"completion":5267,"start":10977,"enrollment":121,"conditions":19092,"interventions":19093},[88],[10979],[4218,1275,1113,1375],{"nctId":6795,"briefTitle":6796,"status":130,"phases":19095,"primaryCompletion":6798,"completion":6799,"start":4382,"enrollment":2997,"conditions":19096,"interventions":19097},[88],[18],[6802,4023,1369,4218,6744,803],{"nctId":6804,"briefTitle":6805,"status":3049,"phases":19099,"primaryCompletion":2326,"completion":6807,"start":5470,"enrollment":2933,"conditions":19100,"interventions":19101},[88],[18],[1376,4218,6744,803,2330],{"nctId":11053,"briefTitle":11054,"status":279,"phases":19103,"primaryCompletion":115,"completion":115,"start":11056,"enrollment":1100,"conditions":19104,"interventions":19105},[88],[11058],[1113,7588,1375,4022,1368,1275],{"nctId":15402,"briefTitle":15403,"status":130,"phases":19107,"primaryCompletion":3571,"completion":3571,"start":14844,"enrollment":15405,"conditions":19108,"interventions":19109},[88],[2770,15407],[4218,1375],{"nctId":14934,"briefTitle":14935,"status":130,"phases":19111,"primaryCompletion":4184,"completion":4184,"start":3819,"enrollment":4551,"conditions":19112,"interventions":19113},[87,88],[14938],[4218,1710,1375],{"nctId":7174,"briefTitle":7175,"status":182,"phases":19115,"primaryCompletion":7177,"completion":7177,"start":5556,"enrollment":1568,"conditions":19116,"interventions":19117},[88],[18],[7180,1376,4218,6744,803],{"nctId":15428,"briefTitle":15429,"status":130,"phases":19119,"primaryCompletion":8305,"completion":8305,"start":5557,"enrollment":8325,"conditions":19120,"interventions":19121},[88],[15432,12006],[4218,15434,1375],{"nctId":4211,"briefTitle":4212,"status":102,"phases":19123,"primaryCompletion":2608,"completion":2608,"start":4214,"enrollment":4171,"conditions":19124,"interventions":19125},[88],[1293,4043,4216],[4218,1113,1709,2369],{"nctId":11166,"briefTitle":11167,"status":130,"phases":19127,"primaryCompletion":8386,"completion":8386,"start":7473,"enrollment":2446,"conditions":19128,"interventions":19129},[88],[3195],[4218,1275,1113,4022],{"trials":19131,"activeCount":124},[19132],{"nctId":7436,"briefTitle":7437,"status":130,"phases":19133,"primaryCompletion":6409,"completion":3777,"start":2580,"enrollment":7439,"conditions":19134,"interventions":19135},[89],[18],[4218,803,1013,1376,6744],{"trials":19137,"activeCount":124},[],{"trials":19139,"activeCount":124},[],{"intervention":3085,"totalTrials":2018,"cells":19141},{"EARLY_PHASE1":19142,"PHASE1":19144,"PHASE2":19158,"PHASE3":19200,"PHASE4":19202,"NA":19204},{"trials":19143,"activeCount":124},[],{"trials":19145,"activeCount":124},[19146,19150,19154],{"nctId":3077,"briefTitle":3078,"status":130,"phases":19147,"primaryCompletion":3080,"completion":3080,"start":3081,"enrollment":3082,"conditions":19148,"interventions":19149},[87],[2512,678,1411,30,648,913,608],[3085,1004,2423,1005,2405],{"nctId":5189,"briefTitle":5190,"status":203,"phases":19151,"primaryCompletion":2212,"completion":2212,"start":3833,"enrollment":124,"conditions":19152,"interventions":19153},[87],[2755,15,21,5193],[2293,1254,1070,894,2424,5195,2195,2196,2374],{"nctId":8284,"briefTitle":8285,"status":130,"phases":19155,"primaryCompletion":8287,"completion":8287,"start":8288,"enrollment":1034,"conditions":19156,"interventions":19157},[87],[785,712,3346,891,8290,4559,3642],[3085,6545,1069,1070,806,894,2196],{"trials":19159,"activeCount":1231,"soonestReadout":504},[19160,19164,19168,19172,19176,19180,19184,19188,19192,19196],{"nctId":4592,"briefTitle":4593,"status":130,"phases":19161,"primaryCompletion":1518,"completion":1518,"start":4595,"enrollment":230,"conditions":19162,"interventions":19163},[88],[1205,643,4597,1122,2512,36,846,3292,712,4598,737,1866,4599,3040,30,3233,3041,3059,914,632,716,882],[3085,1004,2423,803,2712,1070,2293,2195,894,2196],{"nctId":16610,"briefTitle":16611,"status":279,"phases":19165,"primaryCompletion":504,"completion":504,"start":16613,"enrollment":342,"conditions":19166,"interventions":19167},[88],[3134,647,30,648],[3085,3420,1069,1014,1071],{"nctId":3247,"briefTitle":3248,"status":130,"phases":19169,"primaryCompletion":3250,"completion":3250,"start":3251,"enrollment":2159,"conditions":19170,"interventions":19171},[87,88],[359],[3085,2226,1005,2477,806,894,2196],{"nctId":5591,"briefTitle":5592,"status":130,"phases":19173,"primaryCompletion":5594,"completion":5594,"start":5595,"enrollment":517,"conditions":19174,"interventions":19175},[88],[785,359,5597,21],[3085,75,4365,654,2424,1069,2293,806,894,2196],{"nctId":3285,"briefTitle":3286,"status":279,"phases":19177,"primaryCompletion":860,"completion":860,"start":3288,"enrollment":1222,"conditions":19178,"interventions":19179},[88],[1205,643,1122,2512,3290,3291,2471,3292,737,1025,3056,3057,3058,30,3233,3293,3244,648,608,3186,3059,3060,914,3294,651,882],[3296,3085,1004,2423,803,1005,2293,894],{"nctId":4737,"briefTitle":4738,"status":130,"phases":19181,"primaryCompletion":4740,"completion":4740,"start":4741,"enrollment":3354,"conditions":19182,"interventions":19183},[87,88],[4743,3277,3061,4562],[3085,1004,2423,4135,2195,894,2196],{"nctId":4746,"briefTitle":4747,"status":182,"phases":19185,"primaryCompletion":4749,"completion":4749,"start":4750,"enrollment":1568,"conditions":19186,"interventions":19187},[87,88],[1411,712,4752,715],[3085,1004,2423,1069,2369,806,2196],{"nctId":4839,"briefTitle":4840,"status":130,"phases":19189,"primaryCompletion":4842,"completion":4842,"start":4843,"enrollment":230,"conditions":19190,"interventions":19191},[88],[15,4725],[1070,1004,3499,3085,2196,806,2374],{"nctId":9366,"briefTitle":9367,"status":130,"phases":19193,"primaryCompletion":3902,"completion":6384,"start":9369,"enrollment":2997,"conditions":19194,"interventions":19195},[87,88],[4659,30,712],[9372,1070,2293,5195],{"nctId":7417,"briefTitle":7418,"status":102,"phases":19197,"primaryCompletion":404,"completion":404,"start":7420,"enrollment":834,"conditions":19198,"interventions":19199},[87,88],[1122,36,3134,7422,712,4598,3346,1866,891,30,727,3041,3135],[3085,803,7424,1070],{"trials":19201,"activeCount":124},[],{"trials":19203,"activeCount":124},[],{"trials":19205,"activeCount":124},[],{"intervention":3499,"totalTrials":3726,"cells":19207},{"EARLY_PHASE1":19208,"PHASE1":19210,"PHASE2":19224,"PHASE3":19262,"PHASE4":19264,"NA":19266},{"trials":19209,"activeCount":124},[],{"trials":19211,"activeCount":124},[19212,19216,19220],{"nctId":3490,"briefTitle":3491,"status":182,"phases":19213,"primaryCompletion":3493,"completion":3493,"start":3494,"enrollment":1766,"conditions":19214,"interventions":19215},[87],[1729],[1049,3497,1709,3498,3499],{"nctId":4532,"briefTitle":4533,"status":130,"phases":19217,"primaryCompletion":206,"completion":206,"start":4039,"enrollment":1568,"conditions":19218,"interventions":19219},[87],[30,15],[4537,1004,1070,2374,2196,806,3499],{"nctId":3829,"briefTitle":3830,"status":130,"phases":19221,"primaryCompletion":3832,"completion":3832,"start":3833,"enrollment":1496,"conditions":19222,"interventions":19223},[87],[1729],[3497,3836,1709,3499,3837],{"trials":19225,"activeCount":1231,"soonestReadout":3425},[19226,19230,19234,19238,19242,19246,19250,19254,19258],{"nctId":6724,"briefTitle":6725,"status":102,"phases":19227,"primaryCompletion":6727,"completion":6727,"start":6728,"enrollment":6729,"conditions":19228,"interventions":19229},[88],[1729],[6732,803,1070,6733,3499,1114,6734,6735],{"nctId":3664,"briefTitle":3665,"status":203,"phases":19231,"primaryCompletion":3667,"start":3668,"enrollment":124,"conditions":19232,"interventions":19233},[87,88],[1729],[1049,3671,3499],{"nctId":6896,"briefTitle":6897,"status":182,"phases":19235,"primaryCompletion":6899,"completion":6899,"start":6900,"enrollment":834,"conditions":19236,"interventions":19237},[88],[360,2084,1445,6902,1454,6903,6904,6905,1676,1677,1678,1679],[6907,803,1070,3499],{"nctId":4149,"briefTitle":4150,"status":182,"phases":19239,"primaryCompletion":4152,"completion":4152,"start":4153,"enrollment":3197,"conditions":19240,"interventions":19241},[88],[1729],[3497,4156,1709,3499,4157,2383],{"nctId":7163,"briefTitle":7164,"status":279,"phases":19243,"primaryCompletion":7166,"completion":7167,"start":7168,"enrollment":19,"conditions":19244,"interventions":19245},[87,88],[7170],[803,1070,7172,3499],{"nctId":7233,"briefTitle":7234,"status":182,"phases":19247,"primaryCompletion":5434,"completion":5434,"start":7236,"enrollment":166,"conditions":19248,"interventions":19249},[88],[5735],[1070,803,7239,1114,3499],{"nctId":7254,"briefTitle":7255,"status":182,"phases":19251,"primaryCompletion":2778,"completion":2778,"start":3987,"enrollment":121,"conditions":19252,"interventions":19253},[88],[15,7258],[7260,1070,803,1114,3499],{"nctId":7332,"briefTitle":7333,"status":102,"phases":19255,"primaryCompletion":3425,"completion":3426,"start":7335,"enrollment":1568,"conditions":19256,"interventions":19257},[87,88],[7337,1729,7338,7339],[7341,3499,803,1070],{"nctId":4839,"briefTitle":4840,"status":130,"phases":19259,"primaryCompletion":4842,"completion":4842,"start":4843,"enrollment":230,"conditions":19260,"interventions":19261},[88],[15,4725],[1070,1004,3499,3085,2196,806,2374],{"trials":19263,"activeCount":124},[],{"trials":19265,"activeCount":124},[],{"trials":19267,"activeCount":124},[],{"intervention":554,"totalTrials":910,"cells":19269},{"EARLY_PHASE1":19270,"PHASE1":19281,"PHASE2":19299,"PHASE3":19333,"PHASE4":19335,"NA":19337},{"trials":19271,"activeCount":124},[19272],{"nctId":19273,"briefTitle":19274,"status":130,"phases":19275,"primaryCompletion":19276,"completion":19276,"start":15029,"enrollment":539,"conditions":19277,"interventions":19280},"NCT03473730","Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer",[86],"2025-01-27",[19278,1271,10821,1272,19279],"Bladder Urothelial Carcinoma","Stage IV Renal Cell Cancer AJCC V8",[554],{"trials":19282,"activeCount":121,"soonestReadout":2276},[19283,19287,19291],{"nctId":544,"briefTitle":545,"status":546,"phases":19284,"primaryCompletion":548,"completion":490,"start":549,"enrollment":550,"conditions":19285,"interventions":19286},[87],[552,21],[480,62,75,554],{"nctId":2273,"briefTitle":2274,"status":102,"phases":19288,"primaryCompletion":2276,"completion":2276,"start":2277,"enrollment":871,"conditions":19289,"interventions":19290},[87],[2279,2280,2281],[554,62,2283],{"nctId":19292,"briefTitle":19293,"status":130,"phases":19294,"primaryCompletion":2864,"completion":2864,"start":2619,"enrollment":1922,"conditions":19295,"interventions":19297},"NCT03177460","Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer",[87],[5122,5108,5109,5110,5111,19296],"Testosterone Greater Than 150 ng\u002FdL",[554,19298],"FMS Inhibitor JNJ-40346527",{"trials":19300,"activeCount":166,"soonestReadout":1939},[19301,19309,19317,19323,19327],{"nctId":19302,"briefTitle":19303,"status":203,"phases":19304,"primaryCompletion":19305,"completion":19305,"start":19306,"enrollment":124,"conditions":19307,"interventions":19308},"NCT03035357","Neoadjuvant Listeria or Daratumumab in Prostate Cancer",[88],"2019-03-01","2017-03-01",[7652,27],[554],{"nctId":19310,"briefTitle":19311,"status":203,"phases":19312,"primaryCompletion":8814,"completion":19313,"start":19314,"enrollment":124,"conditions":19315,"interventions":19316},"NCT03207542","Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed\u002FRefractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)",[88],"2021-07","2018-07",[1399],[554],{"nctId":19318,"briefTitle":19319,"status":182,"phases":19320,"primaryCompletion":5362,"completion":5362,"start":2265,"enrollment":1483,"conditions":19321,"interventions":19322},"NCT03067571","Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[88],[1067,608,610],[554],{"nctId":2796,"briefTitle":2797,"status":102,"phases":19324,"primaryCompletion":1939,"completion":1939,"start":2799,"enrollment":517,"conditions":19325,"interventions":19326},[88],[2223,2224],[75,554,62,2283],{"nctId":19328,"briefTitle":19329,"status":182,"phases":19330,"primaryCompletion":8024,"completion":8024,"start":16722,"enrollment":2018,"conditions":19331,"interventions":19332},"NCT03622775","Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant",[88],[2223],[554],{"trials":19334,"activeCount":124},[],{"trials":19336,"activeCount":124},[],{"trials":19338,"activeCount":124},[],{"intervention":6802,"totalTrials":1483,"cells":19340},{"EARLY_PHASE1":19341,"PHASE1":19347,"PHASE2":19349,"PHASE3":19378,"PHASE4":19380,"NA":19382},{"trials":19342,"activeCount":166,"soonestReadout":10669},[19343],{"nctId":10666,"briefTitle":10667,"status":546,"phases":19344,"primaryCompletion":10669,"completion":10670,"start":10671,"enrollment":1222,"conditions":19345,"interventions":19346},[86],[10673,10674],[1275,1683,6802,10676,10677,1684,10678,10679,10680,10681,10682],{"trials":19348,"activeCount":124},[],{"trials":19350,"activeCount":121,"soonestReadout":193},[19351,19358,19362,19366,19370,19374],{"nctId":19352,"briefTitle":19353,"status":130,"phases":19354,"primaryCompletion":14273,"completion":14273,"start":19355,"enrollment":1766,"conditions":19356,"interventions":19357},"NCT01202409","CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater",[88],"2010-11-02",[4195],[6802],{"nctId":10000,"briefTitle":10001,"status":102,"phases":19359,"primaryCompletion":999,"completion":999,"start":10003,"enrollment":924,"conditions":19360,"interventions":19361},[88],[10005,10006,7696,7697,7698,7699,10007,5079,7700,7701,1363],[1369,1376,6802],{"nctId":6795,"briefTitle":6796,"status":130,"phases":19363,"primaryCompletion":6798,"completion":6799,"start":4382,"enrollment":2997,"conditions":19364,"interventions":19365},[88],[18],[6802,4023,1369,4218,6744,803],{"nctId":10054,"briefTitle":10055,"status":130,"phases":19367,"primaryCompletion":10057,"completion":10057,"start":10058,"enrollment":357,"conditions":19368,"interventions":19369},[88],[5080,5081,5082,5083,5084,5085,5086,5087,5088,5089,1363],[1369,1376,6802],{"nctId":16099,"briefTitle":16100,"status":102,"phases":19371,"primaryCompletion":193,"completion":193,"start":2167,"enrollment":7377,"conditions":19372,"interventions":19373},[88],[16103,14008,16104,2084,16105,5008,5009,5010],[6802,874],{"nctId":7303,"briefTitle":7304,"status":203,"phases":19375,"primaryCompletion":754,"completion":754,"start":7306,"enrollment":124,"conditions":19376,"interventions":19377},[88],[7308,7309,7310,7311,7312,7296,5079,7313,7314,7315,7316,7317,1363],[1369,803,1013,1376,6802,53],{"trials":19379,"activeCount":124},[],{"trials":19381,"activeCount":124},[],{"trials":19383,"activeCount":124},[],{"intervention":693,"totalTrials":1483,"cells":19385},{"EARLY_PHASE1":19386,"PHASE1":19388,"PHASE2":19390,"PHASE3":19436,"PHASE4":19438,"NA":19440},{"trials":19387,"activeCount":124},[],{"trials":19389,"activeCount":124},[],{"trials":19391,"activeCount":1231,"soonestReadout":1698},[19392,19396,19400,19408,19412,19422,19426],{"nctId":685,"briefTitle":686,"status":130,"phases":19393,"primaryCompletion":688,"completion":688,"start":689,"enrollment":676,"conditions":19394,"interventions":19395},[87,88],[608,610],[692,693,510,694,695,696,480,510],{"nctId":16719,"briefTitle":16720,"status":102,"phases":19397,"primaryCompletion":193,"completion":193,"start":16722,"enrollment":550,"conditions":19398,"interventions":19399},[88],[13147,16724,16725,13148,13149,1803,16726],[693,1377],{"nctId":19401,"briefTitle":19402,"status":102,"phases":19403,"primaryCompletion":1698,"completion":2608,"start":19404,"enrollment":3820,"conditions":19405,"interventions":19406},"NCT04266912","Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors",[87,88],"2020-03-17",[361,3457,7891],[693,19407],"Berzosertib",{"nctId":1762,"briefTitle":1763,"status":182,"phases":19409,"primaryCompletion":1717,"completion":1717,"start":1765,"enrollment":1766,"conditions":19410,"interventions":19411},[87,88],[1768,1769,1343,1770,1771,1772,1344,1773,1312,1774,1348,1775,1349,1776,1350,1777,1351,1352,1353,1778,1779,1355,1356,1780,1357,1781,1358,1359,1782,1319,1360,1783,1361,1784,1362],[718,693,1786,1050,53,1787],{"nctId":19413,"briefTitle":19414,"status":102,"phases":19415,"primaryCompletion":19416,"completion":8064,"start":19417,"enrollment":19418,"conditions":19419,"interventions":19420},"NCT03217747","Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies",[87,88],"2025-09-02","2017-08-02",173,[1343,3544,360,361,3545,5123,3457,3546,3547,3548],[693,19421,7370],"Ivuxolimab",{"nctId":10579,"briefTitle":10580,"status":182,"phases":19423,"primaryCompletion":10582,"completion":10582,"start":7595,"enrollment":1766,"conditions":19424,"interventions":19425},[87,88],[846,608,610],[693,510],{"nctId":19427,"briefTitle":19428,"status":130,"phases":19429,"primaryCompletion":19430,"completion":19430,"start":5120,"enrollment":517,"conditions":19431,"interventions":19434},"NCT03990571","Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma",[88],"2023-03-20",[19432,1670,19433],"Metastatic Adenoid Cystic Carcinoma","Recurrent Adenoid Cystic Carcinoma",[693,19435],"Axitinib",{"trials":19437,"activeCount":124},[],{"trials":19439,"activeCount":124},[],{"trials":19441,"activeCount":124},[],{"intervention":2269,"totalTrials":230,"cells":19443},{"EARLY_PHASE1":19444,"PHASE1":19446,"PHASE2":19452,"PHASE3":19474,"PHASE4":19476,"NA":19478},{"trials":19445,"activeCount":124},[],{"trials":19447,"activeCount":124},[19448],{"nctId":2261,"briefTitle":2262,"status":130,"phases":19449,"primaryCompletion":2264,"completion":2264,"start":2265,"enrollment":1409,"conditions":19450,"interventions":19451},[87],[2267],[62,2269,2270,2271,1709,1376],{"trials":19453,"activeCount":1231,"soonestReadout":549},[19454,19458,19462,19466,19470],{"nctId":2385,"briefTitle":2386,"status":182,"phases":19455,"primaryCompletion":2388,"completion":2388,"start":2389,"enrollment":240,"conditions":19456,"interventions":19457},[88],[2391,2392],[2394,62,2395,2269],{"nctId":2625,"briefTitle":2626,"status":279,"phases":19459,"primaryCompletion":2628,"completion":674,"start":2629,"enrollment":406,"conditions":19460,"interventions":19461},[88],[1638,2631],[1376,62,2269,2270],{"nctId":3341,"briefTitle":3342,"status":279,"phases":19463,"primaryCompletion":549,"completion":1088,"start":3344,"enrollment":1131,"conditions":19464,"interventions":19465},[88],[3346],[3348,803,2462,809,2269,2395],{"nctId":2803,"briefTitle":2804,"status":130,"phases":19467,"primaryCompletion":2806,"completion":2806,"start":2807,"enrollment":406,"conditions":19468,"interventions":19469},[88],[2809],[1376,62,2811,2269],{"nctId":2860,"briefTitle":2861,"status":279,"phases":19471,"primaryCompletion":2863,"completion":2863,"start":2864,"enrollment":2865,"conditions":19472,"interventions":19473},[87,88],[2867,2868],[62,2269,2270,1376],{"trials":19475,"activeCount":124},[],{"trials":19477,"activeCount":124},[],{"trials":19479,"activeCount":124},[],{"intervention":2283,"totalTrials":230,"cells":19481},{"EARLY_PHASE1":19482,"PHASE1":19484,"PHASE2":19498,"PHASE3":19520,"PHASE4":19522,"NA":19524},{"trials":19483,"activeCount":124},[],{"trials":19485,"activeCount":166,"soonestReadout":2276},[19486,19490],{"nctId":2273,"briefTitle":2274,"status":102,"phases":19487,"primaryCompletion":2276,"completion":2276,"start":2277,"enrollment":871,"conditions":19488,"interventions":19489},[87],[2279,2280,2281],[554,62,2283],{"nctId":19491,"briefTitle":19492,"status":130,"phases":19493,"primaryCompletion":19494,"completion":19494,"start":19495,"enrollment":910,"conditions":19496,"interventions":19497},"NCT02942095","Study of Ixazomib and Erlotinib in Solid Tumors",[87],"2022-12-07","2017-03-06",[1924],[2283,3847],{"trials":19499,"activeCount":121,"soonestReadout":193},[19500,19504,19508,19512],{"nctId":12108,"briefTitle":12109,"status":102,"phases":19501,"primaryCompletion":193,"completion":193,"start":12111,"enrollment":406,"conditions":19502,"interventions":19503},[88],[7942,1346,12113,1356,1360],[1013,804,2369,4135,2283,8569],{"nctId":8561,"briefTitle":8562,"status":182,"phases":19505,"primaryCompletion":8564,"completion":8565,"start":8566,"enrollment":1231,"conditions":19506,"interventions":19507},[88],[789,790],[2283,8569,894],{"nctId":2796,"briefTitle":2797,"status":102,"phases":19509,"primaryCompletion":1939,"completion":1939,"start":2799,"enrollment":517,"conditions":19510,"interventions":19511},[88],[2223,2224],[75,554,62,2283],{"nctId":19513,"briefTitle":19514,"status":182,"phases":19515,"primaryCompletion":19516,"completion":19516,"start":19517,"enrollment":3197,"conditions":19518,"interventions":19519},"NCT02302846","Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission",[88],"2017-05-30","2015-03-20",[15],[2283],{"trials":19521,"activeCount":124},[],{"trials":19523,"activeCount":124},[],{"trials":19525,"activeCount":124},[],{"intervention":10678,"totalTrials":3197,"cells":19527},{"EARLY_PHASE1":19528,"PHASE1":19534,"PHASE2":19553,"PHASE3":19559,"PHASE4":19561,"NA":19563},{"trials":19529,"activeCount":166,"soonestReadout":10669},[19530],{"nctId":10666,"briefTitle":10667,"status":546,"phases":19531,"primaryCompletion":10669,"completion":10670,"start":10671,"enrollment":1222,"conditions":19532,"interventions":19533},[86],[10673,10674],[1275,1683,6802,10676,10677,1684,10678,10679,10680,10681,10682],{"trials":19535,"activeCount":166,"soonestReadout":19548},[19536,19540,19544],{"nctId":15159,"briefTitle":15160,"status":182,"phases":19537,"primaryCompletion":15162,"completion":5143,"start":2864,"enrollment":166,"conditions":19538,"interventions":19539},[87],[7337,15164],[10678,1374],{"nctId":13219,"briefTitle":13220,"status":203,"phases":19541,"primaryCompletion":3945,"completion":3945,"start":11590,"enrollment":124,"conditions":19542,"interventions":19543},[87],[24,13223],[1786,10678],{"nctId":19545,"briefTitle":19546,"status":546,"phases":19547,"primaryCompletion":19548,"completion":19549,"start":18773,"enrollment":550,"conditions":19550,"interventions":19551},"NCT07382726","Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial",[87],"2027-12-24","2029-12-24",[10145],[10678,19552],"Iza-bren",{"trials":19554,"activeCount":166,"soonestReadout":12905},[19555],{"nctId":12902,"briefTitle":12903,"status":279,"phases":19556,"primaryCompletion":12905,"completion":12905,"start":12906,"enrollment":2004,"conditions":19557,"interventions":19558},[87,88],[10674,12908],[1683,12910,10678],{"trials":19560,"activeCount":124},[],{"trials":19562,"activeCount":124},[],{"trials":19564,"activeCount":124},[],{"intervention":11680,"totalTrials":3197,"cells":19566},{"EARLY_PHASE1":19567,"PHASE1":19569,"PHASE2":19578,"PHASE3":19608,"PHASE4":19610,"NA":19612},{"trials":19568,"activeCount":124},[],{"trials":19570,"activeCount":166,"soonestReadout":16160},[19571],{"nctId":19572,"briefTitle":19573,"status":279,"phases":19574,"primaryCompletion":16160,"completion":16160,"start":19575,"enrollment":628,"conditions":19576,"interventions":19577},"NCT03968406","Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers",[87],"2019-09-26",[10817,1456,1457,1458,1460,1461,13185,13191,1462,1463,1464,10713,13192,13194,1465,1466,1467,10714,13195,1468,1469,1470,1471,1472,13196],[11680],{"trials":19579,"activeCount":121,"soonestReadout":446},[19580,19589,19596,19604],{"nctId":19581,"briefTitle":19582,"status":279,"phases":19583,"primaryCompletion":446,"completion":281,"start":19584,"enrollment":406,"conditions":19585,"interventions":19586},"NCT05873192","Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer",[88],"2025-06-03",[27],[19587,7589,11680,3720,19588],"ADT","Luprolide",{"nctId":19590,"briefTitle":19591,"status":130,"phases":19592,"primaryCompletion":19593,"completion":1120,"start":16857,"enrollment":593,"conditions":19594,"interventions":19595},"NCT02282345","Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer",[88],"2018-04-26",[11641,8170,8171,7699,5079],[11680],{"nctId":19597,"briefTitle":19598,"status":102,"phases":19599,"primaryCompletion":446,"completion":446,"start":19600,"enrollment":1045,"conditions":19601,"interventions":19603},"NCT02286687","Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes",[88],"2014-12-22",[2922,8169,4908,4909,2924,19602,2925,2926],"PALB2 Gene Mutation",[11680],{"nctId":11674,"briefTitle":11675,"status":203,"phases":19605,"primaryCompletion":11677,"completion":11677,"start":1727,"enrollment":124,"conditions":19606,"interventions":19607},[88],[4031],[718,11680],{"trials":19609,"activeCount":124},[],{"trials":19611,"activeCount":124},[],{"trials":19613,"activeCount":124},[],{"intervention":11035,"totalTrials":296,"cells":19615},{"EARLY_PHASE1":19616,"PHASE1":19618,"PHASE2":19620,"PHASE3":19638,"PHASE4":19640,"NA":19642},{"trials":19617,"activeCount":124},[],{"trials":19619,"activeCount":124},[],{"trials":19621,"activeCount":1231,"soonestReadout":504},[19622,19626,19630,19634],{"nctId":11564,"briefTitle":11565,"status":102,"phases":19623,"primaryCompletion":224,"completion":224,"start":2549,"enrollment":1609,"conditions":19624,"interventions":19625},[88],[11568,11569],[718,11035,1370],{"nctId":11572,"briefTitle":11573,"status":130,"phases":19627,"primaryCompletion":6396,"completion":6396,"start":3714,"enrollment":2446,"conditions":19628,"interventions":19629},[88],[11576,11091,11577,5832,11578,2924,7946,2085,11579,2926,2086,11580],[718,11035],{"nctId":11027,"briefTitle":11028,"status":102,"phases":19631,"primaryCompletion":504,"completion":504,"start":11030,"enrollment":1409,"conditions":19632,"interventions":19633},[88],[11032,1312,11033,1960,1316,1353,6638],[718,1275,11035],{"nctId":11046,"briefTitle":11047,"status":102,"phases":19635,"primaryCompletion":3943,"completion":3943,"start":10324,"enrollment":676,"conditions":19636,"interventions":19637},[88],[8186,1590,11050,8187,8188,1594,8189],[718,1275,11035,4023,1376,9970],{"trials":19639,"activeCount":124},[],{"trials":19641,"activeCount":124},[],{"trials":19643,"activeCount":124},[],{"intervention":13648,"totalTrials":296,"cells":19645},{"EARLY_PHASE1":19646,"PHASE1":19648,"PHASE2":19659,"PHASE3":19677,"PHASE4":19679,"NA":19681},{"trials":19647,"activeCount":124},[],{"trials":19649,"activeCount":124},[19650],{"nctId":19651,"briefTitle":19652,"status":203,"phases":19653,"primaryCompletion":19654,"completion":19654,"start":19655,"enrollment":124,"conditions":19656,"interventions":19658},"NCT05961696","A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia",[87],"2023-10-03","2023-07-05",[19657],"Refractory B-cell Acute Lymphoblastic Leukemia",[13648],{"trials":19660,"activeCount":1231,"soonestReadout":446},[19661,19667,19673],{"nctId":19662,"briefTitle":19663,"status":279,"phases":19664,"primaryCompletion":446,"completion":281,"start":10143,"enrollment":593,"conditions":19665,"interventions":19666},"NCT06563505","A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed\u002FRefractory Marginal Zone Lymphoma",[88],[21],[13648,8591],{"nctId":19668,"briefTitle":19669,"status":546,"phases":19670,"primaryCompletion":2628,"completion":674,"start":1864,"enrollment":406,"conditions":19671,"interventions":19672},"NCT07566364","Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD",[88],[8602],[13648],{"nctId":13640,"briefTitle":13641,"status":279,"phases":19674,"primaryCompletion":13643,"completion":13643,"start":13644,"enrollment":593,"conditions":19675,"interventions":19676},[88],[1866,3393,13646],[13648,13649,3338,1402],{"trials":19678,"activeCount":124},[],{"trials":19680,"activeCount":124},[],{"trials":19682,"activeCount":124},[],{"intervention":1198,"totalTrials":296,"cells":19684},{"EARLY_PHASE1":19685,"PHASE1":19687,"PHASE2":19702,"PHASE3":19716,"PHASE4":19718,"NA":19720},{"trials":19686,"activeCount":124},[],{"trials":19688,"activeCount":166,"soonestReadout":6282},[19689,19698],{"nctId":19690,"briefTitle":19691,"status":203,"phases":19692,"primaryCompletion":19693,"completion":19693,"start":19693,"enrollment":124,"conditions":19694,"interventions":19696},"NCT07052994","A Phase Ia\u002FIb Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed \u002FRefractory Pediatric Acute Leukemia Patients",[87],"2026-05-21",[19695],"Pediatric Acute Leukemia",[1198,19697,7021],"Cytrabine",{"nctId":13015,"briefTitle":13016,"status":546,"phases":19699,"primaryCompletion":6282,"completion":13018,"start":12507,"enrollment":1131,"conditions":19700,"interventions":19701},[87],[1083,1198,7228,13020],[1198,1083],{"trials":19703,"activeCount":121,"soonestReadout":403},[19704,19712],{"nctId":19705,"briefTitle":19706,"status":279,"phases":19707,"primaryCompletion":403,"completion":6008,"start":19708,"enrollment":517,"conditions":19709,"interventions":19711},"NCT06229912","A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes",[88],"2024-06-04",[15,19710],"HOX Gene",[1198],{"nctId":1190,"briefTitle":1191,"status":279,"phases":19713,"primaryCompletion":1193,"completion":1194,"start":1195,"enrollment":186,"conditions":19714,"interventions":19715},[87,88],[36],[480,1198],{"trials":19717,"activeCount":124},[],{"trials":19719,"activeCount":124},[],{"trials":19721,"activeCount":124},[],{"intervention":1965,"totalTrials":296,"cells":19723},{"EARLY_PHASE1":19724,"PHASE1":19726,"PHASE2":19728,"PHASE3":19746,"PHASE4":19748,"NA":19750},{"trials":19725,"activeCount":124},[],{"trials":19727,"activeCount":124},[],{"trials":19729,"activeCount":1231,"soonestReadout":7970},[19730,19734,19738,19742],{"nctId":16108,"briefTitle":16109,"status":182,"phases":19731,"primaryCompletion":1043,"completion":1043,"start":16111,"enrollment":296,"conditions":19732,"interventions":19733},[88],[1350,1351,1352],[1965,16114,874],{"nctId":7967,"briefTitle":7968,"status":102,"phases":19735,"primaryCompletion":7970,"completion":7970,"start":7971,"enrollment":406,"conditions":19736,"interventions":19737},[88],[1594,1595],[1965,53,874],{"nctId":1954,"briefTitle":1955,"status":102,"phases":19739,"primaryCompletion":1957,"completion":1957,"start":1958,"enrollment":901,"conditions":19740,"interventions":19741},[88],[1960,1316,1961,1962,1544,1546,1549,1365],[1964,1965,1684,1050,874],{"nctId":16132,"briefTitle":16133,"status":102,"phases":19743,"primaryCompletion":2455,"completion":2455,"start":16135,"enrollment":8325,"conditions":19744,"interventions":19745},[88],[1544,1546],[1965,874],{"trials":19747,"activeCount":124},[],{"trials":19749,"activeCount":124},[],{"trials":19751,"activeCount":124},[],{"intervention":564,"totalTrials":1231,"cells":19753},{"EARLY_PHASE1":19754,"PHASE1":19756,"PHASE2":19762,"PHASE3":19772,"PHASE4":19774,"NA":19776},{"trials":19755,"activeCount":124},[],{"trials":19757,"activeCount":166,"soonestReadout":446},[19758],{"nctId":556,"briefTitle":557,"status":279,"phases":19759,"primaryCompletion":446,"completion":446,"start":559,"enrollment":560,"conditions":19760,"interventions":19761},[87],[36],[563,564,565,566,480],{"trials":19763,"activeCount":121,"soonestReadout":115},[19764,19768],{"nctId":615,"briefTitle":616,"status":279,"phases":19765,"primaryCompletion":618,"completion":618,"start":619,"enrollment":381,"conditions":19766,"interventions":19767},[87,88],[36,608,610],[563,564,566,480],{"nctId":10437,"briefTitle":10438,"status":279,"phases":19769,"primaryCompletion":115,"completion":115,"start":10440,"enrollment":3379,"conditions":19770,"interventions":19771},[88],[36,10442,737,10443,3233,3112,3113],[510,564],{"trials":19773,"activeCount":124},[],{"trials":19775,"activeCount":124},[],{"trials":19777,"activeCount":124},[],{"intervention":511,"totalTrials":1231,"cells":19779},{"EARLY_PHASE1":19780,"PHASE1":19782,"PHASE2":19801,"PHASE3":19807,"PHASE4":19809,"NA":19811},{"trials":19781,"activeCount":124},[],{"trials":19783,"activeCount":121,"soonestReadout":504},[19784,19788],{"nctId":501,"briefTitle":502,"status":279,"phases":19785,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":19786,"interventions":19787},[87],[36],[510,480,511],{"nctId":19789,"briefTitle":19790,"status":546,"phases":19791,"primaryCompletion":19792,"completion":19793,"start":19794,"enrollment":593,"conditions":19795,"interventions":19800},"NCT07579208","A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma",[87],"2028-07-30","2030-07-30","2026-10-24",[2306,8266,19796,19797,19798,19799,7740],"IL13Ra","EGFRvIII","Chimera Antigen Receptor (CAR)","NR3C1",[511,511],{"trials":19802,"activeCount":166,"soonestReadout":6818},[19803],{"nctId":6815,"briefTitle":6816,"status":279,"phases":19804,"primaryCompletion":6818,"completion":6819,"start":6820,"enrollment":3521,"conditions":19805,"interventions":19806},[87,88],[3195,6822,2631],[803,1070,1683,511],{"trials":19808,"activeCount":124},[],{"trials":19810,"activeCount":124},[],{"trials":19812,"activeCount":124},[],{"intervention":3550,"totalTrials":1231,"cells":19814},{"EARLY_PHASE1":19815,"PHASE1":19817,"PHASE2":19829,"PHASE3":19835,"PHASE4":19837,"NA":19839},{"trials":19816,"activeCount":124},[],{"trials":19818,"activeCount":121,"soonestReadout":446},[19819,19823],{"nctId":3537,"briefTitle":3538,"status":102,"phases":19820,"primaryCompletion":446,"completion":446,"start":3540,"enrollment":3541,"conditions":19821,"interventions":19822},[87],[3543,3544,1848,361,3545,1803,3546,1360,3547,3548],[1049,3550],{"nctId":19824,"briefTitle":19825,"status":102,"phases":19826,"primaryCompletion":571,"completion":1863,"start":868,"enrollment":539,"conditions":19827,"interventions":19828},"NCT05633979","Phase 1b Study of EZH1\u002F2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low\u002FUltra-low\u002FNull Metastatic Breast Cancer",[87],[18],[10680,3550],{"trials":19830,"activeCount":166,"soonestReadout":238},[19831],{"nctId":8605,"briefTitle":8606,"status":279,"phases":19832,"primaryCompletion":238,"completion":238,"start":8608,"enrollment":1034,"conditions":19833,"interventions":19834},[87,88],[21],[894,1402,3550],{"trials":19836,"activeCount":124},[],{"trials":19838,"activeCount":124},[],{"trials":19840,"activeCount":124},[],{"intervention":13099,"totalTrials":1231,"cells":19842},{"EARLY_PHASE1":19843,"PHASE1":19845,"PHASE2":19851,"PHASE3":19864,"PHASE4":19866,"NA":19868},{"trials":19844,"activeCount":124},[],{"trials":19846,"activeCount":166,"soonestReadout":3425},[19847],{"nctId":12558,"briefTitle":12559,"status":279,"phases":19848,"primaryCompletion":3425,"completion":3426,"start":12561,"enrollment":406,"conditions":19849,"interventions":19850},[87],[12563,12564],[612,12566,12567],{"trials":19852,"activeCount":121,"soonestReadout":19857},[19853,19860],{"nctId":19854,"briefTitle":19855,"status":279,"phases":19856,"primaryCompletion":19857,"completion":19857,"start":8463,"enrollment":676,"conditions":19858,"interventions":19859},"NCT06817720","Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",[88],"2027-03-07",[3315],[13099],{"nctId":13092,"briefTitle":13093,"status":546,"phases":19861,"primaryCompletion":6952,"completion":6953,"start":13095,"enrollment":1034,"conditions":19862,"interventions":19863},[88],[13097,1083,12567,7228,912],[1083,13099],{"trials":19865,"activeCount":124},[],{"trials":19867,"activeCount":124},[],{"trials":19869,"activeCount":124},[],{"intervention":8007,"totalTrials":1231,"cells":19871},{"EARLY_PHASE1":19872,"PHASE1":19874,"PHASE2":19876,"PHASE3":19901,"PHASE4":19903,"NA":19905},{"trials":19873,"activeCount":124},[],{"trials":19875,"activeCount":124},[],{"trials":19877,"activeCount":1231,"soonestReadout":446},[19878,19888,19892],{"nctId":19879,"briefTitle":19880,"status":279,"phases":19881,"primaryCompletion":537,"completion":1481,"start":19882,"enrollment":2004,"conditions":19883,"interventions":19885},"NCT07011654","Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)",[87,88],"2025-09-19",[19884],"Metastatic Triple-Negative Breast Cancer",[19886,19887],"Sacituzumab govitecan","Naxitamab",{"nctId":8001,"briefTitle":8002,"status":102,"phases":19889,"primaryCompletion":446,"completion":446,"start":8004,"enrollment":2159,"conditions":19890,"interventions":19891},[88],[18],[8007,53],{"nctId":19893,"briefTitle":19894,"status":279,"phases":19895,"primaryCompletion":1735,"completion":1735,"start":19896,"enrollment":406,"conditions":19897,"interventions":19900},"NCT05884320","Phase II Trial of Sacituzumab Govitecan in Recurrent and\u002For Metastatic Secretory Gland Cancers",[88],"2023-07-27",[19898,19899],"Gland","Salivary Gland Cancers",[8007],{"trials":19902,"activeCount":124},[],{"trials":19904,"activeCount":124},[],{"trials":19906,"activeCount":124},[],{"intervention":3338,"totalTrials":1231,"cells":19908},{"EARLY_PHASE1":19909,"PHASE1":19911,"PHASE2":19913,"PHASE3":19927,"PHASE4":19929,"NA":19931},{"trials":19910,"activeCount":124},[],{"trials":19912,"activeCount":124},[],{"trials":19914,"activeCount":1231,"soonestReadout":7216},[19915,19919,19923],{"nctId":3328,"briefTitle":3329,"status":279,"phases":19916,"primaryCompletion":281,"completion":571,"start":2855,"enrollment":2997,"conditions":19917,"interventions":19918},[87,88],[3332,3333,3334,3335,3336],[3338,2462,803,3339],{"nctId":7213,"briefTitle":7214,"status":102,"phases":19920,"primaryCompletion":7216,"completion":7216,"start":7217,"enrollment":2933,"conditions":19921,"interventions":19922},[88],[7219],[668,803,804,1402,809,894,3338,1016],{"nctId":13640,"briefTitle":13641,"status":279,"phases":19924,"primaryCompletion":13643,"completion":13643,"start":13644,"enrollment":593,"conditions":19925,"interventions":19926},[88],[1866,3393,13646],[13648,13649,3338,1402],{"trials":19928,"activeCount":124},[],{"trials":19930,"activeCount":124},[],{"trials":19932,"activeCount":124},[],{"intervention":19934,"totalTrials":1231,"cells":19935},"Psilocybin",{"EARLY_PHASE1":19936,"PHASE1":19938,"PHASE2":19940,"PHASE3":19966,"PHASE4":19968,"NA":19970},{"trials":19937,"activeCount":124},[],{"trials":19939,"activeCount":124},[],{"trials":19941,"activeCount":1231,"soonestReadout":446},[19942,19949,19957],{"nctId":19943,"briefTitle":19944,"status":279,"phases":19945,"primaryCompletion":2166,"completion":19946,"start":11638,"enrollment":1131,"conditions":19947,"interventions":19948},"NCT06801041","TRIPS - Treatment to Improve Depression and\u002For Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors",[88],"2029-03-31",[5366,5365,5349],[19934],{"nctId":19950,"briefTitle":19951,"status":546,"phases":19952,"primaryCompletion":591,"completion":592,"start":19953,"enrollment":2946,"conditions":19954,"interventions":19956},"NCT07227909","NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy",[88],"2026-11-04",[19934,19955],"Neuropathy",[19934,19934],{"nctId":19958,"briefTitle":19959,"status":279,"phases":19960,"primaryCompletion":446,"completion":446,"start":19961,"enrollment":406,"conditions":19962,"interventions":19965},"NCT06200155","Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy",[88],"2024-04-16",[19963,19964,1942],"Depression, Anxiety","Psilocybin-Assisted Psychotherapy",[19934],{"trials":19967,"activeCount":124},[],{"trials":19969,"activeCount":124},[],{"trials":19971,"activeCount":124},[],{"intervention":2293,"totalTrials":3379,"cells":19973},{"EARLY_PHASE1":19974,"PHASE1":19980,"PHASE2":20026,"PHASE3":20235,"PHASE4":20249,"NA":20251},{"trials":19975,"activeCount":124},[19976],{"nctId":3014,"briefTitle":3015,"status":130,"phases":19977,"primaryCompletion":3017,"completion":3017,"start":3018,"enrollment":1231,"conditions":19978,"interventions":19979},[86],[2134,3020],[803,1069,1005,2293,2195,2196],{"trials":19981,"activeCount":124},[19982,19986,19990,19994,19998,20002,20006,20010,20014,20018,20022],{"nctId":5439,"briefTitle":5440,"status":130,"phases":19983,"primaryCompletion":5442,"completion":5442,"start":5443,"enrollment":1240,"conditions":19984,"interventions":19985},[87],[21,5445],[5447,4365,2424,654,2293],{"nctId":4508,"briefTitle":4509,"status":130,"phases":19987,"primaryCompletion":2242,"completion":2242,"start":4511,"enrollment":959,"conditions":19988,"interventions":19989},[87],[21],[2405,2369,1004,2293,894,2374,2368,4514],{"nctId":4516,"briefTitle":4517,"status":130,"phases":19991,"primaryCompletion":4519,"completion":4519,"start":4520,"enrollment":1922,"conditions":19992,"interventions":19993},[87],[4522,15,21,4523,4524],[2293,1070,2757,2196,894,4526,1004,2423],{"nctId":3047,"briefTitle":3048,"status":3049,"phases":19995,"primaryCompletion":3051,"completion":3051,"start":3052,"enrollment":2018,"conditions":19996,"interventions":19997},[87],[1205,643,2512,678,1025,3054,3055,3056,3057,3058,30,913,608,665,3059,3060,666,914,528,3061,3062,529,651,682,882],[803,1005,1402,2293,2195,3064,894,2196],{"nctId":5189,"briefTitle":5190,"status":203,"phases":19999,"primaryCompletion":2212,"completion":2212,"start":3833,"enrollment":124,"conditions":20000,"interventions":20001},[87],[2755,15,21,5193],[2293,1254,1070,894,2424,5195,2195,2196,2374],{"nctId":4539,"briefTitle":4540,"status":130,"phases":20003,"primaryCompletion":4542,"completion":4542,"start":2969,"enrollment":817,"conditions":20004,"interventions":20005},[87],[15,21,2245],[1004,2369,2293,4545,2368],{"nctId":2285,"briefTitle":2286,"status":182,"phases":20007,"primaryCompletion":2288,"completion":2288,"start":2289,"enrollment":1231,"conditions":20008,"interventions":20009},[87],[2245],[2292,2293,62],{"nctId":3128,"briefTitle":3129,"status":130,"phases":20011,"primaryCompletion":3131,"completion":3131,"start":3132,"enrollment":95,"conditions":20012,"interventions":20013},[87],[1122,36,846,3134,644,737,1025,2653,30,727,3135,3136,3059,3060,2223,882],[803,1069,1005,2293,894,2196],{"nctId":4547,"briefTitle":4548,"status":130,"phases":20015,"primaryCompletion":3667,"completion":3667,"start":4550,"enrollment":4551,"conditions":20016,"interventions":20017},[87],[30,15],[1004,1070,894,803,2423,2293,2196,2195,2374],{"nctId":3159,"briefTitle":3160,"status":203,"phases":20019,"primaryCompletion":1174,"completion":1174,"start":3162,"enrollment":124,"conditions":20020,"interventions":20021},[87],[3164,3165,3166,3167,3168,3169,3170,3171,3172,3173,3174,3175,3176,3177,3178],[2424,1005,2194,2293,2195,2196,1254],{"nctId":4555,"briefTitle":4556,"status":130,"phases":20023,"primaryCompletion":3519,"completion":3519,"start":675,"enrollment":676,"conditions":20024,"interventions":20025},[87],[4559,4560,4561,3061,4562],[1004,2369,2293,1374,894,2405],{"trials":20027,"activeCount":1231,"soonestReadout":860},[20028,20032,20036,20040,20044,20048,20052,20056,20066,20070,20074,20078,20082,20086,20090,20094,20098,20102,20106,20110,20114,20122,20126,20130,20134,20138,20142,20146,20150,20154,20158,20162,20166,20170,20174,20178,20182,20186,20192,20196,20200,20204,20211,20215,20219,20223,20227],{"nctId":5519,"briefTitle":5520,"status":130,"phases":20029,"primaryCompletion":4382,"completion":4382,"start":5522,"enrollment":492,"conditions":20030,"interventions":20031},[88],[21,15],[5525,5526,5527,803,2424,1070,2293,894,806,2196],{"nctId":2361,"briefTitle":2362,"status":203,"phases":20033,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":124,"conditions":20034,"interventions":20035},[88],[21],[2368,2340,2369,1004,2293,894,62,2370,2371,2372,2373,2374],{"nctId":5529,"briefTitle":5530,"status":182,"phases":20037,"primaryCompletion":2836,"completion":2836,"start":4193,"enrollment":2159,"conditions":20038,"interventions":20039},[88],[21],[5527,2374,4629,5526,5534,5535,654,2424,2293,5536,1070,803],{"nctId":2397,"briefTitle":2398,"status":130,"phases":20041,"primaryCompletion":2400,"completion":2400,"start":2401,"enrollment":2402,"conditions":20042,"interventions":20043},[87,88],[33,21],[510,2405,2369,1004,2293,62,2371,2372,894],{"nctId":4592,"briefTitle":4593,"status":130,"phases":20045,"primaryCompletion":1518,"completion":1518,"start":4595,"enrollment":230,"conditions":20046,"interventions":20047},[88],[1205,643,4597,1122,2512,36,846,3292,712,4598,737,1866,4599,3040,30,3233,3041,3059,914,632,716,882],[3085,1004,2423,803,2712,1070,2293,2195,894,2196],{"nctId":4602,"briefTitle":4603,"status":130,"phases":20049,"primaryCompletion":4605,"completion":4605,"start":2968,"enrollment":3409,"conditions":20050,"interventions":20051},[88],[21],[2369,1004,2293,2368],{"nctId":9115,"briefTitle":9116,"status":182,"phases":20053,"primaryCompletion":2846,"completion":2846,"start":5232,"enrollment":834,"conditions":20054,"interventions":20055},[88],[15,21,2245,4580],[1070,2293,2439,2196,806,2374],{"nctId":20057,"briefTitle":20058,"status":130,"phases":20059,"primaryCompletion":20060,"completion":20060,"start":2580,"enrollment":517,"conditions":20061,"interventions":20062},"NCT01538472","Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma",[87,88],"2011-11",[21],[20063,20064,5247,5526,20065,2584,2293,2374],"Y Zevalin","In Zevalin","VP -16",{"nctId":5546,"briefTitle":5547,"status":130,"phases":20067,"primaryCompletion":5434,"completion":5434,"start":3902,"enrollment":5549,"conditions":20068,"interventions":20069},[88],[21],[4365,2424,654,2293,894],{"nctId":4631,"briefTitle":4632,"status":130,"phases":20071,"primaryCompletion":4634,"completion":4634,"start":4635,"enrollment":2946,"conditions":20072,"interventions":20073},[88],[3396,4637,2223,2224],[1004,4135,2293,2340],{"nctId":2479,"briefTitle":2480,"status":130,"phases":20075,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":1308,"conditions":20076,"interventions":20077},[88],[2245],[2368,62,2369,1004,2293,2374],{"nctId":4644,"briefTitle":4645,"status":130,"phases":20079,"primaryCompletion":4382,"completion":4382,"start":4647,"enrollment":663,"conditions":20080,"interventions":20081},[88],[1400,21],[1004,2293],{"nctId":6825,"briefTitle":6826,"status":182,"phases":20083,"primaryCompletion":6828,"completion":6828,"start":5557,"enrollment":517,"conditions":20084,"interventions":20085},[88],[6830],[1070,2293,803],{"nctId":8460,"briefTitle":8461,"status":182,"phases":20087,"primaryCompletion":8463,"completion":8463,"start":8464,"enrollment":1568,"conditions":20088,"interventions":20089},[88],[1122,2502,5597,21],[6545,2712,1070,2477,2293,894,2196],{"nctId":5562,"briefTitle":5563,"status":130,"phases":20091,"primaryCompletion":5565,"completion":5565,"start":5566,"enrollment":406,"conditions":20092,"interventions":20093},[88],[5568,21],[2450,4365,2424,654,2293,894],{"nctId":9173,"briefTitle":9174,"status":130,"phases":20095,"primaryCompletion":2932,"completion":2932,"start":9176,"enrollment":1766,"conditions":20096,"interventions":20097},[88],[18],[1070,2293],{"nctId":5591,"briefTitle":5592,"status":130,"phases":20099,"primaryCompletion":5594,"completion":5594,"start":5595,"enrollment":517,"conditions":20100,"interventions":20101},[88],[785,359,5597,21],[3085,75,4365,654,2424,1069,2293,806,894,2196],{"nctId":9184,"briefTitle":9185,"status":182,"phases":20103,"primaryCompletion":3668,"completion":3668,"start":6409,"enrollment":3197,"conditions":20104,"interventions":20105},[88],[18,1530],[1275,1070,2293,4537],{"nctId":2598,"briefTitle":2599,"status":203,"phases":20107,"primaryCompletion":2601,"start":2602,"enrollment":124,"conditions":20108,"interventions":20109},[88],[2245],[2227,2605,2369,1004,2293,2368,62,2370,2371,2372],{"nctId":8542,"briefTitle":8543,"status":130,"phases":20111,"primaryCompletion":2806,"completion":2806,"start":6790,"enrollment":901,"conditions":20112,"interventions":20113},[88],[1400],[2293,1070,894],{"nctId":20115,"briefTitle":20116,"status":130,"phases":20117,"primaryCompletion":8305,"completion":8305,"start":6828,"enrollment":1975,"conditions":20118,"interventions":20120},"NCT00651937","Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden",[88],[1400,20119],"Primary Amyloidosis",[2293,20121],"Granulocyte-colony stimulating factor",{"nctId":3285,"briefTitle":3286,"status":279,"phases":20123,"primaryCompletion":860,"completion":860,"start":3288,"enrollment":1222,"conditions":20124,"interventions":20125},[88],[1205,643,1122,2512,3290,3291,2471,3292,737,1025,3056,3057,3058,30,3233,3293,3244,648,608,3186,3059,3060,914,3294,651,882],[3296,3085,1004,2423,803,1005,2293,894],{"nctId":5600,"briefTitle":5601,"status":130,"phases":20127,"primaryCompletion":5603,"completion":5603,"start":5604,"enrollment":3354,"conditions":20128,"interventions":20129},[88],[5606],[2369,1710,2293,1369,1114,2495,2424],{"nctId":3309,"briefTitle":3310,"status":130,"phases":20131,"primaryCompletion":3312,"completion":3312,"start":3313,"enrollment":628,"conditions":20132,"interventions":20133},[88],[2460,36,30,3315],[803,1114,1069,2293,2462,2196,2757,3317],{"nctId":7054,"briefTitle":7055,"status":130,"phases":20135,"primaryCompletion":7057,"completion":7057,"start":7058,"enrollment":1034,"conditions":20136,"interventions":20137},[88],[2245],[1379,803,2293],{"nctId":5626,"briefTitle":5627,"status":130,"phases":20139,"primaryCompletion":5629,"completion":5629,"start":5630,"enrollment":492,"conditions":20140,"interventions":20141},[88],[891,4559,5632,5633,4561,5634,5635],[4365,5515,654,2424,1069,1402,2293,894],{"nctId":5237,"briefTitle":5238,"status":130,"phases":20143,"primaryCompletion":5240,"completion":5240,"start":5241,"enrollment":971,"conditions":20144,"interventions":20145},[88],[2530,5243,5244,5245],[5247,2293,1254,1070,803,1114],{"nctId":10244,"briefTitle":10245,"status":182,"phases":20147,"primaryCompletion":4843,"completion":4843,"start":4192,"enrollment":2018,"conditions":20148,"interventions":20149},[88],[1530],[1275,1369,1710,2369,2293],{"nctId":7110,"briefTitle":7111,"status":130,"phases":20151,"primaryCompletion":3152,"completion":3152,"start":7113,"enrollment":2700,"conditions":20152,"interventions":20153},[87,88],[1205,846,7115,644,647,30,608,649,682],[803,1070,2293,2195,3064,2196],{"nctId":9275,"briefTitle":9276,"status":182,"phases":20155,"primaryCompletion":9278,"completion":9278,"start":9279,"enrollment":1231,"conditions":20156,"interventions":20157},[87,88],[15,2245,4580],[1070,2293,2439,2196,9282,2374,7415,1014],{"nctId":5253,"briefTitle":5254,"status":130,"phases":20159,"primaryCompletion":5256,"completion":5256,"start":5257,"enrollment":5258,"conditions":20160,"interventions":20161},[88],[5260,15,4760],[803,1070,2293,1114,894,1254,2196,5262,2374],{"nctId":4790,"briefTitle":4791,"status":279,"phases":20163,"primaryCompletion":548,"completion":490,"start":4793,"enrollment":517,"conditions":20164,"interventions":20165},[88],[1400,4795,4796],[4798,1402,4622,2293,1004,2374],{"nctId":13661,"briefTitle":13662,"status":130,"phases":20167,"primaryCompletion":13664,"completion":13664,"start":13665,"enrollment":2647,"conditions":20168,"interventions":20169},[88],[3396,3135],[13551,1402,2293,3064,13668],{"nctId":13670,"briefTitle":13671,"status":130,"phases":20171,"primaryCompletion":10449,"completion":10449,"start":13673,"enrollment":2402,"conditions":20172,"interventions":20173},[87,88],[2245,2755],[1402,2293],{"nctId":5264,"briefTitle":5265,"status":130,"phases":20175,"primaryCompletion":5267,"completion":5267,"start":5268,"enrollment":1409,"conditions":20176,"interventions":20177},[88],[15,21],[2293,1254,1070,2758],{"nctId":4831,"briefTitle":4832,"status":203,"phases":20179,"primaryCompletion":4834,"start":4835,"enrollment":124,"conditions":20180,"interventions":20181},[87,88],[21],[1004,2370,2371,2372,2235,510,2369,2293],{"nctId":5694,"briefTitle":5695,"status":203,"phases":20183,"primaryCompletion":5697,"completion":5697,"start":5697,"enrollment":124,"conditions":20184,"interventions":20185},[87,88],[3039,891,4559,5632,3277,4561,5634],[4365,654,2424,1069,2293,894,5700],{"nctId":20187,"briefTitle":20188,"status":203,"phases":20189,"primaryCompletion":2527,"start":3494,"enrollment":124,"conditions":20190,"interventions":20191},"NCT00968396","Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts",[88],[1400],[2293],{"nctId":9366,"briefTitle":9367,"status":130,"phases":20193,"primaryCompletion":3902,"completion":6384,"start":9369,"enrollment":2997,"conditions":20194,"interventions":20195},[87,88],[4659,30,712],[9372,1070,2293,5195],{"nctId":9374,"briefTitle":9375,"status":130,"phases":20197,"primaryCompletion":3761,"completion":3761,"start":5663,"enrollment":901,"conditions":20198,"interventions":20199},[88],[9378],[2369,1070,2293,4668,2196,1069,806],{"nctId":3443,"briefTitle":3444,"status":182,"phases":20201,"primaryCompletion":3446,"completion":3446,"start":3447,"enrollment":166,"conditions":20202,"interventions":20203},[88],[3449,3450,3451,3452,2570,3453,3454,3455,3456,3457,3458,3459],[3420,2424,1005,2194,2293,2195,2196,1254],{"nctId":20205,"briefTitle":20206,"status":130,"phases":20207,"primaryCompletion":4183,"completion":4183,"start":8415,"enrollment":473,"conditions":20208,"interventions":20209},"NCT00661544","Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients",[87,88],[1400,2755],[16012,2293,20210],"Ascorbic Acid",{"nctId":8882,"briefTitle":8883,"status":130,"phases":20212,"primaryCompletion":4382,"completion":4382,"start":6384,"enrollment":2004,"conditions":20213,"interventions":20214},[88],[1400,15,21],[1070,2293,894],{"nctId":7385,"briefTitle":7386,"status":279,"phases":20216,"primaryCompletion":3943,"completion":3943,"start":7388,"enrollment":448,"conditions":20217,"interventions":20218},[87,88],[726],[6545,803,2712,1070,2293,2195,894,2196],{"nctId":9403,"briefTitle":9404,"status":130,"phases":20220,"primaryCompletion":4184,"completion":4184,"start":2580,"enrollment":1922,"conditions":20221,"interventions":20222},[88],[21,4871],[1070,2293,4537],{"nctId":2897,"briefTitle":2898,"status":182,"phases":20224,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":186,"conditions":20225,"interventions":20226},[87,88],[21],[1402,2405,2369,1004,2293,894,62,2370,2371,2372,2904,2368],{"nctId":20228,"briefTitle":20229,"status":130,"phases":20230,"primaryCompletion":4786,"completion":4786,"start":6352,"enrollment":1034,"conditions":20231,"interventions":20232},"NCT00469209","Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients",[87,88],[2245],[20233,12277,2293,20234],"Trisenox","Vitamin C",{"trials":20236,"activeCount":124},[20237,20241,20245],{"nctId":5729,"briefTitle":5730,"status":182,"phases":20238,"primaryCompletion":5732,"completion":5732,"start":5733,"enrollment":1231,"conditions":20239,"interventions":20240},[88,89],[5735],[1369,2424,2293],{"nctId":4874,"briefTitle":4875,"status":130,"phases":20242,"primaryCompletion":4877,"completion":4877,"start":4878,"enrollment":4879,"conditions":20243,"interventions":20244},[89],[2245],[1004,2293,2374,4882],{"nctId":4367,"briefTitle":4368,"status":130,"phases":20246,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":20247,"interventions":20248},[89],[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":20250,"activeCount":124},[],{"trials":20252,"activeCount":124},[20253],{"nctId":9447,"briefTitle":9448,"status":130,"phases":20254,"primaryCompletion":6409,"completion":6409,"start":9176,"enrollment":4171,"conditions":20255,"interventions":20256},[91],[9378],[1070,2293],{"intervention":1431,"totalTrials":910,"cells":20258},{"EARLY_PHASE1":20259,"PHASE1":20261,"PHASE2":20289,"PHASE3":20310,"PHASE4":20312,"NA":20314},{"trials":20260,"activeCount":124},[],{"trials":20262,"activeCount":166,"soonestReadout":490},[20263,20271,20275,20279,20285],{"nctId":20264,"briefTitle":20265,"status":130,"phases":20266,"primaryCompletion":2619,"completion":2619,"start":20267,"enrollment":20268,"conditions":20269,"interventions":20270},"NCT01339871","Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies",[87],"2011-04-20",152,[1942],[1431,2405],{"nctId":14042,"briefTitle":14043,"status":130,"phases":20272,"primaryCompletion":4272,"completion":4272,"start":14045,"enrollment":2933,"conditions":20273,"interventions":20274},[87],[33,1924],[1431,2840],{"nctId":1423,"briefTitle":1424,"status":546,"phases":20276,"primaryCompletion":490,"completion":1426,"start":1427,"enrollment":550,"conditions":20277,"interventions":20278},[87],[1429],[1431,531,1049,1050],{"nctId":20280,"briefTitle":20281,"status":130,"phases":20282,"primaryCompletion":10449,"completion":10449,"start":3668,"enrollment":357,"conditions":20283,"interventions":20284},"NCT01454804","Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors",[87],[33],[1431,7180,4227,1431],{"nctId":16695,"briefTitle":16696,"status":182,"phases":20286,"primaryCompletion":16698,"completion":16698,"start":2326,"enrollment":16699,"conditions":20287,"interventions":20288},[87],[33],[16702,1431,1377],{"trials":20290,"activeCount":166,"soonestReadout":10132},[20291,20299,20306],{"nctId":20292,"briefTitle":20293,"status":130,"phases":20294,"primaryCompletion":20295,"completion":20295,"start":20296,"enrollment":34,"conditions":20297,"interventions":20298},"NCT01392183","Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)",[88],"2019-09-08","2012-10-24",[1333],[1431,6656,2352],{"nctId":20300,"briefTitle":20301,"status":203,"phases":20302,"primaryCompletion":20303,"start":3761,"enrollment":124,"conditions":20304,"interventions":20305},"NCT02348398","Phase II Study of Pazopanib and Topotecan in Cervical Cancer",[88],"2019-08",[11077],[1431,1379],{"nctId":11150,"briefTitle":11151,"status":102,"phases":20307,"primaryCompletion":10132,"completion":10132,"start":11153,"enrollment":10752,"conditions":20308,"interventions":20309},[88],[1333],[1431,1275,2840],{"trials":20311,"activeCount":124},[],{"trials":20313,"activeCount":124},[],{"trials":20315,"activeCount":166,"soonestReadout":281},[20316],{"nctId":12224,"briefTitle":12225,"status":279,"phases":20317,"primaryCompletion":281,"completion":281,"start":6635,"enrollment":1131,"conditions":20318,"interventions":20319},[91],[12228,12229,12230],[1013,804,2840,12232,2495,4022,1431,12233,3497,6656,1016],{"intervention":2374,"totalTrials":1328,"cells":20321},{"EARLY_PHASE1":20322,"PHASE1":20324,"PHASE2":20361,"PHASE3":20470,"PHASE4":20476,"NA":20478},{"trials":20323,"activeCount":124},[],{"trials":20325,"activeCount":166,"soonestReadout":956},[20326,20330,20334,20338,20342,20346,20353,20357],{"nctId":4508,"briefTitle":4509,"status":130,"phases":20327,"primaryCompletion":2242,"completion":2242,"start":4511,"enrollment":959,"conditions":20328,"interventions":20329},[87],[21],[2405,2369,1004,2293,894,2374,2368,4514],{"nctId":4532,"briefTitle":4533,"status":130,"phases":20331,"primaryCompletion":206,"completion":206,"start":4039,"enrollment":1568,"conditions":20332,"interventions":20333},[87],[30,15],[4537,1004,1070,2374,2196,806,3499],{"nctId":5189,"briefTitle":5190,"status":203,"phases":20335,"primaryCompletion":2212,"completion":2212,"start":3833,"enrollment":124,"conditions":20336,"interventions":20337},[87],[2755,15,21,5193],[2293,1254,1070,894,2424,5195,2195,2196,2374],{"nctId":6509,"briefTitle":6510,"status":130,"phases":20339,"primaryCompletion":6512,"completion":6512,"start":6513,"enrollment":3197,"conditions":20340,"interventions":20341},[87],[15,21],[894,1070,803,2757,6516,2374],{"nctId":9025,"briefTitle":9026,"status":203,"phases":20343,"primaryCompletion":4016,"completion":4016,"start":4016,"enrollment":124,"conditions":20344,"interventions":20345},[87],[9029,9030,9031,9032,9033,9034],[1070,654,2374,9031,9032],{"nctId":20347,"briefTitle":20348,"status":279,"phases":20349,"primaryCompletion":956,"completion":956,"start":13130,"enrollment":296,"conditions":20350,"interventions":20352},"NCT06414889","Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder",[87],[20351],"RUNX1 Familial Platelet Disorder",[2374,4622],{"nctId":4547,"briefTitle":4548,"status":130,"phases":20354,"primaryCompletion":3667,"completion":3667,"start":4550,"enrollment":4551,"conditions":20355,"interventions":20356},[87],[30,15],[1004,1070,894,803,2423,2293,2196,2195,2374],{"nctId":18172,"briefTitle":18173,"status":130,"phases":20358,"primaryCompletion":18175,"completion":18175,"start":18176,"enrollment":1922,"conditions":20359,"interventions":20360},[87],[4659,15],[2374,4622,2207],{"trials":20362,"activeCount":166,"soonestReadout":548},[20363,20367,20371,20375,20379,20383,20387,20391,20395,20399,20403,20407,20411,20415,20419,20423,20427,20431,20435,20439,20443,20447,20454,20458,20462,20466],{"nctId":2361,"briefTitle":2362,"status":203,"phases":20364,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":124,"conditions":20365,"interventions":20366},[88],[21],[2368,2340,2369,1004,2293,894,62,2370,2371,2372,2373,2374],{"nctId":5529,"briefTitle":5530,"status":182,"phases":20368,"primaryCompletion":2836,"completion":2836,"start":4193,"enrollment":2159,"conditions":20369,"interventions":20370},[88],[21],[5527,2374,4629,5526,5534,5535,654,2424,2293,5536,1070,803],{"nctId":9115,"briefTitle":9116,"status":182,"phases":20372,"primaryCompletion":2846,"completion":2846,"start":5232,"enrollment":834,"conditions":20373,"interventions":20374},[88],[15,21,2245,4580],[1070,2293,2439,2196,806,2374],{"nctId":20057,"briefTitle":20058,"status":130,"phases":20376,"primaryCompletion":20060,"completion":20060,"start":2580,"enrollment":517,"conditions":20377,"interventions":20378},[87,88],[21],[20063,20064,5247,5526,20065,2584,2293,2374],{"nctId":6754,"briefTitle":6755,"status":130,"phases":20380,"primaryCompletion":6757,"completion":6757,"start":6758,"enrollment":861,"conditions":20381,"interventions":20382},[88],[1122],[803,1016,1013,4330,2374,806,2584,808],{"nctId":4624,"briefTitle":4625,"status":203,"phases":20384,"primaryCompletion":4619,"completion":4619,"start":4153,"enrollment":124,"conditions":20385,"interventions":20386},[88],[15],[1004,803,2374,4629],{"nctId":2479,"briefTitle":2480,"status":130,"phases":20388,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":1308,"conditions":20389,"interventions":20390},[88],[2245],[2368,62,2369,1004,2293,2374],{"nctId":19010,"briefTitle":19011,"status":130,"phases":20392,"primaryCompletion":5434,"completion":5434,"start":2944,"enrollment":1140,"conditions":20393,"interventions":20394},[88],[30,3134],[4537,3420,1014,2374],{"nctId":5553,"briefTitle":5554,"status":130,"phases":20396,"primaryCompletion":5556,"completion":5556,"start":5557,"enrollment":381,"conditions":20397,"interventions":20398},[88],[21],[2424,2374,4629,5560,894],{"nctId":2577,"briefTitle":2578,"status":130,"phases":20400,"primaryCompletion":1558,"completion":1558,"start":2580,"enrollment":2581,"conditions":20401,"interventions":20402},[88],[21],[803,1114,1016,806,2584,62,2374,2585],{"nctId":4678,"briefTitle":4679,"status":130,"phases":20404,"primaryCompletion":4681,"completion":4681,"start":4682,"enrollment":1034,"conditions":20405,"interventions":20406},[88],[2755,15,21],[1254,2423,1004,4537,2374,2196,806,803,1114],{"nctId":8616,"briefTitle":8617,"status":130,"phases":20408,"primaryCompletion":8619,"completion":8619,"start":2740,"enrollment":1131,"conditions":20409,"interventions":20410},[88],[15,21],[894,8622,8623,1070,6545,4537,2196,806,8624,2374],{"nctId":2674,"briefTitle":2675,"status":130,"phases":20412,"primaryCompletion":2677,"completion":2677,"start":2678,"enrollment":2004,"conditions":20413,"interventions":20414},[88],[15],[894,2681,803,1013,1114,2682,2683,806,2584,2374,1071,62],{"nctId":2695,"briefTitle":2696,"status":130,"phases":20416,"primaryCompletion":2698,"completion":2698,"start":2699,"enrollment":2700,"conditions":20417,"interventions":20418},[88],[15],[2321,803,1013,1016,62,806,654,1114,2374],{"nctId":11370,"briefTitle":11371,"status":130,"phases":20420,"primaryCompletion":5267,"completion":5267,"start":10346,"enrollment":1568,"conditions":20421,"interventions":20422},[88],[30],[11375,11376,2374,809],{"nctId":9275,"briefTitle":9276,"status":182,"phases":20424,"primaryCompletion":9278,"completion":9278,"start":9279,"enrollment":1231,"conditions":20425,"interventions":20426},[87,88],[15,2245,4580],[1070,2293,2439,2196,9282,2374,7415,1014],{"nctId":5253,"briefTitle":5254,"status":130,"phases":20428,"primaryCompletion":5256,"completion":5256,"start":5257,"enrollment":5258,"conditions":20429,"interventions":20430},[88],[5260,15,4760],[803,1070,2293,1114,894,1254,2196,5262,2374],{"nctId":4790,"briefTitle":4791,"status":279,"phases":20432,"primaryCompletion":548,"completion":490,"start":4793,"enrollment":517,"conditions":20433,"interventions":20434},[88],[1400,4795,4796],[4798,1402,4622,2293,1004,2374],{"nctId":5667,"briefTitle":5668,"status":130,"phases":20436,"primaryCompletion":5670,"completion":5670,"start":5671,"enrollment":676,"conditions":20437,"interventions":20438},[88],[21],[2425,2495,2424,1114,2374],{"nctId":4815,"briefTitle":4816,"status":130,"phases":20440,"primaryCompletion":4818,"completion":4818,"start":4819,"enrollment":4820,"conditions":20441,"interventions":20442},[88],[15,36,2838,3315,712,4580,4822,4823,1400,30],[4825,1004,2196,806,2374],{"nctId":7285,"briefTitle":7286,"status":130,"phases":20444,"primaryCompletion":6065,"completion":6065,"start":6410,"enrollment":492,"conditions":20445,"interventions":20446},[88],[891,21],[75,894,803,1114,2374],{"nctId":20448,"briefTitle":20449,"status":130,"phases":20450,"primaryCompletion":2828,"completion":11731,"start":9828,"enrollment":2018,"conditions":20451,"interventions":20452},"NCT00483067","2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)",[88],[15],[20453,2584,2374],"2-CdA",{"nctId":2833,"briefTitle":2834,"status":130,"phases":20455,"primaryCompletion":2232,"completion":2232,"start":2836,"enrollment":628,"conditions":20456,"interventions":20457},[87,88],[15,2838],[2840,803,1016,1013,62,1114,806,2584,2841,2374],{"nctId":4839,"briefTitle":4840,"status":130,"phases":20459,"primaryCompletion":4842,"completion":4842,"start":4843,"enrollment":230,"conditions":20460,"interventions":20461},[88],[15,4725],[1070,1004,3499,3085,2196,806,2374],{"nctId":2886,"briefTitle":2887,"status":130,"phases":20463,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":20464,"interventions":20465},[88],[15,1122],[894,803,1013,1016,62,806,654,2374,1114,2894,1071,2895],{"nctId":2906,"briefTitle":2907,"status":130,"phases":20467,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":20468,"interventions":20469},[88],[2913,2914],[894,803,1013,1016,62,2374,654,806],{"trials":20471,"activeCount":124},[20472],{"nctId":4874,"briefTitle":4875,"status":130,"phases":20473,"primaryCompletion":4877,"completion":4877,"start":4878,"enrollment":4879,"conditions":20474,"interventions":20475},[89],[2245],[1004,2293,2374,4882],{"trials":20477,"activeCount":124},[],{"trials":20479,"activeCount":124},[],{"intervention":2423,"totalTrials":1409,"cells":20481},{"EARLY_PHASE1":20482,"PHASE1":20484,"PHASE2":20515,"PHASE3":20624,"PHASE4":20630,"NA":20632},{"trials":20483,"activeCount":124},[],{"trials":20485,"activeCount":124},[20486,20490,20494,20504,20508],{"nctId":4516,"briefTitle":4517,"status":130,"phases":20487,"primaryCompletion":4519,"completion":4519,"start":4520,"enrollment":1922,"conditions":20488,"interventions":20489},[87],[4522,15,21,4523,4524],[2293,1070,2757,2196,894,4526,1004,2423],{"nctId":3077,"briefTitle":3078,"status":130,"phases":20491,"primaryCompletion":3080,"completion":3080,"start":3081,"enrollment":3082,"conditions":20492,"interventions":20493},[87],[2512,678,1411,30,648,913,608],[3085,1004,2423,1005,2405],{"nctId":20495,"briefTitle":20496,"status":130,"phases":20497,"completion":8415,"start":20498,"enrollment":1222,"conditions":20499,"interventions":20503},"NCT00028418","Clofarabine in Chronic Lymphocytic Leukemia",[87],"1999-02",[20500,20501,15,20502],"Hematologic Neoplasms","Lymphoproliferative Disorders","Leukemia, Lymphocytic, Chronic",[2423],{"nctId":4547,"briefTitle":4548,"status":130,"phases":20505,"primaryCompletion":3667,"completion":3667,"start":4550,"enrollment":4551,"conditions":20506,"interventions":20507},[87],[30,15],[1004,1070,894,803,2423,2293,2196,2195,2374],{"nctId":20509,"briefTitle":20510,"status":182,"phases":20511,"primaryCompletion":6628,"completion":4183,"start":20512,"enrollment":186,"conditions":20513,"interventions":20514},"NCT00081887","Study of Weekly Clofarabine for the Treatment of Relapsed\u002FRefractory Chronic Lymphocytic Leukemia",[87],"2004-05",[712,15],[2423],{"trials":20516,"activeCount":121,"soonestReadout":860},[20517,20521,20525,20529,20533,20539,20545,20552,20556,20560,20564,20568,20572,20576,20580,20584,20590,20594,20598,20602,20612,20616,20620],{"nctId":2407,"briefTitle":2408,"status":279,"phases":20518,"primaryCompletion":2410,"completion":2410,"start":2411,"enrollment":924,"conditions":20519,"interventions":20520},[88],[913,2413,2414,2415,2416,2417,914,2418,2419,2420,2421],[75,2423,803,62,2424,2425,1071,894,2426],{"nctId":4592,"briefTitle":4593,"status":130,"phases":20522,"primaryCompletion":1518,"completion":1518,"start":4595,"enrollment":230,"conditions":20523,"interventions":20524},[88],[1205,643,4597,1122,2512,36,846,3292,712,4598,737,1866,4599,3040,30,3233,3041,3059,914,632,716,882],[3085,1004,2423,803,2712,1070,2293,2195,894,2196],{"nctId":9550,"briefTitle":9551,"status":130,"phases":20526,"primaryCompletion":7770,"completion":7770,"start":9553,"enrollment":3541,"conditions":20527,"interventions":20528},[87,88],[15],[612,655,654,2423],{"nctId":4609,"briefTitle":4610,"status":130,"phases":20530,"primaryCompletion":3571,"completion":3571,"start":4612,"enrollment":2647,"conditions":20531,"interventions":20532},[88],[36,30,3315],[2423,1004,1070,4537,1069],{"nctId":20534,"briefTitle":20535,"status":130,"phases":20536,"primaryCompletion":3832,"completion":3832,"start":2828,"enrollment":3541,"conditions":20537,"interventions":20538},"NCT00299156","Oral Clofarabine Study in Patients With Myelodysplastic Syndrome",[88],[30,737],[2423],{"nctId":20540,"briefTitle":20541,"status":182,"phases":20542,"primaryCompletion":184,"completion":184,"start":3996,"enrollment":492,"conditions":20543,"interventions":20544},"NCT01160354","Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)",[87,88],[4659],[4622,2423],{"nctId":20546,"briefTitle":20547,"status":130,"phases":20548,"primaryCompletion":5988,"completion":5988,"start":12101,"enrollment":20549,"conditions":20550,"interventions":20551},"NCT00088218","Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).",[88],95,[36,30],[2423,2584],{"nctId":2534,"briefTitle":2535,"status":130,"phases":20553,"primaryCompletion":2537,"completion":2537,"start":1000,"enrollment":834,"conditions":20554,"interventions":20555},[88],[1047,643,2539,2540,848,2541,2542,851],[2423,654,62,655,894,2207,2544,1016,810],{"nctId":3285,"briefTitle":3286,"status":279,"phases":20557,"primaryCompletion":860,"completion":860,"start":3288,"enrollment":1222,"conditions":20558,"interventions":20559},[88],[1205,643,1122,2512,3290,3291,2471,3292,737,1025,3056,3057,3058,30,3233,3293,3244,648,608,3186,3059,3060,914,3294,651,882],[3296,3085,1004,2423,803,1005,2293,894],{"nctId":4678,"briefTitle":4679,"status":130,"phases":20561,"primaryCompletion":4681,"completion":4681,"start":4682,"enrollment":1034,"conditions":20562,"interventions":20563},[88],[2755,15,21],[1254,2423,1004,4537,2374,2196,806,803,1114],{"nctId":4702,"briefTitle":4703,"status":203,"phases":20565,"primaryCompletion":4705,"completion":4705,"start":4705,"enrollment":124,"conditions":20566,"interventions":20567},[88],[4707,3272,2415,4559,4708,4560,4709],[1004,2423,803,2369,2195,894,2196,2405],{"nctId":4712,"briefTitle":4713,"status":130,"phases":20569,"primaryCompletion":4715,"completion":4716,"start":4635,"enrollment":95,"conditions":20570,"interventions":20571},[88],[15],[1004,1070,2423,4537,2373,803,2196,2757,612,654,655],{"nctId":9246,"briefTitle":9247,"status":130,"phases":20573,"primaryCompletion":9249,"completion":9249,"start":9250,"enrollment":9251,"conditions":20574,"interventions":20575},[87,88],[15],[2423,655,654,1070],{"nctId":4737,"briefTitle":4738,"status":130,"phases":20577,"primaryCompletion":4740,"completion":4740,"start":4741,"enrollment":3354,"conditions":20578,"interventions":20579},[87,88],[4743,3277,3061,4562],[3085,1004,2423,4135,2195,894,2196],{"nctId":4746,"briefTitle":4747,"status":182,"phases":20581,"primaryCompletion":4749,"completion":4749,"start":4750,"enrollment":1568,"conditions":20582,"interventions":20583},[87,88],[1411,712,4752,715],[3085,1004,2423,1069,2369,806,2196],{"nctId":20585,"briefTitle":20586,"status":130,"phases":20587,"primaryCompletion":20060,"completion":20060,"start":10260,"enrollment":1034,"conditions":20588,"interventions":20589},"NCT00422032","2 Arm Study of Clofarabine IV in MDS Patients",[88],[30,15],[2423],{"nctId":7186,"briefTitle":7187,"status":130,"phases":20591,"primaryCompletion":2326,"completion":2326,"start":2828,"enrollment":240,"conditions":20592,"interventions":20593},[87,88],[2913,2653,1122],[2423,803],{"nctId":9735,"briefTitle":9736,"status":130,"phases":20595,"primaryCompletion":185,"completion":185,"start":5556,"enrollment":9738,"conditions":20596,"interventions":20597},[88],[36,30],[2423,654,612],{"nctId":4800,"briefTitle":4801,"status":130,"phases":20599,"primaryCompletion":3493,"completion":3493,"start":4723,"enrollment":1100,"conditions":20600,"interventions":20601},[88],[15,21,4804,1122],[1004,2423,4537],{"nctId":20603,"briefTitle":20604,"status":130,"phases":20605,"primaryCompletion":20606,"completion":20606,"start":20607,"enrollment":1034,"conditions":20608,"interventions":20610},"NCT00065143","Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome",[88],"2006-02-22","2003-06-23",[20609,1036],"Leukemia, Myeloid",[20611,2584],"clofarabine",{"nctId":12746,"briefTitle":12747,"status":130,"phases":20613,"primaryCompletion":4184,"completion":4184,"start":8340,"enrollment":924,"conditions":20614,"interventions":20615},[88],[30],[612,2423],{"nctId":9790,"briefTitle":9791,"status":130,"phases":20617,"primaryCompletion":3494,"completion":3494,"start":8340,"enrollment":3379,"conditions":20618,"interventions":20619},[88],[36],[2423,655,654],{"nctId":9796,"briefTitle":9797,"status":130,"phases":20621,"primaryCompletion":9799,"completion":9799,"start":9800,"enrollment":3409,"conditions":20622,"interventions":20623},[88],[15,4580],[2423,654],{"trials":20625,"activeCount":124},[20626],{"nctId":4864,"briefTitle":4865,"status":130,"phases":20627,"primaryCompletion":4867,"completion":4867,"start":4868,"enrollment":4869,"conditions":20628,"interventions":20629},[89],[4871,15,4523],[1070,2423,1004,4537,2196,806],{"trials":20631,"activeCount":124},[],{"trials":20633,"activeCount":124},[],{"intervention":1599,"totalTrials":3726,"cells":20635},{"EARLY_PHASE1":20636,"PHASE1":20638,"PHASE2":20663,"PHASE3":20689,"PHASE4":20695,"NA":20697},{"trials":20637,"activeCount":124},[],{"trials":20639,"activeCount":166,"soonestReadout":1939},[20640,20644,20648,20655,20659],{"nctId":6442,"briefTitle":6443,"status":130,"phases":20641,"primaryCompletion":6445,"completion":6445,"start":6446,"enrollment":1568,"conditions":20642,"interventions":20643},[87],[6448,6449,6450,6451],[1599,6453,803,6454],{"nctId":3505,"briefTitle":3506,"status":3049,"phases":20645,"primaryCompletion":3508,"completion":3509,"start":3510,"enrollment":1240,"conditions":20646,"interventions":20647},[87],[3512,1318],[1599,3514,803,1049],{"nctId":20649,"briefTitle":20650,"status":182,"phases":20651,"primaryCompletion":10287,"completion":10287,"start":20652,"enrollment":121,"conditions":20653,"interventions":20654},"NCT01630564","Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies",[87],"2013-03-11",[359],[1599,13668],{"nctId":6554,"briefTitle":6555,"status":182,"phases":20656,"primaryCompletion":6557,"completion":6557,"start":6558,"enrollment":166,"conditions":20657,"interventions":20658},[87],[5028,6560,1898,6561,6562,6563,6564,5008,5039,5040,6565,5009,5010],[6567,1599,803,53],{"nctId":3139,"briefTitle":3140,"status":102,"phases":20660,"primaryCompletion":1939,"completion":1939,"start":3142,"enrollment":1240,"conditions":20661,"interventions":20662},[87],[1316,1961,1962,1544,1546,1549],[1599,803,1005,3145,3146],{"trials":20664,"activeCount":166,"soonestReadout":815},[20665,20669,20673,20677,20681,20685],{"nctId":3201,"briefTitle":3202,"status":130,"phases":20666,"primaryCompletion":3204,"completion":3204,"start":3205,"enrollment":1496,"conditions":20667,"interventions":20668},[87,88],[1316,1961,1549],[1599,3208,803,1005,3145],{"nctId":3618,"briefTitle":3619,"status":130,"phases":20670,"primaryCompletion":3621,"completion":3621,"start":3622,"enrollment":834,"conditions":20671,"interventions":20672},[88],[1316,1549],[1599,3625,803,1049],{"nctId":1580,"briefTitle":1581,"status":102,"phases":20674,"primaryCompletion":815,"completion":815,"start":1583,"enrollment":406,"conditions":20675,"interventions":20676},[88],[1585,1586,1587,1588,360,1589,1454,1590,1591,1460,1592,1593,1594,1595,1596,1597],[1599,1600,1601,803,1070,1049,1050],{"nctId":3319,"briefTitle":3320,"status":130,"phases":20678,"primaryCompletion":3322,"completion":3322,"start":3323,"enrollment":550,"conditions":20679,"interventions":20680},[88],[1316,1544,1546,1549],[1599,803,1005,53,3326],{"nctId":3374,"briefTitle":3375,"status":130,"phases":20682,"primaryCompletion":3377,"completion":3377,"start":3378,"enrollment":3379,"conditions":20683,"interventions":20684},[87,88],[1205,3381,3382,36,846,678,644,3383,3384,737,1067,30,649,682,882],[1599,3386,1004,1005],{"nctId":7360,"briefTitle":7361,"status":130,"phases":20686,"primaryCompletion":7363,"completion":7363,"start":7364,"enrollment":3197,"conditions":20687,"interventions":20688},[87,88],[7366,6448,7367,1460],[1599,7369,803,7370],{"trials":20690,"activeCount":124},[20691],{"nctId":4347,"briefTitle":4348,"status":130,"phases":20692,"primaryCompletion":4350,"completion":4351,"start":4352,"enrollment":342,"conditions":20693,"interventions":20694},[89],[1729,4354],[1599,4109,1709,1869,1868],{"trials":20696,"activeCount":124},[],{"trials":20698,"activeCount":124},[],{"intervention":1868,"totalTrials":910,"cells":20700},{"EARLY_PHASE1":20701,"PHASE1":20703,"PHASE2":20705,"PHASE3":20727,"PHASE4":20750,"NA":20752},{"trials":20702,"activeCount":124},[],{"trials":20704,"activeCount":124},[],{"trials":20706,"activeCount":121,"soonestReadout":1427},[20707,20711,20715,20719,20723],{"nctId":8320,"briefTitle":8321,"status":130,"phases":20708,"primaryCompletion":8323,"completion":8323,"start":8324,"enrollment":8325,"conditions":20709,"interventions":20710},[88],[8327,8328,8329],[4331,1869,804,894,1868],{"nctId":3962,"briefTitle":3963,"status":102,"phases":20712,"primaryCompletion":1427,"completion":1427,"start":3965,"enrollment":3726,"conditions":20713,"interventions":20714},[88],[3967,1293],[1786,806,1868,804,1709],{"nctId":1860,"briefTitle":1861,"status":546,"phases":20716,"primaryCompletion":571,"completion":1863,"start":1864,"enrollment":1568,"conditions":20717,"interventions":20718},[88],[1866],[1050,804,1868,1869],{"nctId":8750,"briefTitle":8751,"status":130,"phases":20720,"primaryCompletion":8753,"completion":8753,"start":2699,"enrollment":226,"conditions":20721,"interventions":20722},[88],[21],[894,2977,4331,1868,1869],{"nctId":5687,"briefTitle":5688,"status":130,"phases":20724,"primaryCompletion":2890,"completion":2890,"start":5690,"enrollment":1308,"conditions":20725,"interventions":20726},[88],[27],[804,2958,2424,2959,1376,1868],{"trials":20728,"activeCount":124},[20729,20738,20742,20746],{"nctId":20730,"briefTitle":20731,"status":130,"phases":20732,"primaryCompletion":2847,"completion":3902,"start":20733,"enrollment":448,"conditions":20734,"interventions":20736},"NCT00038558","Prophylactic Use of Filgrastim SD\u002F01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy",[89],"2001-11",[20735],"Hodgkin Disease",[11877,2977,4331,1868,20737],"DTIC",{"nctId":12206,"briefTitle":12207,"status":130,"phases":20739,"primaryCompletion":4887,"completion":4887,"start":12209,"enrollment":12210,"conditions":20740,"interventions":20741},[89],[27],[11341,2957,12213,11342,2959,11344,12214,1868],{"nctId":4347,"briefTitle":4348,"status":130,"phases":20743,"primaryCompletion":4350,"completion":4351,"start":4352,"enrollment":342,"conditions":20744,"interventions":20745},[89],[1729,4354],[1599,4109,1709,1869,1868],{"nctId":2950,"briefTitle":2951,"status":182,"phases":20747,"primaryCompletion":2602,"start":2953,"enrollment":2954,"conditions":20748,"interventions":20749},[89],[27],[1710,2957,2958,2959,809,1868,62],{"trials":20751,"activeCount":124},[],{"trials":20753,"activeCount":124},[],{"intervention":1869,"totalTrials":1483,"cells":20755},{"EARLY_PHASE1":20756,"PHASE1":20758,"PHASE2":20764,"PHASE3":20790,"PHASE4":20796,"NA":20798},{"trials":20757,"activeCount":124},[],{"trials":20759,"activeCount":124},[20760],{"nctId":13435,"briefTitle":13436,"status":130,"phases":20761,"primaryCompletion":6828,"completion":6828,"start":2213,"enrollment":3521,"conditions":20762,"interventions":20763},[87],[1729],[1402,1869],{"trials":20765,"activeCount":121,"soonestReadout":1939},[20766,20770,20774,20778,20786],{"nctId":8320,"briefTitle":8321,"status":130,"phases":20767,"primaryCompletion":8323,"completion":8323,"start":8324,"enrollment":8325,"conditions":20768,"interventions":20769},[88],[8327,8328,8329],[4331,1869,804,894,1868],{"nctId":7841,"briefTitle":7842,"status":102,"phases":20771,"primaryCompletion":1939,"completion":1939,"start":7844,"enrollment":448,"conditions":20772,"interventions":20773},[88],[1866],[7847,804,53,1869],{"nctId":1860,"briefTitle":1861,"status":546,"phases":20775,"primaryCompletion":571,"completion":1863,"start":1864,"enrollment":1568,"conditions":20776,"interventions":20777},[88],[1866],[1050,804,1868,1869],{"nctId":20779,"briefTitle":20780,"status":130,"phases":20781,"primaryCompletion":7399,"completion":7399,"start":20782,"enrollment":1328,"conditions":20783,"interventions":20784},"NCT01404936","Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease",[88],"1996-07",[21],[20785,2977,4331,4156,1869],"Interferon-2A",{"nctId":8750,"briefTitle":8751,"status":130,"phases":20787,"primaryCompletion":8753,"completion":8753,"start":2699,"enrollment":226,"conditions":20788,"interventions":20789},[88],[21],[894,2977,4331,1868,1869],{"trials":20791,"activeCount":124},[20792],{"nctId":4347,"briefTitle":4348,"status":130,"phases":20793,"primaryCompletion":4350,"completion":4351,"start":4352,"enrollment":342,"conditions":20794,"interventions":20795},[89],[1729,4354],[1599,4109,1709,1869,1868],{"trials":20797,"activeCount":124},[],{"trials":20799,"activeCount":124},[],{"intervention":2425,"totalTrials":95,"cells":20801},{"EARLY_PHASE1":20802,"PHASE1":20804,"PHASE2":20806,"PHASE3":20863,"PHASE4":20865,"NA":20867},{"trials":20803,"activeCount":124},[],{"trials":20805,"activeCount":124},[],{"trials":20807,"activeCount":121,"soonestReadout":2104},[20808,20812,20816,20820,20828,20832,20836,20840,20844,20851,20859],{"nctId":2407,"briefTitle":2408,"status":279,"phases":20809,"primaryCompletion":2410,"completion":2410,"start":2411,"enrollment":924,"conditions":20810,"interventions":20811},[88],[913,2413,2414,2415,2416,2417,914,2418,2419,2420,2421],[75,2423,803,62,2424,2425,1071,894,2426],{"nctId":2497,"briefTitle":2498,"status":279,"phases":20813,"primaryCompletion":2104,"completion":2104,"start":2500,"enrollment":1975,"conditions":20814,"interventions":20815},[88],[2502,2503],[1083,803,654,62,804,2477,805,806,2425,809,894,810],{"nctId":2506,"briefTitle":2507,"status":182,"phases":20817,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":296,"conditions":20818,"interventions":20819},[88],[2512,2502,2472],[803,654,62,804,2477,1373,805,806,2425,809,894,810],{"nctId":20821,"briefTitle":20822,"status":182,"phases":20823,"primaryCompletion":20824,"completion":20824,"start":20825,"enrollment":296,"conditions":20826,"interventions":20827},"NCT01258933","Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy",[88],"2024-10-18","2011-07-06",[15,21],[2425],{"nctId":5580,"briefTitle":5581,"status":130,"phases":20829,"primaryCompletion":5583,"completion":5583,"start":5584,"enrollment":2779,"conditions":20830,"interventions":20831},[88],[5586,5587,3056,5588,913,2415,914,2419],[803,804,2424,2425,809,894,810],{"nctId":13557,"briefTitle":13558,"status":130,"phases":20833,"primaryCompletion":3018,"completion":3018,"start":13560,"enrollment":593,"conditions":20834,"interventions":20835},[88],[712,2923,13507,13562,10176,13563,13508,13564,716,13565],[1402,2425],{"nctId":2642,"briefTitle":2643,"status":130,"phases":20837,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":2647,"conditions":20838,"interventions":20839},[88],[1122,2649,2650,2651,785,2652,2653],[803,654,62,804,806,2425,810],{"nctId":7014,"briefTitle":7015,"status":182,"phases":20841,"primaryCompletion":1984,"completion":1984,"start":7017,"enrollment":166,"conditions":20842,"interventions":20843},[88],[15,7019,2653,21],[654,7021,1016,809,7022,2425,894,806,803,805,1013,4514,7023],{"nctId":20845,"briefTitle":20846,"status":130,"phases":20847,"primaryCompletion":20848,"completion":20848,"start":8386,"enrollment":1559,"conditions":20849,"interventions":20850},"NCT01243190","Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)\u002FSmall Lymphocytic Lymphoma (SLL)",[88],"2023-03-28",[712],[2425],{"nctId":20852,"briefTitle":20853,"status":130,"phases":20854,"primaryCompletion":20855,"completion":20855,"start":20856,"enrollment":1240,"conditions":20857,"interventions":20858},"NCT01444716","Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia",[88],"2020-06-11","2011-12-15",[712],[2425],{"nctId":5667,"briefTitle":5668,"status":130,"phases":20860,"primaryCompletion":5670,"completion":5670,"start":5671,"enrollment":676,"conditions":20861,"interventions":20862},[88],[21],[2425,2495,2424,1114,2374],{"trials":20864,"activeCount":124},[],{"trials":20866,"activeCount":124},[],{"trials":20868,"activeCount":124},[],{"intervention":4135,"totalTrials":95,"cells":20870},{"EARLY_PHASE1":20871,"PHASE1":20873,"PHASE2":20879,"PHASE3":20929,"PHASE4":20931,"NA":20933},{"trials":20872,"activeCount":124},[],{"trials":20874,"activeCount":124},[20875],{"nctId":7591,"briefTitle":7592,"status":130,"phases":20876,"primaryCompletion":7594,"completion":7594,"start":7595,"enrollment":910,"conditions":20877,"interventions":20878},[87],[7597,7598,7599,7600,7601,7602,7603],[4135,4023,7605,53],{"trials":20880,"activeCount":121,"soonestReadout":2608},[20881,20885,20895,20899,20903,20907,20911,20915,20921,20925],{"nctId":4631,"briefTitle":4632,"status":130,"phases":20882,"primaryCompletion":4634,"completion":4634,"start":4635,"enrollment":2946,"conditions":20883,"interventions":20884},[88],[3396,4637,2223,2224],[1004,4135,2293,2340],{"nctId":20886,"briefTitle":20887,"status":130,"phases":20888,"primaryCompletion":20889,"completion":20889,"start":20890,"enrollment":20891,"conditions":20892,"interventions":20893},"NCT00005991","Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer",[88],"2003-02-14","1997-08-25",76,[18],[4046,20894],"pegylated liposomal doxorubicin hydrochloride",{"nctId":12108,"briefTitle":12109,"status":102,"phases":20896,"primaryCompletion":193,"completion":193,"start":12111,"enrollment":406,"conditions":20897,"interventions":20898},[88],[7942,1346,12113,1356,1360],[1013,804,2369,4135,2283,8569],{"nctId":4036,"briefTitle":4037,"status":130,"phases":20900,"primaryCompletion":4039,"completion":4039,"start":4040,"enrollment":3541,"conditions":20901,"interventions":20902},[88],[1293,4042,4043],[2878,4045,2882,4046,4047],{"nctId":4119,"briefTitle":4120,"status":130,"phases":20904,"primaryCompletion":4122,"completion":4122,"start":4123,"enrollment":2933,"conditions":20905,"interventions":20906},[88],[4125,4126,4127,4128,4129,4130,4131,4132,4133],[1709,4135,4023],{"nctId":12156,"briefTitle":12157,"status":102,"phases":20908,"primaryCompletion":2608,"completion":2608,"start":12159,"enrollment":6385,"conditions":20909,"interventions":20910},[87,88],[1803,12161,12162],[804,4135,8569],{"nctId":4737,"briefTitle":4738,"status":130,"phases":20912,"primaryCompletion":4740,"completion":4740,"start":4741,"enrollment":3354,"conditions":20913,"interventions":20914},[87,88],[4743,3277,3061,4562],[3085,1004,2423,4135,2195,894,2196],{"nctId":20916,"briefTitle":20917,"status":130,"phases":20918,"primaryCompletion":5663,"completion":5663,"start":3214,"enrollment":3521,"conditions":20919,"interventions":20920},"NCT00068432","Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer",[88],[4107],[3808,4135],{"nctId":4220,"briefTitle":4221,"status":130,"phases":20922,"primaryCompletion":4223,"completion":4223,"start":4224,"enrollment":492,"conditions":20923,"interventions":20924},[88],[24],[4227,1709,4135],{"nctId":12014,"briefTitle":12015,"status":130,"phases":20926,"primaryCompletion":4184,"completion":4184,"start":9923,"enrollment":517,"conditions":20927,"interventions":20928},[88],[12018,12019,12020,12021,12022,12023,12024,12025,12026,12027,12028],[12030,1376,2957,1071],{"trials":20930,"activeCount":124},[],{"trials":20932,"activeCount":124},[],{"trials":20934,"activeCount":124},[],{"intervention":6516,"totalTrials":910,"cells":20936},{"EARLY_PHASE1":20937,"PHASE1":20939,"PHASE2":20976,"PHASE3":20993,"PHASE4":20995,"NA":20997},{"trials":20938,"activeCount":124},[],{"trials":20940,"activeCount":166,"soonestReadout":14037},[20941,20945,20952,20960,20964,20968,20972],{"nctId":11268,"briefTitle":11269,"status":130,"phases":20942,"primaryCompletion":6974,"completion":6974,"start":8340,"enrollment":11271,"conditions":20943,"interventions":20944},[87],[1942],[1710,6516,809],{"nctId":20946,"briefTitle":20947,"status":130,"phases":20948,"primaryCompletion":2242,"completion":2242,"start":13673,"enrollment":20949,"conditions":20950,"interventions":20951},"NCT01087983","Lapatinib With Sirolimus or Metformin",[87],111,[33],[7180,6516,14121],{"nctId":20953,"briefTitle":20954,"status":130,"phases":20955,"primaryCompletion":20956,"completion":20956,"start":20957,"enrollment":3584,"conditions":20958,"interventions":20959},"NCT01266057","Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer",[87],"2021-02-11","2011-04-28",[33],[12420,6516,2405],{"nctId":6509,"briefTitle":6510,"status":130,"phases":20961,"primaryCompletion":6512,"completion":6512,"start":6513,"enrollment":3197,"conditions":20962,"interventions":20963},[87],[15,21],[894,1070,803,2757,6516,2374],{"nctId":14034,"briefTitle":14035,"status":102,"phases":20965,"primaryCompletion":14037,"completion":14037,"start":13673,"enrollment":14038,"conditions":20966,"interventions":20967},[87],[1942],[6516,2405,2840,6656],{"nctId":12864,"briefTitle":12865,"status":130,"phases":20969,"primaryCompletion":2777,"completion":2777,"start":3987,"enrollment":12867,"conditions":20970,"interventions":20971},[87],[1942],[6516,1683],{"nctId":6625,"briefTitle":6626,"status":182,"phases":20973,"primaryCompletion":2836,"completion":2836,"start":6628,"enrollment":296,"conditions":20974,"interventions":20975},[87],[15,21,2245],[894,803,1070,1114,6516],{"trials":20977,"activeCount":166,"soonestReadout":20982},[20978,20989],{"nctId":20979,"briefTitle":20980,"status":279,"phases":20981,"primaryCompletion":20982,"completion":20983,"start":20984,"enrollment":230,"conditions":20985,"interventions":20988},"NCT06261060","Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder",[88],"2026-06-11","2028-06-11","2024-06-20",[20986,20987],"Familial Platelet Disorder","Hematopoietic",[6516],{"nctId":16346,"briefTitle":16347,"status":182,"phases":20990,"primaryCompletion":2768,"completion":2768,"start":4612,"enrollment":2018,"conditions":20991,"interventions":20992},[88],[7246,30,15,21],[2195,4537,6516],{"trials":20994,"activeCount":124},[],{"trials":20996,"activeCount":124},[],{"trials":20998,"activeCount":124},[],{"intervention":2712,"totalTrials":186,"cells":21000},{"EARLY_PHASE1":21001,"PHASE1":21003,"PHASE2":21009,"PHASE3":21044,"PHASE4":21046,"NA":21048},{"trials":21002,"activeCount":124},[],{"trials":21004,"activeCount":124},[21005],{"nctId":3181,"briefTitle":3182,"status":130,"phases":21006,"primaryCompletion":3184,"completion":3184,"start":640,"enrollment":406,"conditions":21007,"interventions":21008},[87],[3186,610],[654,1069,2712,1005,3188],{"trials":21010,"activeCount":121,"soonestReadout":3943},[21011,21015,21019,21023,21027,21036,21040],{"nctId":4592,"briefTitle":4593,"status":130,"phases":21012,"primaryCompletion":1518,"completion":1518,"start":4595,"enrollment":230,"conditions":21013,"interventions":21014},[88],[1205,643,4597,1122,2512,36,846,3292,712,4598,737,1866,4599,3040,30,3233,3041,3059,914,632,716,882],[3085,1004,2423,803,2712,1070,2293,2195,894,2196],{"nctId":3222,"briefTitle":3223,"status":279,"phases":21016,"primaryCompletion":3225,"completion":3225,"start":3226,"enrollment":3227,"conditions":21017,"interventions":21018},[88],[3229,3230,3231,647,1067,3232,3233,3234,3235,652],[654,612,2712,1005,694,655],{"nctId":8460,"briefTitle":8461,"status":182,"phases":21020,"primaryCompletion":8463,"completion":8463,"start":8464,"enrollment":1568,"conditions":21021,"interventions":21022},[88],[1122,2502,5597,21],[6545,2712,1070,2477,2293,894,2196],{"nctId":2704,"briefTitle":2705,"status":182,"phases":21024,"primaryCompletion":2707,"completion":2707,"start":2708,"enrollment":871,"conditions":21025,"interventions":21026},[87,88],[2710,2223,2224],[62,2712,2292],{"nctId":21028,"briefTitle":21029,"status":130,"phases":21030,"primaryCompletion":21031,"completion":21031,"start":21032,"enrollment":2933,"conditions":21033,"interventions":21034},"NCT03417284","Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation",[87,88],"2024-07-18","2019-10-09",[3135],[2712,21035],"Melphalan Hydrochloride",{"nctId":2852,"briefTitle":2853,"status":182,"phases":21037,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":296,"conditions":21038,"interventions":21039},[87,88],[2413,1142,1143,1144,2421,1145],[803,654,62,2712,1113,805,1114,806,1071,809,894,1015,1016],{"nctId":7385,"briefTitle":7386,"status":279,"phases":21041,"primaryCompletion":3943,"completion":3943,"start":7388,"enrollment":448,"conditions":21042,"interventions":21043},[87,88],[726],[6545,803,2712,1070,2293,2195,894,2196],{"trials":21045,"activeCount":124},[],{"trials":21047,"activeCount":124},[],{"trials":21049,"activeCount":124},[],{"intervention":9970,"totalTrials":1483,"cells":21051},{"EARLY_PHASE1":21052,"PHASE1":21054,"PHASE2":21084,"PHASE3":21098,"PHASE4":21100,"NA":21102},{"trials":21053,"activeCount":124},[],{"trials":21055,"activeCount":124},[21056,21060,21068,21072,21076],{"nctId":12807,"briefTitle":12808,"status":130,"phases":21057,"primaryCompletion":12810,"completion":12810,"start":12811,"enrollment":2997,"conditions":21058,"interventions":21059},[87],[12813,12814,361,5008,5009,5010,1951],[1683,1372,9970],{"nctId":21061,"briefTitle":21062,"status":130,"phases":21063,"primaryCompletion":21064,"completion":21064,"start":12734,"enrollment":230,"conditions":21065,"interventions":21066},"NCT01603212","Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor",[87],"2017-07-05",[1729],[9970,5447,21067],"Interferon Alpha-2b",{"nctId":14026,"briefTitle":14027,"status":130,"phases":21069,"primaryCompletion":14029,"completion":14029,"start":14030,"enrollment":2159,"conditions":21070,"interventions":21071},[87],[1942,3305],[9970,2840,6656],{"nctId":9963,"briefTitle":9964,"status":130,"phases":21073,"primaryCompletion":9966,"completion":9966,"start":9967,"enrollment":871,"conditions":21074,"interventions":21075},[87],[33],[9970,1369,1376],{"nctId":21077,"briefTitle":21078,"status":130,"phases":21079,"primaryCompletion":1567,"completion":1567,"start":21080,"enrollment":4171,"conditions":21081,"interventions":21083},"NCT01531361","Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations",[87],"2012-02-06",[2922,21082,2924,2925,2926],"BRAF Gene Mutation",[16702,2544,9970],{"trials":21085,"activeCount":121,"soonestReadout":5310},[21086,21090],{"nctId":11046,"briefTitle":11047,"status":102,"phases":21087,"primaryCompletion":3943,"completion":3943,"start":10324,"enrollment":676,"conditions":21088,"interventions":21089},[88],[8186,1590,11050,8187,8188,1594,8189],[718,1275,11035,4023,1376,9970],{"nctId":21091,"briefTitle":21092,"status":102,"phases":21093,"primaryCompletion":5310,"completion":5310,"start":21094,"enrollment":628,"conditions":21095,"interventions":21096},"NCT01709292","Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer",[88],"2012-11-07",[17318],[9970,21097],"Vemurafenib (Post Surgery) - Group A + C",{"trials":21099,"activeCount":124},[],{"trials":21101,"activeCount":124},[],{"trials":21103,"activeCount":124},[],{"intervention":12862,"totalTrials":1483,"cells":21105},{"EARLY_PHASE1":21106,"PHASE1":21108,"PHASE2":21114,"PHASE3":21168,"PHASE4":21170,"NA":21172},{"trials":21107,"activeCount":124},[],{"trials":21109,"activeCount":124},[21110],{"nctId":12855,"briefTitle":12856,"status":130,"phases":21111,"primaryCompletion":12858,"completion":12858,"start":12859,"enrollment":2865,"conditions":21112,"interventions":21113},[87],[33],[12862,1683],{"trials":21115,"activeCount":121,"soonestReadout":1427},[21116,21124,21134,21142,21152,21160],{"nctId":21117,"briefTitle":21118,"status":102,"phases":21119,"primaryCompletion":1427,"completion":1427,"start":21120,"enrollment":1222,"conditions":21121,"interventions":21122},"NCT03844620","Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer",[88],"2019-01-29",[6905,1672,1673,1674,1675,1676,1677,1678,1679],[12862,21123],"Trifluridine and Tipiracil Hydrochloride",{"nctId":21125,"briefTitle":21126,"status":102,"phases":21127,"primaryCompletion":21128,"completion":21129,"start":21130,"enrollment":1231,"conditions":21131,"interventions":21133},"NCT06087263","Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.",[88],"2032-07-01","2034-07-01","2024-06-18",[21132],"Gastrointestinal Stromal Tumors",[12862],{"nctId":21135,"briefTitle":21136,"status":203,"phases":21137,"primaryCompletion":21138,"completion":21138,"start":2669,"enrollment":124,"conditions":21139,"interventions":21140},"NCT07137390","A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR\u002FMSS, Resectable, Lung-limited Metastatic Colorectal Cancer",[87,88],"2026-01-22",[3195],[12862,21141],"Lorigerlimab",{"nctId":21143,"briefTitle":21144,"status":203,"phases":21145,"primaryCompletion":21146,"completion":21146,"start":21147,"enrollment":124,"conditions":21148,"interventions":21150},"NCT05900648","Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)",[88],"2024-02-09","2023-05-17",[3195,3154,21149],"Rectum Cancer",[12862,21151],"XmAb20717",{"nctId":21153,"briefTitle":21154,"status":203,"phases":21155,"primaryCompletion":21138,"completion":21138,"start":21156,"enrollment":124,"conditions":21157,"interventions":21159},"NCT07223567","A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR\u002FMSS Localized Rectal Cancer",[88],"2025-10-27",[10947,21158],"Rectal Cancer Recurrent",[12862,21141],{"nctId":21161,"briefTitle":21162,"status":1479,"phases":21163,"primaryCompletion":4005,"completion":4006,"start":21164,"enrollment":834,"conditions":21165,"interventions":21167},"NCT07071961","Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]",[88],"2026-02-11",[3195,12862,21166],"High Risk Patients",[12862,21141],{"trials":21169,"activeCount":124},[],{"trials":21171,"activeCount":124},[],{"trials":21173,"activeCount":124},[],{"intervention":4622,"totalTrials":230,"cells":21175},{"EARLY_PHASE1":21176,"PHASE1":21178,"PHASE2":21188,"PHASE3":21206,"PHASE4":21208,"NA":21210},{"trials":21177,"activeCount":124},[],{"trials":21179,"activeCount":166,"soonestReadout":956},[21180,21184],{"nctId":20347,"briefTitle":20348,"status":279,"phases":21181,"primaryCompletion":956,"completion":956,"start":13130,"enrollment":296,"conditions":21182,"interventions":21183},[87],[20351],[2374,4622],{"nctId":18172,"briefTitle":18173,"status":130,"phases":21185,"primaryCompletion":18175,"completion":18175,"start":18176,"enrollment":1922,"conditions":21186,"interventions":21187},[87],[4659,15],[2374,4622,2207],{"trials":21189,"activeCount":166,"soonestReadout":548},[21190,21194,21198,21202],{"nctId":4616,"briefTitle":4617,"status":130,"phases":21191,"primaryCompletion":3805,"completion":3805,"start":4619,"enrollment":2997,"conditions":21192,"interventions":21193},[87,88],[2755,15],[4622,1069,1070,1004,4526],{"nctId":20540,"briefTitle":20541,"status":182,"phases":21195,"primaryCompletion":184,"completion":184,"start":3996,"enrollment":492,"conditions":21196,"interventions":21197},[87,88],[4659],[4622,2423],{"nctId":17427,"briefTitle":17428,"status":130,"phases":21199,"primaryCompletion":4835,"completion":4835,"start":7177,"enrollment":492,"conditions":21200,"interventions":21201},[88],[4522],[1069,4622],{"nctId":4790,"briefTitle":4791,"status":279,"phases":21203,"primaryCompletion":548,"completion":490,"start":4793,"enrollment":517,"conditions":21204,"interventions":21205},[88],[1400,4795,4796],[4798,1402,4622,2293,1004,2374],{"trials":21207,"activeCount":124},[],{"trials":21209,"activeCount":124},[],{"trials":21211,"activeCount":124},[],{"intervention":7589,"totalTrials":230,"cells":21213},{"EARLY_PHASE1":21214,"PHASE1":21216,"PHASE2":21231,"PHASE3":21249,"PHASE4":21251,"NA":21253},{"trials":21215,"activeCount":124},[],{"trials":21217,"activeCount":166,"soonestReadout":1151},[21218,21222],{"nctId":7581,"briefTitle":7582,"status":279,"phases":21219,"primaryCompletion":1151,"completion":1152,"start":7584,"enrollment":4299,"conditions":21220,"interventions":21221},[87],[3305],[7587,1375,1113,7588,1275,53,7589],{"nctId":21223,"briefTitle":21224,"status":130,"phases":21225,"primaryCompletion":21226,"completion":21226,"start":4905,"enrollment":550,"conditions":21227,"interventions":21230},"NCT03207529","Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer",[87],"2023-12-31",[11534,7308,7309,7310,7311,7312,21228,7699,5234,7313,7314,7315,7316,7317,21229,10825,14083,1363],"Androgen Receptor Positive","PTEN Positive",[16562,7589],{"trials":21232,"activeCount":166,"soonestReadout":446},[21233,21237,21241,21245],{"nctId":11846,"briefTitle":11847,"status":130,"phases":21234,"primaryCompletion":11849,"completion":11849,"start":11850,"enrollment":628,"conditions":21235,"interventions":21236},[88],[5079,5080,5081,5082,5083,5084,5085,5086,5087,5088,5089,1363],[7589,1376],{"nctId":19581,"briefTitle":19582,"status":279,"phases":21238,"primaryCompletion":446,"completion":281,"start":19584,"enrollment":406,"conditions":21239,"interventions":21240},[88],[27],[19587,7589,11680,3720,19588],{"nctId":10083,"briefTitle":10084,"status":130,"phases":21242,"primaryCompletion":10086,"completion":10086,"start":10087,"enrollment":676,"conditions":21243,"interventions":21244},[88],[10089,10090,10091,10092,10093,10094,10095,10096,10097],[1369,7589,1376],{"nctId":11378,"briefTitle":11379,"status":130,"phases":21246,"primaryCompletion":11381,"completion":11381,"start":11382,"enrollment":34,"conditions":21247,"interventions":21248},[88],[27],[3699,809,7589,11385],{"trials":21250,"activeCount":124},[],{"trials":21252,"activeCount":124},[],{"trials":21254,"activeCount":124},[],{"intervention":15690,"totalTrials":3197,"cells":21256},{"EARLY_PHASE1":21257,"PHASE1":21259,"PHASE2":21268,"PHASE3":21295,"PHASE4":21297,"NA":21299},{"trials":21258,"activeCount":124},[],{"trials":21260,"activeCount":124},[21261],{"nctId":21262,"briefTitle":21263,"status":130,"phases":21264,"primaryCompletion":185,"start":5988,"enrollment":1766,"conditions":21265,"interventions":21266},"NCT00631527","Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer",[87],[27],[3718,3719,15690,21267],"Casodex",{"trials":21269,"activeCount":121,"soonestReadout":3943},[21270,21274,21280,21288],{"nctId":15679,"briefTitle":15680,"status":102,"phases":21271,"primaryCompletion":3943,"completion":3943,"start":15682,"enrollment":507,"conditions":21272,"interventions":21273},[88],[7656,1521,15684,1346,15685,15686,15687,1360,15688],[1421,15690],{"nctId":21275,"briefTitle":21276,"status":130,"phases":21277,"primaryCompletion":10449,"completion":10449,"start":4153,"enrollment":2402,"conditions":21278,"interventions":21279},"NCT00465179","Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer",[88],[6830,1333],[15690],{"nctId":21281,"briefTitle":21282,"status":102,"phases":21283,"primaryCompletion":224,"completion":224,"start":21284,"enrollment":3354,"conditions":21285,"interventions":21286},"NCT00329043","Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy",[88],"2006-05-15",[27],[21287,15690],"LHRH Agonist",{"nctId":21289,"briefTitle":21290,"status":182,"phases":21291,"primaryCompletion":3213,"completion":3213,"start":8306,"enrollment":3197,"conditions":21292,"interventions":21294},"NCT00912912","Sunitinib Malate in Refractory Germ Cell Tumors",[88],[21293],"Genitourinary Disease",[15690],{"trials":21296,"activeCount":124},[],{"trials":21298,"activeCount":124},[],{"trials":21300,"activeCount":124},[],{"intervention":520,"totalTrials":3197,"cells":21302},{"EARLY_PHASE1":21303,"PHASE1":21305,"PHASE2":21311,"PHASE3":21345,"PHASE4":21347,"NA":21349},{"trials":21304,"activeCount":124},[],{"trials":21306,"activeCount":166,"soonestReadout":281},[21307],{"nctId":513,"briefTitle":514,"status":279,"phases":21308,"primaryCompletion":281,"completion":281,"start":516,"enrollment":517,"conditions":21309,"interventions":21310},[87],[36],[520,480],{"trials":21312,"activeCount":166,"soonestReadout":403},[21313,21317,21326,21336],{"nctId":821,"briefTitle":822,"status":279,"phases":21314,"primaryCompletion":403,"completion":403,"start":824,"enrollment":357,"conditions":21315,"interventions":21316},[87,88],[36],[827,480,520],{"nctId":21318,"briefTitle":21319,"status":203,"phases":21320,"primaryCompletion":13086,"completion":13086,"start":21321,"enrollment":124,"conditions":21322,"interventions":21324},"NCT06297629","A Phase I\u002FII Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine\u002FCedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation",[88],"2024-07-01",[21323],"Allogeneic Stem Cell Transplantation",[520,21325],"Donor Lymphocyte",{"nctId":21327,"briefTitle":21328,"status":203,"phases":21329,"primaryCompletion":17564,"completion":404,"start":21330,"enrollment":124,"conditions":21331,"interventions":21334},"NCT06284460","Phase I\u002FII Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic\u002FMyeloproliferative Neoplasms",[87,88],"2025-01-31",[21332,21333,727],"Pathway Mutant Myelodysplastic Syndromes","Myelodysplastic Neoplasm",[21335,520],"ASTX029",{"nctId":21337,"briefTitle":21338,"status":203,"phases":21339,"primaryCompletion":21340,"completion":21340,"start":21341,"enrollment":124,"conditions":21342,"interventions":21343},"NCT06113289","A Phase 1B\u002F2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia",[87,88],"2025-03-06","2024-02-08",[36],[520,21344],"ASTX029-01",{"trials":21346,"activeCount":124},[],{"trials":21348,"activeCount":124},[],{"trials":21350,"activeCount":124},[],{"intervention":1370,"totalTrials":296,"cells":21352},{"EARLY_PHASE1":21353,"PHASE1":21355,"PHASE2":21365,"PHASE3":21375,"PHASE4":21377,"NA":21379},{"trials":21354,"activeCount":124},[],{"trials":21356,"activeCount":166,"soonestReadout":446},[21357,21361],{"nctId":17571,"briefTitle":17572,"status":279,"phases":21358,"primaryCompletion":446,"completion":281,"start":17574,"enrollment":473,"conditions":21359,"interventions":21360},[87],[17576],[1370,4022,3497],{"nctId":1337,"briefTitle":1338,"status":182,"phases":21362,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":21363,"interventions":21364},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"trials":21366,"activeCount":166,"soonestReadout":224},[21367,21371],{"nctId":11564,"briefTitle":11565,"status":102,"phases":21368,"primaryCompletion":224,"completion":224,"start":2549,"enrollment":1609,"conditions":21369,"interventions":21370},[88],[11568,11569],[718,11035,1370],{"nctId":6737,"briefTitle":6738,"status":130,"phases":21372,"primaryCompletion":6740,"completion":6740,"start":6741,"enrollment":2700,"conditions":21373,"interventions":21374},[88],[18],[1376,1370,4218,6744,803,1013],{"trials":21376,"activeCount":124},[],{"trials":21378,"activeCount":124},[],{"trials":21380,"activeCount":124},[],{"intervention":3720,"totalTrials":296,"cells":21382},{"EARLY_PHASE1":21383,"PHASE1":21385,"PHASE2":21387,"PHASE3":21405,"PHASE4":21407,"NA":21409},{"trials":21384,"activeCount":124},[],{"trials":21386,"activeCount":124},[],{"trials":21388,"activeCount":121,"soonestReadout":446},[21389,21393,21397,21401],{"nctId":19581,"briefTitle":19582,"status":279,"phases":21390,"primaryCompletion":446,"completion":281,"start":19584,"enrollment":406,"conditions":21391,"interventions":21392},[88],[27],[19587,7589,11680,3720,19588],{"nctId":5126,"briefTitle":5127,"status":203,"phases":21394,"primaryCompletion":5129,"completion":5129,"start":4448,"enrollment":124,"conditions":21395,"interventions":21396},[88],[5131,3545,5132,3546,3547,3548],[3700,3720,3780],{"nctId":11332,"briefTitle":11333,"status":102,"phases":21398,"primaryCompletion":11335,"completion":11335,"start":11336,"enrollment":11337,"conditions":21399,"interventions":21400},[88],[5122,11339],[3699,11341,3720,11342,11343,3780,11344,809],{"nctId":3711,"briefTitle":3712,"status":182,"phases":21402,"primaryCompletion":3714,"completion":3714,"start":3715,"enrollment":406,"conditions":21403,"interventions":21404},[88],[27],[1049,3718,3719,3720],{"trials":21406,"activeCount":124},[],{"trials":21408,"activeCount":124},[],{"trials":21410,"activeCount":124},[],{"intervention":8569,"totalTrials":296,"cells":21412},{"EARLY_PHASE1":21413,"PHASE1":21415,"PHASE2":21417,"PHASE3":21435,"PHASE4":21437,"NA":21439},{"trials":21414,"activeCount":124},[],{"trials":21416,"activeCount":124},[],{"trials":21418,"activeCount":121,"soonestReadout":2608},[21419,21423,21427,21431],{"nctId":12108,"briefTitle":12109,"status":102,"phases":21420,"primaryCompletion":193,"completion":193,"start":12111,"enrollment":406,"conditions":21421,"interventions":21422},[88],[7942,1346,12113,1356,1360],[1013,804,2369,4135,2283,8569],{"nctId":8561,"briefTitle":8562,"status":182,"phases":21424,"primaryCompletion":8564,"completion":8565,"start":8566,"enrollment":1231,"conditions":21425,"interventions":21426},[88],[789,790],[2283,8569,894],{"nctId":12156,"briefTitle":12157,"status":102,"phases":21428,"primaryCompletion":2608,"completion":2608,"start":12159,"enrollment":6385,"conditions":21429,"interventions":21430},[87,88],[1803,12161,12162],[804,4135,8569],{"nctId":13599,"briefTitle":13600,"status":130,"phases":21432,"primaryCompletion":13602,"completion":13602,"start":13603,"enrollment":3354,"conditions":21433,"interventions":21434},[88],[4743,3135],[8569,1402],{"trials":21436,"activeCount":124},[],{"trials":21438,"activeCount":124},[],{"trials":21440,"activeCount":124},[],{"intervention":1015,"totalTrials":296,"cells":21442},{"EARLY_PHASE1":21443,"PHASE1":21445,"PHASE2":21447,"PHASE3":21468,"PHASE4":21470,"NA":21472},{"trials":21444,"activeCount":124},[],{"trials":21446,"activeCount":124},[],{"trials":21448,"activeCount":121,"soonestReadout":446},[21449,21453,21457,21464],{"nctId":12654,"briefTitle":12655,"status":102,"phases":21450,"primaryCompletion":12657,"completion":12657,"start":12658,"enrollment":3354,"conditions":21451,"interventions":21452},[87,88],[737,10536,10537,3244],[612,1015],{"nctId":1007,"briefTitle":1008,"status":279,"phases":21454,"primaryCompletion":446,"completion":446,"start":1010,"enrollment":517,"conditions":21455,"interventions":21456},[88],[847],[803,654,62,1013,805,806,1014,809,894,1015,480,1016],{"nctId":21458,"briefTitle":21459,"status":182,"phases":21460,"primaryCompletion":21461,"completion":21461,"start":12858,"enrollment":1231,"conditions":21462,"interventions":21463},"NCT04317781","Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant",[88],"2023-07-11",[847],[1015],{"nctId":2852,"briefTitle":2853,"status":182,"phases":21465,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":296,"conditions":21466,"interventions":21467},[87,88],[2413,1142,1143,1144,2421,1145],[803,654,62,2712,1113,805,1114,806,1071,809,894,1015,1016],{"trials":21469,"activeCount":124},[],{"trials":21471,"activeCount":124},[],{"trials":21473,"activeCount":124},[],{"intervention":917,"totalTrials":1231,"cells":21475},{"EARLY_PHASE1":21476,"PHASE1":21478,"PHASE2":21480,"PHASE3":21497,"PHASE4":21499,"NA":21501},{"trials":21477,"activeCount":124},[],{"trials":21479,"activeCount":124},[],{"trials":21481,"activeCount":121,"soonestReadout":999},[21482,21489,21493],{"nctId":21483,"briefTitle":21484,"status":279,"phases":21485,"primaryCompletion":571,"completion":571,"start":21486,"enrollment":676,"conditions":21487,"interventions":21488},"NCT01746836","Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib",[88],"2013-01-17",[1025,1026,649],[917],{"nctId":905,"briefTitle":906,"status":182,"phases":21490,"primaryCompletion":908,"completion":908,"start":909,"enrollment":910,"conditions":21491,"interventions":21492},[87,88],[644,912,913,649,914,650,915],[62,917,894,480],{"nctId":2726,"briefTitle":2727,"status":102,"phases":21494,"primaryCompletion":999,"completion":999,"start":2729,"enrollment":2730,"conditions":21495,"interventions":21496},[88],[1205,1122,2649,2471,644,912,2732],[803,654,62,1013,804,806,1124,917,809,894,1016,810],{"trials":21498,"activeCount":124},[],{"trials":21500,"activeCount":124},[],{"trials":21502,"activeCount":124},[],{"intervention":13618,"totalTrials":1231,"cells":21504},{"EARLY_PHASE1":21505,"PHASE1":21507,"PHASE2":21524,"PHASE3":21530,"PHASE4":21532,"NA":21534},{"trials":21506,"activeCount":124},[],{"trials":21508,"activeCount":166,"soonestReadout":1299},[21509,21517],{"nctId":21510,"briefTitle":21511,"status":182,"phases":21512,"primaryCompletion":21513,"completion":21513,"start":21514,"enrollment":230,"conditions":21515,"interventions":21516},"NCT05065047","Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma",[87],"2025-11-06","2023-01-05",[1400],[13618],{"nctId":21518,"briefTitle":21519,"status":279,"phases":21520,"primaryCompletion":1299,"completion":1299,"start":21521,"enrollment":406,"conditions":21522,"interventions":21523},"NCT05055063","A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma",[87],"2022-05-18",[2245],[13618],{"trials":21525,"activeCount":166,"soonestReadout":224},[21526],{"nctId":13611,"briefTitle":13612,"status":279,"phases":21527,"primaryCompletion":224,"completion":224,"start":13614,"enrollment":25,"conditions":21528,"interventions":21529},[88],[13616],[13618,1402],{"trials":21531,"activeCount":124},[],{"trials":21533,"activeCount":124},[],{"trials":21535,"activeCount":124},[],{"intervention":1177,"totalTrials":1231,"cells":21537},{"EARLY_PHASE1":21538,"PHASE1":21540,"PHASE2":21542,"PHASE3":21559,"PHASE4":21561,"NA":21563},{"trials":21539,"activeCount":124},[],{"trials":21541,"activeCount":124},[],{"trials":21543,"activeCount":121,"soonestReadout":71},[21544,21548,21555],{"nctId":73,"briefTitle":74,"status":102,"phases":21545,"primaryCompletion":71,"completion":6954,"start":8366,"enrollment":4171,"conditions":21546,"interventions":21547},[88],[8368],[75,894,1177],{"nctId":21549,"briefTitle":21550,"status":130,"phases":21551,"completion":10784,"start":2580,"enrollment":4171,"conditions":21552,"interventions":21553},"NCT00562770","Oral Valganciclovir Versus Valacyclovir",[88],[712,15],[21554,1177],"Valganciclovir",{"nctId":1170,"briefTitle":1171,"status":279,"phases":21556,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1034,"conditions":21557,"interventions":21558},[88],[15],[893,669,480,1177,1178],{"trials":21560,"activeCount":124},[],{"trials":21562,"activeCount":124},[],{"trials":21564,"activeCount":124},[],{"intervention":531,"totalTrials":1231,"cells":21566},{"EARLY_PHASE1":21567,"PHASE1":21569,"PHASE2":21579,"PHASE3":21585,"PHASE4":21587,"NA":21589},{"trials":21568,"activeCount":124},[],{"trials":21570,"activeCount":166,"soonestReadout":490},[21571,21575],{"nctId":522,"briefTitle":523,"status":203,"phases":21572,"primaryCompletion":525,"completion":525,"start":526,"enrollment":124,"conditions":21573,"interventions":21574},[87],[528,529],[531,480],{"nctId":1423,"briefTitle":1424,"status":546,"phases":21576,"primaryCompletion":490,"completion":1426,"start":1427,"enrollment":550,"conditions":21577,"interventions":21578},[87],[1429],[1431,531,1049,1050],{"trials":21580,"activeCount":166,"soonestReadout":12083},[21581],{"nctId":12080,"briefTitle":12081,"status":279,"phases":21582,"primaryCompletion":12083,"completion":12084,"start":12085,"enrollment":473,"conditions":21583,"interventions":21584},[88],[12087],[531,804],{"trials":21586,"activeCount":124},[],{"trials":21588,"activeCount":124},[],{"trials":21590,"activeCount":124},[],{"intervention":12927,"totalTrials":1231,"cells":21592},{"EARLY_PHASE1":21593,"PHASE1":21595,"PHASE2":21597,"PHASE3":21613,"PHASE4":21615,"NA":21617},{"trials":21594,"activeCount":124},[],{"trials":21596,"activeCount":124},[],{"trials":21598,"activeCount":121,"soonestReadout":238},[21599,21603,21607],{"nctId":18273,"briefTitle":18274,"status":182,"phases":21600,"primaryCompletion":18276,"completion":18276,"start":18277,"enrollment":296,"conditions":21601,"interventions":21602},[88],[7312,5234,7317],[12927,10904,18073,14086,2206,14130],{"nctId":12920,"briefTitle":12921,"status":102,"phases":21604,"primaryCompletion":281,"completion":281,"start":12923,"enrollment":4171,"conditions":21605,"interventions":21606},[87,88],[1667,1898,1669,1671,1899,1672,1900,1901,1673,1902,1903,1674,1904,1905,1675,1906,1907,1676,1908,1909,1677,1910,1911,1678,1912,1913,1679,1914,1680,12925,1681],[12927,1683,12928],{"nctId":21608,"briefTitle":21609,"status":102,"phases":21610,"primaryCompletion":238,"completion":238,"start":781,"enrollment":550,"conditions":21611,"interventions":21612},"NCT03531645","Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma",[88],[5799],[18073,12927],{"trials":21614,"activeCount":124},[],{"trials":21616,"activeCount":124},[],{"trials":21618,"activeCount":124},[],{"intervention":8580,"totalTrials":1231,"cells":21620},{"EARLY_PHASE1":21621,"PHASE1":21623,"PHASE2":21625,"PHASE3":21644,"PHASE4":21646,"NA":21648},{"trials":21622,"activeCount":124},[],{"trials":21624,"activeCount":124},[],{"trials":21626,"activeCount":121,"soonestReadout":193},[21627,21631,21635],{"nctId":15253,"briefTitle":15254,"status":279,"phases":21628,"primaryCompletion":193,"completion":193,"start":15256,"enrollment":517,"conditions":21629,"interventions":21630},[88],[15258],[8580,669,15260],{"nctId":8571,"briefTitle":8572,"status":279,"phases":21632,"primaryCompletion":8574,"completion":8575,"start":148,"enrollment":406,"conditions":21633,"interventions":21634},[88],[8577,8578,8579,894,8580],[668,894,8580],{"nctId":21636,"briefTitle":21637,"status":203,"phases":21638,"primaryCompletion":21639,"completion":21640,"start":21641,"enrollment":124,"conditions":21642,"interventions":21643},"NCT06670105","A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma",[88],"2030-01-06","2032-01-06","2025-06-06",[5445],[8580],{"trials":21645,"activeCount":124},[],{"trials":21647,"activeCount":124},[],{"trials":21649,"activeCount":124},[],{"intervention":21651,"totalTrials":1231,"cells":21652},"Pentoxifylline",{"EARLY_PHASE1":21653,"PHASE1":21655,"PHASE2":21657,"PHASE3":21696,"PHASE4":21698,"NA":21700},{"trials":21654,"activeCount":124},[],{"trials":21656,"activeCount":124},[],{"trials":21658,"activeCount":121,"soonestReadout":4006},[21659,21672,21685],{"nctId":21660,"briefTitle":21661,"status":279,"phases":21662,"primaryCompletion":4006,"completion":21663,"start":21664,"enrollment":21665,"conditions":21666,"interventions":21669},"NCT06494111","Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline\u002FTocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)",[88],"2031-03-01","2025-02-13",295,[21667,21668],"Lymphedema","Fibrosis",[21670,21651,21671],"Pravastatin","Tocopherol",{"nctId":21673,"briefTitle":21674,"status":279,"phases":21675,"primaryCompletion":21663,"completion":21676,"start":11677,"enrollment":21677,"conditions":21678,"interventions":21681},"NCT06912763","Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)",[88],"2033-03-01",250,[21679,21667,21680,21668],"Fibrosis Syndrome","Head &Amp; Neck Cancer",[21670,21651,21682,21683,21684],"ketoprofen","Pirfenidoneone","tocopherol",{"nctId":21686,"briefTitle":21687,"status":130,"phases":21688,"primaryCompletion":21689,"completion":21689,"start":21690,"enrollment":2779,"conditions":21691,"interventions":21695},"NCT03830164","Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer",[88],"2022-11-02","2019-11-20",[21692,5122,21693,21694],"Male Erectile Disorder","Erectile Dysfunction, CTCAE","Impotence",[17844,21651],{"trials":21697,"activeCount":124},[],{"trials":21699,"activeCount":124},[],{"trials":21701,"activeCount":124},[],{"intervention":13551,"totalTrials":1231,"cells":21703},{"EARLY_PHASE1":21704,"PHASE1":21706,"PHASE2":21708,"PHASE3":21724,"PHASE4":21726,"NA":21728},{"trials":21705,"activeCount":124},[],{"trials":21707,"activeCount":124},[],{"trials":21709,"activeCount":121,"soonestReadout":815},[21710,21714,21720],{"nctId":13545,"briefTitle":13546,"status":102,"phases":21711,"primaryCompletion":815,"completion":815,"start":13548,"enrollment":5774,"conditions":21712,"interventions":21713},[88],[4743,3135],[13551,1402],{"nctId":21715,"briefTitle":21716,"status":102,"phases":21717,"primaryCompletion":224,"completion":224,"start":10985,"enrollment":1568,"conditions":21718,"interventions":21719},"NCT04517851","Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis",[88],[2133,746,2134],[13551],{"nctId":13661,"briefTitle":13662,"status":130,"phases":21721,"primaryCompletion":13664,"completion":13664,"start":13665,"enrollment":2647,"conditions":21722,"interventions":21723},[88],[3396,3135],[13551,1402,2293,3064,13668],{"trials":21725,"activeCount":124},[],{"trials":21727,"activeCount":124},[],{"trials":21729,"activeCount":124},[],{"intervention":2270,"totalTrials":1231,"cells":21731},{"EARLY_PHASE1":21732,"PHASE1":21734,"PHASE2":21740,"PHASE3":21750,"PHASE4":21752,"NA":21754},{"trials":21733,"activeCount":124},[],{"trials":21735,"activeCount":124},[21736],{"nctId":2261,"briefTitle":2262,"status":130,"phases":21737,"primaryCompletion":2264,"completion":2264,"start":2265,"enrollment":1409,"conditions":21738,"interventions":21739},[87],[2267],[62,2269,2270,2271,1709,1376],{"trials":21741,"activeCount":121,"soonestReadout":2863},[21742,21746],{"nctId":2625,"briefTitle":2626,"status":279,"phases":21743,"primaryCompletion":2628,"completion":674,"start":2629,"enrollment":406,"conditions":21744,"interventions":21745},[88],[1638,2631],[1376,62,2269,2270],{"nctId":2860,"briefTitle":2861,"status":279,"phases":21747,"primaryCompletion":2863,"completion":2863,"start":2864,"enrollment":2865,"conditions":21748,"interventions":21749},[87,88],[2867,2868],[62,2269,2270,1376],{"trials":21751,"activeCount":124},[],{"trials":21753,"activeCount":124},[],{"trials":21755,"activeCount":124},[],{"intervention":2088,"totalTrials":1231,"cells":21757},{"EARLY_PHASE1":21758,"PHASE1":21766,"PHASE2":21768,"PHASE3":21782,"PHASE4":21784,"NA":21786},{"trials":21759,"activeCount":124},[21760],{"nctId":21761,"briefTitle":21762,"status":1479,"phases":21763,"primaryCompletion":446,"completion":446,"start":5405,"enrollment":1496,"conditions":21764,"interventions":21765},"NCT04975217","Fecal Microbial Transplants for the Treatment of Pancreatic Cancer",[86],[8173],[2088],{"trials":21767,"activeCount":124},[],{"trials":21769,"activeCount":121,"soonestReadout":21774},[21770,21778],{"nctId":21771,"briefTitle":21772,"status":279,"phases":21773,"primaryCompletion":21774,"completion":21774,"start":21775,"enrollment":517,"conditions":21776,"interventions":21777},"NCT06218602","Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.",[88],"2026-08-01","2024-02-19",[21],[2088],{"nctId":2080,"briefTitle":2081,"status":102,"phases":21779,"primaryCompletion":224,"completion":224,"start":773,"enrollment":1568,"conditions":21780,"interventions":21781},[88],[2084,2085,1676,2086,1677,1678,1679],[2088,2089,2090,1050,53,2091],{"trials":21783,"activeCount":124},[],{"trials":21785,"activeCount":124},[],{"trials":21787,"activeCount":124},[],{"intervention":1964,"totalTrials":1231,"cells":21789},{"EARLY_PHASE1":21790,"PHASE1":21792,"PHASE2":21800,"PHASE3":21810,"PHASE4":21812,"NA":21814},{"trials":21791,"activeCount":124},[],{"trials":21793,"activeCount":124},[21794],{"nctId":21795,"briefTitle":21796,"status":130,"phases":21797,"primaryCompletion":1327,"completion":1327,"start":4427,"enrollment":1240,"conditions":21798,"interventions":21799},"NCT04132505","Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer",[87],[6564,8115],[1964,12420],{"trials":21801,"activeCount":121,"soonestReadout":1299},[21802,21806],{"nctId":17287,"briefTitle":17288,"status":279,"phases":21803,"primaryCompletion":1299,"completion":1299,"start":17290,"enrollment":1328,"conditions":21804,"interventions":21805},[88],[1312,1316,1353],[1964,1684],{"nctId":1954,"briefTitle":1955,"status":102,"phases":21807,"primaryCompletion":1957,"completion":1957,"start":1958,"enrollment":901,"conditions":21808,"interventions":21809},[88],[1960,1316,1961,1962,1544,1546,1549,1365],[1964,1965,1684,1050,874],{"trials":21811,"activeCount":124},[],{"trials":21813,"activeCount":124},[],{"trials":21815,"activeCount":124},[],{"intervention":21817,"totalTrials":1231,"cells":21818},"Osimertinib",{"EARLY_PHASE1":21819,"PHASE1":21821,"PHASE2":21830,"PHASE3":21846,"PHASE4":21848,"NA":21850},{"trials":21820,"activeCount":124},[],{"trials":21822,"activeCount":124},[21823],{"nctId":21824,"briefTitle":21825,"status":130,"phases":21826,"primaryCompletion":19896,"completion":19896,"start":21827,"enrollment":1609,"conditions":21828,"interventions":21829},"NCT04479306","Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer",[87],"2020-06-18",[1836,1358,1319,1361,1362],[8156,21817,1839],{"trials":21831,"activeCount":121,"soonestReadout":504},[21832,21840],{"nctId":21833,"briefTitle":21834,"status":102,"phases":21835,"primaryCompletion":504,"completion":504,"start":2856,"enrollment":507,"conditions":21836,"interventions":21838},"NCT05017025","Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer",[87,88],[21837,4206,1355,1357,1358,1359,1319,1361,1362],"Advanced Lung Non-Squamous Non-Small Cell Carcinoma",[21839,21817],"Aurora A Kinase Inhibitor LY3295668",{"nctId":21841,"briefTitle":21842,"status":102,"phases":21843,"primaryCompletion":2455,"completion":2455,"start":10440,"enrollment":19418,"conditions":21844,"interventions":21845},"NCT03410043","Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study",[88],[1388,1836,1358,1319,1361,1362],[21817],{"trials":21847,"activeCount":124},[],{"trials":21849,"activeCount":124},[],{"trials":21851,"activeCount":124},[],{"intervention":21853,"totalTrials":121,"cells":21854},"Canakinumab",{"EARLY_PHASE1":21855,"PHASE1":21857,"PHASE2":21859,"PHASE3":21874,"PHASE4":21876,"NA":21878},{"trials":21856,"activeCount":124},[],{"trials":21858,"activeCount":124},[],{"trials":21860,"activeCount":121,"soonestReadout":446},[21861,21868],{"nctId":21862,"briefTitle":21863,"status":279,"phases":21864,"primaryCompletion":224,"completion":224,"start":21865,"enrollment":676,"conditions":21866,"interventions":21867},"NCT04789681","Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial",[88],"2021-07-20",[344,1837,2052,2053,2054,2055,1389,1390,1391,1355,1357,1358,1359],[21853],{"nctId":21869,"briefTitle":21870,"status":279,"phases":21871,"primaryCompletion":446,"completion":446,"start":3889,"enrollment":20891,"conditions":21872,"interventions":21873},"NCT04239157","A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS\u002FIPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia",[88],[737,30,850,609,853,632],[21853],{"trials":21875,"activeCount":124},[],{"trials":21877,"activeCount":124},[],{"trials":21879,"activeCount":124},[],{"intervention":15197,"totalTrials":121,"cells":21881},{"EARLY_PHASE1":21882,"PHASE1":21884,"PHASE2":21886,"PHASE3":21896,"PHASE4":21898,"NA":21900},{"trials":21883,"activeCount":124},[],{"trials":21885,"activeCount":124},[],{"trials":21887,"activeCount":121,"soonestReadout":446},[21888,21892],{"nctId":15189,"briefTitle":15190,"status":279,"phases":21889,"primaryCompletion":224,"completion":224,"start":970,"enrollment":1034,"conditions":21890,"interventions":21891},[88],[11534,7308,7309,7310,7311,7312,15193,15194,7699,5234,7313,7314,7315,7316,7317],[15196,15197,1374],{"nctId":15203,"briefTitle":15204,"status":102,"phases":21893,"primaryCompletion":446,"completion":446,"start":15206,"enrollment":724,"conditions":21894,"interventions":21895},[88],[1458,1460,1461],[15209,1374,15197],{"trials":21897,"activeCount":124},[],{"trials":21899,"activeCount":124},[],{"trials":21901,"activeCount":124},[],{"intervention":11265,"totalTrials":121,"cells":21903},{"EARLY_PHASE1":21904,"PHASE1":21906,"PHASE2":21912,"PHASE3":21921,"PHASE4":21923,"NA":21925},{"trials":21905,"activeCount":124},[],{"trials":21907,"activeCount":166,"soonestReadout":772},[21908],{"nctId":11239,"briefTitle":11240,"status":279,"phases":21909,"primaryCompletion":772,"completion":772,"start":11242,"enrollment":11243,"conditions":21910,"interventions":21911},[87],[11245,11246,11247,11248,11249,11250,11251,11252,1344,1312,11253,1388,11254,360,11255,11256,11257,11258,11259,11260,11261,11262,1348,1349,1350,1351,1352,1353,11263,1837,2052,2053,2054,2055,1389,1390,1391,1355,1357,1358,1359,1319,1361,1362],[11265,809,11266],{"trials":21913,"activeCount":166,"soonestReadout":224},[21914],{"nctId":21915,"briefTitle":21916,"status":102,"phases":21917,"primaryCompletion":224,"completion":224,"start":21918,"enrollment":2997,"conditions":21919,"interventions":21920},"NCT04407247","Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma",[87,88],"2020-07-09",[11253,1388,11254,360,1729],[11265,11266],{"trials":21922,"activeCount":124},[],{"trials":21924,"activeCount":124},[],{"trials":21926,"activeCount":124},[],{"intervention":11266,"totalTrials":121,"cells":21928},{"EARLY_PHASE1":21929,"PHASE1":21931,"PHASE2":21937,"PHASE3":21943,"PHASE4":21945,"NA":21947},{"trials":21930,"activeCount":124},[],{"trials":21932,"activeCount":166,"soonestReadout":772},[21933],{"nctId":11239,"briefTitle":11240,"status":279,"phases":21934,"primaryCompletion":772,"completion":772,"start":11242,"enrollment":11243,"conditions":21935,"interventions":21936},[87],[11245,11246,11247,11248,11249,11250,11251,11252,1344,1312,11253,1388,11254,360,11255,11256,11257,11258,11259,11260,11261,11262,1348,1349,1350,1351,1352,1353,11263,1837,2052,2053,2054,2055,1389,1390,1391,1355,1357,1358,1359,1319,1361,1362],[11265,809,11266],{"trials":21938,"activeCount":166,"soonestReadout":224},[21939],{"nctId":21915,"briefTitle":21916,"status":102,"phases":21940,"primaryCompletion":224,"completion":224,"start":21918,"enrollment":2997,"conditions":21941,"interventions":21942},[87,88],[11253,1388,11254,360,1729],[11265,11266],{"trials":21944,"activeCount":124},[],{"trials":21946,"activeCount":124},[],{"trials":21948,"activeCount":124},[],{"intervention":499,"totalTrials":121,"cells":21950},{"EARLY_PHASE1":21951,"PHASE1":21953,"PHASE2":21959,"PHASE3":21965,"PHASE4":21967,"NA":21969},{"trials":21952,"activeCount":124},[],{"trials":21954,"activeCount":166,"soonestReadout":224},[21955],{"nctId":487,"briefTitle":488,"status":279,"phases":21956,"primaryCompletion":224,"completion":490,"start":491,"enrollment":492,"conditions":21957,"interventions":21958},[87],[494,495,496,497],[480,499],{"trials":21960,"activeCount":166,"soonestReadout":281},[21961],{"nctId":13083,"briefTitle":13084,"status":279,"phases":21962,"primaryCompletion":281,"completion":571,"start":13086,"enrollment":517,"conditions":21963,"interventions":21964},[87,88],[9033,13088],[1083,2477,499,13090],{"trials":21966,"activeCount":124},[],{"trials":21968,"activeCount":124},[],{"trials":21970,"activeCount":124},[],{"intervention":12385,"totalTrials":121,"cells":21972},{"EARLY_PHASE1":21973,"PHASE1":21975,"PHASE2":21977,"PHASE3":21987,"PHASE4":21989,"NA":21991},{"trials":21974,"activeCount":124},[],{"trials":21976,"activeCount":124},[],{"trials":21978,"activeCount":121,"soonestReadout":504},[21979,21983],{"nctId":12376,"briefTitle":12377,"status":102,"phases":21980,"primaryCompletion":1939,"completion":1939,"start":12379,"enrollment":2018,"conditions":21981,"interventions":21982},[88],[4018,12381,12382,12383,8175,8176],[1786,2369,4023,12385],{"nctId":13358,"briefTitle":13359,"status":102,"phases":21984,"primaryCompletion":504,"completion":504,"start":13361,"enrollment":1308,"conditions":21985,"interventions":21986},[88],[13363,13364,11593,13365,1508,1591,13366,1592],[1786,12385],{"trials":21988,"activeCount":124},[],{"trials":21990,"activeCount":124},[],{"trials":21992,"activeCount":124},[],{"intervention":15209,"totalTrials":121,"cells":21994},{"EARLY_PHASE1":21995,"PHASE1":22005,"PHASE2":22007,"PHASE3":22013,"PHASE4":22015,"NA":22017},{"trials":21996,"activeCount":166,"soonestReadout":446},[21997],{"nctId":21998,"briefTitle":21999,"status":102,"phases":22000,"primaryCompletion":446,"completion":446,"start":11639,"enrollment":1664,"conditions":22001,"interventions":22004},"NCT02659241","Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[86],[11535,5059,11540,2631,22002,22003,4912,4957,4958,4959,4960,4961,4962,4963,4964,4965,4966,4967,4968,4969,4970,4971],"Fallopian Tube High Grade Serous Adenocarcinoma","Ovarian High Grade Serous Adenocarcinoma",[15209],{"trials":22006,"activeCount":124},[],{"trials":22008,"activeCount":166,"soonestReadout":446},[22009],{"nctId":15203,"briefTitle":15204,"status":102,"phases":22010,"primaryCompletion":446,"completion":446,"start":15206,"enrollment":724,"conditions":22011,"interventions":22012},[88],[1458,1460,1461],[15209,1374,15197],{"trials":22014,"activeCount":124},[],{"trials":22016,"activeCount":124},[],{"trials":22018,"activeCount":124},[],{"intervention":13487,"totalTrials":121,"cells":22020},{"EARLY_PHASE1":22021,"PHASE1":22023,"PHASE2":22025,"PHASE3":22038,"PHASE4":22040,"NA":22042},{"trials":22022,"activeCount":124},[],{"trials":22024,"activeCount":124},[],{"trials":22026,"activeCount":121,"soonestReadout":815},[22027,22031],{"nctId":13481,"briefTitle":13482,"status":279,"phases":22028,"primaryCompletion":224,"completion":224,"start":13484,"enrollment":2402,"conditions":22029,"interventions":22030},[88],[1400],[13487,13488],{"nctId":22032,"briefTitle":22033,"status":102,"phases":22034,"primaryCompletion":815,"completion":22035,"start":5941,"enrollment":2402,"conditions":22036,"interventions":22037},"NCT02960555","Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)",[88],"2030-04-30",[7505],[13487],{"trials":22039,"activeCount":124},[],{"trials":22041,"activeCount":124},[],{"trials":22043,"activeCount":124},[],{"intervention":14198,"totalTrials":121,"cells":22045},{"EARLY_PHASE1":22046,"PHASE1":22048,"PHASE2":22054,"PHASE3":22066,"PHASE4":22068,"NA":22070},{"trials":22047,"activeCount":124},[],{"trials":22049,"activeCount":166,"soonestReadout":4005},[22050],{"nctId":14192,"briefTitle":14193,"status":279,"phases":22051,"primaryCompletion":4005,"completion":4006,"start":14195,"enrollment":1034,"conditions":22052,"interventions":22053},[87],[27],[14198,12910],{"trials":22055,"activeCount":166,"soonestReadout":22060},[22056],{"nctId":22057,"briefTitle":22058,"status":279,"phases":22059,"primaryCompletion":22060,"completion":22060,"start":22061,"enrollment":924,"conditions":22062,"interventions":22064},"NCT06085664","A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy",[87,88],"2026-06-15","2023-12-04",[27,22063],"Radical Prostatectomy",[14198,22065],"Piflufolastat F18",{"trials":22067,"activeCount":124},[],{"trials":22069,"activeCount":124},[],{"trials":22071,"activeCount":124},[],{"intervention":22065,"totalTrials":121,"cells":22073},{"EARLY_PHASE1":22074,"PHASE1":22076,"PHASE2":22085,"PHASE3":22091,"PHASE4":22093,"NA":22095},{"trials":22075,"activeCount":124},[],{"trials":22077,"activeCount":166,"soonestReadout":1299},[22078],{"nctId":22079,"briefTitle":22080,"status":279,"phases":22081,"primaryCompletion":1299,"completion":1299,"start":22082,"enrollment":593,"conditions":22083,"interventions":22084},"NCT05394259","A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer",[87],"2022-10-28",[4107,18,1828],[22065],{"trials":22086,"activeCount":166,"soonestReadout":22060},[22087],{"nctId":22057,"briefTitle":22058,"status":279,"phases":22088,"primaryCompletion":22060,"completion":22060,"start":22061,"enrollment":924,"conditions":22089,"interventions":22090},[87,88],[27,22063],[14198,22065],{"trials":22092,"activeCount":124},[],{"trials":22094,"activeCount":124},[],{"trials":22096,"activeCount":124},[],{"intervention":10874,"totalTrials":121,"cells":22098},{"EARLY_PHASE1":22099,"PHASE1":22101,"PHASE2":22107,"PHASE3":22116,"PHASE4":22118,"NA":22120},{"trials":22100,"activeCount":124},[],{"trials":22102,"activeCount":166,"soonestReadout":10870},[22103],{"nctId":10867,"briefTitle":10868,"status":279,"phases":22104,"primaryCompletion":10870,"completion":10871,"start":10872,"enrollment":1243,"conditions":22105,"interventions":22106},[87],[2306,10874,10875,10876,10877,10878,10879],[10874,10881,1275],{"trials":22108,"activeCount":166,"soonestReadout":2302},[22109],{"nctId":22110,"briefTitle":22111,"status":279,"phases":22112,"primaryCompletion":2302,"completion":2303,"start":21513,"enrollment":1409,"conditions":22113,"interventions":22115},"NCT07133425","A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer",[88],[10135,22114],"ICI-refractory",[10874],{"trials":22117,"activeCount":124},[],{"trials":22119,"activeCount":124},[],{"trials":22121,"activeCount":124},[],{"intervention":8591,"totalTrials":121,"cells":22123},{"EARLY_PHASE1":22124,"PHASE1":22126,"PHASE2":22128,"PHASE3":22138,"PHASE4":22140,"NA":22142},{"trials":22125,"activeCount":124},[],{"trials":22127,"activeCount":124},[],{"trials":22129,"activeCount":121,"soonestReadout":446},[22130,22134],{"nctId":19662,"briefTitle":19663,"status":279,"phases":22131,"primaryCompletion":446,"completion":281,"start":10143,"enrollment":593,"conditions":22132,"interventions":22133},[88],[21],[13648,8591],{"nctId":8583,"briefTitle":8584,"status":102,"phases":22135,"primaryCompletion":8586,"completion":8586,"start":8587,"enrollment":1034,"conditions":22136,"interventions":22137},[88],[8589],[894,8591],{"trials":22139,"activeCount":124},[],{"trials":22141,"activeCount":124},[],{"trials":22143,"activeCount":124},[],{"intervention":1740,"totalTrials":121,"cells":22145},{"EARLY_PHASE1":22146,"PHASE1":22148,"PHASE2":22150,"PHASE3":22160,"PHASE4":22162,"NA":22164},{"trials":22147,"activeCount":124},[],{"trials":22149,"activeCount":124},[],{"trials":22151,"activeCount":121,"soonestReadout":3738},[22152,22156],{"nctId":1732,"briefTitle":1733,"status":279,"phases":22153,"primaryCompletion":1735,"completion":1735,"start":1736,"enrollment":406,"conditions":22154,"interventions":22155},[88],[1738],[1740,1050,1552],{"nctId":3735,"briefTitle":3736,"status":279,"phases":22157,"primaryCompletion":3738,"completion":3739,"start":3740,"enrollment":1568,"conditions":22158,"interventions":22159},[88],[3742],[3744,1049,1740],{"trials":22161,"activeCount":124},[],{"trials":22163,"activeCount":124},[],{"trials":22165,"activeCount":124},[],{"intervention":8058,"totalTrials":121,"cells":22167},{"EARLY_PHASE1":22168,"PHASE1":22170,"PHASE2":22172,"PHASE3":22188,"PHASE4":22190,"NA":22192},{"trials":22169,"activeCount":124},[],{"trials":22171,"activeCount":124},[],{"trials":22173,"activeCount":121,"soonestReadout":8053},[22174,22184],{"nctId":22175,"briefTitle":22176,"status":279,"phases":22177,"primaryCompletion":22178,"completion":22179,"start":22180,"enrollment":959,"conditions":22181,"interventions":22183},"NCT07023432","Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)",[88],"2028-04-14","2030-04-14","2025-11-17",[22182,1271],"Active Surveillance",[8058],{"nctId":8050,"briefTitle":8051,"status":279,"phases":22185,"primaryCompletion":8053,"completion":8054,"start":8055,"enrollment":1496,"conditions":22186,"interventions":22187},[88],[1271],[53,8058],{"trials":22189,"activeCount":124},[],{"trials":22191,"activeCount":124},[],{"trials":22193,"activeCount":124},[],{"intervention":21670,"totalTrials":121,"cells":22195},{"EARLY_PHASE1":22196,"PHASE1":22198,"PHASE2":22200,"PHASE3":22210,"PHASE4":22212,"NA":22214},{"trials":22197,"activeCount":124},[],{"trials":22199,"activeCount":124},[],{"trials":22201,"activeCount":121,"soonestReadout":4006},[22202,22206],{"nctId":21660,"briefTitle":21661,"status":279,"phases":22203,"primaryCompletion":4006,"completion":21663,"start":21664,"enrollment":21665,"conditions":22204,"interventions":22205},[88],[21667,21668],[21670,21651,21671],{"nctId":21673,"briefTitle":21674,"status":279,"phases":22207,"primaryCompletion":21663,"completion":21676,"start":11677,"enrollment":21677,"conditions":22208,"interventions":22209},[88],[21679,21667,21680,21668],[21670,21651,21682,21683,21684],{"trials":22211,"activeCount":124},[],{"trials":22213,"activeCount":124},[],{"trials":22215,"activeCount":124},[],{"intervention":21671,"totalTrials":121,"cells":22217},{"EARLY_PHASE1":22218,"PHASE1":22220,"PHASE2":22222,"PHASE3":22232,"PHASE4":22234,"NA":22236},{"trials":22219,"activeCount":124},[],{"trials":22221,"activeCount":124},[],{"trials":22223,"activeCount":121,"soonestReadout":4006},[22224,22228],{"nctId":21660,"briefTitle":21661,"status":279,"phases":22225,"primaryCompletion":4006,"completion":21663,"start":21664,"enrollment":21665,"conditions":22226,"interventions":22227},[88],[21667,21668],[21670,21651,21671],{"nctId":21673,"briefTitle":21674,"status":279,"phases":22229,"primaryCompletion":21663,"completion":21676,"start":11677,"enrollment":21677,"conditions":22230,"interventions":22231},[88],[21679,21667,21680,21668],[21670,21651,21682,21683,21684],{"trials":22233,"activeCount":124},[],{"trials":22235,"activeCount":124},[],{"trials":22237,"activeCount":124},[],{"intervention":12941,"totalTrials":121,"cells":22239},{"EARLY_PHASE1":22240,"PHASE1":22242,"PHASE2":22248,"PHASE3":22254,"PHASE4":22256,"NA":22258},{"trials":22241,"activeCount":124},[],{"trials":22243,"activeCount":166,"soonestReadout":14052},[22244],{"nctId":14049,"briefTitle":14050,"status":546,"phases":22245,"primaryCompletion":14052,"completion":14053,"start":14054,"enrollment":2004,"conditions":22246,"interventions":22247},[87],[14056,12942,14057,14058],[12942,14060,2840],{"trials":22249,"activeCount":166,"soonestReadout":12329},[22250],{"nctId":12934,"briefTitle":12935,"status":279,"phases":22251,"primaryCompletion":12329,"completion":12329,"start":12937,"enrollment":1922,"conditions":22252,"interventions":22253},[88],[12939],[12941,1683,12942],{"trials":22255,"activeCount":124},[],{"trials":22257,"activeCount":124},[],{"trials":22259,"activeCount":124},[],{"intervention":12942,"totalTrials":121,"cells":22261},{"EARLY_PHASE1":22262,"PHASE1":22264,"PHASE2":22270,"PHASE3":22276,"PHASE4":22278,"NA":22280},{"trials":22263,"activeCount":124},[],{"trials":22265,"activeCount":166,"soonestReadout":14052},[22266],{"nctId":14049,"briefTitle":14050,"status":546,"phases":22267,"primaryCompletion":14052,"completion":14053,"start":14054,"enrollment":2004,"conditions":22268,"interventions":22269},[87],[14056,12942,14057,14058],[12942,14060,2840],{"trials":22271,"activeCount":166,"soonestReadout":12329},[22272],{"nctId":12934,"briefTitle":12935,"status":279,"phases":22273,"primaryCompletion":12329,"completion":12329,"start":12937,"enrollment":1922,"conditions":22274,"interventions":22275},[88],[12939],[12941,1683,12942],{"trials":22277,"activeCount":124},[],{"trials":22279,"activeCount":124},[],{"trials":22281,"activeCount":124},[],{"intervention":1945,"totalTrials":121,"cells":22283},{"EARLY_PHASE1":22284,"PHASE1":22286,"PHASE2":22295,"PHASE3":22301,"PHASE4":22303,"NA":22305},{"trials":22285,"activeCount":124},[],{"trials":22287,"activeCount":166,"soonestReadout":16160},[22288],{"nctId":22289,"briefTitle":22290,"status":279,"phases":22291,"primaryCompletion":16160,"completion":16160,"start":22292,"enrollment":1034,"conditions":22293,"interventions":22294},"NCT06414902","18F-AraG PET\u002FCT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer",[87],"2024-09-04",[2770],[1945],{"trials":22296,"activeCount":166,"soonestReadout":1939},[22297],{"nctId":1936,"briefTitle":1937,"status":279,"phases":22298,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1222,"conditions":22299,"interventions":22300},[87,88],[1942,1271],[1944,1050,1421,1945],{"trials":22302,"activeCount":124},[],{"trials":22304,"activeCount":124},[],{"trials":22306,"activeCount":124},[],{"intervention":22308,"totalTrials":121,"cells":22309},"Sacituzumab Tirumotecan",{"EARLY_PHASE1":22310,"PHASE1":22312,"PHASE2":22314,"PHASE3":22338,"PHASE4":22340,"NA":22342},{"trials":22311,"activeCount":124},[],{"trials":22313,"activeCount":124},[],{"trials":22315,"activeCount":121,"soonestReadout":22330},[22316,22326],{"nctId":22317,"briefTitle":22318,"status":546,"phases":22319,"primaryCompletion":21663,"completion":21676,"start":22320,"enrollment":1131,"conditions":22321,"interventions":22325},"NCT07511023","Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus\u002FRectum",[88],"2026-09-25",[7863,22308,22322,22323,22324],"Refractory Metastatic","Unresectable Squamous","Cell Carcinoma of the Anus\u002F Rectum",[22308],{"nctId":22327,"briefTitle":22328,"status":546,"phases":22329,"primaryCompletion":22330,"completion":2303,"start":104,"enrollment":1131,"conditions":22331,"interventions":22336},"NCT07438626","Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma",[88],"2028-06-01",[22332,22333,22334,22335],"Phase II","Sacituzumab","Tirumotecan","SMARCB1-deficient Renal Medullary Carcinoma",[22337],"Sacituzumab tirumotecan",{"trials":22339,"activeCount":124},[],{"trials":22341,"activeCount":124},[],{"trials":22343,"activeCount":124},[],{"intervention":2459,"totalTrials":121,"cells":22345},{"EARLY_PHASE1":22346,"PHASE1":22348,"PHASE2":22354,"PHASE3":22365,"PHASE4":22367,"NA":22369},{"trials":22347,"activeCount":124},[],{"trials":22349,"activeCount":166,"soonestReadout":2302},[22350],{"nctId":2299,"briefTitle":2300,"status":279,"phases":22351,"primaryCompletion":2302,"completion":2303,"start":701,"enrollment":406,"conditions":22352,"interventions":22353},[87],[2305,2306,2307],[2309,62,1070,2310,2311],{"trials":22355,"activeCount":166,"soonestReadout":22360},[22356],{"nctId":22357,"briefTitle":22358,"status":102,"phases":22359,"primaryCompletion":22360,"completion":22361,"start":22362,"enrollment":676,"conditions":22363,"interventions":22364},"NCT07316010","Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma",[88],"2029-03-21","2031-03-21","2026-03-17",[6956],[2459],{"trials":22366,"activeCount":124},[],{"trials":22368,"activeCount":124},[],{"trials":22370,"activeCount":124},[],{"intervention":10681,"totalTrials":121,"cells":22372},{"EARLY_PHASE1":22373,"PHASE1":22379,"PHASE2":22381,"PHASE3":22392,"PHASE4":22394,"NA":22396},{"trials":22374,"activeCount":166,"soonestReadout":10669},[22375],{"nctId":10666,"briefTitle":10667,"status":546,"phases":22376,"primaryCompletion":10669,"completion":10670,"start":10671,"enrollment":1222,"conditions":22377,"interventions":22378},[86],[10673,10674],[1275,1683,6802,10676,10677,1684,10678,10679,10680,10681,10682],{"trials":22380,"activeCount":124},[],{"trials":22382,"activeCount":166,"soonestReadout":3879},[22383],{"nctId":22384,"briefTitle":22385,"status":279,"phases":22386,"primaryCompletion":3879,"completion":12905,"start":22387,"enrollment":406,"conditions":22388,"interventions":22390},"NCT05673928","A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)",[88],"2023-05-16",[22389,1520],"Metastatic Solid Tumor",[22391,10681],"Trastuzumab emtansine",{"trials":22393,"activeCount":124},[],{"trials":22395,"activeCount":124},[],{"trials":22397,"activeCount":124},[],{"intervention":4798,"totalTrials":121,"cells":22399},{"EARLY_PHASE1":22400,"PHASE1":22402,"PHASE2":22404,"PHASE3":22421,"PHASE4":22423,"NA":22425},{"trials":22401,"activeCount":124},[],{"trials":22403,"activeCount":124},[],{"trials":22405,"activeCount":121,"soonestReadout":281},[22406,22410],{"nctId":4790,"briefTitle":4791,"status":279,"phases":22407,"primaryCompletion":548,"completion":490,"start":4793,"enrollment":517,"conditions":22408,"interventions":22409},[88],[1400,4795,4796],[4798,1402,4622,2293,1004,2374],{"nctId":22411,"briefTitle":22412,"status":279,"phases":22413,"primaryCompletion":281,"completion":571,"start":1238,"enrollment":1240,"conditions":22414,"interventions":22420},"NCT07382739","A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) \"PRIME-EMD-PMD\"",[88],[7863,22415,4798,22416,22417,22418,22419],"Radiotherapy-Induced Immune Priming","Relapsed Refractory Multiple Myeloma (RRMM)","Extramedullary Disease in Multiple Myeloma","Paramedullary Disease","PMD",[4798],{"trials":22422,"activeCount":124},[],{"trials":22424,"activeCount":124},[],{"trials":22426,"activeCount":124},[],{"intervention":6612,"totalTrials":121,"cells":22428},{"EARLY_PHASE1":22429,"PHASE1":22431,"PHASE2":22437,"PHASE3":22443,"PHASE4":22445,"NA":22447},{"trials":22430,"activeCount":124},[],{"trials":22432,"activeCount":166,"soonestReadout":193},[22433],{"nctId":6606,"briefTitle":6607,"status":279,"phases":22434,"primaryCompletion":193,"completion":591,"start":6609,"enrollment":628,"conditions":22435,"interventions":22436},[87],[18],[803,6612,6135],{"trials":22438,"activeCount":166,"soonestReadout":15578},[22439],{"nctId":15575,"briefTitle":15576,"status":279,"phases":22440,"primaryCompletion":15578,"completion":15579,"start":15580,"enrollment":1260,"conditions":22441,"interventions":22442},[87,88],[15582,15583],[6612,598],{"trials":22444,"activeCount":124},[],{"trials":22446,"activeCount":124},[],{"trials":22448,"activeCount":124},[],{"intervention":2089,"totalTrials":121,"cells":22450},{"EARLY_PHASE1":22451,"PHASE1":22453,"PHASE2":22455,"PHASE3":22467,"PHASE4":22469,"NA":22471},{"trials":22452,"activeCount":124},[],{"trials":22454,"activeCount":124},[],{"trials":22456,"activeCount":121,"soonestReadout":999},[22457,22461],{"nctId":2080,"briefTitle":2081,"status":102,"phases":22458,"primaryCompletion":224,"completion":224,"start":773,"enrollment":1568,"conditions":22459,"interventions":22460},[88],[2084,2085,1676,2086,1677,1678,1679],[2088,2089,2090,1050,53,2091],{"nctId":22462,"briefTitle":22463,"status":279,"phases":22464,"primaryCompletion":999,"completion":2628,"start":6165,"enrollment":1034,"conditions":22465,"interventions":22466},"NCT06569368","Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy",[88],[4989],[2089],{"trials":22468,"activeCount":124},[],{"trials":22470,"activeCount":124},[],{"trials":22472,"activeCount":124},[],{"intervention":2495,"totalTrials":1131,"cells":22474},{"EARLY_PHASE1":22475,"PHASE1":22477,"PHASE2":22491,"PHASE3":22537,"PHASE4":22547,"NA":22549},{"trials":22476,"activeCount":124},[],{"trials":22478,"activeCount":124},[22479,22483,22487],{"nctId":5431,"briefTitle":5432,"status":130,"phases":22480,"primaryCompletion":5434,"completion":5434,"start":5435,"enrollment":2779,"conditions":22481,"interventions":22482},[87],[1866,21],[75,1369,2424,2495,1114],{"nctId":5453,"briefTitle":5454,"status":130,"phases":22484,"primaryCompletion":1307,"completion":1307,"start":3251,"enrollment":492,"conditions":22485,"interventions":22486},[87],[5457,3271,5458,5459,5460,3275,3276,5461,5462,5463,3280],[1369,2424,2495,5465],{"nctId":9941,"briefTitle":9942,"status":130,"phases":22488,"primaryCompletion":8340,"completion":8340,"start":3819,"enrollment":121,"conditions":22489,"interventions":22490},[87],[1924],[1379,2495,1369],{"trials":22492,"activeCount":166,"soonestReadout":2490},[22493,22497,22501,22505,22509,22513,22517,22521,22525,22529,22533],{"nctId":2487,"briefTitle":2488,"status":102,"phases":22494,"primaryCompletion":2490,"completion":2490,"start":2491,"enrollment":134,"conditions":22495,"interventions":22496},[88],[21],[62,2494,2495,1114,1369],{"nctId":3984,"briefTitle":3985,"status":130,"phases":22498,"primaryCompletion":3987,"completion":3987,"start":3988,"enrollment":2446,"conditions":22499,"interventions":22500},[88],[2971,3990],[2368,2977,2495,1016,1709],{"nctId":3993,"briefTitle":3994,"status":130,"phases":22502,"primaryCompletion":3996,"completion":3996,"start":3997,"enrollment":406,"conditions":22503,"interventions":22504},[88],[3999],[2495,1376,1709],{"nctId":10072,"briefTitle":10073,"status":130,"phases":22506,"primaryCompletion":3571,"completion":3571,"start":10075,"enrollment":2581,"conditions":22507,"interventions":22508},[87,88],[1924,1942],[2831,1369,2977,2495],{"nctId":4036,"briefTitle":4037,"status":130,"phases":22510,"primaryCompletion":4039,"completion":4039,"start":4040,"enrollment":3541,"conditions":22511,"interventions":22512},[88],[1293,4042,4043],[2878,4045,2882,4046,4047],{"nctId":5600,"briefTitle":5601,"status":130,"phases":22514,"primaryCompletion":5603,"completion":5603,"start":5604,"enrollment":3354,"conditions":22515,"interventions":22516},[88],[5606],[2369,1710,2293,1369,1114,2495,2424],{"nctId":5617,"briefTitle":5618,"status":130,"phases":22518,"primaryCompletion":5620,"completion":5620,"start":5621,"enrollment":2933,"conditions":22519,"interventions":22520},[87,88],[5623],[2340,2495,1114,1369,2424,1071],{"nctId":5638,"briefTitle":5639,"status":130,"phases":22522,"primaryCompletion":1307,"completion":1307,"start":5641,"enrollment":1131,"conditions":22523,"interventions":22524},[88],[3273,3278],[75,1369,2424,2495],{"nctId":4166,"briefTitle":4167,"status":130,"phases":22526,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":22527,"interventions":22528},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"nctId":5667,"briefTitle":5668,"status":130,"phases":22530,"primaryCompletion":5670,"completion":5670,"start":5671,"enrollment":676,"conditions":22531,"interventions":22532},[88],[21],[2425,2495,2424,1114,2374],{"nctId":2784,"briefTitle":2785,"status":182,"phases":22534,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":1609,"conditions":22535,"interventions":22536},[88],[2790],[62,1013,2792,2495,1114,2793,2794,810],{"trials":22538,"activeCount":124},[22539,22543],{"nctId":4305,"briefTitle":4306,"status":130,"phases":22540,"primaryCompletion":4308,"completion":4308,"start":4309,"enrollment":2402,"conditions":22541,"interventions":22542},[89],[21],[4312,4313,4045,2879,2880,2882,4314,4315,4047,4316,4317,4318,4319,2884],{"nctId":4367,"briefTitle":4368,"status":130,"phases":22544,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":22545,"interventions":22546},[89],[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":22548,"activeCount":124},[],{"trials":22550,"activeCount":166,"soonestReadout":281},[22551,22555,22559,22569],{"nctId":12224,"briefTitle":12225,"status":279,"phases":22552,"primaryCompletion":281,"completion":281,"start":6635,"enrollment":1131,"conditions":22553,"interventions":22554},[91],[12228,12229,12230],[1013,804,2840,12232,2495,4022,1431,12233,3497,6656,1016],{"nctId":4379,"briefTitle":4380,"status":182,"phases":22556,"primaryCompletion":4382,"completion":4382,"start":2932,"enrollment":1483,"conditions":22557,"interventions":22558},[91],[4384],[1013,1709,806,1113,4386,2495,2369,4387,1114],{"nctId":22560,"briefTitle":22561,"status":130,"phases":22562,"primaryCompletion":22563,"completion":22563,"start":22564,"enrollment":240,"conditions":22565,"interventions":22566},"NCT00283621","Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide",[91],"2006-04-12","2003-06-02",[2971],[22567,22568,2977,2495],"Aranesp","Neulasta",{"nctId":2994,"briefTitle":2995,"status":130,"phases":22570,"primaryCompletion":184,"completion":184,"start":2778,"enrollment":2997,"conditions":22571,"interventions":22572},[91],[2971,2935,2999,3000],[3002,62,3003,3004,1013,1114,2495,1016],{"intervention":22574,"totalTrials":121,"cells":22575},"Letermovir",{"EARLY_PHASE1":22576,"PHASE1":22578,"PHASE2":22580,"PHASE3":22590,"PHASE4":22592,"NA":22594},{"trials":22577,"activeCount":124},[],{"trials":22579,"activeCount":124},[],{"trials":22581,"activeCount":166,"soonestReadout":21774},[22582],{"nctId":22583,"briefTitle":22584,"status":279,"phases":22585,"primaryCompletion":21774,"completion":2410,"start":22586,"enrollment":593,"conditions":22587,"interventions":22589},"NCT06575374","Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell",[88],"2024-12-12",[22588],"Cell Therapy",[22574],{"trials":22591,"activeCount":124},[],{"trials":22593,"activeCount":124},[],{"trials":22595,"activeCount":166,"soonestReadout":446},[22596],{"nctId":22597,"briefTitle":22598,"status":279,"phases":22599,"primaryCompletion":446,"completion":446,"start":22600,"enrollment":5797,"conditions":22601,"interventions":22604},"NCT06639854","The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients",[91],"2024-11-20",[22602,22603],"Cytomegalovirus Cell Mediated Immunity","Hematopoietic Cell Transplant",[22574],{"intervention":3780,"totalTrials":230,"cells":22606},{"EARLY_PHASE1":22607,"PHASE1":22609,"PHASE2":22611,"PHASE3":22638,"PHASE4":22648,"NA":22650},{"trials":22608,"activeCount":124},[],{"trials":22610,"activeCount":124},[],{"trials":22612,"activeCount":166,"soonestReadout":11335},[22613,22617,22621,22625,22634],{"nctId":12098,"briefTitle":12099,"status":130,"phases":22614,"primaryCompletion":2602,"completion":2602,"start":12101,"enrollment":1975,"conditions":22615,"interventions":22616},[88],[7818,27],[2957,12104,12105,12106],{"nctId":5126,"briefTitle":5127,"status":203,"phases":22618,"primaryCompletion":5129,"completion":5129,"start":4448,"enrollment":124,"conditions":22619,"interventions":22620},[88],[5131,3545,5132,3546,3547,3548],[3700,3720,3780],{"nctId":11332,"briefTitle":11333,"status":102,"phases":22622,"primaryCompletion":11335,"completion":11335,"start":11336,"enrollment":11337,"conditions":22623,"interventions":22624},[88],[5122,11339],[3699,11341,3720,11342,11343,3780,11344,809],{"nctId":22626,"briefTitle":22627,"status":130,"phases":22628,"primaryCompletion":2968,"completion":2968,"start":2890,"enrollment":1034,"conditions":22629,"interventions":22633},"NCT00429494","GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients",[88],[22630,22631,22632],"Amenorrhea","Premature Ovarian Failure","Ovarian Function Insufficiency",[3780],{"nctId":3774,"briefTitle":3775,"status":130,"phases":22635,"primaryCompletion":2909,"completion":2909,"start":3777,"enrollment":1766,"conditions":22636,"interventions":22637},[88],[27],[3780,1049],{"trials":22639,"activeCount":124},[22640],{"nctId":22641,"briefTitle":22642,"status":182,"phases":22643,"primaryCompletion":22644,"completion":22644,"start":22645,"enrollment":3354,"conditions":22646,"interventions":22647},"NCT00003645","Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence",[89],"2017-03-20","1999-06-14",[27],[11342,3780],{"trials":22649,"activeCount":124},[],{"trials":22651,"activeCount":124},[],{"intervention":11342,"totalTrials":296,"cells":22653},{"EARLY_PHASE1":22654,"PHASE1":22656,"PHASE2":22658,"PHASE3":22664,"PHASE4":22680,"NA":22682},{"trials":22655,"activeCount":124},[],{"trials":22657,"activeCount":124},[],{"trials":22659,"activeCount":166,"soonestReadout":11335},[22660],{"nctId":11332,"briefTitle":11333,"status":102,"phases":22661,"primaryCompletion":11335,"completion":11335,"start":11336,"enrollment":11337,"conditions":22662,"interventions":22663},[88],[5122,11339],[3699,11341,3720,11342,11343,3780,11344,809],{"trials":22665,"activeCount":124},[22666,22672,22676],{"nctId":22667,"briefTitle":22668,"status":182,"phases":22669,"primaryCompletion":12066,"completion":12066,"start":11135,"enrollment":2865,"conditions":22670,"interventions":22671},"NCT00388804","External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer",[89],[27],[11341,3718,3719,11342],{"nctId":22641,"briefTitle":22642,"status":182,"phases":22673,"primaryCompletion":22644,"completion":22644,"start":22645,"enrollment":3354,"conditions":22674,"interventions":22675},[89],[27],[11342,3780],{"nctId":12206,"briefTitle":12207,"status":130,"phases":22677,"primaryCompletion":4887,"completion":4887,"start":12209,"enrollment":12210,"conditions":22678,"interventions":22679},[89],[27],[11341,2957,12213,11342,2959,11344,12214,1868],{"trials":22681,"activeCount":124},[],{"trials":22683,"activeCount":124},[],{"intervention":366,"totalTrials":1231,"cells":22685},{"EARLY_PHASE1":22686,"PHASE1":22692,"PHASE2":22694,"PHASE3":22704,"PHASE4":22710,"NA":22712},{"trials":22687,"activeCount":124},[22688],{"nctId":352,"briefTitle":353,"status":182,"phases":22689,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":22690,"interventions":22691},[86],[359,360,361],[363,347,364,365,366,367],{"trials":22693,"activeCount":124},[],{"trials":22695,"activeCount":166,"soonestReadout":860},[22696],{"nctId":22697,"briefTitle":22698,"status":102,"phases":22699,"primaryCompletion":860,"completion":860,"start":3121,"enrollment":10174,"conditions":22700,"interventions":22702},"NCT06232577","5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial",[88],[22701],"Intra-abdominal Cancer",[363,22703,366],"Tramadol",{"trials":22705,"activeCount":124},[22706],{"nctId":5792,"briefTitle":5793,"status":182,"phases":22707,"primaryCompletion":5795,"completion":5795,"start":5796,"enrollment":5797,"conditions":22708,"interventions":22709},[89],[5799,5800],[5802,5750,366],{"trials":22711,"activeCount":124},[],{"trials":22713,"activeCount":124},[],{"intervention":11341,"totalTrials":1231,"cells":22715},{"EARLY_PHASE1":22716,"PHASE1":22718,"PHASE2":22720,"PHASE3":22726,"PHASE4":22736,"NA":22738},{"trials":22717,"activeCount":124},[],{"trials":22719,"activeCount":124},[],{"trials":22721,"activeCount":166,"soonestReadout":11335},[22722],{"nctId":11332,"briefTitle":11333,"status":102,"phases":22723,"primaryCompletion":11335,"completion":11335,"start":11336,"enrollment":11337,"conditions":22724,"interventions":22725},[88],[5122,11339],[3699,11341,3720,11342,11343,3780,11344,809],{"trials":22727,"activeCount":124},[22728,22732],{"nctId":22667,"briefTitle":22668,"status":182,"phases":22729,"primaryCompletion":12066,"completion":12066,"start":11135,"enrollment":2865,"conditions":22730,"interventions":22731},[89],[27],[11341,3718,3719,11342],{"nctId":12206,"briefTitle":12207,"status":130,"phases":22733,"primaryCompletion":4887,"completion":4887,"start":12209,"enrollment":12210,"conditions":22734,"interventions":22735},[89],[27],[11341,2957,12213,11342,2959,11344,12214,1868],{"trials":22737,"activeCount":124},[],{"trials":22739,"activeCount":124},[],{"intervention":11344,"totalTrials":121,"cells":22741},{"EARLY_PHASE1":22742,"PHASE1":22744,"PHASE2":22746,"PHASE3":22752,"PHASE4":22758,"NA":22760},{"trials":22743,"activeCount":124},[],{"trials":22745,"activeCount":124},[],{"trials":22747,"activeCount":166,"soonestReadout":11335},[22748],{"nctId":11332,"briefTitle":11333,"status":102,"phases":22749,"primaryCompletion":11335,"completion":11335,"start":11336,"enrollment":11337,"conditions":22750,"interventions":22751},[88],[5122,11339],[3699,11341,3720,11342,11343,3780,11344,809],{"trials":22753,"activeCount":124},[22754],{"nctId":12206,"briefTitle":12207,"status":130,"phases":22755,"primaryCompletion":4887,"completion":4887,"start":12209,"enrollment":12210,"conditions":22756,"interventions":22757},[89],[27],[11341,2957,12213,11342,2959,11344,12214,1868],{"trials":22759,"activeCount":124},[],{"trials":22761,"activeCount":124},[],{"intervention":5767,"totalTrials":121,"cells":22763},{"EARLY_PHASE1":22764,"PHASE1":22766,"PHASE2":22768,"PHASE3":22774,"PHASE4":22784,"NA":22786},{"trials":22765,"activeCount":124},[],{"trials":22767,"activeCount":124},[],{"trials":22769,"activeCount":166,"soonestReadout":5762},[22770],{"nctId":5759,"briefTitle":5760,"status":102,"phases":22771,"primaryCompletion":5762,"completion":5762,"start":5763,"enrollment":1975,"conditions":22772,"interventions":22773},[88],[5765],[5767,5750],{"trials":22775,"activeCount":124},[22776],{"nctId":22777,"briefTitle":22778,"status":203,"phases":22779,"primaryCompletion":10760,"completion":10760,"start":6352,"enrollment":124,"conditions":22780,"interventions":22782},"NCT00528502","Lidocaine Supplement for Minimal Invasive Parathyroid Surgery",[89],[22781],"Parathyroid Disease",[5767,22783],"Saline",{"trials":22785,"activeCount":124},[],{"trials":22787,"activeCount":124},[],{"intervention":6545,"totalTrials":95,"cells":22789},{"EARLY_PHASE1":22790,"PHASE1":22792,"PHASE2":22806,"PHASE3":22845,"PHASE4":22847,"NA":22849},{"trials":22791,"activeCount":124},[],{"trials":22793,"activeCount":124},[22794,22798,22802],{"nctId":10841,"briefTitle":10842,"status":130,"phases":22795,"primaryCompletion":2777,"completion":2777,"start":10844,"enrollment":7377,"conditions":22796,"interventions":22797},[87],[1942],[6545,1275],{"nctId":6540,"briefTitle":6541,"status":203,"phases":22799,"primaryCompletion":2365,"completion":2365,"start":185,"enrollment":124,"conditions":22800,"interventions":22801},[87],[15],[1070,803,894,6545],{"nctId":8284,"briefTitle":8285,"status":130,"phases":22803,"primaryCompletion":8287,"completion":8287,"start":8288,"enrollment":1034,"conditions":22804,"interventions":22805},[87],[785,712,3346,891,8290,4559,3642],[3085,6545,1069,1070,806,894,2196],{"trials":22807,"activeCount":166,"soonestReadout":3943},[22808,22812,22819,22825,22829,22833,22837,22841],{"nctId":8302,"briefTitle":8303,"status":182,"phases":22809,"primaryCompletion":8305,"completion":8305,"start":8306,"enrollment":2779,"conditions":22810,"interventions":22811},[88],[3346],[6545,2449,894],{"nctId":22813,"briefTitle":22814,"status":203,"phases":22815,"primaryCompletion":22816,"start":3832,"enrollment":124,"conditions":22817,"interventions":22818},"NCT01649622","Bendamustine in Acute Lymphoblastic Leukemia\u002FLymphoma (ALL)",[88],"2018-12",[15,21],[6545],{"nctId":22820,"briefTitle":22821,"status":182,"phases":22822,"primaryCompletion":8753,"completion":8753,"start":4731,"enrollment":2159,"conditions":22823,"interventions":22824},"NCT00790855","Bendamustine in Acute Leukemia and MDS",[87,88],[36,30,1122,3315],[6545],{"nctId":8460,"briefTitle":8461,"status":182,"phases":22826,"primaryCompletion":8463,"completion":8463,"start":8464,"enrollment":1568,"conditions":22827,"interventions":22828},[88],[1122,2502,5597,21],[6545,2712,1070,2477,2293,894,2196],{"nctId":8616,"briefTitle":8617,"status":130,"phases":22830,"primaryCompletion":8619,"completion":8619,"start":2740,"enrollment":1131,"conditions":22831,"interventions":22832},[88],[15,21],[894,8622,8623,1070,6545,4537,2196,806,8624,2374],{"nctId":8795,"briefTitle":8796,"status":182,"phases":22834,"primaryCompletion":8798,"completion":8798,"start":8799,"enrollment":2865,"conditions":22835,"interventions":22836},[88],[712],[1402,1070,894,4537,6545,1178],{"nctId":8888,"briefTitle":8889,"status":130,"phases":22838,"primaryCompletion":8891,"completion":8891,"start":8892,"enrollment":240,"conditions":22839,"interventions":22840},[87,88],[15],[6545,1070,894],{"nctId":7385,"briefTitle":7386,"status":279,"phases":22842,"primaryCompletion":3943,"completion":3943,"start":7388,"enrollment":448,"conditions":22843,"interventions":22844},[87,88],[726],[6545,803,2712,1070,2293,2195,894,2196],{"trials":22846,"activeCount":124},[],{"trials":22848,"activeCount":124},[],{"trials":22850,"activeCount":124},[],{"intervention":2330,"totalTrials":95,"cells":22852},{"EARLY_PHASE1":22853,"PHASE1":22855,"PHASE2":22861,"PHASE3":22924,"PHASE4":22926,"NA":22928},{"trials":22854,"activeCount":124},[],{"trials":22856,"activeCount":124},[22857],{"nctId":2323,"briefTitle":2324,"status":182,"phases":22858,"primaryCompletion":2326,"completion":2326,"start":2327,"enrollment":1568,"conditions":22859,"interventions":22860},[87],[18],[1710,2330,62],{"trials":22862,"activeCount":166,"soonestReadout":18310},[22863,22869,22875,22879,22886,22893,22897,22903,22910,22916],{"nctId":22864,"briefTitle":22865,"status":130,"phases":22866,"primaryCompletion":185,"completion":185,"start":10346,"enrollment":1328,"conditions":22867,"interventions":22868},"NCT00087685","RAD001 in Recurrent Endometrial Cancer Patients",[88],[2809],[2330],{"nctId":22870,"briefTitle":22871,"status":130,"phases":22872,"primaryCompletion":3668,"completion":3668,"start":10760,"enrollment":1243,"conditions":22873,"interventions":22874},"NCT00607113","Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma",[88],[2049],[4234,2330],{"nctId":6804,"briefTitle":6805,"status":3049,"phases":22876,"primaryCompletion":2326,"completion":6807,"start":5470,"enrollment":2933,"conditions":22877,"interventions":22878},[88],[18],[1376,4218,6744,803,2330],{"nctId":22880,"briefTitle":22881,"status":130,"phases":22882,"primaryCompletion":3494,"completion":3494,"start":4351,"enrollment":517,"conditions":22883,"interventions":22885},"NCT00317720","Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer",[87,88],[18,22884],"Neoplasm Metastasis",[4227,2330],{"nctId":22887,"briefTitle":22888,"status":130,"phases":22889,"primaryCompletion":4842,"completion":4842,"start":3987,"enrollment":2446,"conditions":22890,"interventions":22892},"NCT00942734","Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma",[88],[22891],"Head And Neck Cancer",[3847,2330],{"nctId":18307,"briefTitle":18308,"status":102,"phases":22894,"primaryCompletion":18310,"completion":5382,"start":18311,"enrollment":924,"conditions":22895,"interventions":22896},[88],[2809],[14086,2330],{"nctId":22898,"briefTitle":22899,"status":130,"phases":22900,"primaryCompletion":4612,"completion":4612,"start":12168,"enrollment":1409,"conditions":22901,"interventions":22902},"NCT00081874","RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma",[87,88],[15,891,3429],[2330],{"nctId":22904,"briefTitle":22905,"status":130,"phases":22906,"primaryCompletion":4723,"completion":4723,"start":9923,"enrollment":1496,"conditions":22907,"interventions":22909},"NCT00449748","Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis",[88],[22908],"Systemic Mastocytosis",[2330],{"nctId":22911,"briefTitle":22912,"status":182,"phases":22913,"primaryCompletion":13673,"completion":13673,"start":6828,"enrollment":834,"conditions":22914,"interventions":22915},"NCT00640978","Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer",[88],[4107],[2330,3847],{"nctId":22917,"briefTitle":22918,"status":130,"phases":22919,"primaryCompletion":3987,"completion":3987,"start":7473,"enrollment":37,"conditions":22920,"interventions":22922},"NCT00113360","RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma",[88],[2049,22921],"Islet Cell Carcinoma",[2330,22923],"Octreotide Depot",{"trials":22925,"activeCount":124},[],{"trials":22927,"activeCount":124},[],{"trials":22929,"activeCount":124},[],{"intervention":4227,"totalTrials":186,"cells":22931},{"EARLY_PHASE1":22932,"PHASE1":22934,"PHASE2":22948,"PHASE3":22973,"PHASE4":22975,"NA":22977},{"trials":22933,"activeCount":124},[],{"trials":22935,"activeCount":124},[22936,22940,22944],{"nctId":10910,"briefTitle":10911,"status":130,"phases":22937,"primaryCompletion":10913,"completion":10913,"start":10914,"enrollment":10915,"conditions":22938,"interventions":22939},[87],[1942],[1275,2207,3847,4227,7180,10918,1683],{"nctId":20280,"briefTitle":20281,"status":130,"phases":22941,"primaryCompletion":10449,"completion":10449,"start":3668,"enrollment":357,"conditions":22942,"interventions":22943},[87],[33],[1431,7180,4227,1431],{"nctId":14075,"briefTitle":14076,"status":130,"phases":22945,"primaryCompletion":4867,"completion":4867,"start":14078,"enrollment":1609,"conditions":22946,"interventions":22947},[87],[1343,11800,14080,14081,14082,13135,10825,14083,14084,5087,5088,5089,7298],[2840,14086,4227],{"trials":22949,"activeCount":166,"soonestReadout":5310},[22950,22954,22958,22962,22966],{"nctId":22880,"briefTitle":22881,"status":130,"phases":22951,"primaryCompletion":3494,"completion":3494,"start":4351,"enrollment":517,"conditions":22952,"interventions":22953},[87,88],[18,22884],[4227,2330],{"nctId":8021,"briefTitle":8022,"status":102,"phases":22955,"primaryCompletion":5310,"completion":238,"start":8024,"enrollment":1100,"conditions":22956,"interventions":22957},[88],[8026,8027,8028,8029],[8031,53,7301,4227],{"nctId":4220,"briefTitle":4221,"status":130,"phases":22959,"primaryCompletion":4223,"completion":4223,"start":4224,"enrollment":492,"conditions":22960,"interventions":22961},[88],[24],[4227,1709,4135],{"nctId":7291,"briefTitle":7292,"status":182,"phases":22963,"primaryCompletion":7294,"completion":7294,"start":5035,"enrollment":1240,"conditions":22964,"interventions":22965},[87,88],[7296,7297,5234,5086,5087,5088,5089,7298],[803,1013,7300,1376,7301,4227],{"nctId":22967,"briefTitle":22968,"status":203,"phases":22969,"primaryCompletion":13585,"start":3725,"enrollment":124,"conditions":22970,"interventions":22971},"NCT01479179","Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab",[87,88],[18],[22972,4227],"AMG 479",{"trials":22974,"activeCount":124},[],{"trials":22976,"activeCount":124},[],{"trials":22978,"activeCount":124},[],{"intervention":10918,"totalTrials":1483,"cells":22980},{"EARLY_PHASE1":22981,"PHASE1":22983,"PHASE2":22999,"PHASE3":23024,"PHASE4":23026,"NA":23028},{"trials":22982,"activeCount":124},[],{"trials":22984,"activeCount":124},[22985,22991,22995],{"nctId":22986,"briefTitle":22987,"status":130,"phases":22988,"primaryCompletion":2698,"completion":2698,"start":3762,"enrollment":3820,"conditions":22989,"interventions":22990},"NCT01122615","Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)",[87],[6830,1333],[10918,6656],{"nctId":13421,"briefTitle":13422,"status":130,"phases":22992,"primaryCompletion":3805,"start":4183,"enrollment":163,"conditions":22993,"interventions":22994},[87],[1924],[1028,3847,7180,1402,2207,10918,9894],{"nctId":10910,"briefTitle":10911,"status":130,"phases":22996,"primaryCompletion":10913,"completion":10913,"start":10914,"enrollment":10915,"conditions":22997,"interventions":22998},[87],[1942],[1275,2207,3847,4227,7180,10918,1683],{"trials":23000,"activeCount":166,"soonestReadout":23020},[23001,23008,23012,23016],{"nctId":23002,"briefTitle":23003,"status":130,"phases":23004,"primaryCompletion":12605,"completion":12605,"start":2846,"enrollment":1034,"conditions":23005,"interventions":23007},"NCT02060370","Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)",[88],[23006,1333],"Genitourinary Cancer",[10918],{"nctId":11403,"briefTitle":11404,"status":130,"phases":23009,"primaryCompletion":11406,"completion":11406,"start":11407,"enrollment":11408,"conditions":23010,"interventions":23011},[88],[27],[3699,809,10918,1028],{"nctId":14161,"briefTitle":14162,"status":182,"phases":23013,"primaryCompletion":10410,"completion":10410,"start":3996,"enrollment":606,"conditions":23014,"interventions":23015},[88],[1333],[2840,10918],{"nctId":23017,"briefTitle":23018,"status":102,"phases":23019,"primaryCompletion":23020,"completion":23020,"start":23021,"enrollment":676,"conditions":23022,"interventions":23023},"NCT00715442","Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)",[88],"2026-12-04","2008-06-24",[1521],[10918],{"trials":23025,"activeCount":124},[],{"trials":23027,"activeCount":124},[],{"trials":23029,"activeCount":124},[],{"intervention":3420,"totalTrials":230,"cells":23031},{"EARLY_PHASE1":23032,"PHASE1":23034,"PHASE2":23036,"PHASE3":23062,"PHASE4":23064,"NA":23066},{"trials":23033,"activeCount":124},[],{"trials":23035,"activeCount":124},[],{"trials":23037,"activeCount":166,"soonestReadout":504},[23038,23042,23046,23050,23054,23058],{"nctId":16610,"briefTitle":16611,"status":279,"phases":23039,"primaryCompletion":504,"completion":504,"start":16613,"enrollment":342,"conditions":23040,"interventions":23041},[88],[3134,647,30,648],[3085,3420,1069,1014,1071],{"nctId":19010,"briefTitle":19011,"status":130,"phases":23043,"primaryCompletion":5434,"completion":5434,"start":2944,"enrollment":1140,"conditions":23044,"interventions":23045},[88],[30,3134],[4537,3420,1014,2374],{"nctId":12722,"briefTitle":12723,"status":130,"phases":23047,"primaryCompletion":12725,"completion":12725,"start":12726,"enrollment":2779,"conditions":23048,"interventions":23049},[87,88],[15,1036],[1069,3420,612],{"nctId":4807,"briefTitle":4808,"status":130,"phases":23051,"primaryCompletion":4810,"completion":4810,"start":4811,"enrollment":628,"conditions":23052,"interventions":23053},[87,88],[15],[1069,1004,803,3420,612,806,1014,2196],{"nctId":3413,"briefTitle":3414,"status":130,"phases":23055,"primaryCompletion":2953,"completion":2953,"start":3416,"enrollment":1140,"conditions":23056,"interventions":23057},[88],[3418,15,1036],[1069,599,3420,654,1005,655,1014],{"nctId":3443,"briefTitle":3444,"status":182,"phases":23059,"primaryCompletion":3446,"completion":3446,"start":3447,"enrollment":166,"conditions":23060,"interventions":23061},[88],[3449,3450,3451,3452,2570,3453,3454,3455,3456,3457,3458,3459],[3420,2424,1005,2194,2293,2195,2196,1254],{"trials":23063,"activeCount":124},[],{"trials":23065,"activeCount":124},[],{"trials":23067,"activeCount":124},[],{"intervention":3432,"totalTrials":3197,"cells":23069},{"EARLY_PHASE1":23070,"PHASE1":23072,"PHASE2":23074,"PHASE3":23106,"PHASE4":23108,"NA":23110},{"trials":23071,"activeCount":124},[],{"trials":23073,"activeCount":124},[],{"trials":23075,"activeCount":166,"soonestReadout":3425},[23076,23080,23088,23095,23102],{"nctId":12602,"briefTitle":12603,"status":182,"phases":23077,"primaryCompletion":12605,"completion":12605,"start":6065,"enrollment":230,"conditions":23078,"interventions":23079},[88],[15],[3432,612],{"nctId":23081,"briefTitle":23082,"status":130,"phases":23083,"primaryCompletion":23084,"completion":23084,"start":7177,"enrollment":1409,"conditions":23085,"interventions":23086},"NCT01893372","Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)",[88],"2019-01-06",[15],[3432,23087],"Hypomethylating Agent",{"nctId":23089,"briefTitle":23090,"status":130,"phases":23091,"primaryCompletion":16597,"completion":16597,"start":23092,"enrollment":3354,"conditions":23093,"interventions":23094},"NCT01000051","Eltrombopag for Post Transplant Thrombocytopenia",[88],"2010-02-17",[13565],[3432],{"nctId":23096,"briefTitle":23097,"status":130,"phases":23098,"primaryCompletion":341,"completion":341,"start":23099,"enrollment":3820,"conditions":23100,"interventions":23101},"NCT01168921","Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)",[88],"2010-11-03",[13526,15],[3432],{"nctId":3422,"briefTitle":3423,"status":279,"phases":23103,"primaryCompletion":3425,"completion":3426,"start":3427,"enrollment":406,"conditions":23104,"interventions":23105},[88],[2135,3429],[598,3431,3432,1004,3433,2462,803,1114,2196],{"trials":23107,"activeCount":124},[],{"trials":23109,"activeCount":124},[],{"trials":23111,"activeCount":124},[],{"intervention":16012,"totalTrials":3197,"cells":23113},{"EARLY_PHASE1":23114,"PHASE1":23116,"PHASE2":23118,"PHASE3":23146,"PHASE4":23148,"NA":23150},{"trials":23115,"activeCount":124},[],{"trials":23117,"activeCount":124},[],{"trials":23119,"activeCount":166,"soonestReadout":18430},[23120,23127,23131,23135,23142],{"nctId":23121,"briefTitle":23122,"status":203,"phases":23123,"primaryCompletion":9827,"completion":9827,"start":2945,"enrollment":124,"conditions":23124,"interventions":23125},"NCT00006090","Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia",[88],[15],[23126],"arsenic trioxide",{"nctId":16006,"briefTitle":16007,"status":130,"phases":23128,"primaryCompletion":2288,"completion":2288,"start":2969,"enrollment":959,"conditions":23129,"interventions":23130},[88],[16010],[2247,16012,655,694],{"nctId":18427,"briefTitle":18428,"status":279,"phases":23132,"primaryCompletion":18430,"completion":18430,"start":2729,"enrollment":9213,"conditions":23133,"interventions":23134},[88],[18432],[16012,694,18434],{"nctId":23136,"briefTitle":23137,"status":203,"phases":23138,"primaryCompletion":6790,"completion":6790,"start":23139,"enrollment":124,"conditions":23140,"interventions":23141},"NCT00006091","Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment",[88],"2000-06-19",[15],[23126],{"nctId":20205,"briefTitle":20206,"status":130,"phases":23143,"primaryCompletion":4183,"completion":4183,"start":8415,"enrollment":473,"conditions":23144,"interventions":23145},[87,88],[1400,2755],[16012,2293,20210],{"trials":23147,"activeCount":124},[],{"trials":23149,"activeCount":124},[],{"trials":23151,"activeCount":124},[],{"intervention":18073,"totalTrials":3197,"cells":23153},{"EARLY_PHASE1":23154,"PHASE1":23156,"PHASE2":23158,"PHASE3":23191,"PHASE4":23193,"NA":23195},{"trials":23155,"activeCount":124},[],{"trials":23157,"activeCount":124},[],{"trials":23159,"activeCount":166,"soonestReadout":238},[23160,23164,23172,23176,23180],{"nctId":18273,"briefTitle":18274,"status":182,"phases":23161,"primaryCompletion":18276,"completion":18276,"start":18277,"enrollment":296,"conditions":23162,"interventions":23163},[88],[7312,5234,7317],[12927,10904,18073,14086,2206,14130],{"nctId":23165,"briefTitle":23166,"status":182,"phases":23167,"primaryCompletion":3638,"completion":23168,"start":11142,"enrollment":1483,"conditions":23169,"interventions":23170},"NCT05082025","Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and\u002For PR+ Cancers With PI3K (PIK3CA, PIK3R1) and\u002For PTEN Alterations",[88],"2025-12-12",[2809,1530],[17196,23171],"fulvestrant",{"nctId":21608,"briefTitle":21609,"status":102,"phases":23173,"primaryCompletion":238,"completion":238,"start":781,"enrollment":550,"conditions":23174,"interventions":23175},[88],[5799],[18073,12927],{"nctId":18068,"briefTitle":18069,"status":182,"phases":23177,"primaryCompletion":2806,"completion":2806,"start":2836,"enrollment":95,"conditions":23178,"interventions":23179},[87,88],[18],[18073,12438,1028],{"nctId":23181,"briefTitle":23182,"status":182,"phases":23183,"primaryCompletion":23184,"completion":23184,"start":23185,"enrollment":230,"conditions":23186,"interventions":23189},"NCT06408168","Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)",[88],"2025-12-08","2024-08-08",[23187,23188],"Hormone Receptor-positive Human Epidermal Growth Factor 2-negative","Metastatic Invasive LObular Carcinoma",[18073,23190],"Repotrectinib",{"trials":23192,"activeCount":124},[],{"trials":23194,"activeCount":124},[],{"trials":23196,"activeCount":124},[],{"intervention":2596,"totalTrials":3197,"cells":23198},{"EARLY_PHASE1":23199,"PHASE1":23201,"PHASE2":23203,"PHASE3":23228,"PHASE4":23230,"NA":23232},{"trials":23200,"activeCount":124},[],{"trials":23202,"activeCount":124},[],{"trials":23204,"activeCount":166,"soonestReadout":5310},[23205,23209,23213,23217,23221],{"nctId":2587,"briefTitle":2588,"status":182,"phases":23206,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":95,"conditions":23207,"interventions":23208},[88],[1142,2593,1144,2594],[803,654,1028,62,1013,1113,805,806,809,894,2596,1016],{"nctId":10502,"briefTitle":10503,"status":130,"phases":23210,"primaryCompletion":10505,"completion":10505,"start":10506,"enrollment":4291,"conditions":23211,"interventions":23212},[88],[741,2133,746,2134],[510,2596],{"nctId":15553,"briefTitle":15554,"status":130,"phases":23214,"primaryCompletion":10913,"completion":10913,"start":15556,"enrollment":166,"conditions":23215,"interventions":23216},[88],[8589,15558],[598,2596],{"nctId":12699,"briefTitle":12700,"status":130,"phases":23218,"primaryCompletion":12702,"completion":12702,"start":12703,"enrollment":406,"conditions":23219,"interventions":23220},[87,88],[12705,12706,3244,608,610],[612,2596],{"nctId":23222,"briefTitle":23223,"status":102,"phases":23224,"primaryCompletion":5310,"completion":5310,"start":23225,"enrollment":1496,"conditions":23226,"interventions":23227},"NCT02131584","Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia",[88],"2014-09-02",[712],[2596],{"trials":23229,"activeCount":124},[],{"trials":23231,"activeCount":124},[],{"trials":23233,"activeCount":124},[],{"intervention":7370,"totalTrials":296,"cells":23235},{"EARLY_PHASE1":23236,"PHASE1":23238,"PHASE2":23244,"PHASE3":23263,"PHASE4":23265,"NA":23267},{"trials":23237,"activeCount":124},[],{"trials":23239,"activeCount":124},[23240],{"nctId":12838,"briefTitle":12839,"status":130,"phases":23241,"primaryCompletion":12841,"completion":12841,"start":689,"enrollment":1240,"conditions":23242,"interventions":23243},[87],[1898,1676,1677,1678,1679],[1683,1372,7370],{"trials":23245,"activeCount":166,"soonestReadout":19416},[23246,23255,23259],{"nctId":23247,"briefTitle":23248,"status":182,"phases":23249,"primaryCompletion":23250,"completion":23250,"start":16597,"enrollment":1231,"conditions":23251,"interventions":23253},"NCT03258008","Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer",[88],"2021-11-05",[7649,7651,23252],"Oropharyngeal Cancer",[7370,23254],"ISA101b",{"nctId":19413,"briefTitle":19414,"status":102,"phases":23256,"primaryCompletion":19416,"completion":8064,"start":19417,"enrollment":19418,"conditions":23257,"interventions":23258},[87,88],[1343,3544,360,361,3545,5123,3457,3546,3547,3548],[693,19421,7370],{"nctId":7360,"briefTitle":7361,"status":130,"phases":23260,"primaryCompletion":7363,"completion":7363,"start":7364,"enrollment":3197,"conditions":23261,"interventions":23262},[87,88],[7366,6448,7367,1460],[1599,7369,803,7370],{"trials":23264,"activeCount":124},[],{"trials":23266,"activeCount":124},[],{"trials":23268,"activeCount":124},[],{"intervention":4777,"totalTrials":296,"cells":23270},{"EARLY_PHASE1":23271,"PHASE1":23273,"PHASE2":23293,"PHASE3":23303,"PHASE4":23305,"NA":23307},{"trials":23272,"activeCount":124},[],{"trials":23274,"activeCount":124},[23275,23284],{"nctId":23276,"briefTitle":23277,"status":130,"phases":23278,"primaryCompletion":23279,"completion":23279,"start":23280,"enrollment":1568,"conditions":23281,"interventions":23283},"NCT03989466","Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia",[87],"2024-09-24","2020-01-15",[9054,23282],"T-Cell Prolymphocytic Leukemia",[2439,4777],{"nctId":23285,"briefTitle":23286,"status":182,"phases":23287,"primaryCompletion":7725,"completion":7725,"start":23288,"enrollment":186,"conditions":23289,"interventions":23291},"NCT04239989","Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant",[87],"2021-10-08",[23290],"Bronchiolitis Obliterans",[4777,23292],"Itacitinib Adipate",{"trials":23294,"activeCount":166,"soonestReadout":2455},[23295,23299],{"nctId":4771,"briefTitle":4772,"status":102,"phases":23296,"primaryCompletion":2455,"completion":2455,"start":4774,"enrollment":2004,"conditions":23297,"interventions":23298},[88],[680],[1004,803,1070,4777,2196,1254],{"nctId":4847,"briefTitle":4848,"status":203,"phases":23300,"primaryCompletion":4715,"completion":4715,"start":4715,"enrollment":124,"conditions":23301,"interventions":23302},[88],[4851,680,359],[1004,1070,4777,806,2196],{"trials":23304,"activeCount":124},[],{"trials":23306,"activeCount":124},[],{"trials":23308,"activeCount":124},[],{"intervention":12420,"totalTrials":296,"cells":23310},{"EARLY_PHASE1":23311,"PHASE1":23313,"PHASE2":23323,"PHASE3":23333,"PHASE4":23335,"NA":23337},{"trials":23312,"activeCount":124},[],{"trials":23314,"activeCount":124},[23315,23319],{"nctId":20953,"briefTitle":20954,"status":130,"phases":23316,"primaryCompletion":20956,"completion":20956,"start":20957,"enrollment":3584,"conditions":23317,"interventions":23318},[87],[33],[12420,6516,2405],{"nctId":21795,"briefTitle":21796,"status":130,"phases":23320,"primaryCompletion":1327,"completion":1327,"start":4427,"enrollment":1240,"conditions":23321,"interventions":23322},[87],[6564,8115],[1964,12420],{"trials":23324,"activeCount":166,"soonestReadout":860},[23325,23329],{"nctId":12414,"briefTitle":12415,"status":102,"phases":23326,"primaryCompletion":860,"completion":860,"start":12417,"enrollment":2004,"conditions":23327,"interventions":23328},[87,88],[1591,1592],[1710,2369,12420],{"nctId":18294,"briefTitle":18295,"status":130,"phases":23330,"primaryCompletion":18297,"completion":18297,"start":4338,"enrollment":1568,"conditions":23331,"interventions":23332},[87,88],[8026,16556,16557,8027,13133,13134,7308,7309,7310,7311,7312,16558,16559,16560,13137,13138,7313,7314,7315,7316,7317],[12420,14086,2206],{"trials":23334,"activeCount":124},[],{"trials":23336,"activeCount":124},[],{"trials":23338,"activeCount":124},[],{"intervention":808,"totalTrials":1231,"cells":23340},{"EARLY_PHASE1":23341,"PHASE1":23343,"PHASE2":23345,"PHASE3":23359,"PHASE4":23361,"NA":23363},{"trials":23342,"activeCount":124},[],{"trials":23344,"activeCount":124},[],{"trials":23346,"activeCount":166,"soonestReadout":772},[23347,23351,23355],{"nctId":6754,"briefTitle":6755,"status":130,"phases":23348,"primaryCompletion":6757,"completion":6757,"start":6758,"enrollment":861,"conditions":23349,"interventions":23350},[88],[1122],[803,1016,1013,4330,2374,806,2584,808],{"nctId":794,"briefTitle":795,"status":279,"phases":23352,"primaryCompletion":772,"completion":772,"start":797,"enrollment":798,"conditions":23353,"interventions":23354},[88],[800,801],[803,654,62,804,805,806,807,808,809,480,810],{"nctId":1135,"briefTitle":1136,"status":182,"phases":23356,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":1140,"conditions":23357,"interventions":23358},[87,88],[1142,1143,1144,1145],[803,654,62,806,807,808,809,894,480,1016],{"trials":23360,"activeCount":124},[],{"trials":23362,"activeCount":124},[],{"trials":23364,"activeCount":124},[],{"intervention":14130,"totalTrials":1231,"cells":23366},{"EARLY_PHASE1":23367,"PHASE1":23369,"PHASE2":23371,"PHASE3":23397,"PHASE4":23399,"NA":23401},{"trials":23368,"activeCount":124},[],{"trials":23370,"activeCount":124},[],{"trials":23372,"activeCount":166,"soonestReadout":3258},[23373,23377,23381],{"nctId":18273,"briefTitle":18274,"status":182,"phases":23374,"primaryCompletion":18276,"completion":18276,"start":18277,"enrollment":296,"conditions":23375,"interventions":23376},[88],[7312,5234,7317],[12927,10904,18073,14086,2206,14130],{"nctId":14123,"briefTitle":14124,"status":102,"phases":23378,"primaryCompletion":3258,"completion":3258,"start":14126,"enrollment":861,"conditions":23379,"interventions":23380},[88],[1457,10089,10703,14128,10707,10708,10709,10710,10711,10712,10713,10714,1472],[2840,14086,14130],{"nctId":23382,"briefTitle":23383,"status":130,"phases":23384,"primaryCompletion":23385,"completion":23385,"start":23386,"enrollment":871,"conditions":23387,"interventions":23396},"NCT02420691","Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin",[88],"2019-06-05","2015-08-25",[23388,23389,23390,23391,23392,23393,23394,23395],"Advanced Digestive System Neuroendocrine Neoplasm","Duodenal Neuroendocrine Tumor G1","Functional Pancreatic Neuroendocrine Tumor","Gastric Neuroendocrine Tumor","Intermediate Grade Lung Neuroendocrine Neoplasm","Low Grade Lung Neuroendocrine Neoplasm","Nonfunctional Pancreatic Neuroendocrine Tumor","Thymus Neoplasm",[14130],{"trials":23398,"activeCount":124},[],{"trials":23400,"activeCount":124},[],{"trials":23402,"activeCount":124},[],{"intervention":11343,"totalTrials":1231,"cells":23404},{"EARLY_PHASE1":23405,"PHASE1":23407,"PHASE2":23409,"PHASE3":23423,"PHASE4":23425,"NA":23427},{"trials":23406,"activeCount":124},[],{"trials":23408,"activeCount":124},[],{"trials":23410,"activeCount":166,"soonestReadout":11335},[23411,23415,23419],{"nctId":12098,"briefTitle":12099,"status":130,"phases":23412,"primaryCompletion":2602,"completion":2602,"start":12101,"enrollment":1975,"conditions":23413,"interventions":23414},[88],[7818,27],[2957,12104,12105,12106],{"nctId":14916,"briefTitle":14917,"status":130,"phases":23416,"primaryCompletion":8551,"completion":8551,"start":6758,"enrollment":2865,"conditions":23417,"interventions":23418},[88],[27],[1710,2321,3718,11343],{"nctId":11332,"briefTitle":11333,"status":102,"phases":23420,"primaryCompletion":11335,"completion":11335,"start":11336,"enrollment":11337,"conditions":23421,"interventions":23422},[88],[5122,11339],[3699,11341,3720,11342,11343,3780,11344,809],{"trials":23424,"activeCount":124},[],{"trials":23426,"activeCount":124},[],{"trials":23428,"activeCount":124},[],{"intervention":8019,"totalTrials":1231,"cells":23430},{"EARLY_PHASE1":23431,"PHASE1":23433,"PHASE2":23435,"PHASE3":23451,"PHASE4":23453,"NA":23455},{"trials":23432,"activeCount":124},[],{"trials":23434,"activeCount":124},[],{"trials":23436,"activeCount":166,"soonestReadout":446},[23437,23441,23447],{"nctId":18221,"briefTitle":18222,"status":130,"phases":23438,"primaryCompletion":5954,"completion":5954,"start":18224,"enrollment":834,"conditions":23439,"interventions":23440},[88],[15],[8019,2207],{"nctId":23442,"briefTitle":23443,"status":182,"phases":23444,"primaryCompletion":4290,"completion":4290,"start":8753,"enrollment":186,"conditions":23445,"interventions":23446},"NCT01542684","Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)",[88],[15],[8019,4629],{"nctId":8013,"briefTitle":8014,"status":279,"phases":23448,"primaryCompletion":446,"completion":446,"start":8016,"enrollment":628,"conditions":23449,"interventions":23450},[88],[5623],[8019,53],{"trials":23452,"activeCount":124},[],{"trials":23454,"activeCount":124},[],{"trials":23456,"activeCount":124},[],{"intervention":807,"totalTrials":1231,"cells":23458},{"EARLY_PHASE1":23459,"PHASE1":23461,"PHASE2":23470,"PHASE3":23480,"PHASE4":23482,"NA":23484},{"trials":23460,"activeCount":124},[],{"trials":23462,"activeCount":124},[23463],{"nctId":23464,"briefTitle":23465,"status":130,"phases":23466,"primaryCompletion":8760,"completion":8760,"start":23467,"enrollment":1409,"conditions":23468,"interventions":23469},"NCT01094860","Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed\u002FRefractory Lymphoid Malignancies",[87],"2010-06-08",[15],[807],{"trials":23471,"activeCount":166,"soonestReadout":772},[23472,23476],{"nctId":794,"briefTitle":795,"status":279,"phases":23473,"primaryCompletion":772,"completion":772,"start":797,"enrollment":798,"conditions":23474,"interventions":23475},[88],[800,801],[803,654,62,804,805,806,807,808,809,480,810],{"nctId":1135,"briefTitle":1136,"status":182,"phases":23477,"primaryCompletion":1138,"completion":1138,"start":1139,"enrollment":1140,"conditions":23478,"interventions":23479},[87,88],[1142,1143,1144,1145],[803,654,62,806,807,808,809,894,480,1016],{"trials":23481,"activeCount":124},[],{"trials":23483,"activeCount":124},[],{"trials":23485,"activeCount":124},[],{"intervention":1178,"totalTrials":1231,"cells":23487},{"EARLY_PHASE1":23488,"PHASE1":23490,"PHASE2":23492,"PHASE3":23509,"PHASE4":23511,"NA":23513},{"trials":23489,"activeCount":124},[],{"trials":23491,"activeCount":124},[],{"trials":23493,"activeCount":166,"soonestReadout":1173},[23494,23498,23502],{"nctId":8795,"briefTitle":8796,"status":182,"phases":23495,"primaryCompletion":8798,"completion":8798,"start":8799,"enrollment":2865,"conditions":23496,"interventions":23497},[88],[712],[1402,1070,894,4537,6545,1178],{"nctId":1170,"briefTitle":1171,"status":279,"phases":23499,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1034,"conditions":23500,"interventions":23501},[88],[15],[893,669,480,1177,1178],{"nctId":23503,"briefTitle":23504,"status":130,"phases":23505,"primaryCompletion":5240,"completion":5240,"start":12066,"enrollment":2581,"conditions":23506,"interventions":23507},"NCT01200485","Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2",[88],[15,21],[23508,1178],"Rasburicase",{"trials":23510,"activeCount":124},[],{"trials":23512,"activeCount":124},[],{"trials":23514,"activeCount":124},[],{"intervention":5113,"totalTrials":121,"cells":23516},{"EARLY_PHASE1":23517,"PHASE1":23519,"PHASE2":23521,"PHASE3":23538,"PHASE4":23540,"NA":23542},{"trials":23518,"activeCount":124},[],{"trials":23520,"activeCount":124},[],{"trials":23522,"activeCount":166,"soonestReadout":5103},[23523,23527],{"nctId":5100,"briefTitle":5101,"status":279,"phases":23524,"primaryCompletion":5103,"completion":5103,"start":5104,"enrollment":4733,"conditions":23525,"interventions":23526},[88],[5106,5107,5108,5109,5110,5111,3547],[3699,5113,3700,5114,809],{"nctId":23528,"briefTitle":23529,"status":130,"phases":23530,"primaryCompletion":23531,"completion":23531,"start":23532,"enrollment":606,"conditions":23533,"interventions":23537},"NCT01409200","Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis",[88],"2026-02-05","2012-03-26",[23534,23535,23536,3697],"Metastatic Malignant Neoplasm in Lymph Node","Prostate Ductal Adenocarcinoma","Stage III Prostate Adenocarcinoma AJCC v7",[5113,19435],{"trials":23539,"activeCount":124},[],{"trials":23541,"activeCount":124},[],{"trials":23543,"activeCount":124},[],{"intervention":2395,"totalTrials":121,"cells":23545},{"EARLY_PHASE1":23546,"PHASE1":23548,"PHASE2":23550,"PHASE3":23560,"PHASE4":23562,"NA":23564},{"trials":23547,"activeCount":124},[],{"trials":23549,"activeCount":124},[],{"trials":23551,"activeCount":166,"soonestReadout":549},[23552,23556],{"nctId":2385,"briefTitle":2386,"status":182,"phases":23553,"primaryCompletion":2388,"completion":2388,"start":2389,"enrollment":240,"conditions":23554,"interventions":23555},[88],[2391,2392],[2394,62,2395,2269],{"nctId":3341,"briefTitle":3342,"status":279,"phases":23557,"primaryCompletion":549,"completion":1088,"start":3344,"enrollment":1131,"conditions":23558,"interventions":23559},[88],[3346],[3348,803,2462,809,2269,2395],{"trials":23561,"activeCount":124},[],{"trials":23563,"activeCount":124},[],{"trials":23565,"activeCount":124},[],{"intervention":363,"totalTrials":121,"cells":23567},{"EARLY_PHASE1":23568,"PHASE1":23574,"PHASE2":23576,"PHASE3":23582,"PHASE4":23584,"NA":23586},{"trials":23569,"activeCount":124},[23570],{"nctId":352,"briefTitle":353,"status":182,"phases":23571,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":23572,"interventions":23573},[86],[359,360,361],[363,347,364,365,366,367],{"trials":23575,"activeCount":124},[],{"trials":23577,"activeCount":166,"soonestReadout":860},[23578],{"nctId":22697,"briefTitle":22698,"status":102,"phases":23579,"primaryCompletion":860,"completion":860,"start":3121,"enrollment":10174,"conditions":23580,"interventions":23581},[88],[22701],[363,22703,366],{"trials":23583,"activeCount":124},[],{"trials":23585,"activeCount":124},[],{"trials":23587,"activeCount":124},[],{"intervention":2078,"totalTrials":121,"cells":23589},{"EARLY_PHASE1":23590,"PHASE1":23592,"PHASE2":23594,"PHASE3":23604,"PHASE4":23606,"NA":23608},{"trials":23591,"activeCount":124},[],{"trials":23593,"activeCount":124},[],{"trials":23595,"activeCount":166,"soonestReadout":224},[23596,23600],{"nctId":2432,"briefTitle":2433,"status":130,"phases":23597,"primaryCompletion":2435,"completion":2435,"start":2436,"enrollment":550,"conditions":23598,"interventions":23599},[88],[15],[2439,2424,62,806,2078],{"nctId":2067,"briefTitle":2068,"status":102,"phases":23601,"primaryCompletion":224,"completion":224,"start":2070,"enrollment":1328,"conditions":23602,"interventions":23603},[88],[1344,1312,2072,1794,1387,2073,1795,1796,1797,360,2074,1799,1315,1316,1800,1801,2075,1802,1348,1349,1350,1351,1352,1353,1779,1355,1809,1810,1811,1780,1357,1781,1358,1359,1782,2076,1812,1813,1814,1361,1362,1365],[1049,1050,2078],{"trials":23605,"activeCount":124},[],{"trials":23607,"activeCount":124},[],{"trials":23609,"activeCount":124},[],{"intervention":10026,"totalTrials":121,"cells":23611},{"EARLY_PHASE1":23612,"PHASE1":23614,"PHASE2":23616,"PHASE3":23626,"PHASE4":23628,"NA":23630},{"trials":23613,"activeCount":124},[],{"trials":23615,"activeCount":124},[],{"trials":23617,"activeCount":166,"soonestReadout":10022},[23618,23622],{"nctId":10019,"briefTitle":10020,"status":279,"phases":23619,"primaryCompletion":10022,"completion":224,"start":10023,"enrollment":406,"conditions":23620,"interventions":23621},[87,88],[27],[10026,3701,1369],{"nctId":11123,"briefTitle":11124,"status":203,"phases":23623,"primaryCompletion":11126,"completion":11126,"start":2141,"enrollment":124,"conditions":23624,"interventions":23625},[87,88],[11128],[718,1275,10026],{"trials":23627,"activeCount":124},[],{"trials":23629,"activeCount":124},[],{"trials":23631,"activeCount":124},[],{"intervention":3348,"totalTrials":121,"cells":23633},{"EARLY_PHASE1":23634,"PHASE1":23636,"PHASE2":23638,"PHASE3":23648,"PHASE4":23650,"NA":23652},{"trials":23635,"activeCount":124},[],{"trials":23637,"activeCount":124},[],{"trials":23639,"activeCount":166,"soonestReadout":549},[23640,23644],{"nctId":6766,"briefTitle":6767,"status":130,"phases":23641,"primaryCompletion":6769,"completion":6769,"start":6770,"enrollment":492,"conditions":23642,"interventions":23643},[88],[359,4559,4708,6772,6773,4561,6774,6775,6776],[6778,3348,803,1070],{"nctId":3341,"briefTitle":3342,"status":279,"phases":23645,"primaryCompletion":549,"completion":1088,"start":3344,"enrollment":1131,"conditions":23646,"interventions":23647},[88],[3346],[3348,803,2462,809,2269,2395],{"trials":23649,"activeCount":124},[],{"trials":23651,"activeCount":124},[],{"trials":23653,"activeCount":124},[],{"intervention":5778,"totalTrials":121,"cells":23655},{"EARLY_PHASE1":23656,"PHASE1":23658,"PHASE2":23660,"PHASE3":23673,"PHASE4":23675,"NA":23677},{"trials":23657,"activeCount":124},[],{"trials":23659,"activeCount":124},[],{"trials":23661,"activeCount":166,"soonestReadout":5772},[23662,23669],{"nctId":23663,"briefTitle":23664,"status":130,"phases":23665,"primaryCompletion":3509,"completion":3509,"start":2335,"enrollment":22,"conditions":23666,"interventions":23668},"NCT03745794","Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery",[88],[23667],"Pancreatic Carcinoma",[5778],{"nctId":5769,"briefTitle":5770,"status":102,"phases":23670,"primaryCompletion":5772,"completion":446,"start":5773,"enrollment":5774,"conditions":23671,"interventions":23672},[88],[5776],[5750,5778],{"trials":23674,"activeCount":124},[],{"trials":23676,"activeCount":124},[],{"trials":23678,"activeCount":124},[],{"intervention":1103,"totalTrials":121,"cells":23680},{"EARLY_PHASE1":23681,"PHASE1":23683,"PHASE2":23685,"PHASE3":23701,"PHASE4":23703,"NA":23705},{"trials":23682,"activeCount":124},[],{"trials":23684,"activeCount":124},[],{"trials":23686,"activeCount":166,"soonestReadout":1078},[23687,23697],{"nctId":23688,"briefTitle":23689,"status":182,"phases":23690,"primaryCompletion":23691,"completion":23691,"start":1099,"enrollment":834,"conditions":23692,"interventions":23696},"NCT02420795","Akt\u002FERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[87,88],"2020-11-16",[23693,23694,789,3060,790,3062,23695],"Central Nervous System Lymphoma","Gastric Mantle Cell Lymphoma","Splenic Mantle Cell Lymphoma",[1103],{"nctId":1096,"briefTitle":1097,"status":279,"phases":23698,"primaryCompletion":1078,"completion":1078,"start":1099,"enrollment":1100,"conditions":23699,"interventions":23700},[87,88],[913,608,609,914,610,632],[1103,480],{"trials":23702,"activeCount":124},[],{"trials":23704,"activeCount":124},[],{"trials":23706,"activeCount":124},[],{"intervention":749,"totalTrials":121,"cells":23708},{"EARLY_PHASE1":23709,"PHASE1":23711,"PHASE2":23713,"PHASE3":23723,"PHASE4":23725,"NA":23727},{"trials":23710,"activeCount":124},[],{"trials":23712,"activeCount":124},[],{"trials":23714,"activeCount":166,"soonestReadout":193},[23715,23719],{"nctId":730,"briefTitle":731,"status":102,"phases":23716,"primaryCompletion":193,"completion":193,"start":733,"enrollment":517,"conditions":23717,"interventions":23718},[87,88],[36,735,736,737,738,739,30,740,741,742,727,743,744,745,746,747],[510,749,480],{"nctId":7886,"briefTitle":7887,"status":182,"phases":23720,"primaryCompletion":7889,"completion":7889,"start":2017,"enrollment":121,"conditions":23721,"interventions":23722},[87,88],[2569,361,7891],[53,749],{"trials":23724,"activeCount":124},[],{"trials":23726,"activeCount":124},[],{"trials":23728,"activeCount":124},[],{"intervention":23730,"totalTrials":121,"cells":23731},"Tepotinib",{"EARLY_PHASE1":23732,"PHASE1":23734,"PHASE2":23745,"PHASE3":23754,"PHASE4":23756,"NA":23758},{"trials":23733,"activeCount":124},[],{"trials":23735,"activeCount":124},[23736],{"nctId":23737,"briefTitle":23738,"status":203,"phases":23739,"primaryCompletion":3621,"completion":3621,"start":23740,"enrollment":124,"conditions":23741,"interventions":23742},"NCT05120960","A Phase 1a\u002F1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors",[87],"2023-02-27",[13732],[23743,23744],"tepotinib","tepotinib plus osimertinib",{"trials":23746,"activeCount":166,"soonestReadout":224},[23747],{"nctId":23748,"briefTitle":23749,"status":102,"phases":23750,"primaryCompletion":224,"completion":224,"start":21130,"enrollment":1231,"conditions":23751,"interventions":23752},"NCT06083857","PhI\u002FII Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer",[87,88],[10145],[23753,23730],"Amivantamab",{"trials":23755,"activeCount":124},[],{"trials":23757,"activeCount":124},[],{"trials":23759,"activeCount":124},[],{"intervention":5465,"totalTrials":121,"cells":23761},{"EARLY_PHASE1":23762,"PHASE1":23764,"PHASE2":23770,"PHASE3":23776,"PHASE4":23778,"NA":23780},{"trials":23763,"activeCount":124},[],{"trials":23765,"activeCount":124},[23766],{"nctId":5453,"briefTitle":5454,"status":130,"phases":23767,"primaryCompletion":1307,"completion":1307,"start":3251,"enrollment":492,"conditions":23768,"interventions":23769},[87],[5457,3271,5458,5459,5460,3275,3276,5461,5462,5463,3280],[1369,2424,2495,5465],{"trials":23771,"activeCount":166,"soonestReadout":3943},[23772],{"nctId":8072,"briefTitle":8073,"status":102,"phases":23773,"primaryCompletion":3943,"completion":3943,"start":8075,"enrollment":2865,"conditions":23774,"interventions":23775},[87,88],[3271,5458,8077,3274,8078,3276,5461,8079,3279,3280,8080],[53,5465],{"trials":23777,"activeCount":124},[],{"trials":23779,"activeCount":124},[],{"trials":23781,"activeCount":124},[],{"intervention":8031,"totalTrials":121,"cells":23783},{"EARLY_PHASE1":23784,"PHASE1":23786,"PHASE2":23788,"PHASE3":23803,"PHASE4":23805,"NA":23807},{"trials":23785,"activeCount":124},[],{"trials":23787,"activeCount":124},[],{"trials":23789,"activeCount":166,"soonestReadout":5310},[23790,23794],{"nctId":8021,"briefTitle":8022,"status":102,"phases":23791,"primaryCompletion":5310,"completion":238,"start":8024,"enrollment":1100,"conditions":23792,"interventions":23793},[88],[8026,8027,8028,8029],[8031,53,7301,4227],{"nctId":23795,"briefTitle":23796,"status":130,"phases":23797,"primaryCompletion":23798,"completion":23798,"start":23799,"enrollment":195,"conditions":23800,"interventions":23801},"NCT02366130","Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer",[88],"2020-12-16","2015-02-11",[18],[23802,14024,8031],"Ra-223 dichloride",{"trials":23804,"activeCount":124},[],{"trials":23806,"activeCount":124},[],{"trials":23808,"activeCount":124},[],{"intervention":7301,"totalTrials":121,"cells":23810},{"EARLY_PHASE1":23811,"PHASE1":23813,"PHASE2":23815,"PHASE3":23825,"PHASE4":23827,"NA":23829},{"trials":23812,"activeCount":124},[],{"trials":23814,"activeCount":124},[],{"trials":23816,"activeCount":166,"soonestReadout":5310},[23817,23821],{"nctId":8021,"briefTitle":8022,"status":102,"phases":23818,"primaryCompletion":5310,"completion":238,"start":8024,"enrollment":1100,"conditions":23819,"interventions":23820},[88],[8026,8027,8028,8029],[8031,53,7301,4227],{"nctId":7291,"briefTitle":7292,"status":182,"phases":23822,"primaryCompletion":7294,"completion":7294,"start":5035,"enrollment":1240,"conditions":23823,"interventions":23824},[87,88],[7296,7297,5234,5086,5087,5088,5089,7298],[803,1013,7300,1376,7301,4227],{"trials":23826,"activeCount":124},[],{"trials":23828,"activeCount":124},[],{"trials":23830,"activeCount":124},[],{"intervention":6686,"totalTrials":166,"cells":23832},{"EARLY_PHASE1":23833,"PHASE1":23835,"PHASE2":23837,"PHASE3":23843,"PHASE4":23845,"NA":23847},{"trials":23834,"activeCount":124},[],{"trials":23836,"activeCount":124},[],{"trials":23838,"activeCount":166,"soonestReadout":6680},[23839],{"nctId":6677,"briefTitle":6678,"status":279,"phases":23840,"primaryCompletion":6680,"completion":6681,"start":6682,"enrollment":240,"conditions":23841,"interventions":23842},[87,88],[4107,1530,6684],[6686,803,1070],{"trials":23844,"activeCount":124},[],{"trials":23846,"activeCount":124},[],{"trials":23848,"activeCount":124},[],{"intervention":23850,"totalTrials":166,"cells":23851},"DMSA",{"EARLY_PHASE1":23852,"PHASE1":23854,"PHASE2":23856,"PHASE3":23868,"PHASE4":23870,"NA":23872},{"trials":23853,"activeCount":124},[],{"trials":23855,"activeCount":124},[],{"trials":23857,"activeCount":166,"soonestReadout":6282},[23858],{"nctId":23859,"briefTitle":23860,"status":279,"phases":23861,"primaryCompletion":6282,"completion":13018,"start":23862,"enrollment":342,"conditions":23863,"interventions":23864},"NCT06811233","Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study",[88],"2025-05-08",[3395],[23850,23865,23866,23867],"Ca-EDTA","Magnesium Sulfate","Multivitamin",{"trials":23869,"activeCount":124},[],{"trials":23871,"activeCount":124},[],{"trials":23873,"activeCount":124},[],{"intervention":23865,"totalTrials":166,"cells":23875},{"EARLY_PHASE1":23876,"PHASE1":23878,"PHASE2":23880,"PHASE3":23886,"PHASE4":23888,"NA":23890},{"trials":23877,"activeCount":124},[],{"trials":23879,"activeCount":124},[],{"trials":23881,"activeCount":166,"soonestReadout":6282},[23882],{"nctId":23859,"briefTitle":23860,"status":279,"phases":23883,"primaryCompletion":6282,"completion":13018,"start":23862,"enrollment":342,"conditions":23884,"interventions":23885},[88],[3395],[23850,23865,23866,23867],{"trials":23887,"activeCount":124},[],{"trials":23889,"activeCount":124},[],{"trials":23891,"activeCount":124},[],{"intervention":23866,"totalTrials":166,"cells":23893},{"EARLY_PHASE1":23894,"PHASE1":23896,"PHASE2":23898,"PHASE3":23904,"PHASE4":23906,"NA":23908},{"trials":23895,"activeCount":124},[],{"trials":23897,"activeCount":124},[],{"trials":23899,"activeCount":166,"soonestReadout":6282},[23900],{"nctId":23859,"briefTitle":23860,"status":279,"phases":23901,"primaryCompletion":6282,"completion":13018,"start":23862,"enrollment":342,"conditions":23902,"interventions":23903},[88],[3395],[23850,23865,23866,23867],{"trials":23905,"activeCount":124},[],{"trials":23907,"activeCount":124},[],{"trials":23909,"activeCount":124},[],{"intervention":23867,"totalTrials":166,"cells":23911},{"EARLY_PHASE1":23912,"PHASE1":23914,"PHASE2":23916,"PHASE3":23922,"PHASE4":23924,"NA":23926},{"trials":23913,"activeCount":124},[],{"trials":23915,"activeCount":124},[],{"trials":23917,"activeCount":166,"soonestReadout":6282},[23918],{"nctId":23859,"briefTitle":23860,"status":279,"phases":23919,"primaryCompletion":6282,"completion":13018,"start":23862,"enrollment":342,"conditions":23920,"interventions":23921},[88],[3395],[23850,23865,23866,23867],{"trials":23923,"activeCount":124},[],{"trials":23925,"activeCount":124},[],{"trials":23927,"activeCount":124},[],{"intervention":5219,"totalTrials":166,"cells":23929},{"EARLY_PHASE1":23930,"PHASE1":23932,"PHASE2":23934,"PHASE3":23940,"PHASE4":23942,"NA":23944},{"trials":23931,"activeCount":124},[],{"trials":23933,"activeCount":124},[],{"trials":23935,"activeCount":166,"soonestReadout":1325},[23936],{"nctId":5213,"briefTitle":5214,"status":279,"phases":23937,"primaryCompletion":1325,"completion":1326,"start":5216,"enrollment":1328,"conditions":23938,"interventions":23939},[88],[4760],[5219,1070,1254,2196,2757],{"trials":23941,"activeCount":124},[],{"trials":23943,"activeCount":124},[],{"trials":23945,"activeCount":124},[],{"intervention":23947,"totalTrials":166,"cells":23948},"NBTXR3",{"EARLY_PHASE1":23949,"PHASE1":23951,"PHASE2":23953,"PHASE3":23965,"PHASE4":23967,"NA":23969},{"trials":23950,"activeCount":124},[],{"trials":23952,"activeCount":124},[],{"trials":23954,"activeCount":166,"soonestReadout":23959},[23955],{"nctId":23956,"briefTitle":23957,"status":279,"phases":23958,"primaryCompletion":23959,"completion":23960,"start":23961,"enrollment":517,"conditions":23962,"interventions":23964},"NCT07224152","NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer",[87,88],"2028-08-30","2030-08-30","2026-03-27",[23963],"Locally-Advanced Non-Small Cell Lung Cancer",[23947],{"trials":23966,"activeCount":124},[],{"trials":23968,"activeCount":124},[],{"trials":23970,"activeCount":124},[],{"intervention":16164,"totalTrials":166,"cells":23972},{"EARLY_PHASE1":23973,"PHASE1":23975,"PHASE2":23977,"PHASE3":23983,"PHASE4":23985,"NA":23987},{"trials":23974,"activeCount":124},[],{"trials":23976,"activeCount":124},[],{"trials":23978,"activeCount":166,"soonestReadout":16160},[23979],{"nctId":16157,"briefTitle":16158,"status":279,"phases":23980,"primaryCompletion":16160,"completion":12505,"start":16161,"enrollment":1131,"conditions":23981,"interventions":23982},[87,88],[1080],[565,16164],{"trials":23984,"activeCount":124},[],{"trials":23986,"activeCount":124},[],{"trials":23988,"activeCount":124},[],{"intervention":15196,"totalTrials":166,"cells":23990},{"EARLY_PHASE1":23991,"PHASE1":23993,"PHASE2":23995,"PHASE3":24001,"PHASE4":24003,"NA":24005},{"trials":23992,"activeCount":124},[],{"trials":23994,"activeCount":124},[],{"trials":23996,"activeCount":166,"soonestReadout":224},[23997],{"nctId":15189,"briefTitle":15190,"status":279,"phases":23998,"primaryCompletion":224,"completion":224,"start":970,"enrollment":1034,"conditions":23999,"interventions":24000},[88],[11534,7308,7309,7310,7311,7312,15193,15194,7699,5234,7313,7314,7315,7316,7317],[15196,15197,1374],{"trials":24002,"activeCount":124},[],{"trials":24004,"activeCount":124},[],{"trials":24006,"activeCount":124},[],{"intervention":24008,"totalTrials":166,"cells":24009},"Lorlatinib",{"EARLY_PHASE1":24010,"PHASE1":24012,"PHASE2":24014,"PHASE3":24026,"PHASE4":24028,"NA":24030},{"trials":24011,"activeCount":124},[],{"trials":24013,"activeCount":124},[],{"trials":24015,"activeCount":166,"soonestReadout":24020},[24016],{"nctId":24017,"briefTitle":24018,"status":279,"phases":24019,"primaryCompletion":24020,"completion":24021,"start":24022,"enrollment":406,"conditions":24023,"interventions":24025},"NCT07415005","Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer",[88],"2028-07-22","2030-07-22","2026-04-24",[24024],"Advanced Non-Small Cell Lung Cancer",[24008],{"trials":24027,"activeCount":124},[],{"trials":24029,"activeCount":124},[],{"trials":24031,"activeCount":124},[],{"intervention":2426,"totalTrials":166,"cells":24033},{"EARLY_PHASE1":24034,"PHASE1":24036,"PHASE2":24038,"PHASE3":24044,"PHASE4":24046,"NA":24048},{"trials":24035,"activeCount":124},[],{"trials":24037,"activeCount":124},[],{"trials":24039,"activeCount":166,"soonestReadout":2410},[24040],{"nctId":2407,"briefTitle":2408,"status":279,"phases":24041,"primaryCompletion":2410,"completion":2410,"start":2411,"enrollment":924,"conditions":24042,"interventions":24043},[88],[913,2413,2414,2415,2416,2417,914,2418,2419,2420,2421],[75,2423,803,62,2424,2425,1071,894,2426],{"trials":24045,"activeCount":124},[],{"trials":24047,"activeCount":124},[],{"trials":24049,"activeCount":124},[],{"intervention":5867,"totalTrials":166,"cells":24051},{"EARLY_PHASE1":24052,"PHASE1":24054,"PHASE2":24056,"PHASE3":24062,"PHASE4":24064,"NA":24066},{"trials":24053,"activeCount":124},[],{"trials":24055,"activeCount":124},[],{"trials":24057,"activeCount":166,"soonestReadout":47},[24058],{"nctId":45,"briefTitle":46,"status":102,"phases":24059,"primaryCompletion":47,"completion":604,"start":2289,"enrollment":5549,"conditions":24060,"interventions":24061},[88],[33],[48,5867],{"trials":24063,"activeCount":124},[],{"trials":24065,"activeCount":124},[],{"trials":24067,"activeCount":124},[],{"intervention":24069,"totalTrials":166,"cells":24070},"Nirogacestat",{"EARLY_PHASE1":24071,"PHASE1":24073,"PHASE2":24075,"PHASE3":24083,"PHASE4":24085,"NA":24087},{"trials":24072,"activeCount":124},[],{"trials":24074,"activeCount":124},[],{"trials":24076,"activeCount":166,"soonestReadout":193},[24077],{"nctId":24078,"briefTitle":24079,"status":279,"phases":24080,"primaryCompletion":193,"completion":10132,"start":2984,"enrollment":517,"conditions":24081,"interventions":24082},"NCT05879146","Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study",[88],[3071],[24069],{"trials":24084,"activeCount":124},[],{"trials":24086,"activeCount":124},[],{"trials":24088,"activeCount":124},[],{"intervention":1532,"totalTrials":166,"cells":24090},{"EARLY_PHASE1":24091,"PHASE1":24093,"PHASE2":24095,"PHASE3":24101,"PHASE4":24103,"NA":24105},{"trials":24092,"activeCount":124},[],{"trials":24094,"activeCount":124},[],{"trials":24096,"activeCount":166,"soonestReadout":1527},[24097],{"nctId":1524,"briefTitle":1525,"status":102,"phases":24098,"primaryCompletion":1527,"completion":1528,"start":1164,"enrollment":1131,"conditions":24099,"interventions":24100},[88],[1530],[1050,1532],{"trials":24102,"activeCount":124},[],{"trials":24104,"activeCount":124},[],{"trials":24106,"activeCount":124},[],{"intervention":14221,"totalTrials":166,"cells":24108},{"EARLY_PHASE1":24109,"PHASE1":24111,"PHASE2":24113,"PHASE3":24119,"PHASE4":24121,"NA":24123},{"trials":24110,"activeCount":124},[],{"trials":24112,"activeCount":124},[],{"trials":24114,"activeCount":166,"soonestReadout":14217},[24115],{"nctId":14214,"briefTitle":14215,"status":546,"phases":24116,"primaryCompletion":14217,"completion":14218,"start":549,"enrollment":1131,"conditions":24117,"interventions":24118},[88],[1729],[12910,14221,14222],{"trials":24120,"activeCount":124},[],{"trials":24122,"activeCount":124},[],{"trials":24124,"activeCount":124},[],{"intervention":14222,"totalTrials":166,"cells":24126},{"EARLY_PHASE1":24127,"PHASE1":24129,"PHASE2":24131,"PHASE3":24137,"PHASE4":24139,"NA":24141},{"trials":24128,"activeCount":124},[],{"trials":24130,"activeCount":124},[],{"trials":24132,"activeCount":166,"soonestReadout":14217},[24133],{"nctId":14214,"briefTitle":14215,"status":546,"phases":24134,"primaryCompletion":14217,"completion":14218,"start":549,"enrollment":1131,"conditions":24135,"interventions":24136},[88],[1729],[12910,14221,14222],{"trials":24138,"activeCount":124},[],{"trials":24140,"activeCount":124},[],{"trials":24142,"activeCount":124},[],{"intervention":22703,"totalTrials":166,"cells":24144},{"EARLY_PHASE1":24145,"PHASE1":24147,"PHASE2":24149,"PHASE3":24155,"PHASE4":24157,"NA":24159},{"trials":24146,"activeCount":124},[],{"trials":24148,"activeCount":124},[],{"trials":24150,"activeCount":166,"soonestReadout":860},[24151],{"nctId":22697,"briefTitle":22698,"status":102,"phases":24152,"primaryCompletion":860,"completion":860,"start":3121,"enrollment":10174,"conditions":24153,"interventions":24154},[88],[22701],[363,22703,366],{"trials":24156,"activeCount":124},[],{"trials":24158,"activeCount":124},[],{"trials":24160,"activeCount":124},[],{"intervention":24162,"totalTrials":166,"cells":24163},"Brachytherapy",{"EARLY_PHASE1":24164,"PHASE1":24166,"PHASE2":24168,"PHASE3":24177,"PHASE4":24179,"NA":24181},{"trials":24165,"activeCount":124},[],{"trials":24167,"activeCount":124},[],{"trials":24169,"activeCount":166,"soonestReadout":5310},[24170],{"nctId":24171,"briefTitle":24172,"status":102,"phases":24173,"primaryCompletion":5310,"completion":238,"start":24174,"enrollment":7574,"conditions":24175,"interventions":24176},"NCT00525720","Brachytherapy for Prostatic Carcinoma Patients",[88],"2006-08-01",[27],[24162],{"trials":24178,"activeCount":124},[],{"trials":24180,"activeCount":124},[],{"trials":24182,"activeCount":124},[],{"intervention":656,"totalTrials":166,"cells":24184},{"EARLY_PHASE1":24185,"PHASE1":24187,"PHASE2":24189,"PHASE3":24195,"PHASE4":24197,"NA":24199},{"trials":24186,"activeCount":124},[],{"trials":24188,"activeCount":124},[],{"trials":24190,"activeCount":166,"soonestReadout":639},[24191],{"nctId":636,"briefTitle":637,"status":279,"phases":24192,"primaryCompletion":639,"completion":639,"start":640,"enrollment":641,"conditions":24193,"interventions":24194},[88],[643,36,644,645,646,647,30,648,608,649,610,650,651,652],[599,654,565,655,656,480],{"trials":24196,"activeCount":124},[],{"trials":24198,"activeCount":124},[],{"trials":24200,"activeCount":124},[],{"intervention":24202,"totalTrials":166,"cells":24203},"BGB-16673",{"EARLY_PHASE1":24204,"PHASE1":24206,"PHASE2":24208,"PHASE3":24219,"PHASE4":24221,"NA":24223},{"trials":24205,"activeCount":124},[],{"trials":24207,"activeCount":124},[],{"trials":24209,"activeCount":166,"soonestReadout":24214},[24210],{"nctId":24211,"briefTitle":24212,"status":546,"phases":24213,"primaryCompletion":24214,"completion":18616,"start":549,"enrollment":517,"conditions":24215,"interventions":24217},"NCT07508995","A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)",[88],"2031-07-01",[24216],"Chronic Lymphocytic Leukemia (CLL)",[24202,24218],"BGB-11417",{"trials":24220,"activeCount":124},[],{"trials":24222,"activeCount":124},[],{"trials":24224,"activeCount":124},[],{"intervention":24218,"totalTrials":166,"cells":24226},{"EARLY_PHASE1":24227,"PHASE1":24229,"PHASE2":24231,"PHASE3":24237,"PHASE4":24239,"NA":24241},{"trials":24228,"activeCount":124},[],{"trials":24230,"activeCount":124},[],{"trials":24232,"activeCount":166,"soonestReadout":24214},[24233],{"nctId":24211,"briefTitle":24212,"status":546,"phases":24234,"primaryCompletion":24214,"completion":18616,"start":549,"enrollment":517,"conditions":24235,"interventions":24236},[88],[24216],[24202,24218],{"trials":24238,"activeCount":124},[],{"trials":24240,"activeCount":124},[],{"trials":24242,"activeCount":124},[],{"intervention":6732,"totalTrials":166,"cells":24244},{"EARLY_PHASE1":24245,"PHASE1":24247,"PHASE2":24249,"PHASE3":24255,"PHASE4":24257,"NA":24259},{"trials":24246,"activeCount":124},[],{"trials":24248,"activeCount":124},[],{"trials":24250,"activeCount":166,"soonestReadout":6727},[24251],{"nctId":6724,"briefTitle":6725,"status":102,"phases":24252,"primaryCompletion":6727,"completion":6727,"start":6728,"enrollment":6729,"conditions":24253,"interventions":24254},[88],[1729],[6732,803,1070,6733,3499,1114,6734,6735],{"trials":24256,"activeCount":124},[],{"trials":24258,"activeCount":124},[],{"trials":24260,"activeCount":124},[],{"intervention":6733,"totalTrials":166,"cells":24262},{"EARLY_PHASE1":24263,"PHASE1":24265,"PHASE2":24267,"PHASE3":24273,"PHASE4":24275,"NA":24277},{"trials":24264,"activeCount":124},[],{"trials":24266,"activeCount":124},[],{"trials":24268,"activeCount":166,"soonestReadout":6727},[24269],{"nctId":6724,"briefTitle":6725,"status":102,"phases":24270,"primaryCompletion":6727,"completion":6727,"start":6728,"enrollment":6729,"conditions":24271,"interventions":24272},[88],[1729],[6732,803,1070,6733,3499,1114,6734,6735],{"trials":24274,"activeCount":124},[],{"trials":24276,"activeCount":124},[],{"trials":24278,"activeCount":124},[],{"intervention":6734,"totalTrials":166,"cells":24280},{"EARLY_PHASE1":24281,"PHASE1":24283,"PHASE2":24285,"PHASE3":24291,"PHASE4":24293,"NA":24295},{"trials":24282,"activeCount":124},[],{"trials":24284,"activeCount":124},[],{"trials":24286,"activeCount":166,"soonestReadout":6727},[24287],{"nctId":6724,"briefTitle":6725,"status":102,"phases":24288,"primaryCompletion":6727,"completion":6727,"start":6728,"enrollment":6729,"conditions":24289,"interventions":24290},[88],[1729],[6732,803,1070,6733,3499,1114,6734,6735],{"trials":24292,"activeCount":124},[],{"trials":24294,"activeCount":124},[],{"trials":24296,"activeCount":124},[],{"intervention":6735,"totalTrials":166,"cells":24298},{"EARLY_PHASE1":24299,"PHASE1":24301,"PHASE2":24303,"PHASE3":24309,"PHASE4":24311,"NA":24313},{"trials":24300,"activeCount":124},[],{"trials":24302,"activeCount":124},[],{"trials":24304,"activeCount":166,"soonestReadout":6727},[24305],{"nctId":6724,"briefTitle":6725,"status":102,"phases":24306,"primaryCompletion":6727,"completion":6727,"start":6728,"enrollment":6729,"conditions":24307,"interventions":24308},[88],[1729],[6732,803,1070,6733,3499,1114,6734,6735],{"trials":24310,"activeCount":124},[],{"trials":24312,"activeCount":124},[],{"trials":24314,"activeCount":124},[],{"intervention":1578,"totalTrials":166,"cells":24316},{"EARLY_PHASE1":24317,"PHASE1":24319,"PHASE2":24321,"PHASE3":24327,"PHASE4":24329,"NA":24331},{"trials":24318,"activeCount":124},[],{"trials":24320,"activeCount":124},[],{"trials":24322,"activeCount":166,"soonestReadout":161},[24323],{"nctId":1564,"briefTitle":1565,"status":279,"phases":24324,"primaryCompletion":161,"completion":161,"start":1567,"enrollment":1568,"conditions":24325,"interventions":24326},[87,88],[1570,1571,1572,1573,1574,1575,1576],[1371,1050,1578],{"trials":24328,"activeCount":124},[],{"trials":24330,"activeCount":124},[],{"trials":24332,"activeCount":124},[],{"intervention":1600,"totalTrials":166,"cells":24334},{"EARLY_PHASE1":24335,"PHASE1":24337,"PHASE2":24339,"PHASE3":24345,"PHASE4":24347,"NA":24349},{"trials":24336,"activeCount":124},[],{"trials":24338,"activeCount":124},[],{"trials":24340,"activeCount":166,"soonestReadout":815},[24341],{"nctId":1580,"briefTitle":1581,"status":102,"phases":24342,"primaryCompletion":815,"completion":815,"start":1583,"enrollment":406,"conditions":24343,"interventions":24344},[88],[1585,1586,1587,1588,360,1589,1454,1590,1591,1460,1592,1593,1594,1595,1596,1597],[1599,1600,1601,803,1070,1049,1050],{"trials":24346,"activeCount":124},[],{"trials":24348,"activeCount":124},[],{"trials":24350,"activeCount":124},[],{"intervention":1601,"totalTrials":166,"cells":24352},{"EARLY_PHASE1":24353,"PHASE1":24355,"PHASE2":24357,"PHASE3":24363,"PHASE4":24365,"NA":24367},{"trials":24354,"activeCount":124},[],{"trials":24356,"activeCount":124},[],{"trials":24358,"activeCount":166,"soonestReadout":815},[24359],{"nctId":1580,"briefTitle":1581,"status":102,"phases":24360,"primaryCompletion":815,"completion":815,"start":1583,"enrollment":406,"conditions":24361,"interventions":24362},[88],[1585,1586,1587,1588,360,1589,1454,1590,1591,1460,1592,1593,1594,1595,1596,1597],[1599,1600,1601,803,1070,1049,1050],{"trials":24364,"activeCount":124},[],{"trials":24366,"activeCount":124},[],{"trials":24368,"activeCount":124},[],{"intervention":14231,"totalTrials":166,"cells":24370},{"EARLY_PHASE1":24371,"PHASE1":24373,"PHASE2":24375,"PHASE3":24381,"PHASE4":24383,"NA":24385},{"trials":24372,"activeCount":124},[],{"trials":24374,"activeCount":124},[],{"trials":24376,"activeCount":166,"soonestReadout":1735},[24377],{"nctId":14224,"briefTitle":14225,"status":279,"phases":24378,"primaryCompletion":1735,"completion":1735,"start":14227,"enrollment":517,"conditions":24379,"interventions":24380},[88],[14229],[14231,12910],{"trials":24382,"activeCount":124},[],{"trials":24384,"activeCount":124},[],{"trials":24386,"activeCount":124},[],{"intervention":21123,"totalTrials":166,"cells":24388},{"EARLY_PHASE1":24389,"PHASE1":24391,"PHASE2":24393,"PHASE3":24399,"PHASE4":24401,"NA":24403},{"trials":24390,"activeCount":124},[],{"trials":24392,"activeCount":124},[],{"trials":24394,"activeCount":166,"soonestReadout":1427},[24395],{"nctId":21117,"briefTitle":21118,"status":102,"phases":24396,"primaryCompletion":1427,"completion":1427,"start":21120,"enrollment":1222,"conditions":24397,"interventions":24398},[88],[6905,1672,1673,1674,1675,1676,1677,1678,1679],[12862,21123],{"trials":24400,"activeCount":124},[],{"trials":24402,"activeCount":124},[],{"trials":24404,"activeCount":124},[],{"intervention":9584,"totalTrials":166,"cells":24406},{"EARLY_PHASE1":24407,"PHASE1":24409,"PHASE2":24411,"PHASE3":24417,"PHASE4":24419,"NA":24421},{"trials":24408,"activeCount":124},[],{"trials":24410,"activeCount":124},[],{"trials":24412,"activeCount":166,"soonestReadout":505},[24413],{"nctId":9578,"briefTitle":9579,"status":546,"phases":24414,"primaryCompletion":505,"completion":9581,"start":404,"enrollment":8325,"conditions":24415,"interventions":24416},[87,88],[3395],[654,9584],{"trials":24418,"activeCount":124},[],{"trials":24420,"activeCount":124},[],{"trials":24422,"activeCount":124},[],{"intervention":705,"totalTrials":166,"cells":24424},{"EARLY_PHASE1":24425,"PHASE1":24427,"PHASE2":24429,"PHASE3":24435,"PHASE4":24437,"NA":24439},{"trials":24426,"activeCount":124},[],{"trials":24428,"activeCount":124},[],{"trials":24430,"activeCount":166,"soonestReadout":548},[24431],{"nctId":698,"briefTitle":699,"status":279,"phases":24432,"primaryCompletion":548,"completion":490,"start":701,"enrollment":492,"conditions":24433,"interventions":24434},[88],[552,703],[612,480,705],{"trials":24436,"activeCount":124},[],{"trials":24438,"activeCount":124},[],{"trials":24440,"activeCount":124},[],{"intervention":3956,"totalTrials":166,"cells":24442},{"EARLY_PHASE1":24443,"PHASE1":24445,"PHASE2":24447,"PHASE3":24453,"PHASE4":24455,"NA":24457},{"trials":24444,"activeCount":124},[],{"trials":24446,"activeCount":124},[],{"trials":24448,"activeCount":166,"soonestReadout":1727},[24449],{"nctId":3950,"briefTitle":3951,"status":102,"phases":24450,"primaryCompletion":1727,"completion":504,"start":3953,"enrollment":676,"conditions":24451,"interventions":24452},[88],[242],[1710,3956,1709],{"trials":24454,"activeCount":124},[],{"trials":24456,"activeCount":124},[],{"trials":24458,"activeCount":124},[],{"intervention":24460,"totalTrials":166,"cells":24461},"Orbital Radiation",{"EARLY_PHASE1":24462,"PHASE1":24464,"PHASE2":24466,"PHASE3":24488,"PHASE4":24490,"NA":24492},{"trials":24463,"activeCount":124},[],{"trials":24465,"activeCount":124},[],{"trials":24467,"activeCount":166,"soonestReadout":956},[24468],{"nctId":24469,"briefTitle":24470,"status":102,"phases":24471,"primaryCompletion":956,"completion":956,"start":24472,"enrollment":676,"conditions":24473,"interventions":24487},"NCT02494700","Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma",[88],"2015-07-06",[24474,8377,8378,24475,24476,24477,8379,8380,24478,24479,24480,8403,8404,8903,24481,24482,8406,8407,8905,24483,24484,24485,24486],"Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage I Indolent Adult Non-Hodgkin Lymphoma","Ann Arbor Stage I Mantle Cell Lymphoma","Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage II Indolent Adult Non-Hodgkin Lymphoma","Ann Arbor Stage II Mantle Cell Lymphoma","Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage III Mantle Cell Lymphoma","Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage IV Mantle Cell Lymphoma","Ocular Adnexal Lymphoma","Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma","Orbit Lymphoma",[24460],{"trials":24489,"activeCount":124},[],{"trials":24491,"activeCount":124},[],{"trials":24493,"activeCount":124},[],{"intervention":13247,"totalTrials":166,"cells":24495},{"EARLY_PHASE1":24496,"PHASE1":24498,"PHASE2":24500,"PHASE3":24506,"PHASE4":24508,"NA":24510},{"trials":24497,"activeCount":124},[],{"trials":24499,"activeCount":124},[],{"trials":24501,"activeCount":166,"soonestReadout":224},[24502],{"nctId":13241,"briefTitle":13242,"status":279,"phases":24503,"primaryCompletion":224,"completion":224,"start":13244,"enrollment":2865,"conditions":24504,"interventions":24505},[88],[24],[13247,1786],{"trials":24507,"activeCount":124},[],{"trials":24509,"activeCount":124},[],{"trials":24511,"activeCount":124},[],{"intervention":19587,"totalTrials":166,"cells":24513},{"EARLY_PHASE1":24514,"PHASE1":24516,"PHASE2":24518,"PHASE3":24524,"PHASE4":24526,"NA":24528},{"trials":24515,"activeCount":124},[],{"trials":24517,"activeCount":124},[],{"trials":24519,"activeCount":166,"soonestReadout":446},[24520],{"nctId":19581,"briefTitle":19582,"status":279,"phases":24521,"primaryCompletion":446,"completion":281,"start":19584,"enrollment":406,"conditions":24522,"interventions":24523},[88],[27],[19587,7589,11680,3720,19588],{"trials":24525,"activeCount":124},[],{"trials":24527,"activeCount":124},[],{"trials":24529,"activeCount":124},[],{"intervention":19588,"totalTrials":166,"cells":24531},{"EARLY_PHASE1":24532,"PHASE1":24534,"PHASE2":24536,"PHASE3":24542,"PHASE4":24544,"NA":24546},{"trials":24533,"activeCount":124},[],{"trials":24535,"activeCount":124},[],{"trials":24537,"activeCount":166,"soonestReadout":446},[24538],{"nctId":19581,"briefTitle":19582,"status":279,"phases":24539,"primaryCompletion":446,"completion":281,"start":19584,"enrollment":406,"conditions":24540,"interventions":24541},[88],[27],[19587,7589,11680,3720,19588],{"trials":24543,"activeCount":124},[],{"trials":24545,"activeCount":124},[],{"trials":24547,"activeCount":124},[],{"intervention":2494,"totalTrials":166,"cells":24549},{"EARLY_PHASE1":24550,"PHASE1":24552,"PHASE2":24554,"PHASE3":24560,"PHASE4":24562,"NA":24564},{"trials":24551,"activeCount":124},[],{"trials":24553,"activeCount":124},[],{"trials":24555,"activeCount":166,"soonestReadout":2490},[24556],{"nctId":2487,"briefTitle":2488,"status":102,"phases":24557,"primaryCompletion":2490,"completion":2490,"start":2491,"enrollment":134,"conditions":24558,"interventions":24559},[88],[21],[62,2494,2495,1114,1369],{"trials":24561,"activeCount":124},[],{"trials":24563,"activeCount":124},[],{"trials":24565,"activeCount":124},[],{"intervention":18040,"totalTrials":166,"cells":24567},{"EARLY_PHASE1":24568,"PHASE1":24570,"PHASE2":24572,"PHASE3":24578,"PHASE4":24580,"NA":24582},{"trials":24569,"activeCount":124},[],{"trials":24571,"activeCount":124},[],{"trials":24573,"activeCount":166,"soonestReadout":18036},[24574],{"nctId":18033,"briefTitle":18034,"status":546,"phases":24575,"primaryCompletion":18036,"completion":18036,"start":18037,"enrollment":517,"conditions":24576,"interventions":24577},[88],[3315],[1028,18040],{"trials":24579,"activeCount":124},[],{"trials":24581,"activeCount":124},[],{"trials":24583,"activeCount":124},[],{"intervention":16716,"totalTrials":166,"cells":24585},{"EARLY_PHASE1":24586,"PHASE1":24588,"PHASE2":24590,"PHASE3":24596,"PHASE4":24598,"NA":24600},{"trials":24587,"activeCount":124},[],{"trials":24589,"activeCount":124},[],{"trials":24591,"activeCount":166,"soonestReadout":238},[24592],{"nctId":16710,"briefTitle":16711,"status":102,"phases":24593,"primaryCompletion":238,"completion":238,"start":16713,"enrollment":1496,"conditions":24594,"interventions":24595},[88],[3967,7818],[1377,16716,16717],{"trials":24597,"activeCount":124},[],{"trials":24599,"activeCount":124},[],{"trials":24601,"activeCount":124},[],{"intervention":16717,"totalTrials":166,"cells":24603},{"EARLY_PHASE1":24604,"PHASE1":24606,"PHASE2":24608,"PHASE3":24614,"PHASE4":24616,"NA":24618},{"trials":24605,"activeCount":124},[],{"trials":24607,"activeCount":124},[],{"trials":24609,"activeCount":166,"soonestReadout":238},[24610],{"nctId":16710,"briefTitle":16711,"status":102,"phases":24611,"primaryCompletion":238,"completion":238,"start":16713,"enrollment":1496,"conditions":24612,"interventions":24613},[88],[3967,7818],[1377,16716,16717],{"trials":24615,"activeCount":124},[],{"trials":24617,"activeCount":124},[],{"trials":24619,"activeCount":124},[],{"intervention":24621,"totalTrials":166,"cells":24622},"Low Dose Radiation Therapy",{"EARLY_PHASE1":24623,"PHASE1":24625,"PHASE2":24627,"PHASE3":24635,"PHASE4":24637,"NA":24639},{"trials":24624,"activeCount":124},[],{"trials":24626,"activeCount":124},[],{"trials":24628,"activeCount":166,"soonestReadout":224},[24629],{"nctId":24630,"briefTitle":24631,"status":279,"phases":24632,"primaryCompletion":224,"completion":224,"start":1663,"enrollment":1975,"conditions":24633,"interventions":24634},"NCT04054167","Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",[88],[789,790],[24621],{"trials":24636,"activeCount":124},[],{"trials":24638,"activeCount":124},[],{"trials":24640,"activeCount":124},[],{"intervention":15260,"totalTrials":166,"cells":24642},{"EARLY_PHASE1":24643,"PHASE1":24645,"PHASE2":24647,"PHASE3":24653,"PHASE4":24655,"NA":24657},{"trials":24644,"activeCount":124},[],{"trials":24646,"activeCount":124},[],{"trials":24648,"activeCount":166,"soonestReadout":193},[24649],{"nctId":15253,"briefTitle":15254,"status":279,"phases":24650,"primaryCompletion":193,"completion":193,"start":15256,"enrollment":517,"conditions":24651,"interventions":24652},[88],[15258],[8580,669,15260],{"trials":24654,"activeCount":124},[],{"trials":24656,"activeCount":124},[],{"trials":24658,"activeCount":124},[],{"intervention":24660,"totalTrials":166,"cells":24661},"Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes",{"EARLY_PHASE1":24662,"PHASE1":24664,"PHASE2":24666,"PHASE3":24676,"PHASE4":24678,"NA":24680},{"trials":24663,"activeCount":124},[],{"trials":24665,"activeCount":124},[],{"trials":24667,"activeCount":166,"soonestReadout":5995},[24668],{"nctId":24669,"briefTitle":24670,"status":102,"phases":24671,"primaryCompletion":5995,"completion":5995,"start":24672,"enrollment":2446,"conditions":24673,"interventions":24675},"NCT02210078","Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection",[88],"2015-02-19",[24674,359,360],"Cytomegaloviral Infection",[24660],{"trials":24677,"activeCount":124},[],{"trials":24679,"activeCount":124},[],{"trials":24681,"activeCount":124},[],{"intervention":7830,"totalTrials":166,"cells":24683},{"EARLY_PHASE1":24684,"PHASE1":24686,"PHASE2":24688,"PHASE3":24694,"PHASE4":24696,"NA":24698},{"trials":24685,"activeCount":124},[],{"trials":24687,"activeCount":124},[],{"trials":24689,"activeCount":166,"soonestReadout":224},[24690],{"nctId":7824,"briefTitle":7825,"status":102,"phases":24691,"primaryCompletion":224,"completion":224,"start":7827,"enrollment":2159,"conditions":24692,"interventions":24693},[87,88],[7686,1316],[7830,53],{"trials":24695,"activeCount":124},[],{"trials":24697,"activeCount":124},[],{"trials":24699,"activeCount":124},[],{"intervention":12928,"totalTrials":166,"cells":24701},{"EARLY_PHASE1":24702,"PHASE1":24704,"PHASE2":24706,"PHASE3":24712,"PHASE4":24714,"NA":24716},{"trials":24703,"activeCount":124},[],{"trials":24705,"activeCount":124},[],{"trials":24707,"activeCount":166,"soonestReadout":281},[24708],{"nctId":12920,"briefTitle":12921,"status":102,"phases":24709,"primaryCompletion":281,"completion":281,"start":12923,"enrollment":4171,"conditions":24710,"interventions":24711},[87,88],[1667,1898,1669,1671,1899,1672,1900,1901,1673,1902,1903,1674,1904,1905,1675,1906,1907,1676,1908,1909,1677,1910,1911,1678,1912,1913,1679,1914,1680,12925,1681],[12927,1683,12928],{"trials":24713,"activeCount":124},[],{"trials":24715,"activeCount":124},[],{"trials":24717,"activeCount":124},[],{"intervention":15268,"totalTrials":166,"cells":24719},{"EARLY_PHASE1":24720,"PHASE1":24722,"PHASE2":24724,"PHASE3":24730,"PHASE4":24732,"NA":24734},{"trials":24721,"activeCount":124},[],{"trials":24723,"activeCount":124},[],{"trials":24725,"activeCount":166,"soonestReadout":224},[24726],{"nctId":15262,"briefTitle":15263,"status":102,"phases":24727,"primaryCompletion":224,"completion":224,"start":15265,"enrollment":1922,"conditions":24728,"interventions":24729},[88],[3346,3071],[669,15268],{"trials":24731,"activeCount":124},[],{"trials":24733,"activeCount":124},[],{"trials":24735,"activeCount":124},[],{"intervention":24737,"totalTrials":166,"cells":24738},"Isopropyl Alcohol",{"EARLY_PHASE1":24739,"PHASE1":24741,"PHASE2":24743,"PHASE3":24751,"PHASE4":24753,"NA":24755},{"trials":24740,"activeCount":124},[],{"trials":24742,"activeCount":124},[],{"trials":24744,"activeCount":166,"soonestReadout":1194},[24745],{"nctId":24746,"briefTitle":24747,"status":546,"phases":24748,"primaryCompletion":1194,"completion":1194,"start":7923,"enrollment":5347,"conditions":24749,"interventions":24750},"NCT04181463","Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer",[88],[2613],[24737],{"trials":24752,"activeCount":124},[],{"trials":24754,"activeCount":124},[],{"trials":24756,"activeCount":124},[],{"intervention":4011,"totalTrials":166,"cells":24758},{"EARLY_PHASE1":24759,"PHASE1":24761,"PHASE2":24763,"PHASE3":24769,"PHASE4":24771,"NA":24773},{"trials":24760,"activeCount":124},[],{"trials":24762,"activeCount":124},[],{"trials":24764,"activeCount":166,"soonestReadout":4005},[24765],{"nctId":4002,"briefTitle":4003,"status":279,"phases":24766,"primaryCompletion":4005,"completion":4006,"start":4007,"enrollment":676,"conditions":24767,"interventions":24768},[87,88],[4009],[2369,1709,1786,4011],{"trials":24770,"activeCount":124},[],{"trials":24772,"activeCount":124},[],{"trials":24774,"activeCount":124},[],{"intervention":19407,"totalTrials":166,"cells":24776},{"EARLY_PHASE1":24777,"PHASE1":24779,"PHASE2":24781,"PHASE3":24787,"PHASE4":24789,"NA":24791},{"trials":24778,"activeCount":124},[],{"trials":24780,"activeCount":124},[],{"trials":24782,"activeCount":166,"soonestReadout":1698},[24783],{"nctId":19401,"briefTitle":19402,"status":102,"phases":24784,"primaryCompletion":1698,"completion":2608,"start":19404,"enrollment":3820,"conditions":24785,"interventions":24786},[87,88],[361,3457,7891],[693,19407],{"trials":24788,"activeCount":124},[],{"trials":24790,"activeCount":124},[],{"trials":24792,"activeCount":124},[],{"intervention":3263,"totalTrials":166,"cells":24794},{"EARLY_PHASE1":24795,"PHASE1":24797,"PHASE2":24799,"PHASE3":24805,"PHASE4":24807,"NA":24809},{"trials":24796,"activeCount":124},[],{"trials":24798,"activeCount":124},[],{"trials":24800,"activeCount":166,"soonestReadout":1427},[24801],{"nctId":3255,"briefTitle":3256,"status":279,"phases":24802,"primaryCompletion":1427,"completion":3258,"start":3259,"enrollment":1559,"conditions":24803,"interventions":24804},[87,88],[3261],[2462,803,3263],{"trials":24806,"activeCount":124},[],{"trials":24808,"activeCount":124},[],{"trials":24810,"activeCount":124},[],{"intervention":11021,"totalTrials":166,"cells":24812},{"EARLY_PHASE1":24813,"PHASE1":24815,"PHASE2":24817,"PHASE3":24823,"PHASE4":24825,"NA":24827},{"trials":24814,"activeCount":124},[],{"trials":24816,"activeCount":124},[],{"trials":24818,"activeCount":166,"soonestReadout":11014},[24819],{"nctId":11011,"briefTitle":11012,"status":279,"phases":24820,"primaryCompletion":11014,"completion":11015,"start":11016,"enrollment":448,"conditions":24821,"interventions":24822},[87,88],[11018,11019],[11021,718,1275],{"trials":24824,"activeCount":124},[],{"trials":24826,"activeCount":124},[],{"trials":24828,"activeCount":124},[],{"intervention":24830,"totalTrials":166,"cells":24831},"Methylphenidate Hydrochloride",{"EARLY_PHASE1":24832,"PHASE1":24834,"PHASE2":24836,"PHASE3":24848,"PHASE4":24850,"NA":24852},{"trials":24833,"activeCount":124},[],{"trials":24835,"activeCount":124},[],{"trials":24837,"activeCount":166,"soonestReadout":24842},[24838],{"nctId":24839,"briefTitle":24840,"status":102,"phases":24841,"primaryCompletion":24842,"completion":281,"start":24843,"enrollment":1154,"conditions":24844,"interventions":24846},"NCT01628029","Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer",[88],"2025-12-22","2014-01-15",[359,360,24845],"Sleep Disorder",[24830,24847],"Therapeutic Melatonin",{"trials":24849,"activeCount":124},[],{"trials":24851,"activeCount":124},[],{"trials":24853,"activeCount":124},[],{"intervention":24847,"totalTrials":166,"cells":24855},{"EARLY_PHASE1":24856,"PHASE1":24858,"PHASE2":24860,"PHASE3":24866,"PHASE4":24868,"NA":24870},{"trials":24857,"activeCount":124},[],{"trials":24859,"activeCount":124},[],{"trials":24861,"activeCount":166,"soonestReadout":24842},[24862],{"nctId":24839,"briefTitle":24840,"status":102,"phases":24863,"primaryCompletion":24842,"completion":281,"start":24843,"enrollment":1154,"conditions":24864,"interventions":24865},[88],[359,360,24845],[24830,24847],{"trials":24867,"activeCount":124},[],{"trials":24869,"activeCount":124},[],{"trials":24871,"activeCount":124},[],{"intervention":24873,"totalTrials":166,"cells":24874},"Standard Therapy",{"EARLY_PHASE1":24875,"PHASE1":24877,"PHASE2":24879,"PHASE3":24888,"PHASE4":24890,"NA":24892},{"trials":24876,"activeCount":124},[],{"trials":24878,"activeCount":124},[],{"trials":24880,"activeCount":166,"soonestReadout":404},[24881],{"nctId":24882,"briefTitle":24883,"status":102,"phases":24884,"primaryCompletion":404,"completion":404,"start":24885,"enrollment":1328,"conditions":24886,"interventions":24887},"NCT00929214","Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients",[88],"2009-06-24",[18],[24873],{"trials":24889,"activeCount":124},[],{"trials":24891,"activeCount":124},[],{"trials":24893,"activeCount":124},[],{"intervention":10496,"totalTrials":166,"cells":24895},{"EARLY_PHASE1":24896,"PHASE1":24898,"PHASE2":24900,"PHASE3":24906,"PHASE4":24908,"NA":24910},{"trials":24897,"activeCount":124},[],{"trials":24899,"activeCount":124},[],{"trials":24901,"activeCount":166,"soonestReadout":10492},[24902],{"nctId":10489,"briefTitle":10490,"status":279,"phases":24903,"primaryCompletion":10492,"completion":10492,"start":10493,"enrollment":676,"conditions":24904,"interventions":24905},[88],[1047,643,737,10443,30,608,610],[510,10496],{"trials":24907,"activeCount":124},[],{"trials":24909,"activeCount":124},[],{"trials":24911,"activeCount":124},[],{"intervention":19421,"totalTrials":166,"cells":24913},{"EARLY_PHASE1":24914,"PHASE1":24916,"PHASE2":24918,"PHASE3":24924,"PHASE4":24926,"NA":24928},{"trials":24915,"activeCount":124},[],{"trials":24917,"activeCount":124},[],{"trials":24919,"activeCount":166,"soonestReadout":19416},[24920],{"nctId":19413,"briefTitle":19414,"status":102,"phases":24921,"primaryCompletion":19416,"completion":8064,"start":19417,"enrollment":19418,"conditions":24922,"interventions":24923},[87,88],[1343,3544,360,361,3545,5123,3457,3546,3547,3548],[693,19421,7370],{"trials":24925,"activeCount":124},[],{"trials":24927,"activeCount":124},[],{"trials":24929,"activeCount":124},[],{"intervention":15531,"totalTrials":166,"cells":24931},{"EARLY_PHASE1":24932,"PHASE1":24934,"PHASE2":24936,"PHASE3":24942,"PHASE4":24944,"NA":24946},{"trials":24933,"activeCount":124},[],{"trials":24935,"activeCount":124},[],{"trials":24937,"activeCount":166,"soonestReadout":4006},[24938],{"nctId":15522,"briefTitle":15523,"status":279,"phases":24939,"primaryCompletion":4006,"completion":15525,"start":15526,"enrollment":1922,"conditions":24940,"interventions":24941},[87,88],[2134,15528,15529],[598,15531],{"trials":24943,"activeCount":124},[],{"trials":24945,"activeCount":124},[],{"trials":24947,"activeCount":124},[],{"intervention":24949,"totalTrials":166,"cells":24950},"Ustekinumab",{"EARLY_PHASE1":24951,"PHASE1":24953,"PHASE2":24955,"PHASE3":24964,"PHASE4":24966,"NA":24968},{"trials":24952,"activeCount":124},[],{"trials":24954,"activeCount":124},[],{"trials":24956,"activeCount":166,"soonestReadout":2166},[24957],{"nctId":24958,"briefTitle":24959,"status":279,"phases":24960,"primaryCompletion":2166,"completion":2166,"start":24961,"enrollment":1496,"conditions":24962,"interventions":24963},"NCT06807593","Treatment of Immune Checkpoint Inhibitor-related Diarrhea and\u002F or Colitis With Ustekinumab in Cancer Patients",[88],"2026-02-24",[5349],[24949],{"trials":24965,"activeCount":124},[],{"trials":24967,"activeCount":124},[],{"trials":24969,"activeCount":124},[],{"intervention":24971,"totalTrials":166,"cells":24972},"tofacitinib 2% cream",{"EARLY_PHASE1":24973,"PHASE1":24975,"PHASE2":24977,"PHASE3":24987,"PHASE4":24989,"NA":24991},{"trials":24974,"activeCount":124},[],{"trials":24976,"activeCount":124},[],{"trials":24978,"activeCount":166,"soonestReadout":24983},[24979],{"nctId":24980,"briefTitle":24981,"status":279,"phases":24982,"primaryCompletion":24983,"completion":24983,"start":8143,"enrollment":1131,"conditions":24984,"interventions":24986},"NCT06698822","A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA",[88],"2026-10-19",[24985],"Cutaneous T-Cell Lymphoma",[24971],{"trials":24988,"activeCount":124},[],{"trials":24990,"activeCount":124},[],{"trials":24992,"activeCount":124},[],{"intervention":827,"totalTrials":166,"cells":24994},{"EARLY_PHASE1":24995,"PHASE1":24997,"PHASE2":24999,"PHASE3":25005,"PHASE4":25007,"NA":25009},{"trials":24996,"activeCount":124},[],{"trials":24998,"activeCount":124},[],{"trials":25000,"activeCount":166,"soonestReadout":403},[25001],{"nctId":821,"briefTitle":822,"status":279,"phases":25002,"primaryCompletion":403,"completion":403,"start":824,"enrollment":357,"conditions":25003,"interventions":25004},[87,88],[36],[827,480,520],{"trials":25006,"activeCount":124},[],{"trials":25008,"activeCount":124},[],{"trials":25010,"activeCount":124},[],{"intervention":25012,"totalTrials":166,"cells":25013},"ONC-PluReceptor NK cells",{"EARLY_PHASE1":25014,"PHASE1":25016,"PHASE2":25018,"PHASE3":25027,"PHASE4":25029,"NA":25031},{"trials":25015,"activeCount":124},[],{"trials":25017,"activeCount":124},[],{"trials":25019,"activeCount":166,"soonestReadout":6952},[25020],{"nctId":25021,"briefTitle":25022,"status":279,"phases":25023,"primaryCompletion":6952,"completion":6953,"start":24961,"enrollment":406,"conditions":25024,"interventions":25026},"NCT07283679","Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",[87,88],[3272,25025],"Refractory B-cell Non-Hodgkin Lymphoma",[25012],{"trials":25028,"activeCount":124},[],{"trials":25030,"activeCount":124},[],{"trials":25032,"activeCount":124},[],{"intervention":25034,"totalTrials":166,"cells":25035},"P-Sam",{"EARLY_PHASE1":25036,"PHASE1":25038,"PHASE2":25040,"PHASE3":25050,"PHASE4":25052,"NA":25054},{"trials":25037,"activeCount":124},[],{"trials":25039,"activeCount":124},[],{"trials":25041,"activeCount":166,"soonestReadout":548},[25042],{"nctId":25043,"briefTitle":25044,"status":279,"phases":25045,"primaryCompletion":548,"completion":490,"start":25046,"enrollment":3521,"conditions":25047,"interventions":25049},"NCT07162480","Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R\u002FM) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)",[88],"2026-04-29",[25048],"Adenoid Cystic Carcinoma",[25034],{"trials":25051,"activeCount":124},[],{"trials":25053,"activeCount":124},[],{"trials":25055,"activeCount":124},[],{"intervention":25057,"totalTrials":166,"cells":25058},"Naproxen",{"EARLY_PHASE1":25059,"PHASE1":25061,"PHASE2":25063,"PHASE3":25075,"PHASE4":25077,"NA":25079},{"trials":25060,"activeCount":124},[],{"trials":25062,"activeCount":124},[],{"trials":25064,"activeCount":166,"soonestReadout":1078},[25065],{"nctId":25066,"briefTitle":25067,"status":279,"phases":25068,"primaryCompletion":1078,"completion":1078,"start":25069,"enrollment":517,"conditions":25070,"interventions":25073},"NCT05411718","A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome",[88],"2023-03-21",[25071,3195,25072],"T Cells","Lynch Syndrome",[25057,25074],"Aspirin",{"trials":25076,"activeCount":124},[],{"trials":25078,"activeCount":124},[],{"trials":25080,"activeCount":124},[],{"intervention":25082,"totalTrials":166,"cells":25083},"Luspatercept",{"EARLY_PHASE1":25084,"PHASE1":25086,"PHASE2":25088,"PHASE3":25096,"PHASE4":25098,"NA":25100},{"trials":25085,"activeCount":124},[],{"trials":25087,"activeCount":124},[],{"trials":25089,"activeCount":166,"soonestReadout":7861},[25090],{"nctId":25091,"briefTitle":25092,"status":279,"phases":25093,"primaryCompletion":7861,"completion":7861,"start":1888,"enrollment":517,"conditions":25094,"interventions":25095},"NCT06113302","A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)",[88],[1036],[25082],{"trials":25097,"activeCount":124},[],{"trials":25099,"activeCount":124},[],{"trials":25101,"activeCount":124},[],{"intervention":25103,"totalTrials":166,"cells":25104},"MBG-453 + Azacitidine",{"EARLY_PHASE1":25105,"PHASE1":25107,"PHASE2":25109,"PHASE3":25118,"PHASE4":25120,"NA":25122},{"trials":25106,"activeCount":124},[],{"trials":25108,"activeCount":124},[],{"trials":25110,"activeCount":166,"soonestReadout":471},[25111],{"nctId":25112,"briefTitle":25113,"status":102,"phases":25114,"primaryCompletion":471,"completion":1735,"start":25115,"enrollment":1231,"conditions":25116,"interventions":25117},"NCT06664879","ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial",[87,88],"2024-12-30",[2391],[25103],{"trials":25119,"activeCount":124},[],{"trials":25121,"activeCount":124},[],{"trials":25123,"activeCount":124},[],{"intervention":10137,"totalTrials":166,"cells":25125},{"EARLY_PHASE1":25126,"PHASE1":25128,"PHASE2":25130,"PHASE3":25136,"PHASE4":25138,"NA":25140},{"trials":25127,"activeCount":124},[],{"trials":25129,"activeCount":124},[],{"trials":25131,"activeCount":166,"soonestReadout":10132},[25132],{"nctId":10129,"briefTitle":10130,"status":102,"phases":25133,"primaryCompletion":10132,"completion":10132,"start":10133,"enrollment":901,"conditions":25134,"interventions":25135},[88],[24,10135],[10137,1369,1376],{"trials":25137,"activeCount":124},[],{"trials":25139,"activeCount":124},[],{"trials":25141,"activeCount":124},[],{"intervention":3296,"totalTrials":166,"cells":25143},{"EARLY_PHASE1":25144,"PHASE1":25146,"PHASE2":25148,"PHASE3":25154,"PHASE4":25156,"NA":25158},{"trials":25145,"activeCount":124},[],{"trials":25147,"activeCount":124},[],{"trials":25149,"activeCount":166,"soonestReadout":860},[25150],{"nctId":3285,"briefTitle":3286,"status":279,"phases":25151,"primaryCompletion":860,"completion":860,"start":3288,"enrollment":1222,"conditions":25152,"interventions":25153},[88],[1205,643,1122,2512,3290,3291,2471,3292,737,1025,3056,3057,3058,30,3233,3293,3244,648,608,3186,3059,3060,914,3294,651,882],[3296,3085,1004,2423,803,1005,2293,894],{"trials":25155,"activeCount":124},[],{"trials":25157,"activeCount":124},[],{"trials":25159,"activeCount":124},[],{"intervention":25161,"totalTrials":166,"cells":25162},"AMB-05X",{"EARLY_PHASE1":25163,"PHASE1":25165,"PHASE2":25167,"PHASE3":25176,"PHASE4":25178,"NA":25180},{"trials":25164,"activeCount":124},[],{"trials":25166,"activeCount":124},[],{"trials":25168,"activeCount":166,"soonestReadout":2302},[25169],{"nctId":25170,"briefTitle":25171,"status":279,"phases":25172,"primaryCompletion":2302,"completion":2302,"start":25173,"enrollment":1568,"conditions":25174,"interventions":25175},"NCT06617858","Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment",[88],"2024-12-04",[3195],[25161],{"trials":25177,"activeCount":124},[],{"trials":25179,"activeCount":124},[],{"trials":25181,"activeCount":124},[],{"intervention":23753,"totalTrials":166,"cells":25183},{"EARLY_PHASE1":25184,"PHASE1":25186,"PHASE2":25188,"PHASE3":25194,"PHASE4":25196,"NA":25198},{"trials":25185,"activeCount":124},[],{"trials":25187,"activeCount":124},[],{"trials":25189,"activeCount":166,"soonestReadout":224},[25190],{"nctId":23748,"briefTitle":23749,"status":102,"phases":25191,"primaryCompletion":224,"completion":224,"start":21130,"enrollment":1231,"conditions":25192,"interventions":25193},[87,88],[10145],[23753,23730],{"trials":25195,"activeCount":124},[],{"trials":25197,"activeCount":124},[],{"trials":25199,"activeCount":124},[],{"intervention":3307,"totalTrials":166,"cells":25201},{"EARLY_PHASE1":25202,"PHASE1":25204,"PHASE2":25206,"PHASE3":25212,"PHASE4":25214,"NA":25216},{"trials":25203,"activeCount":124},[],{"trials":25205,"activeCount":124},[],{"trials":25207,"activeCount":166,"soonestReadout":3301},[25208],{"nctId":3298,"briefTitle":3299,"status":102,"phases":25209,"primaryCompletion":3301,"completion":3302,"start":3303,"enrollment":2004,"conditions":25210,"interventions":25211},[87,88],[3305],[3307,2462,803],{"trials":25213,"activeCount":124},[],{"trials":25215,"activeCount":124},[],{"trials":25217,"activeCount":124},[],{"intervention":6958,"totalTrials":166,"cells":25219},{"EARLY_PHASE1":25220,"PHASE1":25222,"PHASE2":25224,"PHASE3":25230,"PHASE4":25232,"NA":25234},{"trials":25221,"activeCount":124},[],{"trials":25223,"activeCount":124},[],{"trials":25225,"activeCount":166,"soonestReadout":6952},[25226],{"nctId":6949,"briefTitle":6950,"status":546,"phases":25227,"primaryCompletion":6952,"completion":6953,"start":6954,"enrollment":1222,"conditions":25228,"interventions":25229},[88],[6956,1866],[1070,803,6958,3103],{"trials":25231,"activeCount":124},[],{"trials":25233,"activeCount":124},[],{"trials":25235,"activeCount":124},[],{"intervention":19887,"totalTrials":166,"cells":25237},{"EARLY_PHASE1":25238,"PHASE1":25240,"PHASE2":25242,"PHASE3":25248,"PHASE4":25250,"NA":25252},{"trials":25239,"activeCount":124},[],{"trials":25241,"activeCount":124},[],{"trials":25243,"activeCount":166,"soonestReadout":537},[25244],{"nctId":19879,"briefTitle":19880,"status":279,"phases":25245,"primaryCompletion":537,"completion":1481,"start":19882,"enrollment":2004,"conditions":25246,"interventions":25247},[87,88],[19884],[19886,19887],{"trials":25249,"activeCount":124},[],{"trials":25251,"activeCount":124},[],{"trials":25253,"activeCount":124},[],{"intervention":25255,"totalTrials":166,"cells":25256},"[18F]-4FN",{"EARLY_PHASE1":25257,"PHASE1":25259,"PHASE2":25261,"PHASE3":25275,"PHASE4":25277,"NA":25279},{"trials":25258,"activeCount":124},[],{"trials":25260,"activeCount":124},[],{"trials":25262,"activeCount":166,"soonestReadout":25267},[25263],{"nctId":25264,"briefTitle":25265,"status":279,"phases":25266,"primaryCompletion":25267,"completion":25268,"start":25269,"enrollment":834,"conditions":25270,"interventions":25274},"NCT07325253","A Pilot Study to Correlate 4-18F- Fluoro-1-naphthol 18F-4FN PET\u002FCT Imaging With Chronic Graft Versus Host Disease Manifestations",[88],"2028-01-03","2030-01-03","2025-11-18",[25271,25272,25273],"Pilot Study","PET\u002FCT Imaging","Host Disease Manifestation",[25255],{"trials":25276,"activeCount":124},[],{"trials":25278,"activeCount":124},[],{"trials":25280,"activeCount":124},[],{"intervention":25282,"totalTrials":166,"cells":25283},"AK104",{"EARLY_PHASE1":25284,"PHASE1":25286,"PHASE2":25288,"PHASE3":25297,"PHASE4":25299,"NA":25301},{"trials":25285,"activeCount":124},[],{"trials":25287,"activeCount":124},[],{"trials":25289,"activeCount":166,"soonestReadout":2410},[25290],{"nctId":25291,"briefTitle":25292,"status":102,"phases":25293,"primaryCompletion":2410,"completion":2410,"start":3152,"enrollment":550,"conditions":25294,"interventions":25296},"NCT05063916","Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix",[88],[1748,25295,11077],"Cervix Cancer",[25282],{"trials":25298,"activeCount":124},[],{"trials":25300,"activeCount":124},[],{"trials":25302,"activeCount":124},[],{"intervention":7928,"totalTrials":166,"cells":25304},{"EARLY_PHASE1":25305,"PHASE1":25307,"PHASE2":25309,"PHASE3":25315,"PHASE4":25317,"NA":25319},{"trials":25306,"activeCount":124},[],{"trials":25308,"activeCount":124},[],{"trials":25310,"activeCount":166,"soonestReadout":7921},[25311],{"nctId":7918,"briefTitle":7919,"status":546,"phases":25312,"primaryCompletion":7921,"completion":7922,"start":7923,"enrollment":4733,"conditions":25313,"interventions":25314},[88],[1597,7925,7926,7863],[7928,53],{"trials":25316,"activeCount":124},[],{"trials":25318,"activeCount":124},[],{"trials":25320,"activeCount":124},[],{"intervention":10539,"totalTrials":166,"cells":25322},{"EARLY_PHASE1":25323,"PHASE1":25325,"PHASE2":25327,"PHASE3":25333,"PHASE4":25335,"NA":25337},{"trials":25324,"activeCount":124},[],{"trials":25326,"activeCount":124},[],{"trials":25328,"activeCount":166,"soonestReadout":10533},[25329],{"nctId":10530,"briefTitle":10531,"status":102,"phases":25330,"primaryCompletion":10533,"completion":10533,"start":10103,"enrollment":628,"conditions":25331,"interventions":25332},[87,88],[10535,10536,10537,30,850,609],[510,10539],{"trials":25334,"activeCount":124},[],{"trials":25336,"activeCount":124},[],{"trials":25338,"activeCount":124},[],{"intervention":25340,"totalTrials":166,"cells":25341},"Targeted Therapy Based on Molecular Profiling",{"EARLY_PHASE1":25342,"PHASE1":25344,"PHASE2":25346,"PHASE3":25357,"PHASE4":25359,"NA":25361},{"trials":25343,"activeCount":124},[],{"trials":25345,"activeCount":124},[],{"trials":25347,"activeCount":166,"soonestReadout":571},[25348],{"nctId":25349,"briefTitle":25350,"status":102,"phases":25351,"primaryCompletion":571,"completion":571,"start":25352,"enrollment":25353,"conditions":25354,"interventions":25355},"NCT02152254","Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)",[88],"2014-05-13",1362,[2924,2925],[25340,25356],"Standard-of-Care Therapy",{"trials":25358,"activeCount":124},[],{"trials":25360,"activeCount":124},[],{"trials":25362,"activeCount":124},[],{"intervention":25356,"totalTrials":166,"cells":25364},{"EARLY_PHASE1":25365,"PHASE1":25367,"PHASE2":25369,"PHASE3":25375,"PHASE4":25377,"NA":25379},{"trials":25366,"activeCount":124},[],{"trials":25368,"activeCount":124},[],{"trials":25370,"activeCount":166,"soonestReadout":571},[25371],{"nctId":25349,"briefTitle":25350,"status":102,"phases":25372,"primaryCompletion":571,"completion":571,"start":25352,"enrollment":25353,"conditions":25373,"interventions":25374},[88],[2924,2925],[25340,25356],{"trials":25376,"activeCount":124},[],{"trials":25378,"activeCount":124},[],{"trials":25380,"activeCount":124},[],{"intervention":25382,"totalTrials":166,"cells":25383},"Avapritinib",{"EARLY_PHASE1":25384,"PHASE1":25386,"PHASE2":25388,"PHASE3":25399,"PHASE4":25401,"NA":25403},{"trials":25385,"activeCount":124},[],{"trials":25387,"activeCount":124},[],{"trials":25389,"activeCount":166,"soonestReadout":446},[25390],{"nctId":25391,"briefTitle":25392,"status":279,"phases":25393,"primaryCompletion":446,"completion":446,"start":2590,"enrollment":676,"conditions":25394,"interventions":25398},"NCT04771520","Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors",[88],[7312,7543,1637,7544,2569,25395,25396,2790,361,1316,25397,12228,7548,1656,7549,7553,7554,7555,7316,7317,1675,1359,1676,1319,1677,1361,1678,1362,1679],"Locally Advanced Melanoma","Locally Advanced Primary Malignant Central Nervous System Neoplasm","Metastatic Primary Malignant Central Nervous System Neoplasm",[25382],{"trials":25400,"activeCount":124},[],{"trials":25402,"activeCount":124},[],{"trials":25404,"activeCount":124},[],{"intervention":7989,"totalTrials":166,"cells":25406},{"EARLY_PHASE1":25407,"PHASE1":25409,"PHASE2":25411,"PHASE3":25417,"PHASE4":25419,"NA":25421},{"trials":25408,"activeCount":124},[],{"trials":25410,"activeCount":124},[],{"trials":25412,"activeCount":166,"soonestReadout":193},[25413],{"nctId":7983,"briefTitle":7984,"status":102,"phases":25414,"primaryCompletion":193,"completion":591,"start":7986,"enrollment":186,"conditions":25415,"interventions":25416},[88],[2809],[7989,53],{"trials":25418,"activeCount":124},[],{"trials":25420,"activeCount":124},[],{"trials":25422,"activeCount":124},[],{"intervention":25424,"totalTrials":166,"cells":25425},"Duloxetine",{"EARLY_PHASE1":25426,"PHASE1":25428,"PHASE2":25430,"PHASE3":25440,"PHASE4":25442,"NA":25444},{"trials":25427,"activeCount":124},[],{"trials":25429,"activeCount":124},[],{"trials":25431,"activeCount":166,"soonestReadout":446},[25432],{"nctId":25433,"briefTitle":25434,"status":279,"phases":25435,"primaryCompletion":446,"completion":446,"start":2787,"enrollment":25436,"conditions":25437,"interventions":25439},"NCT04560673","Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy",[88],380,[25438,359,360],"Chemotherapy-Induced Peripheral Neuropathy",[25424],{"trials":25441,"activeCount":124},[],{"trials":25443,"activeCount":124},[],{"trials":25445,"activeCount":124},[],{"intervention":3339,"totalTrials":166,"cells":25447},{"EARLY_PHASE1":25448,"PHASE1":25450,"PHASE2":25452,"PHASE3":25458,"PHASE4":25460,"NA":25462},{"trials":25449,"activeCount":124},[],{"trials":25451,"activeCount":124},[],{"trials":25453,"activeCount":166,"soonestReadout":281},[25454],{"nctId":3328,"briefTitle":3329,"status":279,"phases":25455,"primaryCompletion":281,"completion":571,"start":2855,"enrollment":2997,"conditions":25456,"interventions":25457},[87,88],[3332,3333,3334,3335,3336],[3338,2462,803,3339],{"trials":25459,"activeCount":124},[],{"trials":25461,"activeCount":124},[],{"trials":25463,"activeCount":124},[],{"intervention":1916,"totalTrials":166,"cells":25465},{"EARLY_PHASE1":25466,"PHASE1":25468,"PHASE2":25470,"PHASE3":25476,"PHASE4":25478,"NA":25480},{"trials":25467,"activeCount":124},[],{"trials":25469,"activeCount":124},[],{"trials":25471,"activeCount":166,"soonestReadout":471},[25472],{"nctId":1893,"briefTitle":1894,"status":102,"phases":25473,"primaryCompletion":471,"completion":471,"start":1896,"enrollment":240,"conditions":25474,"interventions":25475},[87,88],[1667,1898,1669,1899,1900,1901,1902,1903,1904,1905,1906,1907,1908,1909,1910,1911,1912,1913,1914,1680,1681],[1916,1050],{"trials":25477,"activeCount":124},[],{"trials":25479,"activeCount":124},[],{"trials":25481,"activeCount":124},[],{"intervention":18737,"totalTrials":166,"cells":25483},{"EARLY_PHASE1":25484,"PHASE1":25486,"PHASE2":25488,"PHASE3":25494,"PHASE4":25496,"NA":25498},{"trials":25485,"activeCount":124},[],{"trials":25487,"activeCount":124},[],{"trials":25489,"activeCount":166,"soonestReadout":16160},[25490],{"nctId":18731,"briefTitle":18732,"status":279,"phases":25491,"primaryCompletion":16160,"completion":16160,"start":11126,"enrollment":871,"conditions":25492,"interventions":25493},[87,88],[18735],[3884,18737],{"trials":25495,"activeCount":124},[],{"trials":25497,"activeCount":124},[],{"trials":25499,"activeCount":124},[],{"intervention":25501,"totalTrials":166,"cells":25502},"TAS-102",{"EARLY_PHASE1":25503,"PHASE1":25505,"PHASE2":25507,"PHASE3":25516,"PHASE4":25518,"NA":25520},{"trials":25504,"activeCount":124},[],{"trials":25506,"activeCount":124},[],{"trials":25508,"activeCount":166,"soonestReadout":12951},[25509],{"nctId":25510,"briefTitle":25511,"status":279,"phases":25512,"primaryCompletion":12951,"completion":12951,"start":25513,"enrollment":448,"conditions":25514,"interventions":25515},"NCT05343013","TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy",[88],"2022-06-06",[3195],[25501],{"trials":25517,"activeCount":124},[],{"trials":25519,"activeCount":124},[],{"trials":25521,"activeCount":124},[],{"intervention":7068,"totalTrials":166,"cells":25523},{"EARLY_PHASE1":25524,"PHASE1":25526,"PHASE2":25528,"PHASE3":25534,"PHASE4":25536,"NA":25538},{"trials":25525,"activeCount":124},[],{"trials":25527,"activeCount":124},[],{"trials":25529,"activeCount":166,"soonestReadout":1735},[25530],{"nctId":7062,"briefTitle":7063,"status":279,"phases":25531,"primaryCompletion":1735,"completion":7065,"start":2106,"enrollment":517,"conditions":25532,"interventions":25533},[88],[6956],[809,894,803,1016,7068],{"trials":25535,"activeCount":124},[],{"trials":25537,"activeCount":124},[],{"trials":25539,"activeCount":124},[],{"intervention":25541,"totalTrials":166,"cells":25542},"Extended Release Metformin Hydrochloride",{"EARLY_PHASE1":25543,"PHASE1":25545,"PHASE2":25547,"PHASE3":25559,"PHASE4":25561,"NA":25563},{"trials":25544,"activeCount":124},[],{"trials":25546,"activeCount":124},[],{"trials":25548,"activeCount":166,"soonestReadout":25553},[25549],{"nctId":25550,"briefTitle":25551,"status":102,"phases":25552,"primaryCompletion":25553,"completion":25554,"start":25555,"enrollment":1100,"conditions":25556,"interventions":25558},"NCT05023967","Metformin and Nightly Fasting in Women With Early Breast Cancer",[88],"2025-12-09","2026-12-16","2023-04-04",[8026,8027,25557,5079],"Breast Ductal Carcinoma In Situ",[25541],{"trials":25560,"activeCount":124},[],{"trials":25562,"activeCount":124},[],{"trials":25564,"activeCount":124},[],{"intervention":25566,"totalTrials":166,"cells":25567},"Tislelizumab",{"EARLY_PHASE1":25568,"PHASE1":25570,"PHASE2":25572,"PHASE3":25585,"PHASE4":25587,"NA":25589},{"trials":25569,"activeCount":124},[],{"trials":25571,"activeCount":124},[],{"trials":25573,"activeCount":166,"soonestReadout":404},[25574],{"nctId":25575,"briefTitle":25576,"status":279,"phases":25577,"primaryCompletion":404,"completion":25578,"start":25579,"enrollment":1131,"conditions":25580,"interventions":25584},"NCT07136077","A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy",[88],"2028-04-01","2025-09-18",[3040,25581,3195,25582,25566,25583],"Adjuvant Chemotherapy","Fruquintinib","ctDNA",[25566,25582],{"trials":25586,"activeCount":124},[],{"trials":25588,"activeCount":124},[],{"trials":25590,"activeCount":124},[],{"intervention":25582,"totalTrials":166,"cells":25592},{"EARLY_PHASE1":25593,"PHASE1":25595,"PHASE2":25597,"PHASE3":25603,"PHASE4":25605,"NA":25607},{"trials":25594,"activeCount":124},[],{"trials":25596,"activeCount":124},[],{"trials":25598,"activeCount":166,"soonestReadout":404},[25599],{"nctId":25575,"briefTitle":25576,"status":279,"phases":25600,"primaryCompletion":404,"completion":25578,"start":25579,"enrollment":1131,"conditions":25601,"interventions":25602},[88],[3040,25581,3195,25582,25566,25583],[25566,25582],{"trials":25604,"activeCount":124},[],{"trials":25606,"activeCount":124},[],{"trials":25608,"activeCount":124},[],{"intervention":13072,"totalTrials":166,"cells":25610},{"EARLY_PHASE1":25611,"PHASE1":25613,"PHASE2":25615,"PHASE3":25621,"PHASE4":25623,"NA":25625},{"trials":25612,"activeCount":124},[],{"trials":25614,"activeCount":124},[],{"trials":25616,"activeCount":166,"soonestReadout":6952},[25617],{"nctId":13065,"briefTitle":13066,"status":102,"phases":25618,"primaryCompletion":6952,"completion":6953,"start":13068,"enrollment":1231,"conditions":25619,"interventions":25620},[88],[13070],[1083,13072,13073],{"trials":25622,"activeCount":124},[],{"trials":25624,"activeCount":124},[],{"trials":25626,"activeCount":124},[],{"intervention":13073,"totalTrials":166,"cells":25628},{"EARLY_PHASE1":25629,"PHASE1":25631,"PHASE2":25633,"PHASE3":25639,"PHASE4":25641,"NA":25643},{"trials":25630,"activeCount":124},[],{"trials":25632,"activeCount":124},[],{"trials":25634,"activeCount":166,"soonestReadout":6952},[25635],{"nctId":13065,"briefTitle":13066,"status":102,"phases":25636,"primaryCompletion":6952,"completion":6953,"start":13068,"enrollment":1231,"conditions":25637,"interventions":25638},[88],[13070],[1083,13072,13073],{"trials":25640,"activeCount":124},[],{"trials":25642,"activeCount":124},[],{"trials":25644,"activeCount":124},[],{"intervention":25646,"totalTrials":166,"cells":25647},"Obecabtagene autoleucel",{"EARLY_PHASE1":25648,"PHASE1":25650,"PHASE2":25652,"PHASE3":25663,"PHASE4":25665,"NA":25667},{"trials":25649,"activeCount":124},[],{"trials":25651,"activeCount":124},[],{"trials":25653,"activeCount":166,"soonestReadout":25658},[25654],{"nctId":25655,"briefTitle":25656,"status":279,"phases":25657,"primaryCompletion":25658,"completion":639,"start":25659,"enrollment":406,"conditions":25660,"interventions":25662},"NCT07053059","Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)",[88],"2028-05-31","2025-08-26",[25661],"Acute Lymphocytic Leukemia (ALL)",[25646],{"trials":25664,"activeCount":124},[],{"trials":25666,"activeCount":124},[],{"trials":25668,"activeCount":124},[],{"intervention":25670,"totalTrials":166,"cells":25671},"Mirtazapine",{"EARLY_PHASE1":25672,"PHASE1":25674,"PHASE2":25676,"PHASE3":25686,"PHASE4":25688,"NA":25690},{"trials":25673,"activeCount":124},[],{"trials":25675,"activeCount":124},[],{"trials":25677,"activeCount":166,"soonestReadout":224},[25678],{"nctId":25679,"briefTitle":25680,"status":102,"phases":25681,"primaryCompletion":224,"completion":224,"start":25682,"enrollment":4551,"conditions":25683,"interventions":25685},"NCT00488072","Effects of Mirtazapine on Appetite in Advanced Cancer Patients",[88],"2007-01-08",[1942,5956,5946,25684],"Insomnia",[25670],{"trials":25687,"activeCount":124},[],{"trials":25689,"activeCount":124},[],{"trials":25691,"activeCount":124},[],{"intervention":25693,"totalTrials":166,"cells":25694},"Selpercatinib",{"EARLY_PHASE1":25695,"PHASE1":25697,"PHASE2":25699,"PHASE3":25710,"PHASE4":25712,"NA":25714},{"trials":25696,"activeCount":124},[],{"trials":25698,"activeCount":124},[],{"trials":25700,"activeCount":166,"soonestReadout":1325},[25701],{"nctId":25702,"briefTitle":25703,"status":102,"phases":25704,"primaryCompletion":1325,"completion":1325,"start":25705,"enrollment":406,"conditions":25706,"interventions":25709},"NCT04759911","Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer",[88],"2021-02-26",[25707,1590,10831,1594,15731,25708,1595],"Malignant Thyroid Gland Neoplasm","Thyroid Gland Papillary Carcinoma",[25693],{"trials":25711,"activeCount":124},[],{"trials":25713,"activeCount":124},[],{"trials":25715,"activeCount":124},[],{"intervention":25717,"totalTrials":166,"cells":25718},"Mesenchymal Stem Cell",{"EARLY_PHASE1":25719,"PHASE1":25721,"PHASE2":25723,"PHASE3":25734,"PHASE4":25736,"NA":25738},{"trials":25720,"activeCount":124},[],{"trials":25722,"activeCount":124},[],{"trials":25724,"activeCount":166,"soonestReadout":7970},[25725],{"nctId":25726,"briefTitle":25727,"status":102,"phases":25728,"primaryCompletion":7970,"completion":7970,"start":662,"enrollment":3541,"conditions":25729,"interventions":25733},"NCT04565665","Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia",[87,88],[25730,25731,359,360,25732],"COVID-19 Infection","COVID-19-Associated Acute Respiratory Distress Syndrome","Symptomatic COVID-19 Infection Laboratory-Confirmed",[25717],{"trials":25735,"activeCount":124},[],{"trials":25737,"activeCount":124},[],{"trials":25739,"activeCount":124},[],{"intervention":10229,"totalTrials":166,"cells":25741},{"EARLY_PHASE1":25742,"PHASE1":25744,"PHASE2":25746,"PHASE3":25752,"PHASE4":25754,"NA":25756},{"trials":25743,"activeCount":124},[],{"trials":25745,"activeCount":124},[],{"trials":25747,"activeCount":166,"soonestReadout":224},[25748],{"nctId":10222,"briefTitle":10223,"status":102,"phases":25749,"primaryCompletion":224,"completion":224,"start":2185,"enrollment":1100,"conditions":25750,"interventions":25751},[88],[3543,3544,3545,10226,10227,3546],[3701,1369,10229,5114],{"trials":25753,"activeCount":124},[],{"trials":25755,"activeCount":124},[],{"trials":25757,"activeCount":124},[],{"intervention":964,"totalTrials":166,"cells":25759},{"EARLY_PHASE1":25760,"PHASE1":25762,"PHASE2":25764,"PHASE3":25770,"PHASE4":25772,"NA":25774},{"trials":25761,"activeCount":124},[],{"trials":25763,"activeCount":124},[],{"trials":25765,"activeCount":166,"soonestReadout":956},[25766],{"nctId":953,"briefTitle":954,"status":279,"phases":25767,"primaryCompletion":956,"completion":957,"start":958,"enrollment":959,"conditions":25768,"interventions":25769},[87,88],[961],[963,480,612,964],{"trials":25771,"activeCount":124},[],{"trials":25773,"activeCount":124},[],{"trials":25775,"activeCount":124},[],{"intervention":10238,"totalTrials":166,"cells":25777},{"EARLY_PHASE1":25778,"PHASE1":25780,"PHASE2":25782,"PHASE3":25788,"PHASE4":25790,"NA":25792},{"trials":25779,"activeCount":124},[],{"trials":25781,"activeCount":124},[],{"trials":25783,"activeCount":166,"soonestReadout":504},[25784],{"nctId":10231,"briefTitle":10232,"status":102,"phases":25785,"primaryCompletion":504,"completion":504,"start":10234,"enrollment":724,"conditions":25786,"interventions":25787},[88],[10236,5106],[3701,1369,10238,1374],{"trials":25789,"activeCount":124},[],{"trials":25791,"activeCount":124},[],{"trials":25793,"activeCount":124},[],{"intervention":1944,"totalTrials":166,"cells":25795},{"EARLY_PHASE1":25796,"PHASE1":25798,"PHASE2":25800,"PHASE3":25806,"PHASE4":25808,"NA":25810},{"trials":25797,"activeCount":124},[],{"trials":25799,"activeCount":124},[],{"trials":25801,"activeCount":166,"soonestReadout":1939},[25802],{"nctId":1936,"briefTitle":1937,"status":279,"phases":25803,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":1222,"conditions":25804,"interventions":25805},[87,88],[1942,1271],[1944,1050,1421,1945],{"trials":25807,"activeCount":124},[],{"trials":25809,"activeCount":124},[],{"trials":25811,"activeCount":124},[],{"intervention":25813,"totalTrials":166,"cells":25814},"Emapalumab",{"EARLY_PHASE1":25815,"PHASE1":25817,"PHASE2":25819,"PHASE3":25831,"PHASE4":25833,"NA":25835},{"trials":25816,"activeCount":124},[],{"trials":25818,"activeCount":124},[],{"trials":25820,"activeCount":166,"soonestReadout":25825},[25821],{"nctId":25822,"briefTitle":25823,"status":279,"phases":25824,"primaryCompletion":25825,"completion":25826,"start":25827,"enrollment":507,"conditions":25828,"interventions":25830},"NCT06285825","A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia",[88],"2026-08-22","2028-08-22","2024-07-05",[25829],"Cytopenia",[25813],{"trials":25832,"activeCount":124},[],{"trials":25834,"activeCount":124},[],{"trials":25836,"activeCount":124},[],{"intervention":985,"totalTrials":166,"cells":25838},{"EARLY_PHASE1":25839,"PHASE1":25841,"PHASE2":25843,"PHASE3":25849,"PHASE4":25851,"NA":25853},{"trials":25840,"activeCount":124},[],{"trials":25842,"activeCount":124},[],{"trials":25844,"activeCount":166,"soonestReadout":404},[25845],{"nctId":976,"briefTitle":977,"status":279,"phases":25846,"primaryCompletion":404,"completion":979,"start":980,"enrollment":517,"conditions":25847,"interventions":25848},[87,88],[982,983],[985,510,480],{"trials":25850,"activeCount":124},[],{"trials":25852,"activeCount":124},[],{"trials":25854,"activeCount":124},[],{"intervention":3358,"totalTrials":166,"cells":25856},{"EARLY_PHASE1":25857,"PHASE1":25859,"PHASE2":25861,"PHASE3":25867,"PHASE4":25869,"NA":25871},{"trials":25858,"activeCount":124},[],{"trials":25860,"activeCount":124},[],{"trials":25862,"activeCount":166,"soonestReadout":1662},[25863],{"nctId":3350,"briefTitle":3351,"status":279,"phases":25864,"primaryCompletion":1662,"completion":1662,"start":3353,"enrollment":3354,"conditions":25865,"interventions":25866},[87,88],[3356],[1005,803,3358],{"trials":25868,"activeCount":124},[],{"trials":25870,"activeCount":124},[],{"trials":25872,"activeCount":124},[],{"intervention":25874,"totalTrials":166,"cells":25875},"Imetelstat",{"EARLY_PHASE1":25876,"PHASE1":25878,"PHASE2":25880,"PHASE3":25890,"PHASE4":25892,"NA":25894},{"trials":25877,"activeCount":124},[],{"trials":25879,"activeCount":124},[],{"trials":25881,"activeCount":166,"soonestReadout":860},[25882],{"nctId":25883,"briefTitle":25884,"status":546,"phases":25885,"primaryCompletion":860,"completion":860,"start":25886,"enrollment":406,"conditions":25887,"interventions":25889},"NCT07549451","Phase 2 Study Of Imetelstat for Patient With Myelodysplastic\u002FMyeloproliferative Neoplasms",[88],"2026-10-08",[22332,25874,25888],"Myelodysplastic (MDS) \u002F Myeloproliferative (MPN) Diseases",[25874],{"trials":25891,"activeCount":124},[],{"trials":25893,"activeCount":124},[],{"trials":25895,"activeCount":124},[],{"intervention":3372,"totalTrials":166,"cells":25897},{"EARLY_PHASE1":25898,"PHASE1":25900,"PHASE2":25902,"PHASE3":25908,"PHASE4":25910,"NA":25912},{"trials":25899,"activeCount":124},[],{"trials":25901,"activeCount":124},[],{"trials":25903,"activeCount":166,"soonestReadout":238},[25904],{"nctId":3364,"briefTitle":3365,"status":279,"phases":25905,"primaryCompletion":238,"completion":238,"start":3367,"enrollment":676,"conditions":25906,"interventions":25907},[87,88],[1772,3369,3370],[3372,2462,803],{"trials":25909,"activeCount":124},[],{"trials":25911,"activeCount":124},[],{"trials":25913,"activeCount":124},[],{"intervention":25915,"totalTrials":166,"cells":25916},"Belumosudil mesylate",{"EARLY_PHASE1":25917,"PHASE1":25919,"PHASE2":25921,"PHASE3":25929,"PHASE4":25931,"NA":25933},{"trials":25918,"activeCount":124},[],{"trials":25920,"activeCount":124},[],{"trials":25922,"activeCount":166,"soonestReadout":5995},[25923],{"nctId":25924,"briefTitle":25925,"status":279,"phases":25926,"primaryCompletion":5995,"completion":6282,"start":2864,"enrollment":593,"conditions":25927,"interventions":25928},"NCT06105554","Phase I\u002FII Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed\u002FRefractory Multiple Myeloma",[87,88],[1400],[25915],{"trials":25930,"activeCount":124},[],{"trials":25932,"activeCount":124},[],{"trials":25934,"activeCount":124},[],{"intervention":7138,"totalTrials":166,"cells":25936},{"EARLY_PHASE1":25937,"PHASE1":25939,"PHASE2":25941,"PHASE3":25947,"PHASE4":25949,"NA":25951},{"trials":25938,"activeCount":124},[],{"trials":25940,"activeCount":124},[],{"trials":25942,"activeCount":166,"soonestReadout":7133},[25943],{"nctId":7130,"briefTitle":7131,"status":279,"phases":25944,"primaryCompletion":7133,"completion":7134,"start":1282,"enrollment":406,"conditions":25945,"interventions":25946},[88],[7136],[7138,803,1013,1016,809],{"trials":25948,"activeCount":124},[],{"trials":25950,"activeCount":124},[],{"trials":25952,"activeCount":124},[],{"intervention":3402,"totalTrials":166,"cells":25954},{"EARLY_PHASE1":25955,"PHASE1":25957,"PHASE2":25959,"PHASE3":25965,"PHASE4":25967,"NA":25969},{"trials":25956,"activeCount":124},[],{"trials":25958,"activeCount":124},[],{"trials":25960,"activeCount":166,"soonestReadout":1427},[25961],{"nctId":3388,"briefTitle":3389,"status":279,"phases":25962,"primaryCompletion":1427,"completion":1427,"start":3391,"enrollment":1975,"conditions":25963,"interventions":25964},[87,88],[3393,3394,3395,1400,3396,1866,3397,3398,3399,3400],[803,3402,2462],{"trials":25966,"activeCount":124},[],{"trials":25968,"activeCount":124},[],{"trials":25970,"activeCount":124},[],{"intervention":22391,"totalTrials":166,"cells":25972},{"EARLY_PHASE1":25973,"PHASE1":25975,"PHASE2":25977,"PHASE3":25983,"PHASE4":25985,"NA":25987},{"trials":25974,"activeCount":124},[],{"trials":25976,"activeCount":124},[],{"trials":25978,"activeCount":166,"soonestReadout":3879},[25979],{"nctId":22384,"briefTitle":22385,"status":279,"phases":25980,"primaryCompletion":3879,"completion":12905,"start":22387,"enrollment":406,"conditions":25981,"interventions":25982},[88],[22389,1520],[22391,10681],{"trials":25984,"activeCount":124},[],{"trials":25986,"activeCount":124},[],{"trials":25988,"activeCount":124},[],{"intervention":25990,"totalTrials":166,"cells":25991},"Larotrectinib Sulfate",{"EARLY_PHASE1":25992,"PHASE1":25994,"PHASE2":25996,"PHASE3":26005,"PHASE4":26007,"NA":26009},{"trials":25993,"activeCount":124},[],{"trials":25995,"activeCount":124},[],{"trials":25997,"activeCount":166,"soonestReadout":26002},[25998],{"nctId":25999,"briefTitle":26000,"status":279,"phases":26001,"primaryCompletion":26002,"completion":26002,"start":8166,"enrollment":2018,"conditions":26003,"interventions":26004},"NCT04879121","Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors",[88],"2027-11-11",[2569,361],[25990],{"trials":26006,"activeCount":124},[],{"trials":26008,"activeCount":124},[],{"trials":26010,"activeCount":124},[],{"intervention":3744,"totalTrials":166,"cells":26012},{"EARLY_PHASE1":26013,"PHASE1":26015,"PHASE2":26017,"PHASE3":26023,"PHASE4":26025,"NA":26027},{"trials":26014,"activeCount":124},[],{"trials":26016,"activeCount":124},[],{"trials":26018,"activeCount":166,"soonestReadout":3738},[26019],{"nctId":3735,"briefTitle":3736,"status":279,"phases":26020,"primaryCompletion":3738,"completion":3739,"start":3740,"enrollment":1568,"conditions":26021,"interventions":26022},[88],[3742],[3744,1049,1740],{"trials":26024,"activeCount":124},[],{"trials":26026,"activeCount":124},[],{"trials":26028,"activeCount":124},[],{"intervention":7172,"totalTrials":166,"cells":26030},{"EARLY_PHASE1":26031,"PHASE1":26033,"PHASE2":26035,"PHASE3":26041,"PHASE4":26043,"NA":26045},{"trials":26032,"activeCount":124},[],{"trials":26034,"activeCount":124},[],{"trials":26036,"activeCount":166,"soonestReadout":7166},[26037],{"nctId":7163,"briefTitle":7164,"status":279,"phases":26038,"primaryCompletion":7166,"completion":7167,"start":7168,"enrollment":19,"conditions":26039,"interventions":26040},[87,88],[7170],[803,1070,7172,3499],{"trials":26042,"activeCount":124},[],{"trials":26044,"activeCount":124},[],{"trials":26046,"activeCount":124},[],{"intervention":21682,"totalTrials":166,"cells":26048},{"EARLY_PHASE1":26049,"PHASE1":26051,"PHASE2":26053,"PHASE3":26059,"PHASE4":26061,"NA":26063},{"trials":26050,"activeCount":124},[],{"trials":26052,"activeCount":124},[],{"trials":26054,"activeCount":166,"soonestReadout":21663},[26055],{"nctId":21673,"briefTitle":21674,"status":279,"phases":26056,"primaryCompletion":21663,"completion":21676,"start":11677,"enrollment":21677,"conditions":26057,"interventions":26058},[88],[21679,21667,21680,21668],[21670,21651,21682,21683,21684],{"trials":26060,"activeCount":124},[],{"trials":26062,"activeCount":124},[],{"trials":26064,"activeCount":124},[],{"intervention":21683,"totalTrials":166,"cells":26066},{"EARLY_PHASE1":26067,"PHASE1":26069,"PHASE2":26071,"PHASE3":26077,"PHASE4":26079,"NA":26081},{"trials":26068,"activeCount":124},[],{"trials":26070,"activeCount":124},[],{"trials":26072,"activeCount":166,"soonestReadout":21663},[26073],{"nctId":21673,"briefTitle":21674,"status":279,"phases":26074,"primaryCompletion":21663,"completion":21676,"start":11677,"enrollment":21677,"conditions":26075,"interventions":26076},[88],[21679,21667,21680,21668],[21670,21651,21682,21683,21684],{"trials":26078,"activeCount":124},[],{"trials":26080,"activeCount":124},[],{"trials":26082,"activeCount":124},[],{"intervention":26084,"totalTrials":166,"cells":26085},"Focal Cryoablation",{"EARLY_PHASE1":26086,"PHASE1":26088,"PHASE2":26090,"PHASE3":26099,"PHASE4":26101,"NA":26103},{"trials":26087,"activeCount":124},[],{"trials":26089,"activeCount":124},[],{"trials":26091,"activeCount":166,"soonestReadout":10132},[26092],{"nctId":26093,"briefTitle":26094,"status":279,"phases":26095,"primaryCompletion":10132,"completion":10132,"start":26096,"enrollment":406,"conditions":26097,"interventions":26098},"NCT05454488","An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer",[88],"2022-07-25",[27],[26084],{"trials":26100,"activeCount":124},[],{"trials":26102,"activeCount":124},[],{"trials":26104,"activeCount":124},[],{"intervention":21097,"totalTrials":166,"cells":26106},{"EARLY_PHASE1":26107,"PHASE1":26109,"PHASE2":26111,"PHASE3":26117,"PHASE4":26119,"NA":26121},{"trials":26108,"activeCount":124},[],{"trials":26110,"activeCount":124},[],{"trials":26112,"activeCount":166,"soonestReadout":5310},[26113],{"nctId":21091,"briefTitle":21092,"status":102,"phases":26114,"primaryCompletion":5310,"completion":5310,"start":21094,"enrollment":628,"conditions":26115,"interventions":26116},[88],[17318],[9970,21097],{"trials":26118,"activeCount":124},[],{"trials":26120,"activeCount":124},[],{"trials":26122,"activeCount":124},[],{"intervention":18327,"totalTrials":166,"cells":26124},{"EARLY_PHASE1":26125,"PHASE1":26127,"PHASE2":26129,"PHASE3":26135,"PHASE4":26137,"NA":26139},{"trials":26126,"activeCount":124},[],{"trials":26128,"activeCount":124},[],{"trials":26130,"activeCount":166,"soonestReadout":18322},[26131],{"nctId":18319,"briefTitle":18320,"status":279,"phases":26132,"primaryCompletion":18322,"completion":18322,"start":18323,"enrollment":1131,"conditions":26133,"interventions":26134},[88],[18,18325],[18327,14086,18328],{"trials":26136,"activeCount":124},[],{"trials":26138,"activeCount":124},[],{"trials":26140,"activeCount":124},[],{"intervention":18328,"totalTrials":166,"cells":26142},{"EARLY_PHASE1":26143,"PHASE1":26145,"PHASE2":26147,"PHASE3":26153,"PHASE4":26155,"NA":26157},{"trials":26144,"activeCount":124},[],{"trials":26146,"activeCount":124},[],{"trials":26148,"activeCount":166,"soonestReadout":18322},[26149],{"nctId":18319,"briefTitle":18320,"status":279,"phases":26150,"primaryCompletion":18322,"completion":18322,"start":18323,"enrollment":1131,"conditions":26151,"interventions":26152},[88],[18,18325],[18327,14086,18328],{"trials":26154,"activeCount":124},[],{"trials":26156,"activeCount":124},[],{"trials":26158,"activeCount":124},[],{"intervention":26160,"totalTrials":166,"cells":26161},"Loncastuximab Tesirine",{"EARLY_PHASE1":26162,"PHASE1":26164,"PHASE2":26166,"PHASE3":26175,"PHASE4":26177,"NA":26179},{"trials":26163,"activeCount":124},[],{"trials":26165,"activeCount":124},[],{"trials":26167,"activeCount":166,"soonestReadout":26172},[26168],{"nctId":26169,"briefTitle":26170,"status":279,"phases":26171,"primaryCompletion":26172,"completion":26172,"start":1033,"enrollment":406,"conditions":26173,"interventions":26174},"NCT05464719","A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy",[88],"2030-01-30",[6956,21],[26160],{"trials":26176,"activeCount":124},[],{"trials":26178,"activeCount":124},[],{"trials":26180,"activeCount":124},[],{"intervention":8793,"totalTrials":166,"cells":26182},{"EARLY_PHASE1":26183,"PHASE1":26185,"PHASE2":26187,"PHASE3":26193,"PHASE4":26195,"NA":26197},{"trials":26184,"activeCount":124},[],{"trials":26186,"activeCount":124},[],{"trials":26188,"activeCount":166,"soonestReadout":8781},[26189],{"nctId":8778,"briefTitle":8779,"status":102,"phases":26190,"primaryCompletion":8781,"completion":8781,"start":3965,"enrollment":2997,"conditions":26191,"interventions":26192},[87,88],[8783,8404,8405,8784,8406,8407,8408,8785,8786,8787,8788,5634,8789,6774,790,8790,6775,6776,8791,715],[8793,1402,894],{"trials":26194,"activeCount":124},[],{"trials":26196,"activeCount":124},[],{"trials":26198,"activeCount":124},[],{"intervention":18434,"totalTrials":166,"cells":26200},{"EARLY_PHASE1":26201,"PHASE1":26203,"PHASE2":26205,"PHASE3":26211,"PHASE4":26213,"NA":26215},{"trials":26202,"activeCount":124},[],{"trials":26204,"activeCount":124},[],{"trials":26206,"activeCount":166,"soonestReadout":18430},[26207],{"nctId":18427,"briefTitle":18428,"status":279,"phases":26208,"primaryCompletion":18430,"completion":18430,"start":2729,"enrollment":9213,"conditions":26209,"interventions":26210},[88],[18432],[16012,694,18434],{"trials":26212,"activeCount":124},[],{"trials":26214,"activeCount":124},[],{"trials":26216,"activeCount":124},[],{"intervention":14268,"totalTrials":166,"cells":26218},{"EARLY_PHASE1":26219,"PHASE1":26221,"PHASE2":26223,"PHASE3":26229,"PHASE4":26231,"NA":26233},{"trials":26220,"activeCount":124},[],{"trials":26222,"activeCount":124},[],{"trials":26224,"activeCount":166,"soonestReadout":1088},[26225],{"nctId":14262,"briefTitle":14263,"status":279,"phases":26226,"primaryCompletion":1088,"completion":14252,"start":14265,"enrollment":517,"conditions":26227,"interventions":26228},[88],[1924],[14268,12910],{"trials":26230,"activeCount":124},[],{"trials":26232,"activeCount":124},[],{"trials":26234,"activeCount":124},[],{"intervention":26236,"totalTrials":166,"cells":26237},"SGN-35",{"EARLY_PHASE1":26238,"PHASE1":26240,"PHASE2":26242,"PHASE3":26255,"PHASE4":26257,"NA":26259},{"trials":26239,"activeCount":124},[],{"trials":26241,"activeCount":124},[],{"trials":26243,"activeCount":166,"soonestReadout":10132},[26244],{"nctId":26245,"briefTitle":26246,"status":102,"phases":26247,"primaryCompletion":10132,"completion":10132,"start":2968,"enrollment":31,"conditions":26248,"interventions":26254},"NCT01352520","SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)",[88],[26249,26250,26251,5457,26252,26253,21,2742],"CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma","Lymphoma, Primary Cutaneous Anaplastic Large Cell","Lymphomatoid Papulosis","Skin Lymphoma","Cutaneous Lymphomas",[26236],{"trials":26256,"activeCount":124},[],{"trials":26258,"activeCount":124},[],{"trials":26260,"activeCount":124},[],{"intervention":13649,"totalTrials":166,"cells":26262},{"EARLY_PHASE1":26263,"PHASE1":26265,"PHASE2":26267,"PHASE3":26273,"PHASE4":26275,"NA":26277},{"trials":26264,"activeCount":124},[],{"trials":26266,"activeCount":124},[],{"trials":26268,"activeCount":166,"soonestReadout":13643},[26269],{"nctId":13640,"briefTitle":13641,"status":279,"phases":26270,"primaryCompletion":13643,"completion":13643,"start":13644,"enrollment":593,"conditions":26271,"interventions":26272},[88],[1866,3393,13646],[13648,13649,3338,1402],{"trials":26274,"activeCount":124},[],{"trials":26276,"activeCount":124},[],{"trials":26278,"activeCount":124},[],{"intervention":2090,"totalTrials":166,"cells":26280},{"EARLY_PHASE1":26281,"PHASE1":26283,"PHASE2":26285,"PHASE3":26291,"PHASE4":26293,"NA":26295},{"trials":26282,"activeCount":124},[],{"trials":26284,"activeCount":124},[],{"trials":26286,"activeCount":166,"soonestReadout":224},[26287],{"nctId":2080,"briefTitle":2081,"status":102,"phases":26288,"primaryCompletion":224,"completion":224,"start":773,"enrollment":1568,"conditions":26289,"interventions":26290},[88],[2084,2085,1676,2086,1677,1678,1679],[2088,2089,2090,1050,53,2091],{"trials":26292,"activeCount":124},[],{"trials":26294,"activeCount":124},[],{"trials":26296,"activeCount":124},[],{"intervention":4267,"totalTrials":166,"cells":26298},{"EARLY_PHASE1":26299,"PHASE1":26301,"PHASE2":26303,"PHASE3":26309,"PHASE4":26311,"NA":26313},{"trials":26300,"activeCount":124},[],{"trials":26302,"activeCount":124},[],{"trials":26304,"activeCount":166,"soonestReadout":4250},[26305],{"nctId":4247,"briefTitle":4248,"status":102,"phases":26306,"primaryCompletion":4250,"completion":4250,"start":1896,"enrollment":492,"conditions":26307,"interventions":26308},[88],[4252,4253,4254,4255,4256,4257,4258,4259,4260,4261,4262,4263,4264,4265],[1709,4267],{"trials":26310,"activeCount":124},[],{"trials":26312,"activeCount":124},[],{"trials":26314,"activeCount":124},[],{"intervention":7248,"totalTrials":166,"cells":26316},{"EARLY_PHASE1":26317,"PHASE1":26319,"PHASE2":26321,"PHASE3":26327,"PHASE4":26329,"NA":26331},{"trials":26318,"activeCount":124},[],{"trials":26320,"activeCount":124},[],{"trials":26322,"activeCount":166,"soonestReadout":7065},[26323],{"nctId":7241,"briefTitle":7242,"status":546,"phases":26324,"primaryCompletion":7065,"completion":7244,"start":115,"enrollment":3082,"conditions":26325,"interventions":26326},[88],[7246],[7248,894,1070,803],{"trials":26328,"activeCount":124},[],{"trials":26330,"activeCount":124},[],{"trials":26332,"activeCount":124},[],{"intervention":13090,"totalTrials":166,"cells":26334},{"EARLY_PHASE1":26335,"PHASE1":26337,"PHASE2":26339,"PHASE3":26345,"PHASE4":26347,"NA":26349},{"trials":26336,"activeCount":124},[],{"trials":26338,"activeCount":124},[],{"trials":26340,"activeCount":166,"soonestReadout":281},[26341],{"nctId":13083,"briefTitle":13084,"status":279,"phases":26342,"primaryCompletion":281,"completion":571,"start":13086,"enrollment":517,"conditions":26343,"interventions":26344},[87,88],[9033,13088],[1083,2477,499,13090],{"trials":26346,"activeCount":124},[],{"trials":26348,"activeCount":124},[],{"trials":26350,"activeCount":124},[],{"intervention":2099,"totalTrials":166,"cells":26352},{"EARLY_PHASE1":26353,"PHASE1":26355,"PHASE2":26357,"PHASE3":26363,"PHASE4":26365,"NA":26367},{"trials":26354,"activeCount":124},[],{"trials":26356,"activeCount":124},[],{"trials":26358,"activeCount":166,"soonestReadout":1864},[26359],{"nctId":2093,"briefTitle":2094,"status":102,"phases":26360,"primaryCompletion":1864,"completion":1864,"start":2096,"enrollment":1496,"conditions":26361,"interventions":26362},[88],[1346],[2099,1050],{"trials":26364,"activeCount":124},[],{"trials":26366,"activeCount":124},[],{"trials":26368,"activeCount":124},[],{"intervention":2109,"totalTrials":166,"cells":26370},{"EARLY_PHASE1":26371,"PHASE1":26373,"PHASE2":26375,"PHASE3":26381,"PHASE4":26383,"NA":26385},{"trials":26372,"activeCount":124},[],{"trials":26374,"activeCount":124},[],{"trials":26376,"activeCount":166,"soonestReadout":2104},[26377],{"nctId":2101,"briefTitle":2102,"status":279,"phases":26378,"primaryCompletion":2104,"completion":2105,"start":2106,"enrollment":473,"conditions":26379,"interventions":26380},[88],[1521],[2109,1050],{"trials":26382,"activeCount":124},[],{"trials":26384,"activeCount":124},[],{"trials":26386,"activeCount":124},[],{"intervention":2116,"totalTrials":166,"cells":26388},{"EARLY_PHASE1":26389,"PHASE1":26391,"PHASE2":26393,"PHASE3":26399,"PHASE4":26401,"NA":26403},{"trials":26390,"activeCount":124},[],{"trials":26392,"activeCount":124},[],{"trials":26394,"activeCount":166,"soonestReadout":2104},[26395],{"nctId":2111,"briefTitle":2112,"status":102,"phases":26396,"primaryCompletion":2104,"completion":2104,"start":868,"enrollment":676,"conditions":26397,"interventions":26398},[87,88],[1521],[1049,1050,2116],{"trials":26400,"activeCount":124},[],{"trials":26402,"activeCount":124},[],{"trials":26404,"activeCount":124},[],{"intervention":21839,"totalTrials":166,"cells":26406},{"EARLY_PHASE1":26407,"PHASE1":26409,"PHASE2":26411,"PHASE3":26417,"PHASE4":26419,"NA":26421},{"trials":26408,"activeCount":124},[],{"trials":26410,"activeCount":124},[],{"trials":26412,"activeCount":166,"soonestReadout":504},[26413],{"nctId":21833,"briefTitle":21834,"status":102,"phases":26414,"primaryCompletion":504,"completion":504,"start":2856,"enrollment":507,"conditions":26415,"interventions":26416},[87,88],[21837,4206,1355,1357,1358,1359,1319,1361,1362],[21839,21817],{"trials":26418,"activeCount":124},[],{"trials":26420,"activeCount":124},[],{"trials":26422,"activeCount":124},[],{"intervention":4285,"totalTrials":166,"cells":26424},{"EARLY_PHASE1":26425,"PHASE1":26427,"PHASE2":26429,"PHASE3":26435,"PHASE4":26437,"NA":26439},{"trials":26426,"activeCount":124},[],{"trials":26428,"activeCount":124},[],{"trials":26430,"activeCount":166,"soonestReadout":4281},[26431],{"nctId":4278,"briefTitle":4279,"status":279,"phases":26432,"primaryCompletion":4281,"completion":4281,"start":4282,"enrollment":2159,"conditions":26433,"interventions":26434},[88],[24],[4285,1709,1369,1377],{"trials":26436,"activeCount":124},[],{"trials":26438,"activeCount":124},[],{"trials":26440,"activeCount":124},[],{"intervention":26442,"totalTrials":166,"cells":26443},"Navlimetostat",{"EARLY_PHASE1":26444,"PHASE1":26446,"PHASE2":26448,"PHASE3":26459,"PHASE4":26461,"NA":26463},{"trials":26445,"activeCount":124},[],{"trials":26447,"activeCount":124},[],{"trials":26449,"activeCount":166,"soonestReadout":26454},[26450],{"nctId":26451,"briefTitle":26452,"status":546,"phases":26453,"primaryCompletion":26454,"completion":26455,"start":1078,"enrollment":539,"conditions":26456,"interventions":26457},"NCT07579221","Ph1\u002F2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer",[87,88],"2029-08-01","2031-08-01",[10135],[26442,26458],"Pumitamig",{"trials":26460,"activeCount":124},[],{"trials":26462,"activeCount":124},[],{"trials":26464,"activeCount":124},[],{"intervention":26458,"totalTrials":166,"cells":26466},{"EARLY_PHASE1":26467,"PHASE1":26469,"PHASE2":26471,"PHASE3":26477,"PHASE4":26479,"NA":26481},{"trials":26468,"activeCount":124},[],{"trials":26470,"activeCount":124},[],{"trials":26472,"activeCount":166,"soonestReadout":26454},[26473],{"nctId":26451,"briefTitle":26452,"status":546,"phases":26474,"primaryCompletion":26454,"completion":26455,"start":1078,"enrollment":539,"conditions":26475,"interventions":26476},[87,88],[10135],[26442,26458],{"trials":26478,"activeCount":124},[],{"trials":26480,"activeCount":124},[],{"trials":26482,"activeCount":124},[],{"intervention":4486,"totalTrials":166,"cells":26484},{"EARLY_PHASE1":26485,"PHASE1":26487,"PHASE2":26489,"PHASE3":26495,"PHASE4":26497,"NA":26499},{"trials":26486,"activeCount":124},[],{"trials":26488,"activeCount":124},[],{"trials":26490,"activeCount":166,"soonestReadout":224},[26491],{"nctId":4479,"briefTitle":4480,"status":279,"phases":26492,"primaryCompletion":224,"completion":224,"start":4482,"enrollment":1222,"conditions":26493,"interventions":26494},[88],[36,644,645,1067,4484,727,912],[599,654,4486,694,655],{"trials":26496,"activeCount":124},[],{"trials":26498,"activeCount":124},[],{"trials":26500,"activeCount":124},[],{"intervention":3431,"totalTrials":166,"cells":26502},{"EARLY_PHASE1":26503,"PHASE1":26505,"PHASE2":26507,"PHASE3":26513,"PHASE4":26515,"NA":26517},{"trials":26504,"activeCount":124},[],{"trials":26506,"activeCount":124},[],{"trials":26508,"activeCount":166,"soonestReadout":3425},[26509],{"nctId":3422,"briefTitle":3423,"status":279,"phases":26510,"primaryCompletion":3425,"completion":3426,"start":3427,"enrollment":406,"conditions":26511,"interventions":26512},[88],[2135,3429],[598,3431,3432,1004,3433,2462,803,1114,2196],{"trials":26514,"activeCount":124},[],{"trials":26516,"activeCount":124},[],{"trials":26518,"activeCount":124},[],{"intervention":3433,"totalTrials":166,"cells":26520},{"EARLY_PHASE1":26521,"PHASE1":26523,"PHASE2":26525,"PHASE3":26531,"PHASE4":26533,"NA":26535},{"trials":26522,"activeCount":124},[],{"trials":26524,"activeCount":124},[],{"trials":26526,"activeCount":166,"soonestReadout":3425},[26527],{"nctId":3422,"briefTitle":3423,"status":279,"phases":26528,"primaryCompletion":3425,"completion":3426,"start":3427,"enrollment":406,"conditions":26529,"interventions":26530},[88],[2135,3429],[598,3431,3432,1004,3433,2462,803,1114,2196],{"trials":26532,"activeCount":124},[],{"trials":26534,"activeCount":124},[],{"trials":26536,"activeCount":124},[],{"intervention":7341,"totalTrials":166,"cells":26538},{"EARLY_PHASE1":26539,"PHASE1":26541,"PHASE2":26543,"PHASE3":26549,"PHASE4":26551,"NA":26553},{"trials":26540,"activeCount":124},[],{"trials":26542,"activeCount":124},[],{"trials":26544,"activeCount":166,"soonestReadout":3425},[26545],{"nctId":7332,"briefTitle":7333,"status":102,"phases":26546,"primaryCompletion":3425,"completion":3426,"start":7335,"enrollment":1568,"conditions":26547,"interventions":26548},[87,88],[7337,1729,7338,7339],[7341,3499,803,1070],{"trials":26550,"activeCount":124},[],{"trials":26552,"activeCount":124},[],{"trials":26554,"activeCount":124},[],{"intervention":26556,"totalTrials":166,"cells":26557},"Allogeneic BK-specific Cytotoxic T-lymphocytes",{"EARLY_PHASE1":26558,"PHASE1":26560,"PHASE2":26562,"PHASE3":26577,"PHASE4":26579,"NA":26581},{"trials":26559,"activeCount":124},[],{"trials":26561,"activeCount":124},[],{"trials":26563,"activeCount":166,"soonestReadout":3943},[26564],{"nctId":26565,"briefTitle":26566,"status":279,"phases":26567,"primaryCompletion":3943,"completion":3943,"start":26568,"enrollment":1222,"conditions":26569,"interventions":26576},"NCT02479698","Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and\u002For JC Virus",[88],"2015-07-23",[26570,26571,26572,26573,2613,5407,26574,26575],"Acquired Immunodeficiency Syndrome","BK Virus Infection","Human Immunodeficiency Virus","JC Virus Infection","Merkel Cell Polyomavirus Infection","Viral Encephalitis",[26556],{"trials":26578,"activeCount":124},[],{"trials":26580,"activeCount":124},[],{"trials":26582,"activeCount":124},[],{"intervention":21287,"totalTrials":166,"cells":26584},{"EARLY_PHASE1":26585,"PHASE1":26587,"PHASE2":26589,"PHASE3":26595,"PHASE4":26597,"NA":26599},{"trials":26586,"activeCount":124},[],{"trials":26588,"activeCount":124},[],{"trials":26590,"activeCount":166,"soonestReadout":224},[26591],{"nctId":21281,"briefTitle":21282,"status":102,"phases":26592,"primaryCompletion":224,"completion":224,"start":21284,"enrollment":3354,"conditions":26593,"interventions":26594},[88],[27],[21287,15690],{"trials":26596,"activeCount":124},[],{"trials":26598,"activeCount":124},[],{"trials":26600,"activeCount":124},[],{"intervention":10622,"totalTrials":166,"cells":26602},{"EARLY_PHASE1":26603,"PHASE1":26605,"PHASE2":26607,"PHASE3":26613,"PHASE4":26615,"NA":26617},{"trials":26604,"activeCount":124},[],{"trials":26606,"activeCount":124},[],{"trials":26608,"activeCount":166,"soonestReadout":10617},[26609],{"nctId":10614,"briefTitle":10615,"status":279,"phases":26610,"primaryCompletion":10617,"completion":10618,"start":10619,"enrollment":901,"conditions":26611,"interventions":26612},[87,88],[2391],[510,10622],{"trials":26614,"activeCount":124},[],{"trials":26616,"activeCount":124},[],{"trials":26618,"activeCount":124},[],{"intervention":13356,"totalTrials":166,"cells":26620},{"EARLY_PHASE1":26621,"PHASE1":26623,"PHASE2":26625,"PHASE3":26631,"PHASE4":26633,"NA":26635},{"trials":26622,"activeCount":124},[],{"trials":26624,"activeCount":124},[],{"trials":26626,"activeCount":166,"soonestReadout":13348},[26627],{"nctId":13345,"briefTitle":13346,"status":102,"phases":26628,"primaryCompletion":13348,"completion":13348,"start":13349,"enrollment":2865,"conditions":26629,"interventions":26630},[88],[13351,1769,1388,13352,6905,13353,13354,8174,1672,1355,8177,1673,1357,1674,1358,1675,1359,1676,1319,8115,1677,1361,1678,1362,1679],[13356,1786],{"trials":26632,"activeCount":124},[],{"trials":26634,"activeCount":124},[],{"trials":26636,"activeCount":124},[],{"intervention":43,"totalTrials":166,"cells":26638},{"EARLY_PHASE1":26639,"PHASE1":26641,"PHASE2":26643,"PHASE3":26650,"PHASE4":26652,"NA":26654},{"trials":26640,"activeCount":124},[],{"trials":26642,"activeCount":124},[],{"trials":26644,"activeCount":166,"soonestReadout":42},[26645],{"nctId":40,"briefTitle":41,"status":102,"phases":26646,"primaryCompletion":42,"completion":2628,"start":26647,"enrollment":12867,"conditions":26648,"interventions":26649},[87,88],"2011-10-14",[33,1924],[43],{"trials":26651,"activeCount":124},[],{"trials":26653,"activeCount":124},[],{"trials":26655,"activeCount":124},[],{"intervention":26657,"totalTrials":166,"cells":26658},"Enfortumab Vedotin",{"EARLY_PHASE1":26659,"PHASE1":26661,"PHASE2":26663,"PHASE3":26674,"PHASE4":26676,"NA":26678},{"trials":26660,"activeCount":124},[],{"trials":26662,"activeCount":124},[],{"trials":26664,"activeCount":166,"soonestReadout":26669},[26665],{"nctId":26666,"briefTitle":26667,"status":279,"phases":26668,"primaryCompletion":26669,"completion":26669,"start":26670,"enrollment":1243,"conditions":26671,"interventions":26673},"NCT06434350","Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)",[87,88],"2027-09-24","2024-10-10",[26672],"Advanced Bladder Cancer",[26657],{"trials":26675,"activeCount":124},[],{"trials":26677,"activeCount":124},[],{"trials":26679,"activeCount":124},[],{"intervention":26681,"totalTrials":166,"cells":26682},"Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA",{"EARLY_PHASE1":26683,"PHASE1":26685,"PHASE2":26687,"PHASE3":26697,"PHASE4":26699,"NA":26701},{"trials":26684,"activeCount":124},[],{"trials":26686,"activeCount":124},[],{"trials":26688,"activeCount":166,"soonestReadout":815},[26689],{"nctId":26690,"briefTitle":26691,"status":279,"phases":26692,"primaryCompletion":815,"completion":815,"start":26693,"enrollment":3521,"conditions":26694,"interventions":26696},"NCT03608631","iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation",[87,88],"2021-01-27",[26695,6564,8173,8115],"KRAS NP_004976.2:p.G12D",[26681],{"trials":26698,"activeCount":124},[],{"trials":26700,"activeCount":124},[],{"trials":26702,"activeCount":124},[],{"intervention":26704,"totalTrials":166,"cells":26705},"Baloxavir Marboxil",{"EARLY_PHASE1":26706,"PHASE1":26708,"PHASE2":26710,"PHASE3":26721,"PHASE4":26723,"NA":26725},{"trials":26707,"activeCount":124},[],{"trials":26709,"activeCount":124},[],{"trials":26711,"activeCount":166,"soonestReadout":161},[26712],{"nctId":26713,"briefTitle":26714,"status":279,"phases":26715,"primaryCompletion":161,"completion":161,"start":26716,"enrollment":1034,"conditions":26717,"interventions":26719},"NCT04712539","Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients",[88],"2021-10-11",[359,26718],"Influenza",[26704,26720],"Oseltamivir",{"trials":26722,"activeCount":124},[],{"trials":26724,"activeCount":124},[],{"trials":26726,"activeCount":124},[],{"intervention":26720,"totalTrials":166,"cells":26728},{"EARLY_PHASE1":26729,"PHASE1":26731,"PHASE2":26733,"PHASE3":26739,"PHASE4":26741,"NA":26743},{"trials":26730,"activeCount":124},[],{"trials":26732,"activeCount":124},[],{"trials":26734,"activeCount":166,"soonestReadout":161},[26735],{"nctId":26713,"briefTitle":26714,"status":279,"phases":26736,"primaryCompletion":161,"completion":161,"start":26716,"enrollment":1034,"conditions":26737,"interventions":26738},[88],[359,26718],[26704,26720],{"trials":26740,"activeCount":124},[],{"trials":26742,"activeCount":124},[],{"trials":26744,"activeCount":124},[],{"intervention":12509,"totalTrials":166,"cells":26746},{"EARLY_PHASE1":26747,"PHASE1":26749,"PHASE2":26751,"PHASE3":26757,"PHASE4":26759,"NA":26761},{"trials":26748,"activeCount":124},[],{"trials":26750,"activeCount":124},[],{"trials":26752,"activeCount":166,"soonestReadout":12505},[26753],{"nctId":12502,"briefTitle":12503,"status":279,"phases":26754,"primaryCompletion":12505,"completion":12506,"start":12507,"enrollment":1034,"conditions":26755,"interventions":26756},[88],[8577,12509,12510],[12509,2369,4023,12512],{"trials":26758,"activeCount":124},[],{"trials":26760,"activeCount":124},[],{"trials":26762,"activeCount":124},[],{"intervention":12512,"totalTrials":166,"cells":26764},{"EARLY_PHASE1":26765,"PHASE1":26767,"PHASE2":26769,"PHASE3":26775,"PHASE4":26777,"NA":26779},{"trials":26766,"activeCount":124},[],{"trials":26768,"activeCount":124},[],{"trials":26770,"activeCount":166,"soonestReadout":12505},[26771],{"nctId":12502,"briefTitle":12503,"status":279,"phases":26772,"primaryCompletion":12505,"completion":12506,"start":12507,"enrollment":1034,"conditions":26773,"interventions":26774},[88],[8577,12509,12510],[12509,2369,4023,12512],{"trials":26776,"activeCount":124},[],{"trials":26778,"activeCount":124},[],{"trials":26780,"activeCount":124},[],{"intervention":26782,"totalTrials":166,"cells":26783},"Arm A: 177Lu rhPSMA-10.1",{"EARLY_PHASE1":26784,"PHASE1":26786,"PHASE2":26788,"PHASE3":26798,"PHASE4":26800,"NA":26802},{"trials":26785,"activeCount":124},[],{"trials":26787,"activeCount":124},[],{"trials":26789,"activeCount":166,"soonestReadout":446},[26790],{"nctId":26791,"briefTitle":26792,"status":102,"phases":26793,"primaryCompletion":446,"completion":224,"start":26794,"enrollment":230,"conditions":26795,"interventions":26796},"NCT06066437","NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial",[87,88],"2024-03-29",[27],[26782,26797],"Arm B: 177Lu rhPSMA-10.1 plus Degarelix",{"trials":26799,"activeCount":124},[],{"trials":26801,"activeCount":124},[],{"trials":26803,"activeCount":124},[],{"intervention":26797,"totalTrials":166,"cells":26805},{"EARLY_PHASE1":26806,"PHASE1":26808,"PHASE2":26810,"PHASE3":26816,"PHASE4":26818,"NA":26820},{"trials":26807,"activeCount":124},[],{"trials":26809,"activeCount":124},[],{"trials":26811,"activeCount":166,"soonestReadout":446},[26812],{"nctId":26791,"briefTitle":26792,"status":102,"phases":26813,"primaryCompletion":446,"completion":224,"start":26794,"enrollment":230,"conditions":26814,"interventions":26815},[87,88],[27],[26782,26797],{"trials":26817,"activeCount":124},[],{"trials":26819,"activeCount":124},[],{"trials":26821,"activeCount":124},[],{"intervention":26823,"totalTrials":166,"cells":26824},"Ixabepilone",{"EARLY_PHASE1":26825,"PHASE1":26827,"PHASE2":26829,"PHASE3":26839,"PHASE4":26841,"NA":26843},{"trials":26826,"activeCount":124},[],{"trials":26828,"activeCount":124},[],{"trials":26830,"activeCount":166,"soonestReadout":446},[26831],{"nctId":26832,"briefTitle":26833,"status":102,"phases":26834,"primaryCompletion":446,"completion":446,"start":26835,"enrollment":1001,"conditions":26836,"interventions":26838},"NCT00877500","Ixabepilone in Treating Participants With Significant Residual Disease of HER2\u002FNeu Negative Invasive Breast Cancer After Systemic Therapy",[88],"2009-03-30",[26837,7699,5079],"Bilateral Breast Carcinoma",[26823],{"trials":26840,"activeCount":124},[],{"trials":26842,"activeCount":124},[],{"trials":26844,"activeCount":124},[],{"intervention":7424,"totalTrials":166,"cells":26846},{"EARLY_PHASE1":26847,"PHASE1":26849,"PHASE2":26851,"PHASE3":26857,"PHASE4":26859,"NA":26861},{"trials":26848,"activeCount":124},[],{"trials":26850,"activeCount":124},[],{"trials":26852,"activeCount":166,"soonestReadout":404},[26853],{"nctId":7417,"briefTitle":7418,"status":102,"phases":26854,"primaryCompletion":404,"completion":404,"start":7420,"enrollment":834,"conditions":26855,"interventions":26856},[87,88],[1122,36,3134,7422,712,4598,3346,1866,891,30,727,3041,3135],[3085,803,7424,1070],{"trials":26858,"activeCount":124},[],{"trials":26860,"activeCount":124},[],{"trials":26862,"activeCount":124},[],{"intervention":14121,"totalTrials":1496,"cells":26864},{"EARLY_PHASE1":26865,"PHASE1":26875,"PHASE2":26895,"PHASE3":26919,"PHASE4":26929,"NA":26931},{"trials":26866,"activeCount":124},[26867],{"nctId":26868,"briefTitle":26869,"status":130,"phases":26870,"primaryCompletion":26871,"completion":26871,"start":26872,"enrollment":871,"conditions":26873,"interventions":26874},"NCT01205672","Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer",[86],"2017-05-28","2010-09-16",[2809],[14121],{"trials":26876,"activeCount":124},[26877,26881,26889],{"nctId":20946,"briefTitle":20947,"status":130,"phases":26878,"primaryCompletion":2242,"completion":2242,"start":13673,"enrollment":20949,"conditions":26879,"interventions":26880},[87],[33],[7180,6516,14121],{"nctId":26882,"briefTitle":26883,"status":130,"phases":26884,"primaryCompletion":26885,"completion":26885,"start":9877,"enrollment":2004,"conditions":26886,"interventions":26888},"NCT03017833","Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers",[87],"2022-12-21",[1343,361,2570,26887],"Refractory Neoplasm",[14121,1839],{"nctId":26890,"briefTitle":26891,"status":182,"phases":26892,"primaryCompletion":18078,"completion":18078,"start":23532,"enrollment":1240,"conditions":26893,"interventions":26894},"NCT01529593","Temsirolimus in Combination With Metformin in Patients With Advanced Cancers",[87],[33],[6656,14121],{"trials":26896,"activeCount":166,"soonestReadout":999},[26897,26901,26907,26911],{"nctId":14114,"briefTitle":14115,"status":182,"phases":26898,"primaryCompletion":14117,"completion":14117,"start":4542,"enrollment":3820,"conditions":26899,"interventions":26900},[88],[18],[2840,14120,14121],{"nctId":26902,"briefTitle":26903,"status":182,"phases":26904,"primaryCompletion":18530,"completion":18530,"start":2909,"enrollment":166,"conditions":26905,"interventions":26906},"NCT02360059","Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer",[88],[18],[14121],{"nctId":14138,"briefTitle":14139,"status":102,"phases":26908,"primaryCompletion":999,"completion":999,"start":14141,"enrollment":2933,"conditions":26909,"interventions":26910},[88],[2809],[14121,14086,2840],{"nctId":26912,"briefTitle":26913,"status":182,"phases":26914,"primaryCompletion":26915,"completion":26915,"start":26916,"enrollment":2159,"conditions":26917,"interventions":26918},"NCT02285855","Metformin in Non Small Cell Lung Cancer (NSCLC)",[88],"2019-01-05","2015-02-20",[24],[14121],{"trials":26920,"activeCount":124},[26921],{"nctId":26922,"briefTitle":26923,"status":130,"phases":26924,"primaryCompletion":18113,"completion":18113,"start":26925,"enrollment":1409,"conditions":26926,"interventions":26928},"NCT01697566","An Endometrial Cancer Chemoprevention Study of Metformin",[89],"2013-05-30",[26927],"Gynecology",[14121],{"trials":26930,"activeCount":124},[],{"trials":26932,"activeCount":124},[26933],{"nctId":26934,"briefTitle":26935,"status":130,"phases":26936,"primaryCompletion":3761,"completion":3761,"start":8386,"enrollment":3521,"conditions":26937,"interventions":26939},"NCT01318564","Diabetic Treatment Adherence",[],[26938],"Endocrine System Diseases",[14121],{"intervention":25074,"totalTrials":296,"cells":26941},{"EARLY_PHASE1":26942,"PHASE1":26944,"PHASE2":26946,"PHASE3":26958,"PHASE4":26967,"NA":26969},{"trials":26943,"activeCount":124},[],{"trials":26945,"activeCount":124},[],{"trials":26947,"activeCount":166,"soonestReadout":1078},[26948,26952],{"nctId":25066,"briefTitle":25067,"status":279,"phases":26949,"primaryCompletion":1078,"completion":1078,"start":25069,"enrollment":517,"conditions":26950,"interventions":26951},[88],[25071,3195,25072],[25057,25074],{"nctId":26953,"briefTitle":26954,"status":182,"phases":26955,"primaryCompletion":4723,"completion":4723,"start":4731,"enrollment":166,"conditions":26956,"interventions":26957},"NCT00790452","Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma",[88],[11042],[25074],{"trials":26959,"activeCount":124},[26960],{"nctId":26961,"briefTitle":26962,"status":182,"phases":26963,"primaryCompletion":5988,"completion":5988,"start":4086,"enrollment":3197,"conditions":26964,"interventions":26966},"NCT00501345","Aspirin in Patients With Myocardial Infarction and Thrombocytopenia",[89],[13565,26965],"Myocardial Infarction",[25074],{"trials":26968,"activeCount":124},[],{"trials":26970,"activeCount":124},[26971],{"nctId":26972,"briefTitle":26973,"status":130,"phases":26974,"primaryCompletion":26975,"completion":26975,"start":26976,"enrollment":834,"conditions":26977,"interventions":26978},"NCT05036109","DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease",[91],"2026-02-04","2021-10-12",[3195,3154],[25074,26979],"Vitamin D",{"intervention":26981,"totalTrials":1231,"cells":26982},"Nicotine Replacement Therapy",{"EARLY_PHASE1":26983,"PHASE1":26985,"PHASE2":26987,"PHASE3":26997,"PHASE4":26999,"NA":27001},{"trials":26984,"activeCount":124},[],{"trials":26986,"activeCount":124},[],{"trials":26988,"activeCount":166,"soonestReadout":504},[26989],{"nctId":26990,"briefTitle":26991,"status":102,"phases":26992,"primaryCompletion":504,"completion":504,"start":26993,"enrollment":26994,"conditions":26995,"interventions":26996},"NCT00494728","Smoking Cessation for Depressed Smokers",[87,88],"2007-06-28",91,[119,5366],[26981],{"trials":26998,"activeCount":124},[],{"trials":27000,"activeCount":124},[],{"trials":27002,"activeCount":124},[27003,27009],{"nctId":27004,"briefTitle":27005,"status":130,"phases":27006,"primaryCompletion":18530,"completion":18530,"start":3833,"enrollment":4733,"conditions":27007,"interventions":27008},"NCT01008748","Determinants of Smoking Cessation Among Latinos",[91],[108],[26981],{"nctId":27010,"briefTitle":27011,"status":3049,"phases":27012,"primaryCompletion":27013,"completion":27013,"start":27014,"enrollment":2891,"conditions":27015,"interventions":27016},"NCT00384696","Risk Perception Among Quitting Smokers",[],"2020-12-31","2006-02-10",[119],[26981],{"intervention":27018,"totalTrials":1231,"cells":27019},"Cidofovir",{"EARLY_PHASE1":27020,"PHASE1":27022,"PHASE2":27031,"PHASE3":27041,"PHASE4":27043,"NA":27045},{"trials":27021,"activeCount":124},[],{"trials":27023,"activeCount":124},[27024],{"nctId":27025,"briefTitle":27026,"status":130,"phases":27027,"primaryCompletion":2122,"completion":2122,"start":8730,"enrollment":230,"conditions":27028,"interventions":27029},"NCT01816646","Intravesical Cidofovir for Hemorrhagic Cystitis",[87],[4522],[27018,27030],"Probenecid",{"trials":27032,"activeCount":166,"soonestReadout":27037},[27033],{"nctId":27034,"briefTitle":27035,"status":102,"phases":27036,"primaryCompletion":27037,"completion":27037,"start":27038,"enrollment":2159,"conditions":27039,"interventions":27040},"NCT01295645","Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis",[88],"2028-03-15","2011-03-17",[4523],[27018],{"trials":27042,"activeCount":124},[],{"trials":27044,"activeCount":124},[],{"trials":27046,"activeCount":124},[27047],{"nctId":27048,"briefTitle":27049,"status":203,"phases":27050,"enrollment":124,"conditions":27051,"interventions":27054},"NCT00956176","Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients With Hemorrhagic Cystitis",[91],[27052,27053],"Cystitis","Bladder Diseases",[27018],{"intervention":2091,"totalTrials":1231,"cells":27056},{"EARLY_PHASE1":27057,"PHASE1":27059,"PHASE2":27061,"PHASE3":27080,"PHASE4":27082,"NA":27084},{"trials":27058,"activeCount":124},[],{"trials":27060,"activeCount":124},[],{"trials":27062,"activeCount":166,"soonestReadout":224},[27063,27076],{"nctId":27064,"briefTitle":27065,"status":130,"phases":27066,"primaryCompletion":405,"completion":405,"start":27067,"enrollment":1222,"conditions":27068,"interventions":27069},"NCT04983901","PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN",[88],"2021-09-14",[359,360],[27070,27071,27072,27073,2091,27074,27075],"Imipenem\u002FCilastatin\u002FRelebactam","Cefepime","Meropenem","Piperacillin-Tazobactam","Daptomycin","Linezolid",{"nctId":2080,"briefTitle":2081,"status":102,"phases":27077,"primaryCompletion":224,"completion":224,"start":773,"enrollment":1568,"conditions":27078,"interventions":27079},[88],[2084,2085,1676,2086,1677,1678,1679],[2088,2089,2090,1050,53,2091],{"trials":27081,"activeCount":124},[],{"trials":27083,"activeCount":124},[],{"trials":27085,"activeCount":124},[27086],{"nctId":27087,"briefTitle":27088,"status":182,"phases":27089,"primaryCompletion":4843,"completion":4843,"start":10844,"enrollment":166,"conditions":27090,"interventions":27092},"NCT01157533","Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients",[91],[27091],"Infection",[2091],{"intervention":6656,"totalTrials":834,"cells":27094},{"EARLY_PHASE1":27095,"PHASE1":27103,"PHASE2":27157,"PHASE3":27169,"PHASE4":27171,"NA":27173},{"trials":27096,"activeCount":124},[27097],{"nctId":27098,"briefTitle":27099,"status":130,"phases":27100,"primaryCompletion":6367,"start":3996,"enrollment":1568,"conditions":27101,"interventions":27102},"NCT01417065","Temsirolimus In Phase 0",[86],[1942],[6656],{"trials":27104,"activeCount":296,"soonestReadout":8064},[27105,27113,27117,27121,27125,27129,27133,27137,27141,27145,27149,27153],{"nctId":27106,"briefTitle":27107,"status":130,"phases":27108,"primaryCompletion":27109,"completion":27109,"start":6651,"enrollment":550,"conditions":27110,"interventions":27112},"NCT02420613","Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma",[87],"2025-03-28",[27111],"Diffuse Intrinsic Pontine Glioma",[6656,2405],{"nctId":10740,"briefTitle":10741,"status":102,"phases":27114,"primaryCompletion":446,"completion":446,"start":10743,"enrollment":1664,"conditions":27115,"interventions":27116},[87],[2922,10745,3512,2926],[1275,1371,1113,1375,10747,6656],{"nctId":10749,"briefTitle":10750,"status":130,"phases":27118,"primaryCompletion":3493,"completion":3493,"start":3996,"enrollment":10752,"conditions":27119,"interventions":27120},[87],[33],[1402,1275,2207,6656,1402,1375,1113,10755],{"nctId":10764,"briefTitle":10765,"status":130,"phases":27122,"primaryCompletion":10767,"completion":10767,"start":10768,"enrollment":10769,"conditions":27123,"interventions":27124},[87],[1942],[1275,6656],{"nctId":10804,"briefTitle":10805,"status":182,"phases":27126,"primaryCompletion":10807,"completion":10807,"start":10808,"enrollment":10809,"conditions":27127,"interventions":27128},[87],[2922,10811,10812,10813,10814,10815,10816,10817,10818,2613,10819,10820,10821,10822,2924,1803,10823,10824,10825,10826,10827,10828,10829,2925,10830,10831,2926,10832,5086,10833,5087,5088,5089,7298,10834,10835,10836,10837,10838],[1275,1683,6656,9894],{"nctId":14026,"briefTitle":14027,"status":130,"phases":27130,"primaryCompletion":14029,"completion":14029,"start":14030,"enrollment":2159,"conditions":27131,"interventions":27132},[87],[1942,3305],[9970,2840,6656],{"nctId":22986,"briefTitle":22987,"status":130,"phases":27134,"primaryCompletion":2698,"completion":2698,"start":3762,"enrollment":3820,"conditions":27135,"interventions":27136},[87],[6830,1333],[10918,6656],{"nctId":14034,"briefTitle":14035,"status":102,"phases":27138,"primaryCompletion":14037,"completion":14037,"start":13673,"enrollment":14038,"conditions":27139,"interventions":27140},[87],[1942],[6516,2405,2840,6656],{"nctId":9955,"briefTitle":9956,"status":102,"phases":27142,"primaryCompletion":8064,"completion":8064,"start":9958,"enrollment":9959,"conditions":27143,"interventions":27144},[87],[1942],[6656,1275,1376,2207,1369],{"nctId":26890,"briefTitle":26891,"status":182,"phases":27146,"primaryCompletion":18078,"completion":18078,"start":23532,"enrollment":1240,"conditions":27147,"interventions":27148},[87],[33],[6656,14121],{"nctId":10920,"briefTitle":10921,"status":130,"phases":27150,"primaryCompletion":61,"completion":61,"start":10923,"enrollment":4733,"conditions":27151,"interventions":27152},[87],[1942],[2585,1275,6656],{"nctId":6648,"briefTitle":6649,"status":102,"phases":27154,"primaryCompletion":999,"completion":999,"start":6651,"enrollment":2779,"conditions":27155,"interventions":27156},[87],[1343,6653,2570,6654],[803,1028,6656],{"trials":27158,"activeCount":124},[27159,27165],{"nctId":27160,"briefTitle":27161,"status":182,"phases":27162,"primaryCompletion":6367,"completion":6367,"start":12649,"enrollment":1559,"conditions":27163,"interventions":27164},"NCT00877773","Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients",[87,88],[33],[6656],{"nctId":20292,"briefTitle":20293,"status":130,"phases":27166,"primaryCompletion":20295,"completion":20295,"start":20296,"enrollment":34,"conditions":27167,"interventions":27168},[88],[1333],[1431,6656,2352],{"trials":27170,"activeCount":124},[],{"trials":27172,"activeCount":124},[],{"trials":27174,"activeCount":166,"soonestReadout":281},[27175],{"nctId":12224,"briefTitle":12225,"status":279,"phases":27176,"primaryCompletion":281,"completion":281,"start":6635,"enrollment":1131,"conditions":27177,"interventions":27178},[91],[12228,12229,12230],[1013,804,2840,12232,2495,4022,1431,12233,3497,6656,1016],{"intervention":576,"totalTrials":296,"cells":27180},{"EARLY_PHASE1":27181,"PHASE1":27183,"PHASE2":27201,"PHASE3":27203,"PHASE4":27205,"NA":27207},{"trials":27182,"activeCount":124},[],{"trials":27184,"activeCount":296,"soonestReadout":17002},[27185,27189,27193,27197],{"nctId":16999,"briefTitle":17000,"status":546,"phases":27186,"primaryCompletion":17002,"completion":17003,"start":1427,"enrollment":1131,"conditions":27187,"interventions":27188},[87],[36],[576,963],{"nctId":568,"briefTitle":569,"status":279,"phases":27190,"primaryCompletion":281,"completion":571,"start":572,"enrollment":492,"conditions":27191,"interventions":27192},[87],[494,574],[576,480,510],{"nctId":578,"briefTitle":579,"status":279,"phases":27194,"primaryCompletion":281,"completion":571,"start":581,"enrollment":492,"conditions":27195,"interventions":27196},[87],[36],[480,584,576],{"nctId":16890,"briefTitle":16891,"status":279,"phases":27198,"primaryCompletion":11550,"completion":11551,"start":16893,"enrollment":1559,"conditions":27199,"interventions":27200},[87],[36],[576,613],{"trials":27202,"activeCount":124},[],{"trials":27204,"activeCount":124},[],{"trials":27206,"activeCount":124},[],{"trials":27208,"activeCount":124},[],{"intervention":10680,"totalTrials":1231,"cells":27210},{"EARLY_PHASE1":27211,"PHASE1":27217,"PHASE2":27227,"PHASE3":27229,"PHASE4":27231,"NA":27233},{"trials":27212,"activeCount":166,"soonestReadout":10669},[27213],{"nctId":10666,"briefTitle":10667,"status":546,"phases":27214,"primaryCompletion":10669,"completion":10670,"start":10671,"enrollment":1222,"conditions":27215,"interventions":27216},[86],[10673,10674],[1275,1683,6802,10676,10677,1684,10678,10679,10680,10681,10682],{"trials":27218,"activeCount":121,"soonestReadout":571},[27219,27223],{"nctId":17234,"briefTitle":17235,"status":546,"phases":27220,"primaryCompletion":17237,"completion":17238,"start":1864,"enrollment":1034,"conditions":27221,"interventions":27222},[87],[18],[17241,10680,3103],{"nctId":19824,"briefTitle":19825,"status":102,"phases":27224,"primaryCompletion":571,"completion":1863,"start":868,"enrollment":539,"conditions":27225,"interventions":27226},[87],[18],[10680,3550],{"trials":27228,"activeCount":124},[],{"trials":27230,"activeCount":124},[],{"trials":27232,"activeCount":124},[],{"trials":27234,"activeCount":124},[],{"intervention":2206,"totalTrials":296,"cells":27236},{"EARLY_PHASE1":27237,"PHASE1":27239,"PHASE2":27249,"PHASE3":27259,"PHASE4":27261,"NA":27263},{"trials":27238,"activeCount":124},[],{"trials":27240,"activeCount":121,"soonestReadout":224},[27241,27245],{"nctId":13997,"briefTitle":13998,"status":102,"phases":27242,"primaryCompletion":14000,"completion":14000,"start":14001,"enrollment":5549,"conditions":27243,"interventions":27244},[87],[1343,14003,1386,14004,14005,14006,14007,14008,361,3457],[2840,7300,2206,874],{"nctId":2200,"briefTitle":2201,"status":102,"phases":27246,"primaryCompletion":224,"completion":224,"start":2203,"enrollment":507,"conditions":27247,"interventions":27248},[87],[913,608,914,610],[612,62,2206,2207],{"trials":27250,"activeCount":124},[27251,27255],{"nctId":18273,"briefTitle":18274,"status":182,"phases":27252,"primaryCompletion":18276,"completion":18276,"start":18277,"enrollment":296,"conditions":27253,"interventions":27254},[88],[7312,5234,7317],[12927,10904,18073,14086,2206,14130],{"nctId":18294,"briefTitle":18295,"status":130,"phases":27256,"primaryCompletion":18297,"completion":18297,"start":4338,"enrollment":1568,"conditions":27257,"interventions":27258},[87,88],[8026,16556,16557,8027,13133,13134,7308,7309,7310,7311,7312,16558,16559,16560,13137,13138,7313,7314,7315,7316,7317],[12420,14086,2206],{"trials":27260,"activeCount":124},[],{"trials":27262,"activeCount":124},[],{"trials":27264,"activeCount":124},[],{"intervention":27266,"totalTrials":1231,"cells":27267},"Hyperpolarized Carbon C 13 Pyruvate",{"EARLY_PHASE1":27268,"PHASE1":27270,"PHASE2":27288,"PHASE3":27298,"PHASE4":27300,"NA":27302},{"trials":27269,"activeCount":124},[],{"trials":27271,"activeCount":121,"soonestReadout":860},[27272,27280],{"nctId":27273,"briefTitle":27274,"status":279,"phases":27275,"primaryCompletion":860,"completion":860,"start":27276,"enrollment":924,"conditions":27277,"interventions":27279},"NCT04589624","An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and\u002For Systemic Therapy",[87],"2020-08-12",[27278],"Thyroid Gland Carcinoma",[27266],{"nctId":27281,"briefTitle":27282,"status":279,"phases":27283,"primaryCompletion":281,"completion":281,"start":27284,"enrollment":2018,"conditions":27285,"interventions":27287},"NCT03830151","Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors",[87],"2019-05-16",[27286],"Primary Brain Neoplasm",[27266],{"trials":27289,"activeCount":124},[27290],{"nctId":27291,"briefTitle":27292,"status":203,"phases":27293,"primaryCompletion":27294,"completion":27294,"start":7040,"enrollment":124,"conditions":27295,"interventions":27297},"NCT03581500","Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer",[88],"2024-10-16",[5122,27296,5146,5108,5109,5110,5111,3546,3547,3548],"PSA Level Greater Than Ten",[27266],{"trials":27299,"activeCount":124},[],{"trials":27301,"activeCount":124},[],{"trials":27303,"activeCount":124},[],{"intervention":10717,"totalTrials":121,"cells":27305},{"EARLY_PHASE1":27306,"PHASE1":27308,"PHASE2":27318,"PHASE3":27320,"PHASE4":27322,"NA":27324},{"trials":27307,"activeCount":124},[],{"trials":27309,"activeCount":121,"soonestReadout":504},[27310,27314],{"nctId":10694,"briefTitle":10695,"status":279,"phases":27311,"primaryCompletion":4028,"completion":505,"start":7816,"enrollment":2700,"conditions":27312,"interventions":27313},[87],[10698,10699,1343,1770,10700,10701,1344,1312,1348,1349,1350,1351,1352,1353,10702,10703,10704,6638,10705,10706,4914,10707,4917,10708,4920,4922,4924,10709,4927,10710,10711,10712,1463,10713,1466,10714,1470,1472],[1275,10716,1376,10717],{"nctId":15175,"briefTitle":15176,"status":102,"phases":27315,"primaryCompletion":504,"completion":504,"start":15178,"enrollment":15179,"conditions":27316,"interventions":27317},[87],[15181,15182,15183,7698,7699,4911,7701,10825,1458,1460,1461,10090,10091,7298,10095,1363],[10717,1374,15185],{"trials":27319,"activeCount":124},[],{"trials":27321,"activeCount":124},[],{"trials":27323,"activeCount":124},[],{"trials":27325,"activeCount":124},[],{"intervention":1331,"totalTrials":121,"cells":27327},{"EARLY_PHASE1":27328,"PHASE1":27330,"PHASE2":27342,"PHASE3":27344,"PHASE4":27346,"NA":27348},{"trials":27329,"activeCount":124},[],{"trials":27331,"activeCount":121,"soonestReadout":1325},[27332,27338],{"nctId":27333,"briefTitle":27334,"status":279,"phases":27335,"primaryCompletion":224,"completion":548,"start":13130,"enrollment":550,"conditions":27336,"interventions":27337},"NCT06285890","Phase I Study of HC-7366 for Acute Myeloid Leukemia",[87],[36],[1331],{"nctId":1322,"briefTitle":1323,"status":279,"phases":27339,"primaryCompletion":1325,"completion":1326,"start":1327,"enrollment":1328,"conditions":27340,"interventions":27341},[87],[1330,1331,1332,1333],[1050,1331,1335],{"trials":27343,"activeCount":124},[],{"trials":27345,"activeCount":124},[],{"trials":27347,"activeCount":124},[],{"trials":27349,"activeCount":124},[],{"intervention":12828,"totalTrials":121,"cells":27351},{"EARLY_PHASE1":27352,"PHASE1":27363,"PHASE2":27369,"PHASE3":27371,"PHASE4":27373,"NA":27375},{"trials":27353,"activeCount":166,"soonestReadout":27358},[27354],{"nctId":27355,"briefTitle":27356,"status":279,"phases":27357,"primaryCompletion":27358,"completion":27358,"start":27359,"enrollment":517,"conditions":27360,"interventions":27362},"NCT05804227","Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas",[86],"2027-09-22","2023-04-20",[27361],"Gliomas",[12828,12828],{"trials":27364,"activeCount":166,"soonestReadout":12824},[27365],{"nctId":12821,"briefTitle":12822,"status":279,"phases":27366,"primaryCompletion":12824,"completion":12824,"start":12825,"enrollment":2159,"conditions":27367,"interventions":27368},[87],[10674],[1683,12828,1684],{"trials":27370,"activeCount":124},[],{"trials":27372,"activeCount":124},[],{"trials":27374,"activeCount":124},[],{"trials":27376,"activeCount":124},[],{"intervention":3104,"totalTrials":121,"cells":27378},{"EARLY_PHASE1":27379,"PHASE1":27381,"PHASE2":27391,"PHASE3":27393,"PHASE4":27395,"NA":27397},{"trials":27380,"activeCount":124},[],{"trials":27382,"activeCount":121,"soonestReadout":3193},[27383,27387],{"nctId":3095,"briefTitle":3096,"status":279,"phases":27384,"primaryCompletion":3098,"completion":3099,"start":3100,"enrollment":2700,"conditions":27385,"interventions":27386},[87],[1924],[3103,3104,2462,803],{"nctId":3190,"briefTitle":3191,"status":279,"phases":27388,"primaryCompletion":3193,"completion":3193,"start":1407,"enrollment":924,"conditions":27389,"interventions":27390},[87],[3195,3040],[1005,803,1683,3104,3103],{"trials":27392,"activeCount":124},[],{"trials":27394,"activeCount":124},[],{"trials":27396,"activeCount":124},[],{"trials":27398,"activeCount":124},[],{"intervention":27400,"totalTrials":3197,"cells":27401},"Indocyanine Green",{"EARLY_PHASE1":27402,"PHASE1":27404,"PHASE2":27426,"PHASE3":27435,"PHASE4":27437,"NA":27439},{"trials":27403,"activeCount":124},[],{"trials":27405,"activeCount":166,"soonestReadout":1299},[27406,27413,27419],{"nctId":27407,"briefTitle":27408,"status":130,"phases":27409,"primaryCompletion":6974,"completion":6974,"start":27410,"enrollment":1131,"conditions":27411,"interventions":27412},"NCT01295931","Nuclear and Near-Infrared (NIR) Imaging in Melanoma",[87],"2011-02",[1729],[27400],{"nctId":27414,"briefTitle":27415,"status":546,"phases":27416,"primaryCompletion":1299,"completion":1299,"start":1238,"enrollment":1131,"conditions":27417,"interventions":27418},"NCT05038098","Magnetic Sentinel Lymph Node Mapping in Gastric Cancer",[87],[1638],[27400],{"nctId":27420,"briefTitle":27421,"status":130,"phases":27422,"primaryCompletion":2289,"completion":2289,"start":13673,"enrollment":406,"conditions":27423,"interventions":27424},"NCT01095913","Fluorescent Dyes for Lymph Node Mapping",[87],[18],[27425],"Indocyanine green",{"trials":27427,"activeCount":124},[27428],{"nctId":27429,"briefTitle":27430,"status":203,"phases":27431,"primaryCompletion":7986,"completion":7986,"start":18945,"enrollment":124,"conditions":27432,"interventions":27433},"NCT05092750","Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer",[87,88],[3195],[27434],"indocyanine green",{"trials":27436,"activeCount":124},[],{"trials":27438,"activeCount":124},[],{"trials":27440,"activeCount":166,"soonestReadout":3425},[27441],{"nctId":27442,"briefTitle":27443,"status":279,"phases":27444,"primaryCompletion":3425,"completion":404,"start":27445,"enrollment":27446,"conditions":27447,"interventions":27448},"NCT03941756","Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma",[91],"2018-08-14",252,[7308,7296,7297,1729],[27400],{"intervention":3729,"totalTrials":296,"cells":27450},{"EARLY_PHASE1":27451,"PHASE1":27453,"PHASE2":27459,"PHASE3":27465,"PHASE4":27467,"NA":27473},{"trials":27452,"activeCount":124},[],{"trials":27454,"activeCount":166,"soonestReadout":1864},[27455],{"nctId":7641,"briefTitle":7642,"status":102,"phases":27456,"primaryCompletion":1864,"completion":1864,"start":7644,"enrollment":550,"conditions":27457,"interventions":27458},[87],[7646,7647,7648,5799,7649,7650,7651,7652,7653,7654,7655,7656],[53,7658,3729],{"trials":27460,"activeCount":124},[27461],{"nctId":3722,"briefTitle":3723,"status":182,"phases":27462,"primaryCompletion":1558,"completion":1558,"start":3725,"enrollment":3726,"conditions":27463,"interventions":27464},[87,88],[1729],[3729,1049,3497],{"trials":27466,"activeCount":124},[],{"trials":27468,"activeCount":124},[27469],{"nctId":6079,"briefTitle":6080,"status":182,"phases":27470,"primaryCompletion":6082,"completion":6082,"start":6083,"enrollment":1231,"conditions":27471,"interventions":27472},[90],[33,6085],[6087,5810,3729],{"trials":27474,"activeCount":166,"soonestReadout":6008},[27475],{"nctId":27476,"briefTitle":27477,"status":279,"phases":27478,"primaryCompletion":6008,"completion":6008,"start":11357,"enrollment":27479,"conditions":27480,"interventions":27482},"NCT03465774","Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions",[],208,[27481],"Pleural Neoplasm",[3729],{"intervention":2405,"totalTrials":550,"cells":27484},{"EARLY_PHASE1":27485,"PHASE1":27487,"PHASE2":27529,"PHASE3":27569,"PHASE4":27571,"NA":27573},{"trials":27486,"activeCount":124},[],{"trials":27488,"activeCount":166,"soonestReadout":14037},[27489,27493,27497,27505,27509,27513,27517,27521,27525],{"nctId":4508,"briefTitle":4509,"status":130,"phases":27490,"primaryCompletion":2242,"completion":2242,"start":4511,"enrollment":959,"conditions":27491,"interventions":27492},[87],[21],[2405,2369,1004,2293,894,2374,2368,4514],{"nctId":18134,"briefTitle":18135,"status":203,"phases":27494,"primaryCompletion":18137,"start":3725,"enrollment":124,"conditions":27495,"interventions":27496},[87],[33],[18140,2207,2405],{"nctId":27498,"briefTitle":27499,"status":130,"phases":27500,"primaryCompletion":16960,"completion":16960,"start":27501,"enrollment":1154,"conditions":27502,"interventions":27503},"NCT02042989","MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies",[87],"2014-06-27",[33],[27504,2405],"MLN9708",{"nctId":27106,"briefTitle":27107,"status":130,"phases":27506,"primaryCompletion":27109,"completion":27109,"start":6651,"enrollment":550,"conditions":27507,"interventions":27508},[87],[27111],[6656,2405],{"nctId":3077,"briefTitle":3078,"status":130,"phases":27510,"primaryCompletion":3080,"completion":3080,"start":3081,"enrollment":3082,"conditions":27511,"interventions":27512},[87],[2512,678,1411,30,648,913,608],[3085,1004,2423,1005,2405],{"nctId":20953,"briefTitle":20954,"status":130,"phases":27514,"primaryCompletion":20956,"completion":20956,"start":20957,"enrollment":3584,"conditions":27515,"interventions":27516},[87],[33],[12420,6516,2405],{"nctId":20264,"briefTitle":20265,"status":130,"phases":27518,"primaryCompletion":2619,"completion":2619,"start":20267,"enrollment":20268,"conditions":27519,"interventions":27520},[87],[1942],[1431,2405],{"nctId":14034,"briefTitle":14035,"status":102,"phases":27522,"primaryCompletion":14037,"completion":14037,"start":13673,"enrollment":14038,"conditions":27523,"interventions":27524},[87],[1942],[6516,2405,2840,6656],{"nctId":4555,"briefTitle":4556,"status":130,"phases":27526,"primaryCompletion":3519,"completion":3519,"start":675,"enrollment":676,"conditions":27527,"interventions":27528},[87],[4559,4560,4561,3061,4562],[1004,2369,2293,1374,894,2405],{"trials":27530,"activeCount":124},[27531,27535,27539,27543,27547,27551,27555,27561,27565],{"nctId":2397,"briefTitle":2398,"status":130,"phases":27532,"primaryCompletion":2400,"completion":2400,"start":2401,"enrollment":2402,"conditions":27533,"interventions":27534},[87,88],[33,21],[510,2405,2369,1004,2293,62,2371,2372,894],{"nctId":9557,"briefTitle":9558,"status":130,"phases":27536,"primaryCompletion":2316,"completion":2316,"start":9560,"enrollment":9561,"conditions":27537,"interventions":27538},[88],[3395,9563],[655,654,2405],{"nctId":10461,"briefTitle":10462,"status":130,"phases":27540,"primaryCompletion":8339,"completion":10464,"start":10465,"enrollment":971,"conditions":27541,"interventions":27542},[88],[15],[2405,510],{"nctId":16447,"briefTitle":16448,"status":182,"phases":27544,"primaryCompletion":4152,"completion":4152,"start":4619,"enrollment":166,"conditions":27545,"interventions":27546},[88],[21],[2405,75],{"nctId":4702,"briefTitle":4703,"status":203,"phases":27548,"primaryCompletion":4705,"completion":4705,"start":4705,"enrollment":124,"conditions":27549,"interventions":27550},[88],[4707,3272,2415,4559,4708,4560,4709],[1004,2423,803,2369,2195,894,2196,2405],{"nctId":17608,"briefTitle":17609,"status":182,"phases":27552,"primaryCompletion":17611,"completion":17611,"start":17612,"enrollment":2581,"conditions":27553,"interventions":27554},[87,88],[17604,17614],[2405,17616,3497],{"nctId":27556,"briefTitle":27557,"status":182,"phases":27558,"primaryCompletion":2768,"completion":2768,"start":8306,"enrollment":1231,"conditions":27559,"interventions":27560},"NCT00831493","Vorinostat Plus Radiation Therapy in Pancreatic Cancer",[87,88],[4107],[2405],{"nctId":17672,"briefTitle":17673,"status":182,"phases":27562,"primaryCompletion":2698,"completion":2698,"start":2968,"enrollment":871,"conditions":27563,"interventions":27564},[87,88],[11176,17604],[2405,3847,3497],{"nctId":2897,"briefTitle":2898,"status":182,"phases":27566,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":186,"conditions":27567,"interventions":27568},[87,88],[21],[1402,2405,2369,1004,2293,894,62,2370,2371,2372,2904,2368],{"trials":27570,"activeCount":124},[],{"trials":27572,"activeCount":124},[],{"trials":27574,"activeCount":124},[],{"intervention":4209,"totalTrials":910,"cells":27576},{"EARLY_PHASE1":27577,"PHASE1":27579,"PHASE2":27627,"PHASE3":27656,"PHASE4":27658,"NA":27660},{"trials":27578,"activeCount":124},[],{"trials":27580,"activeCount":166,"soonestReadout":1299},[27581,27591,27598,27605,27614],{"nctId":27582,"briefTitle":27583,"status":203,"phases":27584,"primaryCompletion":14149,"completion":14149,"start":27585,"enrollment":124,"conditions":27586,"interventions":27589},"NCT04756505","Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial",[87],"2021-03-07",[7312,27587,5234,27588,7317],"Hormone Receptor Positive Breast Adenocarcinoma","Metastatic HER2 Negative Breast Adenocarcinoma",[4209,27590],"Immunocytokine NHS-IL12",{"nctId":27592,"briefTitle":27593,"status":130,"phases":27594,"primaryCompletion":20824,"completion":20824,"start":27595,"enrollment":1131,"conditions":27596,"interventions":27597},"NCT03620201","M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer",[87],"2018-08-03",[8027,13133,13134,7308,7309,7310,7311,13136,13137,13138,7313,7314,7315,7316],[4209],{"nctId":27599,"briefTitle":27600,"status":130,"phases":27601,"primaryCompletion":6521,"completion":6521,"start":27602,"enrollment":628,"conditions":27603,"interventions":27604},"NCT03524170","Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer",[87],"2018-04-30",[7312,5234,7317],[4209],{"nctId":27606,"briefTitle":27607,"status":182,"phases":27608,"primaryCompletion":27609,"completion":27609,"start":10287,"enrollment":1664,"conditions":27610,"interventions":27612},"NCT03579472","M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer",[87],"2022-09-21",[7312,27611,7317],"Metastatic Triple-Negative Breast Carcinoma",[4209,27613],"Eribulin Mesylate",{"nctId":27615,"briefTitle":27616,"status":102,"phases":27617,"primaryCompletion":1299,"completion":1299,"start":27618,"enrollment":121,"conditions":27619,"interventions":27626},"NCT04708067","Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma",[87],"2021-08-31",[27620,27621,27622,27623,27624,27625],"Locally Advanced Intrahepatic Cholangiocarcinoma","Metastatic Intrahepatic Cholangiocarcinoma","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8","Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8",[4209],{"trials":27628,"activeCount":124},[27629,27638,27645,27652],{"nctId":27630,"briefTitle":27631,"status":182,"phases":27632,"primaryCompletion":27633,"completion":27633,"start":27634,"enrollment":186,"conditions":27635,"interventions":27636},"NCT04789668","Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases",[87,88],"2023-12-08","2021-01-15",[7312,1312,359,27587,1315,1960,361,1316,27611,1353,7317,1319,1361,1362],[4209,27637],"Pimasertib",{"nctId":27639,"briefTitle":27640,"status":182,"phases":27641,"primaryCompletion":2688,"completion":2688,"start":5056,"enrollment":121,"conditions":27642,"interventions":27644},"NCT04560686","Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer",[88],[27643,1837,2052,2053,2054,2055,1389,1390,1391,1357,1358],"Resectable Lung Non-Small Cell Carcinoma",[4209],{"nctId":27646,"briefTitle":27647,"status":182,"phases":27648,"primaryCompletion":4978,"completion":4978,"start":2707,"enrollment":1231,"conditions":27649,"interventions":27651},"NCT04220775","Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer",[87,88],[7750,27650],"Second Primary Squamous Cell Carcinoma of the Head and Neck",[4209],{"nctId":4199,"briefTitle":4200,"status":182,"phases":27653,"primaryCompletion":4202,"completion":4202,"start":4203,"enrollment":1231,"conditions":27654,"interventions":27655},[88],[4205,4206,1355,1357,1358,1359,1319,1361,1362,4207],[4209,1377,1369,1709],{"trials":27657,"activeCount":124},[],{"trials":27659,"activeCount":124},[],{"trials":27661,"activeCount":124},[],{"intervention":19435,"totalTrials":3197,"cells":27663},{"EARLY_PHASE1":27664,"PHASE1":27666,"PHASE2":27688,"PHASE3":27706,"PHASE4":27708,"NA":27710},{"trials":27665,"activeCount":124},[],{"trials":27667,"activeCount":166,"soonestReadout":224},[27668,27679],{"nctId":27669,"briefTitle":27670,"status":182,"phases":27671,"primaryCompletion":27672,"completion":27672,"start":22644,"enrollment":296,"conditions":27673,"interventions":27678},"NCT02782403","Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia",[87],"2019-11-11",[27674,27675,27676,27677],"Accelerated Phase Chronic Myelogenous Leukemia (CML)","Blast Phase Chronic Myelogenous Leukemia (CML)","Chronic Phase Phase Chronic Myelogenous Leukemia (CML)","Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)",[19435,16861],{"nctId":27680,"briefTitle":27681,"status":279,"phases":27682,"primaryCompletion":224,"completion":224,"start":27683,"enrollment":20949,"conditions":27684,"interventions":27685},"NCT04693468","Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial",[87],"2020-12-01",[1343,361,2570],[19435,16702,27686,27687],"Palbociclib Isethionate","Talazoparib Tosylate",{"trials":27689,"activeCount":124},[27690,27694,27702],{"nctId":23528,"briefTitle":23529,"status":130,"phases":27691,"primaryCompletion":23531,"completion":23531,"start":23532,"enrollment":606,"conditions":27692,"interventions":27693},[88],[23534,23535,23536,3697],[5113,19435],{"nctId":27695,"briefTitle":27696,"status":130,"phases":27697,"primaryCompletion":27698,"completion":27699,"start":27410,"enrollment":2865,"conditions":27700,"interventions":27701},"NCT01263769","Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)",[88],"2021-02","2023-06-05",[1333],[19435],{"nctId":19427,"briefTitle":19428,"status":130,"phases":27703,"primaryCompletion":19430,"completion":19430,"start":5120,"enrollment":517,"conditions":27704,"interventions":27705},[88],[19432,1670,19433],[693,19435],{"trials":27707,"activeCount":124},[],{"trials":27709,"activeCount":124},[],{"trials":27711,"activeCount":124},[],{"intervention":10747,"totalTrials":296,"cells":27713},{"EARLY_PHASE1":27714,"PHASE1":27716,"PHASE2":27722,"PHASE3":27736,"PHASE4":27738,"NA":27740},{"trials":27715,"activeCount":124},[],{"trials":27717,"activeCount":166,"soonestReadout":446},[27718],{"nctId":10740,"briefTitle":10741,"status":102,"phases":27719,"primaryCompletion":446,"completion":446,"start":10743,"enrollment":1664,"conditions":27720,"interventions":27721},[87],[2922,10745,3512,2926],[1275,1371,1113,1375,10747,6656],{"trials":27723,"activeCount":124},[27724,27728,27732],{"nctId":10966,"briefTitle":10967,"status":130,"phases":27725,"primaryCompletion":10969,"completion":10969,"start":10970,"enrollment":539,"conditions":27726,"interventions":27727},[88],[5079,1363],[1275,2840,10747],{"nctId":20886,"briefTitle":20887,"status":130,"phases":27729,"primaryCompletion":20889,"completion":20889,"start":20890,"enrollment":20891,"conditions":27730,"interventions":27731},[88],[18],[4046,20894],{"nctId":7266,"briefTitle":7267,"status":130,"phases":27733,"primaryCompletion":2602,"completion":2602,"start":2213,"enrollment":1975,"conditions":27734,"interventions":27735},[88],[21],[1069,1071,894,803,7271,809,810],{"trials":27737,"activeCount":124},[],{"trials":27739,"activeCount":124},[],{"trials":27741,"activeCount":124},[],{"intervention":7300,"totalTrials":1231,"cells":27743},{"EARLY_PHASE1":27744,"PHASE1":27746,"PHASE2":27752,"PHASE3":27766,"PHASE4":27768,"NA":27770},{"trials":27745,"activeCount":124},[],{"trials":27747,"activeCount":166,"soonestReadout":14000},[27748],{"nctId":13997,"briefTitle":13998,"status":102,"phases":27749,"primaryCompletion":14000,"completion":14000,"start":14001,"enrollment":5549,"conditions":27750,"interventions":27751},[87],[1343,14003,1386,14004,14005,14006,14007,14008,361,3457],[2840,7300,2206,874],{"trials":27753,"activeCount":124},[27754,27762],{"nctId":27755,"briefTitle":27756,"status":182,"phases":27757,"primaryCompletion":11016,"completion":11016,"start":27758,"enrollment":1496,"conditions":27759,"interventions":27760},"NCT05243641","Neratinib and Capmatinib Combination (Phase Ib\u002FII) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test",[87,88],"2022-08-18",[12304,18],[7300,27761],"Capmatinib",{"nctId":7291,"briefTitle":7292,"status":182,"phases":27763,"primaryCompletion":7294,"completion":7294,"start":5035,"enrollment":1240,"conditions":27764,"interventions":27765},[87,88],[7296,7297,5234,5086,5087,5088,5089,7298],[803,1013,7300,1376,7301,4227],{"trials":27767,"activeCount":124},[],{"trials":27769,"activeCount":124},[],{"trials":27771,"activeCount":124},[],{"intervention":13235,"totalTrials":1231,"cells":27773},{"EARLY_PHASE1":27774,"PHASE1":27776,"PHASE2":27782,"PHASE3":27792,"PHASE4":27794,"NA":27796},{"trials":27775,"activeCount":124},[],{"trials":27777,"activeCount":166,"soonestReadout":8641},[27778],{"nctId":15153,"briefTitle":15154,"status":102,"phases":27779,"primaryCompletion":8641,"completion":8641,"start":6531,"enrollment":861,"conditions":27780,"interventions":27781},[87],[7646,7647,5799,7652,7655],[13235,1374],{"trials":27783,"activeCount":124},[27784,27788],{"nctId":13228,"briefTitle":13229,"status":130,"phases":27785,"primaryCompletion":13231,"completion":13231,"start":13232,"enrollment":517,"conditions":27786,"interventions":27787},[87,88],[1836,1319,1361,1362],[1786,13235,13140],{"nctId":13304,"briefTitle":13305,"status":203,"phases":27789,"primaryCompletion":13307,"completion":13308,"start":9357,"enrollment":124,"conditions":27790,"interventions":27791},[88],[12265,13310,13311],[13235,1786],{"trials":27793,"activeCount":124},[],{"trials":27795,"activeCount":124},[],{"trials":27797,"activeCount":124},[],{"intervention":17196,"totalTrials":1231,"cells":27799},{"EARLY_PHASE1":27800,"PHASE1":27802,"PHASE2":27816,"PHASE3":27822,"PHASE4":27824,"NA":27826},{"trials":27801,"activeCount":124},[],{"trials":27803,"activeCount":166,"soonestReadout":446},[27804,27812],{"nctId":27805,"briefTitle":27806,"status":203,"phases":27807,"primaryCompletion":27808,"completion":27808,"start":27808,"enrollment":124,"conditions":27809,"interventions":27810},"NCT05010096","BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors",[87],"2022-03-22",[2569,13289,361,2570],[17196,27811],"Elimusertib",{"nctId":17190,"briefTitle":17191,"status":102,"phases":27813,"primaryCompletion":446,"completion":446,"start":17193,"enrollment":2004,"conditions":27814,"interventions":27815},[87],[8170,8171,15183,4911,1454,4912,1670,1457,1458,1460,1461],[17196,5114],{"trials":27817,"activeCount":124},[27818],{"nctId":23165,"briefTitle":23166,"status":182,"phases":27819,"primaryCompletion":3638,"completion":23168,"start":11142,"enrollment":1483,"conditions":27820,"interventions":27821},[88],[2809,1530],[17196,23171],{"trials":27823,"activeCount":124},[],{"trials":27825,"activeCount":124},[],{"trials":27827,"activeCount":124},[],{"intervention":5515,"totalTrials":1231,"cells":27829},{"EARLY_PHASE1":27830,"PHASE1":27832,"PHASE2":27846,"PHASE3":27852,"PHASE4":27854,"NA":27856},{"trials":27831,"activeCount":124},[],{"trials":27833,"activeCount":166,"soonestReadout":193},[27834,27842],{"nctId":27835,"briefTitle":27836,"status":279,"phases":27837,"primaryCompletion":193,"completion":193,"start":13644,"enrollment":448,"conditions":27838,"interventions":27841},"NCT04991870","Phase I CB-NK-TGF-ßR2-\u002FNR3C1- in rGBM",[87],[7998,27839,27840],"Recurrent Supratentorial Glioblastoma","Supratentorial Gliosarcoma",[5515],{"nctId":5484,"briefTitle":5485,"status":182,"phases":27843,"primaryCompletion":2016,"completion":2016,"start":5487,"enrollment":3726,"conditions":27844,"interventions":27845},[87],[5489,5490,5491,1459,5492,5493,5494,5495,5496,5497,5498,2570,5499,5500,5501,5502,5503,5504,5505,5506,5507,5508,5509,5510,5511,3457,5512,5513],[5515,803,2424],{"trials":27847,"activeCount":124},[27848],{"nctId":5626,"briefTitle":5627,"status":130,"phases":27849,"primaryCompletion":5629,"completion":5629,"start":5630,"enrollment":492,"conditions":27850,"interventions":27851},[88],[891,4559,5632,5633,4561,5634,5635],[4365,5515,654,2424,1069,1402,2293,894],{"trials":27853,"activeCount":124},[],{"trials":27855,"activeCount":124},[],{"trials":27857,"activeCount":124},[],{"intervention":3145,"totalTrials":121,"cells":27859},{"EARLY_PHASE1":27860,"PHASE1":27862,"PHASE2":27868,"PHASE3":27874,"PHASE4":27876,"NA":27878},{"trials":27861,"activeCount":124},[],{"trials":27863,"activeCount":166,"soonestReadout":1939},[27864],{"nctId":3139,"briefTitle":3140,"status":102,"phases":27865,"primaryCompletion":1939,"completion":1939,"start":3142,"enrollment":1240,"conditions":27866,"interventions":27867},[87],[1316,1961,1962,1544,1546,1549],[1599,803,1005,3145,3146],{"trials":27869,"activeCount":124},[27870],{"nctId":3201,"briefTitle":3202,"status":130,"phases":27871,"primaryCompletion":3204,"completion":3204,"start":3205,"enrollment":1496,"conditions":27872,"interventions":27873},[87,88],[1316,1961,1549],[1599,3208,803,1005,3145],{"trials":27875,"activeCount":124},[],{"trials":27877,"activeCount":124},[],{"trials":27879,"activeCount":124},[],{"intervention":10692,"totalTrials":121,"cells":27881},{"EARLY_PHASE1":27882,"PHASE1":27884,"PHASE2":27890,"PHASE3":27896,"PHASE4":27898,"NA":27900},{"trials":27883,"activeCount":124},[],{"trials":27885,"activeCount":166,"soonestReadout":446},[27886],{"nctId":10686,"briefTitle":10687,"status":279,"phases":27887,"primaryCompletion":446,"completion":446,"start":10689,"enrollment":1240,"conditions":27888,"interventions":27889},[87],[1530],[1376,1275,10692],{"trials":27891,"activeCount":124},[27892],{"nctId":18941,"briefTitle":18942,"status":203,"phases":27893,"primaryCompletion":18944,"completion":18944,"start":18945,"enrollment":124,"conditions":27894,"interventions":27895},[87,88],[18947,18948],[4022,1372,10692],{"trials":27897,"activeCount":124},[],{"trials":27899,"activeCount":124},[],{"trials":27901,"activeCount":124},[],{"intervention":11545,"totalTrials":121,"cells":27903},{"EARLY_PHASE1":27904,"PHASE1":27906,"PHASE2":27912,"PHASE3":27924,"PHASE4":27926,"NA":27928},{"trials":27905,"activeCount":124},[],{"trials":27907,"activeCount":166,"soonestReadout":549},[27908],{"nctId":11529,"briefTitle":11530,"status":279,"phases":27909,"primaryCompletion":549,"completion":549,"start":11532,"enrollment":357,"conditions":27910,"interventions":27911},[87],[11534,10698,11535,11536,11537,11538,11539,5059,11540,1772,7308,7309,7310,7311,7312,11541,360,5234,1442,1443,11128,11542,1444,11543,1445,1446,1346,7313,7314,7315,7316,7317,4913,1570,4914,4915,1356,10707,4916,1571,4917,4918,10708,4919,4920,4921,4922,4923,1572,4924,4925,10709,4926,4927,4928,10710,10711,10712,1462,1573,1463,1464,1360,10713,1465,1574,1466,1467,10714,1469,1575,1470,1471,1472],[718,11545,4023],{"trials":27913,"activeCount":124},[27914],{"nctId":27915,"briefTitle":27916,"status":130,"phases":27917,"primaryCompletion":27918,"completion":27918,"start":27919,"enrollment":871,"conditions":27920,"interventions":27923},"NCT02302833","Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery",[88],"2024-11-12","2015-02-17",[27921,7941,7944,27922,7951,7952],"Locally Advanced Paraganglioma","Regional Adrenal Gland Pheochromocytoma",[11545],{"trials":27925,"activeCount":124},[],{"trials":27927,"activeCount":124},[],{"trials":27929,"activeCount":124},[],{"intervention":27931,"totalTrials":121,"cells":27932},"Edetate Calcium Disodium",{"EARLY_PHASE1":27933,"PHASE1":27935,"PHASE2":27946,"PHASE3":27958,"PHASE4":27960,"NA":27962},{"trials":27934,"activeCount":124},[],{"trials":27936,"activeCount":166,"soonestReadout":815},[27937],{"nctId":27938,"briefTitle":27939,"status":279,"phases":27940,"primaryCompletion":815,"completion":815,"start":1408,"enrollment":8325,"conditions":27941,"interventions":27944},"NCT03630991","Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy",[87],[36,846,644,4598,1067,30,3244,727,608,649,609,1092,610,650,632,651,27942,27943],"Secondary Myelodysplastic Syndrome","Very High Risk Myelodysplastic Syndrome",[27931,27945],"Succimer",{"trials":27947,"activeCount":124},[27948],{"nctId":27949,"briefTitle":27950,"status":203,"phases":27951,"enrollment":124,"conditions":27952,"interventions":27955},"NCT01101412","Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies",[87,88],[27953,27091,15,21,3243,5203,1036,27954,2936],"Chronic Myeloproliferative Disorders","Myelodysplastic\u002FMyeloproliferative Neoplasms",[27931,27956,27957],"Ethanol","Trimethoprim-sulfamethoxazole",{"trials":27959,"activeCount":124},[],{"trials":27961,"activeCount":124},[],{"trials":27963,"activeCount":124},[],{"intervention":10147,"totalTrials":121,"cells":27965},{"EARLY_PHASE1":27966,"PHASE1":27968,"PHASE2":27978,"PHASE3":27984,"PHASE4":27986,"NA":27988},{"trials":27967,"activeCount":124},[],{"trials":27969,"activeCount":166,"soonestReadout":27974},[27970],{"nctId":27971,"briefTitle":27972,"status":102,"phases":27973,"primaryCompletion":27974,"completion":27974,"start":27975,"enrollment":1328,"conditions":27976,"interventions":27977},"NCT03707938","Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer",[87],"2026-01-28","2018-12-18",[2020,1385,1388,1836,1319,1361,1362],[10147],{"trials":27979,"activeCount":124},[27980],{"nctId":10139,"briefTitle":10140,"status":203,"phases":27981,"primaryCompletion":10142,"completion":10142,"start":10143,"enrollment":124,"conditions":27982,"interventions":27983},[88],[10145],[10147,1369,1377],{"trials":27985,"activeCount":124},[],{"trials":27987,"activeCount":124},[],{"trials":27989,"activeCount":124},[],{"intervention":6135,"totalTrials":121,"cells":27991},{"EARLY_PHASE1":27992,"PHASE1":27994,"PHASE2":28000,"PHASE3":28006,"PHASE4":28008,"NA":28010},{"trials":27993,"activeCount":124},[],{"trials":27995,"activeCount":166,"soonestReadout":193},[27996],{"nctId":6606,"briefTitle":6607,"status":279,"phases":27997,"primaryCompletion":193,"completion":591,"start":6609,"enrollment":628,"conditions":27998,"interventions":27999},[87],[18],[803,6612,6135],{"trials":28001,"activeCount":124},[28002],{"nctId":6126,"briefTitle":6127,"status":203,"phases":28003,"primaryCompletion":6129,"completion":6129,"start":6130,"enrollment":124,"conditions":28004,"interventions":28005},[88],[6132,6133],[6135,6117],{"trials":28007,"activeCount":124},[],{"trials":28009,"activeCount":124},[],{"trials":28011,"activeCount":124},[],{"intervention":16702,"totalTrials":296,"cells":28013},{"EARLY_PHASE1":28014,"PHASE1":28016,"PHASE2":28034,"PHASE3":28036,"PHASE4":28038,"NA":28040},{"trials":28015,"activeCount":124},[],{"trials":28017,"activeCount":166,"soonestReadout":224},[28018,28022,28026,28030],{"nctId":17978,"briefTitle":17979,"status":130,"phases":28019,"primaryCompletion":17981,"completion":17981,"start":3571,"enrollment":2933,"conditions":28020,"interventions":28021},[87],[33],[16702,1028],{"nctId":27680,"briefTitle":27681,"status":279,"phases":28023,"primaryCompletion":224,"completion":224,"start":27683,"enrollment":20949,"conditions":28024,"interventions":28025},[87],[1343,361,2570],[19435,16702,27686,27687],{"nctId":21077,"briefTitle":21078,"status":130,"phases":28027,"primaryCompletion":1567,"completion":1567,"start":21080,"enrollment":4171,"conditions":28028,"interventions":28029},[87],[2922,21082,2924,2925,2926],[16702,2544,9970],{"nctId":16695,"briefTitle":16696,"status":182,"phases":28031,"primaryCompletion":16698,"completion":16698,"start":2326,"enrollment":16699,"conditions":28032,"interventions":28033},[87],[33],[16702,1431,1377],{"trials":28035,"activeCount":124},[],{"trials":28037,"activeCount":124},[],{"trials":28039,"activeCount":124},[],{"trials":28041,"activeCount":124},[],{"intervention":28043,"totalTrials":121,"cells":28044},"Mesenchymal Stem Cell Transplantation",{"EARLY_PHASE1":28045,"PHASE1":28047,"PHASE2":28066,"PHASE3":28068,"PHASE4":28070,"NA":28072},{"trials":28046,"activeCount":124},[],{"trials":28048,"activeCount":166,"soonestReadout":28063},[28049,28059],{"nctId":28050,"briefTitle":28051,"status":130,"phases":28052,"primaryCompletion":28053,"completion":28053,"start":28054,"enrollment":1483,"conditions":28055,"interventions":28058},"NCT02408432","Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines",[87],"2021-12-08","2016-01-11",[28056,28057],"Cardiomyopathy","Heart Failure",[28043],{"nctId":28060,"briefTitle":28061,"status":279,"phases":28062,"primaryCompletion":28063,"completion":28063,"start":3269,"enrollment":2647,"conditions":28064,"interventions":28065},"NCT02962661","Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines",[87],"2026-07-30",[28056,28057,359,360],[28043,28043],{"trials":28067,"activeCount":124},[],{"trials":28069,"activeCount":124},[],{"trials":28071,"activeCount":124},[],{"trials":28073,"activeCount":124},[],{"intervention":12836,"totalTrials":121,"cells":28075},{"EARLY_PHASE1":28076,"PHASE1":28078,"PHASE2":28091,"PHASE3":28093,"PHASE4":28095,"NA":28097},{"trials":28077,"activeCount":124},[],{"trials":28079,"activeCount":166,"soonestReadout":238},[28080,28084],{"nctId":12830,"briefTitle":12831,"status":102,"phases":28081,"primaryCompletion":238,"completion":238,"start":12833,"enrollment":628,"conditions":28082,"interventions":28083},[87],[3154,3195],[12836,4022,1683],{"nctId":28085,"briefTitle":28086,"status":203,"phases":28087,"primaryCompletion":28088,"completion":28088,"start":1993,"enrollment":124,"conditions":28089,"interventions":28090},"NCT05634525","Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients",[87],"2025-07-21",[12255],[12836],{"trials":28092,"activeCount":124},[],{"trials":28094,"activeCount":124},[],{"trials":28096,"activeCount":124},[],{"trials":28098,"activeCount":124},[],{"intervention":28100,"totalTrials":121,"cells":28101},"Hyperpolarized 13-C-pyruvate",{"EARLY_PHASE1":28102,"PHASE1":28104,"PHASE2":28119,"PHASE3":28121,"PHASE4":28123,"NA":28125},{"trials":28103,"activeCount":124},[],{"trials":28105,"activeCount":166,"soonestReadout":193},[28106,28112],{"nctId":28107,"briefTitle":28108,"status":1479,"phases":28109,"primaryCompletion":1427,"completion":3258,"start":3621,"enrollment":406,"conditions":28110,"interventions":28111},"NCT05866679","Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging",[87],[1530],[28100],{"nctId":28113,"briefTitle":28114,"status":279,"phases":28115,"primaryCompletion":193,"completion":193,"start":14203,"enrollment":1131,"conditions":28116,"interventions":28118},"NCT05873699","Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection",[87],[28117],"Pancreatic Cyst",[28100],{"trials":28120,"activeCount":124},[],{"trials":28122,"activeCount":124},[],{"trials":28124,"activeCount":124},[],{"trials":28126,"activeCount":124},[],{"intervention":17569,"totalTrials":121,"cells":28128},{"EARLY_PHASE1":28129,"PHASE1":28131,"PHASE2":28145,"PHASE3":28147,"PHASE4":28149,"NA":28151},{"trials":28130,"activeCount":124},[],{"trials":28132,"activeCount":166,"soonestReadout":17563},[28133,28137],{"nctId":17560,"briefTitle":17561,"status":102,"phases":28134,"primaryCompletion":17563,"completion":17564,"start":17565,"enrollment":1240,"conditions":28135,"interventions":28136},[87],[17567,7740,7998],[17569,3497],{"nctId":28138,"briefTitle":28139,"status":130,"phases":28140,"primaryCompletion":28141,"completion":28141,"start":28142,"enrollment":3820,"conditions":28143,"interventions":28144},"NCT00047502","Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia",[87],"2006-04-10","2002-11-01",[4725],[17569,2321],{"trials":28146,"activeCount":124},[],{"trials":28148,"activeCount":124},[],{"trials":28150,"activeCount":124},[],{"trials":28152,"activeCount":124},[],{"intervention":28154,"totalTrials":166,"cells":28155},"NP-101",{"EARLY_PHASE1":28156,"PHASE1":28158,"PHASE2":28166,"PHASE3":28168,"PHASE4":28170,"NA":28172},{"trials":28157,"activeCount":124},[],{"trials":28159,"activeCount":166,"soonestReadout":1088},[28160],{"nctId":28161,"briefTitle":28162,"status":279,"phases":28163,"primaryCompletion":1088,"completion":14252,"start":980,"enrollment":1328,"conditions":28164,"interventions":28165},"NCT06563375","Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors",[87],[3305],[28154],{"trials":28167,"activeCount":124},[],{"trials":28169,"activeCount":124},[],{"trials":28171,"activeCount":124},[],{"trials":28173,"activeCount":124},[],{"intervention":28175,"totalTrials":166,"cells":28176},"Gadolinium",{"EARLY_PHASE1":28177,"PHASE1":28179,"PHASE2":28189,"PHASE3":28191,"PHASE4":28193,"NA":28195},{"trials":28178,"activeCount":124},[],{"trials":28180,"activeCount":166,"soonestReadout":28185},[28181],{"nctId":28182,"briefTitle":28183,"status":279,"phases":28184,"primaryCompletion":28185,"completion":28185,"start":28186,"enrollment":2337,"conditions":28187,"interventions":28188},"NCT02390635","PET\u002FMRI, 18F-FDG PET\u002FCT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia",[87],"2027-09-15","2020-07-15",[36,18432],[28175],{"trials":28190,"activeCount":124},[],{"trials":28192,"activeCount":124},[],{"trials":28194,"activeCount":124},[],{"trials":28196,"activeCount":124},[],{"intervention":10716,"totalTrials":166,"cells":28198},{"EARLY_PHASE1":28199,"PHASE1":28201,"PHASE2":28207,"PHASE3":28209,"PHASE4":28211,"NA":28213},{"trials":28200,"activeCount":124},[],{"trials":28202,"activeCount":166,"soonestReadout":4028},[28203],{"nctId":10694,"briefTitle":10695,"status":279,"phases":28204,"primaryCompletion":4028,"completion":505,"start":7816,"enrollment":2700,"conditions":28205,"interventions":28206},[87],[10698,10699,1343,1770,10700,10701,1344,1312,1348,1349,1350,1351,1352,1353,10702,10703,10704,6638,10705,10706,4914,10707,4917,10708,4920,4922,4924,10709,4927,10710,10711,10712,1463,10713,1466,10714,1470,1472],[1275,10716,1376,10717],{"trials":28208,"activeCount":124},[],{"trials":28210,"activeCount":124},[],{"trials":28212,"activeCount":124},[],{"trials":28214,"activeCount":124},[],{"intervention":15151,"totalTrials":166,"cells":28216},{"EARLY_PHASE1":28217,"PHASE1":28219,"PHASE2":28225,"PHASE3":28227,"PHASE4":28229,"NA":28231},{"trials":28218,"activeCount":124},[],{"trials":28220,"activeCount":166,"soonestReadout":5025},[28221],{"nctId":15144,"briefTitle":15145,"status":279,"phases":28222,"primaryCompletion":5025,"completion":15147,"start":15148,"enrollment":593,"conditions":28223,"interventions":28224},[87],[1942,3305],[15151,1374],{"trials":28226,"activeCount":124},[],{"trials":28228,"activeCount":124},[],{"trials":28230,"activeCount":124},[],{"trials":28232,"activeCount":124},[],{"intervention":28234,"totalTrials":166,"cells":28235},"Fluorine F 18 L-glutamate Derivative 18F-FSPG",{"EARLY_PHASE1":28236,"PHASE1":28238,"PHASE2":28252,"PHASE3":28254,"PHASE4":28256,"NA":28258},{"trials":28237,"activeCount":124},[],{"trials":28239,"activeCount":166,"soonestReadout":860},[28240],{"nctId":28241,"briefTitle":28242,"status":102,"phases":28243,"primaryCompletion":860,"completion":860,"start":28244,"enrollment":971,"conditions":28245,"interventions":28249},"NCT02379377","18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant",[87],"2022-02-15",[28246,1758,3947,28247,28248],"Adult Hepatocellular Carcinoma","Benign Liver Tumor","Metastases to Liver",[28234,28250,28251],"Carbon C 11 Acetate","Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose",{"trials":28253,"activeCount":124},[],{"trials":28255,"activeCount":124},[],{"trials":28257,"activeCount":124},[],{"trials":28259,"activeCount":124},[],{"intervention":28250,"totalTrials":166,"cells":28261},{"EARLY_PHASE1":28262,"PHASE1":28264,"PHASE2":28270,"PHASE3":28272,"PHASE4":28274,"NA":28276},{"trials":28263,"activeCount":124},[],{"trials":28265,"activeCount":166,"soonestReadout":860},[28266],{"nctId":28241,"briefTitle":28242,"status":102,"phases":28267,"primaryCompletion":860,"completion":860,"start":28244,"enrollment":971,"conditions":28268,"interventions":28269},[87],[28246,1758,3947,28247,28248],[28234,28250,28251],{"trials":28271,"activeCount":124},[],{"trials":28273,"activeCount":124},[],{"trials":28275,"activeCount":124},[],{"trials":28277,"activeCount":124},[],{"intervention":28251,"totalTrials":166,"cells":28279},{"EARLY_PHASE1":28280,"PHASE1":28282,"PHASE2":28288,"PHASE3":28290,"PHASE4":28292,"NA":28294},{"trials":28281,"activeCount":124},[],{"trials":28283,"activeCount":166,"soonestReadout":860},[28284],{"nctId":28241,"briefTitle":28242,"status":102,"phases":28285,"primaryCompletion":860,"completion":860,"start":28244,"enrollment":971,"conditions":28286,"interventions":28287},[87],[28246,1758,3947,28247,28248],[28234,28250,28251],{"trials":28289,"activeCount":124},[],{"trials":28291,"activeCount":124},[],{"trials":28293,"activeCount":124},[],{"trials":28295,"activeCount":124},[],{"intervention":28297,"totalTrials":166,"cells":28298},"Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes",{"EARLY_PHASE1":28299,"PHASE1":28301,"PHASE2":28311,"PHASE3":28313,"PHASE4":28315,"NA":28317},{"trials":28300,"activeCount":124},[],{"trials":28302,"activeCount":166,"soonestReadout":3425},[28303],{"nctId":28304,"briefTitle":28305,"status":279,"phases":28306,"primaryCompletion":3425,"completion":3425,"start":28307,"enrollment":834,"conditions":28308,"interventions":28310},"NCT03425526","Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease",[87],"2018-03-15",[359,28309],"Immunocompromised",[28297],{"trials":28312,"activeCount":124},[],{"trials":28314,"activeCount":124},[],{"trials":28316,"activeCount":124},[],{"trials":28318,"activeCount":124},[],{"intervention":28320,"totalTrials":166,"cells":28321},"LVGN3616 + LVGN6051 + Nab-Paclitaxel",{"EARLY_PHASE1":28322,"PHASE1":28324,"PHASE2":28340,"PHASE3":28342,"PHASE4":28344,"NA":28346},{"trials":28323,"activeCount":124},[],{"trials":28325,"activeCount":166,"soonestReadout":1299},[28326],{"nctId":28327,"briefTitle":28328,"status":102,"phases":28329,"primaryCompletion":1299,"completion":1299,"start":3080,"enrollment":28330,"conditions":28331,"interventions":28336},"NCT05075993","Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors",[87],352,[28332,12006,28333,11128,28334,1445,28335,1318],"Metastatic Esophageal","Metastatic Head and Neck Carcinoma","Metastatic HPV Related Solid Tumors","Metastatic Soft Tissue Sarcoma",[28320,28337,28338,28339],"LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide","LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel","LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide",{"trials":28341,"activeCount":124},[],{"trials":28343,"activeCount":124},[],{"trials":28345,"activeCount":124},[],{"trials":28347,"activeCount":124},[],{"intervention":28337,"totalTrials":166,"cells":28349},{"EARLY_PHASE1":28350,"PHASE1":28352,"PHASE2":28358,"PHASE3":28360,"PHASE4":28362,"NA":28364},{"trials":28351,"activeCount":124},[],{"trials":28353,"activeCount":166,"soonestReadout":1299},[28354],{"nctId":28327,"briefTitle":28328,"status":102,"phases":28355,"primaryCompletion":1299,"completion":1299,"start":3080,"enrollment":28330,"conditions":28356,"interventions":28357},[87],[28332,12006,28333,11128,28334,1445,28335,1318],[28320,28337,28338,28339],{"trials":28359,"activeCount":124},[],{"trials":28361,"activeCount":124},[],{"trials":28363,"activeCount":124},[],{"trials":28365,"activeCount":124},[],{"intervention":28338,"totalTrials":166,"cells":28367},{"EARLY_PHASE1":28368,"PHASE1":28370,"PHASE2":28376,"PHASE3":28378,"PHASE4":28380,"NA":28382},{"trials":28369,"activeCount":124},[],{"trials":28371,"activeCount":166,"soonestReadout":1299},[28372],{"nctId":28327,"briefTitle":28328,"status":102,"phases":28373,"primaryCompletion":1299,"completion":1299,"start":3080,"enrollment":28330,"conditions":28374,"interventions":28375},[87],[28332,12006,28333,11128,28334,1445,28335,1318],[28320,28337,28338,28339],{"trials":28377,"activeCount":124},[],{"trials":28379,"activeCount":124},[],{"trials":28381,"activeCount":124},[],{"trials":28383,"activeCount":124},[],{"intervention":28339,"totalTrials":166,"cells":28385},{"EARLY_PHASE1":28386,"PHASE1":28388,"PHASE2":28394,"PHASE3":28396,"PHASE4":28398,"NA":28400},{"trials":28387,"activeCount":124},[],{"trials":28389,"activeCount":166,"soonestReadout":1299},[28390],{"nctId":28327,"briefTitle":28328,"status":102,"phases":28391,"primaryCompletion":1299,"completion":1299,"start":3080,"enrollment":28330,"conditions":28392,"interventions":28393},[87],[28332,12006,28333,11128,28334,1445,28335,1318],[28320,28337,28338,28339],{"trials":28395,"activeCount":124},[],{"trials":28397,"activeCount":124},[],{"trials":28399,"activeCount":124},[],{"trials":28401,"activeCount":124},[],{"intervention":28403,"totalTrials":166,"cells":28404},"Loperamide",{"EARLY_PHASE1":28405,"PHASE1":28407,"PHASE2":28416,"PHASE3":28418,"PHASE4":28420,"NA":28422},{"trials":28406,"activeCount":124},[],{"trials":28408,"activeCount":166,"soonestReadout":224},[28409],{"nctId":28410,"briefTitle":28411,"status":279,"phases":28412,"primaryCompletion":224,"completion":224,"start":17217,"enrollment":517,"conditions":28413,"interventions":28415},"NCT04038619","Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients",[87],[11253,28414,11254,1729,24,1530,11078,18,11077],"Diarrhea",[28403],{"trials":28417,"activeCount":124},[],{"trials":28419,"activeCount":124},[],{"trials":28421,"activeCount":124},[],{"trials":28423,"activeCount":124},[],{"intervention":17241,"totalTrials":166,"cells":28425},{"EARLY_PHASE1":28426,"PHASE1":28428,"PHASE2":28434,"PHASE3":28436,"PHASE4":28438,"NA":28440},{"trials":28427,"activeCount":124},[],{"trials":28429,"activeCount":166,"soonestReadout":17237},[28430],{"nctId":17234,"briefTitle":17235,"status":546,"phases":28431,"primaryCompletion":17237,"completion":17238,"start":1864,"enrollment":1034,"conditions":28432,"interventions":28433},[87],[18],[17241,10680,3103],{"trials":28435,"activeCount":124},[],{"trials":28437,"activeCount":124},[],{"trials":28439,"activeCount":124},[],{"trials":28441,"activeCount":124},[],{"intervention":28443,"totalTrials":166,"cells":28444},"Aerosolized Aldesleukin",{"EARLY_PHASE1":28445,"PHASE1":28447,"PHASE2":28459,"PHASE3":28461,"PHASE4":28463,"NA":28465},{"trials":28446,"activeCount":124},[],{"trials":28448,"activeCount":166,"soonestReadout":28453},[28449],{"nctId":28450,"briefTitle":28451,"status":102,"phases":28452,"primaryCompletion":28453,"completion":28453,"start":28454,"enrollment":3082,"conditions":28455,"interventions":28458},"NCT01590069","Aerosolized Aldesleukin in Treating Patients With Lung Metastases",[87],"2029-04-30","2012-06-28",[5006,1316,11593,28456,2971,1549,28457,1273],"Metastatic Renal Cell Cancer","Stage IV Osteosarcoma AJCC v7",[28443],{"trials":28460,"activeCount":124},[],{"trials":28462,"activeCount":124},[],{"trials":28464,"activeCount":124},[],{"trials":28466,"activeCount":124},[],{"intervention":3073,"totalTrials":166,"cells":28468},{"EARLY_PHASE1":28469,"PHASE1":28471,"PHASE2":28477,"PHASE3":28479,"PHASE4":28481,"NA":28483},{"trials":28470,"activeCount":124},[],{"trials":28472,"activeCount":166,"soonestReadout":2455},[28473],{"nctId":3066,"briefTitle":3067,"status":102,"phases":28474,"primaryCompletion":2455,"completion":2455,"start":3069,"enrollment":871,"conditions":28475,"interventions":28476},[87],[3071,1316,1729],[3073,3074,803,3075,1114,1005],{"trials":28478,"activeCount":124},[],{"trials":28480,"activeCount":124},[],{"trials":28482,"activeCount":124},[],{"trials":28484,"activeCount":124},[],{"intervention":3074,"totalTrials":166,"cells":28486},{"EARLY_PHASE1":28487,"PHASE1":28489,"PHASE2":28495,"PHASE3":28497,"PHASE4":28499,"NA":28501},{"trials":28488,"activeCount":124},[],{"trials":28490,"activeCount":166,"soonestReadout":2455},[28491],{"nctId":3066,"briefTitle":3067,"status":102,"phases":28492,"primaryCompletion":2455,"completion":2455,"start":3069,"enrollment":871,"conditions":28493,"interventions":28494},[87],[3071,1316,1729],[3073,3074,803,3075,1114,1005],{"trials":28496,"activeCount":124},[],{"trials":28498,"activeCount":124},[],{"trials":28500,"activeCount":124},[],{"trials":28502,"activeCount":124},[],{"intervention":7577,"totalTrials":166,"cells":28504},{"EARLY_PHASE1":28505,"PHASE1":28507,"PHASE2":28513,"PHASE3":28515,"PHASE4":28517,"NA":28519},{"trials":28506,"activeCount":124},[],{"trials":28508,"activeCount":166,"soonestReadout":860},[28509],{"nctId":7571,"briefTitle":7572,"status":279,"phases":28510,"primaryCompletion":860,"completion":860,"start":3520,"enrollment":7574,"conditions":28511,"interventions":28512},[87],[2084,6902,5008,6565,5009,5010],[7577,53,7578,7579],{"trials":28514,"activeCount":124},[],{"trials":28516,"activeCount":124},[],{"trials":28518,"activeCount":124},[],{"trials":28520,"activeCount":124},[],{"intervention":7578,"totalTrials":166,"cells":28522},{"EARLY_PHASE1":28523,"PHASE1":28525,"PHASE2":28531,"PHASE3":28533,"PHASE4":28535,"NA":28537},{"trials":28524,"activeCount":124},[],{"trials":28526,"activeCount":166,"soonestReadout":860},[28527],{"nctId":7571,"briefTitle":7572,"status":279,"phases":28528,"primaryCompletion":860,"completion":860,"start":3520,"enrollment":7574,"conditions":28529,"interventions":28530},[87],[2084,6902,5008,6565,5009,5010],[7577,53,7578,7579],{"trials":28532,"activeCount":124},[],{"trials":28534,"activeCount":124},[],{"trials":28536,"activeCount":124},[],{"trials":28538,"activeCount":124},[],{"intervention":7579,"totalTrials":166,"cells":28540},{"EARLY_PHASE1":28541,"PHASE1":28543,"PHASE2":28549,"PHASE3":28551,"PHASE4":28553,"NA":28555},{"trials":28542,"activeCount":124},[],{"trials":28544,"activeCount":166,"soonestReadout":860},[28545],{"nctId":7571,"briefTitle":7572,"status":279,"phases":28546,"primaryCompletion":860,"completion":860,"start":3520,"enrollment":7574,"conditions":28547,"interventions":28548},[87],[2084,6902,5008,6565,5009,5010],[7577,53,7578,7579],{"trials":28550,"activeCount":124},[],{"trials":28552,"activeCount":124},[],{"trials":28554,"activeCount":124},[],{"trials":28556,"activeCount":124},[],{"intervention":28558,"totalTrials":166,"cells":28559},"Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine",{"EARLY_PHASE1":28560,"PHASE1":28562,"PHASE2":28573,"PHASE3":28575,"PHASE4":28577,"NA":28579},{"trials":28561,"activeCount":124},[],{"trials":28563,"activeCount":166,"soonestReadout":28568},[28564],{"nctId":28565,"briefTitle":28566,"status":102,"phases":28567,"primaryCompletion":28568,"completion":28568,"start":28569,"enrollment":910,"conditions":28570,"interventions":28572},"NCT01209871","Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma",[87],"2026-02-20","2015-02-26",[28571],"Lymphoplasmacytic Lymphoma",[28558],{"trials":28574,"activeCount":124},[],{"trials":28576,"activeCount":124},[],{"trials":28578,"activeCount":124},[],{"trials":28580,"activeCount":124},[],{"intervention":28582,"totalTrials":166,"cells":28583},"UGN-201",{"EARLY_PHASE1":28584,"PHASE1":28586,"PHASE2":28596,"PHASE3":28598,"PHASE4":28600,"NA":28602},{"trials":28585,"activeCount":124},[],{"trials":28587,"activeCount":166,"soonestReadout":1427},[28588],{"nctId":28589,"briefTitle":28590,"status":102,"phases":28591,"primaryCompletion":1427,"completion":1427,"start":28592,"enrollment":1496,"conditions":28593,"interventions":28595},"NCT05055050","A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630",[87],"2022-01-24",[1293,28594],"Bladder",[28582],{"trials":28597,"activeCount":124},[],{"trials":28599,"activeCount":124},[],{"trials":28601,"activeCount":124},[],{"trials":28603,"activeCount":124},[],{"intervention":10386,"totalTrials":166,"cells":28605},{"EARLY_PHASE1":28606,"PHASE1":28608,"PHASE2":28614,"PHASE3":28616,"PHASE4":28618,"NA":28620},{"trials":28607,"activeCount":124},[],{"trials":28609,"activeCount":166,"soonestReadout":10382},[28610],{"nctId":10379,"briefTitle":10380,"status":279,"phases":28611,"primaryCompletion":10382,"completion":10383,"start":889,"enrollment":628,"conditions":28612,"interventions":28613},[87],[30,36],[510,10386],{"trials":28615,"activeCount":124},[],{"trials":28617,"activeCount":124},[],{"trials":28619,"activeCount":124},[],{"trials":28621,"activeCount":124},[],{"intervention":542,"totalTrials":166,"cells":28623},{"EARLY_PHASE1":28624,"PHASE1":28626,"PHASE2":28632,"PHASE3":28634,"PHASE4":28636,"NA":28638},{"trials":28625,"activeCount":124},[],{"trials":28627,"activeCount":166,"soonestReadout":536},[28628],{"nctId":533,"briefTitle":534,"status":102,"phases":28629,"primaryCompletion":536,"completion":537,"start":538,"enrollment":539,"conditions":28630,"interventions":28631},[87],[36],[510,480,542],{"trials":28633,"activeCount":124},[],{"trials":28635,"activeCount":124},[],{"trials":28637,"activeCount":124},[],{"trials":28639,"activeCount":124},[],{"intervention":17545,"totalTrials":166,"cells":28641},{"EARLY_PHASE1":28642,"PHASE1":28644,"PHASE2":28650,"PHASE3":28652,"PHASE4":28654,"NA":28656},{"trials":28643,"activeCount":124},[],{"trials":28645,"activeCount":166,"soonestReadout":224},[28646],{"nctId":17539,"briefTitle":17540,"status":279,"phases":28647,"primaryCompletion":224,"completion":224,"start":17542,"enrollment":1409,"conditions":28648,"interventions":28649},[87],[11042,11688],[17545,3497],{"trials":28651,"activeCount":124},[],{"trials":28653,"activeCount":124},[],{"trials":28655,"activeCount":124},[],{"trials":28657,"activeCount":124},[],{"intervention":28659,"totalTrials":166,"cells":28660},"Yttrium-90 (Y-90) resin microspheres",{"EARLY_PHASE1":28661,"PHASE1":28663,"PHASE2":28672,"PHASE3":28674,"PHASE4":28676,"NA":28678},{"trials":28662,"activeCount":124},[],{"trials":28664,"activeCount":166,"soonestReadout":3407},[28665],{"nctId":28666,"briefTitle":28667,"status":279,"phases":28668,"primaryCompletion":3407,"completion":3407,"start":1230,"enrollment":676,"conditions":28669,"interventions":28671},"NCT05195710","Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases",[87],[28670],"Metastases",[28659],{"trials":28673,"activeCount":124},[],{"trials":28675,"activeCount":124},[],{"trials":28677,"activeCount":124},[],{"trials":28679,"activeCount":124},[],{"intervention":28681,"totalTrials":166,"cells":28682},"CD8+T cells",{"EARLY_PHASE1":28683,"PHASE1":28685,"PHASE2":28696,"PHASE3":28698,"PHASE4":28700,"NA":28702},{"trials":28684,"activeCount":124},[],{"trials":28686,"activeCount":166,"soonestReadout":28691},[28687],{"nctId":28688,"briefTitle":28689,"status":546,"phases":28690,"primaryCompletion":28691,"completion":28692,"start":1427,"enrollment":186,"conditions":28693,"interventions":28695},"NCT07414979","Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma",[87],"2028-03-22","2030-03-22",[28694],"Leptomeningeal Melanoma",[28681],{"trials":28697,"activeCount":124},[],{"trials":28699,"activeCount":124},[],{"trials":28701,"activeCount":124},[],{"trials":28703,"activeCount":124},[],{"intervention":6507,"totalTrials":166,"cells":28705},{"EARLY_PHASE1":28706,"PHASE1":28708,"PHASE2":28714,"PHASE3":28716,"PHASE4":28718,"NA":28720},{"trials":28707,"activeCount":124},[],{"trials":28709,"activeCount":166,"soonestReadout":571},[28710],{"nctId":6500,"briefTitle":6501,"status":279,"phases":28711,"primaryCompletion":571,"completion":1863,"start":6503,"enrollment":517,"conditions":28712,"interventions":28713},[87],[6505],[803,6507],{"trials":28715,"activeCount":124},[],{"trials":28717,"activeCount":124},[],{"trials":28719,"activeCount":124},[],{"trials":28721,"activeCount":124},[],{"intervention":28723,"totalTrials":166,"cells":28724},"Oncolytic Adenovirus Ad5-DNX-2401",{"EARLY_PHASE1":28725,"PHASE1":28727,"PHASE2":28738,"PHASE3":28740,"PHASE4":28742,"NA":28744},{"trials":28726,"activeCount":124},[],{"trials":28728,"activeCount":166,"soonestReadout":238},[28729],{"nctId":28730,"briefTitle":28731,"status":279,"phases":28732,"primaryCompletion":238,"completion":238,"start":28733,"enrollment":593,"conditions":28734,"interventions":28737},"NCT03896568","MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma",[87],"2019-02-12",[28735,28736,7740,7998,3176],"IDH1 wt Allele","Recurrent Anaplastic Astrocytoma",[28723],{"trials":28739,"activeCount":124},[],{"trials":28741,"activeCount":124},[],{"trials":28743,"activeCount":124},[],{"trials":28745,"activeCount":124},[],{"intervention":7587,"totalTrials":166,"cells":28747},{"EARLY_PHASE1":28748,"PHASE1":28750,"PHASE2":28756,"PHASE3":28758,"PHASE4":28760,"NA":28762},{"trials":28749,"activeCount":124},[],{"trials":28751,"activeCount":166,"soonestReadout":1151},[28752],{"nctId":7581,"briefTitle":7582,"status":279,"phases":28753,"primaryCompletion":1151,"completion":1152,"start":7584,"enrollment":4299,"conditions":28754,"interventions":28755},[87],[3305],[7587,1375,1113,7588,1275,53,7589],{"trials":28757,"activeCount":124},[],{"trials":28759,"activeCount":124},[],{"trials":28761,"activeCount":124},[],{"trials":28763,"activeCount":124},[],{"intervention":9918,"totalTrials":166,"cells":28765},{"EARLY_PHASE1":28766,"PHASE1":28768,"PHASE2":28774,"PHASE3":28776,"PHASE4":28778,"NA":28780},{"trials":28767,"activeCount":124},[],{"trials":28769,"activeCount":166,"soonestReadout":9914},[28770],{"nctId":9911,"briefTitle":9912,"status":102,"phases":28771,"primaryCompletion":9914,"completion":9914,"start":9915,"enrollment":3726,"conditions":28772,"interventions":28773},[87],[1315,1836,1359,1319,1361,1362],[1275,1369,9918,1377],{"trials":28775,"activeCount":124},[],{"trials":28777,"activeCount":124},[],{"trials":28779,"activeCount":124},[],{"trials":28781,"activeCount":124},[],{"intervention":12566,"totalTrials":166,"cells":28783},{"EARLY_PHASE1":28784,"PHASE1":28786,"PHASE2":28792,"PHASE3":28794,"PHASE4":28796,"NA":28798},{"trials":28785,"activeCount":124},[],{"trials":28787,"activeCount":166,"soonestReadout":3425},[28788],{"nctId":12558,"briefTitle":12559,"status":279,"phases":28789,"primaryCompletion":3425,"completion":3426,"start":12561,"enrollment":406,"conditions":28790,"interventions":28791},[87],[12563,12564],[612,12566,12567],{"trials":28793,"activeCount":124},[],{"trials":28795,"activeCount":124},[],{"trials":28797,"activeCount":124},[],{"trials":28799,"activeCount":124},[],{"intervention":28801,"totalTrials":166,"cells":28802},"M032",{"EARLY_PHASE1":28803,"PHASE1":28805,"PHASE2":28815,"PHASE3":28817,"PHASE4":28819,"NA":28821},{"trials":28804,"activeCount":124},[],{"trials":28806,"activeCount":166,"soonestReadout":548},[28807],{"nctId":28808,"briefTitle":28809,"status":279,"phases":28810,"primaryCompletion":548,"completion":490,"start":28811,"enrollment":1131,"conditions":28812,"interventions":28814},"NCT07076498","Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation",[87],"2026-04-23",[28813],"Glioma",[28801],{"trials":28816,"activeCount":124},[],{"trials":28818,"activeCount":124},[],{"trials":28820,"activeCount":124},[],{"trials":28822,"activeCount":124},[],{"intervention":27945,"totalTrials":166,"cells":28824},{"EARLY_PHASE1":28825,"PHASE1":28827,"PHASE2":28833,"PHASE3":28835,"PHASE4":28837,"NA":28839},{"trials":28826,"activeCount":124},[],{"trials":28828,"activeCount":166,"soonestReadout":815},[28829],{"nctId":27938,"briefTitle":27939,"status":279,"phases":28830,"primaryCompletion":815,"completion":815,"start":1408,"enrollment":8325,"conditions":28831,"interventions":28832},[87],[36,846,644,4598,1067,30,3244,727,608,649,609,1092,610,650,632,651,27942,27943],[27931,27945],{"trials":28834,"activeCount":124},[],{"trials":28836,"activeCount":124},[],{"trials":28838,"activeCount":124},[],{"trials":28840,"activeCount":124},[],{"intervention":28842,"totalTrials":166,"cells":28843},"4-[18F]Fluoro-1-Naphthol",{"EARLY_PHASE1":28844,"PHASE1":28846,"PHASE2":28856,"PHASE3":28858,"PHASE4":28860,"NA":28862},{"trials":28845,"activeCount":124},[],{"trials":28847,"activeCount":166,"soonestReadout":3258},[28848],{"nctId":28849,"briefTitle":28850,"status":279,"phases":28851,"primaryCompletion":3258,"completion":3258,"start":28852,"enrollment":2581,"conditions":28853,"interventions":28855},"NCT05335811","First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging",[87],"2022-10-06",[28854],"Endocrine Neoplasia",[28842],{"trials":28857,"activeCount":124},[],{"trials":28859,"activeCount":124},[],{"trials":28861,"activeCount":124},[],{"trials":28863,"activeCount":124},[],{"intervention":28865,"totalTrials":166,"cells":28866},"JV-213",{"EARLY_PHASE1":28867,"PHASE1":28869,"PHASE2":28880,"PHASE3":28882,"PHASE4":28884,"NA":28886},{"trials":28868,"activeCount":124},[],{"trials":28870,"activeCount":166,"soonestReadout":281},[28871],{"nctId":28872,"briefTitle":28873,"status":279,"phases":28874,"primaryCompletion":281,"completion":281,"start":28875,"enrollment":1922,"conditions":28876,"interventions":28879},"NCT05773040","A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas",[87],"2023-04-14",[28877,28878],"Lymphomas","B-cell Lymphomas",[28865],{"trials":28881,"activeCount":124},[],{"trials":28883,"activeCount":124},[],{"trials":28885,"activeCount":124},[],{"trials":28887,"activeCount":124},[],{"intervention":28889,"totalTrials":166,"cells":28890},"Virus-specific Cytotoxic T-lymphocytes",{"EARLY_PHASE1":28891,"PHASE1":28893,"PHASE2":28903,"PHASE3":28905,"PHASE4":28907,"NA":28909},{"trials":28892,"activeCount":124},[],{"trials":28894,"activeCount":166,"soonestReadout":193},[28895],{"nctId":28896,"briefTitle":28897,"status":279,"phases":28898,"primaryCompletion":193,"completion":193,"start":28899,"enrollment":406,"conditions":28900,"interventions":28902},"NCT05101213","Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients",[87],"2023-01-06",[28901,26571,24674,359,26573,360,25732],"Adenovirus Infection",[28889],{"trials":28904,"activeCount":124},[],{"trials":28906,"activeCount":124},[],{"trials":28908,"activeCount":124},[],{"trials":28910,"activeCount":124},[],{"intervention":10881,"totalTrials":166,"cells":28912},{"EARLY_PHASE1":28913,"PHASE1":28915,"PHASE2":28921,"PHASE3":28923,"PHASE4":28925,"NA":28927},{"trials":28914,"activeCount":124},[],{"trials":28916,"activeCount":166,"soonestReadout":10870},[28917],{"nctId":10867,"briefTitle":10868,"status":279,"phases":28918,"primaryCompletion":10870,"completion":10871,"start":10872,"enrollment":1243,"conditions":28919,"interventions":28920},[87],[2306,10874,10875,10876,10877,10878,10879],[10874,10881,1275],{"trials":28922,"activeCount":124},[],{"trials":28924,"activeCount":124},[],{"trials":28926,"activeCount":124},[],{"trials":28928,"activeCount":124},[],{"intervention":28930,"totalTrials":166,"cells":28931},"DNX-2401",{"EARLY_PHASE1":28932,"PHASE1":28934,"PHASE2":28943,"PHASE3":28945,"PHASE4":28947,"NA":28949},{"trials":28933,"activeCount":124},[],{"trials":28935,"activeCount":166,"soonestReadout":18503},[28936],{"nctId":28937,"briefTitle":28938,"status":546,"phases":28939,"primaryCompletion":18503,"completion":28940,"start":1427,"enrollment":676,"conditions":28941,"interventions":28942},"NCT07444606","Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases",[87],"2029-01-30",[1729],[28930],{"trials":28944,"activeCount":124},[],{"trials":28946,"activeCount":124},[],{"trials":28948,"activeCount":124},[],{"trials":28950,"activeCount":124},[],{"intervention":3862,"totalTrials":166,"cells":28952},{"EARLY_PHASE1":28953,"PHASE1":28955,"PHASE2":28961,"PHASE3":28963,"PHASE4":28965,"NA":28967},{"trials":28954,"activeCount":124},[],{"trials":28956,"activeCount":166,"soonestReadout":446},[28957],{"nctId":3850,"briefTitle":3851,"status":279,"phases":28958,"primaryCompletion":446,"completion":446,"start":3853,"enrollment":448,"conditions":28959,"interventions":28960},[87],[3855,3856,3857,3858,3859,3860],[1709,3862],{"trials":28962,"activeCount":124},[],{"trials":28964,"activeCount":124},[],{"trials":28966,"activeCount":124},[],{"trials":28968,"activeCount":124},[],{"intervention":28970,"totalTrials":166,"cells":28971},"EphA2-targeting DOPC-encapsulated siRNA",{"EARLY_PHASE1":28972,"PHASE1":28974,"PHASE2":28983,"PHASE3":28985,"PHASE4":28987,"NA":28989},{"trials":28973,"activeCount":124},[],{"trials":28975,"activeCount":166,"soonestReadout":815},[28976],{"nctId":28977,"briefTitle":28978,"status":102,"phases":28979,"primaryCompletion":815,"completion":815,"start":28980,"enrollment":2446,"conditions":28981,"interventions":28982},"NCT01591356","EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors",[87],"2015-07-01",[1343],[28970],{"trials":28984,"activeCount":124},[],{"trials":28986,"activeCount":124},[],{"trials":28988,"activeCount":124},[],{"trials":28990,"activeCount":124},[],{"intervention":3126,"totalTrials":166,"cells":28992},{"EARLY_PHASE1":28993,"PHASE1":28995,"PHASE2":29001,"PHASE3":29003,"PHASE4":29005,"NA":29007},{"trials":28994,"activeCount":124},[],{"trials":28996,"activeCount":166,"soonestReadout":1078},[28997],{"nctId":3117,"briefTitle":3118,"status":279,"phases":28998,"primaryCompletion":1078,"completion":3120,"start":3121,"enrollment":1559,"conditions":28999,"interventions":29000},[87],[3123,3124],[2462,3126,803],{"trials":29002,"activeCount":124},[],{"trials":29004,"activeCount":124},[],{"trials":29006,"activeCount":124},[],{"trials":29008,"activeCount":124},[],{"intervention":6588,"totalTrials":166,"cells":29010},{"EARLY_PHASE1":29011,"PHASE1":29013,"PHASE2":29019,"PHASE3":29021,"PHASE4":29023,"NA":29025},{"trials":29012,"activeCount":124},[],{"trials":29014,"activeCount":166,"soonestReadout":6584},[29015],{"nctId":6581,"briefTitle":6582,"status":546,"phases":29016,"primaryCompletion":6584,"completion":6585,"start":1864,"enrollment":517,"conditions":29017,"interventions":29018},[87],[1271],[803,1070,6588],{"trials":29020,"activeCount":124},[],{"trials":29022,"activeCount":124},[],{"trials":29024,"activeCount":124},[],{"trials":29026,"activeCount":124},[],{"intervention":27686,"totalTrials":166,"cells":29028},{"EARLY_PHASE1":29029,"PHASE1":29031,"PHASE2":29037,"PHASE3":29039,"PHASE4":29041,"NA":29043},{"trials":29030,"activeCount":124},[],{"trials":29032,"activeCount":166,"soonestReadout":224},[29033],{"nctId":27680,"briefTitle":27681,"status":279,"phases":29034,"primaryCompletion":224,"completion":224,"start":27683,"enrollment":20949,"conditions":29035,"interventions":29036},[87],[1343,361,2570],[19435,16702,27686,27687],{"trials":29038,"activeCount":124},[],{"trials":29040,"activeCount":124},[],{"trials":29042,"activeCount":124},[],{"trials":29044,"activeCount":124},[],{"intervention":27687,"totalTrials":166,"cells":29046},{"EARLY_PHASE1":29047,"PHASE1":29049,"PHASE2":29055,"PHASE3":29057,"PHASE4":29059,"NA":29061},{"trials":29048,"activeCount":124},[],{"trials":29050,"activeCount":166,"soonestReadout":224},[29051],{"nctId":27680,"briefTitle":27681,"status":279,"phases":29052,"primaryCompletion":224,"completion":224,"start":27683,"enrollment":20949,"conditions":29053,"interventions":29054},[87],[1343,361,2570],[19435,16702,27686,27687],{"trials":29056,"activeCount":124},[],{"trials":29058,"activeCount":124},[],{"trials":29060,"activeCount":124},[],{"trials":29062,"activeCount":124},[],{"intervention":29064,"totalTrials":166,"cells":29065},"JV-394",{"EARLY_PHASE1":29066,"PHASE1":29068,"PHASE2":29080,"PHASE3":29082,"PHASE4":29084,"NA":29086},{"trials":29067,"activeCount":124},[],{"trials":29069,"activeCount":166,"soonestReadout":29074},[29070],{"nctId":29071,"briefTitle":29072,"status":279,"phases":29073,"primaryCompletion":29074,"completion":29075,"start":29076,"enrollment":1922,"conditions":29077,"interventions":29079},"NCT07382817","Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r\u002Fr CD94+ T\u002FNK Cell Neoplasms",[87],"2029-12-09","2031-12-09","2026-02-18",[29078],"Neoplasms",[29064],{"trials":29081,"activeCount":124},[],{"trials":29083,"activeCount":124},[],{"trials":29085,"activeCount":124},[],{"trials":29087,"activeCount":124},[],{"intervention":29089,"totalTrials":166,"cells":29090},"HP 129Xe MRI",{"EARLY_PHASE1":29091,"PHASE1":29093,"PHASE2":29101,"PHASE3":29103,"PHASE4":29105,"NA":29107},{"trials":29092,"activeCount":124},[],{"trials":29094,"activeCount":166,"soonestReadout":1088},[29095],{"nctId":29096,"briefTitle":29097,"status":279,"phases":29098,"primaryCompletion":1088,"completion":14252,"start":1238,"enrollment":3082,"conditions":29099,"interventions":29100},"NCT06909201","Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity",[87],[24],[29089],{"trials":29102,"activeCount":124},[],{"trials":29104,"activeCount":124},[],{"trials":29106,"activeCount":124},[],{"trials":29108,"activeCount":124},[],{"intervention":3146,"totalTrials":166,"cells":29110},{"EARLY_PHASE1":29111,"PHASE1":29113,"PHASE2":29119,"PHASE3":29121,"PHASE4":29123,"NA":29125},{"trials":29112,"activeCount":124},[],{"trials":29114,"activeCount":166,"soonestReadout":1939},[29115],{"nctId":3139,"briefTitle":3140,"status":102,"phases":29116,"primaryCompletion":1939,"completion":1939,"start":3142,"enrollment":1240,"conditions":29117,"interventions":29118},[87],[1316,1961,1962,1544,1546,1549],[1599,803,1005,3145,3146],{"trials":29120,"activeCount":124},[],{"trials":29122,"activeCount":124},[],{"trials":29124,"activeCount":124},[],{"trials":29126,"activeCount":124},[],{"intervention":7658,"totalTrials":166,"cells":29128},{"EARLY_PHASE1":29129,"PHASE1":29131,"PHASE2":29137,"PHASE3":29139,"PHASE4":29141,"NA":29143},{"trials":29130,"activeCount":124},[],{"trials":29132,"activeCount":166,"soonestReadout":1864},[29133],{"nctId":7641,"briefTitle":7642,"status":102,"phases":29134,"primaryCompletion":1864,"completion":1864,"start":7644,"enrollment":550,"conditions":29135,"interventions":29136},[87],[7646,7647,7648,5799,7649,7650,7651,7652,7653,7654,7655,7656],[53,7658,3729],{"trials":29138,"activeCount":124},[],{"trials":29140,"activeCount":124},[],{"trials":29142,"activeCount":124},[],{"trials":29144,"activeCount":124},[],{"intervention":29146,"totalTrials":166,"cells":29147},"PLM-102",{"EARLY_PHASE1":29148,"PHASE1":29150,"PHASE2":29158,"PHASE3":29160,"PHASE4":29162,"NA":29164},{"trials":29149,"activeCount":124},[],{"trials":29151,"activeCount":166,"soonestReadout":1152},[29152],{"nctId":29153,"briefTitle":29154,"status":546,"phases":29155,"primaryCompletion":1152,"completion":1055,"start":1864,"enrollment":3726,"conditions":29156,"interventions":29157},"NCT07549464","Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia",[87],[36],[29146],{"trials":29159,"activeCount":124},[],{"trials":29161,"activeCount":124},[],{"trials":29163,"activeCount":124},[],{"trials":29165,"activeCount":124},[],{"intervention":584,"totalTrials":166,"cells":29167},{"EARLY_PHASE1":29168,"PHASE1":29170,"PHASE2":29176,"PHASE3":29178,"PHASE4":29180,"NA":29182},{"trials":29169,"activeCount":124},[],{"trials":29171,"activeCount":166,"soonestReadout":281},[29172],{"nctId":578,"briefTitle":579,"status":279,"phases":29173,"primaryCompletion":281,"completion":571,"start":581,"enrollment":492,"conditions":29174,"interventions":29175},[87],[36],[480,584,576],{"trials":29177,"activeCount":124},[],{"trials":29179,"activeCount":124},[],{"trials":29181,"activeCount":124},[],{"trials":29183,"activeCount":124},[],{"intervention":29185,"totalTrials":166,"cells":29186},"Anti-PR1\u002FHLA-A2 Monoclonal Antibody Hu8F4",{"EARLY_PHASE1":29187,"PHASE1":29189,"PHASE2":29199,"PHASE3":29201,"PHASE4":29203,"NA":29205},{"trials":29188,"activeCount":124},[],{"trials":29190,"activeCount":166,"soonestReadout":3425},[29191],{"nctId":29192,"briefTitle":29193,"status":102,"phases":29194,"primaryCompletion":3425,"completion":3425,"start":13129,"enrollment":2647,"conditions":29195,"interventions":29198},"NCT02530034","Hu8F4 in Treating Patients With Advanced Hematologic Malignancies",[87],[846,644,359,1067,29196,29197,3429,608,850,853,651],"Myelodysplastic Syndrome With Excess Blasts-1","Myelodysplastic Syndrome With Excess Blasts-2",[29185],{"trials":29200,"activeCount":124},[],{"trials":29202,"activeCount":124},[],{"trials":29204,"activeCount":124},[],{"trials":29206,"activeCount":124},[],{"intervention":19552,"totalTrials":166,"cells":29208},{"EARLY_PHASE1":29209,"PHASE1":29211,"PHASE2":29217,"PHASE3":29219,"PHASE4":29221,"NA":29223},{"trials":29210,"activeCount":124},[],{"trials":29212,"activeCount":166,"soonestReadout":19548},[29213],{"nctId":19545,"briefTitle":19546,"status":546,"phases":29214,"primaryCompletion":19548,"completion":19549,"start":18773,"enrollment":550,"conditions":29215,"interventions":29216},[87],[10145],[10678,19552],{"trials":29218,"activeCount":124},[],{"trials":29220,"activeCount":124},[],{"trials":29222,"activeCount":124},[],{"trials":29224,"activeCount":124},[],{"intervention":12315,"totalTrials":166,"cells":29226},{"EARLY_PHASE1":29227,"PHASE1":29229,"PHASE2":29235,"PHASE3":29237,"PHASE4":29239,"NA":29241},{"trials":29228,"activeCount":124},[],{"trials":29230,"activeCount":166,"soonestReadout":1299},[29231],{"nctId":12308,"briefTitle":12309,"status":102,"phases":29232,"primaryCompletion":1299,"completion":1299,"start":12311,"enrollment":1766,"conditions":29233,"interventions":29234},[87],[12313],[2369,12315,12316],{"trials":29236,"activeCount":124},[],{"trials":29238,"activeCount":124},[],{"trials":29240,"activeCount":124},[],{"trials":29242,"activeCount":124},[],{"intervention":12316,"totalTrials":166,"cells":29244},{"EARLY_PHASE1":29245,"PHASE1":29247,"PHASE2":29253,"PHASE3":29255,"PHASE4":29257,"NA":29259},{"trials":29246,"activeCount":124},[],{"trials":29248,"activeCount":166,"soonestReadout":1299},[29249],{"nctId":12308,"briefTitle":12309,"status":102,"phases":29250,"primaryCompletion":1299,"completion":1299,"start":12311,"enrollment":1766,"conditions":29251,"interventions":29252},[87],[12313],[2369,12315,12316],{"trials":29254,"activeCount":124},[],{"trials":29256,"activeCount":124},[],{"trials":29258,"activeCount":124},[],{"trials":29260,"activeCount":124},[],{"intervention":2310,"totalTrials":166,"cells":29262},{"EARLY_PHASE1":29263,"PHASE1":29265,"PHASE2":29271,"PHASE3":29273,"PHASE4":29275,"NA":29277},{"trials":29264,"activeCount":124},[],{"trials":29266,"activeCount":166,"soonestReadout":2302},[29267],{"nctId":2299,"briefTitle":2300,"status":279,"phases":29268,"primaryCompletion":2302,"completion":2303,"start":701,"enrollment":406,"conditions":29269,"interventions":29270},[87],[2305,2306,2307],[2309,62,1070,2310,2311],{"trials":29272,"activeCount":124},[],{"trials":29274,"activeCount":124},[],{"trials":29276,"activeCount":124},[],{"trials":29278,"activeCount":124},[],{"intervention":2311,"totalTrials":166,"cells":29280},{"EARLY_PHASE1":29281,"PHASE1":29283,"PHASE2":29289,"PHASE3":29291,"PHASE4":29293,"NA":29295},{"trials":29282,"activeCount":124},[],{"trials":29284,"activeCount":166,"soonestReadout":2302},[29285],{"nctId":2299,"briefTitle":2300,"status":279,"phases":29286,"primaryCompletion":2302,"completion":2303,"start":701,"enrollment":406,"conditions":29287,"interventions":29288},[87],[2305,2306,2307],[2309,62,1070,2310,2311],{"trials":29290,"activeCount":124},[],{"trials":29292,"activeCount":124},[],{"trials":29294,"activeCount":124},[],{"trials":29296,"activeCount":124},[],{"intervention":12581,"totalTrials":166,"cells":29298},{"EARLY_PHASE1":29299,"PHASE1":29301,"PHASE2":29307,"PHASE3":29309,"PHASE4":29311,"NA":29313},{"trials":29300,"activeCount":124},[],{"trials":29302,"activeCount":166,"soonestReadout":1299},[29303],{"nctId":12573,"briefTitle":12574,"status":102,"phases":29304,"primaryCompletion":1299,"completion":1299,"start":12576,"enrollment":910,"conditions":29305,"interventions":29306},[87],[12578,12579],[612,12581],{"trials":29308,"activeCount":124},[],{"trials":29310,"activeCount":124},[],{"trials":29312,"activeCount":124},[],{"trials":29314,"activeCount":124},[],{"intervention":14073,"totalTrials":166,"cells":29316},{"EARLY_PHASE1":29317,"PHASE1":29319,"PHASE2":29325,"PHASE3":29327,"PHASE4":29329,"NA":29331},{"trials":29318,"activeCount":124},[],{"trials":29320,"activeCount":166,"soonestReadout":446},[29321],{"nctId":14066,"briefTitle":14067,"status":102,"phases":29322,"primaryCompletion":446,"completion":446,"start":2901,"enrollment":1609,"conditions":29323,"interventions":29324},[87],[14070,2569,361,14071,3845,8040],[14073,2840],{"trials":29326,"activeCount":124},[],{"trials":29328,"activeCount":124},[],{"trials":29330,"activeCount":124},[],{"trials":29332,"activeCount":124},[],{"intervention":15185,"totalTrials":166,"cells":29334},{"EARLY_PHASE1":29335,"PHASE1":29337,"PHASE2":29343,"PHASE3":29345,"PHASE4":29347,"NA":29349},{"trials":29336,"activeCount":124},[],{"trials":29338,"activeCount":166,"soonestReadout":504},[29339],{"nctId":15175,"briefTitle":15176,"status":102,"phases":29340,"primaryCompletion":504,"completion":504,"start":15178,"enrollment":15179,"conditions":29341,"interventions":29342},[87],[15181,15182,15183,7698,7699,4911,7701,10825,1458,1460,1461,10090,10091,7298,10095,1363],[10717,1374,15185],{"trials":29344,"activeCount":124},[],{"trials":29346,"activeCount":124},[],{"trials":29348,"activeCount":124},[],{"trials":29350,"activeCount":124},[],{"intervention":29352,"totalTrials":166,"cells":29353},"Cefazolin",{"EARLY_PHASE1":29354,"PHASE1":29356,"PHASE2":29365,"PHASE3":29367,"PHASE4":29369,"NA":29371},{"trials":29355,"activeCount":124},[],{"trials":29357,"activeCount":166,"soonestReadout":1299},[29358],{"nctId":29359,"briefTitle":29360,"status":102,"phases":29361,"primaryCompletion":1299,"completion":1299,"start":29362,"enrollment":1131,"conditions":29363,"interventions":29364},"NCT04875728","The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma",[87],"2020-09-08",[11246,11247,11248,11249,11250,11251,11252,11256,11257,11258,11259,11260,11261,11262],[29352],{"trials":29366,"activeCount":124},[],{"trials":29368,"activeCount":124},[],{"trials":29370,"activeCount":124},[],{"trials":29372,"activeCount":124},[],{"intervention":6646,"totalTrials":166,"cells":29374},{"EARLY_PHASE1":29375,"PHASE1":29377,"PHASE2":29383,"PHASE3":29385,"PHASE4":29387,"NA":29389},{"trials":29376,"activeCount":124},[],{"trials":29378,"activeCount":166,"soonestReadout":238},[29379],{"nctId":6641,"briefTitle":6642,"status":279,"phases":29380,"primaryCompletion":238,"completion":238,"start":2629,"enrollment":517,"conditions":29381,"interventions":29382},[87],[1593,1585],[803,6646],{"trials":29384,"activeCount":124},[],{"trials":29386,"activeCount":124},[],{"trials":29388,"activeCount":124},[],{"trials":29390,"activeCount":124},[],{"intervention":29392,"totalTrials":166,"cells":29393},"Alpelisib + Pembrolizumab",{"EARLY_PHASE1":29394,"PHASE1":29396,"PHASE2":29408,"PHASE3":29410,"PHASE4":29412,"NA":29414},{"trials":29395,"activeCount":124},[],{"trials":29397,"activeCount":166,"soonestReadout":2002},[29398],{"nctId":29399,"briefTitle":29400,"status":279,"phases":29401,"primaryCompletion":2002,"completion":29402,"start":29403,"enrollment":676,"conditions":29404,"interventions":29407},"NCT06545682","Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)",[87],"2029-08-03","2024-10-15",[29405,18,29406],"Melanoma (Skin Cancer)","Brain Metastasases",[29392],{"trials":29409,"activeCount":124},[],{"trials":29411,"activeCount":124},[],{"trials":29413,"activeCount":124},[],{"trials":29415,"activeCount":124},[],{"intervention":29417,"totalTrials":166,"cells":29418},"G207",{"EARLY_PHASE1":29419,"PHASE1":29421,"PHASE2":29461,"PHASE3":29463,"PHASE4":29465,"NA":29467},{"trials":29420,"activeCount":124},[],{"trials":29422,"activeCount":166,"soonestReadout":549},[29423],{"nctId":29424,"briefTitle":29425,"status":279,"phases":29426,"primaryCompletion":549,"completion":29427,"start":29428,"enrollment":628,"conditions":29429,"interventions":29460},"NCT03911388","HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors",[87],"2027-09-01","2019-09-12",[29430,17604,29431,29078,29432,29433,29434,29435,29436,29437,29438,29439,29440,29441,29442,29443,29444,29445,29446,29447,29448,29449,29450,29451,17995,29452,29453,29454,29455,29456,29457,29458,29459],"Neoplasms, Brain","Glioblastoma of Cerebellum","Astrocytoma","Astrocytoma, Cerebellar","Neuroectodermal Tumors","Neuroectodermal Tumors, Primitive","Cerebellar PNET, Childhood","Cerebellar Neoplasms","Cerebellar Neoplasms, Primary","Cerebellar Neoplasm, Malignant","Cerebellar Neoplasm Malignant Primary","Neoplasm Metastases","Neoplasm Malignant","Neoplasms, Neuroepithelial","Neoplasms, Germ Cell and Embryonal","Neoplasms by Histologic Type","Neoplasms, Glandular and Epithelial","Neoplasms, Nerve Tissue","Central Nervous System Neoplasms, Primary","Central Nervous System Neoplasms, Malignant","Nervous System Neoplasms","Neoplasms by Site","Central Nervous System Diseases","Nervous System Diseases","Medulloblastoma Recurrent","HSV","Virus","Pediatric Brain Tumor","Nervous System Cancer","Primitive Neuroectodermal Tumor (PNET) of Cerebellum",[29417],{"trials":29462,"activeCount":124},[],{"trials":29464,"activeCount":124},[],{"trials":29466,"activeCount":124},[],{"trials":29468,"activeCount":124},[],{"intervention":12336,"totalTrials":166,"cells":29470},{"EARLY_PHASE1":29471,"PHASE1":29473,"PHASE2":29479,"PHASE3":29481,"PHASE4":29483,"NA":29485},{"trials":29472,"activeCount":124},[],{"trials":29474,"activeCount":166,"soonestReadout":12329},[29475],{"nctId":12326,"briefTitle":12327,"status":279,"phases":29476,"primaryCompletion":12329,"completion":12330,"start":12331,"enrollment":550,"conditions":29477,"interventions":29478},[87],[12333,12334],[2369,12336],{"trials":29480,"activeCount":124},[],{"trials":29482,"activeCount":124},[],{"trials":29484,"activeCount":124},[],{"trials":29486,"activeCount":124},[],{"intervention":14206,"totalTrials":166,"cells":29488},{"EARLY_PHASE1":29489,"PHASE1":29491,"PHASE2":29497,"PHASE3":29499,"PHASE4":29501,"NA":29503},{"trials":29490,"activeCount":124},[],{"trials":29492,"activeCount":166,"soonestReadout":604},[29493],{"nctId":14200,"briefTitle":14201,"status":102,"phases":29494,"primaryCompletion":604,"completion":604,"start":14203,"enrollment":2911,"conditions":29495,"interventions":29496},[87],[24],[12910,14206],{"trials":29498,"activeCount":124},[],{"trials":29500,"activeCount":124},[],{"trials":29502,"activeCount":124},[],{"trials":29504,"activeCount":124},[],{"intervention":29506,"totalTrials":166,"cells":29507},"AL101",{"EARLY_PHASE1":29508,"PHASE1":29510,"PHASE2":29518,"PHASE3":29520,"PHASE4":29522,"NA":29524},{"trials":29509,"activeCount":124},[],{"trials":29511,"activeCount":166,"soonestReadout":281},[29512],{"nctId":29513,"briefTitle":29514,"status":102,"phases":29515,"primaryCompletion":281,"completion":281,"start":7816,"enrollment":2779,"conditions":29516,"interventions":29517},"NCT04973683","AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer",[87],[25048,19432],[29506],{"trials":29519,"activeCount":124},[],{"trials":29521,"activeCount":124},[],{"trials":29523,"activeCount":124},[],{"trials":29525,"activeCount":124},[],{"intervention":3075,"totalTrials":121,"cells":29527},{"EARLY_PHASE1":29528,"PHASE1":29530,"PHASE2":29536,"PHASE3":29538,"PHASE4":29540,"NA":29542},{"trials":29529,"activeCount":124},[],{"trials":29531,"activeCount":166,"soonestReadout":2455},[29532],{"nctId":3066,"briefTitle":3067,"status":102,"phases":29533,"primaryCompletion":2455,"completion":2455,"start":3069,"enrollment":871,"conditions":29534,"interventions":29535},[87],[3071,1316,1729],[3073,3074,803,3075,1114,1005],{"trials":29537,"activeCount":124},[],{"trials":29539,"activeCount":124},[],{"trials":29541,"activeCount":124},[],{"trials":29543,"activeCount":124},[29544],{"nctId":29545,"briefTitle":29546,"status":203,"phases":29547,"primaryCompletion":7757,"start":3571,"enrollment":124,"conditions":29548,"interventions":29549},"NCT01508260","Ultrafiltration (Aquapheresis) in Patients With Leukemia and Severe Fluid Overload",[91],[15],[3075],{"intervention":29551,"totalTrials":1231,"cells":29552},"Gadobutrol",{"EARLY_PHASE1":29553,"PHASE1":29569,"PHASE2":29571,"PHASE3":29573,"PHASE4":29575,"NA":29577},{"trials":29554,"activeCount":166,"soonestReadout":238},[29555],{"nctId":29556,"briefTitle":29557,"status":102,"phases":29558,"primaryCompletion":238,"completion":238,"start":29559,"enrollment":448,"conditions":29560,"interventions":29568},"NCT04219904","PET\u002FMRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer",[86],"2018-09-07",[29561,29562,29563,29564,29565,29566,29567],"Stage IA Cervical Cancer","Stage IA1 Cervical Cancer","Stage IA2 Cervical Cancer","Stage IB Cervical Cancer","Stage IB1 Cervical Cancer","Stage IB2 Cervical Cancer","Stage IB3 Cervical Cancer",[29551],{"trials":29570,"activeCount":124},[],{"trials":29572,"activeCount":124},[],{"trials":29574,"activeCount":124},[],{"trials":29576,"activeCount":124},[],{"trials":29578,"activeCount":166,"soonestReadout":104},[29579,29587],{"nctId":29580,"briefTitle":29581,"status":102,"phases":29582,"primaryCompletion":104,"completion":104,"start":12762,"enrollment":1222,"conditions":29583,"interventions":29585},"NCT02156739","Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions",[91],[1828,5808,3512,29584],"Primary Malignant Liver Neoplasm",[29551,29586],"Gadoxetate Disodium",{"nctId":29588,"briefTitle":29589,"status":130,"phases":29590,"primaryCompletion":29591,"completion":29591,"start":29592,"enrollment":230,"conditions":29593,"interventions":29595},"NCT04132843","Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions",[91],"2022-09-01","2020-01-10",[29594,21,1960,3175],"Brain Neoplasm",[29596,29551],"Gadobenate Dimeglumine",{"intervention":29598,"totalTrials":121,"cells":29599},"Proflavine Hemisulfate",{"EARLY_PHASE1":29600,"PHASE1":29611,"PHASE2":29613,"PHASE3":29615,"PHASE4":29617,"NA":29619},{"trials":29601,"activeCount":166,"soonestReadout":5762},[29602],{"nctId":29603,"briefTitle":29604,"status":102,"phases":29605,"primaryCompletion":5762,"completion":5762,"start":29606,"enrollment":3379,"conditions":29607,"interventions":29610},"NCT02790853","Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders",[86],"2016-05-25",[29608,10814,29609,1719],"Dysplasia","Oral Disorder",[29598],{"trials":29612,"activeCount":124},[],{"trials":29614,"activeCount":124},[],{"trials":29616,"activeCount":124},[],{"trials":29618,"activeCount":124},[],{"trials":29620,"activeCount":166,"soonestReadout":2166},[29621],{"nctId":29622,"briefTitle":29623,"status":279,"phases":29624,"primaryCompletion":2166,"completion":2166,"start":355,"enrollment":861,"conditions":29625,"interventions":29627},"NCT05554133","Precision Optical Guidance for Oral Biopsy",[91],[29626],"Oral Lesions",[29628],"Proflavine hemisulfate",{"intervention":13140,"totalTrials":1496,"cells":29630},{"EARLY_PHASE1":29631,"PHASE1":29649,"PHASE2":29663,"PHASE3":29681,"PHASE4":29683,"NA":29685},{"trials":29632,"activeCount":166,"soonestReadout":224},[29633,29637,29645],{"nctId":13126,"briefTitle":13127,"status":130,"phases":29634,"primaryCompletion":13129,"completion":13130,"start":13131,"enrollment":834,"conditions":29635,"interventions":29636},[86],[8027,13133,13134,7308,7309,7310,7311,11800,7699,13135,13136,13137,13138,7313,7314,7315,7316],[1786,13140],{"nctId":29638,"briefTitle":29639,"status":130,"phases":29640,"primaryCompletion":29641,"completion":29641,"start":29642,"enrollment":1409,"conditions":29643,"interventions":29644},"NCT02626130","Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer",[86],"2022-06-20","2016-03-30",[1271,28456,1273],[13140],{"nctId":13142,"briefTitle":13143,"status":102,"phases":29646,"primaryCompletion":224,"completion":224,"start":9278,"enrollment":2700,"conditions":29647,"interventions":29648},[86],[13146,13147,13148,13149,13150,13151,13152,13153,13154,13155,13156,13157,13158,13159,13160,13161,13162,13163,13164],[1786,13140],{"trials":29650,"activeCount":124},[29651,29655,29659],{"nctId":13169,"briefTitle":13170,"status":130,"phases":29652,"primaryCompletion":13172,"completion":13172,"start":13173,"enrollment":1131,"conditions":29653,"interventions":29654},[87],[13175,13176,13177,11093,11095,13178,1441,13179,13180,13181,13182,13183,1456,13184,13185,13186,13187,13188,3856,13189,3857,13190,3858,3859,13191,13192,13193,13194,13195,3860,1468,13196,13197,11110,13198,13199],[1786,13140],{"nctId":13202,"briefTitle":13203,"status":130,"phases":29656,"primaryCompletion":173,"completion":173,"start":13205,"enrollment":2865,"conditions":29657,"interventions":29658},[87],[13207,1619,1620],[1786,13140],{"nctId":13210,"briefTitle":13211,"status":130,"phases":29660,"primaryCompletion":13213,"completion":13213,"start":13214,"enrollment":628,"conditions":29661,"interventions":29662},[87],[1877,13216,5008,5009,5010],[1786,13140],{"trials":29664,"activeCount":124},[29665,29669,29673,29677],{"nctId":13228,"briefTitle":13229,"status":130,"phases":29666,"primaryCompletion":13231,"completion":13231,"start":13232,"enrollment":517,"conditions":29667,"interventions":29668},[87,88],[1836,1319,1361,1362],[1786,13235,13140],{"nctId":13283,"briefTitle":13284,"status":130,"phases":29670,"primaryCompletion":13286,"completion":13286,"start":13287,"enrollment":2004,"conditions":29671,"interventions":29672},[88],[3544,13289,5122,3546,3547,3548],[1786,13140],{"nctId":13325,"briefTitle":13326,"status":130,"phases":29674,"primaryCompletion":11652,"completion":11652,"start":13328,"enrollment":1222,"conditions":29675,"interventions":29676},[88],[1452,1454,1455,1458,1460,1461,13320,11741,13321],[1786,13140],{"nctId":13336,"briefTitle":13337,"status":130,"phases":29678,"primaryCompletion":13339,"completion":13339,"start":13340,"enrollment":6385,"conditions":29679,"interventions":29680},[88],[13342],[1786,13140],{"trials":29682,"activeCount":124},[],{"trials":29684,"activeCount":124},[],{"trials":29686,"activeCount":124},[],{"intervention":29688,"totalTrials":166,"cells":29689},"18F-FTX",{"EARLY_PHASE1":29690,"PHASE1":29699,"PHASE2":29701,"PHASE3":29703,"PHASE4":29705,"NA":29707},{"trials":29691,"activeCount":166,"soonestReadout":1299},[29692],{"nctId":29693,"briefTitle":29694,"status":102,"phases":29695,"primaryCompletion":1299,"completion":1299,"start":29696,"enrollment":1131,"conditions":29697,"interventions":29698},"NCT05047913","Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR",[86],"2021-09-20",[13732,11077],[29688],{"trials":29700,"activeCount":124},[],{"trials":29702,"activeCount":124},[],{"trials":29704,"activeCount":124},[],{"trials":29706,"activeCount":124},[],{"trials":29708,"activeCount":124},[],{"intervention":29710,"totalTrials":166,"cells":29711},"Tirzepatide",{"EARLY_PHASE1":29712,"PHASE1":29721,"PHASE2":29723,"PHASE3":29725,"PHASE4":29727,"NA":29729},{"trials":29713,"activeCount":166,"soonestReadout":446},[29714],{"nctId":29715,"briefTitle":29716,"status":279,"phases":29717,"primaryCompletion":446,"completion":281,"start":14265,"enrollment":406,"conditions":29718,"interventions":29720},"NCT06759701","Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study",[86],[29719,27],"Diabetes",[29710],{"trials":29722,"activeCount":124},[],{"trials":29724,"activeCount":124},[],{"trials":29726,"activeCount":124},[],{"trials":29728,"activeCount":124},[],{"trials":29730,"activeCount":124},[],{"intervention":29732,"totalTrials":166,"cells":29733},"Technetium Tc-99m Sestamibi",{"EARLY_PHASE1":29734,"PHASE1":29743,"PHASE2":29745,"PHASE3":29747,"PHASE4":29749,"NA":29751},{"trials":29735,"activeCount":166,"soonestReadout":5382},[29736],{"nctId":29737,"briefTitle":29738,"status":102,"phases":29739,"primaryCompletion":5382,"completion":5382,"start":29740,"enrollment":724,"conditions":29741,"interventions":29742},"NCT02744053","DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer",[86],"2016-11-07",[7698,7699,7701,1363],[29732],{"trials":29744,"activeCount":124},[],{"trials":29746,"activeCount":124},[],{"trials":29748,"activeCount":124},[],{"trials":29750,"activeCount":124},[],{"trials":29752,"activeCount":124},[],{"intervention":29754,"totalTrials":166,"cells":29755},"Paclitaxel\u002FBev",{"EARLY_PHASE1":29756,"PHASE1":29767,"PHASE2":29769,"PHASE3":29771,"PHASE4":29773,"NA":29775},{"trials":29757,"activeCount":166,"soonestReadout":1299},[29758],{"nctId":29759,"briefTitle":29760,"status":102,"phases":29761,"primaryCompletion":1299,"completion":1299,"start":5405,"enrollment":2779,"conditions":29762,"interventions":29765},"NCT05053750","TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",[86],[29763,29764,9925],"Epithelial Ovarian","Fallopian Tube",[29754,29766],"Paclitaxel\u002FBev + ZA",{"trials":29768,"activeCount":124},[],{"trials":29770,"activeCount":124},[],{"trials":29772,"activeCount":124},[],{"trials":29774,"activeCount":124},[],{"trials":29776,"activeCount":124},[],{"intervention":29766,"totalTrials":166,"cells":29778},{"EARLY_PHASE1":29779,"PHASE1":29785,"PHASE2":29787,"PHASE3":29789,"PHASE4":29791,"NA":29793},{"trials":29780,"activeCount":166,"soonestReadout":1299},[29781],{"nctId":29759,"briefTitle":29760,"status":102,"phases":29782,"primaryCompletion":1299,"completion":1299,"start":5405,"enrollment":2779,"conditions":29783,"interventions":29784},[86],[29763,29764,9925],[29754,29766],{"trials":29786,"activeCount":124},[],{"trials":29788,"activeCount":124},[],{"trials":29790,"activeCount":124},[],{"trials":29792,"activeCount":124},[],{"trials":29794,"activeCount":124},[],{"intervention":110,"totalTrials":166,"cells":29796},{"EARLY_PHASE1":29797,"PHASE1":29803,"PHASE2":29805,"PHASE3":29807,"PHASE4":29809,"NA":29811},{"trials":29798,"activeCount":166,"soonestReadout":104},[29799],{"nctId":100,"briefTitle":101,"status":102,"phases":29800,"primaryCompletion":104,"completion":104,"start":105,"enrollment":106,"conditions":29801,"interventions":29802},[86],[108],[94,110],{"trials":29804,"activeCount":124},[],{"trials":29806,"activeCount":124},[],{"trials":29808,"activeCount":124},[],{"trials":29810,"activeCount":124},[],{"trials":29812,"activeCount":124},[],{"intervention":10676,"totalTrials":166,"cells":29814},{"EARLY_PHASE1":29815,"PHASE1":29821,"PHASE2":29823,"PHASE3":29825,"PHASE4":29827,"NA":29829},{"trials":29816,"activeCount":166,"soonestReadout":10669},[29817],{"nctId":10666,"briefTitle":10667,"status":546,"phases":29818,"primaryCompletion":10669,"completion":10670,"start":10671,"enrollment":1222,"conditions":29819,"interventions":29820},[86],[10673,10674],[1275,1683,6802,10676,10677,1684,10678,10679,10680,10681,10682],{"trials":29822,"activeCount":124},[],{"trials":29824,"activeCount":124},[],{"trials":29826,"activeCount":124},[],{"trials":29828,"activeCount":124},[],{"trials":29830,"activeCount":124},[],{"intervention":10677,"totalTrials":166,"cells":29832},{"EARLY_PHASE1":29833,"PHASE1":29839,"PHASE2":29841,"PHASE3":29843,"PHASE4":29845,"NA":29847},{"trials":29834,"activeCount":166,"soonestReadout":10669},[29835],{"nctId":10666,"briefTitle":10667,"status":546,"phases":29836,"primaryCompletion":10669,"completion":10670,"start":10671,"enrollment":1222,"conditions":29837,"interventions":29838},[86],[10673,10674],[1275,1683,6802,10676,10677,1684,10678,10679,10680,10681,10682],{"trials":29840,"activeCount":124},[],{"trials":29842,"activeCount":124},[],{"trials":29844,"activeCount":124},[],{"trials":29846,"activeCount":124},[],{"trials":29848,"activeCount":124},[],{"intervention":10679,"totalTrials":166,"cells":29850},{"EARLY_PHASE1":29851,"PHASE1":29857,"PHASE2":29859,"PHASE3":29861,"PHASE4":29863,"NA":29865},{"trials":29852,"activeCount":166,"soonestReadout":10669},[29853],{"nctId":10666,"briefTitle":10667,"status":546,"phases":29854,"primaryCompletion":10669,"completion":10670,"start":10671,"enrollment":1222,"conditions":29855,"interventions":29856},[86],[10673,10674],[1275,1683,6802,10676,10677,1684,10678,10679,10680,10681,10682],{"trials":29858,"activeCount":124},[],{"trials":29860,"activeCount":124},[],{"trials":29862,"activeCount":124},[],{"trials":29864,"activeCount":124},[],{"trials":29866,"activeCount":124},[],{"intervention":10682,"totalTrials":166,"cells":29868},{"EARLY_PHASE1":29869,"PHASE1":29875,"PHASE2":29877,"PHASE3":29879,"PHASE4":29881,"NA":29883},{"trials":29870,"activeCount":166,"soonestReadout":10669},[29871],{"nctId":10666,"briefTitle":10667,"status":546,"phases":29872,"primaryCompletion":10669,"completion":10670,"start":10671,"enrollment":1222,"conditions":29873,"interventions":29874},[86],[10673,10674],[1275,1683,6802,10676,10677,1684,10678,10679,10680,10681,10682],{"trials":29876,"activeCount":124},[],{"trials":29878,"activeCount":124},[],{"trials":29880,"activeCount":124},[],{"trials":29882,"activeCount":124},[],{"trials":29884,"activeCount":124},[],{"intervention":29886,"totalTrials":166,"cells":29887},"Alteplase",{"EARLY_PHASE1":29888,"PHASE1":29896,"PHASE2":29898,"PHASE3":29900,"PHASE4":29902,"NA":29904},{"trials":29889,"activeCount":166,"soonestReadout":1299},[29890],{"nctId":29891,"briefTitle":29892,"status":279,"phases":29893,"primaryCompletion":1299,"completion":1299,"start":13484,"enrollment":406,"conditions":29894,"interventions":29895},"NCT06184321","Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion",[86],[359,360],[29886],{"trials":29897,"activeCount":124},[],{"trials":29899,"activeCount":124},[],{"trials":29901,"activeCount":124},[],{"trials":29903,"activeCount":124},[],{"trials":29905,"activeCount":124},[],{"intervention":29907,"totalTrials":166,"cells":29908},"Qutenza Patch",{"EARLY_PHASE1":29909,"PHASE1":29919,"PHASE2":29921,"PHASE3":29923,"PHASE4":29925,"NA":29927},{"trials":29910,"activeCount":166,"soonestReadout":1325},[29911],{"nctId":29912,"briefTitle":29913,"status":279,"phases":29914,"primaryCompletion":1325,"completion":1325,"start":29915,"enrollment":1131,"conditions":29916,"interventions":29918},"NCT06744816","Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study",[86],"2025-12-11",[29917],"Peripheral Neuropathy Due to Chemotherapy",[29907],{"trials":29920,"activeCount":124},[],{"trials":29922,"activeCount":124},[],{"trials":29924,"activeCount":124},[],{"trials":29926,"activeCount":124},[],{"trials":29928,"activeCount":124},[],{"intervention":29930,"totalTrials":121,"cells":29931},"Tc99m sestamibi",{"EARLY_PHASE1":29932,"PHASE1":29934,"PHASE2":29936,"PHASE3":29938,"PHASE4":29940,"NA":29942},{"trials":29933,"activeCount":124},[],{"trials":29935,"activeCount":124},[],{"trials":29937,"activeCount":124},[],{"trials":29939,"activeCount":124},[],{"trials":29941,"activeCount":124},[],{"trials":29943,"activeCount":121,"soonestReadout":224},[29944,29950],{"nctId":29945,"briefTitle":29946,"status":102,"phases":29947,"primaryCompletion":3407,"completion":3407,"start":4578,"enrollment":724,"conditions":29948,"interventions":29949},"NCT02324387","Tc99m Sestamibi Molecular Breast Imaging",[91],[18],[29930],{"nctId":29951,"briefTitle":29952,"status":279,"phases":29953,"primaryCompletion":224,"completion":224,"start":29954,"enrollment":7574,"conditions":29955,"interventions":29956},"NCT05042687","Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer",[91],"2021-12-13",[18],[29930],{"intervention":29958,"totalTrials":296,"cells":29959},"Proflavine",{"EARLY_PHASE1":29960,"PHASE1":29970,"PHASE2":29972,"PHASE3":29980,"PHASE4":29982,"NA":29984},{"trials":29961,"activeCount":124},[29962],{"nctId":29963,"briefTitle":29964,"status":130,"phases":29965,"primaryCompletion":29966,"completion":29966,"start":2436,"enrollment":676,"conditions":29967,"interventions":29968},"NCT02420665","Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia",[86],"2021-05-14",[11077],[29958,29969],"Acetic Acid",{"trials":29971,"activeCount":124},[],{"trials":29973,"activeCount":124},[29974],{"nctId":29975,"briefTitle":29976,"status":203,"phases":29977,"primaryCompletion":10449,"completion":10449,"enrollment":124,"conditions":29978,"interventions":29979},"NCT02095847","High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection",[88],[11078],[29958],{"trials":29981,"activeCount":124},[],{"trials":29983,"activeCount":124},[],{"trials":29985,"activeCount":166,"soonestReadout":281},[29986,29995],{"nctId":29987,"briefTitle":29988,"status":130,"phases":29989,"primaryCompletion":29990,"completion":29990,"start":29991,"enrollment":910,"conditions":29992,"interventions":29994},"NCT02206048","Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix",[91],"2021-04-21","2015-10-02",[29993],"Cervix Carcinoma",[29958],{"nctId":29996,"briefTitle":29997,"status":279,"phases":29998,"primaryCompletion":281,"completion":281,"start":29999,"enrollment":10116,"conditions":30000,"interventions":30002},"NCT01269190","Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery",[91],"2010-12-30",[30001],"Oral Cavity Neoplasm",[29958],{"intervention":30004,"totalTrials":121,"cells":30005},"Indocyanine Green Solution",{"EARLY_PHASE1":30006,"PHASE1":30008,"PHASE2":30010,"PHASE3":30020,"PHASE4":30022,"NA":30024},{"trials":30007,"activeCount":124},[],{"trials":30009,"activeCount":124},[],{"trials":30011,"activeCount":124},[30012],{"nctId":30013,"briefTitle":30014,"status":203,"phases":30015,"primaryCompletion":30016,"completion":30016,"start":30017,"enrollment":124,"conditions":30018,"interventions":30019},"NCT04987281","Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study",[88],"2023-12-27","2022-01-26",[1388,5006,1837],[30004],{"trials":30021,"activeCount":124},[],{"trials":30023,"activeCount":124},[],{"trials":30025,"activeCount":166,"soonestReadout":1527},[30026],{"nctId":30027,"briefTitle":30028,"status":102,"phases":30029,"primaryCompletion":1527,"completion":281,"start":30030,"enrollment":1699,"conditions":30031,"interventions":30037},"NCT01737619","PET\u002FCT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer",[91],"2013-04-03",[30032,30033,30034,30035,30036],"Endometrial Clear Cell Adenocarcinoma","Endometrial Mixed Adenocarcinoma","Endometrial Serous Adenocarcinoma","Grade 3 Endometrial Endometrioid Adenocarcinoma","Malignant Mixed Mesodermal (Mullerian) Tumor",[30004],{"intervention":30039,"totalTrials":121,"cells":30040},"Iodinated Contrast Agent",{"EARLY_PHASE1":30041,"PHASE1":30043,"PHASE2":30045,"PHASE3":30047,"PHASE4":30049,"NA":30051},{"trials":30042,"activeCount":124},[],{"trials":30044,"activeCount":124},[],{"trials":30046,"activeCount":124},[],{"trials":30048,"activeCount":124},[],{"trials":30050,"activeCount":124},[],{"trials":30052,"activeCount":166,"soonestReadout":815},[30053,30060],{"nctId":30054,"briefTitle":30055,"status":130,"phases":30056,"primaryCompletion":30057,"completion":30057,"start":12702,"enrollment":6066,"conditions":30058,"interventions":30059},"NCT05036083","Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion",[91],"2024-03-25",[10005,5079],[30039],{"nctId":30061,"briefTitle":30062,"status":279,"phases":30063,"primaryCompletion":815,"completion":815,"start":30064,"enrollment":1260,"conditions":30065,"interventions":30066},"NCT05056844","Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge",[91],"2021-04-15",[10005],[30039],{"intervention":30068,"totalTrials":166,"cells":30069},"Barium",{"EARLY_PHASE1":30070,"PHASE1":30072,"PHASE2":30074,"PHASE3":30076,"PHASE4":30078,"NA":30080},{"trials":30071,"activeCount":124},[],{"trials":30073,"activeCount":124},[],{"trials":30075,"activeCount":124},[],{"trials":30077,"activeCount":124},[],{"trials":30079,"activeCount":124},[],{"trials":30081,"activeCount":166,"soonestReadout":1299},[30082],{"nctId":30083,"briefTitle":30084,"status":102,"phases":30085,"primaryCompletion":1299,"completion":1299,"start":30086,"enrollment":5312,"conditions":30087,"interventions":30088},"NCT02662907","Cough, Expiratory Training, and Chronic Aspiration After Head and Neck Radiotherapy",[91],"2016-02-01",[242],[30068],{"intervention":29586,"totalTrials":166,"cells":30090},{"EARLY_PHASE1":30091,"PHASE1":30093,"PHASE2":30095,"PHASE3":30097,"PHASE4":30099,"NA":30101},{"trials":30092,"activeCount":124},[],{"trials":30094,"activeCount":124},[],{"trials":30096,"activeCount":124},[],{"trials":30098,"activeCount":124},[],{"trials":30100,"activeCount":124},[],{"trials":30102,"activeCount":166,"soonestReadout":104},[30103],{"nctId":29580,"briefTitle":29581,"status":102,"phases":30104,"primaryCompletion":104,"completion":104,"start":12762,"enrollment":1222,"conditions":30105,"interventions":30106},[91],[1828,5808,3512,29584],[29551,29586],{"intervention":12232,"totalTrials":166,"cells":30108},{"EARLY_PHASE1":30109,"PHASE1":30111,"PHASE2":30113,"PHASE3":30115,"PHASE4":30117,"NA":30119},{"trials":30110,"activeCount":124},[],{"trials":30112,"activeCount":124},[],{"trials":30114,"activeCount":124},[],{"trials":30116,"activeCount":124},[],{"trials":30118,"activeCount":124},[],{"trials":30120,"activeCount":166,"soonestReadout":281},[30121],{"nctId":12224,"briefTitle":12225,"status":279,"phases":30122,"primaryCompletion":281,"completion":281,"start":6635,"enrollment":1131,"conditions":30123,"interventions":30124},[91],[12228,12229,12230],[1013,804,2840,12232,2495,4022,1431,12233,3497,6656,1016],{"intervention":12233,"totalTrials":166,"cells":30126},{"EARLY_PHASE1":30127,"PHASE1":30129,"PHASE2":30131,"PHASE3":30133,"PHASE4":30135,"NA":30137},{"trials":30128,"activeCount":124},[],{"trials":30130,"activeCount":124},[],{"trials":30132,"activeCount":124},[],{"trials":30134,"activeCount":124},[],{"trials":30136,"activeCount":124},[],{"trials":30138,"activeCount":166,"soonestReadout":281},[30139],{"nctId":12224,"briefTitle":12225,"status":279,"phases":30140,"primaryCompletion":281,"completion":281,"start":6635,"enrollment":1131,"conditions":30141,"interventions":30142},[91],[12228,12229,12230],[1013,804,2840,12232,2495,4022,1431,12233,3497,6656,1016],{"intervention":30144,"totalTrials":166,"cells":30145},"VUEWAY",{"EARLY_PHASE1":30146,"PHASE1":30148,"PHASE2":30150,"PHASE3":30152,"PHASE4":30154,"NA":30156},{"trials":30147,"activeCount":124},[],{"trials":30149,"activeCount":124},[],{"trials":30151,"activeCount":124},[],{"trials":30153,"activeCount":124},[],{"trials":30155,"activeCount":124},[],{"trials":30157,"activeCount":166,"soonestReadout":3943},[30158],{"nctId":30159,"briefTitle":30160,"status":546,"phases":30161,"primaryCompletion":3943,"completion":3944,"start":30162,"enrollment":517,"conditions":30163,"interventions":30165},"NCT07415018","Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease",[91],"2026-07-22",[30164],"Leptomeningeal Disease",[30144,30166],"Gadavist",{"intervention":30166,"totalTrials":166,"cells":30168},{"EARLY_PHASE1":30169,"PHASE1":30171,"PHASE2":30173,"PHASE3":30175,"PHASE4":30177,"NA":30179},{"trials":30170,"activeCount":124},[],{"trials":30172,"activeCount":124},[],{"trials":30174,"activeCount":124},[],{"trials":30176,"activeCount":124},[],{"trials":30178,"activeCount":124},[],{"trials":30180,"activeCount":166,"soonestReadout":3943},[30181],{"nctId":30159,"briefTitle":30160,"status":546,"phases":30182,"primaryCompletion":3943,"completion":3944,"start":30162,"enrollment":517,"conditions":30183,"interventions":30184},[91],[30164],[30144,30166],{"intervention":30186,"totalTrials":166,"cells":30187},"Lu-177",{"EARLY_PHASE1":30188,"PHASE1":30190,"PHASE2":30192,"PHASE3":30194,"PHASE4":30196,"NA":30198},{"trials":30189,"activeCount":124},[],{"trials":30191,"activeCount":124},[],{"trials":30193,"activeCount":124},[],{"trials":30195,"activeCount":124},[],{"trials":30197,"activeCount":124},[],{"trials":30199,"activeCount":166,"soonestReadout":549},[30200],{"nctId":30201,"briefTitle":30202,"status":279,"phases":30203,"primaryCompletion":549,"completion":1088,"start":5143,"enrollment":448,"conditions":30204,"interventions":30206},"NCT07169825","Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and\u002For Bone Marrow Function",[91],[30205],"Lu-177 PSMA",[30186],{"intervention":30208,"totalTrials":166,"cells":30209},"Immunotherapeutic Agent",{"EARLY_PHASE1":30210,"PHASE1":30212,"PHASE2":30214,"PHASE3":30216,"PHASE4":30218,"NA":30220},{"trials":30211,"activeCount":124},[],{"trials":30213,"activeCount":124},[],{"trials":30215,"activeCount":124},[],{"trials":30217,"activeCount":124},[],{"trials":30219,"activeCount":124},[],{"trials":30221,"activeCount":166,"soonestReadout":1427},[30222],{"nctId":30223,"briefTitle":30224,"status":102,"phases":30225,"primaryCompletion":1427,"completion":1427,"start":30226,"enrollment":1568,"conditions":30227,"interventions":30228},"NCT04150939","Cryoablation for the Treatment of Metastatic Cancer",[91],"2019-12-23",[2924],[30208],{"intervention":30230,"totalTrials":166,"cells":30231},"Immune Checkpoint Inhibitor",{"EARLY_PHASE1":30232,"PHASE1":30234,"PHASE2":30236,"PHASE3":30238,"PHASE4":30240,"NA":30242},{"trials":30233,"activeCount":124},[],{"trials":30235,"activeCount":124},[],{"trials":30237,"activeCount":124},[],{"trials":30239,"activeCount":124},[],{"trials":30241,"activeCount":124},[],{"trials":30243,"activeCount":166,"soonestReadout":1299},[30244],{"nctId":30245,"briefTitle":30246,"status":279,"phases":30247,"primaryCompletion":1299,"completion":1299,"start":30248,"enrollment":1045,"conditions":30249,"interventions":30250},"NCT04913311","Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer",[],"2021-01-21",[1388],[30230],{"intervention":6044,"totalTrials":166,"cells":30252},{"EARLY_PHASE1":30253,"PHASE1":30255,"PHASE2":30257,"PHASE3":30259,"PHASE4":30261,"NA":30263},{"trials":30254,"activeCount":124},[],{"trials":30256,"activeCount":124},[],{"trials":30258,"activeCount":124},[],{"trials":30260,"activeCount":124},[],{"trials":30262,"activeCount":124},[],{"trials":30264,"activeCount":166,"soonestReadout":193},[30265],{"nctId":6035,"briefTitle":6036,"status":279,"phases":30266,"primaryCompletion":193,"completion":193,"start":6038,"enrollment":195,"conditions":30267,"interventions":30268},[91],[6040,6041,6042],[6044,5802],{"intervention":30270,"totalTrials":166,"cells":30271},"Pneumonia vaccine",{"EARLY_PHASE1":30272,"PHASE1":30274,"PHASE2":30276,"PHASE3":30278,"PHASE4":30280,"NA":30282},{"trials":30273,"activeCount":124},[],{"trials":30275,"activeCount":124},[],{"trials":30277,"activeCount":124},[],{"trials":30279,"activeCount":124},[],{"trials":30281,"activeCount":124},[],{"trials":30283,"activeCount":166,"soonestReadout":30288},[30284],{"nctId":30285,"briefTitle":30286,"status":279,"phases":30287,"primaryCompletion":30288,"completion":30288,"start":30289,"enrollment":1975,"conditions":30290,"interventions":30294},"NCT06181656","Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation",[],"2027-07-04","2024-02-05",[30291,2770,30292,30293],"Pneumococcal Vaccine","Lymphopenia","Chemoradiation",[30270],{"intervention":30296,"totalTrials":166,"cells":30297},"CD34 Positive Stem Cell",{"EARLY_PHASE1":30298,"PHASE1":30300,"PHASE2":30302,"PHASE3":30304,"PHASE4":30306,"NA":30308},{"trials":30299,"activeCount":124},[],{"trials":30301,"activeCount":124},[],{"trials":30303,"activeCount":124},[],{"trials":30305,"activeCount":124},[],{"trials":30307,"activeCount":124},[],{"trials":30309,"activeCount":166,"soonestReadout":4005},[30310],{"nctId":30311,"briefTitle":30312,"status":279,"phases":30313,"primaryCompletion":4005,"completion":4005,"start":12548,"enrollment":4733,"conditions":30314,"interventions":30315},"NCT02438904","Compassionate Access of the Miltenyi Device for CD34+ Cell Selection",[91],[4522],[30296],{"intervention":7805,"totalTrials":3197,"cells":30317},{"EARLY_PHASE1":30318,"PHASE1":30320,"PHASE2":30322,"PHASE3":30339,"PHASE4":30349,"NA":30361},{"trials":30319,"activeCount":124},[],{"trials":30321,"activeCount":124},[],{"trials":30323,"activeCount":124},[30324,30328],{"nctId":7787,"briefTitle":7788,"status":130,"phases":30325,"primaryCompletion":7790,"completion":7790,"start":1958,"enrollment":1568,"conditions":30326,"interventions":30327},[88],[7792,7793,7794,7795,7796,7797,7798,7799,7800,7801,7802],[7804,53,7805],{"nctId":30329,"briefTitle":30330,"status":130,"phases":30331,"primaryCompletion":8113,"completion":8113,"start":30332,"enrollment":473,"conditions":30333,"interventions":30338},"NCT01502072","Respiratory Syncytial Virus - RSV Protocol",[88],"2011-12-28",[30334,30335,30336,30337,5349,4597],"Bone Marrow Transplant Infection","Infection in Marrow Transplant Recipients","Respiratory Syncytial Virus Infections","Respiratory Syncytial Virus Pneumonia",[7805,7805],{"trials":30340,"activeCount":124},[30341],{"nctId":30342,"briefTitle":30343,"status":182,"phases":30344,"primaryCompletion":2316,"completion":2316,"start":4290,"enrollment":166,"conditions":30345,"interventions":30346},"NCT01821963","Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)",[89],[27091],[30347,7805,30348],"Pegylated Interferon Alfa 2a","Telaprevir",{"trials":30350,"activeCount":124},[30351,30355],{"nctId":11211,"briefTitle":11212,"status":182,"phases":30352,"primaryCompletion":958,"completion":958,"start":11214,"enrollment":121,"conditions":30353,"interventions":30354},[90],[1996],[1275,718,11217,11218,11219,7805],{"nctId":30356,"briefTitle":30357,"status":130,"phases":30358,"primaryCompletion":4619,"completion":4619,"start":4665,"enrollment":240,"conditions":30359,"interventions":30360},"NCT00500578","Intermittent Use of Aerosolized Ribavirin for Treatment of RSV",[90],[7246],[7805,7805],{"trials":30362,"activeCount":124},[],{"intervention":23508,"totalTrials":1231,"cells":30364},{"EARLY_PHASE1":30365,"PHASE1":30367,"PHASE2":30369,"PHASE3":30382,"PHASE4":30384,"NA":30394},{"trials":30366,"activeCount":124},[],{"trials":30368,"activeCount":124},[],{"trials":30370,"activeCount":124},[30371,30378],{"nctId":30372,"briefTitle":30373,"status":130,"phases":30374,"primaryCompletion":9923,"completion":9923,"start":10784,"enrollment":550,"conditions":30375,"interventions":30377},"NCT00360438","Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and\u002For Lymphoma at High Risk of TLS",[87,88],[15,21,30376],"Tumor Lysis Syndrome",[23508],{"nctId":23503,"briefTitle":23504,"status":130,"phases":30379,"primaryCompletion":5240,"completion":5240,"start":12066,"enrollment":2581,"conditions":30380,"interventions":30381},[88],[15,21],[23508,1178],{"trials":30383,"activeCount":124},[],{"trials":30385,"activeCount":124},[30386],{"nctId":30387,"briefTitle":30388,"status":130,"phases":30389,"primaryCompletion":4016,"completion":4016,"start":30390,"enrollment":1496,"conditions":30391,"interventions":30392},"NCT04745910","Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome",[90],"2022-04-05",[359,360,30376],[30393,23508],"Pegloticase",{"trials":30395,"activeCount":124},[],{"intervention":30397,"totalTrials":121,"cells":30398},"Nesiritide",{"EARLY_PHASE1":30399,"PHASE1":30401,"PHASE2":30403,"PHASE3":30405,"PHASE4":30407,"NA":30433},{"trials":30400,"activeCount":124},[],{"trials":30402,"activeCount":124},[],{"trials":30404,"activeCount":124},[],{"trials":30406,"activeCount":124},[],{"trials":30408,"activeCount":124},[30409,30422],{"nctId":30410,"briefTitle":30411,"status":182,"phases":30412,"primaryCompletion":30413,"completion":30413,"start":30414,"enrollment":910,"conditions":30415,"interventions":30421},"NCT00083772","Use of Nesiritide in the Management of Acute Diastolic Heart Failure",[90],"2006-04-24","2004-05-17",[28057,30416,30417,30418,30419,30420],"Cardiovascular Disease","Acute Heart Failure","Diastolic Heart Failure","Congestive Heart Failure","Heart Disease",[30397],{"nctId":30423,"briefTitle":30424,"status":182,"phases":30425,"primaryCompletion":30426,"completion":30426,"start":30427,"enrollment":1568,"conditions":30428,"interventions":30432},"NCT00075179","Natrecor in Pulmonary Hypertension",[90],"2006-03-28","2003-12-31",[30429,5349,30430,30431],"Pulmonary Hypertension","Lung Disease","Cardiothoracic Surgery",[30397],{"trials":30434,"activeCount":124},[],{"intervention":30436,"totalTrials":121,"cells":30437},"Sugammadex",{"EARLY_PHASE1":30438,"PHASE1":30440,"PHASE2":30442,"PHASE3":30444,"PHASE4":30446,"NA":30471},{"trials":30439,"activeCount":124},[],{"trials":30441,"activeCount":124},[],{"trials":30443,"activeCount":124},[],{"trials":30445,"activeCount":124},[],{"trials":30447,"activeCount":124},[30448,30460],{"nctId":30449,"briefTitle":30450,"status":130,"phases":30451,"primaryCompletion":30452,"completion":30453,"start":30454,"enrollment":1222,"conditions":30455,"interventions":30456},"NCT03210376","Neuromuscular Blockade on Shoulder Pain of Elderly",[90],"2018-09-30","2020-10-22","2017-11-17",[7647,5799,7652,7656],[30457,30458,30436,30459],"Deep Neuromuscular Blockade","Moderate Neuromuscular Blockade","Neostigmine",{"nctId":30461,"briefTitle":30462,"status":130,"phases":30463,"primaryCompletion":30464,"completion":30465,"start":30466,"enrollment":2700,"conditions":30467,"interventions":30468},"NCT03138967","Investigation of Sugammadex in Outpatient Urological Procedures",[90],"2018-09-01","2019-11-24","2017-09-18",[7656,1293],[30469,30436,30459,30470],"Rocuronium","Glycopyrrolate",{"trials":30472,"activeCount":124},[],{"intervention":30459,"totalTrials":121,"cells":30474},{"EARLY_PHASE1":30475,"PHASE1":30477,"PHASE2":30479,"PHASE3":30481,"PHASE4":30483,"NA":30493},{"trials":30476,"activeCount":124},[],{"trials":30478,"activeCount":124},[],{"trials":30480,"activeCount":124},[],{"trials":30482,"activeCount":124},[],{"trials":30484,"activeCount":124},[30485,30489],{"nctId":30449,"briefTitle":30450,"status":130,"phases":30486,"primaryCompletion":30452,"completion":30453,"start":30454,"enrollment":1222,"conditions":30487,"interventions":30488},[90],[7647,5799,7652,7656],[30457,30458,30436,30459],{"nctId":30461,"briefTitle":30462,"status":130,"phases":30490,"primaryCompletion":30464,"completion":30465,"start":30466,"enrollment":2700,"conditions":30491,"interventions":30492},[90],[7656,1293],[30469,30436,30459,30470],{"trials":30494,"activeCount":124},[],{"intervention":6113,"totalTrials":121,"cells":30496},{"EARLY_PHASE1":30497,"PHASE1":30499,"PHASE2":30501,"PHASE3":30503,"PHASE4":30505,"NA":30519},{"trials":30498,"activeCount":124},[],{"trials":30500,"activeCount":124},[],{"trials":30502,"activeCount":124},[],{"trials":30504,"activeCount":124},[],{"trials":30506,"activeCount":124},[30507,30511],{"nctId":6107,"briefTitle":6108,"status":130,"phases":30508,"primaryCompletion":6110,"completion":6110,"start":4635,"enrollment":381,"conditions":30509,"interventions":30510},[90],[33,5979],[6113,5811],{"nctId":30512,"briefTitle":30513,"status":182,"phases":30514,"primaryCompletion":16135,"completion":16135,"start":30515,"enrollment":1231,"conditions":30516,"interventions":30517},"NCT01812759","Fentanyl for Breakthrough Pain in the Emergency Department",[90],"2014-01-10",[5979],[6113,30518],"Hydromorphone PCA",{"trials":30520,"activeCount":124},[],{"intervention":30522,"totalTrials":166,"cells":30523},"Tolvaptan",{"EARLY_PHASE1":30524,"PHASE1":30526,"PHASE2":30528,"PHASE3":30530,"PHASE4":30532,"NA":30540},{"trials":30525,"activeCount":124},[],{"trials":30527,"activeCount":124},[],{"trials":30529,"activeCount":124},[],{"trials":30531,"activeCount":124},[],{"trials":30533,"activeCount":124},[30534],{"nctId":30535,"briefTitle":30536,"status":130,"phases":30537,"primaryCompletion":8730,"completion":8730,"start":3901,"enrollment":901,"conditions":30538,"interventions":30539},"NCT01199198","Tolvaptan in Hyponatremic Cancer Patients",[90],[33],[30522],{"trials":30541,"activeCount":124},[],{"intervention":155,"totalTrials":166,"cells":30543},{"EARLY_PHASE1":30544,"PHASE1":30546,"PHASE2":30548,"PHASE3":30550,"PHASE4":30552,"NA":30558},{"trials":30545,"activeCount":124},[],{"trials":30547,"activeCount":124},[],{"trials":30549,"activeCount":124},[],{"trials":30551,"activeCount":124},[],{"trials":30553,"activeCount":124},[30554],{"nctId":144,"briefTitle":145,"status":130,"phases":30555,"primaryCompletion":147,"completion":148,"start":149,"enrollment":150,"conditions":30556,"interventions":30557},[90],[152,153],[155,94,156],{"trials":30559,"activeCount":124},[],{"intervention":30393,"totalTrials":166,"cells":30561},{"EARLY_PHASE1":30562,"PHASE1":30564,"PHASE2":30566,"PHASE3":30568,"PHASE4":30570,"NA":30576},{"trials":30563,"activeCount":124},[],{"trials":30565,"activeCount":124},[],{"trials":30567,"activeCount":124},[],{"trials":30569,"activeCount":124},[],{"trials":30571,"activeCount":124},[30572],{"nctId":30387,"briefTitle":30388,"status":130,"phases":30573,"primaryCompletion":4016,"completion":4016,"start":30390,"enrollment":1496,"conditions":30574,"interventions":30575},[90],[359,360,30376],[30393,23508],{"trials":30577,"activeCount":124},[],{"intervention":30579,"totalTrials":166,"cells":30580},"Methoxsalen+ECP",{"EARLY_PHASE1":30581,"PHASE1":30583,"PHASE2":30585,"PHASE3":30587,"PHASE4":30589,"NA":30600},{"trials":30582,"activeCount":124},[],{"trials":30584,"activeCount":124},[],{"trials":30586,"activeCount":124},[],{"trials":30588,"activeCount":124},[],{"trials":30590,"activeCount":124},[30591],{"nctId":30592,"briefTitle":30593,"status":130,"phases":30594,"primaryCompletion":30595,"completion":30595,"start":30596,"enrollment":1483,"conditions":30597,"interventions":30599},"NCT00221039","Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A",[90],"2011-04-05","2004-04-02",[30598,5457],"Cutaneous T Cell Lymphoma",[30579],{"trials":30601,"activeCount":124},[],{"intervention":11217,"totalTrials":166,"cells":30603},{"EARLY_PHASE1":30604,"PHASE1":30606,"PHASE2":30608,"PHASE3":30610,"PHASE4":30612,"NA":30618},{"trials":30605,"activeCount":124},[],{"trials":30607,"activeCount":124},[],{"trials":30609,"activeCount":124},[],{"trials":30611,"activeCount":124},[],{"trials":30613,"activeCount":124},[30614],{"nctId":11211,"briefTitle":11212,"status":182,"phases":30615,"primaryCompletion":958,"completion":958,"start":11214,"enrollment":121,"conditions":30616,"interventions":30617},[90],[1996],[1275,718,11217,11218,11219,7805],{"trials":30619,"activeCount":124},[],{"intervention":11218,"totalTrials":166,"cells":30621},{"EARLY_PHASE1":30622,"PHASE1":30624,"PHASE2":30626,"PHASE3":30628,"PHASE4":30630,"NA":30636},{"trials":30623,"activeCount":124},[],{"trials":30625,"activeCount":124},[],{"trials":30627,"activeCount":124},[],{"trials":30629,"activeCount":124},[],{"trials":30631,"activeCount":124},[30632],{"nctId":11211,"briefTitle":11212,"status":182,"phases":30633,"primaryCompletion":958,"completion":958,"start":11214,"enrollment":121,"conditions":30634,"interventions":30635},[90],[1996],[1275,718,11217,11218,11219,7805],{"trials":30637,"activeCount":124},[],{"intervention":11219,"totalTrials":166,"cells":30639},{"EARLY_PHASE1":30640,"PHASE1":30642,"PHASE2":30644,"PHASE3":30646,"PHASE4":30648,"NA":30654},{"trials":30641,"activeCount":124},[],{"trials":30643,"activeCount":124},[],{"trials":30645,"activeCount":124},[],{"trials":30647,"activeCount":124},[],{"trials":30649,"activeCount":124},[30650],{"nctId":11211,"briefTitle":11212,"status":182,"phases":30651,"primaryCompletion":958,"completion":958,"start":11214,"enrollment":121,"conditions":30652,"interventions":30653},[90],[1996],[1275,718,11217,11218,11219,7805],{"trials":30655,"activeCount":124},[],{"intervention":30457,"totalTrials":166,"cells":30657},{"EARLY_PHASE1":30658,"PHASE1":30660,"PHASE2":30662,"PHASE3":30664,"PHASE4":30666,"NA":30672},{"trials":30659,"activeCount":124},[],{"trials":30661,"activeCount":124},[],{"trials":30663,"activeCount":124},[],{"trials":30665,"activeCount":124},[],{"trials":30667,"activeCount":124},[30668],{"nctId":30449,"briefTitle":30450,"status":130,"phases":30669,"primaryCompletion":30452,"completion":30453,"start":30454,"enrollment":1222,"conditions":30670,"interventions":30671},[90],[7647,5799,7652,7656],[30457,30458,30436,30459],{"trials":30673,"activeCount":124},[],{"intervention":30458,"totalTrials":166,"cells":30675},{"EARLY_PHASE1":30676,"PHASE1":30678,"PHASE2":30680,"PHASE3":30682,"PHASE4":30684,"NA":30690},{"trials":30677,"activeCount":124},[],{"trials":30679,"activeCount":124},[],{"trials":30681,"activeCount":124},[],{"trials":30683,"activeCount":124},[],{"trials":30685,"activeCount":124},[30686],{"nctId":30449,"briefTitle":30450,"status":130,"phases":30687,"primaryCompletion":30452,"completion":30453,"start":30454,"enrollment":1222,"conditions":30688,"interventions":30689},[90],[7647,5799,7652,7656],[30457,30458,30436,30459],{"trials":30691,"activeCount":124},[],{"intervention":6087,"totalTrials":166,"cells":30693},{"EARLY_PHASE1":30694,"PHASE1":30696,"PHASE2":30698,"PHASE3":30700,"PHASE4":30702,"NA":30708},{"trials":30695,"activeCount":124},[],{"trials":30697,"activeCount":124},[],{"trials":30699,"activeCount":124},[],{"trials":30701,"activeCount":124},[],{"trials":30703,"activeCount":124},[30704],{"nctId":6079,"briefTitle":6080,"status":182,"phases":30705,"primaryCompletion":6082,"completion":6082,"start":6083,"enrollment":1231,"conditions":30706,"interventions":30707},[90],[33,6085],[6087,5810,3729],{"trials":30709,"activeCount":124},[],{"intervention":30518,"totalTrials":166,"cells":30711},{"EARLY_PHASE1":30712,"PHASE1":30714,"PHASE2":30716,"PHASE3":30718,"PHASE4":30720,"NA":30726},{"trials":30713,"activeCount":124},[],{"trials":30715,"activeCount":124},[],{"trials":30717,"activeCount":124},[],{"trials":30719,"activeCount":124},[],{"trials":30721,"activeCount":124},[30722],{"nctId":30512,"briefTitle":30513,"status":182,"phases":30723,"primaryCompletion":16135,"completion":16135,"start":30515,"enrollment":1231,"conditions":30724,"interventions":30725},[90],[5979],[6113,30518],{"trials":30727,"activeCount":124},[],{"intervention":30729,"totalTrials":166,"cells":30730},"Regadenoson",{"EARLY_PHASE1":30731,"PHASE1":30733,"PHASE2":30735,"PHASE3":30737,"PHASE4":30739,"NA":30751},{"trials":30732,"activeCount":124},[],{"trials":30734,"activeCount":124},[],{"trials":30736,"activeCount":124},[],{"trials":30738,"activeCount":124},[],{"trials":30740,"activeCount":124},[30741],{"nctId":30742,"briefTitle":30743,"status":130,"phases":30744,"primaryCompletion":30745,"completion":30745,"start":30746,"enrollment":30747,"conditions":30748,"interventions":30750},"NCT02130453","Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking",[90],"2024-06-28","2014-09-30",161,[30749],"Ischemia",[30729],{"trials":30752,"activeCount":124},[],{"intervention":30754,"totalTrials":166,"cells":30755},"Fluciclovine F18",{"EARLY_PHASE1":30756,"PHASE1":30758,"PHASE2":30760,"PHASE3":30762,"PHASE4":30764,"NA":30774},{"trials":30757,"activeCount":124},[],{"trials":30759,"activeCount":124},[],{"trials":30761,"activeCount":124},[],{"trials":30763,"activeCount":124},[],{"trials":30765,"activeCount":124},[30766],{"nctId":30767,"briefTitle":30768,"status":182,"phases":30769,"primaryCompletion":30770,"completion":30770,"start":30771,"enrollment":121,"conditions":30772,"interventions":30773},"NCT04134208","An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer",[90],"2022-06-28","2019-09-19",[3545,3548],[30754],{"trials":30775,"activeCount":124},[],{"intervention":30469,"totalTrials":166,"cells":30777},{"EARLY_PHASE1":30778,"PHASE1":30780,"PHASE2":30782,"PHASE3":30784,"PHASE4":30786,"NA":30792},{"trials":30779,"activeCount":124},[],{"trials":30781,"activeCount":124},[],{"trials":30783,"activeCount":124},[],{"trials":30785,"activeCount":124},[],{"trials":30787,"activeCount":124},[30788],{"nctId":30461,"briefTitle":30462,"status":130,"phases":30789,"primaryCompletion":30464,"completion":30465,"start":30466,"enrollment":2700,"conditions":30790,"interventions":30791},[90],[7656,1293],[30469,30436,30459,30470],{"trials":30793,"activeCount":124},[],{"intervention":30470,"totalTrials":166,"cells":30795},{"EARLY_PHASE1":30796,"PHASE1":30798,"PHASE2":30800,"PHASE3":30802,"PHASE4":30804,"NA":30810},{"trials":30797,"activeCount":124},[],{"trials":30799,"activeCount":124},[],{"trials":30801,"activeCount":124},[],{"trials":30803,"activeCount":124},[],{"trials":30805,"activeCount":124},[30806],{"nctId":30461,"briefTitle":30462,"status":130,"phases":30807,"primaryCompletion":30464,"completion":30465,"start":30466,"enrollment":2700,"conditions":30808,"interventions":30809},[90],[7656,1293],[30469,30436,30459,30470],{"trials":30811,"activeCount":124},[],{"intervention":3847,"totalTrials":3521,"cells":30813},{"EARLY_PHASE1":30814,"PHASE1":30816,"PHASE2":30865,"PHASE3":30944,"PHASE4":30956,"NA":30958},{"trials":30815,"activeCount":124},[],{"trials":30817,"activeCount":124},[30818,30825,30829,30833,30837,30841,30845,30849,30853,30857,30861],{"nctId":30819,"briefTitle":30820,"status":130,"phases":30821,"primaryCompletion":4835,"completion":4835,"start":8753,"enrollment":2647,"conditions":30822,"interventions":30823},"NCT01532011","Erlotinib in Combination With Pralatrexate in Advanced Malignancies",[87],[33,1924],[3847,30824],"Pralatrexate",{"nctId":10757,"briefTitle":10758,"status":130,"phases":30826,"primaryCompletion":5240,"completion":5240,"start":10760,"enrollment":539,"conditions":30827,"interventions":30828},[87],[4107],[1275,3847,1368],{"nctId":12845,"briefTitle":12846,"status":130,"phases":30830,"primaryCompletion":1558,"start":12649,"enrollment":3541,"conditions":30831,"interventions":30832},[87],[33],[3847,1683],{"nctId":14841,"briefTitle":14842,"status":130,"phases":30834,"primaryCompletion":12066,"completion":12066,"start":14844,"enrollment":1496,"conditions":30835,"interventions":30836},[87],[242],[3847,1710],{"nctId":3839,"briefTitle":3840,"status":130,"phases":30838,"primaryCompletion":3842,"completion":3842,"start":3843,"enrollment":676,"conditions":30839,"interventions":30840},[87],[1836,1702,1703,1705,1706,1707,3845],[1709,1710,3847,3848],{"nctId":10897,"briefTitle":10898,"status":130,"phases":30842,"primaryCompletion":1567,"completion":1567,"start":10900,"enrollment":10901,"conditions":30843,"interventions":30844},[87],[1924,1942],[10904,1275,2840,2207,3847],{"nctId":19491,"briefTitle":19492,"status":130,"phases":30846,"primaryCompletion":19494,"completion":19494,"start":19495,"enrollment":910,"conditions":30847,"interventions":30848},[87],[1924],[2283,3847],{"nctId":13421,"briefTitle":13422,"status":130,"phases":30850,"primaryCompletion":3805,"start":4183,"enrollment":163,"conditions":30851,"interventions":30852},[87],[1924],[1028,3847,7180,1402,2207,10918,9894],{"nctId":10910,"briefTitle":10911,"status":130,"phases":30854,"primaryCompletion":10913,"completion":10913,"start":10914,"enrollment":10915,"conditions":30855,"interventions":30856},[87],[1942],[1275,2207,3847,4227,7180,10918,1683],{"nctId":12886,"briefTitle":12887,"status":203,"phases":30858,"primaryCompletion":2121,"start":3832,"enrollment":124,"conditions":30859,"interventions":30860},[87],[33],[1683,3847],{"nctId":10943,"briefTitle":10944,"status":130,"phases":30862,"primaryCompletion":2243,"completion":2243,"start":4192,"enrollment":1766,"conditions":30863,"interventions":30864},[87],[10947],[1275,1368,3847],{"trials":30866,"activeCount":124},[30867,30871,30879,30883,30889,30893,30897,30901,30907,30911,30920,30924,30928,30932,30936,30940],{"nctId":18021,"briefTitle":18022,"status":130,"phases":30868,"primaryCompletion":6367,"completion":6367,"start":16514,"enrollment":1140,"conditions":30869,"interventions":30870},[87,88],[24,10135],[1028,3847],{"nctId":30872,"briefTitle":30873,"status":130,"phases":30874,"primaryCompletion":932,"completion":932,"start":30875,"enrollment":924,"conditions":30876,"interventions":30878},"NCT01198028","Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma",[88],"2011-03-10",[7946,30877],"Recurrent Skin Squamous Cell Carcinoma",[3847],{"nctId":12362,"briefTitle":12363,"status":182,"phases":30880,"primaryCompletion":3725,"start":4697,"enrollment":3197,"conditions":30881,"interventions":30882},[88],[4107],[2369,3847],{"nctId":30884,"briefTitle":30885,"status":130,"phases":30886,"primaryCompletion":5240,"completion":5240,"start":8719,"enrollment":7377,"conditions":30887,"interventions":30888},"NCT00410059","BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC",[88],[24],[3847],{"nctId":22887,"briefTitle":22888,"status":130,"phases":30890,"primaryCompletion":4842,"completion":4842,"start":3987,"enrollment":2446,"conditions":30891,"interventions":30892},[88],[22891],[3847,2330],{"nctId":12430,"briefTitle":12431,"status":130,"phases":30894,"primaryCompletion":12433,"completion":12433,"start":12434,"enrollment":3409,"conditions":30895,"interventions":30896},[87,88],[4107,12436],[12438,2369,3847],{"nctId":11061,"briefTitle":11062,"status":130,"phases":30898,"primaryCompletion":11064,"completion":11064,"start":11065,"enrollment":195,"conditions":30899,"interventions":30900},[88],[1996],[1275,3847],{"nctId":30902,"briefTitle":30903,"status":182,"phases":30904,"primaryCompletion":184,"completion":184,"start":27410,"enrollment":1496,"conditions":30905,"interventions":30906},"NCT01059305","Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin",[88],[4354],[3847],{"nctId":10188,"briefTitle":10189,"status":203,"phases":30908,"primaryCompletion":4834,"start":6367,"enrollment":124,"conditions":30909,"interventions":30910},[87,88],[24],[10193,3847,1376,1369],{"nctId":30912,"briefTitle":30913,"status":130,"phases":30914,"primaryCompletion":30915,"completion":30915,"start":30916,"enrollment":1609,"conditions":30917,"interventions":30918},"NCT00411632","BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",[88],"2018-02-23","2006-11-29",[24],[30919,3847],"Bexarotene",{"nctId":18245,"briefTitle":18246,"status":130,"phases":30921,"primaryCompletion":18248,"completion":18248,"start":18249,"enrollment":18250,"conditions":30922,"interventions":30923},[88],[24],[3847,18047,18253,2207,3847,18253],{"nctId":22911,"briefTitle":22912,"status":182,"phases":30925,"primaryCompletion":13673,"completion":13673,"start":6828,"enrollment":834,"conditions":30926,"interventions":30927},[88],[4107],[2330,3847],{"nctId":5043,"briefTitle":5044,"status":130,"phases":30929,"primaryCompletion":5046,"completion":5046,"start":5047,"enrollment":2581,"conditions":30930,"interventions":30931},[88],[242],[1710,3847,4896],{"nctId":10284,"briefTitle":10285,"status":130,"phases":30933,"primaryCompletion":10287,"completion":10287,"start":3818,"enrollment":1154,"conditions":30934,"interventions":30935},[88],[10135,24],[3847,1369,1376],{"nctId":17672,"briefTitle":17673,"status":182,"phases":30937,"primaryCompletion":2698,"completion":2698,"start":2968,"enrollment":871,"conditions":30938,"interventions":30939},[87,88],[11176,17604],[2405,3847,3497],{"nctId":11184,"briefTitle":11185,"status":130,"phases":30941,"primaryCompletion":3668,"completion":3668,"start":4169,"enrollment":2933,"conditions":30942,"interventions":30943},[88],[1828,1996],[1275,3847],{"trials":30945,"activeCount":124},[30946],{"nctId":30947,"briefTitle":30948,"status":130,"phases":30949,"primaryCompletion":30950,"completion":30950,"start":30951,"enrollment":30952,"conditions":30953,"interventions":30955},"NCT00402779","Erlotinib Prevention of Oral Cancer (EPOC)",[89],"2018-06-04","2006-11-03",303,[30954],"Oral Cancer",[3847],{"trials":30957,"activeCount":124},[],{"trials":30959,"activeCount":124},[],{"intervention":2584,"totalTrials":1568,"cells":30961},{"EARLY_PHASE1":30962,"PHASE1":30964,"PHASE2":30974,"PHASE3":31032,"PHASE4":31038,"NA":31040},{"trials":30963,"activeCount":124},[],{"trials":30965,"activeCount":124},[30966],{"nctId":30967,"briefTitle":30968,"status":130,"phases":30969,"primaryCompletion":4842,"completion":4842,"start":30970,"enrollment":20891,"conditions":30971,"interventions":30972},"NCT00303290","PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML",[87],"2000-01",[3315],[30973,2584],"Peg Interferon Alpha 2b",{"trials":30975,"activeCount":124},[30976,30980,30984,30988,30994,30998,31002,31006,31010,31016,31020,31024,31028],{"nctId":5519,"briefTitle":5520,"status":130,"phases":30977,"primaryCompletion":4382,"completion":4382,"start":5522,"enrollment":492,"conditions":30978,"interventions":30979},[88],[21,15],[5525,5526,5527,803,2424,1070,2293,894,806,2196],{"nctId":20057,"briefTitle":20058,"status":130,"phases":30981,"primaryCompletion":20060,"completion":20060,"start":2580,"enrollment":517,"conditions":30982,"interventions":30983},[87,88],[21],[20063,20064,5247,5526,20065,2584,2293,2374],{"nctId":6754,"briefTitle":6755,"status":130,"phases":30985,"primaryCompletion":6757,"completion":6757,"start":6758,"enrollment":861,"conditions":30986,"interventions":30987},[88],[1122],[803,1016,1013,4330,2374,806,2584,808],{"nctId":30989,"briefTitle":30990,"status":130,"phases":30991,"primaryCompletion":5988,"completion":5988,"start":10075,"enrollment":95,"conditions":30992,"interventions":30993},"NCT00382590","Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)\u002F Myelodysplastic Syndrome (MDS) Patients",[88],[4659,30,15],[13589,2584,9894],{"nctId":16018,"briefTitle":16019,"status":130,"phases":30995,"primaryCompletion":3901,"completion":3901,"start":5733,"enrollment":959,"conditions":30996,"interventions":30997},[87,88],[2391,36,16022],[655,2207,2584],{"nctId":20546,"briefTitle":20547,"status":130,"phases":30999,"primaryCompletion":5988,"completion":5988,"start":12101,"enrollment":20549,"conditions":31000,"interventions":31001},[88],[36,30],[2423,2584],{"nctId":2577,"briefTitle":2578,"status":130,"phases":31003,"primaryCompletion":1558,"completion":1558,"start":2580,"enrollment":2581,"conditions":31004,"interventions":31005},[88],[21],[803,1114,1016,806,2584,62,2374,2585],{"nctId":10510,"briefTitle":10511,"status":130,"phases":31007,"primaryCompletion":4723,"completion":4723,"start":3988,"enrollment":593,"conditions":31008,"interventions":31009},[87,88],[4659,30,15],[510,2584],{"nctId":31011,"briefTitle":31012,"status":130,"phases":31013,"primaryCompletion":10075,"completion":9923,"start":8415,"enrollment":1496,"conditions":31014,"interventions":31015},"NCT00451997","Gleevec\u002FLow-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes",[88],[20609,1036],[17901,2584],{"nctId":2674,"briefTitle":2675,"status":130,"phases":31017,"primaryCompletion":2677,"completion":2677,"start":2678,"enrollment":2004,"conditions":31018,"interventions":31019},[88],[15],[894,2681,803,1013,1114,2682,2683,806,2584,2374,1071,62],{"nctId":20603,"briefTitle":20604,"status":130,"phases":31021,"primaryCompletion":20606,"completion":20606,"start":20607,"enrollment":1034,"conditions":31022,"interventions":31023},[88],[20609,1036],[20611,2584],{"nctId":20448,"briefTitle":20449,"status":130,"phases":31025,"primaryCompletion":2828,"completion":11731,"start":9828,"enrollment":2018,"conditions":31026,"interventions":31027},[88],[15],[20453,2584,2374],{"nctId":2833,"briefTitle":2834,"status":130,"phases":31029,"primaryCompletion":2232,"completion":2232,"start":2836,"enrollment":628,"conditions":31030,"interventions":31031},[87,88],[15,2838],[2840,803,1016,1013,62,1114,806,2584,2841,2374],{"trials":31033,"activeCount":124},[31034],{"nctId":4321,"briefTitle":4322,"status":130,"phases":31035,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":31036,"interventions":31037},[89],[21],[1070,4329,4330,894,3671,1013,1016,4331,803,2424,1709,2584,4332,4333,809],{"trials":31039,"activeCount":124},[],{"trials":31041,"activeCount":124},[],{"intervention":3808,"totalTrials":1496,"cells":31043},{"EARLY_PHASE1":31044,"PHASE1":31046,"PHASE2":31062,"PHASE3":31095,"PHASE4":31109,"NA":31111},{"trials":31045,"activeCount":124},[],{"trials":31047,"activeCount":124},[31048,31052],{"nctId":3802,"briefTitle":3803,"status":130,"phases":31049,"primaryCompletion":3805,"start":2580,"enrollment":1131,"conditions":31050,"interventions":31051},[87],[24],[3808,1709,3809],{"nctId":31053,"briefTitle":31054,"status":130,"phases":31055,"primaryCompletion":31056,"completion":31056,"start":31057,"enrollment":492,"conditions":31058,"interventions":31060},"NCT00685568","Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis",[87],"2006-04-21","2002-11-21",[3195,31059],"Precancerous Condition",[31061],"celecoxib",{"trials":31063,"activeCount":124},[31064,31070,31074,31078,31082,31086],{"nctId":31065,"briefTitle":31066,"status":182,"phases":31067,"primaryCompletion":4697,"completion":4697,"start":2213,"enrollment":166,"conditions":31068,"interventions":31069},"NCT00527982","Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer",[88],[242,24],[3808],{"nctId":17618,"briefTitle":17619,"status":130,"phases":31071,"primaryCompletion":3996,"completion":3996,"start":2580,"enrollment":1308,"conditions":31072,"interventions":31073},[88],[17622,17604,11176],[1368,3808,3497,17554,17624],{"nctId":12165,"briefTitle":12166,"status":182,"phases":31075,"primaryCompletion":12168,"completion":7473,"start":4086,"enrollment":2779,"conditions":31076,"interventions":31077},[88],[7818,27],[3808,804],{"nctId":17659,"briefTitle":17660,"status":130,"phases":31079,"primaryCompletion":2602,"completion":2602,"start":2213,"enrollment":16699,"conditions":31080,"interventions":31081},[88],[11302,17604],[3808,17616,3497,2383],{"nctId":20916,"briefTitle":20917,"status":130,"phases":31083,"primaryCompletion":5663,"completion":5663,"start":3214,"enrollment":3521,"conditions":31084,"interventions":31085},[88],[4107],[3808,4135],{"nctId":31087,"briefTitle":31088,"status":130,"phases":31089,"primaryCompletion":31090,"completion":31090,"start":31091,"enrollment":240,"conditions":31092,"interventions":31094},"NCT00503035","Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers",[88],"2021-04-02","2003-08-20",[31093],"Familial Adenomatous Polyposis",[3808],{"trials":31096,"activeCount":124},[31097,31101],{"nctId":17947,"briefTitle":17948,"status":182,"phases":31098,"primaryCompletion":5556,"completion":5556,"start":4084,"enrollment":95,"conditions":31099,"interventions":31100},[89],[18,3195,5979],[1368,3808],{"nctId":31102,"briefTitle":31103,"status":130,"phases":31104,"primaryCompletion":5470,"completion":3833,"start":20733,"enrollment":31105,"conditions":31106,"interventions":31108},"NCT00981201","Celecoxib as a Chemopreventive Agent in Current and Former Smokers",[89],219,[119,31107],"Prevention",[3808,3808],{"trials":31110,"activeCount":124},[],{"trials":31112,"activeCount":124},[],{"intervention":4365,"totalTrials":186,"cells":31114},{"EARLY_PHASE1":31115,"PHASE1":31117,"PHASE2":31123,"PHASE3":31145,"PHASE4":31155,"NA":31157},{"trials":31116,"activeCount":124},[],{"trials":31118,"activeCount":124},[31119],{"nctId":5439,"briefTitle":5440,"status":130,"phases":31120,"primaryCompletion":5442,"completion":5442,"start":5443,"enrollment":1240,"conditions":31121,"interventions":31122},[87],[21,5445],[5447,4365,2424,654,2293],{"trials":31124,"activeCount":124},[31125,31129,31133,31137,31141],{"nctId":5546,"briefTitle":5547,"status":130,"phases":31126,"primaryCompletion":5434,"completion":5434,"start":3902,"enrollment":5549,"conditions":31127,"interventions":31128},[88],[21],[4365,2424,654,2293,894],{"nctId":5562,"briefTitle":5563,"status":130,"phases":31130,"primaryCompletion":5565,"completion":5565,"start":5566,"enrollment":406,"conditions":31131,"interventions":31132},[88],[5568,21],[2450,4365,2424,654,2293,894],{"nctId":5591,"briefTitle":5592,"status":130,"phases":31134,"primaryCompletion":5594,"completion":5594,"start":5595,"enrollment":517,"conditions":31135,"interventions":31136},[88],[785,359,5597,21],[3085,75,4365,654,2424,1069,2293,806,894,2196],{"nctId":5626,"briefTitle":5627,"status":130,"phases":31138,"primaryCompletion":5629,"completion":5629,"start":5630,"enrollment":492,"conditions":31139,"interventions":31140},[88],[891,4559,5632,5633,4561,5634,5635],[4365,5515,654,2424,1069,1402,2293,894],{"nctId":5694,"briefTitle":5695,"status":203,"phases":31142,"primaryCompletion":5697,"completion":5697,"start":5697,"enrollment":124,"conditions":31143,"interventions":31144},[87,88],[3039,891,4559,5632,3277,4561,5634],[4365,654,2424,1069,2293,894,5700],{"trials":31146,"activeCount":124},[31147,31151],{"nctId":4357,"briefTitle":4358,"status":130,"phases":31148,"primaryCompletion":4360,"completion":4360,"start":4361,"enrollment":4362,"conditions":31149,"interventions":31150},[89],[18],[1069,4365,1709,803,2424,1254],{"nctId":4367,"briefTitle":4368,"status":130,"phases":31152,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":31153,"interventions":31154},[89],[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":31156,"activeCount":124},[],{"trials":31158,"activeCount":124},[],{"intervention":4109,"totalTrials":1483,"cells":31160},{"EARLY_PHASE1":31161,"PHASE1":31163,"PHASE2":31171,"PHASE3":31192,"PHASE4":31202,"NA":31204},{"trials":31162,"activeCount":124},[],{"trials":31164,"activeCount":124},[31165],{"nctId":31166,"briefTitle":31167,"status":130,"phases":31168,"primaryCompletion":185,"completion":185,"start":3214,"enrollment":1922,"conditions":31169,"interventions":31170},"NCT00082719","Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium",[87],[1293,4043],[4109],{"trials":31172,"activeCount":124},[31173,31180,31184,31188],{"nctId":31174,"briefTitle":31175,"status":130,"phases":31176,"primaryCompletion":4193,"completion":4193,"start":31177,"enrollment":834,"conditions":31178,"interventions":31179},"NCT00002965","Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas",[88],"1997-01",[11302],[4109],{"nctId":4102,"briefTitle":4103,"status":130,"phases":31181,"primaryCompletion":4085,"completion":4085,"start":4105,"enrollment":1409,"conditions":31182,"interventions":31183},[88],[4107],[4109,1709,1371],{"nctId":5645,"briefTitle":5646,"status":130,"phases":31185,"primaryCompletion":2953,"completion":2953,"start":5648,"enrollment":195,"conditions":31186,"interventions":31187},[88],[21],[4109,803,2424,1114],{"nctId":9824,"briefTitle":9825,"status":130,"phases":31189,"primaryCompletion":9827,"completion":9827,"start":9828,"enrollment":861,"conditions":31190,"interventions":31191},[88],[15],[4109,654,634],{"trials":31193,"activeCount":124},[31194,31198],{"nctId":4347,"briefTitle":4348,"status":130,"phases":31195,"primaryCompletion":4350,"completion":4351,"start":4352,"enrollment":342,"conditions":31196,"interventions":31197},[89],[1729,4354],[1599,4109,1709,1869,1868],{"nctId":4367,"briefTitle":4368,"status":130,"phases":31199,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":31200,"interventions":31201},[89],[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":31203,"activeCount":124},[],{"trials":31205,"activeCount":124},[],{"intervention":17901,"totalTrials":1483,"cells":31207},{"EARLY_PHASE1":31208,"PHASE1":31210,"PHASE2":31219,"PHASE3":31250,"PHASE4":31259,"NA":31261},{"trials":31209,"activeCount":124},[],{"trials":31211,"activeCount":124},[31212],{"nctId":31213,"briefTitle":31214,"status":130,"phases":31215,"primaryCompletion":2528,"completion":2528,"start":7400,"enrollment":134,"conditions":31216,"interventions":31217},"NCT00040105","Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia",[87],[5244],[31218,17901],"Zarnestra",{"trials":31220,"activeCount":124},[31221,31225,31233,31237,31243],{"nctId":31011,"briefTitle":31012,"status":130,"phases":31222,"primaryCompletion":10075,"completion":9923,"start":8415,"enrollment":1496,"conditions":31223,"interventions":31224},[88],[20609,1036],[17901,2584],{"nctId":31226,"briefTitle":31227,"status":182,"phases":31228,"primaryCompletion":4162,"completion":4162,"start":7487,"enrollment":31229,"conditions":31230,"interventions":31232},"NCT00038649","Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C",[88],117,[31231],"Myelogenous Leukemia, Chronic, Chronic Phase",[17901],{"nctId":17894,"briefTitle":17895,"status":182,"phases":31234,"primaryCompletion":8719,"completion":17897,"start":4647,"enrollment":871,"conditions":31235,"interventions":31236},[87,88],[3305,17318],[1368,17900,17901],{"nctId":31238,"briefTitle":31239,"status":130,"phases":31240,"primaryCompletion":2969,"completion":8730,"start":4040,"enrollment":2997,"conditions":31241,"interventions":31242},"NCT01092741","Late Chronic Phase Chronic Myelogenous Leukemia",[88],[15],[17901],{"nctId":31244,"briefTitle":31245,"status":130,"phases":31246,"primaryCompletion":2890,"completion":17897,"start":2699,"enrollment":676,"conditions":31247,"interventions":31249},"NCT00048672","Therapy of Early Chronic Phase CML With Gleevec",[88],[31248],"Leukemia, Myeloid, Chronic-Phase",[17901],{"trials":31251,"activeCount":124},[31252],{"nctId":31253,"briefTitle":31254,"status":130,"phases":31255,"primaryCompletion":9923,"completion":10938,"start":5241,"enrollment":25,"conditions":31256,"interventions":31257},"NCT00050531","High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)",[89],[5244],[17901,31258,4387],"Peg-alpha interferon",{"trials":31260,"activeCount":124},[],{"trials":31262,"activeCount":124},[],{"intervention":2371,"totalTrials":230,"cells":31264},{"EARLY_PHASE1":31265,"PHASE1":31267,"PHASE2":31269,"PHASE3":31291,"PHASE4":31301,"NA":31303},{"trials":31266,"activeCount":124},[],{"trials":31268,"activeCount":124},[],{"trials":31270,"activeCount":124},[31271,31275,31279,31283,31287],{"nctId":2361,"briefTitle":2362,"status":203,"phases":31272,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":124,"conditions":31273,"interventions":31274},[88],[21],[2368,2340,2369,1004,2293,894,62,2370,2371,2372,2373,2374],{"nctId":2397,"briefTitle":2398,"status":130,"phases":31276,"primaryCompletion":2400,"completion":2400,"start":2401,"enrollment":2402,"conditions":31277,"interventions":31278},[87,88],[33,21],[510,2405,2369,1004,2293,62,2371,2372,894],{"nctId":2598,"briefTitle":2599,"status":203,"phases":31280,"primaryCompletion":2601,"start":2602,"enrollment":124,"conditions":31281,"interventions":31282},[88],[2245],[2227,2605,2369,1004,2293,2368,62,2370,2371,2372],{"nctId":4831,"briefTitle":4832,"status":203,"phases":31284,"primaryCompletion":4834,"start":4835,"enrollment":124,"conditions":31285,"interventions":31286},[87,88],[21],[1004,2370,2371,2372,2235,510,2369,2293],{"nctId":2897,"briefTitle":2898,"status":182,"phases":31288,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":186,"conditions":31289,"interventions":31290},[87,88],[21],[1402,2405,2369,1004,2293,894,62,2370,2371,2372,2904,2368],{"trials":31292,"activeCount":124},[31293],{"nctId":31294,"briefTitle":31295,"status":182,"phases":31296,"primaryCompletion":31297,"completion":31297,"start":31298,"enrollment":2337,"conditions":31299,"interventions":31300},"NCT01952847","Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis",[89],"2021-03-03","2014-07-10",[33],[2371],{"trials":31302,"activeCount":124},[],{"trials":31304,"activeCount":124},[],{"intervention":1373,"totalTrials":230,"cells":31306},{"EARLY_PHASE1":31307,"PHASE1":31309,"PHASE2":31315,"PHASE3":31333,"PHASE4":31339,"NA":31341},{"trials":31308,"activeCount":124},[],{"trials":31310,"activeCount":124},[31311],{"nctId":1337,"briefTitle":1338,"status":182,"phases":31312,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":31313,"interventions":31314},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"trials":31316,"activeCount":124},[31317,31321,31325,31329],{"nctId":2506,"briefTitle":2507,"status":182,"phases":31318,"primaryCompletion":2509,"completion":2509,"start":2510,"enrollment":296,"conditions":31319,"interventions":31320},[88],[2512,2502,2472],[803,654,62,804,2477,1373,805,806,2425,809,894,810],{"nctId":2515,"briefTitle":2516,"status":182,"phases":31322,"primaryCompletion":2518,"completion":2518,"start":2519,"enrollment":230,"conditions":31323,"interventions":31324},[88],[2521,1142,1144],[1083,803,654,62,1069,1373,805,806,1071,894,810],{"nctId":11297,"briefTitle":11298,"status":130,"phases":31326,"primaryCompletion":9512,"completion":10760,"start":11300,"enrollment":296,"conditions":31327,"interventions":31328},[88],[11302],[11304,1373,11305,806,809,11306,810],{"nctId":4166,"briefTitle":4167,"status":130,"phases":31330,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":31331,"interventions":31332},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"trials":31334,"activeCount":124},[31335],{"nctId":4367,"briefTitle":4368,"status":130,"phases":31336,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":31337,"interventions":31338},[89],[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":31340,"activeCount":124},[],{"trials":31342,"activeCount":124},[],{"intervention":4331,"totalTrials":3197,"cells":31344},{"EARLY_PHASE1":31345,"PHASE1":31347,"PHASE2":31349,"PHASE3":31363,"PHASE4":31373,"NA":31375},{"trials":31346,"activeCount":124},[],{"trials":31348,"activeCount":124},[],{"trials":31350,"activeCount":124},[31351,31355,31359],{"nctId":8320,"briefTitle":8321,"status":130,"phases":31352,"primaryCompletion":8323,"completion":8323,"start":8324,"enrollment":8325,"conditions":31353,"interventions":31354},[88],[8327,8328,8329],[4331,1869,804,894,1868],{"nctId":20779,"briefTitle":20780,"status":130,"phases":31356,"primaryCompletion":7399,"completion":7399,"start":20782,"enrollment":1328,"conditions":31357,"interventions":31358},[88],[21],[20785,2977,4331,4156,1869],{"nctId":8750,"briefTitle":8751,"status":130,"phases":31360,"primaryCompletion":8753,"completion":8753,"start":2699,"enrollment":226,"conditions":31361,"interventions":31362},[88],[21],[894,2977,4331,1868,1869],{"trials":31364,"activeCount":124},[31365,31369],{"nctId":20730,"briefTitle":20731,"status":130,"phases":31366,"primaryCompletion":2847,"completion":3902,"start":20733,"enrollment":448,"conditions":31367,"interventions":31368},[89],[20735],[11877,2977,4331,1868,20737],{"nctId":4321,"briefTitle":4322,"status":130,"phases":31370,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":31371,"interventions":31372},[89],[21],[1070,4329,4330,894,3671,1013,1016,4331,803,2424,1709,2584,4332,4333,809],{"trials":31374,"activeCount":124},[],{"trials":31376,"activeCount":124},[],{"intervention":17616,"totalTrials":3197,"cells":31378},{"EARLY_PHASE1":31379,"PHASE1":31381,"PHASE2":31383,"PHASE3":31402,"PHASE4":31416,"NA":31418},{"trials":31380,"activeCount":124},[],{"trials":31382,"activeCount":124},[],{"trials":31384,"activeCount":124},[31385,31389,31393],{"nctId":17608,"briefTitle":17609,"status":182,"phases":31386,"primaryCompletion":17611,"completion":17611,"start":17612,"enrollment":2581,"conditions":31387,"interventions":31388},[87,88],[17604,17614],[2405,17616,3497],{"nctId":17659,"briefTitle":17660,"status":130,"phases":31390,"primaryCompletion":2602,"completion":2602,"start":2213,"enrollment":16699,"conditions":31391,"interventions":31392},[88],[11302,17604],[3808,17616,3497,2383],{"nctId":31394,"briefTitle":31395,"status":130,"phases":31396,"primaryCompletion":31397,"completion":31397,"start":31398,"enrollment":2911,"conditions":31399,"interventions":31401},"NCT00038376","Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies",[88],"2005-06-30","1990-05-08",[31400,5457,20500],"Lymphoma, T-Cell",[17616,5681],{"trials":31403,"activeCount":124},[31404,31410],{"nctId":31405,"briefTitle":31406,"status":203,"phases":31407,"enrollment":124,"conditions":31408,"interventions":31409},"NCT00003564","Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas",[89],[11302],[17616,11306],{"nctId":31411,"briefTitle":31412,"status":203,"phases":31413,"enrollment":124,"conditions":31414,"interventions":31415},"NCT00003599","Vitamin E in Preventing the Side Effects of Isotretinoin in Former and Current Smokers Who Are Receiving Isotretinoin to Prevent Lung Cancer",[89],[24],[17616],{"trials":31417,"activeCount":124},[],{"trials":31419,"activeCount":124},[],{"intervention":31421,"totalTrials":3197,"cells":31422},"Fenretinide",{"EARLY_PHASE1":31423,"PHASE1":31425,"PHASE2":31435,"PHASE3":31451,"PHASE4":31469,"NA":31471},{"trials":31424,"activeCount":124},[],{"trials":31426,"activeCount":124},[31427],{"nctId":31428,"briefTitle":31429,"status":182,"phases":31430,"primaryCompletion":10260,"completion":8719,"start":31431,"enrollment":166,"conditions":31432,"interventions":31433},"NCT00102635","4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)",[87],"2005-01-20",[242],[31421,31434],"SCH66336",{"trials":31436,"activeCount":124},[31437,31445],{"nctId":31438,"briefTitle":31439,"status":130,"phases":31440,"primaryCompletion":2945,"completion":10272,"start":31441,"enrollment":901,"conditions":31442,"interventions":31443},"NCT00003099","Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer",[88],"1996-05",[18],[31421,31444],"Tamoxifen Citrate",{"nctId":31446,"briefTitle":31447,"status":130,"phases":31448,"primaryCompletion":12101,"completion":12101,"start":13863,"enrollment":95,"conditions":31449,"interventions":31450},"NCT00006471","Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",[88],[242],[31421],{"trials":31452,"activeCount":124},[31453,31461],{"nctId":31454,"briefTitle":31455,"status":130,"phases":31456,"primaryCompletion":31457,"completion":31457,"start":31458,"enrollment":20949,"conditions":31459,"interventions":31460},"NCT00004154","Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer",[89],"2005-03-01","1998-07-30",[1293],[31421],{"nctId":31462,"briefTitle":31463,"status":130,"phases":31464,"primaryCompletion":31465,"completion":31465,"start":31466,"enrollment":2865,"conditions":31467,"interventions":31468},"NCT00003075","Fenretinide in Treating Patients With Cervical Neoplasia",[89],"2001-05-01","1993-03-05",[11077,31059],[31421],{"trials":31470,"activeCount":124},[],{"trials":31472,"activeCount":124},[],{"intervention":3718,"totalTrials":3197,"cells":31474},{"EARLY_PHASE1":31475,"PHASE1":31477,"PHASE2":31483,"PHASE3":31501,"PHASE4":31507,"NA":31509},{"trials":31476,"activeCount":124},[],{"trials":31478,"activeCount":124},[31479],{"nctId":21262,"briefTitle":21263,"status":130,"phases":31480,"primaryCompletion":185,"start":5988,"enrollment":1766,"conditions":31481,"interventions":31482},[87],[27],[3718,3719,15690,21267],{"trials":31484,"activeCount":124},[31485,31493,31497],{"nctId":31486,"briefTitle":31487,"status":130,"phases":31488,"primaryCompletion":3805,"completion":3805,"start":10977,"enrollment":4551,"conditions":31489,"interventions":31490},"NCT00254397","Melanoma Vaccine With Peptides and Leuprolide",[88],[1729],[3718,31491,31492],"GP100: 209-217(210M) Peptide","MAGE-3 Peptide",{"nctId":14916,"briefTitle":14917,"status":130,"phases":31494,"primaryCompletion":8551,"completion":8551,"start":6758,"enrollment":2865,"conditions":31495,"interventions":31496},[88],[27],[1710,2321,3718,11343],{"nctId":3711,"briefTitle":3712,"status":182,"phases":31498,"primaryCompletion":3714,"completion":3714,"start":3715,"enrollment":406,"conditions":31499,"interventions":31500},[88],[27],[1049,3718,3719,3720],{"trials":31502,"activeCount":124},[31503],{"nctId":22667,"briefTitle":22668,"status":182,"phases":31504,"primaryCompletion":12066,"completion":12066,"start":11135,"enrollment":2865,"conditions":31505,"interventions":31506},[89],[27],[11341,3718,3719,11342],{"trials":31508,"activeCount":124},[],{"trials":31510,"activeCount":124},[],{"intervention":17844,"totalTrials":296,"cells":31512},{"EARLY_PHASE1":31513,"PHASE1":31515,"PHASE2":31517,"PHASE3":31534,"PHASE4":31542,"NA":31544},{"trials":31514,"activeCount":124},[],{"trials":31516,"activeCount":124},[],{"trials":31518,"activeCount":124},[31519,31526,31530],{"nctId":31520,"briefTitle":31521,"status":130,"phases":31522,"primaryCompletion":4843,"completion":4843,"start":6384,"enrollment":95,"conditions":31523,"interventions":31524},"NCT00490698","Zoledronate With Atorvastatin in Renal Cell Carcinoma",[88],[1333,1521],[31525,17844],"Zoledronate",{"nctId":17837,"briefTitle":17838,"status":182,"phases":31527,"primaryCompletion":17840,"completion":17840,"start":17841,"enrollment":230,"conditions":31528,"interventions":31529},[88],[13134,7308,7309,7310,7311,7698,7699,10007,7701,13138,7313,7314,7315,7316,5085,5086,5087,5088,5089,1363],[17844,1368],{"nctId":21686,"briefTitle":21687,"status":130,"phases":31531,"primaryCompletion":21689,"completion":21689,"start":21690,"enrollment":2779,"conditions":31532,"interventions":31533},[88],[21692,5122,21693,21694],[17844,21651],{"trials":31535,"activeCount":124},[31536],{"nctId":31537,"briefTitle":31538,"status":182,"phases":31539,"primaryCompletion":2212,"completion":2212,"start":6757,"enrollment":121,"conditions":31540,"interventions":31541},"NCT01259284","Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer",[88,89],[33],[17844],{"trials":31543,"activeCount":124},[],{"trials":31545,"activeCount":124},[],{"intervention":259,"totalTrials":296,"cells":31547},{"EARLY_PHASE1":31548,"PHASE1":31550,"PHASE2":31552,"PHASE3":31569,"PHASE4":31579,"NA":31581},{"trials":31549,"activeCount":124},[],{"trials":31551,"activeCount":124},[],{"trials":31553,"activeCount":124},[31554,31562],{"nctId":31555,"briefTitle":31556,"status":182,"phases":31557,"primaryCompletion":2289,"completion":2289,"start":3571,"enrollment":166,"conditions":31558,"interventions":31559},"NCT01219673","Symptom Burden in Head and Neck Cancer",[87,88],[22891],[31560,31561,259],"Armodafinil","Minocycline",{"nctId":31563,"briefTitle":31564,"status":203,"phases":31565,"enrollment":124,"conditions":31566,"interventions":31568},"NCT01048983","Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)",[87,88],[31567],"Non Small Cell Lung Cancer",[31560,259,31561,18140],{"trials":31570,"activeCount":124},[31571,31575],{"nctId":251,"briefTitle":252,"status":130,"phases":31572,"primaryCompletion":254,"completion":254,"start":255,"enrollment":256,"conditions":31573,"interventions":31574},[88,89],[153,108],[259,156],{"nctId":261,"briefTitle":262,"status":130,"phases":31576,"primaryCompletion":264,"completion":265,"start":266,"enrollment":267,"conditions":31577,"interventions":31578},[89],[108],[156,259],{"trials":31580,"activeCount":124},[],{"trials":31582,"activeCount":124},[],{"intervention":3719,"totalTrials":296,"cells":31584},{"EARLY_PHASE1":31585,"PHASE1":31587,"PHASE2":31593,"PHASE3":31599,"PHASE4":31611,"NA":31613},{"trials":31586,"activeCount":124},[],{"trials":31588,"activeCount":124},[31589],{"nctId":21262,"briefTitle":21263,"status":130,"phases":31590,"primaryCompletion":185,"start":5988,"enrollment":1766,"conditions":31591,"interventions":31592},[87],[27],[3718,3719,15690,21267],{"trials":31594,"activeCount":124},[31595],{"nctId":3711,"briefTitle":3712,"status":182,"phases":31596,"primaryCompletion":3714,"completion":3714,"start":3715,"enrollment":406,"conditions":31597,"interventions":31598},[88],[27],[1049,3718,3719,3720],{"trials":31600,"activeCount":124},[31601,31605],{"nctId":22667,"briefTitle":22668,"status":182,"phases":31602,"primaryCompletion":12066,"completion":12066,"start":11135,"enrollment":2865,"conditions":31603,"interventions":31604},[89],[27],[11341,3718,3719,11342],{"nctId":31606,"briefTitle":31607,"status":182,"phases":31608,"primaryCompletion":9859,"completion":9859,"start":2317,"enrollment":166,"conditions":31609,"interventions":31610},"NCT00429403","Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer",[89],[18],[3719],{"trials":31612,"activeCount":124},[],{"trials":31614,"activeCount":124},[],{"intervention":4174,"totalTrials":1231,"cells":31616},{"EARLY_PHASE1":31617,"PHASE1":31619,"PHASE2":31621,"PHASE3":31627,"PHASE4":31637,"NA":31639},{"trials":31618,"activeCount":124},[],{"trials":31620,"activeCount":124},[],{"trials":31622,"activeCount":124},[31623],{"nctId":4166,"briefTitle":4167,"status":130,"phases":31624,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":31625,"interventions":31626},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"trials":31628,"activeCount":124},[31629,31633],{"nctId":4305,"briefTitle":4306,"status":130,"phases":31630,"primaryCompletion":4308,"completion":4308,"start":4309,"enrollment":2402,"conditions":31631,"interventions":31632},[89],[21],[4312,4313,4045,2879,2880,2882,4314,4315,4047,4316,4317,4318,4319,2884],{"nctId":4367,"briefTitle":4368,"status":130,"phases":31634,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":31635,"interventions":31636},[89],[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":31638,"activeCount":124},[],{"trials":31640,"activeCount":124},[],{"intervention":31642,"totalTrials":1231,"cells":31643},"Palonosetron",{"EARLY_PHASE1":31644,"PHASE1":31646,"PHASE2":31648,"PHASE3":31662,"PHASE4":31673,"NA":31675},{"trials":31645,"activeCount":124},[],{"trials":31647,"activeCount":124},[],{"trials":31649,"activeCount":124},[31650,31656],{"nctId":31651,"briefTitle":31652,"status":130,"phases":31653,"primaryCompletion":8306,"completion":8306,"start":8719,"enrollment":406,"conditions":31654,"interventions":31655},"NCT00412425","Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting",[87,88],[1729],[31642],{"nctId":31657,"briefTitle":31658,"status":130,"phases":31659,"primaryCompletion":3833,"completion":3833,"start":2213,"enrollment":1045,"conditions":31660,"interventions":31661},"NCT01031498","Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting",[88],[4659,2935],[2793,31642],{"trials":31663,"activeCount":124},[31664],{"nctId":31665,"briefTitle":31666,"status":130,"phases":31667,"primaryCompletion":2061,"completion":2061,"start":31668,"enrollment":1140,"conditions":31669,"interventions":31670},"NCT03040726","Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer",[88,89],"2017-05-03",[2613,2972,2973],[31671,31642,31672],"Netupitant","Palonosetron Hydrochloride",{"trials":31674,"activeCount":124},[],{"trials":31676,"activeCount":124},[],{"intervention":4330,"totalTrials":1231,"cells":31678},{"EARLY_PHASE1":31679,"PHASE1":31681,"PHASE2":31683,"PHASE3":31689,"PHASE4":31704,"NA":31706},{"trials":31680,"activeCount":124},[],{"trials":31682,"activeCount":124},[],{"trials":31684,"activeCount":124},[31685],{"nctId":6754,"briefTitle":6755,"status":130,"phases":31686,"primaryCompletion":6757,"completion":6757,"start":6758,"enrollment":861,"conditions":31687,"interventions":31688},[88],[1122],[803,1016,1013,4330,2374,806,2584,808],{"trials":31690,"activeCount":124},[31691,31695],{"nctId":4321,"briefTitle":4322,"status":130,"phases":31692,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":31693,"interventions":31694},[89],[21],[1070,4329,4330,894,3671,1013,1016,4331,803,2424,1709,2584,4332,4333,809],{"nctId":31696,"briefTitle":31697,"status":130,"phases":31698,"primaryCompletion":31699,"completion":31699,"start":4835,"enrollment":901,"conditions":31700,"interventions":31701},"NCT02740127","Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis",[89],"2020-05-10",[7652],[6070,31702,4330,31703,6069],"Epinephrine","Clonidine",{"trials":31705,"activeCount":124},[],{"trials":31707,"activeCount":124},[],{"intervention":3671,"totalTrials":1231,"cells":31709},{"EARLY_PHASE1":31710,"PHASE1":31712,"PHASE2":31714,"PHASE3":31728,"PHASE4":31734,"NA":31736},{"trials":31711,"activeCount":124},[],{"trials":31713,"activeCount":124},[],{"trials":31715,"activeCount":124},[31716,31720],{"nctId":3664,"briefTitle":3665,"status":203,"phases":31717,"primaryCompletion":3667,"start":3668,"enrollment":124,"conditions":31718,"interventions":31719},[87,88],[1729],[1049,3671,3499],{"nctId":31721,"briefTitle":31722,"status":203,"phases":31723,"start":12066,"enrollment":124,"conditions":31724,"interventions":31725},"NCT00962715","Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia",[87,88],[712],[31726,31727,3671],"Influenza Vaccine Trivalent Inactivated","Pegylated interferon",{"trials":31729,"activeCount":124},[31730],{"nctId":4321,"briefTitle":4322,"status":130,"phases":31731,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":31732,"interventions":31733},[89],[21],[1070,4329,4330,894,3671,1013,1016,4331,803,2424,1709,2584,4332,4333,809],{"trials":31735,"activeCount":124},[],{"trials":31737,"activeCount":124},[],{"intervention":18104,"totalTrials":1231,"cells":31739},{"EARLY_PHASE1":31740,"PHASE1":31742,"PHASE2":31744,"PHASE3":31754,"PHASE4":31763,"NA":31765},{"trials":31741,"activeCount":124},[],{"trials":31743,"activeCount":124},[],{"trials":31745,"activeCount":124},[31746,31750],{"nctId":12098,"briefTitle":12099,"status":130,"phases":31747,"primaryCompletion":2602,"completion":2602,"start":12101,"enrollment":1975,"conditions":31748,"interventions":31749},[88],[7818,27],[2957,12104,12105,12106],{"nctId":18097,"briefTitle":18098,"status":130,"phases":31751,"primaryCompletion":18100,"completion":18100,"start":18101,"enrollment":2004,"conditions":31752,"interventions":31753},[87,88],[18,5418],[1028,18104],{"trials":31755,"activeCount":124},[31756],{"nctId":31757,"briefTitle":31758,"status":130,"phases":31759,"primaryCompletion":2212,"completion":2212,"start":10260,"enrollment":2610,"conditions":31760,"interventions":31761},"NCT00352846","Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss",[89],[8942,21],[18104,26979,31762],"Calcium Carbonate",{"trials":31764,"activeCount":124},[],{"trials":31766,"activeCount":124},[],{"intervention":2958,"totalTrials":1231,"cells":31768},{"EARLY_PHASE1":31769,"PHASE1":31771,"PHASE2":31773,"PHASE3":31779,"PHASE4":31789,"NA":31791},{"trials":31770,"activeCount":124},[],{"trials":31772,"activeCount":124},[],{"trials":31774,"activeCount":124},[31775],{"nctId":5687,"briefTitle":5688,"status":130,"phases":31776,"primaryCompletion":2890,"completion":2890,"start":5690,"enrollment":1308,"conditions":31777,"interventions":31778},[88],[27],[804,2958,2424,2959,1376,1868],{"trials":31780,"activeCount":124},[31781,31785],{"nctId":12206,"briefTitle":12207,"status":130,"phases":31782,"primaryCompletion":4887,"completion":4887,"start":12209,"enrollment":12210,"conditions":31783,"interventions":31784},[89],[27],[11341,2957,12213,11342,2959,11344,12214,1868],{"nctId":2950,"briefTitle":2951,"status":182,"phases":31786,"primaryCompletion":2602,"start":2953,"enrollment":2954,"conditions":31787,"interventions":31788},[89],[27],[1710,2957,2958,2959,809,1868,62],{"trials":31790,"activeCount":124},[],{"trials":31792,"activeCount":124},[],{"intervention":2959,"totalTrials":1231,"cells":31794},{"EARLY_PHASE1":31795,"PHASE1":31797,"PHASE2":31799,"PHASE3":31805,"PHASE4":31815,"NA":31817},{"trials":31796,"activeCount":124},[],{"trials":31798,"activeCount":124},[],{"trials":31800,"activeCount":124},[31801],{"nctId":5687,"briefTitle":5688,"status":130,"phases":31802,"primaryCompletion":2890,"completion":2890,"start":5690,"enrollment":1308,"conditions":31803,"interventions":31804},[88],[27],[804,2958,2424,2959,1376,1868],{"trials":31806,"activeCount":124},[31807,31811],{"nctId":12206,"briefTitle":12207,"status":130,"phases":31808,"primaryCompletion":4887,"completion":4887,"start":12209,"enrollment":12210,"conditions":31809,"interventions":31810},[89],[27],[11341,2957,12213,11342,2959,11344,12214,1868],{"nctId":2950,"briefTitle":2951,"status":182,"phases":31812,"primaryCompletion":2602,"start":2953,"enrollment":2954,"conditions":31813,"interventions":31814},[89],[27],[1710,2957,2958,2959,809,1868,62],{"trials":31816,"activeCount":124},[],{"trials":31818,"activeCount":124},[],{"intervention":4318,"totalTrials":121,"cells":31820},{"EARLY_PHASE1":31821,"PHASE1":31823,"PHASE2":31825,"PHASE3":31827,"PHASE4":31837,"NA":31839},{"trials":31822,"activeCount":124},[],{"trials":31824,"activeCount":124},[],{"trials":31826,"activeCount":124},[],{"trials":31828,"activeCount":124},[31829,31833],{"nctId":4305,"briefTitle":4306,"status":130,"phases":31830,"primaryCompletion":4308,"completion":4308,"start":4309,"enrollment":2402,"conditions":31831,"interventions":31832},[89],[21],[4312,4313,4045,2879,2880,2882,4314,4315,4047,4316,4317,4318,4319,2884],{"nctId":4367,"briefTitle":4368,"status":130,"phases":31834,"primaryCompletion":4370,"completion":4370,"start":4371,"enrollment":1001,"conditions":31835,"interventions":31836},[89],[21],[4174,1069,4109,4365,1709,803,654,2424,655,2495,1373,2293,806,1014,4318,810],{"trials":31838,"activeCount":124},[],{"trials":31840,"activeCount":124},[],{"intervention":31842,"totalTrials":121,"cells":31843},"Voriconazole",{"EARLY_PHASE1":31844,"PHASE1":31846,"PHASE2":31848,"PHASE3":31857,"PHASE4":31866,"NA":31868},{"trials":31845,"activeCount":124},[],{"trials":31847,"activeCount":124},[],{"trials":31849,"activeCount":124},[31850],{"nctId":31851,"briefTitle":31852,"status":130,"phases":31853,"primaryCompletion":4723,"completion":4723,"start":8719,"enrollment":1100,"conditions":31854,"interventions":31855},"NCT00418951","Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections",[88],[4659,30],[31842,31856,31856],"Liposomal amphotericin B",{"trials":31858,"activeCount":124},[31859],{"nctId":31860,"briefTitle":31861,"status":130,"phases":31862,"primaryCompletion":9859,"completion":9859,"start":8306,"enrollment":3820,"conditions":31863,"interventions":31865},"NCT00904995","Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis",[89],[15,31864],"Fungal Infection",[31842,31842],{"trials":31867,"activeCount":124},[],{"trials":31869,"activeCount":124},[],{"intervention":11306,"totalTrials":121,"cells":31871},{"EARLY_PHASE1":31872,"PHASE1":31874,"PHASE2":31876,"PHASE3":31882,"PHASE4":31888,"NA":31890},{"trials":31873,"activeCount":124},[],{"trials":31875,"activeCount":124},[],{"trials":31877,"activeCount":124},[31878],{"nctId":11297,"briefTitle":11298,"status":130,"phases":31879,"primaryCompletion":9512,"completion":10760,"start":11300,"enrollment":296,"conditions":31880,"interventions":31881},[88],[11302],[11304,1373,11305,806,809,11306,810],{"trials":31883,"activeCount":124},[31884],{"nctId":31405,"briefTitle":31406,"status":203,"phases":31885,"enrollment":124,"conditions":31886,"interventions":31887},[89],[11302],[17616,11306],{"trials":31889,"activeCount":124},[],{"trials":31891,"activeCount":124},[],{"intervention":5981,"totalTrials":121,"cells":31893},{"EARLY_PHASE1":31894,"PHASE1":31896,"PHASE2":31898,"PHASE3":31904,"PHASE4":31910,"NA":31912},{"trials":31895,"activeCount":124},[],{"trials":31897,"activeCount":124},[],{"trials":31899,"activeCount":124},[31900],{"nctId":5975,"briefTitle":5976,"status":182,"phases":31901,"primaryCompletion":185,"completion":185,"start":3818,"enrollment":3197,"conditions":31902,"interventions":31903},[88],[5979],[365,5981],{"trials":31905,"activeCount":124},[31906],{"nctId":5985,"briefTitle":5986,"status":182,"phases":31907,"primaryCompletion":185,"completion":185,"start":5988,"enrollment":593,"conditions":31908,"interventions":31909},[89],[1942,1924],[365,5981],{"trials":31911,"activeCount":124},[],{"trials":31913,"activeCount":124},[],{"intervention":2939,"totalTrials":121,"cells":31915},{"EARLY_PHASE1":31916,"PHASE1":31918,"PHASE2":31920,"PHASE3":31922,"PHASE4":31932,"NA":31934},{"trials":31917,"activeCount":124},[],{"trials":31919,"activeCount":124},[],{"trials":31921,"activeCount":124},[],{"trials":31923,"activeCount":124},[31924,31928],{"nctId":2929,"briefTitle":2930,"status":130,"phases":31925,"primaryCompletion":2846,"completion":2846,"start":2932,"enrollment":2933,"conditions":31926,"interventions":31927},[89],[2935,2936],[2881,2938,2939],{"nctId":31665,"briefTitle":31666,"status":130,"phases":31929,"primaryCompletion":2061,"completion":2061,"start":31668,"enrollment":1140,"conditions":31930,"interventions":31931},[88,89],[2613,2972,2973],[31671,31642,31672],{"trials":31933,"activeCount":124},[],{"trials":31935,"activeCount":124},[],{"intervention":31937,"totalTrials":121,"cells":31938},"Eltrombopag Olamine",{"EARLY_PHASE1":31939,"PHASE1":31941,"PHASE2":31943,"PHASE3":31955,"PHASE4":31965,"NA":31967},{"trials":31940,"activeCount":124},[],{"trials":31942,"activeCount":124},[],{"trials":31944,"activeCount":124},[31945],{"nctId":31946,"briefTitle":31947,"status":130,"phases":31948,"primaryCompletion":31949,"completion":31949,"start":31950,"enrollment":473,"conditions":31951,"interventions":31954},"NCT01927731","Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant",[88],"2023-06-06","2013-10-14",[31952,31953,4743],"Bone Marrow Transplantation Recipient","Cord Blood Transplant Recipient",[31937],{"trials":31956,"activeCount":124},[31957],{"nctId":31958,"briefTitle":31959,"status":130,"phases":31960,"primaryCompletion":31961,"completion":31961,"start":31962,"enrollment":871,"conditions":31963,"interventions":31964},"NCT01428635","Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy",[88,89],"2022-01-03","2012-01-13",[1205,644,1025,2134,13565],[31937],{"trials":31966,"activeCount":124},[],{"trials":31968,"activeCount":124},[],{"intervention":11877,"totalTrials":121,"cells":31970},{"EARLY_PHASE1":31971,"PHASE1":31973,"PHASE2":31975,"PHASE3":31981,"PHASE4":31987,"NA":31989},{"trials":31972,"activeCount":124},[],{"trials":31974,"activeCount":124},[],{"trials":31976,"activeCount":124},[31977],{"nctId":11870,"briefTitle":11871,"status":130,"phases":31978,"primaryCompletion":11873,"completion":11873,"start":11874,"enrollment":448,"conditions":31979,"interventions":31980},[88],[8942],[11877,1376,1379],{"trials":31982,"activeCount":124},[31983],{"nctId":20730,"briefTitle":20731,"status":130,"phases":31984,"primaryCompletion":2847,"completion":3902,"start":20733,"enrollment":448,"conditions":31985,"interventions":31986},[89],[20735],[11877,2977,4331,1868,20737],{"trials":31988,"activeCount":124},[],{"trials":31990,"activeCount":124},[],{"intervention":31992,"totalTrials":121,"cells":31993},"Posaconazole",{"EARLY_PHASE1":31994,"PHASE1":31996,"PHASE2":31998,"PHASE3":32006,"PHASE4":32016,"NA":32018},{"trials":31995,"activeCount":124},[],{"trials":31997,"activeCount":124},[],{"trials":31999,"activeCount":124},[32000],{"nctId":32001,"briefTitle":32002,"status":130,"phases":32003,"primaryCompletion":8730,"completion":8730,"start":3833,"enrollment":448,"conditions":32004,"interventions":32005},"NCT00936117","Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia",[88],[15,31864],[31992],{"trials":32007,"activeCount":124},[32008],{"nctId":32009,"briefTitle":32010,"status":130,"phases":32011,"primaryCompletion":5434,"completion":5434,"start":7236,"enrollment":4171,"conditions":32012,"interventions":32014},"NCT00750737","Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)",[89],[32013,4760],"Invasive Fungal Infections",[31992,32015],"ABLC",{"trials":32017,"activeCount":124},[],{"trials":32019,"activeCount":124},[],{"intervention":14611,"totalTrials":121,"cells":32021},{"EARLY_PHASE1":32022,"PHASE1":32024,"PHASE2":32026,"PHASE3":32034,"PHASE4":32040,"NA":32042},{"trials":32023,"activeCount":124},[],{"trials":32025,"activeCount":124},[],{"trials":32027,"activeCount":124},[32028],{"nctId":32029,"briefTitle":32030,"status":130,"phases":32031,"primaryCompletion":10272,"completion":10272,"start":2945,"enrollment":2779,"conditions":32032,"interventions":32033},"NCT00038168","Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma",[87,88],[27],[11964,14611],{"trials":32035,"activeCount":124},[32036],{"nctId":14605,"briefTitle":14606,"status":130,"phases":32037,"primaryCompletion":8503,"completion":7155,"start":2807,"enrollment":4690,"conditions":32038,"interventions":32039},[89],[18],[14610,14611,1371,14612,6744],{"trials":32041,"activeCount":124},[],{"trials":32043,"activeCount":124},[],{"intervention":14612,"totalTrials":121,"cells":32045},{"EARLY_PHASE1":32046,"PHASE1":32048,"PHASE2":32050,"PHASE3":32059,"PHASE4":32065,"NA":32067},{"trials":32047,"activeCount":124},[],{"trials":32049,"activeCount":124},[],{"trials":32051,"activeCount":124},[32052],{"nctId":32053,"briefTitle":32054,"status":130,"phases":32055,"primaryCompletion":3213,"completion":3213,"start":4887,"enrollment":1222,"conditions":32056,"interventions":32057},"NCT00496873","Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan",[88],[21],[14612,32058,5247],"Nipent",{"trials":32060,"activeCount":124},[32061],{"nctId":14605,"briefTitle":14606,"status":130,"phases":32062,"primaryCompletion":8503,"completion":7155,"start":2807,"enrollment":4690,"conditions":32063,"interventions":32064},[89],[18],[14610,14611,1371,14612,6744],{"trials":32066,"activeCount":124},[],{"trials":32068,"activeCount":124},[],{"intervention":32070,"totalTrials":121,"cells":32071},"Testosterone",{"EARLY_PHASE1":32072,"PHASE1":32074,"PHASE2":32076,"PHASE3":32084,"PHASE4":32092,"NA":32094},{"trials":32073,"activeCount":124},[],{"trials":32075,"activeCount":124},[],{"trials":32077,"activeCount":124},[32078],{"nctId":32079,"briefTitle":32080,"status":203,"phases":32081,"primaryCompletion":7236,"completion":7236,"start":4192,"enrollment":124,"conditions":32082,"interventions":32083},"NCT00577980","Testosterone in Castration-Resistant Prostate Cancer",[88],[27],[32070],{"trials":32085,"activeCount":124},[32086],{"nctId":32087,"briefTitle":32088,"status":130,"phases":32089,"primaryCompletion":4542,"completion":4542,"start":3833,"enrollment":1140,"conditions":32090,"interventions":32091},"NCT00965341","Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients",[89],[1942],[32070],{"trials":32093,"activeCount":124},[],{"trials":32095,"activeCount":124},[],{"intervention":9372,"totalTrials":121,"cells":32097},{"EARLY_PHASE1":32098,"PHASE1":32100,"PHASE2":32102,"PHASE3":32108,"PHASE4":32116,"NA":32118},{"trials":32099,"activeCount":124},[],{"trials":32101,"activeCount":124},[],{"trials":32103,"activeCount":124},[32104],{"nctId":9366,"briefTitle":9367,"status":130,"phases":32105,"primaryCompletion":3902,"completion":6384,"start":9369,"enrollment":2997,"conditions":32106,"interventions":32107},[87,88],[4659,30,712],[9372,1070,2293,5195],{"trials":32109,"activeCount":124},[32110],{"nctId":32111,"briefTitle":32112,"status":182,"phases":32113,"primaryCompletion":8503,"completion":8503,"start":9369,"enrollment":1231,"conditions":32114,"interventions":32115},"NCT00038805","Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)",[88,89],[15],[9372],{"trials":32117,"activeCount":124},[],{"trials":32119,"activeCount":124},[],{"intervention":32121,"totalTrials":121,"cells":32122},"Fentanyl Sublingual Spray",{"EARLY_PHASE1":32123,"PHASE1":32125,"PHASE2":32127,"PHASE3":32135,"PHASE4":32145,"NA":32147},{"trials":32124,"activeCount":124},[],{"trials":32126,"activeCount":124},[],{"trials":32128,"activeCount":124},[32129],{"nctId":32130,"briefTitle":32131,"status":182,"phases":32132,"primaryCompletion":3483,"completion":3483,"start":1538,"enrollment":230,"conditions":32133,"interventions":32134},"NCT02514252","Sublingual Fentanyl for the Management of Breakthrough Pain",[88],[33],[32121],{"trials":32136,"activeCount":124},[32137],{"nctId":32138,"briefTitle":32139,"status":130,"phases":32140,"primaryCompletion":32141,"completion":26693,"start":32142,"enrollment":676,"conditions":32143,"interventions":32144},"NCT02597478","Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea",[88,89],"2018-09-27","2016-01-04",[33],[32121],{"trials":32146,"activeCount":124},[],{"trials":32148,"activeCount":124},[],{"intervention":6069,"totalTrials":121,"cells":32150},{"EARLY_PHASE1":32151,"PHASE1":32153,"PHASE2":32155,"PHASE3":32157,"PHASE4":32167,"NA":32169},{"trials":32152,"activeCount":124},[],{"trials":32154,"activeCount":124},[],{"trials":32156,"activeCount":124},[],{"trials":32158,"activeCount":124},[32159,32163],{"nctId":6062,"briefTitle":6063,"status":130,"phases":32160,"primaryCompletion":6065,"completion":6065,"start":5522,"enrollment":6066,"conditions":32161,"interventions":32162},[89],[18],[6069,5810,6070,6071],{"nctId":31696,"briefTitle":31697,"status":130,"phases":32164,"primaryCompletion":31699,"completion":31699,"start":4835,"enrollment":901,"conditions":32165,"interventions":32166},[89],[7652],[6070,31702,4330,31703,6069],{"trials":32168,"activeCount":124},[],{"trials":32170,"activeCount":124},[],{"intervention":6070,"totalTrials":121,"cells":32172},{"EARLY_PHASE1":32173,"PHASE1":32175,"PHASE2":32177,"PHASE3":32179,"PHASE4":32189,"NA":32191},{"trials":32174,"activeCount":124},[],{"trials":32176,"activeCount":124},[],{"trials":32178,"activeCount":124},[],{"trials":32180,"activeCount":124},[32181,32185],{"nctId":6062,"briefTitle":6063,"status":130,"phases":32182,"primaryCompletion":6065,"completion":6065,"start":5522,"enrollment":6066,"conditions":32183,"interventions":32184},[89],[18],[6069,5810,6070,6071],{"nctId":31696,"briefTitle":31697,"status":130,"phases":32186,"primaryCompletion":31699,"completion":31699,"start":4835,"enrollment":901,"conditions":32187,"interventions":32188},[89],[7652],[6070,31702,4330,31703,6069],{"trials":32190,"activeCount":124},[],{"trials":32192,"activeCount":124},[],{"intervention":4313,"totalTrials":166,"cells":32194},{"EARLY_PHASE1":32195,"PHASE1":32197,"PHASE2":32199,"PHASE3":32201,"PHASE4":32207,"NA":32209},{"trials":32196,"activeCount":124},[],{"trials":32198,"activeCount":124},[],{"trials":32200,"activeCount":124},[],{"trials":32202,"activeCount":124},[32203],{"nctId":4305,"briefTitle":4306,"status":130,"phases":32204,"primaryCompletion":4308,"completion":4308,"start":4309,"enrollment":2402,"conditions":32205,"interventions":32206},[89],[21],[4312,4313,4045,2879,2880,2882,4314,4315,4047,4316,4317,4318,4319,2884],{"trials":32208,"activeCount":124},[],{"trials":32210,"activeCount":124},[],{"intervention":32212,"totalTrials":166,"cells":32213},"Gabapentin",{"EARLY_PHASE1":32214,"PHASE1":32216,"PHASE2":32218,"PHASE3":32220,"PHASE4":32230,"NA":32232},{"trials":32215,"activeCount":124},[],{"trials":32217,"activeCount":124},[],{"trials":32219,"activeCount":124},[],{"trials":32221,"activeCount":124},[32222],{"nctId":32223,"briefTitle":32224,"status":203,"phases":32225,"primaryCompletion":7594,"completion":7594,"start":18945,"enrollment":124,"conditions":32226,"interventions":32229},"NCT05100160","Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)",[89],[32227,32228],"Thoracic","Pulmonary Disease",[32212],{"trials":32231,"activeCount":124},[],{"trials":32233,"activeCount":124},[],{"intervention":5789,"totalTrials":166,"cells":32235},{"EARLY_PHASE1":32236,"PHASE1":32238,"PHASE2":32240,"PHASE3":32242,"PHASE4":32248,"NA":32250},{"trials":32237,"activeCount":124},[],{"trials":32239,"activeCount":124},[],{"trials":32241,"activeCount":124},[],{"trials":32243,"activeCount":124},[32244],{"nctId":5782,"briefTitle":5783,"status":130,"phases":32245,"primaryCompletion":4448,"completion":4448,"start":5785,"enrollment":1308,"conditions":32246,"interventions":32247},[89],[5787],[5789,5790,5750],{"trials":32249,"activeCount":124},[],{"trials":32251,"activeCount":124},[],{"intervention":5790,"totalTrials":166,"cells":32253},{"EARLY_PHASE1":32254,"PHASE1":32256,"PHASE2":32258,"PHASE3":32260,"PHASE4":32266,"NA":32268},{"trials":32255,"activeCount":124},[],{"trials":32257,"activeCount":124},[],{"trials":32259,"activeCount":124},[],{"trials":32261,"activeCount":124},[32262],{"nctId":5782,"briefTitle":5783,"status":130,"phases":32263,"primaryCompletion":4448,"completion":4448,"start":5785,"enrollment":1308,"conditions":32264,"interventions":32265},[89],[5787],[5789,5790,5750],{"trials":32267,"activeCount":124},[],{"trials":32269,"activeCount":124},[],{"intervention":2938,"totalTrials":166,"cells":32271},{"EARLY_PHASE1":32272,"PHASE1":32274,"PHASE2":32276,"PHASE3":32278,"PHASE4":32284,"NA":32286},{"trials":32273,"activeCount":124},[],{"trials":32275,"activeCount":124},[],{"trials":32277,"activeCount":124},[],{"trials":32279,"activeCount":124},[32280],{"nctId":2929,"briefTitle":2930,"status":130,"phases":32281,"primaryCompletion":2846,"completion":2846,"start":2932,"enrollment":2933,"conditions":32282,"interventions":32283},[89],[2935,2936],[2881,2938,2939],{"trials":32285,"activeCount":124},[],{"trials":32287,"activeCount":124},[],{"intervention":31258,"totalTrials":166,"cells":32289},{"EARLY_PHASE1":32290,"PHASE1":32292,"PHASE2":32294,"PHASE3":32296,"PHASE4":32302,"NA":32304},{"trials":32291,"activeCount":124},[],{"trials":32293,"activeCount":124},[],{"trials":32295,"activeCount":124},[],{"trials":32297,"activeCount":124},[32298],{"nctId":31253,"briefTitle":31254,"status":130,"phases":32299,"primaryCompletion":9923,"completion":10938,"start":5241,"enrollment":25,"conditions":32300,"interventions":32301},[89],[5244],[17901,31258,4387],{"trials":32303,"activeCount":124},[],{"trials":32305,"activeCount":124},[],{"intervention":32307,"totalTrials":166,"cells":32308},"alpha-lipoic acid",{"EARLY_PHASE1":32309,"PHASE1":32311,"PHASE2":32313,"PHASE3":32315,"PHASE4":32326,"NA":32328},{"trials":32310,"activeCount":124},[],{"trials":32312,"activeCount":124},[],{"trials":32314,"activeCount":124},[],{"trials":32316,"activeCount":124},[32317],{"nctId":32318,"briefTitle":32319,"status":130,"phases":32320,"primaryCompletion":206,"completion":206,"start":9512,"enrollment":32321,"conditions":32322,"interventions":32325},"NCT00112996","Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer",[89],244,[32323,2936,32324],"Neurotoxicity","Unspecified Childhood Solid Tumor, Protocol Specific",[32307],{"trials":32327,"activeCount":124},[],{"trials":32329,"activeCount":124},[],{"intervention":32331,"totalTrials":166,"cells":32332},"Sleep enhancement intervention",{"EARLY_PHASE1":32333,"PHASE1":32335,"PHASE2":32337,"PHASE3":32339,"PHASE4":32349,"NA":32351},{"trials":32334,"activeCount":124},[],{"trials":32336,"activeCount":124},[],{"trials":32338,"activeCount":124},[],{"trials":32340,"activeCount":124},[32341],{"nctId":32342,"briefTitle":32343,"status":182,"phases":32344,"primaryCompletion":32345,"completion":32345,"start":32346,"enrollment":6066,"conditions":32347,"interventions":32348},"NCT05456360","Implementation of Digital Vital Sign Monitoring to Decrease Sleep Interruption and Enhance Recovery in Phase II of the PROmoting Sleep, Patient Engagement and Recovery (PROSPER) Project",[88,89],"2023-10-30","2023-03-01",[5364],[32331],{"trials":32350,"activeCount":124},[],{"trials":32352,"activeCount":124},[],{"intervention":30347,"totalTrials":166,"cells":32354},{"EARLY_PHASE1":32355,"PHASE1":32357,"PHASE2":32359,"PHASE3":32361,"PHASE4":32367,"NA":32369},{"trials":32356,"activeCount":124},[],{"trials":32358,"activeCount":124},[],{"trials":32360,"activeCount":124},[],{"trials":32362,"activeCount":124},[32363],{"nctId":30342,"briefTitle":30343,"status":182,"phases":32364,"primaryCompletion":2316,"completion":2316,"start":4290,"enrollment":166,"conditions":32365,"interventions":32366},[89],[27091],[30347,7805,30348],{"trials":32368,"activeCount":124},[],{"trials":32370,"activeCount":124},[],{"intervention":30348,"totalTrials":166,"cells":32372},{"EARLY_PHASE1":32373,"PHASE1":32375,"PHASE2":32377,"PHASE3":32379,"PHASE4":32385,"NA":32387},{"trials":32374,"activeCount":124},[],{"trials":32376,"activeCount":124},[],{"trials":32378,"activeCount":124},[],{"trials":32380,"activeCount":124},[32381],{"nctId":30342,"briefTitle":30343,"status":182,"phases":32382,"primaryCompletion":2316,"completion":2316,"start":4290,"enrollment":166,"conditions":32383,"interventions":32384},[89],[27091],[30347,7805,30348],{"trials":32386,"activeCount":124},[],{"trials":32388,"activeCount":124},[],{"intervention":32390,"totalTrials":166,"cells":32391},"Granisetron",{"EARLY_PHASE1":32392,"PHASE1":32394,"PHASE2":32396,"PHASE3":32398,"PHASE4":32407,"NA":32409},{"trials":32393,"activeCount":124},[],{"trials":32395,"activeCount":124},[],{"trials":32397,"activeCount":124},[],{"trials":32399,"activeCount":124},[32400],{"nctId":32401,"briefTitle":32402,"status":130,"phases":32403,"primaryCompletion":5697,"completion":5697,"start":8753,"enrollment":20891,"conditions":32404,"interventions":32406},"NCT01536392","Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation",[89],[32405],"Cancer of the Cervix",[32390,2793],{"trials":32408,"activeCount":124},[],{"trials":32410,"activeCount":124},[],{"intervention":32015,"totalTrials":166,"cells":32412},{"EARLY_PHASE1":32413,"PHASE1":32415,"PHASE2":32417,"PHASE3":32419,"PHASE4":32425,"NA":32427},{"trials":32414,"activeCount":124},[],{"trials":32416,"activeCount":124},[],{"trials":32418,"activeCount":124},[],{"trials":32420,"activeCount":124},[32421],{"nctId":32009,"briefTitle":32010,"status":130,"phases":32422,"primaryCompletion":5434,"completion":5434,"start":7236,"enrollment":4171,"conditions":32423,"interventions":32424},[89],[32013,4760],[31992,32015],{"trials":32426,"activeCount":124},[],{"trials":32428,"activeCount":124},[],{"intervention":31671,"totalTrials":166,"cells":32430},{"EARLY_PHASE1":32431,"PHASE1":32433,"PHASE2":32435,"PHASE3":32437,"PHASE4":32443,"NA":32445},{"trials":32432,"activeCount":124},[],{"trials":32434,"activeCount":124},[],{"trials":32436,"activeCount":124},[],{"trials":32438,"activeCount":124},[32439],{"nctId":31665,"briefTitle":31666,"status":130,"phases":32440,"primaryCompletion":2061,"completion":2061,"start":31668,"enrollment":1140,"conditions":32441,"interventions":32442},[88,89],[2613,2972,2973],[31671,31642,31672],{"trials":32444,"activeCount":124},[],{"trials":32446,"activeCount":124},[],{"intervention":20737,"totalTrials":166,"cells":32448},{"EARLY_PHASE1":32449,"PHASE1":32451,"PHASE2":32453,"PHASE3":32455,"PHASE4":32461,"NA":32463},{"trials":32450,"activeCount":124},[],{"trials":32452,"activeCount":124},[],{"trials":32454,"activeCount":124},[],{"trials":32456,"activeCount":124},[32457],{"nctId":20730,"briefTitle":20731,"status":130,"phases":32458,"primaryCompletion":2847,"completion":3902,"start":20733,"enrollment":448,"conditions":32459,"interventions":32460},[89],[20735],[11877,2977,4331,1868,20737],{"trials":32462,"activeCount":124},[],{"trials":32464,"activeCount":124},[],{"intervention":32466,"totalTrials":166,"cells":32467},"Ibandronate",{"EARLY_PHASE1":32468,"PHASE1":32470,"PHASE2":32472,"PHASE3":32474,"PHASE4":32484,"NA":32486},{"trials":32469,"activeCount":124},[],{"trials":32471,"activeCount":124},[],{"trials":32473,"activeCount":124},[],{"trials":32475,"activeCount":124},[32476],{"nctId":32477,"briefTitle":32478,"status":130,"phases":32479,"primaryCompletion":3714,"completion":3714,"start":32480,"enrollment":959,"conditions":32481,"interventions":32482},"NCT00824993","Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients",[89],"2008-12-09",[7246],[32466,32483],"Vitamin Supplements",{"trials":32485,"activeCount":124},[],{"trials":32487,"activeCount":124},[],{"intervention":32483,"totalTrials":166,"cells":32489},{"EARLY_PHASE1":32490,"PHASE1":32492,"PHASE2":32494,"PHASE3":32496,"PHASE4":32502,"NA":32504},{"trials":32491,"activeCount":124},[],{"trials":32493,"activeCount":124},[],{"trials":32495,"activeCount":124},[],{"trials":32497,"activeCount":124},[32498],{"nctId":32477,"briefTitle":32478,"status":130,"phases":32499,"primaryCompletion":3714,"completion":3714,"start":32480,"enrollment":959,"conditions":32500,"interventions":32501},[89],[7246],[32466,32483],{"trials":32503,"activeCount":124},[],{"trials":32505,"activeCount":124},[],{"intervention":12214,"totalTrials":166,"cells":32507},{"EARLY_PHASE1":32508,"PHASE1":32510,"PHASE2":32512,"PHASE3":32514,"PHASE4":32520,"NA":32522},{"trials":32509,"activeCount":124},[],{"trials":32511,"activeCount":124},[],{"trials":32513,"activeCount":124},[],{"trials":32515,"activeCount":124},[32516],{"nctId":12206,"briefTitle":12207,"status":130,"phases":32517,"primaryCompletion":4887,"completion":4887,"start":12209,"enrollment":12210,"conditions":32518,"interventions":32519},[89],[27],[11341,2957,12213,11342,2959,11344,12214,1868],{"trials":32521,"activeCount":124},[],{"trials":32523,"activeCount":124},[],{"intervention":32525,"totalTrials":166,"cells":32526},"Actonel",{"EARLY_PHASE1":32527,"PHASE1":32529,"PHASE2":32531,"PHASE3":32533,"PHASE4":32541,"NA":32543},{"trials":32528,"activeCount":124},[],{"trials":32530,"activeCount":124},[],{"trials":32532,"activeCount":124},[],{"trials":32534,"activeCount":124},[32535],{"nctId":32536,"briefTitle":32537,"status":130,"phases":32538,"primaryCompletion":2846,"completion":2846,"start":2847,"enrollment":2647,"conditions":32539,"interventions":32540},"NCT00452439","A Study of Actonel for the Prevention of Bone Loss",[89],[15,21],[32525],{"trials":32542,"activeCount":124},[],{"trials":32544,"activeCount":124},[],{"intervention":4329,"totalTrials":166,"cells":32546},{"EARLY_PHASE1":32547,"PHASE1":32549,"PHASE2":32551,"PHASE3":32553,"PHASE4":32559,"NA":32561},{"trials":32548,"activeCount":124},[],{"trials":32550,"activeCount":124},[],{"trials":32552,"activeCount":124},[],{"trials":32554,"activeCount":124},[32555],{"nctId":4321,"briefTitle":4322,"status":130,"phases":32556,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":32557,"interventions":32558},[89],[21],[1070,4329,4330,894,3671,1013,1016,4331,803,2424,1709,2584,4332,4333,809],{"trials":32560,"activeCount":124},[],{"trials":32562,"activeCount":124},[],{"intervention":4332,"totalTrials":166,"cells":32564},{"EARLY_PHASE1":32565,"PHASE1":32567,"PHASE2":32569,"PHASE3":32571,"PHASE4":32577,"NA":32579},{"trials":32566,"activeCount":124},[],{"trials":32568,"activeCount":124},[],{"trials":32570,"activeCount":124},[],{"trials":32572,"activeCount":124},[32573],{"nctId":4321,"briefTitle":4322,"status":130,"phases":32574,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":32575,"interventions":32576},[89],[21],[1070,4329,4330,894,3671,1013,1016,4331,803,2424,1709,2584,4332,4333,809],{"trials":32578,"activeCount":124},[],{"trials":32580,"activeCount":124},[],{"intervention":4333,"totalTrials":166,"cells":32582},{"EARLY_PHASE1":32583,"PHASE1":32585,"PHASE2":32587,"PHASE3":32589,"PHASE4":32595,"NA":32597},{"trials":32584,"activeCount":124},[],{"trials":32586,"activeCount":124},[],{"trials":32588,"activeCount":124},[],{"trials":32590,"activeCount":124},[32591],{"nctId":4321,"briefTitle":4322,"status":130,"phases":32592,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":4326,"conditions":32593,"interventions":32594},[89],[21],[1070,4329,4330,894,3671,1013,1016,4331,803,2424,1709,2584,4332,4333,809],{"trials":32596,"activeCount":124},[],{"trials":32598,"activeCount":124},[],{"intervention":32600,"totalTrials":166,"cells":32601},"OraTest",{"EARLY_PHASE1":32602,"PHASE1":32604,"PHASE2":32606,"PHASE3":32608,"PHASE4":32616,"NA":32618},{"trials":32603,"activeCount":124},[],{"trials":32605,"activeCount":124},[],{"trials":32607,"activeCount":124},[],{"trials":32609,"activeCount":124},[32610],{"nctId":32611,"briefTitle":32612,"status":182,"phases":32613,"primaryCompletion":4786,"completion":4786,"start":8719,"enrollment":166,"conditions":32614,"interventions":32615},"NCT00537199","OraTest in Combination With Visual Examination and Visual Examination Alone",[89],[22891,14245],[32600],{"trials":32617,"activeCount":124},[],{"trials":32619,"activeCount":124},[],{"intervention":32621,"totalTrials":166,"cells":32622},"Targretin Gel 1%",{"EARLY_PHASE1":32623,"PHASE1":32625,"PHASE2":32627,"PHASE3":32629,"PHASE4":32638,"NA":32640},{"trials":32624,"activeCount":124},[],{"trials":32626,"activeCount":124},[],{"trials":32628,"activeCount":124},[],{"trials":32630,"activeCount":124},[32631],{"nctId":32632,"briefTitle":32633,"status":130,"phases":32634,"primaryCompletion":6384,"completion":6628,"start":14884,"enrollment":4171,"conditions":32635,"interventions":32637},"NCT00063076","Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata",[88,89],[32636],"Alopecia Areata",[32621],{"trials":32639,"activeCount":124},[],{"trials":32641,"activeCount":124},[],{"intervention":32643,"totalTrials":166,"cells":32644},"IR Methylphenidate",{"EARLY_PHASE1":32645,"PHASE1":32647,"PHASE2":32649,"PHASE3":32651,"PHASE4":32661,"NA":32663},{"trials":32646,"activeCount":124},[],{"trials":32648,"activeCount":124},[],{"trials":32650,"activeCount":124},[],{"trials":32652,"activeCount":124},[32653],{"nctId":32654,"briefTitle":32655,"status":182,"phases":32656,"primaryCompletion":2836,"completion":2836,"start":2847,"enrollment":1240,"conditions":32657,"interventions":32658},"NCT00418691","Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning",[89],[13732],[32643,32659,32660],"Modafinil","SR Methylphenidate",{"trials":32662,"activeCount":124},[],{"trials":32664,"activeCount":124},[],{"intervention":32659,"totalTrials":166,"cells":32666},{"EARLY_PHASE1":32667,"PHASE1":32669,"PHASE2":32671,"PHASE3":32673,"PHASE4":32679,"NA":32681},{"trials":32668,"activeCount":124},[],{"trials":32670,"activeCount":124},[],{"trials":32672,"activeCount":124},[],{"trials":32674,"activeCount":124},[32675],{"nctId":32654,"briefTitle":32655,"status":182,"phases":32676,"primaryCompletion":2836,"completion":2836,"start":2847,"enrollment":1240,"conditions":32677,"interventions":32678},[89],[13732],[32643,32659,32660],{"trials":32680,"activeCount":124},[],{"trials":32682,"activeCount":124},[],{"intervention":32660,"totalTrials":166,"cells":32684},{"EARLY_PHASE1":32685,"PHASE1":32687,"PHASE2":32689,"PHASE3":32691,"PHASE4":32697,"NA":32699},{"trials":32686,"activeCount":124},[],{"trials":32688,"activeCount":124},[],{"trials":32690,"activeCount":124},[],{"trials":32692,"activeCount":124},[32693],{"nctId":32654,"briefTitle":32655,"status":182,"phases":32694,"primaryCompletion":2836,"completion":2836,"start":2847,"enrollment":1240,"conditions":32695,"interventions":32696},[89],[13732],[32643,32659,32660],{"trials":32698,"activeCount":124},[],{"trials":32700,"activeCount":124},[],{"intervention":31762,"totalTrials":166,"cells":32702},{"EARLY_PHASE1":32703,"PHASE1":32705,"PHASE2":32707,"PHASE3":32709,"PHASE4":32715,"NA":32717},{"trials":32704,"activeCount":124},[],{"trials":32706,"activeCount":124},[],{"trials":32708,"activeCount":124},[],{"trials":32710,"activeCount":124},[32711],{"nctId":31757,"briefTitle":31758,"status":130,"phases":32712,"primaryCompletion":2212,"completion":2212,"start":10260,"enrollment":2610,"conditions":32713,"interventions":32714},[89],[8942,21],[18104,26979,31762],{"trials":32716,"activeCount":124},[],{"trials":32718,"activeCount":124},[],{"intervention":32720,"totalTrials":166,"cells":32721},"I-131 Metaiodobenzylguanidine",{"EARLY_PHASE1":32722,"PHASE1":32724,"PHASE2":32726,"PHASE3":32728,"PHASE4":32737,"NA":32739},{"trials":32723,"activeCount":124},[],{"trials":32725,"activeCount":124},[],{"trials":32727,"activeCount":124},[],{"trials":32729,"activeCount":124},[32730],{"nctId":32731,"briefTitle":32732,"status":130,"phases":32733,"primaryCompletion":7473,"completion":7473,"start":20733,"enrollment":1568,"conditions":32734,"interventions":32736},"NCT00037869","High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors",[89],[32735,17937],"Neuroendocrine Tumors",[32720],{"trials":32738,"activeCount":124},[],{"trials":32740,"activeCount":124},[],{"intervention":4882,"totalTrials":166,"cells":32742},{"EARLY_PHASE1":32743,"PHASE1":32745,"PHASE2":32747,"PHASE3":32749,"PHASE4":32755,"NA":32757},{"trials":32744,"activeCount":124},[],{"trials":32746,"activeCount":124},[],{"trials":32748,"activeCount":124},[],{"trials":32750,"activeCount":124},[32751],{"nctId":4874,"briefTitle":4875,"status":130,"phases":32752,"primaryCompletion":4877,"completion":4877,"start":4878,"enrollment":4879,"conditions":32753,"interventions":32754},[89],[2245],[1004,2293,2374,4882],{"trials":32756,"activeCount":124},[],{"trials":32758,"activeCount":124},[],{"intervention":32760,"totalTrials":166,"cells":32761},"I-131 Iodocholesterol",{"EARLY_PHASE1":32762,"PHASE1":32764,"PHASE2":32766,"PHASE3":32768,"PHASE4":32780,"NA":32782},{"trials":32763,"activeCount":124},[],{"trials":32765,"activeCount":124},[],{"trials":32767,"activeCount":124},[],{"trials":32769,"activeCount":124},[32770],{"nctId":32771,"briefTitle":32772,"status":130,"phases":32773,"primaryCompletion":6409,"completion":6409,"start":32774,"enrollment":32775,"conditions":32776,"interventions":32779},"NCT00037843","Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening",[89],"1988-12",114,[32777,32778],"Adrenal Gland Diseases","Adrenal Gland Neoplasms",[32760],{"trials":32781,"activeCount":124},[],{"trials":32783,"activeCount":124},[],{"intervention":32785,"totalTrials":166,"cells":32786},"Donepezil",{"EARLY_PHASE1":32787,"PHASE1":32789,"PHASE2":32791,"PHASE3":32793,"PHASE4":32801,"NA":32803},{"trials":32788,"activeCount":124},[],{"trials":32790,"activeCount":124},[],{"trials":32792,"activeCount":124},[],{"trials":32794,"activeCount":124},[32795],{"nctId":32796,"briefTitle":32797,"status":182,"phases":32798,"primaryCompletion":5470,"completion":5470,"start":4758,"enrollment":2159,"conditions":32799,"interventions":32800},"NCT00352664","The Effect of Donepezil on Sedation and Other Symptoms",[89],[1942],[32785],{"trials":32802,"activeCount":124},[],{"trials":32804,"activeCount":124},[],{"intervention":32806,"totalTrials":166,"cells":32807},"Platelet Transfusion",{"EARLY_PHASE1":32808,"PHASE1":32810,"PHASE2":32812,"PHASE3":32814,"PHASE4":32822,"NA":32824},{"trials":32809,"activeCount":124},[],{"trials":32811,"activeCount":124},[],{"trials":32813,"activeCount":124},[],{"trials":32815,"activeCount":124},[32816],{"nctId":32817,"briefTitle":32818,"status":182,"phases":32819,"primaryCompletion":10260,"completion":10260,"start":14980,"enrollment":296,"conditions":32820,"interventions":32821},"NCT00074763","Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets",[89],[15,21],[32806],{"trials":32823,"activeCount":124},[],{"trials":32825,"activeCount":124},[],{"intervention":32827,"totalTrials":166,"cells":32828},"rhTPO",{"EARLY_PHASE1":32829,"PHASE1":32831,"PHASE2":32833,"PHASE3":32835,"PHASE4":32843,"NA":32845},{"trials":32830,"activeCount":124},[],{"trials":32832,"activeCount":124},[],{"trials":32834,"activeCount":124},[],{"trials":32836,"activeCount":124},[32837],{"nctId":32838,"briefTitle":32839,"status":130,"phases":32840,"primaryCompletion":8503,"completion":8503,"start":7487,"enrollment":676,"conditions":32841,"interventions":32842},"NCT00283582","Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy",[89],[2971],[32827],{"trials":32844,"activeCount":124},[],{"trials":32846,"activeCount":124},[],{"intervention":6071,"totalTrials":166,"cells":32848},{"EARLY_PHASE1":32849,"PHASE1":32851,"PHASE2":32853,"PHASE3":32855,"PHASE4":32861,"NA":32863},{"trials":32850,"activeCount":124},[],{"trials":32852,"activeCount":124},[],{"trials":32854,"activeCount":124},[],{"trials":32856,"activeCount":124},[32857],{"nctId":6062,"briefTitle":6063,"status":130,"phases":32858,"primaryCompletion":6065,"completion":6065,"start":5522,"enrollment":6066,"conditions":32859,"interventions":32860},[89],[18],[6069,5810,6070,6071],{"trials":32862,"activeCount":124},[],{"trials":32864,"activeCount":124},[],{"intervention":32866,"totalTrials":166,"cells":32867},"Insulin Glargine",{"EARLY_PHASE1":32868,"PHASE1":32870,"PHASE2":32872,"PHASE3":32874,"PHASE4":32883,"NA":32885},{"trials":32869,"activeCount":124},[],{"trials":32871,"activeCount":124},[],{"trials":32873,"activeCount":124},[],{"trials":32875,"activeCount":124},[32876],{"nctId":32877,"briefTitle":32878,"status":182,"phases":32879,"primaryCompletion":2326,"completion":2326,"start":12168,"enrollment":901,"conditions":32880,"interventions":32881},"NCT00500240","Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)",[89],[15,21],[32866,32882],"Insulin Aspart",{"trials":32884,"activeCount":124},[],{"trials":32886,"activeCount":124},[],{"intervention":32882,"totalTrials":166,"cells":32888},{"EARLY_PHASE1":32889,"PHASE1":32891,"PHASE2":32893,"PHASE3":32895,"PHASE4":32901,"NA":32903},{"trials":32890,"activeCount":124},[],{"trials":32892,"activeCount":124},[],{"trials":32894,"activeCount":124},[],{"trials":32896,"activeCount":124},[32897],{"nctId":32877,"briefTitle":32878,"status":182,"phases":32898,"primaryCompletion":2326,"completion":2326,"start":12168,"enrollment":901,"conditions":32899,"interventions":32900},[89],[15,21],[32866,32882],{"trials":32902,"activeCount":124},[],{"trials":32904,"activeCount":124},[],{"intervention":31702,"totalTrials":166,"cells":32906},{"EARLY_PHASE1":32907,"PHASE1":32909,"PHASE2":32911,"PHASE3":32913,"PHASE4":32919,"NA":32921},{"trials":32908,"activeCount":124},[],{"trials":32910,"activeCount":124},[],{"trials":32912,"activeCount":124},[],{"trials":32914,"activeCount":124},[32915],{"nctId":31696,"briefTitle":31697,"status":130,"phases":32916,"primaryCompletion":31699,"completion":31699,"start":4835,"enrollment":901,"conditions":32917,"interventions":32918},[89],[7652],[6070,31702,4330,31703,6069],{"trials":32920,"activeCount":124},[],{"trials":32922,"activeCount":124},[],{"intervention":31703,"totalTrials":166,"cells":32924},{"EARLY_PHASE1":32925,"PHASE1":32927,"PHASE2":32929,"PHASE3":32931,"PHASE4":32937,"NA":32939},{"trials":32926,"activeCount":124},[],{"trials":32928,"activeCount":124},[],{"trials":32930,"activeCount":124},[],{"trials":32932,"activeCount":124},[32933],{"nctId":31696,"briefTitle":31697,"status":130,"phases":32934,"primaryCompletion":31699,"completion":31699,"start":4835,"enrollment":901,"conditions":32935,"interventions":32936},[89],[7652],[6070,31702,4330,31703,6069],{"trials":32938,"activeCount":124},[],{"trials":32940,"activeCount":124},[],{"intervention":4629,"totalTrials":95,"cells":32942},{"EARLY_PHASE1":32943,"PHASE1":32945,"PHASE2":32951,"PHASE3":33005,"PHASE4":33007,"NA":33009},{"trials":32944,"activeCount":124},[],{"trials":32946,"activeCount":124},[32947],{"nctId":8258,"briefTitle":8259,"status":130,"phases":32948,"primaryCompletion":5120,"completion":5120,"start":4612,"enrollment":230,"conditions":32949,"interventions":32950},[87],[21,15,8262,8263,8264],[4629,894,8266],{"trials":32952,"activeCount":124},[32953,32957,32961,32965,32969,32979,32983,32987,32993,32997],{"nctId":5529,"briefTitle":5530,"status":182,"phases":32954,"primaryCompletion":2836,"completion":2836,"start":4193,"enrollment":2159,"conditions":32955,"interventions":32956},[88],[21],[5527,2374,4629,5526,5534,5535,654,2424,2293,5536,1070,803],{"nctId":4624,"briefTitle":4625,"status":203,"phases":32958,"primaryCompletion":4619,"completion":4619,"start":4153,"enrollment":124,"conditions":32959,"interventions":32960},[88],[15],[1004,803,2374,4629],{"nctId":5553,"briefTitle":5554,"status":130,"phases":32962,"primaryCompletion":5556,"completion":5556,"start":5557,"enrollment":381,"conditions":32963,"interventions":32964},[88],[21],[2424,2374,4629,5560,894],{"nctId":8523,"briefTitle":8524,"status":130,"phases":32966,"primaryCompletion":8526,"completion":8526,"start":8527,"enrollment":8528,"conditions":32967,"interventions":32968},[88],[15],[4629,894],{"nctId":32970,"briefTitle":32971,"status":182,"phases":32972,"primaryCompletion":32973,"completion":32973,"start":32974,"enrollment":121,"conditions":32975,"interventions":32976},"NCT01174082","Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant",[88],"2017-02-23","2010-07-20",[2245],[32977,32978,4629],"KLH Vaccine","KLH-id Vaccine",{"nctId":23442,"briefTitle":23443,"status":182,"phases":32980,"primaryCompletion":4290,"completion":4290,"start":8753,"enrollment":186,"conditions":32981,"interventions":32982},[88],[15],[8019,4629],{"nctId":8727,"briefTitle":8728,"status":130,"phases":32984,"primaryCompletion":2969,"completion":8730,"start":3997,"enrollment":924,"conditions":32985,"interventions":32986},[88],[21],[894,4629],{"nctId":32988,"briefTitle":32989,"status":130,"phases":32990,"primaryCompletion":2836,"completion":2836,"start":2910,"enrollment":550,"conditions":32991,"interventions":32992},"NCT00429104","Herceptin and GM-CSF for Metastatic Breast Cancer",[88],[18],[14610,4629],{"nctId":10269,"briefTitle":10270,"status":130,"phases":32994,"primaryCompletion":4619,"completion":4619,"start":10272,"enrollment":7377,"conditions":32995,"interventions":32996},[88],[1530,9926,5787],[1369,4629,10275],{"nctId":32998,"briefTitle":32999,"status":182,"phases":33000,"primaryCompletion":8730,"completion":8730,"start":2969,"enrollment":3197,"conditions":33001,"interventions":33002},"NCT00415857","Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)",[88],[15],[33003,33004,2681,4629],"Peptide Vaccine","Peginterferon alfa-2b",{"trials":33006,"activeCount":124},[],{"trials":33008,"activeCount":124},[],{"trials":33010,"activeCount":124},[],{"intervention":9894,"totalTrials":1496,"cells":33012},{"EARLY_PHASE1":33013,"PHASE1":33015,"PHASE2":33037,"PHASE3":33064,"PHASE4":33066,"NA":33068},{"trials":33014,"activeCount":124},[],{"trials":33016,"activeCount":124},[33017,33021,33025,33029,33033],{"nctId":10359,"briefTitle":10360,"status":130,"phases":33018,"primaryCompletion":4723,"completion":4723,"start":2944,"enrollment":34,"conditions":33019,"interventions":33020},[87],[33],[510,9894],{"nctId":9889,"briefTitle":9890,"status":130,"phases":33022,"primaryCompletion":3805,"completion":3805,"start":6409,"enrollment":593,"conditions":33023,"interventions":33024},[87],[1924],[510,9894,1369],{"nctId":10804,"briefTitle":10805,"status":182,"phases":33026,"primaryCompletion":10807,"completion":10807,"start":10808,"enrollment":10809,"conditions":33027,"interventions":33028},[87],[2922,10811,10812,10813,10814,10815,10816,10817,10818,2613,10819,10820,10821,10822,2924,1803,10823,10824,10825,10826,10827,10828,10829,2925,10830,10831,2926,10832,5086,10833,5087,5088,5089,7298,10834,10835,10836,10837,10838],[1275,1683,6656,9894],{"nctId":10861,"briefTitle":10862,"status":130,"phases":33030,"primaryCompletion":4162,"completion":4162,"start":4183,"enrollment":7694,"conditions":33031,"interventions":33032},[87],[1942],[9894,1275],{"nctId":13421,"briefTitle":13422,"status":130,"phases":33034,"primaryCompletion":3805,"start":4183,"enrollment":163,"conditions":33035,"interventions":33036},[87],[1924],[1028,3847,7180,1402,2207,10918,9894],{"trials":33038,"activeCount":124},[33039,33043,33047,33053,33060],{"nctId":30989,"briefTitle":30990,"status":130,"phases":33040,"primaryCompletion":5988,"completion":5988,"start":10075,"enrollment":95,"conditions":33041,"interventions":33042},[88],[4659,30,15],[13589,2584,9894],{"nctId":12637,"briefTitle":12638,"status":130,"phases":33044,"primaryCompletion":12640,"completion":12640,"start":12641,"enrollment":2700,"conditions":33045,"interventions":33046},[87,88],[15,1036],[612,12644],{"nctId":33048,"briefTitle":33049,"status":130,"phases":33050,"primaryCompletion":5470,"completion":4192,"start":5663,"enrollment":1240,"conditions":33051,"interventions":33052},"NCT00326170","Phase II 5-Azacytidine Plus VPA Plus ATRA",[88],[30,4659],[13589,9894,2247],{"nctId":33054,"briefTitle":33055,"status":182,"phases":33056,"primaryCompletion":15536,"completion":15536,"start":33057,"enrollment":1231,"conditions":33058,"interventions":33059},"NCT01900730","Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter",[88],"2014-07-31",[18],[9894],{"nctId":12672,"briefTitle":12673,"status":130,"phases":33061,"primaryCompletion":12586,"completion":12586,"start":2969,"enrollment":12675,"conditions":33062,"interventions":33063},[88],[30,4659],[612,9894],{"trials":33065,"activeCount":124},[],{"trials":33067,"activeCount":124},[],{"trials":33069,"activeCount":124},[],{"intervention":2227,"totalTrials":910,"cells":33071},{"EARLY_PHASE1":33072,"PHASE1":33074,"PHASE2":33110,"PHASE3":33131,"PHASE4":33133,"NA":33135},{"trials":33073,"activeCount":124},[],{"trials":33075,"activeCount":124},[33076,33084,33088,33092,33096,33106],{"nctId":33077,"briefTitle":33078,"status":130,"phases":33079,"primaryCompletion":27284,"completion":27284,"start":33080,"enrollment":20891,"conditions":33081,"interventions":33082},"NCT01372540","Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia",[87],"2012-02-24",[3396,2223,2224],[2227,33083],"Filanesib",{"nctId":2217,"briefTitle":2218,"status":130,"phases":33085,"primaryCompletion":2220,"completion":2220,"start":2221,"enrollment":550,"conditions":33086,"interventions":33087},[87],[2223,2224],[2226,2227,62],{"nctId":2249,"briefTitle":2250,"status":130,"phases":33089,"primaryCompletion":2252,"completion":2252,"start":2253,"enrollment":121,"conditions":33090,"interventions":33091},[87],[21],[2227,62],{"nctId":15026,"briefTitle":15027,"status":182,"phases":33093,"primaryCompletion":15029,"completion":15029,"start":10636,"enrollment":186,"conditions":33094,"interventions":33095},[87],[21],[767,2227],{"nctId":33097,"briefTitle":33098,"status":130,"phases":33099,"primaryCompletion":33100,"completion":33100,"start":33101,"enrollment":3379,"conditions":33102,"interventions":33105},"NCT01301807","Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma",[87],"2019-11-07","2011-07-28",[33103,33104,2223,2224],"Non-Secretory Plasma Cell Myeloma","Plasmacytosis",[2227,2340],{"nctId":8293,"briefTitle":8294,"status":182,"phases":33107,"primaryCompletion":8296,"completion":8296,"start":3769,"enrollment":550,"conditions":33108,"interventions":33109},[87],[21],[2227,1402,894],{"trials":33111,"activeCount":124},[33112,33120,33124],{"nctId":33113,"briefTitle":33114,"status":182,"phases":33115,"primaryCompletion":33116,"completion":33116,"start":33117,"enrollment":230,"conditions":33118,"interventions":33119},"NCT02042950","A Phase II Study of Carfilzomib in the Treatment of Relapsed\u002FRefractory Mantle Cell Lymphoma",[88],"2017-12-20","2014-07-14",[21],[2227],{"nctId":2598,"briefTitle":2599,"status":203,"phases":33121,"primaryCompletion":2601,"start":2602,"enrollment":124,"conditions":33122,"interventions":33123},[88],[2245],[2227,2605,2369,1004,2293,2368,62,2370,2371,2372],{"nctId":33125,"briefTitle":33126,"status":130,"phases":33127,"primaryCompletion":33128,"completion":33128,"start":7177,"enrollment":1496,"conditions":33129,"interventions":33130},"NCT01775930","Carfilzomib in Refractory Renal Cell Carcinoma (RCC)",[88],"2019-01-18",[1333],[2227],{"trials":33132,"activeCount":124},[],{"trials":33134,"activeCount":124},[],{"trials":33136,"activeCount":124},[],{"intervention":2368,"totalTrials":186,"cells":33138},{"EARLY_PHASE1":33139,"PHASE1":33141,"PHASE2":33151,"PHASE3":33177,"PHASE4":33179,"NA":33181},{"trials":33140,"activeCount":124},[],{"trials":33142,"activeCount":124},[33143,33147],{"nctId":4508,"briefTitle":4509,"status":130,"phases":33144,"primaryCompletion":2242,"completion":2242,"start":4511,"enrollment":959,"conditions":33145,"interventions":33146},[87],[21],[2405,2369,1004,2293,894,2374,2368,4514],{"nctId":4539,"briefTitle":4540,"status":130,"phases":33148,"primaryCompletion":4542,"completion":4542,"start":2969,"enrollment":817,"conditions":33149,"interventions":33150},[87],[15,21,2245],[1004,2369,2293,4545,2368],{"trials":33152,"activeCount":124},[33153,33157,33161,33165,33169,33173],{"nctId":2361,"briefTitle":2362,"status":203,"phases":33154,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":124,"conditions":33155,"interventions":33156},[88],[21],[2368,2340,2369,1004,2293,894,62,2370,2371,2372,2373,2374],{"nctId":4602,"briefTitle":4603,"status":130,"phases":33158,"primaryCompletion":4605,"completion":4605,"start":2968,"enrollment":3409,"conditions":33159,"interventions":33160},[88],[21],[2369,1004,2293,2368],{"nctId":2479,"briefTitle":2480,"status":130,"phases":33162,"primaryCompletion":2482,"completion":2482,"start":2483,"enrollment":1308,"conditions":33163,"interventions":33164},[88],[2245],[2368,62,2369,1004,2293,2374],{"nctId":3984,"briefTitle":3985,"status":130,"phases":33166,"primaryCompletion":3987,"completion":3987,"start":3988,"enrollment":2446,"conditions":33167,"interventions":33168},[88],[2971,3990],[2368,2977,2495,1016,1709],{"nctId":2598,"briefTitle":2599,"status":203,"phases":33170,"primaryCompletion":2601,"start":2602,"enrollment":124,"conditions":33171,"interventions":33172},[88],[2245],[2227,2605,2369,1004,2293,2368,62,2370,2371,2372],{"nctId":2897,"briefTitle":2898,"status":182,"phases":33174,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":186,"conditions":33175,"interventions":33176},[87,88],[21],[1402,2405,2369,1004,2293,894,62,2370,2371,2372,2904,2368],{"trials":33178,"activeCount":124},[],{"trials":33180,"activeCount":124},[],{"trials":33182,"activeCount":124},[],{"intervention":3848,"totalTrials":186,"cells":33184},{"EARLY_PHASE1":33185,"PHASE1":33187,"PHASE2":33217,"PHASE3":33254,"PHASE4":33256,"NA":33258},{"trials":33186,"activeCount":124},[],{"trials":33188,"activeCount":124},[33189,33193,33199,33209,33213],{"nctId":17963,"briefTitle":17964,"status":130,"phases":33190,"primaryCompletion":1558,"start":12649,"enrollment":3541,"conditions":33191,"interventions":33192},[87],[1942],[3848,1028],{"nctId":33194,"briefTitle":33195,"status":130,"phases":33196,"primaryCompletion":1558,"start":12649,"enrollment":834,"conditions":33197,"interventions":33198},"NCT00903734","An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status",[87],[33],[3848],{"nctId":33200,"briefTitle":33201,"status":130,"phases":33202,"primaryCompletion":1527,"completion":1527,"start":33203,"enrollment":473,"conditions":33204,"interventions":33208},"NCT00954226","Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer",[87],"2009-08-05",[33205,33206,33207,11576],"Recurrent Head and Neck Carcinoma","Recurrent Salivary Gland Carcinoma","Recurrent Skin Carcinoma",[3848],{"nctId":3839,"briefTitle":3840,"status":130,"phases":33210,"primaryCompletion":3842,"completion":3842,"start":3843,"enrollment":676,"conditions":33211,"interventions":33212},[87],[1836,1702,1703,1705,1706,1707,3845],[1709,1710,3847,3848],{"nctId":16408,"briefTitle":16409,"status":130,"phases":33214,"primaryCompletion":1558,"start":12649,"enrollment":628,"conditions":33215,"interventions":33216},[87],[1942],[3848,75],{"trials":33218,"activeCount":124},[33219,33231,33235],{"nctId":33220,"briefTitle":33221,"status":130,"phases":33222,"primaryCompletion":816,"completion":816,"start":33223,"enrollment":1409,"conditions":33224,"interventions":33230},"NCT01664897","Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[88],"2013-05-16",[846,33225,33226,33227,33228,33229,13708,737,30,648,3186],"Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11","Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11","Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1","Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A","Adult Acute Promyelocytic Leukemia With PML-RARA",[3848],{"nctId":4049,"briefTitle":4050,"status":130,"phases":33232,"primaryCompletion":4052,"completion":4052,"start":4053,"enrollment":4054,"conditions":33233,"interventions":33234},[88],[4056,4057,4058,4059,4060,4061,4062,4063,4064,4065,4066,4067,4068,4069,4070,1620,4071,4072,4073,4074,4075,4076,4077,4078],[1369,1709,1710,3848],{"nctId":33236,"briefTitle":33237,"status":130,"phases":33238,"primaryCompletion":33239,"completion":33240,"start":8900,"enrollment":1240,"conditions":33241,"interventions":33253},"NCT00749892","Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer",[88],"2019-06-30","2019-11-26",[1804,1805,1806,1807,33242,33243,33244,33245,33246,33247,33248,33249,7773,33250,33251,33252,1809,1810,1811,1780],"Stage 0a Bladder Cancer AJCC v8","Stage 0a Renal Pelvis Cancer AJCC v8","Stage 0a Ureter Cancer AJCC v8","Stage 0a Urethral Cancer AJCC v8","Stage 0is Bladder Cancer AJCC v8","Stage 0is Renal Pelvis Cancer AJCC v8","Stage 0is Ureter Cancer AJCC v8","Stage 0is Urethral Cancer AJCC v8","Stage II Renal Pelvis Cancer AJCC v8","Stage II Ureter Cancer AJCC v8","Stage II Urethral Cancer AJCC v8",[3848],{"trials":33255,"activeCount":124},[],{"trials":33257,"activeCount":124},[],{"trials":33259,"activeCount":124},[],{"intervention":4234,"totalTrials":1483,"cells":33261},{"EARLY_PHASE1":33262,"PHASE1":33264,"PHASE2":33270,"PHASE3":33298,"PHASE4":33300,"NA":33302},{"trials":33263,"activeCount":124},[],{"trials":33265,"activeCount":124},[33266],{"nctId":14537,"briefTitle":14538,"status":130,"phases":33267,"primaryCompletion":8340,"completion":8340,"start":6352,"enrollment":3379,"conditions":33268,"interventions":33269},[87],[1996,14541],[1371,4234,1113,1375],{"trials":33271,"activeCount":124},[33272,33276,33280,33284,33288,33294],{"nctId":22870,"briefTitle":22871,"status":130,"phases":33273,"primaryCompletion":3668,"completion":3668,"start":10760,"enrollment":1243,"conditions":33274,"interventions":33275},[88],[2049],[4234,2330],{"nctId":8412,"briefTitle":8413,"status":130,"phases":33277,"primaryCompletion":5522,"completion":5522,"start":8415,"enrollment":2018,"conditions":33278,"interventions":33279},[88],[21],[4234,894],{"nctId":17850,"briefTitle":17851,"status":130,"phases":33281,"primaryCompletion":4619,"completion":4619,"start":11135,"enrollment":448,"conditions":33282,"interventions":33283},[88],[10947],[4234,1368],{"nctId":12448,"briefTitle":12449,"status":130,"phases":33285,"primaryCompletion":5522,"completion":11731,"start":6352,"enrollment":95,"conditions":33286,"interventions":33287},[88],[12452],[4234,2369],{"nctId":33289,"briefTitle":33290,"status":130,"phases":33291,"primaryCompletion":21284,"completion":21284,"start":5301,"enrollment":1243,"conditions":33292,"interventions":33293},"NCT00043823","Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer",[87,88],[24],[4234,9998],{"nctId":4229,"briefTitle":4230,"status":130,"phases":33295,"primaryCompletion":2846,"completion":2846,"start":4183,"enrollment":1034,"conditions":33296,"interventions":33297},[88],[1293],[4234,1709,1013,806,4235],{"trials":33299,"activeCount":124},[],{"trials":33301,"activeCount":124},[],{"trials":33303,"activeCount":124},[],{"intervention":13589,"totalTrials":1483,"cells":33305},{"EARLY_PHASE1":33306,"PHASE1":33308,"PHASE2":33310,"PHASE3":33345,"PHASE4":33347,"NA":33349},{"trials":33307,"activeCount":124},[],{"trials":33309,"activeCount":124},[],{"trials":33311,"activeCount":124},[33312,33316,33323,33327,33331,33335,33339],{"nctId":18469,"briefTitle":18470,"status":182,"phases":33313,"primaryCompletion":3761,"completion":3761,"start":206,"enrollment":166,"conditions":33314,"interventions":33315},[87,88],[15],[2011,13589],{"nctId":33317,"briefTitle":33318,"status":130,"phases":33319,"primaryCompletion":1558,"completion":1558,"start":8386,"enrollment":2700,"conditions":33320,"interventions":33321},"NCT01202877","PKC412 and 5-Azacytidine",[87,88],[15],[18535,33322],"PKC412",{"nctId":30989,"briefTitle":30990,"status":130,"phases":33324,"primaryCompletion":5988,"completion":5988,"start":10075,"enrollment":95,"conditions":33325,"interventions":33326},[88],[4659,30,15],[13589,2584,9894],{"nctId":33048,"briefTitle":33049,"status":130,"phases":33328,"primaryCompletion":5470,"completion":4192,"start":5663,"enrollment":1240,"conditions":33329,"interventions":33330},[88],[30,4659],[13589,9894,2247],{"nctId":18526,"briefTitle":18527,"status":203,"phases":33332,"primaryCompletion":18529,"start":18530,"enrollment":124,"conditions":33333,"interventions":33334},[87,88],[15,18532,18533],[1124,18535],{"nctId":13582,"briefTitle":13583,"status":130,"phases":33336,"primaryCompletion":13585,"completion":13585,"start":13586,"enrollment":25,"conditions":33337,"interventions":33338},[87,88],[15],[13589,1402],{"nctId":33340,"briefTitle":33341,"status":182,"phases":33342,"primaryCompletion":4842,"completion":4842,"start":4612,"enrollment":910,"conditions":33343,"interventions":33344},"NCT00413478","5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia",[88],[712,15],[13589],{"trials":33346,"activeCount":124},[],{"trials":33348,"activeCount":124},[],{"trials":33350,"activeCount":124},[],{"intervention":2340,"totalTrials":230,"cells":33352},{"EARLY_PHASE1":33353,"PHASE1":33355,"PHASE2":33365,"PHASE3":33383,"PHASE4":33385,"NA":33387},{"trials":33354,"activeCount":124},[],{"trials":33356,"activeCount":124},[33357,33361],{"nctId":33097,"briefTitle":33098,"status":130,"phases":33358,"primaryCompletion":33100,"completion":33100,"start":33101,"enrollment":3379,"conditions":33359,"interventions":33360},[87],[33103,33104,2223,2224],[2227,2340],{"nctId":2332,"briefTitle":2333,"status":130,"phases":33362,"primaryCompletion":2335,"completion":2335,"start":2336,"enrollment":2337,"conditions":33363,"interventions":33364},[87],[2245],[2340,75,1402,62],{"trials":33366,"activeCount":124},[33367,33371,33375,33379],{"nctId":2361,"briefTitle":2362,"status":203,"phases":33368,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":124,"conditions":33369,"interventions":33370},[88],[21],[2368,2340,2369,1004,2293,894,62,2370,2371,2372,2373,2374],{"nctId":4631,"briefTitle":4632,"status":130,"phases":33372,"primaryCompletion":4634,"completion":4634,"start":4635,"enrollment":2946,"conditions":33373,"interventions":33374},[88],[3396,4637,2223,2224],[1004,4135,2293,2340],{"nctId":5617,"briefTitle":5618,"status":130,"phases":33376,"primaryCompletion":5620,"completion":5620,"start":5621,"enrollment":2933,"conditions":33377,"interventions":33378},[87,88],[5623],[2340,2495,1114,1369,2424,1071],{"nctId":14132,"briefTitle":14133,"status":130,"phases":33380,"primaryCompletion":6065,"completion":6065,"start":2836,"enrollment":2004,"conditions":33381,"interventions":33382},[87,88],[21],[2340,2840],{"trials":33384,"activeCount":124},[],{"trials":33386,"activeCount":124},[],{"trials":33388,"activeCount":124},[],{"intervention":1379,"totalTrials":230,"cells":33390},{"EARLY_PHASE1":33391,"PHASE1":33393,"PHASE2":33403,"PHASE3":33426,"PHASE4":33428,"NA":33430},{"trials":33392,"activeCount":124},[],{"trials":33394,"activeCount":124},[33395,33399],{"nctId":9941,"briefTitle":9942,"status":130,"phases":33396,"primaryCompletion":8340,"completion":8340,"start":3819,"enrollment":121,"conditions":33397,"interventions":33398},[87],[1924],[1379,2495,1369],{"nctId":1337,"briefTitle":1338,"status":182,"phases":33400,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":33401,"interventions":33402},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"trials":33404,"activeCount":124},[33405,33409,33413,33417],{"nctId":11870,"briefTitle":11871,"status":130,"phases":33406,"primaryCompletion":11873,"completion":11873,"start":11874,"enrollment":448,"conditions":33407,"interventions":33408},[88],[8942],[11877,1376,1379],{"nctId":7054,"briefTitle":7055,"status":130,"phases":33410,"primaryCompletion":7057,"completion":7057,"start":7058,"enrollment":1034,"conditions":33411,"interventions":33412},[88],[2245],[1379,803,2293],{"nctId":20300,"briefTitle":20301,"status":203,"phases":33414,"primaryCompletion":20303,"start":3761,"enrollment":124,"conditions":33415,"interventions":33416},[88],[11077],[1431,1379],{"nctId":33418,"briefTitle":33419,"status":130,"phases":33420,"primaryCompletion":6740,"completion":6740,"start":33421,"enrollment":1766,"conditions":33422,"interventions":33424},"NCT00317772","Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer",[87,88],"2004-09-02",[1530,33423,9926],"Peritoneal Neoplasms",[1379,33425],"Gefitinib",{"trials":33427,"activeCount":124},[],{"trials":33429,"activeCount":124},[],{"trials":33431,"activeCount":124},[],{"intervention":7180,"totalTrials":230,"cells":33433},{"EARLY_PHASE1":33434,"PHASE1":33436,"PHASE2":33454,"PHASE3":33464,"PHASE4":33466,"NA":33468},{"trials":33435,"activeCount":124},[],{"trials":33437,"activeCount":124},[33438,33442,33446,33450],{"nctId":20946,"briefTitle":20947,"status":130,"phases":33439,"primaryCompletion":2242,"completion":2242,"start":13673,"enrollment":20949,"conditions":33440,"interventions":33441},[87],[33],[7180,6516,14121],{"nctId":13421,"briefTitle":13422,"status":130,"phases":33443,"primaryCompletion":3805,"start":4183,"enrollment":163,"conditions":33444,"interventions":33445},[87],[1924],[1028,3847,7180,1402,2207,10918,9894],{"nctId":10910,"briefTitle":10911,"status":130,"phases":33447,"primaryCompletion":10913,"completion":10913,"start":10914,"enrollment":10915,"conditions":33448,"interventions":33449},[87],[1942],[1275,2207,3847,4227,7180,10918,1683],{"nctId":20280,"briefTitle":20281,"status":130,"phases":33451,"primaryCompletion":10449,"completion":10449,"start":3668,"enrollment":357,"conditions":33452,"interventions":33453},[87],[33],[1431,7180,4227,1431],{"trials":33455,"activeCount":124},[33456,33460],{"nctId":7174,"briefTitle":7175,"status":182,"phases":33457,"primaryCompletion":7177,"completion":7177,"start":5556,"enrollment":1568,"conditions":33458,"interventions":33459},[88],[18],[7180,1376,4218,6744,803],{"nctId":11172,"briefTitle":11173,"status":130,"phases":33461,"primaryCompletion":8339,"completion":8339,"start":3987,"enrollment":628,"conditions":33462,"interventions":33463},[88],[11176,11177],[1275,7180],{"trials":33465,"activeCount":124},[],{"trials":33467,"activeCount":124},[],{"trials":33469,"activeCount":124},[],{"intervention":2372,"totalTrials":3197,"cells":33471},{"EARLY_PHASE1":33472,"PHASE1":33474,"PHASE2":33476,"PHASE3":33498,"PHASE4":33500,"NA":33502},{"trials":33473,"activeCount":124},[],{"trials":33475,"activeCount":124},[],{"trials":33477,"activeCount":124},[33478,33482,33486,33490,33494],{"nctId":2361,"briefTitle":2362,"status":203,"phases":33479,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":124,"conditions":33480,"interventions":33481},[88],[21],[2368,2340,2369,1004,2293,894,62,2370,2371,2372,2373,2374],{"nctId":2397,"briefTitle":2398,"status":130,"phases":33483,"primaryCompletion":2400,"completion":2400,"start":2401,"enrollment":2402,"conditions":33484,"interventions":33485},[87,88],[33,21],[510,2405,2369,1004,2293,62,2371,2372,894],{"nctId":2598,"briefTitle":2599,"status":203,"phases":33487,"primaryCompletion":2601,"start":2602,"enrollment":124,"conditions":33488,"interventions":33489},[88],[2245],[2227,2605,2369,1004,2293,2368,62,2370,2371,2372],{"nctId":4831,"briefTitle":4832,"status":203,"phases":33491,"primaryCompletion":4834,"start":4835,"enrollment":124,"conditions":33492,"interventions":33493},[87,88],[21],[1004,2370,2371,2372,2235,510,2369,2293],{"nctId":2897,"briefTitle":2898,"status":182,"phases":33495,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":186,"conditions":33496,"interventions":33497},[87,88],[21],[1402,2405,2369,1004,2293,894,62,2370,2371,2372,2904,2368],{"trials":33499,"activeCount":124},[],{"trials":33501,"activeCount":124},[],{"trials":33503,"activeCount":124},[],{"intervention":1372,"totalTrials":3197,"cells":33505},{"EARLY_PHASE1":33506,"PHASE1":33508,"PHASE2":33522,"PHASE3":33537,"PHASE4":33539,"NA":33541},{"trials":33507,"activeCount":124},[],{"trials":33509,"activeCount":124},[33510,33514,33518],{"nctId":12807,"briefTitle":12808,"status":130,"phases":33511,"primaryCompletion":12810,"completion":12810,"start":12811,"enrollment":2997,"conditions":33512,"interventions":33513},[87],[12813,12814,361,5008,5009,5010,1951],[1683,1372,9970],{"nctId":12838,"briefTitle":12839,"status":130,"phases":33515,"primaryCompletion":12841,"completion":12841,"start":689,"enrollment":1240,"conditions":33516,"interventions":33517},[87],[1898,1676,1677,1678,1679],[1683,1372,7370],{"nctId":1337,"briefTitle":1338,"status":182,"phases":33519,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":33520,"interventions":33521},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"trials":33523,"activeCount":124},[33524,33528],{"nctId":18941,"briefTitle":18942,"status":203,"phases":33525,"primaryCompletion":18944,"completion":18944,"start":18945,"enrollment":124,"conditions":33526,"interventions":33527},[87,88],[18947,18948],[4022,1372,10692],{"nctId":33529,"briefTitle":33530,"status":130,"phases":33531,"primaryCompletion":33532,"completion":33532,"start":33533,"enrollment":676,"conditions":33534,"interventions":33535},"NCT00003245","Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma",[88],"2004-07-30","1998-02-18",[21],[33536],"irinotecan hydrochloride",{"trials":33538,"activeCount":124},[],{"trials":33540,"activeCount":124},[],{"trials":33542,"activeCount":124},[],{"intervention":10263,"totalTrials":3197,"cells":33544},{"EARLY_PHASE1":33545,"PHASE1":33547,"PHASE2":33563,"PHASE3":33582,"PHASE4":33584,"NA":33586},{"trials":33546,"activeCount":124},[],{"trials":33548,"activeCount":124},[33549,33556],{"nctId":33550,"briefTitle":33551,"status":182,"phases":33552,"primaryCompletion":27410,"completion":27410,"start":5522,"enrollment":1496,"conditions":33553,"interventions":33554},"NCT00533169","ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma",[87],[5735],[10263,33555],"Retinoic Acid",{"nctId":33557,"briefTitle":33558,"status":182,"phases":33559,"primaryCompletion":4542,"completion":4542,"start":33560,"enrollment":1231,"conditions":33561,"interventions":33562},"NCT00745732","Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)",[87],"2008-10-09",[10135],[10263],{"trials":33564,"activeCount":124},[33565,33572,33578],{"nctId":33566,"briefTitle":33567,"status":182,"phases":33568,"primaryCompletion":6367,"completion":6367,"start":6384,"enrollment":3521,"conditions":33569,"interventions":33571},"NCT00402896","Malignant Pleural Effusion With ZD6474",[88],[24,33570],"Pleural Effusion",[10263],{"nctId":33573,"briefTitle":33574,"status":130,"phases":33575,"primaryCompletion":3571,"completion":3571,"start":8719,"enrollment":2700,"conditions":33576,"interventions":33577},"NCT00410189","BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC",[88],[24],[10263],{"nctId":10257,"briefTitle":10258,"status":182,"phases":33579,"primaryCompletion":9560,"completion":9560,"start":10260,"enrollment":296,"conditions":33580,"interventions":33581},[88],[24],[10263,1369,1376],{"trials":33583,"activeCount":124},[],{"trials":33585,"activeCount":124},[],{"trials":33587,"activeCount":124},[],{"intervention":2449,"totalTrials":296,"cells":33589},{"EARLY_PHASE1":33590,"PHASE1":33592,"PHASE2":33598,"PHASE3":33612,"PHASE4":33614,"NA":33616},{"trials":33591,"activeCount":124},[],{"trials":33593,"activeCount":124},[33594],{"nctId":16400,"briefTitle":16401,"status":130,"phases":33595,"primaryCompletion":16403,"completion":16403,"start":16404,"enrollment":924,"conditions":33596,"interventions":33597},[87],[27],[2449,75],{"trials":33599,"activeCount":124},[33600,33604,33608],{"nctId":8302,"briefTitle":8303,"status":182,"phases":33601,"primaryCompletion":8305,"completion":8305,"start":8306,"enrollment":2779,"conditions":33602,"interventions":33603},[88],[3346],[6545,2449,894],{"nctId":2441,"briefTitle":2442,"status":130,"phases":33605,"primaryCompletion":2444,"completion":2444,"start":2445,"enrollment":2446,"conditions":33606,"interventions":33607},[88],[21],[1070,2449,894,2450,62],{"nctId":6925,"briefTitle":6926,"status":130,"phases":33609,"primaryCompletion":6928,"completion":6928,"start":6929,"enrollment":406,"conditions":33610,"interventions":33611},[88],[712],[1070,803,2449,894,1069],{"trials":33613,"activeCount":124},[],{"trials":33615,"activeCount":124},[],{"trials":33617,"activeCount":124},[],{"intervention":2351,"totalTrials":296,"cells":33619},{"EARLY_PHASE1":33620,"PHASE1":33622,"PHASE2":33631,"PHASE3":33649,"PHASE4":33651,"NA":33653},{"trials":33621,"activeCount":124},[],{"trials":33623,"activeCount":124},[33624],{"nctId":33625,"briefTitle":33626,"status":182,"phases":33627,"primaryCompletion":10046,"completion":10046,"start":33628,"enrollment":871,"conditions":33629,"interventions":33630},"NCT01067066","A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma",[87],"2010-02-03",[1729],[2351,3823],{"trials":33632,"activeCount":124},[33633,33637,33643],{"nctId":2344,"briefTitle":2345,"status":130,"phases":33634,"primaryCompletion":2347,"completion":2347,"start":2348,"enrollment":628,"conditions":33635,"interventions":33636},[88],[18],[2351,62,2352,2353],{"nctId":33638,"briefTitle":33639,"status":203,"phases":33640,"primaryCompletion":18530,"start":8730,"enrollment":124,"conditions":33641,"interventions":33642},"NCT01340729","Open-Label Study of TPI 287 for Patients With Metastatic Melanoma",[87,88],[1316],[2351],{"nctId":33644,"briefTitle":33645,"status":182,"phases":33646,"primaryCompletion":2968,"completion":3832,"start":4152,"enrollment":539,"conditions":33647,"interventions":33648},"NCT01113463","TPI 287 in Patients With Recurrent Glioblastoma Multiforme",[88],[11176],[2351],{"trials":33650,"activeCount":124},[],{"trials":33652,"activeCount":124},[],{"trials":33654,"activeCount":124},[],{"intervention":15480,"totalTrials":296,"cells":33656},{"EARLY_PHASE1":33657,"PHASE1":33659,"PHASE2":33674,"PHASE3":33692,"PHASE4":33694,"NA":33696},{"trials":33658,"activeCount":124},[],{"trials":33660,"activeCount":124},[33661,33665],{"nctId":15473,"briefTitle":15474,"status":182,"phases":33662,"primaryCompletion":12780,"completion":12780,"start":15476,"enrollment":186,"conditions":33663,"interventions":33664},[87],[4598,15478,3040,1026],[1028,2321,15480,598],{"nctId":33666,"briefTitle":33667,"status":182,"phases":33668,"primaryCompletion":33669,"completion":33669,"start":33670,"enrollment":166,"conditions":33671,"interventions":33672},"NCT02225574","An Open-Label, Phase I\u002FII Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)",[87],"2017-02-02","2015-03-11",[15],[33673,15480],"MEK-162",{"trials":33675,"activeCount":124},[33676,33682],{"nctId":33677,"briefTitle":33678,"status":203,"phases":33679,"start":6757,"enrollment":124,"conditions":33680,"interventions":33681},"NCT01270893","Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)",[88],[4195],[15480],{"nctId":33683,"briefTitle":33684,"status":130,"phases":33685,"primaryCompletion":33686,"completion":33686,"start":33687,"enrollment":33688,"conditions":33689,"interventions":33691},"NCT00129740","Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)",[88],"2018-07-11","2005-06-27",148,[33690],"Leukemia, Myelogenous, Chronic",[15480],{"trials":33693,"activeCount":124},[],{"trials":33695,"activeCount":124},[],{"trials":33697,"activeCount":124},[],{"intervention":2370,"totalTrials":296,"cells":33699},{"EARLY_PHASE1":33700,"PHASE1":33702,"PHASE2":33704,"PHASE3":33722,"PHASE4":33724,"NA":33726},{"trials":33701,"activeCount":124},[],{"trials":33703,"activeCount":124},[],{"trials":33705,"activeCount":124},[33706,33710,33714,33718],{"nctId":2361,"briefTitle":2362,"status":203,"phases":33707,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":124,"conditions":33708,"interventions":33709},[88],[21],[2368,2340,2369,1004,2293,894,62,2370,2371,2372,2373,2374],{"nctId":2598,"briefTitle":2599,"status":203,"phases":33711,"primaryCompletion":2601,"start":2602,"enrollment":124,"conditions":33712,"interventions":33713},[88],[2245],[2227,2605,2369,1004,2293,2368,62,2370,2371,2372],{"nctId":4831,"briefTitle":4832,"status":203,"phases":33715,"primaryCompletion":4834,"start":4835,"enrollment":124,"conditions":33716,"interventions":33717},[87,88],[21],[1004,2370,2371,2372,2235,510,2369,2293],{"nctId":2897,"briefTitle":2898,"status":182,"phases":33719,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":186,"conditions":33720,"interventions":33721},[87,88],[21],[1402,2405,2369,1004,2293,894,62,2370,2371,2372,2904,2368],{"trials":33723,"activeCount":124},[],{"trials":33725,"activeCount":124},[],{"trials":33727,"activeCount":124},[],{"intervention":9998,"totalTrials":296,"cells":33729},{"EARLY_PHASE1":33730,"PHASE1":33732,"PHASE2":33734,"PHASE3":33758,"PHASE4":33760,"NA":33762},{"trials":33731,"activeCount":124},[],{"trials":33733,"activeCount":124},[],{"trials":33735,"activeCount":124},[33736,33740,33748,33752],{"nctId":9993,"briefTitle":9994,"status":182,"phases":33737,"primaryCompletion":9560,"completion":9560,"start":6758,"enrollment":3197,"conditions":33738,"interventions":33739},[88],[24],[9998,1376,1369],{"nctId":33741,"briefTitle":33742,"status":130,"phases":33743,"primaryCompletion":33744,"completion":33744,"start":33745,"enrollment":1559,"conditions":33746,"interventions":33747},"NCT00871923","Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer",[88],"2019-12-04","2009-03-26",[10145,11176],[9998],{"nctId":33289,"briefTitle":33290,"status":130,"phases":33749,"primaryCompletion":21284,"completion":21284,"start":5301,"enrollment":1243,"conditions":33750,"interventions":33751},[87,88],[24],[4234,9998],{"nctId":33753,"briefTitle":33754,"status":182,"phases":33755,"primaryCompletion":4382,"completion":4382,"start":11731,"enrollment":95,"conditions":33756,"interventions":33757},"NCT00739063","Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer",[88],[18],[9998],{"trials":33759,"activeCount":124},[],{"trials":33761,"activeCount":124},[],{"trials":33763,"activeCount":124},[],{"intervention":8156,"totalTrials":296,"cells":33765},{"EARLY_PHASE1":33766,"PHASE1":33768,"PHASE2":33781,"PHASE3":33795,"PHASE4":33797,"NA":33799},{"trials":33767,"activeCount":124},[],{"trials":33769,"activeCount":124},[33770,33777],{"nctId":33771,"briefTitle":33772,"status":203,"phases":33773,"primaryCompletion":18529,"start":18530,"enrollment":124,"conditions":33774,"interventions":33775},"NCT02812056","Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies",[87],[7647,5799,7651,7652],[8156,33776],"TAK-228",{"nctId":21824,"briefTitle":21825,"status":130,"phases":33778,"primaryCompletion":19896,"completion":19896,"start":21827,"enrollment":1609,"conditions":33779,"interventions":33780},[87],[1836,1358,1319,1361,1362],[8156,21817,1839],{"trials":33782,"activeCount":124},[33783,33791],{"nctId":33784,"briefTitle":33785,"status":130,"phases":33786,"primaryCompletion":33787,"completion":33787,"start":33788,"enrollment":3521,"conditions":33789,"interventions":33790},"NCT02293005","Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma",[88],"2021-07-06","2015-05-20",[24,2319],[8156],{"nctId":8149,"briefTitle":8150,"status":130,"phases":33792,"primaryCompletion":8152,"completion":8152,"start":8153,"enrollment":628,"conditions":33793,"interventions":33794},[87,88],[450,360],[8156,53],{"trials":33796,"activeCount":124},[],{"trials":33798,"activeCount":124},[],{"trials":33800,"activeCount":124},[],{"intervention":2772,"totalTrials":296,"cells":33802},{"EARLY_PHASE1":33803,"PHASE1":33805,"PHASE2":33815,"PHASE3":33825,"PHASE4":33827,"NA":33829},{"trials":33804,"activeCount":124},[],{"trials":33806,"activeCount":124},[33807,33811],{"nctId":10729,"briefTitle":10730,"status":130,"phases":33808,"primaryCompletion":2777,"completion":2777,"start":3987,"enrollment":342,"conditions":33809,"interventions":33810},[87],[33],[10734,2772,1275,1683,1113,2772,1275],{"nctId":12875,"briefTitle":12876,"status":130,"phases":33812,"primaryCompletion":11088,"completion":11088,"start":12878,"enrollment":5162,"conditions":33813,"interventions":33814},[87],[3195],[2772,1683,1028,1113,1375],{"trials":33816,"activeCount":124},[33817,33821],{"nctId":12368,"briefTitle":12369,"status":130,"phases":33818,"primaryCompletion":12371,"completion":12371,"start":12372,"enrollment":1240,"conditions":33819,"interventions":33820},[88],[4107],[1375,4022,2772,2369],{"nctId":2764,"briefTitle":2765,"status":130,"phases":33822,"primaryCompletion":2767,"completion":2767,"start":2768,"enrollment":296,"conditions":33823,"interventions":33824},[87,88],[2770],[1710,2772,62],{"trials":33826,"activeCount":124},[],{"trials":33828,"activeCount":124},[],{"trials":33830,"activeCount":124},[],{"intervention":3064,"totalTrials":296,"cells":33832},{"EARLY_PHASE1":33833,"PHASE1":33835,"PHASE2":33851,"PHASE3":33861,"PHASE4":33863,"NA":33865},{"trials":33834,"activeCount":124},[],{"trials":33836,"activeCount":124},[33837,33841],{"nctId":3047,"briefTitle":3048,"status":3049,"phases":33838,"primaryCompletion":3051,"completion":3051,"start":3052,"enrollment":2018,"conditions":33839,"interventions":33840},[87],[1205,643,2512,678,1025,3054,3055,3056,3057,3058,30,913,608,665,3059,3060,666,914,528,3061,3062,529,651,682,882],[803,1005,1402,2293,2195,3064,894,2196],{"nctId":33842,"briefTitle":33843,"status":130,"phases":33844,"primaryCompletion":33845,"completion":33845,"start":33846,"enrollment":3726,"conditions":33847,"interventions":33850},"NCT02271711","Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent\u002FRefractory Brain Tumors",[87],"2020-08-28","2015-03-17",[33848,33849,3177],"Recurrent Childhood Medulloblastoma","Recurrent Ependymoma",[3064],{"trials":33852,"activeCount":124},[33853,33857],{"nctId":7110,"briefTitle":7111,"status":130,"phases":33854,"primaryCompletion":3152,"completion":3152,"start":7113,"enrollment":2700,"conditions":33855,"interventions":33856},[87,88],[1205,846,7115,644,647,30,608,649,682],[803,1070,2293,2195,3064,2196],{"nctId":13661,"briefTitle":13662,"status":130,"phases":33858,"primaryCompletion":13664,"completion":13664,"start":13665,"enrollment":2647,"conditions":33859,"interventions":33860},[88],[3396,3135],[13551,1402,2293,3064,13668],{"trials":33862,"activeCount":124},[],{"trials":33864,"activeCount":124},[],{"trials":33866,"activeCount":124},[],{"intervention":1839,"totalTrials":296,"cells":33868},{"EARLY_PHASE1":33869,"PHASE1":33871,"PHASE2":33885,"PHASE3":33891,"PHASE4":33893,"NA":33895},{"trials":33870,"activeCount":124},[],{"trials":33872,"activeCount":124},[33873,33877,33881],{"nctId":9873,"briefTitle":9874,"status":130,"phases":33874,"primaryCompletion":9876,"completion":9876,"start":9877,"enrollment":1328,"conditions":33875,"interventions":33876},[87],[2570,3457],[1369,1376,1839],{"nctId":26882,"briefTitle":26883,"status":130,"phases":33878,"primaryCompletion":26885,"completion":26885,"start":9877,"enrollment":2004,"conditions":33879,"interventions":33880},[87],[1343,361,2570,26887],[14121,1839],{"nctId":21824,"briefTitle":21825,"status":130,"phases":33882,"primaryCompletion":19896,"completion":19896,"start":21827,"enrollment":1609,"conditions":33883,"interventions":33884},[87],[1836,1358,1319,1361,1362],[8156,21817,1839],{"trials":33886,"activeCount":124},[33887],{"nctId":1831,"briefTitle":1832,"status":203,"phases":33888,"primaryCompletion":1834,"completion":1834,"start":1834,"enrollment":124,"conditions":33889,"interventions":33890},[87,88],[1388,1836,1837,1389,1390,1391,1355,1357,1358,1359,1319,1361,1362],[1050,1839],{"trials":33892,"activeCount":124},[],{"trials":33894,"activeCount":124},[],{"trials":33896,"activeCount":124},[],{"intervention":21141,"totalTrials":296,"cells":33898},{"EARLY_PHASE1":33899,"PHASE1":33901,"PHASE2":33903,"PHASE3":33923,"PHASE4":33925,"NA":33927},{"trials":33900,"activeCount":124},[],{"trials":33902,"activeCount":124},[],{"trials":33904,"activeCount":124},[33905,33909,33915,33919],{"nctId":21135,"briefTitle":21136,"status":203,"phases":33906,"primaryCompletion":21138,"completion":21138,"start":2669,"enrollment":124,"conditions":33907,"interventions":33908},[87,88],[3195],[12862,21141],{"nctId":33910,"briefTitle":33911,"status":1479,"phases":33912,"primaryCompletion":504,"completion":504,"start":3529,"enrollment":2997,"conditions":33913,"interventions":33914},"NCT05475171","Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)",[88],[7818,11077],[21141],{"nctId":21153,"briefTitle":21154,"status":203,"phases":33916,"primaryCompletion":21138,"completion":21138,"start":21156,"enrollment":124,"conditions":33917,"interventions":33918},[88],[10947,21158],[12862,21141],{"nctId":21161,"briefTitle":21162,"status":1479,"phases":33920,"primaryCompletion":4005,"completion":4006,"start":21164,"enrollment":834,"conditions":33921,"interventions":33922},[88],[3195,12862,21166],[12862,21141],{"trials":33924,"activeCount":124},[],{"trials":33926,"activeCount":124},[],{"trials":33928,"activeCount":124},[],{"intervention":17554,"totalTrials":296,"cells":33930},{"EARLY_PHASE1":33931,"PHASE1":33933,"PHASE2":33939,"PHASE3":33962,"PHASE4":33964,"NA":33966},{"trials":33932,"activeCount":124},[],{"trials":33934,"activeCount":124},[33935],{"nctId":17547,"briefTitle":17548,"status":130,"phases":33936,"primaryCompletion":17550,"completion":17550,"start":17551,"enrollment":539,"conditions":33937,"interventions":33938},[87],[11161,1729],[17554,3497,2383],{"trials":33940,"activeCount":124},[33941,33945,33953],{"nctId":17618,"briefTitle":17619,"status":130,"phases":33942,"primaryCompletion":3996,"completion":3996,"start":2580,"enrollment":1308,"conditions":33943,"interventions":33944},[88],[17622,17604,11176],[1368,3808,3497,17554,17624],{"nctId":33946,"briefTitle":33947,"status":130,"phases":33948,"primaryCompletion":3667,"completion":3667,"start":8340,"enrollment":2946,"conditions":33949,"interventions":33950},"NCT01067469","Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)",[88],[11176,11042],[33951,33952,17554],"Standard Dose Bevacizumab","Low Dose Bevacizumab",{"nctId":33954,"briefTitle":33955,"status":182,"phases":33956,"primaryCompletion":33957,"completion":33957,"start":33958,"enrollment":1483,"conditions":33959,"interventions":33961},"NCT03022578","Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma",[88],"2021-02-16","2017-11-07",[33960,28736,7740],"IDH Family Wildtype",[17554],{"trials":33963,"activeCount":124},[],{"trials":33965,"activeCount":124},[],{"trials":33967,"activeCount":124},[],{"intervention":5526,"totalTrials":1231,"cells":33969},{"EARLY_PHASE1":33970,"PHASE1":33972,"PHASE2":33974,"PHASE3":33988,"PHASE4":33990,"NA":33992},{"trials":33971,"activeCount":124},[],{"trials":33973,"activeCount":124},[],{"trials":33975,"activeCount":124},[33976,33980,33984],{"nctId":5519,"briefTitle":5520,"status":130,"phases":33977,"primaryCompletion":4382,"completion":4382,"start":5522,"enrollment":492,"conditions":33978,"interventions":33979},[88],[21,15],[5525,5526,5527,803,2424,1070,2293,894,806,2196],{"nctId":5529,"briefTitle":5530,"status":182,"phases":33981,"primaryCompletion":2836,"completion":2836,"start":4193,"enrollment":2159,"conditions":33982,"interventions":33983},[88],[21],[5527,2374,4629,5526,5534,5535,654,2424,2293,5536,1070,803],{"nctId":20057,"briefTitle":20058,"status":130,"phases":33985,"primaryCompletion":20060,"completion":20060,"start":2580,"enrollment":517,"conditions":33986,"interventions":33987},[87,88],[21],[20063,20064,5247,5526,20065,2584,2293,2374],{"trials":33989,"activeCount":124},[],{"trials":33991,"activeCount":124},[],{"trials":33993,"activeCount":124},[],{"intervention":16861,"totalTrials":1231,"cells":33995},{"EARLY_PHASE1":33996,"PHASE1":33998,"PHASE2":34004,"PHASE3":34021,"PHASE4":34023,"NA":34025},{"trials":33997,"activeCount":124},[],{"trials":33999,"activeCount":124},[34000],{"nctId":27669,"briefTitle":27670,"status":182,"phases":34001,"primaryCompletion":27672,"completion":27672,"start":22644,"enrollment":296,"conditions":34002,"interventions":34003},[87],[27674,27675,27676,27677],[19435,16861],{"trials":34005,"activeCount":124},[34006,34017],{"nctId":34007,"briefTitle":34008,"status":182,"phases":34009,"primaryCompletion":7420,"completion":7420,"start":34010,"enrollment":186,"conditions":34011,"interventions":34016},"NCT02906696","Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure",[88],"2016-10-28",[34012,34013,34014,34015,1025],"Blasts Under 15 Percent of Bone Marrow Nucleated Cells","Blasts Under 15 Percent of Peripheral Blood White Cells","Blasts Under 30 Percent of Bone Marrow Nucleated Cells","Blasts Under 30 Percent of Peripheral Blood White Cells",[16861],{"nctId":16853,"briefTitle":16854,"status":130,"phases":34018,"primaryCompletion":16856,"completion":16856,"start":16857,"enrollment":492,"conditions":34019,"interventions":34020},[87,88],[2471,644,16859,7348,1026,649,650],[16861,2477],{"trials":34022,"activeCount":124},[],{"trials":34024,"activeCount":124},[],{"trials":34026,"activeCount":124},[],{"intervention":3892,"totalTrials":1231,"cells":34028},{"EARLY_PHASE1":34029,"PHASE1":34031,"PHASE2":34037,"PHASE3":34051,"PHASE4":34053,"NA":34055},{"trials":34030,"activeCount":124},[],{"trials":34032,"activeCount":124},[34033],{"nctId":3886,"briefTitle":3887,"status":130,"phases":34034,"primaryCompletion":3889,"completion":3889,"start":3484,"enrollment":1483,"conditions":34035,"interventions":34036},[87],[24],[1709,3892],{"trials":34038,"activeCount":124},[34039,34045],{"nctId":34040,"briefTitle":34041,"status":182,"phases":34042,"primaryCompletion":4619,"completion":4619,"start":2969,"enrollment":1231,"conditions":34043,"interventions":34044},"NCT00409331","Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment",[88],[242],[3892],{"nctId":34046,"briefTitle":34047,"status":130,"phases":34048,"primaryCompletion":6628,"completion":6628,"start":20512,"enrollment":628,"conditions":34049,"interventions":34050},"NCT00078845","Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors",[88],[18,24,32323,1530,27,2936],[3892],{"trials":34052,"activeCount":124},[],{"trials":34054,"activeCount":124},[],{"trials":34056,"activeCount":124},[],{"intervention":2544,"totalTrials":1231,"cells":34058},{"EARLY_PHASE1":34059,"PHASE1":34061,"PHASE2":34067,"PHASE3":34077,"PHASE4":34079,"NA":34081},{"trials":34060,"activeCount":124},[],{"trials":34062,"activeCount":124},[34063],{"nctId":21077,"briefTitle":21078,"status":130,"phases":34064,"primaryCompletion":1567,"completion":1567,"start":21080,"enrollment":4171,"conditions":34065,"interventions":34066},[87],[2922,21082,2924,2925,2926],[16702,2544,9970],{"trials":34068,"activeCount":124},[34069,34073],{"nctId":18194,"briefTitle":18195,"status":130,"phases":34070,"primaryCompletion":18197,"completion":18197,"start":18198,"enrollment":517,"conditions":34071,"interventions":34072},[88],[18200,7793,18201,7796,7797,7798,7799,7800,7801,7802,18202],[2207,2544],{"nctId":2534,"briefTitle":2535,"status":130,"phases":34074,"primaryCompletion":2537,"completion":2537,"start":1000,"enrollment":834,"conditions":34075,"interventions":34076},[88],[1047,643,2539,2540,848,2541,2542,851],[2423,654,62,655,894,2207,2544,1016,810],{"trials":34078,"activeCount":124},[],{"trials":34080,"activeCount":124},[],{"trials":34082,"activeCount":124},[],{"intervention":27074,"totalTrials":1231,"cells":34084},{"EARLY_PHASE1":34085,"PHASE1":34087,"PHASE2":34089,"PHASE3":34109,"PHASE4":34111,"NA":34113},{"trials":34086,"activeCount":124},[],{"trials":34088,"activeCount":124},[],{"trials":34090,"activeCount":124},[34091,34098,34102],{"nctId":34092,"briefTitle":34093,"status":130,"phases":34094,"primaryCompletion":4542,"completion":4542,"start":4153,"enrollment":406,"conditions":34095,"interventions":34097},"NCT00467272","Catheter Related - Gram Positive Bloodstream Infections",[88],[34096],"Bloodstream Infection",[27074],{"nctId":27064,"briefTitle":27065,"status":130,"phases":34099,"primaryCompletion":405,"completion":405,"start":27067,"enrollment":1222,"conditions":34100,"interventions":34101},[88],[359,360],[27070,27071,27072,27073,2091,27074,27075],{"nctId":34103,"briefTitle":34104,"status":130,"phases":34105,"primaryCompletion":5733,"completion":4542,"start":4039,"enrollment":95,"conditions":34106,"interventions":34108},"NCT00507247","Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus",[88],[34107],"Staphylococcus Aureus",[27074],{"trials":34110,"activeCount":124},[],{"trials":34112,"activeCount":124},[],{"trials":34114,"activeCount":124},[],{"intervention":5247,"totalTrials":1231,"cells":34116},{"EARLY_PHASE1":34117,"PHASE1":34119,"PHASE2":34121,"PHASE3":34135,"PHASE4":34137,"NA":34139},{"trials":34118,"activeCount":124},[],{"trials":34120,"activeCount":124},[],{"trials":34122,"activeCount":124},[34123,34127,34131],{"nctId":20057,"briefTitle":20058,"status":130,"phases":34124,"primaryCompletion":20060,"completion":20060,"start":2580,"enrollment":517,"conditions":34125,"interventions":34126},[87,88],[21],[20063,20064,5247,5526,20065,2584,2293,2374],{"nctId":5237,"briefTitle":5238,"status":130,"phases":34128,"primaryCompletion":5240,"completion":5240,"start":5241,"enrollment":971,"conditions":34129,"interventions":34130},[88],[2530,5243,5244,5245],[5247,2293,1254,1070,803,1114],{"nctId":32053,"briefTitle":32054,"status":130,"phases":34132,"primaryCompletion":3213,"completion":3213,"start":4887,"enrollment":1222,"conditions":34133,"interventions":34134},[88],[21],[14612,32058,5247],{"trials":34136,"activeCount":124},[],{"trials":34138,"activeCount":124},[],{"trials":34140,"activeCount":124},[],{"intervention":2585,"totalTrials":1231,"cells":34142},{"EARLY_PHASE1":34143,"PHASE1":34145,"PHASE2":34155,"PHASE3":34161,"PHASE4":34163,"NA":34165},{"trials":34144,"activeCount":124},[],{"trials":34146,"activeCount":124},[34147,34151],{"nctId":12272,"briefTitle":12273,"status":130,"phases":34148,"primaryCompletion":3725,"completion":3725,"start":7473,"enrollment":9,"conditions":34149,"interventions":34150},[87],[1924],[2585,2369,12277],{"nctId":10920,"briefTitle":10921,"status":130,"phases":34152,"primaryCompletion":61,"completion":61,"start":10923,"enrollment":4733,"conditions":34153,"interventions":34154},[87],[1942],[2585,1275,6656],{"trials":34156,"activeCount":124},[34157],{"nctId":2577,"briefTitle":2578,"status":130,"phases":34158,"primaryCompletion":1558,"completion":1558,"start":2580,"enrollment":2581,"conditions":34159,"interventions":34160},[88],[21],[803,1114,1016,806,2584,62,2374,2585],{"trials":34162,"activeCount":124},[],{"trials":34164,"activeCount":124},[],{"trials":34166,"activeCount":124},[],{"intervention":12277,"totalTrials":1231,"cells":34168},{"EARLY_PHASE1":34169,"PHASE1":34171,"PHASE2":34185,"PHASE3":34191,"PHASE4":34193,"NA":34195},{"trials":34170,"activeCount":124},[],{"trials":34172,"activeCount":124},[34173,34177],{"nctId":12272,"briefTitle":12273,"status":130,"phases":34174,"primaryCompletion":3725,"completion":3725,"start":7473,"enrollment":9,"conditions":34175,"interventions":34176},[87],[1924],[2585,2369,12277],{"nctId":34178,"briefTitle":34179,"status":130,"phases":34180,"primaryCompletion":3725,"completion":3725,"start":4697,"enrollment":1975,"conditions":34181,"interventions":34182},"NCT00770731","Study of Temsirolimus, Topotecan, and Bortezomib",[87],[1942],[34183,34184,12277],"Torisel","Hycamtin",{"trials":34186,"activeCount":124},[34187],{"nctId":20228,"briefTitle":20229,"status":130,"phases":34188,"primaryCompletion":4786,"completion":4786,"start":6352,"enrollment":1034,"conditions":34189,"interventions":34190},[87,88],[2245],[20233,12277,2293,20234],{"trials":34192,"activeCount":124},[],{"trials":34194,"activeCount":124},[],{"trials":34196,"activeCount":124},[],{"intervention":974,"totalTrials":1231,"cells":34198},{"EARLY_PHASE1":34199,"PHASE1":34201,"PHASE2":34203,"PHASE3":34217,"PHASE4":34219,"NA":34221},{"trials":34200,"activeCount":124},[],{"trials":34202,"activeCount":124},[],{"trials":34204,"activeCount":124},[34205,34209,34213],{"nctId":8419,"briefTitle":8420,"status":203,"phases":34206,"primaryCompletion":8422,"completion":3880,"start":8423,"enrollment":124,"conditions":34207,"interventions":34208},[88],[6956,5445],[974,894,8426,8427],{"nctId":7957,"briefTitle":7958,"status":182,"phases":34210,"primaryCompletion":3446,"completion":3446,"start":7960,"enrollment":296,"conditions":34211,"interventions":34212},[88],[7962,7963],[53,974,7965,1710],{"nctId":966,"briefTitle":967,"status":182,"phases":34214,"primaryCompletion":969,"completion":969,"start":970,"enrollment":971,"conditions":34215,"interventions":34216},[87,88],[36,608,610],[510,974,480],{"trials":34218,"activeCount":124},[],{"trials":34220,"activeCount":124},[],{"trials":34222,"activeCount":124},[],{"intervention":34224,"totalTrials":1231,"cells":34225},"Sintilimab",{"EARLY_PHASE1":34226,"PHASE1":34228,"PHASE2":34230,"PHASE3":34259,"PHASE4":34261,"NA":34263},{"trials":34227,"activeCount":124},[],{"trials":34229,"activeCount":124},[],{"trials":34231,"activeCount":124},[34232,34239,34248],{"nctId":34233,"briefTitle":34234,"status":130,"phases":34235,"primaryCompletion":10057,"completion":10057,"start":16698,"enrollment":1496,"conditions":34236,"interventions":34238},"NCT05024968","Sintilimab in Cancer of Unknown Primary",[88],[34237],"Cancer of Unknown Primary Site",[34224],{"nctId":34240,"briefTitle":34241,"status":182,"phases":34242,"primaryCompletion":34243,"completion":34243,"start":34244,"enrollment":230,"conditions":34245,"interventions":34247},"NCT05026736","Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study",[88],"2025-08-12","2021-08-23",[34246,13363,13365],"Locally Advanced Angiosarcoma",[34224],{"nctId":34249,"briefTitle":34250,"status":182,"phases":34251,"primaryCompletion":34252,"completion":34252,"start":34253,"enrollment":230,"conditions":34254,"interventions":34258},"NCT05017103","Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study",[88],"2024-02-20","2021-07-13",[34255,34256,1509,34257],"Locally Advanced Undifferentiated Pleomorphic Sarcoma","Metastatic Undifferentiated Pleomorphic Sarcoma","Unresectable Undifferentiated Pleomorphic Sarcoma",[34224],{"trials":34260,"activeCount":124},[],{"trials":34262,"activeCount":124},[],{"trials":34264,"activeCount":124},[],{"intervention":4452,"totalTrials":1231,"cells":34266},{"EARLY_PHASE1":34267,"PHASE1":34269,"PHASE2":34271,"PHASE3":34291,"PHASE4":34293,"NA":34295},{"trials":34268,"activeCount":124},[],{"trials":34270,"activeCount":124},[],{"trials":34272,"activeCount":124},[34273,34281,34287],{"nctId":34274,"briefTitle":34275,"status":130,"phases":34276,"primaryCompletion":34277,"completion":34277,"start":2901,"enrollment":2581,"conditions":34278,"interventions":34279},"NCT02684162","Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant",[88],"2024-10-08",[36,737,30,608,609],[34280,4452],"Donor Lymphocytes",{"nctId":34282,"briefTitle":34283,"status":130,"phases":34284,"primaryCompletion":12761,"completion":12761,"start":13992,"enrollment":1222,"conditions":34285,"interventions":34286},"NCT02131597","Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes",[88],[1067],[4452],{"nctId":4445,"briefTitle":4446,"status":130,"phases":34288,"primaryCompletion":4448,"completion":4448,"start":4449,"enrollment":1559,"conditions":34289,"interventions":34290},[88],[652],[599,4452,655],{"trials":34292,"activeCount":124},[],{"trials":34294,"activeCount":124},[],{"trials":34296,"activeCount":124},[],{"intervention":9655,"totalTrials":1231,"cells":34298},{"EARLY_PHASE1":34299,"PHASE1":34301,"PHASE2":34307,"PHASE3":34321,"PHASE4":34323,"NA":34325},{"trials":34300,"activeCount":124},[],{"trials":34302,"activeCount":124},[34303],{"nctId":12545,"briefTitle":12546,"status":182,"phases":34304,"primaryCompletion":1984,"completion":1984,"start":12548,"enrollment":121,"conditions":34305,"interventions":34306},[87],[15],[9655,612],{"trials":34308,"activeCount":124},[34309,34317],{"nctId":34310,"briefTitle":34311,"status":130,"phases":34312,"primaryCompletion":34313,"completion":34313,"start":34314,"enrollment":473,"conditions":34315,"interventions":34316},"NCT02159872","Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure",[88],"2020-04-14","2015-05-18",[15],[9655],{"nctId":9649,"briefTitle":9650,"status":130,"phases":34318,"primaryCompletion":9652,"completion":9652,"start":7155,"enrollment":593,"conditions":34319,"interventions":34320},[88],[15],[9655,654],{"trials":34322,"activeCount":124},[],{"trials":34324,"activeCount":124},[],{"trials":34326,"activeCount":124},[],{"intervention":2247,"totalTrials":1231,"cells":34328},{"EARLY_PHASE1":34329,"PHASE1":34331,"PHASE2":34337,"PHASE3":34347,"PHASE4":34349,"NA":34351},{"trials":34330,"activeCount":124},[],{"trials":34332,"activeCount":124},[34333],{"nctId":2239,"briefTitle":2240,"status":182,"phases":34334,"primaryCompletion":2242,"completion":2242,"start":2243,"enrollment":121,"conditions":34335,"interventions":34336},[87],[2245],[1402,62,2247],{"trials":34338,"activeCount":124},[34339,34343],{"nctId":16006,"briefTitle":16007,"status":130,"phases":34340,"primaryCompletion":2288,"completion":2288,"start":2969,"enrollment":959,"conditions":34341,"interventions":34342},[88],[16010],[2247,16012,655,694],{"nctId":33048,"briefTitle":33049,"status":130,"phases":34344,"primaryCompletion":5470,"completion":4192,"start":5663,"enrollment":1240,"conditions":34345,"interventions":34346},[88],[30,4659],[13589,9894,2247],{"trials":34348,"activeCount":124},[],{"trials":34350,"activeCount":124},[],{"trials":34352,"activeCount":124},[],{"intervention":31434,"totalTrials":1231,"cells":34354},{"EARLY_PHASE1":34355,"PHASE1":34357,"PHASE2":34372,"PHASE3":34383,"PHASE4":34385,"NA":34387},{"trials":34356,"activeCount":124},[],{"trials":34358,"activeCount":124},[34359,34368],{"nctId":34360,"briefTitle":34361,"status":130,"phases":34362,"primaryCompletion":8503,"completion":8503,"start":34363,"enrollment":1609,"conditions":34364,"interventions":34367},"NCT00038584","A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer",[87],"1999-06",[34365,34366],"Carcinoma, Squamous Cell","Cancer of Head and Neck",[31434],{"nctId":31428,"briefTitle":31429,"status":182,"phases":34369,"primaryCompletion":10260,"completion":8719,"start":31431,"enrollment":166,"conditions":34370,"interventions":34371},[87],[242],[31421,31434],{"trials":34373,"activeCount":124},[34374],{"nctId":34375,"briefTitle":34376,"status":130,"phases":34377,"primaryCompletion":34378,"completion":34378,"start":34379,"enrollment":2018,"conditions":34380,"interventions":34382},"NCT00038597","Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)",[88],"2004-05-07","2001-04-30",[34381],"Myelogenous Leukemia, Chronic",[31434],{"trials":34384,"activeCount":124},[],{"trials":34386,"activeCount":124},[],{"trials":34388,"activeCount":124},[],{"intervention":27073,"totalTrials":1231,"cells":34390},{"EARLY_PHASE1":34391,"PHASE1":34393,"PHASE2":34395,"PHASE3":34420,"PHASE4":34422,"NA":34424},{"trials":34392,"activeCount":124},[],{"trials":34394,"activeCount":124},[],{"trials":34396,"activeCount":124},[34397,34407,34411],{"nctId":34398,"briefTitle":34399,"status":130,"phases":34400,"primaryCompletion":34401,"completion":14149,"start":1290,"enrollment":1222,"conditions":34402,"interventions":34404},"NCT03485950","Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam",[88],"2021-05-01",[34403],"Other Infectious Diseases",[27071,34405,27072,27073,34406],"Ceftolozane","Tazobactam",{"nctId":27064,"briefTitle":27065,"status":130,"phases":34408,"primaryCompletion":405,"completion":405,"start":27067,"enrollment":1222,"conditions":34409,"interventions":34410},[88],[359,360],[27070,27071,27072,27073,2091,27074,27075],{"nctId":34412,"briefTitle":34413,"status":203,"phases":34414,"primaryCompletion":34415,"completion":34415,"start":14029,"enrollment":124,"conditions":34416,"interventions":34418},"NCT03862079","Fecal Transplant +\u002F- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics",[88],"2021-12-31",[34417],"Graft-versus-host Disease Prevention",[34419,27073],"Nystatin",{"trials":34421,"activeCount":124},[],{"trials":34423,"activeCount":124},[],{"trials":34425,"activeCount":124},[],{"intervention":2038,"totalTrials":1231,"cells":34427},{"EARLY_PHASE1":34428,"PHASE1":34430,"PHASE2":34432,"PHASE3":34446,"PHASE4":34448,"NA":34450},{"trials":34429,"activeCount":124},[],{"trials":34431,"activeCount":124},[],{"trials":34433,"activeCount":124},[34434,34438,34442],{"nctId":8597,"briefTitle":8598,"status":130,"phases":34435,"primaryCompletion":4934,"completion":4934,"start":8600,"enrollment":1483,"conditions":34436,"interventions":34437},[88],[15,712,8602],[2038,894],{"nctId":2031,"briefTitle":2032,"status":182,"phases":34439,"primaryCompletion":2034,"completion":2034,"start":2035,"enrollment":1496,"conditions":34440,"interventions":34441},[88],[15],[2038,1050,510],{"nctId":10632,"briefTitle":10633,"status":182,"phases":34443,"primaryCompletion":10635,"completion":10635,"start":10636,"enrollment":593,"conditions":34444,"interventions":34445},[88],[643,846,608,610],[510,2038],{"trials":34447,"activeCount":124},[],{"trials":34449,"activeCount":124},[],{"trials":34451,"activeCount":124},[],{"intervention":14024,"totalTrials":1231,"cells":34453},{"EARLY_PHASE1":34454,"PHASE1":34456,"PHASE2":34462,"PHASE3":34476,"PHASE4":34478,"NA":34480},{"trials":34455,"activeCount":124},[],{"trials":34457,"activeCount":124},[34458],{"nctId":14017,"briefTitle":14018,"status":130,"phases":34459,"primaryCompletion":14020,"completion":14020,"start":14021,"enrollment":6385,"conditions":34460,"interventions":34461},[87],[2922,2924,2925,2926],[6778,14024,2840],{"trials":34463,"activeCount":124},[34464,34472],{"nctId":34465,"briefTitle":34466,"status":182,"phases":34467,"primaryCompletion":34468,"completion":34468,"start":34469,"enrollment":1483,"conditions":34470,"interventions":34471},"NCT01952054","Denosumab for Breast Cancer With Bone Mets",[88],"2018-10-10","2015-02-09",[18],[14024],{"nctId":23795,"briefTitle":23796,"status":130,"phases":34473,"primaryCompletion":23798,"completion":23798,"start":23799,"enrollment":195,"conditions":34474,"interventions":34475},[88],[18],[23802,14024,8031],{"trials":34477,"activeCount":124},[],{"trials":34479,"activeCount":124},[],{"trials":34481,"activeCount":124},[],{"intervention":2194,"totalTrials":1231,"cells":34483},{"EARLY_PHASE1":34484,"PHASE1":34490,"PHASE2":34496,"PHASE3":34502,"PHASE4":34504,"NA":34506},{"trials":34485,"activeCount":124},[34486],{"nctId":2181,"briefTitle":2182,"status":203,"phases":34487,"primaryCompletion":2184,"completion":2184,"start":2185,"enrollment":124,"conditions":34488,"interventions":34489},[86],[2187,2188,2189,2190,2191,2192],[75,1004,803,62,1005,2194,2195,894,2196],{"trials":34491,"activeCount":124},[34492],{"nctId":3159,"briefTitle":3160,"status":203,"phases":34493,"primaryCompletion":1174,"completion":1174,"start":3162,"enrollment":124,"conditions":34494,"interventions":34495},[87],[3164,3165,3166,3167,3168,3169,3170,3171,3172,3173,3174,3175,3176,3177,3178],[2424,1005,2194,2293,2195,2196,1254],{"trials":34497,"activeCount":124},[34498],{"nctId":3443,"briefTitle":3444,"status":182,"phases":34499,"primaryCompletion":3446,"completion":3446,"start":3447,"enrollment":166,"conditions":34500,"interventions":34501},[88],[3449,3450,3451,3452,2570,3453,3454,3455,3456,3457,3458,3459],[3420,2424,1005,2194,2293,2195,2196,1254],{"trials":34503,"activeCount":124},[],{"trials":34505,"activeCount":124},[],{"trials":34507,"activeCount":124},[],{"intervention":11464,"totalTrials":1231,"cells":34509},{"EARLY_PHASE1":34510,"PHASE1":34512,"PHASE2":34514,"PHASE3":34535,"PHASE4":34537,"NA":34539},{"trials":34511,"activeCount":124},[],{"trials":34513,"activeCount":124},[],{"trials":34515,"activeCount":124},[34516,34523,34531],{"nctId":34517,"briefTitle":34518,"status":182,"phases":34519,"primaryCompletion":2232,"completion":2232,"start":3725,"enrollment":230,"conditions":34520,"interventions":34522},"NCT01266070","TKI 258 in Von Hippel-Lindau Syndrome (VHL)",[88],[34521],"Von Hippel-Lindau Syndrome",[11464],{"nctId":34524,"briefTitle":34525,"status":130,"phases":34526,"primaryCompletion":34527,"completion":34527,"start":34528,"enrollment":492,"conditions":34529,"interventions":34530},"NCT01262027","TKI258 for Metastatic Inflammatory Breast Cancer Patients",[88],"2015-11-25","2012-01-27",[18],[11464],{"nctId":11459,"briefTitle":11460,"status":182,"phases":34532,"primaryCompletion":5829,"completion":5829,"start":640,"enrollment":296,"conditions":34533,"interventions":34534},[88],[27],[11464,3699,809],{"trials":34536,"activeCount":124},[],{"trials":34538,"activeCount":124},[],{"trials":34540,"activeCount":124},[],{"intervention":7021,"totalTrials":1231,"cells":34542},{"EARLY_PHASE1":34543,"PHASE1":34545,"PHASE2":34551,"PHASE3":34561,"PHASE4":34563,"NA":34565},{"trials":34544,"activeCount":124},[],{"trials":34546,"activeCount":124},[34547],{"nctId":19690,"briefTitle":19691,"status":203,"phases":34548,"primaryCompletion":19693,"completion":19693,"start":19693,"enrollment":124,"conditions":34549,"interventions":34550},[87],[19695],[1198,19697,7021],{"trials":34552,"activeCount":124},[34553,34557],{"nctId":7014,"briefTitle":7015,"status":182,"phases":34554,"primaryCompletion":1984,"completion":1984,"start":7017,"enrollment":166,"conditions":34555,"interventions":34556},[88],[15,7019,2653,21],[654,7021,1016,809,7022,2425,894,806,803,805,1013,4514,7023],{"nctId":7222,"briefTitle":7223,"status":130,"phases":34558,"primaryCompletion":7225,"completion":7225,"start":7226,"enrollment":1100,"conditions":34559,"interventions":34560},[88],[7228,2653],[7021,1016,7230,7231,803,654,805,806,1013,7023],{"trials":34562,"activeCount":124},[],{"trials":34564,"activeCount":124},[],{"trials":34566,"activeCount":124},[],{"intervention":2292,"totalTrials":1231,"cells":34568},{"EARLY_PHASE1":34569,"PHASE1":34571,"PHASE2":34587,"PHASE3":34593,"PHASE4":34595,"NA":34597},{"trials":34570,"activeCount":124},[],{"trials":34572,"activeCount":124},[34573,34577],{"nctId":2285,"briefTitle":2286,"status":182,"phases":34574,"primaryCompletion":2288,"completion":2288,"start":2289,"enrollment":1231,"conditions":34575,"interventions":34576},[87],[2245],[2292,2293,62],{"nctId":34578,"briefTitle":34579,"status":182,"phases":34580,"primaryCompletion":34581,"completion":34581,"start":34582,"enrollment":1568,"conditions":34583,"interventions":34586},"NCT01198067","Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia",[87],"2025-05-02","2010-10-06",[34584,34585],"Recurrent Waldenstrom Macroglobulinemia","Refractory Waldenstrom Macroglobulinemia",[2292],{"trials":34588,"activeCount":124},[34589],{"nctId":2704,"briefTitle":2705,"status":182,"phases":34590,"primaryCompletion":2707,"completion":2707,"start":2708,"enrollment":871,"conditions":34591,"interventions":34592},[87,88],[2710,2223,2224],[62,2712,2292],{"trials":34594,"activeCount":124},[],{"trials":34596,"activeCount":124},[],{"trials":34598,"activeCount":124},[],{"intervention":33425,"totalTrials":121,"cells":34600},{"EARLY_PHASE1":34601,"PHASE1":34603,"PHASE2":34605,"PHASE3":34618,"PHASE4":34620,"NA":34622},{"trials":34602,"activeCount":124},[],{"trials":34604,"activeCount":124},[],{"trials":34606,"activeCount":124},[34607,34614],{"nctId":34608,"briefTitle":34609,"status":130,"phases":34610,"primaryCompletion":18530,"completion":18530,"start":20512,"enrollment":1609,"conditions":34611,"interventions":34613},"NCT00509002","Iressa Study in Patients With Salivary Gland Cancer",[88],[34612],"Salivary Gland Cancer",[33425],{"nctId":33418,"briefTitle":33419,"status":130,"phases":34615,"primaryCompletion":6740,"completion":6740,"start":33421,"enrollment":1766,"conditions":34616,"interventions":34617},[87,88],[1530,33423,9926],[1379,33425],{"trials":34619,"activeCount":124},[],{"trials":34621,"activeCount":124},[],{"trials":34623,"activeCount":124},[],{"intervention":2352,"totalTrials":121,"cells":34625},{"EARLY_PHASE1":34626,"PHASE1":34628,"PHASE2":34630,"PHASE3":34640,"PHASE4":34642,"NA":34644},{"trials":34627,"activeCount":124},[],{"trials":34629,"activeCount":124},[],{"trials":34631,"activeCount":124},[34632,34636],{"nctId":2344,"briefTitle":2345,"status":130,"phases":34633,"primaryCompletion":2347,"completion":2347,"start":2348,"enrollment":628,"conditions":34634,"interventions":34635},[88],[18],[2351,62,2352,2353],{"nctId":20292,"briefTitle":20293,"status":130,"phases":34637,"primaryCompletion":20295,"completion":20295,"start":20296,"enrollment":34,"conditions":34638,"interventions":34639},[88],[1333],[1431,6656,2352],{"trials":34641,"activeCount":124},[],{"trials":34643,"activeCount":124},[],{"trials":34645,"activeCount":124},[],{"intervention":3498,"totalTrials":121,"cells":34647},{"EARLY_PHASE1":34648,"PHASE1":34650,"PHASE2":34656,"PHASE3":34662,"PHASE4":34664,"NA":34666},{"trials":34649,"activeCount":124},[],{"trials":34651,"activeCount":124},[34652],{"nctId":3490,"briefTitle":3491,"status":182,"phases":34653,"primaryCompletion":3493,"completion":3493,"start":3494,"enrollment":1766,"conditions":34654,"interventions":34655},[87],[1729],[1049,3497,1709,3498,3499],{"trials":34657,"activeCount":124},[34658],{"nctId":12752,"briefTitle":12753,"status":182,"phases":34659,"primaryCompletion":2836,"completion":2836,"start":5733,"enrollment":121,"conditions":34660,"interventions":34661},[88],[1521],[612,3498],{"trials":34663,"activeCount":124},[],{"trials":34665,"activeCount":124},[],{"trials":34667,"activeCount":124},[],{"intervention":4582,"totalTrials":121,"cells":34669},{"EARLY_PHASE1":34670,"PHASE1":34672,"PHASE2":34674,"PHASE3":34684,"PHASE4":34686,"NA":34688},{"trials":34671,"activeCount":124},[],{"trials":34673,"activeCount":124},[],{"trials":34675,"activeCount":124},[34676,34680],{"nctId":4574,"briefTitle":4575,"status":182,"phases":34677,"primaryCompletion":4577,"completion":4577,"start":4578,"enrollment":296,"conditions":34678,"interventions":34679},[88],[4580],[4582,1004,1070],{"nctId":12709,"briefTitle":12710,"status":182,"phases":34681,"primaryCompletion":12712,"completion":12712,"start":12713,"enrollment":1231,"conditions":34682,"interventions":34683},[88],[15],[4582,12716,612],{"trials":34685,"activeCount":124},[],{"trials":34687,"activeCount":124},[],{"trials":34689,"activeCount":124},[],{"intervention":2373,"totalTrials":121,"cells":34691},{"EARLY_PHASE1":34692,"PHASE1":34694,"PHASE2":34696,"PHASE3":34706,"PHASE4":34708,"NA":34710},{"trials":34693,"activeCount":124},[],{"trials":34695,"activeCount":124},[],{"trials":34697,"activeCount":124},[34698,34702],{"nctId":2361,"briefTitle":2362,"status":203,"phases":34699,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":124,"conditions":34700,"interventions":34701},[88],[21],[2368,2340,2369,1004,2293,894,62,2370,2371,2372,2373,2374],{"nctId":4712,"briefTitle":4713,"status":130,"phases":34703,"primaryCompletion":4715,"completion":4716,"start":4635,"enrollment":95,"conditions":34704,"interventions":34705},[88],[15],[1004,1070,2423,4537,2373,803,2196,2757,612,654,655],{"trials":34707,"activeCount":124},[],{"trials":34709,"activeCount":124},[],{"trials":34711,"activeCount":124},[],{"intervention":5534,"totalTrials":121,"cells":34713},{"EARLY_PHASE1":34714,"PHASE1":34716,"PHASE2":34725,"PHASE3":34731,"PHASE4":34733,"NA":34735},{"trials":34715,"activeCount":124},[],{"trials":34717,"activeCount":124},[34718],{"nctId":34719,"briefTitle":34720,"status":182,"phases":34721,"primaryCompletion":2944,"completion":2944,"start":34722,"enrollment":121,"conditions":34723,"interventions":34724},"NCT00048100","Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes",[87],"2001-02",[5243],[5534],{"trials":34726,"activeCount":124},[34727],{"nctId":5529,"briefTitle":5530,"status":182,"phases":34728,"primaryCompletion":2836,"completion":2836,"start":4193,"enrollment":2159,"conditions":34729,"interventions":34730},[88],[21],[5527,2374,4629,5526,5534,5535,654,2424,2293,5536,1070,803],{"trials":34732,"activeCount":124},[],{"trials":34734,"activeCount":124},[],{"trials":34736,"activeCount":124},[],{"intervention":634,"totalTrials":121,"cells":34738},{"EARLY_PHASE1":34739,"PHASE1":34741,"PHASE2":34743,"PHASE3":34753,"PHASE4":34755,"NA":34757},{"trials":34740,"activeCount":124},[],{"trials":34742,"activeCount":124},[],{"trials":34744,"activeCount":124},[34745,34749],{"nctId":623,"briefTitle":624,"status":182,"phases":34746,"primaryCompletion":626,"completion":626,"start":627,"enrollment":628,"conditions":34747,"interventions":34748},[87,88],[359,630,608,609,631,610,632],[634,480],{"nctId":9824,"briefTitle":9825,"status":130,"phases":34750,"primaryCompletion":9827,"completion":9827,"start":9828,"enrollment":861,"conditions":34751,"interventions":34752},[88],[15],[4109,654,634],{"trials":34754,"activeCount":124},[],{"trials":34756,"activeCount":124},[],{"trials":34758,"activeCount":124},[],{"intervention":18465,"totalTrials":121,"cells":34760},{"EARLY_PHASE1":34761,"PHASE1":34763,"PHASE2":34769,"PHASE3":34777,"PHASE4":34779,"NA":34781},{"trials":34762,"activeCount":124},[],{"trials":34764,"activeCount":124},[34765],{"nctId":18456,"briefTitle":18457,"status":203,"phases":34766,"primaryCompletion":18459,"completion":18459,"start":7757,"enrollment":124,"conditions":34767,"interventions":34768},[87],[1399,18461,18462,18463],[2011,18465],{"trials":34770,"activeCount":124},[34771],{"nctId":34772,"briefTitle":34773,"status":182,"phases":34774,"primaryCompletion":7644,"completion":7644,"start":19306,"enrollment":296,"conditions":34775,"interventions":34776},"NCT02727777","Phase II Study of TAK228 in Relapsed Lymphoma",[87,88],[21],[18465],{"trials":34778,"activeCount":124},[],{"trials":34780,"activeCount":124},[],{"trials":34782,"activeCount":124},[],{"intervention":4514,"totalTrials":121,"cells":34784},{"EARLY_PHASE1":34785,"PHASE1":34787,"PHASE2":34793,"PHASE3":34799,"PHASE4":34801,"NA":34803},{"trials":34786,"activeCount":124},[],{"trials":34788,"activeCount":124},[34789],{"nctId":4508,"briefTitle":4509,"status":130,"phases":34790,"primaryCompletion":2242,"completion":2242,"start":4511,"enrollment":959,"conditions":34791,"interventions":34792},[87],[21],[2405,2369,1004,2293,894,2374,2368,4514],{"trials":34794,"activeCount":124},[34795],{"nctId":7014,"briefTitle":7015,"status":182,"phases":34796,"primaryCompletion":1984,"completion":1984,"start":7017,"enrollment":166,"conditions":34797,"interventions":34798},[88],[15,7019,2653,21],[654,7021,1016,809,7022,2425,894,806,803,805,1013,4514,7023],{"trials":34800,"activeCount":124},[],{"trials":34802,"activeCount":124},[],{"trials":34804,"activeCount":124},[],{"intervention":12590,"totalTrials":121,"cells":34806},{"EARLY_PHASE1":34807,"PHASE1":34809,"PHASE2":34815,"PHASE3":34821,"PHASE4":34823,"NA":34825},{"trials":34808,"activeCount":124},[],{"trials":34810,"activeCount":124},[34811],{"nctId":12583,"briefTitle":12584,"status":182,"phases":34812,"primaryCompletion":12586,"completion":12586,"start":12587,"enrollment":539,"conditions":34813,"interventions":34814},[87],[1729],[612,12590],{"trials":34816,"activeCount":124},[34817],{"nctId":17594,"briefTitle":17595,"status":130,"phases":34818,"primaryCompletion":4835,"completion":4835,"start":2317,"enrollment":2581,"conditions":34819,"interventions":34820},[88],[1729],[3497,12590],{"trials":34822,"activeCount":124},[],{"trials":34824,"activeCount":124},[],{"trials":34826,"activeCount":124},[],{"intervention":34828,"totalTrials":121,"cells":34829},"Dolastatin 10",{"EARLY_PHASE1":34830,"PHASE1":34832,"PHASE2":34842,"PHASE3":34852,"PHASE4":34854,"NA":34856},{"trials":34831,"activeCount":124},[],{"trials":34833,"activeCount":124},[34834],{"nctId":34835,"briefTitle":34836,"status":130,"phases":34837,"primaryCompletion":34838,"completion":34838,"start":34839,"enrollment":406,"conditions":34840,"interventions":34841},"NCT00003693","Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia",[87],"2001-10-30","1998-12-18",[15,1036],[34828],{"trials":34843,"activeCount":124},[34844],{"nctId":34845,"briefTitle":34846,"status":130,"phases":34847,"primaryCompletion":34848,"completion":34848,"start":34849,"enrollment":910,"conditions":34850,"interventions":34851},"NCT00003677","Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer",[88],"2002-01-16","1999-02-01",[4107],[34828],{"trials":34853,"activeCount":124},[],{"trials":34855,"activeCount":124},[],{"trials":34857,"activeCount":124},[],{"intervention":1562,"totalTrials":121,"cells":34859},{"EARLY_PHASE1":34860,"PHASE1":34862,"PHASE2":34864,"PHASE3":34874,"PHASE4":34876,"NA":34878},{"trials":34861,"activeCount":124},[],{"trials":34863,"activeCount":124},[],{"trials":34865,"activeCount":124},[34866,34870],{"nctId":1554,"briefTitle":1555,"status":130,"phases":34867,"primaryCompletion":1557,"completion":1557,"start":1558,"enrollment":1559,"conditions":34868,"interventions":34869},[87,88],[15,36,30],[1050,655,654,1562,62],{"nctId":2674,"briefTitle":2675,"status":130,"phases":34871,"primaryCompletion":2677,"completion":2677,"start":2678,"enrollment":2004,"conditions":34872,"interventions":34873},[88],[15],[894,2681,803,1013,1114,2682,2683,806,2584,2374,1071,62],{"trials":34875,"activeCount":124},[],{"trials":34877,"activeCount":124},[],{"trials":34879,"activeCount":124},[],{"intervention":27957,"totalTrials":121,"cells":34881},{"EARLY_PHASE1":34882,"PHASE1":34884,"PHASE2":34886,"PHASE3":34896,"PHASE4":34898,"NA":34900},{"trials":34883,"activeCount":124},[],{"trials":34885,"activeCount":124},[],{"trials":34887,"activeCount":124},[34888,34892],{"nctId":27949,"briefTitle":27950,"status":203,"phases":34889,"enrollment":124,"conditions":34890,"interventions":34891},[87,88],[27953,27091,15,21,3243,5203,1036,27954,2936],[27931,27956,27957],{"nctId":4166,"briefTitle":4167,"status":130,"phases":34893,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":34894,"interventions":34895},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"trials":34897,"activeCount":124},[],{"trials":34899,"activeCount":124},[],{"trials":34901,"activeCount":124},[],{"intervention":3809,"totalTrials":121,"cells":34903},{"EARLY_PHASE1":34904,"PHASE1":34906,"PHASE2":34912,"PHASE3":34920,"PHASE4":34922,"NA":34924},{"trials":34905,"activeCount":124},[],{"trials":34907,"activeCount":124},[34908],{"nctId":3802,"briefTitle":3803,"status":130,"phases":34909,"primaryCompletion":3805,"start":2580,"enrollment":1131,"conditions":34910,"interventions":34911},[87],[24],[3808,1709,3809],{"trials":34913,"activeCount":124},[34914],{"nctId":34915,"briefTitle":34916,"status":130,"phases":34917,"primaryCompletion":4723,"completion":4723,"start":4732,"enrollment":959,"conditions":34918,"interventions":34919},"NCT00412542","Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas",[88],[17604,28813],[2383,3809],{"trials":34921,"activeCount":124},[],{"trials":34923,"activeCount":124},[],{"trials":34925,"activeCount":124},[],{"intervention":4526,"totalTrials":121,"cells":34927},{"EARLY_PHASE1":34928,"PHASE1":34930,"PHASE2":34936,"PHASE3":34942,"PHASE4":34944,"NA":34946},{"trials":34929,"activeCount":124},[],{"trials":34931,"activeCount":124},[34932],{"nctId":4516,"briefTitle":4517,"status":130,"phases":34933,"primaryCompletion":4519,"completion":4519,"start":4520,"enrollment":1922,"conditions":34934,"interventions":34935},[87],[4522,15,21,4523,4524],[2293,1070,2757,2196,894,4526,1004,2423],{"trials":34937,"activeCount":124},[34938],{"nctId":4616,"briefTitle":4617,"status":130,"phases":34939,"primaryCompletion":3805,"completion":3805,"start":4619,"enrollment":2997,"conditions":34940,"interventions":34941},[87,88],[2755,15],[4622,1069,1070,1004,4526],{"trials":34943,"activeCount":124},[],{"trials":34945,"activeCount":124},[],{"trials":34947,"activeCount":124},[],{"intervention":13866,"totalTrials":121,"cells":34949},{"EARLY_PHASE1":34950,"PHASE1":34952,"PHASE2":34954,"PHASE3":34967,"PHASE4":34969,"NA":34971},{"trials":34951,"activeCount":124},[],{"trials":34953,"activeCount":124},[],{"trials":34955,"activeCount":124},[34956,34963],{"nctId":34957,"briefTitle":34958,"status":182,"phases":34959,"primaryCompletion":13673,"completion":13673,"start":34960,"enrollment":134,"conditions":34961,"interventions":34962},"NCT00453193","Alemtuzumab and Pentostatin In T-cell Neoplasms",[88],"2004-09",[21,15],[13866,2439],{"nctId":13860,"briefTitle":13861,"status":130,"phases":34964,"primaryCompletion":2836,"completion":2836,"start":13863,"enrollment":1045,"conditions":34965,"interventions":34966},[87,88],[15,21],[13866,2196,806],{"trials":34968,"activeCount":124},[],{"trials":34970,"activeCount":124},[],{"trials":34972,"activeCount":124},[],{"intervention":6778,"totalTrials":121,"cells":34974},{"EARLY_PHASE1":34975,"PHASE1":34977,"PHASE2":34983,"PHASE3":34989,"PHASE4":34991,"NA":34993},{"trials":34976,"activeCount":124},[],{"trials":34978,"activeCount":124},[34979],{"nctId":14017,"briefTitle":14018,"status":130,"phases":34980,"primaryCompletion":14020,"completion":14020,"start":14021,"enrollment":6385,"conditions":34981,"interventions":34982},[87],[2922,2924,2925,2926],[6778,14024,2840],{"trials":34984,"activeCount":124},[34985],{"nctId":6766,"briefTitle":6767,"status":130,"phases":34986,"primaryCompletion":6769,"completion":6769,"start":6770,"enrollment":492,"conditions":34987,"interventions":34988},[88],[359,4559,4708,6772,6773,4561,6774,6775,6776],[6778,3348,803,1070],{"trials":34990,"activeCount":124},[],{"trials":34992,"activeCount":124},[],{"trials":34994,"activeCount":124},[],{"intervention":34996,"totalTrials":121,"cells":34997},"PEG-interferon alfa-2b",{"EARLY_PHASE1":34998,"PHASE1":35000,"PHASE2":35002,"PHASE3":35017,"PHASE4":35019,"NA":35021},{"trials":34999,"activeCount":124},[],{"trials":35001,"activeCount":124},[],{"trials":35003,"activeCount":124},[35004,35010],{"nctId":35005,"briefTitle":35006,"status":130,"phases":35007,"primaryCompletion":2828,"completion":2828,"start":2847,"enrollment":1231,"conditions":35008,"interventions":35009},"NCT00276523","PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery",[88],[242],[34996],{"nctId":35011,"briefTitle":35012,"status":182,"phases":35013,"primaryCompletion":10977,"completion":9923,"start":3438,"enrollment":406,"conditions":35014,"interventions":35016},"NCT00085384","PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer",[87,88],[9926,1530,35015],"Peritoneal Cavity Cancer",[34996,34996,34996],{"trials":35018,"activeCount":124},[],{"trials":35020,"activeCount":124},[],{"trials":35022,"activeCount":124},[],{"intervention":10904,"totalTrials":121,"cells":35024},{"EARLY_PHASE1":35025,"PHASE1":35027,"PHASE2":35033,"PHASE3":35039,"PHASE4":35041,"NA":35043},{"trials":35026,"activeCount":124},[],{"trials":35028,"activeCount":124},[35029],{"nctId":10897,"briefTitle":10898,"status":130,"phases":35030,"primaryCompletion":1567,"completion":1567,"start":10900,"enrollment":10901,"conditions":35031,"interventions":35032},[87],[1924,1942],[10904,1275,2840,2207,3847],{"trials":35034,"activeCount":124},[35035],{"nctId":18273,"briefTitle":18274,"status":182,"phases":35036,"primaryCompletion":18276,"completion":18276,"start":18277,"enrollment":296,"conditions":35037,"interventions":35038},[88],[7312,5234,7317],[12927,10904,18073,14086,2206,14130],{"trials":35040,"activeCount":124},[],{"trials":35042,"activeCount":124},[],{"trials":35044,"activeCount":124},[],{"intervention":13668,"totalTrials":121,"cells":35046},{"EARLY_PHASE1":35047,"PHASE1":35049,"PHASE2":35055,"PHASE3":35061,"PHASE4":35063,"NA":35065},{"trials":35048,"activeCount":124},[],{"trials":35050,"activeCount":124},[35051],{"nctId":20649,"briefTitle":20650,"status":182,"phases":35052,"primaryCompletion":10287,"completion":10287,"start":20652,"enrollment":121,"conditions":35053,"interventions":35054},[87],[359],[1599,13668],{"trials":35056,"activeCount":124},[35057],{"nctId":13661,"briefTitle":13662,"status":130,"phases":35058,"primaryCompletion":13664,"completion":13664,"start":13665,"enrollment":2647,"conditions":35059,"interventions":35060},[88],[3396,3135],[13551,1402,2293,3064,13668],{"trials":35062,"activeCount":124},[],{"trials":35064,"activeCount":124},[],{"trials":35066,"activeCount":124},[],{"intervention":1693,"totalTrials":121,"cells":35068},{"EARLY_PHASE1":35069,"PHASE1":35071,"PHASE2":35073,"PHASE3":35083,"PHASE4":35085,"NA":35087},{"trials":35070,"activeCount":124},[],{"trials":35072,"activeCount":124},[],{"trials":35074,"activeCount":124},[35075,35079],{"nctId":1686,"briefTitle":1687,"status":130,"phases":35076,"primaryCompletion":1689,"completion":1689,"start":472,"enrollment":924,"conditions":35077,"interventions":35078},[87,88],[1271,1272,1691,1273],[1050,1693],{"nctId":1841,"briefTitle":1842,"status":182,"phases":35080,"primaryCompletion":1844,"completion":1844,"start":1845,"enrollment":1568,"conditions":35081,"interventions":35082},[88],[1847,1848,1360],[1050,1693],{"trials":35084,"activeCount":124},[],{"trials":35086,"activeCount":124},[],{"trials":35088,"activeCount":124},[],{"intervention":2226,"totalTrials":121,"cells":35090},{"EARLY_PHASE1":35091,"PHASE1":35093,"PHASE2":35099,"PHASE3":35105,"PHASE4":35107,"NA":35109},{"trials":35092,"activeCount":124},[],{"trials":35094,"activeCount":124},[35095],{"nctId":2217,"briefTitle":2218,"status":130,"phases":35096,"primaryCompletion":2220,"completion":2220,"start":2221,"enrollment":550,"conditions":35097,"interventions":35098},[87],[2223,2224],[2226,2227,62],{"trials":35100,"activeCount":124},[35101],{"nctId":3247,"briefTitle":3248,"status":130,"phases":35102,"primaryCompletion":3250,"completion":3250,"start":3251,"enrollment":2159,"conditions":35103,"interventions":35104},[87,88],[359],[3085,2226,1005,2477,806,894,2196],{"trials":35106,"activeCount":124},[],{"trials":35108,"activeCount":124},[],{"trials":35110,"activeCount":124},[],{"intervention":18047,"totalTrials":121,"cells":35112},{"EARLY_PHASE1":35113,"PHASE1":35115,"PHASE2":35117,"PHASE3":35127,"PHASE4":35129,"NA":35131},{"trials":35114,"activeCount":124},[],{"trials":35116,"activeCount":124},[],{"trials":35118,"activeCount":124},[35119,35123],{"nctId":18042,"briefTitle":18043,"status":182,"phases":35120,"primaryCompletion":2777,"completion":2777,"start":5267,"enrollment":1090,"conditions":35121,"interventions":35122},[88],[18],[1028,18047],{"nctId":18245,"briefTitle":18246,"status":130,"phases":35124,"primaryCompletion":18248,"completion":18248,"start":18249,"enrollment":18250,"conditions":35125,"interventions":35126},[88],[24],[3847,18047,18253,2207,3847,18253],{"trials":35128,"activeCount":124},[],{"trials":35130,"activeCount":124},[],{"trials":35132,"activeCount":124},[],{"intervention":2831,"totalTrials":121,"cells":35134},{"EARLY_PHASE1":35135,"PHASE1":35137,"PHASE2":35139,"PHASE3":35149,"PHASE4":35151,"NA":35153},{"trials":35136,"activeCount":124},[],{"trials":35138,"activeCount":124},[],{"trials":35140,"activeCount":124},[35141,35145],{"nctId":10072,"briefTitle":10073,"status":130,"phases":35142,"primaryCompletion":3571,"completion":3571,"start":10075,"enrollment":2581,"conditions":35143,"interventions":35144},[87,88],[1924,1942],[2831,1369,2977,2495],{"nctId":2825,"briefTitle":2826,"status":130,"phases":35146,"primaryCompletion":2326,"completion":2326,"start":2828,"enrollment":676,"conditions":35147,"interventions":35148},[87,88],[21],[2831,894,803,1016,1013,62,806,654],{"trials":35150,"activeCount":124},[],{"trials":35152,"activeCount":124},[],{"trials":35154,"activeCount":124},[],{"intervention":2235,"totalTrials":121,"cells":35156},{"EARLY_PHASE1":35157,"PHASE1":35159,"PHASE2":35165,"PHASE3":35171,"PHASE4":35173,"NA":35175},{"trials":35158,"activeCount":124},[],{"trials":35160,"activeCount":124},[35161],{"nctId":2229,"briefTitle":2230,"status":203,"phases":35162,"primaryCompletion":2121,"start":2232,"enrollment":124,"conditions":35163,"interventions":35164},[87],[21],[2235,894,1709,654,62,2236,2237],{"trials":35166,"activeCount":124},[35167],{"nctId":4831,"briefTitle":4832,"status":203,"phases":35168,"primaryCompletion":4834,"start":4835,"enrollment":124,"conditions":35169,"interventions":35170},[87,88],[21],[1004,2370,2371,2372,2235,510,2369,2293],{"trials":35172,"activeCount":124},[],{"trials":35174,"activeCount":124},[],{"trials":35176,"activeCount":124},[],{"intervention":27071,"totalTrials":121,"cells":35178},{"EARLY_PHASE1":35179,"PHASE1":35181,"PHASE2":35183,"PHASE3":35193,"PHASE4":35195,"NA":35197},{"trials":35180,"activeCount":124},[],{"trials":35182,"activeCount":124},[],{"trials":35184,"activeCount":124},[35185,35189],{"nctId":34398,"briefTitle":34399,"status":130,"phases":35186,"primaryCompletion":34401,"completion":14149,"start":1290,"enrollment":1222,"conditions":35187,"interventions":35188},[88],[34403],[27071,34405,27072,27073,34406],{"nctId":27064,"briefTitle":27065,"status":130,"phases":35190,"primaryCompletion":405,"completion":405,"start":27067,"enrollment":1222,"conditions":35191,"interventions":35192},[88],[359,360],[27070,27071,27072,27073,2091,27074,27075],{"trials":35194,"activeCount":124},[],{"trials":35196,"activeCount":124},[],{"trials":35198,"activeCount":124},[],{"intervention":27072,"totalTrials":121,"cells":35200},{"EARLY_PHASE1":35201,"PHASE1":35203,"PHASE2":35205,"PHASE3":35215,"PHASE4":35217,"NA":35219},{"trials":35202,"activeCount":124},[],{"trials":35204,"activeCount":124},[],{"trials":35206,"activeCount":124},[35207,35211],{"nctId":34398,"briefTitle":34399,"status":130,"phases":35208,"primaryCompletion":34401,"completion":14149,"start":1290,"enrollment":1222,"conditions":35209,"interventions":35210},[88],[34403],[27071,34405,27072,27073,34406],{"nctId":27064,"briefTitle":27065,"status":130,"phases":35212,"primaryCompletion":405,"completion":405,"start":27067,"enrollment":1222,"conditions":35213,"interventions":35214},[88],[359,360],[27070,27071,27072,27073,2091,27074,27075],{"trials":35216,"activeCount":124},[],{"trials":35218,"activeCount":124},[],{"trials":35220,"activeCount":124},[],{"intervention":14120,"totalTrials":121,"cells":35222},{"EARLY_PHASE1":35223,"PHASE1":35225,"PHASE2":35234,"PHASE3":35240,"PHASE4":35242,"NA":35244},{"trials":35224,"activeCount":124},[],{"trials":35226,"activeCount":124},[35227],{"nctId":35228,"briefTitle":35229,"status":130,"phases":35230,"primaryCompletion":11134,"completion":11134,"start":3987,"enrollment":448,"conditions":35231,"interventions":35232},"NCT00933309","The Impact of Obesity and Obesity Treatments on Breast Cancer",[87],[18],[14120,35233],"Avandamet",{"trials":35235,"activeCount":124},[35236],{"nctId":14114,"briefTitle":14115,"status":182,"phases":35237,"primaryCompletion":14117,"completion":14117,"start":4542,"enrollment":3820,"conditions":35238,"interventions":35239},[88],[18],[2840,14120,14121],{"trials":35241,"activeCount":124},[],{"trials":35243,"activeCount":124},[],{"trials":35245,"activeCount":124},[],{"intervention":16562,"totalTrials":121,"cells":35247},{"EARLY_PHASE1":35248,"PHASE1":35250,"PHASE2":35256,"PHASE3":35262,"PHASE4":35264,"NA":35266},{"trials":35249,"activeCount":124},[],{"trials":35251,"activeCount":124},[35252],{"nctId":21223,"briefTitle":21224,"status":130,"phases":35253,"primaryCompletion":21226,"completion":21226,"start":4905,"enrollment":550,"conditions":35254,"interventions":35255},[87],[11534,7308,7309,7310,7311,7312,21228,7699,5234,7313,7314,7315,7316,7317,21229,10825,14083,1363],[16562,7589],{"trials":35257,"activeCount":124},[35258],{"nctId":16551,"briefTitle":16552,"status":182,"phases":35259,"primaryCompletion":3268,"completion":3268,"start":16554,"enrollment":230,"conditions":35260,"interventions":35261},[88],[8026,16556,16557,8027,13133,13134,7308,7309,7310,7311,16558,16559,16560,13136,13137,13138,7313,7314,7315,7316,14083,1363],[16562,4023],{"trials":35263,"activeCount":124},[],{"trials":35265,"activeCount":124},[],{"trials":35267,"activeCount":124},[],{"intervention":12438,"totalTrials":121,"cells":35269},{"EARLY_PHASE1":35270,"PHASE1":35272,"PHASE2":35274,"PHASE3":35284,"PHASE4":35286,"NA":35288},{"trials":35271,"activeCount":124},[],{"trials":35273,"activeCount":124},[],{"trials":35275,"activeCount":124},[35276,35280],{"nctId":12430,"briefTitle":12431,"status":130,"phases":35277,"primaryCompletion":12433,"completion":12433,"start":12434,"enrollment":3409,"conditions":35278,"interventions":35279},[87,88],[4107,12436],[12438,2369,3847],{"nctId":18068,"briefTitle":18069,"status":182,"phases":35281,"primaryCompletion":2806,"completion":2806,"start":2836,"enrollment":95,"conditions":35282,"interventions":35283},[87,88],[18],[18073,12438,1028],{"trials":35285,"activeCount":124},[],{"trials":35287,"activeCount":124},[],{"trials":35289,"activeCount":124},[],{"intervention":7916,"totalTrials":121,"cells":35291},{"EARLY_PHASE1":35292,"PHASE1":35303,"PHASE2":35305,"PHASE3":35311,"PHASE4":35313,"NA":35315},{"trials":35293,"activeCount":124},[35294],{"nctId":35295,"briefTitle":35296,"status":203,"phases":35297,"primaryCompletion":35298,"completion":35298,"start":35299,"enrollment":124,"conditions":35300,"interventions":35301},"NCT05845307","Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck",[86],"2025-11-13","2025-06-20",[7963],[35302,7916],"Control Group",{"trials":35304,"activeCount":124},[],{"trials":35306,"activeCount":124},[35307],{"nctId":7910,"briefTitle":7911,"status":203,"phases":35308,"primaryCompletion":7913,"completion":7913,"start":7913,"enrollment":124,"conditions":35309,"interventions":35310},[87,88],[450],[7916,53],{"trials":35312,"activeCount":124},[],{"trials":35314,"activeCount":124},[],{"trials":35316,"activeCount":124},[],{"intervention":2271,"totalTrials":121,"cells":35318},{"EARLY_PHASE1":35319,"PHASE1":35321,"PHASE2":35327,"PHASE3":35333,"PHASE4":35335,"NA":35337},{"trials":35320,"activeCount":124},[],{"trials":35322,"activeCount":124},[35323],{"nctId":2261,"briefTitle":2262,"status":130,"phases":35324,"primaryCompletion":2264,"completion":2264,"start":2265,"enrollment":1409,"conditions":35325,"interventions":35326},[87],[2267],[62,2269,2270,2271,1709,1376],{"trials":35328,"activeCount":124},[35329],{"nctId":4269,"briefTitle":4270,"status":130,"phases":35330,"primaryCompletion":4272,"completion":4272,"start":4273,"enrollment":871,"conditions":35331,"interventions":35332},[88],[4195],[2271,1709,4276],{"trials":35334,"activeCount":124},[],{"trials":35336,"activeCount":124},[],{"trials":35338,"activeCount":124},[],{"intervention":8764,"totalTrials":121,"cells":35340},{"EARLY_PHASE1":35341,"PHASE1":35343,"PHASE2":35345,"PHASE3":35358,"PHASE4":35360,"NA":35362},{"trials":35342,"activeCount":124},[],{"trials":35344,"activeCount":124},[],{"trials":35346,"activeCount":124},[35347,35354],{"nctId":35348,"briefTitle":35349,"status":130,"phases":35350,"primaryCompletion":8760,"completion":8760,"start":35351,"enrollment":406,"conditions":35352,"interventions":35353},"NCT01752426","Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL",[87,88],"2012-12-17",[15],[8764],{"nctId":8757,"briefTitle":8758,"status":130,"phases":35355,"primaryCompletion":8760,"completion":8760,"start":8761,"enrollment":517,"conditions":35356,"interventions":35357},[88],[15],[894,8764],{"trials":35359,"activeCount":124},[],{"trials":35361,"activeCount":124},[],{"trials":35363,"activeCount":124},[],{"intervention":1378,"totalTrials":121,"cells":35365},{"EARLY_PHASE1":35366,"PHASE1":35368,"PHASE2":35374,"PHASE3":35380,"PHASE4":35382,"NA":35384},{"trials":35367,"activeCount":124},[],{"trials":35369,"activeCount":124},[35370],{"nctId":1337,"briefTitle":1338,"status":182,"phases":35371,"primaryCompletion":626,"completion":626,"start":1340,"enrollment":1341,"conditions":35372,"interventions":35373},[87],[1343,1344,1312,1345,1315,361,1316,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1319,1360,1361,1362,1363,1364,1365,1366],[1368,1369,803,1013,1370,1371,1049,1372,1373,1050,1374,1375,1376,53,1377,1378,1379],{"trials":35375,"activeCount":124},[35376],{"nctId":18232,"briefTitle":18233,"status":130,"phases":35377,"primaryCompletion":2900,"completion":2900,"start":18235,"enrollment":539,"conditions":35378,"interventions":35379},[87,88],[15,36],[1378,2207],{"trials":35381,"activeCount":124},[],{"trials":35383,"activeCount":124},[],{"trials":35385,"activeCount":124},[],{"intervention":3836,"totalTrials":121,"cells":35387},{"EARLY_PHASE1":35388,"PHASE1":35390,"PHASE2":35396,"PHASE3":35405,"PHASE4":35407,"NA":35409},{"trials":35389,"activeCount":124},[],{"trials":35391,"activeCount":124},[35392],{"nctId":3829,"briefTitle":3830,"status":130,"phases":35393,"primaryCompletion":3832,"completion":3832,"start":3833,"enrollment":1496,"conditions":35394,"interventions":35395},[87],[1729],[3497,3836,1709,3499,3837],{"trials":35397,"activeCount":124},[35398],{"nctId":35399,"briefTitle":35400,"status":130,"phases":35401,"primaryCompletion":3761,"completion":3761,"start":3725,"enrollment":1240,"conditions":35402,"interventions":35404},"NCT01730586","Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas",[88],[3195,35403],"Cancer of Gastrointestinal Tract",[3836],{"trials":35406,"activeCount":124},[],{"trials":35408,"activeCount":124},[],{"trials":35410,"activeCount":124},[],{"intervention":10889,"totalTrials":121,"cells":35412},{"EARLY_PHASE1":35413,"PHASE1":35415,"PHASE2":35421,"PHASE3":35430,"PHASE4":35432,"NA":35434},{"trials":35414,"activeCount":124},[],{"trials":35416,"activeCount":124},[35417],{"nctId":10883,"briefTitle":10884,"status":203,"phases":35418,"primaryCompletion":10886,"completion":10886,"start":10886,"enrollment":124,"conditions":35419,"interventions":35420},[87],[3947,1996],[10889,718,1275],{"trials":35422,"activeCount":124},[35423],{"nctId":35424,"briefTitle":35425,"status":182,"phases":35426,"primaryCompletion":18297,"completion":18297,"start":970,"enrollment":1568,"conditions":35427,"interventions":35429},"NCT04228042","Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer",[87,88],[35428],"Renal Pelvis and Ureter Urothelial Carcinoma",[10889],{"trials":35431,"activeCount":124},[],{"trials":35433,"activeCount":124},[],{"trials":35435,"activeCount":124},[],{"intervention":4156,"totalTrials":121,"cells":35437},{"EARLY_PHASE1":35438,"PHASE1":35440,"PHASE2":35442,"PHASE3":35452,"PHASE4":35454,"NA":35456},{"trials":35439,"activeCount":124},[],{"trials":35441,"activeCount":124},[],{"trials":35443,"activeCount":124},[35444,35448],{"nctId":20779,"briefTitle":20780,"status":130,"phases":35445,"primaryCompletion":7399,"completion":7399,"start":20782,"enrollment":1328,"conditions":35446,"interventions":35447},[88],[21],[20785,2977,4331,4156,1869],{"nctId":4149,"briefTitle":4150,"status":182,"phases":35449,"primaryCompletion":4152,"completion":4152,"start":4153,"enrollment":3197,"conditions":35450,"interventions":35451},[88],[1729],[3497,4156,1709,3499,4157,2383],{"trials":35453,"activeCount":124},[],{"trials":35455,"activeCount":124},[],{"trials":35457,"activeCount":124},[],{"intervention":7023,"totalTrials":121,"cells":35459},{"EARLY_PHASE1":35460,"PHASE1":35462,"PHASE2":35464,"PHASE3":35474,"PHASE4":35476,"NA":35478},{"trials":35461,"activeCount":124},[],{"trials":35463,"activeCount":124},[],{"trials":35465,"activeCount":124},[35466,35470],{"nctId":7014,"briefTitle":7015,"status":182,"phases":35467,"primaryCompletion":1984,"completion":1984,"start":7017,"enrollment":166,"conditions":35468,"interventions":35469},[88],[15,7019,2653,21],[654,7021,1016,809,7022,2425,894,806,803,805,1013,4514,7023],{"nctId":7222,"briefTitle":7223,"status":130,"phases":35471,"primaryCompletion":7225,"completion":7225,"start":7226,"enrollment":1100,"conditions":35472,"interventions":35473},[88],[7228,2653],[7021,1016,7230,7231,803,654,805,806,1013,7023],{"trials":35475,"activeCount":124},[],{"trials":35477,"activeCount":124},[],{"trials":35479,"activeCount":124},[],{"intervention":2681,"totalTrials":121,"cells":35481},{"EARLY_PHASE1":35482,"PHASE1":35484,"PHASE2":35486,"PHASE3":35496,"PHASE4":35498,"NA":35500},{"trials":35483,"activeCount":124},[],{"trials":35485,"activeCount":124},[],{"trials":35487,"activeCount":124},[35488,35492],{"nctId":2674,"briefTitle":2675,"status":130,"phases":35489,"primaryCompletion":2677,"completion":2677,"start":2678,"enrollment":2004,"conditions":35490,"interventions":35491},[88],[15],[894,2681,803,1013,1114,2682,2683,806,2584,2374,1071,62],{"nctId":32998,"briefTitle":32999,"status":182,"phases":35493,"primaryCompletion":8730,"completion":8730,"start":2969,"enrollment":3197,"conditions":35494,"interventions":35495},[88],[15],[33003,33004,2681,4629],{"trials":35497,"activeCount":124},[],{"trials":35499,"activeCount":124},[],{"trials":35501,"activeCount":124},[],{"intervention":21151,"totalTrials":121,"cells":35503},{"EARLY_PHASE1":35504,"PHASE1":35506,"PHASE2":35508,"PHASE3":35528,"PHASE4":35530,"NA":35532},{"trials":35505,"activeCount":124},[],{"trials":35507,"activeCount":124},[],{"trials":35509,"activeCount":124},[35510,35514],{"nctId":21143,"briefTitle":21144,"status":203,"phases":35511,"primaryCompletion":21146,"completion":21146,"start":21147,"enrollment":124,"conditions":35512,"interventions":35513},[88],[3195,3154,21149],[12862,21151],{"nctId":35515,"briefTitle":35516,"status":1479,"phases":35517,"primaryCompletion":1193,"completion":1193,"start":35518,"enrollment":342,"conditions":35519,"interventions":35527},"NCT05337735","A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers",[88],"2022-08-05",[35520,35521,35522,35523,35524,5623,35525,35526],"Microsatellite High Cancers","Peritoneal Mesothelioma","Extrapulmonary High Grade","Neuroendocrine Carcinomas","Cervical Carcinoma","Pleural Mesothelioma","Small Cell Lung Cancer",[21151],{"trials":35529,"activeCount":124},[],{"trials":35531,"activeCount":124},[],{"trials":35533,"activeCount":124},[],{"intervention":11964,"totalTrials":121,"cells":35535},{"EARLY_PHASE1":35536,"PHASE1":35538,"PHASE2":35540,"PHASE3":35550,"PHASE4":35552,"NA":35554},{"trials":35537,"activeCount":124},[],{"trials":35539,"activeCount":124},[],{"trials":35541,"activeCount":124},[35542,35546],{"nctId":32029,"briefTitle":32030,"status":130,"phases":35543,"primaryCompletion":10272,"completion":10272,"start":2945,"enrollment":2779,"conditions":35544,"interventions":35545},[87,88],[27],[11964,14611],{"nctId":11958,"briefTitle":11959,"status":130,"phases":35547,"primaryCompletion":2847,"completion":4647,"start":11961,"enrollment":517,"conditions":35548,"interventions":35549},[87,88],[27],[11964,2383,1376],{"trials":35551,"activeCount":124},[],{"trials":35553,"activeCount":124},[],{"trials":35555,"activeCount":124},[],{"intervention":23802,"totalTrials":121,"cells":35557},{"EARLY_PHASE1":35558,"PHASE1":35560,"PHASE2":35562,"PHASE3":35576,"PHASE4":35578,"NA":35580},{"trials":35559,"activeCount":124},[],{"trials":35561,"activeCount":124},[],{"trials":35563,"activeCount":124},[35564,35568],{"nctId":23795,"briefTitle":23796,"status":130,"phases":35565,"primaryCompletion":23798,"completion":23798,"start":23799,"enrollment":195,"conditions":35566,"interventions":35567},[88],[18],[23802,14024,8031],{"nctId":35569,"briefTitle":35570,"status":130,"phases":35571,"primaryCompletion":2645,"completion":2645,"start":35572,"enrollment":550,"conditions":35573,"interventions":35574},"NCT01833520","Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma",[87,88],"2013-10-16",[2971],[35575],"Ra-223 Dichloride",{"trials":35577,"activeCount":124},[],{"trials":35579,"activeCount":124},[],{"trials":35581,"activeCount":124},[],{"intervention":7415,"totalTrials":121,"cells":35583},{"EARLY_PHASE1":35584,"PHASE1":35586,"PHASE2":35588,"PHASE3":35598,"PHASE4":35600,"NA":35602},{"trials":35585,"activeCount":124},[],{"trials":35587,"activeCount":124},[],{"trials":35589,"activeCount":124},[35590,35594],{"nctId":9275,"briefTitle":9276,"status":182,"phases":35591,"primaryCompletion":9278,"completion":9278,"start":9279,"enrollment":1231,"conditions":35592,"interventions":35593},[87,88],[15,2245,4580],[1070,2293,2439,2196,9282,2374,7415,1014],{"nctId":7405,"briefTitle":7406,"status":130,"phases":35595,"primaryCompletion":7408,"completion":7408,"start":7409,"enrollment":2446,"conditions":35596,"interventions":35597},[87,88],[7411,2838,712,7412],[1070,803,1114,7414,7415],{"trials":35599,"activeCount":124},[],{"trials":35601,"activeCount":124},[],{"trials":35603,"activeCount":124},[],{"intervention":2758,"totalTrials":121,"cells":35605},{"EARLY_PHASE1":35606,"PHASE1":35608,"PHASE2":35610,"PHASE3":35620,"PHASE4":35622,"NA":35624},{"trials":35607,"activeCount":124},[],{"trials":35609,"activeCount":124},[],{"trials":35611,"activeCount":124},[35612,35616],{"nctId":2749,"briefTitle":2750,"status":203,"phases":35613,"primaryCompletion":2752,"completion":2752,"start":2753,"enrollment":124,"conditions":35614,"interventions":35615},[88],[2755],[1070,62,803,75,894,1004,803,2196,2757,2758],{"nctId":5264,"briefTitle":5265,"status":130,"phases":35617,"primaryCompletion":5267,"completion":5267,"start":5268,"enrollment":1409,"conditions":35618,"interventions":35619},[88],[15,21],[2293,1254,1070,2758],{"trials":35621,"activeCount":124},[],{"trials":35623,"activeCount":124},[],{"trials":35625,"activeCount":124},[],{"intervention":5681,"totalTrials":121,"cells":35627},{"EARLY_PHASE1":35628,"PHASE1":35630,"PHASE2":35632,"PHASE3":35642,"PHASE4":35644,"NA":35646},{"trials":35629,"activeCount":124},[],{"trials":35631,"activeCount":124},[],{"trials":35633,"activeCount":124},[35634,35638],{"nctId":31394,"briefTitle":31395,"status":130,"phases":35635,"primaryCompletion":31397,"completion":31397,"start":31398,"enrollment":2911,"conditions":35636,"interventions":35637},[88],[31400,5457,20500],[17616,5681],{"nctId":5675,"briefTitle":5676,"status":130,"phases":35639,"primaryCompletion":3818,"completion":2528,"start":5678,"enrollment":406,"conditions":35640,"interventions":35641},[88],[4384],[2424,5681],{"trials":35643,"activeCount":124},[],{"trials":35645,"activeCount":124},[],{"trials":35647,"activeCount":124},[],{"intervention":27613,"totalTrials":121,"cells":35649},{"EARLY_PHASE1":35650,"PHASE1":35652,"PHASE2":35658,"PHASE3":35669,"PHASE4":35671,"NA":35673},{"trials":35651,"activeCount":124},[],{"trials":35653,"activeCount":124},[35654],{"nctId":27606,"briefTitle":27607,"status":182,"phases":35655,"primaryCompletion":27609,"completion":27609,"start":10287,"enrollment":1664,"conditions":35656,"interventions":35657},[87],[7312,27611,7317],[4209,27613],{"trials":35659,"activeCount":124},[35660],{"nctId":35661,"briefTitle":35662,"status":182,"phases":35663,"primaryCompletion":35664,"completion":35664,"start":35665,"enrollment":230,"conditions":35666,"interventions":35667},"NCT05041101","Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer",[87,88],"2024-09-06","2021-12-21",[7296,11568,11569],[27613,35668],"Grapiprant",{"trials":35670,"activeCount":124},[],{"trials":35672,"activeCount":124},[],{"trials":35674,"activeCount":124},[],{"intervention":2850,"totalTrials":121,"cells":35676},{"EARLY_PHASE1":35677,"PHASE1":35679,"PHASE2":35681,"PHASE3":35691,"PHASE4":35693,"NA":35695},{"trials":35678,"activeCount":124},[],{"trials":35680,"activeCount":124},[],{"trials":35682,"activeCount":124},[35683,35687],{"nctId":14977,"briefTitle":14978,"status":203,"phases":35684,"primaryCompletion":14980,"completion":14980,"start":2910,"enrollment":124,"conditions":35685,"interventions":35686},[88],[10145],[2850,1710],{"nctId":2843,"briefTitle":2844,"status":182,"phases":35688,"primaryCompletion":2846,"completion":2846,"start":2847,"enrollment":676,"conditions":35689,"interventions":35690},[88],[1293],[1710,2850,62],{"trials":35692,"activeCount":124},[],{"trials":35694,"activeCount":124},[],{"trials":35696,"activeCount":124},[],{"intervention":35698,"totalTrials":166,"cells":35699},"Pazopanib Hydrochloride",{"EARLY_PHASE1":35700,"PHASE1":35702,"PHASE2":35704,"PHASE3":35713,"PHASE4":35715,"NA":35717},{"trials":35701,"activeCount":124},[],{"trials":35703,"activeCount":124},[],{"trials":35705,"activeCount":124},[35706],{"nctId":35707,"briefTitle":35708,"status":130,"phases":35709,"primaryCompletion":4987,"completion":4987,"start":35710,"enrollment":507,"conditions":35711,"interventions":35712},"NCT01436227","Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome",[88],"2012-01-17",[34521],[35698],{"trials":35714,"activeCount":124},[],{"trials":35716,"activeCount":124},[],{"trials":35718,"activeCount":124},[],{"intervention":2353,"totalTrials":166,"cells":35720},{"EARLY_PHASE1":35721,"PHASE1":35723,"PHASE2":35725,"PHASE3":35731,"PHASE4":35733,"NA":35735},{"trials":35722,"activeCount":124},[],{"trials":35724,"activeCount":124},[],{"trials":35726,"activeCount":124},[35727],{"nctId":2344,"briefTitle":2345,"status":130,"phases":35728,"primaryCompletion":2347,"completion":2347,"start":2348,"enrollment":628,"conditions":35729,"interventions":35730},[88],[18],[2351,62,2352,2353],{"trials":35732,"activeCount":124},[],{"trials":35734,"activeCount":124},[],{"trials":35736,"activeCount":124},[],{"intervention":15499,"totalTrials":166,"cells":35738},{"EARLY_PHASE1":35739,"PHASE1":35741,"PHASE2":35743,"PHASE3":35749,"PHASE4":35751,"NA":35753},{"trials":35740,"activeCount":124},[],{"trials":35742,"activeCount":124},[],{"trials":35744,"activeCount":124},[35745],{"nctId":15491,"briefTitle":15492,"status":130,"phases":35746,"primaryCompletion":15494,"completion":15494,"start":15495,"enrollment":2911,"conditions":35747,"interventions":35748},[88],[15497,3244,3429],[15499,598],{"trials":35750,"activeCount":124},[],{"trials":35752,"activeCount":124},[],{"trials":35754,"activeCount":124},[],{"intervention":1488,"totalTrials":166,"cells":35756},{"EARLY_PHASE1":35757,"PHASE1":35759,"PHASE2":35761,"PHASE3":35767,"PHASE4":35769,"NA":35771},{"trials":35758,"activeCount":124},[],{"trials":35760,"activeCount":124},[],{"trials":35762,"activeCount":124},[35763],{"nctId":1477,"briefTitle":1478,"status":1479,"phases":35764,"primaryCompletion":537,"completion":1481,"start":1482,"enrollment":1483,"conditions":35765,"interventions":35766},[88],[1485,1486,1050,1275],[1050,1275,1488,1489],{"trials":35768,"activeCount":124},[],{"trials":35770,"activeCount":124},[],{"trials":35772,"activeCount":124},[],{"intervention":1489,"totalTrials":166,"cells":35774},{"EARLY_PHASE1":35775,"PHASE1":35777,"PHASE2":35779,"PHASE3":35785,"PHASE4":35787,"NA":35789},{"trials":35776,"activeCount":124},[],{"trials":35778,"activeCount":124},[],{"trials":35780,"activeCount":124},[35781],{"nctId":1477,"briefTitle":1478,"status":1479,"phases":35782,"primaryCompletion":537,"completion":1481,"start":1482,"enrollment":1483,"conditions":35783,"interventions":35784},[88],[1485,1486,1050,1275],[1050,1275,1488,1489],{"trials":35786,"activeCount":124},[],{"trials":35788,"activeCount":124},[],{"trials":35790,"activeCount":124},[],{"intervention":35792,"totalTrials":166,"cells":35793},"Balstilimab",{"EARLY_PHASE1":35794,"PHASE1":35796,"PHASE2":35798,"PHASE3":35809,"PHASE4":35811,"NA":35813},{"trials":35795,"activeCount":124},[],{"trials":35797,"activeCount":124},[],{"trials":35799,"activeCount":124},[35800],{"nctId":35801,"briefTitle":35802,"status":203,"phases":35803,"primaryCompletion":35804,"completion":35804,"start":35805,"enrollment":124,"conditions":35806,"interventions":35808},"NCT05363709","BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients",[88],"2026-05-04","2023-10-18",[35807,23252],"HPV",[35792],{"trials":35810,"activeCount":124},[],{"trials":35812,"activeCount":124},[],{"trials":35814,"activeCount":124},[],{"intervention":35816,"totalTrials":166,"cells":35817},"Anti-PD-L1\u002FTGFbetaRII Fusion Protein M7824",{"EARLY_PHASE1":35818,"PHASE1":35820,"PHASE2":35822,"PHASE3":35832,"PHASE4":35834,"NA":35836},{"trials":35819,"activeCount":124},[],{"trials":35821,"activeCount":124},[],{"trials":35823,"activeCount":124},[35824],{"nctId":35825,"briefTitle":35826,"status":130,"phases":35827,"primaryCompletion":2141,"completion":2141,"start":11193,"enrollment":296,"conditions":35828,"interventions":35831},"NCT03436563","M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability",[87,88],[35829,35830,361,4989,6905,1907,1908,1909,1910,1911,1912],"Colon Adenocarcinoma","High-Frequency Microsatellite Instability",[35816],{"trials":35833,"activeCount":124},[],{"trials":35835,"activeCount":124},[],{"trials":35837,"activeCount":124},[],{"intervention":23254,"totalTrials":166,"cells":35839},{"EARLY_PHASE1":35840,"PHASE1":35842,"PHASE2":35844,"PHASE3":35850,"PHASE4":35852,"NA":35854},{"trials":35841,"activeCount":124},[],{"trials":35843,"activeCount":124},[],{"trials":35845,"activeCount":124},[35846],{"nctId":23247,"briefTitle":23248,"status":182,"phases":35847,"primaryCompletion":23250,"completion":23250,"start":16597,"enrollment":1231,"conditions":35848,"interventions":35849},[88],[7649,7651,23252],[7370,23254],{"trials":35851,"activeCount":124},[],{"trials":35853,"activeCount":124},[],{"trials":35855,"activeCount":124},[],{"intervention":3208,"totalTrials":166,"cells":35857},{"EARLY_PHASE1":35858,"PHASE1":35860,"PHASE2":35862,"PHASE3":35868,"PHASE4":35870,"NA":35872},{"trials":35859,"activeCount":124},[],{"trials":35861,"activeCount":124},[],{"trials":35863,"activeCount":124},[35864],{"nctId":3201,"briefTitle":3202,"status":130,"phases":35865,"primaryCompletion":3204,"completion":3204,"start":3205,"enrollment":1496,"conditions":35866,"interventions":35867},[87,88],[1316,1961,1549],[1599,3208,803,1005,3145],{"trials":35869,"activeCount":124},[],{"trials":35871,"activeCount":124},[],{"trials":35873,"activeCount":124},[],{"intervention":5535,"totalTrials":166,"cells":35875},{"EARLY_PHASE1":35876,"PHASE1":35878,"PHASE2":35880,"PHASE3":35886,"PHASE4":35888,"NA":35890},{"trials":35877,"activeCount":124},[],{"trials":35879,"activeCount":124},[],{"trials":35881,"activeCount":124},[35882],{"nctId":5529,"briefTitle":5530,"status":182,"phases":35883,"primaryCompletion":2836,"completion":2836,"start":4193,"enrollment":2159,"conditions":35884,"interventions":35885},[88],[21],[5527,2374,4629,5526,5534,5535,654,2424,2293,5536,1070,803],{"trials":35887,"activeCount":124},[],{"trials":35889,"activeCount":124},[],{"trials":35891,"activeCount":124},[],{"intervention":5536,"totalTrials":166,"cells":35893},{"EARLY_PHASE1":35894,"PHASE1":35896,"PHASE2":35898,"PHASE3":35904,"PHASE4":35906,"NA":35908},{"trials":35895,"activeCount":124},[],{"trials":35897,"activeCount":124},[],{"trials":35899,"activeCount":124},[35900],{"nctId":5529,"briefTitle":5530,"status":182,"phases":35901,"primaryCompletion":2836,"completion":2836,"start":4193,"enrollment":2159,"conditions":35902,"interventions":35903},[88],[21],[5527,2374,4629,5526,5534,5535,654,2424,2293,5536,1070,803],{"trials":35905,"activeCount":124},[],{"trials":35907,"activeCount":124},[],{"trials":35909,"activeCount":124},[],{"intervention":35911,"totalTrials":166,"cells":35912},"Smac Mimetic LCL161",{"EARLY_PHASE1":35913,"PHASE1":35915,"PHASE2":35917,"PHASE3":35927,"PHASE4":35929,"NA":35931},{"trials":35914,"activeCount":124},[],{"trials":35916,"activeCount":124},[],{"trials":35918,"activeCount":124},[35919],{"nctId":35920,"briefTitle":35921,"status":130,"phases":35922,"primaryCompletion":35923,"completion":35923,"start":35924,"enrollment":676,"conditions":35925,"interventions":35926},"NCT02098161","LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis",[88],"2022-05-19","2014-12-18",[746,2134,3020],[35911],{"trials":35928,"activeCount":124},[],{"trials":35930,"activeCount":124},[],{"trials":35932,"activeCount":124},[],{"intervention":2394,"totalTrials":166,"cells":35934},{"EARLY_PHASE1":35935,"PHASE1":35937,"PHASE2":35939,"PHASE3":35945,"PHASE4":35947,"NA":35949},{"trials":35936,"activeCount":124},[],{"trials":35938,"activeCount":124},[],{"trials":35940,"activeCount":124},[35941],{"nctId":2385,"briefTitle":2386,"status":182,"phases":35942,"primaryCompletion":2388,"completion":2388,"start":2389,"enrollment":240,"conditions":35943,"interventions":35944},[88],[2391,2392],[2394,62,2395,2269],{"trials":35946,"activeCount":124},[],{"trials":35948,"activeCount":124},[],{"trials":35950,"activeCount":124},[],{"intervention":5020,"totalTrials":166,"cells":35952},{"EARLY_PHASE1":35953,"PHASE1":35955,"PHASE2":35957,"PHASE3":35963,"PHASE4":35965,"NA":35967},{"trials":35954,"activeCount":124},[],{"trials":35956,"activeCount":124},[],{"trials":35958,"activeCount":124},[35959],{"nctId":5013,"briefTitle":5014,"status":203,"phases":35960,"primaryCompletion":5016,"start":5017,"enrollment":124,"conditions":35961,"interventions":35962},[88],[21],[4896,5020],{"trials":35964,"activeCount":124},[],{"trials":35966,"activeCount":124},[],{"trials":35968,"activeCount":124},[],{"intervention":8343,"totalTrials":166,"cells":35970},{"EARLY_PHASE1":35971,"PHASE1":35973,"PHASE2":35975,"PHASE3":35981,"PHASE4":35983,"NA":35985},{"trials":35972,"activeCount":124},[],{"trials":35974,"activeCount":124},[],{"trials":35976,"activeCount":124},[35977],{"nctId":8336,"briefTitle":8337,"status":130,"phases":35978,"primaryCompletion":8339,"completion":8339,"start":8340,"enrollment":507,"conditions":35979,"interventions":35980},[88],[21],[8343,894],{"trials":35982,"activeCount":124},[],{"trials":35984,"activeCount":124},[],{"trials":35986,"activeCount":124},[],{"intervention":35988,"totalTrials":166,"cells":35989},"Eflornithine",{"EARLY_PHASE1":35990,"PHASE1":35992,"PHASE2":35994,"PHASE3":36003,"PHASE4":36005,"NA":36007},{"trials":35991,"activeCount":124},[],{"trials":35993,"activeCount":124},[],{"trials":35995,"activeCount":124},[35996],{"nctId":35997,"briefTitle":35998,"status":130,"phases":35999,"primaryCompletion":11873,"completion":11873,"start":36000,"enrollment":1045,"conditions":36001,"interventions":36002},"NCT00006079","Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia",[88],"1998-06-19",[11077,31059],[35988],{"trials":36004,"activeCount":124},[],{"trials":36006,"activeCount":124},[],{"trials":36008,"activeCount":124},[],{"intervention":36010,"totalTrials":166,"cells":36011},"CEP-701",{"EARLY_PHASE1":36012,"PHASE1":36014,"PHASE2":36016,"PHASE3":36024,"PHASE4":36026,"NA":36028},{"trials":36013,"activeCount":124},[],{"trials":36015,"activeCount":124},[],{"trials":36017,"activeCount":124},[36018],{"nctId":36019,"briefTitle":36020,"status":130,"phases":36021,"primaryCompletion":3762,"completion":3762,"start":4183,"enrollment":2159,"conditions":36022,"interventions":36023},"NCT00494585","CEP-701 for PH-negative Myelofibrosis",[88],[15,3429],[36010],{"trials":36025,"activeCount":124},[],{"trials":36027,"activeCount":124},[],{"trials":36029,"activeCount":124},[],{"intervention":6710,"totalTrials":166,"cells":36031},{"EARLY_PHASE1":36032,"PHASE1":36034,"PHASE2":36036,"PHASE3":36042,"PHASE4":36044,"NA":36046},{"trials":36033,"activeCount":124},[],{"trials":36035,"activeCount":124},[],{"trials":36037,"activeCount":124},[36038],{"nctId":6704,"briefTitle":6705,"status":182,"phases":36039,"primaryCompletion":2510,"completion":6707,"start":5671,"enrollment":550,"conditions":36040,"interventions":36041},[88],[15],[803,894,6710],{"trials":36043,"activeCount":124},[],{"trials":36045,"activeCount":124},[],{"trials":36047,"activeCount":124},[],{"intervention":10017,"totalTrials":166,"cells":36049},{"EARLY_PHASE1":36050,"PHASE1":36052,"PHASE2":36054,"PHASE3":36060,"PHASE4":36062,"NA":36064},{"trials":36051,"activeCount":124},[],{"trials":36053,"activeCount":124},[],{"trials":36055,"activeCount":124},[36056],{"nctId":10010,"briefTitle":10011,"status":130,"phases":36057,"primaryCompletion":10013,"completion":10013,"start":10014,"enrollment":3354,"conditions":36058,"interventions":36059},[88],[24],[1369,1377,1275,10017],{"trials":36061,"activeCount":124},[],{"trials":36063,"activeCount":124},[],{"trials":36065,"activeCount":124},[],{"intervention":36067,"totalTrials":166,"cells":36068},"Bimiralisib",{"EARLY_PHASE1":36069,"PHASE1":36071,"PHASE2":36073,"PHASE3":36083,"PHASE4":36085,"NA":36087},{"trials":36070,"activeCount":124},[],{"trials":36072,"activeCount":124},[],{"trials":36074,"activeCount":124},[36075],{"nctId":36076,"briefTitle":36077,"status":182,"phases":36078,"primaryCompletion":5056,"completion":36079,"start":755,"enrollment":186,"conditions":36080,"interventions":36082},"NCT03740100","Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations",[88],"2020-12-09",[36081],"HNSCC",[36067],{"trials":36084,"activeCount":124},[],{"trials":36086,"activeCount":124},[],{"trials":36088,"activeCount":124},[],{"intervention":31525,"totalTrials":166,"cells":36090},{"EARLY_PHASE1":36091,"PHASE1":36093,"PHASE2":36095,"PHASE3":36101,"PHASE4":36103,"NA":36105},{"trials":36092,"activeCount":124},[],{"trials":36094,"activeCount":124},[],{"trials":36096,"activeCount":124},[36097],{"nctId":31520,"briefTitle":31521,"status":130,"phases":36098,"primaryCompletion":4843,"completion":4843,"start":6384,"enrollment":95,"conditions":36099,"interventions":36100},[88],[1333,1521],[31525,17844],{"trials":36102,"activeCount":124},[],{"trials":36104,"activeCount":124},[],{"trials":36106,"activeCount":124},[],{"intervention":36108,"totalTrials":166,"cells":36109},"Fentanyl Pectin Nasal Spray",{"EARLY_PHASE1":36110,"PHASE1":36112,"PHASE2":36114,"PHASE3":36123,"PHASE4":36125,"NA":36127},{"trials":36111,"activeCount":124},[],{"trials":36113,"activeCount":124},[],{"trials":36115,"activeCount":124},[36116],{"nctId":36117,"briefTitle":36118,"status":130,"phases":36119,"primaryCompletion":36120,"completion":36120,"start":3378,"enrollment":1328,"conditions":36121,"interventions":36122},"NCT01832402","Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea",[88],"2019-11-25",[33],[36108],{"trials":36124,"activeCount":124},[],{"trials":36126,"activeCount":124},[],{"trials":36128,"activeCount":124},[],{"intervention":3625,"totalTrials":166,"cells":36130},{"EARLY_PHASE1":36131,"PHASE1":36133,"PHASE2":36135,"PHASE3":36141,"PHASE4":36143,"NA":36145},{"trials":36132,"activeCount":124},[],{"trials":36134,"activeCount":124},[],{"trials":36136,"activeCount":124},[36137],{"nctId":3618,"briefTitle":3619,"status":130,"phases":36138,"primaryCompletion":3621,"completion":3621,"start":3622,"enrollment":834,"conditions":36139,"interventions":36140},[88],[1316,1549],[1599,3625,803,1049],{"trials":36142,"activeCount":124},[],{"trials":36144,"activeCount":124},[],{"trials":36146,"activeCount":124},[],{"intervention":13471,"totalTrials":166,"cells":36148},{"EARLY_PHASE1":36149,"PHASE1":36151,"PHASE2":36153,"PHASE3":36159,"PHASE4":36161,"NA":36163},{"trials":36150,"activeCount":124},[],{"trials":36152,"activeCount":124},[],{"trials":36154,"activeCount":124},[36155],{"nctId":13466,"briefTitle":13467,"status":182,"phases":36156,"primaryCompletion":9859,"completion":9859,"start":5988,"enrollment":166,"conditions":36157,"interventions":36158},[88],[15],[1402,13471],{"trials":36160,"activeCount":124},[],{"trials":36162,"activeCount":124},[],{"trials":36164,"activeCount":124},[],{"intervention":17835,"totalTrials":166,"cells":36166},{"EARLY_PHASE1":36167,"PHASE1":36169,"PHASE2":36171,"PHASE3":36177,"PHASE4":36179,"NA":36181},{"trials":36168,"activeCount":124},[],{"trials":36170,"activeCount":124},[],{"trials":36172,"activeCount":124},[36173],{"nctId":17830,"briefTitle":17831,"status":182,"phases":36174,"primaryCompletion":8719,"completion":8719,"start":2213,"enrollment":121,"conditions":36175,"interventions":36176},[88],[18,7818],[17835,1368],{"trials":36178,"activeCount":124},[],{"trials":36180,"activeCount":124},[],{"trials":36182,"activeCount":124},[],{"intervention":27956,"totalTrials":166,"cells":36184},{"EARLY_PHASE1":36185,"PHASE1":36187,"PHASE2":36189,"PHASE3":36195,"PHASE4":36197,"NA":36199},{"trials":36186,"activeCount":124},[],{"trials":36188,"activeCount":124},[],{"trials":36190,"activeCount":124},[36191],{"nctId":27949,"briefTitle":27950,"status":203,"phases":36192,"enrollment":124,"conditions":36193,"interventions":36194},[87,88],[27953,27091,15,21,3243,5203,1036,27954,2936],[27931,27956,27957],{"trials":36196,"activeCount":124},[],{"trials":36198,"activeCount":124},[],{"trials":36200,"activeCount":124},[],{"intervention":36202,"totalTrials":166,"cells":36203},"Revlimid",{"EARLY_PHASE1":36204,"PHASE1":36206,"PHASE2":36208,"PHASE3":36216,"PHASE4":36218,"NA":36220},{"trials":36205,"activeCount":124},[],{"trials":36207,"activeCount":124},[],{"trials":36209,"activeCount":124},[36210],{"nctId":36211,"briefTitle":36212,"status":130,"phases":36213,"primaryCompletion":2778,"completion":2778,"start":4619,"enrollment":2159,"conditions":36214,"interventions":36215},"NCT00360672","Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome",[88],[4659,30],[36202],{"trials":36217,"activeCount":124},[],{"trials":36219,"activeCount":124},[],{"trials":36221,"activeCount":124},[],{"intervention":8389,"totalTrials":166,"cells":36223},{"EARLY_PHASE1":36224,"PHASE1":36226,"PHASE2":36228,"PHASE3":36234,"PHASE4":36236,"NA":36238},{"trials":36225,"activeCount":124},[],{"trials":36227,"activeCount":124},[],{"trials":36229,"activeCount":124},[36230],{"nctId":8383,"briefTitle":8384,"status":182,"phases":36231,"primaryCompletion":8386,"completion":8386,"start":4351,"enrollment":230,"conditions":36232,"interventions":36233},[88],[21],[2450,894,8389],{"trials":36235,"activeCount":124},[],{"trials":36237,"activeCount":124},[],{"trials":36239,"activeCount":124},[],{"intervention":20063,"totalTrials":166,"cells":36241},{"EARLY_PHASE1":36242,"PHASE1":36244,"PHASE2":36246,"PHASE3":36252,"PHASE4":36254,"NA":36256},{"trials":36243,"activeCount":124},[],{"trials":36245,"activeCount":124},[],{"trials":36247,"activeCount":124},[36248],{"nctId":20057,"briefTitle":20058,"status":130,"phases":36249,"primaryCompletion":20060,"completion":20060,"start":2580,"enrollment":517,"conditions":36250,"interventions":36251},[87,88],[21],[20063,20064,5247,5526,20065,2584,2293,2374],{"trials":36253,"activeCount":124},[],{"trials":36255,"activeCount":124},[],{"trials":36257,"activeCount":124},[],{"intervention":20064,"totalTrials":166,"cells":36259},{"EARLY_PHASE1":36260,"PHASE1":36262,"PHASE2":36264,"PHASE3":36270,"PHASE4":36272,"NA":36274},{"trials":36261,"activeCount":124},[],{"trials":36263,"activeCount":124},[],{"trials":36265,"activeCount":124},[36266],{"nctId":20057,"briefTitle":20058,"status":130,"phases":36267,"primaryCompletion":20060,"completion":20060,"start":2580,"enrollment":517,"conditions":36268,"interventions":36269},[87,88],[21],[20063,20064,5247,5526,20065,2584,2293,2374],{"trials":36271,"activeCount":124},[],{"trials":36273,"activeCount":124},[],{"trials":36275,"activeCount":124},[],{"intervention":20065,"totalTrials":166,"cells":36277},{"EARLY_PHASE1":36278,"PHASE1":36280,"PHASE2":36282,"PHASE3":36288,"PHASE4":36290,"NA":36292},{"trials":36279,"activeCount":124},[],{"trials":36281,"activeCount":124},[],{"trials":36283,"activeCount":124},[36284],{"nctId":20057,"briefTitle":20058,"status":130,"phases":36285,"primaryCompletion":20060,"completion":20060,"start":2580,"enrollment":517,"conditions":36286,"interventions":36287},[87,88],[21],[20063,20064,5247,5526,20065,2584,2293,2374],{"trials":36289,"activeCount":124},[],{"trials":36291,"activeCount":124},[],{"trials":36293,"activeCount":124},[],{"intervention":36295,"totalTrials":166,"cells":36296},"Deoxycoformycin",{"EARLY_PHASE1":36297,"PHASE1":36299,"PHASE2":36301,"PHASE3":36312,"PHASE4":36314,"NA":36316},{"trials":36298,"activeCount":124},[],{"trials":36300,"activeCount":124},[],{"trials":36302,"activeCount":124},[36303],{"nctId":36304,"briefTitle":36305,"status":130,"phases":36306,"primaryCompletion":30916,"completion":30916,"start":36307,"enrollment":1034,"conditions":36308,"interventions":36311},"NCT00038025","A Study Of Deoxycoformycin(DCF)\u002FPentostatin In Lymphoid Malignancies",[88],"1994-09-06",[36309,36310,712],"Peripheral T-cell Lymphoma","Cutaneous T-cell Lymphoma",[36295],{"trials":36313,"activeCount":124},[],{"trials":36315,"activeCount":124},[],{"trials":36317,"activeCount":124},[],{"intervention":36319,"totalTrials":166,"cells":36320},"Erdafitinib",{"EARLY_PHASE1":36321,"PHASE1":36323,"PHASE2":36325,"PHASE3":36338,"PHASE4":36340,"NA":36342},{"trials":36322,"activeCount":124},[],{"trials":36324,"activeCount":124},[],{"trials":36326,"activeCount":124},[36327],{"nctId":36328,"briefTitle":36329,"status":182,"phases":36330,"primaryCompletion":36331,"completion":36331,"start":36332,"enrollment":95,"conditions":36333,"interventions":36337},"NCT04754425","Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer",[88],"2026-02-02","2021-07-15",[3544,36334,13289,36335,36336,3546,3547,3548],"Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents","Metastatic Prostate Adenocarcinoma","Metastatic Prostate Small Cell Neuroendocrine Carcinoma",[36319],{"trials":36339,"activeCount":124},[],{"trials":36341,"activeCount":124},[],{"trials":36343,"activeCount":124},[],{"intervention":36345,"totalTrials":166,"cells":36346},"Cyclosporine Eye Drops",{"EARLY_PHASE1":36347,"PHASE1":36349,"PHASE2":36351,"PHASE3":36362,"PHASE4":36364,"NA":36366},{"trials":36348,"activeCount":124},[],{"trials":36350,"activeCount":124},[],{"trials":36352,"activeCount":124},[36353],{"nctId":36354,"briefTitle":36355,"status":203,"phases":36356,"start":5267,"enrollment":124,"conditions":36357,"interventions":36359},"NCT00824811","Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel",[88],[36358],"Epiphora",[36345,36360,36361],"Lubricant Eye Drops","Fluorometholone Eye Drops",{"trials":36363,"activeCount":124},[],{"trials":36365,"activeCount":124},[],{"trials":36367,"activeCount":124},[],{"intervention":36360,"totalTrials":166,"cells":36369},{"EARLY_PHASE1":36370,"PHASE1":36372,"PHASE2":36374,"PHASE3":36380,"PHASE4":36382,"NA":36384},{"trials":36371,"activeCount":124},[],{"trials":36373,"activeCount":124},[],{"trials":36375,"activeCount":124},[36376],{"nctId":36354,"briefTitle":36355,"status":203,"phases":36377,"start":5267,"enrollment":124,"conditions":36378,"interventions":36379},[88],[36358],[36345,36360,36361],{"trials":36381,"activeCount":124},[],{"trials":36383,"activeCount":124},[],{"trials":36385,"activeCount":124},[],{"intervention":36361,"totalTrials":166,"cells":36387},{"EARLY_PHASE1":36388,"PHASE1":36390,"PHASE2":36392,"PHASE3":36398,"PHASE4":36400,"NA":36402},{"trials":36389,"activeCount":124},[],{"trials":36391,"activeCount":124},[],{"trials":36393,"activeCount":124},[36394],{"nctId":36354,"briefTitle":36355,"status":203,"phases":36395,"start":5267,"enrollment":124,"conditions":36396,"interventions":36397},[88],[36358],[36345,36360,36361],{"trials":36399,"activeCount":124},[],{"trials":36401,"activeCount":124},[],{"trials":36403,"activeCount":124},[],{"intervention":33322,"totalTrials":166,"cells":36405},{"EARLY_PHASE1":36406,"PHASE1":36408,"PHASE2":36410,"PHASE3":36416,"PHASE4":36418,"NA":36420},{"trials":36407,"activeCount":124},[],{"trials":36409,"activeCount":124},[],{"trials":36411,"activeCount":124},[36412],{"nctId":33317,"briefTitle":33318,"status":130,"phases":36413,"primaryCompletion":1558,"completion":1558,"start":8386,"enrollment":2700,"conditions":36414,"interventions":36415},[87,88],[15],[18535,33322],{"trials":36417,"activeCount":124},[],{"trials":36419,"activeCount":124},[],{"trials":36421,"activeCount":124},[],{"intervention":17606,"totalTrials":166,"cells":36423},{"EARLY_PHASE1":36424,"PHASE1":36426,"PHASE2":36428,"PHASE3":36434,"PHASE4":36436,"NA":36438},{"trials":36425,"activeCount":124},[],{"trials":36427,"activeCount":124},[],{"trials":36429,"activeCount":124},[36430],{"nctId":17600,"briefTitle":17601,"status":130,"phases":36431,"primaryCompletion":5556,"completion":5556,"start":6852,"enrollment":2581,"conditions":36432,"interventions":36433},[87,88],[17604],[3497,17606],{"trials":36435,"activeCount":124},[],{"trials":36437,"activeCount":124},[],{"trials":36439,"activeCount":124},[],{"intervention":14894,"totalTrials":166,"cells":36441},{"EARLY_PHASE1":36442,"PHASE1":36444,"PHASE2":36446,"PHASE3":36452,"PHASE4":36454,"NA":36456},{"trials":36443,"activeCount":124},[],{"trials":36445,"activeCount":124},[],{"trials":36447,"activeCount":124},[36448],{"nctId":14889,"briefTitle":14890,"status":130,"phases":36449,"primaryCompletion":4184,"completion":4184,"start":2944,"enrollment":517,"conditions":36450,"interventions":36451},[88],[27],[14894,1710],{"trials":36453,"activeCount":124},[],{"trials":36455,"activeCount":124},[],{"trials":36457,"activeCount":124},[],{"intervention":36459,"totalTrials":166,"cells":36460},"TK1258",{"EARLY_PHASE1":36461,"PHASE1":36463,"PHASE2":36465,"PHASE3":36475,"PHASE4":36477,"NA":36479},{"trials":36462,"activeCount":124},[],{"trials":36464,"activeCount":124},[],{"trials":36466,"activeCount":124},[36467],{"nctId":36468,"briefTitle":36469,"status":130,"phases":36470,"primaryCompletion":36471,"completion":36471,"start":36472,"enrollment":4171,"conditions":36473,"interventions":36474},"NCT00831792","TKI258 in Castrate Resistant Prostate Cancer",[88],"2017-06-12","2010-04-07",[27],[36459],{"trials":36476,"activeCount":124},[],{"trials":36478,"activeCount":124},[],{"trials":36480,"activeCount":124},[],{"intervention":8426,"totalTrials":166,"cells":36482},{"EARLY_PHASE1":36483,"PHASE1":36485,"PHASE2":36487,"PHASE3":36493,"PHASE4":36495,"NA":36497},{"trials":36484,"activeCount":124},[],{"trials":36486,"activeCount":124},[],{"trials":36488,"activeCount":124},[36489],{"nctId":8419,"briefTitle":8420,"status":203,"phases":36490,"primaryCompletion":8422,"completion":3880,"start":8423,"enrollment":124,"conditions":36491,"interventions":36492},[88],[6956,5445],[974,894,8426,8427],{"trials":36494,"activeCount":124},[],{"trials":36496,"activeCount":124},[],{"trials":36498,"activeCount":124},[],{"intervention":8427,"totalTrials":166,"cells":36500},{"EARLY_PHASE1":36501,"PHASE1":36503,"PHASE2":36505,"PHASE3":36511,"PHASE4":36513,"NA":36515},{"trials":36502,"activeCount":124},[],{"trials":36504,"activeCount":124},[],{"trials":36506,"activeCount":124},[36507],{"nctId":8419,"briefTitle":8420,"status":203,"phases":36508,"primaryCompletion":8422,"completion":3880,"start":8423,"enrollment":124,"conditions":36509,"interventions":36510},[88],[6956,5445],[974,894,8426,8427],{"trials":36512,"activeCount":124},[],{"trials":36514,"activeCount":124},[],{"trials":36516,"activeCount":124},[],{"intervention":36518,"totalTrials":166,"cells":36519},"PTK 787",{"EARLY_PHASE1":36520,"PHASE1":36522,"PHASE2":36524,"PHASE3":36532,"PHASE4":36534,"NA":36536},{"trials":36521,"activeCount":124},[],{"trials":36523,"activeCount":124},[],{"trials":36525,"activeCount":124},[36526],{"nctId":36527,"briefTitle":36528,"status":130,"phases":36529,"primaryCompletion":6384,"completion":6384,"start":12101,"enrollment":910,"conditions":36530,"interventions":36531},"NCT00088231","PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP",[87,88],[4659,18054,4725],[2321,36518],{"trials":36533,"activeCount":124},[],{"trials":36535,"activeCount":124},[],{"trials":36537,"activeCount":124},[],{"intervention":36539,"totalTrials":166,"cells":36540},"Iressa",{"EARLY_PHASE1":36541,"PHASE1":36543,"PHASE2":36545,"PHASE3":36553,"PHASE4":36555,"NA":36557},{"trials":36542,"activeCount":124},[],{"trials":36544,"activeCount":124},[],{"trials":36546,"activeCount":124},[36547],{"nctId":36548,"briefTitle":36549,"status":130,"phases":36550,"primaryCompletion":3805,"completion":3805,"start":20512,"enrollment":517,"conditions":36551,"interventions":36552},"NCT00054691","ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin",[88],[4354],[36539],{"trials":36554,"activeCount":124},[],{"trials":36556,"activeCount":124},[],{"trials":36558,"activeCount":124},[],{"intervention":34280,"totalTrials":166,"cells":36560},{"EARLY_PHASE1":36561,"PHASE1":36563,"PHASE2":36565,"PHASE3":36571,"PHASE4":36573,"NA":36575},{"trials":36562,"activeCount":124},[],{"trials":36564,"activeCount":124},[],{"trials":36566,"activeCount":124},[36567],{"nctId":34274,"briefTitle":34275,"status":130,"phases":36568,"primaryCompletion":34277,"completion":34277,"start":2901,"enrollment":2581,"conditions":36569,"interventions":36570},[88],[36,737,30,608,609],[34280,4452],{"trials":36572,"activeCount":124},[],{"trials":36574,"activeCount":124},[],{"trials":36576,"activeCount":124},[],{"intervention":23087,"totalTrials":166,"cells":36578},{"EARLY_PHASE1":36579,"PHASE1":36581,"PHASE2":36583,"PHASE3":36589,"PHASE4":36591,"NA":36593},{"trials":36580,"activeCount":124},[],{"trials":36582,"activeCount":124},[],{"trials":36584,"activeCount":124},[36585],{"nctId":23081,"briefTitle":23082,"status":130,"phases":36586,"primaryCompletion":23084,"completion":23084,"start":7177,"enrollment":1409,"conditions":36587,"interventions":36588},[88],[15],[3432,23087],{"trials":36590,"activeCount":124},[],{"trials":36592,"activeCount":124},[],{"trials":36594,"activeCount":124},[],{"intervention":692,"totalTrials":166,"cells":36596},{"EARLY_PHASE1":36597,"PHASE1":36599,"PHASE2":36601,"PHASE3":36607,"PHASE4":36609,"NA":36611},{"trials":36598,"activeCount":124},[],{"trials":36600,"activeCount":124},[],{"trials":36602,"activeCount":124},[36603],{"nctId":685,"briefTitle":686,"status":130,"phases":36604,"primaryCompletion":688,"completion":688,"start":689,"enrollment":676,"conditions":36605,"interventions":36606},[87,88],[608,610],[692,693,510,694,695,696,480,510],{"trials":36608,"activeCount":124},[],{"trials":36610,"activeCount":124},[],{"trials":36612,"activeCount":124},[],{"intervention":695,"totalTrials":166,"cells":36614},{"EARLY_PHASE1":36615,"PHASE1":36617,"PHASE2":36619,"PHASE3":36625,"PHASE4":36627,"NA":36629},{"trials":36616,"activeCount":124},[],{"trials":36618,"activeCount":124},[],{"trials":36620,"activeCount":124},[36621],{"nctId":685,"briefTitle":686,"status":130,"phases":36622,"primaryCompletion":688,"completion":688,"start":689,"enrollment":676,"conditions":36623,"interventions":36624},[87,88],[608,610],[692,693,510,694,695,696,480,510],{"trials":36626,"activeCount":124},[],{"trials":36628,"activeCount":124},[],{"trials":36630,"activeCount":124},[],{"intervention":696,"totalTrials":166,"cells":36632},{"EARLY_PHASE1":36633,"PHASE1":36635,"PHASE2":36637,"PHASE3":36643,"PHASE4":36645,"NA":36647},{"trials":36634,"activeCount":124},[],{"trials":36636,"activeCount":124},[],{"trials":36638,"activeCount":124},[36639],{"nctId":685,"briefTitle":686,"status":130,"phases":36640,"primaryCompletion":688,"completion":688,"start":689,"enrollment":676,"conditions":36641,"interventions":36642},[87,88],[608,610],[692,693,510,694,695,696,480,510],{"trials":36644,"activeCount":124},[],{"trials":36646,"activeCount":124},[],{"trials":36648,"activeCount":124},[],{"intervention":12396,"totalTrials":166,"cells":36650},{"EARLY_PHASE1":36651,"PHASE1":36653,"PHASE2":36655,"PHASE3":36661,"PHASE4":36663,"NA":36665},{"trials":36652,"activeCount":124},[],{"trials":36654,"activeCount":124},[],{"trials":36656,"activeCount":124},[36657],{"nctId":12391,"briefTitle":12392,"status":130,"phases":36658,"primaryCompletion":8956,"completion":8956,"start":4183,"enrollment":1975,"conditions":36659,"interventions":36660},[88],[4107],[2369,12396],{"trials":36662,"activeCount":124},[],{"trials":36664,"activeCount":124},[],{"trials":36666,"activeCount":124},[],{"intervention":36668,"totalTrials":166,"cells":36669},"Tesetaxel",{"EARLY_PHASE1":36670,"PHASE1":36672,"PHASE2":36674,"PHASE3":36682,"PHASE4":36684,"NA":36686},{"trials":36671,"activeCount":124},[],{"trials":36673,"activeCount":124},[],{"trials":36675,"activeCount":124},[36676],{"nctId":36677,"briefTitle":36678,"status":130,"phases":36679,"primaryCompletion":6974,"completion":6974,"start":8551,"enrollment":539,"conditions":36680,"interventions":36681},"NCT01064713","Phase II Study of Tesetaxel in Metastatic Melanoma",[88],[1770,5349],[36668],{"trials":36683,"activeCount":124},[],{"trials":36685,"activeCount":124},[],{"trials":36687,"activeCount":124},[],{"intervention":7760,"totalTrials":166,"cells":36689},{"EARLY_PHASE1":36690,"PHASE1":36692,"PHASE2":36694,"PHASE3":36700,"PHASE4":36702,"NA":36704},{"trials":36691,"activeCount":124},[],{"trials":36693,"activeCount":124},[],{"trials":36695,"activeCount":124},[36696],{"nctId":7753,"briefTitle":7754,"status":203,"phases":36697,"primaryCompletion":7756,"completion":7756,"start":7757,"enrollment":124,"conditions":36698,"interventions":36699},[87,88],[1729],[7760,53],{"trials":36701,"activeCount":124},[],{"trials":36703,"activeCount":124},[],{"trials":36705,"activeCount":124},[],{"intervention":8447,"totalTrials":166,"cells":36707},{"EARLY_PHASE1":36708,"PHASE1":36710,"PHASE2":36712,"PHASE3":36718,"PHASE4":36720,"NA":36722},{"trials":36709,"activeCount":124},[],{"trials":36711,"activeCount":124},[],{"trials":36713,"activeCount":124},[36714],{"nctId":8441,"briefTitle":8442,"status":130,"phases":36715,"primaryCompletion":2519,"completion":2519,"start":8444,"enrollment":861,"conditions":36716,"interventions":36717},[88],[1122],[8447,894],{"trials":36719,"activeCount":124},[],{"trials":36721,"activeCount":124},[],{"trials":36723,"activeCount":124},[],{"intervention":36725,"totalTrials":166,"cells":36726},"Liposomal Vincristine",{"EARLY_PHASE1":36727,"PHASE1":36729,"PHASE2":36731,"PHASE3":36740,"PHASE4":36742,"NA":36744},{"trials":36728,"activeCount":124},[],{"trials":36730,"activeCount":124},[],{"trials":36732,"activeCount":124},[36733],{"nctId":36734,"briefTitle":36735,"status":130,"phases":36736,"primaryCompletion":34960,"completion":2213,"start":2945,"enrollment":1409,"conditions":36737,"interventions":36739},"NCT00038207","Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies",[88],[1593,21,15,36738,4384],"Wilms' Tumor",[36725],{"trials":36741,"activeCount":124},[],{"trials":36743,"activeCount":124},[],{"trials":36745,"activeCount":124},[],{"intervention":36747,"totalTrials":166,"cells":36748},"Mifepristone",{"EARLY_PHASE1":36749,"PHASE1":36751,"PHASE2":36753,"PHASE3":36761,"PHASE4":36763,"NA":36765},{"trials":36750,"activeCount":124},[],{"trials":36752,"activeCount":124},[],{"trials":36754,"activeCount":124},[36755],{"nctId":36756,"briefTitle":36757,"status":130,"phases":36758,"primaryCompletion":5733,"completion":2932,"start":5268,"enrollment":2018,"conditions":36759,"interventions":36760},"NCT00505739","Mifepristone for Patients With Endometrial Cancer and LGESS",[88],[2809],[36747],{"trials":36762,"activeCount":124},[],{"trials":36764,"activeCount":124},[],{"trials":36766,"activeCount":124},[],{"intervention":5560,"totalTrials":166,"cells":36768},{"EARLY_PHASE1":36769,"PHASE1":36771,"PHASE2":36773,"PHASE3":36779,"PHASE4":36781,"NA":36783},{"trials":36770,"activeCount":124},[],{"trials":36772,"activeCount":124},[],{"trials":36774,"activeCount":124},[36775],{"nctId":5553,"briefTitle":5554,"status":130,"phases":36776,"primaryCompletion":5556,"completion":5556,"start":5557,"enrollment":381,"conditions":36777,"interventions":36778},[88],[21],[2424,2374,4629,5560,894],{"trials":36780,"activeCount":124},[],{"trials":36782,"activeCount":124},[],{"trials":36784,"activeCount":124},[],{"intervention":36786,"totalTrials":166,"cells":36787},"ABT-510",{"EARLY_PHASE1":36788,"PHASE1":36790,"PHASE2":36792,"PHASE3":36800,"PHASE4":36802,"NA":36804},{"trials":36789,"activeCount":124},[],{"trials":36791,"activeCount":124},[],{"trials":36793,"activeCount":124},[36794],{"nctId":36795,"briefTitle":36796,"status":130,"phases":36797,"primaryCompletion":6828,"completion":6828,"start":14844,"enrollment":230,"conditions":36798,"interventions":36799},"NCT00113334","Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer",[87,88],[242],[36786],{"trials":36801,"activeCount":124},[],{"trials":36803,"activeCount":124},[],{"trials":36805,"activeCount":124},[],{"intervention":36807,"totalTrials":166,"cells":36808},"Poziotinib Hydrochloride",{"EARLY_PHASE1":36809,"PHASE1":36811,"PHASE2":36813,"PHASE3":36824,"PHASE4":36826,"NA":36828},{"trials":36810,"activeCount":124},[],{"trials":36812,"activeCount":124},[],{"trials":36814,"activeCount":124},[36815],{"nctId":36816,"briefTitle":36817,"status":203,"phases":36818,"primaryCompletion":36819,"completion":36819,"start":36820,"enrollment":124,"conditions":36821,"interventions":36822},"NCT05045404","Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer",[88],"2023-02-02","2021-06-16",[1315,1319,1361,1362],[36807,36823],"1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE",{"trials":36825,"activeCount":124},[],{"trials":36827,"activeCount":124},[],{"trials":36829,"activeCount":124},[],{"intervention":36823,"totalTrials":166,"cells":36831},{"EARLY_PHASE1":36832,"PHASE1":36834,"PHASE2":36836,"PHASE3":36842,"PHASE4":36844,"NA":36846},{"trials":36833,"activeCount":124},[],{"trials":36835,"activeCount":124},[],{"trials":36837,"activeCount":124},[36838],{"nctId":36816,"briefTitle":36817,"status":203,"phases":36839,"primaryCompletion":36819,"completion":36819,"start":36820,"enrollment":124,"conditions":36840,"interventions":36841},[88],[1315,1319,1361,1362],[36807,36823],{"trials":36843,"activeCount":124},[],{"trials":36845,"activeCount":124},[],{"trials":36847,"activeCount":124},[],{"intervention":10479,"totalTrials":166,"cells":36849},{"EARLY_PHASE1":36850,"PHASE1":36852,"PHASE2":36854,"PHASE3":36860,"PHASE4":36862,"NA":36864},{"trials":36851,"activeCount":124},[],{"trials":36853,"activeCount":124},[],{"trials":36855,"activeCount":124},[36856],{"nctId":10469,"briefTitle":10470,"status":130,"phases":36857,"primaryCompletion":10472,"completion":10472,"start":10473,"enrollment":3521,"conditions":36858,"interventions":36859},[87,88],[10475,10442,10476,737,1067,10477,30],[510,10479],{"trials":36861,"activeCount":124},[],{"trials":36863,"activeCount":124},[],{"trials":36865,"activeCount":124},[],{"intervention":36867,"totalTrials":166,"cells":36868},"AmnioFix®",{"EARLY_PHASE1":36869,"PHASE1":36871,"PHASE2":36873,"PHASE3":36882,"PHASE4":36884,"NA":36886},{"trials":36870,"activeCount":124},[],{"trials":36872,"activeCount":124},[],{"trials":36874,"activeCount":124},[36875],{"nctId":36876,"briefTitle":36877,"status":203,"phases":36878,"primaryCompletion":36879,"start":8718,"enrollment":124,"conditions":36880,"interventions":36881},"NCT02645591","Randomized AmnioFix Study During Radical Prostatectomy",[88],"2019-11",[27],[36867],{"trials":36883,"activeCount":124},[],{"trials":36885,"activeCount":124},[],{"trials":36887,"activeCount":124},[],{"intervention":7804,"totalTrials":166,"cells":36889},{"EARLY_PHASE1":36890,"PHASE1":36892,"PHASE2":36894,"PHASE3":36900,"PHASE4":36902,"NA":36904},{"trials":36891,"activeCount":124},[],{"trials":36893,"activeCount":124},[],{"trials":36895,"activeCount":124},[36896],{"nctId":7787,"briefTitle":7788,"status":130,"phases":36897,"primaryCompletion":7790,"completion":7790,"start":1958,"enrollment":1568,"conditions":36898,"interventions":36899},[88],[7792,7793,7794,7795,7796,7797,7798,7799,7800,7801,7802],[7804,53,7805],{"trials":36901,"activeCount":124},[],{"trials":36903,"activeCount":124},[],{"trials":36905,"activeCount":124},[],{"intervention":13269,"totalTrials":166,"cells":36907},{"EARLY_PHASE1":36908,"PHASE1":36910,"PHASE2":36912,"PHASE3":36918,"PHASE4":36920,"NA":36922},{"trials":36909,"activeCount":124},[],{"trials":36911,"activeCount":124},[],{"trials":36913,"activeCount":124},[36914],{"nctId":13257,"briefTitle":13258,"status":182,"phases":36915,"primaryCompletion":1518,"completion":1518,"start":13260,"enrollment":1243,"conditions":36916,"interventions":36917},[88],[13262,13263,2924,13264,1456,2925,13265,13185,13186,2926,13266,13191,13267,13192,13193,13194,13195,3860,1468,13196,13197],[13269,1786],{"trials":36919,"activeCount":124},[],{"trials":36921,"activeCount":124},[],{"trials":36923,"activeCount":124},[],{"intervention":15520,"totalTrials":166,"cells":36925},{"EARLY_PHASE1":36926,"PHASE1":36928,"PHASE2":36930,"PHASE3":36936,"PHASE4":36938,"NA":36940},{"trials":36927,"activeCount":124},[],{"trials":36929,"activeCount":124},[],{"trials":36931,"activeCount":124},[36932],{"nctId":15513,"briefTitle":15514,"status":203,"phases":36933,"primaryCompletion":15516,"completion":15516,"start":15517,"enrollment":124,"conditions":36934,"interventions":36935},[88],[3429],[598,15520],{"trials":36937,"activeCount":124},[],{"trials":36939,"activeCount":124},[],{"trials":36941,"activeCount":124},[],{"intervention":36943,"totalTrials":166,"cells":36944},"TNP-470",{"EARLY_PHASE1":36945,"PHASE1":36947,"PHASE2":36949,"PHASE3":36958,"PHASE4":36960,"NA":36962},{"trials":36946,"activeCount":124},[],{"trials":36948,"activeCount":124},[],{"trials":36950,"activeCount":124},[36951],{"nctId":36952,"briefTitle":36953,"status":182,"phases":36954,"primaryCompletion":36955,"completion":36955,"start":3997,"enrollment":230,"conditions":36956,"interventions":36957},"NCT00038701","Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas",[88],"2004-05-11",[12452],[36943],{"trials":36959,"activeCount":124},[],{"trials":36961,"activeCount":124},[],{"trials":36963,"activeCount":124},[],{"intervention":36965,"totalTrials":166,"cells":36966},"Synthetic Tumor-Specific Breakpoint Peptide Vaccine",{"EARLY_PHASE1":36967,"PHASE1":36969,"PHASE2":36971,"PHASE3":36979,"PHASE4":36981,"NA":36983},{"trials":36968,"activeCount":124},[],{"trials":36970,"activeCount":124},[],{"trials":36972,"activeCount":124},[36973],{"nctId":36974,"briefTitle":36975,"status":130,"phases":36976,"primaryCompletion":11731,"completion":11731,"start":3988,"enrollment":95,"conditions":36977,"interventions":36978},"NCT00267085","Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease",[88],[3315,3040],[36965],{"trials":36980,"activeCount":124},[],{"trials":36982,"activeCount":124},[],{"trials":36984,"activeCount":124},[],{"intervention":4439,"totalTrials":166,"cells":36986},{"EARLY_PHASE1":36987,"PHASE1":36989,"PHASE2":36991,"PHASE3":36997,"PHASE4":36999,"NA":37001},{"trials":36988,"activeCount":124},[],{"trials":36990,"activeCount":124},[],{"trials":36992,"activeCount":124},[36993],{"nctId":4432,"briefTitle":4433,"status":130,"phases":36994,"primaryCompletion":4435,"completion":4435,"start":4436,"enrollment":1609,"conditions":36995,"interventions":36996},[87,88],[651],[599,654,4439],{"trials":36998,"activeCount":124},[],{"trials":37000,"activeCount":124},[],{"trials":37002,"activeCount":124},[],{"intervention":37004,"totalTrials":166,"cells":37005},"LOXL2 Inhibitor PAT-1251",{"EARLY_PHASE1":37006,"PHASE1":37008,"PHASE2":37010,"PHASE3":37019,"PHASE4":37021,"NA":37023},{"trials":37007,"activeCount":124},[],{"trials":37009,"activeCount":124},[],{"trials":37011,"activeCount":124},[37012],{"nctId":37013,"briefTitle":37014,"status":203,"phases":37015,"primaryCompletion":37016,"completion":37016,"start":37016,"enrollment":124,"conditions":37017,"interventions":37018},"NCT04054245","PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis",[88],"2019-07-24",[2133,746,2134],[37004],{"trials":37020,"activeCount":124},[],{"trials":37022,"activeCount":124},[],{"trials":37024,"activeCount":124},[],{"intervention":31444,"totalTrials":166,"cells":37026},{"EARLY_PHASE1":37027,"PHASE1":37029,"PHASE2":37031,"PHASE3":37037,"PHASE4":37039,"NA":37041},{"trials":37028,"activeCount":124},[],{"trials":37030,"activeCount":124},[],{"trials":37032,"activeCount":124},[37033],{"nctId":31438,"briefTitle":31439,"status":130,"phases":37034,"primaryCompletion":2945,"completion":10272,"start":31441,"enrollment":901,"conditions":37035,"interventions":37036},[88],[18],[31421,31444],{"trials":37038,"activeCount":124},[],{"trials":37040,"activeCount":124},[],{"trials":37042,"activeCount":124},[],{"intervention":7822,"totalTrials":166,"cells":37044},{"EARLY_PHASE1":37045,"PHASE1":37047,"PHASE2":37049,"PHASE3":37055,"PHASE4":37057,"NA":37059},{"trials":37046,"activeCount":124},[],{"trials":37048,"activeCount":124},[],{"trials":37050,"activeCount":124},[37051],{"nctId":7811,"briefTitle":7812,"status":182,"phases":37052,"primaryCompletion":7814,"completion":7815,"start":7816,"enrollment":910,"conditions":37053,"interventions":37054},[88],[7818,7819,7820],[7822,53],{"trials":37056,"activeCount":124},[],{"trials":37058,"activeCount":124},[],{"trials":37060,"activeCount":124},[],{"intervention":37062,"totalTrials":166,"cells":37063},"Telavancin",{"EARLY_PHASE1":37064,"PHASE1":37066,"PHASE2":37068,"PHASE3":37077,"PHASE4":37079,"NA":37081},{"trials":37065,"activeCount":124},[],{"trials":37067,"activeCount":124},[],{"trials":37069,"activeCount":124},[37070],{"nctId":37071,"briefTitle":37072,"status":130,"phases":37073,"primaryCompletion":2122,"completion":2122,"start":8386,"enrollment":517,"conditions":37074,"interventions":37076},"NCT01321879","Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients",[88],[27091,37075],"Bacteremia",[37062],{"trials":37078,"activeCount":124},[],{"trials":37080,"activeCount":124},[],{"trials":37082,"activeCount":124},[],{"intervention":7839,"totalTrials":166,"cells":37084},{"EARLY_PHASE1":37085,"PHASE1":37087,"PHASE2":37089,"PHASE3":37095,"PHASE4":37097,"NA":37099},{"trials":37086,"activeCount":124},[],{"trials":37088,"activeCount":124},[],{"trials":37090,"activeCount":124},[37091],{"nctId":7832,"briefTitle":7833,"status":130,"phases":37092,"primaryCompletion":405,"completion":405,"start":7835,"enrollment":1131,"conditions":37093,"interventions":37094},[88],[6564,7837,6565],[7839,53],{"trials":37096,"activeCount":124},[],{"trials":37098,"activeCount":124},[],{"trials":37100,"activeCount":124},[],{"intervention":37102,"totalTrials":166,"cells":37103},"Femara",{"EARLY_PHASE1":37104,"PHASE1":37106,"PHASE2":37108,"PHASE3":37116,"PHASE4":37118,"NA":37120},{"trials":37105,"activeCount":124},[],{"trials":37107,"activeCount":124},[],{"trials":37109,"activeCount":124},[37110],{"nctId":37111,"briefTitle":37112,"status":203,"phases":37113,"primaryCompletion":4697,"completion":4697,"start":6828,"enrollment":124,"conditions":37114,"interventions":37115},"NCT00634894","Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[88],[1530,9926,5787],[37102],{"trials":37117,"activeCount":124},[],{"trials":37119,"activeCount":124},[],{"trials":37121,"activeCount":124},[],{"intervention":37123,"totalTrials":166,"cells":37124},"Ferric Carboxymaltose",{"EARLY_PHASE1":37125,"PHASE1":37127,"PHASE2":37129,"PHASE3":37140,"PHASE4":37142,"NA":37144},{"trials":37126,"activeCount":124},[],{"trials":37128,"activeCount":124},[],{"trials":37130,"activeCount":124},[37131],{"nctId":37132,"briefTitle":37133,"status":182,"phases":37134,"primaryCompletion":37135,"completion":37135,"start":37136,"enrollment":1231,"conditions":37137,"interventions":37139},"NCT02949947","Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy",[88],"2019-03-06","2017-12-18",[7653,37138],"Gastrointestinal Stromal Tumor With Neurogenic Differentiation",[37123],{"trials":37141,"activeCount":124},[],{"trials":37143,"activeCount":124},[],{"trials":37145,"activeCount":124},[],{"intervention":37147,"totalTrials":166,"cells":37148},"MEK 162",{"EARLY_PHASE1":37149,"PHASE1":37151,"PHASE2":37153,"PHASE3":37162,"PHASE4":37164,"NA":37166},{"trials":37150,"activeCount":124},[],{"trials":37152,"activeCount":124},[],{"trials":37154,"activeCount":124},[37155],{"nctId":37156,"briefTitle":37157,"status":182,"phases":37158,"primaryCompletion":23385,"completion":23385,"start":37159,"enrollment":1766,"conditions":37160,"interventions":37161},"NCT02089230","MEK Inhibitor 162 Relapsed and\u002For Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy",[87,88],"2014-08-27",[15],[37147],{"trials":37163,"activeCount":124},[],{"trials":37165,"activeCount":124},[],{"trials":37167,"activeCount":124},[],{"intervention":2532,"totalTrials":166,"cells":37169},{"EARLY_PHASE1":37170,"PHASE1":37172,"PHASE2":37174,"PHASE3":37180,"PHASE4":37182,"NA":37184},{"trials":37171,"activeCount":124},[],{"trials":37173,"activeCount":124},[],{"trials":37175,"activeCount":124},[37176],{"nctId":2524,"briefTitle":2525,"status":130,"phases":37177,"primaryCompletion":2527,"completion":2527,"start":2528,"enrollment":1609,"conditions":37178,"interventions":37179},[88],[2530],[806,1016,2532,62,894],{"trials":37181,"activeCount":124},[],{"trials":37183,"activeCount":124},[],{"trials":37185,"activeCount":124},[],{"intervention":11304,"totalTrials":166,"cells":37187},{"EARLY_PHASE1":37188,"PHASE1":37190,"PHASE2":37192,"PHASE3":37198,"PHASE4":37200,"NA":37202},{"trials":37189,"activeCount":124},[],{"trials":37191,"activeCount":124},[],{"trials":37193,"activeCount":124},[37194],{"nctId":11297,"briefTitle":11298,"status":130,"phases":37195,"primaryCompletion":9512,"completion":10760,"start":11300,"enrollment":296,"conditions":37196,"interventions":37197},[88],[11302],[11304,1373,11305,806,809,11306,810],{"trials":37199,"activeCount":124},[],{"trials":37201,"activeCount":124},[],{"trials":37203,"activeCount":124},[],{"intervention":11305,"totalTrials":166,"cells":37205},{"EARLY_PHASE1":37206,"PHASE1":37208,"PHASE2":37210,"PHASE3":37216,"PHASE4":37218,"NA":37220},{"trials":37207,"activeCount":124},[],{"trials":37209,"activeCount":124},[],{"trials":37211,"activeCount":124},[37212],{"nctId":11297,"briefTitle":11298,"status":130,"phases":37213,"primaryCompletion":9512,"completion":10760,"start":11300,"enrollment":296,"conditions":37214,"interventions":37215},[88],[11302],[11304,1373,11305,806,809,11306,810],{"trials":37217,"activeCount":124},[],{"trials":37219,"activeCount":124},[],{"trials":37221,"activeCount":124},[],{"intervention":37223,"totalTrials":166,"cells":37224},"177Lu-PSMA-617",{"EARLY_PHASE1":37225,"PHASE1":37227,"PHASE2":37229,"PHASE3":37239,"PHASE4":37241,"NA":37243},{"trials":37226,"activeCount":124},[],{"trials":37228,"activeCount":124},[],{"trials":37230,"activeCount":124},[37231],{"nctId":37232,"briefTitle":37233,"status":203,"phases":37234,"primaryCompletion":35804,"completion":35804,"start":37235,"enrollment":124,"conditions":37236,"interventions":37238},"NCT07025512","177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia",[88],"2025-08-03",[37237,25829,15497,13565],"Metastatic Castration Resistant Prostate Cancer",[37223],{"trials":37240,"activeCount":124},[],{"trials":37242,"activeCount":124},[],{"trials":37244,"activeCount":124},[],{"intervention":1760,"totalTrials":166,"cells":37246},{"EARLY_PHASE1":37247,"PHASE1":37249,"PHASE2":37251,"PHASE3":37257,"PHASE4":37259,"NA":37261},{"trials":37248,"activeCount":124},[],{"trials":37250,"activeCount":124},[],{"trials":37252,"activeCount":124},[37253],{"nctId":1752,"briefTitle":1753,"status":203,"phases":37254,"primaryCompletion":1755,"completion":1755,"start":1756,"enrollment":124,"conditions":37255,"interventions":37256},[88],[1758],[1050,1760],{"trials":37258,"activeCount":124},[],{"trials":37260,"activeCount":124},[],{"trials":37262,"activeCount":124},[],{"intervention":31491,"totalTrials":166,"cells":37264},{"EARLY_PHASE1":37265,"PHASE1":37267,"PHASE2":37269,"PHASE3":37275,"PHASE4":37277,"NA":37279},{"trials":37266,"activeCount":124},[],{"trials":37268,"activeCount":124},[],{"trials":37270,"activeCount":124},[37271],{"nctId":31486,"briefTitle":31487,"status":130,"phases":37272,"primaryCompletion":3805,"completion":3805,"start":10977,"enrollment":4551,"conditions":37273,"interventions":37274},[88],[1729],[3718,31491,31492],{"trials":37276,"activeCount":124},[],{"trials":37278,"activeCount":124},[],{"trials":37280,"activeCount":124},[],{"intervention":31492,"totalTrials":166,"cells":37282},{"EARLY_PHASE1":37283,"PHASE1":37285,"PHASE2":37287,"PHASE3":37293,"PHASE4":37295,"NA":37297},{"trials":37284,"activeCount":124},[],{"trials":37286,"activeCount":124},[],{"trials":37288,"activeCount":124},[37289],{"nctId":31486,"briefTitle":31487,"status":130,"phases":37290,"primaryCompletion":3805,"completion":3805,"start":10977,"enrollment":4551,"conditions":37291,"interventions":37292},[88],[1729],[3718,31491,31492],{"trials":37294,"activeCount":124},[],{"trials":37296,"activeCount":124},[],{"trials":37298,"activeCount":124},[],{"intervention":37300,"totalTrials":166,"cells":37301},"calcium aluminosilicate anti-diarrheal",{"EARLY_PHASE1":37302,"PHASE1":37304,"PHASE2":37306,"PHASE3":37316,"PHASE4":37318,"NA":37320},{"trials":37303,"activeCount":124},[],{"trials":37305,"activeCount":124},[],{"trials":37307,"activeCount":124},[37308],{"nctId":37309,"briefTitle":37310,"status":130,"phases":37311,"primaryCompletion":37312,"completion":37312,"start":37313,"enrollment":1222,"conditions":37314,"interventions":37315},"NCT00748215","Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan",[88],"2014-08-12","2009-02-04",[9885,3195,28414],[37300],{"trials":37317,"activeCount":124},[],{"trials":37319,"activeCount":124},[],{"trials":37321,"activeCount":124},[],{"intervention":1787,"totalTrials":166,"cells":37323},{"EARLY_PHASE1":37324,"PHASE1":37326,"PHASE2":37328,"PHASE3":37334,"PHASE4":37336,"NA":37338},{"trials":37325,"activeCount":124},[],{"trials":37327,"activeCount":124},[],{"trials":37329,"activeCount":124},[37330],{"nctId":1762,"briefTitle":1763,"status":182,"phases":37331,"primaryCompletion":1717,"completion":1717,"start":1765,"enrollment":1766,"conditions":37332,"interventions":37333},[87,88],[1768,1769,1343,1770,1771,1772,1344,1773,1312,1774,1348,1775,1349,1776,1350,1777,1351,1352,1353,1778,1779,1355,1356,1780,1357,1781,1358,1359,1782,1319,1360,1783,1361,1784,1362],[718,693,1786,1050,53,1787],{"trials":37335,"activeCount":124},[],{"trials":37337,"activeCount":124},[],{"trials":37339,"activeCount":124},[],{"intervention":37341,"totalTrials":166,"cells":37342},"Lutetium Lu 177 Dotatate",{"EARLY_PHASE1":37343,"PHASE1":37345,"PHASE2":37347,"PHASE3":37366,"PHASE4":37368,"NA":37370},{"trials":37344,"activeCount":124},[],{"trials":37346,"activeCount":124},[],{"trials":37348,"activeCount":124},[37349],{"nctId":37350,"briefTitle":37351,"status":203,"phases":37352,"primaryCompletion":37353,"completion":37353,"start":37354,"enrollment":124,"conditions":37355,"interventions":37365},"NCT04106843","Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers",[88],"2020-09-03","2019-06-13",[37356,27921,7941,7944,37357,37358,37359,37360,37361,37362,37363,37364,7951,7952],"Locally Advanced Adrenal Gland Pheochromocytoma","Metastatic Parathyroid Gland Carcinoma","Pituitary Gland Carcinoma","Somatostatin Receptor Positive","Stage III Thyroid Gland Medullary Carcinoma AJCC v8","Stage IV Thyroid Gland Medullary Carcinoma AJCC v8","Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8","Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8","Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8",[37341],{"trials":37367,"activeCount":124},[],{"trials":37369,"activeCount":124},[],{"trials":37371,"activeCount":124},[],{"intervention":37373,"totalTrials":166,"cells":37374},"Rivoceranib",{"EARLY_PHASE1":37375,"PHASE1":37377,"PHASE2":37379,"PHASE3":37389,"PHASE4":37391,"NA":37393},{"trials":37376,"activeCount":124},[],{"trials":37378,"activeCount":124},[],{"trials":37380,"activeCount":124},[37381],{"nctId":37382,"briefTitle":37383,"status":203,"phases":37384,"primaryCompletion":11816,"completion":11816,"start":37385,"enrollment":124,"conditions":37386,"interventions":37388},"NCT06308575","A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma",[88],"2024-11-01",[17342,37387],"Recurrent Olfactory Neuroblastoma",[37373],{"trials":37390,"activeCount":124},[],{"trials":37392,"activeCount":124},[],{"trials":37394,"activeCount":124},[],{"intervention":30291,"totalTrials":166,"cells":37396},{"EARLY_PHASE1":37397,"PHASE1":37399,"PHASE2":37401,"PHASE3":37409,"PHASE4":37411,"NA":37413},{"trials":37398,"activeCount":124},[],{"trials":37400,"activeCount":124},[],{"trials":37402,"activeCount":124},[37403],{"nctId":37404,"briefTitle":37405,"status":130,"phases":37406,"primaryCompletion":3901,"completion":3901,"start":10346,"enrollment":2865,"conditions":37407,"interventions":37408},"NCT00323557","Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients",[88],[15],[4387,30291],{"trials":37410,"activeCount":124},[],{"trials":37412,"activeCount":124},[],{"trials":37414,"activeCount":124},[],{"intervention":37416,"totalTrials":166,"cells":37417},"Mirvetuximab Soravtansine",{"EARLY_PHASE1":37418,"PHASE1":37420,"PHASE2":37422,"PHASE3":37431,"PHASE4":37433,"NA":37435},{"trials":37419,"activeCount":124},[],{"trials":37421,"activeCount":124},[],{"trials":37423,"activeCount":124},[37424],{"nctId":37425,"briefTitle":37426,"status":130,"phases":37427,"primaryCompletion":880,"completion":880,"start":5829,"enrollment":724,"conditions":37428,"interventions":37430},"NCT03106077","Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer",[88],[8027,13133,13134,7308,7309,7310,7311,7312,7698,37429,7699,7701,13136,13137,13138,7313,7314,7315,7316,7317,1363],"Folate Receptor Alpha Positive",[37416],{"trials":37432,"activeCount":124},[],{"trials":37434,"activeCount":124},[],{"trials":37436,"activeCount":124},[],{"intervention":34405,"totalTrials":166,"cells":37438},{"EARLY_PHASE1":37439,"PHASE1":37441,"PHASE2":37443,"PHASE3":37449,"PHASE4":37451,"NA":37453},{"trials":37440,"activeCount":124},[],{"trials":37442,"activeCount":124},[],{"trials":37444,"activeCount":124},[37445],{"nctId":34398,"briefTitle":34399,"status":130,"phases":37446,"primaryCompletion":34401,"completion":14149,"start":1290,"enrollment":1222,"conditions":37447,"interventions":37448},[88],[34403],[27071,34405,27072,27073,34406],{"trials":37450,"activeCount":124},[],{"trials":37452,"activeCount":124},[],{"trials":37454,"activeCount":124},[],{"intervention":34406,"totalTrials":166,"cells":37456},{"EARLY_PHASE1":37457,"PHASE1":37459,"PHASE2":37461,"PHASE3":37467,"PHASE4":37469,"NA":37471},{"trials":37458,"activeCount":124},[],{"trials":37460,"activeCount":124},[],{"trials":37462,"activeCount":124},[37463],{"nctId":34398,"briefTitle":34399,"status":130,"phases":37464,"primaryCompletion":34401,"completion":14149,"start":1290,"enrollment":1222,"conditions":37465,"interventions":37466},[88],[34403],[27071,34405,27072,27073,34406],{"trials":37468,"activeCount":124},[],{"trials":37470,"activeCount":124},[],{"trials":37472,"activeCount":124},[],{"intervention":37474,"totalTrials":166,"cells":37475},"Ex Vivo-activated Autologous Lymph Node Lymphocytes",{"EARLY_PHASE1":37476,"PHASE1":37478,"PHASE2":37480,"PHASE3":37491,"PHASE4":37493,"NA":37495},{"trials":37477,"activeCount":124},[],{"trials":37479,"activeCount":124},[],{"trials":37481,"activeCount":124},[37482],{"nctId":37483,"briefTitle":37484,"status":130,"phases":37485,"primaryCompletion":27602,"completion":27602,"start":37486,"enrollment":186,"conditions":37487,"interventions":37490},"NCT02530515","Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia",[88],"2015-12-18",[15497,5945,712,13507,37488,10176,13563,13508,4752,665,715,37489,13565,5946],"Infectious Disorder","Secondary Malignant Neoplasm",[37474],{"trials":37492,"activeCount":124},[],{"trials":37494,"activeCount":124},[],{"trials":37496,"activeCount":124},[],{"intervention":31726,"totalTrials":166,"cells":37498},{"EARLY_PHASE1":37499,"PHASE1":37501,"PHASE2":37503,"PHASE3":37509,"PHASE4":37511,"NA":37513},{"trials":37500,"activeCount":124},[],{"trials":37502,"activeCount":124},[],{"trials":37504,"activeCount":124},[37505],{"nctId":31721,"briefTitle":31722,"status":203,"phases":37506,"start":12066,"enrollment":124,"conditions":37507,"interventions":37508},[87,88],[712],[31726,31727,3671],{"trials":37510,"activeCount":124},[],{"trials":37512,"activeCount":124},[],{"trials":37514,"activeCount":124},[],{"intervention":31727,"totalTrials":166,"cells":37516},{"EARLY_PHASE1":37517,"PHASE1":37519,"PHASE2":37521,"PHASE3":37527,"PHASE4":37529,"NA":37531},{"trials":37518,"activeCount":124},[],{"trials":37520,"activeCount":124},[],{"trials":37522,"activeCount":124},[37523],{"nctId":31721,"briefTitle":31722,"status":203,"phases":37524,"start":12066,"enrollment":124,"conditions":37525,"interventions":37526},[87,88],[712],[31726,31727,3671],{"trials":37528,"activeCount":124},[],{"trials":37530,"activeCount":124},[],{"trials":37532,"activeCount":124},[],{"intervention":37534,"totalTrials":166,"cells":37535},"Amoxicillin",{"EARLY_PHASE1":37536,"PHASE1":37538,"PHASE2":37540,"PHASE3":37555,"PHASE4":37557,"NA":37559},{"trials":37537,"activeCount":124},[],{"trials":37539,"activeCount":124},[],{"trials":37541,"activeCount":124},[37542],{"nctId":37543,"briefTitle":37544,"status":130,"phases":37545,"primaryCompletion":37546,"completion":37546,"start":37547,"enrollment":3197,"conditions":37548,"interventions":37549},"NCT00002682","Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach",[88],"2001-10-08","1995-08-10",[21],[37534,37550,37551,37552,37553,37554],"Bismuth Subsalicylate","Clarithromycin","Metronidazole Hydrochloride","Omeprazole","Tetracycline Hydrochloride",{"trials":37556,"activeCount":124},[],{"trials":37558,"activeCount":124},[],{"trials":37560,"activeCount":124},[],{"intervention":37550,"totalTrials":166,"cells":37562},{"EARLY_PHASE1":37563,"PHASE1":37565,"PHASE2":37567,"PHASE3":37573,"PHASE4":37575,"NA":37577},{"trials":37564,"activeCount":124},[],{"trials":37566,"activeCount":124},[],{"trials":37568,"activeCount":124},[37569],{"nctId":37543,"briefTitle":37544,"status":130,"phases":37570,"primaryCompletion":37546,"completion":37546,"start":37547,"enrollment":3197,"conditions":37571,"interventions":37572},[88],[21],[37534,37550,37551,37552,37553,37554],{"trials":37574,"activeCount":124},[],{"trials":37576,"activeCount":124},[],{"trials":37578,"activeCount":124},[],{"intervention":37551,"totalTrials":166,"cells":37580},{"EARLY_PHASE1":37581,"PHASE1":37583,"PHASE2":37585,"PHASE3":37591,"PHASE4":37593,"NA":37595},{"trials":37582,"activeCount":124},[],{"trials":37584,"activeCount":124},[],{"trials":37586,"activeCount":124},[37587],{"nctId":37543,"briefTitle":37544,"status":130,"phases":37588,"primaryCompletion":37546,"completion":37546,"start":37547,"enrollment":3197,"conditions":37589,"interventions":37590},[88],[21],[37534,37550,37551,37552,37553,37554],{"trials":37592,"activeCount":124},[],{"trials":37594,"activeCount":124},[],{"trials":37596,"activeCount":124},[],{"intervention":37552,"totalTrials":166,"cells":37598},{"EARLY_PHASE1":37599,"PHASE1":37601,"PHASE2":37603,"PHASE3":37609,"PHASE4":37611,"NA":37613},{"trials":37600,"activeCount":124},[],{"trials":37602,"activeCount":124},[],{"trials":37604,"activeCount":124},[37605],{"nctId":37543,"briefTitle":37544,"status":130,"phases":37606,"primaryCompletion":37546,"completion":37546,"start":37547,"enrollment":3197,"conditions":37607,"interventions":37608},[88],[21],[37534,37550,37551,37552,37553,37554],{"trials":37610,"activeCount":124},[],{"trials":37612,"activeCount":124},[],{"trials":37614,"activeCount":124},[],{"intervention":37553,"totalTrials":166,"cells":37616},{"EARLY_PHASE1":37617,"PHASE1":37619,"PHASE2":37621,"PHASE3":37627,"PHASE4":37629,"NA":37631},{"trials":37618,"activeCount":124},[],{"trials":37620,"activeCount":124},[],{"trials":37622,"activeCount":124},[37623],{"nctId":37543,"briefTitle":37544,"status":130,"phases":37624,"primaryCompletion":37546,"completion":37546,"start":37547,"enrollment":3197,"conditions":37625,"interventions":37626},[88],[21],[37534,37550,37551,37552,37553,37554],{"trials":37628,"activeCount":124},[],{"trials":37630,"activeCount":124},[],{"trials":37632,"activeCount":124},[],{"intervention":37554,"totalTrials":166,"cells":37634},{"EARLY_PHASE1":37635,"PHASE1":37637,"PHASE2":37639,"PHASE3":37645,"PHASE4":37647,"NA":37649},{"trials":37636,"activeCount":124},[],{"trials":37638,"activeCount":124},[],{"trials":37640,"activeCount":124},[37641],{"nctId":37543,"briefTitle":37544,"status":130,"phases":37642,"primaryCompletion":37546,"completion":37546,"start":37547,"enrollment":3197,"conditions":37643,"interventions":37644},[88],[21],[37534,37550,37551,37552,37553,37554],{"trials":37646,"activeCount":124},[],{"trials":37648,"activeCount":124},[],{"trials":37650,"activeCount":124},[],{"intervention":37652,"totalTrials":166,"cells":37653},"Ramucirumab",{"EARLY_PHASE1":37654,"PHASE1":37656,"PHASE2":37658,"PHASE3":37671,"PHASE4":37673,"NA":37675},{"trials":37655,"activeCount":124},[],{"trials":37657,"activeCount":124},[],{"trials":37659,"activeCount":124},[37660],{"nctId":37661,"briefTitle":37662,"status":130,"phases":37663,"primaryCompletion":37664,"completion":37664,"start":37665,"enrollment":2402,"conditions":37666,"interventions":37670},"NCT02520141","Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery",[88],"2022-06-29","2015-12-29",[3947,37667,37668,4125,4126,4127,37669,4128,4129,4130,4131,4133],"Liver and Intrahepatic Bile Duct Carcinoma","Stage III Gallbladder Cancer AJCC v7","Stage IV Gallbladder Cancer AJCC v7",[37652],{"trials":37672,"activeCount":124},[],{"trials":37674,"activeCount":124},[],{"trials":37676,"activeCount":124},[],{"intervention":2605,"totalTrials":166,"cells":37678},{"EARLY_PHASE1":37679,"PHASE1":37681,"PHASE2":37683,"PHASE3":37689,"PHASE4":37691,"NA":37693},{"trials":37680,"activeCount":124},[],{"trials":37682,"activeCount":124},[],{"trials":37684,"activeCount":124},[37685],{"nctId":2598,"briefTitle":2599,"status":203,"phases":37686,"primaryCompletion":2601,"start":2602,"enrollment":124,"conditions":37687,"interventions":37688},[88],[2245],[2227,2605,2369,1004,2293,2368,62,2370,2371,2372],{"trials":37690,"activeCount":124},[],{"trials":37692,"activeCount":124},[],{"trials":37694,"activeCount":124},[],{"intervention":27761,"totalTrials":166,"cells":37696},{"EARLY_PHASE1":37697,"PHASE1":37699,"PHASE2":37701,"PHASE3":37707,"PHASE4":37709,"NA":37711},{"trials":37698,"activeCount":124},[],{"trials":37700,"activeCount":124},[],{"trials":37702,"activeCount":124},[37703],{"nctId":27755,"briefTitle":27756,"status":182,"phases":37704,"primaryCompletion":11016,"completion":11016,"start":27758,"enrollment":1496,"conditions":37705,"interventions":37706},[87,88],[12304,18],[7300,27761],{"trials":37708,"activeCount":124},[],{"trials":37710,"activeCount":124},[],{"trials":37712,"activeCount":124},[],{"intervention":37714,"totalTrials":166,"cells":37715},"HDIL-2",{"EARLY_PHASE1":37716,"PHASE1":37718,"PHASE2":37720,"PHASE3":37731,"PHASE4":37733,"NA":37735},{"trials":37717,"activeCount":124},[],{"trials":37719,"activeCount":124},[],{"trials":37721,"activeCount":124},[37722],{"nctId":37723,"briefTitle":37724,"status":130,"phases":37725,"primaryCompletion":37726,"completion":37726,"start":37727,"enrollment":1559,"conditions":37728,"interventions":37729},"NCT01266603","High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI",[88],"2018-11-01","2011-02-22",[1729],[37714,37730],"recMAGE-A3 + AS15",{"trials":37732,"activeCount":124},[],{"trials":37734,"activeCount":124},[],{"trials":37736,"activeCount":124},[],{"intervention":37730,"totalTrials":166,"cells":37738},{"EARLY_PHASE1":37739,"PHASE1":37741,"PHASE2":37743,"PHASE3":37749,"PHASE4":37751,"NA":37753},{"trials":37740,"activeCount":124},[],{"trials":37742,"activeCount":124},[],{"trials":37744,"activeCount":124},[37745],{"nctId":37723,"briefTitle":37724,"status":130,"phases":37746,"primaryCompletion":37726,"completion":37726,"start":37727,"enrollment":1559,"conditions":37747,"interventions":37748},[88],[1729],[37714,37730],{"trials":37750,"activeCount":124},[],{"trials":37752,"activeCount":124},[],{"trials":37754,"activeCount":124},[],{"intervention":6907,"totalTrials":166,"cells":37756},{"EARLY_PHASE1":37757,"PHASE1":37759,"PHASE2":37761,"PHASE3":37767,"PHASE4":37769,"NA":37771},{"trials":37758,"activeCount":124},[],{"trials":37760,"activeCount":124},[],{"trials":37762,"activeCount":124},[37763],{"nctId":6896,"briefTitle":6897,"status":182,"phases":37764,"primaryCompletion":6899,"completion":6899,"start":6900,"enrollment":834,"conditions":37765,"interventions":37766},[88],[360,2084,1445,6902,1454,6903,6904,6905,1676,1677,1678,1679],[6907,803,1070,3499],{"trials":37768,"activeCount":124},[],{"trials":37770,"activeCount":124},[],{"trials":37772,"activeCount":124},[],{"intervention":37774,"totalTrials":166,"cells":37775},"LBH589",{"EARLY_PHASE1":37776,"PHASE1":37778,"PHASE2":37780,"PHASE3":37788,"PHASE4":37790,"NA":37792},{"trials":37777,"activeCount":124},[],{"trials":37779,"activeCount":124},[],{"trials":37781,"activeCount":124},[37782],{"nctId":37783,"briefTitle":37784,"status":182,"phases":37785,"primaryCompletion":11040,"completion":11040,"start":6410,"enrollment":539,"conditions":37786,"interventions":37787},"NCT00939159","Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)",[88],[30],[37774],{"trials":37789,"activeCount":124},[],{"trials":37791,"activeCount":124},[],{"trials":37793,"activeCount":124},[],{"intervention":837,"totalTrials":166,"cells":37795},{"EARLY_PHASE1":37796,"PHASE1":37798,"PHASE2":37800,"PHASE3":37806,"PHASE4":37808,"NA":37810},{"trials":37797,"activeCount":124},[],{"trials":37799,"activeCount":124},[],{"trials":37801,"activeCount":124},[37802],{"nctId":829,"briefTitle":830,"status":182,"phases":37803,"primaryCompletion":832,"completion":832,"start":833,"enrollment":834,"conditions":37804,"interventions":37805},[87,88],[36,608,610],[654,837,480],{"trials":37807,"activeCount":124},[],{"trials":37809,"activeCount":124},[],{"trials":37811,"activeCount":124},[],{"intervention":6923,"totalTrials":166,"cells":37813},{"EARLY_PHASE1":37814,"PHASE1":37816,"PHASE2":37818,"PHASE3":37824,"PHASE4":37826,"NA":37828},{"trials":37815,"activeCount":124},[],{"trials":37817,"activeCount":124},[],{"trials":37819,"activeCount":124},[37820],{"nctId":6916,"briefTitle":6917,"status":182,"phases":37821,"primaryCompletion":184,"completion":184,"start":6919,"enrollment":4171,"conditions":37822,"interventions":37823},[88],[6921],[1016,1013,803,4386,6923],{"trials":37825,"activeCount":124},[],{"trials":37827,"activeCount":124},[],{"trials":37829,"activeCount":124},[],{"intervention":8555,"totalTrials":166,"cells":37831},{"EARLY_PHASE1":37832,"PHASE1":37834,"PHASE2":37836,"PHASE3":37842,"PHASE4":37844,"NA":37846},{"trials":37833,"activeCount":124},[],{"trials":37835,"activeCount":124},[],{"trials":37837,"activeCount":124},[37838],{"nctId":8548,"briefTitle":8549,"status":130,"phases":37839,"primaryCompletion":4192,"completion":8551,"start":2953,"enrollment":1328,"conditions":37840,"interventions":37841},[88],[8553],[8555,894],{"trials":37843,"activeCount":124},[],{"trials":37845,"activeCount":124},[],{"trials":37847,"activeCount":124},[],{"intervention":13542,"totalTrials":166,"cells":37849},{"EARLY_PHASE1":37850,"PHASE1":37852,"PHASE2":37854,"PHASE3":37860,"PHASE4":37862,"NA":37864},{"trials":37851,"activeCount":124},[],{"trials":37853,"activeCount":124},[],{"trials":37855,"activeCount":124},[37856],{"nctId":13535,"briefTitle":13536,"status":182,"phases":37857,"primaryCompletion":13538,"completion":13538,"start":13539,"enrollment":1231,"conditions":37858,"interventions":37859},[88],[2742],[1402,13542,13543],{"trials":37861,"activeCount":124},[],{"trials":37863,"activeCount":124},[],{"trials":37865,"activeCount":124},[],{"intervention":13543,"totalTrials":166,"cells":37867},{"EARLY_PHASE1":37868,"PHASE1":37870,"PHASE2":37872,"PHASE3":37878,"PHASE4":37880,"NA":37882},{"trials":37869,"activeCount":124},[],{"trials":37871,"activeCount":124},[],{"trials":37873,"activeCount":124},[37874],{"nctId":13535,"briefTitle":13536,"status":182,"phases":37875,"primaryCompletion":13538,"completion":13538,"start":13539,"enrollment":1231,"conditions":37876,"interventions":37877},[88],[2742],[1402,13542,13543],{"trials":37879,"activeCount":124},[],{"trials":37881,"activeCount":124},[],{"trials":37883,"activeCount":124},[],{"intervention":20121,"totalTrials":166,"cells":37885},{"EARLY_PHASE1":37886,"PHASE1":37888,"PHASE2":37890,"PHASE3":37896,"PHASE4":37898,"NA":37900},{"trials":37887,"activeCount":124},[],{"trials":37889,"activeCount":124},[],{"trials":37891,"activeCount":124},[37892],{"nctId":20115,"briefTitle":20116,"status":130,"phases":37893,"primaryCompletion":8305,"completion":8305,"start":6828,"enrollment":1975,"conditions":37894,"interventions":37895},[88],[1400,20119],[2293,20121],{"trials":37897,"activeCount":124},[],{"trials":37899,"activeCount":124},[],{"trials":37901,"activeCount":124},[],{"intervention":16114,"totalTrials":166,"cells":37903},{"EARLY_PHASE1":37904,"PHASE1":37906,"PHASE2":37908,"PHASE3":37914,"PHASE4":37916,"NA":37918},{"trials":37905,"activeCount":124},[],{"trials":37907,"activeCount":124},[],{"trials":37909,"activeCount":124},[37910],{"nctId":16108,"briefTitle":16109,"status":182,"phases":37911,"primaryCompletion":1043,"completion":1043,"start":16111,"enrollment":296,"conditions":37912,"interventions":37913},[88],[1350,1351,1352],[1965,16114,874],{"trials":37915,"activeCount":124},[],{"trials":37917,"activeCount":124},[],{"trials":37919,"activeCount":124},[],{"intervention":27637,"totalTrials":166,"cells":37921},{"EARLY_PHASE1":37922,"PHASE1":37924,"PHASE2":37926,"PHASE3":37932,"PHASE4":37934,"NA":37936},{"trials":37923,"activeCount":124},[],{"trials":37925,"activeCount":124},[],{"trials":37927,"activeCount":124},[37928],{"nctId":27630,"briefTitle":27631,"status":182,"phases":37929,"primaryCompletion":27633,"completion":27633,"start":27634,"enrollment":186,"conditions":37930,"interventions":37931},[87,88],[7312,1312,359,27587,1315,1960,361,1316,27611,1353,7317,1319,1361,1362],[4209,27637],{"trials":37933,"activeCount":124},[],{"trials":37935,"activeCount":124},[],{"trials":37937,"activeCount":124},[],{"intervention":3282,"totalTrials":166,"cells":37939},{"EARLY_PHASE1":37940,"PHASE1":37942,"PHASE2":37944,"PHASE3":37950,"PHASE4":37952,"NA":37954},{"trials":37941,"activeCount":124},[],{"trials":37943,"activeCount":124},[],{"trials":37945,"activeCount":124},[37946],{"nctId":3265,"briefTitle":3266,"status":130,"phases":37947,"primaryCompletion":3268,"completion":3268,"start":3269,"enrollment":195,"conditions":37948,"interventions":37949},[87,88],[3271,3272,3273,3274,3275,3276,3277,3278,3279,3280],[3282,803,1070,1005,3283],{"trials":37951,"activeCount":124},[],{"trials":37953,"activeCount":124},[],{"trials":37955,"activeCount":124},[],{"intervention":3283,"totalTrials":166,"cells":37957},{"EARLY_PHASE1":37958,"PHASE1":37960,"PHASE2":37962,"PHASE3":37968,"PHASE4":37970,"NA":37972},{"trials":37959,"activeCount":124},[],{"trials":37961,"activeCount":124},[],{"trials":37963,"activeCount":124},[37964],{"nctId":3265,"briefTitle":3266,"status":130,"phases":37965,"primaryCompletion":3268,"completion":3268,"start":3269,"enrollment":195,"conditions":37966,"interventions":37967},[87,88],[3271,3272,3273,3274,3275,3276,3277,3278,3279,3280],[3282,803,1070,1005,3283],{"trials":37969,"activeCount":124},[],{"trials":37971,"activeCount":124},[],{"trials":37973,"activeCount":124},[],{"intervention":37975,"totalTrials":166,"cells":37976},"Pemetrexed Disodium",{"EARLY_PHASE1":37977,"PHASE1":37979,"PHASE2":37981,"PHASE3":37991,"PHASE4":37993,"NA":37995},{"trials":37978,"activeCount":124},[],{"trials":37980,"activeCount":124},[],{"trials":37982,"activeCount":124},[37983],{"nctId":37984,"briefTitle":37985,"status":182,"phases":37986,"primaryCompletion":37987,"completion":37987,"start":37988,"enrollment":1483,"conditions":37989,"interventions":37990},"NCT02693717","Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer",[88],"2019-12-30","2017-05-09",[1803],[37975],{"trials":37992,"activeCount":124},[],{"trials":37994,"activeCount":124},[],{"trials":37996,"activeCount":124},[],{"intervention":15540,"totalTrials":166,"cells":37998},{"EARLY_PHASE1":37999,"PHASE1":38001,"PHASE2":38003,"PHASE3":38009,"PHASE4":38011,"NA":38013},{"trials":38000,"activeCount":124},[],{"trials":38002,"activeCount":124},[],{"trials":38004,"activeCount":124},[38005],{"nctId":15533,"briefTitle":15534,"status":130,"phases":38006,"primaryCompletion":15536,"completion":15536,"start":15537,"enrollment":448,"conditions":38007,"interventions":38008},[88],[4580],[598,15540],{"trials":38010,"activeCount":124},[],{"trials":38012,"activeCount":124},[],{"trials":38014,"activeCount":124},[],{"intervention":11044,"totalTrials":166,"cells":38016},{"EARLY_PHASE1":38017,"PHASE1":38019,"PHASE2":38021,"PHASE3":38027,"PHASE4":38029,"NA":38031},{"trials":38018,"activeCount":124},[],{"trials":38020,"activeCount":124},[],{"trials":38022,"activeCount":124},[38023],{"nctId":11037,"briefTitle":11038,"status":203,"phases":38024,"primaryCompletion":2365,"start":11040,"enrollment":124,"conditions":38025,"interventions":38026},[88],[11042],[11044,1275],{"trials":38028,"activeCount":124},[],{"trials":38030,"activeCount":124},[],{"trials":38032,"activeCount":124},[],{"intervention":38034,"totalTrials":166,"cells":38035},"Gallium Ga 68-labeled PSMA-11",{"EARLY_PHASE1":38036,"PHASE1":38038,"PHASE2":38040,"PHASE3":38049,"PHASE4":38051,"NA":38053},{"trials":38037,"activeCount":124},[],{"trials":38039,"activeCount":124},[],{"trials":38041,"activeCount":124},[38042],{"nctId":38043,"briefTitle":38044,"status":203,"phases":38045,"primaryCompletion":38046,"completion":38046,"start":38046,"enrollment":124,"conditions":38047,"interventions":38048},"NCT05034562","Gallium-68 PSMA-11 PET in Participants With Prostate Cancer",[88],"2022-09-26",[3545,11339,3546,3547,3548],[38034],{"trials":38050,"activeCount":124},[],{"trials":38052,"activeCount":124},[],{"trials":38054,"activeCount":124},[],{"intervention":2623,"totalTrials":166,"cells":38056},{"EARLY_PHASE1":38057,"PHASE1":38059,"PHASE2":38061,"PHASE3":38067,"PHASE4":38069,"NA":38071},{"trials":38058,"activeCount":124},[],{"trials":38060,"activeCount":124},[],{"trials":38062,"activeCount":124},[38063],{"nctId":2616,"briefTitle":2617,"status":130,"phases":38064,"primaryCompletion":2619,"completion":2619,"start":2620,"enrollment":357,"conditions":38065,"interventions":38066},[88],[15],[2623,655,654,62],{"trials":38068,"activeCount":124},[],{"trials":38070,"activeCount":124},[],{"trials":38072,"activeCount":124},[],{"intervention":32977,"totalTrials":166,"cells":38074},{"EARLY_PHASE1":38075,"PHASE1":38077,"PHASE2":38079,"PHASE3":38085,"PHASE4":38087,"NA":38089},{"trials":38076,"activeCount":124},[],{"trials":38078,"activeCount":124},[],{"trials":38080,"activeCount":124},[38081],{"nctId":32970,"briefTitle":32971,"status":182,"phases":38082,"primaryCompletion":32973,"completion":32973,"start":32974,"enrollment":121,"conditions":38083,"interventions":38084},[88],[2245],[32977,32978,4629],{"trials":38086,"activeCount":124},[],{"trials":38088,"activeCount":124},[],{"trials":38090,"activeCount":124},[],{"intervention":32978,"totalTrials":166,"cells":38092},{"EARLY_PHASE1":38093,"PHASE1":38095,"PHASE2":38097,"PHASE3":38103,"PHASE4":38105,"NA":38107},{"trials":38094,"activeCount":124},[],{"trials":38096,"activeCount":124},[],{"trials":38098,"activeCount":124},[38099],{"nctId":32970,"briefTitle":32971,"status":182,"phases":38100,"primaryCompletion":32973,"completion":32973,"start":32974,"enrollment":121,"conditions":38101,"interventions":38102},[88],[2245],[32977,32978,4629],{"trials":38104,"activeCount":124},[],{"trials":38106,"activeCount":124},[],{"trials":38108,"activeCount":124},[],{"intervention":38110,"totalTrials":166,"cells":38111},"GSK2118436",{"EARLY_PHASE1":38112,"PHASE1":38114,"PHASE2":38116,"PHASE3":38125,"PHASE4":38127,"NA":38129},{"trials":38113,"activeCount":124},[],{"trials":38115,"activeCount":124},[],{"trials":38117,"activeCount":124},[38118],{"nctId":38119,"briefTitle":38120,"status":130,"phases":38121,"primaryCompletion":10938,"completion":10938,"start":4542,"enrollment":3521,"conditions":38122,"interventions":38123},"NCT01619774","An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor",[88],[1729],[38110,38124],"GSK1120212",{"trials":38126,"activeCount":124},[],{"trials":38128,"activeCount":124},[],{"trials":38130,"activeCount":124},[],{"intervention":38124,"totalTrials":166,"cells":38132},{"EARLY_PHASE1":38133,"PHASE1":38135,"PHASE2":38137,"PHASE3":38143,"PHASE4":38145,"NA":38147},{"trials":38134,"activeCount":124},[],{"trials":38136,"activeCount":124},[],{"trials":38138,"activeCount":124},[38139],{"nctId":38119,"briefTitle":38120,"status":130,"phases":38140,"primaryCompletion":10938,"completion":10938,"start":4542,"enrollment":3521,"conditions":38141,"interventions":38142},[88],[1729],[38110,38124],{"trials":38144,"activeCount":124},[],{"trials":38146,"activeCount":124},[],{"trials":38148,"activeCount":124},[],{"intervention":8622,"totalTrials":166,"cells":38150},{"EARLY_PHASE1":38151,"PHASE1":38153,"PHASE2":38155,"PHASE3":38161,"PHASE4":38163,"NA":38165},{"trials":38152,"activeCount":124},[],{"trials":38154,"activeCount":124},[],{"trials":38156,"activeCount":124},[38157],{"nctId":8616,"briefTitle":8617,"status":130,"phases":38158,"primaryCompletion":8619,"completion":8619,"start":2740,"enrollment":1131,"conditions":38159,"interventions":38160},[88],[15,21],[894,8622,8623,1070,6545,4537,2196,806,8624,2374],{"trials":38162,"activeCount":124},[],{"trials":38164,"activeCount":124},[],{"trials":38166,"activeCount":124},[],{"intervention":8623,"totalTrials":166,"cells":38168},{"EARLY_PHASE1":38169,"PHASE1":38171,"PHASE2":38173,"PHASE3":38179,"PHASE4":38181,"NA":38183},{"trials":38170,"activeCount":124},[],{"trials":38172,"activeCount":124},[],{"trials":38174,"activeCount":124},[38175],{"nctId":8616,"briefTitle":8617,"status":130,"phases":38176,"primaryCompletion":8619,"completion":8619,"start":2740,"enrollment":1131,"conditions":38177,"interventions":38178},[88],[15,21],[894,8622,8623,1070,6545,4537,2196,806,8624,2374],{"trials":38180,"activeCount":124},[],{"trials":38182,"activeCount":124},[],{"trials":38184,"activeCount":124},[],{"intervention":8624,"totalTrials":166,"cells":38186},{"EARLY_PHASE1":38187,"PHASE1":38189,"PHASE2":38191,"PHASE3":38197,"PHASE4":38199,"NA":38201},{"trials":38188,"activeCount":124},[],{"trials":38190,"activeCount":124},[],{"trials":38192,"activeCount":124},[38193],{"nctId":8616,"briefTitle":8617,"status":130,"phases":38194,"primaryCompletion":8619,"completion":8619,"start":2740,"enrollment":1131,"conditions":38195,"interventions":38196},[88],[15,21],[894,8622,8623,1070,6545,4537,2196,806,8624,2374],{"trials":38198,"activeCount":124},[],{"trials":38200,"activeCount":124},[],{"trials":38202,"activeCount":124},[],{"intervention":14247,"totalTrials":166,"cells":38204},{"EARLY_PHASE1":38205,"PHASE1":38207,"PHASE2":38209,"PHASE3":38215,"PHASE4":38217,"NA":38219},{"trials":38206,"activeCount":124},[],{"trials":38208,"activeCount":124},[],{"trials":38210,"activeCount":124},[38211],{"nctId":14239,"briefTitle":14240,"status":203,"phases":38212,"primaryCompletion":14242,"completion":14242,"start":14243,"enrollment":124,"conditions":38213,"interventions":38214},[88],[4031,14245,242],[14247,12910],{"trials":38216,"activeCount":124},[],{"trials":38218,"activeCount":124},[],{"trials":38220,"activeCount":124},[],{"intervention":21325,"totalTrials":166,"cells":38222},{"EARLY_PHASE1":38223,"PHASE1":38225,"PHASE2":38227,"PHASE3":38233,"PHASE4":38235,"NA":38237},{"trials":38224,"activeCount":124},[],{"trials":38226,"activeCount":124},[],{"trials":38228,"activeCount":124},[38229],{"nctId":21318,"briefTitle":21319,"status":203,"phases":38230,"primaryCompletion":13086,"completion":13086,"start":21321,"enrollment":124,"conditions":38231,"interventions":38232},[88],[21323],[520,21325],{"trials":38234,"activeCount":124},[],{"trials":38236,"activeCount":124},[],{"trials":38238,"activeCount":124},[],{"intervention":6969,"totalTrials":166,"cells":38240},{"EARLY_PHASE1":38241,"PHASE1":38243,"PHASE2":38245,"PHASE3":38251,"PHASE4":38253,"NA":38255},{"trials":38242,"activeCount":124},[],{"trials":38244,"activeCount":124},[],{"trials":38246,"activeCount":124},[38247],{"nctId":6964,"briefTitle":6965,"status":130,"phases":38248,"primaryCompletion":3832,"completion":3832,"start":4731,"enrollment":2779,"conditions":38249,"interventions":38250},[87,88],[21],[6969,803,1013,1016,809],{"trials":38252,"activeCount":124},[],{"trials":38254,"activeCount":124},[],{"trials":38256,"activeCount":124},[],{"intervention":38258,"totalTrials":166,"cells":38259},"LL37",{"EARLY_PHASE1":38260,"PHASE1":38262,"PHASE2":38264,"PHASE3":38273,"PHASE4":38275,"NA":38277},{"trials":38261,"activeCount":124},[],{"trials":38263,"activeCount":124},[],{"trials":38265,"activeCount":124},[38266],{"nctId":38267,"briefTitle":38268,"status":130,"phases":38269,"primaryCompletion":4448,"completion":4448,"start":38270,"enrollment":296,"conditions":38271,"interventions":38272},"NCT02225366","Intratumoral Injections of LL37 for Melanoma",[87,88],"2015-07-08",[1729],[38258],{"trials":38274,"activeCount":124},[],{"trials":38276,"activeCount":124},[],{"trials":38278,"activeCount":124},[],{"intervention":31856,"totalTrials":166,"cells":38280},{"EARLY_PHASE1":38281,"PHASE1":38283,"PHASE2":38285,"PHASE3":38291,"PHASE4":38293,"NA":38295},{"trials":38282,"activeCount":124},[],{"trials":38284,"activeCount":124},[],{"trials":38286,"activeCount":124},[38287],{"nctId":31851,"briefTitle":31852,"status":130,"phases":38288,"primaryCompletion":4723,"completion":4723,"start":8719,"enrollment":1100,"conditions":38289,"interventions":38290},[88],[4659,30],[31842,31856,31856],{"trials":38292,"activeCount":124},[],{"trials":38294,"activeCount":124},[],{"trials":38296,"activeCount":124},[],{"intervention":4099,"totalTrials":166,"cells":38298},{"EARLY_PHASE1":38299,"PHASE1":38301,"PHASE2":38303,"PHASE3":38309,"PHASE4":38311,"NA":38313},{"trials":38300,"activeCount":124},[],{"trials":38302,"activeCount":124},[],{"trials":38304,"activeCount":124},[38305],{"nctId":4091,"briefTitle":4092,"status":130,"phases":38306,"primaryCompletion":4094,"completion":4094,"start":4095,"enrollment":628,"conditions":38307,"interventions":38308},[88],[1638,4097,1447],[1709,4099,4100],{"trials":38310,"activeCount":124},[],{"trials":38312,"activeCount":124},[],{"trials":38314,"activeCount":124},[],{"intervention":4100,"totalTrials":166,"cells":38316},{"EARLY_PHASE1":38317,"PHASE1":38319,"PHASE2":38321,"PHASE3":38327,"PHASE4":38329,"NA":38331},{"trials":38318,"activeCount":124},[],{"trials":38320,"activeCount":124},[],{"trials":38322,"activeCount":124},[38323],{"nctId":4091,"briefTitle":4092,"status":130,"phases":38324,"primaryCompletion":4094,"completion":4094,"start":4095,"enrollment":628,"conditions":38325,"interventions":38326},[88],[1638,4097,1447],[1709,4099,4100],{"trials":38328,"activeCount":124},[],{"trials":38330,"activeCount":124},[],{"trials":38332,"activeCount":124},[],{"intervention":38334,"totalTrials":166,"cells":38335},"Haelan",{"EARLY_PHASE1":38336,"PHASE1":38338,"PHASE2":38340,"PHASE3":38348,"PHASE4":38350,"NA":38352},{"trials":38337,"activeCount":124},[],{"trials":38339,"activeCount":124},[],{"trials":38341,"activeCount":124},[38342],{"nctId":38343,"briefTitle":38344,"status":182,"phases":38345,"primaryCompletion":6410,"completion":6410,"start":5733,"enrollment":230,"conditions":38346,"interventions":38347},"NCT00558558","Haelan and Nutrition in Cancer Patients",[88],[5956,5946,6369],[38334],{"trials":38349,"activeCount":124},[],{"trials":38351,"activeCount":124},[],{"trials":38353,"activeCount":124},[],{"intervention":1881,"totalTrials":166,"cells":38355},{"EARLY_PHASE1":38356,"PHASE1":38358,"PHASE2":38360,"PHASE3":38366,"PHASE4":38368,"NA":38370},{"trials":38357,"activeCount":124},[],{"trials":38359,"activeCount":124},[],{"trials":38361,"activeCount":124},[38362],{"nctId":1871,"briefTitle":1872,"status":130,"phases":38363,"primaryCompletion":1874,"completion":1874,"start":1875,"enrollment":240,"conditions":38364,"interventions":38365},[87,88],[1343,1877,1878,1879,361],[1881,1049,1050],{"trials":38367,"activeCount":124},[],{"trials":38369,"activeCount":124},[],{"trials":38371,"activeCount":124},[],{"intervention":38373,"totalTrials":166,"cells":38374},"Rigosertib",{"EARLY_PHASE1":38375,"PHASE1":38377,"PHASE2":38379,"PHASE3":38389,"PHASE4":38391,"NA":38393},{"trials":38376,"activeCount":124},[],{"trials":38378,"activeCount":124},[],{"trials":38380,"activeCount":124},[38381],{"nctId":38382,"briefTitle":38383,"status":182,"phases":38384,"primaryCompletion":38385,"completion":38385,"start":38386,"enrollment":1231,"conditions":38387,"interventions":38388},"NCT02730884","Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia",[88],"2019-08-22","2017-08-16",[15,3429,15497,2135],[38373],{"trials":38390,"activeCount":124},[],{"trials":38392,"activeCount":124},[],{"trials":38394,"activeCount":124},[],{"intervention":20785,"totalTrials":166,"cells":38396},{"EARLY_PHASE1":38397,"PHASE1":38399,"PHASE2":38401,"PHASE3":38407,"PHASE4":38409,"NA":38411},{"trials":38398,"activeCount":124},[],{"trials":38400,"activeCount":124},[],{"trials":38402,"activeCount":124},[38403],{"nctId":20779,"briefTitle":20780,"status":130,"phases":38404,"primaryCompletion":7399,"completion":7399,"start":20782,"enrollment":1328,"conditions":38405,"interventions":38406},[88],[21],[20785,2977,4331,4156,1869],{"trials":38408,"activeCount":124},[],{"trials":38410,"activeCount":124},[],{"trials":38412,"activeCount":124},[],{"intervention":10193,"totalTrials":166,"cells":38414},{"EARLY_PHASE1":38415,"PHASE1":38417,"PHASE2":38419,"PHASE3":38425,"PHASE4":38427,"NA":38429},{"trials":38416,"activeCount":124},[],{"trials":38418,"activeCount":124},[],{"trials":38420,"activeCount":124},[38421],{"nctId":10188,"briefTitle":10189,"status":203,"phases":38422,"primaryCompletion":4834,"start":6367,"enrollment":124,"conditions":38423,"interventions":38424},[87,88],[24],[10193,3847,1376,1369],{"trials":38426,"activeCount":124},[],{"trials":38428,"activeCount":124},[],{"trials":38430,"activeCount":124},[],{"intervention":17624,"totalTrials":166,"cells":38432},{"EARLY_PHASE1":38433,"PHASE1":38435,"PHASE2":38437,"PHASE3":38443,"PHASE4":38445,"NA":38447},{"trials":38434,"activeCount":124},[],{"trials":38436,"activeCount":124},[],{"trials":38438,"activeCount":124},[38439],{"nctId":17618,"briefTitle":17619,"status":130,"phases":38440,"primaryCompletion":3996,"completion":3996,"start":2580,"enrollment":1308,"conditions":38441,"interventions":38442},[88],[17622,17604,11176],[1368,3808,3497,17554,17624],{"trials":38444,"activeCount":124},[],{"trials":38446,"activeCount":124},[],{"trials":38448,"activeCount":124},[],{"intervention":7022,"totalTrials":166,"cells":38450},{"EARLY_PHASE1":38451,"PHASE1":38453,"PHASE2":38455,"PHASE3":38461,"PHASE4":38463,"NA":38465},{"trials":38452,"activeCount":124},[],{"trials":38454,"activeCount":124},[],{"trials":38456,"activeCount":124},[38457],{"nctId":7014,"briefTitle":7015,"status":182,"phases":38458,"primaryCompletion":1984,"completion":1984,"start":7017,"enrollment":166,"conditions":38459,"interventions":38460},[88],[15,7019,2653,21],[654,7021,1016,809,7022,2425,894,806,803,805,1013,4514,7023],{"trials":38462,"activeCount":124},[],{"trials":38464,"activeCount":124},[],{"trials":38466,"activeCount":124},[],{"intervention":38468,"totalTrials":166,"cells":38469},"Alprostadil",{"EARLY_PHASE1":38470,"PHASE1":38472,"PHASE2":38474,"PHASE3":38485,"PHASE4":38487,"NA":38489},{"trials":38471,"activeCount":124},[],{"trials":38473,"activeCount":124},[],{"trials":38475,"activeCount":124},[38476],{"nctId":38477,"briefTitle":38478,"status":130,"phases":38479,"primaryCompletion":10784,"completion":3987,"start":10124,"enrollment":20949,"conditions":38480,"interventions":38481},"NCT00080808","Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer",[88],[27],[38468,38482,38483,38484],"Papaverine","Phentolamine mesylate","Sildenafil citrate",{"trials":38486,"activeCount":124},[],{"trials":38488,"activeCount":124},[],{"trials":38490,"activeCount":124},[],{"intervention":38482,"totalTrials":166,"cells":38492},{"EARLY_PHASE1":38493,"PHASE1":38495,"PHASE2":38497,"PHASE3":38503,"PHASE4":38505,"NA":38507},{"trials":38494,"activeCount":124},[],{"trials":38496,"activeCount":124},[],{"trials":38498,"activeCount":124},[38499],{"nctId":38477,"briefTitle":38478,"status":130,"phases":38500,"primaryCompletion":10784,"completion":3987,"start":10124,"enrollment":20949,"conditions":38501,"interventions":38502},[88],[27],[38468,38482,38483,38484],{"trials":38504,"activeCount":124},[],{"trials":38506,"activeCount":124},[],{"trials":38508,"activeCount":124},[],{"intervention":38483,"totalTrials":166,"cells":38510},{"EARLY_PHASE1":38511,"PHASE1":38513,"PHASE2":38515,"PHASE3":38521,"PHASE4":38523,"NA":38525},{"trials":38512,"activeCount":124},[],{"trials":38514,"activeCount":124},[],{"trials":38516,"activeCount":124},[38517],{"nctId":38477,"briefTitle":38478,"status":130,"phases":38518,"primaryCompletion":10784,"completion":3987,"start":10124,"enrollment":20949,"conditions":38519,"interventions":38520},[88],[27],[38468,38482,38483,38484],{"trials":38522,"activeCount":124},[],{"trials":38524,"activeCount":124},[],{"trials":38526,"activeCount":124},[],{"intervention":38484,"totalTrials":166,"cells":38528},{"EARLY_PHASE1":38529,"PHASE1":38531,"PHASE2":38533,"PHASE3":38539,"PHASE4":38541,"NA":38543},{"trials":38530,"activeCount":124},[],{"trials":38532,"activeCount":124},[],{"trials":38534,"activeCount":124},[38535],{"nctId":38477,"briefTitle":38478,"status":130,"phases":38536,"primaryCompletion":10784,"completion":3987,"start":10124,"enrollment":20949,"conditions":38537,"interventions":38538},[88],[27],[38468,38482,38483,38484],{"trials":38540,"activeCount":124},[],{"trials":38542,"activeCount":124},[],{"trials":38544,"activeCount":124},[],{"intervention":38546,"totalTrials":166,"cells":38547},"Acetylsalicylic acid",{"EARLY_PHASE1":38548,"PHASE1":38550,"PHASE2":38552,"PHASE3":38562,"PHASE4":38564,"NA":38566},{"trials":38549,"activeCount":124},[],{"trials":38551,"activeCount":124},[],{"trials":38553,"activeCount":124},[38554],{"nctId":38555,"briefTitle":38556,"status":182,"phases":38557,"primaryCompletion":14844,"completion":4039,"start":6758,"enrollment":3726,"conditions":38558,"interventions":38559},"NCT00062023","Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer",[88],[3195],[38546,38560,38561],"Sulindac","Ursodiol",{"trials":38563,"activeCount":124},[],{"trials":38565,"activeCount":124},[],{"trials":38567,"activeCount":124},[],{"intervention":38560,"totalTrials":166,"cells":38569},{"EARLY_PHASE1":38570,"PHASE1":38572,"PHASE2":38574,"PHASE3":38580,"PHASE4":38582,"NA":38584},{"trials":38571,"activeCount":124},[],{"trials":38573,"activeCount":124},[],{"trials":38575,"activeCount":124},[38576],{"nctId":38555,"briefTitle":38556,"status":182,"phases":38577,"primaryCompletion":14844,"completion":4039,"start":6758,"enrollment":3726,"conditions":38578,"interventions":38579},[88],[3195],[38546,38560,38561],{"trials":38581,"activeCount":124},[],{"trials":38583,"activeCount":124},[],{"trials":38585,"activeCount":124},[],{"intervention":38561,"totalTrials":166,"cells":38587},{"EARLY_PHASE1":38588,"PHASE1":38590,"PHASE2":38592,"PHASE3":38598,"PHASE4":38600,"NA":38602},{"trials":38589,"activeCount":124},[],{"trials":38591,"activeCount":124},[],{"trials":38593,"activeCount":124},[38594],{"nctId":38555,"briefTitle":38556,"status":182,"phases":38595,"primaryCompletion":14844,"completion":4039,"start":6758,"enrollment":3726,"conditions":38596,"interventions":38597},[88],[3195],[38546,38560,38561],{"trials":38599,"activeCount":124},[],{"trials":38601,"activeCount":124},[],{"trials":38603,"activeCount":124},[],{"intervention":21335,"totalTrials":166,"cells":38605},{"EARLY_PHASE1":38606,"PHASE1":38608,"PHASE2":38610,"PHASE3":38616,"PHASE4":38618,"NA":38620},{"trials":38607,"activeCount":124},[],{"trials":38609,"activeCount":124},[],{"trials":38611,"activeCount":124},[38612],{"nctId":21327,"briefTitle":21328,"status":203,"phases":38613,"primaryCompletion":17564,"completion":404,"start":21330,"enrollment":124,"conditions":38614,"interventions":38615},[87,88],[21332,21333,727],[21335,520],{"trials":38617,"activeCount":124},[],{"trials":38619,"activeCount":124},[],{"trials":38621,"activeCount":124},[],{"intervention":17634,"totalTrials":166,"cells":38623},{"EARLY_PHASE1":38624,"PHASE1":38626,"PHASE2":38628,"PHASE3":38634,"PHASE4":38636,"NA":38638},{"trials":38625,"activeCount":124},[],{"trials":38627,"activeCount":124},[],{"trials":38629,"activeCount":124},[38630],{"nctId":17626,"briefTitle":17627,"status":130,"phases":38631,"primaryCompletion":17629,"completion":17629,"start":17630,"enrollment":3541,"conditions":38632,"interventions":38633},[87,88],[17632,11042,11688,3170,6653,7740],[17634,3497],{"trials":38635,"activeCount":124},[],{"trials":38637,"activeCount":124},[],{"trials":38639,"activeCount":124},[],{"intervention":2682,"totalTrials":166,"cells":38641},{"EARLY_PHASE1":38642,"PHASE1":38644,"PHASE2":38646,"PHASE3":38652,"PHASE4":38654,"NA":38656},{"trials":38643,"activeCount":124},[],{"trials":38645,"activeCount":124},[],{"trials":38647,"activeCount":124},[38648],{"nctId":2674,"briefTitle":2675,"status":130,"phases":38649,"primaryCompletion":2677,"completion":2677,"start":2678,"enrollment":2004,"conditions":38650,"interventions":38651},[88],[15],[894,2681,803,1013,1114,2682,2683,806,2584,2374,1071,62],{"trials":38653,"activeCount":124},[],{"trials":38655,"activeCount":124},[],{"trials":38657,"activeCount":124},[],{"intervention":3317,"totalTrials":166,"cells":38659},{"EARLY_PHASE1":38660,"PHASE1":38662,"PHASE2":38664,"PHASE3":38670,"PHASE4":38672,"NA":38674},{"trials":38661,"activeCount":124},[],{"trials":38663,"activeCount":124},[],{"trials":38665,"activeCount":124},[38666],{"nctId":3309,"briefTitle":3310,"status":130,"phases":38667,"primaryCompletion":3312,"completion":3312,"start":3313,"enrollment":628,"conditions":38668,"interventions":38669},[88],[2460,36,30,3315],[803,1114,1069,2293,2462,2196,2757,3317],{"trials":38671,"activeCount":124},[],{"trials":38673,"activeCount":124},[],{"trials":38675,"activeCount":124},[],{"intervention":7044,"totalTrials":166,"cells":38677},{"EARLY_PHASE1":38678,"PHASE1":38680,"PHASE2":38682,"PHASE3":38688,"PHASE4":38690,"NA":38692},{"trials":38679,"activeCount":124},[],{"trials":38681,"activeCount":124},[],{"trials":38683,"activeCount":124},[38684],{"nctId":7037,"briefTitle":7038,"status":203,"phases":38685,"primaryCompletion":7040,"completion":7040,"start":7041,"enrollment":124,"conditions":38686,"interventions":38687},[88],[1458,1460,1461],[7044,803],{"trials":38689,"activeCount":124},[],{"trials":38691,"activeCount":124},[],{"trials":38693,"activeCount":124},[],{"intervention":15703,"totalTrials":166,"cells":38695},{"EARLY_PHASE1":38696,"PHASE1":38698,"PHASE2":38700,"PHASE3":38706,"PHASE4":38708,"NA":38710},{"trials":38697,"activeCount":124},[],{"trials":38699,"activeCount":124},[],{"trials":38701,"activeCount":124},[38702],{"nctId":15696,"briefTitle":15697,"status":130,"phases":38703,"primaryCompletion":15699,"completion":15699,"start":15700,"enrollment":2933,"conditions":38704,"interventions":38705},[88],[27],[1421,15703],{"trials":38707,"activeCount":124},[],{"trials":38709,"activeCount":124},[],{"trials":38711,"activeCount":124},[],{"intervention":3326,"totalTrials":166,"cells":38713},{"EARLY_PHASE1":38714,"PHASE1":38716,"PHASE2":38718,"PHASE3":38724,"PHASE4":38726,"NA":38728},{"trials":38715,"activeCount":124},[],{"trials":38717,"activeCount":124},[],{"trials":38719,"activeCount":124},[38720],{"nctId":3319,"briefTitle":3320,"status":130,"phases":38721,"primaryCompletion":3322,"completion":3322,"start":3323,"enrollment":550,"conditions":38722,"interventions":38723},[88],[1316,1544,1546,1549],[1599,803,1005,53,3326],{"trials":38725,"activeCount":124},[],{"trials":38727,"activeCount":124},[],{"trials":38729,"activeCount":124},[],{"intervention":38731,"totalTrials":166,"cells":38732},"TALL-104 cells",{"EARLY_PHASE1":38733,"PHASE1":38735,"PHASE2":38737,"PHASE3":38745,"PHASE4":38747,"NA":38749},{"trials":38734,"activeCount":124},[],{"trials":38736,"activeCount":124},[],{"trials":38738,"activeCount":124},[38739],{"nctId":38740,"briefTitle":38741,"status":182,"phases":38742,"primaryCompletion":2806,"completion":2806,"start":2969,"enrollment":1231,"conditions":38743,"interventions":38744},"NCT00415909","TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients",[88],[4725],[2321,38731],{"trials":38746,"activeCount":124},[],{"trials":38748,"activeCount":124},[],{"trials":38750,"activeCount":124},[],{"intervention":10546,"totalTrials":166,"cells":38752},{"EARLY_PHASE1":38753,"PHASE1":38755,"PHASE2":38757,"PHASE3":38763,"PHASE4":38765,"NA":38767},{"trials":38754,"activeCount":124},[],{"trials":38756,"activeCount":124},[],{"trials":38758,"activeCount":124},[38759],{"nctId":10541,"briefTitle":10542,"status":130,"phases":38760,"primaryCompletion":8718,"completion":8718,"start":3996,"enrollment":134,"conditions":38761,"interventions":38762},[87,88],[3195],[510,1368,1375,10546],{"trials":38764,"activeCount":124},[],{"trials":38766,"activeCount":124},[],{"trials":38768,"activeCount":124},[],{"intervention":38770,"totalTrials":166,"cells":38771},"Vitamin B Complex",{"EARLY_PHASE1":38772,"PHASE1":38774,"PHASE2":38776,"PHASE3":38786,"PHASE4":38788,"NA":38790},{"trials":38773,"activeCount":124},[],{"trials":38775,"activeCount":124},[],{"trials":38777,"activeCount":124},[38778],{"nctId":38779,"briefTitle":38780,"status":182,"phases":38781,"primaryCompletion":29403,"completion":29403,"start":38782,"enrollment":1496,"conditions":38783,"interventions":38785},"NCT03564678","Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia",[88],"2018-05-17",[1122,38784],"Hyperbilirubinemia",[38770],{"trials":38787,"activeCount":124},[],{"trials":38789,"activeCount":124},[],{"trials":38791,"activeCount":124},[],{"intervention":4157,"totalTrials":166,"cells":38793},{"EARLY_PHASE1":38794,"PHASE1":38796,"PHASE2":38798,"PHASE3":38804,"PHASE4":38806,"NA":38808},{"trials":38795,"activeCount":124},[],{"trials":38797,"activeCount":124},[],{"trials":38799,"activeCount":124},[38800],{"nctId":4149,"briefTitle":4150,"status":182,"phases":38801,"primaryCompletion":4152,"completion":4152,"start":4153,"enrollment":3197,"conditions":38802,"interventions":38803},[88],[1729],[3497,4156,1709,3499,4157,2383],{"trials":38805,"activeCount":124},[],{"trials":38807,"activeCount":124},[],{"trials":38809,"activeCount":124},[],{"intervention":11375,"totalTrials":166,"cells":38811},{"EARLY_PHASE1":38812,"PHASE1":38814,"PHASE2":38816,"PHASE3":38822,"PHASE4":38824,"NA":38826},{"trials":38813,"activeCount":124},[],{"trials":38815,"activeCount":124},[],{"trials":38817,"activeCount":124},[38818],{"nctId":11370,"briefTitle":11371,"status":130,"phases":38819,"primaryCompletion":5267,"completion":5267,"start":10346,"enrollment":1568,"conditions":38820,"interventions":38821},[88],[30],[11375,11376,2374,809],{"trials":38823,"activeCount":124},[],{"trials":38825,"activeCount":124},[],{"trials":38827,"activeCount":124},[],{"intervention":11376,"totalTrials":166,"cells":38829},{"EARLY_PHASE1":38830,"PHASE1":38832,"PHASE2":38834,"PHASE3":38840,"PHASE4":38842,"NA":38844},{"trials":38831,"activeCount":124},[],{"trials":38833,"activeCount":124},[],{"trials":38835,"activeCount":124},[38836],{"nctId":11370,"briefTitle":11371,"status":130,"phases":38837,"primaryCompletion":5267,"completion":5267,"start":10346,"enrollment":1568,"conditions":38838,"interventions":38839},[88],[30],[11375,11376,2374,809],{"trials":38841,"activeCount":124},[],{"trials":38843,"activeCount":124},[],{"trials":38845,"activeCount":124},[],{"intervention":27070,"totalTrials":166,"cells":38847},{"EARLY_PHASE1":38848,"PHASE1":38850,"PHASE2":38852,"PHASE3":38858,"PHASE4":38860,"NA":38862},{"trials":38849,"activeCount":124},[],{"trials":38851,"activeCount":124},[],{"trials":38853,"activeCount":124},[38854],{"nctId":27064,"briefTitle":27065,"status":130,"phases":38855,"primaryCompletion":405,"completion":405,"start":27067,"enrollment":1222,"conditions":38856,"interventions":38857},[88],[359,360],[27070,27071,27072,27073,2091,27074,27075],{"trials":38859,"activeCount":124},[],{"trials":38861,"activeCount":124},[],{"trials":38863,"activeCount":124},[],{"intervention":27075,"totalTrials":166,"cells":38865},{"EARLY_PHASE1":38866,"PHASE1":38868,"PHASE2":38870,"PHASE3":38876,"PHASE4":38878,"NA":38880},{"trials":38867,"activeCount":124},[],{"trials":38869,"activeCount":124},[],{"trials":38871,"activeCount":124},[38872],{"nctId":27064,"briefTitle":27065,"status":130,"phases":38873,"primaryCompletion":405,"completion":405,"start":27067,"enrollment":1222,"conditions":38874,"interventions":38875},[88],[359,360],[27070,27071,27072,27073,2091,27074,27075],{"trials":38877,"activeCount":124},[],{"trials":38879,"activeCount":124},[],{"trials":38881,"activeCount":124},[],{"intervention":11385,"totalTrials":166,"cells":38883},{"EARLY_PHASE1":38884,"PHASE1":38886,"PHASE2":38888,"PHASE3":38894,"PHASE4":38896,"NA":38898},{"trials":38885,"activeCount":124},[],{"trials":38887,"activeCount":124},[],{"trials":38889,"activeCount":124},[38890],{"nctId":11378,"briefTitle":11379,"status":130,"phases":38891,"primaryCompletion":11381,"completion":11381,"start":11382,"enrollment":34,"conditions":38892,"interventions":38893},[88],[27],[3699,809,7589,11385],{"trials":38895,"activeCount":124},[],{"trials":38897,"activeCount":124},[],{"trials":38899,"activeCount":124},[],{"intervention":12961,"totalTrials":166,"cells":38901},{"EARLY_PHASE1":38902,"PHASE1":38904,"PHASE2":38906,"PHASE3":38912,"PHASE4":38914,"NA":38916},{"trials":38903,"activeCount":124},[],{"trials":38905,"activeCount":124},[],{"trials":38907,"activeCount":124},[38908],{"nctId":12956,"briefTitle":12957,"status":203,"phases":38909,"primaryCompletion":4843,"completion":4843,"start":4723,"enrollment":124,"conditions":38910,"interventions":38911},[88],[3154,3195],[12961,1683,4022],{"trials":38913,"activeCount":124},[],{"trials":38915,"activeCount":124},[],{"trials":38917,"activeCount":124},[],{"intervention":1926,"totalTrials":166,"cells":38919},{"EARLY_PHASE1":38920,"PHASE1":38922,"PHASE2":38924,"PHASE3":38930,"PHASE4":38932,"NA":38934},{"trials":38921,"activeCount":124},[],{"trials":38923,"activeCount":124},[],{"trials":38925,"activeCount":124},[38926],{"nctId":1918,"briefTitle":1919,"status":130,"phases":38927,"primaryCompletion":1165,"completion":1165,"start":1921,"enrollment":1922,"conditions":38928,"interventions":38929},[88],[1924],[1926,1050],{"trials":38931,"activeCount":124},[],{"trials":38933,"activeCount":124},[],{"trials":38935,"activeCount":124},[],{"intervention":38937,"totalTrials":166,"cells":38938},"Recombinant Human Keratinocyte Growth Factor",{"EARLY_PHASE1":38939,"PHASE1":38941,"PHASE2":38943,"PHASE3":38952,"PHASE4":38954,"NA":38956},{"trials":38940,"activeCount":124},[],{"trials":38942,"activeCount":124},[],{"trials":38944,"activeCount":124},[38945],{"nctId":38946,"briefTitle":38947,"status":182,"phases":38948,"primaryCompletion":10272,"completion":10272,"start":11961,"enrollment":1483,"conditions":38949,"interventions":38951},"NCT00038792","Phase I\u002FII Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD",[87,88],[38950],"Acute Graft Versus Host Disease",[38937],{"trials":38953,"activeCount":124},[],{"trials":38955,"activeCount":124},[],{"trials":38957,"activeCount":124},[],{"intervention":38959,"totalTrials":166,"cells":38960},"BIBW 2992",{"EARLY_PHASE1":38961,"PHASE1":38963,"PHASE2":38965,"PHASE3":38973,"PHASE4":38975,"NA":38977},{"trials":38962,"activeCount":124},[],{"trials":38964,"activeCount":124},[],{"trials":38966,"activeCount":124},[38967],{"nctId":38968,"briefTitle":38969,"status":182,"phases":38970,"primaryCompletion":38386,"completion":38386,"start":28980,"enrollment":121,"conditions":38971,"interventions":38972},"NCT02271906","The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting",[88],[24],[38959],{"trials":38974,"activeCount":124},[],{"trials":38976,"activeCount":124},[],{"trials":38978,"activeCount":124},[],{"intervention":30919,"totalTrials":166,"cells":38980},{"EARLY_PHASE1":38981,"PHASE1":38983,"PHASE2":38985,"PHASE3":38991,"PHASE4":38993,"NA":38995},{"trials":38982,"activeCount":124},[],{"trials":38984,"activeCount":124},[],{"trials":38986,"activeCount":124},[38987],{"nctId":30912,"briefTitle":30913,"status":130,"phases":38988,"primaryCompletion":30915,"completion":30915,"start":30916,"enrollment":1609,"conditions":38989,"interventions":38990},[88],[24],[30919,3847],{"trials":38992,"activeCount":124},[],{"trials":38994,"activeCount":124},[],{"trials":38996,"activeCount":124},[],{"intervention":38998,"totalTrials":166,"cells":38999},"gp100",{"EARLY_PHASE1":39000,"PHASE1":39002,"PHASE2":39004,"PHASE3":39016,"PHASE4":39018,"NA":39020},{"trials":39001,"activeCount":124},[],{"trials":39003,"activeCount":124},[],{"trials":39005,"activeCount":124},[39006],{"nctId":39007,"briefTitle":39008,"status":130,"phases":39009,"primaryCompletion":39010,"completion":39010,"start":39011,"enrollment":2997,"conditions":39012,"interventions":39013},"NCT00960752","Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist",[88],"2020-07-20","2010-05-20",[1729],[38998,39014,39015],"R848 gel","MAGE-3",{"trials":39017,"activeCount":124},[],{"trials":39019,"activeCount":124},[],{"trials":39021,"activeCount":124},[],{"intervention":39014,"totalTrials":166,"cells":39023},{"EARLY_PHASE1":39024,"PHASE1":39026,"PHASE2":39028,"PHASE3":39034,"PHASE4":39036,"NA":39038},{"trials":39025,"activeCount":124},[],{"trials":39027,"activeCount":124},[],{"trials":39029,"activeCount":124},[39030],{"nctId":39007,"briefTitle":39008,"status":130,"phases":39031,"primaryCompletion":39010,"completion":39010,"start":39011,"enrollment":2997,"conditions":39032,"interventions":39033},[88],[1729],[38998,39014,39015],{"trials":39035,"activeCount":124},[],{"trials":39037,"activeCount":124},[],{"trials":39039,"activeCount":124},[],{"intervention":39015,"totalTrials":166,"cells":39041},{"EARLY_PHASE1":39042,"PHASE1":39044,"PHASE2":39046,"PHASE3":39052,"PHASE4":39054,"NA":39056},{"trials":39043,"activeCount":124},[],{"trials":39045,"activeCount":124},[],{"trials":39047,"activeCount":124},[39048],{"nctId":39007,"briefTitle":39008,"status":130,"phases":39049,"primaryCompletion":39010,"completion":39010,"start":39011,"enrollment":2997,"conditions":39050,"interventions":39051},[88],[1729],[38998,39014,39015],{"trials":39053,"activeCount":124},[],{"trials":39055,"activeCount":124},[],{"trials":39057,"activeCount":124},[],{"intervention":39059,"totalTrials":166,"cells":39060},"ADCT-602",{"EARLY_PHASE1":39061,"PHASE1":39063,"PHASE2":39065,"PHASE3":39074,"PHASE4":39076,"NA":39078},{"trials":39062,"activeCount":124},[],{"trials":39064,"activeCount":124},[],{"trials":39066,"activeCount":124},[39067],{"nctId":39068,"briefTitle":39069,"status":182,"phases":39070,"primaryCompletion":21513,"completion":21513,"start":39071,"enrollment":1609,"conditions":39072,"interventions":39073},"NCT03698552","ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia",[87,88],"2018-08-24",[3038,7348,912,1142,1144],[39059],{"trials":39075,"activeCount":124},[],{"trials":39077,"activeCount":124},[],{"trials":39079,"activeCount":124},[],{"intervention":39081,"totalTrials":166,"cells":39082},"CLL vaccine using DNA plasmid vector",{"EARLY_PHASE1":39083,"PHASE1":39085,"PHASE2":39087,"PHASE3":39095,"PHASE4":39097,"NA":39099},{"trials":39084,"activeCount":124},[],{"trials":39086,"activeCount":124},[],{"trials":39088,"activeCount":124},[39089],{"nctId":39090,"briefTitle":39091,"status":182,"phases":39092,"primaryCompletion":12101,"completion":7473,"start":12290,"enrollment":121,"conditions":39093,"interventions":39094},"NCT00038415","A Phase I\u002FII Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach",[87,88],[20502],[39081],{"trials":39096,"activeCount":124},[],{"trials":39098,"activeCount":124},[],{"trials":39100,"activeCount":124},[],{"intervention":951,"totalTrials":166,"cells":39102},{"EARLY_PHASE1":39103,"PHASE1":39105,"PHASE2":39107,"PHASE3":39113,"PHASE4":39115,"NA":39117},{"trials":39104,"activeCount":124},[],{"trials":39106,"activeCount":124},[],{"trials":39108,"activeCount":124},[39109],{"nctId":944,"briefTitle":945,"status":203,"phases":39110,"primaryCompletion":947,"completion":947,"start":948,"enrollment":124,"conditions":39111,"interventions":39112},[87,88],[737],[510,951,480],{"trials":39114,"activeCount":124},[],{"trials":39116,"activeCount":124},[],{"trials":39118,"activeCount":124},[],{"intervention":33951,"totalTrials":166,"cells":39120},{"EARLY_PHASE1":39121,"PHASE1":39123,"PHASE2":39125,"PHASE3":39131,"PHASE4":39133,"NA":39135},{"trials":39122,"activeCount":124},[],{"trials":39124,"activeCount":124},[],{"trials":39126,"activeCount":124},[39127],{"nctId":33946,"briefTitle":33947,"status":130,"phases":39128,"primaryCompletion":3667,"completion":3667,"start":8340,"enrollment":2946,"conditions":39129,"interventions":39130},[88],[11176,11042],[33951,33952,17554],{"trials":39132,"activeCount":124},[],{"trials":39134,"activeCount":124},[],{"trials":39136,"activeCount":124},[],{"intervention":33952,"totalTrials":166,"cells":39138},{"EARLY_PHASE1":39139,"PHASE1":39141,"PHASE2":39143,"PHASE3":39149,"PHASE4":39151,"NA":39153},{"trials":39140,"activeCount":124},[],{"trials":39142,"activeCount":124},[],{"trials":39144,"activeCount":124},[39145],{"nctId":33946,"briefTitle":33947,"status":130,"phases":39146,"primaryCompletion":3667,"completion":3667,"start":8340,"enrollment":2946,"conditions":39147,"interventions":39148},[88],[11176,11042],[33951,33952,17554],{"trials":39150,"activeCount":124},[],{"trials":39152,"activeCount":124},[],{"trials":39154,"activeCount":124},[],{"intervention":17900,"totalTrials":166,"cells":39156},{"EARLY_PHASE1":39157,"PHASE1":39159,"PHASE2":39161,"PHASE3":39167,"PHASE4":39169,"NA":39171},{"trials":39158,"activeCount":124},[],{"trials":39160,"activeCount":124},[],{"trials":39162,"activeCount":124},[39163],{"nctId":17894,"briefTitle":17895,"status":182,"phases":39164,"primaryCompletion":8719,"completion":17897,"start":4647,"enrollment":871,"conditions":39165,"interventions":39166},[87,88],[3305,17318],[1368,17900,17901],{"trials":39168,"activeCount":124},[],{"trials":39170,"activeCount":124},[],{"trials":39172,"activeCount":124},[],{"intervention":13323,"totalTrials":166,"cells":39174},{"EARLY_PHASE1":39175,"PHASE1":39177,"PHASE2":39179,"PHASE3":39185,"PHASE4":39187,"NA":39189},{"trials":39176,"activeCount":124},[],{"trials":39178,"activeCount":124},[],{"trials":39180,"activeCount":124},[39181],{"nctId":13314,"briefTitle":13315,"status":182,"phases":39182,"primaryCompletion":13317,"completion":13317,"start":13318,"enrollment":3726,"conditions":39183,"interventions":39184},[87,88],[1452,1454,1455,1458,1460,1461,13320,11741,13321],[13323,1786],{"trials":39186,"activeCount":124},[],{"trials":39188,"activeCount":124},[],{"trials":39190,"activeCount":124},[],{"intervention":39192,"totalTrials":166,"cells":39193},"Intrathecal Rituximab",{"EARLY_PHASE1":39194,"PHASE1":39196,"PHASE2":39198,"PHASE3":39208,"PHASE4":39210,"NA":39212},{"trials":39195,"activeCount":124},[],{"trials":39197,"activeCount":124},[],{"trials":39199,"activeCount":124},[39200],{"nctId":39201,"briefTitle":39202,"status":182,"phases":39203,"primaryCompletion":18175,"completion":18175,"start":39204,"enrollment":296,"conditions":39205,"interventions":39207},"NCT01596127","Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System",[87,88],"2013-01-24",[15,8263,39206],"Metastatic Malignant Neoplasm to the Leptomeninges",[39192],{"trials":39209,"activeCount":124},[],{"trials":39211,"activeCount":124},[],{"trials":39213,"activeCount":124},[],{"intervention":39215,"totalTrials":166,"cells":39216},"PR-1 vaccine",{"EARLY_PHASE1":39217,"PHASE1":39219,"PHASE2":39221,"PHASE3":39229,"PHASE4":39231,"NA":39233},{"trials":39218,"activeCount":124},[],{"trials":39220,"activeCount":124},[],{"trials":39222,"activeCount":124},[39223],{"nctId":39224,"briefTitle":39225,"status":182,"phases":39226,"primaryCompletion":2528,"completion":2528,"start":10784,"enrollment":3726,"conditions":39227,"interventions":39228},"NCT00893997","PR1 Vaccination in Myelodysplastic Syndrome (MDS)",[88],[15,30],[39215],{"trials":39230,"activeCount":124},[],{"trials":39232,"activeCount":124},[],{"trials":39234,"activeCount":124},[],{"intervention":39236,"totalTrials":166,"cells":39237},"TAC-101",{"EARLY_PHASE1":39238,"PHASE1":39240,"PHASE2":39242,"PHASE3":39250,"PHASE4":39252,"NA":39254},{"trials":39239,"activeCount":124},[],{"trials":39241,"activeCount":124},[],{"trials":39243,"activeCount":124},[39244],{"nctId":39245,"briefTitle":39246,"status":130,"phases":39247,"primaryCompletion":5663,"completion":10075,"start":2807,"enrollment":1609,"conditions":39248,"interventions":39249},"NCT00077142","TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)",[87,88],[1996],[39236],{"trials":39251,"activeCount":124},[],{"trials":39253,"activeCount":124},[],{"trials":39255,"activeCount":124},[],{"intervention":39257,"totalTrials":166,"cells":39258},"Recombinant Interleukin-7",{"EARLY_PHASE1":39259,"PHASE1":39261,"PHASE2":39263,"PHASE3":39272,"PHASE4":39274,"NA":39276},{"trials":39260,"activeCount":124},[],{"trials":39262,"activeCount":124},[],{"trials":39264,"activeCount":124},[39265],{"nctId":39266,"briefTitle":39267,"status":130,"phases":39268,"primaryCompletion":32346,"completion":32346,"start":39269,"enrollment":166,"conditions":39270,"interventions":39271},"NCT03941769","2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I\u002FII",[87,88],"2020-09-29",[36,4598,31953,30,727],[39257],{"trials":39273,"activeCount":124},[],{"trials":39275,"activeCount":124},[],{"trials":39277,"activeCount":124},[],{"intervention":39279,"totalTrials":166,"cells":39280},"Ontak",{"EARLY_PHASE1":39281,"PHASE1":39283,"PHASE2":39285,"PHASE3":39293,"PHASE4":39295,"NA":39297},{"trials":39282,"activeCount":124},[],{"trials":39284,"activeCount":124},[],{"trials":39286,"activeCount":124},[39287],{"nctId":39288,"briefTitle":39289,"status":130,"phases":39290,"primaryCompletion":6409,"completion":6409,"start":12101,"enrollment":186,"conditions":39291,"interventions":39292},"NCT00493129","Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)",[88],[15,22908],[39279],{"trials":39294,"activeCount":124},[],{"trials":39296,"activeCount":124},[],{"trials":39298,"activeCount":124},[],{"intervention":39300,"totalTrials":166,"cells":39301},"Voraxaze",{"EARLY_PHASE1":39302,"PHASE1":39304,"PHASE2":39306,"PHASE3":39314,"PHASE4":39316,"NA":39318},{"trials":39303,"activeCount":124},[],{"trials":39305,"activeCount":124},[],{"trials":39307,"activeCount":124},[39308],{"nctId":39309,"briefTitle":39310,"status":182,"phases":39311,"primaryCompletion":10760,"completion":10760,"start":9512,"enrollment":1231,"conditions":39312,"interventions":39313},"NCT00424645","Voraxaze for Delayed Methotrexate Clearance",[87,88],[1187,3305],[39300],{"trials":39315,"activeCount":124},[],{"trials":39317,"activeCount":124},[],{"trials":39319,"activeCount":124},[],{"intervention":39321,"totalTrials":166,"cells":39322},"INCB018424",{"EARLY_PHASE1":39323,"PHASE1":39325,"PHASE2":39327,"PHASE3":39336,"PHASE4":39338,"NA":39340},{"trials":39324,"activeCount":124},[],{"trials":39326,"activeCount":124},[],{"trials":39328,"activeCount":124},[39329],{"nctId":39330,"briefTitle":39331,"status":130,"phases":39332,"primaryCompletion":18175,"completion":18175,"start":39333,"enrollment":240,"conditions":39334,"interventions":39335},"NCT00674479","INCB018424 in Patients With Advanced Hematologic Malignancies",[88],"2008-05-12",[36,2838,30,4725],[39321],{"trials":39337,"activeCount":124},[],{"trials":39339,"activeCount":124},[],{"trials":39341,"activeCount":124},[],{"intervention":39343,"totalTrials":166,"cells":39344},"CYT107",{"EARLY_PHASE1":39345,"PHASE1":39347,"PHASE2":39349,"PHASE3":39361,"PHASE4":39363,"NA":39365},{"trials":39346,"activeCount":124},[],{"trials":39348,"activeCount":124},[],{"trials":39350,"activeCount":124},[39351],{"nctId":39352,"briefTitle":39353,"status":203,"phases":39354,"primaryCompletion":39355,"completion":39356,"start":39357,"enrollment":124,"conditions":39358,"interventions":39360},"NCT03600896","Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation",[87,88],"2023-11","2024-11","2018-11",[39359],"Umbilical Cord Blood Transplant",[39343],{"trials":39362,"activeCount":124},[],{"trials":39364,"activeCount":124},[],{"trials":39366,"activeCount":124},[],{"intervention":994,"totalTrials":166,"cells":39368},{"EARLY_PHASE1":39369,"PHASE1":39371,"PHASE2":39373,"PHASE3":39379,"PHASE4":39381,"NA":39383},{"trials":39370,"activeCount":124},[],{"trials":39372,"activeCount":124},[],{"trials":39374,"activeCount":124},[39375],{"nctId":987,"briefTitle":988,"status":203,"phases":39376,"primaryCompletion":990,"completion":990,"start":991,"enrollment":124,"conditions":39377,"interventions":39378},[87,88],[608,610],[994,612,480],{"trials":39380,"activeCount":124},[],{"trials":39382,"activeCount":124},[],{"trials":39384,"activeCount":124},[],{"intervention":12982,"totalTrials":166,"cells":39386},{"EARLY_PHASE1":39387,"PHASE1":39389,"PHASE2":39391,"PHASE3":39397,"PHASE4":39399,"NA":39401},{"trials":39388,"activeCount":124},[],{"trials":39390,"activeCount":124},[],{"trials":39392,"activeCount":124},[39393],{"nctId":12977,"briefTitle":12978,"status":203,"phases":39394,"primaryCompletion":4835,"start":11040,"enrollment":124,"conditions":39395,"interventions":39396},[88],[242],[1683,12982],{"trials":39398,"activeCount":124},[],{"trials":39400,"activeCount":124},[],{"trials":39402,"activeCount":124},[],{"intervention":4176,"totalTrials":166,"cells":39404},{"EARLY_PHASE1":39405,"PHASE1":39407,"PHASE2":39409,"PHASE3":39415,"PHASE4":39417,"NA":39419},{"trials":39406,"activeCount":124},[],{"trials":39408,"activeCount":124},[],{"trials":39410,"activeCount":124},[39411],{"nctId":4166,"briefTitle":4167,"status":130,"phases":39412,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":39413,"interventions":39414},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"trials":39416,"activeCount":124},[],{"trials":39418,"activeCount":124},[],{"trials":39420,"activeCount":124},[],{"intervention":4178,"totalTrials":166,"cells":39422},{"EARLY_PHASE1":39423,"PHASE1":39425,"PHASE2":39427,"PHASE3":39433,"PHASE4":39435,"NA":39437},{"trials":39424,"activeCount":124},[],{"trials":39426,"activeCount":124},[],{"trials":39428,"activeCount":124},[39429],{"nctId":4166,"briefTitle":4167,"status":130,"phases":39430,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":4171,"conditions":39431,"interventions":39432},[88],[21],[4174,1069,1709,803,654,804,2424,1371,2495,4175,806,1014,4176,809,4177,810,4178],{"trials":39434,"activeCount":124},[],{"trials":39436,"activeCount":124},[],{"trials":39438,"activeCount":124},[],{"intervention":17670,"totalTrials":166,"cells":39440},{"EARLY_PHASE1":39441,"PHASE1":39443,"PHASE2":39445,"PHASE3":39451,"PHASE4":39453,"NA":39455},{"trials":39442,"activeCount":124},[],{"trials":39444,"activeCount":124},[],{"trials":39446,"activeCount":124},[39447],{"nctId":17665,"briefTitle":17666,"status":130,"phases":39448,"primaryCompletion":6628,"completion":3833,"start":6352,"enrollment":1496,"conditions":39449,"interventions":39450},[87,88],[6921],[3497,17670],{"trials":39452,"activeCount":124},[],{"trials":39454,"activeCount":124},[],{"trials":39456,"activeCount":124},[],{"intervention":39458,"totalTrials":166,"cells":39459},"Lorvotuzumab Mertansine",{"EARLY_PHASE1":39460,"PHASE1":39462,"PHASE2":39464,"PHASE3":39473,"PHASE4":39475,"NA":39477},{"trials":39461,"activeCount":124},[],{"trials":39463,"activeCount":124},[],{"trials":39465,"activeCount":124},[39466],{"nctId":39467,"briefTitle":39468,"status":130,"phases":39469,"primaryCompletion":17865,"completion":17865,"start":39470,"enrollment":910,"conditions":39471,"interventions":39472},"NCT02420873","An Open-label Phase II Study of Lorvotuzumab Mertansine",[88],"2015-05-12",[15],[39458],{"trials":39474,"activeCount":124},[],{"trials":39476,"activeCount":124},[],{"trials":39478,"activeCount":124},[],{"intervention":10255,"totalTrials":166,"cells":39480},{"EARLY_PHASE1":39481,"PHASE1":39483,"PHASE2":39485,"PHASE3":39491,"PHASE4":39493,"NA":39495},{"trials":39482,"activeCount":124},[],{"trials":39484,"activeCount":124},[],{"trials":39486,"activeCount":124},[39487],{"nctId":10250,"briefTitle":10251,"status":182,"phases":39488,"primaryCompletion":8730,"completion":8730,"start":4085,"enrollment":1483,"conditions":39489,"interventions":39490},[88],[1729],[10255,1376,1369],{"trials":39492,"activeCount":124},[],{"trials":39494,"activeCount":124},[],{"trials":39496,"activeCount":124},[],{"intervention":39498,"totalTrials":166,"cells":39499},"153 Sm-EDTMP",{"EARLY_PHASE1":39500,"PHASE1":39502,"PHASE2":39504,"PHASE3":39512,"PHASE4":39514,"NA":39516},{"trials":39501,"activeCount":124},[],{"trials":39503,"activeCount":124},[],{"trials":39505,"activeCount":124},[39506],{"nctId":39507,"briefTitle":39508,"status":130,"phases":39509,"primaryCompletion":4842,"completion":4842,"start":4153,"enrollment":3726,"conditions":39510,"interventions":39511},"NCT00429507","Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases",[88],[18,5418],[39498],{"trials":39513,"activeCount":124},[],{"trials":39515,"activeCount":124},[],{"trials":39517,"activeCount":124},[],{"intervention":3386,"totalTrials":166,"cells":39519},{"EARLY_PHASE1":39520,"PHASE1":39522,"PHASE2":39524,"PHASE3":39530,"PHASE4":39532,"NA":39534},{"trials":39521,"activeCount":124},[],{"trials":39523,"activeCount":124},[],{"trials":39525,"activeCount":124},[39526],{"nctId":3374,"briefTitle":3375,"status":130,"phases":39527,"primaryCompletion":3377,"completion":3377,"start":3378,"enrollment":3379,"conditions":39528,"interventions":39529},[87,88],[1205,3381,3382,36,846,678,644,3383,3384,737,1067,30,649,682,882],[1599,3386,1004,1005],{"trials":39531,"activeCount":124},[],{"trials":39533,"activeCount":124},[],{"trials":39535,"activeCount":124},[],{"intervention":34419,"totalTrials":166,"cells":39537},{"EARLY_PHASE1":39538,"PHASE1":39540,"PHASE2":39542,"PHASE3":39548,"PHASE4":39550,"NA":39552},{"trials":39539,"activeCount":124},[],{"trials":39541,"activeCount":124},[],{"trials":39543,"activeCount":124},[39544],{"nctId":34412,"briefTitle":34413,"status":203,"phases":39545,"primaryCompletion":34415,"completion":34415,"start":14029,"enrollment":124,"conditions":39546,"interventions":39547},[88],[34417],[34419,27073],{"trials":39549,"activeCount":124},[],{"trials":39551,"activeCount":124},[],{"trials":39553,"activeCount":124},[],{"intervention":39555,"totalTrials":166,"cells":39556},"Antimicrobial Solution",{"EARLY_PHASE1":39557,"PHASE1":39559,"PHASE2":39561,"PHASE3":39570,"PHASE4":39572,"NA":39574},{"trials":39558,"activeCount":124},[],{"trials":39560,"activeCount":124},[],{"trials":39562,"activeCount":124},[39563],{"nctId":39564,"briefTitle":39565,"status":130,"phases":39566,"primaryCompletion":39567,"completion":39567,"start":4290,"enrollment":2004,"conditions":39568,"interventions":39569},"NCT01539343","Antimicrobial Catheter Lock Solution for the Treatment of Central Line Associated Bloodstream Infection (CLABSI)",[88],"2016-04",[27091],[39555],{"trials":39571,"activeCount":124},[],{"trials":39573,"activeCount":124},[],{"trials":39575,"activeCount":124},[],{"intervention":9282,"totalTrials":166,"cells":39577},{"EARLY_PHASE1":39578,"PHASE1":39580,"PHASE2":39582,"PHASE3":39588,"PHASE4":39590,"NA":39592},{"trials":39579,"activeCount":124},[],{"trials":39581,"activeCount":124},[],{"trials":39583,"activeCount":124},[39584],{"nctId":9275,"briefTitle":9276,"status":182,"phases":39585,"primaryCompletion":9278,"completion":9278,"start":9279,"enrollment":1231,"conditions":39586,"interventions":39587},[87,88],[15,2245,4580],[1070,2293,2439,2196,9282,2374,7415,1014],{"trials":39589,"activeCount":124},[],{"trials":39591,"activeCount":124},[],{"trials":39593,"activeCount":124},[],{"intervention":11431,"totalTrials":166,"cells":39595},{"EARLY_PHASE1":39596,"PHASE1":39598,"PHASE2":39600,"PHASE3":39606,"PHASE4":39608,"NA":39610},{"trials":39597,"activeCount":124},[],{"trials":39599,"activeCount":124},[],{"trials":39601,"activeCount":124},[39602],{"nctId":11423,"briefTitle":11424,"status":130,"phases":39603,"primaryCompletion":11426,"completion":11426,"start":11427,"enrollment":3082,"conditions":39604,"interventions":39605},[88],[745,11429],[11431,809,11431],{"trials":39607,"activeCount":124},[],{"trials":39609,"activeCount":124},[],{"trials":39611,"activeCount":124},[],{"intervention":39613,"totalTrials":166,"cells":39614},"CC-5013",{"EARLY_PHASE1":39615,"PHASE1":39617,"PHASE2":39619,"PHASE3":39627,"PHASE4":39629,"NA":39631},{"trials":39616,"activeCount":124},[],{"trials":39618,"activeCount":124},[],{"trials":39620,"activeCount":124},[39621],{"nctId":39622,"briefTitle":39623,"status":130,"phases":39624,"primaryCompletion":16514,"completion":16514,"start":12101,"enrollment":1243,"conditions":39625,"interventions":39626},"NCT00087672","A Phase II Study of CC-5013 in Myelofibrosis",[88],[3429],[39613],{"trials":39628,"activeCount":124},[],{"trials":39630,"activeCount":124},[],{"trials":39632,"activeCount":124},[],{"intervention":39634,"totalTrials":166,"cells":39635},"Interleukin-11",{"EARLY_PHASE1":39636,"PHASE1":39638,"PHASE2":39640,"PHASE3":39648,"PHASE4":39650,"NA":39652},{"trials":39637,"activeCount":124},[],{"trials":39639,"activeCount":124},[],{"trials":39641,"activeCount":124},[39642],{"nctId":39643,"briefTitle":39644,"status":130,"phases":39645,"primaryCompletion":6757,"completion":6757,"start":4169,"enrollment":186,"conditions":39646,"interventions":39647},"NCT00493181","Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients",[88],[15,4725,3315],[39634],{"trials":39649,"activeCount":124},[],{"trials":39651,"activeCount":124},[],{"trials":39653,"activeCount":124},[],{"intervention":39655,"totalTrials":166,"cells":39656},"Temozolomide and SCH66336",{"EARLY_PHASE1":39657,"PHASE1":39659,"PHASE2":39661,"PHASE3":39670,"PHASE4":39672,"NA":39674},{"trials":39658,"activeCount":124},[],{"trials":39660,"activeCount":124},[],{"trials":39662,"activeCount":124},[39663],{"nctId":39664,"briefTitle":39665,"status":130,"phases":39666,"primaryCompletion":2550,"completion":2550,"start":39667,"enrollment":3820,"conditions":39668,"interventions":39669},"NCT00038493","Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme",[88],"2001-09-21",[17604],[39655],{"trials":39671,"activeCount":124},[],{"trials":39673,"activeCount":124},[],{"trials":39675,"activeCount":124},[],{"intervention":39677,"totalTrials":166,"cells":39678},"Ilorasertib",{"EARLY_PHASE1":39679,"PHASE1":39681,"PHASE2":39683,"PHASE3":39692,"PHASE4":39694,"NA":39696},{"trials":39680,"activeCount":124},[],{"trials":39682,"activeCount":124},[],{"trials":39684,"activeCount":124},[39685],{"nctId":39686,"briefTitle":39687,"status":182,"phases":39688,"primaryCompletion":39689,"completion":39689,"start":225,"enrollment":3726,"conditions":39690,"interventions":39691},"NCT02478320","Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors",[88],"2022-05-12",[33],[39677],{"trials":39693,"activeCount":124},[],{"trials":39695,"activeCount":124},[],{"trials":39697,"activeCount":124},[],{"intervention":39699,"totalTrials":166,"cells":39700},"PEG-Intron",{"EARLY_PHASE1":39701,"PHASE1":39703,"PHASE2":39705,"PHASE3":39715,"PHASE4":39717,"NA":39719},{"trials":39702,"activeCount":124},[],{"trials":39704,"activeCount":124},[],{"trials":39706,"activeCount":124},[39707],{"nctId":39708,"briefTitle":39709,"status":182,"phases":39710,"primaryCompletion":39711,"completion":39711,"start":34722,"enrollment":166,"conditions":39712,"interventions":39714},"NCT00037882","PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron",[88],"2003-12-03",[39713],"Leukemia, Myeloid, Philadelphia-Positive",[39699],{"trials":39716,"activeCount":124},[],{"trials":39718,"activeCount":124},[],{"trials":39720,"activeCount":124},[],{"intervention":23190,"totalTrials":166,"cells":39722},{"EARLY_PHASE1":39723,"PHASE1":39725,"PHASE2":39727,"PHASE3":39733,"PHASE4":39735,"NA":39737},{"trials":39724,"activeCount":124},[],{"trials":39726,"activeCount":124},[],{"trials":39728,"activeCount":124},[39729],{"nctId":23181,"briefTitle":23182,"status":182,"phases":39730,"primaryCompletion":23184,"completion":23184,"start":23185,"enrollment":230,"conditions":39731,"interventions":39732},[88],[23187,23188],[18073,23190],{"trials":39734,"activeCount":124},[],{"trials":39736,"activeCount":124},[],{"trials":39738,"activeCount":124},[],{"intervention":39740,"totalTrials":166,"cells":39741},"Teriparatide",{"EARLY_PHASE1":39742,"PHASE1":39744,"PHASE2":39746,"PHASE3":39757,"PHASE4":39759,"NA":39761},{"trials":39743,"activeCount":124},[],{"trials":39745,"activeCount":124},[],{"trials":39747,"activeCount":124},[39748],{"nctId":39749,"briefTitle":39750,"status":182,"phases":39751,"primaryCompletion":10844,"completion":10844,"start":2932,"enrollment":1483,"conditions":39752,"interventions":39754},"NCT00623974","Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia",[88],[39753],"Hypocalcemia",[39740,39755,39756],"Calcium","Calcitriol",{"trials":39758,"activeCount":124},[],{"trials":39760,"activeCount":124},[],{"trials":39762,"activeCount":124},[],{"intervention":39755,"totalTrials":166,"cells":39764},{"EARLY_PHASE1":39765,"PHASE1":39767,"PHASE2":39769,"PHASE3":39775,"PHASE4":39777,"NA":39779},{"trials":39766,"activeCount":124},[],{"trials":39768,"activeCount":124},[],{"trials":39770,"activeCount":124},[39771],{"nctId":39749,"briefTitle":39750,"status":182,"phases":39772,"primaryCompletion":10844,"completion":10844,"start":2932,"enrollment":1483,"conditions":39773,"interventions":39774},[88],[39753],[39740,39755,39756],{"trials":39776,"activeCount":124},[],{"trials":39778,"activeCount":124},[],{"trials":39780,"activeCount":124},[],{"intervention":39756,"totalTrials":166,"cells":39782},{"EARLY_PHASE1":39783,"PHASE1":39785,"PHASE2":39787,"PHASE3":39793,"PHASE4":39795,"NA":39797},{"trials":39784,"activeCount":124},[],{"trials":39786,"activeCount":124},[],{"trials":39788,"activeCount":124},[39789],{"nctId":39749,"briefTitle":39750,"status":182,"phases":39790,"primaryCompletion":10844,"completion":10844,"start":2932,"enrollment":1483,"conditions":39791,"interventions":39792},[88],[39753],[39740,39755,39756],{"trials":39794,"activeCount":124},[],{"trials":39796,"activeCount":124},[],{"trials":39798,"activeCount":124},[],{"intervention":5262,"totalTrials":166,"cells":39800},{"EARLY_PHASE1":39801,"PHASE1":39803,"PHASE2":39805,"PHASE3":39811,"PHASE4":39813,"NA":39815},{"trials":39802,"activeCount":124},[],{"trials":39804,"activeCount":124},[],{"trials":39806,"activeCount":124},[39807],{"nctId":5253,"briefTitle":5254,"status":130,"phases":39808,"primaryCompletion":5256,"completion":5256,"start":5257,"enrollment":5258,"conditions":39809,"interventions":39810},[88],[5260,15,4760],[803,1070,2293,1114,894,1254,2196,5262,2374],{"trials":39812,"activeCount":124},[],{"trials":39814,"activeCount":124},[],{"trials":39816,"activeCount":124},[],{"intervention":39818,"totalTrials":166,"cells":39819},"AMG 208",{"EARLY_PHASE1":39820,"PHASE1":39822,"PHASE2":39824,"PHASE3":39833,"PHASE4":39835,"NA":39837},{"trials":39821,"activeCount":124},[],{"trials":39823,"activeCount":124},[],{"trials":39825,"activeCount":124},[39826],{"nctId":39827,"briefTitle":39828,"status":203,"phases":39829,"primaryCompletion":39830,"start":6974,"enrollment":124,"conditions":39831,"interventions":39832},"NCT02420587","AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)",[88],"2019-10",[27],[39818],{"trials":39834,"activeCount":124},[],{"trials":39836,"activeCount":124},[],{"trials":39838,"activeCount":124},[],{"intervention":39840,"totalTrials":166,"cells":39841},"BIBF 1120",{"EARLY_PHASE1":39842,"PHASE1":39844,"PHASE2":39846,"PHASE3":39857,"PHASE4":39859,"NA":39861},{"trials":39843,"activeCount":124},[],{"trials":39845,"activeCount":124},[],{"trials":39847,"activeCount":124},[39848],{"nctId":39849,"briefTitle":39850,"status":182,"phases":39851,"primaryCompletion":39852,"completion":39853,"start":39854,"enrollment":1496,"conditions":39855,"interventions":39856},"NCT02389764","Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)",[88],"2018-06-08","2019-06-08","2015-06-22",[18],[39840],{"trials":39858,"activeCount":124},[],{"trials":39860,"activeCount":124},[],{"trials":39862,"activeCount":124},[],{"intervention":15434,"totalTrials":166,"cells":39864},{"EARLY_PHASE1":39865,"PHASE1":39867,"PHASE2":39869,"PHASE3":39875,"PHASE4":39877,"NA":39879},{"trials":39866,"activeCount":124},[],{"trials":39868,"activeCount":124},[],{"trials":39870,"activeCount":124},[39871],{"nctId":15428,"briefTitle":15429,"status":130,"phases":39872,"primaryCompletion":8305,"completion":8305,"start":5557,"enrollment":8325,"conditions":39873,"interventions":39874},[88],[15432,12006],[4218,15434,1375],{"trials":39876,"activeCount":124},[],{"trials":39878,"activeCount":124},[],{"trials":39880,"activeCount":124},[],{"intervention":39882,"totalTrials":166,"cells":39883},"Pyrazoloacridine",{"EARLY_PHASE1":39884,"PHASE1":39886,"PHASE2":39888,"PHASE3":39896,"PHASE4":39898,"NA":39900},{"trials":39885,"activeCount":124},[],{"trials":39887,"activeCount":124},[],{"trials":39889,"activeCount":124},[39890],{"nctId":39891,"briefTitle":39892,"status":203,"phases":39893,"enrollment":124,"conditions":39894,"interventions":39895},"NCT00003714","Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer",[88],[1996,7818],[39882],{"trials":39897,"activeCount":124},[],{"trials":39899,"activeCount":124},[],{"trials":39901,"activeCount":124},[],{"intervention":18253,"totalTrials":166,"cells":39903},{"EARLY_PHASE1":39904,"PHASE1":39906,"PHASE2":39908,"PHASE3":39914,"PHASE4":39916,"NA":39918},{"trials":39905,"activeCount":124},[],{"trials":39907,"activeCount":124},[],{"trials":39909,"activeCount":124},[39910],{"nctId":18245,"briefTitle":18246,"status":130,"phases":39911,"primaryCompletion":18248,"completion":18248,"start":18249,"enrollment":18250,"conditions":39912,"interventions":39913},[88],[24],[3847,18047,18253,2207,3847,18253],{"trials":39915,"activeCount":124},[],{"trials":39917,"activeCount":124},[],{"trials":39919,"activeCount":124},[],{"intervention":39921,"totalTrials":166,"cells":39922},"Cytomegalovirus",{"EARLY_PHASE1":39923,"PHASE1":39925,"PHASE2":39927,"PHASE3":39937,"PHASE4":39939,"NA":39941},{"trials":39924,"activeCount":124},[],{"trials":39926,"activeCount":124},[],{"trials":39928,"activeCount":124},[39929],{"nctId":39930,"briefTitle":39931,"status":130,"phases":39932,"primaryCompletion":39933,"completion":39933,"start":39934,"enrollment":230,"conditions":39935,"interventions":39936},"NCT02210065","Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation",[88],"2019-05-13","2015-03-03",[15,21],[39921],{"trials":39938,"activeCount":124},[],{"trials":39940,"activeCount":124},[],{"trials":39942,"activeCount":124},[],{"intervention":2029,"totalTrials":166,"cells":39944},{"EARLY_PHASE1":39945,"PHASE1":39947,"PHASE2":39949,"PHASE3":39955,"PHASE4":39957,"NA":39959},{"trials":39946,"activeCount":124},[],{"trials":39948,"activeCount":124},[],{"trials":39950,"activeCount":124},[39951],{"nctId":2013,"briefTitle":2014,"status":182,"phases":39952,"primaryCompletion":2016,"completion":2016,"start":2017,"enrollment":2018,"conditions":39953,"interventions":39954},[87,88],[2020,1343,2021,2022,2023,361,2024,1355,1357,1358,1359,2025,1319,2026,1361,2027,1362],[2029,1050],{"trials":39956,"activeCount":124},[],{"trials":39958,"activeCount":124},[],{"trials":39960,"activeCount":124},[],{"intervention":12716,"totalTrials":166,"cells":39962},{"EARLY_PHASE1":39963,"PHASE1":39965,"PHASE2":39967,"PHASE3":39973,"PHASE4":39975,"NA":39977},{"trials":39964,"activeCount":124},[],{"trials":39966,"activeCount":124},[],{"trials":39968,"activeCount":124},[39969],{"nctId":12709,"briefTitle":12710,"status":182,"phases":39970,"primaryCompletion":12712,"completion":12712,"start":12713,"enrollment":1231,"conditions":39971,"interventions":39972},[88],[15],[4582,12716,612],{"trials":39974,"activeCount":124},[],{"trials":39976,"activeCount":124},[],{"trials":39978,"activeCount":124},[],{"intervention":8117,"totalTrials":166,"cells":39980},{"EARLY_PHASE1":39981,"PHASE1":39983,"PHASE2":39985,"PHASE3":39991,"PHASE4":39993,"NA":39995},{"trials":39982,"activeCount":124},[],{"trials":39984,"activeCount":124},[],{"trials":39986,"activeCount":124},[39987],{"nctId":8110,"briefTitle":8111,"status":203,"phases":39988,"primaryCompletion":7375,"completion":7375,"start":8113,"enrollment":124,"conditions":39989,"interventions":39990},[88],[6564,8115],[8117,53],{"trials":39992,"activeCount":124},[],{"trials":39994,"activeCount":124},[],{"trials":39996,"activeCount":124},[],{"intervention":39998,"totalTrials":166,"cells":39999},"Fentanyl Buccal",{"EARLY_PHASE1":40000,"PHASE1":40002,"PHASE2":40004,"PHASE3":40012,"PHASE4":40014,"NA":40016},{"trials":40001,"activeCount":124},[],{"trials":40003,"activeCount":124},[],{"trials":40005,"activeCount":124},[40006],{"nctId":40007,"briefTitle":40008,"status":130,"phases":40009,"primaryCompletion":33744,"completion":33744,"start":13655,"enrollment":593,"conditions":40010,"interventions":40011},"NCT01856114","Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea",[88],[33],[39998],{"trials":40013,"activeCount":124},[],{"trials":40015,"activeCount":124},[],{"trials":40017,"activeCount":124},[],{"intervention":1112,"totalTrials":166,"cells":40019},{"EARLY_PHASE1":40020,"PHASE1":40022,"PHASE2":40024,"PHASE3":40030,"PHASE4":40032,"NA":40034},{"trials":40021,"activeCount":124},[],{"trials":40023,"activeCount":124},[],{"trials":40025,"activeCount":124},[40026],{"nctId":1105,"briefTitle":1106,"status":182,"phases":40027,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":539,"conditions":40028,"interventions":40029},[87,88],[359,913,608,850,609,914,610,853,632],[1112,510,803,654,62,1069,1113,1114,806,809,894,480,1016],{"trials":40031,"activeCount":124},[],{"trials":40033,"activeCount":124},[],{"trials":40035,"activeCount":124},[],{"intervention":40037,"totalTrials":166,"cells":40038},"SU011248",{"EARLY_PHASE1":40039,"PHASE1":40041,"PHASE2":40043,"PHASE3":40052,"PHASE4":40054,"NA":40056},{"trials":40040,"activeCount":124},[],{"trials":40042,"activeCount":124},[],{"trials":40044,"activeCount":124},[40045],{"nctId":40046,"briefTitle":40047,"status":182,"phases":40048,"primaryCompletion":3901,"completion":3901,"start":4039,"enrollment":1568,"conditions":40049,"interventions":40051},"NCT00330564","Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow",[88],[34521,1521,40050],"Hemangioblastoma",[40037],{"trials":40053,"activeCount":124},[],{"trials":40055,"activeCount":124},[],{"trials":40057,"activeCount":124},[],{"intervention":17939,"totalTrials":166,"cells":40059},{"EARLY_PHASE1":40060,"PHASE1":40062,"PHASE2":40064,"PHASE3":40070,"PHASE4":40072,"NA":40074},{"trials":40061,"activeCount":124},[],{"trials":40063,"activeCount":124},[],{"trials":40065,"activeCount":124},[40066],{"nctId":17932,"briefTitle":17933,"status":130,"phases":40067,"primaryCompletion":4665,"completion":4665,"start":5016,"enrollment":1328,"conditions":40068,"interventions":40069},[87,88],[17936,17937],[1368,17939],{"trials":40071,"activeCount":124},[],{"trials":40073,"activeCount":124},[],{"trials":40075,"activeCount":124},[],{"intervention":7230,"totalTrials":166,"cells":40077},{"EARLY_PHASE1":40078,"PHASE1":40080,"PHASE2":40082,"PHASE3":40088,"PHASE4":40090,"NA":40092},{"trials":40079,"activeCount":124},[],{"trials":40081,"activeCount":124},[],{"trials":40083,"activeCount":124},[40084],{"nctId":7222,"briefTitle":7223,"status":130,"phases":40085,"primaryCompletion":7225,"completion":7225,"start":7226,"enrollment":1100,"conditions":40086,"interventions":40087},[88],[7228,2653],[7021,1016,7230,7231,803,654,805,806,1013,7023],{"trials":40089,"activeCount":124},[],{"trials":40091,"activeCount":124},[],{"trials":40093,"activeCount":124},[],{"intervention":7231,"totalTrials":166,"cells":40095},{"EARLY_PHASE1":40096,"PHASE1":40098,"PHASE2":40100,"PHASE3":40106,"PHASE4":40108,"NA":40110},{"trials":40097,"activeCount":124},[],{"trials":40099,"activeCount":124},[],{"trials":40101,"activeCount":124},[40102],{"nctId":7222,"briefTitle":7223,"status":130,"phases":40103,"primaryCompletion":7225,"completion":7225,"start":7226,"enrollment":1100,"conditions":40104,"interventions":40105},[88],[7228,2653],[7021,1016,7230,7231,803,654,805,806,1013,7023],{"trials":40107,"activeCount":124},[],{"trials":40109,"activeCount":124},[],{"trials":40111,"activeCount":124},[],{"intervention":12737,"totalTrials":166,"cells":40113},{"EARLY_PHASE1":40114,"PHASE1":40116,"PHASE2":40118,"PHASE3":40124,"PHASE4":40126,"NA":40128},{"trials":40115,"activeCount":124},[],{"trials":40117,"activeCount":124},[],{"trials":40119,"activeCount":124},[40120],{"nctId":12730,"briefTitle":12731,"status":130,"phases":40121,"primaryCompletion":12733,"completion":12733,"start":12734,"enrollment":1260,"conditions":40122,"interventions":40123},[87,88],[15],[12737,612],{"trials":40125,"activeCount":124},[],{"trials":40127,"activeCount":124},[],{"trials":40129,"activeCount":124},[],{"intervention":1125,"totalTrials":166,"cells":40131},{"EARLY_PHASE1":40132,"PHASE1":40134,"PHASE2":40136,"PHASE3":40142,"PHASE4":40144,"NA":40146},{"trials":40133,"activeCount":124},[],{"trials":40135,"activeCount":124},[],{"trials":40137,"activeCount":124},[40138],{"nctId":1116,"briefTitle":1117,"status":182,"phases":40139,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":296,"conditions":40140,"interventions":40141},[88],[1122,15],[1124,480,1125],{"trials":40143,"activeCount":124},[],{"trials":40145,"activeCount":124},[],{"trials":40147,"activeCount":124},[],{"intervention":8817,"totalTrials":166,"cells":40149},{"EARLY_PHASE1":40150,"PHASE1":40152,"PHASE2":40154,"PHASE3":40160,"PHASE4":40162,"NA":40164},{"trials":40151,"activeCount":124},[],{"trials":40153,"activeCount":124},[],{"trials":40155,"activeCount":124},[40156],{"nctId":8811,"briefTitle":8812,"status":203,"phases":40157,"primaryCompletion":8814,"start":1558,"enrollment":124,"conditions":40158,"interventions":40159},[88],[15],[894,8817],{"trials":40161,"activeCount":124},[],{"trials":40163,"activeCount":124},[],{"trials":40165,"activeCount":124},[],{"intervention":4235,"totalTrials":166,"cells":40167},{"EARLY_PHASE1":40168,"PHASE1":40170,"PHASE2":40172,"PHASE3":40178,"PHASE4":40180,"NA":40182},{"trials":40169,"activeCount":124},[],{"trials":40171,"activeCount":124},[],{"trials":40173,"activeCount":124},[40174],{"nctId":4229,"briefTitle":4230,"status":130,"phases":40175,"primaryCompletion":2846,"completion":2846,"start":4183,"enrollment":1034,"conditions":40176,"interventions":40177},[88],[1293],[4234,1709,1013,806,4235],{"trials":40179,"activeCount":124},[],{"trials":40181,"activeCount":124},[],{"trials":40183,"activeCount":124},[],{"intervention":2782,"totalTrials":166,"cells":40185},{"EARLY_PHASE1":40186,"PHASE1":40188,"PHASE2":40190,"PHASE3":40196,"PHASE4":40198,"NA":40200},{"trials":40187,"activeCount":124},[],{"trials":40189,"activeCount":124},[],{"trials":40191,"activeCount":124},[40192],{"nctId":2774,"briefTitle":2775,"status":130,"phases":40193,"primaryCompletion":2777,"completion":2777,"start":2778,"enrollment":2779,"conditions":40194,"interventions":40195},[87,88],[2245],[1402,75,2782,62],{"trials":40197,"activeCount":124},[],{"trials":40199,"activeCount":124},[],{"trials":40201,"activeCount":124},[],{"intervention":8134,"totalTrials":166,"cells":40203},{"EARLY_PHASE1":40204,"PHASE1":40206,"PHASE2":40208,"PHASE3":40214,"PHASE4":40216,"NA":40218},{"trials":40205,"activeCount":124},[],{"trials":40207,"activeCount":124},[],{"trials":40209,"activeCount":124},[40210],{"nctId":8127,"briefTitle":8128,"status":182,"phases":40211,"primaryCompletion":8130,"completion":8130,"start":8131,"enrollment":2004,"conditions":40212,"interventions":40213},[88],[1343,2570],[53,8134],{"trials":40215,"activeCount":124},[],{"trials":40217,"activeCount":124},[],{"trials":40219,"activeCount":124},[],{"intervention":40221,"totalTrials":166,"cells":40222},"Etanercept",{"EARLY_PHASE1":40223,"PHASE1":40225,"PHASE2":40227,"PHASE3":40235,"PHASE4":40237,"NA":40239},{"trials":40224,"activeCount":124},[],{"trials":40226,"activeCount":124},[],{"trials":40228,"activeCount":124},[40229],{"nctId":40230,"briefTitle":40231,"status":182,"phases":40232,"primaryCompletion":12649,"completion":12649,"start":34960,"enrollment":166,"conditions":40233,"interventions":40234},"NCT00509600","Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia",[88],[15],[40221],{"trials":40236,"activeCount":124},[],{"trials":40238,"activeCount":124},[],{"trials":40240,"activeCount":124},[],{"intervention":40242,"totalTrials":166,"cells":40243},"Amifostine Trihydrate",{"EARLY_PHASE1":40244,"PHASE1":40246,"PHASE2":40248,"PHASE3":40258,"PHASE4":40260,"NA":40262},{"trials":40245,"activeCount":124},[],{"trials":40247,"activeCount":124},[],{"trials":40249,"activeCount":124},[40250],{"nctId":40251,"briefTitle":40252,"status":130,"phases":40253,"primaryCompletion":40254,"completion":40254,"start":40255,"enrollment":3726,"conditions":40256,"interventions":40257},"NCT00003048","Amifostine in Treating Patients With Myelodysplastic Syndrome",[88],"2001-02-12","1997-06-05",[1036],[40242],{"trials":40259,"activeCount":124},[],{"trials":40261,"activeCount":124},[],{"trials":40263,"activeCount":124},[],{"intervention":2792,"totalTrials":166,"cells":40265},{"EARLY_PHASE1":40266,"PHASE1":40268,"PHASE2":40270,"PHASE3":40276,"PHASE4":40278,"NA":40280},{"trials":40267,"activeCount":124},[],{"trials":40269,"activeCount":124},[],{"trials":40271,"activeCount":124},[40272],{"nctId":2784,"briefTitle":2785,"status":182,"phases":40273,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":1609,"conditions":40274,"interventions":40275},[88],[2790],[62,1013,2792,2495,1114,2793,2794,810],{"trials":40277,"activeCount":124},[],{"trials":40279,"activeCount":124},[],{"trials":40281,"activeCount":124},[],{"intervention":2794,"totalTrials":166,"cells":40283},{"EARLY_PHASE1":40284,"PHASE1":40286,"PHASE2":40288,"PHASE3":40294,"PHASE4":40296,"NA":40298},{"trials":40285,"activeCount":124},[],{"trials":40287,"activeCount":124},[],{"trials":40289,"activeCount":124},[40290],{"nctId":2784,"briefTitle":2785,"status":182,"phases":40291,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":1609,"conditions":40292,"interventions":40293},[88],[2790],[62,1013,2792,2495,1114,2793,2794,810],{"trials":40295,"activeCount":124},[],{"trials":40297,"activeCount":124},[],{"trials":40299,"activeCount":124},[],{"intervention":7239,"totalTrials":166,"cells":40301},{"EARLY_PHASE1":40302,"PHASE1":40304,"PHASE2":40306,"PHASE3":40312,"PHASE4":40314,"NA":40316},{"trials":40303,"activeCount":124},[],{"trials":40305,"activeCount":124},[],{"trials":40307,"activeCount":124},[40308],{"nctId":7233,"briefTitle":7234,"status":182,"phases":40309,"primaryCompletion":5434,"completion":5434,"start":7236,"enrollment":166,"conditions":40310,"interventions":40311},[88],[5735],[1070,803,7239,1114,3499],{"trials":40313,"activeCount":124},[],{"trials":40315,"activeCount":124},[],{"trials":40317,"activeCount":124},[],{"intervention":40319,"totalTrials":166,"cells":40320},"Clofarabine 40mg\u002Fm^2",{"EARLY_PHASE1":40321,"PHASE1":40323,"PHASE2":40325,"PHASE3":40338,"PHASE4":40340,"NA":40342},{"trials":40322,"activeCount":124},[],{"trials":40324,"activeCount":124},[],{"trials":40326,"activeCount":124},[40327],{"nctId":40328,"briefTitle":40329,"status":130,"phases":40330,"primaryCompletion":11040,"completion":11040,"start":3214,"enrollment":1001,"conditions":40331,"interventions":40332},"NCT00067028","Clofarabine Combinations in Relapsed\u002FRefractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)",[88],[36,30,3315],[40319,40333,40334,40335,40336,40337],"Idarubicin 10mg\u002Fm^2","Ara-C 0.75 g\u002Fm^2","Clofarabine 22.5mg\u002Fm^2","Ara-C 1 g\u002Fm^2","Idarubicin 6 mg\u002Fm^2",{"trials":40339,"activeCount":124},[],{"trials":40341,"activeCount":124},[],{"trials":40343,"activeCount":124},[],{"intervention":40333,"totalTrials":166,"cells":40345},{"EARLY_PHASE1":40346,"PHASE1":40348,"PHASE2":40350,"PHASE3":40356,"PHASE4":40358,"NA":40360},{"trials":40347,"activeCount":124},[],{"trials":40349,"activeCount":124},[],{"trials":40351,"activeCount":124},[40352],{"nctId":40328,"briefTitle":40329,"status":130,"phases":40353,"primaryCompletion":11040,"completion":11040,"start":3214,"enrollment":1001,"conditions":40354,"interventions":40355},[88],[36,30,3315],[40319,40333,40334,40335,40336,40337],{"trials":40357,"activeCount":124},[],{"trials":40359,"activeCount":124},[],{"trials":40361,"activeCount":124},[],{"intervention":40334,"totalTrials":166,"cells":40363},{"EARLY_PHASE1":40364,"PHASE1":40366,"PHASE2":40368,"PHASE3":40374,"PHASE4":40376,"NA":40378},{"trials":40365,"activeCount":124},[],{"trials":40367,"activeCount":124},[],{"trials":40369,"activeCount":124},[40370],{"nctId":40328,"briefTitle":40329,"status":130,"phases":40371,"primaryCompletion":11040,"completion":11040,"start":3214,"enrollment":1001,"conditions":40372,"interventions":40373},[88],[36,30,3315],[40319,40333,40334,40335,40336,40337],{"trials":40375,"activeCount":124},[],{"trials":40377,"activeCount":124},[],{"trials":40379,"activeCount":124},[],{"intervention":40335,"totalTrials":166,"cells":40381},{"EARLY_PHASE1":40382,"PHASE1":40384,"PHASE2":40386,"PHASE3":40392,"PHASE4":40394,"NA":40396},{"trials":40383,"activeCount":124},[],{"trials":40385,"activeCount":124},[],{"trials":40387,"activeCount":124},[40388],{"nctId":40328,"briefTitle":40329,"status":130,"phases":40389,"primaryCompletion":11040,"completion":11040,"start":3214,"enrollment":1001,"conditions":40390,"interventions":40391},[88],[36,30,3315],[40319,40333,40334,40335,40336,40337],{"trials":40393,"activeCount":124},[],{"trials":40395,"activeCount":124},[],{"trials":40397,"activeCount":124},[],{"intervention":40336,"totalTrials":166,"cells":40399},{"EARLY_PHASE1":40400,"PHASE1":40402,"PHASE2":40404,"PHASE3":40410,"PHASE4":40412,"NA":40414},{"trials":40401,"activeCount":124},[],{"trials":40403,"activeCount":124},[],{"trials":40405,"activeCount":124},[40406],{"nctId":40328,"briefTitle":40329,"status":130,"phases":40407,"primaryCompletion":11040,"completion":11040,"start":3214,"enrollment":1001,"conditions":40408,"interventions":40409},[88],[36,30,3315],[40319,40333,40334,40335,40336,40337],{"trials":40411,"activeCount":124},[],{"trials":40413,"activeCount":124},[],{"trials":40415,"activeCount":124},[],{"intervention":40337,"totalTrials":166,"cells":40417},{"EARLY_PHASE1":40418,"PHASE1":40420,"PHASE2":40422,"PHASE3":40428,"PHASE4":40430,"NA":40432},{"trials":40419,"activeCount":124},[],{"trials":40421,"activeCount":124},[],{"trials":40423,"activeCount":124},[40424],{"nctId":40328,"briefTitle":40329,"status":130,"phases":40425,"primaryCompletion":11040,"completion":11040,"start":3214,"enrollment":1001,"conditions":40426,"interventions":40427},[88],[36,30,3315],[40319,40333,40334,40335,40336,40337],{"trials":40429,"activeCount":124},[],{"trials":40431,"activeCount":124},[],{"trials":40433,"activeCount":124},[],{"intervention":14597,"totalTrials":166,"cells":40435},{"EARLY_PHASE1":40436,"PHASE1":40438,"PHASE2":40440,"PHASE3":40446,"PHASE4":40448,"NA":40450},{"trials":40437,"activeCount":124},[],{"trials":40439,"activeCount":124},[],{"trials":40441,"activeCount":124},[40442],{"nctId":14590,"briefTitle":14591,"status":130,"phases":40443,"primaryCompletion":14593,"completion":14593,"start":14594,"enrollment":517,"conditions":40444,"interventions":40445},[88],[3195,7818],[14597,1371],{"trials":40447,"activeCount":124},[],{"trials":40449,"activeCount":124},[],{"trials":40451,"activeCount":124},[],{"intervention":12766,"totalTrials":166,"cells":40453},{"EARLY_PHASE1":40454,"PHASE1":40456,"PHASE2":40458,"PHASE3":40464,"PHASE4":40466,"NA":40468},{"trials":40455,"activeCount":124},[],{"trials":40457,"activeCount":124},[],{"trials":40459,"activeCount":124},[40460],{"nctId":12758,"briefTitle":12759,"status":130,"phases":40461,"primaryCompletion":12761,"completion":12761,"start":12762,"enrollment":12763,"conditions":40462,"interventions":40463},[88],[15],[12766,612,12767],{"trials":40465,"activeCount":124},[],{"trials":40467,"activeCount":124},[],{"trials":40469,"activeCount":124},[],{"intervention":12767,"totalTrials":166,"cells":40471},{"EARLY_PHASE1":40472,"PHASE1":40474,"PHASE2":40476,"PHASE3":40482,"PHASE4":40484,"NA":40486},{"trials":40473,"activeCount":124},[],{"trials":40475,"activeCount":124},[],{"trials":40477,"activeCount":124},[40478],{"nctId":12758,"briefTitle":12759,"status":130,"phases":40479,"primaryCompletion":12761,"completion":12761,"start":12762,"enrollment":12763,"conditions":40480,"interventions":40481},[88],[15],[12766,612,12767],{"trials":40483,"activeCount":124},[],{"trials":40485,"activeCount":124},[],{"trials":40487,"activeCount":124},[],{"intervention":40489,"totalTrials":166,"cells":40490},"Irofulven",{"EARLY_PHASE1":40491,"PHASE1":40493,"PHASE2":40495,"PHASE3":40505,"PHASE4":40507,"NA":40509},{"trials":40492,"activeCount":124},[],{"trials":40494,"activeCount":124},[],{"trials":40496,"activeCount":124},[40497],{"nctId":40498,"briefTitle":40499,"status":130,"phases":40500,"primaryCompletion":40501,"completion":40501,"start":40502,"enrollment":134,"conditions":40503,"interventions":40504},"NCT00003441","Irofulven in Treating Patients With Metastatic Colorectal Cancer",[88],"2000-11-08","1998-08",[3195],[40489],{"trials":40506,"activeCount":124},[],{"trials":40508,"activeCount":124},[],{"trials":40510,"activeCount":124},[],{"intervention":11148,"totalTrials":166,"cells":40512},{"EARLY_PHASE1":40513,"PHASE1":40515,"PHASE2":40517,"PHASE3":40523,"PHASE4":40525,"NA":40527},{"trials":40514,"activeCount":124},[],{"trials":40516,"activeCount":124},[],{"trials":40518,"activeCount":124},[40519],{"nctId":11139,"briefTitle":11140,"status":182,"phases":40520,"primaryCompletion":11142,"completion":11142,"start":11143,"enrollment":910,"conditions":40521,"interventions":40522},[88],[11145,4937,4938,4939,4940,5062,4941,10215,11146,4942,4943,4944,4945,4946,5063,4947,4948,1458,1460,1461],[1275,11148,1376],{"trials":40524,"activeCount":124},[],{"trials":40526,"activeCount":124},[],{"trials":40528,"activeCount":124},[],{"intervention":35668,"totalTrials":166,"cells":40530},{"EARLY_PHASE1":40531,"PHASE1":40533,"PHASE2":40535,"PHASE3":40541,"PHASE4":40543,"NA":40545},{"trials":40532,"activeCount":124},[],{"trials":40534,"activeCount":124},[],{"trials":40536,"activeCount":124},[40537],{"nctId":35661,"briefTitle":35662,"status":182,"phases":40538,"primaryCompletion":35664,"completion":35664,"start":35665,"enrollment":230,"conditions":40539,"interventions":40540},[87,88],[7296,11568,11569],[27613,35668],{"trials":40542,"activeCount":124},[],{"trials":40544,"activeCount":124},[],{"trials":40546,"activeCount":124},[],{"intervention":10275,"totalTrials":166,"cells":40548},{"EARLY_PHASE1":40549,"PHASE1":40551,"PHASE2":40553,"PHASE3":40559,"PHASE4":40561,"NA":40563},{"trials":40550,"activeCount":124},[],{"trials":40552,"activeCount":124},[],{"trials":40554,"activeCount":124},[40555],{"nctId":10269,"briefTitle":10270,"status":130,"phases":40556,"primaryCompletion":4619,"completion":4619,"start":10272,"enrollment":7377,"conditions":40557,"interventions":40558},[88],[1530,9926,5787],[1369,4629,10275],{"trials":40560,"activeCount":124},[],{"trials":40562,"activeCount":124},[],{"trials":40564,"activeCount":124},[],{"intervention":40566,"totalTrials":166,"cells":40567},"Alimta",{"EARLY_PHASE1":40568,"PHASE1":40570,"PHASE2":40572,"PHASE3":40580,"PHASE4":40582,"NA":40584},{"trials":40569,"activeCount":124},[],{"trials":40571,"activeCount":124},[],{"trials":40573,"activeCount":124},[40574],{"nctId":40575,"briefTitle":40576,"status":130,"phases":40577,"primaryCompletion":2232,"completion":2232,"start":2213,"enrollment":3354,"conditions":40578,"interventions":40579},"NCT00508144","Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer",[88],[24],[40566],{"trials":40581,"activeCount":124},[],{"trials":40583,"activeCount":124},[],{"trials":40585,"activeCount":124},[],{"intervention":2811,"totalTrials":166,"cells":40587},{"EARLY_PHASE1":40588,"PHASE1":40590,"PHASE2":40592,"PHASE3":40598,"PHASE4":40600,"NA":40602},{"trials":40589,"activeCount":124},[],{"trials":40591,"activeCount":124},[],{"trials":40593,"activeCount":124},[40594],{"nctId":2803,"briefTitle":2804,"status":130,"phases":40595,"primaryCompletion":2806,"completion":2806,"start":2807,"enrollment":406,"conditions":40596,"interventions":40597},[88],[2809],[1376,62,2811,2269],{"trials":40599,"activeCount":124},[],{"trials":40601,"activeCount":124},[],{"trials":40603,"activeCount":124},[],{"intervention":12991,"totalTrials":166,"cells":40605},{"EARLY_PHASE1":40606,"PHASE1":40608,"PHASE2":40610,"PHASE3":40616,"PHASE4":40618,"NA":40620},{"trials":40607,"activeCount":124},[],{"trials":40609,"activeCount":124},[],{"trials":40611,"activeCount":124},[40612],{"nctId":12984,"briefTitle":12985,"status":130,"phases":40613,"primaryCompletion":12987,"completion":12987,"start":12988,"enrollment":834,"conditions":40614,"interventions":40615},[88],[450],[1683,12991],{"trials":40617,"activeCount":124},[],{"trials":40619,"activeCount":124},[],{"trials":40621,"activeCount":124},[],{"intervention":7260,"totalTrials":166,"cells":40623},{"EARLY_PHASE1":40624,"PHASE1":40626,"PHASE2":40628,"PHASE3":40634,"PHASE4":40636,"NA":40638},{"trials":40625,"activeCount":124},[],{"trials":40627,"activeCount":124},[],{"trials":40629,"activeCount":124},[40630],{"nctId":7254,"briefTitle":7255,"status":182,"phases":40631,"primaryCompletion":2778,"completion":2778,"start":3987,"enrollment":121,"conditions":40632,"interventions":40633},[88],[15,7258],[7260,1070,803,1114,3499],{"trials":40635,"activeCount":124},[],{"trials":40637,"activeCount":124},[],{"trials":40639,"activeCount":124},[],{"intervention":21344,"totalTrials":166,"cells":40641},{"EARLY_PHASE1":40642,"PHASE1":40644,"PHASE2":40646,"PHASE3":40652,"PHASE4":40654,"NA":40656},{"trials":40643,"activeCount":124},[],{"trials":40645,"activeCount":124},[],{"trials":40647,"activeCount":124},[40648],{"nctId":21337,"briefTitle":21338,"status":203,"phases":40649,"primaryCompletion":21340,"completion":21340,"start":21341,"enrollment":124,"conditions":40650,"interventions":40651},[87,88],[36],[520,21344],{"trials":40653,"activeCount":124},[],{"trials":40655,"activeCount":124},[],{"trials":40657,"activeCount":124},[],{"intervention":21554,"totalTrials":166,"cells":40659},{"EARLY_PHASE1":40660,"PHASE1":40662,"PHASE2":40664,"PHASE3":40670,"PHASE4":40672,"NA":40674},{"trials":40661,"activeCount":124},[],{"trials":40663,"activeCount":124},[],{"trials":40665,"activeCount":124},[40666],{"nctId":21549,"briefTitle":21550,"status":130,"phases":40667,"completion":10784,"start":2580,"enrollment":4171,"conditions":40668,"interventions":40669},[88],[712,15],[21554,1177],{"trials":40671,"activeCount":124},[],{"trials":40673,"activeCount":124},[],{"trials":40675,"activeCount":124},[],{"intervention":4825,"totalTrials":166,"cells":40677},{"EARLY_PHASE1":40678,"PHASE1":40680,"PHASE2":40682,"PHASE3":40688,"PHASE4":40690,"NA":40692},{"trials":40679,"activeCount":124},[],{"trials":40681,"activeCount":124},[],{"trials":40683,"activeCount":124},[40684],{"nctId":4815,"briefTitle":4816,"status":130,"phases":40685,"primaryCompletion":4818,"completion":4818,"start":4819,"enrollment":4820,"conditions":40686,"interventions":40687},[88],[15,36,2838,3315,712,4580,4822,4823,1400,30],[4825,1004,2196,806,2374],{"trials":40689,"activeCount":124},[],{"trials":40691,"activeCount":124},[],{"trials":40693,"activeCount":124},[],{"intervention":11164,"totalTrials":166,"cells":40695},{"EARLY_PHASE1":40696,"PHASE1":40698,"PHASE2":40700,"PHASE3":40706,"PHASE4":40708,"NA":40710},{"trials":40697,"activeCount":124},[],{"trials":40699,"activeCount":124},[],{"trials":40701,"activeCount":124},[40702],{"nctId":11157,"briefTitle":11158,"status":182,"phases":40703,"primaryCompletion":184,"completion":184,"start":8956,"enrollment":3726,"conditions":40704,"interventions":40705},[87,88],[11161,11162],[11164,1275],{"trials":40707,"activeCount":124},[],{"trials":40709,"activeCount":124},[],{"trials":40711,"activeCount":124},[],{"intervention":8147,"totalTrials":166,"cells":40713},{"EARLY_PHASE1":40714,"PHASE1":40716,"PHASE2":40718,"PHASE3":40724,"PHASE4":40726,"NA":40728},{"trials":40715,"activeCount":124},[],{"trials":40717,"activeCount":124},[],{"trials":40719,"activeCount":124},[40720],{"nctId":8140,"briefTitle":8141,"status":182,"phases":40721,"primaryCompletion":8143,"completion":8143,"start":8144,"enrollment":1240,"conditions":40722,"interventions":40723},[87,88],[1729],[8147,53],{"trials":40725,"activeCount":124},[],{"trials":40727,"activeCount":124},[],{"trials":40729,"activeCount":124},[],{"intervention":22923,"totalTrials":166,"cells":40731},{"EARLY_PHASE1":40732,"PHASE1":40734,"PHASE2":40736,"PHASE3":40742,"PHASE4":40744,"NA":40746},{"trials":40733,"activeCount":124},[],{"trials":40735,"activeCount":124},[],{"trials":40737,"activeCount":124},[40738],{"nctId":22917,"briefTitle":22918,"status":130,"phases":40739,"primaryCompletion":3987,"completion":3987,"start":7473,"enrollment":37,"conditions":40740,"interventions":40741},[88],[2049,22921],[2330,22923],{"trials":40743,"activeCount":124},[],{"trials":40745,"activeCount":124},[],{"trials":40747,"activeCount":124},[],{"intervention":40749,"totalTrials":166,"cells":40750},"IFN-alpha2a",{"EARLY_PHASE1":40751,"PHASE1":40753,"PHASE2":40755,"PHASE3":40766,"PHASE4":40768,"NA":40770},{"trials":40752,"activeCount":124},[],{"trials":40754,"activeCount":124},[],{"trials":40756,"activeCount":124},[40757],{"nctId":40758,"briefTitle":40759,"status":130,"phases":40760,"primaryCompletion":40761,"completion":40761,"start":40762,"enrollment":2946,"conditions":40763,"interventions":40765},"NCT00452023","Pegasys® in Patients With Myeloproliferative Diseases",[88],"2023-05-26","2005-04-07",[40764],"Myeloproliferative Disorders",[40749],{"trials":40767,"activeCount":124},[],{"trials":40769,"activeCount":124},[],{"trials":40771,"activeCount":124},[],{"intervention":20453,"totalTrials":166,"cells":40773},{"EARLY_PHASE1":40774,"PHASE1":40776,"PHASE2":40778,"PHASE3":40784,"PHASE4":40786,"NA":40788},{"trials":40775,"activeCount":124},[],{"trials":40777,"activeCount":124},[],{"trials":40779,"activeCount":124},[40780],{"nctId":20448,"briefTitle":20449,"status":130,"phases":40781,"primaryCompletion":2828,"completion":11731,"start":9828,"enrollment":2018,"conditions":40782,"interventions":40783},[88],[15],[20453,2584,2374],{"trials":40785,"activeCount":124},[],{"trials":40787,"activeCount":124},[],{"trials":40789,"activeCount":124},[],{"intervention":21035,"totalTrials":166,"cells":40791},{"EARLY_PHASE1":40792,"PHASE1":40794,"PHASE2":40796,"PHASE3":40802,"PHASE4":40804,"NA":40806},{"trials":40793,"activeCount":124},[],{"trials":40795,"activeCount":124},[],{"trials":40797,"activeCount":124},[40798],{"nctId":21028,"briefTitle":21029,"status":130,"phases":40799,"primaryCompletion":21031,"completion":21031,"start":21032,"enrollment":2933,"conditions":40800,"interventions":40801},[87,88],[3135],[2712,21035],{"trials":40803,"activeCount":124},[],{"trials":40805,"activeCount":124},[],{"trials":40807,"activeCount":124},[],{"intervention":40809,"totalTrials":166,"cells":40810},"PS341",{"EARLY_PHASE1":40811,"PHASE1":40813,"PHASE2":40815,"PHASE3":40824,"PHASE4":40826,"NA":40828},{"trials":40812,"activeCount":124},[],{"trials":40814,"activeCount":124},[],{"trials":40816,"activeCount":124},[40817],{"nctId":40818,"briefTitle":40819,"status":130,"phases":40820,"primaryCompletion":3902,"completion":3902,"start":4105,"enrollment":1034,"conditions":40821,"interventions":40823},"NCT00038571","Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy",[88],[40822],"Lymphoma, B-Cell",[40809],{"trials":40825,"activeCount":124},[],{"trials":40827,"activeCount":124},[],{"trials":40829,"activeCount":124},[],{"intervention":4276,"totalTrials":166,"cells":40831},{"EARLY_PHASE1":40832,"PHASE1":40834,"PHASE2":40836,"PHASE3":40842,"PHASE4":40844,"NA":40846},{"trials":40833,"activeCount":124},[],{"trials":40835,"activeCount":124},[],{"trials":40837,"activeCount":124},[40838],{"nctId":4269,"briefTitle":4270,"status":130,"phases":40839,"primaryCompletion":4272,"completion":4272,"start":4273,"enrollment":871,"conditions":40840,"interventions":40841},[88],[4195],[2271,1709,4276],{"trials":40843,"activeCount":124},[],{"trials":40845,"activeCount":124},[],{"trials":40847,"activeCount":124},[],{"intervention":22972,"totalTrials":166,"cells":40849},{"EARLY_PHASE1":40850,"PHASE1":40852,"PHASE2":40854,"PHASE3":40860,"PHASE4":40862,"NA":40864},{"trials":40851,"activeCount":124},[],{"trials":40853,"activeCount":124},[],{"trials":40855,"activeCount":124},[40856],{"nctId":22967,"briefTitle":22968,"status":203,"phases":40857,"primaryCompletion":13585,"start":3725,"enrollment":124,"conditions":40858,"interventions":40859},[87,88],[18],[22972,4227],{"trials":40861,"activeCount":124},[],{"trials":40863,"activeCount":124},[],{"trials":40865,"activeCount":124},[],{"intervention":40867,"totalTrials":166,"cells":40868},"Methylene Blue",{"EARLY_PHASE1":40869,"PHASE1":40871,"PHASE2":40873,"PHASE3":40884,"PHASE4":40886,"NA":40888},{"trials":40870,"activeCount":124},[],{"trials":40872,"activeCount":124},[],{"trials":40874,"activeCount":124},[40875],{"nctId":40876,"briefTitle":40877,"status":130,"phases":40878,"primaryCompletion":40879,"completion":40879,"start":2335,"enrollment":34,"conditions":40880,"interventions":40883},"NCT03469284","MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)",[88],"2022-02-03",[2613,40881,40882],"Oral Pain","Stomatitis",[40867,40867,40867],{"trials":40885,"activeCount":124},[],{"trials":40887,"activeCount":124},[],{"trials":40889,"activeCount":124},[],{"intervention":10311,"totalTrials":166,"cells":40891},{"EARLY_PHASE1":40892,"PHASE1":40894,"PHASE2":40896,"PHASE3":40902,"PHASE4":40904,"NA":40906},{"trials":40893,"activeCount":124},[],{"trials":40895,"activeCount":124},[],{"trials":40897,"activeCount":124},[40898],{"nctId":10299,"briefTitle":10300,"status":182,"phases":40899,"primaryCompletion":10302,"completion":10302,"start":9278,"enrollment":1483,"conditions":40900,"interventions":40901},[87,88],[4097,10304,10305,10306,10307,10308,10309],[1369,1376,10311],{"trials":40903,"activeCount":124},[],{"trials":40905,"activeCount":124},[],{"trials":40907,"activeCount":124},[],{"intervention":1168,"totalTrials":166,"cells":40909},{"EARLY_PHASE1":40910,"PHASE1":40912,"PHASE2":40914,"PHASE3":40920,"PHASE4":40922,"NA":40924},{"trials":40911,"activeCount":124},[],{"trials":40913,"activeCount":124},[],{"trials":40915,"activeCount":124},[40916],{"nctId":1161,"briefTitle":1162,"status":203,"phases":40917,"primaryCompletion":1164,"completion":1164,"start":1165,"enrollment":124,"conditions":40918,"interventions":40919},[88],[789,790],[1168,480],{"trials":40921,"activeCount":124},[],{"trials":40923,"activeCount":124},[],{"trials":40925,"activeCount":124},[],{"intervention":32058,"totalTrials":166,"cells":40927},{"EARLY_PHASE1":40928,"PHASE1":40930,"PHASE2":40932,"PHASE3":40938,"PHASE4":40940,"NA":40942},{"trials":40929,"activeCount":124},[],{"trials":40931,"activeCount":124},[],{"trials":40933,"activeCount":124},[40934],{"nctId":32053,"briefTitle":32054,"status":130,"phases":40935,"primaryCompletion":3213,"completion":3213,"start":4887,"enrollment":1222,"conditions":40936,"interventions":40937},[88],[21],[14612,32058,5247],{"trials":40939,"activeCount":124},[],{"trials":40941,"activeCount":124},[],{"trials":40943,"activeCount":124},[],{"intervention":12008,"totalTrials":166,"cells":40945},{"EARLY_PHASE1":40946,"PHASE1":40948,"PHASE2":40950,"PHASE3":40956,"PHASE4":40958,"NA":40960},{"trials":40947,"activeCount":124},[],{"trials":40949,"activeCount":124},[],{"trials":40951,"activeCount":124},[40952],{"nctId":12002,"briefTitle":12003,"status":130,"phases":40953,"primaryCompletion":2213,"completion":2213,"start":2945,"enrollment":1609,"conditions":40954,"interventions":40955},[88],[2770,12006],[12008,1376],{"trials":40957,"activeCount":124},[],{"trials":40959,"activeCount":124},[],{"trials":40961,"activeCount":124},[],{"intervention":40963,"totalTrials":166,"cells":40964},"Obatoclax Mesylate",{"EARLY_PHASE1":40965,"PHASE1":40967,"PHASE2":40969,"PHASE3":40977,"PHASE4":40979,"NA":40981},{"trials":40966,"activeCount":124},[],{"trials":40968,"activeCount":124},[],{"trials":40970,"activeCount":124},[40971],{"nctId":40972,"briefTitle":40973,"status":182,"phases":40974,"primaryCompletion":2768,"completion":2768,"start":5267,"enrollment":1231,"conditions":40975,"interventions":40976},"NCT00918931","Obatoclax for Systemic Mastocytosis",[88],[15,22908],[40963],{"trials":40978,"activeCount":124},[],{"trials":40980,"activeCount":124},[],{"trials":40982,"activeCount":124},[],{"intervention":2841,"totalTrials":166,"cells":40984},{"EARLY_PHASE1":40985,"PHASE1":40987,"PHASE2":40989,"PHASE3":40995,"PHASE4":40997,"NA":40999},{"trials":40986,"activeCount":124},[],{"trials":40988,"activeCount":124},[],{"trials":40990,"activeCount":124},[40991],{"nctId":2833,"briefTitle":2834,"status":130,"phases":40992,"primaryCompletion":2232,"completion":2232,"start":2836,"enrollment":628,"conditions":40993,"interventions":40994},[87,88],[15,2838],[2840,803,1016,1013,62,1114,806,2584,2841,2374],{"trials":40996,"activeCount":124},[],{"trials":40998,"activeCount":124},[],{"trials":41000,"activeCount":124},[],{"intervention":18982,"totalTrials":166,"cells":41002},{"EARLY_PHASE1":41003,"PHASE1":41005,"PHASE2":41007,"PHASE3":41013,"PHASE4":41015,"NA":41017},{"trials":41004,"activeCount":124},[],{"trials":41006,"activeCount":124},[],{"trials":41008,"activeCount":124},[41009],{"nctId":18977,"briefTitle":18978,"status":182,"phases":41010,"primaryCompletion":4162,"completion":4162,"start":4511,"enrollment":186,"conditions":41011,"interventions":41012},[88],[3195,5028],[18982,4022],{"trials":41014,"activeCount":124},[],{"trials":41016,"activeCount":124},[],{"trials":41018,"activeCount":124},[],{"intervention":7350,"totalTrials":166,"cells":41020},{"EARLY_PHASE1":41021,"PHASE1":41023,"PHASE2":41025,"PHASE3":41031,"PHASE4":41033,"NA":41035},{"trials":41022,"activeCount":124},[],{"trials":41024,"activeCount":124},[],{"trials":41026,"activeCount":124},[41027],{"nctId":7343,"briefTitle":7344,"status":203,"phases":41028,"primaryCompletion":1230,"completion":1230,"start":7346,"enrollment":124,"conditions":41029,"interventions":41030},[87,88],[3039,7348,3040,1670,1142,665,3060,1144,528,3062],[7350,803,1070],{"trials":41032,"activeCount":124},[],{"trials":41034,"activeCount":124},[],{"trials":41036,"activeCount":124},[],{"intervention":41038,"totalTrials":166,"cells":41039},"Poziotinib",{"EARLY_PHASE1":41040,"PHASE1":41042,"PHASE2":41044,"PHASE3":41055,"PHASE4":41057,"NA":41059},{"trials":41041,"activeCount":124},[],{"trials":41043,"activeCount":124},[],{"trials":41045,"activeCount":124},[41046],{"nctId":41047,"briefTitle":41048,"status":182,"phases":41049,"primaryCompletion":41050,"completion":41050,"start":41051,"enrollment":5549,"conditions":41052,"interventions":41054},"NCT03066206","Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC",[88],"2026-02-16","2017-03-17",[41053,14005,1836,1977],"EGFR Exon 20 Mutation",[41038],{"trials":41056,"activeCount":124},[],{"trials":41058,"activeCount":124},[],{"trials":41060,"activeCount":124},[],{"intervention":41062,"totalTrials":166,"cells":41063},"SB1518",{"EARLY_PHASE1":41064,"PHASE1":41066,"PHASE2":41068,"PHASE3":41076,"PHASE4":41078,"NA":41080},{"trials":41065,"activeCount":124},[],{"trials":41067,"activeCount":124},[],{"trials":41069,"activeCount":124},[41070],{"nctId":41071,"briefTitle":41072,"status":182,"phases":41073,"primaryCompletion":11040,"completion":11040,"start":7399,"enrollment":186,"conditions":41074,"interventions":41075},"NCT01436084","SB1518 for Patients With Myelodysplastic Syndrome (MDS)",[88],[15],[41062],{"trials":41077,"activeCount":124},[],{"trials":41079,"activeCount":124},[],{"trials":41081,"activeCount":124},[],{"intervention":8179,"totalTrials":166,"cells":41083},{"EARLY_PHASE1":41084,"PHASE1":41086,"PHASE2":41088,"PHASE3":41094,"PHASE4":41096,"NA":41098},{"trials":41085,"activeCount":124},[],{"trials":41087,"activeCount":124},[],{"trials":41089,"activeCount":124},[41090],{"nctId":8162,"briefTitle":8163,"status":203,"phases":41091,"primaryCompletion":8165,"completion":8166,"start":8167,"enrollment":124,"conditions":41092,"interventions":41093},[88],[8169,8170,8171,8172,8173,8174,8175,8176,8177,8115],[8179,53],{"trials":41095,"activeCount":124},[],{"trials":41097,"activeCount":124},[],{"trials":41099,"activeCount":124},[],{"intervention":41101,"totalTrials":166,"cells":41102},"NOV-002",{"EARLY_PHASE1":41103,"PHASE1":41105,"PHASE2":41107,"PHASE3":41115,"PHASE4":41117,"NA":41119},{"trials":41104,"activeCount":124},[],{"trials":41106,"activeCount":124},[],{"trials":41108,"activeCount":124},[41109],{"nctId":41110,"briefTitle":41111,"status":203,"phases":41112,"enrollment":124,"conditions":41113,"interventions":41114},"NCT00960726","NOV-002 in Myelodysplastic Syndrome (MDS)",[88],[15,30],[41101],{"trials":41116,"activeCount":124},[],{"trials":41118,"activeCount":124},[],{"trials":41120,"activeCount":124},[],{"intervention":5700,"totalTrials":166,"cells":41122},{"EARLY_PHASE1":41123,"PHASE1":41125,"PHASE2":41127,"PHASE3":41133,"PHASE4":41135,"NA":41137},{"trials":41124,"activeCount":124},[],{"trials":41126,"activeCount":124},[],{"trials":41128,"activeCount":124},[41129],{"nctId":5694,"briefTitle":5695,"status":203,"phases":41130,"primaryCompletion":5697,"completion":5697,"start":5697,"enrollment":124,"conditions":41131,"interventions":41132},[87,88],[3039,891,4559,5632,3277,4561,5634],[4365,654,2424,1069,2293,894,5700],{"trials":41134,"activeCount":124},[],{"trials":41136,"activeCount":124},[],{"trials":41138,"activeCount":124},[],{"intervention":41140,"totalTrials":166,"cells":41141},"DTI-015",{"EARLY_PHASE1":41142,"PHASE1":41144,"PHASE2":41146,"PHASE3":41154,"PHASE4":41156,"NA":41158},{"trials":41143,"activeCount":124},[],{"trials":41145,"activeCount":124},[],{"trials":41147,"activeCount":124},[41148],{"nctId":41149,"briefTitle":41150,"status":130,"phases":41151,"primaryCompletion":4665,"completion":10075,"start":6791,"enrollment":2865,"conditions":41152,"interventions":41153},"NCT00038441","Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas",[87,88],[28813,11161],[41140],{"trials":41155,"activeCount":124},[],{"trials":41157,"activeCount":124},[],{"trials":41159,"activeCount":124},[],{"intervention":41161,"totalTrials":166,"cells":41162},"Ethyl Icosapentate",{"EARLY_PHASE1":41163,"PHASE1":41165,"PHASE2":41167,"PHASE3":41176,"PHASE4":41178,"NA":41180},{"trials":41164,"activeCount":124},[],{"trials":41166,"activeCount":124},[],{"trials":41168,"activeCount":124},[41169],{"nctId":41170,"briefTitle":41171,"status":182,"phases":41172,"primaryCompletion":4448,"completion":4448,"start":41173,"enrollment":121,"conditions":41174,"interventions":41175},"NCT02940223","Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer",[88],"2017-03-16",[2922,2923],[41161],{"trials":41177,"activeCount":124},[],{"trials":41179,"activeCount":124},[],{"trials":41181,"activeCount":124},[],{"intervention":41183,"totalTrials":166,"cells":41184},"Trivalent Baculovirus-expressed Influenza HA vaccine",{"EARLY_PHASE1":41185,"PHASE1":41187,"PHASE2":41189,"PHASE3":41197,"PHASE4":41199,"NA":41201},{"trials":41186,"activeCount":124},[],{"trials":41188,"activeCount":124},[],{"trials":41190,"activeCount":124},[41191],{"nctId":41192,"briefTitle":41193,"status":130,"phases":41194,"primaryCompletion":5435,"completion":5435,"start":3819,"enrollment":3521,"conditions":41195,"interventions":41196},"NCT00307710","Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma",[88],[21],[41183],{"trials":41198,"activeCount":124},[],{"trials":41200,"activeCount":124},[],{"trials":41202,"activeCount":124},[],{"intervention":41204,"totalTrials":166,"cells":41205},"PEG-IFNá-2a",{"EARLY_PHASE1":41206,"PHASE1":41208,"PHASE2":41210,"PHASE3":41218,"PHASE4":41220,"NA":41222},{"trials":41207,"activeCount":124},[],{"trials":41209,"activeCount":124},[],{"trials":41211,"activeCount":124},[41212],{"nctId":41213,"briefTitle":41214,"status":182,"phases":41215,"primaryCompletion":6065,"completion":6065,"start":3668,"enrollment":121,"conditions":41216,"interventions":41217},"NCT01392170","Pegasys in Patients With Chronic Myeloid Leukemia (CML)",[88],[15],[41204],{"trials":41219,"activeCount":124},[],{"trials":41221,"activeCount":124},[],{"trials":41223,"activeCount":124},[],{"intervention":5165,"totalTrials":166,"cells":41225},{"EARLY_PHASE1":41226,"PHASE1":41228,"PHASE2":41230,"PHASE3":41236,"PHASE4":41238,"NA":41240},{"trials":41227,"activeCount":124},[],{"trials":41229,"activeCount":124},[],{"trials":41231,"activeCount":124},[41232],{"nctId":5158,"briefTitle":5159,"status":130,"phases":41233,"primaryCompletion":5161,"completion":5161,"start":4595,"enrollment":5162,"conditions":41234,"interventions":41235},[88],[5122,5146,5107,5109,5111],[3699,3700,5165,809],{"trials":41237,"activeCount":124},[],{"trials":41239,"activeCount":124},[],{"trials":41241,"activeCount":124},[],{"intervention":41243,"totalTrials":166,"cells":41244},"Afimoxifene",{"EARLY_PHASE1":41245,"PHASE1":41247,"PHASE2":41249,"PHASE3":41261,"PHASE4":41263,"NA":41265},{"trials":41246,"activeCount":124},[],{"trials":41248,"activeCount":124},[],{"trials":41250,"activeCount":124},[41251],{"nctId":41252,"briefTitle":41253,"status":130,"phases":41254,"primaryCompletion":41255,"completion":41255,"start":41256,"enrollment":41257,"conditions":41258,"interventions":41260},"NCT03063619","Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast",[88],"2021-10-26","2018-01-30",194,[41259],"Mammographically Dense Breast",[41243],{"trials":41262,"activeCount":124},[],{"trials":41264,"activeCount":124},[],{"trials":41266,"activeCount":124},[],{"intervention":41268,"totalTrials":166,"cells":41269},"SB939",{"EARLY_PHASE1":41270,"PHASE1":41272,"PHASE2":41274,"PHASE3":41282,"PHASE4":41284,"NA":41286},{"trials":41271,"activeCount":124},[],{"trials":41273,"activeCount":124},[],{"trials":41275,"activeCount":124},[41276],{"nctId":41277,"briefTitle":41278,"status":130,"phases":41279,"primaryCompletion":3725,"completion":3725,"start":4382,"enrollment":3820,"conditions":41280,"interventions":41281},"NCT01200498","Study of SB939 in Subjects With Myelofibrosis",[88],[40764],[41268],{"trials":41283,"activeCount":124},[],{"trials":41285,"activeCount":124},[],{"trials":41287,"activeCount":124},[],{"intervention":41289,"totalTrials":166,"cells":41290},"Fluticasone Propionate",{"EARLY_PHASE1":41291,"PHASE1":41293,"PHASE2":41295,"PHASE3":41304,"PHASE4":41306,"NA":41308},{"trials":41292,"activeCount":124},[],{"trials":41294,"activeCount":124},[],{"trials":41296,"activeCount":124},[41297],{"nctId":41298,"briefTitle":41299,"status":182,"phases":41300,"primaryCompletion":4085,"completion":4085,"start":6828,"enrollment":166,"conditions":41301,"interventions":41303},"NCT00656916","Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status",[88],[41302],"Bronchiolitis",[41289],{"trials":41305,"activeCount":124},[],{"trials":41307,"activeCount":124},[],{"trials":41309,"activeCount":124},[],{"intervention":20210,"totalTrials":166,"cells":41311},{"EARLY_PHASE1":41312,"PHASE1":41314,"PHASE2":41316,"PHASE3":41322,"PHASE4":41324,"NA":41326},{"trials":41313,"activeCount":124},[],{"trials":41315,"activeCount":124},[],{"trials":41317,"activeCount":124},[41318],{"nctId":20205,"briefTitle":20206,"status":130,"phases":41319,"primaryCompletion":4183,"completion":4183,"start":8415,"enrollment":473,"conditions":41320,"interventions":41321},[87,88],[1400,2755],[16012,2293,20210],{"trials":41323,"activeCount":124},[],{"trials":41325,"activeCount":124},[],{"trials":41327,"activeCount":124},[],{"intervention":41329,"totalTrials":166,"cells":41330},"Low Dose Thymoglobulin",{"EARLY_PHASE1":41331,"PHASE1":41333,"PHASE2":41335,"PHASE3":41345,"PHASE4":41347,"NA":41349},{"trials":41332,"activeCount":124},[],{"trials":41334,"activeCount":124},[],{"trials":41336,"activeCount":124},[41337],{"nctId":41338,"briefTitle":41339,"status":182,"phases":41340,"primaryCompletion":6409,"completion":6409,"start":2969,"enrollment":166,"conditions":41341,"interventions":41343},"NCT00409695","Thymoglobulin (ATG) Dose Finding Study",[87,88],[41342],"Graft vs Host Disease",[41329,41344],"High Dose Thymoglobulin",{"trials":41346,"activeCount":124},[],{"trials":41348,"activeCount":124},[],{"trials":41350,"activeCount":124},[],{"intervention":41344,"totalTrials":166,"cells":41352},{"EARLY_PHASE1":41353,"PHASE1":41355,"PHASE2":41357,"PHASE3":41363,"PHASE4":41365,"NA":41367},{"trials":41354,"activeCount":124},[],{"trials":41356,"activeCount":124},[],{"trials":41358,"activeCount":124},[41359],{"nctId":41338,"briefTitle":41339,"status":182,"phases":41360,"primaryCompletion":6409,"completion":6409,"start":2969,"enrollment":166,"conditions":41361,"interventions":41362},[87,88],[41342],[41329,41344],{"trials":41364,"activeCount":124},[],{"trials":41366,"activeCount":124},[],{"trials":41368,"activeCount":124},[],{"intervention":1216,"totalTrials":166,"cells":41370},{"EARLY_PHASE1":41371,"PHASE1":41373,"PHASE2":41375,"PHASE3":41381,"PHASE4":41383,"NA":41385},{"trials":41372,"activeCount":124},[],{"trials":41374,"activeCount":124},[],{"trials":41376,"activeCount":124},[41377],{"nctId":1208,"briefTitle":1209,"status":182,"phases":41378,"primaryCompletion":1211,"completion":1211,"start":1212,"enrollment":121,"conditions":41379,"interventions":41380},[88],[1214,15],[1216,480],{"trials":41382,"activeCount":124},[],{"trials":41384,"activeCount":124},[],{"trials":41386,"activeCount":124},[],{"intervention":7369,"totalTrials":166,"cells":41388},{"EARLY_PHASE1":41389,"PHASE1":41391,"PHASE2":41393,"PHASE3":41399,"PHASE4":41401,"NA":41403},{"trials":41390,"activeCount":124},[],{"trials":41392,"activeCount":124},[],{"trials":41394,"activeCount":124},[41395],{"nctId":7360,"briefTitle":7361,"status":130,"phases":41396,"primaryCompletion":7363,"completion":7363,"start":7364,"enrollment":3197,"conditions":41397,"interventions":41398},[87,88],[7366,6448,7367,1460],[1599,7369,803,7370],{"trials":41400,"activeCount":124},[],{"trials":41402,"activeCount":124},[],{"trials":41404,"activeCount":124},[],{"intervention":3772,"totalTrials":166,"cells":41406},{"EARLY_PHASE1":41407,"PHASE1":41409,"PHASE2":41411,"PHASE3":41417,"PHASE4":41419,"NA":41421},{"trials":41408,"activeCount":124},[],{"trials":41410,"activeCount":124},[],{"trials":41412,"activeCount":124},[41413],{"nctId":3766,"briefTitle":3767,"status":130,"phases":41414,"primaryCompletion":3017,"completion":3017,"start":3769,"enrollment":871,"conditions":41415,"interventions":41416},[88],[1729],[3772,1049],{"trials":41418,"activeCount":124},[],{"trials":41420,"activeCount":124},[],{"trials":41422,"activeCount":124},[],{"intervention":41424,"totalTrials":166,"cells":41425},"As Needed Rasburicase",{"EARLY_PHASE1":41426,"PHASE1":41428,"PHASE2":41430,"PHASE3":41439,"PHASE4":41441,"NA":41443},{"trials":41427,"activeCount":124},[],{"trials":41429,"activeCount":124},[],{"trials":41431,"activeCount":124},[41432],{"nctId":41433,"briefTitle":41434,"status":130,"phases":41435,"primaryCompletion":2778,"completion":2778,"start":10760,"enrollment":28,"conditions":41436,"interventions":41437},"NCT00628628","Rasburicase in Patients at Risk for Tumor Lysis Syndrome",[88],[30376],[41424,41438],"Fixed Dose Rasburicase",{"trials":41440,"activeCount":124},[],{"trials":41442,"activeCount":124},[],{"trials":41444,"activeCount":124},[],{"intervention":41438,"totalTrials":166,"cells":41446},{"EARLY_PHASE1":41447,"PHASE1":41449,"PHASE2":41451,"PHASE3":41457,"PHASE4":41459,"NA":41461},{"trials":41448,"activeCount":124},[],{"trials":41450,"activeCount":124},[],{"trials":41452,"activeCount":124},[41453],{"nctId":41433,"briefTitle":41434,"status":130,"phases":41454,"primaryCompletion":2778,"completion":2778,"start":10760,"enrollment":28,"conditions":41455,"interventions":41456},[88],[30376],[41424,41438],{"trials":41458,"activeCount":124},[],{"trials":41460,"activeCount":124},[],{"trials":41462,"activeCount":124},[],{"intervention":41464,"totalTrials":166,"cells":41465},"Technetium Tc-99m Sulfur Colloid",{"EARLY_PHASE1":41466,"PHASE1":41468,"PHASE2":41470,"PHASE3":41481,"PHASE4":41483,"NA":41485},{"trials":41467,"activeCount":124},[],{"trials":41469,"activeCount":124},[],{"trials":41471,"activeCount":124},[41472],{"nctId":41473,"briefTitle":41474,"status":130,"phases":41475,"primaryCompletion":41476,"completion":41476,"start":41477,"enrollment":1131,"conditions":41478,"interventions":41480},"NCT00832429","Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid",[88],"2024-08-27","2009-02-25",[41479],"Eyelid Sebaceous Gland Carcinoma",[41464],{"trials":41482,"activeCount":124},[],{"trials":41484,"activeCount":124},[],{"trials":41486,"activeCount":124},[],{"intervention":2894,"totalTrials":166,"cells":41488},{"EARLY_PHASE1":41489,"PHASE1":41491,"PHASE2":41493,"PHASE3":41499,"PHASE4":41501,"NA":41503},{"trials":41490,"activeCount":124},[],{"trials":41492,"activeCount":124},[],{"trials":41494,"activeCount":124},[41495],{"nctId":2886,"briefTitle":2887,"status":130,"phases":41496,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":41497,"interventions":41498},[88],[15,1122],[894,803,1013,1016,62,806,654,2374,1114,2894,1071,2895],{"trials":41500,"activeCount":124},[],{"trials":41502,"activeCount":124},[],{"trials":41504,"activeCount":124},[],{"intervention":2895,"totalTrials":166,"cells":41506},{"EARLY_PHASE1":41507,"PHASE1":41509,"PHASE2":41511,"PHASE3":41517,"PHASE4":41519,"NA":41521},{"trials":41508,"activeCount":124},[],{"trials":41510,"activeCount":124},[],{"trials":41512,"activeCount":124},[41513],{"nctId":2886,"briefTitle":2887,"status":130,"phases":41514,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":41515,"interventions":41516},[88],[15,1122],[894,803,1013,1016,62,806,654,2374,1114,2894,1071,2895],{"trials":41518,"activeCount":124},[],{"trials":41520,"activeCount":124},[],{"trials":41522,"activeCount":124},[],{"intervention":33003,"totalTrials":166,"cells":41524},{"EARLY_PHASE1":41525,"PHASE1":41527,"PHASE2":41529,"PHASE3":41535,"PHASE4":41537,"NA":41539},{"trials":41526,"activeCount":124},[],{"trials":41528,"activeCount":124},[],{"trials":41530,"activeCount":124},[41531],{"nctId":32998,"briefTitle":32999,"status":182,"phases":41532,"primaryCompletion":8730,"completion":8730,"start":2969,"enrollment":3197,"conditions":41533,"interventions":41534},[88],[15],[33003,33004,2681,4629],{"trials":41536,"activeCount":124},[],{"trials":41538,"activeCount":124},[],{"trials":41540,"activeCount":124},[],{"intervention":33004,"totalTrials":166,"cells":41542},{"EARLY_PHASE1":41543,"PHASE1":41545,"PHASE2":41547,"PHASE3":41553,"PHASE4":41555,"NA":41557},{"trials":41544,"activeCount":124},[],{"trials":41546,"activeCount":124},[],{"trials":41548,"activeCount":124},[41549],{"nctId":32998,"briefTitle":32999,"status":182,"phases":41550,"primaryCompletion":8730,"completion":8730,"start":2969,"enrollment":3197,"conditions":41551,"interventions":41552},[88],[15],[33003,33004,2681,4629],{"trials":41554,"activeCount":124},[],{"trials":41556,"activeCount":124},[],{"trials":41558,"activeCount":124},[],{"intervention":41560,"totalTrials":166,"cells":41561},"AUY922",{"EARLY_PHASE1":41562,"PHASE1":41564,"PHASE2":41566,"PHASE3":41574,"PHASE4":41576,"NA":41578},{"trials":41563,"activeCount":124},[],{"trials":41565,"activeCount":124},[],{"trials":41567,"activeCount":124},[41568],{"nctId":41569,"briefTitle":41570,"status":182,"phases":41571,"primaryCompletion":13585,"completion":13585,"start":11134,"enrollment":871,"conditions":41572,"interventions":41573},"NCT01485536","A Study of the HSP90 Inhibitor AUY922",[88],[21],[41560],{"trials":41575,"activeCount":124},[],{"trials":41577,"activeCount":124},[],{"trials":41579,"activeCount":124},[],{"intervention":2904,"totalTrials":166,"cells":41581},{"EARLY_PHASE1":41582,"PHASE1":41584,"PHASE2":41586,"PHASE3":41592,"PHASE4":41594,"NA":41596},{"trials":41583,"activeCount":124},[],{"trials":41585,"activeCount":124},[],{"trials":41587,"activeCount":124},[41588],{"nctId":2897,"briefTitle":2898,"status":182,"phases":41589,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":186,"conditions":41590,"interventions":41591},[87,88],[21],[1402,2405,2369,1004,2293,894,62,2370,2371,2372,2904,2368],{"trials":41593,"activeCount":124},[],{"trials":41595,"activeCount":124},[],{"trials":41597,"activeCount":124},[],{"intervention":7403,"totalTrials":166,"cells":41599},{"EARLY_PHASE1":41600,"PHASE1":41602,"PHASE2":41604,"PHASE3":41610,"PHASE4":41612,"NA":41614},{"trials":41601,"activeCount":124},[],{"trials":41603,"activeCount":124},[],{"trials":41605,"activeCount":124},[41606],{"nctId":7396,"briefTitle":7397,"status":130,"phases":41607,"primaryCompletion":7399,"completion":7399,"start":7400,"enrollment":3082,"conditions":41608,"interventions":41609},[87,88],[21,15],[7403,894,1070,803],{"trials":41611,"activeCount":124},[],{"trials":41613,"activeCount":124},[],{"trials":41615,"activeCount":124},[],{"intervention":41617,"totalTrials":166,"cells":41618},"IPI-145",{"EARLY_PHASE1":41619,"PHASE1":41621,"PHASE2":41623,"PHASE3":41631,"PHASE4":41633,"NA":41635},{"trials":41620,"activeCount":124},[],{"trials":41622,"activeCount":124},[],{"trials":41624,"activeCount":124},[41625],{"nctId":41626,"briefTitle":41627,"status":203,"phases":41628,"primaryCompletion":2122,"start":2243,"enrollment":124,"conditions":41629,"interventions":41630},"NCT02028039","IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)",[88],[15],[41617],{"trials":41632,"activeCount":124},[],{"trials":41634,"activeCount":124},[],{"trials":41636,"activeCount":124},[],{"intervention":41638,"totalTrials":166,"cells":41639},"Talimogene Laherparepvec",{"EARLY_PHASE1":41640,"PHASE1":41642,"PHASE2":41644,"PHASE3":41655,"PHASE4":41657,"NA":41659},{"trials":41641,"activeCount":124},[],{"trials":41643,"activeCount":124},[],{"trials":41645,"activeCount":124},[41646],{"nctId":41647,"briefTitle":41648,"status":182,"phases":41649,"primaryCompletion":41650,"completion":41650,"start":41651,"enrollment":95,"conditions":41652,"interventions":41654},"NCT02658812","Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery",[88],"2021-12-01","2016-08-01",[41653,10825,7702,7298,7703],"Malignant Chest Wall Neoplasm",[41638],{"trials":41656,"activeCount":124},[],{"trials":41658,"activeCount":124},[],{"trials":41660,"activeCount":124},[],{"intervention":8930,"totalTrials":166,"cells":41662},{"EARLY_PHASE1":41663,"PHASE1":41665,"PHASE2":41667,"PHASE3":41673,"PHASE4":41675,"NA":41677},{"trials":41664,"activeCount":124},[],{"trials":41666,"activeCount":124},[],{"trials":41668,"activeCount":124},[41669],{"nctId":8925,"briefTitle":8926,"status":130,"phases":41670,"primaryCompletion":8339,"completion":4818,"start":6352,"enrollment":2004,"conditions":41671,"interventions":41672},[88],[21],[8930,894],{"trials":41674,"activeCount":124},[],{"trials":41676,"activeCount":124},[],{"trials":41678,"activeCount":124},[],{"intervention":11499,"totalTrials":166,"cells":41680},{"EARLY_PHASE1":41681,"PHASE1":41683,"PHASE2":41685,"PHASE3":41691,"PHASE4":41693,"NA":41695},{"trials":41682,"activeCount":124},[],{"trials":41684,"activeCount":124},[],{"trials":41686,"activeCount":124},[41687],{"nctId":11494,"briefTitle":11495,"status":203,"phases":41688,"enrollment":124,"conditions":41689,"interventions":41690},[88],[27],[11499,809],{"trials":41692,"activeCount":124},[],{"trials":41694,"activeCount":124},[],{"trials":41696,"activeCount":124},[],{"intervention":20233,"totalTrials":166,"cells":41698},{"EARLY_PHASE1":41699,"PHASE1":41701,"PHASE2":41703,"PHASE3":41709,"PHASE4":41711,"NA":41713},{"trials":41700,"activeCount":124},[],{"trials":41702,"activeCount":124},[],{"trials":41704,"activeCount":124},[41705],{"nctId":20228,"briefTitle":20229,"status":130,"phases":41706,"primaryCompletion":4786,"completion":4786,"start":6352,"enrollment":1034,"conditions":41707,"interventions":41708},[87,88],[2245],[20233,12277,2293,20234],{"trials":41710,"activeCount":124},[],{"trials":41712,"activeCount":124},[],{"trials":41714,"activeCount":124},[],{"intervention":20234,"totalTrials":166,"cells":41716},{"EARLY_PHASE1":41717,"PHASE1":41719,"PHASE2":41721,"PHASE3":41727,"PHASE4":41729,"NA":41731},{"trials":41718,"activeCount":124},[],{"trials":41720,"activeCount":124},[],{"trials":41722,"activeCount":124},[41723],{"nctId":20228,"briefTitle":20229,"status":130,"phases":41724,"primaryCompletion":4786,"completion":4786,"start":6352,"enrollment":1034,"conditions":41725,"interventions":41726},[87,88],[2245],[20233,12277,2293,20234],{"trials":41728,"activeCount":124},[],{"trials":41730,"activeCount":124},[],{"trials":41732,"activeCount":124},[],{"intervention":41734,"totalTrials":166,"cells":41735},"Isavuconazole",{"EARLY_PHASE1":41736,"PHASE1":41738,"PHASE2":41740,"PHASE3":41751,"PHASE4":41753,"NA":41755},{"trials":41737,"activeCount":124},[],{"trials":41739,"activeCount":124},[],{"trials":41741,"activeCount":124},[41742],{"nctId":41743,"briefTitle":41744,"status":130,"phases":41745,"primaryCompletion":41746,"completion":41746,"start":41747,"enrollment":3541,"conditions":41748,"interventions":41750},"NCT03019939","Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia",[88],"2020-08-10","2017-03-28",[36,30,41749],"Neutropenia",[41734],{"trials":41752,"activeCount":124},[],{"trials":41754,"activeCount":124},[],{"trials":41756,"activeCount":124},[],{"intervention":7414,"totalTrials":166,"cells":41758},{"EARLY_PHASE1":41759,"PHASE1":41761,"PHASE2":41763,"PHASE3":41769,"PHASE4":41771,"NA":41773},{"trials":41760,"activeCount":124},[],{"trials":41762,"activeCount":124},[],{"trials":41764,"activeCount":124},[41765],{"nctId":7405,"briefTitle":7406,"status":130,"phases":41766,"primaryCompletion":7408,"completion":7408,"start":7409,"enrollment":2446,"conditions":41767,"interventions":41768},[87,88],[7411,2838,712,7412],[1070,803,1114,7414,7415],{"trials":41770,"activeCount":124},[],{"trials":41772,"activeCount":124},[],{"trials":41774,"activeCount":124},[],{"intervention":3823,"totalTrials":1231,"cells":41776},{"EARLY_PHASE1":41777,"PHASE1":41779,"PHASE2":41795,"PHASE3":41797,"PHASE4":41799,"NA":41801},{"trials":41778,"activeCount":124},[],{"trials":41780,"activeCount":124},[41781,41785,41789],{"nctId":3815,"briefTitle":3816,"status":130,"phases":41782,"primaryCompletion":3818,"completion":3818,"start":3819,"enrollment":3820,"conditions":41783,"interventions":41784},[87],[1316],[1709,1710,3823],{"nctId":33625,"briefTitle":33626,"status":182,"phases":41786,"primaryCompletion":10046,"completion":10046,"start":33628,"enrollment":871,"conditions":41787,"interventions":41788},[87],[1729],[2351,3823],{"nctId":41790,"briefTitle":41791,"status":182,"phases":41792,"primaryCompletion":4731,"completion":4731,"start":3819,"enrollment":550,"conditions":41793,"interventions":41794},"NCT00508456","Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM",[87],[17604],[3823],{"trials":41796,"activeCount":124},[],{"trials":41798,"activeCount":124},[],{"trials":41800,"activeCount":124},[],{"trials":41802,"activeCount":124},[],{"intervention":21067,"totalTrials":121,"cells":41804},{"EARLY_PHASE1":41805,"PHASE1":41807,"PHASE2":41822,"PHASE3":41824,"PHASE4":41826,"NA":41828},{"trials":41806,"activeCount":124},[],{"trials":41808,"activeCount":124},[41809,41818],{"nctId":41810,"briefTitle":41811,"status":130,"phases":41812,"primaryCompletion":41813,"completion":41813,"start":41814,"enrollment":1922,"conditions":41815,"interventions":41816},"NCT00629200","Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies",[87],"2010-02-10","2006-09-13",[1942,1924],[41817,21067],"Sodium Stibogluconate",{"nctId":21061,"briefTitle":21062,"status":130,"phases":41819,"primaryCompletion":21064,"completion":21064,"start":12734,"enrollment":230,"conditions":41820,"interventions":41821},[87],[1729],[9970,5447,21067],{"trials":41823,"activeCount":124},[],{"trials":41825,"activeCount":124},[],{"trials":41827,"activeCount":124},[],{"trials":41829,"activeCount":124},[],{"intervention":41831,"totalTrials":121,"cells":41832},"Oxidative Phosphorylation Inhibitor IACS-010759",{"EARLY_PHASE1":41833,"PHASE1":41835,"PHASE2":41853,"PHASE3":41855,"PHASE4":41857,"NA":41859},{"trials":41834,"activeCount":124},[],{"trials":41836,"activeCount":124},[41837,41844],{"nctId":41838,"briefTitle":41839,"status":182,"phases":41840,"primaryCompletion":41841,"completion":41841,"start":15509,"enrollment":539,"conditions":41842,"interventions":41843},"NCT02882321","Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[87],"2022-04-15",[608,610],[41831],{"nctId":41845,"briefTitle":41846,"status":130,"phases":41847,"primaryCompletion":9899,"completion":9899,"start":41848,"enrollment":1409,"conditions":41849,"interventions":41852},"NCT03291938","IACS-010759 in Advanced Cancers",[87],"2017-11-13",[1343,7308,7309,7310,7311,7312,7698,7699,361,8173,7701,7313,7314,7315,7316,7317,41850,41851,8174,8175,8176,8177,8115,1363,1951],"Recurrent Lymphoma","Refractory Lymphoma",[41831],{"trials":41854,"activeCount":124},[],{"trials":41856,"activeCount":124},[],{"trials":41858,"activeCount":124},[],{"trials":41860,"activeCount":124},[],{"intervention":5447,"totalTrials":121,"cells":41862},{"EARLY_PHASE1":41863,"PHASE1":41865,"PHASE2":41875,"PHASE3":41877,"PHASE4":41879,"NA":41881},{"trials":41864,"activeCount":124},[],{"trials":41866,"activeCount":124},[41867,41871],{"nctId":5439,"briefTitle":5440,"status":130,"phases":41868,"primaryCompletion":5442,"completion":5442,"start":5443,"enrollment":1240,"conditions":41869,"interventions":41870},[87],[21,5445],[5447,4365,2424,654,2293],{"nctId":21061,"briefTitle":21062,"status":130,"phases":41872,"primaryCompletion":21064,"completion":21064,"start":12734,"enrollment":230,"conditions":41873,"interventions":41874},[87],[1729],[9970,5447,21067],{"trials":41876,"activeCount":124},[],{"trials":41878,"activeCount":124},[],{"trials":41880,"activeCount":124},[],{"trials":41882,"activeCount":124},[],{"intervention":3905,"totalTrials":121,"cells":41884},{"EARLY_PHASE1":41885,"PHASE1":41887,"PHASE2":41900,"PHASE3":41902,"PHASE4":41904,"NA":41906},{"trials":41886,"activeCount":124},[],{"trials":41888,"activeCount":124},[41889,41896],{"nctId":41890,"briefTitle":41891,"status":203,"phases":41892,"primaryCompletion":2242,"start":4542,"enrollment":124,"conditions":41893,"interventions":41894},"NCT01333423","Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)",[87],[18],[3905,41895],"Seliciclib",{"nctId":3898,"briefTitle":3899,"status":130,"phases":41897,"primaryCompletion":3901,"completion":3901,"start":3902,"enrollment":240,"conditions":41898,"interventions":41899},[87],[1942],[1709,3905],{"trials":41901,"activeCount":124},[],{"trials":41903,"activeCount":124},[],{"trials":41905,"activeCount":124},[],{"trials":41907,"activeCount":124},[],{"intervention":10859,"totalTrials":121,"cells":41909},{"EARLY_PHASE1":41910,"PHASE1":41912,"PHASE2":41925,"PHASE3":41927,"PHASE4":41929,"NA":41931},{"trials":41911,"activeCount":124},[],{"trials":41913,"activeCount":124},[41914,41918],{"nctId":10854,"briefTitle":10855,"status":130,"phases":41915,"primaryCompletion":2777,"completion":2777,"start":8340,"enrollment":959,"conditions":41916,"interventions":41917},[87],[33],[10859,2369,1275,1069],{"nctId":41919,"briefTitle":41920,"status":130,"phases":41921,"primaryCompletion":8305,"completion":8305,"start":7236,"enrollment":3354,"conditions":41922,"interventions":41923},"NCT00732836","Hepatic Arterial Infusion (HAI) of Abraxane",[87],[1996,33,1924],[10859,41924],"IV Abraxane",{"trials":41926,"activeCount":124},[],{"trials":41928,"activeCount":124},[],{"trials":41930,"activeCount":124},[],{"trials":41932,"activeCount":124},[],{"intervention":41934,"totalTrials":166,"cells":41935},"Pegylated Interferon-Alfa 2b",{"EARLY_PHASE1":41936,"PHASE1":41938,"PHASE2":41949,"PHASE3":41951,"PHASE4":41953,"NA":41955},{"trials":41937,"activeCount":124},[],{"trials":41939,"activeCount":124},[41940],{"nctId":41941,"briefTitle":41942,"status":130,"phases":41943,"primaryCompletion":41944,"completion":41944,"start":41945,"enrollment":1664,"conditions":41946,"interventions":41947},"NCT00861406","Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine",[87],"2017-02-24","2009-03-10",[1729],[41934,41948],"GP-100 Peptide Vaccine",{"trials":41950,"activeCount":124},[],{"trials":41952,"activeCount":124},[],{"trials":41954,"activeCount":124},[],{"trials":41956,"activeCount":124},[],{"intervention":41948,"totalTrials":166,"cells":41958},{"EARLY_PHASE1":41959,"PHASE1":41961,"PHASE2":41967,"PHASE3":41969,"PHASE4":41971,"NA":41973},{"trials":41960,"activeCount":124},[],{"trials":41962,"activeCount":124},[41963],{"nctId":41941,"briefTitle":41942,"status":130,"phases":41964,"primaryCompletion":41944,"completion":41944,"start":41945,"enrollment":1664,"conditions":41965,"interventions":41966},[87],[1729],[41934,41948],{"trials":41968,"activeCount":124},[],{"trials":41970,"activeCount":124},[],{"trials":41972,"activeCount":124},[],{"trials":41974,"activeCount":124},[],{"intervention":41976,"totalTrials":166,"cells":41977},"CD5789 0.01% Cream",{"EARLY_PHASE1":41978,"PHASE1":41980,"PHASE2":41988,"PHASE3":41990,"PHASE4":41992,"NA":41994},{"trials":41979,"activeCount":124},[],{"trials":41981,"activeCount":124},[41982],{"nctId":41983,"briefTitle":41984,"status":130,"phases":41985,"primaryCompletion":10449,"completion":10449,"start":3494,"enrollment":95,"conditions":41986,"interventions":41987},"NCT01804335","CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL)",[87],[21],[41976],{"trials":41989,"activeCount":124},[],{"trials":41991,"activeCount":124},[],{"trials":41993,"activeCount":124},[],{"trials":41995,"activeCount":124},[],{"intervention":41997,"totalTrials":166,"cells":41998},"DOTAP:Chol-fus1",{"EARLY_PHASE1":41999,"PHASE1":42001,"PHASE2":42009,"PHASE3":42011,"PHASE4":42013,"NA":42015},{"trials":42000,"activeCount":124},[],{"trials":42002,"activeCount":124},[42003],{"nctId":42004,"briefTitle":42005,"status":130,"phases":42006,"primaryCompletion":12066,"completion":12066,"start":4193,"enrollment":507,"conditions":42007,"interventions":42008},"NCT00059605","Phase I Study of IV DOTAP: Cholesterol-Fus1 in Non-Small-Cell Lung Cancer",[87],[24],[41997],{"trials":42010,"activeCount":124},[],{"trials":42012,"activeCount":124},[],{"trials":42014,"activeCount":124},[],{"trials":42016,"activeCount":124},[],{"intervention":12257,"totalTrials":166,"cells":42018},{"EARLY_PHASE1":42019,"PHASE1":42021,"PHASE2":42027,"PHASE3":42029,"PHASE4":42031,"NA":42033},{"trials":42020,"activeCount":124},[],{"trials":42022,"activeCount":124},[42023],{"nctId":12249,"briefTitle":12250,"status":182,"phases":42024,"primaryCompletion":12252,"completion":12252,"start":12253,"enrollment":296,"conditions":42025,"interventions":42026},[87],[12255],[2369,4023,12257],{"trials":42028,"activeCount":124},[],{"trials":42030,"activeCount":124},[],{"trials":42032,"activeCount":124},[],{"trials":42034,"activeCount":124},[],{"intervention":7569,"totalTrials":166,"cells":42036},{"EARLY_PHASE1":42037,"PHASE1":42039,"PHASE2":42045,"PHASE3":42047,"PHASE4":42049,"NA":42051},{"trials":42038,"activeCount":124},[],{"trials":42040,"activeCount":124},[42041],{"nctId":7562,"briefTitle":7563,"status":203,"phases":42042,"primaryCompletion":7565,"completion":7565,"start":7565,"enrollment":124,"conditions":42043,"interventions":42044},[87],[7567,1530,18,24,4107],[7569,1275,53],{"trials":42046,"activeCount":124},[],{"trials":42048,"activeCount":124},[],{"trials":42050,"activeCount":124},[],{"trials":42052,"activeCount":124},[],{"intervention":42054,"totalTrials":166,"cells":42055},"DLI",{"EARLY_PHASE1":42056,"PHASE1":42058,"PHASE2":42067,"PHASE3":42069,"PHASE4":42071,"NA":42073},{"trials":42057,"activeCount":124},[],{"trials":42059,"activeCount":124},[42060],{"nctId":42061,"briefTitle":42062,"status":130,"phases":42063,"primaryCompletion":42064,"completion":42064,"start":7399,"enrollment":20549,"conditions":42065,"interventions":42066},"NCT01497184","Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood",[87],"2021-03-08",[15,21],[42054],{"trials":42068,"activeCount":124},[],{"trials":42070,"activeCount":124},[],{"trials":42072,"activeCount":124},[],{"trials":42074,"activeCount":124},[],{"intervention":41817,"totalTrials":166,"cells":42076},{"EARLY_PHASE1":42077,"PHASE1":42079,"PHASE2":42085,"PHASE3":42087,"PHASE4":42089,"NA":42091},{"trials":42078,"activeCount":124},[],{"trials":42080,"activeCount":124},[42081],{"nctId":41810,"briefTitle":41811,"status":130,"phases":42082,"primaryCompletion":41813,"completion":41813,"start":41814,"enrollment":1922,"conditions":42083,"interventions":42084},[87],[1942,1924],[41817,21067],{"trials":42086,"activeCount":124},[],{"trials":42088,"activeCount":124},[],{"trials":42090,"activeCount":124},[],{"trials":42092,"activeCount":124},[],{"intervention":13987,"totalTrials":166,"cells":42094},{"EARLY_PHASE1":42095,"PHASE1":42097,"PHASE2":42103,"PHASE3":42105,"PHASE4":42107,"NA":42109},{"trials":42096,"activeCount":124},[],{"trials":42098,"activeCount":124},[42099],{"nctId":13980,"briefTitle":13981,"status":130,"phases":42100,"primaryCompletion":13983,"completion":13983,"start":13984,"enrollment":9213,"conditions":42101,"interventions":42102},[87],[2922,2924,2925,2926],[2840,13987],{"trials":42104,"activeCount":124},[],{"trials":42106,"activeCount":124},[],{"trials":42108,"activeCount":124},[],{"trials":42110,"activeCount":124},[],{"intervention":42112,"totalTrials":166,"cells":42113},"18F-PEG6-IPQA",{"EARLY_PHASE1":42114,"PHASE1":42116,"PHASE2":42124,"PHASE3":42126,"PHASE4":42128,"NA":42130},{"trials":42115,"activeCount":124},[],{"trials":42117,"activeCount":124},[42118],{"nctId":42119,"briefTitle":42120,"status":130,"phases":42121,"primaryCompletion":39567,"completion":39567,"start":5232,"enrollment":230,"conditions":42122,"interventions":42123},"NCT01320059","Study of 18F-Fluoro-PEG6-IPQA",[87],[24],[42112],{"trials":42125,"activeCount":124},[],{"trials":42127,"activeCount":124},[],{"trials":42129,"activeCount":124},[],{"trials":42131,"activeCount":124},[],{"intervention":13995,"totalTrials":166,"cells":42133},{"EARLY_PHASE1":42134,"PHASE1":42136,"PHASE2":42142,"PHASE3":42144,"PHASE4":42146,"NA":42148},{"trials":42135,"activeCount":124},[],{"trials":42137,"activeCount":124},[42138],{"nctId":13989,"briefTitle":13990,"status":130,"phases":42139,"primaryCompletion":5773,"completion":5773,"start":13992,"enrollment":448,"conditions":42140,"interventions":42141},[87],[2770],[2840,13995],{"trials":42143,"activeCount":124},[],{"trials":42145,"activeCount":124},[],{"trials":42147,"activeCount":124},[],{"trials":42149,"activeCount":124},[],{"intervention":14190,"totalTrials":166,"cells":42151},{"EARLY_PHASE1":42152,"PHASE1":42154,"PHASE2":42160,"PHASE3":42162,"PHASE4":42164,"NA":42166},{"trials":42153,"activeCount":124},[],{"trials":42155,"activeCount":124},[42156],{"nctId":14183,"briefTitle":14184,"status":182,"phases":42157,"primaryCompletion":14186,"completion":14186,"start":14187,"enrollment":1231,"conditions":42158,"interventions":42159},[87],[1343,361,7891],[14190,12910],{"trials":42161,"activeCount":124},[],{"trials":42163,"activeCount":124},[],{"trials":42165,"activeCount":124},[],{"trials":42167,"activeCount":124},[],{"intervention":6453,"totalTrials":166,"cells":42169},{"EARLY_PHASE1":42170,"PHASE1":42172,"PHASE2":42178,"PHASE3":42180,"PHASE4":42182,"NA":42184},{"trials":42171,"activeCount":124},[],{"trials":42173,"activeCount":124},[42174],{"nctId":6442,"briefTitle":6443,"status":130,"phases":42175,"primaryCompletion":6445,"completion":6445,"start":6446,"enrollment":1568,"conditions":42176,"interventions":42177},[87],[6448,6449,6450,6451],[1599,6453,803,6454],{"trials":42179,"activeCount":124},[],{"trials":42181,"activeCount":124},[],{"trials":42183,"activeCount":124},[],{"trials":42185,"activeCount":124},[],{"intervention":6454,"totalTrials":166,"cells":42187},{"EARLY_PHASE1":42188,"PHASE1":42190,"PHASE2":42196,"PHASE3":42198,"PHASE4":42200,"NA":42202},{"trials":42189,"activeCount":124},[],{"trials":42191,"activeCount":124},[42192],{"nctId":6442,"briefTitle":6443,"status":130,"phases":42193,"primaryCompletion":6445,"completion":6445,"start":6446,"enrollment":1568,"conditions":42194,"interventions":42195},[87],[6448,6449,6450,6451],[1599,6453,803,6454],{"trials":42197,"activeCount":124},[],{"trials":42199,"activeCount":124},[],{"trials":42201,"activeCount":124},[],{"trials":42203,"activeCount":124},[],{"intervention":3045,"totalTrials":166,"cells":42205},{"EARLY_PHASE1":42206,"PHASE1":42208,"PHASE2":42214,"PHASE3":42216,"PHASE4":42218,"NA":42220},{"trials":42207,"activeCount":124},[],{"trials":42209,"activeCount":124},[42210],{"nctId":3032,"briefTitle":3033,"status":130,"phases":42211,"primaryCompletion":3035,"completion":3035,"start":3036,"enrollment":134,"conditions":42212,"interventions":42213},[87],[643,1122,3038,3039,3040,3041,716,3042,3043],[803,1005,3045],{"trials":42215,"activeCount":124},[],{"trials":42217,"activeCount":124},[],{"trials":42219,"activeCount":124},[],{"trials":42221,"activeCount":124},[],{"intervention":42223,"totalTrials":166,"cells":42224},"FTS",{"EARLY_PHASE1":42225,"PHASE1":42227,"PHASE2":42235,"PHASE3":42237,"PHASE4":42239,"NA":42241},{"trials":42226,"activeCount":124},[],{"trials":42228,"activeCount":124},[42229],{"nctId":42230,"briefTitle":42231,"status":130,"phases":42232,"primaryCompletion":16514,"completion":16514,"start":4039,"enrollment":550,"conditions":42233,"interventions":42234},"NCT00867230","FTS Study in Patients With Advanced Hematologic Malignancies",[87],[30,15],[42223],{"trials":42236,"activeCount":124},[],{"trials":42238,"activeCount":124},[],{"trials":42240,"activeCount":124},[],{"trials":42242,"activeCount":124},[],{"intervention":30824,"totalTrials":166,"cells":42244},{"EARLY_PHASE1":42245,"PHASE1":42247,"PHASE2":42253,"PHASE3":42255,"PHASE4":42257,"NA":42259},{"trials":42246,"activeCount":124},[],{"trials":42248,"activeCount":124},[42249],{"nctId":30819,"briefTitle":30820,"status":130,"phases":42250,"primaryCompletion":4835,"completion":4835,"start":8753,"enrollment":2647,"conditions":42251,"interventions":42252},[87],[33,1924],[3847,30824],{"trials":42254,"activeCount":124},[],{"trials":42256,"activeCount":124},[],{"trials":42258,"activeCount":124},[],{"trials":42260,"activeCount":124},[],{"intervention":33776,"totalTrials":166,"cells":42262},{"EARLY_PHASE1":42263,"PHASE1":42265,"PHASE2":42271,"PHASE3":42273,"PHASE4":42275,"NA":42277},{"trials":42264,"activeCount":124},[],{"trials":42266,"activeCount":124},[42267],{"nctId":33771,"briefTitle":33772,"status":203,"phases":42268,"primaryCompletion":18529,"start":18530,"enrollment":124,"conditions":42269,"interventions":42270},[87],[7647,5799,7651,7652],[8156,33776],{"trials":42272,"activeCount":124},[],{"trials":42274,"activeCount":124},[],{"trials":42276,"activeCount":124},[],{"trials":42278,"activeCount":124},[],{"intervention":42280,"totalTrials":166,"cells":42281},"OPB-31121",{"EARLY_PHASE1":42282,"PHASE1":42284,"PHASE2":42292,"PHASE3":42294,"PHASE4":42296,"NA":42298},{"trials":42283,"activeCount":124},[],{"trials":42285,"activeCount":124},[42286],{"nctId":42287,"briefTitle":42288,"status":130,"phases":42289,"primaryCompletion":3725,"completion":3725,"start":5267,"enrollment":628,"conditions":42290,"interventions":42291},"NCT00955812","STAT3 Inhibitor for Solid Tumors",[87],[1942,3305],[42280],{"trials":42293,"activeCount":124},[],{"trials":42295,"activeCount":124},[],{"trials":42297,"activeCount":124},[],{"trials":42299,"activeCount":124},[],{"intervention":42301,"totalTrials":166,"cells":42302},"SCH 66336",{"EARLY_PHASE1":42303,"PHASE1":42305,"PHASE2":42314,"PHASE3":42316,"PHASE4":42318,"NA":42320},{"trials":42304,"activeCount":124},[],{"trials":42306,"activeCount":124},[42307],{"nctId":42308,"briefTitle":42309,"status":203,"phases":42310,"primaryCompletion":13863,"completion":13863,"start":42311,"enrollment":124,"conditions":42312,"interventions":42313},"NCT00005030","SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver",[87],"1999-09-29",[3195,7818],[42301],{"trials":42315,"activeCount":124},[],{"trials":42317,"activeCount":124},[],{"trials":42319,"activeCount":124},[],{"trials":42321,"activeCount":124},[],{"intervention":9474,"totalTrials":166,"cells":42323},{"EARLY_PHASE1":42324,"PHASE1":42326,"PHASE2":42332,"PHASE3":42334,"PHASE4":42336,"NA":42338},{"trials":42325,"activeCount":124},[],{"trials":42327,"activeCount":124},[42328],{"nctId":9467,"briefTitle":9468,"status":182,"phases":42329,"primaryCompletion":9470,"completion":9470,"start":9471,"enrollment":550,"conditions":42330,"interventions":42331},[87],[36,1067],[510,654,9474],{"trials":42333,"activeCount":124},[],{"trials":42335,"activeCount":124},[],{"trials":42337,"activeCount":124},[],{"trials":42339,"activeCount":124},[],{"intervention":3514,"totalTrials":166,"cells":42341},{"EARLY_PHASE1":42342,"PHASE1":42344,"PHASE2":42350,"PHASE3":42352,"PHASE4":42354,"NA":42356},{"trials":42343,"activeCount":124},[],{"trials":42345,"activeCount":124},[42346],{"nctId":3505,"briefTitle":3506,"status":3049,"phases":42347,"primaryCompletion":3508,"completion":3509,"start":3510,"enrollment":1240,"conditions":42348,"interventions":42349},[87],[3512,1318],[1599,3514,803,1049],{"trials":42351,"activeCount":124},[],{"trials":42353,"activeCount":124},[],{"trials":42355,"activeCount":124},[],{"trials":42357,"activeCount":124},[],{"intervention":10734,"totalTrials":166,"cells":42359},{"EARLY_PHASE1":42360,"PHASE1":42362,"PHASE2":42368,"PHASE3":42370,"PHASE4":42372,"NA":42374},{"trials":42361,"activeCount":124},[],{"trials":42363,"activeCount":124},[42364],{"nctId":10729,"briefTitle":10730,"status":130,"phases":42365,"primaryCompletion":2777,"completion":2777,"start":3987,"enrollment":342,"conditions":42366,"interventions":42367},[87],[33],[10734,2772,1275,1683,1113,2772,1275],{"trials":42369,"activeCount":124},[],{"trials":42371,"activeCount":124},[],{"trials":42373,"activeCount":124},[],{"trials":42375,"activeCount":124},[],{"intervention":14823,"totalTrials":166,"cells":42377},{"EARLY_PHASE1":42378,"PHASE1":42380,"PHASE2":42386,"PHASE3":42388,"PHASE4":42390,"NA":42392},{"trials":42379,"activeCount":124},[],{"trials":42381,"activeCount":124},[42382],{"nctId":14818,"briefTitle":14819,"status":130,"phases":42383,"primaryCompletion":2778,"completion":2778,"start":5435,"enrollment":492,"conditions":42384,"interventions":42385},[87],[1530],[14823,1710],{"trials":42387,"activeCount":124},[],{"trials":42389,"activeCount":124},[],{"trials":42391,"activeCount":124},[],{"trials":42393,"activeCount":124},[],{"intervention":27811,"totalTrials":166,"cells":42395},{"EARLY_PHASE1":42396,"PHASE1":42398,"PHASE2":42404,"PHASE3":42406,"PHASE4":42408,"NA":42410},{"trials":42397,"activeCount":124},[],{"trials":42399,"activeCount":124},[42400],{"nctId":27805,"briefTitle":27806,"status":203,"phases":42401,"primaryCompletion":27808,"completion":27808,"start":27808,"enrollment":124,"conditions":42402,"interventions":42403},[87],[2569,13289,361,2570],[17196,27811],{"trials":42405,"activeCount":124},[],{"trials":42407,"activeCount":124},[],{"trials":42409,"activeCount":124},[],{"trials":42411,"activeCount":124},[],{"intervention":42413,"totalTrials":166,"cells":42414},"Phenethyl Isothiocyanate",{"EARLY_PHASE1":42415,"PHASE1":42417,"PHASE2":42425,"PHASE3":42427,"PHASE4":42429,"NA":42431},{"trials":42416,"activeCount":124},[],{"trials":42418,"activeCount":124},[42419],{"nctId":42420,"briefTitle":42421,"status":203,"phases":42422,"primaryCompletion":12586,"start":2806,"enrollment":124,"conditions":42423,"interventions":42424},"NCT00968461","Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders",[87],[15,20501],[42413],{"trials":42426,"activeCount":124},[],{"trials":42428,"activeCount":124},[],{"trials":42430,"activeCount":124},[],{"trials":42432,"activeCount":124},[],{"intervention":11743,"totalTrials":166,"cells":42434},{"EARLY_PHASE1":42435,"PHASE1":42437,"PHASE2":42443,"PHASE3":42445,"PHASE4":42447,"NA":42449},{"trials":42436,"activeCount":124},[],{"trials":42438,"activeCount":124},[42439],{"nctId":11736,"briefTitle":11737,"status":130,"phases":42440,"primaryCompletion":1736,"completion":1736,"start":11739,"enrollment":901,"conditions":42441,"interventions":42442},[87],[1343,1347,3457,11741],[11743,1376],{"trials":42444,"activeCount":124},[],{"trials":42446,"activeCount":124},[],{"trials":42448,"activeCount":124},[],{"trials":42450,"activeCount":124},[],{"intervention":27504,"totalTrials":166,"cells":42452},{"EARLY_PHASE1":42453,"PHASE1":42455,"PHASE2":42461,"PHASE3":42463,"PHASE4":42465,"NA":42467},{"trials":42454,"activeCount":124},[],{"trials":42456,"activeCount":124},[42457],{"nctId":27498,"briefTitle":27499,"status":130,"phases":42458,"primaryCompletion":16960,"completion":16960,"start":27501,"enrollment":1154,"conditions":42459,"interventions":42460},[87],[33],[27504,2405],{"trials":42462,"activeCount":124},[],{"trials":42464,"activeCount":124},[],{"trials":42466,"activeCount":124},[],{"trials":42468,"activeCount":124},[],{"intervention":9862,"totalTrials":166,"cells":42470},{"EARLY_PHASE1":42471,"PHASE1":42473,"PHASE2":42479,"PHASE3":42481,"PHASE4":42483,"NA":42485},{"trials":42472,"activeCount":124},[],{"trials":42474,"activeCount":124},[42475],{"nctId":9856,"briefTitle":9857,"status":130,"phases":42476,"primaryCompletion":2846,"completion":2846,"start":9859,"enrollment":2911,"conditions":42477,"interventions":42478},[87],[33],[9862,1369,9863,9864],{"trials":42480,"activeCount":124},[],{"trials":42482,"activeCount":124},[],{"trials":42484,"activeCount":124},[],{"trials":42486,"activeCount":124},[],{"intervention":9863,"totalTrials":166,"cells":42488},{"EARLY_PHASE1":42489,"PHASE1":42491,"PHASE2":42497,"PHASE3":42499,"PHASE4":42501,"NA":42503},{"trials":42490,"activeCount":124},[],{"trials":42492,"activeCount":124},[42493],{"nctId":9856,"briefTitle":9857,"status":130,"phases":42494,"primaryCompletion":2846,"completion":2846,"start":9859,"enrollment":2911,"conditions":42495,"interventions":42496},[87],[33],[9862,1369,9863,9864],{"trials":42498,"activeCount":124},[],{"trials":42500,"activeCount":124},[],{"trials":42502,"activeCount":124},[],{"trials":42504,"activeCount":124},[],{"intervention":9864,"totalTrials":166,"cells":42506},{"EARLY_PHASE1":42507,"PHASE1":42509,"PHASE2":42515,"PHASE3":42517,"PHASE4":42519,"NA":42521},{"trials":42508,"activeCount":124},[],{"trials":42510,"activeCount":124},[42511],{"nctId":9856,"briefTitle":9857,"status":130,"phases":42512,"primaryCompletion":2846,"completion":2846,"start":9859,"enrollment":2911,"conditions":42513,"interventions":42514},[87],[33],[9862,1369,9863,9864],{"trials":42516,"activeCount":124},[],{"trials":42518,"activeCount":124},[],{"trials":42520,"activeCount":124},[],{"trials":42522,"activeCount":124},[],{"intervention":42524,"totalTrials":166,"cells":42525},"18F-fluoroacetate",{"EARLY_PHASE1":42526,"PHASE1":42528,"PHASE2":42536,"PHASE3":42538,"PHASE4":42540,"NA":42542},{"trials":42527,"activeCount":124},[],{"trials":42529,"activeCount":124},[42530],{"nctId":42531,"briefTitle":42532,"status":203,"phases":42533,"primaryCompletion":3667,"start":6974,"enrollment":124,"conditions":42534,"interventions":42535},"NCT01320787","18-F-Fluoroacetate as PET Imaging Agent",[87],[11176,18,27],[42524],{"trials":42537,"activeCount":124},[],{"trials":42539,"activeCount":124},[],{"trials":42541,"activeCount":124},[],{"trials":42543,"activeCount":124},[],{"intervention":9871,"totalTrials":166,"cells":42545},{"EARLY_PHASE1":42546,"PHASE1":42548,"PHASE2":42554,"PHASE3":42556,"PHASE4":42558,"NA":42560},{"trials":42547,"activeCount":124},[],{"trials":42549,"activeCount":124},[42550],{"nctId":9866,"briefTitle":9867,"status":130,"phases":42551,"primaryCompletion":8305,"completion":8305,"start":4039,"enrollment":3820,"conditions":42552,"interventions":42553},[87],[24],[9871,1376,1369,1275],{"trials":42555,"activeCount":124},[],{"trials":42557,"activeCount":124},[],{"trials":42559,"activeCount":124},[],{"trials":42561,"activeCount":124},[],{"intervention":3524,"totalTrials":166,"cells":42563},{"EARLY_PHASE1":42564,"PHASE1":42566,"PHASE2":42572,"PHASE3":42574,"PHASE4":42576,"NA":42578},{"trials":42565,"activeCount":124},[],{"trials":42567,"activeCount":124},[42568],{"nctId":3516,"briefTitle":3517,"status":182,"phases":42569,"primaryCompletion":3519,"completion":3519,"start":3520,"enrollment":3521,"conditions":42570,"interventions":42571},[87],[33,1729],[3524,1049],{"trials":42573,"activeCount":124},[],{"trials":42575,"activeCount":124},[],{"trials":42577,"activeCount":124},[],{"trials":42579,"activeCount":124},[],{"intervention":42581,"totalTrials":166,"cells":42582},"Fostamatinib",{"EARLY_PHASE1":42583,"PHASE1":42585,"PHASE2":42594,"PHASE3":42596,"PHASE4":42598,"NA":42600},{"trials":42584,"activeCount":124},[],{"trials":42586,"activeCount":124},[42587],{"nctId":42588,"briefTitle":42589,"status":130,"phases":42590,"primaryCompletion":23185,"completion":23185,"start":42591,"enrollment":95,"conditions":42592,"interventions":42593},"NCT05030675","Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents",[87],"2021-08-13",[853,632],[42581],{"trials":42595,"activeCount":124},[],{"trials":42597,"activeCount":124},[],{"trials":42599,"activeCount":124},[],{"trials":42601,"activeCount":124},[],{"intervention":27590,"totalTrials":166,"cells":42603},{"EARLY_PHASE1":42604,"PHASE1":42606,"PHASE2":42612,"PHASE3":42614,"PHASE4":42616,"NA":42618},{"trials":42605,"activeCount":124},[],{"trials":42607,"activeCount":124},[42608],{"nctId":27582,"briefTitle":27583,"status":203,"phases":42609,"primaryCompletion":14149,"completion":14149,"start":27585,"enrollment":124,"conditions":42610,"interventions":42611},[87],[7312,27587,5234,27588,7317],[4209,27590],{"trials":42613,"activeCount":124},[],{"trials":42615,"activeCount":124},[],{"trials":42617,"activeCount":124},[],{"trials":42619,"activeCount":124},[],{"intervention":42621,"totalTrials":166,"cells":42622},"3 Day Thiarabine",{"EARLY_PHASE1":42623,"PHASE1":42625,"PHASE2":42634,"PHASE3":42636,"PHASE4":42638,"NA":42640},{"trials":42624,"activeCount":124},[],{"trials":42626,"activeCount":124},[42627],{"nctId":42628,"briefTitle":42629,"status":130,"phases":42630,"primaryCompletion":20060,"completion":4162,"start":3996,"enrollment":2004,"conditions":42631,"interventions":42632},"NCT01139151","4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies",[87],[15],[42621,42633],"5 Day Thiarabine",{"trials":42635,"activeCount":124},[],{"trials":42637,"activeCount":124},[],{"trials":42639,"activeCount":124},[],{"trials":42641,"activeCount":124},[],{"intervention":42633,"totalTrials":166,"cells":42643},{"EARLY_PHASE1":42644,"PHASE1":42646,"PHASE2":42652,"PHASE3":42654,"PHASE4":42656,"NA":42658},{"trials":42645,"activeCount":124},[],{"trials":42647,"activeCount":124},[42648],{"nctId":42628,"briefTitle":42629,"status":130,"phases":42649,"primaryCompletion":20060,"completion":4162,"start":3996,"enrollment":2004,"conditions":42650,"interventions":42651},[87],[15],[42621,42633],{"trials":42653,"activeCount":124},[],{"trials":42655,"activeCount":124},[],{"trials":42657,"activeCount":124},[],{"trials":42659,"activeCount":124},[],{"intervention":33083,"totalTrials":166,"cells":42661},{"EARLY_PHASE1":42662,"PHASE1":42664,"PHASE2":42670,"PHASE3":42672,"PHASE4":42674,"NA":42676},{"trials":42663,"activeCount":124},[],{"trials":42665,"activeCount":124},[42666],{"nctId":33077,"briefTitle":33078,"status":130,"phases":42667,"primaryCompletion":27284,"completion":27284,"start":33080,"enrollment":20891,"conditions":42668,"interventions":42669},[87],[3396,2223,2224],[2227,33083],{"trials":42671,"activeCount":124},[],{"trials":42673,"activeCount":124},[],{"trials":42675,"activeCount":124},[],{"trials":42677,"activeCount":124},[],{"intervention":17525,"totalTrials":166,"cells":42679},{"EARLY_PHASE1":42680,"PHASE1":42682,"PHASE2":42688,"PHASE3":42690,"PHASE4":42692,"NA":42694},{"trials":42681,"activeCount":124},[],{"trials":42683,"activeCount":124},[42684],{"nctId":17520,"briefTitle":17521,"status":182,"phases":42685,"primaryCompletion":5267,"completion":5267,"start":4084,"enrollment":95,"conditions":42686,"interventions":42687},[87],[11008],[17525,3497],{"trials":42689,"activeCount":124},[],{"trials":42691,"activeCount":124},[],{"trials":42693,"activeCount":124},[],{"trials":42695,"activeCount":124},[],{"intervention":17535,"totalTrials":166,"cells":42697},{"EARLY_PHASE1":42698,"PHASE1":42700,"PHASE2":42706,"PHASE3":42708,"PHASE4":42710,"NA":42712},{"trials":42699,"activeCount":124},[],{"trials":42701,"activeCount":124},[42702],{"nctId":17527,"briefTitle":17528,"status":182,"phases":42703,"primaryCompletion":17530,"completion":17530,"start":17531,"enrollment":8105,"conditions":42704,"interventions":42705},[87],[11042,11688,17533],[17535,17536,17537,3497],{"trials":42707,"activeCount":124},[],{"trials":42709,"activeCount":124},[],{"trials":42711,"activeCount":124},[],{"trials":42713,"activeCount":124},[],{"intervention":17536,"totalTrials":166,"cells":42715},{"EARLY_PHASE1":42716,"PHASE1":42718,"PHASE2":42724,"PHASE3":42726,"PHASE4":42728,"NA":42730},{"trials":42717,"activeCount":124},[],{"trials":42719,"activeCount":124},[42720],{"nctId":17527,"briefTitle":17528,"status":182,"phases":42721,"primaryCompletion":17530,"completion":17530,"start":17531,"enrollment":8105,"conditions":42722,"interventions":42723},[87],[11042,11688,17533],[17535,17536,17537,3497],{"trials":42725,"activeCount":124},[],{"trials":42727,"activeCount":124},[],{"trials":42729,"activeCount":124},[],{"trials":42731,"activeCount":124},[],{"intervention":17537,"totalTrials":166,"cells":42733},{"EARLY_PHASE1":42734,"PHASE1":42736,"PHASE2":42742,"PHASE3":42744,"PHASE4":42746,"NA":42748},{"trials":42735,"activeCount":124},[],{"trials":42737,"activeCount":124},[42738],{"nctId":17527,"briefTitle":17528,"status":182,"phases":42739,"primaryCompletion":17530,"completion":17530,"start":17531,"enrollment":8105,"conditions":42740,"interventions":42741},[87],[11042,11688,17533],[17535,17536,17537,3497],{"trials":42743,"activeCount":124},[],{"trials":42745,"activeCount":124},[],{"trials":42747,"activeCount":124},[],{"trials":42749,"activeCount":124},[],{"intervention":27030,"totalTrials":166,"cells":42751},{"EARLY_PHASE1":42752,"PHASE1":42754,"PHASE2":42760,"PHASE3":42762,"PHASE4":42764,"NA":42766},{"trials":42753,"activeCount":124},[],{"trials":42755,"activeCount":124},[42756],{"nctId":27025,"briefTitle":27026,"status":130,"phases":42757,"primaryCompletion":2122,"completion":2122,"start":8730,"enrollment":230,"conditions":42758,"interventions":42759},[87],[4522],[27018,27030],{"trials":42761,"activeCount":124},[],{"trials":42763,"activeCount":124},[],{"trials":42765,"activeCount":124},[],{"trials":42767,"activeCount":124},[],{"intervention":9887,"totalTrials":166,"cells":42769},{"EARLY_PHASE1":42770,"PHASE1":42772,"PHASE2":42778,"PHASE3":42780,"PHASE4":42782,"NA":42784},{"trials":42771,"activeCount":124},[],{"trials":42773,"activeCount":124},[42774],{"nctId":9881,"briefTitle":9882,"status":203,"phases":42775,"primaryCompletion":4835,"start":6367,"enrollment":124,"conditions":42776,"interventions":42777},[87],[9885,24],[1369,1710,9887],{"trials":42779,"activeCount":124},[],{"trials":42781,"activeCount":124},[],{"trials":42783,"activeCount":124},[],{"trials":42785,"activeCount":124},[],{"intervention":42787,"totalTrials":166,"cells":42788},"T-Cell",{"EARLY_PHASE1":42789,"PHASE1":42791,"PHASE2":42800,"PHASE3":42802,"PHASE4":42804,"NA":42806},{"trials":42790,"activeCount":124},[],{"trials":42792,"activeCount":124},[42793],{"nctId":42794,"briefTitle":42795,"status":130,"phases":42796,"primaryCompletion":2203,"completion":2203,"start":42797,"enrollment":3197,"conditions":42798,"interventions":42799},"NCT01362452","Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells",[87],"2012-12-07",[15,21],[42787],{"trials":42801,"activeCount":124},[],{"trials":42803,"activeCount":124},[],{"trials":42805,"activeCount":124},[],{"trials":42807,"activeCount":124},[],{"intervention":42809,"totalTrials":166,"cells":42810},"DTGM",{"EARLY_PHASE1":42811,"PHASE1":42813,"PHASE2":42821,"PHASE3":42823,"PHASE4":42825,"NA":42827},{"trials":42812,"activeCount":124},[],{"trials":42814,"activeCount":124},[42815],{"nctId":42816,"briefTitle":42817,"status":182,"phases":42818,"primaryCompletion":4647,"completion":4647,"start":3214,"enrollment":1483,"conditions":42819,"interventions":42820},"NCT00074750","Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)",[87],[4659,737],[42809],{"trials":42822,"activeCount":124},[],{"trials":42824,"activeCount":124},[],{"trials":42826,"activeCount":124},[],{"trials":42828,"activeCount":124},[],{"intervention":2236,"totalTrials":166,"cells":42830},{"EARLY_PHASE1":42831,"PHASE1":42833,"PHASE2":42839,"PHASE3":42841,"PHASE4":42843,"NA":42845},{"trials":42832,"activeCount":124},[],{"trials":42834,"activeCount":124},[42835],{"nctId":2229,"briefTitle":2230,"status":203,"phases":42836,"primaryCompletion":2121,"start":2232,"enrollment":124,"conditions":42837,"interventions":42838},[87],[21],[2235,894,1709,654,62,2236,2237],{"trials":42840,"activeCount":124},[],{"trials":42842,"activeCount":124},[],{"trials":42844,"activeCount":124},[],{"trials":42846,"activeCount":124},[],{"intervention":2237,"totalTrials":166,"cells":42848},{"EARLY_PHASE1":42849,"PHASE1":42851,"PHASE2":42857,"PHASE3":42859,"PHASE4":42861,"NA":42863},{"trials":42850,"activeCount":124},[],{"trials":42852,"activeCount":124},[42853],{"nctId":2229,"briefTitle":2230,"status":203,"phases":42854,"primaryCompletion":2121,"start":2232,"enrollment":124,"conditions":42855,"interventions":42856},[87],[21],[2235,894,1709,654,62,2236,2237],{"trials":42858,"activeCount":124},[],{"trials":42860,"activeCount":124},[],{"trials":42862,"activeCount":124},[],{"trials":42864,"activeCount":124},[],{"intervention":9491,"totalTrials":166,"cells":42866},{"EARLY_PHASE1":42867,"PHASE1":42869,"PHASE2":42875,"PHASE3":42877,"PHASE4":42879,"NA":42881},{"trials":42868,"activeCount":124},[],{"trials":42870,"activeCount":124},[42871],{"nctId":9484,"briefTitle":9485,"status":130,"phases":42872,"primaryCompletion":9487,"completion":9487,"start":9488,"enrollment":593,"conditions":42873,"interventions":42874},[87],[15],[9491,655,654],{"trials":42876,"activeCount":124},[],{"trials":42878,"activeCount":124},[],{"trials":42880,"activeCount":124},[],{"trials":42882,"activeCount":124},[],{"intervention":42884,"totalTrials":166,"cells":42885},"Surface-Controlled Water Soluble Curcumin",{"EARLY_PHASE1":42886,"PHASE1":42888,"PHASE2":42897,"PHASE3":42899,"PHASE4":42901,"NA":42903},{"trials":42887,"activeCount":124},[],{"trials":42889,"activeCount":124},[42890],{"nctId":42891,"briefTitle":42892,"status":130,"phases":42893,"primaryCompletion":2289,"completion":2289,"start":3668,"enrollment":3521,"conditions":42894,"interventions":42895},"NCT01201694","Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)",[87],[33],[42884,42896],"Surface-Controlled Water Soluble Curcumin MTD",{"trials":42898,"activeCount":124},[],{"trials":42900,"activeCount":124},[],{"trials":42902,"activeCount":124},[],{"trials":42904,"activeCount":124},[],{"intervention":42896,"totalTrials":166,"cells":42906},{"EARLY_PHASE1":42907,"PHASE1":42909,"PHASE2":42915,"PHASE3":42917,"PHASE4":42919,"NA":42921},{"trials":42908,"activeCount":124},[],{"trials":42910,"activeCount":124},[42911],{"nctId":42891,"briefTitle":42892,"status":130,"phases":42912,"primaryCompletion":2289,"completion":2289,"start":3668,"enrollment":3521,"conditions":42913,"interventions":42914},[87],[33],[42884,42896],{"trials":42916,"activeCount":124},[],{"trials":42918,"activeCount":124},[],{"trials":42920,"activeCount":124},[],{"trials":42922,"activeCount":124},[],{"intervention":42924,"totalTrials":166,"cells":42925},"1% Chlorhexidine Gluconate Gel",{"EARLY_PHASE1":42926,"PHASE1":42928,"PHASE2":42936,"PHASE3":42938,"PHASE4":42940,"NA":42942},{"trials":42927,"activeCount":124},[],{"trials":42929,"activeCount":124},[42930],{"nctId":42931,"briefTitle":42932,"status":130,"phases":42933,"primaryCompletion":11134,"completion":11134,"start":13586,"enrollment":296,"conditions":42934,"interventions":42935},"NCT01036412","Chlorhexidine Gel Therapy for Cariogenic Oral Microflora",[87],[242],[42924],{"trials":42937,"activeCount":124},[],{"trials":42939,"activeCount":124},[],{"trials":42941,"activeCount":124},[],{"trials":42943,"activeCount":124},[],{"intervention":42945,"totalTrials":166,"cells":42946},"OPB 31121",{"EARLY_PHASE1":42947,"PHASE1":42949,"PHASE2":42957,"PHASE3":42959,"PHASE4":42961,"NA":42963},{"trials":42948,"activeCount":124},[],{"trials":42950,"activeCount":124},[42951],{"nctId":42952,"briefTitle":42953,"status":182,"phases":42954,"primaryCompletion":4511,"completion":4511,"start":11731,"enrollment":230,"conditions":42955,"interventions":42956},"NCT01029509","Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes",[87],[15],[42945],{"trials":42958,"activeCount":124},[],{"trials":42960,"activeCount":124},[],{"trials":42962,"activeCount":124},[],{"trials":42964,"activeCount":124},[],{"intervention":42966,"totalTrials":166,"cells":42967},"Recombinant Interleukin-12",{"EARLY_PHASE1":42968,"PHASE1":42970,"PHASE2":42980,"PHASE3":42982,"PHASE4":42984,"NA":42986},{"trials":42969,"activeCount":124},[],{"trials":42971,"activeCount":124},[42972],{"nctId":42973,"briefTitle":42974,"status":130,"phases":42975,"primaryCompletion":9827,"completion":9827,"start":42976,"enrollment":1409,"conditions":42977,"interventions":42979},"NCT00003046","Interleukin-12 in Treating Patients With Cancer in the Abdomen",[87],"1997-08",[15371,3195,42978,12006,4107],"Gallbladder Cancer",[42966],{"trials":42981,"activeCount":124},[],{"trials":42983,"activeCount":124},[],{"trials":42985,"activeCount":124},[],{"trials":42987,"activeCount":124},[],{"intervention":42989,"totalTrials":166,"cells":42990},"Gallium-67 Citrate",{"EARLY_PHASE1":42991,"PHASE1":42993,"PHASE2":43004,"PHASE3":43006,"PHASE4":43008,"NA":43010},{"trials":42992,"activeCount":124},[],{"trials":42994,"activeCount":124},[42995],{"nctId":42996,"briefTitle":42997,"status":182,"phases":42998,"primaryCompletion":3987,"completion":3987,"start":6628,"enrollment":166,"conditions":42999,"interventions":43002},"NCT00477503","Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA",[87],[43000,43001],"Central Nervous System Tumors","Brain Tumors",[42989,43003],"In-111 DTPA",{"trials":43005,"activeCount":124},[],{"trials":43007,"activeCount":124},[],{"trials":43009,"activeCount":124},[],{"trials":43011,"activeCount":124},[],{"intervention":43003,"totalTrials":166,"cells":43013},{"EARLY_PHASE1":43014,"PHASE1":43016,"PHASE2":43022,"PHASE3":43024,"PHASE4":43026,"NA":43028},{"trials":43015,"activeCount":124},[],{"trials":43017,"activeCount":124},[43018],{"nctId":42996,"briefTitle":42997,"status":182,"phases":43019,"primaryCompletion":3987,"completion":3987,"start":6628,"enrollment":166,"conditions":43020,"interventions":43021},[87],[43000,43001],[42989,43003],{"trials":43023,"activeCount":124},[],{"trials":43025,"activeCount":124},[],{"trials":43027,"activeCount":124},[],{"trials":43029,"activeCount":124},[],{"intervention":4545,"totalTrials":166,"cells":43031},{"EARLY_PHASE1":43032,"PHASE1":43034,"PHASE2":43040,"PHASE3":43042,"PHASE4":43044,"NA":43046},{"trials":43033,"activeCount":124},[],{"trials":43035,"activeCount":124},[43036],{"nctId":4539,"briefTitle":4540,"status":130,"phases":43037,"primaryCompletion":4542,"completion":4542,"start":2969,"enrollment":817,"conditions":43038,"interventions":43039},[87],[15,21,2245],[1004,2369,2293,4545,2368],{"trials":43041,"activeCount":124},[],{"trials":43043,"activeCount":124},[],{"trials":43045,"activeCount":124},[],{"trials":43047,"activeCount":124},[],{"intervention":43049,"totalTrials":166,"cells":43050},"TRPV6 Calcium Channel Inhibitor SOR-C13",{"EARLY_PHASE1":43051,"PHASE1":43053,"PHASE2":43063,"PHASE3":43065,"PHASE4":43067,"NA":43069},{"trials":43052,"activeCount":124},[],{"trials":43054,"activeCount":124},[43055],{"nctId":43056,"briefTitle":43057,"status":130,"phases":43058,"primaryCompletion":43059,"completion":43059,"start":43060,"enrollment":95,"conditions":43061,"interventions":43062},"NCT03784677","A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors",[87],"2023-06-20","2019-07-29",[1343,3457,11741,13354,8174,8175,8176,4914,8177,5108,4917,5109,4924,5110,4927,5111,1463,8115,3546,1466,3547,1470,3548],[43049],{"trials":43064,"activeCount":124},[],{"trials":43066,"activeCount":124},[],{"trials":43068,"activeCount":124},[],{"trials":43070,"activeCount":124},[],{"intervention":43072,"totalTrials":166,"cells":43073},"ABT-751",{"EARLY_PHASE1":43074,"PHASE1":43076,"PHASE2":43084,"PHASE3":43086,"PHASE4":43088,"NA":43090},{"trials":43075,"activeCount":124},[],{"trials":43077,"activeCount":124},[43078],{"nctId":43079,"briefTitle":43080,"status":130,"phases":43081,"primaryCompletion":7473,"completion":7473,"start":6852,"enrollment":507,"conditions":43082,"interventions":43083},"NCT00047489","Study of ABT-751 in Patients With Refractory Hematologic Malignancies",[87],[7246],[43072],{"trials":43085,"activeCount":124},[],{"trials":43087,"activeCount":124},[],{"trials":43089,"activeCount":124},[],{"trials":43091,"activeCount":124},[],{"intervention":43093,"totalTrials":166,"cells":43094},"SCH 900105",{"EARLY_PHASE1":43095,"PHASE1":43097,"PHASE2":43105,"PHASE3":43107,"PHASE4":43109,"NA":43111},{"trials":43096,"activeCount":124},[],{"trials":43098,"activeCount":124},[43099],{"nctId":43100,"briefTitle":43101,"status":203,"phases":43102,"primaryCompletion":6757,"completion":6757,"start":3996,"enrollment":124,"conditions":43103,"interventions":43104},"NCT01189513","SCH-900105 in Recurrent Glioblastoma",[87],[11042],[43093],{"trials":43106,"activeCount":124},[],{"trials":43108,"activeCount":124},[],{"trials":43110,"activeCount":124},[],{"trials":43112,"activeCount":124},[],{"intervention":31218,"totalTrials":166,"cells":43114},{"EARLY_PHASE1":43115,"PHASE1":43117,"PHASE2":43123,"PHASE3":43125,"PHASE4":43127,"NA":43129},{"trials":43116,"activeCount":124},[],{"trials":43118,"activeCount":124},[43119],{"nctId":31213,"briefTitle":31214,"status":130,"phases":43120,"primaryCompletion":2528,"completion":2528,"start":7400,"enrollment":134,"conditions":43121,"interventions":43122},[87],[5244],[31218,17901],{"trials":43124,"activeCount":124},[],{"trials":43126,"activeCount":124},[],{"trials":43128,"activeCount":124},[],{"trials":43130,"activeCount":124},[],{"intervention":43132,"totalTrials":166,"cells":43133},"Atiprimod",{"EARLY_PHASE1":43134,"PHASE1":43136,"PHASE2":43144,"PHASE3":43146,"PHASE4":43148,"NA":43150},{"trials":43135,"activeCount":124},[],{"trials":43137,"activeCount":124},[43138],{"nctId":43139,"briefTitle":43140,"status":182,"phases":43141,"primaryCompletion":5232,"completion":5232,"start":3902,"enrollment":3521,"conditions":43142,"interventions":43143},"NCT00430014","Study of Atiprimod Treatment for Patients With Advanced Cancer",[87],[1942],[43132],{"trials":43145,"activeCount":124},[],{"trials":43147,"activeCount":124},[],{"trials":43149,"activeCount":124},[],{"trials":43151,"activeCount":124},[],{"intervention":17997,"totalTrials":166,"cells":43153},{"EARLY_PHASE1":43154,"PHASE1":43156,"PHASE2":43162,"PHASE3":43164,"PHASE4":43166,"NA":43168},{"trials":43155,"activeCount":124},[],{"trials":43157,"activeCount":124},[43158],{"nctId":17989,"briefTitle":17990,"status":182,"phases":43159,"primaryCompletion":17897,"completion":17897,"start":17992,"enrollment":834,"conditions":43160,"interventions":43161},[87],[11042,17994,17995],[1028,17997],{"trials":43163,"activeCount":124},[],{"trials":43165,"activeCount":124},[],{"trials":43167,"activeCount":124},[],{"trials":43169,"activeCount":124},[],{"intervention":41895,"totalTrials":166,"cells":43171},{"EARLY_PHASE1":43172,"PHASE1":43174,"PHASE2":43180,"PHASE3":43182,"PHASE4":43184,"NA":43186},{"trials":43173,"activeCount":124},[],{"trials":43175,"activeCount":124},[43176],{"nctId":41890,"briefTitle":41891,"status":203,"phases":43177,"primaryCompletion":2242,"start":4542,"enrollment":124,"conditions":43178,"interventions":43179},[87],[18],[3905,41895],{"trials":43181,"activeCount":124},[],{"trials":43183,"activeCount":124},[],{"trials":43185,"activeCount":124},[],{"trials":43187,"activeCount":124},[],{"intervention":43189,"totalTrials":166,"cells":43190},"Doxercalciferol",{"EARLY_PHASE1":43191,"PHASE1":43193,"PHASE2":43201,"PHASE3":43203,"PHASE4":43205,"NA":43207},{"trials":43192,"activeCount":124},[],{"trials":43194,"activeCount":124},[43195],{"nctId":43196,"briefTitle":43197,"status":182,"phases":43198,"primaryCompletion":3777,"completion":3777,"start":6409,"enrollment":166,"conditions":43199,"interventions":43200},"NCT00511017","Doxercalciferol in Recurrent Pediatric Solid Tumors",[87],[1924],[43189],{"trials":43202,"activeCount":124},[],{"trials":43204,"activeCount":124},[],{"trials":43206,"activeCount":124},[],{"trials":43208,"activeCount":124},[],{"intervention":43210,"totalTrials":166,"cells":43211},"Wound Dressing Material",{"EARLY_PHASE1":43212,"PHASE1":43214,"PHASE2":43227,"PHASE3":43229,"PHASE4":43231,"NA":43233},{"trials":43213,"activeCount":124},[],{"trials":43215,"activeCount":124},[43216],{"nctId":43217,"briefTitle":43218,"status":203,"phases":43219,"primaryCompletion":4448,"completion":4448,"start":1875,"enrollment":124,"conditions":43220,"interventions":43226},"NCT03990597","StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord",[87],[43221,43222,28813,43223,3171,43224,43225],"Central Nervous System Sarcoma","Ependymoma","Malignant Intracranial Germ Cell Tumor","Pineoblastoma","Primary Central Nervous System Neoplasm",[43210],{"trials":43228,"activeCount":124},[],{"trials":43230,"activeCount":124},[],{"trials":43232,"activeCount":124},[],{"trials":43234,"activeCount":124},[],{"intervention":3837,"totalTrials":166,"cells":43236},{"EARLY_PHASE1":43237,"PHASE1":43239,"PHASE2":43245,"PHASE3":43247,"PHASE4":43249,"NA":43251},{"trials":43238,"activeCount":124},[],{"trials":43240,"activeCount":124},[43241],{"nctId":3829,"briefTitle":3830,"status":130,"phases":43242,"primaryCompletion":3832,"completion":3832,"start":3833,"enrollment":1496,"conditions":43243,"interventions":43244},[87],[1729],[3497,3836,1709,3499,3837],{"trials":43246,"activeCount":124},[],{"trials":43248,"activeCount":124},[],{"trials":43250,"activeCount":124},[],{"trials":43252,"activeCount":124},[],{"intervention":9928,"totalTrials":166,"cells":43254},{"EARLY_PHASE1":43255,"PHASE1":43257,"PHASE2":43263,"PHASE3":43265,"PHASE4":43267,"NA":43269},{"trials":43256,"activeCount":124},[],{"trials":43258,"activeCount":124},[43259],{"nctId":9920,"briefTitle":9921,"status":130,"phases":43260,"primaryCompletion":9923,"completion":9923,"start":5241,"enrollment":871,"conditions":43261,"interventions":43262},[87],[1530,9925,9926],[9928,1369],{"trials":43264,"activeCount":124},[],{"trials":43266,"activeCount":124},[],{"trials":43268,"activeCount":124},[],{"trials":43270,"activeCount":124},[],{"intervention":6525,"totalTrials":166,"cells":43272},{"EARLY_PHASE1":43273,"PHASE1":43275,"PHASE2":43281,"PHASE3":43283,"PHASE4":43285,"NA":43287},{"trials":43274,"activeCount":124},[],{"trials":43276,"activeCount":124},[43277],{"nctId":6518,"briefTitle":6519,"status":130,"phases":43278,"primaryCompletion":6521,"completion":6521,"start":6522,"enrollment":2779,"conditions":43279,"interventions":43280},[87],[21],[6525,803,894],{"trials":43282,"activeCount":124},[],{"trials":43284,"activeCount":124},[],{"trials":43286,"activeCount":124},[],{"trials":43288,"activeCount":124},[],{"intervention":9939,"totalTrials":166,"cells":43290},{"EARLY_PHASE1":43291,"PHASE1":43293,"PHASE2":43299,"PHASE3":43301,"PHASE4":43303,"NA":43305},{"trials":43292,"activeCount":124},[],{"trials":43294,"activeCount":124},[43295],{"nctId":9934,"briefTitle":9935,"status":130,"phases":43296,"primaryCompletion":3805,"start":7236,"enrollment":195,"conditions":43297,"interventions":43298},[87],[5349,1924],[9939,1369],{"trials":43300,"activeCount":124},[],{"trials":43302,"activeCount":124},[],{"trials":43304,"activeCount":124},[],{"trials":43306,"activeCount":124},[],{"intervention":43308,"totalTrials":166,"cells":43309},"BKM120",{"EARLY_PHASE1":43310,"PHASE1":43312,"PHASE2":43320,"PHASE3":43322,"PHASE4":43324,"NA":43326},{"trials":43311,"activeCount":124},[],{"trials":43313,"activeCount":124},[43314],{"nctId":43315,"briefTitle":43316,"status":130,"phases":43317,"primaryCompletion":3667,"completion":3667,"start":8956,"enrollment":834,"conditions":43318,"interventions":43319},"NCT01396499","Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias",[87],[15],[43308],{"trials":43321,"activeCount":124},[],{"trials":43323,"activeCount":124},[],{"trials":43325,"activeCount":124},[],{"trials":43327,"activeCount":124},[],{"intervention":7605,"totalTrials":166,"cells":43329},{"EARLY_PHASE1":43330,"PHASE1":43332,"PHASE2":43338,"PHASE3":43340,"PHASE4":43342,"NA":43344},{"trials":43331,"activeCount":124},[],{"trials":43333,"activeCount":124},[43334],{"nctId":7591,"briefTitle":7592,"status":130,"phases":43335,"primaryCompletion":7594,"completion":7594,"start":7595,"enrollment":910,"conditions":43336,"interventions":43337},[87],[7597,7598,7599,7600,7601,7602,7603],[4135,4023,7605,53],{"trials":43339,"activeCount":124},[],{"trials":43341,"activeCount":124},[],{"trials":43343,"activeCount":124},[],{"trials":43345,"activeCount":124},[],{"intervention":33673,"totalTrials":166,"cells":43347},{"EARLY_PHASE1":43348,"PHASE1":43350,"PHASE2":43356,"PHASE3":43358,"PHASE4":43360,"NA":43362},{"trials":43349,"activeCount":124},[],{"trials":43351,"activeCount":124},[43352],{"nctId":33666,"briefTitle":33667,"status":182,"phases":43353,"primaryCompletion":33669,"completion":33669,"start":33670,"enrollment":166,"conditions":43354,"interventions":43355},[87],[15],[33673,15480],{"trials":43357,"activeCount":124},[],{"trials":43359,"activeCount":124},[],{"trials":43361,"activeCount":124},[],{"trials":43363,"activeCount":124},[],{"intervention":43365,"totalTrials":166,"cells":43366},"RTA 744",{"EARLY_PHASE1":43367,"PHASE1":43369,"PHASE2":43377,"PHASE3":43379,"PHASE4":43381,"NA":43383},{"trials":43368,"activeCount":124},[],{"trials":43370,"activeCount":124},[43371],{"nctId":43372,"briefTitle":43373,"status":182,"phases":43374,"primaryCompletion":13673,"completion":13673,"start":4612,"enrollment":1483,"conditions":43375,"interventions":43376},"NCT00512460","RTA 744 Injection in Patients With Leptomeningeal Disease",[87],[11008,3305,21,15,13732],[43365],{"trials":43378,"activeCount":124},[],{"trials":43380,"activeCount":124},[],{"trials":43382,"activeCount":124},[],{"trials":43384,"activeCount":124},[],{"intervention":6534,"totalTrials":166,"cells":43386},{"EARLY_PHASE1":43387,"PHASE1":43389,"PHASE2":43395,"PHASE3":43397,"PHASE4":43399,"NA":43401},{"trials":43388,"activeCount":124},[],{"trials":43390,"activeCount":124},[43391],{"nctId":6527,"briefTitle":6528,"status":182,"phases":43392,"primaryCompletion":6530,"completion":6530,"start":6531,"enrollment":95,"conditions":43393,"interventions":43394},[87],[1986,36],[1070,803,6534],{"trials":43396,"activeCount":124},[],{"trials":43398,"activeCount":124},[],{"trials":43400,"activeCount":124},[],{"trials":43402,"activeCount":124},[],{"intervention":43404,"totalTrials":166,"cells":43405},"PR1-primed lymphocyte (PR1-CTL)",{"EARLY_PHASE1":43406,"PHASE1":43408,"PHASE2":43416,"PHASE3":43418,"PHASE4":43420,"NA":43422},{"trials":43407,"activeCount":124},[],{"trials":43409,"activeCount":124},[43410],{"nctId":43411,"briefTitle":43412,"status":203,"phases":43413,"primaryCompletion":10449,"start":6828,"enrollment":124,"conditions":43414,"interventions":43415},"NCT00866346","PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation",[87],[4725],[43404],{"trials":43417,"activeCount":124},[],{"trials":43419,"activeCount":124},[],{"trials":43421,"activeCount":124},[],{"trials":43423,"activeCount":124},[],{"intervention":43425,"totalTrials":166,"cells":43426},"Tezacitabine",{"EARLY_PHASE1":43427,"PHASE1":43429,"PHASE2":43439,"PHASE3":43441,"PHASE4":43443,"NA":43445},{"trials":43428,"activeCount":124},[],{"trials":43430,"activeCount":124},[43431],{"nctId":43432,"briefTitle":43433,"status":130,"phases":43434,"primaryCompletion":43435,"completion":43435,"start":43436,"enrollment":1766,"conditions":43437,"interventions":43438},"NCT00061620","Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies",[87],"2004-02-12","2001-09-06",[4760],[43425],{"trials":43440,"activeCount":124},[],{"trials":43442,"activeCount":124},[],{"trials":43444,"activeCount":124},[],{"trials":43446,"activeCount":124},[],{"intervention":3115,"totalTrials":166,"cells":43448},{"EARLY_PHASE1":43449,"PHASE1":43451,"PHASE2":43457,"PHASE3":43459,"PHASE4":43461,"NA":43463},{"trials":43450,"activeCount":124},[],{"trials":43452,"activeCount":124},[43453],{"nctId":3106,"briefTitle":3107,"status":130,"phases":43454,"primaryCompletion":3109,"completion":3109,"start":3110,"enrollment":1568,"conditions":43455,"interventions":43456},[87],[737,608,3112,610,3113],[654,1005,3115],{"trials":43458,"activeCount":124},[],{"trials":43460,"activeCount":124},[],{"trials":43462,"activeCount":124},[],{"trials":43464,"activeCount":124},[],{"intervention":10401,"totalTrials":166,"cells":43466},{"EARLY_PHASE1":43467,"PHASE1":43469,"PHASE2":43475,"PHASE3":43477,"PHASE4":43479,"NA":43481},{"trials":43468,"activeCount":124},[],{"trials":43470,"activeCount":124},[43471],{"nctId":10396,"briefTitle":10397,"status":182,"phases":43472,"primaryCompletion":2889,"completion":2889,"start":2326,"enrollment":166,"conditions":43473,"interventions":43474},[87],[33],[510,1402,10401],{"trials":43476,"activeCount":124},[],{"trials":43478,"activeCount":124},[],{"trials":43480,"activeCount":124},[],{"trials":43482,"activeCount":124},[],{"intervention":43484,"totalTrials":166,"cells":43485},"Carbon C 11 Glutamine",{"EARLY_PHASE1":43486,"PHASE1":43488,"PHASE2":43502,"PHASE3":43504,"PHASE4":43506,"NA":43508},{"trials":43487,"activeCount":124},[],{"trials":43489,"activeCount":124},[43490],{"nctId":43491,"briefTitle":43492,"status":182,"phases":43493,"primaryCompletion":3867,"completion":3867,"start":43494,"enrollment":230,"conditions":43495,"interventions":43500},"NCT03275974","Glutamine PET Imaging Colorectal Cancer",[87],"2021-04-27",[43496,43497,43498,43499],"RAS Wild Type","Stage IV Colorectal Cancer","Stage IVA Colorectal Cancer","Stage IVB Colorectal Cancer",[43484,43501],"Fluorine F 18 L-glutamate Derivative BAY94-9392",{"trials":43503,"activeCount":124},[],{"trials":43505,"activeCount":124},[],{"trials":43507,"activeCount":124},[],{"trials":43509,"activeCount":124},[],{"intervention":43501,"totalTrials":166,"cells":43511},{"EARLY_PHASE1":43512,"PHASE1":43514,"PHASE2":43520,"PHASE3":43522,"PHASE4":43524,"NA":43526},{"trials":43513,"activeCount":124},[],{"trials":43515,"activeCount":124},[43516],{"nctId":43491,"briefTitle":43492,"status":182,"phases":43517,"primaryCompletion":3867,"completion":3867,"start":43494,"enrollment":230,"conditions":43518,"interventions":43519},[87],[43496,43497,43498,43499],[43484,43501],{"trials":43521,"activeCount":124},[],{"trials":43523,"activeCount":124},[],{"trials":43525,"activeCount":124},[],{"trials":43527,"activeCount":124},[],{"intervention":19298,"totalTrials":166,"cells":43529},{"EARLY_PHASE1":43530,"PHASE1":43532,"PHASE2":43538,"PHASE3":43540,"PHASE4":43542,"NA":43544},{"trials":43531,"activeCount":124},[],{"trials":43533,"activeCount":124},[43534],{"nctId":19292,"briefTitle":19293,"status":130,"phases":43535,"primaryCompletion":2864,"completion":2864,"start":2619,"enrollment":1922,"conditions":43536,"interventions":43537},[87],[5122,5108,5109,5110,5111,19296],[554,19298],{"trials":43539,"activeCount":124},[],{"trials":43541,"activeCount":124},[],{"trials":43543,"activeCount":124},[],{"trials":43545,"activeCount":124},[],{"intervention":5205,"totalTrials":166,"cells":43547},{"EARLY_PHASE1":43548,"PHASE1":43550,"PHASE2":43556,"PHASE3":43558,"PHASE4":43560,"NA":43562},{"trials":43549,"activeCount":124},[],{"trials":43551,"activeCount":124},[43552],{"nctId":5197,"briefTitle":5198,"status":130,"phases":43553,"primaryCompletion":5200,"completion":5200,"start":5201,"enrollment":1483,"conditions":43554,"interventions":43555},[87],[15,21,5203,1036],[803,5205,1254],{"trials":43557,"activeCount":124},[],{"trials":43559,"activeCount":124},[],{"trials":43561,"activeCount":124},[],{"trials":43563,"activeCount":124},[],{"intervention":43565,"totalTrials":166,"cells":43566},"Oral Clofarabine",{"EARLY_PHASE1":43567,"PHASE1":43569,"PHASE2":43577,"PHASE3":43579,"PHASE4":43581,"NA":43583},{"trials":43568,"activeCount":124},[],{"trials":43570,"activeCount":124},[43571],{"nctId":43572,"briefTitle":43573,"status":203,"phases":43574,"primaryCompletion":12649,"completion":12649,"start":4731,"enrollment":124,"conditions":43575,"interventions":43576},"NCT00800566","Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)",[87],[15,712],[43565],{"trials":43578,"activeCount":124},[],{"trials":43580,"activeCount":124},[],{"trials":43582,"activeCount":124},[],{"trials":43584,"activeCount":124},[],{"intervention":43586,"totalTrials":166,"cells":43587},"Autologous Dendritic Cells",{"EARLY_PHASE1":43588,"PHASE1":43590,"PHASE2":43598,"PHASE3":43600,"PHASE4":43602,"NA":43604},{"trials":43589,"activeCount":124},[],{"trials":43591,"activeCount":124},[43592],{"nctId":43593,"briefTitle":43594,"status":182,"phases":43595,"primaryCompletion":13586,"completion":13586,"start":5470,"enrollment":121,"conditions":43596,"interventions":43597},"NCT00514189","Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines",[87],[15],[43586],{"trials":43599,"activeCount":124},[],{"trials":43601,"activeCount":124},[],{"trials":43603,"activeCount":124},[],{"trials":43605,"activeCount":124},[],{"intervention":43607,"totalTrials":166,"cells":43608},"FLT-PET",{"EARLY_PHASE1":43609,"PHASE1":43611,"PHASE2":43619,"PHASE3":43621,"PHASE4":43623,"NA":43625},{"trials":43610,"activeCount":124},[],{"trials":43612,"activeCount":124},[43613],{"nctId":43614,"briefTitle":43615,"status":130,"phases":43616,"primaryCompletion":17290,"completion":17290,"start":10844,"enrollment":1231,"conditions":43617,"interventions":43618},"NCT01143779","FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib",[87],[1942],[43607],{"trials":43620,"activeCount":124},[],{"trials":43622,"activeCount":124},[],{"trials":43624,"activeCount":124},[],{"trials":43626,"activeCount":124},[],{"intervention":41924,"totalTrials":166,"cells":43628},{"EARLY_PHASE1":43629,"PHASE1":43631,"PHASE2":43637,"PHASE3":43639,"PHASE4":43641,"NA":43643},{"trials":43630,"activeCount":124},[],{"trials":43632,"activeCount":124},[43633],{"nctId":41919,"briefTitle":41920,"status":130,"phases":43634,"primaryCompletion":8305,"completion":8305,"start":7236,"enrollment":3354,"conditions":43635,"interventions":43636},[87],[1996,33,1924],[10859,41924],{"trials":43638,"activeCount":124},[],{"trials":43640,"activeCount":124},[],{"trials":43642,"activeCount":124},[],{"trials":43644,"activeCount":124},[],{"intervention":6567,"totalTrials":166,"cells":43646},{"EARLY_PHASE1":43647,"PHASE1":43649,"PHASE2":43655,"PHASE3":43657,"PHASE4":43659,"NA":43661},{"trials":43648,"activeCount":124},[],{"trials":43650,"activeCount":124},[43651],{"nctId":6554,"briefTitle":6555,"status":182,"phases":43652,"primaryCompletion":6557,"completion":6557,"start":6558,"enrollment":166,"conditions":43653,"interventions":43654},[87],[5028,6560,1898,6561,6562,6563,6564,5008,5039,5040,6565,5009,5010],[6567,1599,803,53],{"trials":43656,"activeCount":124},[],{"trials":43658,"activeCount":124},[],{"trials":43660,"activeCount":124},[],{"trials":43662,"activeCount":124},[],{"intervention":43664,"totalTrials":166,"cells":43665},"Mesenchymal Stem Cells",{"EARLY_PHASE1":43666,"PHASE1":43668,"PHASE2":43677,"PHASE3":43679,"PHASE4":43681,"NA":43683},{"trials":43667,"activeCount":124},[],{"trials":43669,"activeCount":124},[43670],{"nctId":43671,"briefTitle":43672,"status":130,"phases":43673,"primaryCompletion":37354,"completion":37354,"start":41944,"enrollment":1131,"conditions":43674,"interventions":43676},"NCT02804945","Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies",[87],[4522,43675],"Adult Respiratory Distress Syndrome",[43664],{"trials":43678,"activeCount":124},[],{"trials":43680,"activeCount":124},[],{"trials":43682,"activeCount":124},[],{"trials":43684,"activeCount":124},[],{"intervention":8266,"totalTrials":166,"cells":43686},{"EARLY_PHASE1":43687,"PHASE1":43689,"PHASE2":43695,"PHASE3":43697,"PHASE4":43699,"NA":43701},{"trials":43688,"activeCount":124},[],{"trials":43690,"activeCount":124},[43691],{"nctId":8258,"briefTitle":8259,"status":130,"phases":43692,"primaryCompletion":5120,"completion":5120,"start":4612,"enrollment":230,"conditions":43693,"interventions":43694},[87],[21,15,8262,8263,8264],[4629,894,8266],{"trials":43696,"activeCount":124},[],{"trials":43698,"activeCount":124},[],{"trials":43700,"activeCount":124},[],{"trials":43702,"activeCount":124},[],{"intervention":9031,"totalTrials":166,"cells":43704},{"EARLY_PHASE1":43705,"PHASE1":43707,"PHASE2":43713,"PHASE3":43715,"PHASE4":43717,"NA":43719},{"trials":43706,"activeCount":124},[],{"trials":43708,"activeCount":124},[43709],{"nctId":9025,"briefTitle":9026,"status":203,"phases":43710,"primaryCompletion":4016,"completion":4016,"start":4016,"enrollment":124,"conditions":43711,"interventions":43712},[87],[9029,9030,9031,9032,9033,9034],[1070,654,2374,9031,9032],{"trials":43714,"activeCount":124},[],{"trials":43716,"activeCount":124},[],{"trials":43718,"activeCount":124},[],{"trials":43720,"activeCount":124},[],{"intervention":9032,"totalTrials":166,"cells":43722},{"EARLY_PHASE1":43723,"PHASE1":43725,"PHASE2":43731,"PHASE3":43733,"PHASE4":43735,"NA":43737},{"trials":43724,"activeCount":124},[],{"trials":43726,"activeCount":124},[43727],{"nctId":9025,"briefTitle":9026,"status":203,"phases":43728,"primaryCompletion":4016,"completion":4016,"start":4016,"enrollment":124,"conditions":43729,"interventions":43730},[87],[9029,9030,9031,9032,9033,9034],[1070,654,2374,9031,9032],{"trials":43732,"activeCount":124},[],{"trials":43734,"activeCount":124},[],{"trials":43736,"activeCount":124},[],{"trials":43738,"activeCount":124},[],{"intervention":3557,"totalTrials":166,"cells":43740},{"EARLY_PHASE1":43741,"PHASE1":43743,"PHASE2":43749,"PHASE3":43751,"PHASE4":43753,"NA":43755},{"trials":43742,"activeCount":124},[],{"trials":43744,"activeCount":124},[43745],{"nctId":3552,"briefTitle":3553,"status":203,"phases":43746,"primaryCompletion":2121,"start":2122,"enrollment":124,"conditions":43747,"interventions":43748},[87],[1729,2971],[1049,803,3557],{"trials":43750,"activeCount":124},[],{"trials":43752,"activeCount":124},[],{"trials":43754,"activeCount":124},[],{"trials":43756,"activeCount":124},[],{"intervention":10413,"totalTrials":166,"cells":43758},{"EARLY_PHASE1":43759,"PHASE1":43761,"PHASE2":43767,"PHASE3":43769,"PHASE4":43771,"NA":43773},{"trials":43760,"activeCount":124},[],{"trials":43762,"activeCount":124},[43763],{"nctId":10407,"briefTitle":10408,"status":130,"phases":43764,"primaryCompletion":5574,"completion":5574,"start":10410,"enrollment":357,"conditions":43765,"interventions":43766},[87],[36,30,3244,727],[510,10413],{"trials":43768,"activeCount":124},[],{"trials":43770,"activeCount":124},[],{"trials":43772,"activeCount":124},[],{"trials":43774,"activeCount":124},[],{"intervention":43776,"totalTrials":166,"cells":43777},"Hum-195\u002FrGel",{"EARLY_PHASE1":43778,"PHASE1":43780,"PHASE2":43790,"PHASE3":43792,"PHASE4":43794,"NA":43796},{"trials":43779,"activeCount":124},[],{"trials":43781,"activeCount":124},[43782],{"nctId":43783,"briefTitle":43784,"status":130,"phases":43785,"primaryCompletion":3494,"completion":3494,"start":43786,"enrollment":3521,"conditions":43787,"interventions":43789},"NCT00038051","Evaluation of the Anti-CD-33 Immunotoxin Hum-195\u002FrGel in Patients With Advanced Myeloid Malignancies",[87],"1999-05",[36,737,40764,43788],"Anemia, Refractory, With Excess of Blasts",[43776],{"trials":43791,"activeCount":124},[],{"trials":43793,"activeCount":124},[],{"trials":43795,"activeCount":124},[],{"trials":43797,"activeCount":124},[],{"intervention":43799,"totalTrials":166,"cells":43800},"Moxetumomab Pasudotox",{"EARLY_PHASE1":43801,"PHASE1":43803,"PHASE2":43813,"PHASE3":43815,"PHASE4":43817,"NA":43819},{"trials":43802,"activeCount":124},[],{"trials":43804,"activeCount":124},[43805],{"nctId":43806,"briefTitle":43807,"status":182,"phases":43808,"primaryCompletion":43809,"completion":43809,"start":43810,"enrollment":834,"conditions":43811,"interventions":43812},"NCT01891981","Study of Moxetumomab Pasudotox in Patients With Relapsed and\u002For Refractory Acute Lymphoblastic Leukemia (ALL)",[87],"2017-04-12","2013-12-17",[15],[43799],{"trials":43814,"activeCount":124},[],{"trials":43816,"activeCount":124},[],{"trials":43818,"activeCount":124},[],{"trials":43820,"activeCount":124},[],{"intervention":43822,"totalTrials":166,"cells":43823},"INGN 201",{"EARLY_PHASE1":43824,"PHASE1":43826,"PHASE2":43835,"PHASE3":43837,"PHASE4":43839,"NA":43841},{"trials":43825,"activeCount":124},[],{"trials":43827,"activeCount":124},[43828],{"nctId":43829,"briefTitle":43830,"status":182,"phases":43831,"primaryCompletion":6828,"completion":4382,"start":6758,"enrollment":296,"conditions":43832,"interventions":43834},"NCT00410865","Wild Type p53 Adenovirus for Oral Premalignancies",[87],[43833],"Mouth Cancer",[43822],{"trials":43836,"activeCount":124},[],{"trials":43838,"activeCount":124},[],{"trials":43840,"activeCount":124},[],{"trials":43842,"activeCount":124},[],{"intervention":43844,"totalTrials":166,"cells":43845},"Prohibitin-TP01",{"EARLY_PHASE1":43846,"PHASE1":43848,"PHASE2":43857,"PHASE3":43859,"PHASE4":43861,"NA":43863},{"trials":43847,"activeCount":124},[],{"trials":43849,"activeCount":124},[43850],{"nctId":43851,"briefTitle":43852,"status":182,"phases":43853,"primaryCompletion":12605,"completion":12605,"start":43854,"enrollment":296,"conditions":43855,"interventions":43856},"NCT01262664","A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity",[87],"2012-05-24",[27],[43844],{"trials":43858,"activeCount":124},[],{"trials":43860,"activeCount":124},[],{"trials":43862,"activeCount":124},[],{"trials":43864,"activeCount":124},[],{"intervention":43866,"totalTrials":166,"cells":43867},"PBI-05204",{"EARLY_PHASE1":43868,"PHASE1":43870,"PHASE2":43878,"PHASE3":43880,"PHASE4":43882,"NA":43884},{"trials":43869,"activeCount":124},[],{"trials":43871,"activeCount":124},[43872],{"nctId":43873,"briefTitle":43874,"status":130,"phases":43875,"primaryCompletion":4290,"completion":4290,"start":5733,"enrollment":8325,"conditions":43876,"interventions":43877},"NCT00554268","Trial of PBI-05204 in Advanced Cancer Patients",[87],[1924],[43866],{"trials":43879,"activeCount":124},[],{"trials":43881,"activeCount":124},[],{"trials":43883,"activeCount":124},[],{"trials":43885,"activeCount":124},[],{"intervention":15651,"totalTrials":166,"cells":43887},{"EARLY_PHASE1":43888,"PHASE1":43890,"PHASE2":43896,"PHASE3":43898,"PHASE4":43900,"NA":43902},{"trials":43889,"activeCount":124},[],{"trials":43891,"activeCount":124},[43892],{"nctId":15645,"briefTitle":15646,"status":130,"phases":43893,"primaryCompletion":1138,"completion":1138,"start":15648,"enrollment":1559,"conditions":43894,"interventions":43895},[87],[1343,3457],[1421,15651],{"trials":43897,"activeCount":124},[],{"trials":43899,"activeCount":124},[],{"trials":43901,"activeCount":124},[],{"trials":43903,"activeCount":124},[],{"intervention":43905,"totalTrials":166,"cells":43906},"RTA 402",{"EARLY_PHASE1":43907,"PHASE1":43909,"PHASE2":43917,"PHASE3":43919,"PHASE4":43921,"NA":43923},{"trials":43908,"activeCount":124},[],{"trials":43910,"activeCount":124},[43911],{"nctId":43912,"briefTitle":43913,"status":130,"phases":43914,"primaryCompletion":13586,"completion":13586,"start":4351,"enrollment":871,"conditions":43915,"interventions":43916},"NCT00508807","RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies",[87],[8263,1924],[43905],{"trials":43918,"activeCount":124},[],{"trials":43920,"activeCount":124},[],{"trials":43922,"activeCount":124},[],{"trials":43924,"activeCount":124},[],{"intervention":35233,"totalTrials":166,"cells":43926},{"EARLY_PHASE1":43927,"PHASE1":43929,"PHASE2":43935,"PHASE3":43937,"PHASE4":43939,"NA":43941},{"trials":43928,"activeCount":124},[],{"trials":43930,"activeCount":124},[43931],{"nctId":35228,"briefTitle":35229,"status":130,"phases":43932,"primaryCompletion":11134,"completion":11134,"start":3987,"enrollment":448,"conditions":43933,"interventions":43934},[87],[18],[14120,35233],{"trials":43936,"activeCount":124},[],{"trials":43938,"activeCount":124},[],{"trials":43940,"activeCount":124},[],{"trials":43942,"activeCount":124},[],{"intervention":43944,"totalTrials":166,"cells":43945},"Fluorothymidine F-18",{"EARLY_PHASE1":43946,"PHASE1":43948,"PHASE2":43957,"PHASE3":43959,"PHASE4":43961,"NA":43963},{"trials":43947,"activeCount":124},[],{"trials":43949,"activeCount":124},[43950],{"nctId":43951,"briefTitle":43952,"status":130,"phases":43953,"primaryCompletion":688,"completion":688,"start":43954,"enrollment":1496,"conditions":43955,"interventions":43956},"NCT00880074","FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies",[87],"2009-04-09",[2613],[43944],{"trials":43958,"activeCount":124},[],{"trials":43960,"activeCount":124},[],{"trials":43962,"activeCount":124},[],{"trials":43964,"activeCount":124},[],{"intervention":3157,"totalTrials":166,"cells":43966},{"EARLY_PHASE1":43967,"PHASE1":43969,"PHASE2":43975,"PHASE3":43977,"PHASE4":43979,"NA":43981},{"trials":43968,"activeCount":124},[],{"trials":43970,"activeCount":124},[43971],{"nctId":3148,"briefTitle":3149,"status":130,"phases":43972,"primaryCompletion":3151,"completion":3151,"start":3152,"enrollment":1568,"conditions":43973,"interventions":43974},[87],[3154,3155],[1683,3157,2462,803],{"trials":43976,"activeCount":124},[],{"trials":43978,"activeCount":124},[],{"trials":43980,"activeCount":124},[],{"trials":43982,"activeCount":124},[],{"intervention":43984,"totalTrials":166,"cells":43985},"VG2025",{"EARLY_PHASE1":43986,"PHASE1":43988,"PHASE2":43996,"PHASE3":43998,"PHASE4":44000,"NA":44002},{"trials":43987,"activeCount":124},[],{"trials":43989,"activeCount":124},[43990],{"nctId":43991,"briefTitle":43992,"status":203,"phases":43993,"primaryCompletion":7737,"completion":7737,"start":7814,"enrollment":124,"conditions":43994,"interventions":43995},"NCT06365918","Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis",[87],[7337,2631],[43984],{"trials":43997,"activeCount":124},[],{"trials":43999,"activeCount":124},[],{"trials":44001,"activeCount":124},[],{"trials":44003,"activeCount":124},[],{"intervention":23744,"totalTrials":166,"cells":44005},{"EARLY_PHASE1":44006,"PHASE1":44008,"PHASE2":44014,"PHASE3":44016,"PHASE4":44018,"NA":44020},{"trials":44007,"activeCount":124},[],{"trials":44009,"activeCount":124},[44010],{"nctId":23737,"briefTitle":23738,"status":203,"phases":44011,"primaryCompletion":3621,"completion":3621,"start":23740,"enrollment":124,"conditions":44012,"interventions":44013},[87],[13732],[23743,23744],{"trials":44015,"activeCount":124},[],{"trials":44017,"activeCount":124},[],{"trials":44019,"activeCount":124},[],{"trials":44021,"activeCount":124},[],{"intervention":44023,"totalTrials":166,"cells":44024},"Gimatecan",{"EARLY_PHASE1":44025,"PHASE1":44027,"PHASE2":44035,"PHASE3":44037,"PHASE4":44039,"NA":44041},{"trials":44026,"activeCount":124},[],{"trials":44028,"activeCount":124},[44029],{"nctId":44030,"briefTitle":44031,"status":130,"phases":44032,"primaryCompletion":2777,"completion":2777,"start":6409,"enrollment":834,"conditions":44033,"interventions":44034},"NCT00493571","Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes",[87],[1036,2392],[44023],{"trials":44036,"activeCount":124},[],{"trials":44038,"activeCount":124},[],{"trials":44040,"activeCount":124},[],{"trials":44042,"activeCount":124},[],{"intervention":44044,"totalTrials":166,"cells":44045},"BikDD Nanoparticle",{"EARLY_PHASE1":44046,"PHASE1":44048,"PHASE2":44057,"PHASE3":44059,"PHASE4":44061,"NA":44063},{"trials":44047,"activeCount":124},[],{"trials":44049,"activeCount":124},[44050],{"nctId":44051,"briefTitle":44052,"status":203,"phases":44053,"primaryCompletion":44054,"completion":44054,"start":10449,"enrollment":124,"conditions":44055,"interventions":44056},"NCT00968604","C-VISA BikDD: Liposome in Advanced Pancreatic Cancer",[87],"2017-03",[4107],[44044],{"trials":44058,"activeCount":124},[],{"trials":44060,"activeCount":124},[],{"trials":44062,"activeCount":124},[],{"trials":44064,"activeCount":124},[],{"intervention":12306,"totalTrials":166,"cells":44066},{"EARLY_PHASE1":44067,"PHASE1":44069,"PHASE2":44075,"PHASE3":44077,"PHASE4":44079,"NA":44081},{"trials":44068,"activeCount":124},[],{"trials":44070,"activeCount":124},[44071],{"nctId":12300,"briefTitle":12301,"status":130,"phases":44072,"primaryCompletion":3805,"completion":3805,"start":3988,"enrollment":2018,"conditions":44073,"interventions":44074},[87],[12304,18],[12306,2369],{"trials":44076,"activeCount":124},[],{"trials":44078,"activeCount":124},[],{"trials":44080,"activeCount":124},[],{"trials":44082,"activeCount":124},[],{"intervention":11803,"totalTrials":166,"cells":44084},{"EARLY_PHASE1":44085,"PHASE1":44087,"PHASE2":44093,"PHASE3":44095,"PHASE4":44097,"NA":44099},{"trials":44086,"activeCount":124},[],{"trials":44088,"activeCount":124},[44089],{"nctId":11795,"briefTitle":11796,"status":130,"phases":44090,"primaryCompletion":1844,"completion":1844,"start":11798,"enrollment":3521,"conditions":44091,"interventions":44092},[87],[1343,7308,7309,7310,7311,11800,7699,361,7313,7314,7315,7316,10825,11801,7891],[11803,1376],{"trials":44094,"activeCount":124},[],{"trials":44096,"activeCount":124},[],{"trials":44098,"activeCount":124},[],{"trials":44100,"activeCount":124},[],{"intervention":44102,"totalTrials":166,"cells":44103},"TTP607",{"EARLY_PHASE1":44104,"PHASE1":44106,"PHASE2":44114,"PHASE3":44116,"PHASE4":44118,"NA":44120},{"trials":44105,"activeCount":124},[],{"trials":44107,"activeCount":124},[44108],{"nctId":44109,"briefTitle":44110,"status":203,"phases":44111,"start":13673,"enrollment":124,"conditions":44112,"interventions":44113},"NCT00939172","TTP607 in Refractory Solid Malignancies",[87],[33,21],[44102],{"trials":44115,"activeCount":124},[],{"trials":44117,"activeCount":124},[],{"trials":44119,"activeCount":124},[],{"trials":44121,"activeCount":124},[],{"intervention":9989,"totalTrials":166,"cells":44123},{"EARLY_PHASE1":44124,"PHASE1":44126,"PHASE2":44132,"PHASE3":44134,"PHASE4":44136,"NA":44138},{"trials":44125,"activeCount":124},[],{"trials":44127,"activeCount":124},[44128],{"nctId":9976,"briefTitle":9977,"status":130,"phases":44129,"primaryCompletion":9487,"completion":9487,"start":9979,"enrollment":1231,"conditions":44130,"interventions":44131},[87],[4097,9981,9982,9983,9984,9985,9986,9987],[1369,9989,1376],{"trials":44133,"activeCount":124},[],{"trials":44135,"activeCount":124},[],{"trials":44137,"activeCount":124},[],{"trials":44139,"activeCount":124},[],{"intervention":10421,"totalTrials":166,"cells":44141},{"EARLY_PHASE1":44142,"PHASE1":44144,"PHASE2":44150,"PHASE3":44152,"PHASE4":44154,"NA":44156},{"trials":44143,"activeCount":124},[],{"trials":44145,"activeCount":124},[44146],{"nctId":10415,"briefTitle":10416,"status":130,"phases":44147,"primaryCompletion":4142,"completion":4142,"start":10418,"enrollment":1231,"conditions":44148,"interventions":44149},[87],[15],[510,10421,510],{"trials":44151,"activeCount":124},[],{"trials":44153,"activeCount":124},[],{"trials":44155,"activeCount":124},[],{"trials":44157,"activeCount":124},[],{"intervention":30973,"totalTrials":166,"cells":44159},{"EARLY_PHASE1":44160,"PHASE1":44162,"PHASE2":44168,"PHASE3":44170,"PHASE4":44172,"NA":44174},{"trials":44161,"activeCount":124},[],{"trials":44163,"activeCount":124},[44164],{"nctId":30967,"briefTitle":30968,"status":130,"phases":44165,"primaryCompletion":4842,"completion":4842,"start":30970,"enrollment":20891,"conditions":44166,"interventions":44167},[87],[3315],[30973,2584],{"trials":44169,"activeCount":124},[],{"trials":44171,"activeCount":124},[],{"trials":44173,"activeCount":124},[],{"trials":44175,"activeCount":124},[],{"intervention":44177,"totalTrials":166,"cells":44178},"Part 1",{"EARLY_PHASE1":44179,"PHASE1":44181,"PHASE2":44192,"PHASE3":44194,"PHASE4":44196,"NA":44198},{"trials":44180,"activeCount":124},[],{"trials":44182,"activeCount":124},[44183],{"nctId":44184,"briefTitle":44185,"status":203,"phases":44186,"primaryCompletion":44187,"completion":44187,"start":44188,"enrollment":124,"conditions":44189,"interventions":44190},"NCT05519527","STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis",[87],"2023-02-15","2022-08-16",[1145,3395],[44177,44191],"Part 2",{"trials":44193,"activeCount":124},[],{"trials":44195,"activeCount":124},[],{"trials":44197,"activeCount":124},[],{"trials":44199,"activeCount":124},[],{"intervention":44191,"totalTrials":166,"cells":44201},{"EARLY_PHASE1":44202,"PHASE1":44204,"PHASE2":44210,"PHASE3":44212,"PHASE4":44214,"NA":44216},{"trials":44203,"activeCount":124},[],{"trials":44205,"activeCount":124},[44206],{"nctId":44184,"briefTitle":44185,"status":203,"phases":44207,"primaryCompletion":44187,"completion":44187,"start":44188,"enrollment":124,"conditions":44208,"interventions":44209},[87],[1145,3395],[44177,44191],{"trials":44211,"activeCount":124},[],{"trials":44213,"activeCount":124},[],{"trials":44215,"activeCount":124},[],{"trials":44217,"activeCount":124},[],{"intervention":44219,"totalTrials":166,"cells":44220},"ZIO-101",{"EARLY_PHASE1":44221,"PHASE1":44223,"PHASE2":44231,"PHASE3":44233,"PHASE4":44235,"NA":44237},{"trials":44222,"activeCount":124},[],{"trials":44224,"activeCount":124},[44225],{"nctId":44226,"briefTitle":44227,"status":130,"phases":44228,"primaryCompletion":9560,"completion":9560,"start":2944,"enrollment":2997,"conditions":44229,"interventions":44230},"NCT00509782","Phase I Trial of ZIO-101 in Patients With Solid Tumors",[87],[1924],[44219],{"trials":44232,"activeCount":124},[],{"trials":44234,"activeCount":124},[],{"trials":44236,"activeCount":124},[],{"trials":44238,"activeCount":124},[],{"intervention":44240,"totalTrials":166,"cells":44241},"MSC-INFβ",{"EARLY_PHASE1":44242,"PHASE1":44244,"PHASE2":44253,"PHASE3":44255,"PHASE4":44257,"NA":44259},{"trials":44243,"activeCount":124},[],{"trials":44245,"activeCount":124},[44246],{"nctId":44247,"briefTitle":44248,"status":130,"phases":44249,"primaryCompletion":37354,"completion":37354,"start":44250,"enrollment":3197,"conditions":44251,"interventions":44252},"NCT02530047","Mesenchymal Stem Cells (MSC) for Ovarian Cancer",[87],"2016-05-16",[1530],[44240],{"trials":44254,"activeCount":124},[],{"trials":44256,"activeCount":124},[],{"trials":44258,"activeCount":124},[],{"trials":44260,"activeCount":124},[],{"intervention":44262,"totalTrials":166,"cells":44263},"[18F] Fluciclatide",{"EARLY_PHASE1":44264,"PHASE1":44266,"PHASE2":44274,"PHASE3":44276,"PHASE4":44278,"NA":44280},{"trials":44265,"activeCount":124},[],{"trials":44267,"activeCount":124},[44268],{"nctId":44269,"briefTitle":44270,"status":203,"phases":44271,"primaryCompletion":2738,"start":2846,"enrollment":124,"conditions":44272,"interventions":44273},"NCT02193672","A Pilot, Exploratory, Non-Randomized Study of PET\u002FCT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy",[87],[33],[44262],{"trials":44275,"activeCount":124},[],{"trials":44277,"activeCount":124},[],{"trials":44279,"activeCount":124},[],{"trials":44281,"activeCount":124},[],{"intervention":11821,"totalTrials":166,"cells":44283},{"EARLY_PHASE1":44284,"PHASE1":44286,"PHASE2":44292,"PHASE3":44294,"PHASE4":44296,"NA":44298},{"trials":44285,"activeCount":124},[],{"trials":44287,"activeCount":124},[44288],{"nctId":11813,"briefTitle":11814,"status":203,"phases":44289,"primaryCompletion":11816,"completion":11816,"start":11817,"enrollment":124,"conditions":44290,"interventions":44291},[87],[11819],[1376,11821,11822,1069],{"trials":44293,"activeCount":124},[],{"trials":44295,"activeCount":124},[],{"trials":44297,"activeCount":124},[],{"trials":44299,"activeCount":124},[],{"intervention":11822,"totalTrials":166,"cells":44301},{"EARLY_PHASE1":44302,"PHASE1":44304,"PHASE2":44310,"PHASE3":44312,"PHASE4":44314,"NA":44316},{"trials":44303,"activeCount":124},[],{"trials":44305,"activeCount":124},[44306],{"nctId":11813,"briefTitle":11814,"status":203,"phases":44307,"primaryCompletion":11816,"completion":11816,"start":11817,"enrollment":124,"conditions":44308,"interventions":44309},[87],[11819],[1376,11821,11822,1069],{"trials":44311,"activeCount":124},[],{"trials":44313,"activeCount":124},[],{"trials":44315,"activeCount":124},[],{"trials":44317,"activeCount":124},[],{"intervention":44319,"totalTrials":166,"cells":44320},"SCH 721015",{"EARLY_PHASE1":44321,"PHASE1":44323,"PHASE2":44331,"PHASE3":44333,"PHASE4":44335,"NA":44337},{"trials":44322,"activeCount":124},[],{"trials":44324,"activeCount":124},[44325],{"nctId":44326,"briefTitle":44327,"status":130,"phases":44328,"primaryCompletion":8718,"completion":8718,"start":12066,"enrollment":1483,"conditions":44329,"interventions":44330},"NCT01162785","1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer",[87],[1293],[44319],{"trials":44332,"activeCount":124},[],{"trials":44334,"activeCount":124},[],{"trials":44336,"activeCount":124},[],{"trials":44338,"activeCount":124},[],{"intervention":19697,"totalTrials":166,"cells":44340},{"EARLY_PHASE1":44341,"PHASE1":44343,"PHASE2":44349,"PHASE3":44351,"PHASE4":44353,"NA":44355},{"trials":44342,"activeCount":124},[],{"trials":44344,"activeCount":124},[44345],{"nctId":19690,"briefTitle":19691,"status":203,"phases":44346,"primaryCompletion":19693,"completion":19693,"start":19693,"enrollment":124,"conditions":44347,"interventions":44348},[87],[19695],[1198,19697,7021],{"trials":44350,"activeCount":124},[],{"trials":44352,"activeCount":124},[],{"trials":44354,"activeCount":124},[],{"trials":44356,"activeCount":124},[],{"intervention":33555,"totalTrials":166,"cells":44358},{"EARLY_PHASE1":44359,"PHASE1":44361,"PHASE2":44367,"PHASE3":44369,"PHASE4":44371,"NA":44373},{"trials":44360,"activeCount":124},[],{"trials":44362,"activeCount":124},[44363],{"nctId":33550,"briefTitle":33551,"status":182,"phases":44364,"primaryCompletion":27410,"completion":27410,"start":5522,"enrollment":1496,"conditions":44365,"interventions":44366},[87],[5735],[10263,33555],{"trials":44368,"activeCount":124},[],{"trials":44370,"activeCount":124},[],{"trials":44372,"activeCount":124},[],{"trials":44374,"activeCount":124},[],{"intervention":9056,"totalTrials":166,"cells":44376},{"EARLY_PHASE1":44377,"PHASE1":44379,"PHASE2":44385,"PHASE3":44387,"PHASE4":44389,"NA":44391},{"trials":44378,"activeCount":124},[],{"trials":44380,"activeCount":124},[44381],{"nctId":9049,"briefTitle":9050,"status":182,"phases":44382,"primaryCompletion":7672,"completion":7672,"start":9052,"enrollment":1766,"conditions":44383,"interventions":44384},[87],[644,630,913,608,649,9054,631,914,610,650,596],[654,1070,9056],{"trials":44386,"activeCount":124},[],{"trials":44388,"activeCount":124},[],{"trials":44390,"activeCount":124},[],{"trials":44392,"activeCount":124},[],{"intervention":44394,"totalTrials":166,"cells":44395},"BMTP-11",{"EARLY_PHASE1":44396,"PHASE1":44398,"PHASE2":44406,"PHASE3":44408,"PHASE4":44410,"NA":44412},{"trials":44397,"activeCount":124},[],{"trials":44399,"activeCount":124},[44400],{"nctId":44401,"briefTitle":44402,"status":130,"phases":44403,"primaryCompletion":2909,"start":2528,"enrollment":1496,"conditions":44404,"interventions":44405},"NCT00872157","BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets",[87],[27],[44394],{"trials":44407,"activeCount":124},[],{"trials":44409,"activeCount":124},[],{"trials":44411,"activeCount":124},[],{"trials":44413,"activeCount":124},[],{"intervention":21267,"totalTrials":166,"cells":44415},{"EARLY_PHASE1":44416,"PHASE1":44418,"PHASE2":44424,"PHASE3":44426,"PHASE4":44428,"NA":44430},{"trials":44417,"activeCount":124},[],{"trials":44419,"activeCount":124},[44420],{"nctId":21262,"briefTitle":21263,"status":130,"phases":44421,"primaryCompletion":185,"start":5988,"enrollment":1766,"conditions":44422,"interventions":44423},[87],[27],[3718,3719,15690,21267],{"trials":44425,"activeCount":124},[],{"trials":44427,"activeCount":124},[],{"trials":44429,"activeCount":124},[],{"trials":44431,"activeCount":124},[],{"intervention":44433,"totalTrials":166,"cells":44434},"Vioxx",{"EARLY_PHASE1":44435,"PHASE1":44437,"PHASE2":44446,"PHASE3":44448,"PHASE4":44450,"NA":44452},{"trials":44436,"activeCount":124},[],{"trials":44438,"activeCount":124},[44439],{"nctId":44440,"briefTitle":44441,"status":182,"phases":44442,"primaryCompletion":44443,"completion":7473,"start":9827,"enrollment":186,"conditions":44444,"interventions":44445},"NCT00038389","Study of Vioxx and Radiation Therapy for Brainstem Glioma",[87],"2004-10",[28813,11161],[44433],{"trials":44447,"activeCount":124},[],{"trials":44449,"activeCount":124},[],{"trials":44451,"activeCount":124},[],{"trials":44453,"activeCount":124},[],{"intervention":44455,"totalTrials":166,"cells":44456},"Tinostamustine",{"EARLY_PHASE1":44457,"PHASE1":44459,"PHASE2":44469,"PHASE3":44471,"PHASE4":44473,"NA":44475},{"trials":44458,"activeCount":124},[],{"trials":44460,"activeCount":124},[44461],{"nctId":44462,"briefTitle":44463,"status":130,"phases":44464,"primaryCompletion":4740,"completion":4740,"start":44465,"enrollment":3197,"conditions":44466,"interventions":44468},"NCT03452930","Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma",[87],"2018-08-13",[11042,11688,44467],"MGMT-Unmethylated Glioblastoma",[44455],{"trials":44470,"activeCount":124},[],{"trials":44472,"activeCount":124},[],{"trials":44474,"activeCount":124},[],{"trials":44476,"activeCount":124},[],{"intervention":11830,"totalTrials":166,"cells":44478},{"EARLY_PHASE1":44479,"PHASE1":44481,"PHASE2":44487,"PHASE3":44489,"PHASE4":44491,"NA":44493},{"trials":44480,"activeCount":124},[],{"trials":44482,"activeCount":124},[44483],{"nctId":11824,"briefTitle":11825,"status":182,"phases":44484,"primaryCompletion":8956,"completion":8956,"start":11827,"enrollment":550,"conditions":44485,"interventions":44486},[87],[1530],[11830,1376],{"trials":44488,"activeCount":124},[],{"trials":44490,"activeCount":124},[],{"trials":44492,"activeCount":124},[],{"trials":44494,"activeCount":124},[],{"intervention":23292,"totalTrials":166,"cells":44496},{"EARLY_PHASE1":44497,"PHASE1":44499,"PHASE2":44505,"PHASE3":44507,"PHASE4":44509,"NA":44511},{"trials":44498,"activeCount":124},[],{"trials":44500,"activeCount":124},[44501],{"nctId":23285,"briefTitle":23286,"status":182,"phases":44502,"primaryCompletion":7725,"completion":7725,"start":23288,"enrollment":186,"conditions":44503,"interventions":44504},[87],[23290],[4777,23292],{"trials":44506,"activeCount":124},[],{"trials":44508,"activeCount":124},[],{"trials":44510,"activeCount":124},[],{"trials":44512,"activeCount":124},[],{"intervention":44514,"totalTrials":166,"cells":44515},"STAT3 Inhibitor WP1066",{"EARLY_PHASE1":44516,"PHASE1":44518,"PHASE2":44528,"PHASE3":44530,"PHASE4":44532,"NA":44534},{"trials":44517,"activeCount":124},[],{"trials":44519,"activeCount":124},[44520],{"nctId":44521,"briefTitle":44522,"status":130,"phases":44523,"primaryCompletion":44524,"completion":44524,"start":44525,"enrollment":186,"conditions":44526,"interventions":44527},"NCT01904123","STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain",[87],"2022-03-16","2018-07-13",[1960,1316,6653,7740,3176],[44514],{"trials":44529,"activeCount":124},[],{"trials":44531,"activeCount":124},[],{"trials":44533,"activeCount":124},[],{"trials":44535,"activeCount":124},[],{"intervention":44537,"totalTrials":166,"cells":44538},"DS-3032b",{"EARLY_PHASE1":44539,"PHASE1":44541,"PHASE2":44549,"PHASE3":44551,"PHASE4":44553,"NA":44555},{"trials":44540,"activeCount":124},[],{"trials":44542,"activeCount":124},[44543],{"nctId":44544,"briefTitle":44545,"status":182,"phases":44546,"primaryCompletion":33100,"completion":33100,"start":214,"enrollment":2779,"conditions":44547,"interventions":44548},"NCT02579824","Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and\u002For Refractory Multiple Myeloma",[87],[2245],[44537],{"trials":44550,"activeCount":124},[],{"trials":44552,"activeCount":124},[],{"trials":44554,"activeCount":124},[],{"trials":44556,"activeCount":124},[],{"intervention":9079,"totalTrials":166,"cells":44558},{"EARLY_PHASE1":44559,"PHASE1":44561,"PHASE2":44567,"PHASE3":44569,"PHASE4":44571,"NA":44573},{"trials":44560,"activeCount":124},[],{"trials":44562,"activeCount":124},[44563],{"nctId":9074,"briefTitle":9075,"status":130,"phases":44564,"primaryCompletion":4085,"completion":4085,"start":6409,"enrollment":3197,"conditions":44565,"interventions":44566},[87],[4760],[9079,1070],{"trials":44568,"activeCount":124},[],{"trials":44570,"activeCount":124},[],{"trials":44572,"activeCount":124},[],{"trials":44574,"activeCount":124},[],{"intervention":44576,"totalTrials":166,"cells":44577},"LY2275796",{"EARLY_PHASE1":44578,"PHASE1":44580,"PHASE2":44588,"PHASE3":44590,"PHASE4":44592,"NA":44594},{"trials":44579,"activeCount":124},[],{"trials":44581,"activeCount":124},[44582],{"nctId":44583,"briefTitle":44584,"status":130,"phases":44585,"primaryCompletion":10844,"completion":10844,"start":4612,"enrollment":628,"conditions":44586,"interventions":44587},"NCT00903708","LY2275796 in Advanced Cancer",[87],[33],[44576],{"trials":44589,"activeCount":124},[],{"trials":44591,"activeCount":124},[],{"trials":44593,"activeCount":124},[],{"trials":44595,"activeCount":124},[],{"intervention":3919,"totalTrials":166,"cells":44597},{"EARLY_PHASE1":44598,"PHASE1":44600,"PHASE2":44606,"PHASE3":44608,"PHASE4":44610,"NA":44612},{"trials":44599,"activeCount":124},[],{"trials":44601,"activeCount":124},[44602],{"nctId":3907,"briefTitle":3908,"status":130,"phases":44603,"primaryCompletion":3910,"completion":3910,"start":3911,"enrollment":134,"conditions":44604,"interventions":44605},[87],[3913,3914,3915,3916,3917],[1709,1710,3919],{"trials":44607,"activeCount":124},[],{"trials":44609,"activeCount":124},[],{"trials":44611,"activeCount":124},[],{"trials":44613,"activeCount":124},[],{"intervention":9516,"totalTrials":166,"cells":44615},{"EARLY_PHASE1":44616,"PHASE1":44618,"PHASE2":44624,"PHASE3":44626,"PHASE4":44628,"NA":44630},{"trials":44617,"activeCount":124},[],{"trials":44619,"activeCount":124},[44620],{"nctId":9509,"briefTitle":9510,"status":130,"phases":44621,"primaryCompletion":9512,"completion":9512,"start":9513,"enrollment":834,"conditions":44622,"interventions":44623},[87],[15,1036],[9516,654],{"trials":44625,"activeCount":124},[],{"trials":44627,"activeCount":124},[],{"trials":44629,"activeCount":124},[],{"trials":44631,"activeCount":124},[],{"intervention":44633,"totalTrials":166,"cells":44634},"8-Chloro-Adenosine",{"EARLY_PHASE1":44635,"PHASE1":44637,"PHASE2":44645,"PHASE3":44647,"PHASE4":44649,"NA":44651},{"trials":44636,"activeCount":124},[],{"trials":44638,"activeCount":124},[44639],{"nctId":44640,"briefTitle":44641,"status":130,"phases":44642,"primaryCompletion":3667,"completion":3667,"start":7236,"enrollment":95,"conditions":44643,"interventions":44644},"NCT00714103","8-Chloro-Adenosine in Chronic Lymphocytic Leukemia",[87],[15,712],[44633],{"trials":44646,"activeCount":124},[],{"trials":44648,"activeCount":124},[],{"trials":44650,"activeCount":124},[],{"trials":44652,"activeCount":124},[],{"intervention":44654,"totalTrials":166,"cells":44655},"CHPP of Cisplatin",{"EARLY_PHASE1":44656,"PHASE1":44658,"PHASE2":44671,"PHASE3":44673,"PHASE4":44675,"NA":44677},{"trials":44657,"activeCount":124},[],{"trials":44659,"activeCount":124},[44660],{"nctId":44661,"briefTitle":44662,"status":130,"phases":44663,"primaryCompletion":12066,"completion":12066,"start":5435,"enrollment":1496,"conditions":44664,"interventions":44670},"NCT00436657","Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer",[87],[33423,44665,44666,6684,5735,44667,2971,6168,44668,44669,3449],"Retroperitoneal Neoplasms","Gastrointestinal Neoplasms","Ovarian Neoplasms","Wilms Tumor","Rhabdomyosarcoma",[44654],{"trials":44672,"activeCount":124},[],{"trials":44674,"activeCount":124},[],{"trials":44676,"activeCount":124},[],{"trials":44678,"activeCount":124},[],{"intervention":44680,"totalTrials":166,"cells":44681},"Group 1: TK216",{"EARLY_PHASE1":44682,"PHASE1":44684,"PHASE2":44699,"PHASE3":44701,"PHASE4":44703,"NA":44705},{"trials":44683,"activeCount":124},[],{"trials":44685,"activeCount":124},[44686],{"nctId":44687,"briefTitle":44688,"status":203,"phases":44689,"primaryCompletion":27013,"completion":27013,"start":44690,"enrollment":124,"conditions":44691,"interventions":44692},"NCT03752138","TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia",[87],"2019-03-31",[608,610],[44680,44693,44694,44695,44696,44697,44698],"Group 2: TK216","Part 2: Decitabine 10mg\u002Fm2","Part 2: Decitabine 20 mg\u002Fm2","Expansion Phase TK216","Expansion Phase Decitabine","Part 2: TK216",{"trials":44700,"activeCount":124},[],{"trials":44702,"activeCount":124},[],{"trials":44704,"activeCount":124},[],{"trials":44706,"activeCount":124},[],{"intervention":44693,"totalTrials":166,"cells":44708},{"EARLY_PHASE1":44709,"PHASE1":44711,"PHASE2":44717,"PHASE3":44719,"PHASE4":44721,"NA":44723},{"trials":44710,"activeCount":124},[],{"trials":44712,"activeCount":124},[44713],{"nctId":44687,"briefTitle":44688,"status":203,"phases":44714,"primaryCompletion":27013,"completion":27013,"start":44690,"enrollment":124,"conditions":44715,"interventions":44716},[87],[608,610],[44680,44693,44694,44695,44696,44697,44698],{"trials":44718,"activeCount":124},[],{"trials":44720,"activeCount":124},[],{"trials":44722,"activeCount":124},[],{"trials":44724,"activeCount":124},[],{"intervention":44694,"totalTrials":166,"cells":44726},{"EARLY_PHASE1":44727,"PHASE1":44729,"PHASE2":44735,"PHASE3":44737,"PHASE4":44739,"NA":44741},{"trials":44728,"activeCount":124},[],{"trials":44730,"activeCount":124},[44731],{"nctId":44687,"briefTitle":44688,"status":203,"phases":44732,"primaryCompletion":27013,"completion":27013,"start":44690,"enrollment":124,"conditions":44733,"interventions":44734},[87],[608,610],[44680,44693,44694,44695,44696,44697,44698],{"trials":44736,"activeCount":124},[],{"trials":44738,"activeCount":124},[],{"trials":44740,"activeCount":124},[],{"trials":44742,"activeCount":124},[],{"intervention":44695,"totalTrials":166,"cells":44744},{"EARLY_PHASE1":44745,"PHASE1":44747,"PHASE2":44753,"PHASE3":44755,"PHASE4":44757,"NA":44759},{"trials":44746,"activeCount":124},[],{"trials":44748,"activeCount":124},[44749],{"nctId":44687,"briefTitle":44688,"status":203,"phases":44750,"primaryCompletion":27013,"completion":27013,"start":44690,"enrollment":124,"conditions":44751,"interventions":44752},[87],[608,610],[44680,44693,44694,44695,44696,44697,44698],{"trials":44754,"activeCount":124},[],{"trials":44756,"activeCount":124},[],{"trials":44758,"activeCount":124},[],{"trials":44760,"activeCount":124},[],{"intervention":44696,"totalTrials":166,"cells":44762},{"EARLY_PHASE1":44763,"PHASE1":44765,"PHASE2":44771,"PHASE3":44773,"PHASE4":44775,"NA":44777},{"trials":44764,"activeCount":124},[],{"trials":44766,"activeCount":124},[44767],{"nctId":44687,"briefTitle":44688,"status":203,"phases":44768,"primaryCompletion":27013,"completion":27013,"start":44690,"enrollment":124,"conditions":44769,"interventions":44770},[87],[608,610],[44680,44693,44694,44695,44696,44697,44698],{"trials":44772,"activeCount":124},[],{"trials":44774,"activeCount":124},[],{"trials":44776,"activeCount":124},[],{"trials":44778,"activeCount":124},[],{"intervention":44697,"totalTrials":166,"cells":44780},{"EARLY_PHASE1":44781,"PHASE1":44783,"PHASE2":44789,"PHASE3":44791,"PHASE4":44793,"NA":44795},{"trials":44782,"activeCount":124},[],{"trials":44784,"activeCount":124},[44785],{"nctId":44687,"briefTitle":44688,"status":203,"phases":44786,"primaryCompletion":27013,"completion":27013,"start":44690,"enrollment":124,"conditions":44787,"interventions":44788},[87],[608,610],[44680,44693,44694,44695,44696,44697,44698],{"trials":44790,"activeCount":124},[],{"trials":44792,"activeCount":124},[],{"trials":44794,"activeCount":124},[],{"trials":44796,"activeCount":124},[],{"intervention":44698,"totalTrials":166,"cells":44798},{"EARLY_PHASE1":44799,"PHASE1":44801,"PHASE2":44807,"PHASE3":44809,"PHASE4":44811,"NA":44813},{"trials":44800,"activeCount":124},[],{"trials":44802,"activeCount":124},[44803],{"nctId":44687,"briefTitle":44688,"status":203,"phases":44804,"primaryCompletion":27013,"completion":27013,"start":44690,"enrollment":124,"conditions":44805,"interventions":44806},[87],[608,610],[44680,44693,44694,44695,44696,44697,44698],{"trials":44808,"activeCount":124},[],{"trials":44810,"activeCount":124},[],{"trials":44812,"activeCount":124},[],{"trials":44814,"activeCount":124},[],{"intervention":3188,"totalTrials":166,"cells":44816},{"EARLY_PHASE1":44817,"PHASE1":44819,"PHASE2":44825,"PHASE3":44827,"PHASE4":44829,"NA":44831},{"trials":44818,"activeCount":124},[],{"trials":44820,"activeCount":124},[44821],{"nctId":3181,"briefTitle":3182,"status":130,"phases":44822,"primaryCompletion":3184,"completion":3184,"start":640,"enrollment":406,"conditions":44823,"interventions":44824},[87],[3186,610],[654,1069,2712,1005,3188],{"trials":44826,"activeCount":124},[],{"trials":44828,"activeCount":124},[],{"trials":44830,"activeCount":124},[],{"trials":44832,"activeCount":124},[],{"intervention":6673,"totalTrials":166,"cells":44834},{"EARLY_PHASE1":44835,"PHASE1":44837,"PHASE2":44843,"PHASE3":44845,"PHASE4":44847,"NA":44849},{"trials":44836,"activeCount":124},[],{"trials":44838,"activeCount":124},[44839],{"nctId":6662,"briefTitle":6663,"status":182,"phases":44840,"primaryCompletion":2518,"completion":2518,"start":6665,"enrollment":296,"conditions":44841,"interventions":44842},[87],[6667,1142,665,6668,789,3060,2593,6669,666,1144,528,6670,790,3062,2594,6671,529],[6673,803,1070],{"trials":44844,"activeCount":124},[],{"trials":44846,"activeCount":124},[],{"trials":44848,"activeCount":124},[],{"trials":44850,"activeCount":124},[],{"intervention":44852,"totalTrials":166,"cells":44853},"LOC-paclitaxel",{"EARLY_PHASE1":44854,"PHASE1":44856,"PHASE2":44864,"PHASE3":44866,"PHASE4":44868,"NA":44870},{"trials":44855,"activeCount":124},[],{"trials":44857,"activeCount":124},[44858],{"nctId":44859,"briefTitle":44860,"status":182,"phases":44861,"primaryCompletion":2288,"completion":2288,"start":13586,"enrollment":1609,"conditions":44862,"interventions":44863},"NCT01039844","Study of Weekly LOC-paclitaxel Injection for Melanoma",[87],[1729],[44852],{"trials":44865,"activeCount":124},[],{"trials":44867,"activeCount":124},[],{"trials":44869,"activeCount":124},[],{"trials":44871,"activeCount":124},[],{"intervention":44873,"totalTrials":166,"cells":44874},"MT-0169",{"EARLY_PHASE1":44875,"PHASE1":44877,"PHASE2":44886,"PHASE3":44888,"PHASE4":44890,"NA":44892},{"trials":44876,"activeCount":124},[],{"trials":44878,"activeCount":124},[44879],{"nctId":44880,"briefTitle":44881,"status":203,"phases":44882,"primaryCompletion":44883,"completion":44883,"start":44883,"enrollment":124,"conditions":44884,"interventions":44885},"NCT06522373","Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed\u002FRefractory or Measurable Residual Disease",[87],"2024-10-21",[15],[44873],{"trials":44887,"activeCount":124},[],{"trials":44889,"activeCount":124},[],{"trials":44891,"activeCount":124},[],{"trials":44893,"activeCount":124},[],{"intervention":44895,"totalTrials":166,"cells":44896},"Fluorine F 18 rhPSMA-7.3",{"EARLY_PHASE1":44897,"PHASE1":44899,"PHASE2":44909,"PHASE3":44911,"PHASE4":44913,"NA":44915},{"trials":44898,"activeCount":124},[],{"trials":44900,"activeCount":124},[44901],{"nctId":44902,"briefTitle":44903,"status":130,"phases":44904,"primaryCompletion":19708,"completion":19708,"start":44905,"enrollment":1409,"conditions":44906,"interventions":44908},"NCT04978675","An Investigational Scan (rh PSMA 7.3 PET\u002FMRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer",[87],"2021-08-04",[5131,44907,5122],"Localized Prostate Carcinoma",[44895],{"trials":44910,"activeCount":124},[],{"trials":44912,"activeCount":124},[],{"trials":44914,"activeCount":124},[],{"trials":44916,"activeCount":124},[],{"intervention":34183,"totalTrials":166,"cells":44918},{"EARLY_PHASE1":44919,"PHASE1":44921,"PHASE2":44927,"PHASE3":44929,"PHASE4":44931,"NA":44933},{"trials":44920,"activeCount":124},[],{"trials":44922,"activeCount":124},[44923],{"nctId":34178,"briefTitle":34179,"status":130,"phases":44924,"primaryCompletion":3725,"completion":3725,"start":4697,"enrollment":1975,"conditions":44925,"interventions":44926},[87],[1942],[34183,34184,12277],{"trials":44928,"activeCount":124},[],{"trials":44930,"activeCount":124},[],{"trials":44932,"activeCount":124},[],{"trials":44934,"activeCount":124},[],{"intervention":34184,"totalTrials":166,"cells":44936},{"EARLY_PHASE1":44937,"PHASE1":44939,"PHASE2":44945,"PHASE3":44947,"PHASE4":44949,"NA":44951},{"trials":44938,"activeCount":124},[],{"trials":44940,"activeCount":124},[44941],{"nctId":34178,"briefTitle":34179,"status":130,"phases":44942,"primaryCompletion":3725,"completion":3725,"start":4697,"enrollment":1975,"conditions":44943,"interventions":44944},[87],[1942],[34183,34184,12277],{"trials":44946,"activeCount":124},[],{"trials":44948,"activeCount":124},[],{"trials":44950,"activeCount":124},[],{"trials":44952,"activeCount":124},[],{"intervention":44954,"totalTrials":166,"cells":44955},"F18 Fluciclovine",{"EARLY_PHASE1":44956,"PHASE1":44964,"PHASE2":44966,"PHASE3":44968,"PHASE4":44970,"NA":44972},{"trials":44957,"activeCount":124},[44958],{"nctId":44959,"briefTitle":44960,"status":203,"phases":44961,"primaryCompletion":7986,"completion":7986,"start":16554,"enrollment":124,"conditions":44962,"interventions":44963},"NCT05054400","Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR",[86],[1520,5349,27361,11042],[44954],{"trials":44965,"activeCount":124},[],{"trials":44967,"activeCount":124},[],{"trials":44969,"activeCount":124},[],{"trials":44971,"activeCount":124},[],{"trials":44973,"activeCount":124},[],{"intervention":4973,"totalTrials":166,"cells":44975},{"EARLY_PHASE1":44976,"PHASE1":44982,"PHASE2":44984,"PHASE3":44986,"PHASE4":44988,"NA":44990},{"trials":44977,"activeCount":124},[44978],{"nctId":4931,"briefTitle":4932,"status":130,"phases":44979,"primaryCompletion":4934,"completion":4934,"start":4935,"enrollment":507,"conditions":44980,"interventions":44981},[86],[4937,4938,4939,4940,4941,4942,4943,4944,4945,4946,4947,4948,4949,4950,4951,4952,4953,4954,4955,4956,4957,4958,4959,4960,4961,4962,4963,4964,4965,4966,4967,4968,4969,4970,4971],[4896,4973],{"trials":44983,"activeCount":124},[],{"trials":44985,"activeCount":124},[],{"trials":44987,"activeCount":124},[],{"trials":44989,"activeCount":124},[],{"trials":44991,"activeCount":124},[],{"intervention":16600,"totalTrials":166,"cells":44993},{"EARLY_PHASE1":44994,"PHASE1":45000,"PHASE2":45002,"PHASE3":45004,"PHASE4":45006,"NA":45008},{"trials":44995,"activeCount":124},[44996],{"nctId":16594,"briefTitle":16595,"status":182,"phases":44997,"primaryCompletion":16597,"completion":16597,"start":162,"enrollment":166,"conditions":44998,"interventions":44999},[86],[21],[1071,16600],{"trials":45001,"activeCount":124},[],{"trials":45003,"activeCount":124},[],{"trials":45005,"activeCount":124},[],{"trials":45007,"activeCount":124},[],{"trials":45009,"activeCount":124},[],{"intervention":45011,"totalTrials":166,"cells":45012},"Quercetin",{"EARLY_PHASE1":45013,"PHASE1":45025,"PHASE2":45027,"PHASE3":45029,"PHASE4":45031,"NA":45033},{"trials":45014,"activeCount":124},[45015],{"nctId":45016,"briefTitle":45017,"status":203,"phases":45018,"primaryCompletion":45019,"completion":45019,"start":45020,"enrollment":124,"conditions":45021,"interventions":45024},"NCT02989129","Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients",[86],"2020-04","2018-04",[45022,45023],"Polyneuropathies and Other Disorders of the Peripheral Nervous System","Chemotherapy Induced Neuropathic Pain",[45011],{"trials":45026,"activeCount":124},[],{"trials":45028,"activeCount":124},[],{"trials":45030,"activeCount":124},[],{"trials":45032,"activeCount":124},[],{"trials":45034,"activeCount":124},[],{"intervention":12245,"totalTrials":166,"cells":45036},{"EARLY_PHASE1":45037,"PHASE1":45043,"PHASE2":45045,"PHASE3":45047,"PHASE4":45049,"NA":45051},{"trials":45038,"activeCount":124},[45039],{"nctId":12239,"briefTitle":12240,"status":182,"phases":45040,"primaryCompletion":12242,"completion":12242,"start":6757,"enrollment":550,"conditions":45041,"interventions":45042},[86],[4107],[2369,12245],{"trials":45044,"activeCount":124},[],{"trials":45046,"activeCount":124},[],{"trials":45048,"activeCount":124},[],{"trials":45050,"activeCount":124},[],{"trials":45052,"activeCount":124},[],{"intervention":364,"totalTrials":166,"cells":45054},{"EARLY_PHASE1":45055,"PHASE1":45061,"PHASE2":45063,"PHASE3":45065,"PHASE4":45067,"NA":45069},{"trials":45056,"activeCount":124},[45057],{"nctId":352,"briefTitle":353,"status":182,"phases":45058,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":45059,"interventions":45060},[86],[359,360,361],[363,347,364,365,366,367],{"trials":45062,"activeCount":124},[],{"trials":45064,"activeCount":124},[],{"trials":45066,"activeCount":124},[],{"trials":45068,"activeCount":124},[],{"trials":45070,"activeCount":124},[],{"intervention":367,"totalTrials":166,"cells":45072},{"EARLY_PHASE1":45073,"PHASE1":45079,"PHASE2":45081,"PHASE3":45083,"PHASE4":45085,"NA":45087},{"trials":45074,"activeCount":124},[45075],{"nctId":352,"briefTitle":353,"status":182,"phases":45076,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":45077,"interventions":45078},[86],[359,360,361],[363,347,364,365,366,367],{"trials":45080,"activeCount":124},[],{"trials":45082,"activeCount":124},[],{"trials":45084,"activeCount":124},[],{"trials":45086,"activeCount":124},[],{"trials":45088,"activeCount":124},[],{"intervention":45090,"totalTrials":166,"cells":45091},"Ferumoxytol",{"EARLY_PHASE1":45092,"PHASE1":45102,"PHASE2":45104,"PHASE3":45106,"PHASE4":45108,"NA":45110},{"trials":45093,"activeCount":124},[45094],{"nctId":45095,"briefTitle":45096,"status":182,"phases":45097,"primaryCompletion":45098,"completion":45098,"start":45099,"enrollment":1483,"conditions":45100,"interventions":45101},"NCT01895829","Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI",[86],"2021-09-07","2013-09-12",[242],[45090],{"trials":45103,"activeCount":124},[],{"trials":45105,"activeCount":124},[],{"trials":45107,"activeCount":124},[],{"trials":45109,"activeCount":124},[],{"trials":45111,"activeCount":124},[],{"intervention":45113,"totalTrials":166,"cells":45114},"Gallium Ga 68-Edotreotide",{"EARLY_PHASE1":45115,"PHASE1":45128,"PHASE2":45130,"PHASE3":45132,"PHASE4":45134,"NA":45136},{"trials":45116,"activeCount":124},[45117],{"nctId":45118,"briefTitle":45119,"status":182,"phases":45120,"primaryCompletion":45121,"completion":45121,"start":45122,"enrollment":296,"conditions":45123,"interventions":45127},"NCT03001349","68Ga-DOTA-TOC PET\u002FCT in Imaging Participants With Neuroendocrine Tumors",[86],"2021-02-05","2017-05-16",[45124,45125,14110,3873,45126,34521],"Meningioma","Metastatic Well Differentiated Neuroendocrine Neoplasm","Somatostatin Positive Neoplastic Cells Present",[45113],{"trials":45129,"activeCount":124},[],{"trials":45131,"activeCount":124},[],{"trials":45133,"activeCount":124},[],{"trials":45135,"activeCount":124},[],{"trials":45137,"activeCount":124},[],{"intervention":45139,"totalTrials":166,"cells":45140},"Arginine recovery supplement",{"EARLY_PHASE1":45141,"PHASE1":45150,"PHASE2":45152,"PHASE3":45154,"PHASE4":45156,"NA":45158},{"trials":45142,"activeCount":124},[45143],{"nctId":45144,"briefTitle":45145,"status":130,"phases":45146,"primaryCompletion":45147,"completion":45147,"start":38386,"enrollment":4171,"conditions":45148,"interventions":45149},"NCT03204266","Oral Supplementation to Enhance Recovery Pilot Study",[86],"2022-05-25",[7656],[45139],{"trials":45151,"activeCount":124},[],{"trials":45153,"activeCount":124},[],{"trials":45155,"activeCount":124},[],{"trials":45157,"activeCount":124},[],{"trials":45159,"activeCount":124},[],{"intervention":45161,"totalTrials":166,"cells":45162},"BMN 673",{"EARLY_PHASE1":45163,"PHASE1":45174,"PHASE2":45176,"PHASE3":45178,"PHASE4":45180,"NA":45182},{"trials":45164,"activeCount":124},[45165],{"nctId":45166,"briefTitle":45167,"status":130,"phases":45168,"primaryCompletion":45169,"completion":45169,"start":45170,"enrollment":296,"conditions":45171,"interventions":45173},"NCT02316834","Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[86],"2022-01-14","2015-06-02",[4940,4911,45172,4948,4957,4958,4959,4960,4961,4962,4963,4964,4965,4966,4967,4968,4969,4970,4971],"Ovarian Mass",[45161],{"trials":45175,"activeCount":124},[],{"trials":45177,"activeCount":124},[],{"trials":45179,"activeCount":124},[],{"trials":45181,"activeCount":124},[],{"trials":45183,"activeCount":124},[],{"intervention":13385,"totalTrials":166,"cells":45185},{"EARLY_PHASE1":45186,"PHASE1":45192,"PHASE2":45194,"PHASE3":45196,"PHASE4":45198,"NA":45200},{"trials":45187,"activeCount":124},[45188],{"nctId":13379,"briefTitle":13380,"status":130,"phases":45189,"primaryCompletion":7905,"completion":7905,"start":13382,"enrollment":406,"conditions":45190,"interventions":45191},[86],[7505],[1402,13385],{"trials":45193,"activeCount":124},[],{"trials":45195,"activeCount":124},[],{"trials":45197,"activeCount":124},[],{"trials":45199,"activeCount":124},[],{"trials":45201,"activeCount":124},[],{"intervention":35302,"totalTrials":166,"cells":45203},{"EARLY_PHASE1":45204,"PHASE1":45210,"PHASE2":45212,"PHASE3":45214,"PHASE4":45216,"NA":45218},{"trials":45205,"activeCount":124},[45206],{"nctId":35295,"briefTitle":35296,"status":203,"phases":45207,"primaryCompletion":35298,"completion":35298,"start":35299,"enrollment":124,"conditions":45208,"interventions":45209},[86],[7963],[35302,7916],{"trials":45211,"activeCount":124},[],{"trials":45213,"activeCount":124},[],{"trials":45215,"activeCount":124},[],{"trials":45217,"activeCount":124},[],{"trials":45219,"activeCount":124},[],{"intervention":45221,"totalTrials":166,"cells":45222},"Sulfur Hexafluoride Lipid Microspheres",{"EARLY_PHASE1":45223,"PHASE1":45233,"PHASE2":45235,"PHASE3":45237,"PHASE4":45239,"NA":45241},{"trials":45224,"activeCount":124},[45225],{"nctId":45226,"briefTitle":45227,"status":130,"phases":45228,"primaryCompletion":8153,"completion":8153,"start":45229,"enrollment":910,"conditions":45230,"interventions":45232},"NCT03407001","Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis",[86],"2018-01-12",[45231],"Cirrhosis",[45221],{"trials":45234,"activeCount":124},[],{"trials":45236,"activeCount":124},[],{"trials":45238,"activeCount":124},[],{"trials":45240,"activeCount":124},[],{"trials":45242,"activeCount":124},[],{"intervention":45244,"totalTrials":166,"cells":45245},"18F-FSPG",{"EARLY_PHASE1":45246,"PHASE1":45255,"PHASE2":45257,"PHASE3":45259,"PHASE4":45261,"NA":45263},{"trials":45247,"activeCount":124},[45248],{"nctId":45249,"briefTitle":45250,"status":182,"phases":45251,"primaryCompletion":581,"completion":581,"start":1825,"enrollment":1231,"conditions":45252,"interventions":45253},"NCT05322135","A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma",[86],[450,242],[45244,45254],"11C-Glutamine",{"trials":45256,"activeCount":124},[],{"trials":45258,"activeCount":124},[],{"trials":45260,"activeCount":124},[],{"trials":45262,"activeCount":124},[],{"trials":45264,"activeCount":124},[],{"intervention":45254,"totalTrials":166,"cells":45266},{"EARLY_PHASE1":45267,"PHASE1":45273,"PHASE2":45275,"PHASE3":45277,"PHASE4":45279,"NA":45281},{"trials":45268,"activeCount":124},[45269],{"nctId":45249,"briefTitle":45250,"status":182,"phases":45270,"primaryCompletion":581,"completion":581,"start":1825,"enrollment":1231,"conditions":45271,"interventions":45272},[86],[450,242],[45244,45254],{"trials":45274,"activeCount":124},[],{"trials":45276,"activeCount":124},[],{"trials":45278,"activeCount":124},[],{"trials":45280,"activeCount":124},[],{"trials":45282,"activeCount":124},[],{"intervention":45284,"totalTrials":166,"cells":45285},"SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes",{"EARLY_PHASE1":45286,"PHASE1":45296,"PHASE2":45298,"PHASE3":45300,"PHASE4":45302,"NA":45304},{"trials":45287,"activeCount":124},[45288],{"nctId":45289,"briefTitle":45290,"status":130,"phases":45291,"primaryCompletion":45292,"completion":45292,"start":45293,"enrollment":507,"conditions":45294,"interventions":45295},"NCT04742595","Viral Specific T Cell Therapy for COVID-19 Related Pneumonia",[86],"2024-09-20","2020-12-18",[359,360,25732],[45284],{"trials":45297,"activeCount":124},[],{"trials":45299,"activeCount":124},[],{"trials":45301,"activeCount":124},[],{"trials":45303,"activeCount":124},[],{"trials":45305,"activeCount":124},[],{"intervention":2321,"totalTrials":492,"cells":45307},{"EARLY_PHASE1":45308,"PHASE1":45310,"PHASE2":45332,"PHASE3":45401,"PHASE4":45403,"NA":45405},{"trials":45309,"activeCount":124},[],{"trials":45311,"activeCount":124},[45312,45316,45320,45324,45328],{"nctId":3526,"briefTitle":3527,"status":130,"phases":45313,"primaryCompletion":3529,"completion":3530,"start":3531,"enrollment":1154,"conditions":45314,"interventions":45315},[87],[1343,3533,1312,3534,361,1316,1353,1365,1951],[2321,1049],{"nctId":15473,"briefTitle":15474,"status":182,"phases":45317,"primaryCompletion":12780,"completion":12780,"start":15476,"enrollment":186,"conditions":45318,"interventions":45319},[87],[4598,15478,3040,1026],[1028,2321,15480,598],{"nctId":14852,"briefTitle":14853,"status":130,"phases":45321,"primaryCompletion":2213,"completion":2213,"start":9827,"enrollment":3521,"conditions":45322,"interventions":45323},[87],[27],[14857,14858],{"nctId":2313,"briefTitle":2314,"status":130,"phases":45325,"primaryCompletion":2316,"completion":2316,"start":2317,"enrollment":1766,"conditions":45326,"interventions":45327},[87],[2319],[1709,2321,1377,62],{"nctId":28138,"briefTitle":28139,"status":130,"phases":45329,"primaryCompletion":28141,"completion":28141,"start":28142,"enrollment":3820,"conditions":45330,"interventions":45331},[87],[4725],[17569,2321],{"trials":45333,"activeCount":124},[45334,45338,45342,45346,45352,45356,45360,45367,45371,45375,45379,45383,45387,45391,45397],{"nctId":14874,"briefTitle":14875,"status":130,"phases":45335,"primaryCompletion":13673,"completion":13673,"start":9512,"enrollment":1483,"conditions":45336,"interventions":45337},[88],[242,14878],[2321,1710],{"nctId":14881,"briefTitle":14882,"status":130,"phases":45339,"primaryCompletion":10784,"completion":7236,"start":14884,"enrollment":3820,"conditions":45340,"interventions":45341},[88],[7818,27],[1710,14887],{"nctId":36527,"briefTitle":36528,"status":130,"phases":45343,"primaryCompletion":6384,"completion":6384,"start":12101,"enrollment":910,"conditions":45344,"interventions":45345},[87,88],[4659,18054,4725],[2321,36518],{"nctId":45347,"briefTitle":45348,"status":130,"phases":45349,"primaryCompletion":5232,"completion":5232,"start":12725,"enrollment":606,"conditions":45350,"interventions":45351},"NCT00510653","Gleevec Study for Patients With Ovarian Cancer",[88],[1530],[2321],{"nctId":4662,"briefTitle":4663,"status":182,"phases":45353,"primaryCompletion":2836,"completion":2836,"start":4665,"enrollment":924,"conditions":45354,"interventions":45355},[88],[15],[2321,1070,1004,4668,2196,806],{"nctId":14916,"briefTitle":14917,"status":130,"phases":45357,"primaryCompletion":8551,"completion":8551,"start":6758,"enrollment":2865,"conditions":45358,"interventions":45359},[88],[27],[1710,2321,3718,11343],{"nctId":45361,"briefTitle":45362,"status":130,"phases":45363,"primaryCompletion":7473,"completion":7473,"start":5268,"enrollment":492,"conditions":45364,"interventions":45366},"NCT00027586","Imatinib Mesylate in Treating Patients With Metastatic Melanoma",[88],[1729,45365],"Skin Neoplasms",[14887],{"nctId":38740,"briefTitle":38741,"status":182,"phases":45368,"primaryCompletion":2806,"completion":2806,"start":2969,"enrollment":1231,"conditions":45369,"interventions":45370},[88],[4725],[2321,38731],{"nctId":2695,"briefTitle":2696,"status":130,"phases":45372,"primaryCompletion":2698,"completion":2698,"start":2699,"enrollment":2700,"conditions":45373,"interventions":45374},[88],[15],[2321,803,1013,1016,62,806,654,1114,2374],{"nctId":14945,"briefTitle":14946,"status":130,"phases":45376,"primaryCompletion":10075,"completion":6828,"start":14884,"enrollment":1001,"conditions":45377,"interventions":45378},[88],[7818,27],[1710,2321],{"nctId":14951,"briefTitle":14952,"status":130,"phases":45380,"primaryCompletion":5733,"completion":7155,"start":7473,"enrollment":492,"conditions":45381,"interventions":45382},[88],[10145],[2321,1710],{"nctId":4720,"briefTitle":4721,"status":130,"phases":45384,"primaryCompletion":4192,"completion":4723,"start":3902,"enrollment":628,"conditions":45385,"interventions":45386},[88],[4725],[1004,803,2321],{"nctId":11943,"briefTitle":11944,"status":182,"phases":45388,"primaryCompletion":8339,"completion":8339,"start":11946,"enrollment":539,"conditions":45389,"interventions":45390},[87,88],[11078],[2321,1376],{"nctId":45392,"briefTitle":45393,"status":130,"phases":45394,"primaryCompletion":7155,"completion":7155,"start":14980,"enrollment":3521,"conditions":45395,"interventions":45396},"NCT00500188","Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST",[88],[21132],[2321],{"nctId":18330,"briefTitle":18331,"status":130,"phases":45398,"primaryCompletion":5954,"completion":5954,"start":18333,"enrollment":7377,"conditions":45399,"interventions":45400},[88],[7312,11800,18335,18336,14081,13135,7317],[2321,14086],{"trials":45402,"activeCount":124},[],{"trials":45404,"activeCount":124},[],{"trials":45406,"activeCount":124},[45407,45413],{"nctId":45408,"briefTitle":45409,"status":130,"phases":45410,"primaryCompletion":5733,"completion":5733,"start":4350,"enrollment":1496,"conditions":45411,"interventions":45412},"NCT00386373","Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients",[91],[15],[2321],{"nctId":45414,"briefTitle":45415,"status":130,"phases":45416,"primaryCompletion":4162,"completion":4162,"start":7487,"enrollment":560,"conditions":45417,"interventions":45418},"NCT00038675","Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate",[91],[737,3315,745,18055,18056],[2321],{"intervention":4537,"totalTrials":1568,"cells":45420},{"EARLY_PHASE1":45421,"PHASE1":45423,"PHASE2":45429,"PHASE3":45479,"PHASE4":45485,"NA":45487},{"trials":45422,"activeCount":124},[],{"trials":45424,"activeCount":124},[45425],{"nctId":4532,"briefTitle":4533,"status":130,"phases":45426,"primaryCompletion":206,"completion":206,"start":4039,"enrollment":1568,"conditions":45427,"interventions":45428},[87],[30,15],[4537,1004,1070,2374,2196,806,3499],{"trials":45430,"activeCount":124},[45431,45435,45439,45443,45447,45451,45455,45459,45463,45467,45471,45475],{"nctId":4567,"briefTitle":4568,"status":130,"phases":45432,"primaryCompletion":1505,"completion":1505,"start":4570,"enrollment":3379,"conditions":45433,"interventions":45434},[88],[3429],[1004,1070,4537],{"nctId":4609,"briefTitle":4610,"status":130,"phases":45436,"primaryCompletion":3571,"completion":3571,"start":4612,"enrollment":2647,"conditions":45437,"interventions":45438},[88],[36,30,3315],[2423,1004,1070,4537,1069],{"nctId":19010,"briefTitle":19011,"status":130,"phases":45440,"primaryCompletion":5434,"completion":5434,"start":2944,"enrollment":1140,"conditions":45441,"interventions":45442},[88],[30,3134],[4537,3420,1014,2374],{"nctId":9184,"briefTitle":9185,"status":182,"phases":45444,"primaryCompletion":3668,"completion":3668,"start":6409,"enrollment":3197,"conditions":45445,"interventions":45446},[88],[18,1530],[1275,1070,2293,4537],{"nctId":4678,"briefTitle":4679,"status":130,"phases":45448,"primaryCompletion":4681,"completion":4681,"start":4682,"enrollment":1034,"conditions":45449,"interventions":45450},[88],[2755,15,21],[1254,2423,1004,4537,2374,2196,806,803,1114],{"nctId":8616,"briefTitle":8617,"status":130,"phases":45452,"primaryCompletion":8619,"completion":8619,"start":2740,"enrollment":1131,"conditions":45453,"interventions":45454},[88],[15,21],[894,8622,8623,1070,6545,4537,2196,806,8624,2374],{"nctId":4712,"briefTitle":4713,"status":130,"phases":45456,"primaryCompletion":4715,"completion":4716,"start":4635,"enrollment":95,"conditions":45457,"interventions":45458},[88],[15],[1004,1070,2423,4537,2373,803,2196,2757,612,654,655],{"nctId":16346,"briefTitle":16347,"status":182,"phases":45460,"primaryCompletion":2768,"completion":2768,"start":4612,"enrollment":2018,"conditions":45461,"interventions":45462},[88],[7246,30,15,21],[2195,4537,6516],{"nctId":4783,"briefTitle":4784,"status":130,"phases":45464,"primaryCompletion":2602,"completion":2602,"start":4786,"enrollment":628,"conditions":45465,"interventions":45466},[88],[2755,15],[1070,1004,4537,510],{"nctId":8795,"briefTitle":8796,"status":182,"phases":45468,"primaryCompletion":8798,"completion":8798,"start":8799,"enrollment":2865,"conditions":45469,"interventions":45470},[88],[712],[1402,1070,894,4537,6545,1178],{"nctId":4800,"briefTitle":4801,"status":130,"phases":45472,"primaryCompletion":3493,"completion":3493,"start":4723,"enrollment":1100,"conditions":45473,"interventions":45474},[88],[15,21,4804,1122],[1004,2423,4537],{"nctId":9403,"briefTitle":9404,"status":130,"phases":45476,"primaryCompletion":4184,"completion":4184,"start":2580,"enrollment":1922,"conditions":45477,"interventions":45478},[88],[21,4871],[1070,2293,4537],{"trials":45480,"activeCount":124},[45481],{"nctId":4864,"briefTitle":4865,"status":130,"phases":45482,"primaryCompletion":4867,"completion":4867,"start":4868,"enrollment":4869,"conditions":45483,"interventions":45484},[89],[4871,15,4523],[1070,2423,1004,4537,2196,806],{"trials":45486,"activeCount":124},[],{"trials":45488,"activeCount":124},[45489],{"nctId":8960,"briefTitle":8961,"status":130,"phases":45490,"primaryCompletion":8306,"completion":8306,"start":6352,"enrollment":1131,"conditions":45491,"interventions":45492},[91],[21,15],[4537,894],{"intervention":31561,"totalTrials":95,"cells":45494},{"EARLY_PHASE1":45495,"PHASE1":45497,"PHASE2":45499,"PHASE3":45566,"PHASE4":45568,"NA":45570},{"trials":45496,"activeCount":124},[],{"trials":45498,"activeCount":124},[],{"trials":45500,"activeCount":124},[45501,45507,45515,45519,45526,45533,45537,45544,45550,45558],{"nctId":45502,"briefTitle":45503,"status":130,"phases":45504,"primaryCompletion":17841,"completion":17841,"start":8956,"enrollment":240,"conditions":45505,"interventions":45506},"NCT01636934","Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy",[88],[24],[31561],{"nctId":45508,"briefTitle":45509,"status":130,"phases":45510,"primaryCompletion":45511,"completion":45511,"start":45512,"enrollment":2730,"conditions":45513,"interventions":45514},"NCT01793051","Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma",[88],"2020-09-18","2013-03-22",[2245],[31561],{"nctId":31555,"briefTitle":31556,"status":182,"phases":45516,"primaryCompletion":2289,"completion":2289,"start":3571,"enrollment":166,"conditions":45517,"interventions":45518},[87,88],[22891],[31560,31561,259],{"nctId":45520,"briefTitle":45521,"status":130,"phases":45522,"primaryCompletion":45523,"completion":45523,"start":4162,"enrollment":9738,"conditions":45524,"interventions":45525},"NCT01906008","Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients",[88],"2019-02-14",[3195],[31561],{"nctId":45527,"briefTitle":45528,"status":130,"phases":45529,"primaryCompletion":4482,"completion":4482,"start":45530,"enrollment":1975,"conditions":45531,"interventions":45532},"NCT01693523","Minocycline Study in Pancreatic Cancer Patients",[88],"2013-01-28",[4107],[31561],{"nctId":31563,"briefTitle":31564,"status":203,"phases":45534,"enrollment":124,"conditions":45535,"interventions":45536},[87,88],[31567],[31560,259,31561,18140],{"nctId":45538,"briefTitle":45539,"status":182,"phases":45540,"primaryCompletion":4818,"completion":4818,"start":45541,"enrollment":406,"conditions":45542,"interventions":45543},"NCT02055963","Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer",[88],"2014-05-06",[22891],[31561],{"nctId":45545,"briefTitle":45546,"status":130,"phases":45547,"primaryCompletion":9652,"completion":9652,"start":3494,"enrollment":492,"conditions":45548,"interventions":45549},"NCT01746043","A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer",[88],[2770],[31560,31561],{"nctId":45551,"briefTitle":45552,"status":130,"phases":45553,"primaryCompletion":45554,"completion":45554,"start":45555,"enrollment":31,"conditions":45556,"interventions":45557},"NCT01283997","Prevention of Treatment Induced Neuropathy in Multiple Myeloma",[88],"2022-08-22","2011-01-25",[2245],[31561],{"nctId":45559,"briefTitle":45560,"status":130,"phases":45561,"primaryCompletion":45562,"completion":45562,"start":45563,"enrollment":2997,"conditions":45564,"interventions":45565},"NCT01173692","Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.",[88],"2020-07-07","2010-07-22",[14245],[31561],{"trials":45567,"activeCount":124},[],{"trials":45569,"activeCount":124},[],{"trials":45571,"activeCount":124},[45572],{"nctId":45573,"briefTitle":45574,"status":130,"phases":45575,"primaryCompletion":2288,"completion":2288,"start":7155,"enrollment":2779,"conditions":45576,"interventions":45577},"NCT01317550","A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil",[91],[24],[31560,31561],{"intervention":2383,"totalTrials":95,"cells":45579},{"EARLY_PHASE1":45580,"PHASE1":45582,"PHASE2":45588,"PHASE3":45624,"PHASE4":45636,"NA":45638},{"trials":45581,"activeCount":124},[],{"trials":45583,"activeCount":124},[45584],{"nctId":17547,"briefTitle":17548,"status":130,"phases":45585,"primaryCompletion":17550,"completion":17550,"start":17551,"enrollment":539,"conditions":45586,"interventions":45587},[87],[11161,1729],[17554,3497,2383],{"trials":45589,"activeCount":124},[45590,45594,45598,45602,45606,45612,45620],{"nctId":2376,"briefTitle":2377,"status":130,"phases":45591,"primaryCompletion":2379,"completion":2379,"start":2380,"enrollment":2337,"conditions":45592,"interventions":45593},[87,88],[2223,2224],[62,1402,2383],{"nctId":4149,"briefTitle":4150,"status":182,"phases":45595,"primaryCompletion":4152,"completion":4152,"start":4153,"enrollment":3197,"conditions":45596,"interventions":45597},[88],[1729],[3497,4156,1709,3499,4157,2383],{"nctId":34915,"briefTitle":34916,"status":130,"phases":45599,"primaryCompletion":4723,"completion":4723,"start":4732,"enrollment":959,"conditions":45600,"interventions":45601},[88],[17604,28813],[2383,3809],{"nctId":17659,"briefTitle":17660,"status":130,"phases":45603,"primaryCompletion":2602,"completion":2602,"start":2213,"enrollment":16699,"conditions":45604,"interventions":45605},[88],[11302,17604],[3808,17616,3497,2383],{"nctId":45607,"briefTitle":45608,"status":130,"phases":45609,"primaryCompletion":2740,"completion":2740,"start":4612,"enrollment":507,"conditions":45610,"interventions":45611},"NCT00379353","The Effects of Thalidomide on Symptom Clusters",[88],[33],[2383],{"nctId":45613,"briefTitle":45614,"status":130,"phases":45615,"primaryCompletion":45616,"completion":45616,"start":45617,"enrollment":550,"conditions":45618,"interventions":45619},"NCT00038181","Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer",[88],"2005-11-29","2000-10-05",[27],[2383],{"nctId":11958,"briefTitle":11959,"status":130,"phases":45621,"primaryCompletion":2847,"completion":4647,"start":11961,"enrollment":517,"conditions":45622,"interventions":45623},[87,88],[27],[11964,2383,1376],{"trials":45625,"activeCount":124},[45626,45630],{"nctId":2941,"briefTitle":2942,"status":130,"phases":45627,"primaryCompletion":2944,"completion":2944,"start":2945,"enrollment":2946,"conditions":45628,"interventions":45629},[88,89],[1400],[2383,62],{"nctId":45631,"briefTitle":45632,"status":130,"phases":45633,"primaryCompletion":14844,"completion":14844,"start":43786,"enrollment":2159,"conditions":45634,"interventions":45635},"NCT00038233","Thalidomide for Multiple Myeloma",[89],[1400],[2383],{"trials":45637,"activeCount":124},[],{"trials":45639,"activeCount":124},[45640],{"nctId":13717,"briefTitle":13718,"status":182,"phases":45641,"primaryCompletion":8718,"completion":8718,"start":2289,"enrollment":1496,"conditions":45642,"interventions":45643},[91],[2245],[2383,1402],{"intervention":2439,"totalTrials":95,"cells":45645},{"EARLY_PHASE1":45646,"PHASE1":45648,"PHASE2":45654,"PHASE3":45698,"PHASE4":45700,"NA":45702},{"trials":45647,"activeCount":124},[],{"trials":45649,"activeCount":124},[45650],{"nctId":23276,"briefTitle":23277,"status":130,"phases":45651,"primaryCompletion":23279,"completion":23279,"start":23280,"enrollment":1568,"conditions":45652,"interventions":45653},[87],[9054,23282],[2439,4777],{"trials":45655,"activeCount":124},[45656,45660,45664,45668,45672,45678,45686,45690,45694],{"nctId":9115,"briefTitle":9116,"status":182,"phases":45657,"primaryCompletion":2846,"completion":2846,"start":5232,"enrollment":834,"conditions":45658,"interventions":45659},[88],[15,21,2245,4580],[1070,2293,2439,2196,806,2374],{"nctId":2432,"briefTitle":2433,"status":130,"phases":45661,"primaryCompletion":2435,"completion":2435,"start":2436,"enrollment":550,"conditions":45662,"interventions":45663},[88],[15],[2439,2424,62,806,2078],{"nctId":34957,"briefTitle":34958,"status":182,"phases":45665,"primaryCompletion":13673,"completion":13673,"start":34960,"enrollment":134,"conditions":45666,"interventions":45667},[88],[21,15],[13866,2439],{"nctId":6849,"briefTitle":6850,"status":130,"phases":45669,"primaryCompletion":6757,"completion":6757,"start":6852,"enrollment":1975,"conditions":45670,"interventions":45671},[88],[712],[1070,803,2439,894],{"nctId":45673,"briefTitle":45674,"status":182,"phases":45675,"primaryCompletion":4162,"completion":4162,"start":3996,"enrollment":1483,"conditions":45676,"interventions":45677},"NCT01191749","Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)",[88],[15],[2439],{"nctId":45679,"briefTitle":45680,"status":203,"phases":45681,"primaryCompletion":45682,"completion":45682,"start":45683,"enrollment":124,"conditions":45684,"interventions":45685},"NCT00129753","Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease",[88],"2006-09-05","2005-06-22",[9378,21],[2439],{"nctId":8704,"briefTitle":8705,"status":182,"phases":45687,"primaryCompletion":4085,"completion":4085,"start":8707,"enrollment":166,"conditions":45688,"interventions":45689},[88],[712,15],[894,2439],{"nctId":9275,"briefTitle":9276,"status":182,"phases":45691,"primaryCompletion":9278,"completion":9278,"start":9279,"enrollment":1231,"conditions":45692,"interventions":45693},[87,88],[15,2245,4580],[1070,2293,2439,2196,9282,2374,7415,1014],{"nctId":7152,"briefTitle":7153,"status":130,"phases":45695,"primaryCompletion":7155,"completion":7155,"start":4887,"enrollment":1034,"conditions":45696,"interventions":45697},[88],[15,712],[803,1070,2439,894],{"trials":45699,"activeCount":124},[],{"trials":45701,"activeCount":124},[],{"trials":45703,"activeCount":124},[45704],{"nctId":7470,"briefTitle":7471,"status":130,"phases":45705,"primaryCompletion":3777,"completion":3777,"start":7473,"enrollment":2446,"conditions":45706,"interventions":45707},[91],[21],[803,1070,894,2439],{"intervention":6744,"totalTrials":1483,"cells":45709},{"EARLY_PHASE1":45710,"PHASE1":45712,"PHASE2":45714,"PHASE3":45732,"PHASE4":45742,"NA":45744},{"trials":45711,"activeCount":124},[],{"trials":45713,"activeCount":124},[],{"trials":45715,"activeCount":124},[45716,45720,45724,45728],{"nctId":6737,"briefTitle":6738,"status":130,"phases":45717,"primaryCompletion":6740,"completion":6740,"start":6741,"enrollment":2700,"conditions":45718,"interventions":45719},[88],[18],[1376,1370,4218,6744,803,1013],{"nctId":6795,"briefTitle":6796,"status":130,"phases":45721,"primaryCompletion":6798,"completion":6799,"start":4382,"enrollment":2997,"conditions":45722,"interventions":45723},[88],[18],[6802,4023,1369,4218,6744,803],{"nctId":6804,"briefTitle":6805,"status":3049,"phases":45725,"primaryCompletion":2326,"completion":6807,"start":5470,"enrollment":2933,"conditions":45726,"interventions":45727},[88],[18],[1376,4218,6744,803,2330],{"nctId":7174,"briefTitle":7175,"status":182,"phases":45729,"primaryCompletion":7177,"completion":7177,"start":5556,"enrollment":1568,"conditions":45730,"interventions":45731},[88],[18],[7180,1376,4218,6744,803],{"trials":45733,"activeCount":124},[45734,45738],{"nctId":7436,"briefTitle":7437,"status":130,"phases":45735,"primaryCompletion":6409,"completion":3777,"start":2580,"enrollment":7439,"conditions":45736,"interventions":45737},[89],[18],[4218,803,1013,1376,6744],{"nctId":14605,"briefTitle":14606,"status":130,"phases":45739,"primaryCompletion":8503,"completion":7155,"start":2807,"enrollment":4690,"conditions":45740,"interventions":45741},[89],[18],[14610,14611,1371,14612,6744],{"trials":45743,"activeCount":124},[],{"trials":45745,"activeCount":124},[45746],{"nctId":7492,"briefTitle":7493,"status":203,"phases":45747,"start":3777,"enrollment":124,"conditions":45748,"interventions":45749},[91],[18],[1376,1371,1013,6744,803,1275],{"intervention":2977,"totalTrials":1483,"cells":45751},{"EARLY_PHASE1":45752,"PHASE1":45754,"PHASE2":45756,"PHASE3":45774,"PHASE4":45780,"NA":45782},{"trials":45753,"activeCount":124},[],{"trials":45755,"activeCount":124},[],{"trials":45757,"activeCount":124},[45758,45762,45766,45770],{"nctId":3984,"briefTitle":3985,"status":130,"phases":45759,"primaryCompletion":3987,"completion":3987,"start":3988,"enrollment":2446,"conditions":45760,"interventions":45761},[88],[2971,3990],[2368,2977,2495,1016,1709],{"nctId":10072,"briefTitle":10073,"status":130,"phases":45763,"primaryCompletion":3571,"completion":3571,"start":10075,"enrollment":2581,"conditions":45764,"interventions":45765},[87,88],[1924,1942],[2831,1369,2977,2495],{"nctId":20779,"briefTitle":20780,"status":130,"phases":45767,"primaryCompletion":7399,"completion":7399,"start":20782,"enrollment":1328,"conditions":45768,"interventions":45769},[88],[21],[20785,2977,4331,4156,1869],{"nctId":8750,"briefTitle":8751,"status":130,"phases":45771,"primaryCompletion":8753,"completion":8753,"start":2699,"enrollment":226,"conditions":45772,"interventions":45773},[88],[21],[894,2977,4331,1868,1869],{"trials":45775,"activeCount":124},[45776],{"nctId":20730,"briefTitle":20731,"status":130,"phases":45777,"primaryCompletion":2847,"completion":3902,"start":20733,"enrollment":448,"conditions":45778,"interventions":45779},[89],[20735],[11877,2977,4331,1868,20737],{"trials":45781,"activeCount":124},[],{"trials":45783,"activeCount":124},[45784,45788],{"nctId":2965,"briefTitle":2966,"status":130,"phases":45785,"primaryCompletion":2968,"completion":2968,"start":2969,"enrollment":240,"conditions":45786,"interventions":45787},[91],[2971,2972,2973],[2975,2976,2977,2978,2979,1114,1016,62],{"nctId":22560,"briefTitle":22561,"status":130,"phases":45789,"primaryCompletion":22563,"completion":22563,"start":22564,"enrollment":240,"conditions":45790,"interventions":45791},[91],[2971],[22567,22568,2977,2495],{"intervention":18140,"totalTrials":230,"cells":45793},{"EARLY_PHASE1":45794,"PHASE1":45796,"PHASE2":45802,"PHASE3":45826,"PHASE4":45828,"NA":45830},{"trials":45795,"activeCount":124},[],{"trials":45797,"activeCount":124},[45798],{"nctId":18134,"briefTitle":18135,"status":203,"phases":45799,"primaryCompletion":18137,"start":3725,"enrollment":124,"conditions":45800,"interventions":45801},[87],[33],[18140,2207,2405],{"trials":45803,"activeCount":124},[45804,45808,45814,45820],{"nctId":31563,"briefTitle":31564,"status":203,"phases":45805,"enrollment":124,"conditions":45806,"interventions":45807},[87,88],[31567],[31560,259,31561,18140],{"nctId":45809,"briefTitle":45810,"status":130,"phases":45811,"primaryCompletion":206,"completion":206,"start":8503,"enrollment":676,"conditions":45812,"interventions":45813},"NCT00094445","Trial of Curcumin in Advanced Pancreatic Cancer",[88],[12452,6684],[18140],{"nctId":45815,"briefTitle":45816,"status":203,"phases":45817,"primaryCompletion":2909,"start":3805,"enrollment":124,"conditions":45818,"interventions":45819},"NCT01269203","Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients",[88],[1400],[18140],{"nctId":45821,"briefTitle":45822,"status":203,"phases":45823,"primaryCompletion":4842,"start":3725,"enrollment":124,"conditions":45824,"interventions":45825},"NCT00969085","Trial of Curcumin in Cutaneous T-cell Lymphoma Patients",[88],[36310],[18140],{"trials":45827,"activeCount":124},[],{"trials":45829,"activeCount":124},[],{"trials":45831,"activeCount":124},[45832],{"nctId":45833,"briefTitle":45834,"status":130,"phases":45835,"primaryCompletion":6410,"completion":6410,"start":8503,"enrollment":924,"conditions":45836,"interventions":45837},"NCT00113841","Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma",[91],[1400],[18140,45838],"Bioperine",{"intervention":31560,"totalTrials":230,"cells":45840},{"EARLY_PHASE1":45841,"PHASE1":45843,"PHASE2":45845,"PHASE3":45867,"PHASE4":45869,"NA":45871},{"trials":45842,"activeCount":124},[],{"trials":45844,"activeCount":124},[],{"trials":45846,"activeCount":124},[45847,45851,45855,45863],{"nctId":31555,"briefTitle":31556,"status":182,"phases":45848,"primaryCompletion":2289,"completion":2289,"start":3571,"enrollment":166,"conditions":45849,"interventions":45850},[87,88],[22891],[31560,31561,259],{"nctId":31563,"briefTitle":31564,"status":203,"phases":45852,"enrollment":124,"conditions":45853,"interventions":45854},[87,88],[31567],[31560,259,31561,18140],{"nctId":45856,"briefTitle":45857,"status":130,"phases":45858,"primaryCompletion":45859,"completion":45859,"start":45860,"enrollment":134,"conditions":45861,"interventions":45862},"NCT01330446","Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer",[87,88],"2022-12-08","2011-05-19",[22891,2923],[31560],{"nctId":45545,"briefTitle":45546,"status":130,"phases":45864,"primaryCompletion":9652,"completion":9652,"start":3494,"enrollment":492,"conditions":45865,"interventions":45866},[88],[2770],[31560,31561],{"trials":45868,"activeCount":124},[],{"trials":45870,"activeCount":124},[],{"trials":45872,"activeCount":124},[45873,45879],{"nctId":45874,"briefTitle":45875,"status":182,"phases":45876,"primaryCompletion":3494,"completion":3494,"start":3901,"enrollment":166,"conditions":45877,"interventions":45878},"NCT01169753","Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients",[91],[3315],[31560],{"nctId":45573,"briefTitle":45574,"status":130,"phases":45880,"primaryCompletion":2288,"completion":2288,"start":7155,"enrollment":2779,"conditions":45881,"interventions":45882},[91],[24],[31560,31561],{"intervention":5527,"totalTrials":3197,"cells":45884},{"EARLY_PHASE1":45885,"PHASE1":45887,"PHASE2":45889,"PHASE3":45909,"PHASE4":45911,"NA":45913},{"trials":45886,"activeCount":124},[],{"trials":45888,"activeCount":124},[],{"trials":45890,"activeCount":124},[45891,45895,45899,45903],{"nctId":5519,"briefTitle":5520,"status":130,"phases":45892,"primaryCompletion":4382,"completion":4382,"start":5522,"enrollment":492,"conditions":45893,"interventions":45894},[88],[21,15],[5525,5526,5527,803,2424,1070,2293,894,806,2196],{"nctId":5529,"briefTitle":5530,"status":182,"phases":45896,"primaryCompletion":2836,"completion":2836,"start":4193,"enrollment":2159,"conditions":45897,"interventions":45898},[88],[21],[5527,2374,4629,5526,5534,5535,654,2424,2293,5536,1070,803],{"nctId":8536,"briefTitle":8537,"status":130,"phases":45900,"primaryCompletion":4612,"completion":6409,"start":7400,"enrollment":473,"conditions":45901,"interventions":45902},[88],[712],[5527,894],{"nctId":45904,"briefTitle":45905,"status":130,"phases":45906,"primaryCompletion":4612,"completion":4612,"start":7400,"enrollment":1496,"conditions":45907,"interventions":45908},"NCT00102661","Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia",[88],[712],[5527],{"trials":45910,"activeCount":124},[],{"trials":45912,"activeCount":124},[],{"trials":45914,"activeCount":124},[45915],{"nctId":45916,"briefTitle":45917,"status":182,"phases":45918,"primaryCompletion":4039,"completion":4039,"start":45919,"enrollment":1766,"conditions":45920,"interventions":45922},"NCT00038883","Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies",[91],"2001-04-09",[20502,2530,45921,31400,40822],"Lymphoma, Low-Grade",[5527],{"intervention":4387,"totalTrials":3197,"cells":45924},{"EARLY_PHASE1":45925,"PHASE1":45927,"PHASE2":45929,"PHASE3":45943,"PHASE4":45949,"NA":45951},{"trials":45926,"activeCount":124},[],{"trials":45928,"activeCount":124},[],{"trials":45930,"activeCount":124},[45931,45935,45939],{"nctId":37404,"briefTitle":37405,"status":130,"phases":45932,"primaryCompletion":3901,"completion":3901,"start":10346,"enrollment":2865,"conditions":45933,"interventions":45934},[88],[15],[4387,30291],{"nctId":7074,"briefTitle":7075,"status":130,"phases":45936,"primaryCompletion":3213,"completion":3213,"start":4612,"enrollment":1034,"conditions":45937,"interventions":45938},[88],[712],[803,1070,4387,894],{"nctId":8715,"briefTitle":8716,"status":130,"phases":45940,"primaryCompletion":8718,"completion":8718,"start":8719,"enrollment":1034,"conditions":45941,"interventions":45942},[88],[21],[894,4387],{"trials":45944,"activeCount":124},[45945],{"nctId":31253,"briefTitle":31254,"status":130,"phases":45946,"primaryCompletion":9923,"completion":10938,"start":5241,"enrollment":25,"conditions":45947,"interventions":45948},[89],[5244],[17901,31258,4387],{"trials":45950,"activeCount":124},[],{"trials":45952,"activeCount":124},[45953],{"nctId":4379,"briefTitle":4380,"status":182,"phases":45954,"primaryCompletion":4382,"completion":4382,"start":2932,"enrollment":1483,"conditions":45955,"interventions":45956},[91],[4384],[1013,1709,806,1113,4386,2495,2369,4387,1114],{"intervention":2793,"totalTrials":3197,"cells":45958},{"EARLY_PHASE1":45959,"PHASE1":45961,"PHASE2":45963,"PHASE3":45979,"PHASE4":45985,"NA":45987},{"trials":45960,"activeCount":124},[],{"trials":45962,"activeCount":124},[],{"trials":45964,"activeCount":124},[45965,45971,45975],{"nctId":45966,"briefTitle":45967,"status":130,"phases":45968,"primaryCompletion":4290,"completion":12586,"start":2836,"enrollment":1222,"conditions":45969,"interventions":45970},"NCT00954941","Ondansetron Versus Aprepitant Plus Ondansetron for Emesis",[88],[4699,4659,30,4725],[2793,7482],{"nctId":31657,"briefTitle":31658,"status":130,"phases":45972,"primaryCompletion":3833,"completion":3833,"start":2213,"enrollment":1045,"conditions":45973,"interventions":45974},[88],[4659,2935],[2793,31642],{"nctId":2784,"briefTitle":2785,"status":182,"phases":45976,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":1609,"conditions":45977,"interventions":45978},[88],[2790],[62,1013,2792,2495,1114,2793,2794,810],{"trials":45980,"activeCount":124},[45981],{"nctId":32401,"briefTitle":32402,"status":130,"phases":45982,"primaryCompletion":5697,"completion":5697,"start":8753,"enrollment":20891,"conditions":45983,"interventions":45984},[89],[32405],[32390,2793],{"trials":45986,"activeCount":124},[],{"trials":45988,"activeCount":124},[45989],{"nctId":7477,"briefTitle":7478,"status":130,"phases":45990,"primaryCompletion":2212,"completion":2212,"start":6828,"enrollment":3820,"conditions":45991,"interventions":45992},[91],[21],[7482,803,1013,1016,809,894,2793],{"intervention":2450,"totalTrials":296,"cells":45994},{"EARLY_PHASE1":45995,"PHASE1":45997,"PHASE2":45999,"PHASE3":46013,"PHASE4":46015,"NA":46017},{"trials":45996,"activeCount":124},[],{"trials":45998,"activeCount":124},[],{"trials":46000,"activeCount":124},[46001,46005,46009],{"nctId":8383,"briefTitle":8384,"status":182,"phases":46002,"primaryCompletion":8386,"completion":8386,"start":4351,"enrollment":230,"conditions":46003,"interventions":46004},[88],[21],[2450,894,8389],{"nctId":2441,"briefTitle":2442,"status":130,"phases":46006,"primaryCompletion":2444,"completion":2444,"start":2445,"enrollment":2446,"conditions":46007,"interventions":46008},[88],[21],[1070,2449,894,2450,62],{"nctId":5562,"briefTitle":5563,"status":130,"phases":46010,"primaryCompletion":5565,"completion":5565,"start":5566,"enrollment":406,"conditions":46011,"interventions":46012},[88],[5568,21],[2450,4365,2424,654,2293,894],{"trials":46014,"activeCount":124},[],{"trials":46016,"activeCount":124},[],{"trials":46018,"activeCount":124},[46019],{"nctId":8953,"briefTitle":8954,"status":130,"phases":46020,"primaryCompletion":8956,"completion":8956,"start":2847,"enrollment":3726,"conditions":46021,"interventions":46022},[91],[8942,21],[894,2450],{"intervention":46024,"totalTrials":1231,"cells":46025},"Dalteparin",{"EARLY_PHASE1":46026,"PHASE1":46028,"PHASE2":46030,"PHASE3":46039,"PHASE4":46041,"NA":46050},{"trials":46027,"activeCount":124},[],{"trials":46029,"activeCount":124},[],{"trials":46031,"activeCount":124},[46032],{"nctId":46033,"briefTitle":46034,"status":182,"phases":46035,"primaryCompletion":7473,"completion":7473,"start":11961,"enrollment":134,"conditions":46036,"interventions":46038},"NCT00041782","Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients",[88],[29078,46037],"Deep Vein Thrombosis",[46024],{"trials":46040,"activeCount":124},[],{"trials":46042,"activeCount":124},[46043],{"nctId":46044,"briefTitle":46045,"status":130,"phases":46046,"primaryCompletion":2602,"completion":2602,"start":4152,"enrollment":6397,"conditions":46047,"interventions":46049},"NCT00966277","Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients",[90],[4107,46048],"Venous Thromboembolism",[46024],{"trials":46051,"activeCount":124},[46052],{"nctId":46053,"briefTitle":46054,"status":130,"phases":46055,"primaryCompletion":46056,"completion":46056,"start":11358,"enrollment":3541,"conditions":46057,"interventions":46061},"NCT00525057","Dalteparin in Preventing DVT in Participants With Cancer",[91],"2020-06-19",[1585,46058,21,46059,46060,3135,1593],"Femur Fracture","Metastatic Neoplasm","Pathologic Fracture",[46024],{"intervention":46063,"totalTrials":1231,"cells":46064},"Procrit",{"EARLY_PHASE1":46065,"PHASE1":46067,"PHASE2":46069,"PHASE3":46071,"PHASE4":46086,"NA":46088},{"trials":46066,"activeCount":124},[],{"trials":46068,"activeCount":124},[],{"trials":46070,"activeCount":124},[],{"trials":46072,"activeCount":124},[46073,46080],{"nctId":46074,"briefTitle":46075,"status":182,"phases":46076,"primaryCompletion":2445,"completion":2445,"start":46077,"enrollment":676,"conditions":46078,"interventions":46079},"NCT00254436","A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients",[89],"2001-10-31",[4195,10947],[46063],{"nctId":46081,"briefTitle":46082,"status":130,"phases":46083,"primaryCompletion":11040,"completion":11040,"start":6828,"enrollment":240,"conditions":46084,"interventions":46085},"NCT00656448","A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS",[89],[4659,30,15],[46063],{"trials":46087,"activeCount":124},[],{"trials":46089,"activeCount":124},[46090],{"nctId":46091,"briefTitle":46092,"status":130,"phases":46093,"primaryCompletion":3901,"completion":3901,"start":4193,"enrollment":46094,"conditions":46095,"interventions":46096},"NCT01099202","Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction\u002FConsolidation Chemotherapy",[91],109,[15],[46063],{"intervention":22783,"totalTrials":1231,"cells":46098},{"EARLY_PHASE1":46099,"PHASE1":46101,"PHASE2":46103,"PHASE3":46105,"PHASE4":46111,"NA":46113},{"trials":46100,"activeCount":124},[],{"trials":46102,"activeCount":124},[],{"trials":46104,"activeCount":124},[],{"trials":46106,"activeCount":124},[46107],{"nctId":22777,"briefTitle":22778,"status":203,"phases":46108,"primaryCompletion":10760,"completion":10760,"start":6352,"enrollment":124,"conditions":46109,"interventions":46110},[89],[22781],[5767,22783],{"trials":46112,"activeCount":124},[],{"trials":46114,"activeCount":124},[46115,46122],{"nctId":46116,"briefTitle":46117,"status":130,"phases":46118,"primaryCompletion":6352,"completion":7236,"start":3214,"enrollment":2402,"conditions":46119,"interventions":46120},"NCT00500565","Pain Management Following TRAM Flap for Breast Reconstruction",[91],[18],[22783,46121],"Bupivicaine",{"nctId":46123,"briefTitle":46124,"status":130,"phases":46125,"primaryCompletion":2806,"completion":2806,"start":5322,"enrollment":46126,"conditions":46127,"interventions":46129},"NCT00423722","Parenteral Hydration in Advanced Cancer Patients",[91],262,[1942,46128],"Dehydration",[22783,22783],{"intervention":4668,"totalTrials":1231,"cells":46131},{"EARLY_PHASE1":46132,"PHASE1":46134,"PHASE2":46136,"PHASE3":46146,"PHASE4":46148,"NA":46150},{"trials":46133,"activeCount":124},[],{"trials":46135,"activeCount":124},[],{"trials":46137,"activeCount":124},[46138,46142],{"nctId":4662,"briefTitle":4663,"status":182,"phases":46139,"primaryCompletion":2836,"completion":2836,"start":4665,"enrollment":924,"conditions":46140,"interventions":46141},[88],[15],[2321,1070,1004,4668,2196,806],{"nctId":9374,"briefTitle":9375,"status":130,"phases":46143,"primaryCompletion":3761,"completion":3761,"start":5663,"enrollment":901,"conditions":46144,"interventions":46145},[88],[9378],[2369,1070,2293,4668,2196,1069,806],{"trials":46147,"activeCount":124},[],{"trials":46149,"activeCount":124},[],{"trials":46151,"activeCount":124},[46152],{"nctId":7463,"briefTitle":7464,"status":130,"phases":46153,"primaryCompletion":6410,"completion":6410,"start":7466,"enrollment":910,"conditions":46154,"interventions":46155},[91],[3134],[1070,803,4668],{"intervention":14610,"totalTrials":1231,"cells":46157},{"EARLY_PHASE1":46158,"PHASE1":46160,"PHASE2":46162,"PHASE3":46168,"PHASE4":46174,"NA":46176},{"trials":46159,"activeCount":124},[],{"trials":46161,"activeCount":124},[],{"trials":46163,"activeCount":124},[46164],{"nctId":32988,"briefTitle":32989,"status":130,"phases":46165,"primaryCompletion":2836,"completion":2836,"start":2910,"enrollment":550,"conditions":46166,"interventions":46167},[88],[18],[14610,4629],{"trials":46169,"activeCount":124},[46170],{"nctId":14605,"briefTitle":14606,"status":130,"phases":46171,"primaryCompletion":8503,"completion":7155,"start":2807,"enrollment":4690,"conditions":46172,"interventions":46173},[89],[18],[14610,14611,1371,14612,6744],{"trials":46175,"activeCount":124},[],{"trials":46177,"activeCount":124},[46178],{"nctId":46179,"briefTitle":46180,"status":130,"phases":46181,"primaryCompletion":4382,"completion":4382,"start":3902,"enrollment":34,"conditions":46182,"interventions":46184},"NCT00496808","Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast",[91],[46183],"Ductal Carcinoma In Situ",[14610],{"intervention":26979,"totalTrials":1231,"cells":46186},{"EARLY_PHASE1":46187,"PHASE1":46189,"PHASE2":46198,"PHASE3":46200,"PHASE4":46206,"NA":46208},{"trials":46188,"activeCount":124},[],{"trials":46190,"activeCount":124},[46191],{"nctId":46192,"briefTitle":46193,"status":130,"phases":46194,"primaryCompletion":10287,"completion":10287,"start":5733,"enrollment":492,"conditions":46195,"interventions":46197},"NCT00538720","Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)",[87],[46196],"Hyperparathyroidism",[26979],{"trials":46199,"activeCount":124},[],{"trials":46201,"activeCount":124},[46202],{"nctId":31757,"briefTitle":31758,"status":130,"phases":46203,"primaryCompletion":2212,"completion":2212,"start":10260,"enrollment":2610,"conditions":46204,"interventions":46205},[89],[8942,21],[18104,26979,31762],{"trials":46207,"activeCount":124},[],{"trials":46209,"activeCount":124},[46210],{"nctId":26972,"briefTitle":26973,"status":130,"phases":46211,"primaryCompletion":26975,"completion":26975,"start":26976,"enrollment":834,"conditions":46212,"interventions":46213},[91],[3195,3154],[25074,26979],{"intervention":46215,"totalTrials":121,"cells":46216},"Fibrin Sealant",{"EARLY_PHASE1":46217,"PHASE1":46219,"PHASE2":46221,"PHASE3":46223,"PHASE4":46225,"NA":46227},{"trials":46218,"activeCount":124},[],{"trials":46220,"activeCount":124},[],{"trials":46222,"activeCount":124},[],{"trials":46224,"activeCount":124},[],{"trials":46226,"activeCount":124},[],{"trials":46228,"activeCount":124},[46229,46235],{"nctId":46230,"briefTitle":46231,"status":130,"phases":46232,"primaryCompletion":4192,"completion":6828,"start":4665,"enrollment":1140,"conditions":46233,"interventions":46234},"NCT00506311","Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients",[91],[1729],[46215],{"nctId":46236,"briefTitle":46237,"status":130,"phases":46238,"primaryCompletion":46239,"completion":46239,"start":46240,"enrollment":4291,"conditions":46241,"interventions":46242},"NCT00504582","Fibrin Melanoma Axillary Node Study in Patients With Melanoma",[91],"2020-04-09","2002-05-15",[1729],[46215],{"intervention":29969,"totalTrials":121,"cells":46244},{"EARLY_PHASE1":46245,"PHASE1":46251,"PHASE2":46253,"PHASE3":46255,"PHASE4":46257,"NA":46259},{"trials":46246,"activeCount":124},[46247],{"nctId":29963,"briefTitle":29964,"status":130,"phases":46248,"primaryCompletion":29966,"completion":29966,"start":2436,"enrollment":676,"conditions":46249,"interventions":46250},[86],[11077],[29958,29969],{"trials":46252,"activeCount":124},[],{"trials":46254,"activeCount":124},[],{"trials":46256,"activeCount":124},[],{"trials":46258,"activeCount":124},[],{"trials":46260,"activeCount":124},[46261],{"nctId":46262,"briefTitle":46263,"status":130,"phases":46264,"primaryCompletion":46265,"completion":46265,"start":11040,"enrollment":7574,"conditions":46266,"interventions":46267},"NCT02335372","Cervical Cancer Screening Study in Brazil",[91],"2021-10-07",[11077],[29969,46268],"Proflavine Solution",{"intervention":46270,"totalTrials":121,"cells":46271},"Nicotine Patches",{"EARLY_PHASE1":46272,"PHASE1":46281,"PHASE2":46283,"PHASE3":46285,"PHASE4":46287,"NA":46289},{"trials":46273,"activeCount":124},[46274],{"nctId":46275,"briefTitle":46276,"status":203,"phases":46277,"primaryCompletion":46278,"completion":46278,"start":46278,"enrollment":124,"conditions":46279,"interventions":46280},"NCT02942212","Health Literacy and Smoking Cessation in Low-SES Diverse Smokers - Project HALT II",[86],"2018-12-14",[108],[46270],{"trials":46282,"activeCount":124},[],{"trials":46284,"activeCount":124},[],{"trials":46286,"activeCount":124},[],{"trials":46288,"activeCount":124},[],{"trials":46290,"activeCount":124},[46291],{"nctId":46292,"briefTitle":46293,"status":130,"phases":46294,"primaryCompletion":46295,"completion":46295,"start":4843,"enrollment":46296,"conditions":46297,"interventions":46299},"NCT01504919","Reducing Cancer Disparities Among Latinos in Texas",[91],"2022-01-18",301,[46298],"Psychosocial Problem",[46270],{"intervention":9360,"totalTrials":121,"cells":46301},{"EARLY_PHASE1":46302,"PHASE1":46304,"PHASE2":46306,"PHASE3":46312,"PHASE4":46314,"NA":46316},{"trials":46303,"activeCount":124},[],{"trials":46305,"activeCount":124},[],{"trials":46307,"activeCount":124},[46308],{"nctId":9352,"briefTitle":9353,"status":203,"phases":46309,"primaryCompletion":9355,"completion":9356,"start":9357,"enrollment":124,"conditions":46310,"interventions":46311},[88],[1187],[1070,654,9360],{"trials":46313,"activeCount":124},[],{"trials":46315,"activeCount":124},[],{"trials":46317,"activeCount":124},[46318],{"nctId":46319,"briefTitle":46320,"status":130,"phases":46321,"primaryCompletion":5232,"completion":5232,"start":6628,"enrollment":1922,"conditions":46322,"interventions":46323},"NCT00506597","Erwinase Study in Patients With Acute Lymphoblastic Leukemia",[91],[15],[9360],{"intervention":7482,"totalTrials":121,"cells":46325},{"EARLY_PHASE1":46326,"PHASE1":46328,"PHASE2":46330,"PHASE3":46336,"PHASE4":46338,"NA":46340},{"trials":46327,"activeCount":124},[],{"trials":46329,"activeCount":124},[],{"trials":46331,"activeCount":124},[46332],{"nctId":45966,"briefTitle":45967,"status":130,"phases":46333,"primaryCompletion":4290,"completion":12586,"start":2836,"enrollment":1222,"conditions":46334,"interventions":46335},[88],[4699,4659,30,4725],[2793,7482],{"trials":46337,"activeCount":124},[],{"trials":46339,"activeCount":124},[],{"trials":46341,"activeCount":124},[46342],{"nctId":7477,"briefTitle":7478,"status":130,"phases":46343,"primaryCompletion":2212,"completion":2212,"start":6828,"enrollment":3820,"conditions":46344,"interventions":46345},[91],[21],[7482,803,1013,1016,809,894,2793],{"intervention":4386,"totalTrials":121,"cells":46347},{"EARLY_PHASE1":46348,"PHASE1":46350,"PHASE2":46352,"PHASE3":46358,"PHASE4":46360,"NA":46362},{"trials":46349,"activeCount":124},[],{"trials":46351,"activeCount":124},[],{"trials":46353,"activeCount":124},[46354],{"nctId":6916,"briefTitle":6917,"status":182,"phases":46355,"primaryCompletion":184,"completion":184,"start":6919,"enrollment":4171,"conditions":46356,"interventions":46357},[88],[6921],[1016,1013,803,4386,6923],{"trials":46359,"activeCount":124},[],{"trials":46361,"activeCount":124},[],{"trials":46363,"activeCount":124},[46364],{"nctId":4379,"briefTitle":4380,"status":182,"phases":46365,"primaryCompletion":4382,"completion":4382,"start":2932,"enrollment":1483,"conditions":46366,"interventions":46367},[91],[4384],[1013,1709,806,1113,4386,2495,2369,4387,1114],{"intervention":4982,"totalTrials":121,"cells":46369},{"EARLY_PHASE1":46370,"PHASE1":46376,"PHASE2":46378,"PHASE3":46380,"PHASE4":46382,"NA":46384},{"trials":46371,"activeCount":124},[46372],{"nctId":4975,"briefTitle":4976,"status":130,"phases":46373,"primaryCompletion":4978,"completion":4978,"start":4979,"enrollment":1328,"conditions":46374,"interventions":46375},[86],[4559,4561],[4896,4982],{"trials":46377,"activeCount":124},[],{"trials":46379,"activeCount":124},[],{"trials":46381,"activeCount":124},[],{"trials":46383,"activeCount":124},[],{"trials":46385,"activeCount":124},[46386],{"nctId":46387,"briefTitle":46388,"status":130,"phases":46389,"primaryCompletion":15256,"completion":15256,"start":1437,"enrollment":95,"conditions":46390,"interventions":46392},"NCT04219969","FDG PET-MRI for the Diagnosis of Spinal Cord Lesions",[91],[46391],"Spinal Cord Neoplasm",[4982],{"intervention":46394,"totalTrials":121,"cells":46395},"Metformin ER",{"EARLY_PHASE1":46396,"PHASE1":46398,"PHASE2":46407,"PHASE3":46409,"PHASE4":46411,"NA":46413},{"trials":46397,"activeCount":124},[],{"trials":46399,"activeCount":124},[46400],{"nctId":46401,"briefTitle":46402,"status":182,"phases":46403,"primaryCompletion":2846,"completion":2846,"start":2806,"enrollment":1231,"conditions":46404,"interventions":46406},"NCT01816659","An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin",[87],[46405],"Colorectal Carcinoma",[46394],{"trials":46408,"activeCount":124},[],{"trials":46410,"activeCount":124},[],{"trials":46412,"activeCount":124},[],{"trials":46414,"activeCount":124},[46415],{"nctId":46416,"briefTitle":46417,"status":203,"phases":46418,"primaryCompletion":8814,"start":2889,"enrollment":124,"conditions":46419,"interventions":46421},"NCT01550900","Prospective Trial of Metformin - Chemoprevention Role",[91],[46420],"Colorectum",[46394],{"intervention":46423,"totalTrials":166,"cells":46424},"Alpharadin",{"EARLY_PHASE1":46425,"PHASE1":46427,"PHASE2":46429,"PHASE3":46431,"PHASE4":46433,"NA":46435},{"trials":46426,"activeCount":124},[],{"trials":46428,"activeCount":124},[],{"trials":46430,"activeCount":124},[],{"trials":46432,"activeCount":124},[],{"trials":46434,"activeCount":124},[],{"trials":46436,"activeCount":124},[46437],{"nctId":46438,"briefTitle":46439,"status":130,"phases":46440,"primaryCompletion":2677,"completion":2677,"start":46441,"enrollment":2159,"conditions":46442,"interventions":46443},"NCT02135484","Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases",[91],"2014-09-19",[27],[46423],{"intervention":6371,"totalTrials":166,"cells":46445},{"EARLY_PHASE1":46446,"PHASE1":46448,"PHASE2":46450,"PHASE3":46452,"PHASE4":46454,"NA":46456},{"trials":46447,"activeCount":124},[],{"trials":46449,"activeCount":124},[],{"trials":46451,"activeCount":124},[],{"trials":46453,"activeCount":124},[],{"trials":46455,"activeCount":124},[],{"trials":46457,"activeCount":124},[46458],{"nctId":6364,"briefTitle":6365,"status":182,"phases":46459,"primaryCompletion":6367,"completion":6367,"start":5988,"enrollment":1568,"conditions":46460,"interventions":46461},[91],[1942,6369],[5368,6371,6372],{"intervention":6372,"totalTrials":166,"cells":46463},{"EARLY_PHASE1":46464,"PHASE1":46466,"PHASE2":46468,"PHASE3":46470,"PHASE4":46472,"NA":46474},{"trials":46465,"activeCount":124},[],{"trials":46467,"activeCount":124},[],{"trials":46469,"activeCount":124},[],{"trials":46471,"activeCount":124},[],{"trials":46473,"activeCount":124},[],{"trials":46475,"activeCount":124},[46476],{"nctId":6364,"briefTitle":6365,"status":182,"phases":46477,"primaryCompletion":6367,"completion":6367,"start":5988,"enrollment":1568,"conditions":46478,"interventions":46479},[91],[1942,6369],[5368,6371,6372],{"intervention":46481,"totalTrials":166,"cells":46482},"Perflutren Protein-Type A Microspheres Injectable Suspension",{"EARLY_PHASE1":46483,"PHASE1":46485,"PHASE2":46487,"PHASE3":46489,"PHASE4":46491,"NA":46493},{"trials":46484,"activeCount":124},[],{"trials":46486,"activeCount":124},[],{"trials":46488,"activeCount":124},[],{"trials":46490,"activeCount":124},[],{"trials":46492,"activeCount":124},[],{"trials":46494,"activeCount":124},[46495],{"nctId":46496,"briefTitle":46497,"status":130,"phases":46498,"primaryCompletion":3493,"completion":3493,"start":1558,"enrollment":871,"conditions":46499,"interventions":46500},"NCT02321527","Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients",[91],[18],[46481],{"intervention":46502,"totalTrials":166,"cells":46503},"Lacosamide",{"EARLY_PHASE1":46504,"PHASE1":46506,"PHASE2":46508,"PHASE3":46510,"PHASE4":46512,"NA":46514},{"trials":46505,"activeCount":124},[],{"trials":46507,"activeCount":124},[],{"trials":46509,"activeCount":124},[],{"trials":46511,"activeCount":124},[],{"trials":46513,"activeCount":124},[],{"trials":46515,"activeCount":124},[46516],{"nctId":46517,"briefTitle":46518,"status":182,"phases":46519,"primaryCompletion":46520,"completion":46520,"start":46521,"enrollment":1609,"conditions":46522,"interventions":46523},"NCT01432171","Lacosamide in Preventing Seizures in Participants With Malignant Glioma",[91],"2017-06-20","2012-07-25",[3170],[46502],{"intervention":46525,"totalTrials":166,"cells":46526},"Dexlansoprazole",{"EARLY_PHASE1":46527,"PHASE1":46529,"PHASE2":46531,"PHASE3":46533,"PHASE4":46535,"NA":46537},{"trials":46528,"activeCount":124},[],{"trials":46530,"activeCount":124},[],{"trials":46532,"activeCount":124},[],{"trials":46534,"activeCount":124},[],{"trials":46536,"activeCount":124},[],{"trials":46538,"activeCount":124},[46539],{"nctId":46540,"briefTitle":46541,"status":203,"phases":46542,"primaryCompletion":4842,"start":3725,"enrollment":124,"conditions":46543,"interventions":46544},"NCT00928161","Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy",[91],[242,23252,6240],[46525],{"intervention":46121,"totalTrials":166,"cells":46546},{"EARLY_PHASE1":46547,"PHASE1":46549,"PHASE2":46551,"PHASE3":46553,"PHASE4":46555,"NA":46557},{"trials":46548,"activeCount":124},[],{"trials":46550,"activeCount":124},[],{"trials":46552,"activeCount":124},[],{"trials":46554,"activeCount":124},[],{"trials":46556,"activeCount":124},[],{"trials":46558,"activeCount":124},[46559],{"nctId":46116,"briefTitle":46117,"status":130,"phases":46560,"primaryCompletion":6352,"completion":7236,"start":3214,"enrollment":2402,"conditions":46561,"interventions":46562},[91],[18],[22783,46121],{"intervention":46564,"totalTrials":166,"cells":46565},"Nicotine",{"EARLY_PHASE1":46566,"PHASE1":46568,"PHASE2":46570,"PHASE3":46572,"PHASE4":46574,"NA":46576},{"trials":46567,"activeCount":124},[],{"trials":46569,"activeCount":124},[],{"trials":46571,"activeCount":124},[],{"trials":46573,"activeCount":124},[],{"trials":46575,"activeCount":124},[],{"trials":46577,"activeCount":124},[46578],{"nctId":46579,"briefTitle":46580,"status":130,"phases":46581,"primaryCompletion":18530,"completion":18530,"start":14844,"enrollment":46582,"conditions":46583,"interventions":46584},"NCT00297479","Group Therapy for Nicotine Dependence: Mindfulness and Smoking",[91],650,[119,136],[46564],{"intervention":2975,"totalTrials":166,"cells":46586},{"EARLY_PHASE1":46587,"PHASE1":46589,"PHASE2":46591,"PHASE3":46593,"PHASE4":46595,"NA":46597},{"trials":46588,"activeCount":124},[],{"trials":46590,"activeCount":124},[],{"trials":46592,"activeCount":124},[],{"trials":46594,"activeCount":124},[],{"trials":46596,"activeCount":124},[],{"trials":46598,"activeCount":124},[46599],{"nctId":2965,"briefTitle":2966,"status":130,"phases":46600,"primaryCompletion":2968,"completion":2968,"start":2969,"enrollment":240,"conditions":46601,"interventions":46602},[91],[2971,2972,2973],[2975,2976,2977,2978,2979,1114,1016,62],{"intervention":2976,"totalTrials":166,"cells":46604},{"EARLY_PHASE1":46605,"PHASE1":46607,"PHASE2":46609,"PHASE3":46611,"PHASE4":46613,"NA":46615},{"trials":46606,"activeCount":124},[],{"trials":46608,"activeCount":124},[],{"trials":46610,"activeCount":124},[],{"trials":46612,"activeCount":124},[],{"trials":46614,"activeCount":124},[],{"trials":46616,"activeCount":124},[46617],{"nctId":2965,"briefTitle":2966,"status":130,"phases":46618,"primaryCompletion":2968,"completion":2968,"start":2969,"enrollment":240,"conditions":46619,"interventions":46620},[91],[2971,2972,2973],[2975,2976,2977,2978,2979,1114,1016,62],{"intervention":2978,"totalTrials":166,"cells":46622},{"EARLY_PHASE1":46623,"PHASE1":46625,"PHASE2":46627,"PHASE3":46629,"PHASE4":46631,"NA":46633},{"trials":46624,"activeCount":124},[],{"trials":46626,"activeCount":124},[],{"trials":46628,"activeCount":124},[],{"trials":46630,"activeCount":124},[],{"trials":46632,"activeCount":124},[],{"trials":46634,"activeCount":124},[46635],{"nctId":2965,"briefTitle":2966,"status":130,"phases":46636,"primaryCompletion":2968,"completion":2968,"start":2969,"enrollment":240,"conditions":46637,"interventions":46638},[91],[2971,2972,2973],[2975,2976,2977,2978,2979,1114,1016,62],{"intervention":2979,"totalTrials":166,"cells":46640},{"EARLY_PHASE1":46641,"PHASE1":46643,"PHASE2":46645,"PHASE3":46647,"PHASE4":46649,"NA":46651},{"trials":46642,"activeCount":124},[],{"trials":46644,"activeCount":124},[],{"trials":46646,"activeCount":124},[],{"trials":46648,"activeCount":124},[],{"trials":46650,"activeCount":124},[],{"trials":46652,"activeCount":124},[46653],{"nctId":2965,"briefTitle":2966,"status":130,"phases":46654,"primaryCompletion":2968,"completion":2968,"start":2969,"enrollment":240,"conditions":46655,"interventions":46656},[91],[2971,2972,2973],[2975,2976,2977,2978,2979,1114,1016,62],{"intervention":46658,"totalTrials":166,"cells":46659},"Nicotine Patch Therapy",{"EARLY_PHASE1":46660,"PHASE1":46662,"PHASE2":46664,"PHASE3":46666,"PHASE4":46668,"NA":46670},{"trials":46661,"activeCount":124},[],{"trials":46663,"activeCount":124},[],{"trials":46665,"activeCount":124},[],{"trials":46667,"activeCount":124},[],{"trials":46669,"activeCount":124},[],{"trials":46671,"activeCount":124},[46672],{"nctId":46673,"briefTitle":46674,"status":130,"phases":46675,"primaryCompletion":18530,"completion":18530,"start":8956,"enrollment":46676,"conditions":46677,"interventions":46678},"NCT01310842","Social Determinants and Smoking Cessation",[],329,[108],[46658],{"intervention":46680,"totalTrials":166,"cells":46681},"Isosulfan Blue",{"EARLY_PHASE1":46682,"PHASE1":46684,"PHASE2":46686,"PHASE3":46688,"PHASE4":46690,"NA":46692},{"trials":46683,"activeCount":124},[],{"trials":46685,"activeCount":124},[],{"trials":46687,"activeCount":124},[],{"trials":46689,"activeCount":124},[],{"trials":46691,"activeCount":124},[],{"trials":46693,"activeCount":124},[46694],{"nctId":46695,"briefTitle":46696,"status":130,"phases":46697,"primaryCompletion":2317,"completion":9560,"start":4887,"enrollment":4690,"conditions":46698,"interventions":46699},"NCT00438477","Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer",[91],[18],[46680],{"intervention":46701,"totalTrials":166,"cells":46702},"Levothyroxine",{"EARLY_PHASE1":46703,"PHASE1":46705,"PHASE2":46707,"PHASE3":46709,"PHASE4":46711,"NA":46713},{"trials":46704,"activeCount":124},[],{"trials":46706,"activeCount":124},[],{"trials":46708,"activeCount":124},[],{"trials":46710,"activeCount":124},[],{"trials":46712,"activeCount":124},[],{"trials":46714,"activeCount":124},[46715],{"nctId":46716,"briefTitle":46717,"status":182,"phases":46718,"primaryCompletion":13673,"completion":13673,"start":4084,"enrollment":3726,"conditions":46719,"interventions":46721},"NCT00488644","Combined Levothyroxine\u002FLiothyronine Supplementation in Hypothyroid Patients With Brain Tumors",[91],[46720,13732],"Hypothyroidism",[46701,46722],"Liothyronine",{"intervention":46722,"totalTrials":166,"cells":46724},{"EARLY_PHASE1":46725,"PHASE1":46727,"PHASE2":46729,"PHASE3":46731,"PHASE4":46733,"NA":46735},{"trials":46726,"activeCount":124},[],{"trials":46728,"activeCount":124},[],{"trials":46730,"activeCount":124},[],{"trials":46732,"activeCount":124},[],{"trials":46734,"activeCount":124},[],{"trials":46736,"activeCount":124},[46737],{"nctId":46716,"briefTitle":46717,"status":182,"phases":46738,"primaryCompletion":13673,"completion":13673,"start":4084,"enrollment":3726,"conditions":46739,"interventions":46740},[91],[46720,13732],[46701,46722],{"intervention":46742,"totalTrials":166,"cells":46743},"Propranolol",{"EARLY_PHASE1":46744,"PHASE1":46746,"PHASE2":46748,"PHASE3":46750,"PHASE4":46752,"NA":46754},{"trials":46745,"activeCount":124},[],{"trials":46747,"activeCount":124},[],{"trials":46749,"activeCount":124},[],{"trials":46751,"activeCount":124},[],{"trials":46753,"activeCount":124},[],{"trials":46755,"activeCount":124},[46756],{"nctId":46757,"briefTitle":46758,"status":182,"phases":46759,"primaryCompletion":46760,"completion":46760,"start":46761,"enrollment":230,"conditions":46762,"interventions":46763},"NCT01902966","Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)",[91],"2020-08-14","2013-09-11",[11077],[46742],{"intervention":46268,"totalTrials":166,"cells":46765},{"EARLY_PHASE1":46766,"PHASE1":46768,"PHASE2":46770,"PHASE3":46772,"PHASE4":46774,"NA":46776},{"trials":46767,"activeCount":124},[],{"trials":46769,"activeCount":124},[],{"trials":46771,"activeCount":124},[],{"trials":46773,"activeCount":124},[],{"trials":46775,"activeCount":124},[],{"trials":46777,"activeCount":124},[46778],{"nctId":46262,"briefTitle":46263,"status":130,"phases":46779,"primaryCompletion":46265,"completion":46265,"start":11040,"enrollment":7574,"conditions":46780,"interventions":46781},[91],[11077],[29969,46268],{"intervention":324,"totalTrials":166,"cells":46783},{"EARLY_PHASE1":46784,"PHASE1":46786,"PHASE2":46788,"PHASE3":46790,"PHASE4":46792,"NA":46794},{"trials":46785,"activeCount":124},[],{"trials":46787,"activeCount":124},[],{"trials":46789,"activeCount":124},[],{"trials":46791,"activeCount":124},[],{"trials":46793,"activeCount":124},[],{"trials":46795,"activeCount":124},[46796],{"nctId":315,"briefTitle":316,"status":130,"phases":46797,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":46798,"interventions":46799},[91],[285,322],[324,288,288,325],{"intervention":325,"totalTrials":166,"cells":46801},{"EARLY_PHASE1":46802,"PHASE1":46804,"PHASE2":46806,"PHASE3":46808,"PHASE4":46810,"NA":46812},{"trials":46803,"activeCount":124},[],{"trials":46805,"activeCount":124},[],{"trials":46807,"activeCount":124},[],{"trials":46809,"activeCount":124},[],{"trials":46811,"activeCount":124},[],{"trials":46813,"activeCount":124},[46814],{"nctId":315,"briefTitle":316,"status":130,"phases":46815,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":46816,"interventions":46817},[91],[285,322],[324,288,288,325],{"intervention":46819,"totalTrials":166,"cells":46820},"3'-Deoxy-3'-18f-Fluorothymidine",{"EARLY_PHASE1":46821,"PHASE1":46823,"PHASE2":46825,"PHASE3":46827,"PHASE4":46829,"NA":46831},{"trials":46822,"activeCount":124},[],{"trials":46824,"activeCount":124},[],{"trials":46826,"activeCount":124},[],{"trials":46828,"activeCount":124},[],{"trials":46830,"activeCount":124},[],{"trials":46832,"activeCount":124},[46833],{"nctId":46834,"briefTitle":46835,"status":203,"phases":46836,"primaryCompletion":4184,"start":4184,"enrollment":124,"conditions":46837,"interventions":46838},"NCT02241668","Fluoro-L-Thymidine Positron Emission Tomography (FLT PET) vs. Adv. Magnetic Resonance (MR) Techniques in Recurrent Glioma",[91],[13732],[46819],{"intervention":46840,"totalTrials":166,"cells":46841},"Epoetin alfa",{"EARLY_PHASE1":46842,"PHASE1":46844,"PHASE2":46846,"PHASE3":46848,"PHASE4":46850,"NA":46852},{"trials":46843,"activeCount":124},[],{"trials":46845,"activeCount":124},[],{"trials":46847,"activeCount":124},[],{"trials":46849,"activeCount":124},[],{"trials":46851,"activeCount":124},[],{"trials":46853,"activeCount":124},[46854],{"nctId":46855,"briefTitle":46856,"status":203,"phases":46857,"primaryCompletion":4647,"completion":4647,"start":46858,"enrollment":124,"conditions":46859,"interventions":46860},"NCT00052221","Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy",[91],"2003-05-20",[2923,2936],[46840],{"intervention":46862,"totalTrials":166,"cells":46863},"Ferumoxtran-10",{"EARLY_PHASE1":46864,"PHASE1":46866,"PHASE2":46868,"PHASE3":46870,"PHASE4":46872,"NA":46874},{"trials":46865,"activeCount":124},[],{"trials":46867,"activeCount":124},[],{"trials":46869,"activeCount":124},[],{"trials":46871,"activeCount":124},[],{"trials":46873,"activeCount":124},[],{"trials":46875,"activeCount":124},[46876],{"nctId":46877,"briefTitle":46878,"status":182,"phases":46879,"primaryCompletion":9512,"completion":9512,"start":5663,"enrollment":1496,"conditions":46880,"interventions":46881},"NCT00147238","A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast",[91],[1293,23006,27],[46862],{"intervention":46883,"totalTrials":166,"cells":46884},"Neoadjuvant treatment",{"EARLY_PHASE1":46885,"PHASE1":46887,"PHASE2":46889,"PHASE3":46891,"PHASE4":46893,"NA":46895},{"trials":46886,"activeCount":124},[],{"trials":46888,"activeCount":124},[],{"trials":46890,"activeCount":124},[],{"trials":46892,"activeCount":124},[],{"trials":46894,"activeCount":124},[],{"trials":46896,"activeCount":124},[46897],{"nctId":46898,"briefTitle":46899,"status":203,"phases":46900,"primaryCompletion":46901,"completion":46901,"start":46901,"enrollment":124,"conditions":46902,"interventions":46906},"NCT07475923","Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)",[],"2026-04-09",[46903,18,25583,46904,46905],"Molecular Surveillance","MRD","Observational Study",[46883],{"intervention":46908,"totalTrials":166,"cells":46909},"DEFINITY",{"EARLY_PHASE1":46910,"PHASE1":46912,"PHASE2":46914,"PHASE3":46916,"PHASE4":46918,"NA":46920},{"trials":46911,"activeCount":124},[],{"trials":46913,"activeCount":124},[],{"trials":46915,"activeCount":124},[],{"trials":46917,"activeCount":124},[],{"trials":46919,"activeCount":124},[],{"trials":46921,"activeCount":124},[46922],{"nctId":46923,"briefTitle":46924,"status":130,"phases":46925,"primaryCompletion":3213,"start":7177,"enrollment":95,"conditions":46926,"interventions":46927},"NCT01894607","Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy",[91],[1333],[46908],{"intervention":29596,"totalTrials":166,"cells":46929},{"EARLY_PHASE1":46930,"PHASE1":46932,"PHASE2":46934,"PHASE3":46936,"PHASE4":46938,"NA":46940},{"trials":46931,"activeCount":124},[],{"trials":46933,"activeCount":124},[],{"trials":46935,"activeCount":124},[],{"trials":46937,"activeCount":124},[],{"trials":46939,"activeCount":124},[],{"trials":46941,"activeCount":124},[46942],{"nctId":29588,"briefTitle":29589,"status":130,"phases":46943,"primaryCompletion":29591,"completion":29591,"start":29592,"enrollment":230,"conditions":46944,"interventions":46945},[91],[29594,21,1960,3175],[29596,29551],{"intervention":46947,"totalTrials":166,"cells":46948},"Brontictuzumab",{"EARLY_PHASE1":46949,"PHASE1":46951,"PHASE2":46953,"PHASE3":46955,"PHASE4":46957,"NA":46959},{"trials":46950,"activeCount":124},[],{"trials":46952,"activeCount":124},[],{"trials":46954,"activeCount":124},[],{"trials":46956,"activeCount":124},[],{"trials":46958,"activeCount":124},[],{"trials":46960,"activeCount":124},[46961],{"nctId":46962,"briefTitle":46963,"status":130,"phases":46964,"primaryCompletion":46965,"completion":46965,"start":37665,"enrollment":166,"conditions":46966,"interventions":46967},"NCT02662608","Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)",[91],"2016-03-06",[25048],[46947],{"intervention":46969,"totalTrials":166,"cells":46970},"18F-fluoromisonidazole",{"EARLY_PHASE1":46971,"PHASE1":46973,"PHASE2":46975,"PHASE3":46977,"PHASE4":46979,"NA":46981},{"trials":46972,"activeCount":124},[],{"trials":46974,"activeCount":124},[],{"trials":46976,"activeCount":124},[],{"trials":46978,"activeCount":124},[],{"trials":46980,"activeCount":124},[],{"trials":46982,"activeCount":124},[46983],{"nctId":46984,"briefTitle":46985,"status":203,"phases":46986,"primaryCompletion":6758,"completion":6758,"start":46987,"enrollment":124,"conditions":46988,"interventions":46989},"NCT00038038","Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole",[91],"1994-01",[4031,7339,17937],[46969],{"intervention":22567,"totalTrials":166,"cells":46991},{"EARLY_PHASE1":46992,"PHASE1":46994,"PHASE2":46996,"PHASE3":46998,"PHASE4":47000,"NA":47002},{"trials":46993,"activeCount":124},[],{"trials":46995,"activeCount":124},[],{"trials":46997,"activeCount":124},[],{"trials":46999,"activeCount":124},[],{"trials":47001,"activeCount":124},[],{"trials":47003,"activeCount":124},[47004],{"nctId":22560,"briefTitle":22561,"status":130,"phases":47005,"primaryCompletion":22563,"completion":22563,"start":22564,"enrollment":240,"conditions":47006,"interventions":47007},[91],[2971],[22567,22568,2977,2495],{"intervention":22568,"totalTrials":166,"cells":47009},{"EARLY_PHASE1":47010,"PHASE1":47012,"PHASE2":47014,"PHASE3":47016,"PHASE4":47018,"NA":47020},{"trials":47011,"activeCount":124},[],{"trials":47013,"activeCount":124},[],{"trials":47015,"activeCount":124},[],{"trials":47017,"activeCount":124},[],{"trials":47019,"activeCount":124},[],{"trials":47021,"activeCount":124},[47022],{"nctId":22560,"briefTitle":22561,"status":130,"phases":47023,"primaryCompletion":22563,"completion":22563,"start":22564,"enrollment":240,"conditions":47024,"interventions":47025},[91],[2971],[22567,22568,2977,2495],{"intervention":2990,"totalTrials":166,"cells":47027},{"EARLY_PHASE1":47028,"PHASE1":47030,"PHASE2":47032,"PHASE3":47034,"PHASE4":47036,"NA":47038},{"trials":47029,"activeCount":124},[],{"trials":47031,"activeCount":124},[],{"trials":47033,"activeCount":124},[],{"trials":47035,"activeCount":124},[],{"trials":47037,"activeCount":124},[],{"trials":47039,"activeCount":124},[47040],{"nctId":2981,"briefTitle":2982,"status":130,"phases":47041,"primaryCompletion":2984,"completion":2984,"start":2985,"enrollment":2986,"conditions":47042,"interventions":47043},[91],[2988,18],[2990,62,2991,2992],{"intervention":2991,"totalTrials":166,"cells":47045},{"EARLY_PHASE1":47046,"PHASE1":47048,"PHASE2":47050,"PHASE3":47052,"PHASE4":47054,"NA":47056},{"trials":47047,"activeCount":124},[],{"trials":47049,"activeCount":124},[],{"trials":47051,"activeCount":124},[],{"trials":47053,"activeCount":124},[],{"trials":47055,"activeCount":124},[],{"trials":47057,"activeCount":124},[47058],{"nctId":2981,"briefTitle":2982,"status":130,"phases":47059,"primaryCompletion":2984,"completion":2984,"start":2985,"enrollment":2986,"conditions":47060,"interventions":47061},[91],[2988,18],[2990,62,2991,2992],{"intervention":2992,"totalTrials":166,"cells":47063},{"EARLY_PHASE1":47064,"PHASE1":47066,"PHASE2":47068,"PHASE3":47070,"PHASE4":47072,"NA":47074},{"trials":47065,"activeCount":124},[],{"trials":47067,"activeCount":124},[],{"trials":47069,"activeCount":124},[],{"trials":47071,"activeCount":124},[],{"trials":47073,"activeCount":124},[],{"trials":47075,"activeCount":124},[47076],{"nctId":2981,"briefTitle":2982,"status":130,"phases":47077,"primaryCompletion":2984,"completion":2984,"start":2985,"enrollment":2986,"conditions":47078,"interventions":47079},[91],[2988,18],[2990,62,2991,2992],{"intervention":45838,"totalTrials":166,"cells":47081},{"EARLY_PHASE1":47082,"PHASE1":47084,"PHASE2":47086,"PHASE3":47088,"PHASE4":47090,"NA":47092},{"trials":47083,"activeCount":124},[],{"trials":47085,"activeCount":124},[],{"trials":47087,"activeCount":124},[],{"trials":47089,"activeCount":124},[],{"trials":47091,"activeCount":124},[],{"trials":47093,"activeCount":124},[47094],{"nctId":45833,"briefTitle":45834,"status":130,"phases":47095,"primaryCompletion":6410,"completion":6410,"start":8503,"enrollment":924,"conditions":47096,"interventions":47097},[91],[1400],[18140,45838],{"intervention":3002,"totalTrials":166,"cells":47099},{"EARLY_PHASE1":47100,"PHASE1":47102,"PHASE2":47104,"PHASE3":47106,"PHASE4":47108,"NA":47110},{"trials":47101,"activeCount":124},[],{"trials":47103,"activeCount":124},[],{"trials":47105,"activeCount":124},[],{"trials":47107,"activeCount":124},[],{"trials":47109,"activeCount":124},[],{"trials":47111,"activeCount":124},[47112],{"nctId":2994,"briefTitle":2995,"status":130,"phases":47113,"primaryCompletion":184,"completion":184,"start":2778,"enrollment":2997,"conditions":47114,"interventions":47115},[91],[2971,2935,2999,3000],[3002,62,3003,3004,1013,1114,2495,1016],{"intervention":3003,"totalTrials":166,"cells":47117},{"EARLY_PHASE1":47118,"PHASE1":47120,"PHASE2":47122,"PHASE3":47124,"PHASE4":47126,"NA":47128},{"trials":47119,"activeCount":124},[],{"trials":47121,"activeCount":124},[],{"trials":47123,"activeCount":124},[],{"trials":47125,"activeCount":124},[],{"trials":47127,"activeCount":124},[],{"trials":47129,"activeCount":124},[47130],{"nctId":2994,"briefTitle":2995,"status":130,"phases":47131,"primaryCompletion":184,"completion":184,"start":2778,"enrollment":2997,"conditions":47132,"interventions":47133},[91],[2971,2935,2999,3000],[3002,62,3003,3004,1013,1114,2495,1016],{"intervention":3004,"totalTrials":166,"cells":47135},{"EARLY_PHASE1":47136,"PHASE1":47138,"PHASE2":47140,"PHASE3":47142,"PHASE4":47144,"NA":47146},{"trials":47137,"activeCount":124},[],{"trials":47139,"activeCount":124},[],{"trials":47141,"activeCount":124},[],{"trials":47143,"activeCount":124},[],{"trials":47145,"activeCount":124},[],{"trials":47147,"activeCount":124},[47148],{"nctId":2994,"briefTitle":2995,"status":130,"phases":47149,"primaryCompletion":184,"completion":184,"start":2778,"enrollment":2997,"conditions":47150,"interventions":47151},[91],[2971,2935,2999,3000],[3002,62,3003,3004,1013,1114,2495,1016],{"intervention":47153,"totalTrials":166,"cells":47154},"Chemotherapy for hematologic malignancy",{"EARLY_PHASE1":47155,"PHASE1":47157,"PHASE2":47159,"PHASE3":47161,"PHASE4":47163,"NA":47165},{"trials":47156,"activeCount":124},[],{"trials":47158,"activeCount":124},[],{"trials":47160,"activeCount":124},[],{"trials":47162,"activeCount":124},[],{"trials":47164,"activeCount":124},[],{"trials":47166,"activeCount":124},[47167],{"nctId":47168,"briefTitle":47169,"status":130,"phases":47170,"primaryCompletion":7400,"completion":7400,"start":47171,"enrollment":3521,"conditions":47172,"interventions":47173},"NCT00042250","IUdR\u002FBUdR Cell Cycle Labelling",[91],"1992-05",[4760],[47153],{"intervention":47175,"totalTrials":166,"cells":47176},"CD8 Depleted Donor Lymphocyte",{"EARLY_PHASE1":47177,"PHASE1":47179,"PHASE2":47181,"PHASE3":47183,"PHASE4":47185,"NA":47187},{"trials":47178,"activeCount":124},[],{"trials":47180,"activeCount":124},[],{"trials":47182,"activeCount":124},[],{"trials":47184,"activeCount":124},[],{"trials":47186,"activeCount":124},[],{"trials":47188,"activeCount":124},[47189],{"nctId":47190,"briefTitle":47191,"status":182,"phases":47192,"primaryCompletion":6852,"completion":6852,"start":9369,"enrollment":1231,"conditions":47193,"interventions":47195},"NCT00038818","CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation",[91],[4725,1400,47194,9378,712],"Non Hodgkin's Lymphoma",[47175],{"intervention":47197,"totalTrials":166,"cells":47198},"methadone hydrochloride",{"EARLY_PHASE1":47199,"PHASE1":47201,"PHASE2":47203,"PHASE3":47205,"PHASE4":47207,"NA":47209},{"trials":47200,"activeCount":124},[],{"trials":47202,"activeCount":124},[],{"trials":47204,"activeCount":124},[],{"trials":47206,"activeCount":124},[],{"trials":47208,"activeCount":124},[],{"trials":47210,"activeCount":124},[47211],{"nctId":47212,"briefTitle":47213,"status":182,"phases":47214,"primaryCompletion":3777,"completion":2768,"start":2528,"enrollment":166,"conditions":47215,"interventions":47216},"NCT00726830","Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer",[91],[11302,27953,15,21,3243,5203,1036,27954,5979,31059,2936],[47197,47217,47218],"morphine sulfate","oxycodone hydrochloride",{"intervention":47217,"totalTrials":166,"cells":47220},{"EARLY_PHASE1":47221,"PHASE1":47223,"PHASE2":47225,"PHASE3":47227,"PHASE4":47229,"NA":47231},{"trials":47222,"activeCount":124},[],{"trials":47224,"activeCount":124},[],{"trials":47226,"activeCount":124},[],{"trials":47228,"activeCount":124},[],{"trials":47230,"activeCount":124},[],{"trials":47232,"activeCount":124},[47233],{"nctId":47212,"briefTitle":47213,"status":182,"phases":47234,"primaryCompletion":3777,"completion":2768,"start":2528,"enrollment":166,"conditions":47235,"interventions":47236},[91],[11302,27953,15,21,3243,5203,1036,27954,5979,31059,2936],[47197,47217,47218],{"intervention":47218,"totalTrials":166,"cells":47238},{"EARLY_PHASE1":47239,"PHASE1":47241,"PHASE2":47243,"PHASE3":47245,"PHASE4":47247,"NA":47249},{"trials":47240,"activeCount":124},[],{"trials":47242,"activeCount":124},[],{"trials":47244,"activeCount":124},[],{"trials":47246,"activeCount":124},[],{"trials":47248,"activeCount":124},[],{"trials":47250,"activeCount":124},[47251],{"nctId":47212,"briefTitle":47213,"status":182,"phases":47252,"primaryCompletion":3777,"completion":2768,"start":2528,"enrollment":166,"conditions":47253,"interventions":47254},[91],[11302,27953,15,21,3243,5203,1036,27954,5979,31059,2936],[47197,47217,47218],{"intervention":47256,"totalTrials":166,"cells":47257},"Feraheme",{"EARLY_PHASE1":47258,"PHASE1":47260,"PHASE2":47262,"PHASE3":47264,"PHASE4":47266,"NA":47268},{"trials":47259,"activeCount":124},[],{"trials":47261,"activeCount":124},[],{"trials":47263,"activeCount":124},[],{"trials":47265,"activeCount":124},[],{"trials":47267,"activeCount":124},[],{"trials":47269,"activeCount":124},[47270],{"nctId":47271,"briefTitle":47272,"status":130,"phases":47273,"primaryCompletion":1608,"completion":1608,"start":2889,"enrollment":1496,"conditions":47274,"interventions":47276},"NCT01815333","Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging",[91],[47275],"Cancer of Lymph Node",[47256],{"intervention":7490,"totalTrials":166,"cells":47278},{"EARLY_PHASE1":47279,"PHASE1":47281,"PHASE2":47283,"PHASE3":47285,"PHASE4":47287,"NA":47289},{"trials":47280,"activeCount":124},[],{"trials":47282,"activeCount":124},[],{"trials":47284,"activeCount":124},[],{"trials":47286,"activeCount":124},[],{"trials":47288,"activeCount":124},[],{"trials":47290,"activeCount":124},[47291],{"nctId":7484,"briefTitle":7485,"status":130,"phases":47292,"primaryCompletion":4192,"completion":3777,"start":7487,"enrollment":3541,"conditions":47293,"interventions":47294},[91],[21,15],[7490,1070,803,894],{"intervention":47296,"totalTrials":166,"cells":47297},"Heparin",{"EARLY_PHASE1":47298,"PHASE1":47300,"PHASE2":47302,"PHASE3":47304,"PHASE4":47306,"NA":47308},{"trials":47299,"activeCount":124},[],{"trials":47301,"activeCount":124},[],{"trials":47303,"activeCount":124},[],{"trials":47305,"activeCount":124},[],{"trials":47307,"activeCount":124},[],{"trials":47309,"activeCount":124},[47310],{"nctId":47311,"briefTitle":47312,"status":203,"phases":47313,"enrollment":124,"conditions":47314,"interventions":47315},"NCT00378781","Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection",[91],[5349],[47296,47316],"Minocycline-EDTA",{"intervention":47316,"totalTrials":166,"cells":47318},{"EARLY_PHASE1":47319,"PHASE1":47321,"PHASE2":47323,"PHASE3":47325,"PHASE4":47327,"NA":47329},{"trials":47320,"activeCount":124},[],{"trials":47322,"activeCount":124},[],{"trials":47324,"activeCount":124},[],{"trials":47326,"activeCount":124},[],{"trials":47328,"activeCount":124},[],{"trials":47330,"activeCount":124},[47331],{"nctId":47311,"briefTitle":47312,"status":203,"phases":47332,"enrollment":124,"conditions":47333,"interventions":47334},[91],[5349],[47296,47316],{"intervention":47336,"totalTrials":166,"cells":47337},"Microarray analysis",{"EARLY_PHASE1":47338,"PHASE1":47340,"PHASE2":47342,"PHASE3":47344,"PHASE4":47346,"NA":47348},{"trials":47339,"activeCount":124},[],{"trials":47341,"activeCount":124},[],{"trials":47343,"activeCount":124},[],{"trials":47345,"activeCount":124},[],{"trials":47347,"activeCount":124},[],{"trials":47349,"activeCount":124},[47350],{"nctId":47351,"briefTitle":47352,"status":182,"phases":47353,"primaryCompletion":4084,"completion":16514,"start":4086,"enrollment":1483,"conditions":47354,"interventions":47355},"NCT00897806","Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer",[],[1530,35015],[47336],{"intervention":47357,"totalTrials":166,"cells":47358},"Dexmedetomidine",{"EARLY_PHASE1":47359,"PHASE1":47361,"PHASE2":47363,"PHASE3":47365,"PHASE4":47367,"NA":47369},{"trials":47360,"activeCount":124},[],{"trials":47362,"activeCount":124},[],{"trials":47364,"activeCount":124},[],{"trials":47366,"activeCount":124},[],{"trials":47368,"activeCount":124},[],{"trials":47370,"activeCount":124},[47371],{"nctId":47372,"briefTitle":47373,"status":130,"phases":47374,"primaryCompletion":2527,"completion":2527,"start":4542,"enrollment":1131,"conditions":47375,"interventions":47376},"NCT01692210","The Effect of Dexmedetomidine of the Immune System",[],[18],[47357],{"intervention":47378,"totalTrials":166,"cells":47379},"Dendritic Cell Activated Lymphocyte",{"EARLY_PHASE1":47380,"PHASE1":47382,"PHASE2":47384,"PHASE3":47386,"PHASE4":47388,"NA":47390},{"trials":47381,"activeCount":124},[],{"trials":47383,"activeCount":124},[],{"trials":47385,"activeCount":124},[],{"trials":47387,"activeCount":124},[],{"trials":47389,"activeCount":124},[],{"trials":47391,"activeCount":124},[47392],{"nctId":47393,"briefTitle":47394,"status":203,"phases":47395,"primaryCompletion":47396,"completion":47396,"start":47397,"enrollment":124,"conditions":47398,"interventions":47399},"NCT00038870","Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes",[91],"2003-01-14","2001-01-31",[4659,4725],[47378],{"intervention":47401,"totalTrials":166,"cells":47402},"Gadolinium-Chelate",{"EARLY_PHASE1":47403,"PHASE1":47405,"PHASE2":47407,"PHASE3":47409,"PHASE4":47411,"NA":47413},{"trials":47404,"activeCount":124},[],{"trials":47406,"activeCount":124},[],{"trials":47408,"activeCount":124},[],{"trials":47410,"activeCount":124},[],{"trials":47412,"activeCount":124},[],{"trials":47414,"activeCount":124},[47415],{"nctId":47416,"briefTitle":47417,"status":130,"phases":47418,"primaryCompletion":7986,"completion":7986,"start":47419,"enrollment":1568,"conditions":47420,"interventions":47421},"NCT04870645","Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis",[91],"2021-03-30",[360],[47401,47422],"Iopamidol",{"intervention":47422,"totalTrials":166,"cells":47424},{"EARLY_PHASE1":47425,"PHASE1":47427,"PHASE2":47429,"PHASE3":47431,"PHASE4":47433,"NA":47435},{"trials":47426,"activeCount":124},[],{"trials":47428,"activeCount":124},[],{"trials":47430,"activeCount":124},[],{"trials":47432,"activeCount":124},[],{"trials":47434,"activeCount":124},[],{"trials":47436,"activeCount":124},[47437],{"nctId":47416,"briefTitle":47417,"status":130,"phases":47438,"primaryCompletion":7986,"completion":7986,"start":47419,"enrollment":1568,"conditions":47439,"interventions":47440},[91],[360],[47401,47422],{"intervention":10351,"totalTrials":166,"cells":47442},{"EARLY_PHASE1":47443,"PHASE1":47445,"PHASE2":47447,"PHASE3":47449,"PHASE4":47451,"NA":47453},{"trials":47444,"activeCount":124},[],{"trials":47446,"activeCount":124},[],{"trials":47448,"activeCount":124},[],{"trials":47450,"activeCount":124},[],{"trials":47452,"activeCount":124},[],{"trials":47454,"activeCount":124},[47455],{"nctId":10343,"briefTitle":10344,"status":130,"phases":47456,"primaryCompletion":10346,"completion":10346,"start":10347,"enrollment":1922,"conditions":47457,"interventions":47458},[91],[10349],[10351,1369],{"intervention":47460,"totalTrials":166,"cells":47461},"Calcium Alumina-Silicate",{"EARLY_PHASE1":47462,"PHASE1":47464,"PHASE2":47466,"PHASE3":47468,"PHASE4":47470,"NA":47472},{"trials":47463,"activeCount":124},[],{"trials":47465,"activeCount":124},[],{"trials":47467,"activeCount":124},[],{"trials":47469,"activeCount":124},[],{"trials":47471,"activeCount":124},[],{"trials":47473,"activeCount":124},[47474],{"nctId":47475,"briefTitle":47476,"status":182,"phases":47477,"primaryCompletion":2846,"completion":2846,"start":2243,"enrollment":121,"conditions":47478,"interventions":47479},"NCT02018653","CASAD for Severe Diarrhea in the Emergency Department",[91],[5349,28414],[47460]]